PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bussmann, C; Bockenhoff, A; Henke, H; Werfel, T; Novak, N				Bussmann, Caroline; Boeckenhoff, Anette; Henke, Henning; Werfel, Thomas; Novak, Natalija			Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; atopic dermatitis; house dust mite; allergen specific immunotherapy	HOUSE-DUST-MITE; BLIND CONTROLLED TRIAL; DERMATOPHAGOIDES-PTERONYSSINUS; SUBLINGUAL IMMUNOTHERAPY; ASTHMATIC-PATIENTS; HYPOSENSITIZATION; CHILDREN; RHINITIS; IMMUNOLOGY; AVOIDANCE	House dust mite (HDM) allergens are perennial indoor allergens, which may play a role as allergic trigger factors in atopic dermatitis (AD). Facilitated by their high enzymatic activity, HDM allergens are capable of penetrating the impaired epidermal skin barrier in patients with AD, gaining access to immune cells. In this way, HDM allergens induce both allergic reactions of the immediate type and allergic reactions of the delayed type, which contribute to impairment of AD. Because allergen reduction achieved by encasing strategies does not always lead to significant improvement of clinical symptoms, specific immunotherapy (SIT) might represent an attractive therapeutic option for long-time treatment of this subgroup of patients with AD. However, systematic studies on the effectiveness of SIT in patients with AD are rare. Furthermore, data on the immunologic changes induced by SIT in patients with AD are not well studied. In this review, we provide an overview of the pathogenic impact of HDM allergens as an example for aeroallergens on the course of AD. In addition, we discuss prophylactic and therapeutic options for the treatment of HDM allergy in patients with AD, including a summary of the current data available on SIT as a potential therapeutic option for patients with AD.	Univ Bonn, Dept Dermatol, D-53127 Bonn, Germany; Univ Dortmund, Dept Stat, D-44221 Dortmund, Germany; Hannover Med Sch, Dept Dermatol, D-3000 Hannover, Germany	University of Bonn; Dortmund University of Technology; Hannover Medical School	Novak, N (corresponding author), Univ Bonn, Dept Dermatol, Siegmund Freud Str 25, D-53127 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de	Werfel, Thomas/B-6921-2012					Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; ARLIAN LG, 1991, EXP APPL ACAROL, V10, P167, DOI 10.1007/BF01198649; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V118, P40, DOI 10.1016/j.jaci.2006.04.044; Bousquet J, 2001, ANN ALLERG ASTHMA IM, V87, P38, DOI 10.1016/S1081-1206(10)62193-X; Brown A, 2003, AM J RESP CELL MOL, V29, P381, DOI 10.1165/rcmb.2003-0060OC; BRUUN EGON, 1949, ACTA ALLERGOL, V2, P122, DOI 10.1111/j.1398-9995.1949.tb03295.x; CHAIT I, 1985, PRACTITIONER, V229, P609; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Cork Michael J, 2005, Community Pract, V78, P440; CORRADO OJ, 1989, ALLERGY, V44, P108, DOI 10.1111/j.1398-9995.1989.tb02233.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; DEFUENMAYOR MCD, 1979, BRIT J DERMATOL, V101, P697; DES RA, 1997, J ALLERGY CLIN IMMUN, V99, P450; Engelhart S, 2002, INT J HYG ENVIR HEAL, V205, P453, DOI 10.1078/1438-4639-00192; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Galli E, 1994, Allergol Immunopathol (Madr), V22, P18; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048, DOI 10.1164/ajrccm.162.6.9909087; GREWE M, 2000, ALLERGO J, V9, P351; HEDGES LV, 1985, STAT METHODS META AN; Heijer A., 1993, ALLERGO J, V2, P3; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; KAUFMAN HS, 1974, ANN ALLERGY, V32, P321; Kawabata A, 2005, J PHARMACOL SCI, V97, P20, DOI 10.1254/jphs.FMJ04005X4; Kleine-Trebbe J, 2006, ALLERGO J, V15, P56; LEROY BP, 1993, J AM ACAD DERMATOL, V28, P232, DOI 10.1016/0190-9622(93)70033-P; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Malling HJ, 2006, ALLERGY, V61, P24, DOI 10.1111/j.1398-9995.2006.01158.x; Mastrandrea F, 2000, Allergol Immunopathol (Madr), V28, P54; MICHILS A, 1994, BRIT J DERMATOL, V130, P134, DOI 10.1111/j.1365-2133.1994.tb06908.x; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; MOSCA M, 1993, ITAL DERMATOL VENERO, V128, P79; Noh GW, 1998, ALLERGY, V53, P1202, DOI 10.1111/j.1398-9995.1998.tb03842.x; Pacor Maria Luisa, 1994, Recenti Progressi in Medicina, V85, P273; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Petrova SI, 2006, ZH MIKROBIOL EPIDEMI, V1, P33; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Rijssenbeek-Nouwens LHM, 2002, CLIN EXP ALLERGY, V32, P117, DOI 10.1046/j.0022-0477.2001.01256.x; RING J, 1982, BRIT J DERMATOL, V107, P597, DOI 10.1111/j.1365-2133.1982.tb00412.x; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; SEIDENARI S, 1986, DERMATOLOGICA, V172, P229, DOI 10.1159/000249342; Silny W, 2006, ALLERGOLOGIE, V29, P171; Silny Wojciech, 2005, Wiad Lek, V58, P47; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Trofimowicz A, 1995, Rocz Akad Med Bialymst, V40, P414; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; Verhagen J, 2005, INT REV IMMUNOL, V24, P533, DOI 10.1080/08830180500371173; Warner A, 1999, ALLERGY, V54, P681, DOI 10.1034/j.1398-9995.1999.00850.x; WARNER JO, 1978, LANCET, V2, P912; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; ZACHARIAE H, 1985, ACTA DERM-VENEREOL, P48; Zwacka G, 1996, ALLERGOLOGIE, V19, P580	60	104	115	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1292	1298		10.1016/j.jaci.2006.07.054	http://dx.doi.org/10.1016/j.jaci.2006.07.054			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157659	Bronze			2022-12-18	WOS:000242880300013
J	Cundall, M; Sun, YC; Miranda, C; Trudeau, JB; Barnes, S; Wenzel, SE				Cundall, M; Sun, YC; Miranda, C; Trudeau, JB; Barnes, S; Wenzel, SE			Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucortcoids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						matrix metalloproteinase-9; neutrophil gelatinase-associated lipocalin; glucocorticoids; asthma; bronchoalveolar lavage	BRONCHOALVEOLAR LAVAGE FLUID; TISSUE INHIBITOR; ALVEOLAR MACROPHAGES; PERIPHERAL-BLOOD; METALLOPROTEINASE-1; INFLAMMATION; AIRWAY; SPUTUM; ACTIVATION; EXPRESSION	Background: Matrix metalloproteinase (MMP)-9 levels are increased in bronchoalveolar lavage (BAL) fluid from patients with severe asthma on high doses of glucocorticoids (GCs). Objective: We sought to identify neutrophils as the source of increased BAL fluid MMP-9 in severe asthma and to evaluate the effects of GCs on this MMP-9. Methods: MMP-9 protein, activity, and mRNA were measured in BAL fluid and cells at baseline, and after in vitro GCs in patients with severe asthma and controls using enzyme immunoassays, zymography, Western blotting, and real-time PCR. Results: The high molecular weight (HMW) form of MMP-9 was significantly increased in severe asthma (P = .02). Western blotting confirmed a heterodimer of MMP-9 and neutrophil gelatinase-associated lipocalin. The HMW MMP-9 correlated with BAL neutrophils (r = .65, P < .0001). BAL cell supernatant MMP-9 protein levels also tended to be higher in patients with severe asthma (overall, P = .09), whereas the HMW activity form was increased (P = .03). MMP-9 protein (and HMW activity) correlated with neutrophils in the cell pellet (r = .75, P < .0001). In contrast to protein and activity, BAL cell mRNA levels were marginally lower in patients with severe asthma than in control subjects (overall, P = .06). Although GCs decreased BAL cell MMP-9 protein and mRNA in vitro, the effect was significantly smaller in severe asthma (P < .01 for both). GCs decreased the pro-MMP-9 activity in patients with severe asthma and normal control subjects, while having no effects on the HMW form (P = .22). Peripheral blood neutrophil MMP-9 protein was not affected by GCs. Conclusions: BAL neutrophils contribute to BAL fluid MMP-9 protein and activity and are poorly inhibited by GCs.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Peking Univ, Hosp 3, Dept Resp Med, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Wenzel, SE (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040600] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00051] Funding Source: Medline; NHLBI NIH HHS [HL-64087] Funding Source: Medline; NIAID NIH HHS [AI-40600] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Betsuyaku T, 1999, AM J RESP CRIT CARE, V159, P1985, DOI 10.1164/ajrccm.159.6.9809043; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Bosse M, 1999, AM J RESP CRIT CARE, V159, P596, DOI 10.1164/ajrccm.159.2.9802045; Cataldo D, 2000, INT ARCH ALLERGY IMM, V123, P259, DOI 10.1159/000024452; Cataldo DD, 2002, CHEST, V122, P1553, DOI 10.1378/chest.122.5.1553; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; COX G, 1995, J IMMUNOL, V154, P4719; Fujisawa T, 1999, INT ARCH ALLERGY IMM, V120, P65, DOI 10.1159/000053598; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449, DOI 10.1164/ajrccm.155.2.9032177; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; Meagher LC, 1996, J IMMUNOL, V156, P4422; Russell REK, 2002, AM J RESP CELL MOL, V26, P602, DOI 10.1165/ajrcmb.26.5.4685; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; Spahn JD, 1996, J IMMUNOL, V157, P2654; Tschesche H, 2001, EUR J BIOCHEM, V268, P1918, DOI 10.1046/j.1432-1327.2001.02066.x; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; ZUCKER S, 1994, CLIN EXP METASTAS, V12, P13, DOI 10.1007/BF01784329	28	104	121	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1064	1071		10.1016/j.jaci.2003.08.013	http://dx.doi.org/10.1016/j.jaci.2003.08.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657859				2022-12-18	WOS:000187154200006
J	Pierzchalska, M; Szabo, Z; Sanak, M; Soja, J; Szczeklik, A				Pierzchalska, M; Szabo, Z; Sanak, M; Soja, J; Szczeklik, A			Deficient prostaglandin E-2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; aspirin-induced asthma; human bronchial fibroblasts; prostaglandins; cyclooxygenase 1; cyclooxygenase 2	SYNTHASE; PATHOGENESIS; CYCLOOXYGENASE-2; CHALLENGE; INDUCTION; CYTOKINES; AIRWAYS; CELLS; COX-2	Background: Regulation of prostaglandin synthesis and the activation of human airway fibroblasts associated with the remodeling of the bronchi play an important role in asthma. Objective: We sought to assess the cyclooxygenase pathways in airway fibroblasts of patients with bronchial asthma. Methods: Generation of prostaglandin E-2 (PGE(2)) and prostaglandin D-2 (PGD(2)) by bronchial fibroblasts was measured by means of mass spectrometry in culture supernatants, and cyclooxgenases expression was estimated by means of RT-PCR and immunoblotting. The cells were isolated from 3 groups of subjects: nonasthmatic patients (n = 10), patients with aspirin-tolerant asthma (ATA, n = 9), and patients with aspirin-intolerant asthma (AIA, n = 7). Results: The cytomix (LPS, 5 mug/mL; IL-1beta, 5 ng/mL; and TNF-alpha, 10 ng/mL; 18 hours) stimulated the production of prostaglandins. Asthmatic patients were characterized by low capacity to produce PGE(2) after cytomix stimulation. In the nonasthmatic patient group the mean PGE(2) production was 32 +/- 33 ngtmL (35-fold of the basic production), in the ATA group it was 16 +/- 18 ng/mL (16-fold), and in the AIA group it was only 5.3 +/- 3.6 ng/mL (4-fold). The mean concentration of PGD2 for nonasthmatic patients, patients with ATA, and patients with AIA was 0.18 +/- 0.16 ng/mL (4.7-fold of the basic production), 0.18 +/- 0.14 ng/mL (4.2-fold), and 0.235 +/- 0.19 ng/mL (1.9-fold), respectively. The observed difference was not due to insufficient cyclooxygenase 2 expression because all groups had similar levels of its mRNA and protein. The patients with AIA had low expression levels of cyclooxygenase 1 protein but not of its mRNA. The PGE(2)/PGD(2) concentration ratio increased after cytomix stimulation in all groups but was significantly less in patients with AIA than in patients with ATA. Conclusions: Our results point to a deficient PGE(2) production under proinflammatory conditions in asthmatic airways. This could weaken local defensive mechanisms and promote cysteinyl leukotriene overproduction.	Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Krakow, Poland; Koranyi Natl Inst Pulm, Budapest, Hungary	Jagiellonian University	Szczeklik, A (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, 8 Skawinska Str, PL-31066 Krakow, Poland.		Sanak, Marek/AAV-1628-2021; Sanak, Marek/A-2115-2008	Sanak, Marek/0000-0001-7635-8103; Pierzchalska, Malgorzata/0000-0002-6830-5842				Belvisi MG, 1997, BRIT J PHARMACOL, V120, P910, DOI 10.1038/sj.bjp.0700963; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Davies DE, 2001, CURR OPIN ALLERGY CL, V1, P67, DOI 10.1097/00130832-200102000-00012; Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050; DIAZ A, 1989, J BIOL CHEM, V264, P11554; Dube J, 1998, LAB INVEST, V78, P297; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Leff AR, 2000, THORAX, V55, pS32, DOI 10.1136/thorax.55.suppl_2.S32; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; Noguchi K, 1996, INFLAMMATION, V20, P555, DOI 10.1007/BF01487046; Pang L, 1998, CLIN EXP ALLERGY, V28, P1050; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905, DOI 10.1164/ajrccm.160.6.9903114; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SHINDO N, 1988, BIOMED ENVIRON MASS, V15, P25, DOI 10.1002/bms.1200150105; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; SZCZEKLIK A, 1990, EUR RESPIR J, V3, P588; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Szczeklik A, 2002, CLIN EXP ALLERGY, V32, P339, DOI 10.1046/j.1365-2222.2002.01333.x; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569; Vancheri C, 2000, AM J RESP CELL MOL, V22, P628, DOI 10.1165/ajrcmb.22.5.3948; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; WILBORN J, 1995, J CLIN INVEST, V95, P1861, DOI 10.1172/JCI117866	38	104	109	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1041	1048		10.1067/mai.2003.1491	http://dx.doi.org/10.1067/mai.2003.1491			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743569	Bronze, Green Published			2022-12-18	WOS:000182904500019
J	Kruse, S; Kuehr, J; Moseler, M; Kopp, MV; Kurz, T; Deichmann, KA; Foster, PS; Mattes, J				Kruse, S; Kuehr, J; Moseler, M; Kopp, MV; Kurz, T; Deichmann, KA; Foster, PS; Mattes, J			Polymorphisms in the IL18 gene are associated with specific sensitization to common allergens and allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-18; IgE; atopy; allergy; sensitazation; rhinitis; polymorphisms	IFN-GAMMA; MOUSE MODEL; SERUM IGE; IL-18; ASTHMA; PROTEIN; CELLS; CYTOKINES; ATOPY	Background: Atopy has been linked to chromosome 11q22, a region that harbors the IL18 gene. IL-18 enhances IL-4/IL-13 production and induces IgE production that is directly associated with the pathogenesis of atopic disorders. Objective: We sought to investigate whether genetic abnormalities in the regulatory regions of the IL18 gene predispose, in part, to susceptibility to atopy. Methods: Among a white population of 105 families, the oldest child was examined with regard to atopic phenotypes and single-nucleotide polymorphisms (SNPs) within the IL18 gene. Results: We have identified 5 novel SNPs in the IL18 gene (-920[t/c],-133[c/g],and-132[a/g] in promoter 2 [upstream of exon 2]; +179[c/a; Ser35Ser] in exon 4; and +486[c/t; Phe137Phe] in exon 6). Three SNPs are located in promoter 2, and one (-133[c/g]; nuclear factor I site) was significantly associated with high serum IgE levels (P = .001; odds ratio, 3.96) and specific sensitization to common allergens (P = .005; OR, 4.12). In addition, previously identified SNPs in exon I (+113[t/g] and +127[c/t]) and in promoter I (-137[g/c], GATA3 site) of the IL18 gene were significantly associated with high IgE levels (P less than or equal to 005; OR, 3.27-3.90) and specific sensitization (P = .02 to.008; OR, 3.27-3.83). The SNP +127(g/t) in exon I was also a susceptibility locus for seasonal allergic rhinitis (P = .008; OR, 3.22). Conclusion: IL18 might be responsible for the linkage effects seen in the chromosomal region 11q22, which has been found previously with the phenotype "sensitization to mite allergen". Thus a suspected direct role of IL18 in the pathogenesis of atopy has been strengthened by the presence of 8 common SNPs in the promoter regions of IL18.	Univ Freiburg, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany; Univ Freiburg, Dept Phys, D-79106 Freiburg, Germany; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	University of Freiburg; University of Freiburg; Australian National University; John Curtin School of Medical Research	Mattes, J (corresponding author), Univ Freiburg, Dept Pediat & Adolescent Med, Mathildenstr 1, D-79106 Freiburg, Germany.		Moseler, Michael/AAV-4925-2021; Foster, Paul/G-5057-2013; MATTES, JOERG/M-5179-2019	Moseler, Michael/0000-0002-7064-1351; , Paul/0000-0002-0827-8299				Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; El-Mezzein REH, 2001, CLIN EXP IMMUNOL, V126, P193, DOI 10.1046/j.1365-2249.2001.01664.x; Giedraitis V, 2001, J NEUROIMMUNOL, V112, P146, DOI 10.1016/S0165-5728(00)00407-0; Heinzmann A, 2001, CURR OPIN ALLERGY CL, V1, P387, DOI 10.1097/01.all.0000011050.36626.ec; HIORT O, 1994, HUM MOL GENET, V3, P1163, DOI 10.1093/hmg/3.7.1163; Hoshino T, 2001, J IMMUNOL, V166, P7014, DOI 10.4049/jimmunol.166.12.7014; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Hurle B, 1998, GENOMICS, V52, P79, DOI 10.1006/geno.1998.5407; Kalina U, 2000, J IMMUNOL, V165, P1307, DOI 10.4049/jimmunol.165.3.1307; Kalina U, 2000, SCAND J IMMUNOL, V52, P525, DOI 10.1046/j.1365-3083.2000.00836.x; Kim YM, 1999, J IMMUNOL, V163, P2000; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; Kleinbaum DG, 1987, APPL REGRESSION ANAL; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Krohn K, 1999, J NEUROCHEM, V72, P1353, DOI 10.1046/j.1471-4159.1999.721353.x; Kruse S, 1999, IMMUNOLOGY, V96, P365; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; MEYERS DA, 1992, GENETIC BASIS COMMON; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Ober C, 2000, CLIN CHEST MED, V21, P245, DOI 10.1016/S0272-5231(05)70264-1; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; SAS, 1996, SAS STAT SOFTW CHANG; Seya T, 2001, INT J MOL MED, V8, P585; Tanaka H, 2001, J ALLERGY CLIN IMMUN, V107, P331, DOI 10.1067/mai.2001.112275; Tone M, 1997, J IMMUNOL, V159, P6156; Verhaeghe B, 2002, ALLERGY, V57, P825, DOI 10.1034/j.1398-9995.2002.23539.x; Wild JS, 2000, J IMMUNOL, V164, P2701, DOI 10.4049/jimmunol.164.5.2701; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811; Zhang YM, 1999, HUM MOL GENET, V8, P601, DOI 10.1093/hmg/8.4.601	36	104	118	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					117	122		10.1067/mai.2003.43	http://dx.doi.org/10.1067/mai.2003.43			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532106				2022-12-18	WOS:000180465500018
J	Sullivan, SD; Weiss, KB; Lynn, H; Mitchell, H; Kattan, M; Gergen, PJ; Evans, R				Sullivan, SD; Weiss, KB; Lynn, H; Mitchell, H; Kattan, M; Gergen, PJ; Evans, R		Natl Cooperative Inner City Asthma	The cost-effectiveness of an inner-city asthma intervention for children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CARE; MORBIDITY; TRIAL; EDUCATION	Background: Comprehensive management efforts to reduce asthma morbidity among children in urban areas with high levels of poverty and large minority populations have been inconclusive. The National Cooperative Inner-City Asthma Study (NCICAS) demonstrated improved symptom outcomes but did not evaluate cost-effectiveness in this population. Objective: We sought to examine the incremental cost-effectiveness of a comprehensive social worker-based education program and environmental control in children with asthma stratified by baseline level of asthma control. Methods: We performed a prospective cost-effectiveness analysis alongside a randomized trial. A total of 1033 children and their families residing in 8 inner-city urban areas in the United States were enrolled in the NCICAS. Outcomes included symptom-free days, cost per symptom-free day gained, and annual costs of asthma morbidity compared by baseline symptom control, previous hospitalization, and previous unscheduled physician visits. Results: The NCICAS intervention significantly reduced asthma symptoms. First-year intervention costs were $245 higher for the intervention children compared with those receiving usual care. There were no additional intervention-related costs during the second year. When compared with usual care, the intervention improved outcomes at an average additional cost of $9.20 per symptom-free day gained (95% CI, -$12.56 to $55.29). The intervention was cost saving in 3 strata of children with increasing asthma severity. Conclusions: A multifaceted asthma intervention program reduced symptom days and was cost-effective for inner-city children with asthma. In children with more severe disease, the intervention was substantially more effective and reduced costs compared with that seen in control children. Organizations serving this population should consider this strategy as part of a comprehensive disease-management program for asthma.	Univ Washington, Dept Pharm, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Hines VA Hosp, Midw Ctr Hlth Serv & Policy Res, Hines, IL USA; Rho Inc, Chapel Hill, NC USA; Mt Sinai Sch Med, New York, NY USA; Agcy Healthcare Res & Qual, Washington, DC USA; Childrens Mem Hosp, Chicago, IL 60614 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Rho; Icahn School of Medicine at Mount Sinai; Agency for Healthcare Research & Quality; Ann & Robert H. Lurie Children's Hospital of Chicago	Sullivan, SD (corresponding author), Univ Washington, Dept Pharm, Box 357630, Seattle, WA 98195 USA.		Nurmagambetov, Tursynbek/A-5689-2012		NIAID NIH HHS [N01 AI-15105, AI-30752, AI-30756, U01 AI-30751, AI-30780, AI-30773-01, AI-30777, AI-30779] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030779, U01AI030756, N01AI015105, U01AI030777, U01AI030780, U01AI030773, U01AI030752, U01AI030751] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Briggs A, 2000, BRIT MED J, V320, P246, DOI 10.1136/bmj.320.7229.246; Briggs AH, 1999, HEALTH ECON, V8, P257, DOI 10.1002/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO;2-E; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; Efron B., 1994, MONOGR STAT APPL PRO, DOI DOI 10.1007/978-1-4899-4541-9; Evans D, 1997, PEDIATRICS, V99, P157, DOI 10.1542/peds.99.2.157; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Gold MR, 1996, COST EFFECTIVENESS H; Grant E N, 1999, Curr Opin Pulm Med, V5, P27, DOI 10.1097/00063198-199901000-00005; Greineder DK, 1999, J ALLERGY CLIN IMMUN, V103, P436, DOI 10.1016/S0091-6749(99)70468-9; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; LEWIS CE, 1984, PEDIATRICS, V74, P478; Lozano P, 1999, PEDIATR ANN, V28, P74, DOI 10.3928/0090-4481-19990101-13; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; Schneider S L, 1997, Nurs Manage, V28, P40; SULLIVAN S, 1996, AM J RESP CRIT CAR S, V154, P84; *US DEP HHS, 2000, ACT ASTHM; Weil CM, 1999, PEDIATRICS, V104, P1274, DOI 10.1542/peds.104.6.1274; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; WIGAL J K, 1990, Pediatric Asthma Allergy and Immunology, V4, P17, DOI 10.1089/pai.1990.4.17; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T	22	104	107	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					576	581		10.1067/mai.2002.128009	http://dx.doi.org/10.1067/mai.2002.128009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373264				2022-12-18	WOS:000178501900006
J	Makabe-Kobayashi, Y; Hori, Y; Adachi, T; Ishigaki-Suzuki, S; Kikuchi, Y; Kagaya, Y; Shirato, K; Nagy, A; Ujike, A; Takai, T; Watanabe, T; Ohtsu, H				Makabe-Kobayashi, Y; Hori, Y; Adachi, T; Ishigaki-Suzuki, S; Kikuchi, Y; Kagaya, Y; Shirato, K; Nagy, A; Ujike, A; Takai, T; Watanabe, T; Ohtsu, H			The control effect of histamine on body temperature and respiratory function in IgE-dependent systemic anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; mast cells; allergy; knockout; histamine; histidine decarboxylase; body temperature; respiration; blood pressure; bronchial asthma	PLATELET-ACTIVATING-FACTOR; MAST-CELL DEGRANULATION; FC-GAMMA-RIII; MICE LACKING; RECEPTORS; INJECTION; METABOLISM; RESPONSES; PLASMA	Background: The systemic anaphylaxis reaction comprises various symptoms, including hypotension, changes in respiration pattern, and hypothermia. Objective: To elucidate the role of histamine in each of these symptoms, we induced the passive systemic anaphylaxis reaction in histidine decarboxylase gene knockout (HDC [-/-]) mice, which lack histamine. Methods: HDC(-/-) mice were generated by knocking out the HDC gene, which codes for the unique histamine-synthesizing enzyme. Twenty-four hours after the injection of IgE, HDC(+/+) and HDC(-/-) mice were injected with allergen and body temperature, blood pressure, and respiratory function were monitored in each mouse. Results: Blood pressure dropped in both the HDC(-/-) mice and the HDC(+/+) mice. In contrast, respiratory frequency dropped and the expiratory respiration time was elongated only in the HDC(+/+) mice. Body temperature was decreased in the HDC(+/+) mice and was practically unchanged in the HDC(-/-) mice. Histamine receptor antagonists blocked the body temperature drop in the HDC(+/+) mice. Intravenous histamine induced similar patterns of body temperature decrease in the HDC(+/+) mice and the HDC(-/-) mice. Mast cell-deficient W/W-v mice did not show the decrease in body temperature; this suggests that the histamine that contributed to the decrease in body temperature was derived from mast cells. Conclusion: According to the results of this investigation, in the passive systemic anaphylaxis reaction, respiratory frequency, expiratory time, and body temperature are shown to be controlled by the activity of histamine, but its contribution to blood pressure is negligible.	Tohoku Univ, Grad Sch Med, Dept Cellular Pharmacol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Resp & Infect Dis, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Expt Immunol, Sendai, Miyagi 980, Japan; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Tohoku University; Tohoku University; Tohoku University; Tohoku University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Ohtsu, H (corresponding author), Tohoku Univ, Grad Sch Med, Dept Cellular Pharmacol, Aoba Ku, Seiryo Cho 2-1, Sendai, Miyagi 9808575, Japan.		Nagy, Andras/G-6465-2013; Li, Yapeng/N-1042-2017	Nagy, Andras/0000-0003-4311-0413; Li, Yapeng/0000-0002-5042-6881; Kikuchi, Yoshihiro/0000-0002-3262-3881				BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; Chen Z, 1995, METHOD FIND EXP CLIN, V17, P669; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; EPSTEIN MAF, 1978, RESP PHYSIOL, V32, P105, DOI 10.1016/0034-5687(78)90103-2; FROESE A, 1984, PROG ALLERGY, V34, P142; HOFFMAN DR, 1986, BIOCHIM BIOPHYS ACTA, V879, P88, DOI 10.1016/0005-2760(86)90270-5; IRMANFLORJANC T, 1994, AGENTS ACTIONS, V41, pC129, DOI 10.1007/BF02007797; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; Kaneko M, 2000, J ALLERGY CLIN IMMUN, V105, P1202, DOI 10.1067/mai.2000.106731; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KLEINETEBBE J, 1995, J IMMUNOL METHODS, V179, P153, DOI 10.1016/0022-1759(94)00279-6; KUNIEVSKY B, 1994, J NEUROCHEM, V63, P2144; Li JTC, 1996, ANN ALLERG ASTHMA IM, V76, P1, DOI 10.1016/S1081-1206(10)63400-X; Lieberman P., 1998, ANAPHYLAXIS ANAPHYLA, V5th; MARTIN TR, 1989, J CLIN INVEST, V83, P1375, DOI 10.1172/JCI114025; MARTINEZALMAGRO A, 1993, SURG RADIOL ANAT, V15, P1, DOI 10.1007/BF01629852; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MURDOCH RD, 1993, BRIT J CLIN PHARMACO, V35, P171, DOI 10.1111/j.1365-2125.1993.tb05682.x; Nagai H, 2000, J ALLERGY CLIN IMMUN, V106, pS91, DOI 10.1067/mai.2000.106778; Ohtsu H, 2001, FEBS LETT, V502, P53, DOI 10.1016/S0014-5793(01)02663-1; OHTSU H, 2002, IN PRESS EUR J IMMUN; ONEILL C, 1992, REPROD FERT DEVELOP, V4, P283, DOI 10.1071/RD9920283; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; PENG ZK, 1994, INT ARCH ALLERGY IMM, V104, P204, DOI 10.1159/000236731; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sakata T, 1997, INFLAMM RES, V46, pS35, DOI 10.1007/s000110050046; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; TANKERSLEY CG, 1994, AM J PHYSIOL-REG I, V267, pR1371, DOI 10.1152/ajpregu.1994.267.5.R1371; TANKERSLEY CG, 1993, J APPL PHYSIOL, V75, P2613, DOI 10.1152/jappl.1993.75.6.2613; Tankersley CG, 2000, J APPL PHYSIOL, V88, P2310, DOI 10.1152/jappl.2000.88.6.2310; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485	35	104	105	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					298	303	UNSP 1/87/125977	10.1067/mai.2002.125977	http://dx.doi.org/10.1067/mai.2002.125977			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170272				2022-12-18	WOS:000177509800016
J	Vartiainen, E; Petays, T; Haahtela, T; Jousilahti, P; Pekkanen, J				Vartiainen, E; Petays, T; Haahtela, T; Jousilahti, P; Pekkanen, J			Allergic diseases, skin prick test responses, and IgE levels in North Karelia, Finland, and the Republic of Karelia, Russia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; epidemiology; Finland; IgE; Russia; skin prick test	RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; ATOPIC SENSITIZATION; SERUM IGE; PREVALENCE; CHILDREN; GERMANY; ADULTS; URBAN; WEST	Background: There is growing evidence to show that atopic diseases are more common in Western Europe than in the former socialist countries of Eastern Europe. Objective: The aim of this study was to assess whether a similar difference exists between the most eastern province of Finland and a neighboring western district of Russia. Methods: A random sample of 25- to 54-year-old subjects was taken from the population registers in the North Karelia Province in eastern Finland and from the Pitkaranta district across the border in the western part of Russia. Participants filled out a questionnaire on atopic and allergic symptoms and participated in a clinical study, which included skin prick tests with 11 airborne allergens and IgE measurements. Results: Self-reported hay fever, allergic eye symptoms, atopic eczema, and asthma were much more common in Finland than in Russia. In Finland 34.2% and in Russia 21.8% had at least one positive skin prick test reaction. In Finland 21.5% but in Russia only 15.8% had at least one elevated allergen-specific IgE value of the 5 values measured. From 6% to 47% of the differences in self-reported symptoms between the countries were explained by atopy, as measured by means of skin prick testing or specific IgE values. Conclusions: A major difference in clinical allergic diseases and signs of symptoms was observed between the 2 geographically adjacent areas. This suggests that the difference in clinical allergy and atopic disposition is related to the differences in lifestyle and environmental factors.	Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, FIN-00300 Helsinki, Finland; Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland	Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital	Vartiainen, E (corresponding author), Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Mannerheimintie 166, FIN-00300 Helsinki, Finland.							[Anonymous], 1989, ALLERGY S10, V10, P1; Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Braback Lennart, 1995, Archives of Disease in Childhood, V72, P487; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; CULLINAN P, 1988, THORAX, V43, P949, DOI 10.1136/thx.43.12.949; Gassner M, 1992, Schweiz Rundsch Med Prax, V81, P426; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; JACKSON RT, 1983, NZ MED J, V96, P727; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; NEWMANTAYLOR A, 1995, LANCET, V345, P296, DOI 10.1016/S0140-6736(95)90280-5; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; PEAT JK, 1992, BMJ-BRIT MED J, V305, P1326, DOI 10.1136/bmj.305.6865.1326; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; PEAT JK, 1995, MED J AUSTRALIA, V163, P22, DOI 10.5694/j.1326-5377.1995.tb126083.x; PUSKA P, 1995, N KARELIA PROJECT 20; Vartiainen E, 2000, INT J EPIDEMIOL, V29, P49, DOI 10.1093/ije/29.1.49; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; Wieringa MH, 1997, EUR RESPIR J, V10, P1460, DOI 10.1183/09031936.97.10071460; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; 1996, CLIN EXP ALLERGY S1, V26, P1	33	104	108	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					643	648		10.1067/mai.2002.123307	http://dx.doi.org/10.1067/mai.2002.123307			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941314				2022-12-18	WOS:000175132600012
J	Chauhan, B; Santiago, L; Hutcheson, PS; Schwartz, HJ; Spitznagel, E; Castro, M; Slavin, RG				Chauhan, B; Santiago, L; Hutcheson, PS; Schwartz, HJ; Spitznagel, E; Castro, M; Slavin, RG			Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MHC class II; polymorphism; alleles; susceptibility; resistance; immune response; allergic bronchopulmonary aspergillosis	COLLAGEN-INDUCED ARTHRITIS; HUMAN IMMUNE-RESPONSE; HLA-DR; RHEUMATOID-ARTHRITIS; TRANSGENIC MICE; POSITIVE ASSOCIATION; INTERFERON-GAMMA; CYSTIC-FIBROSIS; T-CELLS; POLYMORPHISM	Background: Allergic bronchopulmonary aspergillosis (ABPA) is a disease with uncertain pathology. Studies have suggested a pathogenic role for T(H)2 cells. Previously, we demonstrated, in a small group of patients, that T(H)2 reactivity to a major Aspergillus fumigatus antigen was restricted by HLA-DR2 or HLA-DR5 alleles. Objectives: We sought to confirm whether susceptibility to ABPA is exclusively associated with HLA-DR locus and to investigate the involvement of HLA-DQ genes in the development of ABPA. Methods: Genomic DNA was extracted from patients with ABPA, patients without ABPA but with positive A fumigatus skin test responses and asthma or cystic fibrosis, and healthy control subjects. HLA-DR and HLA-DQ genes were detected by using low-resolution typing; high-resolution typing was done only on HLA-DR2- and HLA-DR5-positive individuals by using sequence-specific primers (PCR-SSP). Results: A significantly higher frequency of HLA-DR2 was observed in patients with ABPA versus those without ABPA (corrected P < .01) or healthy control subjects (corrected P < .01). Genotype analysis revealed that susceptibility to ABPA is associated with HLA-DR2 alleles DRB1*1503 and DRB1*1501 and, to a lesser extent, with the HLA-DR5 allele DRB1*1104. The presence of DR4 or DR7 alleles in non-DR2/5 patients with ABPA suggests that these alleles may also be contributing factors in this disease. Another striking observation was the significantly high frequency of HLA-DQ2 in patients without ABPA (67.4%) compared with patients with ABPA (20.5%) and normal control subjects (37.7%), suggesting that these alleles may confer protection in the population without ABPA. Conclusion: These genetic studies suggest that HLA-DR molecules DR2, DR5, and possibly DR4 or DR7 contribute to susceptibility while HLA-DQ2 contributes to resistance and that a combination of these genetic elements determines the outcome of ABPA in patients with cystic fibrosis and asthma.	St Louis Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Surg, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; Case Western Reserve Univ, Dept Med, Sch Med, Cleveland, OH 44106 USA; St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO USA; St Louis Univ, Sch Med, Dept Surg, St Louis, MO USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; Washington Univ, Dept Math, St Louis, MO 63130 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Saint Louis University; Case Western Reserve University; Saint Louis University; Saint Louis University; Saint Louis University; Case Western Reserve University; Washington University (WUSTL); Washington University (WUSTL)	Chauhan, B (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, 1402 S Grand Blvd,R209, St Louis, MO 63104 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043626] Funding Source: NIH RePORTER; NIAID NIH HHS [5RO1AI43626-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSARI AA, 1989, HUM IMMUNOL, V25, P59, DOI 10.1016/0198-8859(89)90070-0; Aron Y, 1999, J ALLERGY CLIN IMMUN, V104, P891, DOI 10.1016/S0091-6749(99)70306-4; Aron Y, 1996, CLIN EXP ALLERGY, V26, P821, DOI 10.1111/j.1365-2222.1996.tb00614.x; Aron Y, 1999, AM J RESP CRIT CARE, V159, P1464, DOI 10.1164/ajrccm.159.5.9807046; BLUMENTHAL M, 1985, J ALLERGY CLIN IMMUN, V75, P155, DOI 10.1016/0091-6749(85)90338-0; Bradley DS, 1997, J CLIN INVEST, V100, P2227, DOI 10.1172/JCI119760; CARBADA B, 1993, HUMAN IMMUNOL, V38, P293; Chauhan B, 1997, J IMMUNOL, V159, P4072; Chauhan B, 1996, J CLIN INVEST, V97, P2324, DOI 10.1172/JCI118675; Del Prete G, 1991, Allerg Immunol (Paris), V23, P239; FREIDHOFF LR, 1988, TISSUE ANTIGENS, V31, P211, DOI 10.1111/j.1399-0039.1988.tb02083.x; Guardiola J, 1996, TISSUE ANTIGENS, V48, P615, DOI 10.1111/j.1399-0039.1996.tb02684.x; KHURANA HGK, 1997, NEW ENGL J MED, V337, P1720; Krco CJ, 1999, J IMMUNOL, V163, P1661; KUMAR V, 1995, P NATL ACAD SCI USA, V92, P9510, DOI 10.1073/pnas.92.21.9510; Leitenberg D, 1999, SEMIN IMMUNOL, V11, P283, DOI 10.1006/smim.1999.0184; MARSH DG, 1989, COLD SPRING HARB SYM, V54, P459; MARSH DG, 1987, IMMUNOGENETICS, V26, P230, DOI 10.1007/BF00346517; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1990, GENETIC ENV FACTORS, P97; MARSH DG, 1992, 11TH P INT HIST WORK, V1, P765; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MURRAY JS, 1989, J EXP MED, V170, P2135, DOI 10.1084/jem.170.6.2135; Nepom BS, 1996, P NATL ACAD SCI USA, V93, P7202, DOI 10.1073/pnas.93.14.7202; NILSEN EM, 1995, GUT, V37, P766, DOI 10.1136/gut.37.6.766; OBRIEN RM, 1995, IMMUNOLOGY, V86, P176; PATTERSON R, 1987, J ALLERGY CLIN IMMUN, V80, P663, DOI 10.1016/0091-6749(87)90285-5; Raju R, 1997, HUM IMMUNOL, V58, P21, DOI 10.1016/S0198-8859(97)00212-7; REID MJ, 1992, J ALLERGY CLIN IMMUN, V89, P593, DOI 10.1016/0091-6749(92)90327-X; Rosenwasser LJ, 1997, AM J RESP CRIT CARE, V156, pS152, DOI 10.1164/ajrccm.156.4.12tac-14; Schountz T, 1996, J IMMUNOL, V157, P3893; Senechal H, 1999, J ALLERGY CLIN IMMUN, V104, P395, DOI 10.1016/S0091-6749(99)70384-2; SIMON M, 1992, P 11 INT HIST WORKSH, P660; Skov M, 1999, PEDIATR PULM, V27, P74, DOI 10.1002/(SICI)1099-0496(199902)27:2<74::AID-PPUL2>3.0.CO;2-L; Song ZM, 1996, J IMMUNOL, V156, P424; SVEJGAAR.A, 1974, TISSUE ANTIGENS, V4, P95; Taneja V, 1997, INT IMMUNOL, V9, P1213, DOI 10.1093/intimm/9.8.1213; TERASAKI PI, 1997, HLA 1997, P330; van der Horst-Bruinsma IE, 1999, HUM IMMUNOL, V60, P152, DOI 10.1016/S0198-8859(98)00101-3; Wen L, 2000, J EXP MED, V191, P97, DOI 10.1084/jem.191.1.97; Yasunaga S, 1996, TISSUE ANTIGENS, V47, P37, DOI 10.1111/j.1399-0039.1996.tb02512.x; Zanelli E, 1997, J IMMUNOL, V158, P3545	42	104	108	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					723	729		10.1067/mai.2000.109913	http://dx.doi.org/10.1067/mai.2000.109913			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031343				2022-12-18	WOS:000089980600016
J	Ziment, I; Tashkin, DP				Ziment, I; Tashkin, DP			Alternative medicine for allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; alternative medicine; herbal therapy; homeopathic remedies; acupuncture; marijuana; psychologic therapies	EXERCISE-INDUCED ASTHMA; BRONCHIAL-ASTHMA; CONTROLLED TRIAL; SIMULATED ACUPUNCTURE; HERBAL MEDICINE; HOMEOPATHY; MARIJUANA; REAL; DELTA-9-TETRAHYDROCANNABINOL; MANAGEMENT	'Orthodox medical approaches to asthma and allergic respiratory diseases are provided in guidelines developed by professional societies and national or state organizations that represent organized medicine. Alternative therapies may include such orthodox medical therapies as obsolescent formerly used agents, unusual but accepted agents, and agents that are in favor for orthodox therapy in other countries. However, the current growth of complementary and alternative medicine is based on the use of nonorthodox remedies that are becoming increasingly popular with patients and that should be familiar to physicians. Asthma and allergies are frequently treated with such remedies by patients, either as part of self-therapy or on the advice of a complementary and alternative medicine practitioner, The most popular alternative medical treatments are herbs (Western and Asiatic), acupuncture, various types of body manipulation, psychologic therapies, homeopathy, and unusual allergy therapies. There is little evidence in favor of most of these unorthodox treatments, although they are very often reported on favorably by patients, The published evidence that might support some alternative medical practices is reviewed so as to help physicians select alternatives that could appropriately be integrated into orthodox practice.	Olive View UCLA Med Ctr, Dept Med 2B182, Sylmar, CA 91342 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ziment, I (corresponding author), Olive View UCLA Med Ctr, Dept Med 2B182, 14445 Olive View Dr, Sylmar, CA 91342 USA.							ALDRICH M, 1999, CANNABIS MED PRACTIC, P35; Baker JC, 1999, THORAX, V54, P115, DOI 10.1136/thx.54.2.115; BATLON J, 1998, NEW ENGL J MED, V339, P1013; BAUER K, 1993, CLIN PHARMACOL THER, V53, P76, DOI 10.1038/clpt.1993.11; BERGER D, 1977, COMP MED EAST WEST, V5, P265, DOI 10.1142/S0147291777000374; Bielory L, 1999, J ASTHMA, V36, P1, DOI 10.3109/02770909909065150; Blumenthal M., 1998, COMPLETE GERMAN COMM; Bodner C, 1999, EUR RESPIR J, V13, P22, DOI 10.1183/09031936.99.13102299; But P, 1996, CLIN REV ALLERG IMMU, V14, P253; CHOW OKW, 1983, LUNG, V161, P321, DOI 10.1007/BF02713881; CHRISTENSEN PA, 1984, ALLERGY, V39, P379, DOI 10.1111/j.1398-9995.1984.tb01956.x; CONNETT GJ, 1994, BRIT MED J, V308, P1282, DOI 10.1136/bmj.308.6939.1282; COSMAN MP, 1983, ANNU REV NUTR, V3, P1, DOI 10.1146/annurev.nu.03.070183.000245; CUTLER EW, 1998, WINNING WAR ASTHMA A; DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0; DIAS PLR, 1982, J ROY SOC MED, V75, P245; DICKEY W, 1994, LANCET, V344, P1585, DOI 10.1016/S0140-6736(94)90400-6; Fogarty A, 2000, Curr Opin Pulm Med, V6, P86, DOI 10.1097/00063198-200001000-00015; FUGHBERMAN A, 1997, ALTERNATIVE MED WHAT; FUNG KP, 1986, LANCET, V2, P1419; GAIER H, 1991, THORSONS ENCY DICT H, P27; Gershwin ME, 1996, CLIN REV ALLERG IMMU, V14, P241; GONG H, 1983, J CLIN PHARMACOL, V23, P127, DOI 10.1002/j.1552-4604.1983.tb02715.x; GONG H, 1984, CLIN PHARMACOL THER, V35, P26, DOI 10.1038/clpt.1984.4; Gupta I, 1998, Eur J Med Res, V3, P511; HARTLEY JPR, 1978, BRIT J CLIN PHARMACO, V5, P523, DOI 10.1111/j.1365-2125.1978.tb01667.x; HOFFMANN D, 1975, P63; Ishizaki T, 1996, EUR RESPIR J, V9, P2691, DOI 10.1183/09031936.96.09122691; *JAP SOC ALL, 1995, ALLERGY, V50, P16; Jobst K A, 1996, J Altern Complement Med, V2, P179, DOI 10.1089/acm.1996.2.179; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; Landwehr LP, 1998, CHEST, V114, P1349, DOI 10.1378/chest.114.5.1349; LANE DJ, 1994, J ASTHMA, V31, P153, DOI 10.3109/02770909409044821; LEHRER PM, 1994, J BEHAV MED, V17, P1, DOI 10.1007/BF01856879; Lewith GT, 1998, THORAX, V53, P898, DOI 10.1136/thx.53.10.898; Lewith GT, 1996, ALLERGY, V51, P761, DOI 10.1111/j.1398-9995.1996.tb04464.x; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Lockie A., 1995, COMPLETE GUIDE HOMEO; LUU M, 1985, RESPIRATION, V48, P340, DOI 10.1159/000194848; Malka S, 1996, CLIN REV ALLERG IMMU, V14, P271; Mann R D, 1984, MODERN DRUG USE ENQU; MATHERLOUGHNAN GP, 1968, BMJ-BRIT MED J, V2, P71; Matsuda LA, 1997, CRIT REV NEUROBIOL, V11, P143, DOI 10.1615/CritRevNeurobiol.v11.i2-3.30; MITCHELL P, 1989, AM J ACUPUNCTURE, V17, P5; ORZELEKONEIL RM, 1980, ARCH INT PHARMACOD T, V246, P71; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; REILLY DT, 1986, LANCET, V2, P881; Reuther I, 1998, J ALTERN COMPLEM MED, V4, P173, DOI 10.1089/acm.1998.4.173; Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005; Roth MD, 1998, AM J RESP CRIT CARE, V157, P928, DOI 10.1164/ajrccm.157.3.9701026; SAKULA A, 1988, J ROY COLL PHYS LOND, V22, P36; Sastre J, 1996, ALLERGY, V51, P117, DOI 10.1111/j.1398-9995.1996.tb04568.x; Schulz V., 1998, RATIONAL PHYTOTHERAP, V3rd ed.; Segen J. C., 1998, DICT ALTERNATIVE MED; Shapiro B, 1976, PHARM MARIJUANA, P277; SHAPIRO BJ, 1977, CHEST, V71, P558, DOI 10.1378/chest.71.4.558b; Singer A, 1998, J ALTERN COMPLEM MED, V4, P132; SINGH V, 1990, LANCET, V335, P1381, DOI 10.1016/0140-6736(90)91254-8; Smoller JW, 1996, AM J RESP CRIT CARE, V154, P6, DOI 10.1164/ajrccm.154.1.8680700; Smyth JM, 1999, JAMA-J AM MED ASSOC, V281, P1304, DOI 10.1001/jama.281.14.1304; STANESCU DC, 1981, J APPL PHYSIOL, V51, P1625, DOI 10.1152/jappl.1981.51.6.1625; TAKISHIMA T, 1982, ANN ALLERGY, V48, P44; TANDON MK, 1989, CHEST, V96, P102, DOI 10.1378/chest.96.1.102; TASHKIN DP, 1985, J ALLERGY CLIN IMMUN, V76, P855, DOI 10.1016/0091-6749(85)90760-2; Tashkin DP, 1999, SCHOOL PSYCHOL INT, V20, P23, DOI 10.1177/0143034399201003; TASHKIN DP, 1974, AM REV RESPIR DIS, V109, P420; TASHKIN DP, 1977, ANN ALLERGY, V39, P379; TASHKIN DP, 1973, NEW ENGL J MED, V289, P336, DOI 10.1056/NEJM197308162890702; TASHKIN DP, 1977, AM REV RESPIR DIS, V115, P57; TASHKIN DP, 1975, AM REV RESPIR DIS, V112, P377; TASHKIN DP, 1993, WESTERN J MED, V158, P635; TERR AI, 1993, ALLERGY PRINCIPLES P, P1767; TYLER ML, POINTERS COMMON REME; VACHON L, 1973, NEW ENGL J MED, V288, P985, DOI 10.1056/NEJM197305102881902; Vallance AK, 1998, J ALTERN COMPLEM MED, V4, P49, DOI 10.1089/acm.1998.4.1-49; Villani F, 1998, RESPIRATION, V65, P265, DOI 10.1159/000029274; VIRSIK K, 1980, PROG RESPIR RES, V14, P271; WATANABE K, 1994, J ETHNOPHARMACOL, V43, P191, DOI 10.1016/0378-8741(94)90042-6; WATSON P, 1997, ASTHMA, P567; WILLIAMS SJ, 1976, THORAX, V31, P720, DOI 10.1136/thx.31.6.720; YU DYC, 1976, CLIN SCI MOL MED, V51, P503, DOI 10.1042/cs0510503; Zhang ZF, 1999, CANCER EPIDEM BIOMAR, V8, P1071; ZIMENT I, 1986, Respiratory Care, V31, P117; Ziment I, 1997, Curr Opin Pulm Med, V3, P61, DOI 10.1097/00063198-199701000-00010; ZIMENT I, 1998, J RESPIR DIS, V19, P630; Ziment I., 1978, RESP PHARM THERAPEUT; ZIMENT I, 1997, ASTHMA, P1689; ZIMENT I, 1992, AM J ASTHMA ALLERGY, V5, P155; ZIMENT L, 1998, J RESPIR DIS, V19, P1070	90	104	105	5	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					603	614		10.1067/mai.2000.109432	http://dx.doi.org/10.1067/mai.2000.109432			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031328	Bronze			2022-12-18	WOS:000089980600001
J	Shoseyov, D; Bibi, H; Shai, P; Shoseyov, N; Shazberg, G; Hurvitz, H				Shoseyov, D; Bibi, H; Shai, P; Shoseyov, N; Shazberg, G; Hurvitz, H			Treatment with hypertonic saline versus normal saline nasal wash of pediatric chronic sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hypertonic saline; chronic sinusitis	CHILDREN; DIAGNOSIS; CILIA	Background: Chronic sinusitis (CS) is a common disease in children, especially those with allergies, that is caused by impaired drainage from the sinuses. Hypertonic NaCl solution has been shown to increase mucociliary clearance and ciliary beat frequency. Objective: We performed a randomized double blind study to compare the effect of nasal wash with hypertonic saline (HS) (3.5%) versus normal saline (NS) (0.9%) on CS. Methods: Thirty patients with CS aged 3 to 16 Sears were studied. They were randomly divided into two treatment groups matched by age and severity of the disease. Each individual was treated with either HS or NS for 4 weeks. All patients were evaluated by two clinical scores (cough and nasal secretions/postnasal drip [PND]) and by a radiology score at the beginning of the study and after 4 weeks. Results: The HS group improved significantly in all scores (average +/- SD): cough score, from 3.6 +/- 0.51 to 1.6 +/- 0.74; nasal secretion/PND score, from 2.86 +/- 0.35 to 1.6 +/- 0.74; and radiology score, from 8.06 +/- 1.28 to 2.66 +/- 1.04. The NS treatment group showed significant improvement only in the PND score (from 2.66 +/- 0.49 to 1.53 +/- 0.83) but no significant change in both the cough score (from 3.53 +/- 0.52 to 3.33 +/- 0.49) and the radiology score (from 8.13 +/- 1.25 to 7.86 +/- 0.91). Clinical observation 1 month after the end of the study showed no change compared with the end of the study in both groups. Conclusion: HS nasal wash is an efficient treatment of CS.	Hadassah Med Sch, Bikur Cholim Hosp, Dept Pediat, Ped Pulmonol Clin, IL-91004 Jerusalem, Israel; Barzilai Govt Hosp, Ashkelon, Israel; SHIRAM Asaf Harofe Med Ctr, Zerifin, Israel; Kupat Cholim Klalit, Family Med Clin Havazelet, Rehovot, Israel	Hebrew University of Jerusalem; Ben Gurion University; Barzilai Medical Center	Shoseyov, D (corresponding author), Hadassah Med Sch, Bikur Cholim Hosp, Dept Pediat, Ped Pulmonol Clin, Strauss St 5, IL-91004 Jerusalem, Israel.							DEVICES E, 1996, EUR RESPIR J, V9, P725; DIAMENT MJ, 1992, J ALLERGY CLIN IMMUN, V90, P442, DOI 10.1016/0091-6749(92)90166-Y; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.3.CO;2-R; EVELOFF JL, 1987, AM J PHYSIOL, V252, pF1, DOI 10.1152/ajprenal.1987.252.1.F1; FOLKESSON HG, 1994, AM J RESP CRIT CARE, V150, P1555, DOI 10.1164/ajrccm.150.6.7952614; LANSLEY AB, 1992, AM J PHYSIOL, V263, pL232, DOI 10.1152/ajplung.1992.263.2.L232; LAZAR RH, 1992, OTOLARYNG HEAD NECK, V107, P29, DOI 10.1177/019459989210700105; LOTHIAN P, 1993, LANCET, V341, P182; MANGETE EDO, 1992, LANCET, V340, P1351, DOI 10.1016/0140-6736(92)92533-L; MANNING SC, 1994, ARCH OTOLARYNGOL, V120, P1142; NGUYEN KL, 1993, J ALLERGY CLIN IMMUN, V92, P824, DOI 10.1016/0091-6749(93)90059-O; OTT NL, 1991, MAYO CLIN PROC, V66, P1238, DOI 10.1016/S0025-6196(12)62475-6; PAVIA D, 1978, AM REV RESPIR DIS, V117, P199; Reimer A, 1978, Acta Otolaryngol Suppl, V356, P1; ROS SP, 1995, PEDIATR RADIOL, V25, P306, DOI 10.1007/BF02011109; SHAPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417, DOI 10.1016/0091-6749(92)90160-4; SLAVIN RG, 1986, J RESPIR DIS, V7, P61; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, P1291; TOSKALA E, 1995, J LARYNGOL OTOL, V109, P509, DOI 10.1017/S0022215100130580; WALD ER, 1991, PEDIATRICS, V87, P129; WALD ER, 1992, J ALLERGY CLIN IMMUN, V90, P469, DOI 10.1016/0091-6749(92)90171-W; WALD ER, 1993, PEDIAT REV, V326, P319; ZEIGER RS, 1992, J ALLERGY CLIN IMMUN, V90, P478, DOI 10.1016/0091-6749(92)90173-Y	23	104	114	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					602	605		10.1016/S0091-6749(98)70166-6	http://dx.doi.org/10.1016/S0091-6749(98)70166-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600495				2022-12-18	WOS:000073697400006
J	Fuchs, T; Spitzauer, S; Vente, C; Hevler, J; Kapiotis, S; Rumpold, H; Kraft, D; Valenta, R				Fuchs, T; Spitzauer, S; Vente, C; Hevler, J; Kapiotis, S; Rumpold, H; Kraft, D; Valenta, R			Natural latex, grass pollen, and weed pollen share IgE epitopes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; timothy grass pollen; mugwort pollen; ragweed pollen; IgE; cross-reactivity	RUBBER ELONGATION-FACTOR; PLANT-DERIVED FOOD; HEVEA-BRASILIENSIS; CROSS-REACTIVITY; MAJOR ALLERGEN; IMMUNOBLOT INHIBITION; CONTACT URTICARIA; IDENTIFICATION; PROTEINS; ANTIBODIES	Background: Because of the frequent use of natural latex products, IgE-mediated reactions to latex proteins represent an important health threat in industrialized countries, Although several latex allergens have been characterized and IgE cross-reactivities with allergens present in plant-derived food have been described, limited information is available regarding the presence of common IgE-binding components in latex and plant pollen, Methods: By using serum IgE from 56 individuals with latex allergy, the IgE-binding components in ammoniated latex milk and latex glove extracts were characterized by immunoblotting. The presence of cross-reactive IgE-binding components in the different latex extracts, extracts from mugwort, ragweed, timothy grass pollen, and recombinant birch pollen allergens (Bet v 1 and Bet v 2 [birch profilin]) was studied by immunoblot inhibitions and quantitative competition experiments. The involvement of carbohydrates in the constitution of cross-reactive IgE epitopes was studied by periodate treatment of extracts. Results: Although sera from certain individuals with latex allergy showed IgE reactivity with protein bands of different molecular weights in Western-blotted latex milk and glove extracts, both extracts contained common IgE epitopes. Although preincubation with recombinant Bet vl and Bet v 2 did not significantly inhibit IgE binding to latex proteins, weed and, in particular, timothy grass pollen extract strongly inhibited IgE binding to latex allergens, The cross-reactive IgE epitopes were sensitive to periodate treatment, Conclusions: Mugwort, ragweed, and timothy grass pollen share IgE epitopes with glycoprotein latex allergens, The presence of common epitopes might in part explain clinical symptoms in patients allergic to pollen on contact with latex.	UNIV VIENNA,AKH,INST GEN & EXPT PATHOL,A-1090 VIENNA,AUSTRIA; UNIV GOTTINGEN,DEPT DERMATOL,D-3400 GOTTINGEN,GERMANY; UNIV VIENNA,AKH,INST MED & CHEM LAB DIAGNOST,VIENNA,AUSTRIA; PHARMACIA & UPJOHN INC,FREIBURG,GERMANY	University of Vienna; University of Gottingen; University of Vienna; Pfizer				Valenta, Rudolf/0000-0001-5944-3365				AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; Akasawa A, 1996, J ALLERGY CLIN IMMUN, V97, P1116, DOI 10.1016/S0091-6749(96)70266-X; ALENIUS H, 1994, J ALLERGY CLIN IMMUN, V93, P859, DOI 10.1016/0091-6749(94)90378-6; Alenius H, 1996, INT ARCH ALLERGY IMM, V109, P362, DOI 10.1159/000237264; Alenius H, 1996, CLIN EXP ALLERGY, V26, P341, DOI 10.1046/j.1365-2222.1996.d01-312.x; Alenius H, 1996, J IMMUNOL, V156, P1618; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; BAUR X, 1995, ALLERGY, V50, P604, DOI 10.1111/j.1398-9995.1995.tb01208.x; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Cahaly Ralph J., 1995, Current Opinion in Pediatrics, V7, P671; CARRILLO T, 1995, J ALLERGY CLIN IMMUN, V96, P699, DOI 10.1016/S0091-6749(95)70273-3; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; Dreborg S., 1989, ALLERGY S10, V44, P31; Drouet M, 1994, Allerg Immunol (Paris), V26, P289; DROUET M, 1994, ALLERG IMMUNOL PARIS, V26, P295; FABRO L, 1989, HAUTARZT, V40, P208; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FROSCH PJ, 1986, CONTACT DERMATITIS, V14, P241, DOI 10.1111/j.1600-0536.1986.tb01233.x; FUCHS T, 1992, ALLERGY PROC, V13, P61, DOI 10.2500/108854192778878881; FUCHS T, 1994, J ALLERGY CLIN IMMUN, V93, P951, DOI 10.1016/0091-6749(94)90393-X; HADJILIADIS D, 1995, J ALLERGY CLIN IMMUN, V96, P431, DOI 10.1016/S0091-6749(95)70067-6; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; Kurup VP, 1996, INT ARCH ALLERGY IMM, V109, P58, DOI 10.1159/000237232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; LUNDBERG M, 1995, ALLERGY, V50, P378, DOI 10.1111/j.1398-9995.1995.tb01165.x; MAYERHAUSEN W, 1989, Z HAUTKRANKHEITEN, V64, P495; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER A, 1979, BRIT J DERMATOL, V101, P587; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1990, ANN ALLERGY, V65, P411; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURJANMAA K, 1989, ALLERGY, V44, P181, DOI 10.1111/j.1398-9995.1989.tb02259.x; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; WOODWARD MP, 1985, J IMMUNOL METHODS, V78, P143, DOI 10.1016/0022-1759(85)90337-0; YAGAMI T, 1995, J ALLERGY CLIN IMMUN, V96, P677, DOI 10.1016/S0091-6749(95)70267-9	56	104	110	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					356	364		10.1016/S0091-6749(97)70249-5	http://dx.doi.org/10.1016/S0091-6749(97)70249-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314348				2022-12-18	WOS:A1997XX47900013
J	Till, S; Dickason, R; Huston, D; Humbert, M; Robinson, D; Larche, M; Durham, S; Kay, AB; Corrigan, C				Till, S; Dickason, R; Huston, D; Humbert, M; Robinson, D; Larche, M; Durham, S; Kay, AB; Corrigan, C			IL-5 secretion by allergen-stimulated CD4+ T cells in primary culture: Relationship to expression of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; T cell; IL-5; asthma; rhinitis; atopy	CYTOKINE PRODUCTION; BRONCHIAL-ASTHMA; HUMAN EOSINOPHILS; ATOPIC ASTHMA; INTERLEUKIN-5; LYMPHOCYTES; ANTIBODIES; RESPONSES; PROFILE; TYPE-1	Background: IL-5-producing allergen-specific T cells are thought to play a prominent role in the pathogenesis of allergic inflammation, We hypothesized that T cell allergen-driven IL-5 synthesis is elevated in patients with atopic disease as compared with that in atopic patients free of disease and nonatopic control subjects. Objectives: The purpose of this study was to compare IL-5 and interferon-gamma (IFN-gamma) secretion and proliferation by peripheral blood T cells from sensitized atopic patients with asthma, rhinitis, and no symptoms and from nonatopic control subjects in response to the allergen Dermatophagoides pteronyssinus (Der p) and the control recall antigen Mycobacterium tuberculosis purified protein derivative (PPD). Methods: To measure allergen-induced IL-5 production and proliferation, me developed a short-term culture technique that required a single antigenic stimulation of freshly isolated peripheral blood mononuclear cells (PBMC), With this technique, we measured Der p- and PPD-induced IL-S production and proliferation in PBMC from atopic patients with asthma who were allergic to Der p, atopic patients with rhinitis, atopic patients with no symptoms, and a group of nonatopic normal control subjects. In four experiments, CD4(+) or CD8(+) T cells were depleted from PBMC to confirm that IL-5 synthesis was T cell dependent, Results: T cell IL-5 production, but not IFN-gamma production, in response to Der p was elevated in atopic patients with asthma and atopic patients with rhinitis compared with findings in atopic patients with no symptoms or nonatopic control subjects. IL-5 production was abrogated by depletion of CD4(+), but not CD8(+), T cells, In subjects with asthma, allergen-driven IL-5 production correlated with bronchial hyperreactivity. Allergen-induced proliferation was also higher in patients with asthma than in atopic subjects with no symptoms or nonatopic controls. T cell IL-5 and IFN-gamma production and proliferation in response to PPD were similar regardless of atopic status or disease. Conclusions: Elevated IL-5 production is a characteristic of allergen-specific peripheral blood CD4(+) T cells from sensitized patients with atopic disease but not atopy per se.	CHARING CROSS & WESTMINSTER MED SCH, DEPT MED, LONDON, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, ALLERGY & CLIN IMMUNOL SECT, LONDON, ENGLAND; BAYLOR COLL MED, DEPT MED, IMMUNOL SECT, HOUSTON, TX 77030 USA; HOP ANTOINE BECLERE, SERV PNEUMOL, CLAMART, FRANCE	Imperial College London; Imperial College London; Baylor College of Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP			Larche, Mark/B-4326-2010	Larche, Mark/0000-0002-1439-7593; Corrigan, Chris/0000-0002-0706-6534; Humbert, Marc/0000-0003-0703-2892; Huston, David/0000-0002-2332-0010; Till, Stephen/0000-0003-4518-3093				BURASTERO SE, 1993, J ALLERGY CLIN IMMUN, V91, P1075, DOI 10.1016/0091-6749(93)90222-2; CORRIGAN CJ, 1995, CLIN EXP ALLERGY, V25, P485, DOI 10.1111/j.1365-2222.1995.tb01084.x; CORRIGAN CJ, 1995, AM J RESP CELL MOL, V12, P567, DOI 10.1165/ajrcmb.12.5.7742019; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; DICKASON RR, 1994, CYTOKINE, V6, P647, DOI 10.1016/1043-4666(94)90053-1; DOI S, 1994, CLIN EXP ALLERGY, V24, P854, DOI 10.1111/j.1365-2222.1994.tb01808.x; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; IMADA M, 1995, IMMUNOLOGY, V85, P373; KAMEI T, 1993, AM J RESP CELL MOL, V9, P378, DOI 10.1165/ajrcmb/9.4.378; KAWANO Y, 1995, BRIT J PHARMACOL, V115, P1141, DOI 10.1111/j.1476-5381.1995.tb15016.x; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; MORI A, 1995, INT IMMUNOL, V7, P449, DOI 10.1093/intimm/7.3.449; OKUBO Y, 1994, INT ARCH ALLERGY IMM, V104, P46, DOI 10.1159/000236750; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012	24	104	112	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					563	569		10.1016/S0091-6749(97)70085-X	http://dx.doi.org/10.1016/S0091-6749(97)70085-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111503				2022-12-18	WOS:A1997WU27400021
J	Spitzauer, S; Pandjaitan, B; Soregi, G; Muhl, S; Ebner, C; Kraft, D; Valenta, R; Rumpold, H				Spitzauer, S; Pandjaitan, B; Soregi, G; Muhl, S; Ebner, C; Kraft, D; Valenta, R; Rumpold, H			IgE cross-reactivities against albumins in patients allergic to animals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						animal hair dander allergy; albumin; IgE-cross-reactivity; recombinant dog albumin fragments; diagnosis	RADIO-IMMUNOELECTROPHORESIS; SERUM-ALBUMIN; DOG; PURIFICATION; PROTEINS; IDENTIFICATION; ORIGIN; CAT	Background: Type I allergic symptoms and severe asthma in particular are frequently caused by animal hair/dander proteins, among which albumins are possible cross-sensitizing allergenic components. Methods: The significance and degree of IgE-cross-reactivities against various albumins were studied in a representative number (n = 200) of patients allergic to animals with hair/dander extracts, purified albumins from different animals, and a recombinant dog albumin fragment expressed in lysogenic Escherichia coli Y1089 and purified as a beta-galactosidase fusion protein. Results: Despite a high degree of sequence homology among different albumins, a remarkable variability of IgE cross-reactivities was observed, indicating that some patients were sensitized preferentially against certain albumins. Most of the patients allergic to albumins, however, reacted to dog, cat, and horse albumin, which also bound a high percentage of albumin-specific IgE. Conclusion: The purified recombinant dog albumin fragment, representing 265 amino acids of the mature protein, bound IgE from all 15 patients allergic to albumin tested suggesting its potential usefulness for diagnosis and perhaps therapy.	UNIV VIENNA,AKH,INST GEN & EXPTL PATHOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,AKH,INST MED & CHEM LAB DIAGNOST,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna				Valenta, Rudolf/0000-0001-5944-3365				CHAPMAN MD, 1989, CURR OPIN IMMUNOL, V1, P647, DOI 10.1016/0952-7915(89)90035-6; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; FORD AW, 1989, CLIN EXP ALLERGY, V19, P183, DOI 10.1111/j.1365-2222.1989.tb02362.x; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; HOFFMAN DR, 1980, ANN ALLERGY, V45, P205; HUYNH TV, 1985, DNA CLONING PRACTICA, V1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN H, 1978, INT ARCH ALLER A IMM, V57, P349, DOI 10.1159/000232124; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; SCHOU C, 1993, CLIN EXP ALLERGY, V23, P7, DOI 10.1111/j.1365-2222.1993.tb02477.x; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; SPITZAUER S, 1993, INT ARCH ALLERGY IMM, V100, P60, DOI 10.1159/000236389; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANTO T, 1982, INT ARCH ALLER A IMM, V69, P311, DOI 10.1159/000233192; WALLS AF, 1985, CLIN ALLERGY, V15, P535, DOI 10.1111/j.1365-2222.1985.tb02307.x; YMAN L, 1973, INT ARCH ALLER A IMM, V44, P358, DOI 10.1159/000230944	18	104	107	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				951	959		10.1016/S0091-6749(95)70233-4	http://dx.doi.org/10.1016/S0091-6749(95)70233-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543754				2022-12-18	WOS:A1995TN12400013
J	DOUGLAS, DM; SUKENICK, E; ANDRADE, WP; BROWN, JS				DOUGLAS, DM; SUKENICK, E; ANDRADE, WP; BROWN, JS			BIPHASIC SYSTEMIC-ANAPHYLAXIS - AN INPATIENT AND OUTPATIENT STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANAPHYLAXIS; PROTRACTED; BIPHASIC; LATE-PHASE REACTION	INHALANT ALLERGEN IMMUNOTHERAPY; IDIOPATHIC ANAPHYLAXIS; FATALITIES	We attempted to ascertain the incidence of systemic biphasic anaphylactic reactions in both outpatients and inpatients. Madigan Army Medical Center is a large teaching facility. The Allergy Clinic staff sees approximately 20,000 patients per year, and an average of 27,000 allergy immunotherapy injections are administered each year. During the years 1988 to 1991 we collected data from a total of 35 patients who had experienced during the 30-minute waiting period in the clinic, symptoms and signs consistent with anaphylaxis. A total of 44 anaphylactic reactions were noted, with only two (5%) involving a biphasic systemic pattern. All patients were observed and treated within the clinic until symptoms and signs had resolved. None of the patients were treated with or were presently using glucocorticosteroids during the time of their reactions. Of the reactions noted 25 (57%) involved only cutaneous manifestations of anaphylaxis, three (7%) involved the laryngeal/upper airway area, eight (18%) involved bronchospasm alone, three (7%) involved the rhinoconjunctivae, and five (11%) involved more than one site or type. None of the patients experienced any symptoms or signs of cardiovascular compromise or collapse after allergy extract injections. During the years 1986 to 1992 a total of 59 patients were admitted to the medical ward or intensive care unit with the diagnosis of systemic anaphylaxis. Of 59 patients, four (7%) experienced a recurrent (biphasic) anaphylactic reaction without reexposure to the initial inciting agent. The remaining 55 patients (93%) did not experience any further systemic anaphylaxis after initial hospital admission and treatment. Two of the patients with biphasic anaphylaxis were first seen with hypotension and generalized urticaria. Of the remaining two patients, one had lip and tongue angioedema, and the other had urticaria only. The biphasic reaction involved antibiotics in two cases and food (shrimp) in the remaining two cases. Forty-two male patients and 17 female patients were included in the study. The age range of male patients was 6 months to 77 years and that of the female patients was 10 to 81 years. There were no deaths in this study. Of the causes for anaphylactic episodes 20 (34%) were drug- or medication-related 12 (20%) were idiopathic, 13 (22%) were related to food, six (10%) were secondary to exercise, two (3%) were related to vaccine administration and three (3%) were secondary to Hymenoptera stings. The four remaining episodes were secondary to contrast dye administration, allergen skin test extract administration, horse serum administration, and allergen extract injection. We conclude that the incidence of biphasic anaphylactic events is lower than that reported in previously published studies.	MADIGAN ARMY MED CTR,DEPT INTERNAL MED,ALLERGY & IMMUNOL SERV,TACOMA,WA 98431	Madigan Army Medical Center								ATKINSON TP, 1992, MED CLIN N AM, V76, P841; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; KALINER MA, 1984, NER ALLERGY P, V5, P324; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; ORFAN NA, 1992, ALLERGY PROC, V13, P35, DOI 10.2500/108854192778878953; POPA VT, 1984, ANN ALLERGY, V53, P151; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; WASSERMAN SI, 1988, ALLERGY PRINCIPLES P, V2, P1365; WEBER R, 1990, AM J ASTHMA ALLERGY, V3, P135; WIGGINS CA, 1989, ANN ALLERGY, V62, P1	15	104	106	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					977	985		10.1016/S0091-6749(94)70044-3	http://dx.doi.org/10.1016/S0091-6749(94)70044-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006319	Bronze			2022-12-18	WOS:A1994NT17200004
J	BURKS, AW; WILLIAMS, LW; THRESHER, W; CONNAUGHTON, C; COCKRELL, G; HELM, RM				BURKS, AW; WILLIAMS, LW; THRESHER, W; CONNAUGHTON, C; COCKRELL, G; HELM, RM			ALLERGENICITY OF PEANUT AND SOYBEAN EXTRACTS ALTERED BY CHEMICAL OR THERMAL-DENATURATION IN PATIENTS WITH ATOPIC-DERMATITIS AND POSITIVE FOOD CHALLENGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PEANUT ALLERGENS; SOYBEAN ALLERGENS; FOOD HYPERSENSITIVITY; ATOPIC DERMATITIS	MAJOR COMPONENT PROTEINS; IMMUNOSORBENT-ASSAY ELISA; MONOCLONAL-ANTIBODIES; IGE ANTIBODIES; SOY CHALLENGES; GROUP-I; HYPERSENSITIVITY; IDENTIFICATION; ANTIGENS; DERMATOPHAGOIDES	Peanuts and soybeans are two of the six most common foods to cause food hypersensitivity reactions in children. We used the serum of 10 patients with atopic dermatitis and positive double-blind, placebo-controlled, food challenges to peanut and two patients with atopic dermatitis and positive double-blind, placebo-controlled, food challenges to soybean to investigate the change in IgE-specific and IgG-specific bending to these proteins altered by either chemical or thermal denaturation. We used IgE- and IgG-specific ELISA-inhibition analyses to compare these effects on the crude peanut and crude soy extracts, as well as on the major allergenic fractions of both proteins. Heating the soy proteins at various temperatures and time intervals did not significantly change the IgE- or IgG-specific binding of the soy positive pooled serum. When the peanut proteins were subjected to similar heating experiments, the IgE- and IgG-specific binding did not change. When these same proteins were treated with enzymes in the immobilized digestive enzyme assay system used to mimic human digestion, the binding of IgE to the crude peanut and crude soy extracts was reduced; 100-fold for peanut and 10-fold for soybean. Therefore it appears that thermal denaturation of peanut and soybean protein extracts does not enhance or reduce IgE- and IgG-specific binding activity. Chemical denaturation appears to minimally reduce the binding of these proteins.	CENT SOYA,FT WAYNE,IN; UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT,DIV PEDIAT IMMUNOL & ALLERGY,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences	BURKS, AW (corresponding author), ARKANSAS CHILDRENS HOSP,800 MARSHALL ST,LITTLE ROCK,AR 72202, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026629] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26629-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JA, 1984, NIH842442 PUBL; ANDERSON MC, 1986, RAST INHIBITION PROC; BERNHISEL-BROADBENT J, 1991, Journal of Allergy and Clinical Immunology, V87, P177, DOI 10.1016/0091-6749(91)91437-X; BLEUMINK E, 1968, INT ARCH ALLER A IMM, V34, P521, DOI 10.1159/000230147; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1990, J ALLERGY CLIN IMMUN, V85, P921, DOI 10.1016/0091-6749(90)90078-I; BURKS AW, 1988, J FOOD SCI, V53, P1456, DOI 10.1111/j.1365-2621.1988.tb09298.x; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; BURKS AW, UNPUB IDENTIFICATION; BUSH RK, 1989, ALLERGY PROC, V10, P261, DOI 10.2500/108854189778959975; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1989, CURR OPIN IMMUNOL, V1, P647, DOI 10.1016/0952-7915(89)90035-6; Crumpton M., 1974, ANTIGENS, V2, P1; ELSAYED S, 1983, ALLERGY, V38, P449, DOI 10.1111/j.1398-9995.1983.tb02353.x; ELSAYED S, 1971, J ALLERGY, V470, P283; ESCH RE, 1989, J IMMUNOL, V142, P179; HEINER DC, 1975, J ALLERGY CLIN IMMUN, V55, P82; JANOLINO VG, 1982, BIOTECHNOL BIOENG, V24, P1069, DOI 10.1002/bit.260240504; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; LEMANSKE RF, 1987, CLIN REV ALLERG, V5, P23; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; MARSH DG, 1982, ANTIGENS, V3, P271; METCALFE DD, 1985, CLIN REV ALLERG, V3, P331, DOI 10.1007/BF02992999; NAISMITH WEF, 1955, BIOCHIM BIOPHYS ACTA, V16, P203, DOI 10.1016/0006-3002(55)90205-5; Nielsen N., 1985, NEW PROTEIN FOODS, P27; OLSON JR, 1986, J IMMUNOL, V136, P2109; PORTER DH, 1984, J AGR FOOD CHEM, V32, P334, DOI 10.1021/jf00122a038; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SCHWARTZ HR, 1980, ANN ALLERGY, V45, P242; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472; SMITH JJ, 1988, MOL IMMUNOL, V25, P355, DOI 10.1016/0161-5890(88)90030-2; SPIES, 1970, J ALLERGY CLIN IMMUN, V45, P208; TAYLOR SL, 1985, FOOD TECHNOL-CHICAGO, V39, P98; THANH VH, 1976, J AGR FOOD CHEM, V24, P1117, DOI 10.1021/jf60208a030; THRESHER WC, 1988, PLANT FOODS HUM NUTR, V39, P59; WOLF WJ, 1956, ARCH BIOCHEM BIOPHYS, V63, P40, DOI 10.1016/0003-9861(56)90007-8; YUNGINGER JW, 1987, 4TH P INT P EHRL SEM, P251; [No title captured]	42	104	111	0	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				889	897		10.1016/0091-6749(92)90461-A	http://dx.doi.org/10.1016/0091-6749(92)90461-A			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1460196	Bronze			2022-12-18	WOS:A1992KD19000005
J	REISMAN, RE; MAURIELLO, PM; DAVIS, GB; GEORGITIS, JW; DEMASI, JM				REISMAN, RE; MAURIELLO, PM; DAVIS, GB; GEORGITIS, JW; DEMASI, JM			A DOUBLE-BLIND-STUDY OF THE EFFECTIVENESS OF A HIGH-EFFICIENCY PARTICULATE AIR (HEPA) FILTER IN THE TREATMENT OF PATIENTS WITH PERENNIAL ALLERGIC RHINITIS AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ENVIRONM AIR CONTROLS INC,HAGERSTOWN,MD; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PEDIAT,WINSTON SALEM,NC 27103	Wake Forest University; Wake Forest Baptist Medical Center	REISMAN, RE (corresponding author), SUNY BUFFALO,BUFFALO GEN HOSP,DEPT MED,DIV ALLERGY,ALLERGY RES LAB,50 HIGH ST,BUFFALO,NY 14203, USA.							HIRSCH SR, 1976, ANN ALLERGY, V36, P30; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; REED CE, 1985, CHEST, V87, pS40; VILLAVECES JW, 1977, ANN ALLERGY, V38, P400; ZWEMER RJ, 1973, ANN ALLERGY, V31, P284	7	104	105	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					1050	1057		10.1016/0091-6749(90)90050-E	http://dx.doi.org/10.1016/0091-6749(90)90050-E			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2191991				2022-12-18	WOS:A1990DK50900011
J	SVENSSON, C; ANDERSSON, M; PERSSON, CGA; VENGE, P; ALKNER, U; PIPKORN, U				SVENSSON, C; ANDERSSON, M; PERSSON, CGA; VENGE, P; ALKNER, U; PIPKORN, U			ALBUMIN, BRADYKININS, AND EOSINOPHIL CATIONIC PROTEIN ON THE NASAL MUCOSAL SURFACE IN PATIENTS WITH HAY-FEVER DURING NATURAL ALLERGEN EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LUND HOSP,DEPT EAR NOSE & THROAT,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT CLIN PHARMACOL,S-22185 LUND,SWEDEN; AB DRACO,DEPT PHARMACOL,S-22101 LUND,SWEDEN; AB DRACO,DEPT BIOANAL,S-22101 LUND,SWEDEN; UNIV HOSP UPPSALA,DEPT CLIN CHEM,UPPSALA,SWEDEN	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Uppsala University; Uppsala University Hospital								ANDERSSON M, 1989, AM REV RESPIR DIS, V139, P911, DOI 10.1164/ajrccm/139.4.911; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BAUMGARTEN CR, 1989, ALLERGOLOGIE, V12, pS248; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DAHL R, 1987, ALLERGIC VASOMOTOR R, P136; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Erjefalt I, 1989, Pulm Pharmacol, V2, P93, DOI 10.1016/0952-0600(89)90030-6; FRIGAS E, 1980, LAB INVEST, V42, P35; GRIEFF L, IN PRESS EUR RESPIR; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; LINDER A, 1988, ALLERGY, V43, P119, DOI 10.1111/j.1398-9995.1988.tb00405.x; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; Mygind N, 1978, NASAL ALLERGY; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PERSSON CGA, 1986, ACTA PHYSIOL SCAND, V126, P615, DOI 10.1111/j.1748-1716.1986.tb07863.x; PERSSON CGA, 1986, LANCET, V2, P1126; PERSSON CGA, 1989, BRONCHITIS, V4, P236; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1988, INT ARCH ALLER A IMM, V87, P349, DOI 10.1159/000234700; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; SVENSSON C, 1989, THORAX, V44, P13, DOI 10.1136/thx.44.1.13; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; WIDDICOMBE JG, 1982, NOSE UPPER AIRWAY PH, P215	34	104	105	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					828	833		10.1016/0091-6749(90)90064-B	http://dx.doi.org/10.1016/0091-6749(90)90064-B			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2332562				2022-12-18	WOS:A1990DD95900002
J	BOUSQUET, J; HEJJAOUI, A; SOUSSANA, M; MICHEL, FB				BOUSQUET, J; HEJJAOUI, A; SOUSSANA, M; MICHEL, FB			DOUBLE-BLIND, PLACEBO-CONTROLLED IMMUNOTHERAPY WITH MIXED GRASS-POLLEN ALLERGOIDS .4. COMPARISON OF THE SAFETY AND EFFICACY OF 2 DOSAGES OF A HIGH-MOLECULAR-WEIGHT ALLERGOID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BOUSQUET, J (corresponding author), CHU MONTPELLIER,HOP AIGUELONGUE,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					[Anonymous], 1986, BMJ-BRIT MED J, V293, P948; ARMITAGE P, 1977, STATISTICAL METHODS; BERG T, 1980, INT ARCH ALLER A IMM, V63, P266, DOI 10.1159/000232636; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, 1985, 3RD P P EHRL SEM REG, P291; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DEUSCHL H, 1977, CLIN ALLERGY, V7, P315, DOI 10.1111/j.1365-2222.1977.tb01459.x; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; DREBORG S, 1983, 2ND P P EHRL S ALL S, P77; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P160, DOI 10.1016/0091-6749(83)90524-9; GRAMMER LC, 1986, J ALLERGY CLIN IMMUN, V78, P1180, DOI 10.1016/0091-6749(86)90269-1; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; LESSOF M, 1983, P INT ALLERGY WORKSH, P1; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MALLING H-J, 1988, Allergy (Copenhagen), V43, P1; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V68, P449, DOI 10.1016/0091-6749(81)90199-8; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NORDVALL SL, 1978, INT ARCH ALLER A IMM, V67, P132; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; NORMAN PS, 1981, PROG ALLERGY, V32, P318; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; Pepys J., 1975, BR J HOSP MED, V14, P412; PUTTONEN E, 1981, INT ARCH ALLER A IMM, V64, P157, DOI 10.1159/000232687; PUTTONEN E, 1982, INT ARCH ALLER A IMM, V68, P1, DOI 10.1159/000233058; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; THOMPSON RA, 1989, LANCET, V1, P259; TURKELTAUB PC, 1986, J ALLERGY CLIN IMMUN, V77, P211; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; WAHL R, 1986, J CHROMATOGR, V351, P39, DOI 10.1016/S0021-9673(01)83470-1	40	104	105	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					490	497		10.1016/0091-6749(90)90160-6	http://dx.doi.org/10.1016/0091-6749(90)90160-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2406327				2022-12-18	WOS:A1990CP51100011
J	MILLER, BD				MILLER, BD			DEPRESSION AND ASTHMA - A POTENTIALLY LETHAL MIXTURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,HLTH SCI CTR,DEPT PSYCHIAT,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	MILLER, BD (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,PEDIAT PSYCHOPHYSIOL TREATMENT UNIT,1400 JACKSON ST,DENVER,CO 80206, USA.							AVNI J, 1969, PSYCHOPHARMACOLOGIA, V14, P184, DOI 10.1007/BF00404216; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; Bengtsson U, 1984, Eur J Respir Dis Suppl, V136, P123; DIRKS JF, 1982, J ASTHMA, V19, P177, DOI 10.3109/02770908209104755; FRITZ GK, 1983, PSYCHOSOMATICS, V24, P959, DOI 10.1016/S0033-3182(83)73121-X; GROSS NJ, 1984, AM REV RESPIR DIS, V129, P856, DOI 10.1164/arrd.1984.129.5.856; GROSS NJ, 1984, NEW ENGL J MED, V311, P421, DOI 10.1056/NEJM198408163110701; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; HOFER MA, 1970, PSYCHOSOM MED, V32, P633, DOI 10.1097/00006842-197011000-00008; Janowsky D S, 1980, Psychopharmacol Bull, V16, P29; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KINSMAN RA, 1980, PSYCHOSOM MED, V42, P397, DOI 10.1097/00006842-198007000-00002; KLINNERT M, 1985, 32ND ANN M AM AC CHI, V1, P37; KNAPP PH, 1966, PSYCHOSOM MED, V28, P114, DOI 10.1097/00006842-196603000-00003; KNAPP PH, 1976, BRONCHIAL ASTHMA MEC, P1055; MEARES RA, 1971, MED J AUSTRALIA, V2, P25, DOI 10.5694/j.1326-5377.1971.tb50396.x; MRAZEK D, 1985, PSYCHIATRIC ASPECTS; NADEL JA, 1976, BRONCHIAL ASTHMA MEC, P155; NADI NS, 1984, NEW ENGL J MED, V311, P225, DOI 10.1056/NEJM198407263110404; NORRISH M, 1977, ARCH DIS CHILD, V52, P912, DOI 10.1136/adc.52.12.912; PINKERTON P, 1972, DEPRESSIVE STATES CH, P187; POZNANSKI EO, 1979, PEDIATRICS, V64, P442; PUIGANTICH J, 1983, ANNU REV MED, V34, P231, DOI 10.1146/annurev.me.34.020183.001311; REITE M, 1974, PSYCHOSOM MED, V36, P363, DOI 10.1097/00006842-197407000-00010; REITE M, 1978, BIOL PSYCHIAT, V13, P91; RICHTER CP, 1957, PSYCHOSOM MED, V19, P191, DOI 10.1097/00006842-195705000-00004; RISCH SC, 1981, J CLIN PSYCHOPHARM, V1, P186, DOI 10.1097/00004714-198107000-00003; Rutter M., 1986, DEPRESSION YOUNG PEO; SANTIAGO SM, 1980, J ASTHMA RES, V17, P75, DOI 10.3109/02770908009105684; SCHNEER HJ, 1963, ASTHMATIC CHILD; SITARAM N, 1980, SCIENCE, V208, P200, DOI 10.1126/science.7361118; SITARAM N, 1982, AM J PSYCHIAT, V139, P571; SMITH LJ, 1980, J ALLERGY CLIN IMMUN, V66, P374, DOI 10.1016/0091-6749(80)90116-5; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; SUGIHARA H, 1965, ANN ALLERGY, V23, P422; TIETZ W, 1975, Journal of Asthma Research, V12, P199, DOI 10.3109/02770907509098947; WOOD DW, 1976, CLIN PEDIATR, V15, P677, DOI 10.1177/000992287601500804	37	104	105	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			481	486		10.1016/0091-6749(87)90080-7	http://dx.doi.org/10.1016/0091-6749(87)90080-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624703				2022-12-18	WOS:A1987K103700028
J	HUDSON, P; CARTIER, A; PINEAU, L; LAFRANCE, M; STAUBIN, JJ; DUBOIS, JY; MALO, JL				HUDSON, P; CARTIER, A; PINEAU, L; LAFRANCE, M; STAUBIN, JJ; DUBOIS, JY; MALO, JL			FOLLOW-UP OF OCCUPATIONAL ASTHMA CAUSED BY CRAB AND VARIOUS AGENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN BLVD, MONTREAL H4J 1C5, QUEBEC, CANADA; CTR SANTE ARCHIPEL, CAP AUX MEULES, QUEBEC, CANADA	Universite de Montreal								[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BURGE PS, 1982, THORAX, V37, P348, DOI 10.1136/thx.37.5.348; BUTCHER BT, 1982, J ALLERGY CLIN IMMUN, V70, P231, DOI 10.1016/0091-6749(82)90058-6; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MOLLER D R, 1984, American Review of Respiratory Disease, V129, pA159; PAGGIARO PL, 1984, CLIN ALLERGY, V14, P463, DOI 10.1111/j.1365-2222.1984.tb02230.x; YEUNG M, 1985, THORAX, V40, P241, DOI 10.1136/thx.40.4.241	16	104	104	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					682	688		10.1016/0091-6749(85)90671-2	http://dx.doi.org/10.1016/0091-6749(85)90671-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	4056252	Bronze			2022-12-18	WOS:A1985AUU3400005
J	GODFREY, S; BALFOURLYNN, L; TOOLEY, M				GODFREY, S; BALFOURLYNN, L; TOOLEY, M			3-YEAR TO 5-YEAR FOLLOW-UP OF USE OF AEROSOL STEROID, BECLOMETHASONE DIPROPIONATE, IN CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HAMMERSMITH HOSP,DEPT PEDIAT,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,DEPT NEONATAL,LONDON W12 0HS,ENGLAND	Imperial College London; Imperial College London								BROWN HM, 1973, BRIT MED J, V3, P161, DOI 10.1136/bmj.3.5872.161; DICKSON W, 1973, ARCH DIS CHILD, V48, P671, DOI 10.1136/adc.48.9.671; FRANCIS RS, 1976, THORAX, V31, P309, DOI 10.1136/thx.31.3.309; GODFREY S, 1973, ARCH DIS CHILD, V48, P665, DOI 10.1136/adc.48.9.665; GODFREY S, 1975, J PEDIATR-US, V87, P465, DOI 10.1016/S0022-3476(75)80663-9; GODFREY S, 1974, BMJ-BRIT MED J, V2, P387, DOI 10.1136/bmj.2.5915.387-b; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; KERREBIJN KF, 1976, J PEDIATR-US, V89, P821, DOI 10.1016/S0022-3476(76)80816-5; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; MORRIS HG, 1975, PEDIATR RES, V9, P579, DOI 10.1203/00006450-197507000-00005; Tanner J. M., 1962, GROWTH ADOLESCENCE, V2nd; 1974, LANCET, V2, P303	12	104	104	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	6					335	339		10.1016/0091-6749(78)90133-1	http://dx.doi.org/10.1016/0091-6749(78)90133-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GA292	712019				2022-12-18	WOS:A1978GA29200004
J	Hamelmann, E; Bateman, ED; Vogelberg, C; Szefler, SJ; Vandewalker, M; Moroni-Zentgraf, P; Avis, M; Unseld, A; Engel, M; Boner, AL				Hamelmann, Eckard; Bateman, Eric D.; Vogelberg, Christian; Szefler, Stanley J.; Vandewalker, Mark; Moroni-Zentgraf, Petra; Avis, Mandy; Unseld, Anna; Engel, Michael; Boner, Attilio L.			Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adolescent; anticholinergic drug; asthma; asthma control; efficacy; FEV1; lung function; Respimat; safety; tiotropium	OF-LIFE QUESTIONNAIRE; STEP-UP THERAPY; LUNG-FUNCTION; INHALED CORTICOSTEROIDS; UNCONTROLLED ASTHMA; SYMPTOMATIC ASTHMA; CHILDREN; SALMETEROL; ADULTS; EXACERBATIONS	Background: Results from phase III clinical trials in adults and phase II clinical trials in children and adolescents demonstrate that tiotropium is an effective treatment when added to inhaled corticosteroid (ICS) maintenance therapy. Objective: We sought to assess the efficacy and safety of once-daily tiotropium Respimat added to ICSs with or without a leukotriene receptor antagonist in a phase III trial in adolescent patients with moderate symptomatic asthma. Methods: In this 48-week, double-blind, placebo-controlled, parallel-group study, 398 patients aged 12 to 17 years were randomized to receive 5 mu g (2 puffs of 2.5 mu g) or 2.5 mg (2 puffs of 1.25 eta g) of once-daily tiotropium or placebo (2 puffs) administered through the Respimat device every evening, each as add-on treatment to ICS background therapy, with or without a leukotriene receptor antagonist; long-acting beta(2)-agonist therapy was not permitted during the study. Results: Improvement in peak FEV1 within 3 hours after dosing at 24 weeks (primary end point) was statistically significant with both tiotropium doses compared with placebo: 5 mg of tiotropium, 174 mL (95% CI, 76-272 mL); 2.5 mu g of tiotropium, 134 mL (95% CI, 34-234 mL). Significant improvements in trough FEV1 at week 24 (a secondary end point) were observed with the 5-mu g dose only. Trends for improvement in asthma control and health-related quality of life over the 48-week treatment period were observed. Conclusions: Once-daily tiotropium significantly improved lung function and was safe and well tolerated when added to at least ICS maintenance therapy in adolescent patients with moderate symptomatic asthma. Larger responses were observed with the 5-mu g tiotropium dose.	[Hamelmann, Eckard] Univ Munster, Akad Lehrkrankenhaus, Evangel Krankenhaus Bielefeld GmbH, Kinderzentrum Bethel,Klin Kinder & Jugendmed, Grenzweg 10, D-33617 Bielefeld, Germany; [Bateman, Eric D.] Univ Cape Town, Dept Med, Cape Town, South Africa; [Vogelberg, Christian] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Szefler, Stanley J.] Childrens Hosp Colorado, Breathing Inst, Dept Pediat, Aurora, CO USA; [Vandewalker, Mark] Clin Res Ozarks, Columbia, MO USA; [Moroni-Zentgraf, Petra; Engel, Michael] Boehringer Ingelheim Pharma GmbH & Co KG, TA Resp Dis, Ingelheim, Germany; [Avis, Mandy] Boehringer Ingelheim GmbH & Co KG, Alkmaar, Netherlands; [Unseld, Anna] Boehringer Ingelheim Pharma GmbH & Co KG, Global Biometr & Data Sci, Biberach, Germany; [Boner, Attilio L.] UO Pediat, SSO Dipartimento Sperimentale Pediat, Policlin G Rossi, Verona, Italy	Evangelical Hospital Bethel (EvKB) - House Gilead I; University of Munster; University of Cape Town; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Children's Hospital Colorado; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Hamelmann, E (corresponding author), Univ Munster, Akad Lehrkrankenhaus, Evangel Krankenhaus Bielefeld GmbH, Kinderzentrum Bethel,Klin Kinder & Jugendmed, Grenzweg 10, D-33617 Bielefeld, Germany.	eckard.hamelmann@evkb.de	Hamelmann, Eckard/AAJ-9124-2021	Szefler, Stanley/0000-0002-6911-3199	Boehringer Ingelheim	Boehringer Ingelheim(Boehringer Ingelheim)	Supported by Boehringer Ingelheim. P.M.-Z., M.E., M.A., and A.U. are all employees of Boehringer Ingelheim.	Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2015, J ALLERGY CLIN IMMUN, V136, P914, DOI 10.1016/j.jaci.2015.03.023; Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004; Beeh KM, 2014, RESP RES, V15, P61; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Cates CJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010314.pub2; Custovic A, 2013, ALLERGY, V68, P1520, DOI 10.1111/all.12275; de Benedictis D, 2007, PEDIATR PULM, V42, P683, DOI 10.1002/ppul.20650; Demoly P, 2009, EUR RESPIR REV, V18, P105, DOI 10.1183/09059180.00001209; Desai M, 2011, CURR ALLERGY ASTHM R, V11, P454, DOI 10.1007/s11882-011-0227-2; Ducharme FM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005535.pub2; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Hedlin G, 2010, EUR RESPIR J, V36, P196, DOI 10.1183/09031936.00104809; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Kerstjens HAM, 2015, LANCET RESP MED, V3, P367, DOI 10.1016/S2213-2600(15)00031-4; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kerstjens HAM, 2011, J ALLERGY CLIN IMMUN, V128, P308, DOI 10.1016/j.jaci.2011.04.039; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Ohta K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124109; Paggiaro P, 2016, J ALLERGY CLIN IMMUN, V4; Partridge MR, 2011, PRIM CARE RESP J, V20, P315, DOI 10.4104/pcrj.2011.00056; Peters SP, 2013, J ALLERGY CLIN IMMUN, V132, P1068, DOI 10.1016/j.jaci.2013.08.003; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Timmer W, 2015, RESP MED, V109, P329, DOI 10.1016/j.rmed.2014.12.005; Vogelberg C, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0175-9; Vogelberg C, 2014, RESP MED, V108, P1268, DOI 10.1016/j.rmed.2014.06.011	32	103	106	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					441	+		10.1016/j.jaci.2016.01.011	http://dx.doi.org/10.1016/j.jaci.2016.01.011			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	26960245	hybrid			2022-12-18	WOS:000380835800014
J	Mingueneau, M; Boudaoud, S; Haskett, S; Reynolds, TL; Nocturne, G; Norton, E; Zhang, XL; Constant, M; Park, D; Wang, WT; Lazure, T; Le Pajolec, C; Ergun, A; Mariette, X				Mingueneau, Michael; Boudaoud, Saida; Haskett, Scott; Reynolds, Taylor L.; Nocturne, Gaetane; Norton, Elizabeth; Zhang, Xueli; Constant, Myrtha; Park, Daniel; Wang, Wenting; Lazure, Thierry; Le Pajolec, Christine; Ergun, Ayla; Mariette, Xavier			Cytometry by time-of-flight immunophenotyping identifies a blood Sjogren's signature correlating with disease activity and glandular inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sjogren's syndrome; autoimmunity; mass cytometry; cytometry by time-of-flight; immunophenotyping; patient stratification; biomarker discovery; therapeutic target	CELL MASS CYTOMETRY; EPITHELIAL-CELLS; B-CELL; EXPRESSION; ACTIVATION; PATHOGENESIS; IMMUNE; SHOWS; SUBSET	Background: Mass cytometry has recently emerged as a promising tool for clinical research. However, few studies have demonstrated its benefit for patient stratification and biomarker identification. Primary Sjogren's syndrome (pSS) is a prototype of chronic autoimmune disease, the pathogenesis of which remains unclear and for which treatment does not exist. Objective: This observational case-control study was designed to discover new cellular biomarkers and therapeutic targets in patients with pSS. Methods: Forty-nine patients with pSS and 45 control subjects were enrolled for clinical evaluation and mass cytometry quantification of 34 protein markers in blood. For a third of these subjects, matched labial salivary gland biopsy specimens were also analyzed by mass cytometry and immunohistochemistry. Results: In salivary gland biopsy specimens from patients with pSS, we identified a high number of activated CD8(+) T cells, terminally differentiated plasma cells, and activated epithelial cells, pointing to new pathogenic mechanisms for future clinical intervention. In blood, we identified a 6-cell disease signature defined by decreased numbers of CD4 and memory B lymphocytes, decreased plasmacytoid dendritic cell numbers, and increased representation of activated CD4 and CD8T cells and plasmablasts. These blood cellular components correlated with clinical parameters and, when taken together, clustered patients into subsets with distinct disease activity and glandular inflammation. Conclusion: This first application of mass cytometry to a well stratified clinical cohort and small biopsy tissues establishes the benefits of such an approach for the discovery of new biomarkers and therapeutic targets. Similar high-dimensional immunophenotyping strategies could be implemented in longitudinal and interventional clinical settings in this and other disease areas.	[Mingueneau, Michael; Haskett, Scott; Reynolds, Taylor L.; Norton, Elizabeth; Zhang, Xueli; Constant, Myrtha; Park, Daniel; Wang, Wenting; Ergun, Ayla] Biogen, Immunol Res, Cambridge, MA USA; [Boudaoud, Saida; Nocturne, Gaetane; Lazure, Thierry; Mariette, Xavier] Univ Paris 11, Fac Med, Le Kremlin Bicetre, France; [Boudaoud, Saida; Nocturne, Gaetane; Lazure, Thierry; Mariette, Xavier] INSERM, U1184, Ctr Immunol Viral Infect & Autoimmune Dis, F-94275 Le Kremlin Bicetre, France; [Nocturne, Gaetane; Lazure, Thierry; Le Pajolec, Christine; Mariette, Xavier] Hop Univ Paris Sud, AP HP, Le Kremlin Bicetre, France	Biogen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay	Mingueneau, M (corresponding author), 115 Broadway, Cambridge, MA USA.	michael.mingueneau@biogen.com	Mingueneau, Michael/O-5313-2019	Mingueneau, Michael/0000-0002-3873-7329; Nocturne, Gaetane/0000-0001-6809-0733	Biogen [UPSud/SAIC N 97731]	Biogen(Biogen)	Supported by an unrestricted grant (UPSud/SAIC N 97731) from Biogen to Universite Paris-Sud.	Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Bendall SC, 2014, CELL, V157, P714, DOI 10.1016/j.cell.2014.04.005; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bohnhorst JO, 2001, SCAND J IMMUNOL, V54, P421, DOI 10.1046/j.1365-3083.2001.00989.x; Cheung RK, 2011, NAT REV RHEUMATOL, V7, P502, DOI 10.1038/nrrheum.2011.110; Cornec D, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4442; Emamian ES, 2009, GENES IMMUN, V10, P285, DOI 10.1038/gene.2009.20; Fisher BA, 2015, ANN RHEUM DIS, V74, P1645, DOI 10.1136/annrheumdis-2015-207499; FOX RI, 1986, ARTHRITIS RHEUM, V29, P1105, DOI 10.1002/art.1780290908; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gaudilliere B, 2015, CYTOM PART A, V87A, P817, DOI 10.1002/cyto.a.22720; Gaudilliere B, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009701; Gottenberg JE, 2006, P NATL ACAD SCI USA, V103, P2770, DOI 10.1073/pnas.0510837103; Gottenberg JE, 2005, ANN RHEUM DIS, V64, P1050, DOI 10.1136/ard.2004.030643; Halliley JL, 2015, IMMUNITY, V43, P132, DOI 10.1016/j.immuni.2015.06.016; Han A, 2013, P NATL ACAD SCI USA, V110, P13073, DOI 10.1073/pnas.1311861110; Hansmann L, 2015, CANCER IMMUNOL RES, V3, P650, DOI 10.1158/2326-6066.CIR-14-0236-T; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Manoussakis MN, 2010, J AUTOIMMUN, V35, P219, DOI 10.1016/j.jaut.2010.06.011; Manoussakis MN, 1999, ARTHRITIS RHEUM, V42, P229, DOI 10.1002/1529-0131(199902)42:2<229::AID-ANR4>3.0.CO;2-X; Mingueneau M, 2014, P NATL ACAD SCI USA, V111, P16466, DOI 10.1073/pnas.1419337111; Nassar AF, 2015, DRUG DISCOV TODAY, V20, P1169, DOI 10.1016/j.drudis.2015.06.001; Newell EW, 2012, IMMUNITY, V36, P142, DOI 10.1016/j.immuni.2012.01.002; Nezos A, 2015, J AUTOIMMUN, V63, P47, DOI 10.1016/j.jaut.2015.07.002; Nishishinya MB, 2015, RHEUMATOL INT, V35, P17, DOI 10.1007/s00296-014-3051-x; Nocturne G, 2015, ARTHRITIS RHEUM 1125; Nocturne G, 2015, BRIT J HAEMATOL, V168, P317, DOI 10.1111/bjh.13192; Nocturne G, 2013, NAT REV RHEUMATOL, V9, P544, DOI 10.1038/nrrheum.2013.110; O'Gorman WE, 2015, J ALLERGY CLIN IMMUN, V136, P1326, DOI 10.1016/j.jaci.2015.04.008; Piskurich JF, 2000, NAT IMMUNOL, V1, P526, DOI 10.1038/82788; Polikowsky HG, 2015, J IMMUNOL, V195, P1364, DOI 10.4049/jimmunol.1500904; Qin BD, 2015, ANN RHEUM DIS, V74, P1983, DOI 10.1136/annrheumdis-2014-205375; Quartuccio L, 2015, AUTOIMMUN REV, V14, P1019, DOI 10.1016/j.autrev.2015.07.002; Rusakiewicz S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005727; Seror R, 2015, ANN RHEUM DIS, V74, P859, DOI 10.1136/annrheumdis-2013-204615; Swiecki M, 2011, J EXP MED, V208, P2367, DOI 10.1084/jem.20110654; Szyszko EA, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3220; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tsunawaki S, 2002, J RHEUMATOL, V29, P1884; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Vogelsang P, 2010, ANN RHEUM DIS, V69, P1235, DOI 10.1136/ard.2009.118158; Yao Y, 2014, J IMMUNOL METHODS, V415, P1, DOI 10.1016/j.jim.2014.10.010	43	103	105	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1809	+		10.1016/j.jaci.2016.01.024	http://dx.doi.org/10.1016/j.jaci.2016.01.024			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27045581				2022-12-18	WOS:000377527200023
J	Liu, AH				Liu, Andrew H.			Revisiting the hygiene hypothesis for allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; hygiene hypothesis; asthma prevention	BACTERIAL-COLONIZATION; ENDOTOXIN EXPOSURE; ATOPIC-DERMATITIS; CONTROLLED-TRIAL; RISK; GUT; MICROBIOME; AIRWAY; SENSITIZATION; CHILDHOOD	The hygiene hypothesis, which describes the protective influence of microbial exposures in early life on the development of allergy and asthma, has continued its swell of academic interest, investigation, and evolution. This article is focused on studies published in the past 3 years that have furthered the substance and shape of hygiene theory, primarily as it relates to allergic airways and asthma. Recent investigations have furthered an overarching "microbiome hypothesis'' to home features, medical practices, and cleanliness behaviors that are suspects in the hygiene effect. Relatively crude markers of the protective microbial environment have been supplanted by culture-independent microbiome science, distinguishing the characteristics of potentially protective microbiomes from pathologic features. Understanding how the microbiome is shaped and affects healthful versus harmful outcomes in the human host is relatively nascent. Good clues are emerging that give mechanistic substance to the theory and could help guide microbe-based therapeutics to fill the allergy and asthma management gap in prevention and disease modification.	[Liu, Andrew H.] Childrens Hosp Colorado, Dept Pediat, Sect Pulm Med, Aurora, CO 80045 USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA; [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health	Liu, AH (corresponding author), Childrens Hosp Colorado, Breathing Inst, 13123 East 16th Ave,Box B395, Aurora, CO 80045 USA.	Liu@childrenscolorado.org						Abreu NA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003783; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Blackley CH, 1873, EXPT RES CAUSE NATUR, P1; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Coyne MJ, 2008, P NATL ACAD SCI USA, V105, P13099, DOI 10.1073/pnas.0804220105; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Debarry J, 2010, ALLERGY, V65, P690, DOI 10.1111/j.1398-9995.2009.02253.x; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Evans H, 2015, J ALLERGY CLIN IMMUN, V135, P343, DOI 10.1016/j.jaci.2014.07.007; Fisher CK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102451; Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Fyhrquist N, 2014, J ALLERGY CLIN IMMUN, V134, P1301, DOI 10.1016/j.jaci.2014.07.059; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Grainger JR, 2010, J EXP MED, V207, P2331, DOI 10.1084/jem.20101074; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Haapakoski R, 2013, J INVEST DERMATOL, V133, P964, DOI 10.1038/jid.2012.356; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; Hesselmar B, 2015, PEDIATRICS, V135, pE590, DOI 10.1542/peds.2014-2968; Hesselmar B, 2013, PEDIATRICS, V131, pE1829, DOI 10.1542/peds.2012-3345; Holbreich M, 2012, J ALLERGY CLIN IMMUN, V129, P1671, DOI 10.1016/j.jaci.2012.03.016; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234; Inoue R, 2007, BRIT J DERMATOL, V156, P499, DOI 10.1111/j.1365-2133.2006.07695.x; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Kallionpaa H, 2014, CLIN IMMUNOL, V155, P136, DOI 10.1016/j.clim.2014.09.009; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Lee SM, 2013, NATURE, V501, P426, DOI 10.1038/nature12447; Litonjua AA, 2014, CONTEMP CLIN TRIALS, V38, P37, DOI 10.1016/j.cct.2014.02.006; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Liu AH, 2010, ASTHMA INFECT, P32; Lodge CJ, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/176484; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Martinez Fernando D, 2014, Ann Am Thorac Soc, V11 Suppl 1, pS7, DOI 10.1513/AnnalsATS.201306-186MG; Matsui EC, 2013, AM J RESP CRIT CARE, V188, P1210, DOI 10.1164/rccm.201305-0889OC; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McSorley HJ, 2015, EXP PARASITOL, V158, P8, DOI 10.1016/j.exppara.2015.02.009; Min KB, 2015, ENVIRON POLLUT, V199, P148, DOI 10.1016/j.envpol.2014.12.012; Mpairwe H, 2011, PEDIAT ALLERG IMM-UK, V22, P305, DOI 10.1111/j.1399-3038.2010.01122.x; Oertli M, 2013, P NATL ACAD SCI USA, V110, P3047, DOI 10.1073/pnas.1211248110; Orsmark-Pietrast C, 2013, EUR RESPIR J, V42, P65, DOI 10.1183/09031936.00077712; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Penders J, 2014, GUT MICROBES, V5, P239, DOI 10.4161/gmic.27905; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Simpson MR, 2015, BMC DERMATOL, V15, DOI 10.1186/s12895-015-0030-1; Smits HH, 2014, J ALLERGY CLIN IMMUN, V134, P1280, DOI 10.1016/j.jaci.2014.08.051; Stiemsma LT, 2015, IMMUNOTARGETS THER, V4, P143, DOI 10.2147/ITT.S61528; Strachan DP, 2015, CLIN EXP ALLERGY, V45, P126, DOI 10.1111/cea.12349; Straubinger K, 2014, J ALLERGY CLIN IMMUN, V134, P1271, DOI 10.1016/j.jaci.2014.05.034; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Valladares R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010507; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; Versini M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0306-7; Weber J, 2015, AM J RESP CRIT CARE, V191, P522, DOI 10.1164/rccm.201410-1899OC; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zuccotti G, 2015, ALLERGY, V70, P1356, DOI 10.1111/all.12700	72	103	109	2	116	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					860	865		10.1016/j.jaci.2015.08.012	http://dx.doi.org/10.1016/j.jaci.2015.08.012			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26449798	Bronze			2022-12-18	WOS:000362976300004
J	MacDonald, KG; Dawson, NAJ; Huang, Q; Dunne, JV; Levings, MK; Broady, R				MacDonald, Katherine G.; Dawson, Nicholas A. J.; Huang, Qing; Dunne, James V.; Levings, Megan K.; Broady, Raewyn			Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cells; forkhead box protein 3; systemic sclerosis; T(H)2 cells; IL-4; IL-13; IL-33; ST2; IL-33 receptor; fibroblasts; skin; fibrosis; human; T-cell plasticity	MAINTAIN IMMUNE HOMEOSTASIS; TH17 CELLS; IN-VIVO; INCREASED FREQUENCY; DISEASE SEVERITY; SCLERODERMA SKIN; EXPRESSION; FOXP3; IL-33; TH2	Background: Systemic sclerosis (SSc) is an autoimmune disorder characterized by fibrosis of the skin and internal organs. Pathologic conversion of regulatory T (Treg) cells into inflammatory cytokine-producing cells is thought to be an important step in the progression of autoimmunity, but whether loss of normal Treg cell function contributes to SSc is unknown. Objective: We sought to determine whether Treg cells in the blood and skin of patients with SSc acquired abnormal production of effector cytokines. Methods: Peripheral blood and skin biopsy specimens were collected from control subjects and patients with limited or diffuse SSc. Flow cytometry was used to evaluate expression of cell-surface proteins and the cytokine production profile of forkhead box protein 3-positive Treg cells compared with forkhead box protein 3-negative conventional T cells. Results: Treg cells in the blood of patients with SSc had a normal phenotype and did not produce T-effector cytokines. In contrast, Treg cells from skin affected by SSc produced significant amounts of IL-4 and IL-13. Although Treg cells in the blood of patients with SSc did not make TH2 cytokines, they contained a significantly higher proportion of skin-homing cells expressing TH2 cell-associated chemokine receptors. Evidence that IL-33 caused the differentiation of skin Treg cells into TH2-like cells, combined with high tissue-localized expression of this cytokine in patients with SSc and expression of the ST2 chain of the IL-33 receptor on skin-localized Treg cells, suggests that IL-33 might be an important stimulator of tissue-localized loss of normal Treg cell function. Conclusion: These data are the first evidence for the presence of TH2-likeTreg cells in human autoimmunity and show that Treg cell plasticity can be tissue specific. Localized dysfunction of Treg cells is a previously unknown factor that might contribute to fibrosis in patients with SSc.	[MacDonald, Katherine G.; Dawson, Nicholas A. J.; Levings, Megan K.] Univ British Columbia, Dept Surg, Vancouver, BC V5Z 4H4, Canada; [Huang, Qing; Dunne, James V.; Broady, Raewyn] Univ British Columbia, Dept Med, Vancouver, BC V5Z 4H4, Canada; Child & Family Res Inst, Vancouver, BC, Canada; [Dunne, James V.] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada	University of British Columbia; University of British Columbia; Child & Family Research Institute; St. Paul's Hospital; University of Saskatchewan	Broady, R (corresponding author), Univ British Columbia, Dept Med, Rm A4-186,950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	rbroady@mail.ubc.ca	Dunne, James/ABF-6157-2021	Dawson, Nicholas/0000-0002-2658-8960; Levings, Megan/0000-0002-0305-5790	Canadian Institute of Health Research [MOP-93793]; STEMCELL Technologies; Child and Family Research Institute; CIHR Skin Research Training Centre	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); STEMCELL Technologies; Child and Family Research Institute; CIHR Skin Research Training Centre(Canadian Institutes of Health Research (CIHR))	Supported by the Canadian Institute of Health Research (MOP-93793 to M.K.L. and R.B.) and STEMCELL Technologies. K.G.M. holds awards from the Child and Family Research Institute, and the CIHR Skin Research Training Centre.	Alexander T, 2013, ANN RHEUM DIS, V72, P1549, DOI 10.1136/annrheumdis-2012-202216; Allan SE, 2008, MOL THER, V16, P194, DOI 10.1038/sj.mt.6300341; Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Antiga E, 2010, BRIT J DERMATOL, V162, P1056, DOI 10.1111/j.1365-2133.2010.09633.x; Beriou G, 2009, BLOOD, V113, P4240, DOI 10.1182/blood-2008-10-183251; Bhattacharyya S, 2012, NAT REV RHEUMATOL, V8, P42, DOI 10.1038/nrrheum.2011.149; Brembilla NC, 2012, EUR CYTOKINE NETW, V23, P128, DOI 10.1684/ecn.2013.0325; Broady R, 2010, BLOOD, V116, P5748, DOI 10.1182/blood-2010-07-295436; Buckner JH, 2010, NAT REV IMMUNOL, V10, P849, DOI 10.1038/nri2889; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Clark RA, 2007, BLOOD, V109, P194, DOI 10.1182/blood-2006-02-002873; Clark RA, 2006, J INVEST DERMATOL, V126, P1059, DOI 10.1038/sj.jid.5700199; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Ding YZ, 2012, TRENDS IMMUNOL, V33, P174, DOI 10.1016/j.it.2012.01.002; Dominguez-Villar M, 2011, NAT MED, V17, P673, DOI 10.1038/nm.2389; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Duhen T, 2012, BLOOD, V119, P4430, DOI 10.1182/blood-2011-11-392324; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; KAHARI VM, 1988, J INVEST DERMATOL, V90, P664, DOI 10.1111/1523-1747.ep12560826; Klein S, 2011, ANN RHEUM DIS, V70, P1475, DOI 10.1136/ard.2009.116525; Kleinewietfeld M, 2013, SEMIN IMMUNOL, V25, P305, DOI 10.1016/j.smim.2013.10.009; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Liston A, 2014, NAT REV IMMUNOL, V14, P154, DOI 10.1038/nri3605; Manetti M, 2010, ANN RHEUM DIS, V69, P598, DOI 10.1136/ard.2009.119321; Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329; Mathian A, 2012, ANN RHEUM DIS, V71, P1227, DOI 10.1136/annrheumdis-2011-200709; Matta BM, 2014, J IMMUNOL, V193, P4010, DOI 10.4049/jimmunol.1400481; Mavilia C, 1997, AM J PATHOL, V151, P1751; McClymont SA, 2011, J IMMUNOL, V186, P3918, DOI 10.4049/jimmunol.1003099; McMurchy AN, 2013, BLOOD, V121, P1265, DOI 10.1182/blood-2012-05-431023; Medsger TA, 1999, J RHEUMATOL, V26, P2159; Medsger TA, 2003, CLIN EXP RHEUMATOL, V21, pS42; Meloni F, 2009, CLIN EXP RHEUMATOL, V27, P765; Nagata K, 1999, J IMMUNOL, V162, P1278; O'Reilly S, 2012, RHEUMATOLOGY, V51, P1540, DOI 10.1093/rheumatology/kes090; Parel Y, 2007, ARTHRITIS RHEUM-US, V56, P3459, DOI 10.1002/art.22927; Pesenacker AM, 2013, BLOOD, V121, P2647, DOI 10.1182/blood-2012-08-443473; Radstake TRDJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005903; Rankin AL, 2010, J IMMUNOL, V184, P1526, DOI 10.4049/jimmunol.0903306; Rodriguez RS, 2014, J CLIN INVEST, V124, P1027, DOI 10.1172/JCI72932; Rodriguez-Reyna TS, 2012, RHEUMATOL INT, V32, P2653, DOI 10.1007/s00296-011-2056-y; Sallusto F, 2008, NAT IMMUNOL, V9, P949, DOI 10.1038/ni.f.214; SalmonEhr V, 1996, ARCH DERMATOL, V132, P802, DOI 10.1001/archderm.132.7.802; Scaletti C, 2002, ARTHRITIS RHEUM, V46, P445, DOI 10.1002/art.10049; SCHARFFETTER K, 1988, EUR J CLIN INVEST, V18, P9, DOI 10.1111/j.1365-2362.1988.tb01158.x; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Seneschal J, 2012, IMMUNITY, V36, P873, DOI 10.1016/j.immuni.2012.03.018; Slobodin G, 2010, CELL IMMUNOL, V261, P77, DOI 10.1016/j.cellimm.2009.12.009; Tani C, 2013, CLIN EXP RHEUMATOL, V31, pS172; Terras S, 2013, ANN RHEUM DIS, V72, P144, DOI 10.1136/annrheumdis-2012-201553; Truchetet ME, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3486; Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood-2005-11-4567; Vent-Schmidt J, 2014, INT REV IMMUNOL, V33, P110, DOI 10.3109/08830185.2013.811657; Vettori S, 2014, J CLIN IMMUNOL, V34, P663, DOI 10.1007/s10875-014-0037-0; Vukmanovic-Stejic M, 2008, J CLIN INVEST, V118, P3639, DOI 10.1172/JCI35834; Wang YQ, 2010, J IMMUNOL, V185, P5983, DOI 10.4049/jimmunol.1001255; Yanaba K, 2011, CLIN RHEUMATOL, V30, P825, DOI 10.1007/s10067-011-1686-5; Yang XQ, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4430; Zhang L, 2014, INFLAMMATION, V37, P1213, DOI 10.1007/s10753-014-9848-7; Zhao Q, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/587376; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674	64	103	106	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					946	+		10.1016/j.jaci.2014.12.1932	http://dx.doi.org/10.1016/j.jaci.2014.12.1932			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25678090				2022-12-18	WOS:000352238600016
J	Thomson, NC; Chaudhuri, R; Heaney, LG; Bucknall, C; Niven, RM; Brightling, CE; Menzies-Gow, AN; Mansur, AH; McSharry, C				Thomson, Neil C.; Chaudhuri, Rekha; Heaney, Liam G.; Bucknall, Christine; Niven, Robert M.; Brightling, Christopher E.; Menzies-Gow, Andrew N.; Mansur, Adel H.; McSharry, Charles			Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; cigarette smoking; exsmokers; asthma control; exacerbations; health care use; airway inflammation; inflammatory biomarker	QUALITY-OF-LIFE; CIGARETTE-SMOKING; ORAL CORTICOSTEROIDS; POPULATION; SYMPTOMS; IMPACT; LUNG; VALIDATION; CHALLENGES; RESPONSES	Background: Clinical outcomes are worse in current smokers and exsmokers with mild-to-moderate asthma compared with never smokers, but little is known about the influence of smoking status in patients with severe asthma. Objectives: We sought to examine the association of current or previous cigarette smoking with clinical and inflammatory variables in patients with severe asthma. Methods: We compared patients' demographics, disease characteristics, and biomarkers of inflammation in current smokers (n = 69 [9%]), exsmokers (n = 210 [28%]), and never smokers (n = 461 [62%]) with severe asthma (n = 760) recruited to the British Thoracic Society Severe Asthma Registry. Results: Current smokers had poorer asthma control, more unscheduled health care visits, more rescue courses of oral steroids, and higher anxiety and depression scale scores than exsmokers or never smokers. Current smokers had a reduced proportion of sputum eosinophils compared with never smokers (1% and 4%, respectively) and lower fraction of expired nitric oxide (50 mL/s; 14 ppb and 35 ppb, respectively). Exsmokers compared with never smokers had an increased proportion of sputum neutrophils (59% and 43%, respectively) but a similar proportion of sputum eosinophils (3%) and fraction of expired nitric oxide (50 mL/s; 35 ppb). Both current smokers and exsmokers had reduced serum specific IgE levels to several common environmental allergens. Conclusion: Current smokers with severe asthma exhibit worse clinical and health care outcomes compared with exsmokers and never smokers with severe asthma. Their inflammatory profiles in sputum and blood differ. (J Allergy Clin Immunol 2013; 131:1008-16.)	[Thomson, Neil C.; Chaudhuri, Rekha; McSharry, Charles] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 OYN, Lanark, Scotland; [Heaney, Liam G.] Queens Univ Belfast, Ctr Infect & Immun, Belfast, Antrim, North Ireland; [Bucknall, Christine] Glasgow Royal Infirm, Manchester, Lancs, England; [Niven, Robert M.] Univ Manchester, Manchester, Lancs, England; [Niven, Robert M.] Univ S Manchester Hosp, Manchester M20 8LR, Lancs, England; [Brightling, Christopher E.] Univ Leicester, Inst Lung Hlth, Leicester, Leics, England; [Menzies-Gow, Andrew N.] Royal Brompton Hosp, London SW3 6LY, England; [Mansur, Adel H.] Univ Birmingham, Birmingham Heartlands Hosp, Birmingham, W Midlands, England	University of Glasgow; Queens University Belfast; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Leicester; Royal Brompton Hospital; Heart of England NHS Foundation Trust; University of Birmingham	Thomson, NC (corresponding author), Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 OYN, Lanark, Scotland.	neil.thomson@glasgow.ac.uk		Niven, Robert/0000-0003-2249-960X; brightling, chris/0000-0002-9345-4903; McSharry, Charles/0000-0003-4758-9038; Thomson, Neil/0000-0003-1632-6630	Aerovance; Asthmatx; AstraZeneca; Centocor; GlaxoSmithKline; MedImmune; Novartis; Synairgen; Nycomed; Novartis UK; Genentech; Medical Research Council UK; NI Chest Heart and Stroke Association; Hoffmann la Roche UK; Asthma UK; Merck Sharpe Dohme; Boehringer; British Thoracic Society; NAPP; Medical Research Scotland	Aerovance; Asthmatx; AstraZeneca(AstraZeneca); Centocor; GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Novartis(Novartis); Synairgen; Nycomed; Novartis UK(Novartis); Genentech(Roche HoldingGenentech); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NI Chest Heart and Stroke Association; Hoffmann la Roche UK; Asthma UK; Merck Sharpe Dohme(Merck & Company); Boehringer(Boehringer Ingelheim); British Thoracic Society; NAPP; Medical Research Scotland	Disclosure of potential conflict of interest: N. C. Thomson is a board member for Asmacure, Chiesi, and Respivert; has received grants from Aerovance, Asthmatx, AstraZeneca, Centocor, GlaxoSmithKline, MedImmune, Novartis, and Synairgen; has received payment for lectures, including service on speakers' bureaus, from AstraZeneca, Boston Scientific, Chiesi, GlaxoSmithKline, and Novartis; and has received travel expenses from Novartis and Nycomed. R. Chaudhuri has received travel expenses from Novartis. L. G. Heaney has received grants from GlaxoSmithKline, MedImmune, Novartis UK, AstraZeneca, Genentech, Medical Research Council UK, NI Chest Heart and Stroke Association, Hoffmann la Roche UK, and Asthma UK; has received payment for lectures, including service on speakers' bureaus, from GlaxoSmithKline, Merck Sharpe & Dohme, Nycomed, Novartis, Genentech, and AstraZeneca; and has received travel/accommodations/ meeting expenses from AstraZeneca, Chiesi, Novartis and GlaxoSmithKline. C. Bucknall has received travel support from Novartis, GlaxoSmithKline, and Boehringer and has received payment for lectures, including service on speakers' bureaus, from Novartis and GlaxoSmithKline. R. M. Niven has consultant arrangements with Vectura, has received payment for lectures from GlaxoSmithKline, Novartis, Chiesi, Boehringer, and AstraZeneca; and has received travel expenses from GlaxoSmithKline, Novartis, and Boehringer. A. N. Menzies-Gow has consultant arrangements with Novartis and Roche; has received grants from Asthma UK; has received payment for lectures, including service on speakers' bureaus, from GlaxoSmithKline and Novartis; and has received travel expenses from Novartis, GlaxoSmithKline, and Boehringer Ingelheim. A. H. Mansur has received travel support from the British Thoracic Society; has consultant arrangements with NAPP and Novartis; has received payment for lectures, including service on speakers' bureaus, from GlaxoSmithKline, Chiesi, Vectura, and Novartis; and has received travel expenses from Boehringer and Novartis. C. McSharry is employed by the National Health Service and has a grant pending with Medical Research Scotland.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Blanchet MR, 2007, J LEUKOCYTE BIOL, V81, P1245, DOI 10.1189/jlb.0906548; Brennan C, 2010, J PSYCHOSOM RES, V69, P371, DOI 10.1016/j.jpsychores.2010.04.006; BYRON KA, 1994, CLIN EXP IMMUNOL, V95, P333, DOI 10.1111/j.1365-2249.1994.tb06533.x; Cerveri I, 2012, INT ARCH ALLERGY IMM, V158, P175, DOI 10.1159/000330900; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chaudhuri R, 2008, ALLERGY, V63, P132, DOI 10.1111/j.1398-9995.2007.01538.x; Clatworthy Jane, 2009, Prim Care Respir J, V18, P300, DOI 10.4104/pcrj.2009.00037; Dawkins L, 2009, ADDICTION, V104, P850, DOI 10.1111/j.1360-0443.2009.02522.x; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Eisner MD, 2007, NICOTINE TOB RES, V9, P53, DOI 10.1080/14622200601078293; Eisner MD, 2001, PUBLIC HEALTH REP, V116, P148, DOI 10.1016/S0033-3549(04)50006-7; Haldar P, 2007, J ALLERGY CLIN IMMUN, V119, P1043, DOI 10.1016/j.jaci.2007.02.042; Heaney LG, 2010, THORAX, V65, P787, DOI 10.1136/thx.2010.137414; Heikkinen H, 2008, NICOTINE TOB RES, V10, P1199, DOI 10.1080/14622200802163142; Jang AS, 2009, J KOREAN MED SCI, V24, P209, DOI 10.3346/jkms.2009.24.2.209; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736; McSharry CP, 2005, J ALLERGY CLIN IMMUN, V116, P88, DOI 10.1016/j.jaci.2005.03.025; McTaggart-Cowan HM, 2008, QUAL LIFE RES, V17, P453, DOI 10.1007/s11136-008-9309-6; Mishra NC, 2008, J IMMUNOL, V180, P7655, DOI 10.4049/jimmunol.180.11.7655; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Mortaz E, 2008, J LEUKOCYTE BIOL, V83, P575, DOI 10.1189/jlb.0907625; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Raherison C, 2004, ALLERGY, V59, P940, DOI 10.1111/j.1398-9995.2004.00491.x; SHERRILL DL, 1994, J ALLERGY CLIN IMMUN, V94, P954, DOI 10.1016/0091-6749(94)90113-9; Spears M, 2011, RESP MED, V105, P1823, DOI 10.1016/j.rmed.2011.06.014; Spears M, 2010, EXPERT REV CLIN IMMU, V6, P257, DOI 10.1586/ECI.09.85; Strine TW, 2007, J ASTHMA, V44, P651, DOI 10.1080/02770900701554896; Tarride JE, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-12; Thomson NC, 2011, ANN RESP MED, V2, P47; Thomson NC, 2012, CHEST, V141, P286, DOI 10.1378/chest.11-1424; Thomson NC, 2009, CURR OPIN PULM MED, V15, P39, DOI 10.1097/MCP.0b013e32831da894; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wilson D, 1999, PREV MED, V29, P139, DOI 10.1006/pmed.1999.0523	43	103	106	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1008	1016		10.1016/j.jaci.2012.12.1574	http://dx.doi.org/10.1016/j.jaci.2012.12.1574			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23419540				2022-12-18	WOS:000317187200007
J	Ryu, JH; Yoo, JY; Kim, MJ; Hwang, SG; Ahn, KC; Ryu, JC; Choi, MK; Joo, JH; Kim, CH; Lee, SN; Lee, WJ; Kim, J; Shin, DM; Kweon, MN; Bae, YS; Yoon, JH				Ryu, Ji-Hwan; Yoo, Jung-Yeon; Kim, Min-Ji; Hwang, Sang-Gyu; Ahn, Kwang Chu; Ryu, Jae-Chan; Choi, Mi-Kyung; Joo, Jung Hee; Kim, Chang-Hoon; Lee, Sang-Nam; Lee, Won-Jae; Kim, Jaesang; Shin, Dong Min; Kweon, Mi-Na; Bae, Yun Soo; Yoon, Joo-Heon			Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; allergic asthma; innate immunity; house dust mite; pathogen associated molecular pattern; beta-glucans; Toll-like receptor; epithelium; reactive oxygen species; dual oxidase 2	DENDRITIC CELLS; EPITHELIAL-CELLS; ACTIVATION; RHINITIS; INFLAMMATION; INNATE; NASAL; RESPONSES; DECTIN-1; ASTHMA	Background: Allergic rhinitis (AR) and asthma are 2 entities of allergic airway diseases that frequently occur together, which is referred to as united airways. In contrast to this general concept, we hypothesized that innate immunity of the upper and lower airways is respectively distinctive, because the immunologic conditions of the nasal and lung mucosa as well as the functions of the immune cells within their epithelia are different. Objective: We wanted to identify distinctive mechanisms of innate immunity in the nose and lung mucosa, which are responsible for house dust mite (HDM)-induced AR and allergic asthma (AA), respectively. Methods: We constructed a mouse model of AR or AA induced by sensitization and consequent provocation with HDM extracts. Results: HDM-derived beta-glucans, rather than LPS, were proven to be essential to activating innate immunity in the nasal mucosa and triggering AR, which depended on Toll-like receptor 2 (TLR2), but not on TLR4; however, the LPS/TLR4 signaling axis, rather than beta-glucans/TLR2, was critical to HDM-induced AA. These differences were attributed to the specific role of beta-glucans and LPS in inducing the surface expression of TLR2 and TLR4 and their translocation to lipid rafts in nasal and bronchial epithelial cells, respectively. We also showed that dual oxidase 2-generated reactive oxygen species mediate both beta-glucan-induced TLR2 activation and LPS-induced TLR4 activation. Conclusions: We describe a novel finding of distinctive innate immunity of the nose and lungs, respectively, which trigger AR and AA, by showing the critical role of HDM-induced TLR activation via dual oxidase 2-mediated reactive oxygen species. (J Allergy Clin Immunol 2013;131:549-61.)	[Ryu, Ji-Hwan; Kim, Min-Ji; Hwang, Sang-Gyu; Ahn, Kwang Chu; Ryu, Jae-Chan; Joo, Jung Hee; Lee, Sang-Nam; Yoon, Joo-Heon] Res Ctr Human Nat Def Syst, Seoul, South Korea; [Ryu, Ji-Hwan; Kim, Min-Ji; Ryu, Jae-Chan; Yoon, Joo-Heon] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; [Yoo, Jung-Yeon; Choi, Mi-Kyung; Kim, Jaesang; Bae, Yun Soo] Ewha Womans Univ, Dept Life Sci, Seoul, South Korea; [Kim, Chang-Hoon; Yoon, Joo-Heon] Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul 120752, South Korea; [Kim, Chang-Hoon; Yoon, Joo-Heon] Yonsei Univ, Coll Med, Airway Mucus Inst, Seoul 120752, South Korea; [Lee, Won-Jae] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea; [Lee, Won-Jae] Natl Creat Res Initiat Ctr Symbiosyst, Seoul, South Korea; [Shin, Dong Min] Yonsei Univ, Coll Dent, Dept Oral Biol, Seoul 120752, South Korea; [Kweon, Mi-Na] Int Vaccine Inst, Div Sci Lab, Mucosal Immunol Sect, Seoul, South Korea	Yonsei University; Yonsei University Health System; Ewha Womans University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Seoul National University (SNU); Yonsei University; Yonsei University Health System; International Vaccine Institute	Yoon, JH (corresponding author), Yonsei Univ, Coll Med, Dept Otorhinolaryngol, 50 Yonsei Ro, Seoul 120752, South Korea.	jhyoon@yuhs.ac	Kim, Chang-Hoon/D-7205-2016; rchnds, rchnds/D-7595-2016; Yoon, Joo-Heon/E-5781-2016	Kim, Chang-Hoon/0000-0003-1238-6396; Shin, Dong Min/0000-0001-6042-0435; Yoon, Joo-Heon/0000-0003-2404-7156; Kim, Minji/0000-0002-8484-6817	Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science, and Technology [2012-0000803, 2010-0022899]; Yonsei University College of Medicine [6-2009-0115]; Basic Science Research Program through the National Research Foundation of Korea; Ministry of Education, Science, and Technology; Yonsei University College of Medicine	Basic Science Research Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Yonsei University College of Medicine(General Electric); Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Yonsei University College of Medicine(General Electric)	Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (grant 2012-0000803 to J.-H.Y. and grant 2010-0022899 to J.-H.R.) and by the Yonsei University College of Medicine (grant 6-2009-0115 to J.-H.R.). None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.; J.-H. Ryu has received grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science, and Technology and Yonsei University College of Medicine. J.-H. Yoon has received grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science, and Technology. The rest of the authors declare that they have no relevant conflicts of interest.	Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Boots AW, 2009, J BIOL CHEM, V284, P17858, DOI 10.1074/jbc.M809761200; Braunstahl Gert-Jan, 2009, Proc Am Thorac Soc, V6, P652, DOI 10.1513/pats.200906-052DP; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Cirillo I, 2009, ALLERGY, V64, P439, DOI 10.1111/j.1398-9995.2008.01851.x; Corren J, 2007, CURR OPIN PULM MED, V13, P13, DOI 10.1097/MCP.0b013e328010d0db; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Fischer H, 2009, ANTIOXID REDOX SIGN, V11, P2453, DOI [10.1089/ars.2009.2558, 10.1089/ARS.2009.2558]; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gattas MV, 2009, FREE RADICAL BIO MED, V47, P1450, DOI 10.1016/j.freeradbiomed.2009.08.017; Greene CM, 2005, J IMMUNOL, V174, P1638, DOI 10.4049/jimmunol.174.3.1638; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Holzinger A, 2001, METH MOL B, V161, P109; Jian W, 2009, AM J OTOLARYNG, V30, P24, DOI 10.1016/j.amjoto.2008.01.003; Joo JH, 2012, ANTIOXID REDOX SIGN, V16, P57, DOI 10.1089/ars.2011.3898; KleinJan A, 2010, CLIN EXP ALLERGY, V40, P494, DOI 10.1111/j.1365-2222.2009.03417.x; KleinJan A, 2006, J ALLERGY CLIN IMMUN, V118, P1117, DOI 10.1016/j.jaci.2006.05.030; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Lina G, 2003, APPL ENVIRON MICROB, V69, P18, DOI 10.1128/AEM.69.1.18-23.2003; Lloyd CM, 2010, NAT MED, V16, P273, DOI 10.1038/nm0310-273; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Nakahira K, 2006, J EXP MED, V203, P2377, DOI 10.1084/jem.20060845; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Nonaka M, 2010, RHINOLOGY, V48, P41, DOI 10.4193/Rhin09.019; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Parker D, 2011, AM J RESP CELL MOL, V45, P189, DOI 10.1165/rcmb.2011-0011RT; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Powers KA, 2006, J EXP MED, V203, P1951, DOI 10.1084/jem.20060943; Rada B, 2010, FEBS LETT, V584, P917, DOI 10.1016/j.febslet.2010.01.025; Rizoli SB, 1999, J SURG RES, V83, P130, DOI 10.1006/jsre.1999.5581; Saenz SA, 2010, TRENDS IMMUNOL, V31, P407, DOI 10.1016/j.it.2010.09.001; Shin DM, 2008, CELL MICROBIOL, V10, P1893, DOI 10.1111/j.1462-5822.2008.01179.x; Steele C, 2005, PLOS PATHOG, V1, P323, DOI 10.1371/journal.ppat.0010042; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; THOMPSON AB, 1995, EUR RESPIR J, V8, P127, DOI 10.1183/09031936.95.08010127; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Viriyakosol S, 2005, INFECT IMMUN, V73, P1553, DOI 10.1128/IAI.73.3.1553-1560.2005; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138; Yadav M, 2006, BLOOD, V108, P3168, DOI 10.1182/blood-2006-05-024406; Yamamoto K, 2006, CLIN EXP ALLERGY, V36, P760, DOI 10.1111/j.1365-2222.2006.02488.x	47	103	104	0	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					549	561		10.1016/j.jaci.2012.07.050	http://dx.doi.org/10.1016/j.jaci.2012.07.050			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23036747				2022-12-18	WOS:000314661500035
J	Li, XN; Ampleford, EJ; Howard, TD; Moore, WC; Torgerson, DG; Li, HS; Busse, WW; Castro, M; Erzurum, SC; Israel, E; Nicolae, DL; Ober, C; Wenzel, SE; Hawkins, GA; Bleecker, ER; Meyers, DA				Li, Xingnan; Ampleford, Elizabeth J.; Howard, Timothy D.; Moore, Wendy C.; Torgerson, Dara G.; Li, Huashi; Busse, William W.; Castro, Mario; Erzurum, Serpil C.; Israel, Elliot; Nicolae, Dan L.; Ober, Carole; Wenzel, Sally E.; Hawkins, Gregory A.; Bleecker, Eugene R.; Meyers, Deborah A.			Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; genetics; genome-wide association study; TNFAIP3 interacting protein 1	SYSTEMIC-LUPUS-ERYTHEMATOSUS; NECROSIS-FACTOR-ALPHA; REGULATORY T-CELLS; COLITIS-RISK LOCI; SUSCEPTIBILITY LOCI; KAPPA-B; RESEARCH-PROGRAM; CROHNS-DISEASE; COMMON VARIANT; DOUBLE-BLIND	Background: Genome-wide association studies (GWASs) of asthma have consistently implicated the ORM1-like 3 and gasdermin B (ORMDL3-GSDMB), IL33, IL-1 receptor-like 1 and IL-18 receptor 1 (IL1RL1-IL18R1), RAD50-IL13, thymic stromal lymphopoietin and WD repeat domain 36 region (TSLP-WDR36), and HLA-DR/DQ regions. Objective: A GWAS of asthma was performed in a non-Hispanic white population. Methods: A GWAS was performed in 813 Severe Asthma Research Program/Collaborative Studies on the Genetics of Asthma/Chicago Asthma Genetics Study cases and 1564 control subjects. The GWAS results were compared with those of the published GWASs of autoimmune diseases. Results: Multiple single nucleotide polymorphisms in the TNFAIP3 interacting protein 1 (TNIP1) gene, which interacts with TNFAIP3 and inhibits the TNF-alpha-induced nuclear factor kappa B inflammation pathway, were associated with asthma: rs1422673 (P = 3.44 x 10(-7)) and rs10036748 (P = 1.41 x 10(-6), r(2) = 0.67). rs1422673 was also associated with asthma in the published GABRIEL (P = .018) and EVE (P = 1.31 x 10(-5)) studies. The minor allele Tof rs20541 in IL13 is the risk allele for asthma but the protective allele for psoriasis. The minor allele Tof rs2395185 in HLA-DRA is the risk allele for asthma but the protective allele for ulcerative colitis. The minor allele A of rs2872507 in GSDMB is the protective allele for asthma but the risk allele for rheumatoid arthritis, Crohn disease, and ulcerative colitis. The T allele of rs10036748 in the TNIP1 gene is the minor protective allele for asthma but the minor or major risk allele for systemic lupus erythematosus and systemic sclerosis in non-Hispanic white or Chinese subjects, respectively. Conclusions: Our study suggests that single nucleotide polymorphisms associated with both asthma and autoimmune diseases might have opposite effects on immunopathogenesis. (J Allergy Clin Immunol 2012; 130:861-8.)	[Li, Xingnan; Ampleford, Elizabeth J.; Howard, Timothy D.; Moore, Wendy C.; Li, Huashi; Hawkins, Gregory A.; Bleecker, Eugene R.; Meyers, Deborah A.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27157 USA; [Busse, William W.] Univ Wisconsin, Dept Med, Madison, WI USA; [Castro, Mario] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Castro, Mario] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Erzurum, Serpil C.] Lerner Res Inst, Cleveland, OH USA; [Israel, Elliot] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA; [Wenzel, Sally E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; [Torgerson, Dara G.; Nicolae, Dan L.; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	Wake Forest University; Wake Forest Baptist Medical Center; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Chicago	Li, XN (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Med Ctr Blvd, Winston Salem, NC 27157 USA.	xinli@wfubmc.edu; dmeyers@wfubmc.edu		Nicolae, Dan/0000-0002-0918-4630; Ober, Carole/0000-0003-4626-9809; Wenzel, Sally/0000-0002-4242-0164	National Institutes of Health (NIH) [HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL87665, HL91762]; NIH grant [HL87665, HL72414, HL101651]; Genentech, Inc; Novartis Pharmaceuticals Corp; NIH [HL87665, HL76285]; Aerovance; Amgen; AstraZeneca; Boehringer-Ingelheim; Centocor; Ception; Forest; Genentech; GlaxoSmithKline; MedImmune; Novartis; Pfizer; Sanofi Aventis; Wyeth; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); National Heart, Lung, and Blood Institute (NHLBI); NIH/NHLBI; NIH; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448, UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153, M01RR007122, M01RR003186, M01RR018390, UL1RR024992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076285, R01HL072414, R01HL069116, R01HL069170, R01HL069349, R01HL091762, R01HL069130, R01HL069149, R01HL069167, RC2HL101651, R01HL069155, R01HL087665, R01HL069174] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech, Inc(Roche HoldingGenentech); Novartis Pharmaceuticals Corp(Novartis); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Aerovance; Amgen(Amgen); AstraZeneca(AstraZeneca); Boehringer-Ingelheim(Boehringer Ingelheim); Centocor; Ception; Forest; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Novartis(Novartis); Pfizer(Pfizer); Sanofi Aventis(Sanofi-Aventis); Wyeth(Wyeth); National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Severe Asthma Research Program (SARP) centers were supported by National Institutes of Health (NIH) grants HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL87665, and HL91762. Genetic studies for SARP and the Collaborative Studies on the Genetics of Asthma (CSGA) were funded by NIH grant HL87665. The STAMPEED study, including SARP/CSGA/Chicago Asthma Genetics Study data, was funded by NIH grant HL87665, HL72414, and HL101651. The clinical Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens study was supported by Genentech, Inc, and Novartis Pharmaceuticals Corp, and the genetic studies were funded by NIH grants HL76285 and HL87665.; W.C. Moore has been a subinvestigator on clinical trials supported by Aerovance, Amgen, AstraZeneca, Boehringer-Ingelheim, Centocor, Ception, Forest, Genentech, GlaxoSmithKline, MedImmune, Novartis, Pfizer, Sanofi Aventis, and Wyeth. W.W. Busse has received grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung, and Blood Institute (NHLBI); is on a board for Merck; and has consulted for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech. D.L. Nicolae has received a grant from the NIH/NHLBI. C. Ober has received grants and travel support from the NIH and lecture honoraria from various entities. S.E. Wenzel has received grants from or has grants pending from Amgen, GlaxoSmithKline, MedImmune, Sanofi Aventis, and Genentech. The rest of the authors declare that they have no relevant conflicts of interest.	Allanore Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002091; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Bell GM, 2011, NAT REV RHEUMATOL, V7, P507, DOI 10.1038/nrrheum.2011.106; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; El Bakkouri K, 2005, J BIOL CHEM, V280, P17938, DOI 10.1074/jbc.M413588200; Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Fuss IJ, 2008, INFLAMM BOWEL DIS, V14, pS110, DOI 10.1002/ibd.20683; Gateva V, 2009, NAT GENET, V41, P1228, DOI 10.1038/ng.468; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hakonarson H, 2008, DIABETES, V57, P1143, DOI 10.2337/db07-1305; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hom G, 2008, NEW ENGL J MED, V358, P900, DOI 10.1056/NEJMoa0707865; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Li X, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Li XN, 2012, J ALLERGY CLIN IMMUN, V129, P575, DOI 10.1016/j.jaci.2011.09.040; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Lluis A, 2011, J ALLERGY CLIN IMMUN, V127, P1587, DOI 10.1016/j.jaci.2011.03.015; Martinez GJ, 2009, J BIOL CHEM, V284, P35283, DOI 10.1074/jbc.C109.078238; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morjaria JB, 2008, THORAX, V63, P584, DOI 10.1136/thx.2007.086314; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Noguchi E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002170; Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Silverberg MS, 2009, NAT GENET, V41, P216, DOI 10.1038/ng.275; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; Sun LD, 2010, NAT GENET, V42, P1005, DOI 10.1038/ng.690; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tran DQ, 2009, P NATL ACAD SCI USA, V106, P13445, DOI 10.1073/pnas.0901944106; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhernakova A, 2009, NAT REV GENET, V10, P43, DOI 10.1038/nrg2489	56	103	104	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					861	+		10.1016/j.jaci.2012.04.041	http://dx.doi.org/10.1016/j.jaci.2012.04.041			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22694930	Green Accepted			2022-12-18	WOS:000309594800004
J	Asarnoj, A; Nilsson, C; Lidholm, J; Glaumann, S; Ostblom, E; Hedlin, G; van Hage, M; Lilja, G; Wickman, M				Asarnoj, Anna; Nilsson, Caroline; Lidholm, Jonas; Glaumann, Susanne; Ostblom, Eva; Hedlin, Gunilla; van Hage, Marianne; Lilja, Gunnar; Wickman, Magnus			Peanut component Ara h 8 sensitization and tolerance to peanut	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ara h 1; Ara h 2; Ara h 3; Ara h 6; Ara h 8; Ara h 9; component-resolved diagnostics; molecular allergology; oral food challenge; peanut allergy; sensitization	ORAL ALLERGY SYNDROME; BIRCH POLLEN; IMMUNOLOGICAL CHARACTERIZATION; ANAPHYLACTIC REACTIONS; POSITION PAPER; CHILDREN; IGE; SYMPTOMS; PROTEIN; FOOD	Background: Isolated Ara h 8 sensitization is suggested to be associated with no or mild symptoms among peanut-sensitized subjects. Objective: We sought to investigate the occurrence of systemic reactions in children with isolated sensitization to Ara h 8. Methods: Participants were 144 children sensitized to Ara h 8 (>= 0.35 kU(A)/L) but not to Ara h 1, Ara h 2, or Ara h 3 (<0.35 kU(A)/L). An open oral challenge with peanut was performed in those subjects who did not consume peanut regularly, and an extended IgE reactivity profile was obtained. If the child had a documented history of systemic reactions up to grade I anaphylaxis, double-blind, placebo-controlled food challenges were performed. Results: One hundred twenty-nine (89.5%) children were either peanut consumers or did not react to peanut challenge. Another 14 (9.7%) children experienced oral cavity symptoms at the first 2 but not subsequent challenge doses. At the time of the doubleblind, placebo-controlled food challenge, 1 boy with a previous mild systemic reaction to peanut experienced lip swelling, stomach cramping, and objective tiredness. Reanalysis of IgE levels showed an increase in peanut IgE levels from 1.5 to 8.8 kU(A)/L, but IgE levels to Ara h 8 remained stable and IgE levels to Ara h 1, Ara h 2, and Ara h 3 were all still less than 0.35 kU(A)/L. The IgE level to Ara h 6 was 0.45 kU(A)/L. Conclusion: Isolated Ara h 8 sensitization indicates tolerance to peanuts in almost all cases. However, sensitization against thus far unidentified determinants in peanut might cause symptoms in rare cases. (J Allergy Clin Immunol 2012; 130:468-72.)	[Asarnoj, Anna; Wickman, Magnus] Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; [Asarnoj, Anna; Hedlin, Gunilla] Karolinska Inst, Astrid Lindgrens Childrens Hosp, Dept Womens & Childrens Hlth, SE-17177 Stockholm, Sweden; [Asarnoj, Anna; Ostblom, Eva; Hedlin, Gunilla; Wickman, Magnus] Karolinska Inst, Ctr Allergy Res, SE-17177 Stockholm, Sweden; [Nilsson, Caroline; Glaumann, Susanne; Ostblom, Eva; Lilja, Gunnar; Wickman, Magnus] Karolinska Inst, Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden; [Nilsson, Caroline; Glaumann, Susanne; Ostblom, Eva] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, SE-17177 Stockholm, Sweden; [Lidholm, Jonas] Thermo Fisher Sci, Uppsala, Sweden; [van Hage, Marianne] Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, SE-17177 Stockholm, Sweden; [van Hage, Marianne] Univ Hosp, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; Thermo Fisher Scientific; Karolinska Institutet	Asarnoj, A (corresponding author), Karolinska Inst, Natl Inst Environm Med, POB 210, SE-17177 Stockholm, Sweden.	anna.asarnoj@ki.se	Asarnoj, Anna/ABC-4112-2020; Nilsson, Caroline/AFK-2402-2022; Nilsson, Caroline/AAF-9663-2022; van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Lidholm, Jonas/0000-0002-7779-3411; Asarnoj, Anna/0000-0002-0797-2369	Swedish Asthma and Allergy Association's Research Foundation; Foundation for Health Care Sciences and Allergy Research; Centre for Allergy Research (CfA); Stockholm County Council; Swedish Research Council, Sweden; Thermo Fisher Scientific; ALK-Abello	Swedish Asthma and Allergy Association's Research Foundation; Foundation for Health Care Sciences and Allergy Research; Centre for Allergy Research (CfA); Stockholm County Council(Stockholm County Council); Swedish Research Council, Sweden(Swedish Research Council); Thermo Fisher Scientific; ALK-Abello	Supported by the Swedish Asthma and Allergy Association's Research Foundation, the Foundation for Health Care Sciences and Allergy Research, the Centre for Allergy Research (CfA), the Stockholm County Council, and the Swedish Research Council, Sweden. Thermo Fisher Scientific kindly provided the reagents for the study and performed some of the IgE determinations.; A. Asarnoj has received research support from Thermo Fisher Scientific. J. Lidholm is employed by Thermo Fisher Scientific. M. van Hage has received lecture fees from Thermo Fisher Scientific. M. Wickman has received lecture fees from ALK-Abello and has received research support from Thermo Fisher Scientific. The rest of the authors declare that they have no relevant conflicts of interest.	Asarnoj A, 2008, CLIN EXP ALLERGY, V38, P1507, DOI 10.1111/j.1365-2222.2008.03046.x; Asarnoj A, 2012, INT ARCH ALLERGY IMM, V159, P209, DOI 10.1159/000336027; Asarnoj A, 2010, ALLERGY, V65, P1189, DOI 10.1111/j.1398-9995.2010.02334.x; Asarnoj A, 2010, ALLERGY, V65, P213, DOI 10.1111/j.1398-9995.2009.02138.x; Asero R, 1996, J ALLERGY CLIN IMMUN, V97, P611, DOI 10.1016/S0091-6749(96)70306-8; Blanc F, 2009, CLIN EXP ALLERGY, V39, P1277, DOI 10.1111/j.1365-2222.2009.03294.x; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Borres MP, 2011, PEDIAT ALLERG IMM-UK, V22, P454, DOI 10.1111/j.1399-3038.2011.01197.x; Burks W, 1998, ALLERGY, V53, P725, DOI 10.1111/j.1398-9995.1998.tb03967.x; Codreanu F, 2011, INT ARCH ALLERGY IMM, V154, P216, DOI 10.1159/000321108; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Hauser Michael, 2010, Allergy Asthma Clin Immunol, V6, P1, DOI 10.1186/1710-1492-6-1; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; Koppelman SJ, 2005, CLIN EXP ALLERGY, V35, P490, DOI 10.1111/j.1365-2222.2005.02204.x; Kosma P, 2011, ACTA PAEDIATR, V100, P305, DOI 10.1111/j.1651-2227.2010.02049.x; Maeda Yuji, 2008, Allergol Int, V57, P79, DOI 10.2332/allergolint.O-07-496; Maleki SJ, 2003, J ALLERGY CLIN IMMUN, V112, P190, DOI 10.1067/mai.2003.1551; Mattsson L, 2010, CLIN EXP ALLERGY, V40, P1276, DOI 10.1111/j.1365-2222.2010.03533.x; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Moverare R, 2011, INT ARCH ALLERGY IMM, V156, P282, DOI 10.1159/000323891; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Sastre J, 2010, CLIN EXP ALLERGY, V40, P1442, DOI 10.1111/j.1365-2222.2010.03585.x; van Odijk J, 2005, ALLERGY, V60, P602, DOI 10.1111/j.1398-9995.2005.00666.x; van Zuuren EJ, 2010, ALLERGY, V65, P1348, DOI 10.1111/j.1398-9995.2010.02357.x; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Vetander M, 2012, CLIN EXP ALLERGY, V42, P568, DOI 10.1111/j.1365-2222.2011.03954.x; Vetander M, 2011, PEDIAT ALLERG IMM-UK, V22, P369, DOI 10.1111/j.1399-3038.2010.01115.x; Vissers YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023998; Webber CM, 2010, ANN ALLERG ASTHMA IM, V104, P101, DOI 10.1016/j.anai.2009.11.007	36	103	106	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					468	472		10.1016/j.jaci.2012.05.019	http://dx.doi.org/10.1016/j.jaci.2012.05.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22738678	Bronze			2022-12-18	WOS:000307002200029
J	Rochat, MK; Illi, S; Ege, MJ; Lau, S; Keil, T; Wahn, U; von Mutius, E				Rochat, Mascha K.; Illi, Sabina; Ege, Markus J.; Lau, Susanne; Keil, Thomas; Wahn, Ulrich; von Mutius, Erika		MAS Grp	Allergic rhinitis as a predictor for wheezing onset in school-aged children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; birth cohort study; wheezing; allergic sensitization; risk factors	1ST 6 YEARS; BRONCHIAL HYPERRESPONSIVENESS; PERSISTENT ASTHMA; AIRWAY DISEASE; BIRTH COHORT; RISK-FACTORS; HAY-FEVER; FOLLOW-UP; LIFE; CHILDHOOD	Background: Rhinitis in older children and adults has been shown to be a predictor for adolescent- and adult-onset asthma. These findings suggest an interaction between the upper and lower airways. Whether rhinitis is a predictor for childhood-onset asthma is unknown. Objective: We sought to investigate whether rhinitis in early childhood is an independent predictor for wheezing between the ages of 5 and 13 years in the German Multicentre Allergy Study birth cohort. Methods: The German Multicentre Allergy Study cohort initially included 1314 healthy children. They were followed from birth to the age of 13 years with regular questionnaires and interviews. Specific IgE levels were measured at yearly intervals. Airway hyperresponsiveness was assessed at 7 years. Results: Allergic rhinitis until the age of 5 years was found to be a predictor for developing wheezing between the ages of 5 and 13 years, with an adjusted relative risk of 3.82 (P <.001). This association was not attributable to the type of sensitization, the severity of sensitization, or atopic dermatitis during the first 2 years of life. In this group of children, 41.5% of all new cases of wheezing occurred among children with preceding allergic rhinitis. Conclusions: The first manifestation of allergic rhinitis occurs in preschool children in whom it is a predictor for subsequent wheezing onset. Preschool children with rhinitis might thus benefit from early assessment of allergic sensitization to identify the children at high risk of wheezing. (J Allergy Clin Immunol 2010;126:1170-5.)	[Rochat, Mascha K.; Illi, Sabina; Ege, Markus J.; von Mutius, Erika] Univ Munich, Childrens Hosp, D-80539 Munich, Germany; [Lau, Susanne; Wahn, Ulrich] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Keil, Thomas] Charite, Inst Social Med & Epidemiol, D-13353 Berlin, Germany	University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rochat, MK (corresponding author), Dr von Haunersche Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.	wehntaler@gmail.com	Ege, Markus/C-1962-2012	Ege, Markus/0000-0001-6643-3923; von Mutius, Erika/0000-0002-8893-4515	German Ministry of Education and Research (BMBF) [01 EE9406]; AstraZeneca Germany; Marie Curie Actions [MEST-CT-2005-020524-GALTRAIN]; European Union; German Research Foundation (DFG); Behring-Rontgen Foundation	German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); AstraZeneca Germany(AstraZeneca); Marie Curie Actions(European Commission); European Union(European Commission); German Research Foundation (DFG)(German Research Foundation (DFG)); Behring-Rontgen Foundation	Supported by the German Ministry of Education and Research (BMBF), grant number 01 EE9406, and cofunded by an unrestricted educational grant from AstraZeneca Germany. M. K. R. was supported by a Marie Curie Actions research grant (MEST-CT-2005-020524-GALTRAIN).; Disclosure of potential conflict of interest: M. J. Ege has received research grants from the European Union, the German Research Foundation (DFG), and the Behring-Rontgen Foundation. The rest of the authors have declared that they have no conflict of interest.	ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bachert C, 2004, IMMUNOL ALLERGY CLIN, V24, P19, DOI 10.1016/S0889-8561(03)00104-8; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bonness S, 2007, CURR OPIN ALLERGY CL, V7, P382, DOI 10.1097/ACI.0b013e3282a643c3; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Braunstahl GJ, 2005, J ALLERGY CLIN IMMUN, V115, P142, DOI 10.1016/j.jaci.2004.10.041; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Choi SH, 2007, ALLERGY, V62, P1051, DOI 10.1111/j.1398-9995.2007.01403.x; Compalati E, 2009, ANN ALLERG ASTHMA IM, V102, P22, DOI 10.1016/S1081-1206(10)60103-2; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Corren J, 2007, CURR OPIN PULM MED, V13, P13, DOI 10.1097/MCP.0b013e328010d0db; Daly LE, 1998, AM J EPIDEMIOL, V147, P783; Dixon AE, 2009, CURR OPIN PULM MED, V15, P19, DOI 10.1097/MCP.0b013e32831da87e; Ferdousi HA, 2005, PEDIAT ALLERG IMM-UK, V16, P478, DOI 10.1111/j.1399-3038.2005.00296.x; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holt PG, 2007, CURR OPIN ALLERGY CL, V7, P547, DOI 10.1097/ACI.0b013e3282f14a17; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Joseph-Bowen J, 2004, J ALLERGY CLIN IMMUN, V114, P1040, DOI 10.1016/j.jaci.2004.07.051; Krouse JH, 2008, OTOLARYNG CLIN N AM, V41, pXI, DOI 10.1016/j.otc.2007.11.015; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Marinho S, 2007, ALLERGY, V62, P385, DOI 10.1111/j.1398-9995.2006.01294.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Niggemann B, 2001, EUR RESPIR J, V17, P246, DOI 10.1183/09031936.01.17202460; Panettieri RA, 2008, J ALLERGY CLIN IMMUN, V121, P607, DOI 10.1016/j.jaci.2008.01.006; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Passalacqua G, 2001, CURR OPIN ALLERGY CL, V1, P7; Porsbjerg C, 2006, CHEST, V129, P309, DOI 10.1378/chest.129.2.309; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014	39	103	106	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1170	U160		10.1016/j.jaci.2010.09.008	http://dx.doi.org/10.1016/j.jaci.2010.09.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21051078				2022-12-18	WOS:000284947800014
J	Siddiqui, S; Mistry, V; Doe, C; Roach, K; Morgan, A; Wardlaw, A; Pavord, I; Bradding, P; Brightling, C				Siddiqui, Salman; Mistry, Vijay; Doe, Camille; Roach, Katy; Morgan, Angela; Wardlaw, Andrew; Pavord, Ian; Bradding, Peter; Brightling, Christopher			Airway hyperresponsiveness is dissociated from airway wall structural remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; nonasthmatic eosinophilic bronchitis; airway hyperresponsiveness; mast cell; remodeling	EOSINOPHILIC BRONCHITIS; SMOOTH-MUSCLE; SEVERE ASTHMA; THICKNESS; RESPONSIVENESS; INFLAMMATION; EXPRESSION; INFILTRATION; EPITHELIUM; CHILDHOOD	Background: Nonasthmatic eosinophilic bronchitis (EB) has emerged as a useful tool to study the structural and inflammatory mechanisms of airway hyperresponsiveness (AHR) in asthma. We have previously shown that vascular remodeling and reticular basement membrane (RBM) thickening are present in EB. However, it is not known whether other features of structural remodeling including increased airway smooth muscle (ASM) mass, matrix deposition, and glandular hyperplasia are also present in EB. Objectives: We sought to determine whether structural remodeling occurs in EB and is associated with AHR and airflow limitation. Methods: Forty-two patients with asthma, 21 patients with EB, and 19 healthy volunteers were recruited. ASM area, RBM thickness, collagen 3 deposition, glandular area, mast cells, and granulocytes were assessed in bronchial biopsy samples. Results: Nonasthmatic eosinophilic bronchitis and asthma were associated with a significant increase in ASM mass and RBM thickness compared with healthy subjects. In contrast, we did not observe any significant differences in collagen 3 deposition in the lamina propria and ASM or the % area of glands in the lamina propria. Univariate analysis demonstrated that mast cell numbers in the ASM were the only feature of remodeling associated with AHR (beta = -0.51; P = .004). Stepwise linear regression revealed that a combination of mast cell numbers in the ASM (beta = -0.43) and disease duration (beta = -0.25; model adjusted R-2 = 0.26; P = .027) best modeled AHR. Conclusion: Mast cell localization to the ASM bundle, but not structural remodeling of the airway wall, is associated with AHR in asthma.	[Siddiqui, Salman; Mistry, Vijay; Doe, Camille; Roach, Katy; Morgan, Angela; Wardlaw, Andrew; Pavord, Ian; Bradding, Peter; Brightling, Christopher] Univ Leicester, Inst Lung Hlth, Leicester LE3 9QP, Leics, England	University of Leicester	Brightling, C (corresponding author), Univ Leicester, Inst Lung Hlth, Leicester LE3 9QP, Leics, England.	ceb17@le.ac.uk		Bradding, Peter/0000-0001-8403-0319; Siddiqui, Salman/0000-0003-3770-7870; Wardlaw, Andrew/0000-0001-6583-0791; brightling, chris/0000-0002-9345-4903; Roach, Katy M/0000-0002-4825-8719; Pavord, Ian/0000-0002-4288-5973	Asthma UK [05/058] Funding Source: researchfish; Wellcome Trust [082265] Funding Source: Medline	Asthma UK; Wellcome Trust(Wellcome TrustEuropean Commission)		Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; Brightling CE, 2006, CHEST, V129, p116S, DOI 10.1378/chest.129.1_suppl.116S; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; Brightling CE, 2000, CLIN EXP ALLERGY, V30, P4; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Juniper E, 1994, HISTAMINE METHACHOLI; LOZEWICZ S, 1990, THORAX, V45, P12, DOI 10.1136/thx.45.1.12; Matsumoto H, 2005, THORAX, V60, P277, DOI 10.1136/thx.2004.028936; Morgan AJ, 2005, J ALLERGY CLIN IMMUN, V116, P594, DOI 10.1016/j.jaci.2005.03.052; Morgan AJ, 2005, CLIN EXP ALLERGY, V35, P1572, DOI 10.1111/j.1365-2222.2005.02383.x; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; Obase Y, 2003, ALLERGY, V58, P213, DOI 10.1034/j.1398-9995.2003.00053.x; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; Park SW, 2004, CHEST, V125, P1998, DOI 10.1378/chest.125.6.1998; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Rasmussen F, 2002, PEDIATR PULM, V34, P164, DOI 10.1002/ppul.10155; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Siddiqui S, 2007, EUR RESPIR J, V30, P1043, DOI 10.1183/09031936.00162506; Siddiqui S, 2007, J ALLERGY CLIN IMMUN, V120, P813, DOI 10.1016/j.jaci.2007.05.028; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; 2007, GLOBAL INITIATIVE AS	42	103	103	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					335	341		10.1016/j.jaci.2008.05.020	http://dx.doi.org/10.1016/j.jaci.2008.05.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18572228	Green Accepted			2022-12-18	WOS:000258426300020
J	Holgate, ST; Holloway, J; Wilson, S; Howarth, PH; Haitchi, HM; Babu, S; Davies, DE				Holgate, ST; Holloway, J; Wilson, S; Howarth, PH; Haitchi, HM; Babu, S; Davies, DE			Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						severe asthma; airway remodeling; tumor necrosis factor; etanercept; anti-IgE; omalizumab; a disintegrin and metalloprotease 33; airway responsiveness; new treatments	NECROSIS-FACTOR-ALPHA; AIRWAY SMOOTH-MUSCLE; LUNG-FUNCTION DECLINE; TO-MODERATE ASTHMA; ADD-ON THERAPY; CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; SUBEPITHELIAL FIBROSIS; EXTRACELLULAR-MATRIX; DEACETYLASE ACTIVITY	Although asthma is defined in terms of reversibility of airflow obstruction, as the disease becomes more severe and chronic, it adopts different characteristics, including a degree of fixed airflow obstruction and corticosteroid refractoriness. Underlying these phenotypes is evidence of airway wall remodeling, which should be distinguished from the increase in smooth muscle linked to airways hyperresponsiveness. Aberrant epithelial-mesenchymal communication leads to a chronic wound scenario, which is characterized by activation of the epithelial-mesenchymal trophic unit, epithelial damage, the laying down of new matrix, and greater involvement of neutrophils in the inflammatory response. In allergic asthmatic patients who remain symptomatic despite high-dose corticosteroid therapy, blockade of IgE with omalizumab confers appreciable clinical benefit. Chronic severe asthma is also accompanied by a marked increase in TNF-alpha production that might contribute to corticosteroid refractoriness. Based on this, TNF blockade with the soluble fusion protein entanercept produces improvement in asthma symptoms, lung function, and quality of life paralleled by a marked reduction in airways hyperresponsiveness. Identification of novel susceptibility genes, such as a disintegrin and metalloprotease 33 (ADAM33), will provide further targets against which to direct novel therapies for asthma, especially at the more severe end of the disease spectrum.	Univ Southampton, Southampton Gen Hosp, Infect Inflammat & Repair Div, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton	Holgate, ST (corresponding author), Univ Southampton, Southampton Gen Hosp, Infect Inflammat & Repair Div, Sch Med, MP810,F Level,S Block, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk	Holloway, John W/B-5424-2009; Davies, Donna E/H-2993-2012	Holloway, John W/0000-0001-9998-0464; Davies, Donna/0000-0002-5117-2991; Haitchi, Hans Michael/0000-0001-8603-302X; Howarth, Peter/0000-0003-0619-7927	MRC [G0400473] Funding Source: UKRI; Medical Research Council [G0400473] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Barnes N, 2005, J ALLERGY CLIN IMMUN, V115, P47, DOI 10.1016/j.jaci.2004.10.011; Barnes Peter J, 2004, Proc Am Thorac Soc, V1, P264, DOI 10.1513/pats.200402-014MS; Beckett PA, 2003, THORAX, V58, P163, DOI 10.1136/thorax.58.2.163; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; BIBI HS, 2005, RESP MED        0723; Bilolikar H, 2005, EUR RESPIR J, V26, P637, DOI 10.1183/09031936.05.00071104; Bisgaard H, 2000, PEDIATR PULM, V29, P221, DOI 10.1002/(SICI)1099-0496(200003)29:3<221::AID-PPUL11>3.3.CO;2-G; Blakey J, 2005, THORAX, V60, P274, DOI 10.1136/thx.2004.027227; Bonacci JV, 2003, CLIN EXP PHARMACOL P, V30, P324, DOI 10.1046/j.1440-1681.2003.03838.x; Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Bridges LC, 2005, CURR PHARM DESIGN, V11, P837, DOI 10.2174/1381612053381747; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179, DOI 10.1165/ajrcmb.27.2.4699; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Chung K Fan, 2004, Treat Respir Med, V3, P279, DOI 10.2165/00151829-200403050-00002; Contopoulos-Ioannidis DG, 2005, J ALLERGY CLIN IMMUN, V115, P963, DOI 10.1016/j.jaci.2004.12.1119; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Currie GP, 2005, CHEST, V128, P2954, DOI 10.1378/chest.128.4.2954; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; de Marco R, 2005, INT ARCH ALLERGY IMM, V138, P225, DOI 10.1159/000088723; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Dulin NO, 2003, CLIN REV ALLERG IMMU, V24, P73, DOI 10.1385/CRIAI:24:1:73; Fabry B, 2003, RESP PHYSIOL NEUROBI, V137, P109, DOI 10.1016/S1569-9048(03)00141-1; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Finn A, 2003, J ALLERGY CLIN IMMUN, V111, P278, DOI 10.1067/mai.2003.54; Garlisi CG, 2003, BIOCHEM BIOPH RES CO, V301, P35, DOI 10.1016/S0006-291X(02)02976-5; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Harrison BDW, 2005, INTERN MED J, V35, P543, DOI 10.1111/j.1445-5994.2005.00901.x; Higgins PS, 2005, CHEST, V128, P3846, DOI 10.1378/chest.128.6.3846; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate ST, 2005, IMMUNOL ALLERGY CLIN, V25, P655, DOI 10.1016/j.iac.2005.07.003; Holgate ST, 2005, BRIT J PHARMACOL, V145, P1009, DOI 10.1038/sj.bjp.0706272; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Huang J, 2005, MOL BIOL CELL, V16, P4982, DOI 10.1091/mbc.E05-03-0258; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; JEFERY PK, 2004, P AM THORAC SOC, V1, P176; Johns DP, 2000, J APPL PHYSIOL, V88, P1413, DOI 10.1152/jappl.2000.88.4.1413; Johnson PRA, 2004, J ALLERGY CLIN IMMUN, V113, P690, DOI 10.1016/j.jaci.2003.12.312; Joubert P, 2005, J ALLERGY CLIN IMMUN, V116, P713, DOI 10.1016/j.jaci.2005.05.042; Kim J, 2006, CLIN EXP ALLERGY, V36, P122, DOI 10.1111/j.1365-2222.2005.02407.x; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; Le Moual N, 2005, AM J RESP CRIT CARE, V172, P440, DOI 10.1164/rccm.200501-111OC; LEE JY, 2005, AM J RESP CRIT  1230; Lordan JL, 2002, J IMMUNOL, V169, P407, DOI 10.4049/jimmunol.169.1.407; Lose F, 2005, THORAX, V60, P623, DOI 10.1136/thx.2004.026930; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Mankad VS, 2005, CLIN REV ALLERG IMMU, V29, P17, DOI 10.1385/CRIAI:29:1:017; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003; Miller LA, 2003, CHEST, V123, p434S, DOI 10.1378/chest.123.3_suppl.434S; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; NEFFEN H, 2005, RESP MED        1215; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; Orth P, 2004, J MOL BIOL, V335, P129, DOI 10.1016/j.jmb.2003.10.037; OSWALD H, 1994, BRIT MED J, V309, P95, DOI 10.1136/bmj.309.6947.95; Pallasaho P, 2005, EUR J EPIDEMIOL, V20, P975, DOI 10.1007/s10654-005-4117-6; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Payne DNR, 2004, THORAX, V59, P862, DOI 10.1136/thx.2003.017244; Pohunek P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/j.1399-3038.2005.00239.x; Powell RM, 2004, AM J RESP CELL MOL, V31, P13, DOI 10.1165/rcmb.2003-0330OC; Prieto L, 2006, INT ARCH ALLERGY IMM, V139, P122, DOI 10.1159/000090387; ROCHE WR, 1989, LANCET, V1, P520; Rouhani FN, 2005, RESP MED, V99, P1175, DOI 10.1016/j.rmed.2005.02.031; Rudmann DG, 2000, AM J PHYSIOL-LUNG C, V279, pL1047, DOI 10.1152/ajplung.2000.279.6.L1047; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; SHAH A, 1995, CLIN EXP ALLERGY, V25, P1038; SHAW TJ, 2003, THORAX S1, V58; SHAW TJ, 2004, EUR RESPIR J, V129, P15; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503-369OC; Thomas PS, 2001, IMMUNOL CELL BIOL, V79, P132, DOI 10.1046/j.1440-1711.2001.00980.x; Thomas PS, 2002, THORAX, V57, P774, DOI 10.1136/thorax.57.9.774; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866; Tran MUT, 2004, CLIN EXP ALLERGY, V34, P1627, DOI 10.1111/j.1365-2222.2004.02057.x; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Umland SP, 2003, AM J RESP CELL MOL, V29, P571, DOI 10.1165/rcmb.2003-0028OC; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; Vonk JM, 2006, CURR OPIN PULM MED, V12, P42, DOI 10.1097/01.mcp.0000188371.30508.54; Wa TCLK, 1999, CLIN EXP ALLERGY, V29, P1204; Walsh GM, 2005, CURR PHARM DESIGN, V11, P3027, DOI 10.2174/1381612054864984; Ward C, 2001, AM J RESP CRIT CARE, V164, P1718, DOI 10.1164/ajrccm.164.9.2102039; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Westergren-Thorsson G, 2002, INT J BIOCHEM CELL B, V34, P1256, DOI 10.1016/S1357-2725(02)00058-4; White AM, 1997, AM J PHYSIOL-LUNG C, V273, pL524, DOI 10.1152/ajplung.1997.273.3.L524; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; YANG Y, 2005, THORAX S2, V60, P78; Zou J, 2005, BIOCHEMISTRY-US, V44, P4247, DOI 10.1021/bi0476230; Zou J, 2004, J BIOL CHEM, V279, P9818, DOI 10.1074/jbc.M309696200; Zuany-Amorim C, 2004, INT ARCH ALLERGY IMM, V133, P154, DOI 10.1159/000076441	117	103	115	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					496	506		10.1016/j.jaci.2006.01.039	http://dx.doi.org/10.1016/j.jaci.2006.01.039			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522446	Bronze			2022-12-18	WOS:000236263100002
J	Nockher, WA; Renz, H				Nockher, WA; Renz, H			Neurotrophins in allergic diseases: From neuronal growth factors to intercellular signaling molecules	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						neurotrophins; nerve growth factor; brain-derived neurotrophic factor; immune system; neurogenic inflammation; allergy; epithelia; keratinocytes; angiogenesis; fibrosis	MAST-CELLS; SUBSTANCE-P; HUMAN KERATINOCYTES; ATOPIC-DERMATITIS; INFLAMMATORY DISEASE; AIRWAY INFLAMMATION; PROTEIN-KINASE; MOUSE MODEL; IFN-GAMMA; IN-VITRO	Understanding the complex pathophysiology of allergic diseases has been a main challenge of clinical and experimental research for many years. It is well known that file allergic inflammation triggers neuronal dysfunction and structural changes in the diseased tissues such as the airways or the skin. Recent evidence has emerged that the inflammatory response is also controlled by resident tissue cells such as neurons and structural cells. Therefore, signaling molecules that mediate inflammatory interactions among immune, neuronal, and structural cells are becoming a focus of allergy research. Neurotrophins, a family of homologous growth factors initially discovered in the nervous system, display such bidirectional signaling. The expression of neurotrophins, such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), is highly upregulated during allergic inflammation. Neurons, structural cells, and invading immune cells were now identified not only as sources but also as targets of neurotrophins within the inflamed tissue. In this review, we provide an actual overview of the role of neurotrophins in the pathobiology of allergic diseases. We discuss recent findings in human and animal studies such as the regulation of neurotrophin expression during allergic inflammation and the effect of neurotrophins on the development and magnitude of allergic reactions.	Univ Marburg, Univ Hosp, Dept Clin Chem & Mol Diagnost, Marburg, Germany	Philipps University Marburg	Nockher, WA (corresponding author), Univ Klinikum Marburg, Abt Klin Chem & Mol Diagnost, Baldingerstr, D-35033 Marburg, Germany.	nockher@med.uni-marburg.de						Alenius H, 2002, J ALLERGY CLIN IMMUN, V109, P106, DOI 10.1067/mai.2002.120553; Aloe L, 1997, ALLERGY, V52, P883, DOI 10.1111/j.1398-9995.1997.tb01247.x; Barouch R, 2000, J NEUROIMMUNOL, V103, P112, DOI 10.1016/S0165-5728(99)00233-7; Bonini S, 2003, INT ARCH ALLERGY IMM, V131, P80, DOI 10.1159/000070922; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; Braun A, 1999, AM J RESP CELL MOL, V21, P537, DOI 10.1165/ajrcmb.21.4.3670; Burbach GJ, 2001, J INVEST DERMATOL, V117, P1075, DOI 10.1046/j.0022-202x.2001.01498.x; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; Caroleo MC, 2001, J NEUROIMMUNOL, V113, P193, DOI 10.1016/S0165-5728(00)00441-0; Carr M J, 2001, Curr Opin Pulm Med, V7, P1, DOI 10.1097/00063198-200101000-00001; De Vries A, 2002, CLIN EXP ALLERGY, V32, P325, DOI 10.1046/j.1365-2222.2002.01283.x; Dinh QT, 2004, CLIN EXP ALLERGY, V34, P1474, DOI 10.1111/j.1365-2222.2004.02066.x; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EMFORS P, 2001, CELL MOL LIFE SCI, V58, P1036; Esche C, 2004, CURR ALLERGY ASTHM R, V4, P276, DOI 10.1007/s11882-004-0071-8; Giustizieri ML, 2004, J ALLERGY CLIN IMMUN, V114, P1176, DOI 10.1016/j.jaci.2004.07.054; Graiani G, 2004, DIABETOLOGIA, V47, P1047, DOI 10.1007/s00125-004-1414-7; Grewe M, 2000, J INVEST DERMATOL, V114, P1108, DOI 10.1046/j.1523-1747.2000.00974.x; HAHN C, 2006, IN PRESS J ALLERGY C; Hoglund CO, 2002, EUR RESPIR J, V20, P1110, DOI 10.1183/09031936.02.00205402; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; James DE, 1999, CLIN EXP ALLERGY, V29, P1309; Johansson O, 2002, ARCH DERMATOL RES, V293, P614, DOI 10.1007/s00403-001-0285-8; Kanbe N, 2000, CLIN EXP ALLERGY, V30, P1113; Kanda N, 2004, J INVEST DERMATOL, V122, P863, DOI 10.1111/j.0022-202X.2004.22432.x; Kanda N, 2003, J INVEST DERMATOL, V121, P570, DOI 10.1046/j.1523-1747.2003.12428.x; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; Khan KMF, 2002, J BIOL CHEM, V277, P2353, DOI 10.1074/jbc.M108989200; Kim H, 2004, J BIOL CHEM, V279, P33538, DOI 10.1074/jbc.M404115200; Kinkelin I, 2000, CELL TISSUE RES, V302, P31, DOI 10.1007/s004410000202; Kobayashi H, 2002, BLOOD, V99, P2214, DOI 10.1182/blood.V99.6.2214; Kohda F, 2002, J DERMATOL SCI, V28, P34, DOI 10.1016/S0923-1811(01)00147-5; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; LAMBIASE A, 1996, INVEST OPHTH VIS SCI, V36, P2127; Levi-Montalcini R, 1990, PROG NEUROENDOCRINOL, V3, P1; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lommatzsch M, 2005, AM J RESP CRIT CARE, V171, P115, DOI 10.1164/rccm.200406-758OC; Lommatzsch M, 1999, AM J PATHOL, V155, P1183, DOI 10.1016/S0002-9440(10)65221-2; Marshall JS, 1999, J IMMUNOL, V162, P4271; McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39, DOI 10.1164/ajrccm.164.supplement_2.2106065; Nakamura M, 2003, BRIT J DERMATOL, V149, P718, DOI 10.1046/j.1365-2133.2003.05586.x; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Nockher WA, 2006, J ALLERGY CLIN IMMUN, V117, P67, DOI 10.1016/j.jaci.2005.08.029; Noga O, 2001, CLIN EXP ALLERGY, V31, P1906, DOI 10.1046/j.1365-2222.2001.01249.x; Noga O, 2002, CLIN EXP ALLERGY, V32, P1348, DOI 10.1046/j.1365-2745.2002.01442.x; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Path G, 2002, AM J RESP CRIT CARE, V166, P818, DOI 10.1164/rccm.200202-134OC; Pons F, 2001, EUR J PHARMACOL, V428, P365, DOI 10.1016/S0014-2999(01)01280-8; Pouliot P, 2005, CLIN EXP ALLERGY, V35, P804, DOI 10.1111/j.1365-2222.2005.02246.x; RAAP U, 2006, IN PRESS J ALLERGY C; Raychaudhuri SP, 1998, ACTA DERM-VENEREOL, V78, P84; Rost B, 2005, REGUL PEPTIDES, V124, P19, DOI 10.1016/j.regpep.2004.06.024; Sanico AM, 2000, AM J RESP CRIT CARE, V161, P1631, DOI 10.1164/ajrccm.161.5.9908028; Sawada J, 2000, BLOOD, V95, P2052, DOI 10.1182/blood.V95.6.2052; Schulte-Herbruggen O, 2005, J NEUROIMMUNOL, V160, P204, DOI 10.1016/j.jneuroim.2004.10.026; Solomon A, 1998, J ALLERGY CLIN IMMUN, V102, P454, DOI 10.1016/S0091-6749(98)70135-6; Toyoda M, 2002, BRIT J DERMATOL, V147, P71, DOI 10.1046/j.1365-2133.2002.04803.x; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002, DOI 10.1164/ajrccm.158.6.9803023; Welker P, 2000, IMMUNOLOGY, V99, P418, DOI 10.1046/j.1365-2567.2000.00984.x; Wilson JW, 2003, CURR ALLERGY ASTHM R, V3, P153, DOI 10.1007/s11882-003-0028-3	66	103	109	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					583	589		10.1016/j.jaci.2005.11.049	http://dx.doi.org/10.1016/j.jaci.2005.11.049			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522457				2022-12-18	WOS:000236263100013
J	Wang, JL; Visness, CM; Sampson, HA				Wang, JL; Visness, CM; Sampson, HA			Food allergen sensitization in inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; food allergy; sensitization; IgE; inner-city children	MANIFESTATIONS	Background: Asthma continues to be an increasing cause of morbidity in the pediatric population, and studies have shown an association between food sensitivity and asthma. Objective: We investigated the degree of food allergen sensitization in inner-city patients with asthma. Methods: Five hundred four random serum samples from the National Cooperative Inner City Asthma Study were evaluated for specific IgE (UniCap) to 6 common food allergens (egg, milk, soy, peanut, wheat, and fish). Statistical analyses were performed to determine food sensitization prevalence and its association with asthma morbidity. Results: Forty-five percent of patients had evidence of sensitization (food-specific IgE >= 0.35 kU/L) to at least 1 food. Nineteen percent had IgE levels at >= 50% positive predictive value for clinical reactivity to at least 1 food, with 4% of patients having levels > 95% positive predictive value for food allergy. Children sensitized to foods had higher rates of asthma hospitalization (P < .01) and required more steroid medications (P = .025). Sensitization to foods also correlated with sensitization to more indoor and outdoor aeroallergens (P < .001). Conclusion: Food allergen sensitization is highly prevalent in the inner-city population with asthma, and it is associated with increased asthma healthcare and medication use. Therefore, food allergen sensitivity may be a marker for increased asthma severity.	Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; Rho Fed Syst Div Inc, Chapel Hill, NC USA	Icahn School of Medicine at Mount Sinai	Sampson, HA (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	hugh.sampson@mssm.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030779, U01AI030780, U01AI030756, U01AI030772, U01AI030777, U01AI030751, N01AI015105, U01AI030752, U01AI030773] Funding Source: NIH RePORTER; NIAID NIH HHS [AI030779, AI-30777, AI-30752, N01-AI-15105, AI-30780, AI-30756, AI-30772, U0I AI-30751, AI-30773-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1992, PEDIATR ALLERGY IMMU, V3, P188, DOI DOI 10.1111/J.1399-3038.1992.TB00048.X; DEY AN, 2004, VITAL HLTH STAT, V10, P3; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; JAMES JM, 1994, AM J RESP CRIT CARE, V149, P59, DOI 10.1164/ajrccm.149.1.8111598; James JM, 2003, PEDIATRICS, V111, P1625; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Mitchell H, 1997, PEDIATR PULM, V24, P237; NOVEMBRE E, 1988, J ALLERGY CLIN IMMUN, V81, P1059, DOI 10.1016/0091-6749(88)90181-9; OEHLING A, 1980, ALLERGOL IMMUNOPATH, V8, P7; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Roberts Graham, 2003, Paediatr Respir Rev, V4, P205, DOI 10.1016/S1526-0542(03)00058-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603	18	103	107	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1076	1080		10.1016/j.jaci.2005.02.014	http://dx.doi.org/10.1016/j.jaci.2005.02.014			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867869				2022-12-18	WOS:000229055100027
J	Li, LB; Goleva, E; Hall, CF; Ou, LS; Leung, DYM				Li, LB; Goleva, E; Hall, CF; Ou, LS; Leung, DYM			Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						superantigens; T cells; steroid resistance; MEK/ERK pathway; corticosteroids; glucocorticoid receptor	GLUCOCORTICOID-RECEPTOR PHOSPHORYLATION; SHOCK-SYNDROME TOXIN-1; N-TERMINAL KINASE; BACTERIAL SUPERANTIGENS; MICROBIAL SUPERANTIGENS; ATOPIC-DERMATITIS; KAWASAKI-DISEASE; POTENTIAL ROLE; CD28; ASTHMA	Background: Microbial superantigens induce human T-cell resistance to corticosteroids. Objective: Understanding the molecular pathways resulting in corticosteroid-resistant T cells is important because this condition can complicate the treatment of inflammation. Methods: The response of human PBMCs to steroids was assessed by using proliferation assays after stimulation with superantigens or anti-CD3 in the presence of various kinase inhibitors. Glucocorticoid receptor alpha (GCRalpha) localization was defined on the basis of intracellular staining. Protein phosphorylation was measured by means of Western blotting. Results: In the current study we found that PBMCs stimulated with superamigen, but not anti-CD3, induced corticosteroid-resistant T cells. However, the purified T cells stimulated either with staphylococcal enterotoxin B (SEB) or anti-CD3 are susceptible to corticosteroid inhibition. These results imply that signals on antigen-presenting cells might act in concert with the T-cell receptor to cause steroid resistance. Blockade of CD40-CD40 ligand interaction had no effect on superamigen-induced corticosteroid resistance. However, CD28 costimulation with T-cell receptor activation induced corticosteroid resistance of human T cells in a dose-dependent manner. Superantigen stimulation, compared with anti-CD3 stimulation, was found to induce a more rapid and sustained phosphorylation of mitogen-activated extracellular signal-regulated kinase (ERK). Treatment with PD98059 and UO126 (specific mitogen-activated protein kinase kinase [MEK]/ERK inhibitors), but not a p38 inhibitor or a c-Jun N-terminal kinase inhibitor, restored the response to steroids, as indicated by proliferation assays. Furthermore, purified ERK1 and ERK2 were able to phosphorylate recombinant human GCRalpha directly in an in vitro kinase assay. Of note, superantigen-induced corticosteroid resistance was associated with abrogation of GCRalpha nuclear translocation. This effect could be reversed by treatment with MEK/ERK pathway inhibitors. Conclusions: These data are compatible with the hypothesis that superantigen-induced corticosteroid resistance involves the Raf-MEK-ERK1/ERK2 pathway of T-cell receptor signaling, which leads to GCRalpha phosphorylation and inhibition of dexamethasone-induced GCRalpha nuclear translocation.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Chang Gung Childrens Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Taoyuan, Taiwan	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Chang Gung Memorial Hospital	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,Room K926I, Denver, CO 80206 USA.	leungd@njc.org			NHLBI NIH HHS [HL 36577, HL 37260] Funding Source: Medline; NIAMS NIH HHS [AR 41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, P01HL036577, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andersen PS, 2001, J BIOL CHEM, V276, P33452, DOI 10.1074/jbc.M103750200; Bachert C, 2003, J ALLERGY CLIN IMMUN, V111, P1131, DOI 10.1016/S0091-6749(03)70044-X; Berridge MJ, 1997, CRIT REV IMMUNOL, V17, P155, DOI 10.1615/CritRevImmunol.v17.i2.30; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; DURONGPISITKUL K, 1995, PEDIATRICS, V96, P1057; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Freiberg BA, 2002, NAT IMMUNOL, V3, P911, DOI 10.1038/ni836; Goleva E, 2002, J IMMUNOL, V169, P5934, DOI 10.4049/jimmunol.169.10.5934; Gonzalo JA, 2001, J IMMUNOL, V166, P1; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Haspot F, 2002, BLOOD, V99, P2228, DOI 10.1182/blood.V99.6.2228; Hauk PJ, 1999, J ALLERGY CLIN IMMUN, V104, P37, DOI 10.1016/S0091-6749(99)70111-9; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002-0144; Jabara HH, 1996, INT IMMUNOL, V8, P1503, DOI 10.1093/intimm/8.10.1503; Jamieson CAM, 2000, P NATL ACAD SCI USA, V97, P7319, DOI 10.1073/pnas.97.13.7319; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Kum WWS, 2002, J INFECT DIS, V185, P555, DOI 10.1086/338634; LEUNG DYM, 1995, J CLIN INVEST, V96, P2106, DOI 10.1172/JCI118263; Leung DYM, 2002, J PEDIATR-US, V140, P742, DOI 10.1067/mpd.2002.123664; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; LEYDEN JJ, 1977, BRIT J DERMATOL, V96, P179, DOI 10.1111/j.1365-2133.1977.tb12541.x; MASON SA, 1993, J BIOL CHEM, V268, P21501; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; MURAILLE E, 1995, CELL IMMUNOL, V162, P315, DOI 10.1006/cimm.1995.1084; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; SCHLIEVERT PM, 1984, J INFECT DIS, V149, P471, DOI 10.1093/infdis/149.3.471; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; Tsitoura DC, 2004, J CLIN INVEST, V113, P619, DOI 10.1172/JCI200418975; WACHS GN, 1976, BRIT J DERMATOL, V95, P323, DOI 10.1111/j.1365-2133.1976.tb07021.x; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; Webster JC, 1997, J BIOL CHEM, V272, P9287; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	40	103	113	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1059	1069		10.1016/j.jaci.2004.08.005	http://dx.doi.org/10.1016/j.jaci.2004.08.005			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536411				2022-12-18	WOS:000225047800011
J	Oba, Y; Salzman, GA				Oba, Y; Salzman, GA			Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adult; atopic asthma; cost; omalizumab; pharmacoeconomics	QUALITY-OF-LIFE; ANTI-IGE ANTIBODY; INHALED CORTICOSTEROIDS; SURGERY	Background: Omalizumab can reduce hospitalization and emergency department visits and improve quality of life in patients with moderate-to-severe, suboptimally controlled allergic asthma. Given the high cost and modest efficacy of this agent, it is not clear that it is cost-effective if given to a broad population with asthma. Objective: The purpose of this study was to evaluate the cost-effectiveness of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. Methods: A retrospective economic analysis was performed to determine the cost-effectiveness of omalizumab using 52-week data from 2 randomized controlled clinical trials in adults and adolescents with moderate-to-severe allergic asthma. The analysis was conducted from a third-party payer's perspective, and only direct costs were considered. Results: The incremental cost-effectiveness ratios showed that the cost to achieve an additional successfully controlled day was $523, and the daily cost to achieve at least a 0.5-point increase in Asthma Quality of Life Questionnaire score was $378 in 2003 dollars. Conclusion: From a pharmacoeconomic standpoint, omalizumab would be better used in allergic asthmatic patients with poorly controlled symptoms despite maximal therapy, given the high cost and modest efficacy of this agent. It could be cost saving if given to nonsmoking patients who are hospitalized 5 or more times or 20 days or longer per year despite maximal asthma therapy.	Univ Missouri, Sch Med, Div Resp & Crit Care Med, Kansas City, MO 64108 USA	University of Missouri System; University of Missouri Kansas City	Oba, Y (corresponding author), Univ Missouri, Sch Med, Div Resp & Crit Care Med, Blue 5 Unit,2411 Holmes, Kansas City, MO 64108 USA.	obay@umkc.edu						Blumenschein K, 1998, ANN ALLERG ASTHMA IM, V80, P189, DOI 10.1016/S1081-1206(10)62954-7; Buhl R, 2002, EUR RESPIR J, V20, P1088, DOI 10.1183/09031936.02.00016502; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; CARRANZA J, 1999, AM J RESP CRIT CARE, V159, pA760; CARRANZAROSENZW.JR, 1999, VALUE HEALTH, V2, P132; *CDCP, 2000, NATL HLTH INT SURV A; Chung KF, 2002, J ALLERGY CLIN IMMUN, V109, pS239, DOI 10.1016/S0091-6749(02)81861-9; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; *DEP DEF PHARM CTR, 2003, PEC UPDATE, V3; Drummond M.F., 2015, METHODS EC EVALUATIO, V4th; *FDA, 2004, PULM ALL DRUGS ADV C; Finn A, 2003, J ALLERGY CLIN IMMUN, V111, P278, DOI 10.1067/mai.2003.54; Hayman JA, 2000, J CLIN ONCOL, V18, P287, DOI 10.1200/JCO.2000.18.2.287; Johannesson M, 1996, HEALTH ECON, V5, P279, DOI 10.1002/(SICI)1099-1050(199607)5:4<279::AID-HEC218>3.3.CO;2-A; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Kallmes DF, 1997, AM J NEURORADIOL, V18, P1453; *MED EC COMP, 2003, DRUG TOP 2003 RED BO; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Paltiel AD, 2001, J ALLERGY CLIN IMMUN, V108, P39, DOI 10.1067/mai.2001.116289; Pennachio Dorothy L, 2003, Med Econ, V80, P96; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Stanford R, 1999, AM J RESP CRIT CARE, V160, P211, DOI 10.1164/ajrccm.160.1.9811040; STANFORD R, 1999, CHEST S2, V116, P247; Storms William W, 2003, J Manag Care Pharm, V9, P534; *US BUR LAB STAT, 2004, CONS PRIC IND    DEC; *VHA PHARM BEN MAN, 2004, NAT PBM DRUG MON OM; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; 1999, PHARMACOECONOMICS S2, V16, P1	30	103	107	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					265	269		10.1016/j.jaci.2004.05.049	http://dx.doi.org/10.1016/j.jaci.2004.05.049			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316501	Bronze			2022-12-18	WOS:000223405600008
J	Garcia-Casado, G; Pacios, LF; Diaz-Perales, A; Sanchez-Monge, R; Lombardero, M; Garcia-Selles, FJ; Polo, F; Barber, D; Salcedo, G				Garcia-Casado, G; Pacios, LF; Diaz-Perales, A; Sanchez-Monge, R; Lombardero, M; Garcia-Selles, FJ; Polo, F; Barber, D; Salcedo, G			Identification of IgE-binding epitopes of the major peach allergen Pru p 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fruit allergy; lipid transfer protein; peach allergen; IgE-binding epitopes; site-directed mutagenesis; 3-dimensional modeling	LIPID-TRANSFER PROTEIN; CRYSTAL-STRUCTURE; ARTEMISIA POLLEN; FRUIT ALLERGY; REACTIVITY; PLANTS; SEEDS; FOODS; ACID	Background: Lipid transfer proteins (LTPs) are clinically relevant plant food panallergens and have been proposed as ideal tools to study true food allergy. Pru p 3, the major peach allergen in the Mediterranean area, is among the best-characterized allergenic members of the UP family. Its diagnostic value for Rosaceae fruit allergy has been demonstrated both in vivo and in vitro. Objective: We sought to locate major IgE-binding epitopes of Pro p 3. Methods: A serum pool and individual sera from patients with peach allergy and positive skin prick test results to Pru p 3 were used. Three-dimensional modeling was achieved by using experimentally available structures of Pru p 3 homologues as templates. Theoretical prediction of potential IgE-binding regions was performed by selecting specific residues on the molecular surface displaying prominent electrostatic potential features. Point mutants of Pro p 3 were constructed by standard polymerase chain reaction procedures with the appropriate primers. Mutants were expressed in P pastoris by means of the pPIC 9 vector and purified from the corresponding supernatants by gel-filtration chromatography followed by RP-HPLC. IgE binding by Pru p 3 mutants was tested by immunodetection and quantified by ELISA and ELISA inhibition assays. Synthetic peptides (10 mer; 5 amino acids overlapping) covering the full Pro p 3 sequence were used to detect IgE epitopes by I-125-anti-IgE immunodetection. Results: Pro p 3 showed a 3-dimensional structure comprising 4 a-helixes and a nonstructured C-terminal coil (residues 73 to 91). Regions around amino acids in positions 23 to 36, 39 to 44, and 80 to 91, particularly residues R39, T40, and R44, K80 and K91, were predicted as potential antibody recognition sites according to their relevant surface and electrostatic properties. Point mutants K80A and K91A were found to have an IgE-binding capacity similar to that of recombinant Pru p 3, but the triple mutant R39A/T40A/R44A showed a substantial decrease (approximately 5 times) of IgE binding. IgE immunodetection of synthetic peptides led to the identification of Pro p 3 sequence regions 11 to 25, 31 to 45, and 71 to 80 as major IgE epitopes. Conclusions: Main IgE-binding regions of the Pru p 3 amino acid sequence were identified. The three major ones comprised the end of an a-helix and some residues of the following inter-helix loop. These data can help to search for Pru p 3 hypoallergenic forms.	ETS Ingn Agron, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain; ETS Ingn Montes, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain; ALK Abello, Dept I&D, Madrid, Spain; Hosp Virgen Arrixaca, Secc Alergia, Murcia, Spain	ALK-Abello AS; Hospital Clinico Universitario Virgen de la Arrixaca	Salcedo, G (corresponding author), ETS Ingn Agron, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain.		Pacios, Luis F/I-5164-2015; Barber, Domingo/Y-9516-2019; Díaz-Perales, Araceli/D-8433-2016; Pacios, Luis F./AAL-6124-2021	Pacios, Luis F/0000-0002-0585-4289; Barber, Domingo/0000-0002-5488-5700; Díaz-Perales, Araceli/0000-0002-1093-3627; Pacios, Luis F./0000-0002-0585-4289				Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Ballmer-Weber BK, 2002, ALLERGY, V57, P873, DOI 10.1034/j.1398-9995.2002.23541.x; BEEZHOLD DH, 2003, J ALLERGY CLIN IM S2, V111; Colombo P, 1998, J IMMUNOL, V160, P2780; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; Garcia-Selles FJ, 2002, INT ARCH ALLERGY IMM, V128, P115, DOI 10.1159/000059401; GINCEL E, 1994, EUR J BIOCHEM, V226, P413, DOI 10.1111/j.1432-1033.1994.tb20066.x; Gomar J, 1996, PROTEIN SCI, V5, P565; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; Lee JY, 1998, J MOL BIOL, V276, P437, DOI 10.1006/jmbi.1997.1550; Lindorff-Larsen K, 2001, FEBS LETT, V488, P145, DOI 10.1016/S0014-5793(00)02424-8; PACIOS LF, 1994, COMPUT CHEM, V18, P377, DOI 10.1016/0097-8485(94)80030-8; Pacios LF, 2001, J CHEM INF COMP SCI, V41, P1427, DOI 10.1021/ci010369n; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Poznanski J, 1999, EUR J BIOCHEM, V259, P692, DOI 10.1046/j.1432-1327.1999.00093.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; SHIN DH, 1995, STRUCTURE, V3, P189, DOI 10.1016/S0969-2126(01)00149-6; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; van Ree R, 2002, BIOCHEM SOC T, V30, P910, DOI 10.1042/BST0300910	25	103	108	2	19	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					599	605		10.1037/mai.2003.1638	http://dx.doi.org/10.1037/mai.2003.1638			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679821				2022-12-18	WOS:000185231200021
J	Gerhold, K; Blumchen, K; Bock, A; Seib, C; Stock, P; Kallinich, T; Lohning, M; Wahn, U; Hamelmann, E				Gerhold, K; Blumchen, K; Bock, A; Seib, C; Stock, P; Kallinich, T; Lohning, M; Wahn, U; Hamelmann, E			Endotoxins prevent murine IgE production,T(H)2 immune responses, and development of airway eosinophilia but not airway hyperreactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mice; eosinophils; T(H)1/T(H)2 cells; cytokines; lipopolysaccharides	TOLL-LIKE RECEPTOR-4; DENDRITIC CELLS; BACTERIAL LIPOPOLYSACCHARIDE; INFLAMMATORY RESPONSE; ALLERGEN CHALLENGE; SENSITIZED MICE; TNF-ALPHA; TH2 CELLS; ASTHMA; MACROPHAGES	Background: Contact with immunomodulatory factors, such as LPS, in early infancy is associated with decreased allergen sensitization. Objective: We sought to study the effects of systemic or airway exposure with LPS on the development of allergen sensitization, eosinophilic airway inflammation, and increased in vivo airway reactivity (AR) in a mouse model. Methods: BALB/c mice were systemically sensitized with ovalbumin (OVA) plus adjuvant on days 1 and W and challenged through the airways with allergen on days 34 to 36. We performed measurement of OVA-specific IgE serum levels, in vitro T(H)2 cytokine production, differential cell counts in bronchoalveolar lavage fluids, and assessment of in vivo AR to inhaled methacholine by means of barometric whole-body plethysmography. Results: Systemic LPS administration before OVA sensitization reduced OVA-specific IgE serum levels (426 76 is 880 104 U/mL, P <.01), T(H)2 cytokine production by splenic mononuclear cells (IL-4: 0.08 +/- 0.01 vs 0.17 +/- 0.01 ng/mL; IL-5: 1.98 +/- 0.52 vs 4.11 +/- 0.54 ng/mL; P <.01), and extent of airway eosinophilia (total cell counts: 93 vs 376 x 10(3)/mL, eosinophils: 23% vs 51%; P <.01) compared with that in OVA-sensitized mice. Local LPS administration to sensitized mice before airway allergen challenges particularly induced IFN-gamma production by peribronchial lymph node cells in vitro (1718 +/- 315 vs 483 +/- 103 ng/mL, P <.01) associated with reduced airway eosinophilia compared with that seen in OVA-sensitized mice. Development of increased AR was not affected by systemic or local LPS exposure. Inhibitory effects of LPS on allergen sensitization and eosinophilic airway inflammation were inhibited bY administration of anti-IL-12 antibodies before LPS exposure. Conclusion: These data indicate that local and systemic application of LPS modulates systemic and local T(H)1/T(H)2 immune responses in a distinct but similarly IL-12-dependent mode.	Univ Hosp Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Deutsch Rheuma Forschungszentrum, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Deutsches Rheuma-Forschungszentrum (DRFZ)	Hamelmann, E (corresponding author), Univ Hosp Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.		Hamelmann, Eckard/AAJ-9124-2021; Löhning, Max/AAL-2967-2021	Löhning, Max/0000-0001-6382-7281				Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Blunck R, 2001, J IMMUNOL, V166, P1009, DOI 10.4049/jimmunol.166.2.1009; BORCHERS MT, 2001, AM J PHYSIOL, V281, P1653; Desmedt M, 1998, J IMMUNOL, V160, P5300; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327, DOI 10.1165/ajrcmb.23.3.3796; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Henderson WR, 2000, J IMMUNOL, V164, P1086, DOI 10.4049/jimmunol.164.2.1086; Hilkens CMU, 1997, BLOOD, V90, P1920, DOI 10.1182/blood.V90.5.1920; HOLT PG, 1981, INT ARCH ALLER A IMM, V65, P42, DOI 10.1159/000232736; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Levitt RC, 1999, J ALLERGY CLIN IMMUN, V103, pS485, DOI 10.1016/S0091-6749(99)70165-X; LeyvaCobian F, 1997, CLIN IMMUNOL IMMUNOP, V85, P1, DOI 10.1006/clin.1997.4426; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1644, DOI 10.1164/ajrccm.151.5.7735627; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Moreland JG, 2001, AM J PHYSIOL-LUNG C, V280, pL173, DOI 10.1152/ajplung.2001.280.1.L173; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Ogata H, 2000, J EXP MED, V192, P23, DOI 10.1084/jem.192.1.23; Ohmori Y, 2001, J LEUKOCYTE BIOL, V69, P598; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Tang CB, 2001, J IMMUNOL, V166, P1471, DOI 10.4049/jimmunol.166.3.1471; Tournoy KG, 2001, J ALLERGY CLIN IMMUN, V107, P483, DOI 10.1067/mai.2001.112693; Tsan MF, 2001, AM J PHYSIOL-CELL PH, V280, pC1422; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Yang M, 2001, AM J RESP CELL MOL, V25, P522, DOI 10.1165/ajrcmb.25.4.4620	40	103	108	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					110	116		10.1067/mai.2002.125831	http://dx.doi.org/10.1067/mai.2002.125831			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110829				2022-12-18	WOS:000176870300021
J	Idzko, M; la Sala, A; Ferrari, D; Panther, E; Herouy, Y; Dichmann, S; Mockenhaupt, M; Di Virgilio, F; Girolomoni, G; Norgauer, J				Idzko, M; la Sala, A; Ferrari, D; Panther, E; Herouy, Y; Dichmann, S; Mockenhaupt, M; Di Virgilio, F; Girolomoni, G; Norgauer, J			Expression and function of histamine receptors in human monocyte-derived dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; histamine; T cells; IL-10; IL-12; chemotaxis	ATOPIC-DERMATITIS; MAST-CELLS; T-CELL; MATURATION; RESPONSES; EFFECTOR; IMMATURE; RELEASE; TH1	Background: Histamine is a well-known mediator eliciting different responses in immune and nonimmune cells, but its role in modulating dendritic cell (DC) functions has been marginally investigated. Objective: The purpose of this investigation was to analyze whether human monocyte-derived DCs express functional histamine receptors according to their maturation stage. Methods: DCs were derived from monocytes and used as immature or LPS-differentiated cells. DCs were tested for histamine receptor expression, chemotaxis, cytokine release, and the capacity to induce T-cell differentiation in response to specific histamine receptor agonists. Results: Immature and mature DCs expressed the mRNA or H-1, H-2, and H-3 histamine receptors. Histamine induced intracellular Ca2+ transients, actin polymerization, and chemotaxis in immature DCs. Maturation of DCs resulted in the loss of these responses. In maturing DCs, however, histamine dose-dependently enhanced intracellular cAMP levels and stimulated IL-10 secretion while inhibiting production of IL-12. As a consequence, histamine might contribute to the impairment of generation of allogeneic type 1 responses via maturing DCs. Specific histamine receptor agonists or antagonists revealed that Ca2+ transients, actin polymerization, and chemotaxis of immature DCs were due to stimulation of H-1 and H-3 subtypes. Modulation of IL-12 and IL-10 secretion by histamine involved the H-2 and H-3 receptors exclusively. Conclusions: Our study suggests that histamine has important biological effects on DC activities, opening the possibility that histamine released during inflammatory or immune responses could regulate DC functions and ultimately favor type 2 lymphocyte-dominated immunity.	Univ Hosp, Dept Expt Dermatol, D-79104 Freiburg, Germany; IRCCS, Ist Dermopat Immacolata, Immunol Lab, Rome, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy	University of Freiburg; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Ferrara; University of Ferrara	Norgauer, J (corresponding author), Univ Hosp, Dept Expt Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.		Ferrari, Davide/F-5644-2015; DI VIRGILIO, Francesco/O-4634-2019; Di Virgilio, Francesco/J-3754-2018; la Sala, Andrea/A-3228-2009; GIROLOMONI, Giampiero/AAC-3405-2022	Ferrari, Davide/0000-0002-5727-9204; DI VIRGILIO, Francesco/0000-0003-3566-1362; Di Virgilio, Francesco/0000-0003-3566-1362; la Sala, Andrea/0000-0003-1268-6516; 				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bissonnette EY, 1996, AM J RESP CELL MOL, V14, P620, DOI 10.1165/ajrcmb.14.6.8652190; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; BURY TB, 1992, ALLERGY, V47, P624, DOI 10.1111/j.1398-9995.1992.tb02385.x; Caron G, 2001, J IMMUNOL, V167, P3682, DOI 10.4049/jimmunol.167.7.3682; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; DELNESTE Y, 1994, CLIN EXP IMMUNOL, V98, P344; Dunzendorfer S, 2001, J IMMUNOL, V166, P2167, DOI 10.4049/jimmunol.166.4.2167; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; FALUS A, 1992, IMMUNOL TODAY, V13, P154; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Hill SJ, 1997, PHARMACOL REV, V49, P253; Hough LB, 2001, MOL PHARMACOL, V59, P415, DOI 10.1124/mol.59.3.415; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lagier B, 1997, CLIN EXP IMMUNOL, V108, P545, DOI 10.1046/j.1365-2249.1997.3791276.x; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; Maestroni GJM, 2000, J IMMUNOL, V165, P6743, DOI 10.4049/jimmunol.165.12.6743; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Sozzani S, 2000, J CLIN IMMUNOL, V20, P151, DOI 10.1023/A:1006659211340; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wollenberg A, 2000, CLIN EXP DERMATOL, V25, P530, DOI 10.1046/j.1365-2230.2000.00699.x; Yang D, 2000, J IMMUNOL, V165, P2694, DOI 10.4049/jimmunol.165.5.2694; ZHENG T, 1994, J IMMUNOL, V153, P4742	27	103	113	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					839	846		10.1067/mai.2002.124044	http://dx.doi.org/10.1067/mai.2002.124044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994709				2022-12-18	WOS:000175687800015
J	Muller, U; Hari, Y; Berchtold, E				Muller, U; Hari, Y; Berchtold, E			Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; bee venom allergy; antihistamine premedication; terfenadine	BEE VENOM IMMUNOTHERAPY; HONEYBEE VENOM; DOUBLE-BLIND; PRETREATMENT; EXPRESSION; HISTAMINE; RUSH; INHIBITION; REDUCTION; MESSENGER	Background: Antihistamine premedication has been used to increase safety of specific-allergen immunotherapy, Its influence on the efficacy of this treatment has not been studied so far. Objective: The goal was to analyze the influence of antihistamine premedication on long-term efficacy of specific-allergen Immunotherapy. Method: Patients included in a double-blind, placebo-controlled trial who received premedication with terfenadine or placebo during initial rush Immunotherapy with honeybee venom in 1988/1989 were assessed in a retrospective analysis for the long-term protective effect, as indicated by the tolerance of a bce sting challenge or field sting during immunotherapy, Results: Of the 52 patients who had participated in the 1988/1989 trial, 47 could be reassessed after an average of 3 years. Of these, 45 were still receiving bee venom immunotherapy A total of 41 patients were stung by bees while receiving Immunotherapy (20 of the terfenadine-premedicated group and 21 of the placebo-premedicated group), 17 with in-field stings and 24 with in-hospital sting challenge. Six (29%) of the patients receiving placebo had a mild-to-moderate systemic allergic reaction, whereas none of the patients receiving terfenadine reacted to the bee sting (P =,012), Conclusions: These results indicate that antihistamine premedication during the initial phase of specific-allergen immunotherapy may enhance the efficacy of this treatment.	Zieglerspital Bern, Div Med, CH-3007 Bern, Switzerland		Muller, U (corresponding author), Zieglerspital Bern, Div Med, Morillonstr 75-91, CH-3007 Bern, Switzerland.							Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; FALUS A, 1992, IMMUNOL TODAY, V13, P154; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; Herman D., 1996, Allergy (Copenhagen), V51, P68; HOL BEA, 1993, AM J RESP CELL MOL, V8, P647, DOI 10.1165/ajrcmb/8.6.647; JARISCH R, 1988, ARB P EHRLICH I BUND, V82, P163; JUTEL M, 1995, J IMMUNOL, V154, P4187; JUTEL M, 1997, ALLERGY S37, V52, P88; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1993, ALLERGY, V48, P37; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Munakata Y, 1999, CLIN EXP ALLERGY, V29, P1281; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Poluektova LY, 1999, IMMUNOPHARMACOLOGY, V41, P77, DOI 10.1016/S0162-3109(98)00057-5; Reimers A, 2000, ALLERGY, V55, P484, DOI 10.1034/j.1398-9995.2000.00520.x; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; Tsicopoulos A, 1996, CLIN EXP ALLERGY, V26, P1119, DOI 10.1111/j.1365-2222.1996.tb00497.x; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116	26	103	109	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					81	86		10.1067/mai.2001.111852	http://dx.doi.org/10.1067/mai.2001.111852			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149995				2022-12-18	WOS:000166533300015
J	Yawalkar, N; Shrikhande, M; Hari, Y; Nievergelt, H; Braathen, LR; Pichler, WJ				Yawalkar, N; Shrikhande, M; Hari, Y; Nievergelt, H; Braathen, LR; Pichler, WJ			Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eotaxin; monocyte chemoattractant protein 3; RANTES; IL-5; IL-8; drug allergy psoriasis; immunohistochemistry	CHEMOKINE EOTAXIN; KERATINOCYTES; INTERLEUKIN-5; EXPRESSION; PROTEIN-4	Background: Cutaneous drug reactions may be associated with increased numbers of eosinophils in the blood and tissue. However, the factors leading to the generation of eosinophilia have not been fully delineated. Objective: The aim of this study was to investigate the in situ expression of IL-5, eotaxin, RANTES, monocyte chemoattractant protein 3, and IL-8 together with the appearance of eosinophils in acute cutaneous drug reactions. Methods: Skin biopsy specimens were obtained from drug-induced maculopapular exanthems (n = 9), from normal skin of control subjects (n = 9), and from the skin of patients with psoriasis (n = 8). The in situ expression of IL-5, eotaxin, RANTES, monocyte chemoattractant protein 3, and IL-8 was analyzed by using immunohistochemistry. Furthermore, the corresponding numbers of eosinophils were determined in the blood and skin sections. Results: Compared with normal skin and psoriatic skin, a significantly higher number of eosinophils was found both in the blood and tissue of patients with a drug-induced exanthem. In comparison with normal skin, immunoreactivity for IL-5 and all the chemokines was also significantly enhanced in drug-induced exanthem, whereas significant differences in psoriatic were only observed for IL-5 and eotaxin. Conclusion: Our data indicate that IL-5 and eotaxin may particularly contribute to the activation and recruitment of eosinophils and thereby play an important pathogenic part in the development of skin inflammation in drug-induced maculopapular exanthems.	Univ Bern, Clin Rheumatol & Clin Immunol Allergol, Bern, Switzerland; Univ Bern, Dept Dermatol, Bern, Switzerland	University of Bern; University of Bern	Yawalkar, N (corresponding author), Inselspital Bern, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland.			Pichler, Werner J./0000-0002-8117-359X				BRANDER C, 1995, J IMMUNOL, V155, P2670; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Djien V, 1999, ANN DERMATOL VENER, V126, P247; Fregert S., 1981, MANUAL CONTACT DERMA, V2nd ed.; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gutierrez-Ramos JC, 1999, IMMUNOL TODAY, V20, P500, DOI 10.1016/S0167-5699(99)01522-4; Hari Y, 1999, INT ARCH ALLERGY IMM, V120, P225, DOI 10.1159/000024271; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; KAUPPINEN K, 1984, ACTA DERM-VENEREOL, V64, P320; KOPONEN M, 1986, J ALLERGY CLIN IMMUN, V78, P645, DOI 10.1016/0091-6749(86)90083-7; Mould AW, 2000, J IMMUNOL, V164, P2142, DOI 10.4049/jimmunol.164.4.2142; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175, DOI 10.1111/j.1365-2222.1997.tb00690.x; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; PICHLER W, 2000, ACI INT, V12, P166; Quackenbush EJ, 1998, BLOOD, V92, P1887, DOI 10.1182/blood.V92.6.1887.418k17_1887_1897; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Schnyder B, 1998, CLIN EXP ALLERGY, V28, P1412, DOI 10.1046/j.1365-2222.1998.00419.x; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; SWANBECK G, 1992, ARCH DERMATOL RES, V284, P215, DOI 10.1007/BF00375796; Taha RA, 2000, J ALLERGY CLIN IMMUN, V105, P1002, DOI 10.1067/mai.2000.106483; Yawalkar N, 2000, CLIN EXP ALLERGY, V30, P847; Yawalkar N, 2000, CONTACT DERMATITIS, V42, P18, DOI 10.1034/j.1600-0536.2000.042001018.x; Yawalkar N, 1999, DERMATOLOGY, V199, P25, DOI 10.1159/000018173; YAWALKAR N, 2000, IN PRESS J INVEST DE; Ying S, 1999, J IMMUNOL, V163, P3976; Zanni MP, 1997, J IMMUNOL, V158, P1139	28	103	113	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1171	1176		10.1067/mai.2000.110922	http://dx.doi.org/10.1067/mai.2000.110922			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112902	Bronze			2022-12-18	WOS:000165930300021
J	Williams, TJ; Jones, CA; Miles, EA; Warner, JO; Warner, JA				Williams, TJ; Jones, CA; Miles, EA; Warner, JO; Warner, JA			Fetal and neonatal IL-13 production during pregnancy and at birth and subsequent development of atopic symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; pregnancy; neonate; atopy	BLOOD MONONUCLEAR-CELLS; INTERFERON-GAMMA PRODUCTION; DECREASED PRODUCTION; IFN-GAMMA; INTERLEUKIN-13; CYTOKINE; RESPONSES; DEFICIENCY; EXPRESSION; GESTATION	Background: Cytokine production at the materno-fetal interface may influence the development of atopy-predisposing immune responses. Because IL-13 possesses IL-4-like activity and may regulate the immune responses observed in atopy, it may contribute to the expression of the atopic phenotype initiated during intrauterine life. Objective: We sought to examine IL-13 expression by fetal and neonatal cells and the placenta. Methods: The production of IL-13 by neonatal and fetal T cells was examined by culturing the cells in the presence or absence of PHA. Production of IL-13 at term was considered in the context of the later development of atopic disease in the child, IL-13 expression in the placenta was assessed by using immunohistochemistry. Results: IL-13 immunoreactivity within the placenta was restricted to 16 to 27 weeks' gestation (6/6 positive vs 0/10 at >27 weeks' gestation). In contrast, spontaneous release of IL-13 by fetal mononuclear cells was first observed from 27 weeks' gestation but was undetectable after 37 weeks' gestation, PHA-stimulated mononuclear cells showed increased IL-13 levels in 80% of samples. Term babies (>37 weeks' gestation) with a parental history of atopy with atopic symptoms by 3 years of age produced significantly lower concentrations of PHA-induced IL-13 when compared with babies with no parental history of atopy (P = .034). Conclusion: Thus babies at risk of atopic disease in infancy display defective IL-13 production at birth. This may represent an inherent immaturity in the development of T cell-cytokine responses in babies at genetic risk for atopy or could be a consequence of downregulation of responses by other factors. Normal pregnancy, irrespective of atopic status, is associated with the production of appreciable quantities of IL-13 initially by the placenta and subsequently by the fetus. The regulation of this production and its consequences for the mother and fetus remains to be elaborated.	Univ Southampton, Sch Med, Southampton, Hants, England	University of Southampton	Warner, JA (corresponding author), Southampton Gen Hosp, Level G 803,Ctr Block,Tremona Rd, Southampton SO16 6YD, Hants, England.		Warner, John/AAF-9587-2020; Miles, Elizabeth A/O-1861-2015	Miles, Elizabeth A/0000-0002-8643-0655	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061858] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61858] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BRYSON YJ, 1980, CELL IMMUNOL, V55, P191, DOI 10.1016/0008-8749(80)90150-1; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Chen NX, 1995, TRANSPLANTATION, V60, P1187; Dealtry GB, 1998, AM J REPROD IMMUNOL, V40, P283; DELASSUS S, 1994, J IMMUNOL, V152, P2411; DURANSCHMIDT K, 1997, PEDIATR RES, V41, P128; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; KotirantaAinamo A, 1997, PEDIATR RES, V41, P110, DOI 10.1203/00006450-199701000-00017; LEE S, 1996, BLOOD, V8, P945; Li T, 1996, J IMMUNOL, V156, P4833; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; LIN H, 1993, J IMMUNOL, V151, P4562; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; RUIZ RGG, 1991, CLIN EXP ALLERGY, V21, P467, DOI 10.1111/j.1365-2222.1991.tb01687.x; Scott ME, 1997, PEDIATR RES, V41, P547, DOI 10.1203/00006450-199704000-00015; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	32	103	108	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					951	959		10.1067/mai.2000.106211	http://dx.doi.org/10.1067/mai.2000.106211			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808176				2022-12-18	WOS:000087185000014
J	Weinberg, EG				Weinberg, EG			Urbanization and childhood asthma: An African perspective	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Africa; urbanization; childhood asthma; prevalence; parasites	EXERCISE-INDUCED BRONCHOSPASM; KENYAN SCHOOL-CHILDREN; PREVALENCE; URBAN; SCHOOLCHILDREN; INFECTION; BIRTH; ATOPY	The increasing prevalence of childhood asthma in the developed world is a cause for concern. Much research is currently being conducted in an attempt to identify possible reasons for this occurrence. A so-called Western lifestyle has been the factor most commonly cited to explain this worrying increase in asthma prevalence. In essence, this implies a way of life where children are exposed from early infancy to a wide range of foods, infections, indoor and outdoor allergens, and irritants and to the effects of motor vehicle pollution, Until fairly recently, children in many African countries lived mainly in rural areas and were not exposed to the effects of a Western lifestyle, Early studies in a limited number of African countries showed a very low rural prevalence of childhood asthma, especially where children lived according to a traditional lifestyle, These same studies showed that asthma was not uncommon in urbanized African children. There has been an increasing tendency over the past 20 years for those in rural communities to move to the large urban centers. More recent childhood asthma prevalence studies, especially those from Kenya and Ghana, have confirmed the urban-rural differences but have shown a much narrower gap. In part this may be the result of exposure of rural children to agricultural pesticides and irritants as well as of an increasing tendency to adopt a more Westernized lifestyle such as the use of beds with mattresses, pillows, and blankets, These circumstances on the African continent provide a natural laboratory in the quest for factors that influence the development of asthma in susceptible children, Once more fully elucidated, it is possible that much valuable information will be available to combat the relentless increase in childhood asthma both here as well as in the developed world.	Univ Cape Town, Allergy & Asthma Clin, Red Cross Childrens Hosp & Inst Child Hlth, ZA-7700 Rondebosch, South Africa	University of Cape Town	Weinberg, EG (corresponding author), Univ Cape Town, Allergy & Asthma Clin, Red Cross Childrens Hosp & Inst Child Hlth, ZA-7700 Rondebosch, South Africa.							Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; BUCHANAN DJ, 1974, POSTGRAD MED J, V50, P680, DOI 10.1136/pgmj.50.589.680; Carlsen KH, 1994, EUR RESPIR REV, V4, P5; CARSWELL GF, 1976, LANCET, V2, P706; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Custovic A, 1999, CLIN EXP ALLERGY, V29, P144; DESOUZA M, 1994, E AFR MED J, V71, P473; EGBUONU L, 1982, PEDIATRICS, V69, P550; Ehrlich RI, 1995, INT J EPIDEMIOL, V24, P1138, DOI 10.1093/ije/24.6.1138; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; LUYT DK, 1995, S AFR MED J, V85, P999; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; MOHAMED N, 1995, THORAX, V50, P74, DOI 10.1136/thx.50.1.74; MORLEY D, 1986, MY NAME IS TODAY; Ng'ang'a LW, 1998, THORAX, V53, P919, DOI 10.1136/thx.53.11.919; Odhiambo JA, 1998, EUR RESPIR J, V12, P1105, DOI 10.1183/09031936.98.12051105; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; Salvi SS, 1999, CLIN EXP ALLERGY, V29, P4; SENTHILSELVAN A, 1992, AM REV RESPIR DIS, V146, P884, DOI 10.1164/ajrccm/146.4.884; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Stein CE, 1997, THORAX, V52, P895, DOI 10.1136/thx.52.10.895; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VANNIEKERK CH, 1979, S AFR MED J, V55, P756; VANNIEKERK CH, 1977, LANCET, V1, P96; YAMANEBERHAN H, 1997, LANCET, V350, P85; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161	32	103	108	0	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				224	231		10.1016/S0091-6749(00)90069-1	http://dx.doi.org/10.1016/S0091-6749(00)90069-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669840				2022-12-18	WOS:000085402200004
J	deShazo, RD; OBrien, M; Chapin, K; SotoAguilar, M; Swain, R; Lyons, M; Bryars, WC; Alsip, S				deShazo, RD; OBrien, M; Chapin, K; SotoAguilar, M; Swain, R; Lyons, M; Bryars, WC; Alsip, S			Criteria for the diagnosis of sinus mycetoma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sinus mycetoma; fungal sinusitis; computed tomographic scans; continuous positive airway pressure	ALLERGIC FUNGAL SINUSITIS; PARA-NASAL SINUSES; ASPERGILLUS SINUSITIS	Recent improvements in the treatment options for fungal disease of the sinuses make rapid distinction between the syndromes of invasive and noninvasive sinusitis necessary. On the basis of the extensive review of the literature detailed here, we developed case-finding criteria for the noninvasive syndrome of sinus mycetoma. Using these criteria, we identified 20 cases of sinus mycetoma in the medical literature and compared findings in these patients to those of five patients with mycetoma evaluated in our clinics. Like those in the literature, our patients appeared immunocompetent and were often first seen for evaluation of symptoms other than those usually associated with sinusitis. Two were first seen with a new-onset seizure disorder and one with nasal obstruction alone, Patients from both groups more commonly had mycetoma in their maxillary sinuses, and fungus failed to grow from the cheesy, grey-green, hyphae-rich material removed at the time of surgery. Clinical features in our five patients, which are not noted in published reports of sinus mycetoma, included frequent atopy, nasal polyps, calcification within the sinus on computed tomography, and an excellent response to surgical treatment. Serendipitously, one patient had both allergic fungal sinusitis and a mycetoma in the same sinus. On the basis of this experience, we have modified our case-finding criteria into proposed diagnostic criteria for sinus mycetoma. The elements of these criteria are designed to: (1) exclude patients with invasive fungal sinusitis and (2) differentiate sinus mycetoma from other forms of noninvasive fungal sinusitis on the basis of specific histopathologic findings. This study and the criteria presented reflect our view that sinus mycetoma represents a distinct but not necessarily isolated element in the spectrum of noninvasive fungal disease of the sinuses.	UNIV S ALABAMA,COLL MED,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,MOBILE,AL 36617; UNIV S ALABAMA,COLL MED,DEPT PATHOL,MOBILE,AL 36617; UNIV S ALABAMA,COLL MED,DEPT SURG,MOBILE,AL 36617	University of South Alabama; University of South Alabama; University of South Alabama	deShazo, RD (corresponding author), UNIV S ALABAMA,COLL MED,DEPT MED,DIV ALLERGY & IMMUNOL,2451 FILLINGIM ST,MASTIN 400A,MOBILE,AL 36617, USA.							ADAMS MF, 1933, ARCH SURG-CHICAGO, V26, P999; ARRINGTON J.B, 1992, LAB METHODS HISTOTEC, P203; AXELSSON H, 1978, ACTA OTO-LARYNGOL, V86, P303, DOI 10.3109/00016487809124751; BHAGAT R, 1993, J ALLERGY CLIN IMMUN, V91, P1094, DOI 10.1016/0091-6749(93)90224-4; BUSCH RF, 1994, ARCH INTERN MED, V154, P815; CAMPBELL MJ, 1964, AM REV RESPIR DIS, V89, P186; COREY JP, 1995, OTOLARYNG HEAD NECK, V113, P110, DOI 10.1016/S0194-5998(95)70153-2; DECARPENTIER JP, 1994, J LARYNGOL OTOL, V108, P314, DOI 10.1017/S0022215100126635; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; FINBY N, 1972, NY J MED, V72, P493; GOLDSTEIN MF, 1992, HOSP PRACT, V27, P73; GOODNIGHT J, 1993, AM J OTOLARYNG, V14, P209, DOI 10.1016/0196-0709(93)90032-3; ISMAIL Y, 1994, ARCH INTERN MED, V154, P815, DOI 10.1001/archinte.1994.00420070145018; ISMAIL Y, 1994, ARCH INTERN MED, V154, P819; Jahrsdoerfer R A, 1979, Am J Otolaryngol, V1, P6, DOI 10.1016/S0196-0709(79)80003-4; Klossek JM, 1997, LARYNGOSCOPE, V107, P112, DOI 10.1097/00005537-199701000-00021; Lydiatt W M, 1994, Ear Nose Throat J, V73, P402; MACKLER SA, 1993, PEDIATR AIDS HIV INF, V4, P9; MCGILL TJ, 1980, LARYNGOSCOPE, V90, P748; MCGINNIS MR, 1977, SOUTHERN MED J, V70, P886, DOI 10.1097/00007611-197707000-00040; MIGLETS AW, 1978, ARCH OTOLARYNGOL, V104, P47; MILOSEV B, 1969, BRIT J SURG, V56, P132, DOI 10.1002/bjs.1800560213; MORGAN MA, 1984, AM J CLIN PATHOL, V82, P597, DOI 10.1093/ajcp/82.5.597; ROSER S M, 1976, Journal of Oral Medicine, V31, P91; ROWEJONES JM, 1994, J OTOLARYNGOL, V23, P92; STAMMBERGER H, 1984, ANN OTO RHINOL LARYN, V93, P251, DOI 10.1177/000348948409300313; STAMMBERGER H, 1991, FUNCTIONAL ENDOSCOPI, P398; STEVENS MH, 1978, ARCH OTOLARYNGOL, V104, P153; WARDER FR, 1975, ARCH OTOLARYNGOL, V101, P683; WATTERS GWR, 1993, J LARYNGOL OTOL, V107, P344, DOI 10.1017/S0022215100122996	30	103	119	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					475	485		10.1016/S0091-6749(97)70073-3	http://dx.doi.org/10.1016/S0091-6749(97)70073-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111491				2022-12-18	WOS:A1997WU27400009
J	Rumbyrt, JS; Katz, JL; Schocket, AL				Rumbyrt, JS; Katz, JL; Schocket, AL			Resolution of chronic urticaria in patients with thyroid autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic urticaria; thyroid autoimmunity; thyroid suppression	ANGIOEDEMA; PATHOGENESIS	Background: Autoimmune disease has been implicated as a cause of chronic urticaria, and anti-thyroid antibodies have been found in patients with chronic urticaria. Because some patients with chronic urticaria and autoimmune hypothyroidism have had clinical resolution with thyroid hormone replacement, we investigated the effect of thyroid hormone in euthyroid patients with chronic urticaria and thyroid autoimmunity. Methods: Ten euthyroid patients with refractory hives were treated with thyroxine. Seven patients had elevated anti-thyroid antibodies at baseline. Thyroid function anti-microsomal and anti-thyroglobulin antibody levels were monitored during treatment. If a clinical response was achieved, thyroxine was discontinued and restarted if symptoms recurred. Results: Seven patients with elevated anti-thyroid antibodies reported resolution of symptoms within 4 weeks. Three patients without elevated anti-thyroid antibodies did not respond. Five patients had a recurrence of symptoms after treatment was stopped, which resolved after treatment was restarted. Thyroid-stimulating hormone levels decreased in all patients with a clinical response. No correlation between clinical resolution and anti-thyroid antibody levels was seen. Conclusion: Thyroid autoimmunity in euthyroid patients may be associated with chronic urticaria, and treatment with thyroid suppression can result in clinical remission.	NATL JEWISH CTR IMMUNOL & RESP DIS,DENVER,CO	National Jewish Health								CLAVEAU J, 1993, J ALLERGY CLIN IMMUN, V92, P132, DOI 10.1016/0091-6749(93)90047-J; HARRIS A, 1983, ANN ALLERGY, V51, P161; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; KANNY G, 1994, J ALLERGY CLIN IMMUN, V93, P222; KAPLAN AP, 1990, ALLERGY PROC, V11, P15, DOI 10.2500/108854190778999546; KAPLAN AP, 1988, ALLERGY PRINCIPLES P, P1377; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; MEKORI YA, 1983, J ALLERGY CLIN IMMUN, V72, P681, DOI 10.1016/0091-6749(83)90629-2; NABOTNY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177; QUARANTA JH, 1989, ANN ALLERGY, V62, P421; SMALL P, 1982, ANN ALLERGY, V48, P172; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x	13	103	105	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				901	905		10.1016/S0091-6749(95)70226-1	http://dx.doi.org/10.1016/S0091-6749(95)70226-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543747	Bronze			2022-12-18	WOS:A1995TN12400006
J	HEFLE, SL; LEMANSKE, RF; BUSH, RK				HEFLE, SL; LEMANSKE, RF; BUSH, RK			ADVERSE REACTION TO LUPINE-FORTIFIED PASTA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LEGUME; HYPERSENSITIVITY; CROSS-REACTION; LUPINE	MAJOR COMPONENT PROTEINS; LEGUME BOTANICAL FAMILY; ATOPIC-DERMATITIS; FOOD HYPERSENSITIVITY; CROSS-ALLERGENICITY; PEANUT ALLERGEN; CHILDREN; IDENTIFICATION; CHALLENGES; SERA	A 5-year-old girl with peanut sensitivity experienced urticaria and angioedema after ingesting a spaghetti-like pasta fortified with sweet lupine seed flour The pasta was extracted and used in immunologic studies in patients with peanut sensitivity to determine whether such individuals are at similar risk. Results of skin prick tests with the lupine pasta extract were positive in five of seven subjects; these patients also reported a history of adverse reactions to green peas. In direct RAST studies IgE binding from pooled sera from patients with peanut sensitivity to the lupine pasta extract was 7 times that of a nonallergic control serum, and individual serum samples demonstrated binding from 1 to 6 times that of the negative control. Direct RAST studies of lupine seed flour with serum samples from patients with peanut allergy demonstrated IgE binding 1 to 11 times that of the negative control. Immunoblotting studies of electrophoretically separated pasta extract and lupine seed flour proteins showed IgE-binding protein bands at approximately 21 kd and in the range of 35 to 55 kd molecular weight We conclude that some peanut-sensitive patients may be at risk for adverse reactions to lupine.	WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI 53705; UNIV WISCONSIN,CTR CLIN SCI,DEPT MED,MADISON,WI; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								BAHNASSEY Y, 1986, CEREAL CHEM, V63, P210; BALLESTER D, 1984, J FOOD SCI, V49, P14, DOI 10.1111/j.1365-2621.1984.tb13657.x; BALLESTER DR, 1984, FOOD CHEM TOXICOL, V22, P45, DOI 10.1016/0278-6915(84)90051-6; BARNETT D, 1986, BIOCHIM BIOPHYS ACTA, V882, P97, DOI 10.1016/0304-4165(86)90060-7; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BUSH RK, 1988, J ALLERGY CLIN IMMUN, V82, P251, DOI 10.1016/0091-6749(88)91007-X; DEPENNA EW, 1987, J FOOD SCI, V52, P1434; DUSZKIEWICZREINHARD W, 1988, CEREAL CHEM, V65, P278; FOLGERT JP, 1993, J ALLERGY CLIN IMMUN, V91, P341; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; IVANOVIC D, 1983, ARCH LATINOAM NUTR, V33, P620; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALLEY A, 1976, CLIN EXP IMMUNOL, V25, P159; MALLEY A, 1975, J ALLERGY CLIN IMMUN, V56, P282, DOI 10.1016/0091-6749(75)90102-5; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; OGAWA T, 1991, J NUTR SCI VITAMINOL, V37, P555, DOI 10.3177/jnsv.37.555; Postiglione L., 1983, Perspectives for peas and lupins as protein crops, P113; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; VANTOORENENBERGEN AW, 1984, ANN ALLERGY, V53, P239	26	103	105	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					167	172		10.1016/0091-6749(94)90036-1	http://dx.doi.org/10.1016/0091-6749(94)90036-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064069				2022-12-18	WOS:A1994PC92600005
J	GALL, H; KALVERAM, KJ; FORCK, G; STERRY, W				GALL, H; KALVERAM, KJ; FORCK, G; STERRY, W			KIWI FRUIT ALLERGY - A NEW BIRCH POLLEN-ASSOCIATED FOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						KIWI FRUIT ALLERGY; CROSS-REACTIVITY; BIRCH POLLEN ALLERGY; FOOD ALLERGY	ACTINIDIA-CHINENSIS; IGE-ANTIBODIES; HYPERSENSITIVITY; SENSITIVITY; FOODSTUFFS; POLLINOSIS; ENZYME	Background: To determine the cross-reacting antigens of kiwi fruit and other foods and pollen, we investigated 22 patients allergic to kiwi fruit: 10 with severe systemic reactions and 12 with localized symptoms confined to oral and pharyngeal mucosa (oral allergy syndrome). Seven patients with birch pollen allergy who tolerated kiwi fruit were included as a control group. Methods: All patients were evaluated by skin testing and RAST; three patients were evaluated by PAST inhibition assays. Results: Prick tests showed positive reactions to kiwi fruit in all patients, whereas specific IgE to kiwi fruit could be demonstrated only in patients with generalized severe symptoms. Surprisingly, all 22 patients with clinical kiwi allergy showed positive prick test results and elevated IgE to birch pollen. Clinically, all complained of rhinitis during birch pollen season. Many patients showed sensitization to grass and mugwort pollen. Also food allergy was found to be associated with kiwi allergy: we found strong reactions to apple and hazelnut; moderate reactions to carrot, potato, and avocado; and weak reactions to wheat and rye pour, pineapple and papaya, and their enzymes bromelain and papain. PAST inhibition studies revealed cross-reacting antigens between birch pollen and kiwi fruit. Interestingly, patients with birch pollen allergy without clinical signs of kiwi allergy had positive prick test reactions to kiwi. Patients with kiwi allergy showed higher concentrations to birch pollen IgE compared with patients with isolated birch pollen allergy. Conclusions: Our results indicate that kiwi allergy is a new manifestation of birch pollen-associated food allergy and is mediated by cross-reacting antigens in the kiwi fruit. Kiwi allergy can be expected in patients with birch pollen allergy exhibiting high levels of IgE to birch pollen.	UNIV MUNSTER,ALLERGOL & OCCUPAT DERMATOL POLICLIN,MUNSTER,GERMANY	University of Munster	GALL, H (corresponding author), UNIV ULM,DERMATOL ABT,OBERER ESELSBERG 40,D-89081 ULM,GERMANY.							ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; BAUR X, 1979, CLIN ALLERGY, V9, P451, DOI 10.1111/j.1365-2222.1979.tb02508.x; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CARNE A, 1978, BIOCHEM J, V173, P73, DOI 10.1042/bj1730073; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DEFILIPPI I, 1981, ANN ALLERGY, V46, P249; DELAHOZ B, 1991, ANN ALLERGY, V67, P487; DEMARTINO M, 1988, ALLERGY, V43, P206; DREBORG S, 1983, ALLERGY, V38, P162; ERIKSSON NE, 1984, ALLERGOL IMMUNOPATH, V12, P28; FALLIERS CJ, 1983, J ASTHMA, V20, P193, DOI 10.3109/02770908309114944; FINE AJ, 1981, J ALLERGY CLIN IMMUN, V68, P235, DOI 10.1016/0091-6749(81)90189-5; Freye HB, 1989, ALLERGOLOGIE, V12, P89; GALL H, 1990, ALLERGOLOGIE, V13, P447; GARCIA BE, 1989, ALLERGOL IMMUNOPATH, V17, P217; Kalveram K J, 1979, Z Hautkr, V54, P197; KUEHR J, 1992, CLIN EXP ALLERGY, V22, P839, DOI 10.1111/j.1365-2222.1992.tb02829.x; MCDOWALL MA, 1970, EUR J BIOCHEM, V14, P214, DOI 10.1111/j.1432-1033.1970.tb00280.x; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; SABBAH A, 1985, ALLERG IMMUNOL, V17, P524; SCHAFER T, 1993, ALLERGY, V48, P291, DOI 10.1111/j.1398-9995.1993.tb00731.x; SEIFERT HU, 1988, ALLERGOLOGIE, V11, P169; VERALDI S, 1990, CONTACT DERMATITIS, V22, P244, DOI 10.1111/j.1600-0536.1990.tb01585.x; VOCKS E, 1988, MUNCHEN MED WOCHEN, V130, P419; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	26	103	105	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					70	76		10.1016/0091-6749(94)90073-6	http://dx.doi.org/10.1016/0091-6749(94)90073-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027500				2022-12-18	WOS:A1994NX39300010
J	KIKAWA, Y; MIYANOMAE, T; INOUE, Y; SAITO, M; NAKAI, A; SHIGEMATSU, Y; HOSOI, S; SUDO, M				KIKAWA, Y; MIYANOMAE, T; INOUE, Y; SAITO, M; NAKAI, A; SHIGEMATSU, Y; HOSOI, S; SUDO, M			URINARY LEUKOTRIENE E4 AFTER EXERCISE CHALLENGE IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EXERCISE-INDUCED ASTHMA; SULFIDOPEPTIDE LEUKOTRIENE; BRONCHOCONSTRICTION; URINARY LEUKOTRIENE E4; MASS SPECTROMETRY; SELECTED ION MONITORING; AIRWAY REACTIVITY	NEUTROPHIL CHEMOTACTIC ACTIVITY; ANTIGEN CHALLENGE; METABOLISM; EXCRETION; RELEASE; HISTAMINE; CELL	To assess the role of sulfidopeptide leukotrienes in the pathogenesis of exercise-induced asthma (EIA), the urinary levels of leukotriene E4 (LTE4), a metabolite of LTC4 and LTD4, were measured by RIA before and after exercise in 13 children with EIA and 10 healthy children. Mass spectrometry was used to confirm the presence of LTE4 in urine and the specificity of the RIA. There was no significant difference in the urinary LTE4 levels before exercise between the children with asthma and healthy children (109 [21 to 265] versus 122 [45 to 156] pg/mg of creatinine; median and range). Urinary LTE4 levels increased significantly after exercise in the children with EIA (from 109 [21 to 265] to 196 [40 to 655] pg/mg of creatinine; median and range; p < 0.05) but not in the healthy children. The children with asthma demonstrated no significant correlation between the LTE4 level after exercise and the degree of bronchoconstriction, as revealed by the maximal percent fall in the peak expiratory flow rate. Taken together with a recent study that pretreatment with a potent and selective LTD4 antagonist markedly attenuated EIA, our findings suggest that sulfidopeptide leukotrienes may play some role in the pathogenesis of this type of asthma with other factors also being involved in determining the overall airway response.	NATL SANATORIUM MINAMI KYOTO HOSP,DEPT PEDIAT,KYOTO,JAPAN		KIKAWA, Y (corresponding author), FUKUI MED SCH,DEPT PEDIAT,FUKUI 91011,JAPAN.							BARNES NC, 1986, ASTHMA CLIN PHARM TH, P194; BELCHER NG, 1988, J ALLERGY CLIN IMMUN, V81, P100, DOI 10.1016/0091-6749(88)90227-8; BEYER G, 1987, PROSTAG LEUKOTR ESS, V29, P229, DOI 10.1016/0262-1746(87)90012-6; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; BRUINS AP, 1991, MASS SPECTROM REV, V10, P53, DOI 10.1002/mas.1280100104; CHIABRANDO C, 1984, PROSTA LEUKOTR MED, V16, P79, DOI 10.1016/0262-1746(84)90088-X; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; KIKAWA Y, 1990, J CHROMATOGR-BIOMED, V532, P387, DOI 10.1016/S0378-4347(00)83788-3; KIKAWA Y, 1991, PEDIATR RES, V29, P455, DOI 10.1203/00006450-199105010-00009; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEE TH, 1986, ASTHMA CLIN PHARM TH, P393; MALTBY NH, 1990, J ALLERGY CLIN IMMUN, V85, P3, DOI 10.1016/0091-6749(90)90214-O; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; MIADONNA A, 1990, J ALLERGY CLIN IMMUN, V85, P906, DOI 10.1016/0091-6749(90)90076-G; ORNING L, 1985, BIOCHEM BIOPH RES CO, V130, P214, DOI 10.1016/0006-291X(85)90404-8; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73, DOI 10.1164/ajrccm/142.1.73; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; STEPHEN L, 1988, J ALLERGY CLIN IMMUN, V81, P711; TAGARI P, 1989, PROSTAG OTH LIPID M, V37, P629, DOI 10.1016/0090-6980(89)90101-9; TAYLOR GW, 1989, LANCET, V1, P584; TAYLOR GW, 1986, MASS SPECTROMETIC IM, P67; VERHAGEN J, 1987, BIOCHEM BIOPH RES CO, V148, P864, DOI 10.1016/0006-291X(87)90955-7; WESTCOTT JY, 1991, AM REV RESPIR DIS, V143, P1322, DOI 10.1164/ajrccm/143.6.1322	25	103	104	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1111	1119		10.1016/0091-6749(92)90294-C	http://dx.doi.org/10.1016/0091-6749(92)90294-C			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1318887				2022-12-18	WOS:A1992HZ74800005
J	BURROWS, B; LEBOWITZ, MD; BARBEE, RA; CLINE, MG				BURROWS, B; LEBOWITZ, MD; BARBEE, RA; CLINE, MG			FINDINGS BEFORE DIAGNOSES OF ASTHMA AMONG THE ELDERLY IN A LONGITUDINAL-STUDY OF A GENERAL-POPULATION SAMPLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; GERIATRICS; ALLERGY; LUNG FUNCTION	SKIN-TEST REACTIVITY; VOLUME; IGE	Forty elderly subjects who denied ever having asthma or emphysema on enrollment in a longitudinal epidemiologic study later reported consulting a doctor for asthma when they were older than 60 years of age. The average age at which the diagnosis was reported was 70.8 years, after a mean follow-up of 8.5 years. Findings on enrollment in the newly diagnosed subjects with asthma are compared with findings in the 1145 subjects who provided follow-up information when they were older than age 60 years but had never developed asthma. At the time of enrollment, most subjects later diagnosed as having asthma already had wheezing symptoms, suggesting at least a mild asthmatic state, and many subjects had impaired ventilatory function, a positive allergy skin test (especially in association with rhinitis), and blood eosinophilia. Thirty-five percent of the subjects recalled "respiratory trouble before age 16" despite denying prior asthma. The likelihood of a new asthma label was very closely related to the age-sex-standardized serum-IgE level before diagnosis. Newly diagnosed subjects with asthma demonstrated much greater rates of decline in FEV1 than control subjects or than subjects who already had known asthma on enrollment. We conclude that (1) symptoms suggesting asthma are usually present for many years before the diagnosis of the disease in elderly subjects, (2) the serum-IgE level is closely related to the likelihood of a subsequent asthma diagnosis, even in this age group, and (3) a rapid fall in lung function often occurs around the time of initial diagnosis.			BURROWS, B (corresponding author), UNIV ARIZONA,COLL MED,CTR RESP SCI,TUCSON,AZ 85724, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BRAMAN SS, 1991, AM REV RESPIR DIS, V143, P336, DOI 10.1164/ajrccm/143.2.336; BRODER I, 1962, J ALLERGY, V33, P513, DOI 10.1016/0021-8707(62)90019-9; BURR ML, 1979, BMJ-BRIT MED J, V1, P1041, DOI 10.1136/bmj.1.6170.1041; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; BURROWS B, 1986, AM REV RESPIR DIS, V133, P974; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; BURROWS B, 1980, AM REV RESPIR DIS, V122, P709, DOI 10.1164/arrd.1980.122.5.709; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; DODGE R, 1986, AM REV RESPIR DIS, V133, P981; FORD RM, 1969, MED J AUSTRALIA, V1, P628, DOI 10.5694/j.1326-5377.1969.tb92346.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LEE HY, 1973, BRIT MED J, V4, P93	15	103	105	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					870	877		10.1016/0091-6749(91)90243-H	http://dx.doi.org/10.1016/0091-6749(91)90243-H			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744357				2022-12-18	WOS:A1991GW26200007
J	VERCELLI, D; GEHA, RS				VERCELLI, D; GEHA, RS			REGULATION OF IGE SYNTHESIS IN HUMANS - A TALE OF 2 SIGNALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EPSTEIN-BARR-VIRUS; HUMAN B-CELLS; HUMAN LYMPHOCYTES-B; HEAVY-CHAIN TRANSCRIPTS; C-EPSILON TRANSCRIPTS; NON-T CELLS; GERM-LINE; SWITCH RECOMBINATION; INTERFERON-GAMMA; MONOCLONAL-ANTIBODY		CHILDRENS HOSP MED CTR,DIV IMMUNOL,300 LONGWOOD AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School								BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; BERTON MT, 1990, J EXP MED, V172, P375, DOI 10.1084/jem.172.1.375; Blackwell T. K., 1988, Molecular Immunology., P1; BORZILLO GV, 1987, J IMMUNOL, V139, P1326; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; CHAN MA, 1990, J IMMUNOL, V144, P3563; CHEN YW, 1986, J EXP MED, V164, P562, DOI 10.1084/jem.164.2.562; CHILSON OP, 1989, EUR J IMMUNOL, V19, P389, DOI 10.1002/eji.1830190225; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1989, J IMMUNOL, V143, P3873; CLARK EA, 1990, J IMMUNOL, V145, P1400; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; CONRAD DH, 1990, J EXP MED, V171, P1497, DOI 10.1084/jem.171.5.1497; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DELPRETE GF, 1990, J CLIN INVEST, V84, P1830; DURDIK J, 1989, P NATL ACAD SCI USA, V86, P2346, DOI 10.1073/pnas.86.7.2346; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Geha R S, 1989, Immunodefic Rev, V1, P155; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GORDON J, 1988, J IMMUNOL, V140, P1425; GRUBER MF, 1989, J IMMUNOL, V142, P4144; HELLMAN L, 1988, EUR J IMMUNOL, V18, P905, DOI 10.1002/eji.1830180611; HENNESSY K, 1983, SCIENCE, V220, P1396, DOI 10.1126/science.6304878; HENNESSY K, 1985, SCIENCE, V227, P1238, DOI 10.1126/science.2983420; HENNESSY K, 1983, P NATL ACAD SCI-BIOL, V80, P5665, DOI 10.1073/pnas.80.18.5665; HUMMEL M, 1987, J IMMUNOL, V138, P3539; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JABARA HH, 1988, J CLIN IMMUNOL, V8, P437, DOI 10.1007/BF00916948; JABARA HH, 1990, J IMMUNOL, V145, P3468; KEPRON MR, 1989, J IMMUNOL, V143, P334; LANZAVECCHIA A, 1984, CLIN EXP IMMUNOL, V55, P197; LEDBETTER JA, 1987, J IMMUNOL, V138, P788; LEDBETTER JA, 1987, LEUCOCYTE TYPING, V3, P432; LEUNG DYM, 1988, HEMATOL ONCOL CLIN N, V2, P81; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; MACKENZIE T, 1989, J EXP MED, V169, P407, DOI 10.1084/jem.169.2.407; MAX EE, 1982, CELL, V29, P691, DOI 10.1016/0092-8674(82)90185-4; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; NEMEROW GR, 1985, J IMMUNOL, V135, P3068; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARRONCHI P, 1990, J IMMUNOL, V144, P2102; PAULIE S, 1989, J IMMUNOL, V142, P590; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PERLMUTTER AP, 1984, P NATL ACAD SCI-BIOL, V81, P7189, DOI 10.1073/pnas.81.22.7189; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; POWERS GD, 1988, J IMMUNOL, V140, P3352; RABIN EM, 1986, J IMMUNOL, V137, P1573; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; RAYNAL MC, 1989, P NATL ACAD SCI USA, V86, P8024, DOI 10.1073/pnas.86.20.8024; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SARFATI M, 1989, J EXP MED, V170, P1775, DOI 10.1084/jem.170.5.1775; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SENO M, 1983, NUCLEIC ACIDS RES, V11, P719, DOI 10.1093/nar/11.3.719; SEVERINSON E, 1990, EUR J IMMUNOL, V20, P1079, DOI 10.1002/eji.1830200520; SHAPIRA S, 1990, FASEB J, V4, P598; SHAPIRA SK, 1991, FASEB J, V5, P5865; SMELAND EB, 1989, J EXP MED, V170, P1463, DOI 10.1084/jem.170.4.1463; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; TOSATO G, 1985, J IMMUNOL, V135, P959; UMETSU DT, 1988, J CLIN IMMUNOL, V8, P163, DOI 10.1007/BF00917562; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; VERCELLI D, 1990, J IMMUNOL, V144, P570; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; VERCELLI D, 1989, J CLIN IMMUNOL, V9, P75, DOI 10.1007/BF00916934; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; VERCELLI D, 1989, ANN ALLERGY, V63, P4; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3542; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; YAOITA Y, 1982, NATURE, V297, P697, DOI 10.1038/297697a0; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YOSHIDA K, 1990, P NATL ACAD SCI USA, V87, P7829, DOI 10.1073/pnas.87.20.7829; ZHANG XH, 1990, J IMMUNOL, V144, P2955	100	103	104	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				285	295		10.1016/0091-6749(91)90087-5	http://dx.doi.org/10.1016/0091-6749(91)90087-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1890258				2022-12-18	WOS:A1991GG12600001
J	CICARDI, M; BERGAMASCHINI, L; CUGNO, M; HACK, E; AGOSTONI, G; AGOSTONI, A				CICARDI, M; BERGAMASCHINI, L; CUGNO, M; HACK, E; AGOSTONI, G; AGOSTONI, A			LONG-TERM TREATMENT OF HEREDITARY ANGIOEDEMA WITH ATTENUATED ANDROGENS - A SURVEY OF A 13-YEAR EXPERIENCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IDIOPATHIC THROMBOCYTOPENIC PURPURA; ANGIONEUROTIC-EDEMA; C1 INHIBITOR; DANAZOL; THERAPY; HETEROGENEITY; DEFICIENCY; HEMOPHILIA; PLASMA; LIVER	Fifty-six patients affected with hereditary angioedema have been followed during long-term prophylaxis with attenuated androgens. The treatment was started in patients who had one or more severe attacks per month. In 24 patients, the therapy lasted for more than 5 years. The minimal effective dose usually did not exceed 2 mg/day of stanozolol or 200 mg/day of danazol. Only in two patients were these doses not sufficient to achieve the complete disappearance of symptoms. Irregular menstruation, but rarely amenorrhea, was the only significant side effect. One patient had to stop the therapy because of laboratory signs of hepatic cell necrosis. In one patient, danazol was administered during the last 8 weeks of pregnancy without side effects for the mother but with transient signs of virilization for the female baby. To find a biochemical marker for the minimal effective dose of androgen derivatives, we measured the plasma levels of C1 C1 INH complexes at different doses of stanozolol in four patients with hereditary angioedema. We found that these complexes, elevated before treatment, promptly reverted to normal values during androgen therapy and remained normal with any reduction of the dose of the drug as long as the patient remained symptom free. Therefore, the measurement of C1 C1 INH complexes appears to reflect the activity of the disease and not the amount of androgen that is administered.	UNIV MILAN,OSPED S PAOLO,OSTET & GINECOL CLIN,I-20122 MILAN,ITALY; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS	University of Milan	CICARDI, M (corresponding author), UNIV MILANO,OSPED S PAOLO,MED CLIN,VIA RUDINI 8,I-20142 MILAN,ITALY.		cicardi, marco/K-9219-2016; Cugno, Massimo/K-8106-2016; BERGAMASCHINI, LUIGI CESARE/T-6367-2017	cicardi, marco/0000-0003-1251-225X; Cugno, Massimo/0000-0002-9918-0763; BERGAMASCHINI, LUIGI CESARE/0000-0002-5103-0942				AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; AHN YS, 1983, NEW ENGL J MED, V308, P1396, DOI 10.1056/NEJM198306093082306; ARIGA T, 1989, J CLIN INVEST, V83, P1888, DOI 10.1172/JCI114095; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; BROEKMANS AW, 1987, THROMB HAEMOSTASIS, V5, P20; BUELLI M, 1985, ACTA HAEMATOL-BASEL, V74, P97, DOI 10.1159/000206176; CHAPPATTE O, 1988, BRIT J OBSTET GYNAEC, V95, P938, DOI 10.1111/j.1471-0528.1988.tb06585.x; CICARDI M, 1987, J CLIN INVEST, V80, P1640, DOI 10.1172/JCI113252; CICARDI M, 1987, CLIN RES, V35, pA606; CICARDI M, 1982, AM J MED SCI, V284, P2, DOI 10.1097/00000441-198207000-00001; CICARDI M, 1983, J ALLERGY CLIN IMMUN, V72, P294, DOI 10.1016/0091-6749(83)90034-9; CUGNO M, 1990, J CLIN INVEST, V85, P1215, DOI 10.1172/JCI114555; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; FALK H, 1979, LANCET, V2, P1120; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GADEK JE, 1979, J CLIN INVEST, V64, P280, DOI 10.1172/JCI109449; GADEK JE, 1980, J CLIN INVEST, V66, P82, DOI 10.1172/JCI109838; GAREWAL HS, 1985, JAMA-J AM MED ASSOC, V253, P1154, DOI 10.1001/jama.253.8.1154; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GRALNICK HR, 1983, NEW ENGL J MED, V308, P1393, DOI 10.1056/NEJM198306093082305; GUGNO M, 1988, COMPLEMENT, V5, P181; HACK CE, 1981, J IMMUNOL, V127, P1450; HOPFL R, 1990, DEUT MED WOCHENSCHR, V115, P133; HOSEA SW, 1980, ANN INTERN MED, V93, P809, DOI 10.7326/0003-4819-93-6-809; LAURELL CB, 1979, J CLIN ENDOCR METAB, V49, P719, DOI 10.1210/jcem-49-5-719; LEVY NJ, 1990, P NATL ACAD SCI USA, V87, P265, DOI 10.1073/pnas.87.1.265; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; PITTS JS, 1978, J LAB CLIN MED, V92, P501; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SCHREIBER AD, 1987, NEW ENGL J MED, V316, P503, DOI 10.1056/NEJM198702263160903; SIMON M, 1986, PRESSE MED, V15, P396; SKRIVER K, 1989, J BIOL CHEM, V264, P3066; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; STOPPALYONNET D, 1987, NEW ENGL J MED, V317, P1, DOI 10.1056/NEJM198707023170101; TAKAGI S, 1987, BIOL ASPECTS FETUS; WESTABY D, 1977, LANCET, V2, P261	37	103	106	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					768	773		10.1016/0091-6749(91)90120-D	http://dx.doi.org/10.1016/0091-6749(91)90120-D			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013670				2022-12-18	WOS:A1991FG05900003
J	SARACLAR, Y; TINAZTEPE, K; ADALIOGLU, G; TUNCER, A				SARACLAR, Y; TINAZTEPE, K; ADALIOGLU, G; TUNCER, A			ACUTE HEMORRHAGIC EDEMA OF INFANCY (AHEI) - A VARIANT OF HENOCH-SCHONLEIN PURPURA OR A DISTINCT CLINICAL ENTITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HACETTEPE UNIV,INST CHILD HLTH,DEPT PEDIAT ALLERGY,ANKARA 00680,TURKEY; HACETTEPE UNIV,INST CHILD HLTH,DEPT PEDIAT PATHOL,ANKARA 06680,TURKEY; FAC MED ANKARA,ANKARA,TURKEY	Hacettepe University; Hacettepe University								ALLEN DM, 1960, AMA J DIS CHILD, V99, P833, DOI 10.1001/archpedi.1960.02070030835021; BARTELS H L J M, 1951, Maandschr Kindergeneeskd, V19, P467; Del Carril MJ, 1936, PRENSA MED ARGENT, V23, P1719; FINK CW, 1986, PEDIATR CLIN N AM, V33, P1203; Finkelstein H., 1938, LEHRBUCH SAUGLINGSKR, P814; FONTAN A, 1965, CONCOURS MED, V22, P1119; GERBEAUX J, 1958, ARCH FR PEDIATR, V15, P1266; GILLIAM JN, 1976, ANN ALLERGY, V37, P328; KNAUER KA, 1983, ALLERGY PRINCIPLES P, P673; LAMY M, 1948, B MEM SOC MED HOP P, V72, P1136; LANDSBERGER M, 1925, Z KINDERHEILKD, V39, P569; LARREGUE M, 1976, PRACTICAL MED YB, P293; Larregue M., 1974, MED CUTANEA, V11, P165; LAUGIER P, 1970, DERMATOLOGICA, V141, P113, DOI 10.1159/000252449; LAWLEY TJ, 1984, NEW ENGL J MED, V311, P1407, DOI 10.1056/NEJM198411293112204; LEIBER B, 1966, KLINISCHEN SYNDROME, V1, P652; MACKEL SE, 1982, ARCH DERMATOL, V118, P296, DOI 10.1001/archderm.118.5.296; MALEVILLE J, 1973, B SOC FR DERMATOL SY, V80, P432; MONORE EW, 1981, J INVEST DERMATOL, V76, P103; POSTMA C, 1954, Ned Tijdschr Geneeskd, V98, P2592; RESNICK AH, 1985, INT J DERMATOL, V24, P139, DOI 10.1111/j.1365-4362.1985.tb05744.x; SAMS WM, 1975, J INVEST DERMATOL, V64, P441, DOI 10.1111/1523-1747.ep12512411; SAMS WM, 1976, ARCH DERMATOL, V112, P219, DOI 10.1001/archderm.112.2.219; SEIDLMAYER H, 1940, Z KINDERHEILKD, V61, P217; Snoussi N, 1973, Arch Belg Dermatol Syphiligr, V29, P259; Snow IM, 1913, J AMER MED ASSOC, V61, P18, DOI 10.1001/jama.1913.04350010020008; van Creveld S., 1934, MAANDSCHRIFT KINDERG, V3, P351	27	103	107	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				473	483		10.1016/S0091-6749(05)80202-7	http://dx.doi.org/10.1016/S0091-6749(05)80202-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229809				2022-12-18	WOS:A1990EG45400006
J	METCALFE, DD; SAMPSON, HA				METCALFE, DD; SAMPSON, HA			WORKSHOP ON EXPERIMENTAL METHODOLOGY FOR CLINICAL-STUDIES OF ADVERSE REACTIONS TO FOODS AND FOOD-ADDITIVES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											METCALFE, DD (corresponding author), NIADDKD,BLDG 10,RM 11C210,BETHESDA,MD 20892, USA.							ANDERSON JA, 1986, J ALLERGY CLIN IMMUN, V78, P140, DOI 10.1016/0091-6749(86)90004-7; ANDERSON JA, 1984, NIH842442 PUBL, P4; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BROOKS CD, 1981, ANN ALLERGY, V47, P316; Clement P A, 1984, Rhinology, V22, P151; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P921; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAUL CB, 1988, J ALLERGY CLIN IMMUN, V81, P1180, DOI 10.1016/0091-6749(88)90888-3; FISCHER T, 1987, OCCUPATIONAL IND DER, P190; HALOPAINEN E, 1976, RHINOLOGY, V14, P181; HALPERN SR, 1961, ANN ALLERGY, V19, P1407; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; JORDAN WP, 1980, ROLE PATCH TESTING A; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAY CD, 1985, J ALLERGY CLIN IMMUN, V75, P329, DOI 10.1016/0091-6749(85)90067-3; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P241, DOI 10.1007/BF00458318; Peltonen L, 1985, Derm Beruf Umwelt, V33, P166; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; REIDENBERG MM, 1968, NEW ENGL J MED, V279, P678, DOI 10.1056/NEJM196809262791304; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SOLOMON WR, 1983, PROVOCATIVE CHALLENG, V2, P133; STEGMAN R, 1975, ARCH OPHTHALMOL-CHIC, V93, P1354; STEVENSON DD, 1986, J ALLERGY CLIN IMMUN, V78, P182, DOI 10.1016/0091-6749(86)90011-4; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VONKROGH G, 1981, J AM ACAD DERMATOL, V5, P328, DOI 10.1016/S0190-9622(81)70099-9; [No title captured]	32	103	103	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	2	S			421	442		10.1016/S0091-6749(05)80252-0	http://dx.doi.org/10.1016/S0091-6749(05)80252-0			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EC771	2212417	Bronze			2022-12-18	WOS:A1990EC77100001
J	SMITH, CM; ANDERSON, SD				SMITH, CM; ANDERSON, SD			INHALATION PROVOCATION TESTS USING NONISOTONIC AEROSOLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									ROYAL PRINCE ALFRED HOSP,DEPT THORAC MED,LEVEL 9,PAGE CHEST PAVIL,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Sydney				Anderson, Sandra/0000-0002-6308-8770				ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1985, CLIN REV ALLERG, V3, P427; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; ANDERSON SD, 1985, J ALLERGY CLIN IMMUN, V76, P763, DOI 10.1016/0091-6749(85)90745-6; BARRETT KE, 1985, AGENTS ACTIONS, V16, P144, DOI 10.1007/BF01983123; BASCOM R, 1986, AM REV RESPIR DIS, V134, P248; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822, DOI 10.1164/arrd.1987.135.4.822; BELCHER NG, 1988, AM REV RESPIR DIS, V137, P1026, DOI 10.1164/ajrccm/137.5.1026; BERNSTEIN IL, 1964, DIS CHEST, V46, P469, DOI 10.1378/chest.46.4.469; BIANCO S, 1983, EUR J RESPIR DIS, V64, P213; BLACK JL, 1985, THORAX, V40, P427, DOI 10.1136/thx.40.6.427; BOUCHER RMG, 1968, ANN ALLERGY, V26, P591; BOULET LP, 1987, THORAX, V42, P953, DOI 10.1136/thx.42.12.953; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; BURTON JDK, 1962, LANCET, V1, P235; CADE JF, 1972, CLIN SCI, V43, P759, DOI 10.1042/cs0430759; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHENEY FW, 1968, ANESTHESIOLOGY, V29, P1099, DOI 10.1097/00000542-196811000-00004; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLEBATCH HJH, 1962, J APPL PHYSIOL, V17, P787, DOI 10.1152/jappl.1962.17.5.787; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; ESCHENBACHER WL, 1985, AM REV RESPIR DIS, V131, P894; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; FABBRI LM, 1984, ANN ALLERGY, V53, P172; FABBRI LM, 1983, J ALLERGY CLIN IMMUN, V71, P468, DOI 10.1016/0091-6749(83)90463-3; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FINNEY MJB, 1987, RESP PHYSIOL, V69, P277, DOI 10.1016/0034-5687(87)90082-X; FLINT KCL, 1987, BLOOMSBURY SERIES CL, P43; FORESI A, 1986, CHEST, V90, P822, DOI 10.1378/chest.90.6.822; GODDARD RF, 1963, J ASTHMA RES, V5, P355; GRAVELYN TR, 1988, AM REV RESPIR DIS, V137, P641, DOI 10.1164/ajrccm/137.3.641; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1985, AIRWAY RESPONSIVENES; HARIPARSAD D, 1983, THORAX, V38, P258, DOI 10.1136/thx.38.4.258; HIGGENBOTTAM T, 1984, B EUR PHYSIOPATHOL R, V20, P553; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KIYINGI KS, 1985, EUR J RESPIR DIS, V66, P256; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LOEHNING RW, 1976, ANESTHESIOLOGY, V41, P306; MAGYAR P, 1984, SCHWEIZ MED WSCHR, V114, P910; MAGYAR P, 1983, ITAL J CHEST DIS, V37, P29; MALO JL, 1986, B EUR PHYSIOPATH RES, V22, P473; MANN JS, 1984, BRIT MED J, V289, P469, DOI 10.1136/bmj.289.6443.469; MATTOLI S, 1987, ANN ALLERGY, V58, P134; MATTOLI S, 1986, CHEST, V90, P727; MERCER TT, 1981, CHEST, V80, pS813; MILLER WC, 1975, AM REV RESPIR DIS, V111, P739; RANKIN JA, 1984, CHEST, V85, P723, DOI 10.1378/chest.85.6.723; RASKIN P, 1968, AM REV RESPIR DIS, V98, P697; ROSATI G, 1983, EUR J RESPIR DIS, V64, P417; ROSENTHAL RR, 1979, J ALLERGY CLIN IMMUN, V64, P562; ROSENTHAL RR, 1984, J ALLERGY CLIN IMMUN, V73, pA179; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SHAW RJ, 1985, ALLERGY, V40, P48, DOI 10.1111/j.1398-9995.1985.tb04154.x; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; SILBER G, 1988, AM REV RESPIR DIS, V137, P606, DOI 10.1164/ajrccm/137.3.606; SMITH CM, 1987, J ALLERGY CLIN IMMUN, V79, P85, DOI 10.1016/S0091-6749(87)80021-0; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; STERK PJ, 1985, AM REV RESPIR DIS, V132, P272; SULLIVAN CE, 1978, J APPL PHYSIOL, V45, P687; TABKA Z, 1988, CHEST, V94, P81, DOI 10.1378/chest.94.1.81; TAGUCHI JT, 1971, CHEST, V60, P356, DOI 10.1378/chest.60.4.356; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; WALTEMATH CL, 1973, AM REV RESPIR DIS, V108, P520; WOLSDORF J, 1969, PAEDIATRICS, V43, P799; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	74	103	109	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				781	790		10.1016/0091-6749(89)90309-6	http://dx.doi.org/10.1016/0091-6749(89)90309-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2681332				2022-12-18	WOS:A1989CA31400018
J	SWANSON, MC; CAMPBELL, AR; KLAUCK, MJ; REED, CE				SWANSON, MC; CAMPBELL, AR; KLAUCK, MJ; REED, CE			CORRELATIONS BETWEEN LEVELS OF MITE AND CAT ALLERGENS IN SETTLED AND AIRBORNE DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS & INTERNAL MED,ROCHESTER,MN 55905	Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021255] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21255] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; GELICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P321; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; REED C E, 1986, Environment International, V12, P115, DOI 10.1016/0160-4120(86)90021-8; SINHA RN, 1971, J ALLERGY CLIN IMMUN, V47, P31; TOVEY E, 1986, P SYDNEY ALLERGEN GR, V5, P108; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	15	103	103	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					776	783		10.1016/0091-6749(89)90014-6	http://dx.doi.org/10.1016/0091-6749(89)90014-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2708737				2022-12-18	WOS:A1989U342000011
J	SAMPSON, HA				SAMPSON, HA			COMPARATIVE-STUDY OF COMMERCIAL FOOD ANTIGEN EXTRACTS FOR THE DIAGNOSIS OF FOOD HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SAMPSON, HA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV IMMUNOL,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439, K07AI000830] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-30] Funding Source: Medline; NIAID NIH HHS [AI24439, AI00830] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1980, ALLERGY, V35, P250, DOI 10.1111/j.1398-9995.1980.tb01763.x; AAS K, 1972, ACTA ALLERGOL, V27, P439; AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BJORKSTEN F, 1984, J ALLERGY CLIN IMMUN, V73, P324, DOI 10.1016/0091-6749(84)90404-4; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BROWN HM, 1981, CLIN ALLERGY, V11, P95, DOI 10.1111/j.1365-2222.1981.tb01571.x; DIRKSEN A, 1985, ALLERGY, V40, P620, DOI 10.1111/j.1398-9995.1985.tb00893.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; DREBORG S, 1987, ALLERGY, V42, P117, DOI 10.1111/j.1398-9995.1987.tb02369.x; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS, P214; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P245, DOI 10.1016/0091-6749(73)90144-9; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; IMBER WE, 1977, J ALLERGY CLIN IMMUN, V60, P47, DOI 10.1016/0091-6749(77)90082-3; JOSEPHSON BM, 1963, ANN ALLERGY, V21, P33; LEE RE, 1977, ANN ALLERGY, V38, P231; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; REINBERG A, 1965, J ALLERGY, V36, P273, DOI 10.1016/0021-8707(65)90086-9; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; TAUDORF E, 1985, ALLERGY, V40, P344, DOI 10.1111/j.1398-9995.1985.tb00245.x; Tuft Louis, 1942, JOUR ALLERGY, V13, P574, DOI 10.1016/S0021-8707(42)90070-4; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VICHYANOND P, 1987, 44TH ANN C AM ALL; VOORHORST R, 1973, ANN ALLERGY, V31, P195	33	103	104	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				718	726		10.1016/0091-6749(88)90070-X	http://dx.doi.org/10.1016/0091-6749(88)90070-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	2461401	Bronze			2022-12-18	WOS:A1988R170800002
J	HINDIALEXANDER, MC; CROPP, GJA				HINDIALEXANDER, MC; CROPP, GJA			EVALUATION OF A FAMILY ASTHMA PROGRAM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT PEDIAT,DIV PULM DIS,BUFFALO,NY 14260; CHILDRENS HOSP,CHILDRENS LUNG CTR,BUFFALO,NY 14222	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ARMITAGE P, 1971, STATISTICAL METHODS; Cook T.D., 1979, QUASIEXPERIMENTATION, V351; GREEN LW, 1980, HLTH ED PLANNING DIA, P132; GREEN LW, 1980, PATIENT ED, P11; HINDIALEXANDER M, 1981, ANN ALLERGY, V46, P143; NORMAN GR, 1982, MED CARE, V20, P623, DOI 10.1097/00005650-198206000-00008; PARCEL GS, 1978, HEALTH EDUC QUART, V6, P149, DOI 10.1177/109019817800600106; VERBRUGGE LM, 1980, MED CARE, V18, P73, DOI 10.1097/00005650-198001000-00006; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; 1970, VITAL STATISTICS 10, V61; 1981, SELF MANAGEMENT ED P, V2; 1981, SELF MANAGEMENT ED P, V1	12	103	103	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					505	510		10.1016/0091-6749(84)90386-5	http://dx.doi.org/10.1016/0091-6749(84)90386-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6491096				2022-12-18	WOS:A1984TN62000008
J	METCALFE, DD				METCALFE, DD			FOOD HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											METCALFE, DD (corresponding author), NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,RM 11C210,BETHESDA,MD 20205, USA.							AAS K, 1969, INT ARCH ALLER A IMM, V36, P152, DOI 10.1159/000230735; AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; ADINOLFI M, 1966, IMMUNOLOGY, V10, P517; ANDERSON JA, NATIONAL I ALLERGY I; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BOCK SA, 1983, ALLERGY PRINCIPLES P, P1415; BRANDTZAEG P, 1976, SCAND J IMMUNOL, V5, P411, DOI 10.1111/j.1365-3083.1976.tb00295.x; Brandtzaeg P, 1976, Scand J Gastroenterol Suppl, V36, P1; BRANDTZAEG P, 1981, MONOGR ALLERGY, V17, P195; BROSTOFF J, 1979, MAST CELL, P380; BUCKLEY RH, 1982, JAMA-J AM MED ASSOC, V248, P2627, DOI 10.1001/jama.248.20.2627; BUISSERET PD, 1978, LANCET, V1, P906; BULL DM, 1971, GASTROENTEROLOGY, V60, P370; CAMPOS JVM, 1958, GASTROENTEROLOGY, V34, P625; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P299, DOI 10.1016/0091-6749(76)90135-4; CORNELL R, 1971, LAB INVEST, V25, P42; CRAWFORD LV, 1980, ALLERGIC DIS INFANCY, P394; DANNAEUS A, 1977, CLIN ALLERGY, V7, P109, DOI 10.1111/j.1365-2222.1977.tb01431.x; DIXON JMS, 1960, J PATHOL BACTERIOL, V79, P131, DOI 10.1002/path.1700790116; DONALDSON RM, 1964, NEW ENGL J MED, V270, P994, DOI 10.1056/NEJM196405072701907; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; Fries J. H., 1959, PEDIATR CLIN N AM, V6, P867, DOI [10.1016/S0031-3955(16)30839-2, DOI 10.1016/S0031-3955(16)30839-2]; GALINDO B, 1970, J IMMUNOL, V105, P227; GIRARD JP, 1970, EUR J CLIN INVEST, V1, P188, DOI 10.1111/j.1365-2362.1970.tb00616.x; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; GOLDSTEIN F, 1962, GASTROENTEROLOGY, V42, pA755; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; Gray I, 1940, ANN INTERN MED, V13, P2050, DOI 10.7326/0003-4819-13-11-2050; HANEBERG B, 1975, CLIN EXP IMMUNOL, V22, P210; HARRIES MG, 1978, CLIN ALLERGY, V8, P423, DOI 10.1111/j.1365-2222.1978.tb01492.x; HEINER DC, 1981, N ENGL SOC ALLERGY P, V2, P192; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; HUGHES JM, 1976, NEW ENGL J MED, V295, P1117, DOI 10.1056/NEJM197611112952006; INGELFINGER FJ, 1949, NEW ENGL J MED, V241, P303, DOI 10.1056/NEJM194908252410805; KATZ AJ, 1977, GASTROENTEROLOGY, V73, P705; KENNEY RA, 1979, ADV BIOCH PHYSL, P363; Kraft S C, 1967, Clin Exp Immunol, V2, P321; KRIEBEL CW, 1969, J IMMUNOL, V103, P1268; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351, DOI 10.1136/adc.50.5.351; LAKE AM, 1980, IMMUNOLOGY, V39, P173; LANGELAND T, 1983, ALLERGY, V38, P131, DOI 10.1111/j.1398-9995.1983.tb01597.x; LINDHOLM S, 1959, ACTA PATHOL MICROB S, V132, P11; MATHEWS KP, 1974, MED CLIN N AM, V58, P185, DOI 10.1016/S0025-7125(16)32187-3; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; METCALFE DD, 1983, CLIN REV ALLERG, V1, P311; METCALFE DD, CLIN REV ALLERGY; MILLER HRP, 1979, INT ARCH ALLER A IMM, V59, P281, DOI 10.1159/000232271; MOROZ LA, 1979, N ENGL J MED, V302, P1126; MULLERSCHOOP JW, 1975, J IMMUNOL, V114, P1757; NORRIS HT, 1963, GASTROENTEROLOGY, V44, P448; OGRA PL, 1969, J IMMUNOL, V102, P1423; OWEN RL, 1974, GASTROENTEROLOGY, V66, P189, DOI 10.1016/s0016-5085(74)80102-2; PARISH W E, 1971, Clinical Allergy, V1, P369, DOI 10.1111/j.1365-2222.1971.tb00788.x; PARROTT DMV, 1976, CLIN GASTROENTEROL, V5, P211; PERKKIO M, 1981, EUR J PEDIATR, V137, P63, DOI 10.1007/BF00441172; Porter JR, 1940, J INFECT DIS, V66, P104, DOI 10.1093/infdis/66.2.104; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; Ratner B, 1934, J CLIN INVEST, V13, P517, DOI 10.1172/JCI100602; REILLY RW, 1959, GASTROENTEROLOGY, V37, P491; REISMAN RE, 1981, J ALLERGY CLIN IMMUN, V67, P333, DOI 10.1016/0091-6749(81)90076-2; SAAVEDRADELGADO A, 1983, IMMUNOL ALLERGY PRAC, V5, P116; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SELBEKK BH, 1978, SCAND J GASTROENTERO, V13, P87, DOI 10.3109/00365527809179811; SHINER M, 1975, LANCET, V1, P136; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; STROMBECK DR, 1974, INFECT IMMUN, V10, P1266, DOI 10.1128/IAI.10.6.1266-1272.1974; TRIGER DR, 1973, IMMUNOLOGY, V25, P941; VANMETRE TE, 1968, J ALLERGY, V41, P195, DOI 10.1016/0021-8707(68)90042-7; WALKER WA, 1974, GASTROENTEROLOGY, V67, P531; WALKER WA, 1983, ANN ALLERGY, V51, P240	79	103	104	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					749	762		10.1016/0091-6749(84)90442-1	http://dx.doi.org/10.1016/0091-6749(84)90442-1			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6609945				2022-12-18	WOS:A1984SV82900001
J	BERQUIST, WE; RACHELEFSKY, GS; KADDEN, M; SIEGEL, SC; KATZ, RM; MICKEY, MR; AMENT, ME				BERQUIST, WE; RACHELEFSKY, GS; KADDEN, M; SIEGEL, SC; KATZ, RM; MICKEY, MR; AMENT, ME			EFFECT OF THEOPHYLLINE ON GASTRO-ESOPHAGEAL REFLUX IN NORMAL ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOSTAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	BERQUIST, WE (corresponding author), UNIV CALIF LOS ANGELES,MARION DAVIES CHILDRENS CLIN,DIV PEDIAT GASTROENTEROL,LOS ANGELES,CA 90024, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00 865] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERQUIST WE, PEDIATRICS; CASTELL DO, 1975, ANN INTERN MED, V83, P390, DOI 10.7326/0003-4819-83-3-390; DANUS O, 1976, J PEDIATR-US, V89, P220, DOI 10.1016/S0022-3476(76)80452-0; EULER AR, 1979, PEDIATRICS, V63, P47; GOYAL RK, 1978, GASTROENTEROLOGY, V74, P598; GOYAL RK, 1973, J CLIN INVEST, V52, P337, DOI 10.1172/JCI107189; KANTROWITZ PA, 1969, GASTROENTEROLOGY, V56, P666; MANSFIELD LE, 1978, ANN ALLERGY, V41, P224; MANSFIELD LE, 1980, 36TH ANN M AM AC ALL; RATTAN S, 1980, GASTROENTEROLOGY, V78, P898; SHAPIRO GG, 1979, PEDIATRICS, V63, P207; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V61, P137, DOI 10.1016/0091-6749(78)90268-3	12	103	103	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					407	411		10.1016/0091-6749(81)90087-7	http://dx.doi.org/10.1016/0091-6749(81)90087-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	7229228				2022-12-18	WOS:A1981LQ56300012
J	Yun, JH; Lamb, A; Chase, R; Singh, D; Parker, MM; Saferali, A; Vestbo, J; Tal-Singer, R; Castaldi, PJ; Silverman, EK; Hersh, CP				Yun, Jeong H.; Lamb, Andrew; Chase, Robert; Singh, Dave; Parker, Margaret M.; Saferali, Aabida; Vestbo, Jorgen; Tal-Singer, Ruth; Castaldi, Peter J.; Silverman, Edwin K.; Hersh, Craig P.		COPDGene Investigator; ECLIPSE Investigator	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic obstructive pulmonary disease; asthma; eosinophil; exacerbation	SHORT-TERM RESPONSE; SPUTUM-EOSINOPHILIA; INHALED CORTICOSTEROIDS; AIRWAY INFLAMMATION; COPD; ASTHMA; OVERLAP; RISK; LUNG; PREDNISOLONE	Background: Eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) is associated with exacerbations and responsivity to steroids, suggesting potential shared mechanisms with eosinophilic asthma. However, there is no consistent blood eosinophil count that has been used to define the increased exacerbation risk. Objective: We sought to investigate blood eosinophil counts associated with exacerbation risk in patients with COPD. Methods: Blood eosinophil counts and exacerbation risk were analyzed in patients with moderate-to-severe COPD by using 2 independent studies of former and current smokers with longitudinal data. The Genetic Epidemiology of COPD (COPDGene) study was analyzed for discovery (n=1,553), and the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study was analyzed for validation (n=1,895). A subset of the ECLIPSE study subjects were used to assess the stability of blood eosinophil counts over time. Results: COPD exacerbation risk increased with higher eosinophil counts. An eosinophil count threshold of 300 cells/mL or greater showed adjusted incidence rate ratios for exacerbations of 1.32 in the COPDGene study (95% CI, 1.10-1.63). The cutoff of 300 cells/mL or greater was validated for prospective risk of exacerbation in the ECLIPSE study, with adjusted incidence rate ratios of 1.22 (95% CI, 1.06-1.41) using 3-year follow-up data. Stratified analysis confirmed that the increased exacerbation risk associated with an eosinophil count of 300 cells/mL or greater was driven by subjects with a history of frequent exacerbations in both the COPDGene and ECLIPSE studies. Conclusions: Patients with moderate-to-severe COPD and blood eosinophil counts of 300 cells/mL or greater had an increased risk exacerbations in the COPDGene study, which was prospectively validated in the ECLIPSE study.	[Yun, Jeong H.; Lamb, Andrew; Chase, Robert; Parker, Margaret M.; Saferali, Aabida; Castaldi, Peter J.; Silverman, Edwin K.; Hersh, Craig P.] Brigham & Womens Hosp, Div Network Med, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Yun, Jeong H.; Silverman, Edwin K.; Hersh, Craig P.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Yun, Jeong H.; Parker, Margaret M.; Saferali, Aabida; Castaldi, Peter J.; Silverman, Edwin K.; Hersh, Craig P.] Harvard Med Sch, Boston, MA USA; [Singh, Dave; Vestbo, Jorgen] Univ Manchester, Manchester, Lancs, England; [Vestbo, Jorgen] Cent Manchester Univ Hosp NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Tal-Singer, Ruth] GlaxoSmithKline R&D, King Of Prussia, PA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Manchester; University of Manchester; GlaxoSmithKline	Hersh, CP (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	craig.hersh@channing.harvard.edu	Vestbo, Jorgen/Y-2912-2019; Rossiter, Harry/B-4609-2014; Singh, Dave/AAH-4342-2020; Strand, Matt/AAU-3762-2021; Tal-Singer, Ruth/AAQ-2925-2021; Boueiz, Adel El/AAV-5966-2021; San Jose Estepar, Raul/AAQ-5657-2020; Kinney, Gregory/M-4867-2013; Feshchenko, Yuriy/ABE-2811-2021	Rossiter, Harry/0000-0002-7884-0726; Singh, Dave/0000-0001-8918-7075; Strand, Matt/0000-0002-9083-5989; Tal-Singer, Ruth/0000-0002-5275-8062; Boueiz, Adel El/0000-0003-1638-8575; San Jose Estepar, Raul/0000-0002-3677-1996; Wan, Emily/0000-0002-4126-2467; Iyer, Anand/0000-0001-7700-0728; Begnaud, Abbie/0000-0001-5634-1638; Kosnik, Mitja/0000-0002-4701-7374; Kinney, Gregory/0000-0002-5218-4986; Comellas, Alejandro/0000-0003-1521-7520; Hoffman, Eric/0000-0001-8456-9437; Feshchenko, Yuriy/0000-0002-4505-8287; Yun, Jeong/0000-0002-4361-8295; Vestbo, Jorgen/0000-0001-6355-6362; Budoff, Matthew/0000-0002-9616-1946; Wise, Robert/0000-0002-8353-2349; sciurba, frank/0000-0001-7468-2225	National Institute of Health [R01HL125583, R01HL130512, R01HL124233, R01HL126596, U01HL089897, U01HL089856, T32HL007427, P01HL105339, P01HL132825]; National Institute of Health Research Manchester Biomedical Research Centre; COPD foundation; GlaxoSmithKline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL089856, R01HL126596, T32HL007427, R01HL130512, R01HL124233, R01HL125583, R01HL089856, U01HL089897, R01HL089897, K08HL141601, P01HL132825, K12HL120004, P01HL105339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Health Research Manchester Biomedical Research Centre(National Institute for Health Research (NIHR)); COPD foundation; GlaxoSmithKline(GlaxoSmithKline); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institute of Health grants R01HL125583, R01HL130512, R01HL124233, R01HL126596, U01HL089897, U01HL089856, T32HL007427, P01HL105339, and P01HL132825. J.V. was supported by the National Institute of Health Research Manchester Biomedical Research Centre. The COPDGene project is also supported by the COPD foundation through contributions made to an industry advisory board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. ECLIPSE was funded by GlaxoSmithKline.	Aleman F, 2016, IMMUNOL ALLERGY CLIN, V36, P559, DOI 10.1016/j.iac.2016.03.006; Au DH, 2009, J GEN INTERN MED, V24, P457, DOI 10.1007/s11606-009-0907-y; Bafadhel M, 2016, CHEST, V150, P320, DOI 10.1016/j.chest.2016.01.026; Bafadhel M, 2014, EUR RESPIR J, V44, P789, DOI 10.1183/09031936.00062614; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC; Barnes NC, 2016, EUR RESPIR J, V47, P1374, DOI 10.1183/13993003.01370-2015; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 2005, THORAX, V60, P193, DOI 10.1136/thx.2004.032516; Brightling CE, 2001, RESP MED, V95, P999, DOI 10.1053/rmed.2001.1195; Brightling CE, 2015, CHEST, V148, P844, DOI 10.1378/chest.15-0915; Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0; Casaburi R, 2013, COPD, V10, P367, DOI 10.3109/15412555.2012.752807; Casanova C, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01162-2017; Couillard S, 2017, CHEST, V151, P366, DOI 10.1016/j.chest.2016.10.003; George L, 2016, THER ADV CHRONIC DIS, V7, P34, DOI 10.1177/2040622315609251; Hardin M, 2014, EUR RESPIR J, V44, P341, DOI 10.1183/09031936.00216013; Hardin M, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-127; Hastie AT, 2017, LANCET RESP MED, V5, P956, DOI 10.1016/S2213-2600(17)30432-0; Ho J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13745-x; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Kerkhof M, 2017, EUR RESPIR J, V50, P10; Kim VL, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00853-2017; Kolsum U, 2017, J ALLERGY CLIN IMMUN, V140, P1181, DOI 10.1016/j.jaci.2017.04.027; Kreindler JL, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000151; Liesker JJW, 2011, RESP MED, V105, P1853, DOI 10.1016/j.rmed.2011.07.002; O'Donnell R, 2006, THORAX, V61, P448, DOI 10.1136/thx.2004.024463; Oshagbemi OA, 2017, AM J RESP CRIT CARE, V195, P1402, DOI 10.1164/rccm.201701-0009LE; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Pavord ID, 2017, NEW ENGL J MED, V377, P1613, DOI 10.1056/NEJMoa1708208; Pavord ID, 2016, LANCET RESP MED, V4, P731, DOI 10.1016/S2213-2600(16)30148-5; Pavord ID, 2016, THORAX, V71, P118, DOI 10.1136/thoraxjnl-2015-207021; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511, DOI 10.1164/ajrccm.158.5.9804028; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7; Regan EA, 2010, COPD, V7, P32, DOI 10.3109/15412550903499522; Saha Shironjit, 2006, Int J Chron Obstruct Pulmon Dis, V1, P39, DOI 10.2147/copd.2006.1.1.39; Siddiqui SH, 2015, AM J RESP CRIT CARE, V192, P523, DOI 10.1164/rccm.201502-0235LE; Sin DD, 2016, EUR RESPIR J, V48, P664, DOI 10.1183/13993003.00436-2016; Singh D, 2014, EUR RESPIR J, V44, P1697, DOI 10.1183/09031936.00162414; Singh D, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-26; Siva R, 2007, EUR RESPIR J, V29, P906, DOI 10.1183/09031936.00146306; Stewart JI, 2012, COPD, V9, P466, DOI 10.3109/15412555.2012.690010; Tran TN, 2014, ANN ALLERG ASTHMA IM, V113, P19, DOI 10.1016/j.anai.2014.04.011; Turato G, 2017, AM J RESP CRIT CARE; Vedel-Krogh S, 2017, CLIN CHEM, V63, P823, DOI 10.1373/clinchem.2016.267450; Vedel-Krogh S, 2016, AM J RESP CRIT CARE, V193, P965, DOI 10.1164/rccm.201509-1869OC; Vestbo J, 2008, EUR RESPIR J, V31, P869, DOI 10.1183/09031936.00111707; Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP; Watz H, 2016, LANCET RESP MED, V4, P390, DOI 10.1016/S2213-2600(16)00100-4; Wedzicha JA, 2017, EUR RESP J, V50; Wells JM, 2012, NEW ENGL J MED, V367, P913, DOI 10.1056/NEJMoa1203830; Woodruff PG, 2017, AM J RESP CRIT CARE, V196, P375, DOI 10.1164/rccm.201705-0973WS; Wurst KE, 2016, EUR RESPIR J, V47, P1559, DOI 10.1183/13993003.02045-2015; Zeiger RS, 2014, J ALLER CL IMM-PRACT, V2, P741, DOI 10.1016/j.jaip.2014.06.005; Zeiger RS, 2017, J ALLERGY CLIN IMMUN; Zysman M, 2017, INT J CHRONIC OBSTR, V12, P1819, DOI 10.2147/COPD.S129787	59	102	110	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2037	+		10.1016/j.jaci.2018.04.010	http://dx.doi.org/10.1016/j.jaci.2018.04.010			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29709670	Green Submitted, Bronze, Green Accepted			2022-12-18	WOS:000434701600011
J	Stokholm, J; Thorsen, J; Chawes, BL; Schjorring, S; Krogfelt, KA; Bonnelykke, K; Bisgaard, H				Stokholm, Jakob; Thorsen, Jonathan; Chawes, Bo L.; Schjorring, Susanne; Krogfelt, Karen A.; Bonnelykke, Klaus; Bisgaard, Hans			Cesarean section changes neonatal gut colonization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cesarean section; microbiota; bacteria; parturition immune diseases	INTESTINAL MICROFLORA; ALLERGIC DISEASES; CHILDHOOD ASTHMA; RISK-FACTORS; BIRTH; INFANTS; DELIVERY; MICROBIOTA; MODE; AGE	Background: Delivery by means of cesarean section has been associated with increased risk of childhood immune-mediated diseases, suggesting a role of early bacterial colonization patterns for immune maturation. Objective: We sought to describe the influence of delivery method on gut and airway colonization patterns in the first year of life in the Copenhagen Prospective Studies on Asthma in Childhood(2010) (COPSAC(2010)) birth cohort. Methods: Seven hundred children from the COPSAC(2010) birth cohort participated in this analysis. Fecal samples were collected at age 1 week, 1 month, and 1 year, and hypopharyngeal aspirates were collected at age 1 week, 1 month, and 3 months and cultured for bacteria. Detailed information on delivery method, intrapartum antibiotics, and lifestyle factors was obtained by personal interviews. Results: Seventy-eight percent of the children were born by means of natural delivery, 12% by means of emergency cesarean section, and 9% by means of elective cesarean section. Birth by means of cesarean section was significantly associated with colonization of the intestinal tract by Citrobacter freundii, Clostridium species, Enterobacter cloacae, Enterococcus faecalis, Klebsiella oxytoca, Klebsiella pneumoniae, and Staphylococcus aureus at age 1 week, whereas colonization by Escherichia coli was associated with natural birth. At age 1 month, these differences were less prominent, and at age 1 year, they were not apparent, which was confirmed by means of multivariate data-driven partial least squares analyses. The initial airway microbiota was unaffected by birth method. Conclusion: Delivery by means of cesarean section was associated with early colonization patterns of the neonatal gut but not of the airways. The differences normalized within the first year of life. We speculate that microbial derangements, as indicated in our study, can demonstrate a possible link between delivery by means of cesarean section and immune-mediated disease.	[Stokholm, Jakob; Thorsen, Jonathan; Chawes, Bo L.; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Copenhagen, Denmark; [Stokholm, Jakob] Naestved Hosp, Dept Pediat, Naestved, Denmark; [Schjorring, Susanne; Krogfelt, Karen A.] Statens Serum Inst, Dept Microbiol & Infect Control, Copenhagen, Denmark	University of Copenhagen; Naestved Hospital; Statens Serum Institut	Bisgaard, H (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Copenhagen, Denmark.	bisgaard@copsac.com	Thorsen, Jonathan/AAQ-9269-2021; Bisgaard, Hans/N-4761-2016; Krogfelt, Karen Angeliki A/O-8145-2016; Krogfelt, Karen Angeliki/P-2430-2018	Thorsen, Jonathan/0000-0003-0200-0461; Bisgaard, Hans/0000-0003-4131-7592; Krogfelt, Karen Angeliki A/0000-0001-7536-3453; Schjorring, Susanne/0000-0001-5575-7252; Chawes, Bo/0000-0001-6846-6243; Stokholm, Jakob/0000-0003-4989-9769; Bonnelykke, Klaus/0000-0003-2003-1018	Danish Ministry of Health; Lundbeck Foundation; Danish Strategic Research Foundation; Danish Advanced Technology Foundation; National Institutes of Health	Danish Ministry of Health; Lundbeck Foundation(Lundbeckfonden); Danish Strategic Research Foundation(Danske Strategiske Forskningsrad (DSF)); Danish Advanced Technology Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	H. Bisgaard has received grants from the Danish Ministry of Health, the Lundbeck Foundation, the Danish Strategic Research Foundation, and the Danish Advanced Technology Foundation, and the National Institutes of Health and has consultant arrangements with Chiesi. The rest of the authors declare that they have no relevant conflicts of interest.	Adlerberth I, 2006, PEDIATR RES, V59, P96, DOI 10.1203/01.pdr.0000191137.12774.b2; Almqvist C, 2012, CLIN EXP ALLERGY, V42, P1369, DOI 10.1111/j.1365-2222.2012.04021.x; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Azad MB, 2015, BJOG; BENNET R, 1986, PEDIATR INFECT DIS J, V5, P533, DOI 10.1097/00006454-198609000-00009; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2013, CLIN EXP ALLERGY, V43, P1384, DOI 10.1111/cea.12213; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; FRYKLUND B, 1992, INFECTION, V20, P253, DOI 10.1007/BF01710789; Hakansson S, 2008, ACTA OBSTET GYN SCAN, V87, P50, DOI 10.1080/00016340701802888; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; Hyde MJ, 2012, BIOL REV, V87, P229, DOI 10.1111/j.1469-185X.2011.00195.x; KEARNS AM, 1995, J HOSP INFECT, V30, P193, DOI 10.1016/S0195-6701(95)90314-3; LUNDEQUIST B, 1985, ACTA PAEDIATR SCAND, V74, P45, DOI 10.1111/j.1651-2227.1985.tb10919.x; McDade TW, 2012, P NATL ACAD SCI USA, V109, P17281, DOI 10.1073/pnas.1202244109; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Prescott SL, 2013, J ALLERGY CLIN IMMUN, V131, P23, DOI 10.1016/j.jaci.2012.11.019; Renz-Polster H, 2005, CLIN EXP ALLERGY, V35, P1466, DOI 10.1111/j.1365-2222.2005.02356.x; Roduit C, 2009, THORAX, V64, P107, DOI 10.1136/thx.2008.100875; Schjorring Susanne, 2011, Int J Microbiol, V2011, P312956, DOI 10.1155/2011/312956; Sevelsted A, 2015, PEDIATRICS, V135, pE92, DOI 10.1542/peds.2014-0596; Smith B, 2012, PEDIATR RES, V71, P115, DOI 10.1038/pr.2011.1; Stokholm J, 2014, CLIN MICROBIOL INFEC, V20, P629, DOI 10.1111/1469-0691.12411; Stokholm J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046226; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; ZEDD AJ, 1984, PEDIATR INFECT DIS J, V3, P429, DOI 10.1097/00006454-198409000-00008	34	102	108	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					881	+		10.1016/j.jaci.2016.01.028	http://dx.doi.org/10.1016/j.jaci.2016.01.028			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27045582	Bronze			2022-12-18	WOS:000385496000024
J	Kristensen, K; Henriksen, L				Kristensen, Kim; Henriksen, Lonny			Cesarean section and disease associated with immune function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cesarean section; immune function; microbiome; microbiota; laryngitis; pneumonia; asthma; gastroenteritis; ulcerative colitis; celiac disease; juvenile arthritis	RESPIRATORY MORBIDITY; RISK; CHILDHOOD; ASTHMA; METAANALYSIS; DELIVERY; HOSPITALIZATION; PREGNANCY; ARTHRITIS; INCREASES	Background: Earlier studies have shown that delivery by cesarean section (CS) is associated with an increased risk of disease associated with immune function in the offspring, but these studies have generally not discriminated between the effect of acute and elective CS. Objective: We sought to further explore these associations using discrimination between the effects of acute versus elective CS. Methods: We performed a population- and national register-based cohort study including all children born in Denmark from January 1997 through December 2012. Hazard ratios for diseases associated with immune function in children delivered by acute and elective CS with vaginal delivery as the reference were calculated by using Cox regression. All analyses were adjusted for gestational age, sex, birth weight, maternal age, maternal smoking during pregnancy, and complications during pregnancy (preeclampsia, eclampsia, hemorrhage, and hyperemesis). Results: A total of 750,569 children aged 0 to 14 years were included. Children delivered by both acute and elective CS had an increased risk of asthma, laryngitis, and gastroenteritis. Children delivered by acute CS had an increased risk of ulcerative colitis and celiac disease, whereas children delivered by elective CS had an increased risk of lower respiratory tract infection and juvenile idiopathic arthritis. The effect of elective CS was higher than the effect of acute CS on the risk of asthma. Conclusion: Children delivered by CS are at increased risk of disease associated with immune function. The effect is mainly on diseases involving the mucosal immune system.	[Kristensen, Kim] Univ Hosp Naestved, Dept Pediat, DK-4700 Naestved, Denmark; [Henriksen, Lonny] Rigshosp, Copenhagen Univ Hosp, Res Unit Womans & Childrens Hlth, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Kristensen, K (corresponding author), Univ Hosp Naestved, Dept Pediat, DK-4700 Naestved, Denmark.	kimk@dadlnet.dk		Henriksen, Lonny/0000-0002-9727-6649	Edith og Henrik Henriksens Mindelegat	Edith og Henrik Henriksens Mindelegat	Supported by Edith og Henrik Henriksens Mindelegat.	Andersen TF, 1999, DAN MED BULL, V46, P263; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Bager P, 2012, INFLAMM BOWEL DIS, V18, P857, DOI 10.1002/ibd.21805; Bedaiwi MK, 2014, CURR OPIN RHEUMATOL, V26, P410, DOI 10.1097/BOR.0000000000000075; Cardwell CR, 2008, DIABETOLOGIA, V51, P726, DOI 10.1007/s00125-008-0941-z; Chen T, 2002, CLIN EXP RHEUMATOL, V20, P193; Decker E, 2010, PEDIATRICS, V125, pE1433, DOI 10.1542/peds.2009-2260; Hakansson S, 2003, CLIN EXP ALLERGY, V33, P757, DOI 10.1046/j.1365-2222.2003.01667.x; Hansen AK, 2008, BMJ-BRIT MED J, V336, P85, DOI 10.1136/bmj.39405.539282.BE; Kristensen K, 2015, PEDIATR INFECT DIS J, V34, P145, DOI 10.1097/INF.0000000000000552; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Malmborg P, 2012, INFLAMM BOWEL DIS, V18, P703, DOI 10.1002/ibd.21741; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; Martin Joyce A, 2011, Natl Vital Stat Rep, V60, P1; Mendola P, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.11.007; Miranda LA, 2005, J PERIODONTOL, V76, P75, DOI 10.1902/jop.2005.76.1.75; Moore HC, 2012, ARCH DIS CHILD, V97, P410, DOI 10.1136/archdischild-2011-300607; Prior E, 2012, AM J CLIN NUTR, V95, P1113, DOI 10.3945/ajcn.111.030254; Protonotariou E, 2010, IN VIVO, V24, P117; Sevelsted A, 2015, PEDIATRICS, V135, pE92, DOI 10.1542/peds.2014-0596; Smith GCS, 2004, ARCH DIS CHILD, V89, P956, DOI 10.1136/adc.2003.045971; Stebbings SM, 2009, J RHEUMATOL, V36, P797, DOI 10.3899/jrheum.080964; Stensballe LG, 2013, J PEDIATR-US, V162, P832, DOI 10.1016/j.jpeds.2012.09.049; Tegethoff M, 2013, PEDIATRICS, V132, P483, DOI 10.1542/peds.2012-3686; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; VESTERMARK V, 1991, EUR J OBSTET GYN R B, V38, P33, DOI 10.1016/0028-2243(91)90204-X	26	102	109	1	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					587	590		10.1016/j.jaci.2015.07.040	http://dx.doi.org/10.1016/j.jaci.2015.07.040			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26371844	Bronze			2022-12-18	WOS:000369235500029
J	Cowan, DC; Taylor, DR; Peterson, LE; Cowan, JO; Palmay, R; Williamson, A; Hammel, J; Erzurum, SC; Hazen, SL; Comhair, SAA				Cowan, Douglas C.; Taylor, D. Robin; Peterson, Laura E.; Cowan, Jan O.; Palmay, Rochelle; Williamson, Avis; Hammel, Jef; Erzurum, Serpil C.; Hazen, Stanley L.; Comhair, Suzy A. A.			Biomarker-based asthma phenotypes of corticosteroid response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; inhaled corticosteroids; biomarker; clinical outcome; sputum eosinophils; urinary bromotyrosine; fraction of exhaled nitric oxide	EXHALED NITRIC-OXIDE; SPUTUM EOSINOPHIL COUNTS; AIRWAY INFLAMMATION; INHALED CORTICOSTEROIDS; EXACERBATIONS; CHILDREN; PREDICT; QUESTIONNAIRE; OXIDANTS; THERAPY	Background: Asthma is a heterogeneous disease with different phenotypes. Inhaled corticosteroid (ICS) therapy is a mainstay of treatment for asthma, but the clinical response to ICSs is variable. Objective: We hypothesized that a panel of inflammatory biomarkers (ie, fraction of exhaled nitric oxide [F-ENO], sputum eosinophil count, and urinary bromotyrosine [BrTyr] level) might predict steroid responsiveness. Methods: The original study from which this analysis originates comprised 2 phases: a steroid-naive phase 1 and a 28-day trial of ICSs (phase 2) during which FENO values, sputum eosinophil counts, and urinary BrTyr levels were measured. The response to ICSs was based on clinical improvements, including a 12% or greater increase in FEV1, a 0.5-point or greater decrease in Asthma Control Questionnaire score, and 2 doubling dose or greater increase in provocative concentration of adenosine 5'-monophosphate causing a 20% decrease in FEV1 (PC(20)AMP). Healthy control subjects were also evaluated in this study for comparison of biomarkers with those seen in asthmatic patients. Results: Asthmatic patients had higher than normal FENO values, sputum eosinophil counts, and urinary BrTyr levels during the steroid-naive phase and after ICS therapy. After 28-day trial of ICSs, FENO values decreased in 82% of asthmatic patients, sputum eosinophil counts decreased in 60%, and urinary BrTyr levels decreased in 58%. Each of the biomarkers at the steroid-naive phase had utility for predicting steroid responsiveness, but the combination of high FENO values and high urinary BrTyr levels had the best power (13.3-fold, P < .01) to predict a favorable response to ICS therapy. However, the magnitude of the decrease in biomarker levels was unrelated to the magnitude of clinical response to ICS therapy. Conclusion: A noninvasive panel of biomarkers in steroid-naive asthmatic patients predicts clinical responsiveness to ICS therapy.	[Cowan, Douglas C.; Taylor, D. Robin; Cowan, Jan O.; Palmay, Rochelle; Williamson, Avis] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand; [Peterson, Laura E.; Hammel, Jef; Erzurum, Serpil C.; Comhair, Suzy A. A.] Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA; [Hazen, Stanley L.] Cleveland Clin, Lerner Res Inst, Dept Cellular & Mol Med, Cleveland, OH 44195 USA; [Erzurum, Serpil C.] Cleveland Clin, Resp Inst, Cleveland, OH 44195 USA	University of Otago; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Comhair, SAA (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Pathobiol, NC2-130,9500 Euclid Ave, Cleveland, OH 44195 USA.	comhais@ccf.org	Hazen, Stanley L/ABD-5845-2021	Cowan, Douglas/0000-0001-7297-9041	Lottery Health New Zealand; Dunedin School of Medicine, National Institutes of Health [HL1034531, HL109250]; Alfred Lerner Memorial Chair; Leonard Krieger Fund; Center of Innovation Award - AB Sciex; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010345, P01HL103453, P01HL081064, R24HL123767, U10HL109250] Funding Source: NIH RePORTER	Lottery Health New Zealand; Dunedin School of Medicine, National Institutes of Health; Alfred Lerner Memorial Chair; Leonard Krieger Fund; Center of Innovation Award - AB Sciex; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by Lottery Health New Zealand, the Dunedin School of Medicine, National Institutes of Health grants HL1034531 and HL109250, and Alfred Lerner Memorial Chair (to S.C.E.). S.C.E. is a Senior Fellow of the American Asthma Foundation. S.L.H. was partially supported by a gift from the Leonard Krieger Fund. Mass spectrometry instrumentation used for BrTyr analyses is housed within the Cleveland Clinic Lerner Research Institute Mass Spectrometry Facility, which is partially supported by a Center of Innovation Award by AB Sciex.	American Thoracic Society, 1991, AM REV RESP DIS, V144, P1202; Anderson SD, 2003, CLIN REV ALLERG IMMU, V24, P27, DOI 10.1385/CRIAI:24:1:27; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P912; Bacci E, 2006, CHEST, V129, P565, DOI 10.1378/chest.129.3.565; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; BROWN HM, 1958, LANCET, V2, P1245; Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722; Deykin A, 2005, J ALLERGY CLIN IMMUN, V115, P720, DOI 10.1016/j.jaci.2004.12.1129; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Fleming L, 2013, AM J RESP CRIT CARE, V188, P400, DOI 10.1164/rccm.201212-2156LE; Fleming L, 2012, THORAX, V67, P193, DOI 10.1136/thx.2010.156836; Giannini D, 2000, CLIN EXP ALLERGY, V30, P1777, DOI 10.1046/j.1365-2222.2000.00919.x; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Lane C, 2004, THORAX, V59, P757, DOI 10.1136/thx.2003.014894; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; National Heart Lung and Blood Institute/ National Asthma Education and Prevention Program, 2007, NIH PUBLICATION, V07-4051; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; POLOSA R, 1991, J ALLERGY CLIN IMMUN, V87, P939, DOI 10.1016/0091-6749(91)90415-K; Puckett JL, 2008, RESP PHYSIOL NEUROBI, V163, P166, DOI 10.1016/j.resp.2008.07.020; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Scott M, 2010, THORAX, V65, P258, DOI 10.1136/thx.2009.125443; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Wedes SH, 2011, J PEDIATR-US, V159, P248, DOI 10.1016/j.jpeds.2011.01.029; Wedes SH, 2009, CTS-CLIN TRANSL SCI, V2, P112, DOI 10.1111/j.1752-8062.2009.00095.x; Wegmann M, 2011, AM J RESP CELL MOL, V45, P667, DOI 10.1165/rcmb.2011-0013TR; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	42	102	105	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					877	+		10.1016/j.jaci.2014.10.026	http://dx.doi.org/10.1016/j.jaci.2014.10.026			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25488689	hybrid, Green Accepted			2022-12-18	WOS:000352238600005
J	O'Reilly, R; Ullmann, N; Irving, S; Bossley, CJ; Sonnappa, S; Zhu, J; Oates, T; Banya, W; Jeffery, PK; Bush, A; Saglani, S				O'Reilly, Ruth; Ullmann, Nicola; Irving, Samantha; Bossley, Cara J.; Sonnappa, Samatha; Zhu, Jie; Oates, Timothy; Banya, Winston; Jeffery, Peter K.; Bush, Andrew; Saglani, Sejal			Increased airway smooth muscle in preschool wheezers who have asthma at school age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Preschool wheeze; airway smooth muscle; asthma; pediatric; pathology	1ST 6 YEARS; BASEMENT-MEMBRANE THICKNESS; EARLY-LIFE; CYSTIC-FIBROSIS; CHILDHOOD ISAAC; FOLLOW-UP; CHILDREN; DISEASE; SPIROMETRY; LUNG	Background: Increased airway smooth muscle (ASM) is a feature of established asthma in schoolchildren, but nothing is known about ASM in preschool wheezers. Objective: We sought to determine endobronchial biopsy specimen ASM area fraction in preschool wheezers and its association with asthma at school age. Methods: ASM area, reticular basement membrane thickness, and mucosal eosinophil and ASM mast cell values were quantified in endobronchial biopsy specimens previously obtained from preschool children undergoing clinically indicated bronchoscopy: severe recurrent wheezers (n = 47; median age, 26 months) and nonwheezing control subjects (n = 21; median age, 15 months). Children were followed up, and asthma status was established at age 6 to 11 years. Preschool airway pathology was examined in relation to asthma at school age. Results: Forty-two (62%) of 68 children had 1 or more evaluable biopsy specimens for ASM. At school age, 51 of 68 children were followed up, and 15 (40%) of 37 preschool wheezers had asthma. Children who had asthma and an evaluable biopsy specimen had increased preschool ASM area fraction (n 5 8; median age, 8.2 years [range, 6-10.4 years]; median ASM, 0.12 [range, 0.08-0.16]) compared with that seen in children without asthma (n = 24; median age, 7.3 years [range, 5.9-11 years]; median ASM, 0.07 [range, 0.02-0.23]; P = 007). However, preschool reticular basement membrane thickness and mucosal eosinophil or ASM mast cell values were not different between those who did or did not have asthma at school age. Conclusion: Increased preschool ASM is associated with those children who have asthma at school age. Thus a focus on early changes in ASM might be important in understanding the subsequent development of childhood asthma. (J Allergy Clin Immunol 2013; 131:1024-32.)	[O'Reilly, Ruth; Ullmann, Nicola; Irving, Samantha; Bossley, Cara J.; Bush, Andrew; Saglani, Sejal] Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England; [Zhu, Jie; Jeffery, Peter K.] Royal Brompton Hosp, Dept Gene Therapy, London, England; [Banya, Winston] Royal Brompton Hosp, Dept Med Stat, London, England; [O'Reilly, Ruth; Ullmann, Nicola; Irving, Samantha; Bossley, Cara J.; Oates, Timothy; Bush, Andrew; Saglani, Sejal] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Sonnappa, Samatha] Portex Unit, London, England; [Sonnappa, Samatha] UCL Inst Child Hlth, Dept Epidemiol & Biostat, London, England	Royal Brompton Hospital; Royal Brompton Hospital; Royal Brompton Hospital; Imperial College London; University of London; University College London	Saglani, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Exhibit Rd, London SW7 2AZ, England.	s.saglani@imperial.ac.uk	Saglani, Sejal/AAE-5072-2019; ULLMANN, NICOLA/K-6140-2016	Saglani, Sejal/0000-0001-5192-6418; Ullmann, Nicola/0000-0003-1111-5690	Asthma UK project grant; Clinical Intermediate Fellowship from the Wellcome Trust, United Kingdom; National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10192, NF-SI-0508-10212] Funding Source: researchfish; Asthma UK [08/010, 10/058] Funding Source: researchfish	Asthma UK project grant; Clinical Intermediate Fellowship from the Wellcome Trust, United Kingdom; National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	R. O'Reilly and S. Saglani were both supported by an Asthma UK project grant. S. Saglani was supported by a Clinical Intermediate Fellowship from the Wellcome Trust, United Kingdom. The project was supported by the National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.	[Anonymous], 2005, AM J RESP CRIT CARE, V171, P912; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Bush A, 2010, LANCET, V376, P814, DOI 10.1016/S0140-6736(10)61054-9; Cane RS, 2001, ARCH DIS CHILD, V84, P31, DOI 10.1136/adc.84.1.31; Carlsen KCL, 2006, ALLERGY, V61, P454, DOI 10.1111/j.1398-9995.2005.00938.x; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Gupta A, 2011, AM J RESP CRIT CARE, V184, P1342, DOI 10.1164/rccm.201107-1239OC; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; HISLOP AA, 1989, AM REV RESPIR DIS, V140, P1717, DOI 10.1164/ajrccm/140.6.1717; Horsley AR, 2008, THORAX, V63, P135, DOI 10.1136/thx.2007.082628; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; James A, 2000, EUR RESPIR J, V15, P782, DOI 10.1034/j.1399-3003.2000.15d25.x; James AL, 2009, EUR RESPIR J, V34, P1040, DOI 10.1183/09031936.00181608; James AL, 2012, AM J RESP CRIT CARE, V185, P1058, DOI 10.1164/rccm.201110-1849OC; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Kaur D, 2011, CHEST; Kaur D, 2010, J IMMUNOL, V185, P6105, DOI 10.4049/jimmunol.1000638; Keen C, 2011, RESP MED, V105, P1476, DOI 10.1016/j.rmed.2011.04.004; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Macleod KA, 2009, THORAX, V64, P33, DOI 10.1136/thx.2007.095018; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Niimi A, 2005, J ALLERGY CLIN IMMUN, V116, P565, DOI 10.1016/j.jaci.2005.07.010; O'Reilly R, 2010, THORAX, V65, pA2, DOI 10.1136/thx.2010.150896.4; O'Reilly R, 2011, EUR RESP SOC ANN C S, P1407; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Raby BA, 2004, PEDIATRICS, V114, pE327, DOI 10.1542/peds.2003-0838-L; Ramsey CD, 2007, J ALLERGY CLIN IMMUN, V119, P150, DOI 10.1016/j.jaci.2006.09.012; Regamey N, 2008, AM J RESP CRIT CARE, V177, P837, DOI 10.1164/rccm.200707-977OC; Saglani S, 2005, ARCH DIS CHILD, V90, P961, DOI 10.1136/adc.2004.071134; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Siddiqui S, 2008, J ALLERGY CLIN IMMUN, V122, P335, DOI 10.1016/j.jaci.2008.05.020; Silkoff PE, 1999, AM J RESP CRIT CARE, V159, P940, DOI 10.1164/ajrccm.159.3.9805044; Sonnappa S, 2010, J ALLERGY CLIN IMMUN, V126, P519, DOI 10.1016/j.jaci.2010.04.018; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; Tsurikisawa N, 2010, RESP MED, V104, P1271, DOI 10.1016/j.rmed.2010.03.026; van Wonderen KE, 2010, EUR RESPIR J, V36, P48, DOI 10.1183/09031936.00154409; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Yeganeh B, 2012, PULM PHARM THER	53	102	103	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1024	+		10.1016/j.jaci.2012.08.044	http://dx.doi.org/10.1016/j.jaci.2012.08.044			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23069488				2022-12-18	WOS:000317187200009
J	Tang, TS; Bieber, T; Williams, HC				Tang, Ting Seng; Bieber, Thomas; Williams, Hywel C.			Does "autoreactivity'' play a role in atopic dermatitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoreactivity; autoimmunity; eczema; atopic dermatitis; atopic eczema; IgE	CELL-MEDIATED AUTOIMMUNITY; IGE-REACTIVE AUTOANTIGENS; ASPERGILLUS-FUMIGATUS; SWEAT ANTIGEN; SERUM IGE; ECZEMA/DERMATITIS SYNDROME; ANTINUCLEAR ANTIBODIES; CROSS-REACTIVITY; ECZEMA; AUTOANTIBODIES	The role of autoimmunity in atopic dermatitis (AD) is unclear. We sought to critically examine the occurrence, correlation with severity, and possible causative role of autoreactivity in patients with AD. Our systematic review of studies identified from MEDLINE included 31 experiments that described autoreactivity in patients with AD. We defined autoreactivity as in vitro or in vivo evidence of immune response to autologous human, generic human, or recombinant human proteins or other tissue/cellular components. Autoreactivity prevalence in patients with AD ranged from 23% to 91% in 14 studies involving 2644 participants, although it did not appear to vary with age, sex, or disease duration. In contrast to studies of AD, IgE autoreactivity was not found in healthy subjects or in those with allergic rhinoconjunctivitis, psoriasis, systemic lupus erythematosus, or other inflammatory diseases (8 studies of 816 participants). Two reports found a positive correlation between autoreactivity and AD severity. We suggest that autoreactivity might be playing a causative role in AD based on the magnitude and specificity of the associations found; plausible mechanisms through IgE autoantibodies, IgG autoantibodies, and T(H)1 autoreactivity; and experimental elicitation of eczematous lesions after provocation. Whether autoantibodies contribute to AD chronicity now needs to be examined in longitudinal studies. (J Allergy Clin Immunol 2012;129:1209-15.)	[Tang, Ting Seng; Williams, Hywel C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2NR, England; [Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany	University of Nottingham; University of Bonn	Tang, TS (corresponding author), Univ Nottingham, Ctr Evidence Based Dermatol, Rm A103,Kings Meadow Campus,Lenton Lane, Nottingham NG7 2NR, England.	kyle.tang@nottingham.ac.uk		williams, hywel/0000-0002-5646-3093	National Institute for Health Research [NF-SI-0611-10246] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Aichberger KJ, 2005, J IMMUNOL, V175, P1286, DOI 10.4049/jimmunol.175.2.1286; Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Batchelor JM, 2010, CLIN EXP DERMATOL, V35, P823, DOI 10.1111/j.1365-2230.2010.03901.x; Bath-Hextall FJ, 2010, BRIT J DERMATOL, V163, P12, DOI 10.1111/j.1365-2133.2010.09743.x; Bieber T, 2005, ACTA DERM-VENEREOL, P7, DOI 10.1080/03658340510012426; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; CARINI C, 1992, INT ARCH ALLERGY IMM, V98, P227, DOI 10.1159/000236189; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Fluckiger S, 2002, EUR J IMMUNOL, V32, P10, DOI 10.1002/1521-4141(200201)32:1<10::AID-IMMU10>3.0.CO;2-I; Hayashi N, 2008, MOD RHEUMATOL, V18, P153, DOI 10.1007/s10165-008-0028-1; Heratizadeh A, 2011, BRIT J DERMATOL, V164, P316, DOI 10.1111/j.1365-2133.2010.10090.x; Hide M, 2002, ACTA DERM-VENEREOL, V82, P335, DOI 10.1080/000155502320624050; Higashi Naoyuki, 2009, Journal of Nippon Medical School, V76, P300; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Kawamoto N, 2003, TISSUE ANTIGENS, V61, P352, DOI 10.1034/j.1399-0039.2003.00046.x; Kikuchi M, 1999, INT J CANCER, V81, P459, DOI 10.1002/(SICI)1097-0215(19990505)81:3<459::AID-IJC21>3.0.CO;2-6; Kinaciyan T, 2002, J ALLERGY CLIN IMMUN, V109, P717, DOI 10.1067/mai.2002.123303; Kortekangas-Savolainen O, 2004, ALLERGY, V59, P168, DOI 10.1046/j.1398-9995.2003.00330.x; Lind SM, 2009, EUR J IMMUNOL, V39, P2293, DOI 10.1002/eji.200839195; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; Mayer C, 1997, INT ARCH ALLERGY IMM, V113, P213, DOI 10.1159/000237550; Mittermann I, 2008, J INVEST DERMATOL, V128, P1451, DOI 10.1038/sj.jid.5701195; Mittermann I, 2004, CURR OPIN ALLERGY CL, V4, P367, DOI 10.1097/00130832-200410000-00007; Mossabeb R, 2002, J INVEST DERMATOL, V119, P820, DOI 10.1046/j.1523-1747.2002.00518.x; Mothes N, 2005, J ALLERGY CLIN IMMUN, V116, P706, DOI 10.1016/j.jaci.2005.06.025; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; Neuber K, 2006, CLIN EXP IMMUNOL, V146, P262, DOI 10.1111/j.1365-2249.2006.03218.x; Ochs RL, 2000, J ALLERGY CLIN IMMUN, V105, P1211, DOI 10.1067/mai.2000.107039; Ogawa Y, 2004, J AUTOIMMUN, V23, P221, DOI 10.1016/j.jaut.2004.07.003; Ohkouchi K, 1999, INT IMMUNOL, V11, P1635, DOI 10.1093/intimm/11.10.1635; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ramakrishna V, 1997, INT J CANCER, V73, P143, DOI 10.1002/(SICI)1097-0215(19970926)73:1<143::AID-IJC22>3.0.CO;2-G; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Seiberler S, 1999, INT ARCH ALLERGY IMM, V120, P117, DOI 10.1159/000024229; Seiberler S, 1999, INT ARCH ALLERGY IMM, V120, P108, DOI 10.1159/000024228; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P85, DOI 10.1016/j.jaci.2009.11.031; Szakos E, 2004, ALLERGY, V59, P164, DOI 10.1046/j.1398-9995.2003.00367.x; TADA J, 1994, DERMATOLOGY, V189, P38, DOI 10.1159/000246756; Takahagi S, 2009, BRIT J DERMATOL, V160, P426, DOI 10.1111/j.1365-2133.2008.08862.x; Tanaka A, 2006, EXP DERMATOL, V15, P283, DOI 10.1111/j.0906-6705.2006.00404.x; TANIGUCHI Y, 1992, ACTA DERM-VENEREOL, P62; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; Valenta R, 2009, TRENDS IMMUNOL, V30, P109, DOI 10.1016/j.it.2008.12.004; Weichel M, 2006, J ALLERGY CLIN IMMUN, V117, P676, DOI 10.1016/j.jaci.2005.11.040; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015	49	102	106	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1209	U360		10.1016/j.jaci.2012.02.002	http://dx.doi.org/10.1016/j.jaci.2012.02.002			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22409986				2022-12-18	WOS:000303418000006
J	Contoli, M; Baraldo, S; Marku, B; Casolari, P; Marwick, JA; Turato, G; Romagnoli, M; Caramori, G; Saetta, M; Fabbri, LM; Papi, A				Contoli, Marco; Baraldo, Simonetta; Marku, Brunilda; Casolari, Paolo; Marwick, John A.; Turato, Graziella; Romagnoli, Micaela; Caramori, Gaetano; Saetta, Marina; Fabbri, Leonardo M.; Papi, Alberto			Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chronic obstructive pulmonary disease; airway inflammation; lung function; exacerbations; comorbidities; natural history	LUNG-FUNCTION DECLINE; SEVERE EXACERBATIONS; RISK-FACTORS; COPD; LIMITATION; INFLAMMATION; THERAPY; HEALTH; SALMETEROL/FLUTICASONE; MAINTENANCE	Background: Both smokers and patients with asthma can experience fixed airflow obstruction, which is associated with distinctive patterns of airway pathology. The influence of fixed airflow obstruction on the prognosis of these patients is unknown. Objective: We sought to investigate lung function decline and exacerbations in a 5-year prospective study of subjects with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease (COPD). We also sought to explore correlations between functional, pathological, and clinical features. Methods: Patients with fixed airflow obstruction due to asthma (n = 16) or COPD (n = 21) and a control group of asthmatic patients with fully reversible airflow obstruction (n = 15) were followed for 5 years. Results: The rates of decline in FEY, were similar in patients with fixed airflow obstruction caused by asthma (-49.7 +/- 10.6 mL/y) or COPD (-51.4 +/- 9.8 mL/y) and were higher than in asthmatic patients with reversible airflow obstruction (-18.1 +/- 10.1 mL/y, P <.01). Exacerbation rates were also higher in patients with fixed airflow obstruction caused by asthma (1.41 +/- 0.26 per patient-year) or COPD (1.98 +/- 0.3 per patient-year) compared with those seen in asthmatic patients with reversible airflow obstruction (0.53 +/- 0.11 per patient-year, P < .01). Baseline exhaled nitric oxide levels and sputum eosinophil counts correlated with the FEV I decline in asthmatic patients with fixed airflow obstruction. By contrast, baseline sputum neutrophil counts, emphysema scores, comorbidities, and exacerbation frequency correlated directly and pulmonary diffusion capacity correlated inversely with the FEVI decline in patients with COPD. Conclusion: In both patients with asthma and those with COPD, fixed airflow obstruction is associated with increased lung function decline and frequency of exacerbations. Nevertheless, the decline in lung function entails the specific pathological and clinical features of the underlying diseases. (J Allergy Clin Immunol 2010;125:830-7.)	[Contoli, Marco; Marku, Brunilda; Casolari, Paolo; Marwick, John A.; Caramori, Gaetano; Papi, Alberto] Univ Ferrara, Res Ctr Asthma & COPD, Dept Clin & Expt Med, I-44100 Ferrara, Italy; [Baraldo, Simonetta; Turato, Graziella; Saetta, Marina] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy; [Romagnoli, Micaela] Pierantoni Morgagni Hosp, Dept Thorac Dis, Forli, Italy; [Marwick, John A.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airways Dis Sect, London, England; [Fabbri, Leonardo M.] Univ Modena & Reggio Emilia, Dept Resp Dis, Modena, Italy	University of Ferrara; University of Padua; Imperial College London; Universita di Modena e Reggio Emilia	Papi, A (corresponding author), Univ Ferrara, Res Ctr Asthma & COPD, Dept Clin & Expt Med, Via Savonarola 9, I-44100 Ferrara, Italy.	ppa@unife.it	Caramori, Gaetano/AAS-8611-2020; Papi, alberto/AAC-1888-2019; Fabbri, Leonardo M/I-4055-2012; Contoli, Marco/K-3947-2018; Baraldo, Simonetta/AAE-3862-2021	Caramori, Gaetano/0000-0002-9807-327X; Fabbri, Leonardo M/0000-0001-8894-1689; Contoli, Marco/0000-0002-2731-5809; Baraldo, Simonetta/0000-0001-8923-7511; SAETTA, MARINA/0000-0002-1547-2102; TURATO, GRAZIELLA/0000-0003-1895-6388; PAPI, ALBERTO/0000-0002-6924-4500	Italian Ministry of Health and the Italian Ministry of Education (MURST); Chiesi Farmaceutici; Boehringer Ingelheim; AstraZeneca; Sigma Tau; Novartis; GlaxoSmithKline; Farmindustria; Abbott Laboratories	Italian Ministry of Health and the Italian Ministry of Education (MURST)(Ministry of Education, Universities and Research (MIUR)); Chiesi Farmaceutici(Chiesi Pharmaceuticals Inc); Boehringer Ingelheim(Boehringer Ingelheim); AstraZeneca(AstraZeneca); Sigma Tau; Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); Farmindustria; Abbott Laboratories(Abbott Laboratories)	Supported by the Italian Ministry of Health and the Italian Ministry of Education (MURST).; Disclosure of potential conflict of interest: M. Contoli has received consulting fees from Chiesi Farmaceutici and has received lecture fees front Boehringer Ingelheim and AstraZeneca. S. Baraldo has received lecture fees front Boehringer Ingelheim. M. Romagnoli has received lecture fees from AstraZeneca. G. Caramori has received lecture fees from Sigma Tau, has received research support front Novartis, mid has served as an expert witness for GlaxoSmithKline. M. Saetta has received lecture fees front AstraZeneca. Farmindustria. GlaxoSmithKline. Abbott Laboratories, and Boehringer Ingelheim and has received research support front GlaxoSmithKline and AstraZeneca. L. M. Fabbri has received fees for lecturing, consultancies, and advisory boards from Nycomed, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche, and Pfizer and has received research support from Chiesi Farmaceutici, Nycomed, Boehringer Ingelheim, Pfizer, Roche, and Novartis. A. Papi has received fees for lecturing, consultancies, and the advisory board from Chiesi Farmaceutici; fees for lecturing and consultancies front GlaxoSmithKline: fees for lecturing from AstraZeneca, Boehringer Ingelheim, and Merck Sharp & Dohme; and research support from AstraZeneca, Chiesi Farmaceutici. Boehringer Ingelheim, and Merck Sharp & Dohme. The rest of the authors have declared that they have no conflict of interest.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; Busse WW, 2008, J ALLERGY CLIN IMMUN, V121, P1167, DOI 10.1016/j.jaci.2008.02.029; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crisafulli E, 2008, THORAX, V63, P487, DOI 10.1136/thx.2007.086371; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277, DOI 10.1164/ajrccm.158.4.9802078; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Efthimiadis A, 2002, EUR RESPIR J, V20, p19S, DOI 10.1183/09031936.02.00001902; Fabbri LM, 2007, LANCET, V370, P797, DOI 10.1016/S0140-6736(07)61383-X; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Global Initiative for Asthma (GINA), 2008, NIH PUBL; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Mannino DM, 2000, ARCH INTERN MED, V160, P1683, DOI 10.1001/archinte.160.11.1683; Mapel DW, 2000, ARCH INTERN MED, V160, P2653, DOI 10.1001/archinte.160.17.2653; Marti S, 2006, EUR RESPIR J, V27, P689, DOI 10.1183/09031936.06.00076405; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miller MR, 2005, EUR RESPIR J, V26, P153, DOI 10.1183/09031936.05.00034505; Mucha Lisa, 2006, Gend Med, V3, P279, DOI 10.1016/S1550-8579(06)80216-0; *NIH GOLD, 2008, NIH PUBL; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; O'Donnell RA, 2004, THORAX, V59, P837, DOI 10.1136/thx.2003.019349; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773, DOI 10.1164/ajrccm.162.5.9910112; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304, DOI 10.1164/ajrccm.163.6.2009116; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; ten Brinke A, 2008, CURR OPIN ALLERGY CL, V8, P63, DOI 10.1097/ACI.0b013e3282f3b5b5; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; van Manen JG, 2001, J CLIN EPIDEMIOL, V54, P287, DOI 10.1016/S0895-4356(01)00346-8; van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907; Wedzicha JA, 2008, AM J RESP CRIT CARE, V177, P19, DOI 10.1164/rccm.200707-973OC; Welte T, 2009, AM J RESP CRIT CARE, V180, P741, DOI 10.1164/rccm.200904-0492OC	45	102	108	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					830	837		10.1016/j.jaci.2010.01.003	http://dx.doi.org/10.1016/j.jaci.2010.01.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20227753				2022-12-18	WOS:000276787900007
J	Hamilton, RG				Hamilton, Robert G.			Clinical laboratory assessment of immediate-type hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Diagnosis; skin testing; RAST; IgE antibody; provocation testing	IMMUNOGLOBULIN-E LEVELS; IGE ANTIBODY-ASSAYS; SKIN PRICK TESTS; IN-VITRO; RECOMBINANT ALLERGENS; MONOCLONAL-ANTIBODIES; HISTAMINE-RELEASE; DIAGNOSTIC-TESTS; FUNGUS SPORES; SERUM	Clinical laboratory analyses aid in the diagnosis and management of human allergic (IgE-dependent) diseases. Diagnosis of immediate-type hypersensitivity begins with a thorough clinical history and physical examination. Once symptoms compatible with an allergic disorder have been identified, a skin test, blood test, or both for allergen-specific IgE antibodies provide confirmation of sensitization, which strengthens the diagnosis. Skin testing provides a biologically relevant immediate-type hypersensitivity response with resultant wheal-and-flare reactions within 15 minutes of allergen application. Allergen-specific IgE antibody in serum is quantified by using 3 laboratory-based autoanalyzers (ImmunoCAP, Immulite, and HYTEC-288) and novel microarray and lateral-flow immunoassays. Technologic advances in serologic allergen-specific IgE measurements have involved increased automation, with enhanced reproducibility, greater quantification, lower analytic sensitivity, and component-supplemented extract-based allergen use. In vivo provocation tests involving inhalation, ingestion, or injection of allergens serve to clarify discordant history and skin- or blood-based measures of sensitization. Other diagnostic allergy laboratory analyses include total and free serum IgE measurement, precipitating IgG antibodies specific for organic dusts, mast cell tryptase, and indicator allergen analyses to assess indoor environments to promote patient-targeted allergen avoidance programs. A critique is provided on the predictive utility of serologic measures of specific IgE for food allergy and asthma. Reasons for the lack of clinical utility for food-specific IgG/IgG4 measurements in allergy diagnosis are examined. When the specific IgE measures are inconsistent with the clinical history, they should be confirmed by means of repeat and alternative method analysis. Ultimately, the patient's clinical history remains the principal arbiter that determines the final diagnosis of allergic disease. (J Allergy Clin Immunol 2010;125:S284-96.)	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Allergy & Clin Immunol Div,Dept Med, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Hamilton, RG (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Allergy & Clin Immunol Div,Dept Med, Room 1A20,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	rhamilt2@jhmi.edu						Altrich ML, 2009, ALLERGY ASTHMA PROC, V30, P28, DOI 10.2500/aap.2009.30.3185; Antico A, 2000, ANN ALLERG ASTHMA IM, V85, P145, DOI 10.1016/S1081-1206(10)62455-6; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BELIN LGA, 1977, CLIN ALLERGY, V7, P55, DOI 10.1111/j.1365-2222.1977.tb01425.x; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bogdanovic J, 2009, J ALLERGY CLIN IMMUN, V123, pS33, DOI 10.1016/j.jaci.2008.12.1067; Brown RH, 1998, ANESTHESIOLOGY, V89, P292, DOI 10.1097/00000542-199808000-00004; BURGE HP, 1977, MYCOPATHOLOGIA, V61, P27, DOI 10.1007/BF00440755; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; COCKROFT DW, 2009, MIDDLETONS ALLERGY P, P1295; Damin DA, 2006, MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION, P947; Diaz-Vazquez C, 2009, PEDIAT ALLERG IMM-UK, V20, P601, DOI 10.1111/j.1399-3038.2008.00827.x; Eckman JA, 2009, J INVEST DERMATOL, V129, P1584, DOI 10.1038/jid.2008.416; EDMONDS RL, 1972, PLANT DIS REP, V56, P704; FAGAN DL, 1982, J ALLERGY CLIN IMMUN, V70, P399, DOI 10.1016/0091-6749(82)90031-8; Fan LL, 2002, CURR OPIN PEDIATR, V14, P323, DOI 10.1097/00008480-200206000-00008; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Garcia-Ara MC, 2004, CLIN EXP ALLERGY, V34, P866, DOI 10.1111/j.1365-2222.2004.01976.x; Golden DBK, 2009, ANN ALLERG ASTHMA IM, V102, P47, DOI 10.1016/S1081-1206(10)60107-X; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; Hamilton RG, 2009, ALLERGY, V64, P317, DOI 10.1111/j.1398-9995.2008.01907.x; HAMILTON RG, 1993, J ALLERGY CLIN IMMUN, V92, P651, DOI 10.1016/0091-6749(93)90007-3; Hamilton RG, 2006, J ALLERGY CLIN IMMUN, V117, P759, DOI 10.1016/j.jaci.2006.01.012; Hamilton RG, 1997, METHODS, V13, P53, DOI 10.1006/meth.1997.0495; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V86, P353, DOI 10.1016/S1081-1206(10)62477-5; HAMILTON RG, 2009, ARCH PATHOL IN PRESS; HAMILTON RG, 2009, PEDIAT ALLERGY PRINC; Hamilton RG, 2008, CLIN IMMUNOLOGY PRIN, P1471; Hamilton Robert G., 2008, P63, DOI 10.1201/9781420003710.ch3; Hamilton RG, 2008, J ALLERGY CLIN IMMUN, V122, P305, DOI 10.1016/j.jaci.2008.05.009; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hogan AD, 1997, METHODS, V13, P43, DOI 10.1006/meth.1997.0494; ISHIZAKA K, 1966, J ALLERGY, V37, P169, DOI 10.1016/0021-8707(66)90091-8; JEFFERIS R, 1985, IMMUNOL LETT, V10, P223, DOI 10.1016/0165-2478(85)90082-3; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; Kaplan AP, 2009, CLIN EXP ALLERGY, V39, P777, DOI 10.1111/j.1365-2222.2009.03256.x; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Kurtz KM, 1999, ANN ALLERG ASTHMA IM, V83, P634, DOI 10.1016/S1081-1206(10)62886-4; LEVY DA, 1966, J IMMUNOL, V97, P203; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1992, J IMMUNOL, V148, P3929; MATSSON P, 2009, ILA20 CLSI; McCann WA, 2002, ANN ALLERG ASTHMA IM, V89, P368, DOI 10.1016/S1081-1206(10)62037-6; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V101, P153, DOI 10.1016/S0091-6749(98)70409-9; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; RANDALL B, 1995, J FORENSIC SCI, V40, P208; Saini SS, 2009, CURR ALLERGY ASTHM R, V9, P286, DOI 10.1007/s11882-009-0040-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Schroeder JT, 2006, MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION, P964; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; SOLOMON W, 1967, MANUAL CLIN ALLERGY; Stapel SO, 2008, ALLERGY, V63, P793, DOI 10.1111/j.1398-9995.2008.01705.x; TOGIAS A, 2009, MIDDLETONS ALLERGY P, P1281; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; Van der Gugten AC, 2008, J ALLERGY CLIN IMMUN, V121, P531, DOI 10.1016/j.jaci.2007.10.042; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; vanderVeen MJ, 1996, J ALLERGY CLIN IMMUN, V98, P1028, DOI 10.1016/S0091-6749(96)80187-4; Vesper S, 2007, J ENVIRON MONITOR, V9, P826, DOI 10.1039/b704359g; Vesper SJ, 2007, J EXPO SCI ENV EPID, V17, P88, DOI 10.1038/sj.jes.7500528; WIDE L, 1967, LANCET, V2, P1105; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; Wood RA, 2009, MIDDLETONS ALLERGY P, P1309; Wood RA, 2007, ANN ALLERG ASTHMA IM, V99, P34, DOI 10.1016/S1081-1206(10)60618-7; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041; Zacharisen MC, 2002, ANN ALLERG ASTHMA IM, V88, P175, DOI 10.1016/S1081-1206(10)61993-X	73	102	108	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S284	S296		10.1016/j.jaci.2009.09.055	http://dx.doi.org/10.1016/j.jaci.2009.09.055			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176264				2022-12-18	WOS:000280170600026
J	Mascarell, L; Lombardi, V; Louise, A; Saint-Lu, N; Chabre, H; Moussu, H; Betbeder, D; Balazuc, AM; Van Overtvelt, L; Moingeon, P				Mascarell, Laurent; Lombardi, Vincent; Louise, Anne; Saint-Lu, Nathalie; Chabre, Henri; Moussu, Helene; Betbeder, Didier; Balazuc, Anne-Marie; Van Overtvelt, Laurence; Moingeon, Philippe			Oral dendritic cells mediate antigen-specific tolerance by stimulating T(H)1 and regulatory CD4+ T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cell; mucosal immunity; sublingual immunotherapy	FC-EPSILON-RI; SUBLINGUAL IMMUNOTHERAPY; IMMUNOLOGICAL CHANGES; ALLERGIC RHINITIS; IMMUNE-RESPONSES; MESSENGER-RNA; EFFICACY; INDUCTION; ACTIVATION; SAFETY	Background: A detailed characterization of oral antigen-presenting cells is critical to improve second-generation sublingual allergy vaccines. Objective: To characterize oral dendritic cells (DCs) within lingual and buccal tissues from BALB/c mice with respect to their surface phenotype, distribution, and capacity to polarize CD4+ T-cell responses. Methods: lit situ analysis of oral DCs was performed by immunohistology. Purified DCs were tested in vitro for their capacity to capture, process, and present the ovalbumin antigen to naive CD4+ T cells. In vivo priming of ovalbumin-specific T cells adoptively transferred to BALB/c mice was analyzed by cytofluorometry in cervical lymph nodes after sublingual administration of mucoadhesive ovalbumin. Results: Three subsets of oral DCs with a distinct tissue distribution were identified: (1) a minor subset of CD207(+) Langerhans cells located in the mucosa itself, (2) a major subpopulation of CD11b(+)CD11c(-) and CD11b(+)CD11c(+) myeloid DCs at the mucosal/submucosal interface, and (3) B220(+)120G8(+) plasmacytoid DCs found in submucosal tissues. Purified myeloid and plasmacytoid oral DCs capture and process the antigen efficiently and are programmed to elicit IFN-gamma and/or IL-10 production together with a suppressive function in naive CD4+ T cells. Targeting the ovalbumin antigen to oral DCs in vivo by using mucoadhesive particles establishes tolerance in the absence of cell depletion through the stimulation of IFN-gamma and IL-10-producing CD4(+) regulatory T cells in cervical lymph nodes. Conclusion: The oral immune system is composed of various subsets of tolerogenic DCs organized in a compartmentalized manner and programmed to induce T(H)1/regulatory T-cell responses.	[Mascarell, Laurent; Lombardi, Vincent; Saint-Lu, Nathalie; Chabre, Henri; Moussu, Helene; Van Overtvelt, Laurence; Moingeon, Philippe] Stallergenes SA, Res & Dev, F-92160 Antony, France; [Louise, Anne; Balazuc, Anne-Marie] Inst Pasteur, Paris, France; [Betbeder, Didier] Univ Lille 2, Fac Med Pole Rech, Physiol Lab, F-59800 Lille, France	Stallergenes Greer; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Lille - ISITE; Universite de Lille	Moingeon, P (corresponding author), Stallergenes SA, Res & Dev, 6 Rue Alexis Tocqueville, F-92160 Antony, France.	pmoingeon@stallergenes.fr	BETBEDER, Didier/A-7558-2015	BETBEDER, Didier/0000-0002-2405-392X	Stallergenes	Stallergenes	Supported by Stallergenes.	Allam JP, 2008, J ALLERGY CLIN IMMUN, V121, P368, DOI 10.1016/j.jaci.2007.09.045; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38, DOI 10.1016/S1081-1206(10)61186-6; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Cuburu N, 2007, VACCINE, V25, P8598, DOI 10.1016/j.vaccine.2007.09.073; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; El Biaze M, 2003, ALLERGY, V58, P844, DOI 10.1034/j.1398-9995.2003.00282.x; Gabrielsson S, 2001, ALLERGY, V56, P293, DOI 10.1034/j.1398-9995.2001.00472.x; Gardner LM, 2004, CLIN EXP ALLERGY, V34, P1209, DOI 10.1111/j.1365-2222.2004.02009.x; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Laaksonen K, 2003, J ALLERGY CLIN IMMUN, V112, P1171, DOI 10.1016/j.jaci.2003.08.043; LOMBARDI V, 2008, CLIN EXP ALLERG 0717; Majori M, 2000, CLIN EXP ALLERGY, V30, P341, DOI 10.1046/j.1365-2222.2000.00701.x; Mascarell L, 2007, VACCINE, V26, P108, DOI 10.1016/j.vaccine.2007.10.050; Mascarell L, 2006, IMMUNOL ALLERGY CLIN, V26, P283, DOI 10.1016/j.iac.2006.02.009; Mavroleon G, 1998, CLIN EXP ALLERGY, V28, P917; Meissner N, 1999, CLIN EXP ALLERGY, V29, P618; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; Norman PS, 2004, J ALLERGY CLIN IMMUN, V113, P1013, DOI 10.1016/j.jaci.2004.03.020; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Oldenhove G, 2003, J EXP MED, V198, P259, DOI 10.1084/jem.20030654; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3, DOI 10.1016/S1081-1206(10)61440-8; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Razafindratsita A, 2007, J ALLERGY CLIN IMMUN, V120, P278, DOI 10.1016/j.jaci.2007.04.009; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Taylor A, 2004, INT ARCH ALLERGY IMM, V135, P73, DOI 10.1159/000080523; WILSON DR, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD002893, 10.1002/14651858]; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1084/jem.20030422	38	102	105	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					603	609		10.1016/j.jaci.2008.06.034	http://dx.doi.org/10.1016/j.jaci.2008.06.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774396	Bronze			2022-12-18	WOS:000259234000025
J	Dijkstra, D; Leurs, R; Chazot, P; Shenton, FC; Stark, H; Werfel, T; Gutzmer, R				Dijkstra, Dorothea; Leurs, Rob; Chazot, Paul; Shenton, Fiona C.; Stark, Holger; Werfel, Thomas; Gutzmer, Ralf			Histamine downregulates monocyte CCL2 production through the histamine H-4 receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine; monocytes; H-4 receptor; CCL2	T-CELLS; PHARMACOLOGICAL CHARACTERIZATION; ANTIINFLAMMATORY PROPERTIES; MEDIATES CHEMOTAXIS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ATOPIC-DERMATITIS; H4 RECEPTOR; MAST-CELLS; 1ST POTENT	Background: The expression of the recently cloned histamine H-4 receptor (H4R) by leukocytes suggests a role in immunomodulation. Objective: The expression and function of the H4R on human monocytes obtained from peripheral blood was investigated. Methods: H4R expression was studied by using How cytometry. Effects of H4R stimulation on Ca2+ mobilization was determined fluorometrically, CCL2 production was determined by means of ELISA, intracellular CCL2 staining was measured with flow cytometry, and CCL2 mRNA was measured by using real-time quantitative LightCycler PCR. The relevance of CCL2 production was determined in chemotaxis transmigration assays. Results: H4R protein was expressed by monocytes and upregulated by IFN-gamma. H4R agonists (clobenpropit and 4-methylhistamine) induce a Ca2+ mobilization in monocytes, which could be blocked with the selective H4R antagonist JNJ7777120. Furthermore, H4R agonists downregulated CCL2 protein production. This effect could also be blocked by JNJ7777120. Supernatants of H4R agonist-stimulated monocytes attracted less monocytes in transmigration assays. The downregulation of CCL2 production was regulated at different levels. First, the synthesis of CCL2 mRNA was significantly decreased. Second, intracellular staining suggested an inhibition of CCL2 secretion after stimulation with H4R agonists. Conclusion: Human monocytes express the H4R, and its stimulation leads to a Ca2+ influx and an inhibition of CCL2 production, resulting in a reduction of monocyte recruitment. Clinical implications: The H4R could represent an important anti-inflammatory receptor on monocytes and could be an interesting target for drug development.	Hannover Med Sch, Dept Dermatol & Allergol, D-30449 Hannover, Germany; Vrije Univ Amsterdam, Dept Med Chem, Leiden Amsterdam Ctr Drug Res, Amsterdam, Netherlands; Univ Durham, Sch Biol & Biomed Sci, Ctr Integrat Neurosci, Durham DH1 3HP, England; Univ Frankfurt, ZAFES, Inst Pharmaceut Chem, Frankfurt, Germany	Hannover Medical School; Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Durham University; Goethe University Frankfurt	Dijkstra, D (corresponding author), Hannover Med Sch, Dept Dermatol & Allergol, Ricklinger Str 5, D-30449 Hannover, Germany.	dijkstra.dorothea@mh-hannover.de	Leurs, Rob/ABB-4299-2021; Werfel, Thomas/B-6921-2012; Shenton, Fiona/A-4397-2012; Leurs, Rob/AAC-8508-2022; Stark, Holger/A-4235-2009	Leurs, Rob/0000-0003-1354-2848; Stark, Holger/0000-0003-3336-1710	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Azuma Y, 2001, INT IMMUNOPHARMACOL, V1, P1867, DOI 10.1016/S1567-5769(01)00112-6; Bissonnette EY, 1996, AM J RESP CELL MOL, V14, P620, DOI 10.1165/ajrcmb.14.6.8652190; Dunford PJ, 2006, J IMMUNOL, V176, P7062, DOI 10.4049/jimmunol.176.11.7062; DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P8, DOI 10.1159/000236796; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; Gantner F, 2002, J PHARMACOL EXP THER, V303, P300, DOI 10.1124/jpet.102.036939; Gutzmer R, 2005, J IMMUNOL, V174, P5224, DOI 10.4049/jimmunol.174.9.5224; Hofstra CL, 2003, J PHARMACOL EXP THER, V305, P1212, DOI 10.1124/jpet.102.046581; Horr B, 2006, INFLAMM RES, V55, pS53, DOI 10.1007/s00011-005-0039-8; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; Jablonowski JA, 2003, J MED CHEM, V46, P3957, DOI 10.1021/jm0341047; Kim Y, 2001, J IMMUNOL, V166, P5183, DOI 10.4049/jimmunol.166.8.5183; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lim HD, 2005, J PHARMACOL EXP THER, V314, P1310, DOI 10.1124/jpet.105.087965; Ling P, 2004, BRIT J PHARMACOL, V142, P161, DOI 10.1038/sj.bjp.0705729; Liu CL, 2001, MOL PHARMACOL, V59, P420, DOI 10.1124/mol.59.3.420; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; Morse KL, 2001, J PHARMACOL EXP THER, V296, P1058; Nakamura T, 2000, BIOCHEM BIOPH RES CO, V279, P615, DOI 10.1006/bbrc.2000.4008; Nakayama T, 2004, J IMMUNOL, V173, P2078, DOI 10.4049/jimmunol.173.3.2078; Nguyen T, 2001, MOL PHARMACOL, V59, P427, DOI 10.1124/mol.59.3.427; Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200; Purwar R, 2006, J INVEST DERMATOL, V126, P1043, DOI 10.1038/sj.jid.5700085; RILEY JF, 1952, J PHYSIOL-LONDON, V117, pP72; SOZZANI S, 1995, J LEUKOCYTE BIOL, V57, P788, DOI 10.1002/jlb.57.5.788; Szalai C, 2001, J ALLERGY CLIN IMMUN, V108, P375, DOI 10.1067/mai.2001.117930; Takeshita K, 2003, J PHARMACOL EXP THER, V307, P1072, DOI 10.1124/jpet.103.057489; Thurmond RL, 2004, J PHARMACOL EXP THER, V309, P404, DOI 10.1124/jpet.103.061754; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; van Rijn RM, 2006, MOL PHARMACOL, V70, P604, DOI 10.1124/mol.105.020818; Vestergaard C, 1997, J DERMATOL SCI, V15, P14, DOI 10.1016/S0923-1811(96)00589-0; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434	32	102	105	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					300	307		10.1016/j.jaci.2007.03.024	http://dx.doi.org/10.1016/j.jaci.2007.03.024			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17507084	Bronze			2022-12-18	WOS:000248654900012
J	Schneider, L; Lumry, W; Vegh, A; Williams, AH; Schmalbach, T				Schneider, Lynda; Lumry, William; Vegh, Arthur; Williams, Anthony H.; Schmalbach, Tess			Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ecallantide; bradykinin; C1 inhibitor; C1-INH; contact; hereditary angioedema; HAE; kallikrein; kinin	C1 INHIBITOR; PLASMA KALLIKREIN; ESTERASE INHIBITOR; HIGH-AFFINITY; DEFICIENCY; BRADYKININ; DANAZOL; COMPLEMENT; THERAPY; PATHOPHYSIOLOGY	Background: Hereditary angioedema (HAE) is a rare, autosomal-dominant disorder caused by C1 inhibitor gene mutation. Patients with HAE experience intermittent attacks of edema affecting the oropharynx, abdomen, gastrointestinal tract, and limbs. C1 inhibitor is the primary endogenous inhibitor of the kallikrein-kinin (contact) cascade. Unregulated kallikrein activation generates bradykinin, the likely mediator of the swelling and pain characterizing HAE attacks. Ecallantide, a novel, recombinant protein, potently inhibits kallikrein. This is the first placebo-controlled assessment in human beings of a therapeutic intervention to) improve symptoms of HAE attacks under the hypothesis that the contact cascade is the putative pathway responsible for HAE pathology. Objective: To determine the safety and efficacy of ecallantide in patients with HAE. Methods: This double-blind, placebo-controlled, ascending-dose study assessed efficacy and tolerability of ecallantide (5, 10, 20, or 40 mg/m(2) intravenously) in individuals experiencing acute HAE attacks (N = 49). Twelve patients were assigned to each dose level: 10 to ecallantide and 2 to placebo, per cohort. Results: Ecallantide treatment ameliorated the symptoms of HAE attacks: 72.5 % (29/40) of patients treated with ecallantide versus 25.0% (2/8) of placebo patients reported significant improvement in symptoms within 4 hours (P =.0169). Ecallantide was well tolerated at all doses. Conclusion: Ecallantide, a potent, specific inhibitor of plasma kallikrein, significantly improved HAE symptoms over placebo. The trial provides strong support for the role of the kallikrein-kinin cascade and its end product, bradykinin, in the pathophysiology of HAE. Further clinical trials are underway. Clinical implications: Ecallantide is a promising new therapy for HAE attacks.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Allergy & Asthma Specialists, Dallas, TX USA; Puget Sound Allergy Asthma & Immunol, Tacoma, WA USA; Dyax Corp, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital	Schneider, L (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	lynda.schneider@childrens.harvard.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR02172] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Antonelli G, 1998, J INTERF CYTOK RES, V18, P345, DOI 10.1089/jir.1998.18.345; Bissler JJ, 1997, P ASSOC AM PHYSICIAN, V109, P164; Bork K, 2005, TRANSFUSION, V45, P1774, DOI 10.1111/j.1537-2995.2005.00602.x; Bork K, 2003, ARCH INTERN MED, V163, P1229, DOI 10.1001/archinte.163.10.1229; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; Caballero T, 2006, J ALLERGY CLIN IMMUN, V117, P476, DOI 10.1016/j.jaci.2005.10.045; CARREER FMJ, 1992, EUR J CLIN CHEM CLIN, V30, P793; CICARDI M, 1991, J ALLERGY CLIN IMMUN, V87, P768, DOI 10.1016/0091-6749(91)90120-D; Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510; Cugno M, 2003, INT IMMUNOPHARMACOL, V3, P311, DOI 10.1016/S1567-5769(02)00162-5; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; De Serres J, 2003, TRANSFUS APHER SCI, V29, P247, DOI 10.1016/j.transci.2003.08.006; FERMAND JP, 1990, AM J MED, V88, P529, DOI 10.1016/0002-9343(90)90434-F; Frank MM, 2005, CURR OPIN PEDIATR, V17, P686, DOI 10.1097/01.mop.0000182382.28552.1c; FRANK MM, 2003, GOLDMAN CECIL TXB ME, P1610; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Hara T, 1999, ENDOSCOPY, V31, P322; HOSEA SW, 1980, ANN INTERN MED, V93, P809, DOI 10.7326/0003-4819-93-6-809; Kaplan AP, 2005, J ALLERGY CLIN IMMUN, V115, P876, DOI 10.1016/j.jaci.2004.12.1132; Levy JH, 2006, EXPERT OPIN INV DRUG, V15, P1077, DOI 10.1517/13543784.15.9.1077; Ley AC, 1996, MOL DIVERS, V2, P119, DOI 10.1007/BF01718709; Longhurst HJ, 2005, INT J CLIN PRACT, V59, P594, DOI 10.1111/j.1742-1241.2005.00352.x; Markland W, 1996, BIOCHEMISTRY-US, V35, P8058, DOI 10.1021/bi952629y; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; OVTVAI ZN, 1991, LAB INVEST, V65, P381; RATNOFF OD, 1969, J EXP MED, V129, P315, DOI 10.1084/jem.129.2.315; ROBERTS HR, 2005, HEMATOLOGY BASCI PRI, P2089; Roche O, 2005, ANN ALLERG ASTHMA IM, V94, P498, DOI 10.1016/S1081-1206(10)61121-0; SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802; SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P855, DOI 10.1016/S0091-6749(87)80277-4; STRANG CJ, 1988, J EXP MED, V168, P1685, DOI 10.1084/jem.168.5.1685; Szeplaki G, 2005, J ALLERGY CLIN IMMUN, V115, P864, DOI 10.1016/j.jaci.2004.12.1130; Tosi M, 1998, IMMUNOBIOLOGY, V199, P358, DOI 10.1016/S0171-2985(98)80040-5; Weiler JM, 2002, J ALLERGY CLIN IMMUN, V109, P995, DOI 10.1067/mai.2002.124892; ZAHEDI R, 1995, J CLIN INVEST, V95, P1299, DOI 10.1172/JCI117780; Zahedi R, 1997, J IMMUNOL, V159, P983	42	102	118	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					416	422		10.1016/j.jaci.2007.04.028	http://dx.doi.org/10.1016/j.jaci.2007.04.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17559913				2022-12-18	WOS:000248654900030
J	Bourdin, A; Neveu, D; Vachier, I; Paganin, F; Godard, P; Chanez, P				Bourdin, Arnaud; Neveu, Dorine; Vachier, Isabelle; Paganin, Fabrice; Godard, Philippe; Chanez, Pascal			Specificity of basement membrane thickening in severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; COPD; remodeling; basement membrane; ROC	SUBEPITHELIAL FIBROSIS; COLLAGEN DEPOSITION; WALL THICKNESS; LUNG-FUNCTION; EXPRESSION; MATRIX-METALLOPROTEINASE-9; TRANSITION; AIRWAYS; BIOPSY	Background: Reticular basement membrane (RBM) thickness is considered a hallmark for airway remodeling in airway diseases such as asthma. It is still unclear whether this measurement could be associated with disease severity or apply to chronic obstructive pulmonary disease (COPD). A wide range of results, at baseline or after therapeutic intervention, have been reported using different measurement methods. Objective: To determine whether increased RBM thickness could be associated specifically with severe asthma and in COPD in large samples. Methods: We blindly measured RBM thickness in endobronchial biopsies from 50 patients with severe asthma (mean age, 53 years; FEV1 66% predicted, inhaled steroids >= 1500 mu g and 20 mg daily dose of oral corticosteroids, lifelong nonsmokers), 50 untreated patients with mild asthma mean age, 33 years; FEV, 93%pred, lifelong nonsmokers), 50 patients with COPD (mean age, 57 years; FEV1 53%pred, all current smokers), and 18 control subjects using 2 different validated quantitative and computer-assisted methods (repeated multiple point-to-point vs area by length ratio). Results: Reticular basement membrane thickness was higher in severe asthma compared with mild asthma and COPD (P =.0053). On the basis of receiver operating characteristic curves, RBM thickness was effective in differentiating severe asthma from other groups (sensitivity and specificity, 98% and 95%, respectively, above a threshold of 5 mu m vs control, 70% and 75% at 7 mu m vs mild, 83% and 68% at 6 mu m vs COPD). Conclusion: Increased RBM thickness was specifically associated with severe asthma, whereas surprisingly, COPD and mild asthma had similar remodeling features. Clinical implications: Reticular basement membrane thickness can be considered a hallmark of severe asthma.	CHU Montpellier, Hop Arnaud De Villeneuve, Serv Malad Resp, Montpellier, France; CHU Montpellier, Hop Arnaud De Villeneuve, Dept Med Informat, Montpellier, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Chanez, P (corresponding author), Hop Arnaud De Villeneuve, F-34295 Montpellier 5, France.	chanez@montp.inserm.fr	Vachier, Isabelle/AAV-5731-2020	Vachier, Isabelle/0000-0003-2730-5165; chanez, pascal/0000-0003-4059-0917				Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Chetta A, 2003, AM J RESP CRIT CARE, V167, P751, DOI 10.1164/rccm.200207-710OC; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Corsico A, 2003, J APPL PHYSIOL, V95, P441, DOI 10.1152/japplphysiol.01018.2002; Deykin A, 2002, AM J RESP CRIT CARE, V165, P1597, DOI 10.1164/rccm.2201081; Elston WJ, 2004, EUR RESPIR J, V24, P375, DOI 10.1183/09031936.04.00063003; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Ferrando RE, 2003, J ALLERGY CLIN IMMUN, V112, P1243, DOI 10.1016/j.jaci.2003.09.038; Fouty B, 2006, EUR RESPIR J, V27, P1160, DOI 10.1183/09031936.06.00078605; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; Jeffery P, 2003, AM J RESP CRIT CARE, V168, pS1, DOI 10.1164/rccm.200202-150WS; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; KIDA K, 1983, AM REV RESPIR DIS, V128, P125, DOI 10.1164/arrd.1983.128.1.125; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Milanese M, 2001, J APPL PHYSIOL, V91, P1035, DOI 10.1152/jappl.2001.91.3.1035; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; *NIH, 2001, NHLBI WHO WORKSH BET; *NIH, 2002, NHLBI WHO WORKSH BET; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; ROCHE WR, 1989, LANCET, V1, P520; Saglani S, 2006, EUR RESPIR J, V28, P505, DOI 10.1183/09031936.06.00056405; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; Ward C, 2005, J HEART LUNG TRANSPL, V24, P533, DOI 10.1016/j.healun.2004.02.018; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	33	102	108	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1367	1374		10.1016/j.jaci.2007.01.055	http://dx.doi.org/10.1016/j.jaci.2007.01.055			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17481707				2022-12-18	WOS:000247232800011
J	Wu, Y; Sanderson, JP; Farrell, J; Drummond, NS; Hanson, A; Bowkett, E; Berry, N; Stachulski, AV; Clarke, SE; Pichler, WJ; Pirmohamed, M; Park, K; Naisbitt, DJ				Wu, Ying; Sanderson, Joseph P.; Farrell, John; Drummond, Nicola S.; Hanson, Anita; Bowkett, Elizabeth; Berry, Neil; Stachulski, Andrew V.; Clarke, Stephen E.; Pichler, Werner J.; Pirmohamed, Munir; Park, Kevin; Naisbitt, Dean J.			Activation of T cells by carbamazepine and carbamazepine metabolites	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						drug hypersensitivity; antigen presentation; T cells; cross-reactivity	DRUG-SPECIFIC CD4(+); LAMOTRIGINE HYPERSENSITIVITY; LYMPHOCYTE-PROLIFERATION; IN-VITRO; SULFAMETHOXAZOLE; OXCARBAZEPINE; BIOACTIVATION; INDIVIDUALS; RECOGNITION; DIAGNOSIS	Background: T-cell-mediated hypersensitivity is a rare but serious manifestation of drug therapy. Objectives: To explore the mechanisms of drug presentation to T cells and the possibility that generation of metabolite-specific T cells may provoke cross-sensitization between drugs. Methods: A lymphocyte transformation test was performed on 13 hypersensitive patients with carbamazepine, oxcarbazepine, and carbamazepine metabolites. Serial dilution experiments were performed to generate drug (metabolite)-specific T-cell clones to explore the structural basis of the T-cell response and mechanisms of antigen presentation. 3-Dimensional energy-minimized structures were generated by using computer modeling. The role of drug metabolism was analyzed with 1-aminobenzotriazole. Results: Lymphocytes and T-cell clones proliferated with carbamazepine, oxcarbazepine, and some (carbamazepine 10,11 epoxide, 10-hydroxy carbamazepine) but not all stable carbamazepine metabolites. Structure activity studies using 29 carbamazepine (metabolite)-specific T-cell clones revealed 4 patterns of drug recognition, which could be explained by generation of preferred 3-dimensional structural conformations. T cells were stimulated by carbamazepine (metabolites) bound directly to MHC in the absence of processing. The activation threshold for T-cell proliferation varied between 5 minutes and 4 hours. 1-Aminobenzotriazole, which inhibits cytochrome,P450 activity, did not prevent carbamazepine-related T-cell proliferation. Substitution of the terminal amine residue of carbamazepine with a methyl group diminished T-cell proliferation. Conclusion: These data show that carbamazepine and certain stable carbamazepine metabolites stimulate T cells rapidly via a direct interaction with MHC and specific T-cell receptors. Clinical implications: Some patients with a history of carbamazepine hypersensitivity possess T cells that cross-react with oxcarbazepine, providing a rationale for cross-sensitivity between the 2 drugs.	Univ Liverpool, Dept Pharmacol, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Dept Chem, Liverpool L69 3GE, Merseyside, England; GlaxoSmithKline Pharmaceut, Dept Drug Metab & Pharmacokinet, Welwyn Garden City, England; Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, Bern, Switzerland	University of Liverpool; University of Liverpool; GlaxoSmithKline; University of Bern; University Hospital of Bern	Naisbitt, DJ (corresponding author), Univ Liverpool, Dept Pharmacol, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	dnes@liv.ac.uk	Sanderson, Joseph/C-5169-2008; Pirmohamed, Munir/H-6004-2011; Berry, Neil G/B-7960-2009; Sanderson, Joseph/N-8308-2019	Sanderson, Joseph/0000-0002-1206-8833; Pirmohamed, Munir/0000-0002-7534-7266; Berry, Neil G/0000-0003-1928-0738; Sanderson, Joseph/0000-0002-1206-8833; Naisbitt, Dean/0000-0003-4107-7832; Pichler, Werner J./0000-0002-8117-359X; Farrell, John/0000-0002-8726-5997	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brown KL, 1999, DEV MED CHILD NEUROL, V41, P267, DOI 10.1017/S0012162299000560; Burkhart C., 2002, Clinical and Experimental Allergy, V32, P1635, DOI 10.1046/j.1365-2222.2002.01513.x; Burkhart C, 2001, BRIT J PHARMACOL, V132, P623, DOI 10.1038/sj.bjp.0703845; DEMONTELLANO PRO, 1984, TETRAHEDRON, V40, P511; Depta JPH, 2004, J ALLERGY CLIN IMMUN, V113, P519, DOI 10.1016/j.jaci.2003.11.030; DICKINSON RG, 1989, EUR J CLIN PHARMACOL, V37, P69; Farrell J, 2004, BRIT J CLIN PHARMACO, V57, P690; FURST SM, 1995, INT J IMMUNOPHARMACO, V17, P445, DOI 10.1016/0192-0561(95)00019-X; Hari Y, 2001, CLIN EXP ALLERGY, V31, P1398, DOI 10.1046/j.1365-2222.2001.01164.x; JENSON NO, 1986, IRISH J MED SCI, V155, P297; Ju C, 1999, J PHARMACOL EXP THER, V288, P51; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; LEVITT M, 1969, J MOL BIOL, V46, P269, DOI 10.1016/0022-2836(69)90421-5; Leyva L, 2000, J ALLERGY CLIN IMMUN, V105, P157, DOI 10.1016/S0091-6749(00)90191-X; Madden S, 1996, DRUG METAB DISPOS, V24, P469; Maggs JL, 1997, DRUG METAB DISPOS, V25, P275; MAPLE JR, 1994, J COMPUT CHEM, V15, P162, DOI 10.1002/jcc.540150207; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Naisbitt DJ, 2003, J ALLERGY CLIN IMMUN, V111, P1393, DOI 10.1067/mai.2003.1507; Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732; Naisbitt DJ, 2002, MOL PHARMACOL, V62, P628, DOI 10.1124/mol.62.3.628; Pearce RE, 2002, DRUG METAB DISPOS, V30, P1170, DOI 10.1124/dmd.30.11.1170; Pichler WJ, 2002, CURR OPIN ALLERGY CL, V2, P301, DOI 10.1097/00130832-200208000-00003; Pichler WJ, 2004, ALLERGY, V59, P809, DOI 10.1111/j.1398-9995.2004.00547.x; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; PIENIMAKI P, 1995, EPILEPSIA, V36, P241, DOI 10.1111/j.1528-1157.1995.tb00991.x; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; SHEAR NH, 1988, J CLIN INVEST, V82, P1826, DOI 10.1172/JCI113798; TOMSON T, 1980, ARCH NEUROL-CHICAGO, V37, P699, DOI 10.1001/archneur.1980.00500600047009; ZAKRZEWSKA JM, 1988, J ALLERGY CLIN IMMUN, V82, P110, DOI 10.1016/0091-6749(88)90059-0; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544	32	102	114	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					233	241		10.1016/j.jaci.2006.03.005	http://dx.doi.org/10.1016/j.jaci.2006.03.005			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815161	Bronze			2022-12-18	WOS:000239184800029
J	Salam, MT; Wenten, M; Gilliland, FD				Salam, Mulharnmad T.; Wenten, Made; Gilliland, Frank D.			Endogenous and exogenous sex steroid hormones and asthma and wheeze in young women	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral contraceptives; sex hormones; estrogen; progesterone; puberty; menarche; wheeze; asthma	SOUTHERN CALIFORNIA COMMUNITIES; PREMENSTRUAL ASTHMA; DIFFERING LEVELS; MENSTRUAL-CYCLE; AIR-POLLUTION; ESTROGEN; AGE; REMISSION; SYMPTOMS; MENARCHE	Background: Emerging evidence suggests that both endogenous and exogenous sex steroid hormones may influence the occurrence of asthma and wheeze among women. Objective: We investigated the associations between exogenous sex hormone (oral contraceptive [OC]) use and wheezing in young women with and without asthma history. To investigate the role of endogenous sex hormones, we examined the association between age at menarche and the development of asthma after puberty. Methods: We conducted a study among 905 women who had undergone menarche. Subjects were between 13 and 28 years of age and had participated in the Children's Health Study. Results: In women without asthma, OC use was associated with higher risk of current wheeze (odds ratio [OR], 1.75; 95% CI, 1.15-2.65). In contrast, OC use was associated with a markedly reduced prevalence of current wheeze in women with a history of asthma (OR, 0.18; 95% CI, 0.06-0.56; P value for interaction = .003). These associations showed significant trends with duration of OC use. Age at menarche was associated with new-onset asthma after puberty. Compared with women who had menarche after age 12 years, women with menarche before age 12 years had a 2.08-fold (95% CI, 1.05-4.12) higher risk of asthma after puberty. Conclusion: Both endogenous and exogenous sex steroid hormones affect asthma and wheeze occurrences in young women. Clinical implications: Because women have higher asthma risk after puberty, and OC use is common among young women, clinicians may inform women with asthma about the potential effects of OC on asthma-related respiratory symptoms.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	University of Southern California	Gilliland, FD (corresponding author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@usc.edu		Salam, Muhammad/0000-0002-3565-8916	NHLBI NIH HHS [5R01HL61768] Funding Source: Medline; NIEHS NIH HHS [5P01ES09581, 5P30 ES07048, 5P01ES011627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009581, P01ES011627, P30ES007048] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal SK, 1999, ANN ALLERG ASTHMA IM, V83, P222, DOI 10.1016/S1081-1206(10)62644-0; ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; APTER D, 1989, INT J CANCER, V44, P783, DOI 10.1002/ijc.2910440506; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BEYNON HLC, 1988, LANCET, V2, P370; BLUMENFELD Z, 1994, FERTIL STERIL, V62, P197; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chandler MHH, 1997, PHARMACOTHERAPY, V17, P224; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; Derimanov GS, 1998, ANN ALLERG ASTHMA IM, V81, P243, DOI 10.1016/S1081-1206(10)62820-7; ELIASSON O, 1986, J ALLERGY CLIN IMMUN, V77, P87, DOI 10.1016/0091-6749(86)90328-3; Ensom MHH, 2003, ANN PHARMACOTHER, V37, P1610, DOI 10.1345/aph.1D090; Gotthardt M, 1996, J Ky Med Assoc, V94, P105; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Haggerty CL, 2003, ANN ALLERG ASTHMA IM, V90, P284, DOI 10.1016/S1081-1206(10)61794-2; HORAN JD, 1968, CAN MED ASSOC J, V99, P130; Kirsch EA, 1999, AM J RESP CELL MOL, V20, P658, DOI 10.1165/ajrcmb.20.4.3241; Lam S M, 1998, J Microbiol Immunol Infect, V31, P197; Matsuo N, 1999, CHEST, V116, P252, DOI 10.1378/chest.116.1.252; MORRIS D, 1988, LANCET, V2, P844; Murray RD, 1999, EUR RESPIR J, V14, P966, DOI 10.1034/j.1399-3003.1999.14d39.x; MYERS JR, 1994, CHEST, V106, P318, DOI 10.1378/chest.106.1.318; PAULI BD, 1989, AM REV RESPIR DIS, V140, P358, DOI 10.1164/ajrccm/140.2.358; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760, DOI 10.1164/ajrccm.159.3.9804143; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768, DOI 10.1164/ajrccm.159.3.9804144; PRIDE SM, 1984, CAN MED ASSOC J, V131, P763; Siroux V, 2004, J ALLERGY CLIN IMMUN, V114, P491, DOI 10.1016/j.jaci.2004.05.027; Skobeloff EM, 1996, ARCH INTERN MED, V156, P1837, DOI 10.1001/archinte.156.16.1837; SPEIR E, 1998, LAM OTHER DIS CHARAC, P351; Tan KS, 1997, AM J RESP CRIT CARE, V155, P1273, DOI 10.1164/ajrccm.155.4.9105066; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; WALDBOTT GL, 1942, J ALLERGY, V13, P124; Westergaard T, 2003, CLIN EXP ALLERGY, V33, P301, DOI 10.1046/j.1365-2222.2003.01441.x; Xu BZ, 2000, THORAX, V55, P691, DOI 10.1136/thorax.55.8.691; Zimmerman JL, 2000, AM J RESP CRIT CARE, V162, P512, DOI 10.1164/ajrccm.162.2.9910105	37	102	103	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1001	1007		10.1016/j.jaci.2006.02.004	http://dx.doi.org/10.1016/j.jaci.2006.02.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675325				2022-12-18	WOS:000237436300005
J	Lambert, C; McCue, J; Ouyang, Y; Li, JM; Rosano, TG; Lazis, A; Freed, BM				Lambert, C; McCue, J; Ouyang, Y; Li, JM; Rosano, TG; Lazis, A; Freed, BM			Acrolein in cigarette smoke inhibits T-cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cigarette smoke; T cell; activation; cytokine; gene expression; acrolein	ALVEOLAR MACROPHAGES; TOBACCO-SMOKE; LUNG-CANCER; INFECTION; RISK; TUBERCULOSIS; RELEASE; LYMPHOCYTE; APOPTOSIS; GAMMA	Background: Cigarette smoking inhibits T-cell responses in the lungs, but the immunosuppressive compounds have not been fully identified. Cigarette smoke extracts inhibit IL-2, IFN-gamma, and TNF-alpha production in stimulated lymphocytes obtained from peripheral blood, even when the extracts were diluted 100-fold to 1000-fold. Objective: The objective of these studies was to identify the immunosuppressive compounds found in cigarette smoke. Methods: Gas chromatography/mass spectroscopy and HPLC were used to identify and quantitate volatile compounds found in cigarette smoke extracts. Bioactivity was measured by viability and production of cytokine mRNA and protein levels in treated human lymphocytes. Results: The vapor phase of the cigarette smoke extract inhibited cytokine production, indicating that the immunosuppressive compounds were volatile. Among the volatile compounds identified in cigarette smoke extracts, only the alpha, P-unsaturated aldehydes, acrolein (inhibitory concentration of 50% [IC50] = 3 mu mol/L) and crotonaldehyde (IC50 = 6 mu mol/L), exhibited significant inhibition of cytokine production. Although the levels of aldehydes varied 10-fold between high-tar (Camel) and ultralow-tar (Carlton) extracts, even ultralow-tar cigarettes produced sufficient levels of acrolein (34 mu mol/L) to suppress cytokine production by > 95%. We determined that the cigarette smoke extract inhibited transcription of cytokine genes. The inhibitory effects of acrolein could be blocked with the thiol compound N-acetylcysteine. Conclusion: The vapor phase from cigarette smoke extracts potently suppresses cytokine production. The compound responsible for this inhibition appears to be acrolein.	Univ Colorado, Div Clin Immunol & Allergy, Dept Med, Denver, CO 80262 USA; Hlth Sci Ctr, Denver, CO USA; Albany Med Ctr, Dept Pathol & Lab Med, Albany, NY USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Albany Medical College	Freed, BM (corresponding author), Univ Colorado, Div Clin Immunol & Allergy, Dept Med, Campus Box B164,4200 E 9th Ave, Denver, CO 80262 USA.	Brian.Freed@uchsc.edu			NIEHS NIH HHS [ES05673] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altet MN, 1996, TUBERCLE LUNG DIS, V77, P537, DOI 10.1016/S0962-8479(96)90052-0; Arcavi L, 2004, ARCH INTERN MED, V164, P2206, DOI 10.1001/archinte.164.20.2206; Ariyothai Niorn, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P219; Baldwin CI, 1998, CLIN EXP IMMUNOL, V113, P166; Becker JC, 1996, P NATL ACAD SCI USA, V93, P7826, DOI 10.1073/pnas.93.15.7826; Blizzard L, 2003, AM J PUBLIC HEALTH, V93, P482, DOI 10.2105/AJPH.93.3.482; BROWN GP, 1989, AM J PHYSIOL, V256, pC260, DOI 10.1152/ajpcell.1989.256.2.C260; DANIELE RP, 1977, AM REV RESPIR DIS, V116, P997; Finkelstein EI, 2001, AM J PHYSIOL-LUNG C, V281, pL732, DOI 10.1152/ajplung.2001.281.3.L732; FISCHER T, 1978, INT ARCH OCC ENV HEA, V41, P267, DOI 10.1007/BF00378756; Frangides Christos Y, 2004, Eur J Intern Med, V15, P364, DOI 10.1016/j.ejim.2004.04.016; Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8; Hess SD, 2003, J IMMUNOL, V170, P400, DOI 10.4049/jimmunol.170.1.400; JOHNSON JD, 1990, CRIT REV TOXICOL, V20, P369, DOI 10.3109/10408449009089870; Jones AM, 2001, J INFECTION, V43, P135, DOI 10.1053/jinf.2001.0874; KARK JD, 1982, NEW ENGL J MED, V307, P1042, DOI 10.1056/NEJM198210213071702; Kataki A, 2002, J LAB CLIN MED, V140, P320, DOI 10.1067/mlc.2002.128317; Kolappan C, 2002, THORAX, V57, P964, DOI 10.1136/thorax.57.11.964; MCCREA KA, 1994, AM J RESP CRIT CARE, V150, P696, DOI 10.1164/ajrccm.150.3.8087340; McCue JM, 2000, J IMMUNOL, V165, P6771, DOI 10.4049/jimmunol.165.12.6771; McCue JM, 2003, MOL IMMUNOL, V39, P995, DOI 10.1016/S0161-5890(03)00046-4; Merimsky O, 2004, ANN ONCOL, V15, P610, DOI 10.1093/annonc/mdh137; Miguez-Burbano MJ, 2003, ADDICT BIOL, V8, P39, DOI 10.1080/1355621031000069864; Mio T, 1997, AM J RESP CRIT CARE, V155, P1770, DOI 10.1164/ajrccm.155.5.9154890; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; Ouyang Y, 2000, J ALLERGY CLIN IMMUN, V106, P280, DOI 10.1067/mai.2000.107751; Pastor P, 1998, CLIN INFECT DIS, V26, P590, DOI 10.1086/514589; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; SOLIMAN DM, 1992, AM J PHYSIOL, V263, pL471, DOI 10.1152/ajplung.1992.263.4.L471; STEDMAN RL, 1968, CHEM REV, V68, P153, DOI 10.1021/cr60252a002; Straus WL, 1996, ARCH INTERN MED, V156, P1685, DOI 10.1001/archinte.156.15.1685; Wewers MD, 1998, AM J RESP CRIT CARE, V158, P1543, DOI 10.1164/ajrccm.158.5.9802035; Wolfe F, 2004, ARTHRITIS RHEUM-US, V50, P372, DOI 10.1002/art.20009; Woolard MD, 2004, J IMMUNOL, V172, P6875, DOI 10.4049/jimmunol.172.11.6875; YAMAGUCHI E, 1993, CHEST, V103, P479, DOI 10.1378/chest.103.2.479; YAMAGUCHI E, 1989, AM REV RESPIR DIS, V140, P397, DOI 10.1164/ajrccm/140.2.397; Yang P, 2004, CARCINOGENESIS, V25, P1935, DOI 10.1093/carcin/bgh203	37	102	104	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					916	922		10.1016/j.jaci.2005.05.046	http://dx.doi.org/10.1016/j.jaci.2005.05.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210070				2022-12-18	WOS:000235686600030
J	Niimi, A; Torrego, A; Nicholson, AG; Cosio, BG; Oates, TB; Chung, KF				Niimi, A; Torrego, A; Nicholson, AG; Cosio, BG; Oates, TB; Chung, KF			Nature of airway inflammation and remodeling in chronic cough	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic cough; airway inflammation; airway remodeling; cough sensitivity	INHALED CORTICOSTEROIDS; INDUCED SPUTUM; SMOOTH-MUSCLE; ASTHMA; SENSITIVITY; MEDIATORS; DIAGNOSIS; RELEASE; REFLEX; LUNG	Background: Chronic cough may be a result of asthma and nonasthma causes, but it is unclear whether there are specific inflammatory or remodeling changes. Objective: We determined airway mucosal changes in patients presenting with asthmatic cough and cough associated with nonasthmatic causes. Methods: Patients with chronic cough of nonasthmatic (n = 33; postnasal drip/rhinitis in 6, gastroesophageal reflux in 5, bronchiectasis in 3, and idiopathic in 19) and asthmatic (n = 14) causes and 15 healthy controls underwent fiberoptic bronchoscopy. Morphometry of bronchial biopsies and capsaicin cough sensitivity were assessed. Results: Compared with controls, submucosal eosinophils and neutrophils were increased in patients with asthmatic cough (P < .005) and submucosal mast cells in patients with nonasthmatic cough (P = .01). Subbasement membrane thickness, goblet cell area, vascularity, and vessel size were also increased in both groups. Smooth muscle area was higher only in patients with nonasthmatic cough (P = .0007 vs control and P = .019 vs asthmatic cough). None of the pathologic changes were related to the duration of coughing. Cough sensitivity was heightened in patients with nonasthmatic cough compared with controls and patients with asthmatic cough. The degree of goblet cell hyperplasia and epithelial shedding positively correlated with cough sensitivity in patients with nonasthmatic cough (r = 0.43; P = .01; and r = 0.40; P = .02, respectively). Conclusion: Features of airway wall remodeling are prominent in the airways with nonasthmatic as well as asthmatic cough. These are linked to chronic cough rather than to asthma. Mast cell hyperplasia rather than eosinophilia is distinctive for nonasthmatic cough.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; Royal Brompton & Harefield NHS Trust, London, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital	Chung, KF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk	Chung, Kian Fan/B-1872-2012; Chung, Kian Fan/I-8456-2019; G.Cosio, Borja/P-4963-2017	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; G.Cosio, Borja/0000-0002-6388-8209				Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Birring SS, 2004, RESP MED, V98, P242, DOI 10.1016/j.rmed.2003.10.005; Birring SS, 2004, AM J RESP CRIT CARE, V169, P15, DOI 10.1164/rccm.200308-1092OC; BOULET LP, 1994, AM J RESP CRIT CARE, V149, P482, DOI 10.1164/ajrccm.149.2.8306050; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bowles WR, 2004, NEUROSCI LETT, V363, P239, DOI 10.1016/j.neulet.2004.03.068; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chaudhuri R, 2004, J ALLERGY CLIN IMMUN, V113, P1063, DOI 10.1016/j.jaci.2004.03.019; CHOUDRY NB, 1989, AM REV RESPIR DIS, V140, P137, DOI 10.1164/ajrccm/140.1.137; Chung KF, 2002, PULM PHARMACOL THER, V15, P267, DOI 10.1006/pupt.2002.0360; Chung KF, 1996, POSTGRAD MED J, V72, P594, DOI 10.1136/pgmj.72.852.594; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; GRONEBERG DA, 2004, AM J RESP CRIT CARE, V169, P15; Halayko AJ, 2003, RESP PHYSIOL NEUROBI, V137, P209, DOI 10.1016/S1569-9048(03)00148-4; Irwin RS, 2000, NEW ENGL J MED, V343, P1715, DOI 10.1056/NEJM200012073432308; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; Jatakanon A, 1999, THORAX, V54, P234, DOI 10.1136/thx.54.3.234; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Lalloo UG, 1998, EUR RESPIR J, V11, P702; Lim S, 2000, AM J RESP CRIT CARE, V162, P1912, DOI 10.1164/ajrccm.162.5.9909081; McGarvey LPA, 1998, THORAX, V53, P738, DOI 10.1136/thx.53.9.738; McGarvey LPA, 1999, EUR RESPIR J, V13, P59; Niimi A, 2000, LANCET, V356, P564, DOI 10.1016/S0140-6736(00)02584-8; Niimi A, 1998, EUR RESPIR J, V11, P1064, DOI 10.1183/09031936.98.11051064; OCONNELL F, 1995, AM J RESP CRIT CARE, V152, P2068, DOI 10.1164/ajrccm.152.6.8520777; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324, DOI 10.1164/ajrccm.162.6.2001041; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; SALEM H, 1964, AM J MED SCI, V247, P585, DOI 10.1097/00000441-196405000-00009; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Tschumperlin DJ, 2002, AM J PHYSIOL-LUNG C, V282, pL904, DOI 10.1152/ajplung.00270.2001; Winston J, 2001, PAIN, V89, P181, DOI 10.1016/S0304-3959(00)00370-5	37	102	109	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					565	570		10.1016/j.jaci.2005.07.010	http://dx.doi.org/10.1016/j.jaci.2005.07.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159625	Bronze			2022-12-18	WOS:000235686500015
J	Johnson, CC; Ownby, DR; Alford, SH; Havstad, SL; Williams, LK; Zoratti, EM; Peterson, EL; Joseph, CLM				Johnson, CC; Ownby, DR; Alford, SH; Havstad, SL; Williams, LK; Zoratti, EM; Peterson, EL; Joseph, CLM			Antibiotic exposure in early infancy and risk for childhood atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; antibiotics; atopy; children; IgE; skin testing	ALLERGIC SENSITIZATION; INFECTIOUS-DISEASES; SERUM IGE; 1ST YEAR; ASTHMA; LIFE; AGE; PREVALENCE; RHINITIS; CHILDREN	Background: The increase in pediatric allergy and asthma parallels the increase in use of antibiotics. Antibiotics disturb the flora of the gastrointestinal tract, possibly perturbing the developing immune system. Objective: We evaluated whether antibiotic use during early infancy increased the risk for atopy. Methods: Antibiotic prescriptions documented in medical records were collected from a birth cohort born from 1987 through 1989 (n=725). At 6 to 7 years of age, 448 were followed by means of examination, including skin prick tests and serum IgE measurements to common allergens. Results: Adjusted odds ratios (aORs) and 95% CIs were calculated comparing children with any versus those with no antibiotic use in the first 6 months and the outcomes of atopy (any positive skin test response), seroatopy (any positive specific IgE test result), either atopy or seroatopy, and both atopy and seroatopy. Atopy increased with antibiotic use approaching statistical significance (aOR, 1.48, 95% Cl, 0.94-2.34; P =.09)., however, the risk was concentrated among children with less than 2 pets in the home (aOR, 1.73; 95% Cl, 1.07-2.80; P=.024) and children breast-fed for 4 or more months (aOR, 3.02; 95% CI, 1.27-7.17; P=.013). The aORs were generally in the same direction for seroatopy and the combined categories. Conclusion: Antibiotic use in early life appears to contribute to increased risk for atopy in certain subgroups of children.	Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI USA; Henry Ford Hlth Syst, Div Gen Med, Dept Internal Med, Detroit, MI USA; Henry Ford Hlth Syst, Sect Allergy & Immunol, Div Pulm Crit Care Allergy Immunol & Sleep Med, Detroit, MI USA; Wayne State Univ, Environm Hlth Sci Ctr Mol & Cellular Toxicol Huma, Detroit, MI 48202 USA; Med Coll Georgia, Sect Allergy Immunol, Augusta, GA USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Wayne State University; University System of Georgia; Augusta University	Johnson, CC (corresponding author), Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, 1 Ford Pl,5C, Detroit, MI 48202 USA.	cjohnso1@hfhs.org		Johnson, Christine Cole/0000-0002-6864-6604	NHLBI NIH HHS [HL 67427] Funding Source: Medline; NIAID NIH HHS [AI 24156, AI 50681] Funding Source: Medline; NIEHS NIH HHS [P03 ES 06639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL067427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI050681, R01AI024156, R01AI050681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Bremner SA, 2003, CLIN EXP ALLERGY, V33, P1518, DOI 10.1046/j.1365-2222.2003.01794.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Cullinan P, 2004, THORAX, V59, P11; Dowell SF, 1998, PEDIATRICS, V101, P163; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Finkelstein JA, 2003, PEDIATRICS, V112, P620, DOI 10.1542/peds.112.3.620; Foliaki S, 2004, INT J EPIDEMIOL, V33, P558, DOI 10.1093/ije/dyh031; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Levy J, 2000, AM J GASTROENTEROL, V95, pS8, DOI 10.1016/S0002-9270(99)00808-4; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; Noverr MC, 2004, INFECT IMMUN, V72, P6206, DOI 10.1128/IAI.72.11.6206-6210.2004; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; OWNBY DR, 1991, J ALLERGY CLIN IMMUN, V88, P555, DOI 10.1016/0091-6749(91)90148-H; Oyama N, 2001, J ALLERGY CLIN IMMUN, V107, P153, DOI 10.1067/mai.2001.111142; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Williams LK, 2004, J ALLERGY CLIN IMMUN, V113, P291, DOI 10.1016/j.jaci.2003.11.010; Wjst M, 2001, EUR J MED RES, V6, P263; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3	27	102	104	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1218	1224		10.1016/j.jaci.2005.04.020	http://dx.doi.org/10.1016/j.jaci.2005.04.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940137				2022-12-18	WOS:000229815400017
J	Green, BJ; Sercombe, JK; Tovey, ER				Green, BJ; Sercombe, JK; Tovey, ER			Fungal fragments and undocumented conidia function as new aeroallergen sources	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; Alternaria species; antigen; conidia; fragment; fungal; hyphae; germination; immunoassay; mold	ALTERNARIA; ASTHMA; GERMINATION; ALLERGENS; EXPOSURE; SPORES	Background: More than 100 genera of fungal conidia are currently recognized as sources of allergens. The contribution of other fungal genera plus airborne fungal hyphae and fragmented conidia to allergic diseases is poorly understood. Objective: We sought to investigate the expression of allergens from airborne wild-type fungi using the Halogen immunoassay, which uses allergic serum IgE to immunostain immobilized allergens extracted from individual fungal particles. Methods: Airborne fungi were collected onto mixed cellulose ester protein-binding membranes for 2.5 hours with volumetric air pumps. Collected fungi were incubated overnight in a humid chamber to promote the germination of conidia. The membranes were laminated with an adhesive cover slip and immunostained with an Altentaria species-sensitive serum IgE pool. The samples were examined by means of light microscopy, and positively immunostained fungal particles were classified and counted. Results: All air samples contained fungal hyphae that expressed soluble allergens and were significantly higher in concentration than counts of conidia of individual well-ebaracterized allergenic genera (P < .05). Resultant immunostaining of fungal hyphae was heterogeneous, and approximately 25% of all hyphae expressed detectable allergen compared with nonstained hyphae (P < .05). Fungal conidia of 10 genera that were previously uncharacterized as allergen sources were shown to demonstrate IgE binding to expressed antigens and accounted for 8% of the total airborne conidia count. Conclusions: Our analysis of wild-type fungi collected indoors presents a new paradigm of natural fungal exposure, which, in addition to commonly recognized species, implicates airborne hyphae, fragmented conidia, and the conidia of a much more diverse range of genera as airborne allergens.	Univ Sydney, Dept Med, Woolcock Allergen Unit, Sydney, NSW 2006, Australia	University of Sydney; Woolcock Institute of Medical Research	Green, BJ (corresponding author), Univ Sydney, Dept Med, Woolcock Allergen Unit, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.	brettg@mail.med.usyd.edu.au	Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Burge HA, 2000, CURR MICROBIOL, V40, P10, DOI 10.1007/s002849910003; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622, DOI 10.2307/3433608; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; Gorny RL, 2002, APPL ENVIRON MICROB, V68, P3522, DOI 10.1128/AEM.68.7.3522-3531.2002; Gots RE, 2003, AIHA J-J SCI OCCUP E, V64, P427, DOI 10.1080/15428110308984836; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; Levetin E., 1995, BIOAEROSOLS, P87; Li DW, 1995, MYCOPATHOLOGIA, V131, P149, DOI 10.1007/BF01102894; Li ZJ, 2002, BIOTECHNOL LETT, V24, P1, DOI 10.1023/A:1013848325193; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; MARFENINA OE, 1994, MICROBIOLOGY+, V63, P603; MARK D, 1986, ANN OCCUP HYG, V30, P89, DOI 10.1093/annhyg/30.1.89; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; PAUL GC, 1994, BIOTECHNOL BIOENG, V44, P655, DOI 10.1002/bit.260440513	17	102	105	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1043	1048		10.1016/j.jaci.2005.02.009	http://dx.doi.org/10.1016/j.jaci.2005.02.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867864				2022-12-18	WOS:000229055100022
J	Foster, B; Metcalfe, DD; Prussin, C				Foster, B; Metcalfe, DD; Prussin, C			Human dendritic cell 1 and dendritic cell 2 subsets express Fc epsilon F-RI: Correlation with serum IgE and allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cell; IgE; IgE receptor asthma; allergy; flow cytometry	HIGH-AFFINITY RECEPTOR; HUMAN BASOPHILS; PERIPHERAL-BLOOD; LANGERHANS CELLS; IN-VITRO; ALPHA; EOSINOPHILS; MONOCYTES; DISEASES; ANTIBODY	Background: Type 1 dendritic cells (DC1) express the high-affinity IgE receptor (FcepsilonFRI); however, the regulation of FcepsilonRI expression by DCs is not well understood. Type 2 DC (DC2) expression of FcepsilonRI has not been demonstrated. Objective: We hypothesized that DC2 cells also express FcepsilonRI and that expression of FcepsilonRI by the DC1 and DC2 subsets correlates with serum IgE and allergic asthma disease status. Methods: To test these hypotheses, we quantitated FcepsilonRI a chain expression by the peripheral blood precursor DC1 (pDC1) and pDC2 subsets by using flow cytometry. Results: FcepsilonRI was expressed by the pDC1 and pDC2 subsets, as well as tissue DCs from tonsils. Relative FcepsilonRI expression by basophil, pDC1, and pDC2 subsets was 12:6.5:1, respectively. In both pDC subsets, FcepsilonRI expression was significantly greater in allergic asthmatic subjects than in nonatopic control subjects. pDC1 and pDC2 expression of FcepsilonRI was highly correlated to serum IgE concentration. The pDC1, pDC2, and basophil subsets demonstrated a similar magnitude of increase in FcepsilonRI expression relative to changes in serum IgE. Conclusions: FcepsilonRI expression is characteristic of both the DC1 and DC2 subsets. Furthermore, FcepsilonRI expression by these cells is highly correlated to serum IgE and to basophil FcepsilonRI expression and is greater in subjects with allergic asthma. These data support the concept that novel therapeutic approaches directly targeted at FcepsilonRI expression would affect both the sensitization and the effector phases of the allergen-specific immune response.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Prussin, C (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Room 11C205, Bethesda, MD 20892 USA.			Prussin, Calman/0000-0002-3917-3326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000709] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Dzionek A, 2002, HUM IMMUNOL, V63, P1133, DOI 10.1016/S0198-8859(02)00752-8; Foster B, 2002, J ALLERGY CLIN IMMUN, V109, P287, DOI 10.1067/mai.2002.121454; FOSTER B, 2003, CURRENT PROTOCOLS IM; Holloway JA, 2001, J ALLERGY CLIN IMMUN, V107, P1009, DOI 10.1067/mai.2001.115039; Jensen BM, 2003, CLIN EXP ALLERGY, V33, P655, DOI 10.1046/j.1365-2222.2003.01653.x; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kraft S, 1998, J IMMUNOL, V161, P1000; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Maurer D, 1998, J IMMUNOL, V161, P2731; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Saini SS, 2002, CURR OPIN IMMUNOL, V14, P694, DOI 10.1016/S0952-7915(02)00404-1; Semper AE, 1995, ADV EXP MED BIOL, V378, P135; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663	26	102	106	2	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1132	1138		10.1016/j.jaci.2003.09.011	http://dx.doi.org/10.1016/j.jaci.2003.09.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657872				2022-12-18	WOS:000187154200016
J	Silverman, EK; Kwiatkowski, DJ; Sylvia, JS; Lazarus, R; Drazen, JM; Lange, C; Laird, NM; Weiss, ST				Silverman, EK; Kwiatkowski, DJ; Sylvia, JS; Lazarus, R; Drazen, JM; Lange, C; Laird, NM; Weiss, ST			Family-based association analysis of beta(2)-adrenergic receptor polymorphisms in the Childhood Asthma Management Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; genetics; association analysis; single nucleotide polymorphism; haplotype; bronchodilator	GENETIC POLYMORPHISMS; LINKAGE; HAPLOTYPES; ALBUTEROL; HYPERRESPONSIVENESS; GENOTYPE; CHILDREN; TESTS	Background: beta(2)-Adrenergic receptor (B2AR) polymorphisms have been associated with a variety of asthma-related phenotypes, but association results have been inconsistent across different studies. Objective: We sought to apply family-based association methods to individual single nucleotide polymorphisms (SNPs) and haplotypes of SNPs in B2AR to define the relationship of these genetic variants to asthma-related phenotypes. Methods: DNA samples were obtained from 707 Childhood Asthma Management Program participants, representing 650 sibships, as well as their parents. Genotyping was performed at 8 B2AR SNPs. Qualitative asthma-related phenotypes were analyzed with single SNPs and haplotypes by using TRANSMIT; quantitative asthma-related phenotypes were analyzed with the Family-Based Association Test. Results: Several SNPs, including SNP -654 and SNP +46, demonstrated significant associations (P<.05) to postbronchodilator FEV1 as both a qualitative (<80% of predicted value) and quantitative phenotype. Quantitative phenotypic association analysis demonstrated significant evidence for association of SNP +523 with bronchodilator responsiveness expressed as a percentage of baseline FEV1 (P=.012) or a percentage of predicted FEV1 (P=.008). Similar evidence for association between the +523 SNP and qualitative bronchodilator responsiveness phenotypes was also found. Analysis of haplotypes supported an association of B2AR variants with spirometric values and bronchodilator responsiveness. Conclusion: B2AR variants are associated with spirometric values and bronchodilator responsiveness, but different regions of the gene provide evidence for association with these phenotypes.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Sch Med, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Silverman, EK (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.			lazarus, ross/0000-0003-3939-1961	NHLBI NIH HHS [N01-HR-16052, N01-HR-16045, N01-HR-16044, N01-HR-16046, N01-HR-16049, R01 HL66386, N01-HR-16051, N01-HR-16050, N01-HR-16048, U01 HL 66795, N01-HR-16047] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016044, N01HR016047, N01HR016049, N01HR016048, N01HR016046, N01HR016052, N01HR016050, N01HR016051, N01HR016045] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066386, U01HL066795] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Cervino ACL, 2000, AM J HUM GENET, V67, P120, DOI 10.1086/302992; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; COULTAS DB, 1988, AM REV RESPIR DIS, V138, P1386, DOI 10.1164/ajrccm/138.6.1386; D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968, DOI 10.1164/ajrccm.158.6.9804126; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519, DOI 10.1016/S0009-9236(99)70071-8; Marsh DG, 1997, NAT GENET, V15, P389; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; OHE M, 1995, THORAX, V50, P353, DOI 10.1136/thx.50.4.353; Ott J, 1999, ANAL HUMAN GENETIC L; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Raby BA, 2001, CURR OPIN MOL THER, V3, P554; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Summerhill E, 2000, AM J RESP CRIT CARE, V162, P599, DOI 10.1164/ajrccm.162.2.9910108; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787, DOI 10.1164/ajrccm.158.3.9801035; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201	26	102	107	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					870	876		10.1016/S0091-6749(03)02023-2	http://dx.doi.org/10.1016/S0091-6749(03)02023-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610472				2022-12-18	WOS:000186553300007
J	Simons, FER; Chan, ES; Gu, XC; Simons, KJ				Simons, FER; Chan, ES; Gu, XC; Simons, KJ			Epinephrine for the out-of-hospital (first-aid) treatment of anaphylaxis in infants: Is the ampule/syringe/needle method practical?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epinephrine; adrenaline; systemic anaphylaxis; acute allergic reaction; infants; first aid; EpiPen; Ana-Kit		Background: Little information is available about administration of an accurate epinephrine dose to infants experiencing anaphylaxis outside the hospital setting. Objective: Our purpose was to perform a prospective, controlled study of (1) the time needed by parents to draw up an infant epinephrine dose from an ampule and (2) the dose accuracy. Methods: We gave 18 parents written instructions and asked them to draw up epinephrine 0.09 mL. We timed them by means of a stopwatch and measured the epinephrine content (in micrograms) in each dose by using HPLC-UV. Eighteen resident physicians, 18 general duty nurses, and 18 emergency department nurses served as controls. Results: The parents took significantly longer (P<.05) than the controls to draw up the dose; the mean ( SEM) times were 142<plus/minus>13 seconds (range, 83-248) for the parents. 52 +/-3 seconds (range, 30-83) for the physicians, 40 +/-2 seconds (range, 26-71) for the general duty nurses, and 29 +/-0.09 seconds (range, 27-33) for the emergency department nurses. The control groups did not differ significantly from each other in speed (P>.05). The epinephrine content of the doses drawn up by the parents ranged 40-fold in contrast to the physicians' doses (7- to 8-fold), general duty nurses' doses (3-fold), and emergency department nurses' doses (2-fold). The mean epinephrine content did not differ significantly (P>.05) among the 4 groups. Conclusions: Most parents were unable to draw up an infant epinephrine dose rapidly or accurately. Most health care professionals drew up the dose rapidly; however, their accuracy was compromised by inherent variations of epinephrine concentrations in the ampules (United States Pharmacopeia compendial limits, 90% to 115%) and the inherent difficulty of measuring low volumes (<0.1 mL) of epinephrine. User-friendly premeasured epinephrine doses suitable for infants should be developed.	Univ Manitoba, Fac Pharm, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Fac Pharm, Div Pharmaceut Sci, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; University of Manitoba	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.			Chan, Edmond/0000-0003-2947-1175				AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; DIPCHAND AI, 1997, HOSPITAL SICK CHILDR, P18; GENNARO AR, 2000, REMINGTON SCI PRACTI, P100; Hoffmann BB, 1996, GOODMAN GILMANS PHAR, P204; Korenblat P, 1999, ALLERGY ASTHMA PROC, V20, P383, DOI 10.2500/108854199778251834; Lieberman P., 1998, ALLERGY PRINCIPLES P, P1079; LINZER JF, 1999, GELLIS KAGANS CURREN, V16, P1058; *MED EC, 2001, PHYS DESK REF; National Center for Health Statistics, 2001, NAT HLTH NUTR EX SUR; NETER J, 1993, APPL LINEAR STAT MOD, P517; NICKLAS RA, 1998, J ALLERGY CLIN IMMUN, V101, pS465; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; REPCHINSKY C, 2001, COMPENDIUM PHARM SPE, P521; SALHANICK SD, 2001, PRIMARY PEDIAT CARE, P1947; Schiff RI, 1996, RUDOLPHS PEDIAT, P474; SCHWEICH PJ, 1999, OSKIS PEDIAT PRINCIP, P566; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V86, P597, DOI 10.1016/S1081-1206(10)62284-3; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P622, DOI 10.1016/S1081-1206(10)62289-2; Simons FER, 2000, J ALLERGY CLIN IMMUN, V105, P1025, DOI 10.1067/mai.2000.106042; SLY RM, 2000, NELSONS TXB PEDIAT, P686; Wasserman SI, 1997, ALLERGY, P565	21	102	103	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1040	1044		10.1067/mai.2001.119916	http://dx.doi.org/10.1067/mai.2001.119916			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742286				2022-12-18	WOS:000172938400024
J	Pearlman, DS				Pearlman, DS			Pathophysiology of the inflammatory response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopy; asthma; allergic rhinitis; mast cells; interleukins	ENDOTHELIAL ADHESION MOLECULES; PERENNIAL ALLERGIC RHINITIS; ANTIGEN-INDUCED EOSINOPHIL; NASAL-MUCOSA; SUBSTANCE-P; EPITHELIAL-CELLS; ATOPIC PATIENTS; MAST-CELLS; EXPRESSION; ASTHMA	Airway allergic reactions enlist diverse cells and a multitude of chemical mediators that are responsible for the clinical symptoms of allergic rhinitis and asthma, Experiments in vitro and in animal models, as well as increasingly numerous studies in atopic human subjects, are revealing that an orchestrated continuum of cellular activities leading to airway allergic inflammation is set in motion in genetically predisposed individuals at the first exposure to a novel antigen. This sensitization step likely depends on differentiation of and cytokine release by T(H)2 lymphocytes, Among T(H)2-derived cytokines, IL-4 potently enhances B-lymphocyte generation of immunoglobulin E antibodies. The attachment of these antibodies to specific receptors on airway mast cells sets the stage for an acute inflammatory response on subsequent antigen exposure because IgE crosslinking by a bound antigen activates mast cells to release numerous inflammatory mediators. These mast cell-derived mediators collectively produce acute-phase clinical symptoms by enhancing vascular leak, bronchospasm, and activation of nociceptive neurons linked to parasympathetic reflexes, Simultaneously, some mast cell mediators up-regulate expression on endothelial cells of adhesion molecules for leukocytes (eosinophils, but also basophils and lymphocytes), which are keg elements in the late-phase allergic response. Chemoattractant molecules released during the acute phase draw these leukocytes to airways during a relatively symptom-free recruitment phase, where they later release a plethora of cytokines and tissue-damaging proteases that herald a second wave of airway inflammatory trauma (late-phase response). The repetition of these processes, with the possible establishment in airway mucosa of memory T lymphocytes and eosinophils that are maintained by paracrine and autocrine cytokine stimulation, may account for airway hypersensitivity and chronic airway symptoms.	Colorado Allergy & Asthma Clin, Aurora, CO 80012 USA; Univ Colorado, Hlth Sci Ctr, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Pearlman, DS (corresponding author), Colorado Allergy & Asthma Clin, 1450 S Havana,Suite 621, Aurora, CO 80012 USA.							ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; AKUTSU I, 1995, IMMUNOL LETT, V45, P109, DOI 10.1016/0165-2478(94)00241-I; BACHERT C, 1990, Rhinology (Utrecht), V28, P149; Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BUSSE WW, 1995, AM J RESP CRIT CARE, V152, P388, DOI 10.1164/ajrccm.152.1.7599853; CALDERON MA, 1994, J ALLERGY CLIN IMMUN, V93, P635, DOI 10.1016/S0091-6749(94)70075-3; CHANG TW, 1990, BIO-TECHNOL, V8, P122, DOI 10.1038/nbt0290-122; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; Fajac I, 1995, ALLERGY, V50, P970, DOI 10.1111/j.1398-9995.1995.tb02509.x; FOKKENS WJ, 1991, IMMUNOBIOLOGY, V182, P135, DOI 10.1016/S0171-2985(11)80197-X; HORWITZ RJ, 1995, CLIN CHEST MED, V16, P583; JULIUSSON S, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02478.x; KAUFMAN J, 1970, AM REV RESPIR DIS, V101, P768; KAWABORI S, 1995, CLIN EXP ALLERGY, V25, P173, DOI 10.1111/j.1365-2222.1995.tb01023.x; Kuna P, 1996, J ALLERGY CLIN IMMUN, V97, P104, DOI 10.1016/S0091-6749(96)70288-9; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360, DOI 10.1165/ajrcmb.13.3.7654390; Lang DM, 1997, ANN ALLERG ASTHMA IM, V78, P333, DOI 10.1016/S1081-1206(10)63192-4; LEDFORD DK, 1998, J RESP DIS, V19, P647; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; Leung DYM, 1998, MOL GENET METAB, V63, P157, DOI 10.1006/mgme.1998.2682; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; MULLOL J, 1992, J APPL PHYSIOL, V73, P2069, DOI 10.1152/jappl.1992.73.5.2069; Naclerio R, 1997, JAMA-J AM MED ASSOC, V278, P1842, DOI 10.1001/jama.278.22.1842; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; Nonaka M, 1996, AM J RESP CRIT CARE, V153, P1675, DOI 10.1164/ajrccm.153.5.8630619; OKAMOTO Y, 1993, J IMMUNOL, V151, P4391; OKAYAMA M, 1992, J ALLERGY CLIN IMMUN, V89, P1144, DOI 10.1016/0091-6749(92)90298-G; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2049, DOI 10.1164/ajrccm.152.6.8520775; POBER JS, 1987, J IMMUNOL, V138, P3319; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; Spector SL, 1995, ANN ALLERG ASTHMA IM, V75, P463; TERADA N, 1994, J ALLERGY CLIN IMMUN, V94, P629, DOI 10.1016/0091-6749(94)90140-6; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x	41	102	107	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				S132	S137		10.1016/S0091-6749(99)70308-8	http://dx.doi.org/10.1016/S0091-6749(99)70308-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518809	Bronze			2022-12-18	WOS:000083281200029
J	Diaz-Perales, A; Collada, C; Blanco, C; Sanchez-Monge, R; Carrillo, T; Aragoncillo, C; Salcedo, G				Diaz-Perales, A; Collada, C; Blanco, C; Sanchez-Monge, R; Carrillo, T; Aragoncillo, C; Salcedo, G			Cross-reactions in the latex-fruit syndrome: A relevant role of chitinases but not of complex asparagine-linked glycans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex-fruit syndrome; class I chitinases; cross-reactions; plant complex glycans; plant food allergens	HEVEA-BRASILIENSIS; IGE ANTIBODIES; RUBBER LATEX; ALLERGEN; IDENTIFICATION; AVOCADO; PROTEINS; CLONING; REACTIVITY; LYSOZYME	Background: Cross-reactions between latex and plant foods (mainly fruits) have been widely reported. Although the cross-reactive components have not been well identified, class I chitinases seem to be the most credible candidates in chestnut, avocado, and banana. Objective: We sought to evaluate the potential role of chitinases and complex glycans as cross-reactive determinants linked to latex-food allergy, Methods: Extracts from 20 different plant foods and from latex were obtained, These preparations were immunodetected with anticomplex glycans and antichitinase sera raised in rabbits, as well as with sera from patients with latex-fruit allergy and sera from patients allergic to latex without food allergy. Immunoblot inhibition assays were carried out by using a purified class I chitinase from avocado or latex extract as inhibitors. Results: Reactive proteins of approximately 30 to 45 kd (putative class I chitinases) were recognized by both specific polyclonal antibodies to chitinases and sera from patients with latex-fruit allergy in chestnut, cherimoya, passion fruit, kiwi, papaya, mango, tomato, and flour wheat extracts. Prs a 1, the major allergen and class I chitinase from avocado, and the latex extract strongly or fully inhibited IgE binding by these components when tested in immunoblot inhibition assays, Additional bands of 16 to 20 kd, 23 to 28 kd, and 50 to 70 kd were detected by the antichitinase serum but not with the patients' pooled sera. The putative 30- to 45-kd chitinases present in different food extracts did not react with a pool of sera from subjects allergic to latex but not to fruit. Very different immunodetection patterns were produced with the anticomplex glycan serum and the sera from allergic patients. Conclusions: Putative class I chitinases seem to be relevant cross-reactive components in foods associated with the latex-fruit syndrome, but do not play a specific role in allergy to latex but not to fruit. Cross-reactive carbohydrate determinants are not important structures in the context of latex-fruit cross-sensitization.	ETS Ingenieros Agronomos, Dept Biotecnol, Unidad Bioguim, Madrid 28040, Spain; ETS Ingenieros Montes, Dept Biotecnol, Unidad Quim & Bioquim, Madrid, Spain; Hosp Nuestra Senra Pina, Secc Alergia, Las Palmas Gran Canaria, Spain		Salcedo, G (corresponding author), ETS Ingenieros Agronomos, Dept Biotecnol, Unidad Bioguim, Ciudad Univ, Madrid 28040, Spain.		Díaz-Perales, Araceli/D-8433-2016; Blanco, Carlos/B-3895-2012; Collada, Carmen/H-1529-2015	Díaz-Perales, Araceli/0000-0002-1093-3627; Blanco, Carlos/0000-0002-2893-6594; Collada, Carmen/0000-0003-0236-1312				Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Blanco C, 1999, J ALLERGY CLIN IMMUN, V103, P507, DOI 10.1016/S0091-6749(99)70478-1; BLANCO C, 1994, ANN ALLERGY, V73, P309; Blanco C, 1998, CLIN EXP ALLERGY, V28, P971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; COLLADA C, 1992, PLANT PHYSIOL, V100, P778, DOI 10.1104/pp.100.2.778; COLLINGE DB, 1993, PLANT J, V3, P31, DOI 10.1046/j.1365-313X.1993.t01-1-00999.x; Delbourg MF, 1996, ANN ALLERG ASTHMA IM, V76, P321, DOI 10.1016/S1081-1206(10)60032-4; Diaz-Perales A, 1998, J ALLERGY CLIN IMMUN, V102, P127, DOI 10.1016/S0091-6749(98)70063-6; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; Kostyal DA, 1998, CLIN EXP IMMUNOL, V112, P355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; Lavaud F, 1997, CLIN REV ALLERG IMMU, V15, P429, DOI 10.1007/BF02737738; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; Mikkola JH, 1998, J ALLERGY CLIN IMMUN, V102, P1005, DOI 10.1016/S0091-6749(98)70339-2; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; Posch A, 1998, CLIN EXP ALLERGY, V28, P134; RAIKHEL NV, 1993, ANNU REV PLANT PHYS, V44, P591, DOI 10.1146/annurev.pp.44.060193.003111; RAULFHEIMSOTH M, 1997, ENVIRON TOXICOL PHAR, V4, P61; Sanchez-Monge R, 1999, CLIN EXP ALLERGY, V29, P673, DOI 10.1046/j.1365-2222.1999.00526.x; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; WADEE AA, 1990, J ALLERGY CLIN IMMUN, V85, P801, DOI 10.1016/0091-6749(90)90202-F; YAGAMI T, 1995, J ALLERGY CLIN IMMUN, V96, P677, DOI 10.1016/S0091-6749(95)70267-9; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379, DOI 10.1016/S0091-6749(98)70251-9	33	102	107	0	19	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				681	687		10.1016/S0091-6749(99)70342-8	http://dx.doi.org/10.1016/S0091-6749(99)70342-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482846	Bronze			2022-12-18	WOS:000082870000034
J	Koblenzer, CS				Koblenzer, CS			Itching and the atopic skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Atopic Dermatitis - An Update for the Next Millennium	OCT, 1998	NEW YORK, NY			neuropeptides; touch; stress; somatopsychic; psychosomatic; psychotropics	DERMATITIS; URTICARIA; CHILDREN; PRURITUS; ECZEMA; PSYCHOTHERAPY; DERMATOLOGY; STRESS	Itching is one of the major diagnostic criteria of atopic dermatitis and one of its most troublesome symptoms, The symptom of itching may reflect skin disease, internal disease, or emotional disease. Although itching is symptomatic of many inflammatory and psychophysiologic dermatoses, in atopic dermatitis it is a cardinal feature of the disease, Effective control of itching ran go a long way towards controlling the eruption itself; it can also make a major contribution to the physical and emotional well-being of the patient and the patient's total environment.	Thomas Jefferson Univ, Dept Dermatol, Philadelphia, PA 19107 USA	Jefferson University	Koblenzer, CS (corresponding author), 1812 Delancey Pl, Philadelphia, PA 19103 USA.							ALAHMAR HF, 1976, BRIT J DERMATOL, V95, P373, DOI 10.1111/j.1365-2133.1976.tb00838.x; ANZIEU D, 1989, SKIN EGO, P96; BALLANTYNE JC, 1988, PAIN, V33, P149, DOI 10.1016/0304-3959(88)90085-1; BERNHARD JD, 1994, ITCH MECH MANAGEMENT, P37; BRENNER C, 1991, MOSCOW LECTURES ON PSYCHOANALYSIS, P45; COLE WC, 1988, J AM ACAD DERMATOL, V18, P286, DOI 10.1016/S0190-9622(88)70041-9; CREESE I, 1976, EUR J PHARMACOL, V36, P231, DOI 10.1016/0014-2999(76)90277-6; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856, DOI 10.1001/archpedi.1995.02170210030005; DAUD LR, 1993, ARCH DIS CHILD, V69, P670, DOI 10.1136/adc.69.6.670; EDWARDS AE, 1976, ARCH DERMATOL, V112, P339, DOI 10.1001/archderm.112.3.339; EHLERS A, 1995, J CONSULT CLIN PSYCH, V63, P624, DOI 10.1037/0022-006X.63.4.624; GIELER U, 1989, PSYCHOL MANAGEMENT P, P257; GINSBURG IH, 1993, INT J DERMATOL, V32, P656, DOI 10.1111/j.1365-4362.1993.tb04021.x; GRAHAM DT, 1953, J LAB CLIN MED, V42, P238; GUPTA MA, 1994, PSYCHOSOM MED, V56, P36, DOI 10.1097/00006842-199401000-00005; HANAFIN JM, 1980, ACTA DERM-VENEREOL, V92, P44; Jemec GBE, 1996, CLIN EXP DERMATOL, V21, P177, DOI 10.1111/j.1365-2230.1996.tb00057.x; JORDAN JM, 1972, BRIT J DERMATOL, V86, P574, DOI 10.1111/j.1365-2133.1972.tb05072.x; Koblenzer CS, 1997, CLIN DERMATOL, V15, P127, DOI 10.1016/S0738-081X(96)00115-0; KOBLENZER CS, 1988, ARCH DERMATOL, V124, P1673, DOI 10.1001/archderm.124.11.1673; KOBLENZER CS, 1995, J AM ACAD DERMATOL, V32, P609, DOI 10.1016/S0190-9622(05)80001-5; KOBLENZER CS, 1995, PEDIAT DERMATOLOGY W, P1; KOBLENZER CS, 1987, PSYCHOCUTANEOUS DIS, P281; LOTTI T, 1995, J AM ACAD DERMATOL, V33, P482, DOI 10.1016/0190-9622(95)91395-5; McSkimming J, 1984, Australas J Dermatol, V25, P8; MONROE EW, 1989, J AM ACAD DERMATOL, V21, P135, DOI 10.1016/S0190-9622(89)80353-6; MORREN MA, 1994, J AM ACAD DERMATOL, V31, P467, DOI 10.1016/S0190-9622(94)70213-6; MUSAPH H, 1974, PSYCHOTHER PSYCHOSOM, V24, P79, DOI 10.1159/000286677; MUSAPH H, 1964, ITCHING SCRATCHING P, P8; Panconesi E, 1996, DERMATOL CLIN, V14, P399, DOI 10.1016/S0733-8635(05)70368-5; Rothman S, 1941, PHYSIOL REV, V21, P357, DOI 10.1152/physrev.1941.21.2.357; Schachner L, 1998, PEDIATR DERMATOL, V15, P390, DOI 10.1046/j.1525-1470.1998.1998015390.x; SPITZ RA, 1971, 1 YEAR LIFE, P222; Stores G, 1998, PEDIATR DERMATOL, V15, P264, DOI 10.1046/j.1525-1470.1998.1998015264.x; TANTAM D, 1982, PSYCHOTHER PSYCHOSOM, V37, P26, DOI 10.1159/000287552; TOBIN D, 1992, J ALLERGY CLIN IMMUN, V90, P613, DOI 10.1016/0091-6749(92)90134-N; Tuckett R. P, 1994, ITCH MECH MANAGEMENT, P1; WAHLGREN CF, 1992, ALLERGY, V47, P65, DOI 10.1111/j.1398-9995.1992.tb05091.x; YAMAMOTO K, 1989, ACTA DERM-VENEREOL, P31	39	102	107	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	2	S			S109	S113		10.1016/S0091-6749(99)70052-7	http://dx.doi.org/10.1016/S0091-6749(99)70052-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	242FP	10482861				2022-12-18	WOS:000082928500004
J	van der Heide, S; van Aalderen, WMC; Kauffman, HF; Dubois, AEJ; de Monchy, JGR				van der Heide, S; van Aalderen, WMC; Kauffman, HF; Dubois, AEJ; de Monchy, JGR			Clinical effects of air cleaners in homes of asthmatic children sensitized to pet allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						air cleaners; allergen avoidance; allergens; asthma; airway hyperresponsiveness; peak flow amplitude; pets; children	DUST MITE ALLERGENS; FEL-D-I; ATOPIC DISORDERS; CHILDHOOD ASTHMA; PARTICLE-SIZE; DOG CAN-F-1; CAT; AVOIDANCE; HYPERRESPONSIVENESS; RESPONSIVENESS	Background: Exposure to cat and dog allergens is very common in the Western World and is a serious cause of asthma in sensitized subjects. Objective: We sought to study the clinical effects of air cleaners in living rooms and bedrooms of asthmatic children sensitized to cat or dog allergens. Methods: Twenty asthmatic children sensitized to pet allergens (cat/dog) and with an animal at home participated in a double-blind, placebo-controlled, cross-over study in which the effects of air cleaners placed in the living room and bedroom for 3 months were compared with the effects of sham air cleaners. Before and after each study period, lung function, airway hyperresponsiveness (adenosine monophosphate), and peak flow variation were recorded. Cat and dog allergen levels were assessed in the filters of the air cleaners. Results: After a 3-month intervention with active air cleaners, airway hyperresponsiveness decreased significantly, showing a 1.2 doubling dose increase of PC(20)adenosine (P = .003). Peak flow amplitude also decreased (P = .045), Substantial. amounts of airborne cat and dog allergen were captured by the air cleaners in living rooms and bedrooms as well. Allergen levels in floor dust were not changed. Conclusion:In young asthmatic patients sensitized and exposed to pets,in the home, application of air cleaners in living rooms and bedrooms was accompanied by a significant improvement in airway hyperresponsiveness and a decrease in peak flow amplitude.	Univ Groningen Hosp, Dept Allergol, Clin Internal Med, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Beatrix Childrens Hosp, Dept Pediat Pulmonol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	van der Heide, S (corresponding author), Univ Groningen Hosp, Dept Allergol, Clin Internal Med, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.							AALBERS R, 1991, AM REV RESPIR DIS, V144, P352, DOI 10.1164/ajrccm/144.2.352; ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Brand PLP, 1997, EUR RESPIR J, V10, P1242, DOI 10.1183/09031936.97.10061242; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; deBlay F, 1997, J INVEST ALLERG CLIN, V7, P335; Doull IJM, 1997, PEDIATR PULM, V23, P404, DOI 10.1002/(SICI)1099-0496(199706)23:6<404::AID-PPUL2>3.3.CO;2-N; Egbagbe E, 1997, THORAX, V52, P239, DOI 10.1136/thx.52.3.239; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Munir AKM, 1996, ALLERGY, V51, P36; NIEMEIJER NR, 1992, ALLERGY, V47, P431, DOI 10.1111/j.1398-9995.1992.tb02084.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Polosa R, 1997, THORAX, V52, P919, DOI 10.1136/thx.52.10.919; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; vanderHeide S, 1997, ALLERGY, V52, P921, DOI 10.1111/j.1398-9995.1997.tb01252.x; vanderHeide S, 1997, CLIN EXP ALLERGY, V27, P627, DOI 10.1111/j.1365-2222.1997.tb01189.x; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; vanVelzen E, 1996, THORAX, V51, P582, DOI 10.1136/thx.51.6.582; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110	28	102	103	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				447	451		10.1016/S0091-6749(99)70391-X	http://dx.doi.org/10.1016/S0091-6749(99)70391-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452769				2022-12-18	WOS:000082364800040
J	Busse, W; Nelson, H; Wolfe, J; Kalberg, C; Yancey, SW; Rickard, KA				Busse, W; Nelson, H; Wolfe, J; Kalberg, C; Yancey, SW; Rickard, KA			Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						salmeterol xinafoate; zafirlukast; asthma; peak expiratory flow; beta(2)-agonist; leukotriene receptor antagonist	LEUKOTRIENE RECEPTOR ANTAGONIST; LONG-ACTING BETA(2)-AGONIST; TO-MODERATE ASTHMA; THERAPY	Background: Salmeterol, a long-acting beta(2)-agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of asthma in adolescent and adult patients. Objective: We sought to compare the effect of 4 weeks of treatment with inhaled salmeterol xinafoate versus oral zafirlukast in the treatment of persistent asthma. Methods: This was a randomized, double-blind, double-dummy, parallel-group, multicenter clinical trial. Patients, over 80% of whom were on a concurrent inhaled corticosteroid regimen, were treated for 4 weeks with either inhaled salmeterol xinafoate 42 mu g twice daily administered by means of a metered dose inhaler or oral zafirlukast 20 mg twice daily. The primary efficacy measure was morning peak expiratory flow (PEF); secondary efficacy measures included evening PEF, asthma symptom scores, supplemental albuterol use, nighttime awakenings, sleep symptoms, asthma exacerbations, and FEV1. Results: Both inhaled salmeterol and oral zafirlukast resulted in within-group improvements from baseline in measures of pulmonary function, asthma symptoms, and supplemental albuterol use. Salmeterol treatment resulted in significantly greater improvements from baseline compared with zafirlukast for most efficacy measurements, including morning PEF (29.6 vs 13.0 L/min; P less than or equal to .001), percentage of symptom-free days (22.4% vs 8.8%; P less than or equal to .001), and percentage of days and nights with no supplemental albuterol use (30.5% vs 11.3%; P less than or equal to .001), There were no differences in safety profiles as assessed by adverse event monitoring. Conclusion: In patients with persistent asthma, most of whom were concurrently using inhaled corticosteroids, treatment with inhaled salmeterol provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period.	Univ Wisconsin, Sch Med, Dept Med, Clin Sci Ctr 15 220, Madison, WI 53792 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Allergy & Asthma Associates, Santa Clara Valley Res Ctr, San Jose, CA USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	University of Wisconsin System; University of Wisconsin Madison; National Jewish Health; GlaxoSmithKline	Busse, W (corresponding author), Univ Wisconsin, Sch Med, Dept Med, Clin Sci Ctr 15 220, 600 Highland Ave, Madison, WI 53792 USA.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; BATEMAN ED, 1997, AM J RESP CRIT CARE, V155, pA663; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; BUTCHERS PR, 1991, BRIT J PHARMACOL, V104, P672, DOI 10.1111/j.1476-5381.1991.tb12487.x; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DAHL R, 1991, EUR RESPIR J, V4, P1178; Fish JE, 1997, CLIN THER, V19, P675, DOI 10.1016/S0149-2918(97)80092-6; HAY DWP, 1995, TRENDS PHARMACOL SCI, V16, P304, DOI 10.1016/S0165-6147(00)89059-8; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; JOHNSON M, 1995, ANN ALLERG ASTHMA IM, V75, P177; MEYER JM, 1993, ANN PHARMACOTHER, V27, P1478, DOI 10.1177/106002809302701214; *NAT HEART LUNG BL, 1997, NIH PUBL; PEARLMAN DS, 1995, ANN ALLERG ASTHMA IM, V75, P180; Polgar G, 1971, PULMONARY FUNCTION T; Rodger IW, 1997, J INVEST ALLERG CLIN, V7, P279; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; Spector SL, 1997, DRUGS, V54, P369, DOI 10.2165/00003495-199754030-00002; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001	19	102	104	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1075	1080		10.1016/S0091-6749(99)70182-X	http://dx.doi.org/10.1016/S0091-6749(99)70182-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359889	Bronze			2022-12-18	WOS:000080929500016
J	Blanco, C; Diaz-Perales, A; Collada, C; Sanchez-Monge, R; Aragoncillo, C; Castillo, R; Ortega, N; Alvarez, M; Carrillo, T; Salcedo, G				Blanco, C; Diaz-Perales, A; Collada, C; Sanchez-Monge, R; Aragoncillo, C; Castillo, R; Ortega, N; Alvarez, M; Carrillo, T; Salcedo, G			Class I chitinases as potential panallergens involved in the latex-fruit syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						avocado; chestnut; chitinases; hevein-like domain; latex-fruit syndrome; panallergen	NATURAL-RUBBER LATEX; CROSS-REACTING ALLERGENS; HEVEA-BRASILIENSIS; BANANA ALLERGENS; BIRCH POLLEN; BINDING; HYPERSENSITIVITY; IDENTIFICATION; AVOCADO; ANTIBODIES	Background: Latex-fruit cross-sensitization has been fully demonstrated, However, the antigens responsible for this "latex-fruit syndrome" have not been identified. We have recently shown that class I chitinases are relevant chestnut and avocado allergens. Objective: We sought to evaluate the in vivo and in vitro reactions of purified chestnut and avocado chitinases in relation to the latex-fruit syndrome. Methods: From a latex-allergic population, eighteen patients allergic to chestnut, avocado, or both were selected. Skin prick tests (SPTs) were performed with crude chestnut and avocado extracts, chitinase-enriched preparations, and purified class I and II chitinases from both fruits. CAP-inhibition assays with the crude extracts and purified proteins were carried out. Immunodetection with sera from patients with latex-fruit allergy and immunoblot inhibition tests with a latex extract were also performed. Eighteen subjects paired with our patients and 15 patients allergic to latex but not food mere used as control groups. Results: The chestnut class I chitinase elicited positive SPT responses in 13 of 18 patients with latex-fruit allergy (72%), and the avocado class I chitinase elicited positive responses in 12 of 18 (67%) similarly allergic patients. By contrast, class II enzymes without a hevein-like domain did not show SPT responses in the same patient group. Each isolated class I chitinase reached inhibition values higher than 85% in CAP inhibition assays against the corresponding food extract in solid phase, Immunodetection of the crude extracts and the purified class I chitinases revealed a single 32-kd band for both chestnut and avocado. Preincubation with a natural latex extract fully inhibited the IgE binding to the crude extracts, as well as to the purified chestnut and avocado class I chitinases. Conclusion: Chestnut and avocado class I chitinases with an N-terminal hevein-like domain are major allergens that crossreact with latex, Therefore they are probably the panallergens responsible for the latex-fruit syndrome.	Hosp Nuestra Senora del Pino, Secc Alergia, Unidad Invest, Las Palmas Gran Canaria 35005, Spain; ETS Ingn Agron, Dept Biotecnol, Unidad Bioquim, Madrid, Spain; ETS Ingn Montes, Dept Biotecnol, Unidad Quim & Bioquim, Madrid, Spain		Blanco, C (corresponding author), Hosp Nuestra Senora del Pino, Secc Alergia, Unidad Invest, C Angel Guimera 93, Las Palmas Gran Canaria 35005, Spain.		Collada, Carmen/H-1529-2015; Díaz-Perales, Araceli/D-8433-2016; Blanco, Carlos/B-3895-2012	Collada, Carmen/0000-0003-0236-1312; Díaz-Perales, Araceli/0000-0002-1093-3627; Blanco, Carlos/0000-0002-2893-6594				AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; Alenius H, 1996, CLIN EXP ALLERGY, V26, P341, DOI 10.1046/j.1365-2222.1996.d01-312.x; Alenius H, 1996, J IMMUNOL, V156, P1618; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BLANCO C, 1994, ANN ALLERGY, V73, P309; Blanco C, 1998, CLIN EXP ALLERGY, V28, P971; BLANCO C, 1994, ALLERGY, V49, P454, DOI 10.1111/j.1398-9995.1994.tb00839.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; CARRILLO T, 1995, J ALLERGY CLIN IMMUN, V96, P699, DOI 10.1016/S0091-6749(95)70273-3; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; COLLINGE DB, 1993, PLANT J, V3, P31, DOI 10.1046/j.1365-313X.1993.t01-1-00999.x; DECORRES LF, 1993, ANN ALLERGY, V70, P35; Delbourg MF, 1996, ANN ALLERG ASTHMA IM, V76, P321, DOI 10.1016/S1081-1206(10)60032-4; Diaz-Perales A, 1998, J ALLERGY CLIN IMMUN, V102, P127, DOI 10.1016/S0091-6749(98)70063-6; DRENTH J, 1980, J BIOL CHEM, V255, P2652; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; Malling HJ., 2003, ALLERGY, V48, P55; MELCHERS LS, 1994, PLANT J, V5, P469, DOI 10.1046/j.1365-313X.1994.5040469.x; Moller M, 1998, ALLERGY, V53, P289, DOI 10.1111/j.1398-9995.1998.tb03889.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; SANCHEZMONGE R, 1992, BIOCHEM J, V281, P401, DOI 10.1042/bj2810401; SANCHEZMONGE R, 1998, IN PRESS CLIN EXP AL; SLATER JE, 1997, ALLERGY ALLERGIC DIS, P981; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379, DOI 10.1016/S0091-6749(98)70251-9	40	102	104	0	19	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				507	513		10.1016/S0091-6749(99)70478-1	http://dx.doi.org/10.1016/S0091-6749(99)70478-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069887				2022-12-18	WOS:000079175700022
J	LAFFER, S; VALENTA, R; VRTALA, S; SUSANI, M; VANREE, R; KRAFT, D; SCHEINER, O; DUCHENE, M				LAFFER, S; VALENTA, R; VRTALA, S; SUSANI, M; VANREE, R; KRAFT, D; SCHEINER, O; DUCHENE, M			COMPLEMENTARY-DNA CLONING OF THE MAJOR ALLERGEN PHL-P-I FROM TIMOTHY GRASS (PHLEUM-PRATENSE) - RECOMBINANT PHL-P-I INHIBITS IGE BINDING TO GROUP-I ALLERGENS FROM 8 DIFFERENT GRASS SPECIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TIMOTHY GRASS; PHLEUM PRATENSE; ALLERGEN; CDNA CLONING; IGE-IMMUNOBLOT INHIBITION	AMINO-ACID-SEQUENCE; LOLIUM-PERENNE; POLLEN ALLERGEN; CDNA CLONING; IDENTIFICATION; DETERMINANTS; DIAGNOSIS; PROTEINS	Background: Grass pollens, such as pollen from timothy grass (Phleum pratense), represent a major cause of type I allergy. Objective: In this report we attempted to determine how cross-reactive allergenic components of grass pollens from different species can be represented by a minimum number of recombinant allergens. Methods: We isolated and sequenced a timothy grass pollen cDNA coding for the major allergen Phl p I. A recombinant Phl p I-beta-galactosidase fusion protein, which bound to IgE in 87% of patients with grass pollen allergy, was produced in Escherichia coli. Using recombinant Phl p V and Phl p I, we defined representative patients' sera that bound to group I but not to group V allergens, as well as sera with reactivity against group I and group V allergens. IgE immunoblot inhibition studies were done with nitrocellulose-blotted pollen extracts from eight grass species with different geographic distribution. Results: Preadsorption of patients' sera with recombinant nonfusion Phl p I strongly reduced IgE binding to group I allergens from the eight grasses, showing extensive cross-reactivity between species. Conclusion: A single recombinant group I allergen contains many of the IgE epitopes of group I isoallergens from a number of different grass species.	AKH, INST GEN & EXPTL PATHOL, A-1090 VIENNA, AUSTRIA; AUSTRIAN ACAD SCI, SALZBURG, AUSTRIA; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, AMSTERDAM, NETHERLANDS; UNIV VIENNA, INST SPECIF PROPHYLAXIS & TROP MED, VIENNA, AUSTRIA	Austrian Academy of Sciences; University of Vienna			Duchêne, Michael/G-6659-2019	Duchêne, Michael/0000-0003-1232-3600; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243				ANSARI AA, 1989, BIOCHEMISTRY-US, V28, P8665, DOI 10.1021/bi00447a058; ANSARI AA, 1989, J BIOL CHEM, V264, P11181; ANSARI AA, 1987, J IMMUNOL, V139, P4034; AUSUBEL FM, 1990, CURRENT PROTOCOL M S, V9; BASKAR S, 1992, J IMMUNOL, V148, P2378; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; ESCH RE, 1989, J IMMUNOL, V142, P179; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; LAFFER S, 1994, IN PRESS J ALLERGY C; PEREZ M, 1990, J BIOL CHEM, V265, P16210; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANDRING R, 1987, INT ARCH ALLER A IMM, V83, P96, DOI 10.1159/000234338; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VANREE R, 1992, 8TH INT C IMM BUD; VRTALA S, 1993, J IMMUNOL, V151, P4773	27	102	112	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					689	698		10.1016/0091-6749(94)90176-7	http://dx.doi.org/10.1016/0091-6749(94)90176-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930302				2022-12-18	WOS:A1994PM27300007
J	FINDLAY, SR; BARDEN, JM; EASLEY, CB; GLASS, M				FINDLAY, SR; BARDEN, JM; EASLEY, CB; GLASS, M			EFFECT OF THE ORAL LEUKOTRIENE ANTAGONIST, ICI 204,219, ON ANTIGEN-INDUCED BRONCHOCONSTRICTION IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LEUKOTRIENE ANTAGONIST; ICI 204,219; ASTHMA; ALLERGEN; BRONCHOPROVOCATION	RECEPTOR ANTAGONIST; INHALED LEUKOTRIENE-D4; RESPONSIVENESS; INHALATION; INHIBITION; CHALLENGE; AIRWAYS; HUMANS; POTENT	We studied the effect of a single oral dose of ICI 204,219 on subject response to bronchoprovocation and quantitative skin testing with standardized allergen (cat dander). Cat-allergic male subjects with asthma entered the double-blind, randomized, placebo-controlled, crossover study. Each subject received a 40 mg dose of ICI 204,219 or placebo on study days separated by at least 10 days. After dosing, each subject underwent bronchoprovocation with cat allergen until a provocative dose of allergen caused a 20% decrease in FEV1 or a maximum dose of 30,000 AU/ml was reached. Fifteen subjects entered and 13 completed the study. No significant shift in the dose-response curve of the quantitative skin test occurred in any subject. A mean tenfold increase in the interpolated provocative concentration causing a 20% decrease in FEV1 was observed between ICI 204,219 (6996 +/- 3204 AU/ml) and placebo (460 +/- 98 AU/ml). Eight of 12 subjects required more antigen to provoke a bronchoprovocation response after dosing with ICI 204,219 than that required with placebo (range, threefold to 30-fold), three demonstrated no difference (less than twofold), and one subject required less antigen after ICI 204,219 (sevenfold less). Area under the curve measurements were significantly different (p < 0.05) between ICI 204,219 and placebo for the fixed time from the end point of the allergen bronchoprovocation to 5 hours after provocation. In conclusion, this trial demonstrates that a single oral dose of ICI 204,219 antagonizes the bronchoconstriction induced by inhaled cat allergen.	HEALTHQUEST RES,AUSTIN,TX; ICI AMER INC,WILMINGTON,DE 19899									ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; BEASLEY RCW, 1989, J APPL PHYSIOL, V66, P1685, DOI 10.1152/jappl.1989.66.4.1685; BERNSTEIN JA, 1991, J ALLERGY CLIN IMMUN, V87, P93, DOI 10.1016/0091-6749(91)90217-C; BRITTON JR, 1987, J ALLERGY CLIN IMMUN, V79, P811, DOI 10.1016/0091-6749(87)90214-4; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CROPP GJA, 1980, ATS NEWS         SPR, P11; FISH JE, 1979, J ALLERGY CLIN IMMUN, V64, P592, DOI 10.1016/0091-6749(79)90019-8; FULLER RW, 1989, J ALLERGY CLIN IMMUN, V83, P939, DOI 10.1016/0091-6749(89)90109-7; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HAY DWP, 1987, J PHARMACOL EXP THER, V243, P474; HUI KP, 1991, LANCET, V337, P1062, DOI 10.1016/0140-6736(91)91709-4; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; KERN R, 1986, AM REV RESPIR DIS, V133, P1127; KRELL RD, 1990, AM REV RESPIR DIS, V141, P976; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; NEWTON JF, 1988, PHAARMACOLOGIST, V30, P96; POPA V, 1986, CLIN CHEST MED, V7, P367; SMITH LJ, 1990, AM REV RESPIR DIS, V141, P988, DOI 10.1164/ajrccm/141.4_Pt_1.988; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814	23	102	103	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1992	89	5					1040	1045		10.1016/0091-6749(92)90227-S	http://dx.doi.org/10.1016/0091-6749(92)90227-S			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HU542	1583246				2022-12-18	WOS:A1992HU54200015
J	ILIOPOULOS, O; PROUD, D; ADKINSON, NF; NORMAN, PS; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM				ILIOPOULOS, O; PROUD, D; ADKINSON, NF; NORMAN, PS; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM			RELATIONSHIP BETWEEN THE EARLY, LATE, AND RECHALLENGE REACTION TO NASAL CHALLENGE WITH ANTIGEN - OBSERVATIONS ON THE ROLE OF INFLAMMATORY MEDIATORS AND CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LATE ASTHMATIC RESPONSES; ALLERGEN-INDUCED INCREASE; LATE-PHASE REACTIONS; BRONCHIAL RESPONSIVENESS; DERMATOPHAGOIDES-PTERONYSSINUS; AIRWAY CHALLENGE; CONTROLLED TRIAL; HOUSE DUST; HAY-FEVER; HISTAMINE	We challenged each of 55 consecutive ragweed (RW)-allergic patients with hay fever and with graded increasing doses of ragweed extract to investigate the frequency and relationship between the early (ER), late (LPR), and rechallenge reactions (RCRs) to nasal challenge. We evaluated the nasal response by measuring the levels of histamine, TAME-esterase activity, and kinins in the nasal lavage fluid and by grading symptoms. Fifty-one subjects (92.7%) had an ER consisting of a dose-dependent, concommitant increase in both mediators and symptoms. The total amount of TAME-esterase activity and kinins generated during ER correlated significantly with specific serum IgE (ssIgE), intradermal skin test (ST) sensitivity, and basophil histamine release (BHR) to antigen E (p < 0.01 for each). Twenty-four (47%) subjects developed a late increase in mediators and 23 (45%) subjects in symptoms. None of the four subjects without an ER developed an LPR. The levels of the late-appearing mediators were not predicted by ST, ssIgE, or BHR. There was a significant but weak association between the intensity of ER and LPR, but there was no significant difference in the IgE antibodies, ST, BHR, and intensity or threshold of ER between dual and early only reactors. The number of eosinophils and neutrophils in the LPR lavages increased over the prechallenge baseline, and their numbers correlated (p < 0.05) with ER kinins (r = 0.46, 0.37, respectively), ER-TAME-esterase activity (r = 0.28 and 0.24, respectively), and in the case of eosinophils, ER histamine (r = 0.29). More subjects had an increase in cells than developed an LPR (76% versus 47%), suggesting the need for additional factors to explain the activation of the incoming cells and the development of LPR. The intensity of RCR was significantly predicted (p < 0.05) by ssIgE and ST. The RCR histamine, TAME-esterase activity, kinins, and number of sneezes and other symptoms correlated significantly with the corresponding levels in the ER and LPR (p < 0.01 for all). On rechallenge, 21 subjects (41%) had mediator levels greater than levels during ER at the same antigen dose, and an additional 10 subjects (19.5%) had an enhanced symptomatic response without a concomitant increase in mediators. A preceding LPR was not significantly linked to an enhanced RCR, as assessed by increased symptoms or mediator levels. Although 44 subjects (80%) had a late cutaneous reaction, the size of which correlated with the size of the early cutaneous reaction (r = 0.51 and 0.48; p < 0.001 for wheal and erythema, respectively), there was no significant association between the development of a nasal and a cutaneous LPR, nor did cutaneous LPR predict an enhanced nasal RCR.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI 08270, AI 20136] Funding Source: Medline; NIDCD NIH HHS [DC 00320] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270, P50AI020136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000320] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; ANDERSSON M, 1987, ALLERGY, V42, P631, DOI 10.1111/j.1398-9995.1987.tb00395.x; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; Blackley CH., 1873, EXPT RES CAUSES NATU; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOULET LP, 1984, CLIN ALLERGY, V14, P379, DOI 10.1111/j.1365-2222.1984.tb02219.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; GWYNN CM, 1982, LANCET, V1, P254; IMANARI T, 1986, DHEW NIH76791 PUBL, P205; ITO K, 1986, INT ARCH ALLER A IMM, V81, P69, DOI 10.1159/000234110; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; Siegel S., 1956, NONPARAMETRIC STAT B; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; WARNER JO, 1978, LANCET, V2, P912	36	102	103	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				851	861		10.1016/S0091-6749(05)80146-0	http://dx.doi.org/10.1016/S0091-6749(05)80146-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262642				2022-12-18	WOS:A1990EQ04500004
J	BARDIN, PG; VANHEERDEN, BB; JOUBERT, JR				BARDIN, PG; VANHEERDEN, BB; JOUBERT, JR			ABSENCE OF PULMONARY ASPIRATION OF SINUS CONTENTS IN PATIENTS WITH ASTHMA AND SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TYGERBERG HOSP,TYGERBERG,SOUTH AFRICA; UNIV STELLENBOSCH,DEPT INTERNAL MED,PULM UNIT,TYGERBERG 7505,SOUTH AFRICA; UNIV STELLENBOSCH,DEPT INTERNAL MED,NUCL MED UNIT,TYGERBERG 7505,SOUTH AFRICA	Tygerberg Hospital; Stellenbosch University; Stellenbosch University	BARDIN, PG (corresponding author), UNIV STELLENBOSCH,DEPT INTERNAL MED,ALLERGY CLIN,POB 63,TYGERBERG 7505,SOUTH AFRICA.							CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; EGGLESTON PA, 1988, J ALLERGY CLIN IMMUN, V81, P1036, DOI 10.1016/0091-6749(88)90176-5; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; HOGG JC, 1984, AM REV RESPIR DIS, V129, P207; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; LORBER B, 1974, ANN INTERN MED, V81, P329, DOI 10.7326/0003-4819-81-3-329; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; PIERCE AK, 1974, AM REV RESPIR DIS, V110, P647; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; REED CE, 1988, J ALLERGY CLIN IMMUN, V81, P1042, DOI 10.1016/0091-6749(88)90177-7; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SLUDER G, 1919, JAMA-J AM MED ASSOC, V3, P589; WINFIELD JB, 1973, JAMA-J AM MED ASSOC, V233, P1288; YAN K, 1983, EUR J RESPIR DIS, V64, P105	19	102	104	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					82	88		10.1016/S0091-6749(05)80126-5	http://dx.doi.org/10.1016/S0091-6749(05)80126-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2370390	Bronze			2022-12-18	WOS:A1990DQ68800012
J	PERSSON, CGA				PERSSON, CGA			OVERVIEW OF EFFECTS OF THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LUND HOSP,DEPT CLIN PHARMACOL,S-22185 LUND,SWEDEN	Lund University; Skane University Hospital	PERSSON, CGA (corresponding author), AB DRACO,PHARMACOL LAB,POB 34,S-22100 LUND,SWEDEN.							AHMED F, 1985, BRIT J PHARMACOL, V84, P861, DOI 10.1111/j.1476-5381.1985.tb17380.x; AITKEN M L, 1985, American Review of Respiratory Disease, V131, pA68; ANDERSSON KE, 1984, EUR J CLIN PHARMACOL, V26, P33, DOI 10.1007/BF00546705; ANDERSSON KE, 1985, ANTIASTHMA XANTHINES, P1; ANDERSSON KE, 1985, ANTIASTHMA XANTHINES, P362; ANDERSSON P, 1985, ANTIASTHMA XANTHINES, P187; ARANDA JV, 1976, NEW ENGL J MED, V295, P413, DOI 10.1056/NEJM197608192950803; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; BERNASCONI R., 1983, REGULATORY FUNCTION, P1; BERQUIST WE, 1984, J ALLERGY CLIN IMMUN, V73, P253, DOI 10.1016/S0091-6749(84)80016-0; BUSSOLINO F, 1980, IMMUNOLOGY, V40, P367; CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160; DALY JW, 1981, LIFE SCI, V28, P2083, DOI 10.1016/0024-3205(81)90614-7; EKELUND L, 1985, ANTIASTHMA XANTHINES, P202; Ellis EF, 1978, ALLERGY PRINCIPLES P, P434; FINNEY MJB, 1985, BRIT J PHARMACOL, V85, P29, DOI 10.1111/j.1476-5381.1985.tb08827.x; GUILLOT C, 1984, J ALLERGY CLIN IMMUN, V74, P713, DOI 10.1016/0091-6749(84)90235-5; HEDNER T, 1982, NEUROSCI LETT, V33, P147, DOI 10.1016/0304-3940(82)90242-7; HIGHBEE MD, 1982, J ALLERGY CLIN IMMUN, V70, P377; JENNE JW, 1982, J ALLERGY CLIN IMMUN, V70, P413, DOI 10.1016/0091-6749(82)90002-1; JOHANNESSON N, 1985, AM REV RESPIR DIS, V131, P26; KALINER M, 1974, BIOCHEM PHARMACOL, V23, P763, DOI 10.1016/0006-2952(74)90206-8; KARLSSON J-A, 1982, British Journal of Pharmacology, V77, p396P; KARLSSON JA, 1981, BRIT J PHARMACOL, V74, P73, DOI 10.1111/j.1476-5381.1981.tb09956.x; KARLSSON JA, 1984, NEURAL NONNEURAL MEC, P83; KYONG CU, 1982, J ALLERGY CLIN IMMUN, V69, P444, DOI 10.1016/0091-6749(82)90119-1; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LUNELL E, 1983, EUR J RESPIR DIS, V64, P333; MAGNUSSEN I, 1977, ACTA NEUROL SCAND, V55, P131, DOI 10.1111/j.1600-0404.1977.tb05633.x; MARONE G, 1979, J IMMUNOL, V123, P1473; NELSON S, 1985, AM REV RESPIR DIS, V131, P923; OSSWALD H, 1980, INT J BIOCHEM, V12, P263, DOI 10.1016/0020-711X(80)90082-8; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PAVIA D, 1983, EUR J RESPIR DIS, V64, P304; PERRUCHOUD A P, 1984, American Review of Respiratory Disease, V129, pA282; PERSSON CGA, 1982, ARCH INT PHARMACOD T, V258, P267; PERSSON CGA, 1986, J ALLERGY CLIN IMMUN, V78, P817, DOI 10.1016/0091-6749(86)90067-9; PERSSON CGA, 1985, THORAX, V40, P881, DOI 10.1136/thx.40.12.881; PERSSON CGA, 1986, LIFE SCI, V38, P1057, DOI 10.1016/0024-3205(86)90241-9; PERSSON CGA, 1986, ACTA PHYSIOL SCAND, V127, P95, DOI 10.1111/j.1748-1716.1986.tb07880.x; PERSSON CGA, 1982, TRENDS PHARMACOL SCI, V3, P312, DOI 10.1016/0165-6147(82)91153-1; PERSSON CGA, 1980, EUR J RESPIR DIS, V61, P7; PERSSON CGA, 1985, ANTIASTHMA XANTHINES, P61; ROMSON JL, 1983, J PHARMACOL EXP THER, V227, P288; SCHWABE U, 1981, TRENDS PHARMACOL SCI, V2, P299, DOI 10.1016/0165-6147(81)90347-3; STIRT JA, 1981, ANESTH ANALG, V60, P767; TOOGOOD JH, 1985, BRONCHIAL ASTHMA MEC, P698; VESTAL RE, 1983, CIRCULATION, V67, P162, DOI 10.1161/01.CIR.67.1.162; WAHL M, 1976, PFLUG ARCH EUR J PHY, V362, P55, DOI 10.1007/BF00588681; WAHLANDER S, 1985, ANTIASTHMA XANTHINES, P477; WEISSMAN.G, 1971, NATURE-NEW BIOL, V231, P131, DOI 10.1038/newbio231131a0; WOODCOCK AA, 1981, NEW ENGL J MED, V305, P1611, DOI 10.1056/NEJM198112313052703; YANAURA S, 1981, JPN J PHARMACOL, V31, P951, DOI 10.1254/jjp.31.951	53	102	102	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				780	787		10.1016/0091-6749(86)90061-8	http://dx.doi.org/10.1016/0091-6749(86)90061-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	2877016				2022-12-18	WOS:A1986E568400019
J	FAUCI, AS				FAUCI, AS			IMMUNOREGULATION IN AUTOIMMUNITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FAUCI, AS (corresponding author), NIAID,CLIN INVEST LAB,CLIN PHYSIOL SECT,BETHESDA,MD 20205, USA.							ABDOU NI, 1978, J CLIN INVEST, V61, P738, DOI 10.1172/JCI108987; ABDOU NI, 1976, CLIN IMMUNOL IMMUNOP, V6, P192, DOI 10.1016/0090-1229(76)90110-0; AKIZURI M, 1978, CLIN IMMUNOL IMMUNOP, V10, P245; ALARCONSEGOVIA D, 1978, J CLIN INVEST, V62, P1390, DOI 10.1172/JCI109260; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; ANTEL JP, 1979, ANN NEUROL, V5, P338, DOI 10.1002/ana.410050406; ARNETT FC, 1976, MEDICINE, V55, P313, DOI 10.1097/00005792-197607000-00003; BANKHURST AD, 1975, J CLIN INVEST, V56, P1378, DOI 10.1172/JCI108218; BELL DA, 1973, CLIN IMMUNOL IMMUNOP, V1, P293, DOI 10.1016/0090-1229(73)90046-9; BOTZENHARDT U, 1978, J EXP MED, V147, P1435, DOI 10.1084/jem.147.5.1435; BRESNIHAN E, 1977, J CLIN INVEST, V59, P106; BUDMAN DR, 1977, ARTHRITIS RHEUM, V20, P829, DOI 10.1002/art.1780200312; CANTOR H, 1978, J EXP MEDICINE, V147, P116; CHUSED TM, 1978, GENETIC CONTROL AUTO, P1972; COHEN P, 1978, J IMMUNOL, V121, P973; COHEN PL, 1977, J IMMUNOL, V119, P1534; CONTRERAS TJ, CELL IMMUNOL; Coutinho A, 1975, Adv Immunol, V21, P113, DOI 10.1016/S0065-2776(08)60220-5; DECKER JL, 1979, ANN INTERN MED, V91, P587, DOI 10.7326/0003-4819-91-4-587; DECKER JL, 1975, ANN INTERN MED, V82, P391, DOI 10.7326/0003-4819-82-3-391; DEHEER DH, 1978, J IMMUNOL, V120, P825; ESTES D, 1971, MEDICINE, V50, P85, DOI 10.1097/00005792-197103000-00001; FALKOFF RM, 1978, J IMMUNOL, V121, P897; FAUCI AS, 1978, J IMMUNOL, V121, P1473; FAUCI AS, 1979, IMMUNOL REV, V45, P93, DOI 10.1111/j.1600-065X.1979.tb00274.x; FAUCI AS, 1979, ANTIBODY PRODUCTION, P1; FAUCI AS, 1980, MANUAL CLIN IMMUNOLO; FISHBACK M, 1978, J IMMUNOL, V120, P1856; FOURNIE GJ, 1974, J EXP MED, V140, P1189, DOI 10.1084/jem.140.5.1189; GERSHWIN ME, 1979, J IMMUNOL, V122, P710; GINSBURG WW, 1979, CLIN EXP IMMUNOL, V35, P76; GLINSKI W, 1976, J CLIN INVEST, V57, P604, DOI 10.1172/JCI108316; GLINSKI W, 1976, CLIN EXP IMMUNOL, V26, P228; GONZALEZ RL, 1979, CLIN EXP IMMUNOL, V36, P78; GOODWIN JS, 1979, ANN INTERN MED, V90, P169, DOI 10.7326/0003-4819-90-2-169; GRAYSON J, 1979, CLIN RES, V27, pA326; HAMMARSTROM L, 1976, NATURE, V263, P60, DOI 10.1038/263060a0; HAYNES BF, 1977, J IMMUNOL, V118, P2281; HAYNES BF, 1979, J IMMUNOL, V123, P2095; HAYNES BF, 1978, J IMMUNOL, V121, P559; HAYWARD AR, 1978, J IMMUNOL, V121, P1; HOFFMAN R, 1977, NEW ENGL J MED, V296, P10, DOI 10.1056/NEJM197701062960103; HOROWITZ S, 1977, SCIENCE, V197, P999, DOI 10.1126/science.302032; HUSTON DP, 1979, YALE J BIOL MED, V52, P289; IZUI S, 1978, J IMMUNOL, V121, P2213; IZUI S, 1977, J IMMUNOL, V119, P2157; JASIN HE, 1975, ARTHRITIS RHEUM-US, V18, P219, DOI 10.1002/art.1780180305; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KABAYAKAWA T, 1979, J IMMUNOL, V122, P296; KATZ P, 1978, CLIN EXP IMMUNOL, V32, P554; KATZ P, 1978, CLIN IMMUNOL IMMUNOP, V10, P350, DOI 10.1016/0090-1229(78)90192-7; KIOKE T, 1979, ARTHRITIS RHEUM, V22, P123; KRAKAUER RS, 1976, J EXP MED, V144, P662, DOI 10.1084/jem.144.3.662; KUNKEL HG, 1964, ADV IMMUNOL, V4, P355; KUNTZ MM, 1979, J CLIN INVEST, V63, P151, DOI 10.1172/JCI109270; LEWIS RM, 1974, NATURE, V252, P78, DOI 10.1038/252078a0; LIPSKY PE, 1978, J IMMUNOL, V120, P902; MCCOMBS C, 1975, J IMMUNOL, V115, P1695; MCHUGH YE, 1978, J IMMUNOL, V121, P1090; MELLORS RC, 1976, P NATL ACAD SCI USA, V73, P233, DOI 10.1073/pnas.73.1.233; MILLER KB, 1979, NEW ENGL J MED, V301, P803, DOI 10.1056/NEJM197910113011502; MOLLER G, 1978, IMMUNOL REV, V40, P1; MOLLER G, 1979, IMMUNOL REV, V45, P1; Molloy G., 1976, Progress Biophys Molec Biol, V31, P1; MORETTA A, 1979, SCAND J IMMUNOL, V10, P223, DOI 10.1111/j.1365-3083.1979.tb01343.x; MORETTA L, 1978, NATURE, V272, P618, DOI 10.1038/272618a0; MORETTA L, 1979, J IMMUNOL, V122, P984; MORETTA L, 1977, J EXP MED, V146, P184, DOI 10.1084/jem.146.1.184; MORIMOTO C, 1978, CLIN EXP IMMUNOL, V32, P125; MORIMOTO C, 1977, SCAND J IMMUNOL, V6, P575, DOI 10.1111/j.1365-3083.1977.tb02135.x; MOUTSOPOULOS HM, 1980, J CLIN INVEST, V65, P519, DOI 10.1172/JCI109696; MOUTSOPOULOS HM, 1977, J IMMUNOL, V119, P1639; PALMER DW, 1976, CLIN EXP IMMUNOL, V23, P578; PICHLER WJ, 1978, J IMMUNOL, V121, P1540; PRIMI D, 1977, J EXP MED, V145, P21, DOI 10.1084/jem.145.1.21; RAEDER R, 1976, CLIN IMMUNOL IMMUNOP, V6, P174, DOI 10.1016/0090-1229(76)90108-2; REINHERZ EL, 1979, NEW ENGL J MED, V301, P1018, DOI 10.1056/NEJM197911083011902; REINHERZ EL, 1979, NEW ENGL J MED, V300, P1061, DOI 10.1056/NEJM197905103001901; RICE L, 1979, J IMMUNOL, V122, P991; SAGAWA A, 1979, J CLIN INVEST, V63, P536, DOI 10.1172/JCI109333; SAGAWA A, 1978, J CLIN INVEST, V62, P789, DOI 10.1172/JCI109190; SAKANE T, 1977, J IMMUNOL, V119, P1169; SAKANE T, 1978, ARTHRITIS RHEUM, V21, P657, DOI 10.1002/art.1780210608; SAKANE T, 1978, P NATL ACAD SCI USA, V75, P3464, DOI 10.1073/pnas.75.7.3464; SAMARUT C, TRANSPLANTATION; SANTOLI D, 1978, J IMMUNOL, V120, P1369; SCHOCKET AL, 1979, ARTHRITIS RHEUM, V22, P1060, DOI 10.1002/art.1780221003; SCHWARTZ RS, 1975, NEW ENGL J MED, V293, P132; SHIRAI T, 1978, J IMMUNOL, V120, P1942; SHOU L, 1976, J EXP MED, V143, P1100, DOI 10.1084/jem.143.5.1100; SMITH JB, 1978, J IMMUNOL, V121, P1889; STEEL CM, 1977, NATURE, V270, P729, DOI 10.1038/270729a0; STEINBERG AD, 1979, ARTHRITIS RHEUM, V22, P114, DOI 10.1002/art.1780220203; STEVENS RH, 1979, J IMMUNOL, V122, P2498; STOBO JD, 1977, J IMMUNOL, V119, P918; STRELKAUSKAS AJ, 1978, P NATL ACAD SCI USA, V75, P5150, DOI 10.1073/pnas.75.10.5150; TALAL N, 1970, ARTHRITIS RHEUM, V13, P887, DOI 10.1002/art.1780130620; TALAL N, 1976, TRANSPLANT REV, V31, P240; TALAL N, 1977, AUTOIMMUNITY GENETIC; THEOFILOPOULOS AN, 1979, J EXP MED, V149, P516, DOI 10.1084/jem.149.2.516; THOMAS DB, 1972, LANCET, V1, P399; THOMSON PD, 1977, J IMMUNOL, V118, P1480; TOSATO G, 1979, NEW ENGL J MED, V301, P1133, DOI 10.1056/NEJM197911223012101; TWOMEY JJ, 1978, J CLIN INVEST, V62, P713, DOI 10.1172/JCI109180; VANFURTH R, 1966, IMMUNOLOGY, V11, P29; VAUGHAN JH, 1975, ARCH INTERN MED, V135, P1324, DOI 10.1001/archinte.135.10.1324; VOLKMAN D, 1979, MOL BASIS IMMUNE CEL, P483; Waldmann T A, 1977, Prog Clin Immunol, V3, P155	109	102	103	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					5	17		10.1016/0091-6749(80)90132-3	http://dx.doi.org/10.1016/0091-6749(80)90132-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	6966642				2022-12-18	WOS:A1980JZ54100002
J	YUNGINGER, JW; JONES, RT; NESHEIM, ME; GELLER, M				YUNGINGER, JW; JONES, RT; NESHEIM, ME; GELLER, M			STUDIES ON ALTERNARIA ALLERGENS .3. ISOLATION OF A MAJOR ALLERGENIC FRACTION (ALT-I)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,HEMATOL RES LAB,ROCHESTER,MN 55901; UNIV WISCONSIN,HLTH SCI CTR,DEPT MED,ALLERGY & IMMUNOL SECT,MADISON,WI 53706	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Wisconsin System; University of Wisconsin Madison	YUNGINGER, JW (corresponding author), MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901, USA.							AWDEH ZL, 1968, NATURE, V219, P66, DOI 10.1038/219066a0; BONIL.O, 1961, J ALLERGY, V32, P246, DOI 10.1016/0021-8707(61)90055-7; BONILLAS.O, 1969, J ALLERGY, V43, P125, DOI 10.1016/S0021-8707(69)80003-1; CUNNINGHAM S, 1978, NIAID CATALOG RES RE, P981; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; KABAT EA, 1967, EXPT IMMUNOCHEMISTRY, P559; KAPITANY RA, 1973, ANAL BIOCHEM, V56, P361, DOI 10.1016/0003-2697(73)90202-9; LEBEAU LJ, 1952, THESIS U ILLINOIS; LYNCH NR, 1975, CLIN EXP IMMUNOL, V22, P35; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; RADOLA BJ, 1973, ANN NY ACAD SCI, V209, P127, DOI 10.1111/j.1749-6632.1973.tb47523.x; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SOLOMON WR, 1978, ALLERGY PRINCIPLES P, P899; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STERNBERGER LA, 1956, J ALLERGY, V27, P16, DOI 10.1016/0021-8707(56)90034-X; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V57, P293, DOI 10.1016/0091-6749(76)90085-3	21	102	104	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	2					138	147		10.1016/0091-6749(80)90061-5	http://dx.doi.org/10.1016/0091-6749(80)90061-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD119	7190582				2022-12-18	WOS:A1980KD11900008
J	KAWABORI, I; PIERSON, WE; CONQUEST, LL; BIERMAN, CW				KAWABORI, I; PIERSON, WE; CONQUEST, LL; BIERMAN, CW			INCIDENCE OF EXERCISE-INDUCED ASTHMA IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT BIOSTATISTICS,SEATTLE,WA 98195; CHILDRENS ORTHOPEDIC HOSP & MED CTR,DIV ALLERGY,SEATLE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ADAMS FH, 1961, PEDIATRICS, V28, P243; ARETAEUS C, 1969, CLASSICS ALLERGY; CONNOLLY NM, 1970, THORAX, V24, P258; CROMPTON GK, 1968, THORAX, V23, P165, DOI 10.1136/thx.23.2.165; DAVIES SE, 1968, BRIT MED J, V3, P593, DOI 10.1136/bmj.3.5618.593; ECKILDSEN PS, 1945, ARBEJDSFYSIOLOGISKE; ENGSTROM I, 1960, Acta Paediatr, V49, P850, DOI 10.1111/j.1651-2227.1960.tb16095.x; FISHER HK, 1970, AM REV RESPIR DIS, V101, P885; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; FLOYER JA, 1717, TREATISE ASTHMA; GARRETH HE, 1966, STATISTICS PSYCHOLOG; GODFREY S, 1975, PEDIATRICS, V56, P851; HAFEZ F F, 1968, British Journal of Diseases of the Chest, V62, P41, DOI 10.1016/S0007-0971(68)80030-0; HEIMLICH EM, 1966, J ALLERGY, V37, P103; HERBEST E, 1928, DTSCH ARCH KLIN MED, V162, P129; JONES RS, 1962, BRIT J DIS CHEST, V56, P78, DOI 10.1016/S0007-0971(62)80005-9; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; JONES RS, 1970, THORAX, V25, P258, DOI 10.1136/thx.25.2.258-b; Kaltreider NL, 1937, J CLIN INVEST, V16, P23, DOI 10.1172/JCI100836; KJELLMAN B, 1969, SCAND J RESPIR DIS, V50, P41; MCNEILL RS, 1966, Q J MED, V35, P55; MCNEILL RS, 1968, LANCET, V2, P678; MUITTARI A, 1969, BRIT MED J, V4, P170, DOI 10.1136/bmj.4.5676.170-a; OLYMPIC MD, 1972, MED WORLD NEWS  1020, P27; PALMER KNV, 1969, LANCET, V2, P219; PEARSON RSB, 1952, ACTA ALLERGOL, V5, P310; PIERSON WE, 1975, PEDIATRICS, V56, P890; PIERSON WE, 1970, J ALLERGY, V45, P119; PIERSON WE, 1968, J ALLERGY, V41, P93; PIERSON WE, 1969, J ALLERGY, V43, P136, DOI 10.1016/S0021-8707(69)80004-3; REBUCK AS, 1968, LANCET, V2, P429; SEATON A, 1969, BRIT MED J, V3, P556, DOI 10.1136/bmj.3.5670.556; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SIMONSSON BG, 1969, THORAX, V24, P506, DOI 10.1136/thx.24.4.506-b; SLY RM, 1970, ANN ALLERGY, V28, P1; SLY RM, 1967, J ALLERGY, V40, P93, DOI 10.1016/0021-8707(67)90102-5; SLY RM, 1967, ANN ALLERGY, V25, P192; SLY RM, 1969, ANN ALLERGY, V27, P158; SLY RM, 1967, ANN ALLERGY, V25, P324; STANESCU DC, 1970, RESPIRATION, V27, P377, DOI 10.1159/000192694; STERLING GM, 1968, CLIN SCI, V34, P277; WARD FG, 1969, BRIT MED J, V3, P176, DOI 10.1136/bmj.3.5663.176-d; Willis T, 1679, PHARMACEUTICE RATI 2; ZAID G, 1968, J ALLERGY, V42, P177, DOI 10.1016/S0021-8707(68)90113-5; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103; 1973, PEDIATRICS, V52, P886	46	102	103	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	4					447	455		10.1016/0091-6749(76)90188-3	http://dx.doi.org/10.1016/0091-6749(76)90188-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH210	972213	Bronze			2022-12-18	WOS:A1976CH21000001
J	YUNGINGER, JW; GLEICH, GJ				YUNGINGER, JW; GLEICH, GJ			SEASONAL-CHANGES IN SERUM AND NASAL IGE CONCENTRATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO GRAD SCH MED, ALLERGIC DIS RES LAB, ROCHESTER, MN 55901 USA; MAYO GRAD SCH MED, DEPT PEDIAT, ROCHESTER, MN 55901 USA; MAYO GRAD SCH MED, DEPT MED, ROCHESTER, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic								ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; BERG T, 1971, INT ARCH ALLER A IMM, V41, P434, DOI 10.1159/000230537; BULL DM, 1971, GASTROENTEROLOGY, V60, P370; CRABBE PA, 1969, J EXP MED, V130, P723, DOI 10.1084/jem.130.4.723; DIXON WJ, 1957, INTRO STATISTICAL AN; DURHAM OC, 1946, J ALLERGY, V17, P79, DOI 10.1016/0021-8707(46)90025-1; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; ISHIZAKA K, 1970, J ALLERGY, V46, P197, DOI 10.1016/0021-8707(70)90023-7; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KABAT EA, 1967, EXPERIMENTAL IMMUNOC, P557; KUMAR L, 1971, J ALLERGY CLIN IMMUN, V48, P305, DOI 10.1016/0091-6749(71)90032-7; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; ROSSEN RD, 1966, J CLIN INVEST, V45, P768, DOI 10.1172/JCI105391; ROSSEN RD, 1965, P SOC EXP BIOL MED, V119, P1169; STANWORTH DR, 1967, LANCET, V2, P330; TADA T, 1970, Journal of Immunology, V104, P377; TURNER MW, 1970, INT ARCH ALLER A IMM, V37, P409, DOI 10.1159/000230803; VAERMAN JP, 1970, IMMUNOLOGY, V18, P27	25	102	102	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	3					174	186		10.1016/0091-6749(73)90022-5	http://dx.doi.org/10.1016/0091-6749(73)90022-5			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0896	4687913				2022-12-18	WOS:A1973P089600005
J	Hagin, D; Freund, T; Navon, M; Halperin, T; Adir, D; Marom, R; Levi, I; Benor, S; Alcalay, Y; Freund, NT				Hagin, David; Freund, Tal; Navon, Michal; Halperin, Tami; Adir, Dikla; Marom, Rotem; Levi, Inbar; Benor, Shira; Alcalay, Yifat; Freund, Natalia T.			Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inborn errors of immunity; IEI; primary immunodefi-ciency disorders; PIDD; SARS-CoV-2; COVID-19; vaccine; Pfizer-BioNTech; CVID; XLA; NFKB1; STAT1-GOF; STAT3-LOF; HIES; inhibiting antibodies	CELL RESPONSES; CORONAVIRUS	Background: In mid-December 2020, Israel started a nationwide mass vaccination campaign against coronavirus disease 2019 (COVID-19). In the first few weeks, medical personnel, elderly citizens, and patients with chronic diseases were prioritized. As such, patients with primary and secondary immunodeficiencies were encouraged to receive the vaccine. Although the efficacy of RNA-based COVID-19 vaccines has been demonstrated in the general population, little is known about their efficacy and safety in patients with inborn errors of immunity (IEI). Objective: Our aim was to evaluate the humoral and cellular immune response to COVID-19 vaccine in a cohort of patients with IEI. Methods: A total of 26 adult patients were enrolled, and plasma and peripheral blood mononuclear cells were collected from them 2 weeks following the second dose of Pfizer-BioNTech COVID-19 vaccine. Humoral response was evaluated by testing anti-SARS-CoV-2 spike (S) receptor-binding domain and antinucleocapsid antibody titers and evaluating neutralizing ability by inhibition of receptor-binding domain-angiotensin-converting enzyme 2 binding. Cellular immune response was evaluated by using ELISpot, estimating IL-2 and IFN-g secretion in response to pooled SARS-CoV-2 S-or M-peptides. Results: Our cohort included 18 patients with a predominantly antibody deficiency, 2 with combined immunodeficiency, 3 with immune dysregulation, and 3 with other genetically defined diagnoses. Twenty-two of them were receiving immunoglobulin replacement therapy. Of the 26 patients, 18 developed specific antibody response, and 19 showed S-peptide-specific T-cell response. None of the patients reported significant adverse events. Conclusion: Vaccinating patients with IEI is safe, and most patients were able to develop vaccine-specific antibody response, S-protein-specific cellular response, or both.	[Hagin, David; Freund, Tal; Adir, Dikla; Benor, Shira; Alcalay, Yifat] Tel Aviv Univ, Allergy & Clin Immunol Unit, Dept Med, Tel Aviv, Israel; [Halperin, Tami; Marom, Rotem; Levi, Inbar] Tel Aviv Univ, Lab HIV Diag AIDS Ctr, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; [Halperin, Tami; Marom, Rotem; Levi, Inbar] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Navon, Michal; Freund, Natalia T.] Tel Aviv Univ, Dept Clin Microbiol & Immunol, Sackler Fac Med, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Hagin, D (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.; Hagin, D (corresponding author), Tel Aviv Univ, Dept Med, Tel Aviv Sourasky Med Ctr, Allergy & Clin Immunol Unit, Israel 6 Weizmann St, IL-6423906 Tel Aviv, Israel.	Nfreund@tauex.tau.ac.il	Hagin, David/GRS-3442-2022		Israel Science Foundation [41222/18, 3711/20]; Dahlia Greidinger Cancer Fund; Marguerite Stolz Fellowship; Campbell Foundation for AIDS Research; Alrov Foundation	Israel Science Foundation(Israel Science Foundation); Dahlia Greidinger Cancer Fund; Marguerite Stolz Fellowship; Campbell Foundation for AIDS Research; Alrov Foundation	Supported by the Israel Science Foundation (grants 41222/18 and 3711/20 [to N.T.F.]), the Dahlia Greidinger Cancer Fund (to N.T.F.), a Marguerite Stolz Fellowship (N.T.F.), The Campbell Foundation for AIDS Research (to N.T.F.), and the Alrov Foundation (to D.H.).	Aksoy S, 2007, LEUKEMIA LYMPHOMA, V48, P1307, DOI 10.1080/10428190701411441; Bilich T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf7517; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; COVID-19 Treatment Guidelines Panel, COR DIS 2019 COVID 1; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Geers D, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1750; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gustafson CE, 2020, J ALLERGY CLIN IMMUN, V145, P1309, DOI 10.1016/j.jaci.2020.03.017; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Kaleviste E, 2019, EUR J IMMUNOL, V49, P790, DOI 10.1002/eji.201847955; Kaustio M, 2017, J ALLERGY CLIN IMMUN, V140, P782, DOI 10.1016/j.jaci.2016.10.054; Keehner J, 2021, NEW ENGL J MED, V384, P1774, DOI 10.1056/NEJMc2101927; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Liu YP, 2012, J CLIN IMMUNOL, V32, P421, DOI 10.1007/s10875-011-9639-y; Meyts I, 2021, J ALLERGY CLIN IMMUN, V147, P520, DOI 10.1016/j.jaci.2020.09.010; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Mor M, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009165; Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063; Okada S, 2020, J CLIN IMMUNOL, V40, P1065, DOI 10.1007/s10875-020-00847-x; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Post N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244126; Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Rogers Thomas F, 2020, bioRxiv, DOI 10.1101/2020.05.11.088674; Salazar E, 2020, J CLIN INVEST, V130, P6728, DOI 10.1172/JCI141206; Seidel MG, 2019, J ALLER CL IMM-PRACT, V7, P1763, DOI 10.1016/j.jaip.2019.02.004; Shields AM, 2021, J ALLERGY CLIN IMMUN, V147, P870, DOI 10.1016/j.jaci.2020.12.620; Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	36	101	104	4	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2021	148	3					739	749		10.1016/j.jaci.2021.05.029	http://dx.doi.org/10.1016/j.jaci.2021.05.029		SEP 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UP2VR	34087242	Green Published, Bronze			2022-12-18	WOS:000695242900022
J	Gill, MA; Liu, AH; Calatroni, A; Krouse, RZ; Shao, B; Schiltz, A; Gern, JE; Togias, A; Busse, WW				Gill, Michelle A.; Liu, Andrew H.; Calatroni, Agustin; Krouse, Rebecca Z.; Shao, Baomei; Schiltz, Allison; Gern, James E.; Togias, Alkis; Busse, William W.			Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Plasmacytoid dendritic cells; rhinovirus; IFN-alpha; asthma; IgE; omalizumab; Fc epsilon R alpha	INNATE IMMUNE-RESPONSES; EPSILON-F-RI; ASTHMA EXACERBATIONS; VIRAL-INFECTIONS; RECEPTOR; CHILDREN; IGE; RHINOVIRUS; EXPRESSION; ADMISSION	Background: Atopy and viral respiratory tract infections synergistically promote asthma exacerbations. IgE cross-linking inhibits critical virus-induced IFN-alpha responses of plasmacytoid dendritic cells (pDCs), which can be deficient in patients with allergic asthma. Objective: We sought to determine whether reducing IgE levels in vivo with omalizumab treatment increases pDC antiviral IFN-alpha responses in inner-city children with asthma. Methods: PBMCs and pDCs isolated from children with exacerbation-prone asthma before and during omalizumab treatment were stimulated ex vivo with rhinovirus and influenza in the presence or absence of IgE cross-linking. IFN-alpha levels were measured in supernatants, and mRNA expression of IFN-alpha pathway genes was determined by using quantitative RT-PCR (qRT-PCR) in cell pellets. Fc epsilon RI alpha protein levels and mRNA expression were measured in unstimulated cells by using flow cytometry and qRT-PCR, respectively. Changes in these outcomes and associations with clinical outcomes were analyzed, and statistical modeling was used to identify risk factors for asthma exacerbations. Results: Omalizumab treatment increased rhinovirus-and influenza-induced PBMC and rhinovirus-induced pDC IFN-alpha responses in the presence of IgE cross-linking and reduced pDC surface Fc epsilon RI alpha expression. Omalizumab-induced reductions in pDC Fc epsilon RI alpha levels were significantly associated with a lower asthma exacerbation rate during the outcome period and correlated with increases in PBMC IFN-alpha responses. PBMC Fc epsilon RI alpha mRNA expression measured on study entry significantly improved an existing model of exacerbation prediction. Conclusions: These findings indicate that omalizumab treatment augments pDC IFN-alpha responses and attenuates pDC FceRIa protein expression and provide evidence that these effects are related. These results support a potential mechanism underlying clinical observations that allergic sensitization is associated with increased susceptibility to virus-induced asthma exacerbations.	[Gill, Michelle A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Div Infect Dis & Immunol, Dallas, TX USA; [Gill, Michelle A.; Shao, Baomei] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Allergy & Immunol, Dallas, TX USA; [Liu, Andrew H.; Schiltz, Allison] Childrens Hosp Colorado, Aurora, CO USA; [Liu, Andrew H.; Schiltz, Allison] Univ Colorado, Sch Med, Dept Pediat, Div Pulm Med, Aurora, CO USA; [Calatroni, Agustin; Krouse, Rebecca Z.] Rho, Fed Syst Div, Chapel Hill, NC USA; [Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Gern, James E.; Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Div Allergy & Immunol, Dept Med, Madison, WI 53706 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Rho; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wisconsin System; University of Wisconsin Madison	Gill, MA (corresponding author), Univ Texas Southwestern Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Michelle.Gill@UTSouthwestern.edu		Gern, James/0000-0002-6667-4708; Busse, William/0000-0003-2591-4696	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [NIH NIAID 5R01AI098077, HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, UM2AI117870]; National Center for Research Resources, National Institutes of Health [NCATS/NIH UL1TR000150, NCRR/NCAT/NIH UL1TR000077-04, UL1TR000451, UL1TR001105, UL1TR000040, UM1AI109565, UL1TR000075, 1UL1RR025780, UL1TR000154, UL1TR001082]; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health [NCATS/NIH UL1TR000150, NCRR/NCAT/NIH UL1TR000077-04, UL1TR000451, UL1TR001105, UL1TR000040, UM1AI109565, UL1TR000075, 1UL1RR025780, UL1TR000154, UL1TR001082]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077, UL1TR001422, UL1TR000451, UL1TR000075, UL1TR000150, UL1TR000040, UL1TR001105, UL1TR001082, UL1TR000154] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI098077, UM2AI117870, UM1AI109565, UM1AI114271] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services; National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS), National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, under contract and grant numbers NIH NIAID 5R01AI098077, HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, and UM2AI117870. Additional support was provided by the National Center for Research Resources and National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, under grants NCATS/NIH UL1TR000150, NCRR/NCAT/NIH UL1TR000077-04, UL1TR000451, UL1TR001105, UL1TR000040, UM1AI109565, UL1TR000075, 1UL1RR025780, UL1TR000154, and UL1TR001082. The following were donated: omalizumab and matching placebo by Novartis and fluticasone and matching placebo by GlaxoSmithKline under a clinical trial agreement with the University of Wisconsin-Madison; EpiPens by Mylan; and Ayr nasal rinse by B.F. Ascher & Company.	Bajwa G, 2016, J IMMUNOL, V196, P2004, DOI 10.4049/jimmunol.1501557; Bao MS, 2012, J IMMUNOL, V189, P786, DOI 10.4049/jimmunol.1200887; Cao W, 2007, PLOS BIOL, V5, P2190, DOI 10.1371/journal.pbio.0050248; Cao W, 2006, J EXP MED, V203, P1399, DOI 10.1084/jem.20052454; Contoli M, 2015, ALLERGY, V70, P910, DOI 10.1111/all.12627; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hoch HE, 2017, J ALLERGY CLIN IMMUN; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Lynch JP, 2016, J ALLERGY CLIN IMMUN, V138, P1326, DOI 10.1016/j.jaci.2016.02.039; MacGlashan D, 2005, CLIN REV ALLERG IMMU, V29, P49, DOI 10.1385/CRIAI:29:1:049; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Ning S, 2011, GENES IMMUN, V12, P399, DOI 10.1038/gene.2011.21; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Pritchard AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106501; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Roponen M, 2010, EUR RESPIR J, V35, P64, DOI 10.1183/09031936.00172008; Saini SS, 1999, J IMMUNOL, V162, P5624; Schroeder JT, 2010, J ALLERGY CLIN IMMUN, V125, P896, DOI 10.1016/j.jaci.2009.10.021; Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942	32	101	105	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1735	+		10.1016/j.jaci.2017.07.035	http://dx.doi.org/10.1016/j.jaci.2017.07.035			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28870461	Green Accepted, Bronze			2022-12-18	WOS:000432148200020
J	Kiss, M; Czimmerer, Z; Nagy, L				Kiss, Mate; Czimmerer, Zsolt; Nagy, Laszlo			The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Macrophage; dendritic cell; lipid; nuclear receptor; retinoid X receptor; retinoic acid receptor; peroxisome proliferator-associated receptor; liver X receptor; vitamin D receptor; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; asthma	VITAMIN-D-RECEPTOR; RETINOID-X-RECEPTOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; COLLAGEN-INDUCED ARTHRITIS; INFLAMMATORY-BOWEL-DISEASE; GAMMA AGONIST ROSIGLITAZONE; REGULATORY T-CELLS; CULTURED ALVEOLAR MACROPHAGES; SYNOVIAL-FLUID MACROPHAGES; EARLY RHEUMATOID-ARTHRITIS	Nuclear receptors are ligand-activated transcription factors linking lipid signaling to the expression of the genome. There is increasing appreciation of the involvement of this receptor network in the metabolic programming of macrophages and dendritic cells (DCs), essential members of the innate immune system. In this review we focus on the role of retinoid X receptor, retinoic acid receptor, peroxisome proliferator-associated receptor g, liver X receptor, and vitamin D receptor in shaping the immune and metabolic functions of macrophages and DCs. We also provide an overview of the contribution of macrophage- and DC-expressed nuclear receptors to various immunopathologic conditions, such as rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, asthma, and some others. We suggest that systematic analyses of the roles of these receptors and their activating lipid ligands in immunopathologies combined with complementary and focused translational and clinical research will be crucial for the development of new therapies using the many molecules available to target nuclear receptors.	[Kiss, Mate; Czimmerer, Zsolt; Nagy, Laszlo] Univ Debrecen, Res Ctr Mol Med, Dept Biochem & Mol Biol, Med & Hlth Sci Ctr, H-4010 Debrecen, Hungary; [Nagy, Laszlo] Univ Debrecen, Med & Hlth Sci Ctr, MTA DE Lendulet Immunogen Res Grp, H-4010 Debrecen, Hungary	University of Debrecen; University of Debrecen	Nagy, L (corresponding author), Univ Debrecen, Res Ctr Mol Med, Dept Biochem & Mol Biol, Med & Hlth Sci Ctr, Life Sci Bldg,Egyet Ter 1, H-4010 Debrecen, Hungary.	nagyl@med.unideb.hu	Nagy, Laszlo/A-3814-2008; Kiss, Máté/HDL-8582-2022	Nagy, Laszlo/0000-0001-6653-2155; Kiss, Mate/0000-0002-5649-0382	National Excellence Program [TAMOP 4.2.4.A/2-11-1-2012-0001]; European Union; Hungarian Scientific Research Fund [OTKA K100196, TAMOP422_2012_0023]; European Social Fund; European Regional Development Fund	National Excellence Program; European Union(European Commission); Hungarian Scientific Research Fund(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); European Social Fund(European Social Fund (ESF)); European Regional Development Fund(European Commission)	M.K. is supported by the National Excellence Program (TAMOP 4.2.4.A/2-11-1-2012-0001) cofinanced by the European Union and Hungary. L.N. is supported by a grant from the Hungarian Scientific Research Fund (OTKA K100196) and TAMOP422_2012_0023, which is implemented through the New Hungary Development Plan cofinanced by the European Social Fund and the European Regional Development Fund.	A-Gonzalez N, 2011, BBA-MOL BASIS DIS, V1812, P982, DOI 10.1016/j.bbadis.2010.12.015; A-Gonzalez N, 2009, IMMUNITY, V31, P245, DOI 10.1016/j.immuni.2009.06.018; Abou-Raya A, 2013, J RHEUMATOL, V40, P265, DOI 10.3899/jrheum.111594; Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; ADAMS JS, 1985, J CLIN ENDOCR METAB, V60, P960, DOI 10.1210/jcem-60-5-960; Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Alamanos Y, 2006, SEMIN ARTHRITIS RHEU, V36, P182, DOI 10.1016/j.semarthrit.2006.08.006; Alkhouri RH, 2013, J PEDIATR GASTR NUTR, V56, P89, DOI 10.1097/MPG.0b013e31826a105d; Alleva DG, 2002, J LEUKOCYTE BIOL, V71, P677; Alyasin S, 2011, ALLERGY ASTHMA IMMUN, V3, P251, DOI 10.4168/aair.2011.3.4.251; Amital H, 2010, ANN RHEUM DIS, V69, P1155, DOI 10.1136/ard.2009.120329; Ananthakrishnan AN, 2012, GASTROENTEROLOGY, V142, P482, DOI 10.1053/j.gastro.2011.11.040; Aoki T, 2012, TRENDS PHARMACOL SCI, V33, P304, DOI 10.1016/j.tips.2012.02.004; Appel S, 2005, BLOOD, V106, P3888, DOI 10.1182/blood-2004-12-4709; Aprahamian T, 2009, J IMMUNOL, V182, P340, DOI 10.4049/jimmunol.182.1.340; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Arora P, 2002, PEDIATR ALLERGY IMMU, V13, P223, DOI 10.1034/j.1399-3038.2002.00010.x; Asquith DL, 2011, ANN RHEUM DIS, V70, P2225, DOI 10.1136/ard.2011.152652; Asquith DL, 2009, ARTHRITIS RHEUM-US, V60, P2655, DOI 10.1002/art.24717; Asquith DL, 2009, EUR J IMMUNOL, V39, P2040, DOI 10.1002/eji.200939578; Azuma YT, 2010, INT IMMUNOPHARMACOL, V10, P1261, DOI 10.1016/j.intimp.2010.07.007; Azzam KM, 2012, TRENDS ENDOCRIN MET, V23, P169, DOI 10.1016/j.tem.2012.02.001; Baeke F, 2010, CURR OPIN PHARMACOL, V10, P482, DOI 10.1016/j.coph.2010.04.001; Bai AP, 2009, J LEUKOCYTE BIOL, V86, P959, DOI 10.1189/jlb.0109006; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barish GD, 2005, MOL ENDOCRINOL, V19, P2466, DOI 10.1210/me.2004-0529; Barlic J, 2006, CIRCULATION, V114, P807, DOI 10.1161/CIRCULATIONAHA.105.602359; Bassaganya-Riera J, 2004, GASTROENTEROLOGY, V127, P777, DOI 10.1053/j.gastro.2004.06.049; Bassaganya-Riera J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031238; Bassaganya-Riera J, 2011, BRIT J NUTR, V106, P878, DOI 10.1017/S0007114511001188; BEDFORD PA, 1989, CLIN EXP IMMUNOL, V75, P481; Ben-Zvi I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009193; Bensinger SJ, 2008, NATURE, V454, P470, DOI 10.1038/nature07202; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Berer A, 2000, EXP HEMATOL, V28, P575, DOI 10.1016/S0301-472X(00)00143-0; BHALLA AK, 1986, CELL IMMUNOL, V98, P311, DOI 10.1016/0008-8749(86)90291-1; Blanck S, 2013, DIG DIS SCI; Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890; Bousvaros A, 1998, J PEDIATR GASTR NUTR, V26, P129, DOI 10.1097/00005176-199802000-00002; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Bruckner M, 2012, EUR J IMMUNOL, V42, P2949, DOI 10.1002/eji.201242523; Bush TS, 2003, BLOOD, V101, P311, DOI 10.1182/blood.V101.1.311; Calder PC, 2011, BRIT J NUTR, V106, pS1, DOI 10.1017/S0007114511005460; Cantorna MT, 2000, J NUTR, V130, P2648, DOI 10.1093/jn/130.11.2648; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Chan VSF, 2012, AUTOIMMUN REV, V11, P890, DOI 10.1016/j.autrev.2012.03.004; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Checkley W, 2011, EUR RESPIR J, V38, P1310, DOI 10.1183/09031936.00006911; Chen YM, 2005, BIOCHEM BIOPH RES CO, V332, P188, DOI 10.1016/j.bbrc.2005.04.110; Chen ZP, 1998, J MOL BIOL, V275, P55, DOI 10.1006/jmbi.1997.1413; Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; COHEN MS, 1986, J IMMUNOL, V136, P1049; Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116; Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421; Cools N, 2007, J LEUKOCYTE BIOL, V82, P1365, DOI 10.1189/jlb.0307166; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069; Costenbader KH, 2008, ANN RHEUM DIS, V67, P530, DOI 10.1136/ard.2007.072736; Costet P, 2003, MOL CELL BIOL, V23, P7756, DOI 10.1128/MCB.23.21.7756-7766.2003; Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697; CROWLE AJ, 1987, INFECT IMMUN, V55, P2945, DOI 10.1128/IAI.55.12.2945-2950.1987; Cutolo M, 2006, CLIN EXP RHEUMATOL, V24, P702; Cuzzocrea S, 2003, ARTHRITIS RHEUM-US, V48, P3544, DOI 10.1002/art.11351; Cuzzocrea S, 2004, LAB INVEST, V84, P1643, DOI 10.1038/labinvest.3700185; Czimmerer Z, 2012, IMMUNOBIOLOGY, V217, P1301, DOI 10.1016/j.imbio.2012.08.270; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Daniel C, 2008, J PHARMACOL EXP THER, V324, P23, DOI 10.1124/jpet.107.127209; Darmanin S, 2007, J IMMUNOL, V179, P4616, DOI 10.4049/jimmunol.179.7.4616; de Lema GP, 2004, KIDNEY INT, V66, P1018, DOI 10.1111/j.1523-1755.2004.00850.x; DE LUCA LM, 1991, FASEB J, V5, P2924; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Decker P, 2006, RHEUMATOLOGY, V45, P1087, DOI 10.1093/rheumatology/kel061; DeLuca HF, 2004, AM J CLIN NUTR, V80, p1689S, DOI 10.1093/ajcn/80.6.1689S; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Ding DC, 2006, J IMMUNOL, V177, P5878, DOI 10.4049/jimmunol.177.9.5878; DRACH J, 1994, CANCER RES, V54, P1746; Evans NP, 2010, J NUTR, V140, P515, DOI 10.3945/jn.109.115642; Farkas L, 2001, AM J PATHOL, V159, P237, DOI 10.1016/S0002-9440(10)61689-6; Fernandes I, 2003, J MOL ENDOCRINOL, V31, P1, DOI 10.1677/jme.0.0310001; Fontaine C, 2007, CIRC RES, V101, P40, DOI 10.1161/CIRCRESAHA.106.135814; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fritsche J, 2003, BLOOD, V102, P3314, DOI 10.1182/blood-2002-11-3521; Froicu M, 2003, MOL ENDOCRINOL, V17, P2386, DOI 10.1210/me.2003-0281; Froicu M, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-5; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Gauzzi MC, 2005, J IMMUNOL, V174, P270, DOI 10.4049/jimmunol.174.1.270; Geissmann F, 2003, J EXP MED, V198, P623, DOI 10.1084/jem.20030390; Gerl V, 2010, ANN RHEUM DIS, V69, P1370, DOI 10.1136/ard.2009.111021; Germain P, 2006, PHARMACOL REV, V58, P760, DOI 10.1124/pr.58.4.7; Gery S, 2007, EXP HEMATOL, V35, P572, DOI 10.1016/j.exphem.2007.01.049; Geyeregger R, 2007, BLOOD, V109, P4288, DOI 10.1182/blood-2006-08-043422; Ghisletti S, 2007, MOL CELL, V25, P57, DOI 10.1016/j.molcel.2006.11.022; Gill MA, 2012, J ALLERGY CLIN IMMUN, V129, P889, DOI 10.1016/j.jaci.2012.02.028; Glass CK, 2010, NAT REV IMMUNOL, V10, P365, DOI 10.1038/nri2748; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; Gopinath K, 2011, INT J RHEUM DIS, V14, P332, DOI 10.1111/j.1756-185X.2011.01684.x; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Gottfried E, 2006, BIOCHEM BIOPH RES CO, V349, P209, DOI 10.1016/j.bbrc.2006.08.034; Grenningloh R, 2006, J IMMUNOL, V176, P5161, DOI 10.4049/jimmunol.176.9.5161; Griffin MD, 2001, P NATL ACAD SCI USA, V98, P6800, DOI 10.1073/pnas.121172198; Griffin MD, 2000, BIOCHEM BIOPH RES CO, V270, P701, DOI 10.1006/bbrc.2000.2490; Guri AJ, 2011, J NUTR BIOCHEM, V22, P812, DOI 10.1016/j.jnutbio.2010.06.011; Haga HJ, 2013, CLIN RHEUMATOL, V32, P629, DOI 10.1007/s10067-012-2154-6; Hall JA, 2011, IMMUNITY, V35, P13, DOI 10.1016/j.immuni.2011.07.002; Hammad H, 2004, AM J PATHOL, V164, P263, DOI 10.1016/S0002-9440(10)63116-1; Hammond KJL, 2003, CURR OPIN IMMUNOL, V15, P683, DOI 10.1016/j.coi.2003.09.014; Han KH, 2000, J CLIN INVEST, V106, P793, DOI 10.1172/JCI10052; Hanley TM, 2011, J VIROL, V85, P10834, DOI 10.1128/JVI.00789-11; Hanley TM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000981; Hashimoto D, 2011, IMMUNITY, V35, P323, DOI 10.1016/j.immuni.2011.09.007; HAYES ME, 1992, ANN RHEUM DIS, V51, P632, DOI 10.1136/ard.51.5.632; HAYES ME, 1989, ANN RHEUM DIS, V48, P723, DOI 10.1136/ard.48.9.723; Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood-2005-03-1029; Heneka MT, 2007, NAT CLIN PRACT NEURO, V3, P496, DOI 10.1038/ncpneuro0586; Hevener AL, 2007, J CLIN INVEST, V117, P1658, DOI 10.1172/JCI31561; Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hilkens CMU, 2013, CLIN EXP IMMUNOL, V172, P148, DOI 10.1111/cei.12038; Hollams EM, 2011, EUR RESPIR J, V38, P1320, DOI 10.1183/09031936.00029011; Honda K, 2004, J ALLERGY CLIN IMMUN, V113, P882, DOI 10.1016/j.jaci.2004.02.036; Hong C, 2012, J CLIN INVEST, V122, P337, DOI 10.1172/JCI58393; Hontecillas R, 2011, MUCOSAL IMMUNOL, V4, P304, DOI 10.1038/mi.2010.75; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hounoki H, 2008, BONE, V42, P765, DOI 10.1016/j.bone.2007.11.016; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; IJpenberg A, 2004, EMBO J, V23, P2083, DOI 10.1038/sj.emboj.7600209; Iliev ID, 2009, MUCOSAL IMMUNOL, V2, P340, DOI 10.1038/mi.2009.13; JACOBY RK, 1973, BRIT MED J, V2, P96, DOI 10.1136/bmj.2.5858.96; Jakobsson T, 2012, TRENDS PHARMACOL SCI, V33, P394, DOI 10.1016/j.tips.2012.03.013; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jennewein C, 2008, J IMMUNOL, V181, P5646, DOI 10.4049/jimmunol.181.8.5646; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jorgensen SP, 2010, ALIMENT PHARM THER, V32, P377, DOI 10.1111/j.1365-2036.2010.04355.x; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Juarez-Rojas JG, 2012, LUPUS, V21, P27, DOI 10.1177/0961203311422096; Kamada N, 2008, J CLIN INVEST, V118, P2269, DOI [10.1172/JCI34610, 10.1172/JC134610]; Kamada N, 2009, J IMMUNOL, V183, P1724, DOI 10.4049/jimmunol.0804369; Kamen Diane L, 2008, Curr Rheumatol Rep, V10, P273, DOI 10.1007/s11926-008-0044-3; Kaufmann SHE, 2008, NAT IMMUNOL, V9, P705, DOI 10.1038/ni0708-705; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; Khalili H, 2012, GUT, V61, P1686, DOI 10.1136/gutjnl-2011-301574; Khan S, 2009, NAT REV RHEUMATOL, V5, P566, DOI 10.1038/nrrheum.2009.185; Kinne RW, 2000, ARTHRITIS RES, V2, P189, DOI 10.1186/ar86; Kinoshita K, 2003, J IMMUNOL, V170, P5793, DOI 10.4049/jimmunol.170.11.5793; Klotz L, 2007, J IMMUNOL, V178, P2122, DOI 10.4049/jimmunol.178.4.2122; Klotz L, 2009, J IMMUNOL, V183, P129, DOI 10.4049/jimmunol.0804260; Kobayashi M, 2005, ANN ALLERG ASTHMA IM, V95, P468, DOI 10.1016/S1081-1206(10)61173-8; KOEFFLER HP, 1984, CANCER RES, V44, P5624; KOREN R, 1986, FEBS LETT, V205, P113, DOI 10.1016/0014-5793(86)80876-6; Korn S, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-25; Koufany M, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2354; KREUTZ M, 1993, BLOOD, V82, P1300, DOI 10.1182/blood.V82.4.1300.1300; Kull I, 2006, J ALLERGY CLIN IMMUN, V118, P1299, DOI 10.1016/j.jaci.2006.08.022; Kwok SK, 2012, J IMMUNOL, V189, P1062, DOI 10.4049/jimmunol.1102706; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Larsson P, 1998, CLIN EXP IMMUNOL, V114, P277; Lee JW, 2007, GASTROENTEROLOGY, V133, P108, DOI 10.1053/j.gastro.2007.03.113; Lee KS, 2005, FASEB J, V19, P1033, DOI 10.1096/fj.04-3309fje; Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P120, DOI 10.1016/j.jaci.2006.03.021; Lee KS, 2006, J IMMUNOL, V177, P5248, DOI 10.4049/jimmunol.177.8.5248; Lee YH, 2007, OSTEOPOROSIS INT, V19, P3643; Legutko A, 2011, J IMMUNOL, V187, P4517, DOI 10.4049/jimmunol.1101493; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lemotte PK, 1996, EUR J BIOCHEM, V236, P328, DOI 10.1111/j.1432-1033.1996.00328.x; Lerman MA, 2011, LUPUS, V20, P749, DOI 10.1177/0961203310394542; Leslie DS, 2008, IMMUNOLOGY, V125, P289, DOI 10.1111/j.1365-2567.2008.02842.x; Leung BP, 2002, J IMMUNOL, V169, P7071, DOI 10.4049/jimmunol.169.12.7071; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Lewis JD, 2008, GASTROENTEROLOGY, V134, P688, DOI 10.1053/j.gastro.2007.12.012; Lewis JD, 2001, AM J GASTROENTEROL, V96, P3323; Lewis SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024031; Li H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028133; Li Y, 2010, ARCH IMMUNOL THER EX, V58, P355, DOI 10.1007/s00005-010-0093-y; Liang HL, 2008, WORLD J GASTROENTERO, V14, P114, DOI 10.3748/wjg.14.114; Litonjua AA, 2012, CURR OPIN ALLERGY CL, V12, P179, DOI 10.1097/ACI.0b013e3283507927; Liu J, 2011, AM J PHYSIOL-LUNG C, V300, pL710, DOI 10.1152/ajplung.00337.2010; Liu PT, 2007, J IMMUNOL, V179, P2060, DOI 10.4049/jimmunol.179.4.2060; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Ma L, 2005, EUR J IMMUNOL, V35, P3364, DOI 10.1002/eji.200535192; Mandrekar-Colucci S, 2011, EXPERT OPIN THER TAR, V15, P1085, DOI 10.1517/14728222.2011.594043; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Manicassamy S, 2009, NAT MED, V15, P401, DOI 10.1038/nm.1925; Manson JE, 2012, CONTEMP CLIN TRIALS, V33, P159, DOI 10.1016/j.cct.2011.09.009; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marathe C, 2009, J LIPID RES, V50, P214, DOI 10.1194/jlr.M800189-JLR200; Marcy TR, 2004, ANN PHARMACOTHER, V38, P1419, DOI 10.1345/aph.1E072; Maret M, 2007, J NUTR, V137, P2730, DOI 10.1093/jn/137.12.2730; Matikainen S, 1996, BLOOD, V88, P114; Mbalaviele G, 2000, J BIOL CHEM, V275, P14388, DOI 10.1074/jbc.275.19.14388; McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MEHTA K, 1994, J LEUKOCYTE BIOL, V55, P336, DOI 10.1002/jlb.55.3.336; Merlino LA, 2004, ARTHRITIS RHEUM-US, V50, P72, DOI 10.1002/art.11434; Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5; Miheller P, 2009, INFLAMM BOWEL DIS, V15, P1656, DOI 10.1002/ibd.20947; Miranda-Carus ME, 2006, ARTHRITIS RHEUM-US, V54, P1151, DOI 10.1002/art.21731; Mizuno Y, 2006, PEDIATR INT, V48, P261, DOI 10.1111/j.1442-200X.2006.02200.x; Moghaddami M, 2012, IMMUNOL CELL BIOL, V90, P168, DOI 10.1038/icb.2011.22; Mok CC, 2012, LUPUS, V21, P36, DOI 10.1177/0961203311422094; Montemurro P, 1999, BRIT J HAEMATOL, V107, P294, DOI 10.1046/j.1365-2141.1999.01698.x; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mouterde G, 2011, ANN RHEUM DIS, V70, P1251, DOI 10.1136/ard.2010.144402; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Mueller C, 2003, ARCH BIOCHEM BIOPHYS, V418, P186, DOI 10.1016/j.abb.2003.08.006; Mulherin D, 1996, ARTHRITIS RHEUM, V39, P115, DOI 10.1002/art.1780390116; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nagy L, 2012, PHYSIOL REV, V92, P739, DOI 10.1152/physrev.00004.2011; NAKAJIMA H, 1994, BLOOD, V84, P4107, DOI 10.1182/blood.V84.12.4107.bloodjournal84124107; Nakken B, 2011, J IMMUNOL, V187, P240, DOI 10.4049/jimmunol.1002421; Narala VR, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-90; Nencioni A, 2002, J IMMUNOL, V169, P1228, DOI 10.4049/jimmunol.169.3.1228; Nesto RW, 2003, CIRCULATION, V108, P2941, DOI 10.1161/01.CIR.0000103683.99399.7E; Norbury CC, 2006, IMMUNOLOGY, V117, P443, DOI 10.1111/j.1365-2567.2006.02335.x; NORRBY S, 1985, ACTA CHIR SCAND, V151, P465; Nozaki Y, 2005, CLIN EXP IMMUNOL, V139, P74, DOI 10.1111/j.1365-2249.2005.02654.x; Nozaki Y, 2006, CLIN IMMUNOL, V119, P272, DOI 10.1016/j.clim.2005.11.012; Nunez V, 2010, P NATL ACAD SCI USA, V107, P10626, DOI 10.1073/pnas.0913545107; Nurmatov U, 2011, J ALLERGY CLIN IMMUN, V127, P724, DOI 10.1016/j.jaci.2010.11.001; O'Kelly J, 2002, J CLIN INVEST, V109, P1091, DOI 10.1172/JCI200212392; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Oelzner P, 1998, CALCIFIED TISSUE INT, V62, P193, DOI 10.1007/s002239900416; OHTA M, 1985, FEBS LETT, V185, P9, DOI 10.1016/0014-5793(85)80730-4; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Overbergh L, 2000, CLIN EXP IMMUNOL, V120, P139, DOI 10.1046/j.1365-2249.2000.01204.x; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Oxer DS, 2011, LUPUS, V20, P575, DOI 10.1177/0961203310392419; Pai T, 2007, BIOCHEMISTRY-US, V46, P15198, DOI 10.1021/bi701891t; Palma CA, 2012, J CELL MOL MED, V16, P978, DOI 10.1111/j.1582-4934.2011.01514.x; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Park MC, 2010, RHEUMATOLOGY, V49, P882, DOI 10.1093/rheumatology/keq007; Park SJ, 2009, J IMMUNOL, V183, P3259, DOI 10.4049/jimmunol.0900231; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Pedersen AE, 2009, IMMUNOLOGY, V127, P354, DOI 10.1111/j.1365-2567.2008.02996.x; Pedersen G, 2010, AM J GASTROENTEROL, V105, P1595, DOI 10.1038/ajg.2009.749; Penna G, 2005, BLOOD, V106, P3490, DOI 10.1182/blood-2005-05-2044; Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405; Penna G, 2007, J IMMUNOL, V178, P145, DOI 10.4049/jimmunol.178.1.145; Pennell LM, 2012, J AUTOIMMUN, V38, pJ282, DOI 10.1016/j.jaut.2011.11.013; Piemonti L, 2000, J IMMUNOL, V164, P4443, DOI 10.4049/jimmunol.164.9.4443; Poliska S, 2012, INFLAMM BOWEL DIS, V18, P472, DOI 10.1002/ibd.21798; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Racovan M, 2012, RHEUMATOL INT, V32, P3823, DOI 10.1007/s00296-011-2268-1; Ralph AP, 2008, TRENDS MICROBIOL, V16, P336, DOI 10.1016/j.tim.2008.04.003; Ramakers JD, 2007, J CLIN IMMUNOL, V27, P275, DOI 10.1007/s10875-007-9074-2; Rask-Andersen M, 2011, NAT REV DRUG DISCOV, V10, P579, DOI 10.1038/nrd3478; Rebe C, 2009, CIRC RES, V105, P393, DOI 10.1161/CIRCRESAHA.109.201855; REICHEL H, 1987, J CLIN ENDOCR METAB, V64, P1, DOI 10.1210/jcem-64-1-1; REICHEL H, 1987, J CLIN ENDOCR METAB, V65, P1201, DOI 10.1210/jcem-65-6-1201; Reifen R, 2002, J NUTR, V132, P2743, DOI 10.1093/jn/132.9.2743; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Rhinn M, 2012, DEVELOPMENT, V139, P843, DOI 10.1242/dev.065938; Richards DB, 2010, RESP MED, V104, P668, DOI 10.1016/j.rmed.2009.11.006; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; RIGBY WFC, 1990, BLOOD, V76, P189, DOI 10.1182/blood.V76.1.189.bloodjournal761189; ROOK GAW, 1986, IMMUNOLOGY, V57, P159; Rossini M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3195; Roszer T, 2011, J IMMUNOL, V186, P621, DOI 10.4049/jimmunol.1002230; Rousseaux C, 2005, J EXP MED, V201, P1205, DOI 10.1084/jem.20041948; Rovin BH, 2005, KIDNEY INT, V68, P1825, DOI 10.1111/j.1523-1755.2005.00601.x; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sada KE, 2006, J RHEUMATOL, V33, P1545; Sadeghi K, 2006, EUR J IMMUNOL, V36, P361, DOI 10.1002/eji.200425995; Salesi M, 2012, RHEUMATOL INT, V32, P2129, DOI 10.1007/s00296-011-1944-5; Sanchez-Hidalgo M, 2005, BIOCHEM PHARMACOL, V69, P1733, DOI 10.1016/j.bcp.2005.03.024; Sanchez-Martinez R, 2008, MOL CELL BIOL, V28, P3817, DOI 10.1128/MCB.01909-07; Saurer L, 2007, J IMMUNOL, V179, P3504, DOI 10.4049/jimmunol.179.6.3504; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Savina A, 2007, IMMUNOL REV, V219, P143, DOI 10.1111/j.1600-065X.2007.00552.x; Schenk M, 2007, J CLIN INVEST, V117, P3097, DOI 10.1172/JCI30602; Schiefner A, 2009, CURR PHARM DESIGN, V15, P3311, DOI 10.2174/138161209789105108; SCHOELMERICH J, 1985, HEPATO-GASTROENTEROL, V32, P34; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schuster GU, 2008, J IMMUNOL, V180, P1834, DOI 10.4049/jimmunol.180.3.1834; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Shah YM, 2007, AM J PHYSIOL-GASTR L, V292, pG657, DOI 10.1152/ajpgi.00381.2006; Shahin D, 2011, CLIN MED INSIGHTS-AR, V4, P1, DOI 10.4137/CMAMD.S5951; Shiojiri T, 2002, EUR J PHARMACOL, V448, P231, DOI 10.1016/S0014-2999(02)01946-5; Shivananda S, 1996, GUT, V39, P690, DOI 10.1136/gut.39.5.690; Smith S, 1999, NEW ZEAL MED J, V112, P58; Song GG, 2012, CLIN RHEUMATOL, V31, P1733, DOI 10.1007/s10067-012-2080-7; Spears M, 2009, CLIN PHARMACOL THER, V86, P49, DOI 10.1038/clpt.2009.41; Spittler A, 1997, IMMUNOLOGY, V90, P286, DOI 10.1046/j.1365-2567.1997.00148.x; Stables MJ, 2011, PROG LIPID RES, V50, P35, DOI 10.1016/j.plipres.2010.07.005; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Stoop JN, 2010, ARTHRITIS RHEUM-US, V62, P3656, DOI 10.1002/art.27756; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Szanto A, 2004, MOL CELL BIOL, V24, P8154, DOI 10.1128/MCB.24.18.8154-8166.2004; Szanto A, 2010, IMMUNITY, V33, P699, DOI 10.1016/j.immuni.2010.11.009; Szatmari I, 2004, IMMUNITY, V21, P95, DOI 10.1016/j.immuni.2004.06.003; Szatmari I, 2006, ANN NY ACAD SCI, V1088, P207, DOI 10.1196/annals.1366.013; Szatmari I, 2007, BLOOD, V110, P3271, DOI 10.1182/blood-2007-06-096222; Szatmari I, 2006, J BIOL CHEM, V281, P23812, DOI 10.1074/jbc.M604890200; Szatmari I, 2006, J EXP MED, V203, P2351, DOI 10.1084/jem.20060141; Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae; Szeles L, 2010, MOL ENDOCRINOL, V24, P2218, DOI 10.1210/me.2010-0215; Takeda N, 2006, ARTERIOSCL THROM VAS, V26, P1177, DOI 10.1161/01.ATV.0000214296.94849.1c; Takeuchi A, 1998, J IMMUNOL, V160, P209; Tanaka T, 2001, CANCER RES, V61, P2424; Terrier B, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4060; Tetlow LC, 1999, ANN RHEUM DIS, V58, P118, DOI 10.1136/ard.58.2.118; Thomson AW, 2008, ANN RHEUM DIS, V67, P90, DOI 10.1136/ard.2008.099176; Tomita T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1856; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Torocsik D, 2010, J IMMUNOL, V184, P5456, DOI 10.4049/jimmunol.0902399; Trifilieff A, 2003, BRIT J PHARMACOL, V139, P163, DOI 10.1038/sj.bjp.0705232; TSUJI M, 1994, FEBS LETT, V337, P248, DOI 10.1016/0014-5793(94)80201-7; Tucci M, 2008, ARTHRITIS RHEUM-US, V58, P251, DOI 10.1002/art.23186; Ulitsky A, 2011, JPEN-PARENTER ENTER, V35, P308, DOI 10.1177/0148607110381267; Underwood BA, 1996, FASEB J, V10, P1040, DOI 10.1096/fasebj.10.9.8801165; Vagianos K, 2007, JPEN-PARENTER ENTER, V31, P311, DOI 10.1177/0148607107031004311; Valledor AF, 2004, P NATL ACAD SCI USA, V101, P17813, DOI 10.1073/pnas.0407749101; Varol C, 2010, NAT REV IMMUNOL, V10, P415, DOI 10.1038/nri2778; Venegas-Pont M, 2009, AM J PHYSIOL-REG I, V296, pR1282, DOI 10.1152/ajpregu.90992.2008; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Villablanca EJ, 2008, J LEUKOCYTE BIOL, V84, P871, DOI 10.1189/jlb.0108047; Villablanca EJ, 2010, NAT MED, V16, P98, DOI 10.1038/nm.2074; Vivat-Hannah V, 2003, MOL CELL BIOL, V23, P7678, DOI 10.1128/MCB.23.21.7678-7688.2003; Wada Y, 2009, INFLAMM BOWEL DIS, V15, P1548, DOI 10.1002/ibd.20934; Waku T, 2010, EMBO J, V29, P3395, DOI 10.1038/emboj.2010.197; Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Wang XC, 2007, J CLIN IMMUNOL, V27, P193, DOI 10.1007/s10875-006-9068-5; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Welch JS, 2003, P NATL ACAD SCI USA, V100, P6712, DOI 10.1073/pnas.1031789100; Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6; Wittke A, 2004, J IMMUNOL, V173, P3432, DOI 10.4049/jimmunol.173.5.3432; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; WRIGHT JP, 1985, GASTROENTEROLOGY, V88, P512, DOI 10.1016/0016-5085(85)90514-1; XU H, 1993, SCAND J IMMUNOL, V38, P535, DOI 10.1111/j.1365-3083.1993.tb03237.x; Yamamoto K, 2008, BIOCHEM BIOPH RES CO, V367, P566, DOI 10.1016/j.bbrc.2007.12.188; Yang M, 2012, J LEUKOCYTE BIOL, V91, P557, DOI 10.1189/jlb.0711357; Yu SH, 2011, J IMMUNOL, V187, P4907, DOI 10.4049/jimmunol.1101519; Yu SH, 2008, P NATL ACAD SCI USA, V105, P20834, DOI 10.1073/pnas.0808700106; Zapata-Gonzalez F, 2007, J IMMUNOL, V178, P6130, DOI 10.4049/jimmunol.178.10.6130; Zhao S, 2012, BIOCHEM CELL BIOL, V90, P142, DOI [10.1139/O11-079, 10.1139/o11-079]; Zhao WP, 2009, J IMMUNOL, V183, P2729, DOI 10.4049/jimmunol.0804341; Zhu Y, 2005, EUR J IMMUNOL, V35, P217, DOI 10.1002/eji.200425491; Zwerina K, 2011, ANN RHEUM DIS, V70, P1122, DOI 10.1136/ard.2010.142331	364	101	107	0	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					264	286		10.1016/j.jaci.2013.05.044	http://dx.doi.org/10.1016/j.jaci.2013.05.044			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23905916	Green Published			2022-12-18	WOS:000322631700003
J	Kato, A; Hulse, KE; Tan, BK; Schleimer, RP				Kato, Atsushi; Hulse, Kathryn E.; Tan, Bruce K.; Schleimer, Robert P.			B-lymphocyte lineage cells and the respiratory system	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cells; plasma cells; plasmablasts; respiratory diseases	SECRETORY IMMUNOGLOBULIN-A; CLASS SWITCH RECOMBINATION; GERMINAL CENTER FORMATION; AIRWAY EPITHELIAL-CELLS; ALPHA-DEFICIENT MICE; TOLL-LIKE RECEPTORS; TISSUE BALT; PLASMA-CELLS; LOCAL PRODUCTION; CHRONIC RHINOSINUSITIS	Adaptive humoral immune responses in the airways are mediated by B cells and plasma cells that express highly evolved and specific receptors and produce immunoglobulins of most isotypes. In some cases, such as autoimmune diseases or inflammatory diseases caused by excessive exposure to foreign antigens, these same immune cells can cause disease by virtue of overly vigorous responses. This review discusses the generation, differentiation, signaling, activation, and recruitment pathways of B cells and plasma cells, with special emphasis on unique characteristics of subsets of these cells functioning within the respiratory system. The primary sensitization events that generate B cells responsible for effector responses throughout the airways usually occur in the upper airways, tonsils, and adenoid structures that make up the Waldeyer ring. On secondary exposure to antigen in the airways, antigen-processing dendritic cells migrate into secondary lymphoid organs, such as lymph nodes, that drain the upper and lower airways, and further B-cell expansion takes place at those sites. Antigen exposure in the upper or lower airways can also drive expansion of B-lineage cells in the airway mucosal tissue and lead to the formation of inducible lymphoid follicles or aggregates that can mediate local immunity or disease. (J Allergy Clin Immunol 2013; 131: 933-57.)	[Kato, Atsushi; Hulse, Kathryn E.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [Tan, Bruce K.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Rm M-318,240 E Huron, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu		Kato, Atsushi/0000-0001-9144-3138; Hulse, Kathryn/0000-0003-0969-999X; Bayer, Diana/0000-0001-7181-7446	National Institutes of Health [K23DC012067, R01 HL078860, R01 AI072570, R37 HL068546]; Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068546, R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI106683, R01AI072570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported in part by National Institutes of Health grants K23DC012067, R01 HL078860, R01 AI072570, and R37 HL068546 and by a grant from the Ernest S. Bazley Trust.	Alinari L, 2012, ONCOTARGET, V3, P203; Allen CDC, 2007, IMMUNITY, V27, P190, DOI 10.1016/j.immuni.2007.07.009; Aloisi F, 2006, NAT REV IMMUNOL, V6, P205, DOI 10.1038/nri1786; Amoroso A, 2011, FRONT BIOSCI-LANDMRK, V16, P770, DOI 10.2741/3719; Ansel KM, 2002, IMMUNITY, V16, P67, DOI 10.1016/S1074-7613(01)00257-6; Araiza MT, 2007, J CLIN LAB ANAL, V21, P315, DOI 10.1002/jcla.20188; Avery DT, 2008, BLOOD, V112, P1784, DOI 10.1182/blood-2008-02-142745; Avery DT, 2008, J IMMUNOL, V181, P1767, DOI 10.4049/jimmunol.181.3.1767; Baccala R, 2007, NAT MED, V13, P543, DOI 10.1038/nm1590; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Barnett BE, 2012, SCIENCE, V335, P342, DOI 10.1126/science.1213495; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; BELLANTI J, 1969, NEW ENGL J MED, V280, P628, DOI 10.1056/NEJM196903202801202; Beltman JB, 2011, P NATL ACAD SCI USA, V108, P8755, DOI 10.1073/pnas.1101554108; Bergtold A, 2005, IMMUNITY, V23, P503, DOI 10.1016/j.immuni.2005.09.013; Berland R, 2002, ANNU REV IMMUNOL, V20, P253, DOI 10.1146/annurev.immunol.20.100301.064833; Berra A, 2002, CLIN IMMUNOL, V104, P49, DOI 10.1006/clim.2002.5228; Bienenstock J, 2005, IMMUNOL REV, V206, P22, DOI 10.1111/j.0105-2896.2005.00299.x; Bilsborough J, 2008, CLIN EXP ALLERGY, V38, P1959, DOI 10.1111/j.1365-2222.2008.03099.x; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; Borchers AT, 2011, CLIN REV ALLERG IMMU, V40, P117, DOI 10.1007/s12016-010-8211-5; BOSKEN CH, 1992, AM REV RESPIR DIS, V145, P911, DOI 10.1164/ajrccm/145.4_Pt_1.911; Brandtzaeg P, 2008, MUCOSAL IMMUNOL, V1, P31, DOI 10.1038/mi.2007.9; Brandtzaeg P, 1999, IMMUNOL REV, V171, P45, DOI 10.1111/j.1600-065X.1999.tb01342.x; Brandtzaeg P, 2009, SCAND J IMMUNOL, V70, P505, DOI 10.1111/j.1365-3083.2009.02319.x; Brandtzaeg P, 2011, AM J RESP CRIT CARE, V183, P1595, DOI 10.1164/rccm.201011-1783OC; Buch MH, 2011, CURR OPIN RHEUMATOL, V23, P245, DOI 10.1097/BOR.0b013e3283454124; Buckley Rebecca H, 2004, Paediatr Respir Rev, V5 Suppl A, pS225, DOI 10.1016/S1526-0542(04)90043-7; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; CAMPBELL DA, 1985, THORAX, V40, P405, DOI 10.1136/thx.40.6.405; Cancro MP, 2009, NAT REV IMMUNOL, V9, P657, DOI 10.1038/nri2621; Carragher DM, 2008, SEMIN IMMUNOL, V20, P26, DOI 10.1016/j.smim.2007.12.004; Carson KR, 2009, BLOOD, V113, P4834, DOI 10.1182/blood-2008-10-186999; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Cerutti A, 2011, ANNU REV IMMUNOL, V29, P273, DOI 10.1146/annurev-immunol-031210-101317; Chalermskulrat W, 2006, THORAX, V61, P61; Chan TD, 2010, IMMUNOL REV, V237, P90, DOI 10.1111/j.1600-065X.2010.00942.x; Chan TD, 2009, J IMMUNOL, V183, P3139, DOI 10.4049/jimmunol.0901690; Chatzigeorgiou A, 2009, BIOFACTORS, V35, P474, DOI 10.1002/biof.62; Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Chiron D, 2008, BLOOD, V112, P2205, DOI 10.1182/blood-2008-02-140673; Choi YS, 2008, J EXP MED, V205, P3053, DOI 10.1084/jem.20080979; Churg A, 2002, AM J RESP CELL MOL, V27, P368, DOI 10.1165/rcmb.4791; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corthesy B, 2010, FUTURE MICROBIOL, V5, P817, DOI 10.2217/FMB.10.39; Crago S S, 1978, Adv Exp Med Biol, V107, P209; Crestani B, 2005, ALLERGY, V60, P715, DOI 10.1111/j.1398-9995.2005.00761.x; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Cunningham-Rundles C, 2008, J CLIN IMMUNOL, V28, pS42, DOI 10.1007/s10875-008-9182-7; Cunningham-Rundles C, 2005, NAT REV IMMUNOL, V5, P880, DOI 10.1038/nri1713; Cunningham-Rundles C, 2009, CLIN EXP IMMUNOL, V157, P12, DOI 10.1111/j.1365-2249.2009.03952.x; Cupedo T, 2009, NAT IMMUNOL, V10, P66, DOI 10.1038/ni.1668; Cyster JG, 2010, NAT IMMUNOL, V11, P989, DOI 10.1038/ni.1946; Cyster JG, 2003, IMMUNOL REV, V194, P48, DOI 10.1034/j.1600-065X.2003.00041.x; CZERKINSKY C, 1987, P NATL ACAD SCI USA, V84, P2449, DOI 10.1073/pnas.84.8.2449; Debertin AS, 2003, CLIN EXP IMMUNOL, V134, P503, DOI 10.1111/j.1365-2249.2003.02311.x; DELVENTHAL S, 1992, VIRCHOWS ARCH B, V62, P271, DOI 10.1007/BF02899692; DEUSCHL H, 1977, CLIN ALLERGY, V7, P195, DOI 10.1111/j.1365-2222.1977.tb01442.x; Dorner T, 2010, PHARMACOL THERAPEUT, V125, P464, DOI 10.1016/j.pharmthera.2010.01.001; Dorner T, 2009, NAT REV RHEUMATOL, V5, P433, DOI 10.1038/nrrheum.2009.141; Donvik KK, 2011, RHEUMATOL INT, V31, P89, DOI 10.1007/s00296-009-1146-6; Dorner M, 2009, IMMUNOLOGY, V128, P573, DOI 10.1111/j.1365-2567.2009.03143.x; DRENT M, 1993, CHEST, V103, P1720, DOI 10.1378/chest.103.6.1720; Drolet JP, 2010, CLIN EXP ALLERGY, V40, P841, DOI 10.1111/j.1365-2222.2010.03512.x; Eibel H, 2010, CURR OPIN ALLERGY CL, V10, P526, DOI 10.1097/ACI.0b013e32833fea1c; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Fairfax KA, 2008, SEMIN IMMUNOL, V20, P49, DOI 10.1016/j.smim.2007.12.002; Fawaz LM, 2007, J ALLERGY CLIN IMMUN, V120, P1208, DOI 10.1016/j.jaci.2007.08.022; Feghali-Bostwick CA, 2008, AM J RESP CRIT CARE, V177, P156, DOI 10.1164/rccm.200701-014OC; Fizazi K, 2012, EUR J CANCER, V48, P85, DOI 10.1016/j.ejca.2011.10.014; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Gao HW, 2006, ANNU REV PATHOL-MECH, V1, P215, DOI 10.1146/annurev.pathol.1.110304.100155; Gatto D, 2011, J IMMUNOL, V187, P4621, DOI 10.4049/jimmunol.1101542; Gatto D, 2010, J ALLERGY CLIN IMMUN, V126, P898, DOI 10.1016/j.jaci.2010.09.007; GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410; Ghaffar O, 1998, OTOLARYNG HEAD NECK, V118, P504, DOI 10.1016/S0194-5998(98)70209-8; Goodnow CC, 2010, NAT IMMUNOL, V11, P681, DOI 10.1038/ni.1900; Gosman MME, 2006, EUR RESPIR J, V27, P60, DOI 10.1183/09031936.06.00007005; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; GOULD SJ, 1993, J PATHOL, V169, P229, DOI 10.1002/path.1711690209; Goya S, 2003, J PATHOL, V200, P82, DOI 10.1002/path.1321; Grammer AC, 2002, ARTHRITIS RHEUM-US, V46, P1417, DOI 10.1002/art.10287; Griffin DO, 2012, MOL MED, V18, P1003, DOI 10.2119/molmed.2012.00203; Griffin DO, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00122; Griffin DO, 2011, J EXP MED, V208, P2591, DOI 10.1084/jem.20110978; Griffin DO, 2011, J EXP MED, V208, P67, DOI 10.1084/jem.20101499; Hannedouche S, 2011, NATURE, V475, P524, DOI 10.1038/nature10280; Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Heier I, 2011, THORAX, V66, P151, DOI 10.1136/thx.2010.149591; Hiller AS, 1998, SCAND J IMMUNOL, V47, P159; Hirokawa S, 2003, EUR J IMMUNOL, V33, P1824, DOI 10.1002/eji.200323974; HoffmannSommergruber K, 1996, CLIN EXP ALLERGY, V26, P79, DOI 10.1111/j.1365-2222.1996.tb00059.x; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; HUGGINS KG, 1975, LANCET, V2, P148; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Inamine A, 2005, INT IMMUNOL, V17, P581, DOI 10.1093/intimm/dxh241; Inman CF, 2012, IMMUNOL CELL BIOL, V90, P235, DOI 10.1038/icb.2011.35; Iwata T, 2008, J IMMUNOL, V181, P5738, DOI 10.4049/jimmunol.181.8.5738; Jesus AA, 2008, J CLIN IMMUNOL, V28, pS62, DOI 10.1007/s10875-008-9171-x; Johansen FE, 2005, BLOOD, V106, P593, DOI 10.1182/blood-2004-12-4630; JONES E, 1987, J OTOLARYNGOL, V16, P19; KAETZEL CS, 1991, P NATL ACAD SCI USA, V88, P8796, DOI 10.1073/pnas.88.19.8796; Kantarjian H, 2010, CANCER-AM CANCER SOC, V116, P2665, DOI 10.1002/cncr.25079; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kato A, 2009, J ALLERGY CLIN IMMUN, V123, P369, DOI 10.1016/j.jaci.2008.11.022; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kelly-Scumpia KM, 2011, J EXP MED, V208, P1673, DOI 10.1084/jem.20101715; Kelsen SG, 2009, AM J RESP CRIT CARE, V179, P799, DOI 10.1164/rccm.200807-1089OC; Khan WN, 2009, J IMMUNOL, V183, P3561, DOI 10.4049/jimmunol.0800933; Kim DY, 2011, J IMMUNOL, V186, P4253, DOI 10.4049/jimmunol.0903794; King LB, 2009, IMMUNOL REV, V231, P265, DOI 10.1111/j.1600-065X.2009.00822.x; Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; KleinJan A, 2000, EUR RESPIR J, V15, P491, DOI 10.1034/j.1399-3003.2000.15.11.x; Konforte D, 2009, J IMMUNOL, V182, P1781, DOI 10.4049/jimmunol.0803009; Kopp MV, 2011, CURR ALLERGY ASTHM R, V11, P101, DOI 10.1007/s11882-010-0173-4; Koshi R, 2001, J ANAT, V199, P663, DOI 10.1046/j.1469-7580.2001.19960663.x; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; Kumar R, 2012, J ALLERGY CLIN IMMUN, V130, P996, DOI 10.1016/j.jaci.2012.04.047; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Kurosaki T, 2010, ANNU REV IMMUNOL, V28, P21, DOI 10.1146/annurev.immunol.021908.132541; Kurosu K, 2008, J IMMUNOL, V181, P756, DOI 10.4049/jimmunol.181.1.756; Kwon H, 2009, IMMUNITY, V31, P941, DOI 10.1016/j.immuni.2009.10.008; Lafyatis R, 2007, ARTHRITIS RHEUM, V56, P3167, DOI 10.1002/art.22847; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee BJ, 2000, J VIROL, V74, P2786, DOI 10.1128/JVI.74.6.2786-2792.2000; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee L, 2010, J CLIN PHARMACOL, V50, P1397, DOI 10.1177/0091270010361254; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Leijen S, 2012, CLIN CANCER RES, V18, P4794, DOI 10.1158/1078-0432.CCR-12-0868; Leon DEA, 2003, CLIN EXP ALLERGY, V33, P226, DOI 10.1046/j.1365-2222.2003.01526.x; Levine SJ, 2010, ANN INTERN MED, V152, P232, DOI 10.7326/0003-4819-152-4-201002160-00008; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Liu CL, 2011, NATURE, V475, P519, DOI 10.1038/nature10226; Liu LC, 2011, DRUG METAB DISPOS, V39, P1840, DOI 10.1124/dmd.111.040840; Liu M, 2012, HUM IMMUNOL, V73, P511, DOI 10.1016/j.humimm.2012.02.010; Liu Z, 2011, EUR J IMMUNOL, V41, P588, DOI 10.1002/eji.201041354; Luger EO, 2009, J ALLERGY CLIN IMMUN, V124, P819, DOI 10.1016/j.jaci.2009.06.047; Lund FE, 2002, J IMMUNOL, V169, P5236, DOI 10.4049/jimmunol.169.9.5236; Maarof G, 2010, BLOOD, V115, P1718, DOI 10.1182/blood-2009-05-220251; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Mackay F, 2008, CYTOKINE GROWTH F R, V19, P263, DOI 10.1016/j.cytogfr.2008.04.006; Mackay F, 2010, IMMUNOL REV, V237, P205, DOI 10.1111/j.1600-065X.2010.00944.x; Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572; Malin S, 2010, CURR OPIN IMMUNOL, V22, P168, DOI 10.1016/j.coi.2010.02.004; Marchal-Somme J, 2006, J IMMUNOL, V176, P5735, DOI 10.4049/jimmunol.176.10.5735; Marshak-Rothstein A, 2007, ANNU REV IMMUNOL, V25, P419, DOI 10.1146/annurev.immunol.22.012703.104514; MARTINEZCORDERO E, 1992, J INVEST ALLERG CLIN, V2, P254; Maurer MF, 2012, MABS-AUSTIN, V4, P69, DOI 10.4161/mabs.4.1.18713; McDonald KG, 2005, J IMMUNOL, V174, P5720, DOI 10.4049/jimmunol.174.9.5720; McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732; McSharry C, 2003, CLIN EXP ALLERGY, V33, P159, DOI 10.1046/j.1365-2222.2003.01603.x; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; Meyer-Bahlburg A, 2012, J ALLERGY CLIN IMMUN, V129, P559, DOI 10.1016/j.jaci.2011.09.017; Mitsdoerffer M, 2010, P NATL ACAD SCI USA, V107, P14292, DOI 10.1073/pnas.1009234107; Montecino-Rodriguez E, 2006, NAT IMMUNOL, V7, P293, DOI 10.1038/ni1301; Moyron-Quiroz JE, 2004, NAT MED, V10, P927, DOI 10.1038/nm1091; Moyron-Quiroz JE, 2006, IMMUNITY, V25, P643, DOI 10.1016/j.immuni.2006.08.022; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; NAKAJIMA S, 1975, CLIN EXP IMMUNOL, V21, P306; Navarra SV, 2011, LANCET, V377, P721, DOI 10.1016/S0140-6736(10)61354-2; Nunez B, 2011, AM J RESP CRIT CARE, V183, P1025, DOI 10.1164/rccm.201001-0029OC; Ogasawara N, 2011, ACTA OTO-LARYNGOL, V131, P116, DOI 10.3109/00016489.2010.520022; OGRA PL, 1971, NEW ENGL J MED, V284, P59, DOI 10.1056/NEJM197101142840201; Okada T, 2005, PLOS BIOL, V3, P1047, DOI 10.1371/journal.pbio.0030150; Oracki SA, 2010, IMMUNOL REV, V237, P140, DOI 10.1111/j.1600-065X.2010.00940.x; Pal SK, 2010, EXPERT OPIN INV DRUG, V19, P1355, DOI 10.1517/13543784.2010.520701; Park HS, 2003, J IMMUNOL, V171, P2532, DOI 10.4049/jimmunol.171.5.2532; Patadia M, 2010, AM J RHINOL ALLERGY, V24, P11, DOI 10.2500/ajra.2010.24.3386; Patel SP, 2013, CANCER-AM CANCER SOC, V119, P799, DOI 10.1002/cncr.27790; Paus D, 2006, J EXP MED, V203, P1081, DOI 10.1084/jem.20060087; Pereira JP, 2010, INT IMMUNOL, V22, P413, DOI 10.1093/intimm/dxq047; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Pillai S, 2009, NAT REV IMMUNOL, V9, P767, DOI 10.1038/nri2656; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Polosukhin VV, 2011, AM J RESP CRIT CARE, V184, P317, DOI 10.1164/rccm.201010-1629OC; Polverino F, 2010, AM J RESP CRIT CARE, V182, P1011, DOI 10.1164/rccm.200911-1700OC; Pulkkinen V, 2012, ANN MED, V44, P178, DOI 10.3109/07853890.2010.532151; QUIDINGJARBRINK M, 1995, INFECT IMMUN, V63, P853; Randall TD, 2010, ADV IMMUNOL, V107, P187, DOI [10.1016/S0065-2776(10)07002-1, 10.1016/B978-0-12-381300-8.00007-1]; Rangel-Moreno J, 2007, P NATL ACAD SCI USA, V104, P10577, DOI 10.1073/pnas.0700591104; Rangel-Moreno J, 2006, J CLIN INVEST, V116, P3183, DOI 10.1172/JCI28756; Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a; RICHMOND I, 1993, THORAX, V48, P1130, DOI 10.1136/thx.48.11.1130; Rickert RC, 2005, CURR OPIN IMMUNOL, V17, P237, DOI 10.1016/j.coi.2005.03.001; Rickert RC, 2011, IMMUNOL REV, V244, P115, DOI 10.1111/j.1600-065X.2011.01067.x; Sabirov A, 2008, LARYNGOSCOPE, V118, P4, DOI 10.1097/MLG.0b013e3181567a7a; Saetta M, 1997, AM J RESP CRIT CARE, V156, P1633, DOI 10.1164/ajrccm.156.5.9701081; Salomonsson S, 2003, ARTHRITIS RHEUM-US, V48, P3187, DOI 10.1002/art.11311; Salomonsson S, 2003, SCAND J RHEUMATOL, V32, P79, DOI 10.1080/03009740310000076; Salvi S, 1999, CLIN EXP ALLERGY, V29, P1597, DOI 10.1046/j.1365-2222.1999.00644.x; Sanchez-Segura A, 2000, LARYNGOSCOPE, V110, P1183; SATO A, 1992, AM REV RESPIR DIS, V146, P473, DOI 10.1164/ajrccm/146.2.473; Sato M, 2009, J IMMUNOL, V182, P7307, DOI 10.4049/jimmunol.0803606; Seetharam A, 2010, CURR OPIN ORGAN TRAN, V15, P531, DOI 10.1097/MOT.0b013e32833b31f4; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SHATKIN JS, 1994, OTOLARYNG HEAD NECK, V111, P553, DOI 10.1016/S0194-5998(94)70520-8; Shlomchik MJ, 2012, IMMUNOL REV, V247, P52, DOI 10.1111/j.1600-065X.2012.01124.x; Siegel AM, 2011, IMMUNITY, V35, P806, DOI 10.1016/j.immuni.2011.09.016; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Singh D, 2010, J CLIN PHARMACOL, V50, P94, DOI 10.1177/0091270009347873; SMALL P, 1985, ANN ALLERGY, V55, P736; Smith KGC, 2010, NAT REV IMMUNOL, V10, P328, DOI 10.1038/nri2762; Smurthwaite Lyn, 2002, Curr Allergy Asthma Rep, V2, P231, DOI 10.1007/s11882-002-0024-z; Speckmann C, 2008, CLIN IMMUNOL, V129, P448, DOI 10.1016/j.clim.2008.08.002; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Stohl W, 2012, CURR RHEUMATOL REP, V14, P303, DOI 10.1007/s11926-012-0254-6; Suda T, 1999, CHEST, V115, P357, DOI 10.1378/chest.115.2.357; Sun K, 2004, J IMMUNOL, V173, P4576, DOI 10.4049/jimmunol.173.7.4576; Swigris JJ, 2008, CHEST, V133, P271, DOI 10.1378/chest.07-0079; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; Tan BK, 2011, INT FORUM ALLERGY RH, V1, P88, DOI 10.1002/alr.20025; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tan BK, 2010, CURR OPIN OTOLARYNGO, V18, P21, DOI 10.1097/MOO.0b013e3283350053; Tezuka H, 2007, NATURE, V448, P929, DOI 10.1038/nature06033; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; Tjanlund A, 2006, INT IMMUNOL, V18, P807, DOI 10.1093/intimm/dxl017; TOMASI TB, 1965, J EXP MED, V121, P101, DOI 10.1084/jem.121.1.101; TSCHERNIG T, 1995, THORAX, V50, P658, DOI 10.1136/thx.50.6.658; Tschernig T, 2000, PATHOBIOLOGY, V68, P1, DOI 10.1159/000028109; Tsuji M, 2009, SCIENCE, V323, P1488, DOI 10.1126/science.1169152; Vale AM, 2010, J ALLERGY CLIN IMMUN, V125, P778, DOI 10.1016/j.jaci.2010.02.018; van der Strate BWA, 2006, AM J RESP CRIT CARE, V173, P751, DOI 10.1164/rccm.200504-594OC; Van TC, 2011, NAT IMMUNOL, V12, P151, DOI 10.1038/ni.1981; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Vansteenkiste J, 2012, ONCOLOGY-BASEL, V82, P25, DOI 10.1159/000335268; Verbrugghe P, 2008, HISTOCHEM CELL BIOL, V129, P311, DOI 10.1007/s00418-007-0369-4; Vinuesa CG, 2010, IMMUNOL REV, V237, P72, DOI 10.1111/j.1600-065X.2010.00937.x; Vuillemenot BR, 2004, AM J RESP CELL MOL, V30, P438, DOI 10.1165/rcmb.2003-0062OC; Wallace WAH, 1996, J PATHOL, V178, P323; Wallace WAH, 2001, J PATHOL, V195, P251, DOI 10.1002/path.916; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Webb S, 2011, NAT BIOTECHNOL, V29, P860, DOI 10.1038/nbt.1994; Weill JC, 2009, ANNU REV IMMUNOL, V27, P267, DOI 10.1146/annurev.immunol.021908.132607; Westermann J, 1996, IMMUNOL TODAY, V17, P278, DOI 10.1016/0167-5699(96)80545-7; Wilkes DS, 2001, SARCOIDOSIS VASC DIF, V18, P34; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7; Yoshida T, 2005, MICROBIOL IMMUNOL, V49, P529, DOI 10.1111/j.1348-0421.2005.tb03758.x; Yusuf I, 2004, BLOOD, V104, P784, DOI 10.1182/blood-2003-09-3071; Zheng NY, 2004, J CLIN INVEST, V113, P1188, DOI 10.1172/JCI200420255; Zhu J, 2007, AM J RESP CRIT CARE, V175, P1125, DOI 10.1164/rccm.200602-161OC	255	101	103	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					933	957		10.1016/j.jaci.2013.02.023	http://dx.doi.org/10.1016/j.jaci.2013.02.023			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23540615	Green Accepted			2022-12-18	WOS:000317187200001
J	Bartnikas, LM; Gurish, MF; Burton, OT; Leisten, S; Janssen, E; Oettgen, HC; Beaupre, J; Lewis, CN; Austen, KF; Schulte, S; Hornick, JL; Geha, RS; Oyoshi, MK				Bartnikas, Lisa M.; Gurish, Michael F.; Burton, Oliver T.; Leisten, Sabine; Janssen, Erin; Oettgen, Hans C.; Beaupre, Jacqueline; Lewis, Christopher N.; Austen, K. Frank; Schulte, Stephanie; Hornick, Jason L.; Geha, Raif S.; Oyoshi, Michiko K.			Epicutaneous sensitization results in IgE-dependent intestinal mast cell expansion and food-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; epicutaneous sensitization; IgE; mast cells; anaphylaxis	REGULATORY T-CELLS; ORAL TOLERANCE INDUCTION; ALLERGIC RESPONSES; CONNECTIVE-TISSUE; EPITHELIAL-CELLS; DENDRITIC CELLS; PROTEIN ANTIGEN; PERMEABILITY; RECEPTOR; MOUSE	Background: Sensitization to food antigen can occur through cutaneous exposure. Objective: We sought to test the hypothesis that epicutaneous sensitization with food antigen predisposes to IgE-mediated anaphylaxis on oral allergen challenge. Methods: BALB/c mice were epicutaneously sensitized by repeated application of ovalbumin (OVA) to tape-stripped skin over 7 weeks or orally immunized with OVA and cholera toxin (CT) weekly for 8 weeks and then orally challenged with OVA. Body temperature was monitored, and serum mouse mast cell protease 1 levels were determined after challenge. Tissue mast cell (MC) counts were examined by using chloroacetate esterase staining. Levels of serum OVA-specific IgE and IgG(1) antibodies and cytokines in supernatants of OVA-stimulated splenocytes were measured by means of ELISA. Serum IL-4 levels were measured by using an in vivo cytokine capture assay. Results: Epicutaneously sensitized mice exhibited expansion of connective tissue MCs in the jejunum, increased serum IL-4 levels, and systemic anaphylaxis after oral challenge, as evidenced by decreased body temperature and increased serum mouse mast cell protease 1 levels. Intestinal MC expansion and anaphylaxis were IgE dependent because they did not occur in epicutaneously sensitized IgE(-/-) mice. Mice orally immunized with OVA plus CT did not have increased serum IL-4 levels, expanded intestinal MCs, or anaphylaxis after oral challenge, despite OVA-specific IgE levels and splenocyte cytokine production in response to OVA stimulation, which were comparable with those of epicutaneously sensitized mice. Conclusion: Epicutaneously sensitized mice, but not mice orally immunized with antigen plus CT, have expansion of intestinal MCs and IgE-mediated anaphylaxis after single oral antigen challenge. IgE is necessary but not sufficient for food anaphylaxis, and MC expansion in the gut can play an important role in the development of anaphylaxis. (J Allergy Clin Immunol 2013;131:451-60.)	[Bartnikas, Lisa M.; Burton, Oliver T.; Leisten, Sabine; Janssen, Erin; Oettgen, Hans C.; Beaupre, Jacqueline; Lewis, Christopher N.; Geha, Raif S.; Oyoshi, Michiko K.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Bartnikas, Lisa M.; Burton, Oliver T.; Leisten, Sabine; Janssen, Erin; Oettgen, Hans C.; Beaupre, Jacqueline; Lewis, Christopher N.; Geha, Raif S.; Oyoshi, Michiko K.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Gurish, Michael F.; Austen, K. Frank] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Gurish, Michael F.; Austen, K. Frank] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Schulte, Stephanie; Hornick, Jason L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Schulte, Stephanie; Hornick, Jason L.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Oyoshi, MK (corresponding author), Boston Childrens Hosp, Div Immunol, Karp 10,300 Longwood Ave, Boston, MA 02115 USA.	Raif.Geha@childrens.harvard.edu; Michiko.Oyoshi@childrens.harvard.edu		Burton, Oliver/0000-0003-3884-7373; Hornick, Jason/0000-0001-6475-8345; Oettgen, Hans/0000-0003-1199-1391; Janssen, Erin/0000-0002-0687-2550; Lewis, Holly/0000-0002-5238-3774	National Institutes of Health (NIH) [AR-047417, R01-AI083516]; Harvard Digestive Disease Center, NIH [P30 DK34845]; Boston Children's Hospital Faculty Career Development Fellowship/Eleanor and Miles Shore Program for Scholars in Medicine at Harvard Medical School; National Institute of Allergy and Infectious Diseases (NIAID) [RO1-AI083516]; NIH/NIAID [R56 AI100889-01]; US Environmental Protection Agency [83482501]; German Academic Exchange Service (DAAD); National Institutes of Health; American Academy of Allergy, Asthma & Immunology/Food Allergy Initiative Howard Gittis Memorial Third/Fourth Year Fellowship/Junior Faculty Research Award;  [T32-AI-007512]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083516, T32AI007512, R56AI100889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Digestive Disease Center, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boston Children's Hospital Faculty Career Development Fellowship/Eleanor and Miles Shore Program for Scholars in Medicine at Harvard Medical School; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US Environmental Protection Agency(United States Environmental Protection Agency); German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma & Immunology/Food Allergy Initiative Howard Gittis Memorial Third/Fourth Year Fellowship/Junior Faculty Research Award; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health (NIH) grants AR-047417 and R01-AI083516. L. M. B. was supported by training grant T32-AI-007512 and the 2010 American Academy of Allergy, Asthma & Immunology/Food Allergy Initiative Howard Gittis Memorial Third/Fourth Year Fellowship/Junior Faculty Research Award. M.K.O. was supported by the Harvard Digestive Disease Center, NIH grant P30 DK34845, and the Boston Children's Hospital Faculty Career Development Fellowship/Eleanor and Miles Shore Program for Scholars in Medicine at Harvard Medical School. M. F. G. was supported by National Institute of Allergy and Infectious Diseases (NIAID) grant RO1-AI083516. H.C.O. was supported by NIH/NIAID grant R56 AI100889-01 and US Environmental Protection Agency grant 83482501.; S. Leisten has received research support from the German Academic Exchange Service (DAAD). R. S. Geha has received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Andersson MK, 2008, MOL IMMUNOL, V45, P2548, DOI 10.1016/j.molimm.2008.01.012; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Berin MC, 2006, ALLERGY, V61, P64, DOI 10.1111/j.1398-9995.2006.01012.x; Bevilacqua C, 2004, INT ARCH ALLERGY IMM, V135, P108, DOI 10.1159/000080653; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Chen X, 2011, ALLERGY, V66, P1038, DOI 10.1111/j.1398-9995.2011.02585.x; Deschoolmeester ML, 1999, IMMUNOLOGY, V96, P138; Diesner SC, 2008, IMMUNOL LETT, V121, P45, DOI 10.1016/j.imlet.2008.08.006; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Ekoff M, 2007, J IMMUNOL, V178, P4177, DOI 10.4049/jimmunol.178.7.4177; Finkelman F., 2003, CURRENT PROTOCOLS IM, V6, P28, DOI [10.1002/0471142735.im0628s54, DOI 10.1002/0471142735.IM0628S54.CHAPTER]; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Hammerschmidt SI, 2011, J CLIN INVEST, V121, P3051, DOI 10.1172/JCI44262; Hill DJ, 2007, J PEDIATR-US, V151, P359, DOI 10.1016/j.jpeds.2007.04.070; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Jin HL, 2009, J ALLERGY CLIN IMMUN, V123, P875, DOI 10.1016/j.jaci.2009.02.007; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Li HX, 2006, GASTROENTEROLOGY, V131, P47, DOI 10.1053/j.gastro.2006.03.044; Lorentz A, 2005, J IMMUNOL, V174, P6751, DOI 10.4049/jimmunol.174.11.6751; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; Mathias CB, 2009, J IMMUNOL, V182, P2416, DOI 10.4049/jimmunol.0801569; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; O'Regan GM, 2010, CLIN EXP ALLERGY, V40, P965, DOI 10.1111/j.1365-2222.2010.03522.x; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Oliphant CJ, 2011, IMMUNOLOGY, V134, P378, DOI 10.1111/j.1365-2567.2011.03499.x; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Oyoshi MK, 2011, J CLIN INVEST, V121, P2210, DOI 10.1172/JCI43586; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Perrier C, 2011, CLIN EXP ALLERGY, V41, P20, DOI 10.1111/j.1365-2222.2010.03639.x; Perrier C, 2010, CLIN EXP ALLERGY, V40, P153, DOI 10.1111/j.1365-2222.2009.03329.x; Prioult G, 2005, IMMUNOL REV, V206, P204, DOI 10.1111/j.0105-2896.2005.00277.x; Shelburne CP, 2001, IMMUNOL REV, V179, P82, DOI 10.1034/j.1600-065X.2001.790109.x; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Sun JB, 2007, SCAND J IMMUNOL, V66, P278, DOI 10.1111/j.1365-3083.2007.01975.x; Sun JB, 2006, SCAND J IMMUNOL, V64, P251, DOI 10.1111/j.1365-3083.2006.01823.x; Sun JB, 2006, J IMMUNOL, V177, P7634, DOI 10.4049/jimmunol.177.11.7634; Wood LC, 1997, EXP DERMATOL, V6, P98, DOI 10.1111/j.1600-0625.1997.tb00154.x; Xing W, 2011, P NATL ACAD SCI USA, V108, P14210, DOI 10.1073/pnas.1111048108	50	101	102	4	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					451	+		10.1016/j.jaci.2012.11.032	http://dx.doi.org/10.1016/j.jaci.2012.11.032			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23374269	Green Accepted			2022-12-18	WOS:000314661500024
J	Ford, LS; Bloom, KA; Nowak-Wegrzyn, AH; Shreffler, WG; Masilamani, M; Sampson, HA				Ford, Lara S.; Bloom, Katherine A.; Nowak-Wegrzyn, Anna H.; Shreffler, Wayne G.; Masilamani, Madhan; Sampson, Hugh A.			Basophil reactivity, wheal size, and immunoglobulin levels distinguish degrees of cow's milk tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cow's milk allergy; tolerance; extensively heated; baked; immunotherapy; immunomodulation; biomarker; basophil activation	FOOD CHALLENGES; SERUM IGE; ALLERGY; HYPERSENSITIVITY; HISTAMINE; CHILDREN; TESTS	Background: In our previous study about 75% of children with cow's milk allergy tolerated baked milk products, which improved their prognosis and quality of life. Objective: We sought to identify biomarkers of varying degrees of clinical tolerance among a cohort of children with cow's milk allergy. Methods: One hundred thirty-two subjects were initially classified as baked milk-reactive, baked milk-tolerant, or having "outgrown milk allergy'' based on the results of oral food challenges. The baked milk-tolerant group was then divided into 3 groups based on the amount and degree of heat-denatured milk protein that they could tolerate. Serum was analyzed for allergen-specific IgE and IgG(4) levels, basophil reactivity was assessed in whole blood stimulated with serial 10-fold dilutions of milk protein, and skin prick tests (SPTs) were performed to commercial milk extract. Activated basophils were defined by using flow cytometry as CD63(bright)CD203c(+)CD123(+)HLA-DR(dim/-)CD41a(-)lineage(-). Data were analyzed by using the Jonckheere-Terpstra test. Results: Significant differences across the 5 clinical groups were seen for median casein-and milk-specific IgE levels, casein-specific IgG(4) levels, and casein IgE/IgG(4) ratios; milk-specific to nonspecific basophil activation ratio, median basophil reactivity, and spontaneous basophil activation (CD203c expression after stimulation with RPMI); and milk SPT wheal diameters. Casein-and milk-specific IgE level, milk-specific basophil reactivity, and milk SPT wheal diameter are all significantly greater among patients with milk allergy who react to baked milk than among those who tolerate it. Conclusions: The majority of patients with milk allergy are able to tolerate some forms of baked milk in their diets. Different phenotypes of children with cow's milk allergy can be distinguished by casein-and milk-specific IgE levels, milk-specific basophil reactivity, and milk SPT mean wheal diameters. Spontaneous basophil activation is greater among patients with more severe clinical milk reactivity. (J Allergy Clin Immunol 2013;131:180-6.)	[Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Shreffler, Wayne G.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts General Hospital	Sampson, HA (corresponding author), Mt Sinai Sch Med, Dept Pediat, Jaffe Food Allergy Inst, 1 Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	Hugh.Sampson@mssm.edu	Masilamani, Madhan/H-3691-2019	Nowak-Wegrzyn, Anna/0000-0002-0960-9854; Shreffler, Wayne/0000-0001-6465-137X; Masilamani, Madhan/0000-0001-8181-8848	National Institutes of Health/National Institute of Allergy and Infectious Diseases [AI44236, AI066738]; National Center for Research Resources [RR026134]; AAAAI/Elliot; Roslyn Jaffe Third-Year Fellowship Food Allergy Research Award at Mount Sinai School of Medicine; American Academy of Allergy, Asthma & Immunology (AAAAI) Jaffe Third-Year Fellowship Food Allergy Research Award; chair of the AAAAI Fellow-in-Training Committee; Food Allergy Initiative (FAI); National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH); NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044236, U19AI066738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AAAAI/Elliot; Roslyn Jaffe Third-Year Fellowship Food Allergy Research Award at Mount Sinai School of Medicine; American Academy of Allergy, Asthma & Immunology (AAAAI) Jaffe Third-Year Fellowship Food Allergy Research Award; chair of the AAAAI Fellow-in-Training Committee; Food Allergy Initiative (FAI); National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	H.A.S. is funded in part by grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (AI44236 and AI066738) and the National Center for Research Resources (RR026134). L.S.F. is funded by the AAAAI/Elliot and Roslyn Jaffe Third-Year Fellowship Food Allergy Research Award at Mount Sinai School of Medicine.; Disclosure of potential conflict of interest: L. S. Ford has received research support from the American Academy of Allergy, Asthma & Immunology (AAAAI) Jaffe Third-Year Fellowship Food Allergy Research Award and is chair of the AAAAI Fellow-in-Training Committee. H. A. Sampson is a consultant for Allertein Therapeutics, LLC; is on the advisory board for Immusan T and Novartis; has received research support from the Food Allergy Initiative (FAI) and the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH); is a consultant and scientific advisor for the FAI; is a medical advisor for the Food Allergy & Anaphylaxis Network; is a scientific advisor for the University of Nebraska-FARRP; and is 45% owner of Herb Springs, LLC. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; Bromberg P., 2006, SAGX STAT ANAL GENEC; CONROY MC, 1977, J IMMUNOL, V118, P1317; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; MacGlashan D, 1999, J ALLERGY CLIN IMMUN, V104, P492, DOI 10.1016/S0091-6749(99)70399-4; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MARONE G, 1985, INT ARCH ALLER A IMM, V77, P103, DOI 10.1159/000233761; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; PENG ZK, 1992, J ALLERGY CLIN IMMUN, V89, P519, DOI 10.1016/0091-6749(92)90318-V; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Shreffler WG, 2006, CURR OPIN ALLERGY CL, V6, P226, DOI 10.1097/01.all.0000225165.83144.2f; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Team RDC, 2011, R LANG ENV STAT COMP; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.2324.x; Wanich N, 2009, J ALLERGY CLIN IMMUN, V123, pe20	24	101	106	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					180	U261		10.1016/j.jaci.2012.06.003	http://dx.doi.org/10.1016/j.jaci.2012.06.003			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	22819512	Green Accepted			2022-12-18	WOS:000312961200023
J	Leiding, JW; Holland, SM				Leiding, Jennifer W.; Holland, Steven M.			Warts and all: Human papillomavirus in primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunodeficiency; human papillomavirus; warts; squamous; carcinoma; dysplastic	WISKOTT-ALDRICH-SYNDROME; CELL-MEDIATED-IMMUNITY; CERVICAL INTRAEPITHELIAL NEOPLASIA; ADENOSINE-DEAMINASE DEFICIENCY; LEUKOCYTE ADHESION DEFICIENCY; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; DOMINANT EPIDERMODYSPLASIA-VERRUCIFORMIS; HPV-16/18 AS04-ADJUVANTED VACCINE; IDIOPATHIC CD4+ LYMPHOCYTOPENIA	Infection with human papillomavirus (HPV) is almost universal and eventually asymptomatic, but pathologic infection with HPV is severe, recurrent, and recalcitrant to therapy. It is also an underappreciated manifestation of primary immunodeficiency. Mutations in EVER1, EVER2, GATA2, CXCR4, and dedicator of cytokinesis 8 (DOCK8) are typically associated with extensive HPV infections, whereas several other primary immune defects result in severe HPV much less frequently. We review immunodeficiencies with severe HPV infections and the mechanisms underlying them. (J Allergy Clin Immunol 2012;130:1030-48.)	[Leiding, Jennifer W.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Leiding, JW (corresponding author), Univ S Florida, Childrens Reseach Inst, Dept Pediat, Div Allergy Immunol & Rheumatol, 140 7th Ave S Box 9680, St Petersburg, FL 33701 USA.	jleiding@health.usf.edu; smh@nih.gov			Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Abdollahpour H, 2012, BLOOD, V119, P3450, DOI 10.1182/blood-2011-09-378158; Akha AAS, 1999, MEDICINE, V78, P370, DOI 10.1097/00005792-199911000-00002; Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; ALDRICH RA, 1954, PEDIATRICS, V13, P133; AMENT ME, 1969, NEW ENGL J MED, V281, P1019; AMMANN AJ, 1969, NEW ENGL J MED, V281, P469, DOI 10.1056/NEJM196908282810904; Anadolu R, 2001, J AM ACAD DERMATOL, V45, P296, DOI 10.1067/mjd.2001.114575; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDROPHY EJ, 1985, ARCH DERMATOL, V121, P864, DOI 10.1001/archderm.121.7.864; Antonsson A, 2003, J CLIN MICROBIOL, V41, P2509, DOI 10.1128/JCM.41.6.2509-2514.2003; Antony FC, 2002, BRIT J DERMATOL, V147, P182; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; Astori G, 1998, J INVEST DERMATOL, V110, P752, DOI 10.1046/j.1523-1747.1998.00191.x; ATTAL M, 1985, PRESSE MED, V14, P600; Balabanian K, 2005, BLOOD, V105, P2449, DOI 10.1182/blood-2004-06-2289; Balabanian K, 2008, J CLIN INVEST, V118, P1074, DOI 10.1172/JCI33187; Bauer TR, 2008, NAT MED, V14, P93, DOI 10.1038/nm1695; Berthelot C, 2007, J AM ACAD DERMATOL, V56, P882, DOI 10.1016/j.jaad.2007.01.036; Bigley V, 2011, J EXP MED, V208, P227, DOI 10.1084/jem.20101459; BODER E, 1958, PEDIATRICS, V21, P526; Bonagura VR, 2010, APMIS, V118, P455, DOI 10.1111/j.1600-0463.2010.02617.x; Bouma G, 2009, IMMUNOBIOLOGY, V214, P778, DOI 10.1016/j.imbio.2009.06.009; Calvo KR, 2011, HAEMATOL-HEMATOL J, V96, P1221, DOI 10.3324/haematol.2011.041152; CARBONARI M, 1990, NEW ENGL J MED, V322, P73, DOI 10.1056/NEJM199001113220201; Carter JJ, 1996, J INFECT DIS, V174, P927, DOI 10.1093/infdis/174.5.927; Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P1705; Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P541; Chae KM, 2001, J AM ACAD DERMATOL, V44, P124, DOI 10.1067/mjd.2001.111337; Chang MW, 1998, J AM ACAD DERMATOL, V38, P191, DOI 10.1016/S0190-9622(98)70239-7; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Charrier S, 2007, GENE THER, V14, P415, DOI 10.1038/sj.gt.3302863; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Chu EY, 2012, ARCH DERMATOL, V148, P79, DOI 10.1001/archdermatol.2011.262; COLEMAN N, 1994, CANCER-AM CANCER SOC, V74, P884, DOI 10.1002/1097-0142(19940801)74:3<884::AID-CNCR2820740315>3.0.CO;2-C; COOPER KD, 1990, J INVEST DERMATOL, V94, P769, DOI 10.1111/1523-1747.ep12874631; Cossu F, 2010, ITAL J PEDIATR, V36, DOI 10.1186/1824-7288-36-76; Crawford TO, 2006, ARCH DIS CHILD, V91, P610; Crawford T O, 1998, Semin Pediatr Neurol, V5, P287, DOI 10.1016/S1071-9091(98)80007-7; Crequer A, 2012, J CLIN INVEST, V122, P3239, DOI 10.1172/JCI62949; CROWLEY CA, 1980, NEW ENGL J MED, V302, P1163, DOI 10.1056/NEJM198005223022102; Cuellar-Rodriguez J, 2011, BLOOD, V118, P3715, DOI 10.1182/blood-2011-06-365049; de Oliveira WRP, 2003, J AM ACAD DERMATOL, V49, P639, DOI 10.1067/S0190-9622(03)01567-6; de Oliveira WRP, 2003, J EUR ACAD DERMATOL, V17, P394, DOI 10.1046/j.1468-3083.2003.00703.x; de Oliveira WRP, 2003, J DERMATOL, V30, P203, DOI 10.1111/j.1346-8138.2003.tb00372.x; Diaz GA, 2005, IMMUNOL REV, V203, P235, DOI 10.1111/j.0105-2896.2005.00226.x; Dickinson RE, 2011, BLOOD, V118, P2656, DOI 10.1182/blood-2011-06-360313; DRONY S, 1983, NOUV REV FR HEMATOL, V25, P184; Dupre L, 2006, HUM GENE THER, V17, P303, DOI 10.1089/hum.2006.17.303; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; EMBERGER JM, 1979, J GENET HUM, V27, P237; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Etzioni A, 2007, ADV EXP MED BIOL, V601, P51; Evans EML, 1997, CANCER RES, V57, P2943; FACCHETTI F, 1995, J IMMUNOL, V154, P6624; FAIRBANKS LD, 1994, J INHERIT METAB DIS, V17, P135, DOI 10.1007/BF00735418; Fausch SC, 2002, J IMMUNOL, V169, P3242, DOI 10.4049/jimmunol.169.6.3242; FENNEMA JSA, 1995, AIDS, V9, P1071, DOI 10.1097/00002030-199509000-00014; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; Fruchter RG, 1996, OBSTET GYNECOL, V87, P338, DOI 10.1016/0029-7844(95)00408-4; GAILLARD S, 1983, NOUV REV FR HEMATOL, V25, P184; Galy A, 2011, CURR OPIN ALLERGY CL, V11, P545, DOI 10.1097/ACI.0b013e32834c230c; Gatz SA, 2011, BONE MARROW TRANSPL, V46, P552, DOI 10.1038/bmt.2010.169; GIBLETT ER, 1972, LANCET, V2, P1067; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Giuliano AR, 2008, VACCINE, V26, pK17, DOI 10.1016/j.vaccine.2008.06.021; Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537; GLANZMANN E, 1950, Ann Paediatr, V175, P1; GLINSKI W, 1981, DERMATOLOGICA, V162, P141; GLINSKI W, 1976, DERMATOLOGICA, V153, P218, DOI 10.1159/000251060; Gorlin RJ, 2000, AM J MED GENET, V91, P368, DOI 10.1002/(SICI)1096-8628(20000424)91:5<368::AID-AJMG10>3.0.CO;2-9; GREENE SL, 1985, J AM ACAD DERMATOL, V13, P329, DOI 10.1016/S0190-9622(85)70170-3; Griffith LM, 2009, J ALLERGY CLIN IMMUN, V124, P1152, DOI 10.1016/j.jaci.2009.10.022; Gubinelli E, 2002, J DERMATOL, V29, P653, DOI 10.1111/j.1346-8138.2002.tb00197.x; Gulino AV, 2004, BLOOD, V104, P444, DOI 10.1182/blood-2003-10-3532; HAFTEK M, 1985, DERMATOLOGICA, V170, P213, DOI 10.1159/000249535; Hahn CN, 2011, NAT GENET, V43, P1012, DOI 10.1038/ng.913; HANSEN ER, 1990, ARCH DERMATOL, V126, P1604, DOI 10.1001/archderm.126.12.1604; Hanson EP, 2008, J ALLERGY CLIN IMMUN, V122, P1169, DOI 10.1016/j.jaci.2008.08.018; Hayashi J, 2002, INT J DERMATOL, V41, P817, DOI 10.1046/j.1365-4362.2002.01642.x; HAYWARD AR, 1979, LANCET, V1, P1099; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Herve M, 2007, J EXP MED, V204, P1583, DOI 10.1084/jem.20062287; HINTNER H, 1980, HAUTARZT, V31, P428; Hsu AP, 2011, BLOOD, V118, P2653, DOI 10.1182/blood-2011-05-356352; Imashuku S, 2002, ANN HEMATOL, V81, P470, DOI 10.1007/s00277-002-0489-9; JABLONSKA S, 1972, CANCER RES, V32, P583; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jin YZ, 2004, BLOOD, V104, P4010, DOI 10.1182/blood-2003-05-1592; JUDGE MR, 1994, BRIT J DERMATOL, V131, P615, DOI 10.1111/j.1365-2133.1994.tb04971.x; Kainz JT, 1996, DERMATOLOGY, V193, P318, DOI 10.1159/000246277; KAMINSKI M, 1985, ARCH DERMATOL, V121, P84, DOI 10.1001/archderm.121.1.84; Kanodia S, 2007, CURR CANCER DRUG TAR, V7, P79, DOI 10.2174/156800907780006869; Karrer S, 1999, BRIT J DERMATOL, V140, P935, DOI 10.1046/j.1365-2133.1999.02830.x; Kawai T, 2009, CURR OPIN HEMATOL, V16, P20, DOI 10.1097/MOH.0b013e32831ac557; Kim JK, 2010, J DERMATOL SCI, V60, P120, DOI 10.1016/j.jdermsci.2010.08.007; Kobayashi R, 2006, BRIT J HAEMATOL, V135, P362, DOI 10.1111/j.1365-2141.2006.06297.x; Komatsu N, 2008, J INVEST DERMATOL, V128, P1148, DOI 10.1038/sj.jid.5701153; Kreuter A, 2008, ARCH DERMATOL, V144, P366, DOI 10.1001/archderm.144.3.366; KRILL CE, 1964, NEW ENGL J MED, V270, P973, DOI 10.1056/NEJM196405072701902; Lacey CJN, 2005, J CLIN VIROL, V32, pS82, DOI 10.1016/j.jcv.2004.10.020; Laffort C, 2004, LANCET, V363, P2051, DOI 10.1016/S0140-6736(04)16457-X; Lagane B, 2008, BLOOD, V112, P34, DOI 10.1182/blood-2007-07-102103; Lambe T, 2011, EUR J IMMUNOL, V41, P3423, DOI 10.1002/eji.201141759; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lazarczyk M, 2009, MICROBIOL MOL BIOL R, V73, P348, DOI 10.1128/MMBR.00033-08; Lee SJ, 2001, J IMMUNOL, V167, P497, DOI 10.4049/jimmunol.167.1.497; Lehtinen M, 2012, LANCET ONCOL, V13, P89, DOI 10.1016/S1470-2045(11)70286-8; Leone V, 2002, BONE MARROW TRANSPL, V30, P49, DOI 10.1038/sj.bmt.1703581; Leung L, 2011, AUST FAM PHYSICIAN, V40, P40; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; Lin JH, 2009, PEDIATR DERMATOL, V26, P155, DOI 10.1111/j.1525-1470.2009.00874.x; Lopez PM, 1999, INT J DERMATOL, V38, P119, DOI 10.1046/j.1365-4362.1999.00364.x; LUTZNER MA, 1978, B CANCER, V65, P169; Lynn J, 2004, J ALLERGY CLIN IMMUN, V114, P409, DOI 10.1016/j.jaci.2004.02.033; Mahr JA, 1999, IMMUNOL REV, V168, P121, DOI 10.1111/j.1600-065X.1999.tb01287.x; MAJEWSKI S, 1990, J AM ACAD DERMATOL, V22, P423, DOI 10.1016/0190-9622(90)70058-P; MAJEWSKI S, 1986, J AM ACAD DERMATOL, V15, P966, DOI 10.1016/S0190-9622(86)70258-2; Mansour S, 2010, AM J MED GENET A, V152A, P2287, DOI 10.1002/ajmg.a.33445; Marini Alessandra, 2006, J Dtsch Dermatol Ges, V4, P417, DOI 10.1111/j.1610-0387.2006.05944.x; Markowitz Lauri E., 2007, Morbidity and Mortality Weekly Report, V56, P1; MASSING AM, 1963, ARCH DERMATOL, V87, P306, DOI 10.1001/archderm.1963.01590150022004; McDermott DF, 2009, PEDIATR DERMATOL, V26, P306, DOI 10.1111/j.1525-1470.2008.00853.x; McDermott DH, 2011, BLOOD, V118, P4957, DOI 10.1182/blood-2011-07-368084; Micali G, 2003, J AM ACAD DERMATOL, V48, pS9, DOI 10.1067/mjd.2003.111; Moscicki AB, 2004, J INFECT DIS, V190, P37, DOI 10.1086/421467; Nakagawa M, 1997, J INFECT DIS, V175, P927, DOI 10.1086/513992; Nakagawa M, 1999, CLIN DIAGN LAB IMMUN, V6, P494, DOI 10.1128/CDLI.6.4.494-498.1999; Nehme NT, 2012, BLOOD, V119, P3458, DOI 10.1182/blood-2011-09-378364; Notarangelo LD, 2000, CLIN EXP IMMUNOL, V120, P399, DOI 10.1046/j.1365-2249.2000.01142.x; Notarangelo LD, 2002, BLOOD, V99, P2268, DOI 10.1182/blood.V99.6.2268; Notarangelo LD, 2008, CURR OPIN HEMATOL, V15, P30, DOI 10.1097/MOH.0b013e3282f30448; Nowak-Wegrzyn A, 2004, J PEDIATR-US, V144, P505, DOI 10.1016/j.jpeds.2003.12.046; Ochs HD, 2009, BIOL BLOOD MARROW TR, V15, P84, DOI 10.1016/j.bbmt.2008.10.007; OCHS HD, 1980, BLOOD, V55, P243; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; ORMEROD AD, 1983, BRIT J DERMATOL, V108, P211, DOI 10.1111/j.1365-2133.1983.tb00065.x; Orth G, 2006, SEMIN IMMUNOL, V18, P362, DOI 10.1016/j.smim.2006.07.008; Ostergaard P, 2011, NAT GENET, V43, P929, DOI 10.1038/ng.923; OSTROW RS, 1987, ARCH DERMATOL, V123, P1511, DOI 10.1001/archderm.123.11.1511; OXELIUS VA, 1982, NEW ENGL J MED, V306, P515, DOI 10.1056/NEJM198203043060905; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; PAGANELLI R, 1992, J CLIN IMMUNOL, V12, P84, DOI 10.1007/BF00918137; Pai SY, 2006, BONE MARROW TRANSPL, V38, P671, DOI 10.1038/sj.bmt.1705512; Palefsky J, 2009, CURR OPIN HIV AIDS, V4, P52, DOI 10.1097/COH.0b013e32831a7246; Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971; Pasic S, 2005, PEDIATR PULM, V39, P281, DOI 10.1002/ppul.20173; PRAWER SE, 1977, ARCH DERMATOL, V113, P495, DOI 10.1001/archderm.113.4.495; PYRHONEN S, 1980, BRIT J DERMATOL, V102, P247, DOI 10.1111/j.1365-2133.1980.tb08136.x; Ramoz N, 2002, NAT GENET, V32, P579, DOI 10.1038/ng1044; REA JN, 1976, BRIT J PREV SOC MED, V30, P107; REID TMS, 1976, BRIT J DERMATOL, V95, P559, DOI 10.1111/j.1365-2133.1976.tb00870.x; Requena L, 1998, BRIT J DERMATOL, V139, P1081; Rodrigues NP, 2005, BLOOD, V106, P477, DOI 10.1182/blood-2004-08-2989; ROSEN FS, 1966, NEW ENGL J MED, V275, P709, DOI 10.1056/NEJM196609292751307; Salit RB, 2007, BRIT J HAEMATOL, V139, P133, DOI 10.1111/j.1365-2141.2007.06781.x; Sanal O, 1999, J CLIN IMMUNOL, V19, P326, DOI 10.1023/A:1020599810261; Schnyder U W, 1968, Hautarzt, V19, P494; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SEDLACEK V, 1971, HAUTARZT, V22, P390; SHOVLIN CL, 1993, LANCET, V341, P1471, DOI 10.1016/0140-6736(93)90910-9; Stanley MA, 2009, INDIAN J MED RES, V130, P266; Stanley MA, 2003, LOWER GENITAL TRACT, P27; Sterling JC, 2001, BRIT J DERMATOL, V144, P4, DOI 10.1046/j.1365-2133.2001.04066.x; Stetson CL, 2002, J CUTAN PATHOL, V29, P502, DOI 10.1034/j.1600-0560.2002.290809.x; STEVENS DA, 1975, CLIN EXP IMMUNOL, V21, P520; Su HC, 2010, DIS MARKERS, V29, P121, DOI [10.1155/2010/607891, 10.3233/DMA-2010-0751]; Su HC, 2010, CURR OPIN ALLERGY CL, V10, P515, DOI 10.1097/ACI.0b013e32833fd718; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; TANIGAKI T, 1984, DERMATOLOGICA, V169, P97, DOI 10.1159/000249578; Tarzi MD, 2005, J ALLERGY CLIN IMMUN, V116, P1101, DOI 10.1016/j.jaci.2005.08.040; Tassone L, 2010, BLOOD, V116, P4870, DOI 10.1182/blood-2010-03-272096; THIVOLET J, 1977, ACTA DERM-VENEREOL, V57, P317; Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700; Tobin E, 2003, BRIT J DERMATOL, V149, P627, DOI 10.1046/j.1365-2133.2003.05543.x; Uluhan A, 1998, J RHEUMATOL, V25, P1205; Uzel G, 2001, GASTROENTEROLOGY, V121, P958, DOI 10.1053/gast.2001.28022; Uzel G, 2011, J CLIN IMMUNOL, V31, pS20; Uzel G, 2008, BLOOD, V111, P209, DOI 10.1182/blood-2007-04-082552; van Haalen FM, 2009, BRIT J DERMATOL, V161, P148, DOI 10.1111/j.1365-2133.2009.09160.x; VIAC J, 1977, CLIN EXP IMMUNOL, V29, P240; Vicente C, 2012, CRIT REV ONCOL HEMAT, V82, P1, DOI 10.1016/j.critrevonc.2011.04.007; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; Vinh DC, 2010, BLOOD, V115, P1519, DOI 10.1182/blood-2009-03-208629; Vohra S, 2010, INDIAN J DERMATOL VE, V76, P557, DOI 10.4103/0378-6323.69092; WALDMANN TA, 1983, J CLIN INVEST, V71, P282, DOI 10.1172/JCI110768; Weber F, 2001, BRIT J DERMATOL, V144, P1044, DOI 10.1046/j.1365-2133.2001.04196.x; Welters MJP, 2006, INT J CANCER, V118, P950, DOI 10.1002/ijc.21459; Welters MJP, 2003, CANCER RES, V63, P636; WESTON B, 1991, J PEDIATR-US, V118, P229, DOI 10.1016/S0022-3476(05)80488-3; WETZLER M, 1992, JAMA-J AM MED ASSOC, V267, P2179, DOI 10.1001/jama.267.16.2179; Wheeler CM, 2012, LANCET ONCOL, V13, P100, DOI 10.1016/S1470-2045(11)70287-X; WILKINSON RD, 1964, ARCH DERMATOL, V89, P46, DOI 10.1001/archderm.1964.01590250052010; WILLIAMS HC, 1993, BRIT J DERMATOL, V128, P504, DOI 10.1111/j.1365-2133.1993.tb00226.x; Winer RL, 2005, J INFECT DIS, V191, P731, DOI 10.1086/427557; WISKOTT A, 1937, MONATSSCHR KINDERH, V68, P212; WOODWORTH CD, 1992, CANCER RES, V52, P456; YILMAZ GG, 1995, PEDIATR DERMATOL, V12, P235, DOI 10.1111/j.1525-1470.1995.tb00166.x; Zhang QA, 2010, DIS MARKERS, V29, P131, DOI 10.3233/DMA-2010-0737; Zonios DI, 2008, BLOOD, V112, P287, DOI 10.1182/blood-2007-12-127878; ZUELZER WW, 1964, NEW ENGL J MED, V270, P699, DOI 10.1056/NEJM196404022701402	201	101	105	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1030	1048		10.1016/j.jaci.2012.07.049	http://dx.doi.org/10.1016/j.jaci.2012.07.049			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23036745	Green Accepted			2022-12-18	WOS:000310571400002
J	Zimmer, A; Bouley, J; Le Mignon, M; Pliquet, E; Horiot, S; Turfkruyer, M; Baron-Bodo, V; Horak, F; Nony, E; Louise, A; Moussu, H; Mascarell, L; Moingeon, P				Zimmer, Aline; Bouley, Julien; Le Mignon, Maxime; Pliquet, Elodie; Horiot, Stephane; Turfkruyer, Mathilde; Baron-Bodo, Veronique; Horak, Friedrich; Nony, Emmanuel; Louise, Anne; Moussu, Helene; Mascarell, Laurent; Moingeon, Philippe			A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Biomarker; dendritic cell; efficacy; proteomics; sublingual immunotherapy; tolerance	T-CELLS; VENOM IMMUNOTHERAPY; RETINOIC ACID; ANTIGEN; TOLERANCE; MECHANISMS; EXPRESSION; MACROPHAGES; INNATE; STIMULATION	Background: Given their pivotal role in the polarization of T-cell responses, molecular changes at the level of dendritic cells (DCs) could represent an early signature indicative of the subsequent orientation of adaptive immune responses during immunotherapy. Objective: We sought to investigate whether markers of effector and regulatory DCs are affected during allergen immunotherapy in relationship with clinical benefit. Methods: Differential gel electrophoresis and label-free mass spectrometry approaches were used to compare whole proteomes from human monocyte-derived DCs differentiated toward either regulatory or effector functions. The expression of those markers was assessed by using quantitative PCR in PBMCs from 79 patients with grass pollen allergy enrolled in a double-blind, placebo-controlled clinical study evaluating the efficacy of sublingual tablets in an allergen exposure chamber over a 4-month period. Results: We identified several markers associated with DC1 and/or DC17 effector DCs, including CD71, FSCN1, IRF4, NMES1, MX1, TRAF1. A substantial phenotypic heterogeneity was observed among various types of tolerogenic DCs, with ANXA1, Complement component 1 (C1Q), CATC, GILZ, F13A, FKBP5, Stabilin-1 (STAB1), and TPP1 molecules established as shared or restricted regulatory DC markers. The expression of 2 of those DCs markers, C1Q and STAB1, was increased in PBMCs from clinical responders in contrast to that seen in nonresponders or placebo-treated patients. Conclusion: C1Q and STAB1 represent candidate biomarkers of early efficacy of allergen immunotherapy as the hallmark of a regulatory innate immune response predictive of clinical tolerance. (J Allergy Clin Immunol 2012;129:1020-30.)	[Zimmer, Aline; Bouley, Julien; Le Mignon, Maxime; Pliquet, Elodie; Horiot, Stephane; Turfkruyer, Mathilde; Baron-Bodo, Veronique; Nony, Emmanuel; Moussu, Helene; Mascarell, Laurent; Moingeon, Philippe] Stallergenes, F-92183 Antony, France; [Horak, Friedrich] Allergy Ctr Vienna W, Dept Vienna Challenge Chamber, Vienna, Austria; [Louise, Anne] Inst Pasteur, Plateforme Cytometrie Flux IMAGOPOLE, Paris, France	Stallergenes Greer; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Moingeon, P (corresponding author), Stallergenes, 6 Rue Alexis de Tocqueville, F-92183 Antony, France.	pmoingeon@stallergenes.fr	Turfkruyer, Mathilde/M-5424-2019	Turfkruyer, Mathilde/0000-0001-7316-3044; Zimmer, Aline/0000-0003-0279-4863; Nony, Emmanuel/0000-0003-1820-8881	Stallergenes; CIFRE from ANRT (Association Nationale de la Recherche et de la Technologie)	Stallergenes; CIFRE from ANRT (Association Nationale de la Recherche et de la Technologie)	Supported by Stallergenes. A.Z. was supported by a CIFRE fellowship from ANRT (Association Nationale de la Recherche et de la Technologie).	Allam JP, 2011, ALLERGY, V66, P532, DOI 10.1111/j.1398-9995.2010.02510.x; Allam JP, 2010, J ALLERGY CLIN IMMUN, V126, P638, DOI 10.1016/j.jaci.2010.04.039; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Angelini F, 2011, WORLD J PEDIATR, V7, P24, DOI 10.1007/s12519-011-0242-3; Asahina T, 2000, PLACENTA, V21, P388, DOI 10.1053/plac.1999.0489; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bulla R, 2008, MOL IMMUNOL, V45, P2629, DOI 10.1016/j.molimm.2007.12.025; Bussmann C, 2010, ALLERGY, V65, P1558, DOI 10.1111/j.1398-9995.2010.02430.x; Castellano G, 2007, EUR J IMMUNOL, V37, P2803, DOI 10.1002/eji.200636845; Cupurdija K, 2004, AM J REPROD IMMUNOL, V51, P117, DOI 10.1046/j.8755-8920.2003.00128.x; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Ferreira GB, 2008, PROTEOM CLIN APPL, V2, P1349, DOI 10.1002/prca.200800110; Gregori S, 2011, TISSUE ANTIGENS, V77, P89, DOI 10.1111/j.1399-0039.2010.01615.x; Gregori S, 2010, BLOOD, V116, P935, DOI 10.1182/blood-2009-07-234872; Guilliams M, 2010, BLOOD, V115, P1958, DOI 10.1182/blood-2009-09-245274; Hamdi H, 2007, BLOOD, V110, P211, DOI 10.1182/blood-2006-10-052506; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; Jutel M, 2011, ALLERGY, V66, P725, DOI 10.1111/j.1398-9995.2011.02589.x; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Magnan A, 2001, CLIN EXP ALLERGY, V31, P1303, DOI 10.1046/j.1365-2222.2001.01171.x; Mascarell L, 2011, MUCOSAL IMMUNOL, V4, P638, DOI 10.1038/mi.2011.28; Mascarell L, 2008, J ALLERGY CLIN IMMUN, V122, P603, DOI 10.1016/j.jaci.2008.06.034; McLachlan JB, 2008, NAT MED, V14, P536, DOI 10.1038/nm1757; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Monti P, 2003, TRANSPLANTATION, V75, P137, DOI 10.1097/00007890-200301150-00025; Ohtani T, 2009, IMMUNOLOGY, V126, P485, DOI 10.1111/j.1365-2567.2008.02919.x; Palani S, 2011, EUR J IMMUNOL, V41, P2052, DOI 10.1002/eji.201041376; Penna G, 2007, J IMMUNOL, V178, P145, DOI 10.4049/jimmunol.178.1.145; Pulendran B, 2010, NAT IMMUNOL, V11, P647, DOI 10.1038/ni.1894; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Rao NV, 1997, J BIOL CHEM, V272, P10260; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Steinbrink K, 2002, BLOOD, V99, P2468, DOI 10.1182/blood.V99.7.2468; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Tversky JR, 2010, CLIN EXP ALLERGY, V40, P94, DOI 10.1111/j.1365-2222.2009.03388.x; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; van Kooten C, 2011, METHODS MOL BIOL, V677, P149, DOI 10.1007/978-1-60761-869-0_10; Vlad G, 2005, J IMMUNOL, V174, P5907, DOI 10.4049/jimmunol.174.10.5907; WALSH LJ, 1991, LAB INVEST, V65, P732; Watarai H, 2005, PROTEOMICS, V5, P4001, DOI 10.1002/pmic.200401258; Zaba LC, 2007, J CLIN INVEST, V117, P2517, DOI 10.1172/JCI32282; Zimmer A, 2011, J IMMUNOL, V186, P3966, DOI 10.4049/jimmunol.1003184	45	101	108	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1020	1030		10.1016/j.jaci.2012.02.014	http://dx.doi.org/10.1016/j.jaci.2012.02.014			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22464673				2022-12-18	WOS:000302144600018
J	Li, XN; Howard, TD; Moore, WC; Ampleford, EJ; Li, HS; Busse, WW; Calhoun, WJ; Castro, M; Chung, KF; Erzurum, SC; Fitzpatrick, AM; Gaston, B; Israel, E; Jarjour, NN; Teague, WG; Wenzel, SE; Peters, SP; Hawkins, GA; Bleecker, ER; Meyers, DA				Li, Xingnan; Howard, Timothy D.; Moore, Wendy C.; Ampleford, Elizabeth J.; Li, Huashi; Busse, William W.; Calhoun, William J.; Castro, Mario; Chung, Kian Fan; Erzurum, Serpil C.; Fitzpatrick, Anne M.; Gaston, Benjamin; Israel, Elliot; Jarjour, Nizar N.; Teague, W. Gerald; Wenzel, Sally E.; Peters, Stephen P.; Hawkins, Gregory A.; Bleecker, Eugene R.; Meyers, Deborah A.			Importance of hedgehog interacting protein and other lung function genes in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; genetics; asthma severity; meta-analysis; FEV1; FVC; FEV1/FVC; HHIP; FAM13A; PTCH1	GENOME-WIDE ASSOCIATION; VARIANTS; IDENTIFICATION; PHENOTYPES; GENETICS; RISK; COPD; LOCI	Background: Two recent large meta-analyses of genome-wide association studies of lung function in general populations of European descent identified 11 candidate genes/regions. The importance of these genes in lung function in white and African American subjects with asthma is unknown. Objectives: To determine whether genes that regulate lung function in general populations are associated with lung function abnormalities in subjects with asthma from different racial groups. Methods: Single nucleotide polymorphisms (SNPs) were tested in 5 asthma populations (N = 1441) for association with pulmonary function, and meta-analysis was performed across populations. The SNPs with the highest significance were then tested for association with bronchodilator reversibility and bronchial hyperresponsiveness to methacholine. A joint analysis of consistently replicated SNPs was performed to predict lung function in asthma. Results: Hedgehog interacting protein (HHIP) on chromosome 4q31 was associated with lung function in all 5 populations (rs1512288: P-meta = 9.62E-05 and 3.23E-05 for percent predicted FEV1 [ppFEV(1)] and percent predicted forced vital capacity [ppFVC], respectively). The SNPs in HHIP were also associated with reversibility (P < .05) but not bronchial hyperresponsiveness to methacholine. Because of differences in linkage disequilibrium in the African American subjects, the most relevant SNPs in HHIP were identified. A subset of normal lung function genes, including HHIP, family with sequence similarity 13, member A (FAM13A), and patched homolog 1 (PTCH1), together predict lung function abnormalities, a measure of severity in white and African American subjects with asthma. Conclusion: A subset of the genes, including HHIP, that regulate lung function in general populations are associated with abnormal lung function in asthma in non-Hispanic white and African American subjects. (J Allergy Clin Immunol 2011;127:1457-65.)	[Li, Xingnan; Howard, Timothy D.; Moore, Wendy C.; Ampleford, Elizabeth J.; Li, Huashi; Peters, Stephen P.; Hawkins, Gregory A.; Bleecker, Eugene R.; Meyers, Deborah A.] Wake Forest Univ, Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27157 USA; [Busse, William W.] Univ Wisconsin, Dept Med, Madison, WI USA; [Calhoun, William J.] Univ Texas Med Branch, Dept Internal Med, St Louis, MO USA; [Castro, Mario] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Castro, Mario] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Chung, Kian Fan] Imperial Coll Sch Med, Dept Resp Med, London, England; [Erzurum, Serpil C.] Lerner Res Inst, Cleveland, OH USA; [Fitzpatrick, Anne M.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Gaston, Benjamin; Teague, W. Gerald] Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA USA; [Israel, Elliot] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Jarjour, Nizar N.] Univ Wisconsin Hosp & Clin, Dept Med, Madison, WI 53792 USA; [Jarjour, Nizar N.] Univ Wisconsin Hosp & Clin, Dept Publ Hlth Sci, Madison, WI 53792 USA; [Wenzel, Sally E.] Univ Pittsburgh, Pittsburgh, PA USA	Wake Forest University; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Medical Branch Galveston; Washington University (WUSTL); Washington University (WUSTL); Imperial College London; Cleveland Clinic Foundation; Emory University; University of Virginia; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Meyers, DA (corresponding author), Wake Forest Univ, Sch Med, Ctr Genom & Personalized Med Res, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dmeyers@wfubmc.edu	Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Fitzpatrick, Anne/0000-0002-2933-5926; Wenzel, Sally/0000-0002-4242-0164; Calhoun, William/0000-0001-7075-712X	National Institutes of Health (NIH) [HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, HL091762, HL87665]; Genentech, Inc; Novartis Pharmaceuticals Corp; National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute (NHLBI); Novartis; AstraZeneca; GlaxoSmithKline; MedImmune; Boehringer Ingelheim; Pfizer; Merck; Asthmatx; Amgen; Ception; Genentech; Medical Research Council (United Kingdom); Wellcome Trust; Asthma UK; NIH/NHLBI; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992, M01RR018390, M01RR007122, M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069149, R01HL076285, R01HL069116, R01HL069155, R01HL069170, R01HL069349, R01HL087665, R01HL069130, R01HL069167, R01HL069174, R01HL091762] Funding Source: NIH RePORTER; Medical Research Council [G1000758B, G0801056B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech, Inc(Roche HoldingGenentech); Novartis Pharmaceuticals Corp(Novartis); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Novartis(Novartis); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Boehringer Ingelheim(Boehringer Ingelheim); Pfizer(Pfizer); Merck(Merck & Company); Asthmatx; Amgen(Amgen); Ception; Genentech(Roche HoldingGenentech); Medical Research Council (United Kingdom)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Severe Asthma Research Program centers were supported by National Institutes of Health (NIH) grants HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, and HL091762. Genetic studies for the Severe Asthma Research Program and the Collaborative Studies on the Genetics of Asthma were funded by NIH HL87665. The clinical The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens study was supported by Genentech, Inc, and Novartis Pharmaceuticals Corp, and the genetic studies were funded by NIH HL76285 and HL87665.; Disclosure of potential conflict of interest: W. W. Busse is on advisory boards for Centocor and Merck; has consulted for AstraZeneca, Boehringer Ingelheim, Novartis, TEVA, GlaxoSmithKline, Amgen, Pfizer, MedImmune, and Genentech; and has received research support from the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases, the National Heart, Lung, and Blood Institute (NHLBI), Novartis, AstraZeneca, GlaxoSmithKline, MedImmune, and Ception. M. Castro has consulted for Electrocore, NKTT, Schering, Asthmatx, and Cephalon; has served on an advisory board for Genentech; has given lectures funded by AstraZeneca, Boehringer Ingelheim, Pfizer, Merck, and GlaxoSmithKline; has received research support through his institution from Asthmatx, Amgen, Ception, Genentech, MedImmune, Merck, Novartis, NIH, and GlaxoSmithKline; and has received royalties from Elsevier. K. F. Chung has consulted for Gilead; has served on advisory boards for Merck and GlaxoSmithKine; and has received research support from the Medical Research Council (United Kingdom), Asthma UK, and the Wellcome Trust. S. C. Erzurum has received research support from Asthmatx. B. Gaston has received research support from the NIH and has provided legal consultation or expert witness testimony on the topic of exhaled nitric oxide (Apcron). N. N. Jarjour has consulted for Asthmatx and has received research support from Merck and GlaxoSmithKline. W. G. Teague has given lectures for Merck and has received research support from the NIH/NHLBI. S. P. Peters has received research support from the NIH/NHLBI. G. A. Hawkins, E. R. Bleecker, and D. A. Meyers have received research support from the NIH. The rest of the authors have declared that they have no conflict of interest.	Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Cho MH, 2010, NAT GENET, V42, P200, DOI 10.1038/ng.535; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gudbjartsson DF, 2008, NAT GENET, V40, P609, DOI 10.1038/ng.122; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; Jeong JH, 2005, DEVELOPMENT, V132, P143, DOI 10.1242/dev.01566; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Miller LAD, 2004, DEV DYNAM, V231, P57, DOI 10.1002/dvdy.20105; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; *NAT ASTHM ED PREV, 2007, 074051 NAT HEART LUN; *NAT I HLTH, GLOB IN ASTHM GLOB S; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Sadeghnejad A, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-21; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Warburton D, 2005, PEDIATR RES, V57, p26R, DOI 10.1203/01.PDR.0000159570.01327.ED; Weedon MN, 2008, NAT GENET, V40, P575, DOI 10.1038/ng.121; Weiss ST, 2010, NAT GENET, V42, P14, DOI 10.1038/ng0110-14; Wilk JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000429; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589	35	101	105	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1457	1465		10.1016/j.jaci.2011.01.056	http://dx.doi.org/10.1016/j.jaci.2011.01.056			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21397937	Green Accepted			2022-12-18	WOS:000291048500022
J	Silverberg, JI; Kleiman, E; Lev-Tov, H; Silverberg, NB; Durkin, HG; Joks, R; Smith-Norowitz, TA				Silverberg, Jonathan I.; Kleiman, Edward; Lev-Tov, Hadar; Silverberg, Nanette B.; Durkin, Helen G.; Joks, Rauno; Smith-Norowitz, Tamar A.			Association between obesity and atopic dermatitis in childhood: A case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; obesity; overweight; body mass index; weight; eczema; atopy	BODY-MASS INDEX; ADIPOSE-TISSUE; OVERWEIGHT CHILDREN; WEIGHT-REDUCTION; ASTHMA SYMPTOMS; OLD CHILDREN; US CHILDREN; LEPTIN; ADOLESCENTS; PROLIFERATION	Background: Obesity in children is associated with increased asthma and atopy. Objective: We sought to determine whether obesity in childhood or adolescence increases the risk of atopic dermatitis. Methods: This retrospective, practice-based, case-control study randomly sampled 414 children and adolescents (age, 1-21 years) with atopic dermatitis between January 2000 and December 2007 and 828 randomly sampled healthy control subjects. Information was obtained from an electronic medical record. Observations were made before the a priori hypothesis. Results: Obesity in children is associated with increased atopic dermatitis (conditional logistic regression: odds ratio, 2.00; 95% CI, 1.22-3.26; P = .006). These atopic dermatitis-predisposing effects are found when obesity started by less than 2 years of age (adjusted odds ratio [aOR], 15.10; 95% CI, 1.51-151.21; P = .02) and 2 to 5 years (aOR, 2.58; 95% CI, 1.24-5.41; P = .01) but not greater than 5 years (aOR, 1.32; 95% CI, 0.66-2.64; P = .43) and when obesity was prolonged for 2.5 to 5 years (aOR, 2.64; 95% CI, 1.13-6.18; P = .03) and greater than 5 years (aOR, 3.40; 95% CI, 1.34-8.63; P = 0.01). Obesity is associated with more severe atopic dermatitis (ordinal logistic regression: aOR, 2.37; 95% CI, 1.24-5.37; P = .01). Obese children who eventually have atopic dermatitis require more frequent pediatrician visits for the management of atopic dermatitis (ordinal logistic regression: aOR, 2.22; 95% CI, 1.12-4.50; P = .03). Conclusion: Prolonged obesity in early childhood is a risk factor for atopic dermatitis. Weight loss might be an important approach for the prevention and treatment of atopic dermatitis in children. (J Allergy Clin Immunol 2011;127:1180-6.)	[Silverberg, Jonathan I.; Silverberg, Nanette B.] Beth Israel Deaconess Med Ctr, Dept Dermatol, New York, NY 10025 USA; [Silverberg, Jonathan I.; Silverberg, Nanette B.] St Lukes Roosevelt Hosp, New York, NY USA; [Silverberg, Jonathan I.; Durkin, Helen G.; Joks, Rauno; Smith-Norowitz, Tamar A.] Suny Downstate Med Ctr, SUNY Downstate, Ctr Allergy & Asthma Res, Brooklyn, NY 11203 USA; [Silverberg, Jonathan I.; Kleiman, Edward; Lev-Tov, Hadar; Durkin, Helen G.; Joks, Rauno] Suny Downstate Med Ctr, SUNY Downstate, Dept Med, Brooklyn, NY 11203 USA; [Durkin, Helen G.; Smith-Norowitz, Tamar A.] Suny Downstate Med Ctr, SUNY Downstate, Dept Pediat, Brooklyn, NY 11203 USA; [Silverberg, Jonathan I.] Suny Downstate Med Ctr, SUNY Downstate, Sch Publ Hlth, Brooklyn, NY 11203 USA	Harvard University; Beth Israel Deaconess Medical Center; Mount Sinai St. Luke's; Mount Sinai West; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Silverberg, JI (corresponding author), Beth Israel Deaconess Med Ctr, Dept Dermatol, Suite 11B,1090 Amsterdam Ave, New York, NY 10025 USA.	JonathanISilverberg@Gmail.com	silverberg, jonathan/ABH-2765-2021; panduru, mihaela/H-2411-2011	silverberg, jonathan/0000-0003-3686-7805; 				Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; [Anonymous], 1967, HDB METHODS APPL STA; Caldefie-Chezet F, 2003, FREE RADICAL RES, V37, P809, DOI 10.1080/1071576031000097526; Chow SC, 2003, SAMPLE SIZE CALCULAT; De Onis M, 2004, FOOD NUTR BULL, V25, pS1; Dietz WH, 1998, PEDIATRICS, V101, P518; Faggioni R, 2001, FASEB J, V15, P2565, DOI 10.1096/fj.01-0431rev; Fagot-Campagna A, 2001, BMJ-BRIT MED J, V322, P377, DOI 10.1136/bmj.322.7283.377; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Figueroa-Munoz JI, 2001, THORAX, V56, P133, DOI 10.1136/thorax.56.2.133; Freedman DS, 2007, J PEDIATR-US, V150, P12, DOI 10.1016/j.jpeds.2006.08.042; Freedman DS, 2007, J PEDIAT, V150, pe2; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; KAPLAN BA, 1987, HUM BIOL, V59, P921; Kiguchi N, 2009, BIOCHEM BIOPH RES CO, V384, P311, DOI 10.1016/j.bbrc.2009.04.121; Kuczmarski Robert J, 2002, Vital Health Stat 11, P1; LARSEN FS, 1992, ACTA DERM-VENEREOL, P7; Lee SI, 2001, J KOREAN MED SCI, V16, P155, DOI 10.3346/jkms.2001.16.2.155; Lord GM, 2002, J LEUKOCYTE BIOL, V72, P330; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; Mai XM, 2003, ACTA PAEDIATR, V92, P1144, DOI 10.1080/08035250310005666; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Must Aviva, 2003, Nutr Clin Care, V6, P4; Nagel G, 2009, PEDIAT ALLERG IMM-UK, V20, P81, DOI 10.1111/j.1399-3038.2008.00740.x; Ogden CL, 2008, JAMA-J AM MED ASSOC, V299, P2401, DOI 10.1001/jama.299.20.2401; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Rausch ME, 2008, INT J OBESITY, V32, P451, DOI 10.1038/sj.ijo.0803744; Rothe MJ, 1996, LANCET, V348, P769, DOI 10.1016/S0140-6736(05)65206-3; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3rd ed; Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Schwartz M B, 2003, Obes Rev, V4, P57, DOI 10.1046/j.1467-789X.2003.00093.x; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Silverberg JI, 2010, J ALLERGY CLIN IMMUN, V126, P300, DOI 10.1016/j.jaci.2010.05.041; SOMERVILLE SM, 1984, ARCH DIS CHILD, V59, P940, DOI 10.1136/adc.59.10.940; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Tai A, 2009, J ASTHMA, V46, P362, DOI 10.1080/02770900902759260; Tian ZG, 2002, BIOCHEM BIOPH RES CO, V298, P297, DOI 10.1016/S0006-291X(02)02462-2; Violante Rafael, 2005, Rev Alerg Mex, V52, P141; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, pS72, DOI 10.1016/j.jaci.2008.12.246; Vlaski E, 2006, Allergol Immunopathol (Madr), V34, P199; von Kries R, 2001, ALLERGY, V56, P318, DOI 10.1034/j.1398-9995.2001.00727.x; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P1; Wuthrich B, 1999, ANN ALLERG ASTHMA IM, V83, P464, DOI 10.1016/S1081-1206(10)62852-9	50	101	104	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1180	U456		10.1016/j.jaci.2011.01.063	http://dx.doi.org/10.1016/j.jaci.2011.01.063			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21411132				2022-12-18	WOS:000290018600012
J	Maneechotesuwan, K; Ekjiratrakul, W; Kasetsinsombat, K; Wongkajornsilp, A; Barnes, PJ				Maneechotesuwan, Kittipong; Ekjiratrakul, Wuttichai; Kasetsinsombat, Kanda; Wongkajornsilp, Adisak; Barnes, Peter J.			Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Indoleamine 2, 3-dioxygenase; kynurenine; inhaled corticosteroid; simvastatin; asthma	KAPPA-B ACTIVATION; T-CELL PROLIFERATION; TRYPTOPHAN CATABOLISM; DENDRITIC CELLS; SIMVASTATIN TREATMENT; AUTOIMMUNE-DISEASE; ALLERGIC-ASTHMA; INFLAMMATION; INHIBITION; MODEL	Background: We have previously shown that inhaled corticosteroids activate indoleamine 2, 3-dioxygenase (IDO) activity through increased IL-10 secretion. Statins might enhance the anti-inflammatory effects of corticosteroids. Objective: In a double-blind study we added simvastatin to patients with mild asthma receiving a low dose of inhaled budesonide and evaluated sputum eosinophil counts, IL-10 secretion, and IDO activity, as well as their putative signaling pathways. Methods: After a 2-week run-in period without treatment, 50 asthmatic patients were treated with 200 mu g of budesonide and randomly assigned to either 10 mg of simvastatin or matched placebo for 8 weeks. Inflammation was evaluated through eosinophil counts, secretory signaling molecules, and immunocytochemistry of macrophages in sputum. Results: Sputum eosinophil percentages were reduced significantly by the combined therapy with budesonide and simvastatin compared with budesonide alone (P = .02). Corticosteroids activated glucocorticoid-induced TNF receptor ligand, which induces activation of p52 through the noncanonical nuclear factor kappa B pathway, leading to the increased transcription and activation of IDO. Simvastatin enhanced corticosteroid-activated noncanonical nuclear factor kappa B-dependent induction of IDO by activating type I interferons and also enhanced the effect of corticosteroid on IL-10 release. Conclusion: A statin enhances the anti-inflammatory effect of an inhaled corticosteroid in asthma, and this was mediated through the alteration of IDO activity in macrophages. (J Allergy Clin Immunol 2010;126:754-62.)	[Maneechotesuwan, Kittipong; Ekjiratrakul, Wuttichai] Mahidol Univ, Fac Med, Siriraj Hosp, Div Resp Dis & TB,Dept Internal Med, Bangkok 10700, Thailand; [Kasetsinsombat, Kanda; Wongkajornsilp, Adisak] Mahidol Univ, Fac Med, Siriraj Hosp, Dept Pharmacol, Bangkok 10700, Thailand; [Barnes, Peter J.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Mahidol University; Mahidol University; Imperial College London	Maneechotesuwan, K (corresponding author), Mahidol Univ, Fac Med, Siriraj Hosp, Div Resp Dis & TB,Dept Internal Med, 2 Prannok Rd, Bangkok 10700, Thailand.	sikmn@mahidol.ac.th	Wongkajornsilp, Adisak/AAH-7668-2019	Wongkajornsilp, Adisak/0000-0002-3965-0997; Barnes, Peter/0000-0002-5122-4018	Research Development and Medical Education of the Faculty of Medicine Siriraj Hospital, Mahidol University; GlaxoSmithKline; AstraZeneca; Novartis	Research Development and Medical Education of the Faculty of Medicine Siriraj Hospital, Mahidol University; GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Novartis(Novartis)	Supported by the Siriraj Grant for Research Development and Medical Education of the Faculty of Medicine Siriraj Hospital, Mahidol University.; Disclosure of potential conflict of interest: P.J. Barnes has received research support from GlaxoSmithKline, AstraZeneca, and Novartis. The rest of the authors have declared that they have no conflict of interest.	Aprahamian T, 2006, J IMMUNOL, V177, P3028, DOI 10.4049/jimmunol.177.5.3028; Barnes N, 2007, RESP MED, V101, P1652, DOI 10.1016/j.rmed.2007.03.007; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Kim DY, 2007, EUR J PHARMACOL, V557, P76, DOI 10.1016/j.ejphar.2006.11.027; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Maneechotesuwan K, 2008, J ALLERGY CLIN IMMUN, V121, P43, DOI 10.1016/j.jaci.2007.10.011; Maneechotesuwan K, 2007, CHEST, V132, P98, DOI 10.1378/chest.06-2982; McKay A, 2004, J IMMUNOL, V172, P2903, DOI 10.4049/jimmunol.172.5.2903; Mellor AL, 2001, NAT IMMUNOL, V2, P64, DOI 10.1038/83183; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Shirinsky IV, 2009, SCAND J RHEUMATOL, V38, P23, DOI 10.1080/03009740802363776; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P704, DOI 10.1164/rccm.200408-1041OC; Yang CH, 2005, J BIOL CHEM, V280, P31530, DOI 10.1074/jbc.M503120200; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zamvil SS, 2002, NEUROLOGY, V59, P970, DOI 10.1212/WNL.59.7.970; Zeki AA, 2009, AM J RESP CRIT CARE, V180, P731, DOI 10.1164/rccm.200901-0018OC	22	101	104	3	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					754	U121		10.1016/j.jaci.2010.08.005	http://dx.doi.org/10.1016/j.jaci.2010.08.005			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920765				2022-12-18	WOS:000282510000011
J	Chinen, J; Shearer, WT				Chinen, Javier; Shearer, William T.			Secondary immunodeficiencies, including HIV infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Secondary immunodeficiency; immunosuppression; lymphopenia; AIDS	ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE-RESPONSES; RESPIRATORY-INFECTIONS; IFN-GAMMA; CHILDREN; CYTOKINES; SYSTEM; PLASMA; SUPPRESSION; ACTIVATION	Extrinsic factors can adversely affect immune responses, producing states of secondary immunodeficiency and consequent increased risk of infections. These immunodeficiencies, which can be encountered in routine clinical practice, arise from a number of conditions, such as treatment with glucocorticoids and immunomodulatory drugs, surgery and trauma, extreme environmental conditions, and chronic infections, such as those caused by HIV. The most common cause of immunodeficiency is malnutrition, affecting many communities around the world with restricted access to food resources. Protein-calorie deficiency and micronutrient deficiencies have been shown to alter immune responses; of note, recent progress has been made in the influence of vitamin D deficiency in causing failure of immune activation. Other categories of disease that might present with secondary immunodeficiency include metabolic diseases and genetic multisystemic syndromes. The immune defects observed in secondary immunodeficiency are usually heterogeneous in their clinical presentation, and their prognosis depends on the severity of the immune defect. Management of the primary condition often results in improvement of the immunodeficiency; however, this is sometimes not possible, and the risk of infections can be reduced with prompt antimicrobial treatment and prophylaxis. (J Allergy Clin Immunol 2010;125:S195-203.)	[Chinen, Javier] Texas Childrens Hosp, Dept Pediat, Allergy & Immunol Sect, Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Chinen, J (corresponding author), Texas Childrens Hosp, Dept Pediat, Allergy & Immunol Sect, Baylor Coll Med, 1102 Bates St,FC 330-01, Houston, TX 77030 USA.	jxchinen@texaschildrenshospital.org		Shearer, William/0000-0002-2483-2130	National Institutes of Health [AI27551, AI36211, AI6944I, HD41983, RR0188, HD79533, HL72705, HD78522]; David Fund; Pediatrics AIDS Fund; Texas Children's Hospital; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD079533] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD041983] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188, K01RR000188] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211, U01AI027551, U01AI069441] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); David Fund; Pediatrics AIDS Fund; Texas Children's Hospital; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI27551, AI36211, AI6944I, HD41983, RR0188, HD79533, HL72705, and HD78522 and the David Fund, the Pediatrics AIDS Fund, and the Immunology Research Fund, Texas Children's Hospital.	Adams JS, 2007, ANN NY ACAD SCI, V1117, P94, DOI 10.1196/annals.1402.036; Annane D, 2009, JAMA-J AM MED ASSOC, V301, P2362, DOI 10.1001/jama.2009.815; Baker BM, 2009, EXPERT OPIN BIOL TH, V9, P55, DOI [10.1517/14712590802571928, 10.1517/14712590802571928 ]; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Brennan S, 2008, PAEDIATR RESPIR REV, V9, P271, DOI 10.1016/j.prrv.2008.05.008; Castle SC, 2007, CLIN GERIATR MED, V23, P463, DOI 10.1016/j.cger.2007.03.005; *CDCP, 2007, HIV AIDS SURV REP, V19; Cunningham-Rundles S, 2005, J ALLERGY CLIN IMMUN, V115, P1119, DOI 10.1016/j.jaci.2005.04.036; Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8; Daoud AK, 2009, J IMMUNOTOXICOL, V6, P36, DOI 10.1080/15476910802604564; Davis CM, 2008, J ALLERGY CLIN IMMUN, V121, P826, DOI 10.1016/j.jaci.2007.10.021; De Hingh YCM, 2005, J PEDIATR-US, V147, P744, DOI 10.1016/j.jpeds.2005.07.022; Dorshkind K, 2009, NAT REV IMMUNOL, V9, P57, DOI 10.1038/nri2471; Douglas SD, 2005, J PEDIATR-US, V147, P723, DOI 10.1016/j.jpeds.2005.09.002; Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185; Flohe SB, 2008, INNATE IMMUN-LONDON, V14, P333, DOI 10.1177/1753425908100016; Foley RN, 2008, PERITON DIALYSIS INT, V28, pS167; Foster SB, 2008, J ALLERGY CLIN IMMUN, V122, P159, DOI 10.1016/j.jaci.2008.04.043; French MA, 2009, CLIN INFECT DIS, V48, P101, DOI 10.1086/595006; Gomez CR, 2008, EXP GERONTOL, V43, P718, DOI 10.1016/j.exger.2008.05.016; Hamer DH, 2009, J NUTR, V139, P113, DOI 10.3945/jn.108.095091; Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555; Haynes BF, 2008, J ALLERGY CLIN IMMUN, V122, P3, DOI 10.1016/j.jaci.2008.03.036; Heizmann O, 2008, J TRAUMA, V65, P1374, DOI 10.1097/TA.0b013e31818b257d; Hicks C, 2009, CLIN INFECT DIS, V48, P931, DOI 10.1086/597290; Joffre O, 2009, IMMUNOL REV, V227, P234, DOI 10.1111/j.1600-065X.2008.00718.x; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Kusunoki Y, 2008, INT J RADIAT BIOL, V84, P1, DOI 10.1080/09553000701616106; Lee SJ, 2010, J ALLERGY CLIN IMMUN, V125, pS314, DOI 10.1016/j.jaci.2009.08.018; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Lim WH, 2007, KIDNEY INT, V72, P1138, DOI 10.1038/sj.ki.5002425; Lindblom A, 2008, CLIN INFECT DIS, V46, P528, DOI 10.1086/526522; MacArthur RD, 2008, CLIN INFECT DIS, V47, P236, DOI 10.1086/589289; McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5; Newell ML, 2007, LANCET, V369, P617, DOI 10.1016/S0140-6736(07)60288-8; Norris PJ, 2006, AIDS RES HUM RETROV, V22, P757, DOI 10.1089/aid.2006.22.757; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Opelz G, 2009, TRANSPLANTATION, V87, P795, DOI 10.1097/TP.0b013e318199c1c7; Pahwa S, 2007, J ALLERGY CLIN IMMUN, V119, P1538, DOI 10.1016/j.jaci.2006.12.674; Patel RV, 2009, J AM ACAD DERMATOL, V60, P1001, DOI 10.1016/j.jaad.2008.12.031; Paul ME, 2005, J ALLERGY CLIN IMMUN, V115, P848, DOI 10.1016/j.jaci.2004.11.054; Raff AC, 2008, CURR OPIN NEPHROL HY, V17, P560, DOI 10.1097/MNH.0b013e32830f45b6; Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498; Roth DE, 2008, B WORLD HEALTH ORGAN, V86, P356, DOI 10.2471/BLT.07.049114; Saag KG, 2008, ARTHRIT RHEUM-ARTHR, V59, P762, DOI 10.1002/art.23721; Shapiro RL, 2009, J INFECT DIS, V199, P414, DOI 10.1086/596034; Shearer WT, 2009, J ALLERGY CLIN IMMUN, V123, P900, DOI 10.1016/j.jaci.2008.12.016; Shearer WT, 2005, J ALLERGY CLIN IMMUN, V115, P1297, DOI 10.1016/j.jaci.2005.03.003; Shearer WT, 2002, J ALLERGY CLIN IMMUN, V109, P854, DOI 10.1067/mai.2002.123873; Shen L, 2008, J ALLERGY CLIN IMMUN, V122, P22, DOI 10.1016/j.jaci.2008.05.033; Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508; Stahn C, 2008, NAT CLIN PRACT RHEUM, V4, P525, DOI 10.1038/ncprheum0898; Tan HP, 2006, DRUGS, V66, P1535, DOI 10.2165/00003495-200666120-00001; Tschoeke SK, 2007, INJURY, V38, P1346, DOI 10.1016/j.injury.2007.08.041; *UNAIDS, 2008, 2008 REP GLOB AIDS E; Weinberger B, 2008, CLIN INFECT DIS, V46, P1078, DOI 10.1086/529197; Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, 2009, GUID US ANT AG PED H; Yost CC, 2009, BLOOD, V113, P6419, DOI 10.1182/blood-2008-07-171629; [No title captured]; [No title captured]; [No title captured]; [No title captured]	64	101	107	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S195	S203		10.1016/j.jaci.2009.08.040	http://dx.doi.org/10.1016/j.jaci.2009.08.040			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20042227	Green Accepted			2022-12-18	WOS:000280170600017
J	Khodoun, M; Strait, R; Orekov, T; Hogan, S; Karasuyama, H; Herbert, DR; Kohl, J; Finkelman, FD				Khodoun, Marat; Strait, Richard; Orekov, Tatyana; Hogan, Simon; Karasuyama, Hajime; Herbert, De'Broski R.; Koehl, Joerg; Finkelman, Fred D.			Peanuts can contribute to anaphylactic shock by activating complement	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; C3a; complement; anaphylaxis; shock; macrophages; mart cells; basophils; platelet-activating factor; histamine	CELL WALL COMPONENTS; IGE-BINDING EPITOPES; MAST-CELLS; CUTTING EDGE; IN-VIVO; TARGETED DISRUPTION; ACQUIRED-IMMUNITY; ALLERGIC-ASTHMA; EFFECTOR PHASE; BETA-BLOCKERS	Background: Peanut allergy is the most common food-related cause of lethal anaphylaxis and, unlike other food allergies, typically persists into adulthood. Resistance to digestion and dendritic cell activation by the major peanut allergen Ara h 1 are reported to contribute to its allergenicity. Objective: We sought to evaluate whether peanut molecules might also promote anaphylaxis through an innate immune mechanism. Methods: Naive mice were treated with a beta-adrenergic receptor antagonist and long-acting IL-4 to increase sensitivity to vasoactive mediators and injected with peanut extract (PE). Shock was detected and quantified by means of rectal thermometry. Gene-deficient mice and specific antagonists were used to determine the roles of specific cell types, complement, Fc receptors, and vasoactive mediators in shock pathogenesis. Results: PE induces dose-dependent shock. PE activates complement in vivo in mice and in vitro in mice and human subjects. C3a and, to a lesser extent, stimulatory immunoglobulin receptors contribute to PE-induced shock. PE-induced shock depends more on macrophages and basophils than on mast cells. Platelet-activating factor and, to a lesser extent, histamine contribute to PE-induced shock. PE induces shock in the absence of the adaptive immune system. LPS contamination is not responsible for PE-induced shock. PE and IgE-mediated mast cell degranulation synergistically induce shock. Tree nuts have similar effects to PE, and skim milk and egg white do not. Conclusion: Peanuts can contribute to shock by causing production of C3a, which stimulates macrophages, basophils, and mast cells to produce platelet-activating factor and histamine. (J Allergy Clin Immunol 2009;123:342-51.)	[Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Med, Div Immunol, Cincinnati, OH 45267 USA; [Khodoun, Marat; Orekov, Tatyana; Herbert, De'Broski R.; Finkelman, Fred D.] Univ Cincinnati, Coll Med, Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45267 USA; [Strait, Richard] Cincinnati Childrens Hosp, Med Ctr, Div Emergency Med, Cincinnati, OH USA; [Hogan, Simon] Cincinnati Childrens Hosp, Med Ctr, Div Clin Immunol & Allergy, Cincinnati, OH USA; [Koehl, Joerg] Cincinnati Childrens Hosp, Med Ctr, Div Mol Immunol, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH USA; [Karasuyama, Hajime] Tokyo Med & Dent Univ, Grad Sch, Dept Immune Regulat, Tokyo, Japan; [Koehl, Joerg] Med Univ Lubeck, Inst Syst Inflammat Res, Lubeck, Germany	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Tokyo Medical & Dental University (TMDU); University of Lubeck	Finkelman, FD (corresponding author), Univ Cincinnati, Coll Med, Dept Med, Div Immunol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	ffinkelman@pol.net	Herbert, De'Broski/J-7357-2012; Herbert, DeBroski/AAD-3035-2019; Koehl, Joerg/C-8531-2011; Karasuyama, Hajime/A-7966-2011	Herbert, De'Broski/0000-0002-2449-5365; Herbert, DeBroski/0000-0002-2449-5365; Koehl, Joerg/0000-0003-1121-3178; Karasuyama, Hajime/0000-0003-0689-0836	US Department of Veterans Affairs and by National Institutes of Health [R21AI079947, R01GM083204, R01AI052099, AI059305, RO1AI073553, P30DK078392]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073553, R01AI052099, R21AI079947, R01AI057839, R21AI059305, R01AI059305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083204] Funding Source: NIH RePORTER	US Department of Veterans Affairs and by National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by a merit award from the US Department of Veterans Affairs and by National Institutes of Health grants R21AI079947, R01GM083204, R01AI052099 (F.D.F.), AI059305 (J.K.), RO1AI073553 (S.H.), and P30DK078392 (R.S.).	ABUL K, 2003, CELLULAR MOL IMMUNOL; Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Ali H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-19; Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341; Baelder R, 2005, J IMMUNOL, V174, P783, DOI 10.4049/jimmunol.174.2.783; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; BECKER EL, 1968, BRIT J PHARMACOL, V34, P330, DOI 10.1111/j.1476-5381.1968.tb07054.x; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Cauwels A, 2006, J CLIN INVEST, V116, P2244, DOI 10.1172/JCI25426; CAVAILLON JM, 1990, EUR J IMMUNOL, V20, P253, DOI 10.1002/eji.1830200204; DECAROLIS C, 1982, J ALLERGY CLIN IMMUN, V70, P219, DOI 10.1016/0091-6749(82)90045-8; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; GRENCIS RK, 1993, PARASITE IMMUNOL, V15, P55, DOI 10.1111/j.1365-3024.1993.tb00572.x; Hawlisch H, 2004, MOL IMMUNOL, V41, P123, DOI 10.1016/j.molimm.2004.03.019; Hopken UE, 1997, J EXP MED, V186, P749, DOI 10.1084/jem.186.5.749; Hoshino K, 1999, J IMMUNOL, V162, P3749; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; Kojima T, 2007, J IMMUNOL, V179, P7093, DOI 10.4049/jimmunol.179.10.7093; LANG DM, 1995, DRUG SAFETY, V12, P299, DOI 10.2165/00002018-199512050-00002; Leone R, 2005, DRUG SAFETY, V28, P547, DOI 10.2165/00002018-200528060-00006; Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5; Madden KB, 2004, J IMMUNOL, V172, P5616, DOI 10.4049/jimmunol.172.9.5616; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; MENCIAHUERTA JM, 1979, EUR J IMMUNOL, V9, P409, DOI 10.1002/eji.1830090512; Mizgerd JP, 1996, J LEUKOCYTE BIOL, V59, P189, DOI 10.1002/jlb.59.2.189; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MONDINO BJ, 1990, INVEST OPHTH VIS SCI, V31, P1945; Nakajima K, 1997, J BIOL CHEM, V272, P19708, DOI 10.1074/jbc.272.32.19708; Nakano Y, 2003, J ALLERGY CLIN IMMUN, V112, P525, DOI 10.1067/mai.2003.1710; Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200; Palmer K, 2006, CURR OPIN ALLERGY CL, V6, P202, DOI 10.1097/01.all.0000225161.60274.31; Peitzman A B, 1995, Curr Probl Surg, V32, P925, DOI 10.1016/S0011-3840(05)80008-5; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Proust B, 2008, INT ARCH ALLERGY IMM, V146, P212, DOI 10.1159/000115889; REISMAN RE, 1992, MED CLIN N AM, V76, P883, DOI 10.1016/S0025-7125(16)30330-3; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Stager S, 2003, NAT MED, V9, P1287, DOI 10.1038/nm933; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Takeuchi O, 2000, INT IMMUNOL, V12, P113, DOI 10.1093/intimm/12.1.113; TenBrook JA, 2004, J ALLERGY CLIN IMMUN, V113, P977, DOI 10.1016/j.jaci.2004.02.043; Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305; Trendelenburg M, 2005, J IMMUNOL, V175, P6909, DOI 10.4049/jimmunol.175.10.6909; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Urban JF, 2001, J IMMUNOL, V167, P6078, DOI 10.4049/jimmunol.167.11.6078; van Wijk F, 2005, TOXICOL SCI, V86, P333, DOI 10.1093/toxsci/kfi187; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; VONZABERN I, 1984, INT ARCH ALLER A IMM, V75, P164, DOI 10.1159/000233608; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490	63	101	103	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					342	351		10.1016/j.jaci.2008.11.004	http://dx.doi.org/10.1016/j.jaci.2008.11.004			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19121857	Green Accepted			2022-12-18	WOS:000263495000008
J	Saunders, R; Siddiqui, S; Kaur, D; Doe, C; Sutcliffe, A; Hollins, F; Bradding, P; Wardlaw, A; Brightling, CE				Saunders, Ruth; Siddiqui, Salman; Kaur, Davinder; Doe, Camille; Sutcliffe, Amanda; Hollins, Fay; Bradding, Peter; Wardlaw, Andrew; Brightling, Christopher E.			Fibrocyte localization to the airway smooth muscle is a feature of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway smooth muscle; remodeling; mast cells	CIRCULATING FIBROCYTES; HUMAN LUNG; FIBROBLASTS; MIGRATION; MYOFIBROBLASTS; IDENTIFICATION; PROLIFERATION; PROGENITOR; THICKNESS; SKIN	Background: Airway smooth muscle (ASM) hyperplasia is a hallmark of asthma that is associated with disease severity and persistent airflow obstruction. Objectives: We sought to investigate whether fibrocytes, a population of peripheral blood mesenchymal progenitors, are recruited to the ASM compartment in asthma. Methods: We assessed the number of fibrocytes in bronchial biopsy specimens and peripheral blood from subjects with mild-to-severe refractory asthma versus healthy control subjects. In vitro we investigated potential mechanisms controlling fibrocyte migration toward the ASM bundle. Results: Fifty-one subjects with asthma and 33 control subjects were studied. In bronchial biopsy specimens, the number of fibrocytes was increased in the lamina propria of subjects with severe refractory asthma (median [interquartile range] number, 1.9/mm(2) [1.7/mm(2)]) versus healthy control subjects (median [interquartile range] number, 0/mm(2) [0.3/mm(2)], P < .0001) and in the ASM bundle of subjects with asthma of all severities (subjects with severe asthma, median [interquartile range] number, 3.8/mm(2) [9.4/mm(2)]; subjects with mild-to-moderate asthma, median [interquartile range] number, 1.1/mm(2) [2.4/mm(2)]); healthy control subjects, (median [interquartile range] number, 0/mm(2) [0/mm(2)]); P = .0004). In the peripheral blood the fibrocyte number was also increased in subjects with severe refractory asthma (median [interquartile range] number, 1.4 x 10(4)/mL [2.6 x 10(4)/mL]) versus healthy control subjects (median [interquartile range] number, 0.4 x 10(4)/mL [1.0 x 10(4)/mL], P = .002). We identified that in vitro ASM promotes fibrocyte chemotaxis and chemokinesis (distance of migration after 4.5 hours, 31 mu m [2.9 mu m] vs 17 mu m [2.4 mu m], P = .0001), which was in part mediated by platelet-derived growth factor (mean inhibition by neutralizing antibody, 16% [95% CI, 2% to 32%], P = .03) but not by activation of chemokine receptors. Conclusion: This study provides the first evidence that fibrocytes are present in the ASM compartment in asthma and that ASM can augment fibrocyte migration. The importance of fibrocytes in the development of ASM hyperplasia and airway dysfunction in asthma remains to be determined. (J Allergy Clin Immunol 2009;123:376-84.)	[Saunders, Ruth; Siddiqui, Salman; Kaur, Davinder; Doe, Camille; Sutcliffe, Amanda; Hollins, Fay; Bradding, Peter; Wardlaw, Andrew; Brightling, Christopher E.] Univ Leicester, Inst Lung Health, Dept Infect Immun & Inflammat, Leicester LE3 9QP, Leics, England	University of Leicester	Saunders, R (corresponding author), Univ Leicester, Glenfield Hosp, Inst Lung Hlth, Groby Rd, Leicester LE3 9QP, Leics, England.	rms4@le.ac.uk		Saunders, Ruth Mary/0000-0001-8893-6687; Siddiqui, Salman/0000-0003-3770-7870; brightling, chris/0000-0002-9345-4903; Bradding, Peter/0000-0001-8403-0319; Wardlaw, Andrew/0000-0001-6583-0791	GlaxoSmithKline; AstraZeneca; MedImmune; Asthma UK [07/007] Funding Source: researchfish	GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); MedImmune(AstraZenecaMedimmune); Asthma UK	A. Wardlaw has received research support from GlaxoSmithKline and AstraZeneca and has served as an expert witness for GlaxoSmithKline. C. E. Brightling has received research support from AstraZeneca, MedImmune, and GlaxoSmithKline.	Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; [Anonymous], GLOBAL INITIATIVE AS; Bellini A, 2007, LAB INVEST, V87, P858, DOI 10.1038/labinvest.3700654; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bradding P, 2003, J LEUKOCYTE BIOL, V73, P614, DOI 10.1189/jlb.1202602; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Hasegawa M, 2006, AM J RESP CRIT CARE, V173, P1309, DOI 10.1164/rccm.200601-037OC; Hashimoto N, 2004, J CLIN INVEST, V113, P243, DOI 10.1172/JCI200418847; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kaur D, 2006, AM J RESP CRIT CARE, V174, P1179, DOI 10.1164/rccm.200603-394OC; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Larsen K, 2004, AM J RESP CRIT CARE, V170, P1049, DOI 10.1164/rccm.200404-507OC; Lewis CC, 2005, J ALLERGY CLIN IMMUN, V115, P534, DOI 10.1016/j.jaci.2004.11.051; Mori L, 2005, EXP CELL RES, V304, P81, DOI 10.1016/j.yexcr.2004.11.011; Nihlberg K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-50; Pare PD, 1997, CIBA F SYMP, V206, P71; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380; Sehmi R., 2003, Current Drug Targets - Inflammation and Allergy, V2, P271, DOI 10.2174/1568010033484007; Siddiqui S, 2008, J ALLERGY CLIN IMMUN, V122, P335, DOI 10.1016/j.jaci.2008.05.020; Siddiqui S, 2007, J ALLERGY CLIN IMMUN, V120, P813, DOI 10.1016/j.jaci.2007.05.028; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; Trian T, 2007, J EXP MED, V204, P3173, DOI 10.1084/jem.20070956; Wang CH, 2008, AM J RESP CRIT CARE, V178, P583, DOI 10.1164/rccm.200710-1557OC; Ward JE, 2008, EUR RESPIR J, V32, P362, DOI 10.1183/09031936.00119307; Wardlaw AJ, 2000, BRIT MED BULL, V56, P985, DOI 10.1258/0007142001903490; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Yang LJ, 2005, WOUND REPAIR REGEN, V13, P398, DOI 10.1111/j.1067-1927.2005.130407.x; Yoon YS, 2005, BIOL CELL, V97, P253, DOI 10.1042/BC20040099	39	101	109	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					376	384		10.1016/j.jaci.2008.10.048	http://dx.doi.org/10.1016/j.jaci.2008.10.048			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19081612	Green Accepted			2022-12-18	WOS:000263495000013
J	Busse, WW; Pedersen, S; Pauwels, RA; Tan, WC; Chen, YZ; Lamm, CJ; O'Byrne, PM				Busse, William W.; Pedersen, Soren; Pauwels, Romain A.; Tan, Wan C.; Chen, Yu-Zhi; Lamm, Carl Johan; O'Byrne, Paul M.		START Invest Grp	The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study 5-year follow-up: Effectiveness of early intervention with budesonide in mild persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mild persistent asthma; recent-onset asthma; budesonide dry-powder inhalet; inhaled corticosteroid	LUNG-FUNCTION DECLINE; CORTICOSTEROIDS; CHILDREN; DEATHS	Background: The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study enrolled 7241 patients aged 5 to 66 years with recent-onset, mild persistent asthma to assess early intervention with the inhaled corticosteroid budesonide on long-term asthma control. Objective: The open-label phase of the START study was included to determine the effect on lung function and asthma control of adding budesonide to the reference group patients who had not initially received inhaled corticosteroids. Methods: Patients were randomized to double-blind treatment with budesonide, 200 mu g (those aged <11 years) or 400 mu g once daily, or placebo plus the usual asthma therapy for 3 years, after which all patients received 2 years of open-label treatment with budesonide once daily. Results: During the full 5-year study period, postbronchodilator FEV1 percent predicted decreased, irrespective of randomized treatment during the double-blind phase, by an average of 2.22% (SE, 0.15%). However, patients with inhaled budesonide in the double-blind phase had a significantly lower risk (odds ratio, 0.61; P <.001) of a severe asthma-related event during the full 5-year study period than those in the reference group. Moreover, patients in the reference group used more additional asthma medications during both the open-label and double-blind phases. Conclusions: In mild persistent asthma early intervention with inhaled budesonide was associated with improved asthma control and less additional asthma medication use.	[Pedersen, Soren] Univ So Denmark, Kolding Hosp, Madison, WI USA; [Pauwels, Romain A.] Ghent Univ Hosp, Ghent, Belgium; [Tan, Wan C.] Natl Univ Singapore, Queenstown, MD USA; [Tan, Wan C.] Univ British Columbia, St Pauls Hosp, Vancouver, BC V5Z 1M9, Canada; [Chen, Yu-Zhi] Capital Inst Pediat, Beijing, Peoples R China; [Lamm, Carl Johan] AstraZeneca Res & Dev, Lund, Sweden; [O'Byrne, Paul M.] McMaster Univ, Hamilton, ON L8S 4L8, Canada	Kolding Hospital; Ghent University; Ghent University Hospital; National University of Singapore; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; Capital Institute of Pediatrics (CIP); AstraZeneca; McMaster University	Busse, WW (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, J5-219 CSC,Box 2454,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu	Wong, Dennis A/AAH-2958-2020; Panzner, Petr/I-7034-2017; Fabbri, Leonardo/I-4055-2012	Panzner, Petr/0000-0002-1291-450X; Liam, Chong-Kin/0000-0002-3639-9231; Fabbri, Leonardo/0000-0001-8894-1689; Jee, Young-Koo/0000-0001-5800-8038; MIRAGLIA DEL GIUDICE, Michele/0000-0002-8369-5957; O'Byrne, Paul/0000-0003-0979-281X; Alm, Bernt/0000-0002-3557-2995; Hollingsworth, Helen/0000-0001-9007-9012; Visitsunthorn, Nualanong/0000-0002-4342-5100; Pirozynski, Michal/0000-0003-3611-4328; Rossi, Andrea/0000-0001-7095-7121; Teper, Alejandro/0000-0002-7835-9713; Jacobs, Robert/0000-0002-2831-9086				AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Becker JM, 2004, J ALLERGY CLIN IMMUN, V113, P264, DOI 10.1016/j.jaci.2003.10.052; Bisgaard H, 2007, RESP MED, V101, P1477, DOI 10.1016/j.rmed.2007.01.013; Brown H., 1999, APPL MIXED MODELS ME; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; de Marco R, 2007, J ALLERGY CLIN IMMUN, V119, P611, DOI 10.1016/j.jaci.2006.11.696; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Global Strategy for Asthma Management and Prevention, 2006, GLOB STRAT ASTHM MAN; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Jonasson G, 1998, EUR RESPIR J, V12, P1099, DOI 10.1183/09031936.98.12051099; Jonasson G, 2000, ALLERGY, V55, P740, DOI 10.1034/j.1398-9995.2000.00661.x; JONES AH, 1994, RESP MED, V88, P293, DOI 10.1016/0954-6111(94)90059-0; Lange P, 2006, THORAX, V61, P100, DOI 10.1136/thx.2004.037978; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; O'Byrne P, 1996, CAN RESPIR J, V3, P169; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pauwels RA, 2001, CONTROL CLIN TRIALS, V22, P405, DOI 10.1016/S0197-2456(01)00144-1; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; Selroos O, 2004, RESP MED, V98, P254, DOI 10.1016/j.rmed.2003.10.007; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Zeiger RS, 2004, RESP MED, V98, P898, DOI 10.1016/j.rmed.2004.02.016	24	101	111	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1167	1174		10.1016/j.jaci.2008.02.029	http://dx.doi.org/10.1016/j.jaci.2008.02.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18405951	Bronze			2022-12-18	WOS:000255961700014
J	Caughey, GH				Caughey, GH			Tryptase genetics and anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						anaphylaxis; tryptase; mastocytosis; mast cell; basophil	MAST-CELL TRYPTASE; ACTIVATION; HISTAMINE; MASTOCYTOSIS; INHIBITION; RELEASE; CHYMASE; ASTHMA; ALPHA; GAMMA	Tryptases secreted by tissue mast cells and basophils can enter the bloodstream. In human subjects tryptases are encoded by several genes and alleles, including alpha, beta, gamma, and delta. Common variations include complete absence of alpha genes. Until recently, alpha tryptase was considered to be the major tryptase secreted at baseline and in mastocytosis. However, lack of a tryptase genes has little effect on circulating tryptase levels, which are now thought mainly to consist of inactive pro-beta tryptase secreted constitutively rather than stored in granules with mature tryptases. Pro-beta tryptase levels thus might reflect total body mast cell content. In contrast, mature beta tryptase can increase transiently in severe systemic anaphylaxis and confirm the diagnosis. However, it might fail to increase in food anaphylaxis or might increase nonspecifically in samples acquired after death. Thus pro- and mature beta tryptase measurements are useful but associated with false-negative and false-positive results, which need to be considered in drawing clinical conclusions in cases of suspected anaphylaxis.	Vet Adm Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; No Calif Inst Res & Educ, San Francisco, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Northern California Institute for Research & Education	Caughey, GH (corresponding author), Vet Adm Med Ctr, 1111-D,4150 Clement St, San Francisco, CA 94121 USA.	George.Caughey@ucsf.edu			NHLBI NIH HHS [P01 HL024136-250014, P01 HL024136-26, P01 HL024136-28, P01 HL024136-260002, P01 HL024136-25, P01 HL024136, P01 HL024136-27, HL024136, P01 HL024136-270002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; Caughey GH, 2002, MOL IMMUNOL, V38, P1353, DOI 10.1016/S0161-5890(02)00087-1; Edston E, 2003, FORENSIC SCI INT, V131, P8, DOI 10.1016/S0379-0738(02)00383-3; Florian S, 2005, INT ARCH ALLERGY IMM, V136, P273, DOI 10.1159/000083954; Golden David B K, 2004, Novartis Found Symp, V257, P101; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; Krishna MT, 2001, J ALLERGY CLIN IMMUN, V107, P1039, DOI 10.1067/mai.2001.115631; Molinari JF, 1996, AM J RESP CRIT CARE, V154, P649, DOI 10.1164/ajrccm.154.3.8810600; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCUDAMORE CL, 1995, J EXP MED, V182, P1871, DOI 10.1084/jem.182.6.1871; Soto D, 2002, CLIN EXP ALLERGY, V32, P1000, DOI 10.1046/j.1365-2222.2002.01416.x; STACK MS, 1994, J BIOL CHEM, V269, P9416; Thomas VA, 1998, BIOCHEMISTRY-US, V37, P2291, DOI 10.1021/bi972119z; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Wang HW, 2002, J IMMUNOL, V169, P5145, DOI 10.4049/jimmunol.169.9.5145; Wong GW, 2002, J BIOL CHEM, V277, P41906, DOI 10.1074/jbc.M205868200	25	101	103	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1411	1414		10.1016/j.jaci.2006.02.026	http://dx.doi.org/10.1016/j.jaci.2006.02.026			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751005	Green Accepted			2022-12-18	WOS:000238332300031
J	Hallstrand, TS; Fischer, ME; Wurfel, MM; Afari, N; Buchwald, D; Goldberg, J				Hallstrand, TS; Fischer, ME; Wurfel, MM; Afari, N; Buchwald, D; Goldberg, J			Genetic pleiotropy between asthma and obesity in a community-based sample of twins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; obesity; genetic; twin	BODY-MASS INDEX; NECROSIS-FACTOR-ALPHA; ADULT FINNISH TWINS; BETA(2)-ADRENOCEPTOR POLYMORPHISM; BRONCHIAL HYPERRESPONSIVENESS; PHYSICAL-ACTIVITY; COMPLEX TRAITS; LEPTIN LEVELS; YOUNG-ADULTS; REARED APART	Background: Asthma and obesity are common conditions that are strongly associated. This association might be due to shared genetic or environmental causes. Objective: We sought to determine whether a shared genetic cause is responsible for the association between asthma and obesity and to estimate the magnitude of shared genetic cause. Methods: The analyses were performed with 1001 monozygotic and 383 dizygotic same-sex twin pairs within the University of Washington Twin Registry. The presence of asthma was determined by self-report of a physician diagnosis of asthma, and body mass index (BMI) was calculated by using self-reported height and weight. Obesity was defined as a BMI of 30 or greater. The association between asthma and BMI was assessed by means of mixed-effects ordinal regression. Twin correlations examined the association of asthma and obesity. Univariate and bivariate structural equation models estimated the components of variance attributable to genetic and environmental effects. Results: A strong association between asthma and BMI was identified in the sample population (P < .001). Substantial heritability was detected for asthma (53%) and obesity (77%), which is indicative of additive genetic influences on each disorder. The best-fitting model of shared components of variance indicated that 8% of the genetic component of obesity is shared with asthma. Conclusion: The covariation between obesity and asthma is predominantly caused by shared genetic risk factors for both conditions.	Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hallstrand, TS (corresponding author), Univ Washington, Dept Med, Div Pulm & Crit Care, Box 356522,1959 NE Pacific St, Seattle, WA 98195 USA.	tealh@u.washington.edu		Hallstrand, Teal/0000-0002-5059-6872	NHLBI NIH HHS [K23HL04231, K23 HL004231-04, K23 HL004231, K23HL72923, K23 HL072923] Funding Source: Medline; NIAID NIH HHS [U19AI38429, U19 AI038429] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004231, K23HL072923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038429] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Albuquerque RV, 1998, CLIN EXP ALLERGY, V28, P578; Allison DB, 1996, INT J OBESITY, V20, P501; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Becker A, 1997, J REPROD MED, V42, P260; Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045, DOI 10.1164/ajrccm.164.11.2004235; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835, DOI 10.1164/ajrccm.164.10.2105033; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278, DOI 10.1164/ajrccm.160.1.9808032; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Clarke JR, 2000, AM J RESP CRIT CARE, V162, P2188, DOI 10.1164/ajrccm.162.6.9904057; D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968, DOI 10.1164/ajrccm.158.6.9804126; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; EISEN S, 1989, CLIN GENET, V35, P423, DOI 10.1111/j.1399-0004.1989.tb02967.x; FernandezReal JM, 1997, DIABETES, V46, P1468, DOI 10.2337/diabetes.46.9.1468; Figueroa-Munoz JI, 2001, THORAX, V56, P133, DOI 10.1136/thorax.56.2.133; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fredberg JJ, 1999, AM J RESP CRIT CARE, V159, P959, DOI 10.1164/ajrccm.159.3.9804060; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Guerra S, 2002, CHEST, V122, P1256, DOI 10.1378/chest.122.4.1256; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; HANSON B, 1991, AM J HUM GENET, V48, P873; Hedeker D, 1996, COMPUT METH PROG BIO, V49, P157, DOI 10.1016/0169-2607(96)01720-8; Herrmann SM, 1998, EUR J CLIN INVEST, V28, P59; Huovinen E, 2001, THORAX, V56, P234, DOI 10.1136/thorax.56.3.234; Hupfeld CJ, 2003, P NATL ACAD SCI USA, V100, P161, DOI 10.1073/pnas.0235674100; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Jarvis D, 2002, CLIN EXP ALLERGY, V32, P831, DOI 10.1046/j.1365-2222.2002.01380.x; Kaprio J, 2001, INT J OBESITY, V25, P132, DOI 10.1038/sj.ijo.0801526; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123, DOI 10.1164/ajrccm.156.4.12tac9; Kilpelainen M, 2001, ALLERGY, V56, P377, DOI 10.1034/j.1398-9995.2001.056005377.x; Kim S, 2003, ANN EPIDEMIOL, V13, P666, DOI 10.1016/S1047-2797(03)00054-1; Large V, 1997, J CLIN INVEST, V100, P3005, DOI 10.1172/JCI119854; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Los H, 2001, Twin Res, V4, P81, DOI 10.1375/twin.4.2.81; Luder E, 2004, RESP MED, V98, P29, DOI 10.1016/j.rmed.2003.08.004; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Martin N, 1997, NAT GENET, V17, P387, DOI 10.1038/ng1297-387; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Meirhaeghe A, 1999, LANCET, V353, P896, DOI 10.1016/S0140-6736(99)00251-2; Neale M.C.C.L., 2013, METHODOLOGY GENETIC, V67, DOI DOI 10.1007/978-94-015-8018-2; Nieto-Garcia F J, 1990, Epidemiology, V1, P146, DOI 10.1097/00001648-199003000-00011; Pietilainen KH, 1999, INT J OBESITY, V23, P107, DOI 10.1038/sj.ijo.0800767; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Rasmussen F, 2000, EUR RESPIR J, V16, P866, DOI 10.1183/09031936.00.16586600; Sandford AJ, 2000, AM J RESP CRIT CARE, V161, pS202, DOI 10.1164/ajrccm.161.supplement_2.a1q4-11; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; Singh RB, 1998, MAGNESIUM RES, V11, P3; Soutar A, 1997, THORAX, V52, P166, DOI 10.1136/thx.52.2.166; Tantisira KG, 2001, THORAX, V56, P64; TORGERSEN S, 1979, ACTA GENET MED GEMEL, V28, P225, DOI 10.1017/S0001566000009077; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Wamboldt MZ, 2000, AM J MED GENET, V96, P146, DOI 10.1002/(SICI)1096-8628(20000403)96:2<146::AID-AJMG4>3.0.CO;2-J; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS	61	101	106	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1235	1241		10.1016/j.jaci.2005.09.016	http://dx.doi.org/10.1016/j.jaci.2005.09.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337451	Green Accepted			2022-12-18	WOS:000235687000010
J	Hallstrand, TS; Moody, MW; Aitken, ML; Henderson, WR				Hallstrand, TS; Moody, MW; Aitken, ML; Henderson, WR			Airway immunopathology of asthma with exercise-induced bronchoconstriction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exercise-induced bronchoconstriction; epithelial cell; leukotriene; prostaglandin; eosinophil; mast cell	ADENOSINE 5'-MONOPHOSPHATE; CYSTEINYL LEUKOTRIENES; INDUCED BRONCHOSPASM; INFLAMMATION; METHACHOLINE; HYPERVENTILATION; MONTELUKAST; EPITHELIUM; RESPONSES; CHILDREN	Background: Exercise-induced bronchoconstriction (EIB) is a common cause of symptoms in a subgroup of asthmatic subjects. The pathobiology that makes this group of asthmatic subjects susceptible to bronchoconstriction after a brief period of exercise remains poorly understood. Objective: We sought to determine whether there are differences in lower airway inflammation and production of cytokines and eicosanoids between asthmatic subjects with and without EIB. Methods: Two distinct groups of asthmatic subjects based on a priori definitions were identified, one with moderate-to-severe EIB and the other without significant bronchoconstriction after exercise challenge. Both groups met the definition of asthma on the basis of bronchodilator response, bronchial hyperresponsiveness, or both. A comparative immunopathology study was conducted by using induced sputum to identify differences in lower airway inflammation and production of cytokines and eicosanoids. Results: The groups had similar baseline lung function and bronchodilator response and did not have any asthma exacerbations within the prior year. The concentration of columnar epithelial cells was markedly higher in the group with EIB (1.4 X 10(5) vs 2.9 X 10(4) cells/mL, P = .01). The concentration of eosinophils was higher in the group with EIB (3.6 X 10(4) vs 4.9 X 10(3) cells/mL P = .04). Cysteinyl leukotrienes (CysLTs; 727.7 vs 151.9 pg/mL, P = .01) and the ratio of CysLTs to prostaglandin E-2 (1.85 vs 1.04, P = .002) in the airways were higher in the group with EIB. Conclusion: Injury to the airway epithelium, overexpression of CysLTs, relative underproduction of prostaglandin E2, and greater airway eosinophilia are distinctive immunopathologic features of asthma with EIB.	Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA 98195 USA; Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hallstrand, TS (corresponding author), Univ Washington, Dept Med, Div Pulm & Crit Care, Box 356522,1959 NE Pacific St, Seattle, WA 98195 USA.	tealh@u.washington.edu		Hallstrand, Teal/0000-0002-5059-6872	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004231, K23HL004231] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 HL004231] Funding Source: Medline; NHLBI NIH HHS [K23 HL004231, HL04231, K23 HL004231-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Anderson SD, 2002, J ALLERGY CLIN IMMUN, V109, P771, DOI 10.1067/mai.2002.123644; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; Becker JM, 2004, J ALLERGY CLIN IMMUN, V113, P264, DOI 10.1016/j.jaci.2003.10.052; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cabral ALB, 1999, AM J RESP CRIT CARE, V159, P1819, DOI 10.1164/ajrccm.159.6.9805093; Carraro S, 2005, J ALLERGY CLIN IMMUN, V115, P764, DOI 10.1016/j.jaci.2004.10.043; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CRIMI E, 1992, AM REV RESPIR DIS, V146, P507, DOI 10.1164/ajrccm/146.2.507; Davis MS, 2003, MED SCI SPORT EXER, V35, P608, DOI 10.1249/01.MSS.0000058660.88987.A0; De Meer G, 2002, AM J RESP CRIT CARE, V165, P327, DOI 10.1164/ajrccm.165.3.2104066; Erjefalt JS, 2004, THORAX, V59, P136, DOI 10.1136/thorax.2003.004218; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46, DOI 10.1164/ajrccm.164.supplement_2.2106066; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; Freed AN, 1999, AM J RESP CRIT CARE, V159, P1101, DOI 10.1164/ajrccm.159.4.9802072; Freed AN, 1999, J APPL PHYSIOL, V87, P1724, DOI 10.1152/jappl.1999.87.5.1724; Freed AN, 2003, AM J RESP CRIT CARE, V167, P1102, DOI 10.1164/rccm.200201-055OC; FREEZER NJ, 1995, EUR RESPIR J, V8, P1488; GAO YS, 1988, J APPL PHYSIOL, V65, P2400, DOI 10.1152/jappl.1988.65.6.2400; Hallstrand TS, 2002, MED CLIN N AM, V86, P1009, DOI 10.1016/S0025-7125(02)00091-3; Hallstrand TS, 2002, J PEDIATR-US, V141, P343, DOI 10.1067/mpd.2002.125729; HALLSTRAND TS, 2003, AM J RESP CRIT CARE, V167, pA354; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; JONES A, 1994, BRIT J GEN PRACT, V44, P179; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; Kanazawa H, 2002, CHEST, V122, P166, DOI 10.1378/chest.122.1.166; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; MAROTEL C, 1989, Allergie et Immunologie (Paris), V21, P61; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Mickleborough TD, 2003, AM J RESP CRIT CARE, V168, P1181, DOI 10.1164/rccm.200303-373OC; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73, DOI 10.1164/ajrccm/142.1.73; Reiss TF, 1997, THORAX, V52, P1030, DOI 10.1136/thx.52.12.1030; STUARTSMITH K, 1988, J APPL PHYSIOL, V65, P2170, DOI 10.1152/jappl.1988.65.5.2170; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546, DOI 10.1164/ajrccm.163.7.2010145; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879	44	101	105	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					586	593		10.1016/j.jaci.2005.04.035	http://dx.doi.org/10.1016/j.jaci.2005.04.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159628	Green Accepted			2022-12-18	WOS:000235686500018
J	Frossard, CP; Hauser, C; Eigenmann, PA				Frossard, CP; Hauser, C; Eigenmann, PA			Antigen-specific secretory IgA antibodies in the gut are decreased in a mouse model of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; IgA antibody; anaphylaxis tolerance; T lymphocytes; beta-lactoglobulin; IL-10; TGF-beta	MURINE MODEL; PEYER PATCHES; IMMUNOGLOBULIN-A; LAMINA PROPRIA; CHOLERA-TOXIN; PLASMA-CELLS; B-CELLS; LYMPHOCYTES; ANAPHYLAXIS; TGF-BETA-1	Background: A large body of evidence implicates IgA antibodies in the immune response to pathogens present in the gut. Whether IgA antibodies play a similar role in food allergy remains to be determined. Objective: We sought to characterize beta-lactoglobulin (BLG)-specific serum and secretory IgA antibody production in the gut and to define the role of antigen-induced cytokines in IgA production in a murine model of food allergy. Methods: BLG-specific IgA antibodies were measured in the sera and feces of mice anaphylactic or tolerant to BLG. The number of antibody-secreting cells in the spleen and Peyer's patches was determined by means of ELISPOT. Mesenteric lymph node cells and Peyer's patch T cells were transferred to naive mice, and antibody production in the sera and feces in recipient mice, as well as antibody-secreting cell numbers, were measured. Results: Serum IgA antibody titers were strongly increased in anaphylactic mice. In contrast, BLG-specific IgA antibody titers were increased in feces but not in sera from tolerant mice. These results were correlated with an increased number of BLG-specific IgA-secreting cells in Peyer's patches from tolerant mice. The adoptive transfer of Peyer's patch CD3(+) cells from tolerant mice induced an increased number of IgA-secreting cells preferentially in the Peyer's patches of naive recipient mice. Furthermore, an increase of BLG-induced IL-10 and TGF-beta levels was found at IgA production sites. Conclusions: These results suggest a role for secretory IgA in tolerance mechanisms to foods. Peyer's patch CD3(+) cells are primarily involved by favoring IgA production through the release of IL-10 and TGF-beta.	Univ Hosp Geneva, Dept Pediat, Div Immunol & Allergy, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Dept Med, Div Immunol & Allergy, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva	Eigenmann, PA (corresponding author), Univ Hosp Geneva, Dept Pediat, Div Immunol & Allergy, 6 Rue Willy Donze, CH-1211 Geneva 14, Switzerland.	Philippe.Eigenmann@hcuge.ch	Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826				Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P1293, DOI 10.1046/j.1365-2222.2002.01470.x; Cazac BB, 2000, IMMUNITY, V13, P443, DOI 10.1016/S1074-7613(00)00044-3; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; Fayette J, 1997, J EXP MED, V185, P1909, DOI 10.1084/jem.185.11.1909; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V113, P958, DOI 10.1016/j.jaci.2003.12.017; Frossard CP, 2001, PEDIATR RES, V49, P417, DOI 10.1203/00006450-200103000-00018; Hidvegi E, 2002, PEDIATR ALLERGY IMMU, V13, P255, DOI 10.1034/j.1399-3038.2002.01045.x; Kim PH, 1998, J IMMUNOL, V160, P1198; Kolopp-Sarda MN, 2001, CLIN EXP ALLERGY, V31, P47, DOI 10.1046/j.1365-2222.2001.733/ca1804.x; KUITUNEN M, 1995, PEDIATR ALLERGY IMMU, V6, P30, DOI 10.1111/j.1399-3038.1995.tb00254.x; Latcham F, 2003, J PEDIATR-US, V143, P39, DOI 10.1016/S0022-3476(03)00193-8; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; LIKE B, 1986, J BIOL CHEM, V261, P3426; RUSSEL GW, 2004, MUCOSAL IMMUNOLOGY, P225; Shimoda M, 1999, BIOSCI BIOTECH BIOCH, V63, P2123, DOI 10.1271/bbb.63.2123; SNIDER DP, 1994, J IMMUNOL, V153, P647; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; TSENG J, 1981, J IMMUNOL, V127, P2039; TSENG J, 1984, J IMMUNOL, V132, P2730; van Ginkel FW, 1999, J IMMUNOL, V163, P1951	22	101	112	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					377	382		10.1016/j.jaci.2004.03.040	http://dx.doi.org/10.1016/j.jaci.2004.03.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316519				2022-12-18	WOS:000223405600026
J	Arbes, SJ; Cohn, RD; Yin, M; Muilenberg, ML; Burge, HA; Friedman, W; Zeldin, DC				Arbes, SJ; Cohn, RD; Yin, M; Muilenberg, ML; Burge, HA; Friedman, W; Zeldin, DC			House dust mite allergen in US beds: Results from the first National Survey of Lead and Allergens in Housing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	97th International Conference of the American-Thoracic-Society	MAY 18-23, 2001	SAN FRANCISCO, CA	Amer Thorac Soc		house dust mite allergen; indoor allergens; surveys; epidemiology	REDUCING RELATIVE-HUMIDITY; DER-P-I; INDOOR ALLERGENS; RISK FACTOR; AVOIDANCE MEASURES; SEASONAL-VARIATION; ASTHMATIC-PATIENTS; CHILDHOOD ASTHMA; GRASS-POLLEN; EXPOSURE	Background: Although exposure to house dust mite allergen is a major risk factor for allergic sensitization and asthma, nationwide estimates of dust mite allergen levels in US homes have not been reported. Objective: The purpose of this study was to estimate the prevalence of dust mite allergen in beds of US homes and to identify predictors of dust mite allergen concentration. Methods: Data were obtained from the first National Survey of Lead and Allergens in Housing, a cross-sectional survey of 831 permanently occupied noninstitutional housing units that permitted resident children. Dust mite allergen concentration (Der f 1 plus Der p 1) was determined from a dust sample collected from a bed. The percentages of homes with concentrations at or greater than detection, 2.0 mug/g bed dust, and 10.0 mug/g bed dust were estimated. Independent predictors of allergen concentration were assessed with multivariable linear regression. Results: The percentages of US homes with dust mite allergen concentrations at or greater than detection, 2.0 mug/g, and 10.0 mug/g were 84.2% (SE, 1.73), 46.2% (SE, 2.0), and 24.2% (SE, 2.1), respectively. Independent predictors of higher levels were older homes, non-West census regions, single-family homes, no resident children, lower household income, heating sources other than forced air, musty or mildew odor, and higher bedroom humidity. Conclusion: Most US homes have detectable levels of dust mite allergen in a bed. Levels previously associated with allergic sensitization and asthma are common in US bedrooms. Predictors can be used to identify conditions under which homes are more likely to have increased dust mite allergen levels.	NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; Analyt Sci, Durham, NC USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; US Dept Housing & Urban Dev, Off Healthy Homes & Lead Hazard Control, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Harvard T.H. Chan School of Public Health	Zeldin, DC (corresponding author), NIEHS, Div Intramural Res, NIH, 111 Alexander Dr,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.		Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025043, Z01ES025043, Z01ES025034, ZIAES025041, Z01ES025041, ZIAES025034] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adilah N, 1997, NEW ZEAL MED J, V110, P438; Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P852, DOI 10.1016/S0091-6749(99)70298-8; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, P99, DOI 10.1067/mai.2001.112119; Bellanti JA, 2000, ANN ALLERG ASTHMA IM, V84, P249, DOI 10.1016/S1081-1206(10)62762-7; Burge H, 1993, INDOOR ALLERGENS ASS; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Carswell F, 1999, CLIN EXP ALLERGY, V29, P193, DOI 10.1046/j.1365-2222.1999.00499.x; CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P461, DOI 10.1046/j.1365-2222.1999.00513.x; DUSBABEK F, 1975, Folia Parasitologica (Ceske Budejovice), V22, P219; FELDMANMUHSAM B, 1985, J MED ENTOMOL, V22, P663, DOI 10.1093/jmedent/22.6.663; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; FRIEDMAN FM, 1992, ALLERGY PROC, V13, P259, DOI 10.2500/108854192778817095; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; HART BJ, 1990, CLIN EXP ALLERGY, V20, P203, DOI 10.1111/j.1365-2222.1990.tb02669.x; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; Hirsch T, 1998, ENVIRON HEALTH PERSP, V106, P659; Korsgaard J, 1998, ALLERGY, V53, P77, DOI 10.1111/j.1398-9995.1998.tb05003.x; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Mihrshahi S, 2002, ALLERGY, V57, P137, DOI 10.1034/j.1398-9995.2002.5720999.x; Nahm DH, 1998, ANN ALLERG ASTHMA IM, V80, P411, DOI 10.1016/S1081-1206(10)62993-6; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; Pitten FA, 2000, HAUTARZT, V51, P655, DOI 10.1007/s001050051190; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Ricci G, 2000, BRIT J DERMATOL, V143, P379, DOI 10.1046/j.1365-2133.2000.03666.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; *US EPA, 1996, PUBL US EPA; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527, DOI 10.1289/ehp.02110527; Vojta PJ, 2001, ENVIRON HEALTH PERSP, V109, P815, DOI 10.2307/3454824; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Weeks J, 1995, CLIN EXP ALLERGY, V25, P1179, DOI 10.1111/j.1365-2222.1995.tb03041.x	49	101	106	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					408	414		10.1067/mai.2003.16	http://dx.doi.org/10.1067/mai.2003.16			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	644WF	12589364				2022-12-18	WOS:000180942700028
J	Sakaguchi, M; Toda, M; Ebihara, T; Irie, S; Hori, H; Imai, A; Yanagida, M; Miyazawa, H; Ohsuna, H; Ikezawa, Z; Inouye, S				Sakaguchi, M; Toda, M; Ebihara, T; Irie, S; Hori, H; Imai, A; Yanagida, M; Miyazawa, H; Ohsuna, H; Ikezawa, Z; Inouye, S			IgE antibody to fish gelatin (type I collagen) in patients with fish allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; fish allergy; gelatin; IgE	IMMEDIATE-TYPE REACTIONS; CROSS-REACTIVITY; CHILDREN; VACCINES; ANAPHYLAXIS; MEASLES; MUMPS; ERYTHROPOIETIN; DIPHTHERIA; EPITOPES	Background: Most children with anaphylaxis to measles, mumps, and rubella vaccines had shown sensitivity to bovine gelatin that was included in the vaccines. Recently, it was found that bovine type I collagen, which is the main content in the gelatin, is a major allergen in bovine gelatin allergy, Fish meat and skin also contain type I collagen. Objective: The present study was designed to investigate IgE antibody to fish gelatin in children with fish allergy. Methods: Serum samples were taken from patients in 3 groups: (1) 10 patients with fish allergy and specific IgE to fish meat; (2) two patients with allergies to both fish meat and bovine gelatin and specific IgE to fish meat and bovine gelatin; and (3) 15 patients with atopic dermatitis and specific IgE to fish meat. Various fish gelatins (type I collagen) were prepared from fish skin. IgE antibody to fish gelatin was analyzed by using ELISA and immunoblotting. Results: Of 10 patients with fish allergy, 3 had specific IgE to fish gelatin. Of two patients with fish allergy and bovine gelatin allergy, all had specific IgE to fish gelatin. Of 15 patients with atopic dermatitis and specific IgE to fish meat, 5 had specific IgE to fish gelatin. Furthermore, IgE from pooled serum of the patients reacted with both the alpha 1 and alpha 2 chains of fish type I collagen in immunoblots. There is cross-reactivity among gelatins from various fishes, but there is little crossreactivity between fish and bovine gelatins. Conclusion: Some fish-sensitive patients possessed IgE antibody to fish gelatin. Fish gelatin (type I collagen) might be an allergen in subjects with fish allergy.	Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 162, Japan; Natl Inst Infect Dis, Dept Infect Dis Surveillance Ctr, Tokyo 162, Japan; Nippi Res Inst Biomatrix, Tokyo, Japan; Tokyo Med & Dent Univ, Med Res Inst, Div Adult Dis, Tokyo, Japan; Kirin Brewery Co Ltd, Pharmaceut Dev Lab, Gunma, Japan; Kyorin Univ, Sch Hlth Sci, Dept Med Technol, Tokyo, Japan; Yokohama City Univ, Sch Med, Dept Dermatol, Yokohama, Kanagawa 232, Japan	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU); Kirin Brewery Company Limited; Kyorin University; Yokohama City University	Sakaguchi, M (corresponding author), Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Toyama 1-23-1, Tokyo 162, Japan.		Inouye, Sharon/R-7216-2019; EBIHARA, TAKAE/M-9420-2019	EBIHARA, TAKAE/0000-0003-2325-7637				ALBERTS B, 1994, MOL BIOL CELL, P978; ASA K, 1989, INT ARCH ALLER A IMM, V29, P990; BERHISELBROADBE.J, 1992, J ALLERGY CLIN IMMUN, V89, P730; Bugajska-Schretter A, 1998, J ALLERGY CLIN IMMUN, V101, P67, DOI 10.1016/S0091-6749(98)70195-2; DEMRTINO M, 1990, J ALLERGY CLIN IMMUN, V86, P909; Dory D, 1998, ALLERGY, V53, P42, DOI 10.1111/j.1398-9995.1998.tb03772.x; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; GARCIA JE, 1993, NEPHRON, V65, P636, DOI 10.1159/000187578; Hansen TK, 1997, ANN ALLERG ASTHMA IM, V78, P187, DOI 10.1016/S1081-1206(10)63386-8; HASHIZUME S, 1994, CLIN VIROL, V22, P140; HORI H, 1992, MOL IMMUNOL, V29, P759; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; KIMURA S, 1987, COMP BIOCHEM PHYS B, V88, P27, DOI 10.1016/0305-0491(87)90074-5; Kumagai T, 1997, J ALLERGY CLIN IMMUN, V100, P130, DOI 10.1016/S0091-6749(97)70204-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOODY MW, 1993, CLIN REV ALLERG, V11, P159; Nakayama T, 1999, J ALLERGY CLIN IMMUN, V103, P321, DOI 10.1016/S0091-6749(99)70508-7; PASCUAL C, 1992, J PEDIATR, V121, P29; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V104, P695, DOI 10.1016/S0091-6749(99)70344-1; Sakaguchi M, 1998, VACCINE, V16, P1138, DOI 10.1016/S0264-410X(98)80111-4; Sakaguchi M, 1999, IMMUNOLOGY, V96, P286, DOI 10.1046/j.1365-2567.1999.00696.x; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V103, P349, DOI 10.1016/S0091-6749(99)70512-9; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P720, DOI 10.1016/S0091-6749(97)70038-1; SATO K, 1986, B JPN SOC SCI FISH, V52, P1595; Taniguchi K, 1998, J ALLERGY CLIN IMMUN, V102, P1028, DOI 10.1016/S0091-6749(98)70342-2; WAHL R, 1989, CLIN EXP ALLERGY, V19, P77, DOI 10.1111/j.1365-2222.1989.tb02348.x	29	101	105	7	24	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					579	584		10.1067/mai.2000.108499	http://dx.doi.org/10.1067/mai.2000.108499			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984381				2022-12-18	WOS:000089471900024
J	Vliagoftis, H; Worobec, AS; Metcalfe, DD				Vliagoftis, H; Worobec, AS; Metcalfe, DD			The protooncogene c-kit and c-kit ligand in human disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CONSTITUTIVELY ACTIVATING MUTATIONS; RECEPTOR TYROSINE KINASE; HUMAN MAST-CELL; PERIPHERAL-BLOOD; MASTOCYTOSIS; GROWTH				Vliagoftis, H (corresponding author), NIAID,ALLERG DIS LAB,NIH,BLDG 10,RM 11C205,10 CTR DR MSC 1881,BETHESDA,MD 20892, USA.		Vliagoftis, Harissis/C-6480-2013	Vliagoftis, Harissis/0000-0002-5029-855X				Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; KANAKURA Y, 1994, LEUKEMIA S1, V8, P518; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kitayama H, 1996, BLOOD, V88, P995; LEV S, 1994, CRIT REV ONCOGENESIS, V5, P141, DOI 10.1615/CritRevOncog.v5.i2-3.30; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Pignon JM, 1997, BRIT J HAEMATOL, V96, P374, DOI 10.1046/j.1365-2141.1997.d01-2042.x; ROTTEM M, 1994, BLOOD, V84, P2489; SPRITZ RA, 1994, ADV HUM GENET, V22, P1	11	101	122	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					435	440		10.1016/S0091-6749(97)70131-3	http://dx.doi.org/10.1016/S0091-6749(97)70131-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338533				2022-12-18	WOS:A1997YA52900001
J	Posch, A; Chen, ZP; Wheeler, C; Dunn, MJ; RaulfHeimsoth, M; Baur, X				Posch, A; Chen, ZP; Wheeler, C; Dunn, MJ; RaulfHeimsoth, M; Baur, X			Characterization and identification of latex allergens by two-dimensional electrophoresis and protein microsequencing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural rubber later; latex allergy; IgE; two-dimensional electrophoresis; immunoblotting; protein microsequencing; latex proteins	IMMOBILIZED PH GRADIENTS; SPINA-BIFIDA; HEVEA-BRASILIENSIS; POLYACRYLAMIDE; CHILDREN; STATE; GELS	Background: Proteins of natural rubber latex cause IgE-mediated sensitization in 3% to 18% df health care workers and in up to 50% of patients with spina bifida. Objective: This study was aimed at the generation of a comprehensive latex protein database by two-dimensional electrophoresis (2-DE). Methods: Proteins extracted from fresh Hevea brasiliensis latex were separated by 2-DE. IgE-reactive proteins were analyzed by immunoblotting with sera of health care workers with latex allergy. Protein microsequencing and monoclonal antibodies were used to identify the latex allergens. Results: The latex C-serum 2-DE map was very complex and exhibited about 200 distinct polypeptides. The proteins eluted from the latex particles consisted primarily of two groups of acidic proteins located in the 8 to 14 kd and 22 to 24 kd areas of the 2-DE map. Major IgE-reactivity was detected with C-serum proteins in the 56, 45, 30, 20, 14, and <6.5 kd areas of the immunoblots. The 8 to 14 kd particle proteins exhibited distinct IgE reactivity, whereas the 22 to 24 kd proteins were not stained Seven of the soluble IgE-reactive protein spots showed high homology with enolase, superoxide dismutase, triosephosphate isomerase, proteasome subunit, and chitinase and represent previously undescribed latex allergens; whereas nine protein spots corresponded to known latex allergens, namely prohevein, hevein, prohevein C-domain, and hevamine. As identified by monoclonal antibodies, the IgE-reactive latex particle proteins mainly represent the allergenic rubber elongation factor. Conclusions: Two-dimensional electrophoresis, followed by immunoblotting and protein microsequencing, can rapidly identify a large number of IgE-binding latex proteins. The 2-DE latex maps generated will provide valuable information for the development of strategies to isolate the relevant latex allergens. Because the novel latex allergens are common plant enzymes, they may also act as cross-reacting proteins in various foods.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, HAREFIELD HOSP, HEART SCI CTR, LONDON SW7 2AZ, ENGLAND	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Posch, A (corresponding author), BGFA, RES INST OCCUPAT MED, BURKLE CAMP PL 1, D-44789 BOCHUM, GERMANY.							AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; Akasawa A., 1996, Journal of Allergy and Clinical Immunology, V97, P321, DOI 10.1016/S0091-6749(96)80771-8; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; Alenius H, 1996, J IMMUNOL, V156, P1618; ALENIUS H, 1995, INT ARCH ALLERGY IMM, V106, P258, DOI 10.1159/000236851; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; *ASTMS, STAND TEST METH AN P, V95, P1; Baker Cathy S., 1994, V32, P177; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Chen Z, 1996, CLIN EXP ALLERGY, V26, P406, DOI 10.1046/j.1365-2222.1996.d01-327.x; Chen Z., 1996, Journal of Allergy and Clinical Immunology, V97, P428, DOI 10.1016/S0091-6749(96)81200-0; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; GORG A, 1993, BIOCHEM SOC T, V21, P130; GORG A, 1991, ELECTROPHORESIS, V12, P653, DOI 10.1002/elps.1150120910; GORG A, 1995, ELECTROPHORESIS, V16, P1079, DOI 10.1002/elps.11501601183; GORG A, 1988, ADV ELECTROPHORESIS, P1; Kurup VP, 1996, INT ARCH ALLERGY IMM, V109, P58, DOI 10.1159/000237232; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; LU LJ, 1995, J IMMUNOL, V155, P2721; Palosuo T., 1996, Journal of Allergy and Clinical Immunology, V97, P324, DOI 10.1016/S0091-6749(96)80783-4; Righetti P. G., 1990, IMMOBILIZED PH GRADI; SILER DJ, 1995, ANAL BIOCHEM, V229, P278, DOI 10.1006/abio.1995.1413; TOMAZIC VJ, 1995, J ALLERGY CLIN IMMUN, V96, P635, DOI 10.1016/S0091-6749(95)70262-8	28	101	114	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					385	395		10.1016/S0091-6749(97)70057-5	http://dx.doi.org/10.1016/S0091-6749(97)70057-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058695				2022-12-18	WOS:A1997WM42200016
J	BELLINI, A; YOSHIMURA, H; VITTORI, E; MARINI, M; MATTOLI, S				BELLINI, A; YOSHIMURA, H; VITTORI, E; MARINI, M; MATTOLI, S			BRONCHIAL EPITHELIAL-CELLS OF PATIENTS WITH ASTHMA RELEASE CHEMOATTRACTANT FACTORS FOR T-LYMPHOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIRWAY EPITHELIUM; T-LYMPHOCYTES; INTERLEUKIN-8; LYMPHOCYTE CHEMOATTRACTANT FACTOR; ASTHMA	RECOMBINANT HUMAN INTERLEUKIN-5; BRONCHOALVEOLAR LAVAGE FLUID; COLONY-STIMULATING FACTOR; ION-EXCHANGE COLUMNS; EOSINOPHIL FUNCTION; NONALLERGIC ASTHMA; ATOPIC ASTHMA; MESSENGER-RNA; ACTIVATION; EXPRESSION	Background: T lymphocytes may orchestrate the inflammatory response in atopic asthma, but the mechanisms that promote T-cell accumulation in asthmatic airways are still unclear. In this study, we tested the hypothesis that bronchial epithelial cells of patients with atopic, asthma release chemoattractant factors for T lymphocytes. Methods: Sixteen patients with atopic asthma and eight healthy control subjects were selected for this study. Bronchial epithelial cells were isolated from biopsy specimens obtained by means of bronchoscopy and cultured for 48 hours in serum- and hormone-free medium, with or without 10(-6) mol/L histamine. Results: Only the supernatants of cells from donors with asthma showed chemotactic activity for T lymphocytes, and this was significantly increased (p < 0.025) by exposure to histamine. Chemotactic activity was in part mediated by interleukin-8 (IL-8), because an antibody against human IL-8 significantly reduced it (p < 0.05) and the cell supernatants contained appreciable amounts of immunoreactive IL-8 (0.89 +/- 0.39 ng/ml). Both the residual chemotactic activity of unstimulated epithelial cells and the increased activity caused by histamine were mediated by a single protease-sensitive substance with an apparent molecular weight of 56,000 d and an extimated isoelectric point of 8.8 to 9.1. The partially purified chemoattractant specifically enhanced the migration of CD4+ T lymphocytes, and its activity was inhibited by the univalent Fab fragment of a monoclonal antibody against CD4. Conclusion: These results extend our previous observations, indicating an important effector role of bronchial epithelium in asthma.	INST EXPTL MED,DIAGNOST CTR RESP & ALLERG DIS,P BOX 6,VIA ALESSANDRIA 4,I-20144 MILAN,ITALY; UNIV MILAN,DEPT PATHOL & EXPTL BIOL,I-20122 MILAN,ITALY	University of Milan			Mattoli, Sabrina/H-8211-2014	Mattoli, Sabrina/0000-0002-6866-604X				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V87, P1470; BELLINI A, 1993, CHEST, V103, P997, DOI 10.1378/chest.103.4.997; BERMAN JS, 1990, AM REV RESPIR DIS, V142, P238, DOI 10.1164/ajrccm/142.1.238; BERMAN JS, 1985, CELL IMMUNOL, V95, P105, DOI 10.1016/0008-8749(85)90299-0; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CORBO GM, 1988, J ALLERGY CLIN IMMUN, V81, P41, DOI 10.1016/0091-6749(88)90218-7; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DUNNILL MS, 1968, THORAX, V23, P168; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GLYNN A. A., 1960, THORAX, V15, P142, DOI 10.1136/thx.15.2.142; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KORNFELD H, 1985, J IMMUNOL, V134, P3887; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LOPEZ AF, 1987, P NATL ACAD SCI USA, V84, P2761; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MARINI M, 1992, CHEST, V102, P661, DOI 10.1378/chest.102.3.661; MARINI M, 1992, J ALLERGY CLIN IMMUN, V90, P76; MATTOLI S, 1985, J ALLERGY CLIN IMMUN, V76, P214, DOI 10.1016/0091-6749(85)90704-3; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; MATTOLI S, 1991, J CELL PHYSIOL, V149, P260, DOI 10.1002/jcp.1041490212; MIOSSEC P, 1984, J IMMUNOL, V133, P2007; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SALVATO G, 1968, THORAX, V23, P168, DOI 10.1136/thx.23.2.168; SLUYTERMAN LAA, 1978, J CHROMATOGR, V150, P17, DOI 10.1016/S0021-9673(01)92092-8; SLUYTERMAN LAA, 1978, J CHROMATOGR, V150, P31, DOI 10.1016/S0021-9673(01)92093-X; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530, DOI 10.1152/ajplung.1991.260.6.L530; WALKER C, 1991, J IMMUNOL, V146, P1829; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; 1985, AM REV RESPIR DIS, V132, P180	37	101	106	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					412	424		10.1016/0091-6749(93)90120-5	http://dx.doi.org/10.1016/0091-6749(93)90120-5			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360392				2022-12-18	WOS:A1993LX30900007
J	COHN, JR; PIZZI, A				COHN, JR; PIZZI, A			DETERMINANTS OF PATIENT COMPLIANCE WITH ALLERGEN IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGENS ADMINISTRATION AND DOSAGE; ASTHMA; ALLERGIC RHINITIS; DESENSITIZATION IMMUNOLOGICAL ADVERSE EFFECT; HAY FEVER THERAPY; POLLEN IMMUNOLOGY; ASTHMA THERAPY; PATIENT COMPLIANCE		Background: Allergen immunotherapy (AIM) has been demonstrated to be safe and effective in the treatment of allergic respiratory disease. Although it requires considerable patient commitment, little attention has been paid to the factors that contribute to patient compliance. Methods: Patients in a practice based at an urban university hospital, who discontinued AIM, were contacted to determine their reasons for stopping treatment. Results were correlated with demographic and disease data obtained from the patient charts. Results: Review of practice records identified 217 patients on AIM. One hundred forty-eight had allergic rhinitis, (R), 66 had allergic rhinitis and asthma (RA), and 3 had allergic asthma without evidence of rhinitis (A). Seventy-four (50%) of the patients in the R group, 32 (48%) Of the patients in the RA group, and three (100%) of those in the A group discontinued treatment. The groups differed in that 55% of the patients in the R group discontinued treatment because of inconvenience, compared with only 22% of the patients in the RA group (p < 0.01). By contrast, 25% of the patients in the RA group stopped because they thought that they were ''better'' with medication, compared with none of the patients in the R group (p < 0.001). All of the patients in the RA group who stopped because they were better completed at least the first four-vial treatment series. Conclusions: Inconvenience is the major contributing factor in noncompliance with AIM. Regulations designed to protect patients from adverse reactions should balance the potential risk of reactions against the benefits of treatment and the effect of more stringent guidelines on patient compliance.	THOMAS JEFFERSON UNIV,DEPT MED,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT PEDIAT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University								AAS K, 1971, ACTA PAEDIAT SCAN, P264; COHN JH, 1992, J VOICE, V5, P332; DUBUSEK LW, 1992, IMMUNOL ALLERGY CLIN, V11, P107; DYKEWICZ MS, 1992, IMMUNOL ALLERGY CLIN, V12, P125; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; LENFANT C, 1991, J ALLERGY CLIN IMMUN, V88, P425; LEVINE MI, 1979, J ALLERGY CLIN IMMUN, V63, P209; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LOWER TA, 1992, J ALLERGY CLIN IMMUN, V82, P272; OHMANJL, 1974, J ALLERGY CLIN IMMUN, V74, P230; SPIEGEL JR, 1991, PROFESSIONAL VOICE S, P159; 1990, J ALLERGYY CLIN IMMU, V85, P526; 1986, J ALLERGYY CLIN IMMU, V2, P271	15	101	103	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					734	747		10.1016/0091-6749(93)90192-I	http://dx.doi.org/10.1016/0091-6749(93)90192-I			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454795				2022-12-18	WOS:A1993KU20300005
J	WEILER, JM; GELLHAUS, MA; CARTER, JG; MENG, RL; BENSON, PM; HOTTEL, RA; SCHILLIG, KB; VEGH, AB; CLARKE, WR				WEILER, JM; GELLHAUS, MA; CARTER, JG; MENG, RL; BENSON, PM; HOTTEL, RA; SCHILLIG, KB; VEGH, AB; CLARKE, WR			A PROSPECTIVE-STUDY OF THE RISK OF AN IMMEDIATE ADVERSE REACTION TO PROTAMINE SULFATE DURING CARDIOPULMONARY BYPASS-SURGERY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,DEPT MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT ANESTHESIA,IOWA CITY,IA 52242; UNIV IOWA,DEPT SURG,IOWA CITY,IA 52242; UNIV IOWA,DEPT PREVENT MED,IOWA CITY,IA 52242; VET ADM MED CTR,IOWA CITY,IA 52240	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIAID NIH HHS [AI22350] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022350] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSEN JM, 1981, AM J HOSP PHARM, V38, P701, DOI 10.1093/ajhp/38.5.701; BEST N, 1984, BRIT J ANAESTH, V56, P339, DOI 10.1093/bja/56.4.339; CAPLAN SN, 1976, NEW ENGL J MED, V295, P172; CAVAROCCHI NC, 1985, SURGERY, V98, P525; CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901; CHUNG F, 1984, CAN ANAESTH SOC J, V31, P314, DOI 10.1007/BF03007897; COBB CA, 1982, SURG NEUROL, V17, P245, DOI 10.1016/0090-3019(82)90112-4; COLMAN RW, 1987, ANESTHESIOLOGY, V66, P595; FEHR J, 1983, CLIN IMMUNOL IMMUNOP, V29, P7, DOI 10.1016/0090-1229(83)90002-8; GARDINALI M, 1986, PATHOL IMMUNOPATH R, V5, P352, DOI 10.1159/000157026; HAMMERSCHMIDT DE, 1981, J THORAC CARDIOV SUR, V81, P370; HERZIG GP, 1972, BLOOD-J HEMATOL, V39, P554, DOI 10.1182/blood.V39.4.554.554; HOLLAND CL, 1984, CLIN CARDIOL, V7, P157, DOI 10.1002/clc.4960070305; HORROW JC, 1985, ANESTH ANALG, V64, P348; JACKSON DR, 1970, ANGIOLOGY, V21, P295, DOI 10.1177/000331977002100502; KIRKLIN JK, 1986, ANN THORAC SURG, V41, P193, DOI 10.1016/S0003-4975(10)62668-9; KIRKLIN JK, 1983, J THORAC CARDIOV SUR, V86, P845; KNAPE JTA, 1981, ANESTHESIOLOGY, V55, P324, DOI 10.1097/00000542-198109000-00025; LAKIN JD, 1978, J ALLERGY CLIN IMMUN, V61, P102, DOI 10.1016/0091-6749(78)90232-4; LOWENSTEIN E, 1983, ANESTHESIOLOGY, V59, P470, DOI 10.1097/00000542-198311000-00022; MOORTHY SS, 1980, ANESTH ANALG, V39, P77; MOREL DR, 1987, ANESTHESIOLOGY, V66, P597, DOI 10.1097/00000542-198705000-00002; OLINGER GN, 1980, ANN THORAC SURG, V29, P20, DOI 10.1016/S0003-4975(10)61620-7; RAEPPLE E, 1976, IMMUNOCHEMISTRY, V13, P251, DOI 10.1016/0019-2791(76)90223-8; RENT R, 1975, J IMMUNOL, V114, P120; SHARATH MD, 1985, J THORAC CARDIOV SUR, V90, P86; STEWART WJ, 1984, CIRCULATION, V70, P788, DOI 10.1161/01.CIR.70.5.788; TAMIYA T, 1988, ANN THORAC SURG, V46, P47, DOI 10.1016/S0003-4975(10)65851-1; VONTZ FK, 1982, AM SURGEON, V48, P549; WAGNER JL, 1984, ANAL BIOCHEM, V136, P75, DOI 10.1016/0003-2697(84)90308-7; WATSON RA, 1983, UROLOGY, V2, P493; WEILER JM, 1978, J EXP MED, V147, P409, DOI 10.1084/jem.147.2.409; WEILER JM, 1983, IMMUNOPHARMACOLOGY, V6, P245, DOI 10.1016/0162-3109(83)90024-3; WEILER JM, 1985, J ALLERGY CLIN IMMUN, V75, P297, DOI 10.1016/0091-6749(85)90061-2; WEISS ME, 1989, NEW ENGL J MED, V320, P886, DOI 10.1056/NEJM198904063201402; WYSOCKI H, 1982, INT J ARTIF ORGANS, V5, P305, DOI 10.1177/039139888200500507; 1985, VITAL HLTH STATISTIC, V13	37	101	106	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					713	719		10.1016/0091-6749(90)90189-B	http://dx.doi.org/10.1016/0091-6749(90)90189-B			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2182695				2022-12-18	WOS:A1990DA43700006
J	SIMONS, FER				SIMONS, FER			H-1-RECEPTOR ANTAGONISTS - CLINICAL-PHARMACOLOGY AND THERAPEUTICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									UNIV MANITOBA, DEPT PEDIAT & CHILD HLTH, ALLERGY & CLIN IMMUNOL SECT, WINNIPEG R3T 2N2, MANITOBA, CANADA	University of Manitoba								ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; BADIER M, 1988, J ALLERGY CLIN IMMUN, V81, P437, DOI 10.1016/0091-6749(88)90913-X; BANTZ EW, 1987, ANN ALLERGY, V59, P341; BENDE M, 1987, ALLERGY, V42, P512, DOI 10.1111/j.1398-9995.1987.tb00374.x; BERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P177, DOI 10.1016/0091-6749(88)90273-4; BERNSTEIN IL, 1986, J ALLERGY CLIN IMMUN, V77, P37, DOI 10.1016/0091-6749(86)90319-2; BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; BHAMBHANI K, 1983, ANN EMERG MED, V12, P13, DOI 10.1016/S0196-0644(83)80125-5; BLEEHEN SS, 1987, BRIT J DERMATOL, V117, P81, DOI 10.1111/j.1365-2133.1987.tb04095.x; BRADLEY CM, 1987, EUR J CLIN PHARMACOL, V32, P419, DOI 10.1007/BF00543979; BRANDES LJ, 1987, CANCER RES, V47, P4025; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BROSTOFF J, 1982, POSTGRAD MED J, V58, P422, DOI 10.1136/pgmj.58.681.422; BRUTTMANN G, 1987, J INT MED RES, V15, P63, DOI 10.1177/030006058701500201; BURNS JJ, 1963, ANN NY ACAD SCI, V104, P881, DOI 10.1111/j.1749-6632.1963.tb57090.x; CALLIER J, 1981, CURR THER RES CLIN E, V29, P24; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CHAN TB, 1986, BRIT J DIS CHEST, V80, P375, DOI 10.1016/0007-0971(86)90091-4; CLEE MD, 1984, BRIT J DIS CHEST, V78, P180, DOI 10.1016/0007-0971(84)90120-7; CONNELL JT, 1987, AM J RHINOL, V1, P3; CRAFT TM, 1986, BRIT MED J, V292, P660, DOI 10.1136/bmj.292.6521.660; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; DIAMOND L, 1981, ANN ALLERGY, V47, P87; DOCKHORN RJ, 1988, J ALLERGY CLIN IMMUN, V81, P178, DOI 10.1016/0091-6749(88)90275-8; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; DOMS M, 1988, EUR J CLIN PHARMACOL, V34, P619, DOI 10.1007/BF00615227; Douglas W.W., 1985, PHARMACOL BASIS THER, P605; FILLOUX F, 1986, J PEDIATR-US, V108, P1018, DOI 10.1016/S0022-3476(86)80953-2; FOX RW, 1986, J ALLERGY CLIN IMMUN, V78, P1159, DOI 10.1016/0091-6749(86)90266-6; FREEDBERG RS, 1987, JAMA-J AM MED ASSOC, V257, P660, DOI 10.1001/jama.257.5.660; GAFFEY MJ, 1987, AM REV RESPIR DIS, V136, P556, DOI 10.1164/ajrccm/136.3.556; GAILLARD AWK, 1988, EUR J CLIN PHARMACOL, V35, P249, DOI 10.1007/BF00558261; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; GENGO FM, 1988, J ALLERGY CLIN IMMUN, V81, P211, DOI 10.1016/0091-6749(88)90408-3; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; GEORGITIS JW, 1988, ARCH OTOLARYNGOL, V114, P63; GOLDSOBEL AB, 1986, J ALLERGY CLIN IMMUN, V78, P867, DOI 10.1016/0091-6749(86)90232-0; GRANT JA, 1988, J ALLERGY CLIN IMMUN, V81, P563, DOI 10.1016/0091-6749(88)90197-2; GUILL MF, 1986, J ALLERGY CLIN IMMUN, V78, P4, DOI 10.1016/0091-6749(86)90107-7; GUTKOWSKI A, 1985, J INT MED RES, V13, P284, DOI 10.1177/030006058501300507; HAVAS TE, 1986, J ALLERGY CLIN IMMUN, V78, P856, DOI 10.1016/0091-6749(86)90230-7; HENAUER SA, 1988, EUR J CLIN PHARMACOL, V34, P35, DOI 10.1007/BF01061414; HEYKANTS J, 1986, DRUG DEVELOP RES, V8, P71, DOI 10.1002/ddr.430080109; HILBERT J, 1988, J CLIN PHARMACOL, V28, P234, DOI 10.1002/j.1552-4604.1988.tb03138.x; HILBERT J, 1987, J CLIN PHARMACOL, V27, P694, DOI 10.1002/j.1552-4604.1987.tb03090.x; HILBERT J, 1988, J INT MED RES, V16, P50, DOI 10.1177/030006058801600106; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V76, P375, DOI 10.1016/0091-6749(85)90657-8; HORAK F, 1988, ARZNEIMITTEL-FORSCH, V38-1, P124; HOWARD JC, 1979, JAMA-J AM MED ASSOC, V242, P2414, DOI 10.1001/jama.242.22.2414; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; HUANG SM, 1982, EUR J CLIN PHARMACOL, V22, P359, DOI 10.1007/BF00548406; HUTHER KJ, 1977, EUR J CLIN PHARMACOL, V12, P195, DOI 10.1007/BF00609860; JONES TR, 1986, VIRUS RES, V4, P369, DOI 10.1016/0168-1702(86)90083-3; JUHLIN L, 1988, BRIT J DERMATOL, V119, P67, DOI 10.1111/j.1365-2133.1988.tb07103.x; KASSEM N, 1988, ANN ALLERGY, V60, P505; KEMP JP, 1985, ANN ALLERGY, V54, P502; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; KING CTG, 1966, AM J OBSTET GYNECOL, V95, P109, DOI 10.1016/0002-9378(66)90635-1; KRAUSE L, 1983, BRIT MED J, V287, P1199, DOI 10.1136/bmj.287.6400.1199; KRAUSE LB, 1985, BRIT J DERMATOL, V112, P447, DOI 10.1111/j.1365-2133.1985.tb02319.x; KRENZELOK EP, 1982, ANN EMERG MED, V11, P212, DOI 10.1016/S0196-0644(82)80501-5; LANTIN JP, 1988, J ALLERGY CLIN IMMUN, V81, P213, DOI 10.1016/0091-6749(88)90416-2; LEWISTON NJ, 1982, J PEDIATR-US, V101, P458, DOI 10.1016/S0022-3476(82)80087-5; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; LUSCOMBE DK, 1983, PHARMATHERAPEUTICA, V3, P370; LUSKIN SS, 1989, J ALLERGY CLIN IMMUN, V83, P406, DOI 10.1016/0091-6749(89)90126-7; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MATZKE GR, 1987, ANN ALLERGY, V59, P25; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V81, P177, DOI 10.1016/0091-6749(88)90270-9; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; MONASH S, 1950, J INVEST DERMATOL, V15, P1, DOI 10.1038/jid.1950.61; MORAN DM, 1982, J PEDIATR-US, V101, P132, DOI 10.1016/S0022-3476(82)80202-3; MOSER L, 1978, EUR J CLIN PHARMACOL, V14, P417, DOI 10.1007/BF00716383; MURPHYOCONNOR JC, 1984, J INT MED RES, V12, P333, DOI 10.1177/030006058401200603; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PATEL KR, 1987, J ALLERGY CLIN IMMUN, V79, P355, DOI 10.1016/0091-6749(87)90155-2; PAUL E, 1986, EUR J CLIN PHARMACOL, V31, P277, DOI 10.1007/BF00981123; PECOUD A, 1987, INT ARCH ALLER A IMM, V82, P541, DOI 10.1159/000234274; PIERSON W E, 1982, Journal of Allergy and Clinical Immunology, V69, P143; PIPKORN U, 1985, ALLERGY, V40, P491, DOI 10.1111/j.1398-9995.1985.tb00255.x; PRENNER BM, 1977, AM J DIS CHILD, V131, P529, DOI 10.1001/archpedi.1977.02120180043007; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RANDALL JE, 1979, PEDIATRICS, V63, P483; RIHOUX JP, 1985, ANN ALLERGY, V55, P392; ROBERTS J, 1988, J ALLERGY CLIN IMMUN, V81, P210, DOI 10.1016/0091-6749(88)90404-6; ROKENES HK, 1988, CLIN ALLERGY, V18, P63, DOI 10.1111/j.1365-2222.1988.tb02844.x; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; ROMBAUT N, 1986, ANN ALLERGY, V57, P321; ROTH T, 1987, J ALLERGY CLIN IMMUN, V80, P94, DOI 10.1016/S0091-6749(87)80197-5; SALISBURY J, 1987, BRIT J CLIN PRACT, V41, P859; SAXENA SP, 1989, SCIENCE, V243, P1596, DOI 10.1126/science.2928797; SCHNORE SK, 1986, J FAM PRACTICE, V22, P39; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SHALL L, 1988, BRIT J DERMATOL, V119, P525, DOI 10.1111/j.1365-2133.1988.tb03257.x; SIMONS FER, 1982, ANN ALLERGY, V48, P145; SIMONS FER, 1987, J ALLERGY CLIN IMMUN, V80, P884; SIMONS FER, 1984, J ALLERGY CLIN IMMUN, V73, P69, DOI 10.1016/0091-6749(84)90486-X; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V69, P376, DOI 10.1016/0091-6749(82)90149-X; SIMONS FER, 1989, J CLIN PHARMACOL, V29, P809, DOI 10.1002/j.1552-4604.1989.tb03424.x; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V70, P458, DOI 10.1016/0091-6749(82)90009-4; SIMONS FER, 1983, PEDIATR CLIN N AM, V30, P899; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V82, P1068; SIMONS FER, 1988, LANCET, V2, P624; SIMONS FER, 1984, J PEDIATR-US, V104, P123; SIMONS KJ, 1989, J ALLERGY CLIN IMMUN, V83, P276; SIMONS KJ, 1986, J ALLERGY CLIN IMMUN, V77, P326, DOI 10.1016/S0091-6749(86)80112-9; SIMONS KJ, 1987, J ALLERGY CLIN IMMUN, V79, P928, DOI 10.1016/0091-6749(87)90242-9; SIMONS KJ, 1989, CLIN PHARMACOL THER, V45, P9, DOI 10.1038/clpt.1989.2; SKASSABROCIEK W, 1988, J ALLERGY CLIN IMMUN, V81, P725, DOI 10.1016/0091-6749(88)91045-7; STILLWAGON PK, 1987, ANN ALLERGY, V58, P442; STRATTON D, 1984, BRIT J DIS CHEST, V78, P163, DOI 10.1016/0007-0971(84)90117-7; TAYLOR RJ, 1985, J ALLERGY CLIN IMMUN, V76, P103, DOI 10.1016/0091-6749(85)90811-5; THOMPSON JA, 1981, J PHARM SCI-US, V70, P1284, DOI 10.1002/jps.2600701127; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225; TRZECIAKOWSKI JP, 1988, ALLERGY PRINCIPLES P, P715; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8; WOOD SF, 1986, CLIN ALLERGY, V16, P195, DOI 10.1111/j.1365-2222.1986.tb00766.x; WOOD SG, 1987, ANN ALLERGY, V59, P31; YACOBI A, 1980, J PHARM SCI, V69, P1077, DOI 10.1002/jps.2600690924; ZIERLER S, 1986, AM J EPIDEMIOL, V123, P192, DOI 10.1093/oxfordjournals.aje.a114214	126	101	104	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				845	861		10.1016/0091-6749(89)90377-1	http://dx.doi.org/10.1016/0091-6749(89)90377-1			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2574731	Bronze			2022-12-18	WOS:A1989CG29300001
J	CARTIER, A; BERNSTEIN, IL; BURGE, PS; COHN, JR; FABBRI, LM; HARGREAVE, FE; MALO, JL; MCKAY, RT; SALVAGGIO, JE				CARTIER, A; BERNSTEIN, IL; BURGE, PS; COHN, JR; FABBRI, LM; HARGREAVE, FE; MALO, JL; MCKAY, RT; SALVAGGIO, JE			GUIDELINES FOR BRONCHOPROVOCATION ON THE INVESTIGATION OF OCCUPATIONAL ASTHMA - REPORT OF THE SUBCOMMITTEE-ON-BRONCHOPROVOCATION-FOR-OCCUPATIONAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CARTIER, A (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 OUEST BLVD GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.		Fabbri, Leonardo M/I-4055-2012	Fabbri, Leonardo M/0000-0001-8894-1689				BANKS DE, 1986, CHEST, V89, P389, DOI 10.1378/chest.89.3.389; BARDY JD, 1987, AM REV RESPIR DIS, V135, P1033; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; BURGE PS, 1979, THORAX, V34, P317, DOI 10.1136/thx.34.3.317; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P655, DOI 10.1016/0091-6749(79)90031-9; BUTCHER BT, 1982, J ALLERGY CLIN IMMUN, V70, P231, DOI 10.1016/0091-6749(82)90058-6; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P1185, DOI 10.1016/0091-6749(86)90270-8; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V77, P639, DOI 10.1016/0091-6749(86)90359-3; CARTIER A, 1984, CLIN ALLERGY, V14, P193, DOI 10.1111/j.1365-2222.1984.tb02652.x; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V77, P165; CHANYEUNG M, 1986, AM REV RESPIR DIS, V133, P666; CHANYEUNG M, 1987, CHEST, V91, P1305; CHESTER EH, 1979, CHEST, V75, P229, DOI 10.1378/chest.75.2_Supplement.229; COCKCROFT DW, 1984, CLIN ALLERGY, V14, P61, DOI 10.1111/j.1365-2222.1984.tb02191.x; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; DELUCA S, 1988, EUR RESPIR J, V1, P540; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; GERBLICH AA, 1979, J ALLERGY CLIN IMMUN, V64, P658, DOI 10.1016/0091-6749(79)90032-0; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; KOPP SK, 1985, ANN INTERN MED, V102, P623; LARCHEVEQUE J, 1988, J ALLERGY CLIN IMMUN, V81, P244, DOI 10.1016/0091-6749(88)90539-8; LARCHEVEQUE J, 1985, J ALLERGY CLIN IMMUN, V75, P170, DOI 10.1016/0091-6749(85)90398-7; MALO JL, 1988, THORAX, V43, P371, DOI 10.1136/thx.43.5.371; MAPP C, 1987, AM REV RESPIR DIS, V136, P1403, DOI 10.1164/ajrccm/136.6.1403; MAPP CE, 1986, EUR J RESPIR DIS, V69, P276; MCKAY RT, 1986, SEMIN RESPIR MED, V7, P297, DOI 10.1055/s-2007-1012625; PAULI G, 1986, B EUR PHYSIOPATH RES, V22, P399; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1981, B NEW YORK ACAD MED, V57, P608; SIRACUSA A, 1978, CLIN ALLERGY, V8, P195, DOI 10.1111/j.1365-2222.1978.tb00464.x; SMITH AB, 1980, J OCCUP ENVIRON MED, V22, P327, DOI 10.1097/00043764-198005000-00005; TAYLOR AJN, 1984, CLIN IMMUNOL ALLERGY, V4, P3; ZAMMITTABONA M, 1983, AM REV RESPIR DIS, V128, P226	37	101	101	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	2	S			823	829		10.1016/0091-6749(89)90346-1	http://dx.doi.org/10.1016/0091-6749(89)90346-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CC527	2809031				2022-12-18	WOS:A1989CC52700006
J	MADONINI, E; BRIATICOVANGOSA, G; PAPPACODA, A; MACCAGNI, G; CARDANI, A; SAPORITI, F				MADONINI, E; BRIATICOVANGOSA, G; PAPPACODA, A; MACCAGNI, G; CARDANI, A; SAPORITI, F			SEASONAL INCREASE OF BRONCHIAL REACTIVITY IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MADONINI, E (corresponding author), INST SOCIAL RESP DIS, DEPT ALLERGY, VIALE ZARA 81, I-20159 MILANO, ITALY.							BLEECKER ER, 1982, CHEST, V82, P227; BOULET L P, 1982, Journal of Allergy and Clinical Immunology, V69, P95; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; BUCZKO GB, 1984, AM REV RESPIR DIS, V129, P15; CARTIER A, 1980, American Review of Respiratory Disease, V121, P61; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; KIVILOOG J, 1973, SCAND J RESPIR DIS, V54, P539; MADONINI E, 1986, MED TORACICA, V1, P39; PARKER CD, 1965, ARCH INTERN MED, V452, P115; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; ROSENTHAL RR, 1979, CHEST, V75, P228, DOI 10.1378/chest.75.2.228; SMITH JM, 1983, ALLERGY PRINCIPLES P, V2, P771; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; STEVENS WJ, 1980, EUR J RESPIR DIS, V203, P61; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; 1980, ATS NEWS         SPR	21	101	103	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					358	363		10.1016/0091-6749(87)90156-4	http://dx.doi.org/10.1016/0091-6749(87)90156-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	3819219	Bronze			2022-12-18	WOS:A1987G179100011
J	MENARDO, JL; BOUSQUET, J; RODIERE, M; ASTRUC, J; MICHEL, FB				MENARDO, JL; BOUSQUET, J; RODIERE, M; ASTRUC, J; MICHEL, FB			SKIN-TEST REACTIVITY IN INFANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU MONTPELLIER,MALAD INFECT INFANTILES CLIN,F-34059 MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier	MENARDO, JL (corresponding author), CHU MONTPELLIER,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					AAS K, 1975, PEDIATR CLIN N AM, V22, P33; AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; BERTHER T, 1980, SCHWEIZ MED WSCHR, V110, P758; BOUSQUET J, 1983, ANN ALLERGY, V51, P291; BOUSQUET J, 1983, PROVOCATIVE CHALLENG, P45; BOUTIN C, 1980, TESTS CUTANES ALLERG, P288; BUSINCO L, 1979, ANN ALLERGY, V43, P120; CAREY T. NELSON, 1934, JOUR ALLERGY, V5, P488, DOI 10.1016/S0021-8707(34)90248-3; FOUCARD T, 1973, ACTA PAEDIATR SCAND, V62, P633, DOI 10.1111/j.1651-2227.1973.tb17078.x; GUERIN B, 1982, CLIN ALLERGY, V12, P428; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HAMBURGER RN, 1981, DIAGNOSIS TREATMENT, P30; HANNAWAY PJ, 1970, ANN ALLERGY, V28, P413; JOHNSTONE DE, 1981, ANN ALLERGY, V47, P225; KAUFMAN H S, 1971, Clinical Allergy, V1, P363, DOI 10.1111/j.1365-2222.1971.tb00787.x; LESSOF MH, 1980, CLIN ALLERGY, V10, P115, DOI 10.1111/j.1365-2222.1980.tb02088.x; LESSOF MH, 1981, IMMUNOLOGICAL CLIN A, P53; MATHESON A, 1952, PEDIATRICS, V10, P181; MATTHEW DJ, 1977, LANCET, V1, P321; MENARDO JL, 1983, ANN ALLERGY, V51, P535; MENARDO JL, 1982, ANN ALLERGY, V48, P235; MENDOZA GR, 1982, PEDIATRICS, V69, P188; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; NELSON HS, 1983, ANN ALLERGY, V51, P411; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; OSTERBALLE O, 1981, Ugeskrift for Laeger, V143, P3211; PASCUAL HC, 1977, ANN ALLERGY, V39, P325; Pepys J., 1975, BR J HOSP MED, V14, P412; SKASSABROCIEK W, 1985, J ALLERGY CLIN IMMUN, V75, P195, DOI 10.1016/0091-6749(85)90497-X; SQUIRE JR, 1952, BRIT MED J, V1, P1, DOI 10.1136/bmj.1.4748.1; STANWORTH DR, 1980, PSEUDOALLERGIC REACT, V1, P61; STEVENSON DD, 1971, J ALLERGY CLIN IMMUN, V48, P61, DOI 10.1016/0091-6749(71)90088-1; Sulzberger MB, 1940, ARCH DERMATOL SYPH, V41, P1029, DOI 10.1001/archderm.1940.01490120031004; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x; 1983, J ALLERGY CLIN IMMUN, V72, P515	36	101	104	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					646	651		10.1016/0091-6749(85)90088-0	http://dx.doi.org/10.1016/0091-6749(85)90088-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	2409121	Bronze			2022-12-18	WOS:A1985ALA8400003
J	FAUCI, AS				FAUCI, AS			VASCULITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FAUCI, AS (corresponding author), NIAID,IMMUNOREGULAT,BLDG 10,ROOM 11B-13,BETHESDA,MD 20205, USA.							ACKROYD JF, 1953, AM J MED, V14, P605, DOI 10.1016/0002-9343(53)90377-5; ALARCONSEGOVIA D, 1977, MED CLIN N AM, V61, P24; ALLEN NB, 1983, CURRENT THERAPY ALLE, P147; ANSELL BM, 1970, BRIT J DERMATOL, V82, P211, DOI 10.1111/j.1365-2133.1970.tb12426.x; BALLARD HS, 1970, AM J MED, V49, P328, DOI 10.1016/S0002-9343(70)80024-9; BRON KM, 1965, ARCH INTERN MED, V116, P450, DOI 10.1001/archinte.1965.03870030130024; CHURG J, 1951, AM J PATHOL, V27, P277; COCHRANE CG, 1976, TXB IMMUNOPATHOLOGY, V1, P137; CREAM J J, 1970, QJM, V39, P461; CUPPS TR, 1980, AM J MED, V69, P881, DOI 10.1016/S0002-9343(80)80014-3; CUPPS TR, 1982, JAMA, V247, P1194; CUPPS TR, 1981, VASCULITIDES, P1; CUPPS TR, 1983, CURR THER ALLERGY S, P136; DESHAZO RD, 1977, JAMA-J AM MED ASSOC, V238, P1940; DORNFELD L, 1971, J AMER MED ASSOC, V215, P1950, DOI 10.1001/jama.215.12.1950; EPSTEIN WL, 1967, PROG ALLERGY, V11, P36, DOI 10.1159/000287243; FAUCHALD P, 1972, ANN INTERN MED, V77, P845, DOI 10.7326/0003-4819-77-6-845; Fauci A S, 1977, Dis Mon, V23, P1, DOI 10.1016/S0011-5029(77)80004-7; FAUCI AS, 1982, NEW ENGL J MED, V306, P68, DOI 10.1056/NEJM198201143060203; FAUCI AS, 1977, ANN INTERN MED, V87, P782, DOI 10.7326/0003-4819-87-6-782; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1978, AM J MED, V64, P890, DOI 10.1016/0002-9343(78)90533-8; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FAUCI AS, 1978, AM J MED, V64, P729, DOI 10.1016/0002-9343(78)90510-7; FAUCI AS, 1983, CURR THER ALLERGY S, P129; FAUCI AS, 1982, CECIL TXB MED, P1863; FLEMING RJ, 1965, RADIOLOGY, V84, P100, DOI 10.1148/84.1.100; FRAGA A, 1972, ARTHRITIS RHEUM, V15, P617, DOI 10.1002/art.1780150608; FROHNERT PP, 1967, AM J MED, V43, P8, DOI 10.1016/0002-9343(67)90144-1; HAMILTON CR, 1971, MEDICINE, V50, P1, DOI 10.1097/00005792-197101000-00001; HEALEY LA, 1971, ARTHRITIS RHEUM, V14, P138, DOI 10.1002/art.1780140120; HUNDER GG, 1975, ANN INTERN MED, V82, P613, DOI 10.7326/0003-4819-82-5-613; ISRAEL HL, 1977, ANN INTERN MED, V87, P691, DOI 10.7326/0003-4819-87-6-691; KATO H, 1979, PEDIATRICS, V63, P175; KATZ SI, 1977, MEDICINE, V56, P443, DOI 10.1097/00005792-197709000-00005; KATZENSTEIN ALA, 1979, CANCER, V43, P360, DOI 10.1002/1097-0142(197901)43:1<360::AID-CNCR2820430151>3.0.CO;2-8; KAWASAKI T, 1974, PEDIATRICS, V54, P271; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; Kussmaul A, 1866, DTSCH ARCH KLIN MED, P484; LANDING BH, 1977, PEDIATRICS, V59, P651; LIEBOW AA, 1972, HUM PATHOL, V3, P457, DOI 10.1016/S0046-8177(72)80005-4; LINDENAUER SM, 1966, SURGERY, V59, P982; LONGSTRETH PL, 1974, RADIOLOGY, V113, P65, DOI 10.1148/113.1.65; MCKUSICK VA, 1962, AM HEART J, V63, P57, DOI 10.1016/0002-8703(62)90220-X; MEYERS DS, 1974, AM J MED, V56, P412, DOI 10.1016/0002-9343(74)90624-X; Morens D M, 1978, J Infect Dis, V137, P91; MOUTSOPOULOS HM, 1980, ANN INTERN MED, V92, P212, DOI 10.7326/0003-4819-92-2-212; NAKAO K, 1967, CIRCULATION, V35, P1141, DOI 10.1161/01.CIR.35.6.1141; ODUFFY JD, 1971, ANN INTERN MED, V75, P561, DOI 10.7326/0003-4819-75-4-561; ROSE GA, 1957, Q J MED, V26, P43; SAMS WM, 1976, ARCH DERMATOL, V112, P219, DOI 10.1001/archderm.112.2.219; SERGENT JS, 1976, MEDICINE, V55, P1, DOI 10.1097/00005792-197601000-00001; TANAKA N, 1976, ARCH PATHOL LAB MED, V100, P81; VINIJCHAIKUL K, 1967, AM J MED, V43, P15, DOI 10.1016/0002-9343(67)90145-3; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; WINKELMANN RK, 1964, MEDICINE, V43, P59, DOI 10.1097/00005792-196401000-00003; ZEEK PM, 1952, AM J CLIN PATHOL, V22, P777; ZEEK PM, 1953, NEW ENGL J MED, V248, P764, DOI 10.1056/NEJM195304302481805	59	101	101	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					211	223		10.1016/0091-6749(83)90021-0	http://dx.doi.org/10.1016/0091-6749(83)90021-0			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6136539	Bronze			2022-12-18	WOS:A1983RH93800001
J	DESHAZO, RD; NELSON, HS				DESHAZO, RD; NELSON, HS			APPROACH TO THE PATIENT WITH A HISTORY OF LOCAL-ANESTHETIC HYPERSENSITIVITY - EXPERIENCE WITH 90 PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERGY CLIN IMMUNOL SERV,DENVER,CO 80240									ADLER P, 1949, ORAL SURG ORAL MED O, V2, P1029, DOI 10.1016/0030-4220(49)90214-5; ALDRETE JA, 1969, J AMER MED ASSOC, V207, P356, DOI 10.1001/jama.207.2.356; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P173; BATEMAN PP, 1974, MED J AUSTRALIA, V2, P449, DOI 10.5694/j.1326-5377.1974.tb70901.x; BETCHER AM, 1955, ANESTHESIOLOGY, V16, P214, DOI 10.1097/00000542-195503000-00008; COOMBS RRA, 1975, CLIN ASPECTS IMMUNOL, P764; DEJONG RH, 1978, JAMA-J AM MED ASSOC, V239, P1166, DOI 10.1001/jama.239.12.1166; DESWARTE RD, 1972, ALLERGIC DISEASES, P474; GOODMAN M. H., 1939, JOUR INVEST DERMAT, V2, P53; HOLTI G, 1965, Dent Pract Dent Rec, V15, P294; INCAUDO G, 1978, J ALLERGY CLIN IMMUN, V61, P339, DOI 10.1016/0091-6749(78)90057-X; MEYERS FH, 1976, REV MED PHARMACOLOGY, P220; MITCHELL HS, 1953, J CAN DENT ASSOC, V19, P127; NAGEL JE, 1977, JAMA-J AM MED ASSOC, V237, P1594; NELSON HS, 1977, ADV ASTHMA ALLERGY, V4, P22; NOBLE DS, 1961, LANCET, V281, P1436; RAVINDRANATHAN N, 1975, BRIT DENT J, V138, P101, DOI 10.1038/sj.bdj.4803376; RICKLES NH, 1953, ORAL SURG ORAL MED O, V6, P375, DOI 10.1016/0030-4220(53)90063-2; ROOD JP, 1973, BRIT DENT J, V135, P411, DOI 10.1038/sj.bdj.4803093; ROTHMAN S, 1945, J INVEST DERMATOL, V6, P191, DOI 10.1038/jid.1945.15; SHELDON RM, 1967, MANUAL CLIN ALLERGY, P59; SIEGAL S, 1958, J ALLERGY, V29, P329, DOI 10.1016/0021-8707(58)90038-8; SMITH JR, 1961, J ORAL SURG, V19, P418; VERILL PJ, 1975, PRACTITIONER, V214, P380; WALDMAN HB, 1967, J AM DENT ASSOC, V74, P747, DOI 10.14219/jada.archive.1967.0111; WALKER RT, 1971, BRIT DENT J, V130, P2; 1977, ACCEPTED DENTAL THER, P97	27	101	102	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					387	394		10.1016/0091-6749(79)90211-2	http://dx.doi.org/10.1016/0091-6749(79)90211-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	447941				2022-12-18	WOS:A1979GY51400004
J	FISH, JE; PETERMAN, VI; CUGELL, DW				FISH, JE; PETERMAN, VI; CUGELL, DW			EFFECT OF DEEP INSPIRATION ON AIRWAY CONDUCTANCE IN SUBJECTS WITH ALLERGIC RHINITIS AND ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,PULM SECT,CHICAGO,IL 60611	Northwestern University								CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; FELARCA AB, 1966, J ALLERGY, V37, P223, DOI 10.1016/0021-8707(66)90117-1; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; HUGHES R, 1959, J PHYSIOL-LONDON, V146, P85, DOI 10.1113/jphysiol.1959.sp006179; NADEL JA, 1961, J APPL PHYSIOL, V16, P717, DOI 10.1152/jappl.1961.16.4.717; ROSENTHAL R R, 1977, American Review of Respiratory Disease, V115, P72; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SNEDECOR GW, 1973, STATISTICAL METHODS; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; WIDDICOMBE JG, 1954, J PHYSIOL-LONDON, V123, P71, DOI 10.1113/jphysiol.1954.sp005034	12	101	101	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	1					41	46		10.1016/0091-6749(77)90081-1	http://dx.doi.org/10.1016/0091-6749(77)90081-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DN224	874208				2022-12-18	WOS:A1977DN22400006
J	SOLOMON, WR				SOLOMON, WR			ASSESSING FUNGUS PREVALENCE IN DOMESTIC INTERIORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,MED CTR,DEPT INTERN MED,DIV ALLERGY,ANN ARBOR,MI 48100	University of Michigan System; University of Michigan								ADAMS KF, 1965, J PALYNOLOGY, V1, P67; ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; Brodie HJ, 1936, AM J BOT, V23, P309, DOI 10.2307/2436091; DINGLE A N, 1957, Fed Proc, V16, P615; FRANKLAND A. W., 1951, ACTA ALLERGOL, V4, P186, DOI 10.1111/j.1398-9995.1951.tb03408.x; Gregory P.H., 1973, MICROBIOLOGY ATMOSPH, V2nd; GREGORY PH, 1953, ANN APPL BIOL, V40, P651, DOI 10.1111/j.1744-7348.1953.tb01105.x; INGOLD CT, 1971, FUNGAL SPORES THEIR, pCH5; Kethley T W, 1967, Hosp Manage, V103, P84; KRAMER C. L., 1961, TRANS KANSAS ACAD SCI, V64, P110, DOI 10.2307/3626929; LUMPKINS ED, 1973, ANN ALLERGY, V31, P361; OGDEN EC, 1960, J ALLERGY, V31, P307, DOI 10.1016/0021-8707(60)90067-8; SAYER WJ, 1972, AM J CLIN PATHOL, V58, P558; SAYER WJ, 1969, J ALLERGY, V44, P214, DOI 10.1016/0021-8707(69)90088-4; SOLOMON WR, UNPUBLISHED OBSERVAT; SOLOMON WR, 1970, EXCERPTA MEDICA F IN, V211, P67; VANDERWAERDEN B, 1958, MOULD FUNGI BRONCHIA, V1	17	101	102	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	3					235	242		10.1016/0091-6749(75)90095-0	http://dx.doi.org/10.1016/0091-6749(75)90095-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ290	1151016				2022-12-18	WOS:A1975AQ29000009
J	Zhu, ZZ; Guo, YJ; Shi, H; Liu, CL; Panganiban, RA; Chung, W; O'Connor, LJ; Himes, BE; Gazal, S; Hasegawa, K; Camargo, CA; Qi, L; Moffatt, MF; Hu, FB; Lu, Q; Cookson, WOC; Liang, LM				Zhu, Zhaozhong; Guo, Yanjun; Shi, Huwenbo; Liu, Cong-Lin; Panganiban, Ronald Allan; Chung, Wonil; O'Connor, Luke J.; Himes, Blanca E.; Gazal, Steven; Hasegawa, Kohei; Camargo, Carlos A., Jr.; Qi, Lu; Moffatt, Miriam F.; Hu, Frank B.; Lu, Quan; Cookson, William O. C.; Liang, Liming			Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Obesity; metabolic disorder; asthma subtypes; shared genetics; genome-wide association study; RNA sequencing; RT-PCR	GENOME-WIDE ASSOCIATION; BODY-MASS INDEX; FATTY-ACID OXIDATION; AIRWAY INFLAMMATION; LUNG-FUNCTION; MURINE MODEL; CELL; LOCI; TGF-BETA/SMAD3; IDENTIFICATION	Background: Clinical and epidemiologic studies have shown that obesity is associated with asthma and that these associations differ by asthma subtype. Little is known about the shared genetic components between obesity and asthma. Objective: We sought to identify shared genetic associations between obesity-related traits and asthma subtypes in adults. Methods: A cross-trait genome-wide association study (GWAS) was performed using 457,822 subjects of European ancestry from the UK Biobank. Experimental evidence to support the role of genes significantly associated with both obesity-related traits and asthma through a GWAS was sought by using results from obese versus lean mouse RNA sequencing and RT-PCR experiments. Results: We found a substantial positive genetic correlation between body mass index and later-onset asthma defined by asthma age of onset at 16 years or greater (Rg = 0.25, P = 9.56 X 10(-22)). Mendelian randomization analysis provided strong evidence in support of body mass index causally increasing asthma risk. Cross-trait meta-analysis identified 34 shared loci among 3 obesity-related traits and 2 asthma subtypes. GWAS functional analyses identified potential causal relationships between the shared loci and Genotype-Tissue Expression (GTEx) quantitative trait loci and shared immune and cell differentiation related pathways between obesity and asthma. Finally, RNA sequencing data from lungs of obese versus control mice found that 2 genes (acyl-coenzyme A oxidase-like [ACOXL] and myosin light chain 6 [MYL6]) from the cross-trait meta-analysis were differentially expressed, and these findings were validated by using RT-PCR in an independent set of mice. Conclusions: Our work identified shared genetic components between obesity-related traits and specific asthma subtypes, reinforcing the hypothesis that obesity causally increases the risk of asthma and identifying molecular pathways that might underlie both obesity and asthma.	[Zhu, Zhaozhong; Guo, Yanjun; Shi, Huwenbo; Chung, Wonil; O'Connor, Luke J.; Gazal, Steven; Camargo, Carlos A., Jr.; Liang, Liming] Harvard TH Chan Sch Publ Hlth, Program Genet Epidemiol & Stat Genet, Dept Epidemiol, Boston, MA USA; [Zhu, Zhaozhong] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Panganiban, Ronald Allan; Lu, Quan] Harvard TH Chan Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Environm Hlth, Boston, MA USA; [Panganiban, Ronald Allan; Lu, Quan] Harvard TH Chan Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Genet, Boston, MA USA; [Panganiban, Ronald Allan; Lu, Quan] Harvard TH Chan Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Complex Dis, Boston, MA USA; [Hu, Frank B.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA; [Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Zhu, Zhaozhong; Hasegawa, Kohei; Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Guo, Yanjun] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Occupat & Environm Hlth, Sch Publ Hlth, Wuhan, Peoples R China; [Liu, Cong-Lin] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Liu, Cong-Lin] Harvard Med Sch, Boston, MA 02115 USA; [Himes, Blanca E.] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Qi, Lu] Tulane Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA; [Moffatt, Miriam F.; Cookson, William O. C.] Natl Heart & Lung Inst, Sect Genom Med, London, England	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital; Huazhong University of Science & Technology; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania; Tulane University; Imperial College London	Zhu, ZZ (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 655 Huntington Ave,Bldg 1,Room 1406C, Boston, MA 02115 USA.; Zhu, ZZ (corresponding author), Harvard Med Sch, Dept Emergency Med, Massachusetts Gen Hosp, 655 Huntington Ave,Bldg 1,Room 1406C, Boston, MA 02115 USA.; Liang, LM (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 655 Huntington Ave,Bldg 2,Room 207, Boston, MA 02115 USA.; Liang, LM (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, 655 Huntington Ave,Bldg 2,Room 207, Boston, MA 02115 USA.	zhz586@mail.harvard.edu; lliang@hsph.harvard.edu	Camargo, Carlos A./C-2145-2008; Gazal, Steven/AAK-3764-2020; Cookson, William/HHC-1790-2022; Panganiban, Ronald Allan/AAH-3859-2020	Camargo, Carlos A./0000-0002-5071-7654; Panganiban, Ronald Allan/0000-0003-0894-1318	National Heart, Lung, and Blood Institute [R01HL139496]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the National Heart, Lung, and Blood Institute, R01HL139496 (to Q.L.). Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.	Adler-Wailes DC, 2015, INT J OBESITY, V39, P888, DOI 10.1038/ijo.2015.17; Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Ali Z, 2013, RESP MED, V107, P1287, DOI 10.1016/j.rmed.2013.03.019; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Anthoni M, 2008, BRIT J DERMATOL, V159, P546, DOI 10.1111/j.1365-2133.2008.08696.x; Appleton SL, 2006, J ALLERGY CLIN IMMUN, V118, P1284, DOI 10.1016/j.jaci.2006.08.011; Aschard H, 2015, AM J HUM GENET, V96, P329, DOI 10.1016/j.ajhg.2014.12.021; Bergeron C, 2010, CAN RESPIR J, V17, pE85, DOI 10.1155/2010/318029; Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406; Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211; Burgess S, 2017, EPIDEMIOLOGY, V28, P30, DOI 10.1097/EDE.0000000000000559; Burgess S, 2016, GENET EPIDEMIOL, V40, P597, DOI 10.1002/gepi.21998; Chen G, 2014, AM J RESP CRIT CARE, V189, P301, DOI 10.1164/rccm.201306-1181OC; de Nijs SB, 2013, EUR RESPIR REV, V22, P44, DOI 10.1183/09059180.00007112; DiRenzo DM, 2016, CELL SIGNAL, V28, P498, DOI 10.1016/j.cellsig.2016.02.011; Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520; Durrani SR, 2011, J ALLERGY CLIN IMMUN, V128, P439, DOI 10.1016/j.jaci.2011.06.002; Finucane HK, 2015, NAT GENET, V47, P1228, DOI 10.1038/ng.3404; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Fucho R, 2017, FASEB J, V31, P1263, DOI 10.1096/fj.201601156R; Gao N, 2013, J BIOL CHEM, V288, P7596, DOI 10.1074/jbc.M112.427112; Ghosh S, 2014, INFLAMM RES, V63, P475, DOI 10.1007/s00011-014-0719-3; Girodet PO, 2015, AM J RESP CRIT CARE, V191, P876, DOI 10.1164/rccm.201410-1874OC; Gough SCL, 2007, CURR GENOMICS, V8, P453, DOI 10.2174/138920207783591690; Granell R, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001669; Grassel S, 1998, FEBS LETT, V436, P197, DOI 10.1016/S0014-5793(98)01122-3; Guibas GV, 2013, ALLERGY, V68, P1298, DOI 10.1111/all.12245; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Holguin F, 2011, J ALLERGY CLIN IMMUN, V127, P1486, DOI 10.1016/j.jaci.2011.03.036; Hossain P, 2007, NEW ENGL J MED, V356, P213, DOI 10.1056/NEJMp068177; Jeong A, 2017, RESP MED, V125, P25, DOI 10.1016/j.rmed.2017.02.014; Johnston RA, 2008, J APPL PHYSIOL, V104, P1727, DOI 10.1152/japplphysiol.00075.2008; Jones CL, 2014, J BIOL CHEM, V289, P20502, DOI 10.1074/jbc.M114.569889; Lane JM, 2017, NAT GENET, V49, P274, DOI 10.1038/ng.3749; Locke AE, 2015, NATURE, V518, P197, DOI 10.1038/nature14177; Loh PR, 2018, NAT GENET, V50, P906, DOI 10.1038/s41588-018-0144-6; Macsali F, 2011, AM J RESP CRIT CARE, V183, P8, DOI 10.1164/rccm.200912-1886OC; Maller JB, 2012, NAT GENET, V44, P1294, DOI 10.1038/ng.2435; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Muc M, 2016, NUTR RES REV, V29, P194, DOI 10.1017/S0954422416000111; Namgaladze D, 2016, BBA-MOL CELL BIOL L, V1861, P1796, DOI 10.1016/j.bbalip.2016.09.002; O'Connor LJ, 2018, NAT GENET, V50, P1728, DOI 10.1038/s41588-018-0255-0; Orfanos S, 2018, AM J PHYSIOL-LUNG C, V315, pL673, DOI 10.1152/ajplung.00459.2017; Papoutsakis C, 2013, J ACAD NUTR DIET, V113, P77, DOI 10.1016/j.jand.2012.08.025; Peters U, 2018, CHEST, V153, P702, DOI 10.1016/j.chest.2017.07.010; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Royce SG, 2009, ANN ALLERG ASTHMA IM, V102, P238, DOI 10.1016/S1081-1206(10)60087-7; Ryzhov S, 2017, AM J PHYSIOL-HEART C, V312, pH907, DOI 10.1152/ajpheart.00486.2016; Saglani S, 2015, EUR RESPIR J, V46, P1796, DOI 10.1183/13993003.01196-2014; Scott HA, 2011, EUR RESPIR J, V38, P594, DOI 10.1183/09031936.00139810; Scott RA, 2017, DIABETES, V66, P2888, DOI 10.2337/db16-1253; Skaaby T, 2018, ALLERGY, V73, P153, DOI 10.1111/all.13242; Sood A, 2011, EXERC SPORT SCI REV, V39, P48, DOI 10.1097/JES.0b013e318201f0c4; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Surakka I, 2015, NAT GENET, V47, P589, DOI 10.1038/ng.3300; Takimoto T, 2010, J IMMUNOL, V185, P842, DOI 10.4049/jimmunol.0904100; Thierry-Mieg D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s12; Waerner T, 2001, CELL GROWTH DIFFER, V12, P201; Wallace C, 2013, GENET EPIDEMIOL, V37, P802, DOI 10.1002/gepi.21765; Wang J, 2017, NUCLEIC ACIDS RES, V45, pW130, DOI 10.1093/nar/gkx356; Wendell SG, 2014, J ALLERGY CLIN IMMUN, V133, P1255, DOI 10.1016/j.jaci.2013.12.1087; Wilson BJ, 2014, CANCER RES, V74, P4196, DOI 10.1158/0008-5472.CAN-14-0582; Yadav H, 2011, CELL METAB, V14, P67, DOI 10.1016/j.cmet.2011.04.013; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yiallouros PK, 2016, ITAL J PEDIATR, V42, DOI 10.1186/s13052-016-0276-1; Zhao W, 2017, NAT GENET, V49, P1450, DOI 10.1038/ng.3943; Zhu XF, 2015, AM J HUM GENET, V96, P21, DOI 10.1016/j.ajhg.2014.11.011; Zhu ZZ, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1036-8; Zhu ZZ, 2019, HUM GENET, V138, P271, DOI 10.1007/s00439-019-01988-9; Zhu ZZ, 2018, NAT GENET, V50, P857, DOI 10.1038/s41588-018-0121-0; Zhu ZZ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193256; Zhu ZH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02317-2	77	100	100	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					537	549		10.1016/j.jaci.2019.09.035	http://dx.doi.org/10.1016/j.jaci.2019.09.035			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31669095	Green Accepted, Bronze			2022-12-18	WOS:000512887400017
J	Melki, I; Rose, Y; Uggenti, C; Van Eyck, L; Fremond, ML; Kitabayashi, N; Rice, GI; Jenkinson, EM; Boulai, A; Jeremiah, N; Gattorno, M; Volpi, S; Sacco, O; Terheggen-Lagro, SWJ; Tiddens, HAWM; Meyts, I; Morren, MA; De Haes, P; Wouters, C; Legius, E; Corveleyn, A; Rieux-Laucat, F; Bodemer, C; Callebaut, I; Rodero, MP; Crow, YJ				Melki, Isabelle; Rose, Yoann; Uggenti, Carolina; Van Eyck, Lien; Fremond, Marie-Louise; Kitabayashi, Naoki; Rice, Gillian I.; Jenkinson, Emma M.; Boulai, Anais; Jeremiah, Nadia; Gattorno, Marco; Volpi, Sefano; Sacco, Olivero; Terheggen-Lagro, Suzanne W. J.; Tiddens, Harm A. W. M.; Meyts, Isabelle; Morren, Marie-Anne; De Haes, Petra; Wouters, Carine; Legius, Eric; Corveleyn, Anniek; Rieux-Laucat, Frederic; Bodemer, Christine; Callebaut, Isabelle; Rodero, Mathieu P.; Crow, Yanick J.			Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Stimulator of interferon genes (STING); TMEM173 interferon; type I interferonopathy; STING-associated vasculopathy with onset in infancy	ADAPTER; PHOSPHORYLATION; REVEALS; TRIGGER; FUSION	Background: Gain-of-function mutations in transmembrane protein 173 (TMEM173) encoding stimulator of interferon genes (STING) underlie a recently described type I interferonopathy called STING-associated vasculopathy with onset in infancy (SAVI). Objectives: We sought to define the molecular and cellular pathology relating to 3 individuals variably exhibiting the core features of the SAVI phenotype including systemic inflammation, destructive skin lesions, and interstitial lung disease. Methods: Genetic analysis, conformational studies, in vitro assays and ex vivo flow-cytometry were performed. Results: Molecular and in vitro data demonstrate that the pathology in these patients is due to amino acid substitutions at positions 206, 281, and 284 of the human STING protein. These mutations confer cGAMP-independent constitutive activation of type I interferon signaling through TBK1 (TANK-binding kinase), independent from the alternative STING pathway by membrane fusion of enveloped RNA viruses. This constitutive activation was abrogated by ex vivo treatment with the janus kinase 1/2 inhibitor ruxolitinib. Conclusions: Structural analysis indicates that the 3 disease-associated mutations at positions 206, 281, and 284 of the STING protein define a novel cluster of amino acids with functional importance in the regulation of type I interferon signaling.	[Melki, Isabelle; Rose, Yoann; Uggenti, Carolina; Van Eyck, Lien; Fremond, Marie-Louise; Kitabayashi, Naoki; Boulai, Anais; Rodero, Mathieu P.; Crow, Yanick J.] INSERM, UMR 1163, Lab Neurogenet & Neuroinflammat, 24 Blvd Montparnasse, F-75015 Paris, France; [Melki, Isabelle; Rose, Yoann; Uggenti, Carolina; Van Eyck, Lien; Fremond, Marie-Louise; Kitabayashi, Naoki; Boulai, Anais; Jeremiah, Nadia; Rieux-Laucat, Frederic; Bodemer, Christine; Rodero, Mathieu P.; Crow, Yanick J.] Paris Descartes Univ, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Melki, Isabelle] Hop Robert Debre, AP HP, Gen Pediat Infect Dis & Internal Med Dept, Paris, France; [Melki, Isabelle; Fremond, Marie-Louise; Wouters, Carine] Hop Necker Enfants Malad, AP HP, Pediat Hematol Immunol & Rheumatol Dept, Paris, France; [Rice, Gillian I.; Jenkinson, Emma M.; Crow, Yanick J.] Univ Manchester, Div Evolut & Genom Sci, Fac Biol Med & Hlth, Sch Biol Sci, Manchester, Lancs, England; [Gattorno, Marco; Volpi, Sefano] UO Pediat 2 Reumatol, Genoa, Italy; [Sacco, Olivero] UO Pneumol G Gaslini, Genoa, Italy; [Terheggen-Lagro, Suzanne W. J.] Pulmonol Emma Childrens Hosp AMC DD, Dept Paediat, Amsterdam, Netherlands; [Tiddens, Harm A. W. M.] Erasmus MC, Dept Radiol, Rotterdam, Netherlands; [Tiddens, Harm A. W. M.] Sophia Childrens Univ Hosp, Erasmus Med Center, Dept Paediat Resp Med & Allergol, Rotterdam, Netherlands; [Meyts, Isabelle; Wouters, Carine] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium; [Morren, Marie-Anne; De Haes, Petra] Univ Hosp Leuven, Dept Dermatol, Leuven, Belgium; [Legius, Eric; Corveleyn, Anniek] Univ Hosp Leuven, Clin Dept Human Genet, Leuven, Belgium; [Van Eyck, Lien; Meyts, Isabelle; De Haes, Petra; Wouters, Carine] Univ Leuven, Childhood Immunol, Dept Immunol & Microbiol, Leuven, Belgium; [Legius, Eric] Katholieke Univ Leuven, Dept Human Genet, Leuven, Belgium; [Jeremiah, Nadia; Rieux-Laucat, Frederic] INSERM, UMR 1163, Lab Immunogenet Pediat Autoimmun, Paris, France; [Bodemer, Christine] Hop Necker Enfants Malad, Natl Reference Ctr Rare Skin Dis MAGEC, Dermatol Dept, Paris, France; [Callebaut, Isabelle] Univ Pierre & Marie Curie Paris6, Sorbonne Univ, CNRS UMR7590, MNHN,IRD,IUC, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Manchester; Emma Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; KU Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD)	Crow, YJ (corresponding author), INSERM, UMR 1163, Lab Neurogenet & Neuroinflammat, 24 Blvd Montparnasse, F-75015 Paris, France.	yanickcrow@mac.com	Meyts, Isabelle/Z-3295-2019; Morren, Marie-Anne/AAE-9048-2020; Gattorno, Marco/AAL-2974-2020; Frémond, Marie-Louise/AAH-4266-2019; Frémond, Marie-Louise/G-9371-2017; Crow, Yanick J/N-6120-2014; rodero, mathieu/C-8083-2011; Rice, Gillian I/G-3128-2015; Rieux-Laucat, Frédéric/A-7916-2017; Volpi, Stefano/O-3717-2014; Sacco, Oliviero/AAB-1907-2021	Gattorno, Marco/0000-0003-0704-1916; Frémond, Marie-Louise/0000-0002-2798-9141; Frémond, Marie-Louise/0000-0002-2798-9141; Crow, Yanick J/0000-0001-7211-7564; rodero, mathieu/0000-0002-1300-0187; Rice, Gillian I/0000-0002-4223-0571; Rieux-Laucat, Frédéric/0000-0001-7858-7866; Volpi, Stefano/0000-0002-7129-868X; Uggenti, Carolina/0000-0003-2673-5120; Wouters, Carine/0000-0002-6426-8845; Melki, Isabelle/0000-0002-8057-333X; Jeremiah, Nadia/0000-0002-7805-6341; Sacco, Oliviero/0000-0002-9350-9134	European Research Council [GA 309449]; National Research Agency (France) [ANR-10-IAHU-01]; Imagine Institute (France); Research Foundation Flanders (FWO); Telethon (Italy) [GGP15241]; National Research Agency (France) under the "Investments for the Future'' program [ANR-10-IAHU-01]; Telethon, Italy [GGP15241A]	European Research Council(European Research Council (ERC)European Commission); National Research Agency (France); Imagine Institute (France); Research Foundation Flanders (FWO)(FWO); Telethon (Italy)(Fondazione Telethon); National Research Agency (France) under the "Investments for the Future'' program; Telethon, Italy(Fondazione Telethon)	Supported by the European Research Council (GA 309449), the National Research Agency (ANR-10-IAHU-01, France), the Imagine Institute (France), the Research Foundation Flanders (FWO), and Telethon (GGP15241; Italy). Y.J.C. acknowledges the European Research Council (GA 309449: Fellowship) and a state subsidy managed by the National Research Agency (France) under the "Investments for the Future'' program bearing the reference ANR-10-IAHU-01. F.R.-L. acknowledges a state subsidy managed by the National Research agency referenced as Lumugene (ANR-14-CE14-0026-01). I.M. acknowledges the Programme Sante-Sciences MD/PhD of Imagine Institute. S.V. and M.G. gratefully acknowledge the financial support of Telethon, Italy (grant no. GGP15241A). L.V.E is funded by a research grant from the Research Foundation Flanders (FWO).	[Anonymous], 2016, AM J RESP CRIT CARE; [Anonymous], 2015, CELL HOST MICROBE; [Anonymous], 2015, JAMA DERMATOL; Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Crow YJ, 2014, NEW ENGL J MED, V371, P568, DOI 10.1056/NEJMe1407246; Crow YJ, 2011, ANN NY ACAD SCI, V1238, P91, DOI 10.1111/j.1749-6632.2011.06220.x; Fremond ML, 2016, J ALLERGY CLIN IMMUN; Gentili M, 2015, SCIENCE, V349, P1232, DOI 10.1126/science.aab3628; Hasan M, 2016, PHARMACOL RES, V111, P336, DOI 10.1016/j.phrs.2016.04.008; Hasan MS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/705831; Holm CK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10680; Holm CK, 2012, NAT IMMUNOL, V13, P737, DOI 10.1038/ni.2350; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Konno H, 2013, CELL, V155, P688, DOI 10.1016/j.cell.2013.09.049; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Mukai K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11932; Olagnier D, 2012, NAT IMMUNOL, V13, P713, DOI 10.1038/ni.2373; Omoyinmi E, 2015, ARTHRITIS RHEUMATOL, V67, P808, DOI 10.1002/art.38998; Ouyang SY, 2012, IMMUNITY, V36, P1073, DOI 10.1016/j.immuni.2012.03.019; Picard C, 2016, CHEST, V150, pE65, DOI 10.1016/j.chest.2016.02.682; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; Shigemoto T, 2009, J BIOL CHEM, V284, P13348, DOI 10.1074/jbc.M809449200; Shu C, 2012, NAT STRUCT MOL BIOL, V19, P722, DOI 10.1038/nsmb.2331; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Tang ED, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120090; Tungler V, 2016, ANN RHEUM DIS, V75, DOI 10.1136/annrheumdis-2016-210565; Yi GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077846; Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022	33	100	104	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					543	+		10.1016/j.jaci.2016.10.031	http://dx.doi.org/10.1016/j.jaci.2016.10.031			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28087229	Green Submitted, Bronze			2022-12-18	WOS:000406855500026
J	Weinacht, KG; Charbonnier, LM; Alroqi, F; Plant, A; Qiao, Q; Wu, H; Ma, C; Torgerson, TR; Rosenzweig, SD; Fleisher, TA; Notarangelo, LD; Hanson, IC; Forbes, LR; Chatila, TA				Weinacht, Katja G.; Charbonnier, Louis-Marie; Alroqi, Fayhan; Plant, Ashley; Qiao, Qi; Wu, Hao; Ma, Clement; Torgerson, Troy R.; Rosenzweig, Sergio D.; Fleisher, Thomas A.; Notarangelo, Luigi D.; Hanson, Imelda C.; Forbes, Lisa R.; Chatila, Talal A.			Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						STAT1 gain of function; IFN-gamma; ruxolitinib; autoimmunity; T(H)1 cell; T(H)17 cell; follicular T helper cell; T helper cell polarization	CHRONIC MUCOCUTANEOUS CANDIDIASIS; IMMUNE DYSREGULATION; IL-17 IMMUNITY; INBORN-ERRORS; IMMUNODEFICIENCY; DISEASE; DIFFERENTIATION; DEFICIENCY; BINDING; DNA	Background: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired T(H)17 cell differentiation and exaggerated responsiveness to type I and II interferons. Allogeneic bone marrow transplantation has been attempted in severely affected patients, but outcomes have been poor. Objective: We sought to define the effect of increased STAT1 activity on T helper cell polarization and to investigate the therapeutic potential of ruxolitinib in treating autoimmunity secondary to STAT1 GOF mutations. Methods: We used in vitro polarization assays, as well as phenotypic and functional analysis of STAT1-mutated patient cells. Results: We report a child with a novel mutation in the linker domain of STAT1 who had life-threatening autoimmune cytopenias and chronic mucocutaneous candidiasis. Naive lymphocytes from the affected patient displayed increased T(H)1 and follicular T helper cell and suppressed T(H)17 cell responses. The mutation augmented cytokine-induced STAT1 phosphorylation without affecting dephosphorylation kinetics. Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reduced hyperresponsiveness to type I and II interferons, normalized T(H)1 and follicular T helper cell responses, improved T(H)17 differentiation, cured mucocutaneous candidiasis, and maintained remission of immune-mediated cytopenias. Conclusions: Autoimmunity and infection caused by STAT1 GOF mutations are the result of dysregulated T helper cell responses. Janus kinase inhibitor therapy could represent an effective targeted treatment for long-term disease control in severely affected patients for whom hematopoietic stem cell transplantation is not available.	[Weinacht, Katja G.; Plant, Ashley; Ma, Clement] Harvard Med Sch, Div Hematol Oncol, Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [Charbonnier, Louis-Marie; Alroqi, Fayhan; Wu, Hao; Notarangelo, Luigi D.; Chatila, Talal A.] Harvard Med Sch, Div Immunol, Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [Qiao, Qi; Wu, Hao] Harvard Med Sch, Program Mol & Cellular Med, Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [Weinacht, Katja G.; Plant, Ashley; Ma, Clement] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA; [Torgerson, Troy R.] Univ Washington, Dept Immunol, Seattle Childrens Hosp, Seattle, WA 98195 USA; [Torgerson, Troy R.] Univ Washington, Dept Pediat, Immunol Div, Seattle, WA 98195 USA; [Rosenzweig, Sergio D.] NIAID, Primary Immunodeficiency Clin, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Rosenzweig, Sergio D.; Fleisher, Thomas A.] NIH, Dept Lab Med, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA; [Notarangelo, Luigi D.] Harvard Stem Cell Inst, Cambridge, MA USA; [Hanson, Imelda C.; Forbes, Lisa R.] Baylor Coll Med, Houston, TX 77030 USA; [Hanson, Imelda C.; Forbes, Lisa R.] Texas Childrens Hosp, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Hanson, Imelda C.; Forbes, Lisa R.] Texas Childrens Hosp, Ctr Human Immunobiol, Houston, TX 77030 USA; [Weinacht, Katja G.] Stanford Sch Med, Lucile Packard Childrens Hosp, Div Stem Cell Transplantat & Regenerat Med, Stanford, CA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Harvard University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Lucile Packard Children's Hospital (LPCH); Stanford University	Weinacht, KG (corresponding author), Stanford Sch Med, Div Stem Cell Transplantat & Regenerat Med, 300 Pasteur Dr,H320, Stanford, CA 94305 USA.	kgw1@stanford.edu	Plant, Ashley/GVS-9394-2022	Chatila, Talal/0000-0001-7439-2762; Charbonnier, Louis-Marie/0000-0002-4594-7893	National Institutes of Health [2R01AI085090, 1R56AI115699]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI115699, ZIAAI001222, ZIAAI001122, R01AI085090] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010304] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by National Institutes of Health grants 2R01AI085090 and 1R56AI115699 (to T.A.C.).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340; Bohmer Frank-D, 2014, JAKSTAT, V3, pe28087, DOI 10.4161/jkst.28087; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Aldave JC, 2013, J CLIN IMMUNOL, V33, P1273, DOI 10.1007/s10875-013-9947-5; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Dalal, 2014, LYMPHOSIGN J, V1, P97; DeLano W. L, 2002, PYMOL MOL GENETICS G; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Frans G, 2014, J ALLERGY CLIN IMMUN, V134, P1209, DOI 10.1016/j.jaci.2014.05.044; Higgins E, 2015, J ALLERGY CLIN IMMUN, V135, P551, DOI 10.1016/j.jaci.2014.12.1867; Hori T, 2012, J CLIN IMMUNOL, V32, P1213, DOI 10.1007/s10875-012-9744-6; Kinnunen T, 2013, BLOOD, V121, P1595, DOI 10.1182/blood-2012-09-457465; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Kumar N, 2014, J ALLERGY CLIN IMMUN, V134, P236, DOI 10.1016/j.jaci.2014.02.037; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Ma CS, 2016, J EXP MED, V213, P1589, DOI 10.1084/jem.20151467; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Mizoguchi Y, 2014, J LEUKOCYTE BIOL, V95, P667, DOI 10.1189/jlb.0513250; Mossner R, 2016, CLIN INFECT DIS, V62, DOI 10.1093/cid/ciw020; Naqvi, 2014, LYMPHOSIGN J, V1, P87, DOI DOI 10.14785/LPSN-2014-0004; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; O'Shea JJ, 2013, NEW ENGL J MED, V368, P161, DOI 10.1056/NEJMra1202117; Puel A, 2012, CURR OPIN ALLERGY CL, V12, P616, DOI 10.1097/ACI.0b013e328358cc0b; Quintas-Cardama A, 2011, NAT REV DRUG DISCOV, V10, P127, DOI 10.1038/nrd3264; Roifman, 2014, LYMPHOSIGN J, V1, P57; Romberg N, 2013, J ALLERGY CLIN IMMUN, V131, P1691, DOI 10.1016/j.jaci.2013.01.004; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Schmitt N, 2014, NAT IMMUNOL, V15, P856, DOI 10.1038/ni.2947; Sharfe N, 2014, J ALLERGY CLIN IMMUN, V133, P807, DOI 10.1016/j.jaci.2013.09.032; Soltesz B, 2013, J MED GENET, V50, P567, DOI 10.1136/jmedgenet-2013-101570; Subramaniam PS, 2001, CYTOKINE, V15, P175, DOI 10.1006/cyto.2001.0905; Takezaki S, 2012, J IMMUNOL, V189, P1521, DOI 10.4049/jimmunol.1200926; Toth B, 2012, LANCET, V379, P2500, DOI 10.1016/S0140-6736(12)60365-1; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Wildbaum G, 2013, J ALLERGY CLIN IMMUN, V132, P761, DOI 10.1016/j.jaci.2013.04.018; Yamazaki Y, 2014, J IMMUNOL, V193, P4880, DOI 10.4049/jimmunol.1401467; Zheng J, 2015, EUR J IMMUNOL, V45, P2834, DOI 10.1002/eji.201445344	42	100	102	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1629	+		10.1016/j.jaci.2016.11.022	http://dx.doi.org/10.1016/j.jaci.2016.11.022			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	28139313	Bronze, Green Accepted			2022-12-18	WOS:000400465300024
J	Forno, E; Han, YY; Muzumdar, RH; Celedon, JC				Forno, Erick; Han, Yueh-Ying; Muzumdar, Radhika H.; Celedon, Juan C.			Insulin resistance, metabolic syndrome, and lung function in US adolescents with and without asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; lung function; insulin resistance; adiposity; obesity; metabolic syndrome; National Health and Nutrition Examination Survey	SYSTEMIC INFLAMMATION; FUNCTION IMPAIRMENT; PULMONARY-FUNCTION; CHILDHOOD ASTHMA; NATIONAL-HEALTH; UNITED-STATES; OBESITY; ASSOCIATION; PREVALENCE; CHILDREN	Background: Obesity increases both the risk of asthma and asthma severity and is a well-known risk factor for insulin resistance and the metabolic syndrome (MS) in children and adolescents. Objective: We aimed to examine the association among obesity, insulin sensitivity, MS, and lung function in US adolescents with and without asthma. Methods: We performed a cross-sectional study of 1429 adolescents aged 12 to 17 years in the 2007-2010 National Health and Nutrition Examination Survey. Adjusted regression was used to assess the relationships among obesity, insulin sensitivity/resistance, MS, and lung function in children with and without asthma. Results: Insulin resistance was negatively associated with FEV1 and forced vital capacity (FVC) in adolescents with and without asthma, whereas MS was associated with lower FEV1/FVC ratios, with a more pronounced decrease found among asthmatic patients; these associations were driven by overweight/obese adolescents. Higher body mass index was associated with a decrease in FEV1/FVC ratios among adolescents with insulin resistance. Compared with healthy participants, adolescents with MS had an approximately 2% decrease in FEV1/FVC ratios, adolescents with asthma had an approximately 6% decrease, and those with MS and asthma had approximately 10% decreased FEV1/FVC ratios (P < .05). Conclusion: Insulin resistance and MS are associated with worsened lung function in overweight/obese adolescents. Asthma and MS synergistically decrease lung function, as do obesity and insulin resistance. These factors might contribute to the pathogenesis of asthma severity in obese patients and warrant further investigation.	[Forno, Erick; Han, Yueh-Ying; Celedon, Juan C.] Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh,UPMC, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15260 USA; [Muzumdar, Radhika H.] Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh,UPMC, Div Pediat Endocrinol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Forno, E (corresponding author), UPMC, Childrens Hosp Pittsburgh, Div Pulm Med Allergy & Immunol, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	erick.forno@chp.edu	Forno, Erick/I-1476-2019	Forno, Erick/0000-0001-6497-9885	National Institute of Health (NIH) [HD052892]; NIH [HL079966, HL117191]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052892] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079966, R01HL117191, K08HL125666] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	E.F.'s contribution was supported by National Institute of Health (NIH) grant HD052892. J.C.C.'s contribution was supported by NIH grants HL079966 and HL117191 and by an endowment from the Heinz Foundation.	Agrawal A, 2011, AM J RESP CELL MOL, V44, P270, DOI 10.1165/rcmb.2010-0141TR; Agudelo GM, 2014, METAB SYNDR RELAT D, V12, P202, DOI 10.1089/met.2013.0127; Akinbami Lara J, 2012, NCHS Data Brief, P1; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Al-Shawwa BA, 2007, J ASTHMA, V44, P469, DOI 10.1080/02770900701423597; Borrell LN, 2013, AM J RESP CRIT CARE, V187, P697, DOI 10.1164/rccm.201211-2116OC; Brumpton BM, 2013, EUR RESPIR J, V42, P1495, DOI 10.1183/09031936.00046013; Centers for Disease Control and Prevention, 2012, 2007 2008 NAT HLTH N; Centers for Disease Control and Prevention, 2011, SAS PROGR CDC GROWTH; COHEN P, 1995, AM J PHYSIOL-LUNG C, V269, pL151, DOI 10.1152/ajplung.1995.269.2.L151; Cottrell L, 2011, AM J RESP CRIT CARE, V183, P441, DOI 10.1164/rccm.201004-0603OC; de Ferranti SD, 2004, CIRCULATION, V110, P2494, DOI 10.1161/01.CIR.0000145117.40114.C7; Deiuliis JA, 2014, OBESITY, V22, P1264, DOI 10.1002/oby.20642; Dekkers BGJ, 2009, AM J RESP CELL MOL, V41, P494, DOI 10.1165/rcmb.2008-0251OC; Del-Rio-Navarro BE, 2010, J ASTHMA, V47, P501, DOI 10.3109/02770901003702808; Dixon Anne E, 2010, Proc Am Thorac Soc, V7, P325, DOI 10.1513/pats.200903-013ST; Fimognari FL, 2007, J GERONTOL A-BIOL, V62, P760, DOI 10.1093/gerona/62.7.760; Ford ES, 2008, DIABETES CARE, V31, P587, DOI 10.2337/dc07-1030; Forno E, 2014, J ALLERGY CLIN IMMUN, V133, P1308, DOI 10.1016/j.jaci.2013.09.041; Forno E, 2011, J ALLERGY CLIN IMMUN, V127, P741, DOI 10.1016/j.jaci.2010.12.010; Hsiao FC, 2010, METABOLISM, V59, P848, DOI 10.1016/j.metabol.2009.10.001; Jiang SN, 2014, J IMMUNOL, V192, P4795, DOI 10.4049/jimmunol.1302764; Kattan M, 2010, J ALLERGY CLIN IMMUN, V125, P584, DOI 10.1016/j.jaci.2010.01.053; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Kim KM, 2014, ASIA PAC ALLERGY, V4, P99, DOI 10.5415/apallergy.2014.4.2.99; Lecube A, 2010, DIABETES-METAB RES, V26, P639, DOI 10.1002/dmrr.1131; Lee EJ, 2009, J ASTHMA, V46, P339, DOI 10.1080/02770900802660931; Lee JM, 2006, DIABETES CARE, V29, P2427, DOI 10.2337/dc06-0709; Leishangthem Geeta Devi, 2013, ISRN Allergy, V2013, P261297, DOI 10.1155/2013/261297; Leone N, 2009, AM J RESP CRIT CARE, V179, P509, DOI 10.1164/rccm.200807-1195OC; Lim SY, 2010, J KOREAN MED SCI, V25, P1480, DOI 10.3346/jkms.2010.25.10.1480; Lohman TG, 1988, ANTHROPOMETRIC STAND; Mark AL, 2013, AM J PHYSIOL-REG I, V305, pR566, DOI 10.1152/ajpregu.00180.2013; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mishra A, 2007, AM J PHYSIOL-LUNG C, V293, pL305, DOI 10.1152/ajplung.00147.2007; Nagel G, 2009, PEDIAT ALLERG IMM-UK, V20, P81, DOI 10.1111/j.1399-3038.2008.00740.x; Nakajima K, 2008, CHEST, V134, P712, DOI 10.1378/chest.07-3003; Nasrallah MP, 2013, SEMIN NEPHROL, V33, P54, DOI 10.1016/j.semnephrol.2012.12.005; NOVERAL JP, 1994, AM J PHYSIOL-LUNG C, V267, pL761, DOI 10.1152/ajplung.1994.267.6.L761; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ogden Cynthia L, 2013, NCHS Data Brief, P1; Ostchega Y, 2003, J CLIN EPIDEMIOL, V56, P768, DOI 10.1016/S0895-4356(03)00085-4; Rojas-Dotor S, 2013, BIOL RES, V46, P13, DOI 10.4067/S0716-97602013000100002; Sarlus H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-99; SLAUGHTER MH, 1988, HUM BIOL, V60, P709; Sood Akshay, 2013, J Allergy (Cairo), V2013, P785835, DOI 10.1155/2013/785835; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; van Huisstede A, 2013, J OBES, V2013, DOI 10.1155/2013/131349; Vo P, 2013, J ASTHMA, V50, P56, DOI 10.3109/02770903.2012.744035; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049	51	100	103	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					304	+		10.1016/j.jaci.2015.01.010	http://dx.doi.org/10.1016/j.jaci.2015.01.010			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25748066	Green Accepted			2022-12-18	WOS:000359004900011
J	Calderon, MA; Casale, TB; Nelson, HS; Demoly, P				Calderon, Moises A.; Casale, Thomas B.; Nelson, Harold S.; Demoly, Pascal			An evidence-based analysis of house dust mite allergen immunotherapy: A call for more rigorous clinical studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Evidence-based medicine; house dust mite; allergen immunotherapy; subcutaneous; sublingual; allergic rhinitis; allergic asthma; respiratory allergy	SUBLINGUAL-SWALLOW IMMUNOTHERAPY; QUALITY-OF-LIFE; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; PHARMACOLOGICAL-TREATMENT; PERENNIAL RHINITIS; ASTHMA; EFFICACY; CHILDREN	Background: According to meta-analyses and reviews, subcutaneous allergen immunotherapy (SCIT) and sublingual allergen immunotherapy (SLIT) are beneficial in patients with allergic rhinitis (AR) and allergic asthma (AA) induced by house dust mites (HDMs). However, the reported effect sizes have varied greatly from one study to another. Objective: We sought to perform an evidence-based medicine assessment of commercially available SCIT and SLIT formulations in patients with HDM-induced AA and HDM-induced AR. Methods: We searched for double-blind, placebo-controlled randomized clinical trials and analyzed study designs, doses, regimens, patient-reported outcomes, safety reporting, and compliance. Results: Forty-four studies met our inclusion criteria. Some studies tested both SLIT and SCIT or scored both AA and AR outcomes; therefore we reviewed 35 treatment arms in patients with AA (20 for SCIT and 15 for SLIT) and 23 treatment arms in patients with AR (7 for SCIT and 16 for SLIT). The treatment duration ranged from 6 weeks to 3 years. For SCIT, the dose of Der p 1 major allergen (when reported) ranged from 7 to 30 mu g for maintenance doses and 60 to 420 mu g for cumulative doses. For SLIT, the doses of Der p 1 (when reported) were 0.8 to 70 mu g for maintenance doses and 60 to 23,695 mu g for cumulative doses. Safety data were often absent or poorly reported. A statistically significant active versus placebo symptom score was observed more frequently for SCIT than for SLIT. Conclusion: There is no consensus on basic treatment parameters (eg, dose and duration) in HDM SCIT and SLIT. There is an urgent need for rigorous, long-term, double-blind, placebo-controlled randomized clinical trials with an efficacy criterion that reflects the particular features of HDM-induced allergic disease.	[Calderon, Moises A.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London, England; [Casale, Thomas B.] Creighton Univ, Div Allergy & Immunol, Omaha, NE 68178 USA; [Nelson, Harold S.] Natl Jewish Hlth, Div Pediat Allergy & Clin Immunol, Denver, CO USA; [Demoly, Pascal] Univ Hosp Montpellier, Hop Arnaud de Villeneuve, Dept Pneumol & Addictol, INSERM,U657, Montpellier, France	Imperial College London; Royal Brompton Hospital; Creighton University; National Jewish Health; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Demoly, P (corresponding author), Hop Arnaud de Villeneuve, INSERM, Dept Pneumol Addictol, U657, F-34295 Montpellier, France.	pascal.demoly@inserm.fr	Casale, Thomas B/K-4334-2013; Demoly, Pascal/Y-9938-2019	Casale, Thomas B/0000-0002-3149-7377; Demoly, Pascal/0000-0001-7827-7964	ALK-Abello; Menarini; MSD; AstraZeneca; GlaxoSmithKline	ALK-Abello; Menarini(Menarini Group); MSD; AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline)	T. B. Casale has consultancy arrangements with Stallergenes and Merck; is employed by the American Academy of Allergy, Asthma & Immunology; has received one or more grants from or has one or more grants pending with Merck, Stallergenes, and ALK-Abello; and has received one or more payments for lecturing from or is on the speakers' bureau for ALK-Abello. H. S. Nelson has consultancy arrangements with Merck and has received one or more grants from or has one or more grants pending with Circassia. P. Demoly has consultancy arrangements with Chiesi and Pierre Fabre Medicaments and has received one or more payments for lecturing from or is on the speakers' bureau for Menarini, MSD, AstraZeneca, and GlaxoSmithKline. M. A. Calderon declares that he has no relevant conflicts of interest.	Abramson MJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001186.pub2; Ameal A, 2005, ALLERGY, V60, P1178, DOI 10.1111/j.1398-9995.2005.00862.x; [Anonymous], 2008, CHMPEWP185042006 EMA; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; BLAINEY AD, 1984, ALLERGY, V39, P521, DOI 10.1111/j.1398-9995.1984.tb00873.x; Blumberga G, 2006, ALLERGY, V61, P843, DOI 10.1111/j.1398-9995.2006.01088.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet PJ, 2009, ALLERGY, V64, P1737, DOI 10.1111/j.1398-9995.2009.02232.x; Bousquet PJ, 2011, J ALLERGY CLIN IMMUN, V127, P49, DOI 10.1016/j.jaci.2010.09.017; Bozek A, 2013, CLIN EXP ALLERGY, V43, P242, DOI 10.1111/cea.12039; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; BUCHANAN D J, 1980, Medical Journal of Zambia, V15, P14; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, P974, DOI 10.1016/j.jaci.2010.11.045; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Calderon M, 2010, ALLERGY, V65, P420, DOI 10.1111/j.1398-9995.2009.02292.x; Calderon MA, 2011, ALLERGY, V66, P1345, DOI 10.1111/j.1398-9995.2011.02669.x; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Compalati E, 2009, ALLERGY, V64, P1570, DOI 10.1111/j.1398-9995.2009.02129.x; Custovic A, 2005, ALLERGY, V60, P1112, DOI 10.1111/j.1398-9995.2005.00934.x; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; de Bot CMA, 2012, PEDIAT ALLERG IMM-UK, V23, P151, DOI 10.1111/j.1399-3038.2011.01219.x; Demoly Pascal, 2013, Clin Transl Allergy, V3, P7, DOI 10.1186/2045-7022-3-7; Demoly PM, 2013, J ALLERGY CLIN IMMUN, V131, pAB37, DOI 10.1016/j.jaci.2012.12.817; Devillier P, 2011, ALLERGY, V66, P163, DOI 10.1111/j.1398-9995.2010.02473.x; Devillier P, 2014, ALLERGY IN PRESS; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dokic D, 2005, Prilozi, V26, P113; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; EMA/PDCO, 2010, EMAPDCO7376052009; Franco C, 1995, Allergol Immunopathol (Madr), V23, P58; GADDIE J, 1976, BRIT MED J, V2, P1132, DOI 10.1136/bmj.2.6044.1132-e; Garcia-Robaina JC, 2006, J ALLERGY CLIN IMMUN, V118, P1026, DOI 10.1016/j.jaci.2006.07.043; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; Global Initiative for Asthma (GINA), DEC 2010 UPD NHLBI W; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; Lue KH, 2006, PEDIAT ALLERG IMM-UK, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Marcucci F, 2005, PEDIAT ALLERG IMM-UK, V16, P519, DOI 10.1111/j.1399-3038.2005.00301.x; MARYGABRIEL SX, 1977, CLIN ALLERGY, V7, P325; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mite Allergy Subcommittee of the Research Committee of the British Thoracic Association, 1979, BR J DIS CHEST, V73, P260; Mosbech H, 2012, ALLERGY, V67, P89; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1398-9995.2006.01095.x; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; PERONI DG, 1995, ALLERGY, V50, P925, DOI 10.1111/j.1398-9995.1995.tb02500.x; Pham-Thi N, 2007, PEDIAT ALLERG IMM-UK, V18, P47, DOI 10.1111/j.1399-3038.2006.00475.x; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Platts-Mills TAE, 2009, AM J RESP CRIT CARE, V180, P109, DOI 10.1164/rccm.200811-1756PR; Riechelmann H, 2010, AM J RHINOL ALLERGY, V24, pE104, DOI 10.2500/ajra.2010.24.3508; Roux M, 2013, J ALLERGY CLIN IMMUN, V131, pAB37, DOI 10.1016/j.jaci.2012.12.816; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1186/1741-7015-8-18, 10.1136/bmj.c332]; SMITH J M, 1972, Clinical Allergy, V2, P281, DOI 10.1111/j.1365-2222.1972.tb01291.x; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Tovey E, 2012, CURR ALLERGY ASTHM R, V12, P465, DOI 10.1007/s11882-012-0285-0; Tseng SH, 2008, ASIAN PAC J ALLERGY, V26, P105; Varney VA, 2003, CLIN EXP ALLERGY, V33, P1076, DOI 10.1046/j.1365-2222.2003.01735.x; Wang H, 2006, ALLERGY, V61, P191, DOI 10.1111/j.1398-9995.2005.00913.x; WARNER JO, 1978, LANCET, V2, P912; Yukselen A, 2012, INT ARCH ALLERGY IMM, V157, P288, DOI 10.1159/000327566	82	100	102	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1322	1336		10.1016/j.jaci.2013.09.004	http://dx.doi.org/10.1016/j.jaci.2013.09.004			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	24139829				2022-12-18	WOS:000327538200012
J	Brand, S; Kesper, DA; Teich, R; Kilic-Niebergall, E; Pinkenburg, O; Bothur, E; Lohoff, M; Garn, H; Pfefferle, PI; Renz, H				Brand, Stephanie; Kesper, Doerthe Andrea; Teich, Rene; Kilic-Niebergall, Esma; Pinkenburg, Olaf; Bothur, Evita; Lohoff, Michael; Garn, Holger; Pfefferle, Petra Ina; Renz, Harald			DNA methylation of T(H)1/T(H)2 cytokine genes affects sensitization and progress of experimental asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epigenetics; T cells; experimental asthma	CD4(+) T-CELLS; IFN-GAMMA; EPIGENETIC REGULATION; TH2 DIFFERENTIATION; DISEASE; MICE; TRANSCRIPTION; EXPRESSION; MODEL; PROLIFERATION	Background: Epigenetic changes in DNA methylation have recently been demonstrated to be involved in effector T-cell polarization, resulting in differential secretion of T(H)1 and T(H)2 cytokines. However, the contribution to the development of a chronic inflammatory phenotype remains still unclear. Objective: We sought to investigate changes in DNA methylation in marker genes of T-cell subsets during allergen sensitization/challenge and their influence on the development of an allergic airway inflammatory response. Methods: The relationship between changes in DNA methylation and phenotype development were examined in a well-established model of experimental asthma. DNA methylation was investigated at genomic loci associated with T(H)1 (IFNG promoter) or T(H)2 (conserved noncoding sequence 1 [CNS1]) cytokine production by using bisulfite pyrosequencing. Results: Analysis of CD4(+) T cells revealed a significant increase in DNA methylation at the IFNG promoter after allergen sensitization/challenge, which correlated with decreased IFN-gamma cytokine expression, whereas only minor changes were observed at the CNS1 locus. Furthermore, the increase in DNA methylation at the IFNG promoter could be reversed with a DNA methyltransferase (DNMT) inhibitor in vitro and in vivo with beneficial effects on sensitization status and allergic phenotype. The specific importance of the DNA methylation status in CD4(+) T cells could be confirmed by using adoptive transfer experiments. Conclusion: We here report the novel finding that epigenetic regulation in T cells contributes to the development of experimental asthma and can be targeted pharmacologically. (J Allergy Clin Immunol 2012; 129: 1602-10.)	[Renz, Harald] Univ Marburg, Inst Lab Med & Pathobiochem, Mol Diagnost Med Fac, D-35043 Marburg, Germany; [Bothur, Evita; Lohoff, Michael] Univ Marburg, Inst Med Microbiol & Hyg, D-35043 Marburg, Germany; [Teich, Rene] Helmholtz Ctr Infect Res, Braunschweig, Germany	Philipps University Marburg; Philipps University Marburg; Helmholtz Association; Helmholtz-Center for Infection Research	Renz, H (corresponding author), Univ Marburg, Inst Lab Med & Pathobiochem, Mol Diagnost Med Fac, Baldingerstr 1, D-35043 Marburg, Germany.	renzh@med.uni-marburg.de		Garn, Holger/0000-0002-5178-4023	Deutsche Forschungsgemeinschaft [SFB/TR22]; LOEWE Excellence Centre UGMLC (Universities of Giessen & Marburg Lung Centre); Stiftung P.E. Kempkes, Marburg [10/07]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); LOEWE Excellence Centre UGMLC (Universities of Giessen & Marburg Lung Centre); Stiftung P.E. Kempkes, Marburg	Supported by the Deutsche Forschungsgemeinschaft (SFB/TR22), the LOEWE Excellence Centre UGMLC (Universities of Giessen & Marburg Lung Centre), and Stiftung P.E. Kempkes, Marburg (10/07).	Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Conrad ML, 2009, CLIN EXP ALLERGY, V39, P1246, DOI 10.1111/j.1365-2222.2009.03260.x; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Glaab T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-139; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Lal G, 2009, J IMMUNOL, V182, P259, DOI 10.4049/jimmunol.182.1.259; Lantry LE, 1999, CARCINOGENESIS, V20, P343, DOI 10.1093/carcin/20.2.343; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOHOFF M, 1990, EUR J IMMUNOL, V20, P653, DOI 10.1002/eji.1830200328; Martino DJ, 2010, ALLERGY, V65, P7, DOI 10.1111/j.1398-9995.2009.02186.x; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57; Ozdemir C, 2007, CLIN EXP ALLERGY, V37, P1419, DOI 10.1111/j.1365-2222.2007.02721.x; Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Perl A, 2010, AUTOIMMUNITY, V43, P1, DOI 10.3109/08916930903374741; Schoenborn JR, 2007, NAT IMMUNOL, V8, P732, DOI 10.1038/ni1474; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; Surh CD, 2000, J EXP MED, V192, pF9, DOI 10.1084/jem.192.4.F9; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; von Mutius E, 2008, J ALLERGY CLIN IMMUN, V122, P99, DOI 10.1016/j.jaci.2008.05.017; Wang ZJ, 2006, J CLIN INVEST, V116, P2434, DOI 10.1172/JCI25826; Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484; White GP, 2006, PEDIAT ALLERG IMM-UK, V17, P557, DOI 10.1111/j.1399-3038.2006.00465.x; Wise JT, 1999, J IMMUNOL, V162, P5592; YOUNG HA, 1994, J IMMUNOL, V153, P3603; Yu JH, 2009, BLOOD, V113, P5558, DOI 10.1182/blood-2009-02-205732; Zheng QH, 2009, J MOL MED, V87, P1191, DOI 10.1007/s00109-009-0530-8	37	100	104	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1602	+		10.1016/j.jaci.2011.12.963	http://dx.doi.org/10.1016/j.jaci.2011.12.963			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22277202				2022-12-18	WOS:000304764600022
J	DeBrosse, CW; Franciosi, JP; King, EC; Butz, BKB; Greenberg, AB; Collins, MH; Abonia, JP; Assa'ad, A; Putnam, PE; Rothenberg, ME				DeBrosse, Charles W.; Franciosi, James P.; King, Eileen C.; Butz, Bridget K. Buckmeier; Greenberg, Allison B.; Collins, Margaret H.; Abonia, J. Pablo; Assa'ad, Amal; Putnam, Philip E.; Rothenberg, Marc E.			Long-term outcomes in pediatric-onset esophageal eosinophilia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; pediatric; patient-reported outcomes; natural history; eosinophil	PROTON PUMP INHIBITORS; SF-12 HEALTH SURVEY; REFLUX ESOPHAGITIS; CROSS-VALIDATION; CHILDREN; RECOMMENDATIONS; ENDOSCOPY; DYSPHAGIA	Background: Pediatric eosinophilic esophagitis (EoE) is a newly recognized antigen-induced form of chronic esophagitis (CE). Objective: Characterization of long-term clinical outcomes in patients with pediatric EoE is needed. Methods: From histologic review of 3817 pediatric esophageal biopsy specimens from 1982-1999, we conducted a nested case-control study of patients with retrospectively identified histologic eosinophilic esophagitis (rEoE) and CE, as well as an age-matched control cohort. Participants were asked to complete validated health-related outcome questionnaires. Results: At an average of 15 years after initial endoscopy, both cohorts (42/198 patients with rEoE and 67/468 patients with CE, as well as 100 age-matched control subjects) completed questionnaires. Compared with control subjects, quality of life was significantly decreased among patients with rEoE (P < .001) and patients with CE (P < .001). Rates of dysphagia (patients with rEoE, 49%; patients with CE, 37%; control subjects, 6%) and food impaction (patients with rEoE, 40%; patients with CE, 14%; control subjects, 3%) were significantly increased in the rEoE cohort compared with those seen in control subjects (P < .001 and P < .001, respectively). Increased esophageal eosinophil counts (odds ratio [OR], 1.6; 95% CI, 1.1-2.5; P < .05) during childhood were predictive of dysphagia during early adulthood. Food allergy (OR, 2.7; 95% CI, 1.2-6.0; P < .01), allergic rhinitis (OR, 3.5; 95% CI, 1.8-6.8; P < .001), and asthma (OR, 2.1; 95% CI, 1.04-4.3; P = .04) were associated with dysphagia. Food impaction was more common among patients with reported food allergy than among those without (OR, 3.1; 95% CI, 1.2-7.8; P = .02). Conclusions: Esophageal eosinophilia is associated with reduced quality of life and persistent symptoms 15 years after presentation. Increased esophageal eosinophil counts and the occurrence of food allergy and atopy in childhood increase the rate of dysphagia in young adulthood. (J Allergy Clin Immunol 2011; 128: 132-8.)	[DeBrosse, Charles W.; Butz, Bridget K. Buckmeier; Greenberg, Allison B.; Abonia, J. Pablo; Assa'ad, Amal; Rothenberg, Marc E.] Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Franciosi, James P.; Putnam, Philip E.] Cincinnati Childrens Hosp, Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; [King, Eileen C.] Cincinnati Childrens Hosp, Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Collins, Margaret H.] Cincinnati Childrens Hosp, Med Ctr, Div Pathol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	King, Eileen/Q-1815-2015	Abonia, Juan/0000-0003-3788-6485	Campaign Urging Research for Eosinophilic Disease (CURED); Food Allergy Initiative; National Institute of Allergy and Infectious Diseases [T32 AI060515]; NIH/NCRR [5UL1RR026314-02]; Buckeye Foundation; International Group of Eosinophilic Researchers (TIGER); PHS [P30 DK078392]; National Institutes of Health (NIH); Children's Digestive Health and Nutrition Foundation; Food Allergy and Anaphylaxis Network; Department of Defense; Ception Therapeutics; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR026314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER	Campaign Urging Research for Eosinophilic Disease (CURED); Food Allergy Initiative; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Buckeye Foundation; International Group of Eosinophilic Researchers (TIGER); PHS(United States Department of Health & Human ServicesUnited States Public Health Service); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Digestive Health and Nutrition Foundation; Food Allergy and Anaphylaxis Network; Department of Defense(United States Department of Defense); Ception Therapeutics; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the Campaign Urging Research for Eosinophilic Disease (CURED), the Food Allergy Initiative, National Institute of Allergy and Infectious Diseases grant T32 AI060515, PHS grant P30 DK078392, NIH/NCRR grant 5UL1RR026314-02, the Buckeye Foundation, and the International Group of Eosinophilic Researchers (TIGER).; Disclosure of potential conflict of interest: M. H. Collins has received honoraria from Sunovion; is a subcontractor for Meritage Pharma, Cephalon, and the American Academy of Allergy, Asthma & Immunology; is a member of the medical advisory panel for the American Partnership for Eosinophilic Disorders, an executive committee member for the International Gastrointestinal Eosinophil Researchers, and a steering committee member for the Registry for Eosinophilic Gastrointestinal Disorders. J. P. Abonia has received research support from the National Institutes of Health (NIH), Ception Therapeutics, and the Children's Digestive Health and Nutrition Foundation. M. E. Rothenberg has equity interest in Cephalon's reslizumab; has received research support from the NIH, the Food Allergy and Anaphylaxis Network, and the Department of Defense; is treasurer of the International Eosinophil Society; and is on the Medical Advisory Board for American Partnership for Eosinophilic Disorders. The rest of the authors have declared that they have no conflict of interest.	Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; DeBrosse CW, 2010, J ALLERGY CLIN IMMUN, V126, P112, DOI 10.1016/j.jaci.2010.05.027; Dellon ES, 2009, CLIN GASTROENTEROL H, V7, P1305, DOI 10.1016/j.cgh.2009.08.030; Dent J, 2006, ALIMENT PHARM THER, V24, P1269, DOI 10.1111/j.1365-2036.2006.03122.x; Dent J, 2008, BEST PRACT RES CL GA, V22, P585, DOI 10.1016/j.bpg.2008.01.002; Franciosi JP, 2010, J PEDIATR GASTR NUTR, V51, P443, DOI 10.1097/MPG.0b013e3181d67bee; Franciosi JP, 2009, CLIN GASTROENTEROL H, V7, P415, DOI 10.1016/j.cgh.2008.10.006; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Grudell ABM, 2007, DIS ESOPHAGUS, V20, P202, DOI 10.1111/j.1442-2050.2007.00670.x; Lebeau Thierry, 2005, Can J Urol, V12, P2873; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lombardi G, 2007, DIGEST LIVER DIS, V39, P864, DOI 10.1016/j.dld.2007.05.018; Marchetti F, 2003, DIGEST LIVER DIS, V35, P738, DOI 10.1016/S1590-8658(03)00420-1; Modlin IM, 2004, J CLIN GASTROENTEROL, V38, P390, DOI 10.1097/00004836-200405000-00002; Mols F, 2009, QUAL LIFE RES, V18, P403, DOI 10.1007/s11136-009-9455-5; Nelson S P, 2009, J Med Econ, V12, P348, DOI 10.3111/13696990903378680; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Nuevo J, 2009, GASTROENT HEPAT-BARC, V32, P264, DOI 10.1016/j.gastrohep.2008.12.004; Orenstein SR, 2007, AM J GASTROENTEROL, V102, P1298, DOI 10.1111/j.1572-0241.2007.01148.x; Prasad GA, 2007, AM J GASTROENTEROL, V102, P2627, DOI 10.1111/j.1572-0241.2007.01512.x; Prasad GA, 2009, CLIN GASTROENTEROL H, V7, P1055, DOI 10.1016/j.cgh.2009.06.023; Robinson M, 2001, EUR J GASTROEN HEPAT, V13, pS43; Sanderson K, 2002, AUST NZ J PUBL HEAL, V26, P343, DOI 10.1111/j.1467-842X.2002.tb00182.x; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Vandenplas Y, 2009, J PEDIATR GASTR NUTR, V49, P498, DOI 10.1097/MPG.0b013e3181b7f563	27	100	102	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					132	138		10.1016/j.jaci.2011.05.006	http://dx.doi.org/10.1016/j.jaci.2011.05.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21636117	Green Accepted			2022-12-18	WOS:000292245600017
J	Sutherland, ER; Lehman, EB; Teodorescu, M; Wechsler, ME				Sutherland, E. Rand; Lehman, Erik B.; Teodorescu, Mihaela; Wechsler, Michael E.		Natl Heart Lung Blood Inst Asthma	Body mass index and phenotype in subjects with mild-to-moderate persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; obesity; treatment; severity	RANDOMIZED CONTROLLED TRIAL; CLINICAL-RESEARCH NETWORK; OBSTRUCTIVE SLEEP-APNEA; INHALED CORTICOSTEROIDS; PULMONARY-FUNCTION; NOCTURNAL ASTHMA; OBESITY; WOMEN; EPIDEMIOLOGY; ASSOCIATION	Background: Although obesity has been hypothesized to worsen asthma, data from studies of subjects with well-characterized asthma are lacking. Objective: We sought to evaluate the relationship between body mass index (BMI), asthma impairment, and response to therapy. Methods: BMI (in kilograms per meter squared) and asthma phenotypic and treatment response data were extracted from Asthma Clinical Research Network studies. The cross-sectional relationship between BMI and asthma impairment was analyzed, as was the longitudinal relationship between BMI and response to asthma controller therapies. Results: One thousand two hundred sixty-five subjects with mild-to-moderate persistent asthma were evaluated. Analyses of lean versus overweight/obese asthmatic subjects demonstrated small differences in FEV(1) (3.05 vs 2.91 L, P = .001), FEV(1)/forced vital capacity ratio (mean, 83.5% vs 82.4%; P = .01), rescue albuterol use (1.1 vs 1.2 puffs per day, P = .03), and asthma-related quality of life (5.77 vs 5.59, P = .0004). Overweight/obese asthmatic subjects demonstrated a smaller improvement in exhaled nitric oxide levels with inhaled corticosteroid (ICS) treatment than did lean asthmatic subjects (3.6 vs 6.5 ppb, P = .04). With ICS/long-acting beta-agonist treatment, overweight/obese asthmatic subjects demonstrated smaller improvements in lung function than lean asthmatic subjects, with an 80 mL (P = .04) and 1.7% (P = .02) lesser improvement in FEV(1) and FEV(1)/forced vital capacity ratio, respectively. Significant differences in therapeutic response to leukotriene modifiers between BMI categories were not observed. Conclusions: Increased BMI is not associated with clinically significant worsening of impairment in subjects with mild-to-moderate persistent asthma. There is a modest association between increased BMI and reduced therapeutic effect of ICS-containing regimens in this patient population. Prospective studies evaluating the effect of being overweight or obese on treatment response in asthma are warranted. (J Allergy Clin Immunol 2009;123:1328-34.)	[Sutherland, E. Rand] Natl Jewish Hlth, Denver, CO 80206 USA; [Sutherland, E. Rand] Univ Colorado, Denver, CO 80202 USA; [Lehman, Erik B.] Penn State Univ, Dept Hlth Evaluat Sci, Hershey, PA USA; [Teodorescu, Mihaela] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Sleep Inst, Sect Allergy Pulm & Crit Care Med,Dept Med, Madison, WI 53706 USA; [Wechsler, Michael E.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Wechsler, Michael E.] Harvard Univ, Sch Med, Boston, MA USA	National Jewish Health; University of Colorado System; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sutherland, ER (corresponding author), Natl Jewish Hlth, 1400 Jackson St,J-201, Denver, CO 80206 USA.	sutherlande@njhealth.org	Wechsler, Michael/AAC-5506-2019; Wechsler, Michael/B-3979-2013; Sutherland, Everett Rand/B-7666-2008	Wechsler, Michael/0000-0003-3505-2946; Pesola, Gene/0000-0002-3909-8039	National Institutes of Health [HL51831, HL51845, HL51823, HL51843, HL56443, HL51834, HL51810, HL74227, HL74231, HL074204, HL74212, HL74073, HL074206, HL074208, HL74225, HL74218]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL074225, U10HL074212, U10HL056443, U10HL074227, U10HL051845, U10HL074204, U10HL074208, U10HL074218, U10HL051831, U10HL051834, U10HL074231, U10HL074073, U10HL051843, U10HL051823, U10HL074206, U10HL051810] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants (U 10) HL51831, HL51845, HL51823, HL51843. HL56443, HL51834, HL51810, HL74227, HL74231, HL074204, L74212. HL74073. HL074206, HL074208, HL74225, and HL74218.	[Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341; [Anonymous], 2007, 3 US DEP HLTH HUM SE; Beuther DA, 2005, J ALLERGY CLIN IMMUN, V115, P1100, DOI 10.1016/j.jaci.2004.12.1141; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; CHAN CS, 1988, AM REV RESPIR DIS, V137, P1502, DOI 10.1164/ajrccm/137.6.1502; Ciftci TU, 2005, RESP MED, V99, P529, DOI 10.1016/j.rmed.2004.10.011; Denlinger LC, 2007, J ALLERGY CLIN IMMUN, V119, P3, DOI 10.1016/j.jaci.2006.10.015; Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Eneli IU, 2008, THORAX, V63, P671, DOI 10.1136/thx.2007.086470; Flemons WW, 2002, NEW ENGL J MED, V347, P498, DOI 10.1056/NEJMcp012849; Ford ES, 2004, EUR RESPIR J, V24, P740, DOI 10.1183/09031936.04.00088003; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; GUILLEMINAULT C, 1988, EUR RESPIR J, V1, P902; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Jacobson BC, 2006, NEW ENGL J MED, V354, P2340, DOI 10.1056/NEJMoa054391; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Lessard A, 2008, CHEST, V134, P317, DOI 10.1378/chest.07-2959; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Martin RJ, 2001, CONTROL CLIN TRIALS, V22, p207S, DOI 10.1016/S0197-2456(01)00164-7; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; Parameswaran Krishnan, 2006, Can Respir J, V13, P203; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Romieu I, 2003, AM J EPIDEMIOL, V158, P165, DOI 10.1093/aje/kwg131; Shore SA, 2007, J APPL PHYSIOL, V102, P516, DOI 10.1152/japplphysiol.00847.2006; Sin DD, 2008, THORAX, V63, P1018, DOI 10.1136/thx.2007.086819; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025	41	100	103	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1328	1334		10.1016/j.jaci.2009.04.005	http://dx.doi.org/10.1016/j.jaci.2009.04.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19501235	Green Accepted			2022-12-18	WOS:000266799100025
J	Boyano-Martinez, T; Garcia-Ara, C; Pedrosa, M; Diaz-Pena, JM; Quirce, S				Boyano-Martinez, Teresa; Garcia-Ara, Carmen; Pedrosa, Maria; Diaz-Pena, Jose Maria; Quirce, Santiago			Accidental allergic reactions in children allergic to cow's milk proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cow's milk allergy; accidental exposure; accidental ingestion	NATURAL-HISTORY; IGE CONCENTRATIONS; CLINICAL-COURSE; FOOD ALLERGIES; PEANUT ALLERGY; NUT-ALLERGY; TREE NUTS; RISK; HYPERSENSITIVITY; ANAPHYLAXIS	Background: Cow's milk is the main cause of food allergy in children. Patients allergic to food frequently experience accidental exposure. There are few studies analyzing this problem, most of them concerning peanut allergy. Objective: We sought to calculate the frequency of accidental exposure reactions in children allergic to cow's milk during a 12-month period, to analyze the clinical characteristics and circumstances surrounding the reactions, and to identify risk factors for severe reactions. Methods: Eighty-eight children allergic to cow's milk (44 boys; median age, 32.5 months) were included in the study. A systematized questionnaire about accidental exposure was used. Reactions were classified as mild, moderate, and severe. Cow's milk- and casein-specific IgE antibody titers were determined. Results: Thirty-five (40%) children had 53 reactions in the previous year (53% mild, 32% moderate, and 15% severe). Most reactions took place at home (47%) under daily life circumstances (85%). Specific IgE levels to cow's milk were higher in children with severe reactions than in those with moderate (median, 37.70 vs 7.71 KUA/L; P = .04) or mild (3.37 KUA/L; P = .04) reactions. The frequency of severe reactions was 10-fold higher in asthmatic children (odds ratio, 10.2; 95% CI, 1.13-91.54). Conclusions: Reactions to accidental exposure are frequent in children with cow's milk allergy. The proportion of severe reactions was 15%. The risk factors for such reactions included very high levels of specific IgE to cow's milk and casein and asthma. (J Allergy Clin Immunol 2009;123:883-8.)	[Boyano-Martinez, Teresa; Garcia-Ara, Carmen; Pedrosa, Maria; Diaz-Pena, Jose Maria; Quirce, Santiago] Hosp Univ La Paz, Serv Alergia Infantil, Madrid, Spain	Hospital Universitario La Paz	Boyano-Martinez, T (corresponding author), C Ginzo de Limia 55,9C, Madrid 28034, Spain.	med012396@saludalia.com	s, q/AAD-7171-2020	Pedrosa, Maria/0000-0002-5295-870X				Bahna SL, 2004, ALLERGY, V59, P66, DOI 10.1111/j.1398-9995.2004.00567.x; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Garcia-Ara MC, 2004, CLIN EXP ALLERGY, V34, P866, DOI 10.1111/j.1365-2222.2004.01976.x; Garcia-Aymerich J, 2003, THORAX, V58, P100, DOI 10.1136/thorax.58.2.100; Hallett R, 2002, NEW ENGL J MED, V346, P1833, DOI 10.1056/NEJM200206063462320; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Levy Y, 2007, PEDIAT ALLERG IMM-UK, V18, P589, DOI 10.1111/j.1399-3038.2007.00562.x; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Mehl A, 2005, ALLERGY, V60, P1440, DOI 10.1111/j.1398-9995.2005.00909.x; Ostblom E, 2008, ALLERGY, V63, P211, DOI 10.1111/j.1398-9995.2007.01559.x; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Tan BM, 2001, ANN ALLERG ASTHMA IM, V86, P583, DOI 10.1016/S1081-1206(10)62908-0; TKACHYK SJ, 2000, CAN J ALLERGY CLIN I, V5, P6; Vadas P, 2003, J FOOD PROTECT, V66, P1932, DOI 10.4315/0362-028X-66.10.1932; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	32	100	101	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					883	888		10.1016/j.jaci.2008.12.1125	http://dx.doi.org/10.1016/j.jaci.2008.12.1125			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19232704				2022-12-18	WOS:000265058600015
J	Wichmann, FA; Muller, A; Busi, LE; Cianni, N; Massolo, L; Schlink, U; Porta, A; Sly, PD				Wichmann, Fernando A.; Mueller, Andrea; Busi, Luciano E.; Cianni, Natalia; Massolo, Laura; Schlink, Uwe; Porta, Andres; Sly, Peter David			Increased asthma and respiratory symptoms in children exposed to petrochemical pollution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; asthma; lung function testing; particulate matter; volatile organic compounds	VOLATILE ORGANIC-COMPOUNDS; LUNG-FUNCTION GROWTH; AIR-POLLUTION; DOMESTIC EXPOSURE; AMBIENT AIR; ASSOCIATION; URBAN	Background: Epidemiologic studies show statistical associations between levels of air pollutants and respiratory outcomes. Objective: We sought to determine the effects of exposure to petrochemical pollution on the respiratory health of children. Methods: Children aged 6 to 12 years living close to the petrochemical plants in La Plata, Argentina (n = 282), were compared with those living in a region with exposure to heavy traffic (n = 270) or in 2 relatively nonpolluted areas (n = 639). Parents answered a validated questionnaire providing health and demographic data. A random sample (n = 181) had lung function measured. Particulate matter and outdoor and indoor volatile organic compound levels were measured during 4-week study periods and reported as overall means for each study area. Results: Children living near the petrochemical plant had more asthma (24.8% vs 10.1% to 11.5%), more asthma exacerbations (6.7 vs 2.9-3.6 per year), more respiratory symptoms (current wheeze, dyspnea, nocturnal cough, and rhinitis), and lower lung function (>13% decrease in FEV1 percent predicted) than those living in other regions. Length of residence in the area was a significant risk factor, but age, sex, body mass index, proximity to busy roads and other nonpetrochemical industries, length of breast-feeding, and socioeconomic and demographic characteristics of children or their families were not. Conclusion: Exposure to particulate matter and volatile organic compounds arising from petrochemical plants but not from high traffic density was associated ith worse respiratory health in children. (J Allergy Clin Immunol 2009;123:632-8.)	[Wichmann, Fernando A.; Busi, Luciano E.] Prof Dr Fernando Viteri Hosp Ninos SM Ludovica, IDIP, La Plata, Buenos Aires, Argentina; [Cianni, Natalia; Massolo, Laura; Porta, Andres] Univ Nacl La Plata, CIMA, Fac Ciencias Exactas, La Plata, Buenos Aires, Argentina; [Mueller, Andrea; Schlink, Uwe] Umweltforsch GmbH UFZ, Heimholtz Zentrum, Dept Human Exposure Res & Epidemiol, Leipzig, Germany; [Sly, Peter David] Curtin Univ Technol, World Hlth Org Collaborating Ctr Res Childrens En, Telethon Inst Child Hlth Res, Perth, WA, Australia; [Sly, Peter David] Curtin Univ Technol, Sch Publ Hlth, Perth, WA, Australia	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Curtin University; Telethon Kids Institute; University of Western Australia; World Health Organization; Curtin University	Wichmann, FA (corresponding author), Hosp Ninos SM Ludoviva, Inst Invest Pediat, IDIP, La Plata, Buenos Aires, Argentina.	fwichmann@hotmail.com	Schlink, Uwe/D-5357-2015; Sly, Peter D/F-1486-2010	Schlink, Uwe/0000-0002-3109-9459; Sly, Peter D/0000-0001-6305-2201	Scientific Research Commission of the Province of Buenos Aires (CIC-PBA); National University of La Plata; Comision de Investigaciones Cientificas de la Provincia de Buenos Aires; Universidad Nacional de la Plata (Argentina)	Scientific Research Commission of the Province of Buenos Aires (CIC-PBA); National University of La Plata(National University of La Plata); Comision de Investigaciones Cientificas de la Provincia de Buenos Aires; Universidad Nacional de la Plata (Argentina)(National University of La Plata)	The Scientific Research Commission of the Province of Buenos Aires (CIC-PBA) and the National University of La Plata financed the present study.; Disclosure of potential conflict of interest: N. Cianni and A. Porta have received research support from the Comision de Investigaciones Cientificas de la Provincia de Buenos Aires and from Universidad Nacional de la Plata (Argentina). The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Avol Edward, 2005, NEW ENGL J MED, V352, P1276; Calderon-Garciduenas L, 2003, PEDIATR PULM, V36, P148, DOI 10.1002/ppul.10338; CIANNI N, 2006, ACTA TOXICOLOGIA A S, V14, P13; *DNRPA, 2003, CIUD AUT BUEN AIR; Fleiss JL, 1981, STAT METHODS RATES P; Franklin P, 2000, AM J RESP CRIT CARE, V161, P1757, DOI 10.1164/ajrccm.161.5.9905061; Fusco D, 2001, EUR RESPIR J, V17, P1143, DOI 10.1183/09031936.01.00005501; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; GOUVEIA N, 2006, RESP CARDIOVASCULAR, P2269; *IPA, 1999, REP ARG IND PETR SPE; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; Kulkarni N, 2006, NEW ENGL J MED, V355, P21, DOI 10.1056/NEJMoa052972; Mallol J, 2000, PEDIATR PULM, V30, P439, DOI 10.1002/1099-0496(200012)30:6<439::AID-PPUL1>3.0.CO;2-E; Massolo L, 2002, ENVIRON TOXICOL, V17, P219, DOI 10.1002/tox.10054; MASSOLO L, 2004, THESIS FACULTAD CIEN; MASSOLO L, 2006, RELACION ENTRE CONTE, P3; Paramesh H., 2002, Indian Journal of Pediatrics, V69, P309, DOI 10.1007/BF02723216; Rehwagen M, 2005, SCI TOTAL ENVIRON, V348, P199, DOI 10.1016/j.scitotenv.2004.12.050; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Romieu I, 2004, THORAX, V59, P8; Romieu I., 1999, URBAN TRAFFIC POLLUT, P9; RONCO A, 2001, 2 MERC CHEM IND C 7, P1; Rumchev K, 2004, THORAX, V59, P746, DOI 10.1136/thx.2003.013680; Rumchev KB, 2002, EUR RESPIR J, V20, P403, DOI 10.1183/09031936.02.00245002; SLY PD, 2001, AUSTRALASIAN EPIDEMI, V8, P27; *UNLP, 2001, OBS CAL VID PLAT DIA, P328; *US EPA, 2003, REV NAT AMB AIR QUAL; WARE JH, 1993, AM J EPIDEMIOL, V137, P1287, DOI 10.1093/oxfordjournals.aje.a116639; WHO, 2000, GUID AIR QUAL, P32	31	100	101	1	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					632	638		10.1016/j.jaci.2008.09.052	http://dx.doi.org/10.1016/j.jaci.2008.09.052			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19111332				2022-12-18	WOS:000264731200022
J	Ho, MHK; Wong, WHS; Heine, RG; Hosking, CS; Hill, DJ; Allen, KJ				Ho, Marco H. K.; Wong, Wilfred H. S.; Heine, Ralf G.; Hosking, Clifford S.; Hill, David J.; Allen, Katrina J.			Early clinical predictors of remission of peanut allergy in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; tree nut; sesame; clinical predictors; skin prick test; peanut-specific IgE	TREE NUT ALLERGY; SKIN PRICK; FOOD CHALLENGES; NATURAL-HISTORY; YOUNG-CHILDREN; PREVALENCE; IGE; MANAGEMENT; RESOLUTION; TESTS	Background: Understanding predictors of clinical remission would assist in clinical management of peanut allergy. Objective: We sought to determine the early clinical predictors of peanut allergy remission using a longitudinal cohort of young children with peanut allergy. Methods: Consecutive patients less than 2 years of age with peanut allergy were identified on the basis of skin prick test (SPT) wheal size of 95% positive predictive value or greater. Baseline SPT responses to peanuts, tree nuts, and sesame and serum peanut-specific IgE antibody levels were documented, and follow-up studies were conducted at 1- to 2-year intervals for up to 8 years. Peanut food challenges were performed when SPT responses decreased to less than the 95% positive predictive value for peanut allergy. Results: SPT wheal diameters to peanut extract of 6 rum or greater (hazard ratio, 2.16; 95% CI, 1.23-3.786; P = .008) and peanut-specific IgE antibody of 3 kUA/L or greater (hazard ratio, 2.74; 95% CI, 1.13-6.61; P = .025) before the age of 2 years were independent predictors of persistent peanut allergy. Mean SPT wheal diameters of nonremitters increased (r = 0.31, P < .001), whereas those of remitters decreased (r = -0.26, P = .002) between 1 and 4 years of age. Twenty-one percent of young children with peanut allergy became clinically tolerant by age 5 years. Conclusions: Remission of peanut allergy can be predicted by low levels of IgE antibodies to peanut in the first 2 years of life or decreasing levels of IgE sensitization by the age of 3 years.	[Ho, Marco H. K.; Heine, Ralf G.; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Wong, Wilfred H. S.] Univ Hong Kong, Dept Pediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China; [Heine, Ralf G.; Hill, David J.; Allen, Katrina J.] Murdoch Childrens Res, Melbourne, Vic, Australia; [Heine, Ralf G.; Allen, Katrina J.] Univ Melbourne, Dept Pediat, Parkville, Vic 3052, Australia; [Hosking, Clifford S.; Allen, Katrina J.] John Hunter Childrens Hosp, Newcastle, NSW, Australia	Royal Children's Hospital Melbourne; University of Hong Kong; Murdoch Children's Research Institute; University of Melbourne	Allen, KJ (corresponding author), Royal Childrens Hosp, Dept Allergy & Immunol, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Wong, Wilfred/Q-8751-2019; Allen, Katrina/I-4361-2018	Allen, Katrina/0000-0002-1921-4493; Ho, Marco/0000-0003-1802-2120; Wong, Hing Sang Wilfred/0000-0001-8396-2368; Heine, Ralf Gunter/0000-0002-3343-0379				Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Beardslee TA, 2000, INT ARCH ALLERGY IMM, V123, P299, DOI 10.1159/000053642; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; de Leon MP, 2005, CLIN EXP ALLERGY, V35, P1056, DOI 10.1111/j.1365-2222.2005.02310.x; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P421, DOI 10.1111/j.1399-3038.2004.00178.x; Hill DJ, 2001, CLIN EXP ALLERGY, V31, P1031, DOI 10.1046/j.1365-2222.2001.01113.x; Hill DJ, 2001, LANCET, V357, P87, DOI 10.1016/S0140-6736(00)03537-6; Hill DJ, 1997, ENVIRON TOXICOL PHAR, V4, P101, DOI 10.1016/S1382-6689(97)10049-7; Ho MHK, 2006, J ALLERGY CLIN IMMUN, V117, P1506, DOI 10.1016/j.jaci.2006.03.029; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Rance F, 2005, CLIN EXP ALLERGY, V35, P167, DOI 10.1111/j.1365-2222.2005.02162.x; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376	26	100	101	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					731	736		10.1016/j.jaci.2007.11.024	http://dx.doi.org/10.1016/j.jaci.2007.11.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18234313				2022-12-18	WOS:000253918900030
J	Brasier, AR; Victor, S; Boetticher, G; Ju, H; Lee, C; Bleecker, ER; Castro, M; Busse, WW; Calhoun, WJ				Brasier, Allan R.; Victor, Sundar; Boetticher, Gary; Ju, Hyunsu; Lee, Chang; Bleecker, Eugene R.; Castro, Mario; Busse, William W.; Calhoun, William J.			Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inflammation; cytokines; phenotypes; ELISA; hierarchical clustering; bioinformatics; class discovery	GENE-EXPRESSION; NEUTROPHILIC INFLAMMATION; RESEARCH-PROGRAM; CANCER; CLASSIFICATION; DISCOVERY; SUBTYPES; COSTS; LUNG	Background: Asthma is a heterogeneous clinical disorder. Methods for objective identification of disease subtypes will focus on clinical interventions and help identify causative pathways. Few studies have explored phenotypes at a molecular level. Objective: We sought to discriminate asthma phenotypes on the basis of cytokine profiles in bronchoalveolar lavage (BAL) samples from patients with mild-moderate and severe asthma. Methods: Twenty-five cytokines were measured in BAL samples of 84 patients (41 severe, 43 mild-moderate) using bead-based multiplex immunoassays. The normalized data were subjected to statistical and informatics analysis. Results: Four groups of asthmatic profiles could be identified on the basis of unsupervised analysis (hierarchical clustering) that were independent of treatment. One group, enriched in patients with severe asthma, showed differences in BAL cellular content, reductions in baseline pulmonary function, and enhanced response to methacholine provocation. Ten cytokines were identified that accurately predicted this group. Classification methods for predicting methacholine sensitivity were developed. The best model analysis predicted hyperresponders with 88% accuracy in 10 trials by using a 10-fold cross-validation. The cytokines that contributed to this model were IL-2, IL-4, and IL-5. On the basis of this classifier, 3 distinct hyperresponder classes were identified that varied in BAL eosinophil count and PC20 methacholine. Conclusion: Cytokine expression patterns in BAL can be used to identify distinct types of asthma and identify distinct subsets of methacholine hyperresponders. Further biomarker discovery in BAL may be informative.	[Brasier, Allan R.; Victor, Sundar; Lee, Chang; Bleecker, Eugene R.; Busse, William W.; Calhoun, William J.] Univ Texas Galveston, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; [Brasier, Allan R.; Victor, Sundar; Calhoun, William J.] Univ Houston Clear Lake, Scaly Ctr Mol Med, Galveston, TX USA; [Boetticher, Gary] Univ Houston Clear Lake, Dept Comp Sci, Galveston, TX USA; [Ju, Hyunsu] Wake Forest Univ, Sch Med, Scaly Ctr Aging, Winston Salem, NC 27109 USA; [Bleecker, Eugene R.] Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27109 USA; [Castro, Mario] Washington Univ, St Louis, MO USA; [Busse, William W.] Univ Wisconsin, Dept Med, Madison, WI USA	University of Texas System; University of Texas Medical Branch Galveston; University of Houston System; University of Houston; University of Houston Clear Lake; University of Houston System; University of Houston; University of Houston Clear Lake; Wake Forest University; Wake Forest University; Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison	Brasier, AR (corresponding author), Univ Texas Galveston, Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.	arbrasie@utmb.edu		Calhoun, William/0000-0001-7075-712X; Brasier, Allan/0000-0002-5012-4090	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069130, R01HL069149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI062885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL069149-05, R01 HL069130-05, BAA-HL-02-04, R01 HL069149, R01 HL069130, HL69130] Funding Source: Medline; NIAID NIH HHS [AI062885, P01 AI062885-05, P01 AI062885] Funding Source: Medline; NIEHS NIH HHS [P30 ES06676, P30 ES006676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; *BRONCH LAV COOP S, 1990, AM REV RESPIR DIS, V141, pS169; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Deykin A, 2006, J ALLERGY CLIN IMMUN, V118, P565, DOI 10.1016/j.jaci.2006.06.007; ELSEN MB, 1998, P NATL ACAD SCI USA, V95, P14863; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Kapp AV, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-231; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Quinlan J., 2014, C4 5 PROGRAMS MACHIN, DOI DOI 10.1007/BF00993309; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Thomas MS, 2004, J IMMUNOL, V173, P615, DOI 10.4049/jimmunol.173.1.615; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Wenzel Sally, 2003, Paediatr Respir Rev, V4, P306, DOI 10.1016/S1526-0542(03)00095-2; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110	26	100	103	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					30	37		10.1016/j.jaci.2007.10.015	http://dx.doi.org/10.1016/j.jaci.2007.10.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206505	Green Accepted			2022-12-18	WOS:000252372000005
J	Bustamante, J; Aksu, G; Vogt, G; De Beaucoudrey, L; Genel, F; Chapgier, A; Filipe-Santos, O; Feinberg, J; Emile, JF; Kutukculer, N; Casanova, JL				Bustamante, Jacinta; Aksu, Guzide; Vogt, Guillaume; De Beaucoudrey, Ludovic; Genel, Ferah; Chapgier, Ariane; Filipe-Santos, Orchide; Feinberg, Jacqueline; Emile, Jean-Francois; Kutukculer, Necil; Casanova, Jean-Laurent			BCG-osis and tuberculosis in a child with chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BCG; tuberculosis; chronic granulomatous disease	CYBB GENE; PRIMARY IMMUNODEFICIENCIES; NADPH-OXIDASE; MOLECULAR ANALYSIS; CLINICAL-FEATURES; INBORN-ERRORS; FOLLOW-UP; INFECTION; MUTATIONS; IMMUNITY	A few known primary immunodeficiencies confer predisposition to clinical disease caused by weakly virulent mycobacteria, such as BCG vaccines (regional disease, known as BCG-itis, or disseminated disease, known as BCG-osis), or more virulent mycobacteria, such as Mycobacterium tuberculosis (pulmonary and disseminated tuberculosis). We investigated the clinical and genetic features of a 12-year-old boy with both recurrent BCG-osis and disseminated tuberculosis. The patient's phagocytic cells produced no 0(2)(-). A hemizygous splice mutation was found in intron 5 of CYBB, leading to a diagnosis of X-linked chronic granulomatous disease. Chronic granulomatous disease should be suspected in all children with BCG-osis, even in the absence of nonmycobacterial infectious diseases, and in selected children with recurrent BCG-itis or severe tuberculosis.	Univ Paris 05, INSERM, U550, Necker Med Sch, F-75015 Paris, France; Ege Univ, Dept Pediat, Fac Med, Bornova, Turkey; Hop Ambroise Pare, AP HP, Dept Pathol, INSERM U602, F-92100 Boulogne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ege University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Casanova, JL (corresponding author), Univ Paris 05, INSERM, U550, Necker Med Sch, 156 Rue Vaugirard, F-75015 Paris, France.	casanova@neeker.fr	Casanova, Jean-Laurent/I-3418-2017; Bustamante, Jacinta/H-7877-2017; Vogt, Guillaume/L-6046-2015	Bustamante, Jacinta/0000-0002-3439-2482; Vogt, Guillaume/0000-0001-8192-1247; Chapgier, Ariane/0000-0002-1734-0744; Casanova, Jean-Laurent/0000-0002-7782-4169; Aksu, Guzide/0000-0003-2714-0903				Alcais A, 2005, J EXP MED, V202, P1617, DOI 10.1084/jem.20052302; ALLEN DM, 1993, J INFECTION, V26, P83, DOI 10.1016/0163-4453(93)97000-N; Almyroudis NG, 2005, MED MYCOL, V43, pS247, DOI 10.1080/13693780400025203; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Barese C, 2004, J PEDIAT HEMATOL ONC, V26, P656, DOI 10.1097/01.mph.0000139455.29962.be; BEYER P, 1982, PEDIATRIE, V37, P53; BUGHANIM HN, 1995, BLOOD, V86, P3575, DOI 10.1182/blood.V86.9.3575.bloodjournal8693575; Bustamante J, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.043406; Carnide EG, 2005, PEDIATR ALLERGY IMMU, V16, P5, DOI 10.1111/j.1399-3038.2005.00225.x; Casanova JL, 2005, J ALLERGY CLIN IMMUN, V116, P426, DOI 10.1016/j.jaci.2005.03.053; Casanova JL, 2005, J EXP MED, V202, P197, DOI 10.1084/jem.20050854; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; Casanova JL, 2004, NAT REV IMMUNOL, V4, P55, DOI 10.1038/nri1264; Casanova JL, 1996, PEDIATRICS, V98, P774; CHUSID MJ, 1975, JAMA-J AM MED ASSOC, V233, P1295, DOI 10.1001/jama.233.12.1295; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; ESTERLY JR, 1971, PEDIATRICS, V48, P141; Fieschi C, 2003, J EXP MED, V197, P527, DOI 10.1084/jem.20021769; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; GONZALEZ B, 1989, PEDIATR INFECT DIS J, V8, P201; Grumach AS, 1997, J CLIN IMMUNOL, V17, P340, DOI 10.1023/A:1027335000994; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; HIKITA H, 1973, CLIN IMMUNOL, V5, P653; Hodsagi M, 1986, Dev Biol Stand, V58 ( Pt A), P339; Ishibashi F, 2000, HUM GENET, V106, P473, DOI 10.1007/s004390000288; Jendrossek V, 1997, EUR J HAEMATOL, V58, P78; Jirapongsananuruk O, 2003, J ALLERGY CLIN IMMUN, V111, P374, DOI 10.1067/mai.2003.58; KELLER E, 1976, Zeitschrift fuer Erkrankungen der Atmungsorgane, V146, P134; KOBAYASHI Y, 1984, CLIN PEDIATR, V23, P586, DOI 10.1177/000992288402301011; LAU YL, 1991, J PAEDIATR CHILD H, V27, P235, DOI 10.1111/j.1440-1754.1991.tb00399.x; Lau YL, 1998, CLIN INFECT DIS, V26, P226, DOI 10.1086/517036; LEUSEN JHW, 1996, FRONT BIOSCI, V1, P72; Liese JG, 1996, LANCET, V347, P220, DOI 10.1016/S0140-6736(96)90403-1; Lublin M, 2002, ANN SURG, V235, P383, DOI 10.1097/00000658-200203000-00010; Mansoory D, 2003, CLIN INFECT DIS, V37, pE107, DOI 10.1086/377608; Martynova M I, 1980, Pediatriia, P67; MOUY R, 1989, J PEDIATR-US, V114, P555, DOI 10.1016/S0022-3476(89)80693-6; Movahedi M, 2004, INT ARCH ALLERGY IMM, V134, P253, DOI 10.1159/000078774; Noack D, 2001, BBA-MOL BASIS DIS, V1537, P125, DOI 10.1016/S0925-4439(01)00065-5; Oh HB, 2004, J KOREAN MED SCI, V19, P218, DOI 10.3346/jkms.2004.19.2.218; Ohga S, 1997, J INFECTION, V34, P147, DOI 10.1016/S0163-4453(97)92509-3; Pasic S, 2003, J CLIN IMMUNOL, V23, P55, DOI 10.1023/A:1021952315651; Reichenbach J, 2001, CURR OPIN ALLERGY CL, V1, P503, DOI 10.1097/00130832-200112000-00003; Roos D, 2006, HUM MUTAT, V27, P1218, DOI 10.1002/humu.20413; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SMITH PAG, 1984, S AFR MED J, V65, P821; Stasia MJ, 2005, HUM GENET, V116, P72, DOI 10.1007/s00439-004-1208-5; Stasia MJ, 2002, BBA-MOL BASIS DIS, V1586, P316, DOI 10.1016/S0925-4439(01)00110-7; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; URBAN C, 1980, KLIN PADIATR, V192, P13, DOI 10.1055/s-2008-1033853; VERRONEN P, 1974, ACTA PAEDIATR SCAND, V63, P627, DOI 10.1111/j.1651-2227.1974.tb04859.x; Vieira AP, 2004, PEDIATR DERMATOL, V21, P646, DOI 10.1111/j.0736-8046.2004.21606.x; von Goessel H, 2006, EXP HEMATOL, V34, P528, DOI 10.1016/j.exphem.2006.01.005; Weening RS, 2000, CLIN EXP IMMUNOL, V122, P410, DOI 10.1046/j.1365-2249.2000.01405.x; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	56	100	109	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					32	38		10.1016/j.jaci.2007.04.034	http://dx.doi.org/10.1016/j.jaci.2007.04.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17544093				2022-12-18	WOS:000248066400004
J	Beeler, A; Engler, O; Gerber, BO; Pichler, WJ				Beeler, A; Engler, O; Gerber, BO; Pichler, WJ			Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						frequency; T cells; delayed type drug hypersensitivty; tetanus-toxoid; drug avoidance	CYTOKINE PROFILE; FLOW-CYTOMETRY; IN-VIVO; CLONES; SULFAMETHOXAZOLE; LYMPHOCYTES; CARBAMAZEPINE; INDIVIDUALS; RECOGNITION; ENUMERATION	Background: Drug-reactive T cells are involved in most drug-induced hypersensitivity reactions. The frequency of such cells in peripheral blood of patients with drug allergy after remission is unclear. Objective: We determined the frequency of drug-reactive T cells in the peripheral blood of patients 4 months to 12 years after severe delayed-type drug hypersensitivity reactions, and whether the frequency of these cell differs from the frequency of tetanus toxoid-reactive T cells. Methods: We analyzed 5 patients with delayed-type drug hypersensitivity reactions, applying 2 methods: quantification of cytokine-secreting T cells by enzyme-linked immunospot (ELISpot), and fluorescent dye 5,6-carboxylfluorescein diacetate succinimidyl ester (CFSE) intensity distribution analysis of drug-reactive T cells. Results: Frequencies found were between 0.02% and 0.4% of CD4(+) T cells reacting to the respective drugs measured by CFSE analysis, and between 0.01% and 0.08% of T cells as determined by ELISpot. Reactivity was seen neither to drugs to which the patients were not sensitized nor in healthy individuals after stimulation with any of the drugs used. Conclusion: About 1:250 to 1:10,000 of T cells of patients with drug allergy are reactive to the relevant drugs. This frequency of drug-reactive T cells is higher than the frequency of T cells able to recognize recall antigens like tetanus toxoid in the same subjects. A substantial frequency could be observed as long as 12 years later in I patient even after strict drug avoidance. Patients with severe delayed drug hypersensitivity reactions are therefore potentially prone to react again to the incriminated drug even years after strict drug avoidance.	Inselspital Bern, Clin Rheumatol & Clin Immunol Allergol, Div Allergol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Pichler, WJ (corresponding author), Inselspital Bern, Clin Rheumatol & Clin Immunol Allergol, Div Allergol, CH-3010 Bern, Switzerland.	Werner.Pichler@insel.ch		Pichler, Werner J./0000-0002-8117-359X				ADAMS PW, 1991, J IMMUNOL METHODS, V142, P231, DOI 10.1016/0022-1759(91)90111-R; Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Burkhart C., 2002, Clinical and Experimental Allergy, V32, P1635, DOI 10.1046/j.1365-2222.2002.01513.x; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; Depta JPH, 2004, J ALLERGY CLIN IMMUN, V113, P519, DOI 10.1016/j.jaci.2003.11.030; Gerber BO, 2004, CURR OPIN IMMUNOL, V16, P732, DOI 10.1016/j.coi.2004.09.016; GEXCOLLET C, 2006, IN PRESS J INVEST AL; Givan AL, 1999, J IMMUNOL METHODS, V230, P99, DOI 10.1016/S0022-1759(99)00136-2; Hari Y, 2001, CLIN EXP ALLERGY, V31, P1398, DOI 10.1046/j.1365-2222.2001.01164.x; KALISH RS, 1994, J ALLERGY CLIN IMMUN, V94, P465, DOI 10.1016/0091-6749(94)90202-X; Kuechler PC, 2004, ALLERGY, V59, P613, DOI 10.1111/j.1398-9995.2004.00460.x; Luque I, 2001, ALLERGY, V56, P611, DOI 10.1034/j.1398-9995.2001.000115.x; Lyons AB, 2000, J IMMUNOL METHODS, V243, P147, DOI 10.1016/S0022-1759(00)00231-3; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Naisbitt DJ, 2003, J ALLERGY CLIN IMMUN, V111, P1393, DOI 10.1067/mai.2003.1507; Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Novak EJ, 2001, INT IMMUNOL, V13, P799, DOI 10.1093/intimm/13.6.799; Pichler WJ, 2003, CURR OPIN ALLERGY CL, V3, P249, DOI 10.1097/01.all.0000083955.99396.25; Pichler WJ, 2004, ALLERGY, V59, P809, DOI 10.1111/j.1398-9995.2004.00547.x; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Schnyder B, 1998, ALLERGY, V53, P817; Schnyder B, 1998, CLIN EXP ALLERGY, V28, P1412, DOI 10.1046/j.1365-2222.1998.00419.x; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; VANOERS MHJ, 1978, EUR J IMMUNOL, V8, P477, DOI 10.1002/eji.1830080706; von Greyerz S, 1999, J IMMUNOL, V162, P595; von Greyerz S, 2001, INT IMMUNOL, V13, P877, DOI 10.1093/intimm/13.7.877; WESTON SA, 1990, J IMMUNOL METHODS, V133, P87, DOI 10.1016/0022-1759(90)90322-M; WYSSCORAY T, 1993, EUR J IMMUNOL, V23, P3350, DOI 10.1002/eji.1830231243; Zanni MP, 1999, J INVEST DERMATOL, V112, P197, DOI 10.1046/j.1523-1747.1999.00484.x; Zanni MP, 1997, J IMMUNOL, V158, P1139	36	100	110	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					455	462		10.1016/j.jaci.2005.10.030	http://dx.doi.org/10.1016/j.jaci.2005.10.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461148				2022-12-18	WOS:000235687300029
J	Boguniewicz, M; Leung, DYM				Boguniewicz, M; Leung, DYM			Atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; dendritic cells; cytokines; chemokines; superantigens; antimicrobial peptides; topical calcineurin inhibitors	FC-EPSILON-RI; TACROLIMUS OINTMENT 0.03-PERCENT; PIMECROLIMUS CREAM 1-PERCENT; LONG-TERM MANAGEMENT; FLUTICASONE PROPIONATE; ANTIMICROBIAL PEPTIDES; DENDRITIC CELLS; DOUBLE-BLIND; PATCH TEST; T-CELLS	Atopic dermatitis is a common chronic inflammatory skin disease often preceding the development of asthma and allergic disorders, such as food allergy or allergic rhinoconjunctivitis. Pathophysiology involves a complex series of interactions between resident and infiltrating cells orchestrated by proinflammatory cytokines and chemokines. A deficiency of antimicrobial peptides might contribute to the propensity for colonization or infection by microbial organisms seen in atopic dermatitis. New treatment approaches include use of topical steroids as maintenance therapy and use of topical calcineurin inhibitors for early intervention with topical steroids used as rescue therapy.	Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pediat, Denver, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Boguniewicz, M (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, 1400 Jackson St,Room J310, Denver, CO 80206 USA.	boguniewiczm@njc.org						Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Ben-Gashir MA, 2004, J AM ACAD DERMATOL, V50, P349, DOI 10.1016/j.jaad.2003.09.004; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Blauvelt Andrew, 2003, Journal of Allergy and Clinical Immunology, V111, pS560; Boguniewicz Mark, 2003, Journal of Allergy and Clinical Immunology, V112, pS140, DOI 10.1016/j.jaci.2003.09.031; Breuer K, 2004, CLIN EXP ALLERGY, V34, P817, DOI 10.1111/j.1365-2222.2004.1953.x; Chapman MS, 2005, J AM ACAD DERMATOL, V53, pS177, DOI 10.1016/j.jaad.2005.04.061; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Deslouches B, 2005, ANTIMICROB AGENTS CH, V49, P316, DOI 10.1128/AAC.49.1.316-322.2005; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fonacier L, 2005, J ALLERGY CLIN IMMUN, V115, P1249, DOI 10.1016/j.jaci.2005.04.006; Friedlander SF, 2002, J AM ACAD DERMATOL, V46, P387, DOI 10.1067/mjd.2002.118337; Gombert M, 2005, J IMMUNOL, V174, P5082, DOI 10.4049/jimmunol.174.8.5082; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Hanifin JM, 2005, J AM ACAD DERMATOL, V53, pS186, DOI 10.1016/j.jaad.2005.04.062; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Ho VC, 2003, J PEDIATR-US, V142, P155, DOI 10.1067/mpd.2003.65; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kapp A, 2002, J ALLERGY CLIN IMMUN, V110, P277, DOI 10.1067/mai.2002.126500; Kaufmann R, 2004, J ALLERGY CLIN IMMUN, V114, P1183, DOI 10.1016/j.jaci.2004.08.015; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P195, DOI 10.1016/S0091-6749(03)70068-2; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1, DOI 10.1016/S1081-1206(10)61385-3; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P215, DOI 10.1067/mai.2003.1590; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ono SJ, 2003, J ALLERGY CLIN IMMUN, V111, P1185, DOI 10.1067/mai.2003.1594; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Pivarcsi A, 2004, J IMMUNOL, V173, P5810, DOI 10.4049/jimmunol.173.9.5810; Schachner LA, 2005, PEDIATRICS, V116, pE334, DOI 10.1542/peds.2004-2638; Semper AE, 2003, J ALLERGY CLIN IMMUN, V112, P411, DOI 10.1067/mai.2003.1626; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P118, DOI 10.1016/j.jaci.2004.03.056; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2	43	100	109	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		1			S475	S480		10.1016/j.jaci.2005.10.018	http://dx.doi.org/10.1016/j.jaci.2005.10.018			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VS	16455350				2022-12-18	WOS:000235865400011
J	Nguyen, LHP; Manoukian, JJ; Sobol, SE; Tewfik, TL; Mazer, BD; Schloss, MD; Taha, R; Hamid, QA				Nguyen, LHP; Manoukian, JJ; Sobol, SE; Tewfik, TL; Mazer, BD; Schloss, MD; Taha, R; Hamid, QA			Similar allergic inflammation in the middle ear and the upper airway: Evidence linking otitis media with effusion to the united airways concept	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						otitis media with effusion; eustachian tube; adenoid; IL-4; IL-5; IFN-gamma; eosinophil; allergy; united airways; inflammation	COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; CHRONIC SINUSITIS; TISSUE EOSINOPHILIA; CYTOKINE EXPRESSION; ASTHMA; RHINITIS; INTERLEUKIN-5; PROVOCATION; MUCOSA	Background: Otitis media with effusion (OME) is a chronic inflammatory disease of the middle ear space characterized by the accumulation of fluid. Previous investigations have suggested that the immunopathologic mechanism underlying the development of middle ear effusion in patients with allergy is largely due to the effects of T(H)2 mediators. The composition of the inflammatory substrate in the effusions of allergic otitis media is similar to the late-phase allergic response seen elsewhere in the respiratory tract, such as in asthma and in allergic rhinitis. Objective: To determine whether the middle ear compartment may be a component of the united airways in allergic disease by comparing the inflammatory profiles of the middle ear to the upper airway. Methods: Middle ear effusions, torus tubaris (Eustachian tube mucosa at the nasopharyngeal orifice), and adenoidal tissue biopsies were obtained from 45 patients undergoing simultaneous tympanostomy tube placement for OME and adenoidectomy for adenoid hypertrophy. The cellular and cytokine profiles of each site were investigated by using immunocytochemistry (elastase, CD3, major basic protein) and in situ hybridization (IL-4, IL-5, IFN-gamma mRNA). Atopic status was determined for each patient by using skin prick testing. Results: Eleven of the 45 patients with OME (24%) were atopic. The middle ear effusions of atopic patients had significantly higher levels of eosinophils, T lymphocytes, and IL-4 mRNA(+) cells (P < .01) and significantly lower levels of neutrophils and IFN-gamma mRNA(+) cells (P < .01) compared with nonatopic patients. The nasopharyngeal tissue biopsies revealed similar cellular and cytokine profiles. Conclusion: In atopic patients with OME, the allergic inflammation occurs on both sides of the Eustachian tube, both in the middle ear and in the nasopharynx. The results of this study support the concept that the middle ear may be part of the united airway in atopic individuals.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Dept Allergy & Immunol, Montreal, PQ H2X 2P2, Canada; Univ Penn, Sch Med, Div Pediat Otolaryngol, Philadelphia, PA 19104 USA; McGill Univ, Dept Otolaryngol, Montreal, PQ H2X 2P2, Canada	McGill University; McGill University; University of Pennsylvania; McGill University	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urban St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca						BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BERNSTEIN JM, 1993, OTOLARYNG HEAD NECK, V109, P611; BERNSTEIN JM, 1985, AM J OTOLARYNG, V6, P162, DOI 10.1016/S0196-0709(85)80079-X; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; Cypress B K, 1983, Vital Health Stat 13, V75, P1; DURHAM SR, 1992, J IMMUNOL, V148, P2390; HALL L J, 1980, American Journal of Otology, V2, P150; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Hurst DS, 2000, ALLERGY, V55, P435, DOI 10.1034/j.1398-9995.2000.00289.x; MCMAHAN JT, 1981, OTOLARYNG HEAD NECK, V89, P427, DOI 10.1177/019459988108900315; Min YG, 1999, AM J RHINOL, V13, P339, DOI 10.2500/105065899781367546; MOGI G, 1992, ACTA OTO-LARYNGOL, P155; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sobol SE, 2003, LARYNGOSCOPE, V113, P410, DOI 10.1097/00005537-200303000-00004; Sobol SE, 2002, J ALLERGY CLIN IMMUN, V110, P125, DOI 10.1067/mai.2002.125697; SORENSEN CH, 1982, J OTOLARYNGOL, V11, P46; Sugita M, 2003, INTERNAL MED, V42, P636, DOI 10.2169/internalmedicine.42.636; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; Wright ED, 2000, OTOLARYNG HEAD NECK, V123, P533, DOI 10.1067/mhn.2000.109472; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; Zielhuis G A, 1988, Adv Otorhinolaryngol, V40, P65	25	100	121	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1110	1115		10.1016/j.jaci.2004.07.061	http://dx.doi.org/10.1016/j.jaci.2004.07.061			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536418				2022-12-18	WOS:000225047800018
J	Mondino, C; Ciabattoni, G; Koch, P; Pistelli, R; Trove, A; Barnes, PJ; Montuschi, P				Mondino, C; Ciabattoni, G; Koch, P; Pistelli, R; Trove, A; Barnes, PJ; Montuschi, P			Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						leukotrienes; prostaglandins; exhaled breath condensate; exhaled nitric oxide; childhood asthma; airway inflammation; noninvasive markers; corticosteroids	BREATH CONDENSATE; NITRIC-OXIDE; 8-ISOPROSTANE; MONTELUKAST; MARKERS; PROSTAGLANDINS; VALIDATION; DILUTION	Background: Lipid mediators play an important pathophysiologic role in atopic asthmatic children, but their role in the airways or atopic nonasthmatic children is unknown. Objective: We sought (1) to measure leukotriene (LT) E-4, LTB4, 8-isoprostane, prostaglandin E-2, and thromboxane B-2 concentrations in exhaled breath condensate in atopic asthmatic and atopic nonasthmatic children; (2) to measure exhaled nitric oxide (NO) as an independent marker of airway inflammation; and (3) to study the effect of inhaled corticosteroids on exhaled eicosanoids. Methods: Twenty healthy children, 20 atopic nonasthmatic children, 30 steroid-naive atopic asthmatic children, and 25 atopic asthmatic children receiving inhaled corticosteroids were included in a cross-sectional study. An open-label study with inhaled fluticasone (100 mug twice a day for 4 weeks) was undertaken in 14 steroid-naive atopic asthmatic children. Results: Compared with control subjects, exhaled LTE4 (P < .001), LTB4 (P < .001), and 8-isoprostane (P < .001) levels were increased in both steroid-naive and steroid-treated atopic asthmatic children but not in atopic nonasthmatic children (LTE4, P = .14; LTB4, P = .23; and 8-isoprostane, P = .52). Exhaled NO levels were increased in steroid-naive atopic asthmatic children (P < .001) and, to a lesser extent, in atopic nonasthmatic children (P < .01). Inhaled fluticasone reduced exhaled NO (53%, P < .0001) and, to a lesser extent, LTE4 (18%, P < .01) levels but not LTB4, prostaglandin E-2, or 8-isoprostane levels in steroid-naive asthmatic children. Conclusions: Exhaled LTE4, LTB4, and 8-isoprostane levels are increased in atopic asthmatic children but not in atopic nonasthmatic children. In contrast to exhaled NO, these markers seem to be relatively resistant to inhaled corticosteroids.	Univ Cattolica Sacro Cuore, Dept Pharmacol, Fac Med, I-00168 Rome, Italy; IRCCS, IDI, Dept Immunodermatol, Rome, Italy; Univ G dAnnunzio, Sch Pharm, Dept Drug Sci, Chieti, Italy; Osped Pediat Bambino, Dept Pulmonol, Palidoro, Italy; Univ Cattolica Sacro Cuore, Dept Internal Med, Sch Med, I-00168 Rome, Italy; Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, London, England	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Istituto Dermopatico dell'Immacolata (IDI); G d'Annunzio University of Chieti-Pescara; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Imperial College London	Montuschi, P (corresponding author), Univ Cattolica Sacro Cuore, Dept Pharmacol, Fac Med, Largo F Vito 1, I-00168 Rome, Italy.	pmontuschi@rm.unicatt.it		MONTUSCHI, Paolo/0000-0001-5589-1750; Barnes, Peter/0000-0002-5122-4018				[Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104; Baraldi E, 2003, CHEST, V124, P25, DOI 10.1378/chest.124.1.25; Baraldi E, 2003, THORAX, V58, P505, DOI 10.1136/thorax.58.6.505; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Buchvald F, 2003, ANN ALLERG ASTHMA IM, V91, P309, DOI 10.1016/S1081-1206(10)63536-3; Cap P, 2004, THORAX, V59, P465, DOI 10.1136/thx.2003.011866; Csoma Z, 2002, AM J RESP CRIT CARE, V166, P1345, DOI 10.1164/rccm.200203-233OC; Effros RM, 2002, AM J RESP CRIT CARE, V165, P663, DOI 10.1164/ajrccm.165.5.2101018; Effros RM, 2003, AM J RESP CRIT CARE, V168, P1500, DOI 10.1164/rccm.200307-920OC; FLOREY CD, 1993, BRIT MED J, V306, P1181, DOI 10.1136/bmj.306.6886.1181; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Jouaville LF, 2003, CLIN EXP ALLERGY, V33, P1506, DOI 10.1046/j.1365-2222.2003.01800.x; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Leff AR, 2001, ANNU REV MED, V52, P1; Montuschi P, 2003, INFLAMM RES, V52, P502, DOI 10.1007/s00011-003-1212-6; Montuschi P, 2003, THORAX, V58, P585, DOI 10.1136/thorax.58.7.585; Montuschi P, 2003, INFLAMM RES, V52, P69, DOI 10.1007/s000110300003; Montuschi P, 2002, NAT REV DRUG DISCOV, V1, P238, DOI 10.1038/nrd751; Montuschi P, 2002, TRENDS PHARMACOL SCI, V23, P232, DOI 10.1016/S0165-6147(02)02020-5; Montuschi P, 2002, J ALLERGY CLIN IMMUN, V109, P615, DOI 10.1067/mai.2002.122461; Mutlu GM, 2001, AM J RESP CRIT CARE, V164, P731, DOI 10.1164/ajrccm.164.5.2101032; *NAT ASTHM ED PREV, 2002, J ALLERGY CLIN IMMUN, V111, pS141; PATRONO C, 1980, THROMB RES, V17, P317, DOI 10.1016/0049-3848(80)90066-3; Payne DNR, 2003, CURR OPIN ALLERGY CL, V3, P133, DOI 10.1097/01.all.0000064777.71837.06; Phipatanakul W, 2003, ANN ALLERG ASTHMA IM, V91, P49, DOI 10.1016/S1081-1206(10)62058-3; Sandrini A, 2003, CHEST, V124, P1334, DOI 10.1378/chest.124.4.1334; Stone KD, 2003, CURR OPIN PEDIATR, V15, P495, DOI 10.1097/00008480-200310000-00009; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Zaitsu M, 1998, PROSTAG LEUKOTR ESS, V59, P385, DOI 10.1016/S0952-3278(98)90100-4; Zanconato S, 2004, J ALLERGY CLIN IMMUN, V113, P257, DOI 10.1016/j.jaci.2003.10.046	32	100	103	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					761	767		10.1016/j.jaci.2004.06.054	http://dx.doi.org/10.1016/j.jaci.2004.06.054			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480313				2022-12-18	WOS:000224439100007
J	Lorentz, A; Klopp, I; Gebhardt, T; Manns, MP; Bischoff, SC				Lorentz, A; Klopp, I; Gebhardt, T; Manns, MP; Bischoff, SC			Role of activator protein 1, nuclear factor-kappa B, and nuclear factor of activated T cells in IgE receptor-mediated cytokine expression in mature human mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; mast cells; transcription factors; signal transduction; mucosa	IMMUNOGLOBULIN-E RECEPTOR; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; CROSS-LINKING; TNF-ALPHA; IL-5 GENE; KINASE-C; DISEASE; INHIBITION	Background. On activation by cross-linking the high-affinity IgE receptor (Fcepsilon-RI), expression of TNF-alpha, IL-3, IL-5, and IL-13 is induced in human intestinal mast cells. Objective: We sought to examined for the first time, FcepsilonRI signaling in mature human mast cells. Methods: Mast cells were isolated from intestinal tissue and cultured in the presence of stem cell factor. The cells were treated with specific inhibitors before stimulation by means of FcepsilonRI cross-linking. Cytokine mRNA expression was analyzed by means of RT-PCP, and activation of signaling molecules was determined by means of immunocytochemistry, RT-PCR, Western blotting, and protein kinase C (PKC) assay. Results: We found that nuclear factor-kappaB (NF-kappaB), as well as c-Fos and c-Jun, the components of activator protein 1 (AP-1), are activated after FeepsilonRI cross-linking in human intestinal mast cells. Treatment of the cells with specific inhibitors revealed an involvement of NF-kappaB and nuclear factor of activated T cells, as well as the necessity of extracellular signal-regulated kinase 1/2 (ERK-1/2), PKC, and AP-1 for the induced cytokine gene expression. Consistently, we found that activation of c-Fos corresponds with the induced cytokine gene expression and that ERK-1/2, an activator of c-Fus, was actived in response to FcepsilonRI cross-linking. Conclusion: Our data on human mast cells show that the activity of ERK-1/2, PKC, and subsequent activation of AP-1 are necessary for the FcepsilonRI-mediated cytokine expression. Nuclear factor of activated T cells and NF-kappaB seem to be necessary for the induction of TNF-alpha IL-3, and IL-13 but are less important for the transcription of IL-5.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30623 Hannover, Germany	Hannover Medical School	Lorentz, A (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30623 Hannover, Germany.			Gebhardt, Thomas/0000-0002-3768-9468				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bischoff SC, 1999, GUT, V44, P643, DOI 10.1136/gut.44.5.643; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Bischoff SC, 1997, J IMMUNOL, V159, P5560; Csonga R, 1998, J IMMUNOL, V160, P273; DeSilva DR, 1998, J IMMUNOL, V160, P4175; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dombrowicz D, 2001, J EXP MED, V193, P25, DOI 10.1084/jem.193.1.25; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Hommes D, 2002, GASTROENTEROLOGY, V122, P7, DOI 10.1053/gast.2002.30770; HUGHES CCW, 1993, J IMMUNOL, V150, P3148; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; JAFFE JS, 1995, AM J RESP CELL MOL, V13, P665, DOI 10.1165/ajrcmb.13.6.7576704; Kawakami Y, 1998, J IMMUNOL, V161, P1795; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; Lorentz A, 2000, J IMMUNOL, V164, P43, DOI 10.4049/jimmunol.164.1.43; Lorentz A, 2002, BLOOD, V99, P966, DOI 10.1182/blood.V99.3.966; Lorentz A, 1999, EUR J IMMUNOL, V29, P1496, DOI 10.1002/(SICI)1521-4141(199905)29:05<1496::AID-IMMU1496>3.0.CO;2-5; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; NILSSON G, 1994, SCAND J IMMUNOL, V39, P489, DOI 10.1111/j.1365-3083.1994.tb03404.x; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; Reischl IG, 1999, BIOCHEM PHARMACOL, V58, P1841, DOI 10.1016/S0006-2952(99)00226-9; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Ward JG, 1996, DEV BIOL, V173, P174, DOI 10.1006/dbio.1996.0015; YANO H, 1993, J BIOL CHEM, V268, P25846	33	100	101	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1062	1068		10.1067/mai.2003.1342	http://dx.doi.org/10.1067/mai.2003.1342			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743571				2022-12-18	WOS:000182904500021
J	Sagara, H; Okada, T; Okumura, K; Ogawa, H; Ra, C; Fukuda, T; Nakao, A				Sagara, H; Okada, T; Okumura, K; Ogawa, H; Ra, C; Fukuda, T; Nakao, A			Activation of TGF-beta/Smad2 signaling is associated with airway remodeling in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						transforming growth factor beta; Smad; asthma; airway remodeling; subepithelial thickness	FACTOR-BETA 1; SUBEPITHELIAL FIBROSIS; EXPRESSION; BIOPSIES	Background: Transforming growth factor beta (TGF-beta) has been suggested to play an important role in the development of airway remodeling in asthma; this suggestion is based on evidence that expression levels of TGF-beta are correlated with unique parameters of airway remodeling, such as thickness of basement membrane. However, the relevant studies were inconclusive because they were unable to demonstrate active signaling mediated by the cytokine in the airways of asthmatic individuals. Objective: We sought to determine whether TGF-beta signaling was active in the airways of asthmatic subjects and, if so, whether it was correlated with clinicopathologic features associated with the development of airway remodeling in asthma. Methods: We examined the phosphorylation status of Smad2 in bronchial biopsy samples obtained from 40 asthmatic subjects as a marker of active TGF-beta signaling, and we studied its correlation with basement membrane thickness. Results: Expression levels of phosphorylated Smad2 in bronchial biopsy specimens from asthmatic subjects were higher than those in specimens from normal subjects, and they were correlated with basement membrane thickness in asthma. Conclusion: The findings provide evidence that TGF-beta signaling was active in asthmatic airways and that the activity was associated with the development of airway remodeling in asthma.	Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan; Dokkyo Univ, Sch Med, Dept Pulm Med & Clin Immunol, Mibu, Tochigi, Japan	Juntendo University; Dokkyo Medical University	Nakao, A (corresponding author), Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, 2-1-1,Hongo, Tokyo 1138421, Japan.							Brodin G, 1999, CANCER RES, V59, P2731; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fiocchi C, 2001, J CLIN INVEST, V108, P523, DOI 10.1172/JCI13863; Holgate S. T., 2001, Clinical and Experimental Allergy Reviews, V1, P59, DOI 10.1046/j.1472-9725.2001.00006.x; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Makino S, 2000, INT ARCH ALLERGY IMM, V121, P1; MAKINO S, 1984, JPN J ALLERGOL, V33, P167; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Moustakas A, 2001, J CELL SCI, V114, P4359; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Redington AE, 1998, J PATHOL, V186, P410, DOI 10.1002/(SICI)1096-9896(199812)186:4<410::AID-PATH198>3.0.CO;2-9; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; ROCHE WR, 1989, LANCET, V1, P520; Rosendahl A, 2001, AM J RESP CELL MOL, V25, P60, DOI 10.1165/ajrcmb.25.1.4396; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066	17	100	112	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					249	254	UNSP 1/86/126078	10.1067/mai.2002.126078	http://dx.doi.org/10.1067/mai.2002.126078			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170265	Bronze			2022-12-18	WOS:000177509800009
J	Toda, M; Tulic, MK; Levitt, RC; Hamid, Q				Toda, M; Tulic, MK; Levitt, RC; Hamid, Q			A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-9; asthma; HCLCA1; mucus	TRANSGENIC MICE; MESSENGER-RNA; GENE; INTERLEUKIN-9; AIRWAY; CELLS; IDENTIFICATION; HYPERRESPONSIVENESS; INFLAMMATION; EOSINOPHILS	Background: One of the cardinal features of airway remodeling in asthma is mucus gland hyperplasia and mucus overproduction and hypersecretion. Recently, a calcium-activated chloride channel, HCLCA1, was described that is upregulated by IL-9 and thought to regulate the expression of soluble gel-forming mucins, such as MUC5A/C, a critical component of mucus in the airways. Objective: We sought to examine the expression of HCLCA1 in bronchial biopsy specimens of asthmatic subjects compared with those of control subjects and to demonstrate its relationship with IL-9, IL-9 receptor (IL-9R), and markers of mucus production. Methods: Bronchial biopsy specimens from asthmatic (n = 9) and control (n = 10) subjects were stained with periodic acid-Schiff to identify mucus glycoconjugates. IL-9- and IL-9R-positive cells were identified with immunocytochemistry, and HCLCA1 expression was detected by means of in situ hybridization with cRNA probes. Results: We demonstrate significant increases in IL-9 (P < .001) and IL-9R (P < .05) immunoreactivity, as well as increased expression of HCLCA1 mRNA (P < .001), in the epithelium of asthmatic patients compared with that found in control subjects. There was also an increase in the number of mucus-producing cells in biopsy specimens from asthmatic subjects (P < .001). HCLCA1 mRNA was strongly and selectively colocalized with periodic acid-Schiff and IL-9R-positive epithelial cells. In particular, a strong positive correlation was observed between HCLCA1 mRNA expression and IL-9-positive (r = 0.69, P < 0.01) or IL9R-positive (r = 0.79, P < .01) cells. Conclusion: An upregulation of HCLCA1 in the IL-9-responsive mucus-producing epithelium of asthmatic subjects compared with that seen in control subjects supports the hypothesis that this channel may be responsible, in part, for the overproduction of mucus in asthmatic subjects. These preliminary findings suggest the inhibition of HCLCA1 may be an important new therapeutic approach to control mucus overproduction in chronic airway disorders.	Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Genaera Pharmaceut, Plymouth Meeting, PA USA		Hamid, Q (corresponding author), Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Tulic, Meri K/ABB-5138-2020; Tulic, Meri/P-6613-2016	Tulic, Meri K/0000-0002-2661-2369; Tulic, Meri/0000-0002-2661-2369				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Dong Q, 1999, EUR J IMMUNOL, V29, P2130, DOI 10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO;2-S; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; GIAID A, 1993, LANCET, V341, P1550; Gruber AD, 1998, HISTOCHEM CELL BIOL, V110, P43, DOI 10.1007/s004180050263; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1992, BLOOD, V80, P1496; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Komiya T, 1999, BIOCHEM BIOPH RES CO, V255, P347, DOI 10.1006/bbrc.1999.0168; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; Morris AP, 1999, ADV PHARMACOL, V46, P209, DOI 10.1016/S1054-3589(08)60472-X; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Romio L, 1999, GENE, V228, P181, DOI 10.1016/S0378-1119(98)00620-9; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temann UA, 1997, AM J RESP CELL MOL, V16, P471, DOI 10.1165/ajrcmb.16.4.9115759; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; ZHOU Y, 2000, AM J RESP CRIT CARE, V161, pA597	25	100	110	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					246	250		10.1067/mai.2002.121555	http://dx.doi.org/10.1067/mai.2002.121555			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842292	Bronze			2022-12-18	WOS:000174232600006
J	Mullings, RE; Wilson, SJ; Puddicombe, SM; Lordan, JL; Bucchieri, F; Djukanovic, R; Howarth, PH; Harper, S; Holgate, ST; Davies, DE				Mullings, RE; Wilson, SJ; Puddicombe, SM; Lordan, JL; Bucchieri, F; Djukanovic, R; Howarth, PH; Harper, S; Holgate, ST; Davies, DE			Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; epithelium; STAT-6; IL-4; IL-13; T(H)2; phosphorylation; IL-8	GENETIC-VARIANTS; IN-VIVO; KAPPA-B; IL-4; RECEPTOR; ATOPY; CELLS; INTERLEUKIN-13; BIOPSIES; MICE	Background: Asthma is associated with increased production of IL-4 and IL-13. Objective: Because many of the effects of these cytokines are mediated by activation of signal transducer and activator of transcription 6 (STAT-6), we investigated expression and function of this transcription factor in the airways. Methods: STAT-6 expression was investigated through use of immunohistochemistry or RT-PCR applied to bronchial biopsy specimens or brushings from normal control or asthmatic subjects. STAT-6 function was investigated by means of Western blotting and ELISA applied to primary epithelial cell cultures. Results: Immunohistochemistry revealed that the bronchial epithelium was the major site of STAT-6 expression, both cytoplasmic and nuclear staining being observed. The level of STAT-6 expression in subjects with mild asthma (median [range] percent epithelial staining, 3.4% [0% to 16.0%]; n = 14) did not differ significantly from that in normal controls (4.7% [0.0% to 20.0%]; n = 11); however, in subjects with severe asthma, epithelial STAT-6 expression (13.7% [4.8% to 25.7%]; n = 9) was increased in comparison with subjects with mild asthma and normal controls (P < .05). RT-PCR analysis showed that epithelial STAT-6 expression was heterogeneous and comprised both full-length STAT-6 and the dominant-negative variant that lacks the SH2 domain. Treatment of primary cultures of bronchial epithelial cells with IL-4 resulted in STAT-6 phosphorylation and stimulation of IL-8 secretion; however, no difference in the responses of epithelial cells was observed between normal (n = 12) and asthmatic (n = 14) donors. Conclusion: These data demonstrate expression and activation of STAT-6 in normal and asthmatic bronchial epithelium. The activity of this transcription factor is likely to play a key role in mediating the responses of the bronchial epithelium to T(H)2 cytokines that are characteristic of the asthmatic phenotype.	Southampton Gen Hosp, Sch Med, Div Resp Cell & Mol Biol, Southampton SO16 6YD, Hants, England; AstraZeneca, Loughborough, Leics, England	University of Southampton; AstraZeneca	Davies, DE (corresponding author), Southampton Gen Hosp, Sch Med, Div Resp Cell & Mol Biol, Southampton SO16 6YD, Hants, England.		Bucchieri, Fabio/F-8877-2012; Davies, Donna E/H-2993-2012	BUCCHIERI, Fabio/0000-0002-0209-8668; Djukanovic, Ratko/0000-0001-6039-5612; Howarth, Peter/0000-0003-0619-7927; Davies, Donna/0000-0002-5117-2991				Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Bucchieri F, 2000, AM J RESP CRIT CARE, V161, pA153; Christodoulopoulos P, 2001, J ALLERGY CLIN IMMUN, V107, P586, DOI 10.1067/mai.2001.114883; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; DEMOLY P, 1992, AM J RESP CELL MOL, V7, P128, DOI 10.1165/ajrcmb/7.2.128; Ghaffar O, 2000, CLIN EXP ALLERGY, V30, P86; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Izuhara K, 1999, INT J MOL MED, V3, P3; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Kotsimbos TC, 1998, J ALLERGY CLIN IMMUN, V102, P859, DOI 10.1016/S0091-6749(98)70029-6; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Matsukura S, 1999, J IMMUNOL, V163, P6876; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Nakamura Y, 1996, AM J RESP CELL MOL, V15, P680, DOI 10.1165/ajrcmb.15.5.8918375; *NIH, 1995, GLOB STRAT ASTHM MAN, P95; OLIVER MH, 1989, J CELL SCI, V92, P513; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	31	100	117	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					832	838		10.1067/mai.2001.119554	http://dx.doi.org/10.1067/mai.2001.119554			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692112	Bronze			2022-12-18	WOS:000172523800027
J	Panhans-Gross, A; Novak, N; Kraft, S; Bieber, T				Panhans-Gross, A; Novak, N; Kraft, S; Bieber, T			Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; beta-methasone valerate; costimulatory molecules; dendritic cells; FK506; FKBP; skin immune system	FC-EPSILON-RI; ANTIGEN-PRESENTING FUNCTIONS; T-HELPER TYPE-2; ATOPIC-DERMATITIS; CYCLOSPORINE-A; TOPICAL FK506; MAST-CELLS; FK-506; SKIN; OINTMENT	Background: The immunosuppressive macrolide tacrolimus (FK506) has been shown to inhibit allergic contact dermatitis in animal models as well as in human beings. More recently, successful treatment of atopic dermatitis with an ointment containing tacrolimus has been reported. Objectives: We explored the effects of this compound on epidermal Langerhans' cells (LCs), which are known to play an important pathophysiologic role in inflammatory skin diseases. Methods: The expression of the intracellular FK506 binding protein (FKBP12) was monitored on freshly isolated and cultured epidermal LCs. Phenotyping and functional exploration of LCs treated with different concentrations of tacrolimus and beta -methasone valerate (beta Mv) were performed. Results: FKBP12 is expressed in freshly isolated LCs but is lost while they are maturating into mature dendritic cells. Tacrolimus inhibited the expression of IL-2R (CD25) and of the costimulatory molecules CD80 (B7.1) and CD40, Expression of MHC class I and II was also affected, whereas (3D86 (B7.2) expression was not altered. In contrast, beta Mv strongly increased the expression of CD25. Paradoxically, while decreasing CD40 and MHC class I expression, beta Mv significantly increased the expression of MHC class II, CD80, and CD86 on cultured LCs but impaired their allostimulatory activity. Tacrolimus was about 100 times more potent than beta Mv at inhibiting LC stimulatory function. Conclusion: Tacrolimus can exert immunopharmacologic alterations on LCs, which may account, at least in part, for the therapeutic effect of this compound in eczematous skin diseases.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany	University of Bonn	Bieber, T (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.							AOYAMA H, 1995, BRIT J DERMATOL, V133, P494, DOI 10.1111/j.1365-2133.1995.tb02691.x; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; BIEBER T, 1989, J EXP MED, V170, P309, DOI 10.1084/jem.170.1.309; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Bos JD, 1996, ARCH DERMATOL, V132, P419; BOS JD, 1993, IMMUNOL TODAY, V14, P75, DOI 10.1016/0167-5699(93)90062-P; DEMIDEM A, 1992, J INVEST DERMATOL, V98, P181, DOI 10.1111/1523-1747.ep12555823; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; DEPAULIS A, 1991, J IMMUNOL, V147, P4278; dePaulis A, 1997, ARTHRITIS RHEUM-US, V40, P469, DOI 10.1002/art.1780400313; DUPUY P, 1991, J INVEST DERMATOL, V96, P408, DOI 10.1111/1523-1747.ep12469772; FURUE M, 1988, J IMMUNOL, V140, P4139; FURUE M, 1989, J INVEST DERMATOL, V92, P342, DOI 10.1111/1523-1747.ep12277165; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GOTO T, 1991, TRANSPL P, V23, P2713; GRIFFITHS CEM, 1988, TRANSPLANT P, V20, P50; Homey B, 1998, J IMMUNOL, V160, P5331; INAMURA N, 1988, INT J IMMUNOPHARMACO, V10, P991, DOI 10.1016/0192-0561(88)90046-X; Karashima T, 1996, J DERMATOL SCI, V12, P246, DOI 10.1016/0923-1811(95)00480-7; KAWAMURA T, 1995, EUR J IMMUNOL, V25, P1913, DOI 10.1002/eji.1830250718; KINO T, 1987, J ANTIBIOT, V40, P1256, DOI 10.7164/antibiotics.40.1256; KINO T, 1987, TRANSPLANT P, V19, P36; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LAUERMA AI, 1994, DERMATOLOGY, V188, P173, DOI 10.1159/000247133; LAUERMA AI, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91757-Y; LAUERMA AI, 1994, ARCH DERMATOL RES, V286, P337, DOI 10.1007/BF00402225; MEINGASSNER JG, 1992, J INVEST DERMATOL, V98, P851, DOI 10.1111/1523-1747.ep12456939; Michel G, 1996, IMMUNOL TODAY, V17, P106, DOI 10.1016/0167-5699(96)80599-8; MORI A, 1994, INT ARCH ALLERGY IMM, V104, P32, DOI 10.1159/000236745; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; Nakajima A, 1997, INT IMMUNOL, V9, P637, DOI 10.1093/intimm/9.5.637; OCHIAI T, 1988, TRANSPLANT P, V20, P209; OCHIAI T, 1989, TRANSPLANTATION, V48, P193, DOI 10.1097/00007890-198908000-00003; RORDORFADAM C, 1989, DRUG EXP CLIN RES, V15, P355; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; SCHNEIDER G, 1995, IMMUNOBIOLOGY, V193, P268, DOI 10.1016/S0171-2985(11)80554-1; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHULZ BS, 1993, J IMMUNOL, V151, P4399; STARZL TE, 1989, LANCET, V2, P1000; TANAKA H, 1987, TRANSPLANT P, V19, P11; TODO S, 1988, SURGERY, V104, P23949; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596	46	100	111	1	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					345	352		10.1067/mai.2001.112600	http://dx.doi.org/10.1067/mai.2001.112600			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174203				2022-12-18	WOS:000167071400023
J	Radenne, F; Lamblin, C; Vandezande, LM; Tillie-Leblond, I; Darras, J; Tonnel, AB; Wallaert, B				Radenne, F; Lamblin, C; Vandezande, LM; Tillie-Leblond, I; Darras, J; Tonnel, AB; Wallaert, B			Quality of life in nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyposis; quality of life; SF-36 questionnaire; perennial allergic rhinitis; asthma; endonasal ethmoidectomy	PERENNIAL ALLERGIC RHINITIS; HEALTH SURVEY SF-36; OF-LIFE; MEDICAL OUTCOMES; FRENCH VERSION; QUESTIONNAIRE; VALIDITY; OBSTRUCTION; ASTHMA; TESTS	Background: Nasal polyposis (NP) is a frequent inflammatory chronic disease of the upper respiratory tract, which may impair quality of life (QOL), The NP impact, which is frequently associated with lower respiratory disorders, has never before been studied. Objective: We initiated this prospective study to establish internal validity and reliability of the generic SF-36 questionnaire in NP and to determine to what level daily functioning becomes impaired as a result of NP, Methods: Forty-nine consecutive patients with NP were Included. They were assessed for the severity of nasal symptoms and underwent pulmonary function tests, The QOL profiles in patients with NP were compared with those of patients with perennial rhinitis (n = 111) and healthy subjects (n = 116), Results: Cronbach's coefficient alpha demonstrated the high reliability and validity of the SF-36 questionnaire for patients with NP (alpha = .89), NP impaired QOL more than perennial allergic rhinitis (P <.05), The impairment of QOL was greater when NP was associated with asthma (P <.05), SF-36 scores appeared highly correlated to pulmonary function (FEV1, maximal midexpiratory flow, forced vital capacity), suggesting relationships between QOL in NP and associated bronchial obstruction. Severity of nasal symptoms were not related to QOL scales, In addition, sequential evaluations of QOL, nasal symptoms, and pulmonary function were performed 10 months after the first evaluation in 28 patients with NP. These evaluations demonstrated that NP treatment either with nasal steroids or endonasal ethmoidectomy significantly improved both nasal symptoms and QOL without significant change of pulmonary function, Conclusion: Our study clearly demonstrated that the SF-36 questionnaire presented a high internal validity and reliability in patients with NP, NP impaired QOL to a greater degree than perennial allergic rhinitis, QOL improvement after NP treatment is related to nasal symptoms improvement.	CH&U Lille, Hop Albert Calmette, Serv Pneumol & Immunoallergol, Clin Malad Resp, F-59037 Lille, France; Inst Pasteur, INSERM, U416, F-59019 Lille, France; CH&U Lille, Hop Claude Huriez, Serv Otorhinolaryngol, F-59037 Lille, France	Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille	Wallaert, B (corresponding author), CH&U Lille, Hop Albert Calmette, Serv Pneumol & Immunoallergol, Clin Malad Resp, F-59037 Lille, France.							Aaronson N K, 1992, Qual Life Res, V1, P349, DOI 10.1007/BF00434949; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; deGraafintVeld T, 1996, J ALLERGY CLIN IMMUN, V98, P508, DOI 10.1016/S0091-6749(96)70083-0; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; JACOBS RL, 1983, ANN ALLERGY, V51, P500; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 1997, J ALLERGY CLIN IMMUN, V99, pS742, DOI 10.1016/S0091-6749(97)90000-2; JUNIPER EF, 1997, ACI INT, V9, P5; Lamblin C, 1997, AM J RESP CRIT CARE, V155, P99, DOI 10.1164/ajrccm.155.1.9001296; LEPLEGE A, 1995, REV EPIDEMIOL SANTE, V43, P371; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Nunnaly J.C., 1978, PSYCHOMETRIC THEORY, V2nd ed.; Piquet J J, 1989, Ann Otolaryngol Chir Cervicofac, V106, P505; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RUHNO J, 1990, J ALLERGY CLIN IMMUN, V86, P946, DOI 10.1016/S0091-6749(05)80158-7; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; Thomassin J M, 1991, Ann Otolaryngol Chir Cervicofac, V108, P455; Ware J.E., 1993, LINC RI QUAL METR IN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1994, SF36 PHYSICAL MENTAL; Young T, 1997, J ALLERGY CLIN IMMUN, V99, pS757, DOI 10.1016/S0091-6749(97)70124-6	29	100	104	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					79	84		10.1016/S0091-6749(99)70117-X	http://dx.doi.org/10.1016/S0091-6749(99)70117-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400843	Bronze			2022-12-18	WOS:000081738900012
J	Nelson, HS; Ikle, D; Buchmeier, A				Nelson, HS; Ikle, D; Buchmeier, A			Studies of allergen extract stability: The effects of dilution and mixing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							STANDARDIZATION; COCKROACH	Background: However potent the allergy extracts provided by manufacturers, they are subject to deterioration with storage, especially after dilution or mixture with other extracts. Objective: This study was performed to assess separately the deterioration during storage in allergen extract potency caused by dilution or by mixture with allergen extracts that have been reported to contain proteases. Methods: To assess the effect of dilution, three serial 10-fold dilutions of cat, short ragweed, Bermuda grass, and Dermatophagoides farinae extracts were prepared alone or combined with other extracts. They were stored at 4 degrees for 3 and 12 months. To assess the effect of mixing with other extracts that have been reported to contain proteases, extracts of timothy grass, Bermuda grass, short ragweed, Russian thistle, white oak, box elder, D. farinae, and cat were stored alone or combined with one or more extracts of American cockroach, Alternaria spp., Cladosporium spp., Penicillium spp., and a house dust mite mix for 3 months at 4 degrees C. Results: Bermuda grass, cat and house dust mite extracts incurred significant loss of potency at all dilutions with storage. short ragweed was stable at all dilutions. Potency of extracts of timothy grass, Bermuda grass, Russian thistle, white oak, box elder, and cat were all reduced by combination with one or more extracts potentially containing proteases. Only short ragweed and D. farinae, which was in a final concentration of 25% glycerin, were resistant. Alternaria extract was most frequently responsible for loss of potency, followed by cockroach and Cladosporium extracts. Combination with extracts of Penicillium and a house dust mite mix did not reduce the potency of any extract. Conclusions: Both dilution alone and mixture with extracts reported to contain proteases caused loss of potency of most extracts tested. Ragweed was uniquely resistant under both conditions of storage.			Nelson, HS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.		Ikle, David/AAK-7541-2020	Ikle, David/0000-0003-0091-5246				ESCH RE, 1990, REGULATORY CONTROL S, P171; KAGEN S, 1994, J ALLERGY CLIN IMMUN, V93, P253; KNOLL R, 1991, Journal of Allergy and Clinical Immunology, V87, P188, DOI 10.1016/0091-6749(91)91483-A; KORDASH TR, 1993, ANN ALLERGY, V71, P240; LEHRER SB, 1990, ALLERGY PROC, V11, P197, DOI 10.2500/108854190778879846; NELSON HS, 1979, J ALLERGY CLIN IMMUN, V63, P417, DOI 10.1016/0091-6749(79)90216-1; NELSON HS, 1981, J ALLERGY CLIN IMMUN, V67, P64, DOI 10.1016/0091-6749(81)90047-6; NELSON HS, 1993, ALLERGY PROC, V14, P391, DOI 10.2500/108854193778792740; REED CE, 1989, J ALLERGY CLIN IMMUN, V84, P4, DOI 10.1016/0091-6749(89)90171-1; WONGTIM S, 1993, ALLERGY PROC, V14, P263, DOI 10.2500/108854193778811946; YUNGINGER JW, 1991, ANN ALLERGY, V66, P107	11	100	106	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					382	388		10.1016/S0091-6749(96)70162-8	http://dx.doi.org/10.1016/S0091-6749(96)70162-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757215				2022-12-18	WOS:A1996VC99500017
J	Hedlin, G; Heilborn, H; Lilja, G; Norrlind, K; Pegelow, KO; Schou, C; Lowenstein, H				Hedlin, G; Heilborn, H; Lilja, G; Norrlind, K; Pegelow, KO; Schou, C; Lowenstein, H			Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; cat; dog; asthma; bronchial challenge	DANDER EXTRACTS; DOUBLE-BLIND; EFFICACY; ASTHMA; SYSTEM; MITE	Background: A 5-year follow-up study was conducted to investigate the duration of the effects of a 3-year course of immunotherapy with standardized cat or dog extracts in 32 children and adults with asthma caused by animal dander. Methods: Thirty of the subjects could be reached with a questionnaire, 19 underwent bronchial allergen and histamine challenges and four had only a histamine challenge. Specific IgE and IgG(4) levels in serum were measured in those who underwent challenges. Results: Almost all subjects (26 of 30) reported no change (17 subjects) or increased tolerance (9 subjects) on exposure to cats or dogs. In contrast, 17 of the 19 who underwent allergen challenges had increased allergen sensitivity compared with when therapy was stopped (p < 0.01), and the results were no longer significantly different from before therapy was started. Mean provocative concentration of histamine causing a 20% fall in peak expiratory flow was, however, still higher than before therapy in the cat immunotherapy group (p < 0.01) and had not changed significantly during the follow-lip period. In the dog immunotherapy group there was no significant change during or after therapy. Specific IgG(4) had decreased, and specific IgE in serum had remained low and was comparable to the levels measured at the end of the study period. Conclusions: Five yeats after stopping immunotherapy, objectively measured bronchial allergen sensitivity had increased and had approached pretreatment conditions. Asthma symptoms, according to patients' subjective evaluations had continued to be mild in most patients, and bronchial histamine sensitivity had remained stable. These observations could reflect remaining effects of immunotherapy or the natural history of mild asthma.	DEPT PEDIAT,HUDDINGE,SWEDEN; DANDERYD HOSP,DEPT MED,S-18288 DANDERYD,SWEDEN; SACHS CHILDRENS HOSP,STOCKHOLM,SWEDEN; DEPT LUNG MED & ALLERGY,HUDDINGE,SWEDEN; ALK RES,HORSHOLM,DENMARK	Danderyds Hospital								BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; GOLDEN D B K, 1991, Journal of Allergy and Clinical Immunology, V87, P237, DOI 10.1016/0091-6749(91)91675-J; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; HEJJAOUI H, 1992, J ALLERGY CLIN IMMUN, V89, P319; JACOBSEN L, 1990, CLIN CHEM, V36, P1189; JAROLIM E, 1990, J ALLERGY CLIN IMMUN, V85, P996, DOI 10.1016/0091-6749(90)90043-4; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; KJELLMAN B, 1986, ALLERGY, V41, P351, DOI 10.1111/j.1398-9995.1986.tb00312.x; LYNCH MJ, 1989, J BIOLUM CHEMILUM, V4, P615, DOI 10.1002/bio.1170040181; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; VANBEVER HP, 1990, J ALLERGY CLIN IMMUN, V86, P141, DOI 10.1016/S0091-6749(05)80058-2; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; WIHL JA, 1988, ALLERGY, V43, P363, DOI 10.1111/j.1398-9995.1988.tb00430.x; WIHL JA, 1993, ALLERGY, V48, P99	20	100	102	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				879	885		10.1016/S0091-6749(95)70223-7	http://dx.doi.org/10.1016/S0091-6749(95)70223-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543744				2022-12-18	WOS:A1995TN12400003
J	BOGUNIEWICZ, M; MARTIN, RJ; MARTIN, D; GIBSON, U; CELNIKER, A; WILLIAMS, M; LEUNG, DYM				BOGUNIEWICZ, M; MARTIN, RJ; MARTIN, D; GIBSON, U; CELNIKER, A; WILLIAMS, M; LEUNG, DYM			THE EFFECTS OF NEBULIZED RECOMBINANT INTERFERON-GAMMA IN ASTHMATIC AIRWAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							THERAPY		NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; GENENTECH INC,S SAN FRANCISCO,CA	National Jewish Health; National Jewish Health; Roche Holding; Genentech								[Anonymous], 1986, Standards for the Diagnosis and Care of Patients with Chronic Pulmonary Disease (COPD) and Asthma, V136, P225; BOGUNIEWICZ M, 1993, CLIN EXP ALLERGY, V23, P785, DOI 10.1111/j.1365-2222.1993.tb00367.x; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; JAFFE HA, 1991, J CLIN INVEST, V88, P297, DOI 10.1172/JCI115291; MARTIN RJ, 1993, AM REV RESPIR DIS, V148, P1677, DOI 10.1164/ajrccm/148.6_Pt_1.1677; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401	7	100	108	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				133	135		10.1016/S0091-6749(95)70162-1	http://dx.doi.org/10.1016/S0091-6749(95)70162-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822655				2022-12-18	WOS:A1995QC31200018
J	FRANKEN, HH; DUBOIS, AEJ; MINKEMA, HJ; VANDERHEIDE, S; DEMONCHY, JGR				FRANKEN, HH; DUBOIS, AEJ; MINKEMA, HJ; VANDERHEIDE, S; DEMONCHY, JGR			LACK OF REPRODUCIBILITY OF A SINGLE NEGATIVE STING CHALLENGE RESPONSE IN THE ASSESSMENT OF ANAPHYLACTIC RISK IN PATIENTS WITH SUSPECTED YELLOW JACKET HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						STING CHALLENGE; REPRODUCIBILITY	INSECT ALLERGY; DIAGNOSTIC METHODS; NATURAL-HISTORY; VENOM; BEE; IMMUNOTHERAPY; ACTIVATION; SEVERITY	To investigate the reproducibility of a single negative response to sting challenge with a living insect, we rechallenged a group of 61 patients who showed no clinical response to a first sting challenge. All patients had previously had symptoms suggestive of anaphylaxis after a yellow jacket field sting. Thirteen patients (21%) had anaphylactic responses after the second sting challenge, and sh of these patients had severe reactions including symptomatic hypotension requiring administration of Adrenalin. This rate was significantly lower than the response rate of the original patient group to a first sting challenge (39%). Thus although fewer positive responses were observed in patients who had had a previous negative challenge response, the number of anaphylactic reactions was considerable and included patients with potentially life-threatening symptoms. Consequently, a single sting challenge may not be used to select patients for venom immunotherapy.	STATE UNIV HOSP GRONINGEN,DEPT ALLERGOL,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen								ABRISHAMI MA, 1971, ACTA ALLERGOL, V26, P117; [Anonymous], 1988, Clin Allergy, V18, P305; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; FORSTER J, 1991, Journal of Allergy and Clinical Immunology, V87, P238, DOI 10.1016/0091-6749(91)91676-K; HOFFMAN DR, 1986, J ALLERGY CLIN IMMUN, V78, P337, DOI 10.1016/S0091-6749(86)80086-0; HOFFMAN DR, 1981, ANN ALLERGY, V46, P17; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P297; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P553, DOI 10.1016/0091-6749(85)90028-4; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SCHUMACHER MJ, 1992, J ALLERGY CLIN IMMUN, V90, P59, DOI 10.1016/S0091-6749(06)80011-4; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; WICHER DM, 1980, J ALLERGY CLIN IMMUN, V66, P244	19	100	100	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					431	436		10.1016/0091-6749(94)90351-4	http://dx.doi.org/10.1016/0091-6749(94)90351-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120270	Bronze			2022-12-18	WOS:A1994MY58100003
J	VANDERHEIDE, S; DEMONCHY, JGR; DEVRIES, K; BRUGGINK, TM; KAUFFMAN, HF				VANDERHEIDE, S; DEMONCHY, JGR; DEVRIES, K; BRUGGINK, TM; KAUFFMAN, HF			SEASONAL-VARIATION IN AIRWAY HYPERRESPONSIVENESS AND NATURAL EXPOSURE TO HOUSE-DUST MITE ALLERGENS IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; AIRWAY HYPERRESPONSIVENESS; ENVIRONMENT; HOUSE DUST MITES; ALLERGENS; SEASON	BRONCHIAL HYPERREACTIVITY; RESPONSIVENESS; METHACHOLINE; CHILDREN; INCREASES; HISTAMINE	Nonspecific airway hyperresponsiveness is a fundamental characteristic of patients with asthma and can be influenced by several stimuli. In nine patients with asthma and an isolated allergy to house dust mite, the variation of natural exposure to the house dust mite allergin Der p I and the corresponding changes in nonspecific airway hyperresponsiveness were followed up for 1 year. The concentration of Der p I in floor dust from living rooms and bedrooms (as a measure of exposure) reached maximum levels in late summer and the beginning of autumn (August to October), whereas the lowest levels were found during the months of March to May (Delta Der p I = +2.31 mu g/gm and -1.33 mu g/gm respectively, both compared with the year average). Airway hyperresponsiveness (as measured by the provocative concentration of histamine causing a 20% fall in forced expiratory volume in 1 second [PC20] threshold) also showed a seasonal variation, with most severe hyperresponsiveness during the months of August to November, almost the same period in which the exposure to house dust mite allergens reached maximal levels (Delta PC20 histamine = -1.47 mg/ml in November vs +1.79 mg/ml in March, both comapred with the year average). Our results support the view that seasonal changes of exposure to environmental allergens such as house dust mite allergens will have an effect on the level of airway hyperresponsiveness in patients with allergic asthma.			VANDERHEIDE, S (corresponding author), UNIV HOSP GRONINGEN,INTERNAL MED CLIN,DEPT ALLERGOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.							AALBERS R, 1991, AM REV RESPIR DIS, V144, P352, DOI 10.1164/ajrccm/144.2.352; BONER AL, 1985, ANN ALLERGY, V54, P42; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; HALLAS TE, 1983, ALLERGOL IMMUNOPATH, V11, P195; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P423, DOI 10.1164/ajrccm/143.2.423; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; MAPP CE, 1986, EUR J RESPIR DIS, V69, P276; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VERVLOET D, 1991, ALLERGY, V46, P554, DOI 10.1111/j.1398-9995.1991.tb00620.x	23	100	101	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					470	475		10.1016/0091-6749(94)90356-5	http://dx.doi.org/10.1016/0091-6749(94)90356-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120274				2022-12-18	WOS:A1994MY58100008
J	BOCHNER, BS; CHARLESWORTH, EN; LICHTENSTEIN, LM; DERSE, CP; GILLIS, S; DINARELLO, CA; SCHLEIMER, RP				BOCHNER, BS; CHARLESWORTH, EN; LICHTENSTEIN, LM; DERSE, CP; GILLIS, S; DINARELLO, CA; SCHLEIMER, RP			INTERLEUKIN-1 IS RELEASED AT SITES OF HUMAN CUTANEOUS ALLERGIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							VASCULAR ENDOTHELIAL-CELLS; PLATELET-ACTIVATING FACTOR; COLONY-STIMULATING FACTOR; HUMAN MONONUCLEAR-CELLS; NORMAL HUMAN-EPIDERMIS; TUMOR NECROSIS FACTOR; HUMAN BASOPHILS; LATE-PHASE; HISTAMINE-RELEASE; MESSENGER-RNA	Interleukin-1 (IL-1) promotes cell recruitment and influences allergic mediator release. We analyzed histamine, prostaglandin D2, IL-1, and leukocytes accumulating hourly for 12 hours at skin-chamber sites after local ragweed challenge in eight allergic subjects with cutaneous late-phase reactions. Ragweed induced a peak of histamine at 1 hour (p < 0.02), which diminished, and then steadily increased (p < 0.02). Prostaglandin D2 levels peaked by the second hour (p < 0.02) and then decreased, approaching prechallenge levels by 12 hours. Leukocyte infiltration (predominantly neutrophils) was detectable 3 to 4 hours after challenge, although selective enrichment of mononuclear cells, eosinophils, and basophils was observed at later hours (p < 0.02). IL-1 bioactivity was detected in fluids 10 to 12 hours after challenge but not as control sites (p < 0.05). Analysis of IL-1-beta levels by RIA revealed an initial peak at 1 hour of 0.90 ng/ml (p < 0.02) and a second elevation of up to 0.75 ng/ml during the later hours (p < 0.04). Ragweed challenge of three nonatopic subjects did not change levels of the above-mentioned mediators or cells. Bioactivity in chamber fluids from antigen-challenged sites of atopic subjects was significantly neutralized by an anti-IL-beta antiserum, although treatment with anti-IL-1-alpha and anti-IL-1-beta was needed for complete neutralization. IL-1 released locally during cutaneous allergic reactions may contribute to IgE-dependent cutaneous inflammation.	IMMUNEX CORP, SEATTLE, WA USA; TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, BOSTON, MA 02111 USA	Immunex Corporation; Tufts Medical Center; Tufts University	BOCHNER, BS (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR, DEPT MED, DIV CLIN IMMUNOL, OFF 3, 301 BAYSVIEW BLVD, BALTIMORE, MD 21224 USA.				NIADDK NIH HHS [AM31891] Funding Source: Medline; NIAID NIH HHS [AI07290, AI08270] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM031891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1977, J LAB CLIN MED, V90, P1043; ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BAGBY GC, 1986, J CLIN INVEST, V78, P1316, DOI 10.1172/JCI112717; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BOCHNER BS, 1987, J IMMUNOL, V139, P2297; BOCHNER BS, 1987, J IMMUNOL, V139, P2303; BOCHNER BS, 1988, J CLIN INVEST, V81, P1355, DOI 10.1172/JCI113463; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; CAMP RDR, 1986, J IMMUNOL, V137, P3469; CAMP RDR, 1987, BRIT MED BULL, V43, P401, DOI 10.1093/oxfordjournals.bmb.a072190; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; CYBULSKY MI, 1986, AM J PATHOL, V124, P367; DIDIERJEAN L, 1989, J INVEST DERMATOL, V92, P809, DOI 10.1111/1523-1747.ep12696825; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOWD PM, 1987, CLIN EXP IMMUNOL, V67, P606; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; ENDRES S, 1988, CLIN IMMUNOL IMMUNOP, V49, P424, DOI 10.1016/0090-1229(88)90130-4; GAHRING LC, 1985, J CLIN INVEST, V76, P1585, DOI 10.1172/JCI112141; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GOTO K, 1984, BRIT J EXP PATHOL, V65, P521; GRANSTEIN RD, 1986, J CLIN INVEST, V77, P1020, DOI 10.1172/JCI112354; HAAKFRENDSCHO M, 1988, J ALLERGY CLIN IMMUN, V82, P218, DOI 10.1016/0091-6749(88)91002-0; HABICHT GS, 1987, ROLE INTERLEUKIN 1 I, P51; HAUSER C, 1986, J IMMUNOL, V136, P3317; HENOCQ E, 1986, LANCET, V1, P1378; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; KILIAN PL, 1986, J IMMUNOL, V136, P4509; KIMANI G, 1988, J IMMUNOL, V140, P3161; KRONHEIM SR, 1985, J EXP MED, V161, P490, DOI 10.1084/jem.161.3.490; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; LAMAS AM, 1989, J IMMUNOL, V142, P3978; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LEMANSKE RF, 1988, J CLIN IMMUNOL, V8, P1, DOI 10.1007/BF00915151; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MARTIN S, 1988, IMMUNOLOGY, V64, P301; MASSEY WA, 1989, J IMMUNOL, V143, P1875; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MAZINGUE C, 1987, CLIN EXP IMMUNOL, V67, P587; MICHEL L, 1987, J INVEST DERMATOL, V88, P675, DOI 10.1111/1523-1747.ep12470331; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; RAMPART M, 1988, BRIT J PHARMACOL, V94, P1143, DOI 10.1111/j.1476-5381.1988.tb11632.x; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; SCHLEIMER RP, 1986, J IMMUNOL, V136, P649; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SHALIT M, 1988, J IMMUNOL, V141, P821; SHALIT M, 1987, J CLIN IMMUNOL, V7, P456, DOI 10.1007/BF00915055; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351	65	100	102	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				830	839		10.1016/S0091-6749(05)80143-5	http://dx.doi.org/10.1016/S0091-6749(05)80143-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262641				2022-12-18	WOS:A1990EQ04500002
J	BOUSQUET, J; HEJJAOUI, A; MICHEL, FB				BOUSQUET, J; HEJJAOUI, A; MICHEL, FB			SPECIFIC IMMUNOTHERAPY IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											BOUSQUET, J (corresponding author), HOP AIGUELONGUE, MALADIES RESP CLIN, AVE DU MAJOR FLANDRE, F-34059 MONTPELLIER, FRANCE.							AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P432, DOI 10.1016/0091-6749(82)90005-7; AMARALMARQUES R, 1978, ALLERGOL IMMUNOPATH, V6, P231; [Anonymous], 1986, Br Med J (Clin Res Ed), V293, P948; AUKRUST L, 1980, ADV ALLERGOLOGY APPL, P475; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BERTELSEN A, 1989, ALLERGY, V44, P330, DOI 10.1111/j.1398-9995.1989.tb00454.x; BESSOT JC, 1975, REV FR ALLERGOL, V15, P73, DOI 10.1016/S0335-7457(75)80016-5; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1988, ALLERGY, V43, P16, DOI 10.1111/j.1398-9995.1988.tb02437.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; BOUSQUET J, 1989, PROVOCATIVE CHALLENG, P85; BOUSQUET J, 1987, HIGHLIGHTS ASTHMOLOG, P394; BOUSQUET J, IN PRESS J ALLERGY C; BOUSQUET J, IN PRESS N ENGL J ME; BOUSQUET J, 1987, AM REV RESPIR DIS, V135, pA135; BOUSQUET J, 1989, ALLERGY CLIN IMMUNOL, V1, P7; BOUSQUET J, 1986, 12 P INT C ALL CLIN, P397; BOUSQUET J, 1987, REGULATORY CONTROL S, P213; BOUSQUET J, 1985, 3RD P P EHRL SEM REG, P291; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BUCUR J, 1989, ANN ALLERGY, V62, P355; BUSSE WW, 1976, J ALLERGY CLIN IMMUN, V57, P367, DOI 10.1016/0091-6749(76)90094-4; CAPRON A, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P22; CHAPMAN MD, 1984, INT ARCH ALLER A IMM, V73, P314; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CLAUSEN JL, 1982, PULMONARY FUNCTION T; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; DREBORG S, 1986, HDB EXPT IMMUNOLOGY; DREBORG S, 1988, CLIN IMMUNOL ALLERGY, V2, P245; DREBORG S, 1986, NEW TRENDS ALLERGY, V2, P312; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; EISER NM, 1987, BRONCHIAL HYPERRESPO, P173; ELLULMICALLEF R, 1988, ASTHMA BASIC MECHANI, P653; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORGACS P, 1968, BRIT MED J, V3, P774; FORMGREN H, 1984, Journal of Allergy and Clinical Immunology, V73, P140; FRANKLAND AW, 1954, LANCET, V1, P1055; GADDIE J, 1976, BRIT MED J, V2, P561, DOI 10.1136/bmj.2.6035.561; GOLDSTEIN GL, 1981, ANN ALLERGY, V47, P333; GRANT IWB, 1986, CLIN ALLERGY, V16, P7, DOI 10.1111/j.1365-2222.1986.tb01947.x; HEDLIN G, 1989, J ALLERGY CLIN IMMUN, V84, P390, DOI 10.1016/0091-6749(89)90426-0; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; HELM RM, 1987, INT ARCH ALLER A IMM, V82, P178, DOI 10.1159/000234184; HELM RM, 1988, J ALLERGY CLIN IMMUN, V81, P651, DOI 10.1016/0091-6749(88)91035-4; HILL DJ, 1982, BRIT MED J, V284, P306, DOI 10.1136/bmj.284.6312.306; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; JOSEPHS LK, 1989, AM REV RESPIR DIS, V140, P350, DOI 10.1164/ajrccm/140.2.350; KAAD PH, 1982, CLIN ALLERGY, V12, P317, DOI 10.1111/j.1365-2222.1982.tb02534.x; KARLSSON R, 1986, ALLERGY, V41, P141, DOI 10.1111/j.1398-9995.1986.tb00290.x; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LANNER A, 1984, Journal of Allergy and Clinical Immunology, V73, P141; LESSOF M, 1983, P INT ALLERGY WORKSH; LICHTENSTEIN LM, 1984, AM REV RESPIR DIS, V129, P657, DOI 10.1164/arrd.1984.129.5.657; LICHTENSTEIN LM, 1978, AM REV RESPIR DIS, V117, P191; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MALLING H-J, 1988, Allergy (Copenhagen), V43, P1; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MAUNSELL K, 1971, LANCET, V1, P967; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; MCHUGH SM, 1989, CLIN EXP ALLERGY, V19, P327, DOI 10.1111/j.1365-2222.1989.tb02391.x; METZGER WJ, 1983, J ALLERGY CLIN IMMUN, V71, P119, DOI 10.1016/0091-6749(83)90245-2; MOSBECH H, 1986, CLIN ALLERGY, V16, P10, DOI 10.1111/j.1365-2222.1986.tb01948.x; MOSBECH H, 1989, ALLERGY, V44, P499, DOI 10.1111/j.1398-9995.1989.tb04189.x; MOSBECH H, 1989, ALLERGY, V44, P487, DOI 10.1111/j.1398-9995.1989.tb04188.x; MOSBECH H, 1988, INT ARCH ALLER A IMM, V85, P145, DOI 10.1159/000234493; MURRAY AB, 1985, ANN ALLERGY, V54, P541; NAKAGAWA T, 1983, INT ARCH ALLER A IMM, V71, P122, DOI 10.1159/000233374; NEWTON DAG, 1978, BRIT J DIS CHEST, V72, P21, DOI 10.1016/0007-0971(78)90004-9; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1982, PROG ALLERGY, V32, P318; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1989, J ALLERGY CLIN IMMUN, V84, P133, DOI 10.1016/0091-6749(89)90313-8; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; PAUWELS R, 1987, BRONCHIAL HYPERRESPO, P315; PECQUET C, 1989, ALLERGY, V44, P427, DOI 10.1111/j.1398-9995.1989.tb04174.x; PLATTSMILLS TAE, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P279; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; RAK S, 1987, INT ARCH ALLER A IMM, V82, P349, DOI 10.1159/000234224; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; REED CE, 1985, J ALLERGY CLIN IMMUN, V76, P773, DOI 10.1016/0091-6749(85)90746-8; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; ROCHE WR, 1989, LANCET, V1, P520; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; ROHATGI N, 1988, J ALLERGY CLIN IMMUN, V82, P389, DOI 10.1016/0091-6749(88)90010-3; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SEHON AH, 1982, PROG ALLERGY, V32, P161; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; SMITH JM, 1982, CLIN ALLERGY, V2, P281; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR B, 1974, CLIN ALLERGY, V4, P35, DOI 10.1111/j.1365-2222.1974.tb01360.x; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; THOMPSON RA, 1989, LANCET, V1, P259; TSICOPOULOS A, 1988, CLIN EXP IMMUNOL, V71, P433; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3; TURNER MW, 1984, CLIN ALLERGY, V14, P221, DOI 10.1111/j.1365-2222.1984.tb02201.x; VALOVIRTA E, 1986, ANN ALLERGY, V57, P173; VANBEVER HP, 1988, ALLERGY, V43, P378, DOI 10.1111/j.1398-9995.1988.tb00432.x; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399, DOI 10.1111/j.1365-2222.1989.tb02405.x; VANDERZEE JS, 1987, ALLERGY INT TXB, P49; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; VANMETRE TE, 1988, ALLERGY PRINCIPLES P, P1327; VIJAY HM, 1987, INT ARCH ALLER A IMM, V83, P325, DOI 10.1159/000234316; WAHN U, 1988, J ALLERGY CLIN IMMUN, V82, P360, DOI 10.1016/0091-6749(88)90007-3; WARNER JO, 1978, LANCET, V2, P912; WARNER JO, 1986, 12 P INT C ALL CLIN, P323; WOOLCOCK AJ, 1986, AM REV RESPIR DIS, V133, pA156; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; 1979, BR J DIS CHEST, V73, P260; 1990, J ALLERGY CLIN IMMUN, V86, P141	140	100	100	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				292	305		10.1016/S0091-6749(05)80091-0	http://dx.doi.org/10.1016/S0091-6749(05)80091-0			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2212405				2022-12-18	WOS:A1990EA85900002
J	BISGAARD, H; NIELSEN, MD; ANDERSEN, B; ANDERSEN, P; FOGED, N; FUGLSANG, G; HOST, A; LETH, C; PEDERSEN, M; PELCK, I; STAFANGER, G; OSTERBALLE, O				BISGAARD, H; NIELSEN, MD; ANDERSEN, B; ANDERSEN, P; FOGED, N; FUGLSANG, G; HOST, A; LETH, C; PEDERSEN, M; PELCK, I; STAFANGER, G; OSTERBALLE, O			ADRENAL-FUNCTION IN CHILDREN WITH BRONCHIAL-ASTHMA TREATED WITH BECLOMETHASONE DIPROPIONATE OR BUDESONIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RIGSHOSP,DEPT PEDIAT,DK-2100 COPENHAGEN O,DENMARK; CTY HOSP,KOLDING,DENMARK; CTY HOSP,ODENSE,DENMARK; CTY HOSP,ALBORG,DENMARK; CTY HOSP,RANDERS,DENMARK; CTY HOSP,VIBORG,DENMARK; CTY HOSP GLOSTRUP,DEPT CLIN PHYSIOL,GLOSTRUP,DENMARK; CTY HOSP HERLEV,DEPT SURG,HERLEV,DENMARK	Rigshospitalet			Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011; Nielsen, Hanne M/L-9481-2015	Bisgaard, Hans/0000-0003-4131-7592; Nielsen, Hanne M/0000-0002-7285-9100				BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BHAN GL, 1980, LANCET, P96; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; BROWN HM, 1980, PRACTITIONER, V224, P847; BURCH WM, 1982, JAMA-J AM MED ASSOC, V247, P2002, DOI 10.1001/jama.247.14.2002; DAB I, 1979, PHARMATHERAPEUTICA, V2, P209; FRANCIS RS, 1976, THORAX, V31, P309, DOI 10.1136/thx.31.3.309; GODFREY S, 1970, British Journal of Diseases of the Chest, V64, P15, DOI 10.1016/S0007-0971(70)80045-6; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GODFREY S, 1980, TOPICAL STEROIDS AST, P123; GOLDSTEIN D, 1982, J ALLERGY CLIN IMMUN, V69, P199; GRAFFLONNEVIG V, 1979, ALLERGY, V34, P57, DOI 10.1111/j.1398-9995.1979.tb02001.x; GWYNN CM, 1977, BRIT J CLIN PHARMACO, V4, pS269, DOI 10.1111/j.1365-2125.1977.tb04518.x; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HSU TH, 1970, J CLIN ENDOCR METAB, V30, P443, DOI 10.1210/jcem-30-4-443; HUMMER L, 1983, SCAND J CLIN LAB INV, V43, P301; JOHANSSON SA, 1982, EUR J CLIN PHARMACOL, V22, P523, DOI 10.1007/BF00609625; LANTTO O, 1983, SCAND J CLIN LAB INV, V43, P433; LAW CM, 1986, LANCET, V1, P942; LOFDAHL CG, 1984, EUR J RESPIR DIS, V65, P69; MORRISON SJ, 1983, STEROIDS ASTHMA REAP, P193; SHACKLETON CHL, 1980, CLIN CHIM ACTA, V107, P231, DOI 10.1016/0009-8981(80)90451-9; SHACKLETON CHL, 1976, CLIN CHIM ACTA, V69, P267, DOI 10.1016/0009-8981(76)90505-2; SIEGEL CS, 1979, N ENGL J MED, V300, P986; SOKAL RR, 1969, BIOMETRY, P337; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; 1979, LANCET, P589	28	100	101	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1088	1095		10.1016/0091-6749(88)90874-3	http://dx.doi.org/10.1016/0091-6749(88)90874-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3288682				2022-12-18	WOS:A1988P002300004
J	QUINTI, I; BROZEK, C; WOOD, N; GEHA, RS; LEUNG, DYM				QUINTI, I; BROZEK, C; WOOD, N; GEHA, RS; LEUNG, DYM			CIRCULATING IGG AUTOANTIBODIES TO IGE IN ATOPIC SYNDROMES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,CHILDRENS HOSP,DEPT PEDIAT,DIV ALLERGY,300 LONGWOOD AVE,BOSTON,MA 02115	Harvard University; Boston Children's Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI021163, R01AI020373] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-31925-01] Funding Source: Medline; NIAID NIH HHS [AI-20373-01, AI-21163] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROSTOFF J, 1977, LANCET, V2, P741; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1978, IMMUNOL REV, V41, P18; CARINI C, 1983, ANN ALLERGY, V51, P251; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P36, DOI 10.1001/archderm.115.1.36; FERGUSON AC, 1984, J ALLERGY CLIN IMMUN, V74, P678, DOI 10.1016/0091-6749(84)90229-X; GEHA RS, 1983, J CLIN INVEST, V71, P46, DOI 10.1172/JCI110750; GLEICH GJ, 1980, CLIN IMMUNOLOGY, V2, P1321; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; HADDAD Z, 1983, ANN ALLERGY, V51, P225; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HANIFIN JM, 1980, ACTA DERM-VENEREOL, V92, P52; HEIMER R, 1982, ARTHRITIS RHEUM, V25, P1298, DOI 10.1002/art.1780251105; HILL HR, 1974, LANCET, V1, P183; INGANAS M, 1981, INT ARCH ALLER A IMM, V65, P51, DOI 10.1159/000232737; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; JONES HE, 1975, BRIT J DERMATOL, V92, P17; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KENTEN J, 1984, P NATL ACAD SCI-BIOL, V81, P2955, DOI 10.1073/pnas.81.10.2955; LEUNG DYM, 1983, J IMMUNOL, V130, P1678; LEUNG DYM, 1985, CLIN RES, V33, pA161; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; OLOUGHLIN S, 1977, ARCH DERMATOL, V113, P309; PAGINELLI R, 1983, ARCH DIS CHILD, V58, P201; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; ROUZER CA, 1982, P NATL ACAD SCI-BIOL, V79, P5656, DOI 10.1073/pnas.79.18.5656; SCHOPFER K, 1979, NEW ENGL J MED, V300, P835, DOI 10.1056/NEJM197904123001506; SETSUKO I, 1983, CLIN EXP IMMUNOL, V51, P407; STEVENS WJ, 1984, J ALLERGY CLIN IMMUN, V73, P276, DOI 10.1016/S0091-6749(84)80020-2; STONE SP, 1973, ARCH DERMATOL, V108, P806, DOI 10.1001/archderm.108.6.806; WILLIAMS RC, 1972, J CLIN INVEST, V51, P955, DOI 10.1172/JCI106890; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3	36	100	103	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					586	594		10.1016/0091-6749(86)90350-7	http://dx.doi.org/10.1016/0091-6749(86)90350-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3958387				2022-12-18	WOS:A1986A938100010
J	COOK, TJ; MACQUEEN, DM; WITTIG, HJ; THORNBY, JI; LANTOS, RL; VIRTUE, CM				COOK, TJ; MACQUEEN, DM; WITTIG, HJ; THORNBY, JI; LANTOS, RL; VIRTUE, CM			DEGREE AND DURATION OF SKIN-TEST SUPPRESSION AND SIDE-EFFECTS WITH ANTIHISTAMINES - DOUBLE-BLIND CONTROLLED STUDY WITH 5 ANTIHISTAMINES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,COLL MED,INST FOOD & AGR SCI,DEPT STATISTICS,GAINESVILLE,FL 32601; UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32601; UNIV FLORIDA,COLL MED,HOSP PHARM,GAINESVILLE,FL 32601	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida								ARBESMAN CE, 1946, J ALLERGY, V17, P203, DOI 10.1016/0021-8707(46)90145-1; COLLINS J, 1960, J ALLERGY, V31, P387, DOI 10.1016/0021-8707(60)90001-0; DIXON WJ, 1969, BIOMEDICAL COMPUTER; GALANT SP, 1972, J ALLERGY CLIN IMMUN, V49, P119; MOSKO MM, 1950, J ALLERGY, V21, P242, DOI 10.1016/0021-8707(50)90132-8; SCHWARTZ E, 1949, J ALLERGY, V20, P32, DOI 10.1016/0021-8707(49)90081-7; WOLFE HI, 1964, J ALLERGY, V35, P271, DOI 10.1016/0021-8707(64)90016-4; ZIPPIN C, 1971, J ALLERGY, V47, P94	8	100	100	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	2					71	77		10.1016/S0091-6749(73)80002-8	http://dx.doi.org/10.1016/S0091-6749(73)80002-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O7913	4405284				2022-12-18	WOS:A1973O791300002
J	BERNSTEIN, IL; BRANDON, ML; BROWN, EB; FEINBERG, AR; EVANS, RR; SIEGEL, SC; THURSTON, D; YAMATE, M; FRIEDLAENDER, S; HANDELMAN, NI; HADLEY, RA; KRUMHOLZ, RA				BERNSTEIN, IL; BRANDON, ML; BROWN, EB; FEINBERG, AR; EVANS, RR; SIEGEL, SC; THURSTON, D; YAMATE, M; FRIEDLAENDER, S; HANDELMAN, NI; HADLEY, RA; KRUMHOLZ, RA			CONTROLLED STUDY OF CROMOLYN SODIUM SPONSORED BY DRUG COMMITTEE OF AMERICAN ACADEMY OF ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ALTOUNYAN RE, 1971, NEW CONCEPTS ALLERGY, P377; BURGHER LW, 1971, CHEST, V60, P210, DOI 10.1378/chest.60.3.210; CLARKE PS, 1971, BRIT MED J, V1, P317, DOI 10.1136/bmj.1.5744.317; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; GRANT IWB, 1967, LANCET, V2, P673; HERXHEIMER H, 1969, BMJ-BRIT MED J, V2, P220, DOI 10.1136/bmj.2.5651.220; HOWELL JBL, 1967, LANCET, V2, P539; KERR JW, 1970, BMJ-BRIT MED J, V2, P139, DOI 10.1136/bmj.2.5702.139; KIDNER PH, 1968, LANCET, V2, P655; LOPEZ M, 1969, J ALLERGY, V44, P118, DOI 10.1016/0021-8707(69)90008-2; PATEL K R, 1971, Clinical Allergy, V1, P199, DOI 10.1111/j.1365-2222.1971.tb03019.x; PEPYS J, 1970, P S DISODIUM CROMOGL, P208; POPPIUS H, 1970, BRIT MED J, V4, P337, DOI 10.1136/bmj.4.5731.337; ZWI S, 1971, South African Medical Journal, V45, P823	14	100	100	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	4					235	+		10.1016/0091-6749(72)90017-6	http://dx.doi.org/10.1016/0091-6749(72)90017-6			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N6855	4627420	Bronze			2022-12-18	WOS:A1972N685500005
J	Zimmermann, P; Messina, N; Mohn, WW; Finlay, BB; Curtis, N				Zimmermann, Petra; Messina, Nicole; Mohn, William W.; Finlay, B. Brett; Curtis, Nigel			Association between the intestinal microbiota and allergic sensitization, eczema, and asthma: A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Microbiota; Bifidobacterium; Clostridium; Lactobacillus; atopic; allergies; immune regulation	INFANT GUT MICROBIOTA; FECAL MICROFLORA; ATOPIC ECZEMA; 1ST YEAR; EARLY-LIFE; FOOD SENSITIZATION; REDUCED DIVERSITY; IMMUNOGLOBULIN-E; HEALTHY INFANTS; DOUBLE-BLIND	The intestinal microbiota plays an important role in development of the immune system and regulation of immune responses. This review summarizes the association between the intestinal microbiota and the development of allergic sensitization, eczema, and asthma in neonates and children. Overall, a greater relative abundance of Bacteroidaceae, Clostridiaceae, and Enterobacteriaceae and a lower relative abundance of Bifidobacteriaceae and Lactobacillaceae is associated with the development of allergic sensitization, eczema, or asthma. Reduced bacterial diversity can be associated with the development of allergic disease. The association between the composition of the intestinal microbiota and the development of allergic disease or asthma is less consistent in older children than in neonates, suggesting that early-life microbial exposure plays a more important role. Inconsistencies in the results reported from different studies might partly be explained by heterogeneity in design, study populations, diagnostic criteria, microbiota analysis methods, and reporting on different taxonomic levels. Larger studies that better account for antenatal and postnatal factors will further help determine specific microbial intestinal signatures associated with increased risk of allergy and asthma. This will enable the early identification of infants at high risk and facilitate novel strategies and interventions to prevent and treat these conditions, including modifying the intestinal microbiota early in life.	[Zimmermann, Petra; Curtis, Nigel] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Zimmermann, Petra; Curtis, Nigel] Royal Childrens Hosp Melbourne, Infect Dis Unit, Parkville, Vic, Australia; [Zimmermann, Petra; Messina, Nicole; Curtis, Nigel] Murdoch Childrens Res Inst, Infect Dis & Microbiol Res Grp, Parkville, Vic, Australia; [Zimmermann, Petra] Univ Basel, Childrens Hosp, Infect Dis Unit, Basel, Switzerland; [Mohn, William W.; Finlay, B. Brett] Univ British Columbia, Dept Microbiol & Immunol, Life Sci Inst, Vancouver, BC, Canada; [Finlay, B. Brett] Univ British Columbia, Michael Smith Labs, Vancouver, BC, Canada	University of Melbourne; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Basel; University of British Columbia; University of British Columbia	Zimmermann, P (corresponding author), Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.	petra.zimmermann@mcri.edu.au	Zimmermann, Petra/I-4670-2019	Zimmermann, Petra/0000-0002-2388-4318; Messina, Nicole/0000-0001-8404-4462				Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Adlerberth I, 2006, PEDIATR RES, V59, P96, DOI 10.1203/01.pdr.0000191137.12774.b2; ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Arrieta MC, 2018, J ALLERGY CLIN IMMUN, V142, P424, DOI 10.1016/j.jaci.2017.08.041; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Backhed F, 2015, CELL HOST MICROBE, V17, P690, DOI [10.1016/j.chom.2015.05.012, 10.1016/j.chom.2015.04.004]; BENNET R, 1987, INFECTION, V15, P332, DOI 10.1007/BF01647733; BENNET R, 1991, SCAND J INFECT DIS, V23, P63, DOI 10.3109/00365549109023376; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Breitbart M, 2003, J BACTERIOL, V185, P6220, DOI 10.1128/JB.185.20.6220-6223.2003; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Candela M, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-95; Chen CC, 2016, PEDIAT ALLERG IMM-UK, V27, P254, DOI 10.1111/pai.12522; Chernikova DA, 2016, J MATERN-FETAL NEO M, V29, P99, DOI 10.3109/14767058.2014.987748; Coit P, 2016, CLIN IMMUNOL, V170, P70, DOI 10.1016/j.clim.2016.07.026; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Dogra S, 2015, MBIO, V6, DOI 10.1128/mBio.02419-14; Elazab N, 2013, PEDIATRICS, V132, pE666, DOI 10.1542/peds.2013-0246; Eloe-Fadrosh EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062026; Fallani M, 2010, J PEDIATR GASTR NUTR, V51, P77, DOI 10.1097/MPG.0b013e3181d1b11e; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Gore C, 2008, J ALLERGY CLIN IMMUN, V121, P135, DOI 10.1016/j.jaci.2007.07.061; Gosalbes MJ, 2013, CLIN EXP ALLERGY, V43, P198, DOI 10.1111/cea.12063; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Hesla HM, 2014, FEMS MICROBIOL ECOL, V90, P791, DOI 10.1111/1574-6941.12434; Hong PY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009964; Inoue R, 2017, BIOSCI BIOTECH BIOCH, V81, P2396, DOI 10.1080/09168451.2017.1383849; Ismail IH, 2012, PEDIAT ALLERG IMM-UK, V23, P674, DOI 10.1111/j.1399-3038.2012.01328.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Johansson MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023031; Johnson JL, 2015, GLYCOBIOLOGY, V25, P368, DOI 10.1093/glycob/cwu117; Kabeerdoss J, 2014, J NUTR SCI, V3, DOI 10.1017/jns.2013.6; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kendler M, 2006, PEDIAT ALLERG IMM-UK, V17, P141, DOI 10.1111/j.1399-3038.2005.00371.x; Kirjavainen PV, 2001, FEMS IMMUNOL MED MIC, V32, P1, DOI 10.1111/j.1574-695X.2001.tb00526.x; Knip M, 2016, NAT REV ENDOCRINOL, V12, P154, DOI 10.1038/nrendo.2015.218; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Ta LDH, 2018, J ALLERGY CLIN IMMUN, V142, P86, DOI 10.1016/j.jaci.2018.01.032; Lee MJ, 2018, J ALLERGY CLIN IMMUN, V141, P1310, DOI 10.1016/j.jaci.2017.11.045; Madan JC, 2012, ARCH DIS CHILD-FETAL, V97, pF456, DOI 10.1136/fetalneonatal-2011-301373; Mah KW, 2006, INT ARCH ALLERGY IMM, V140, P157, DOI 10.1159/000092555; Mahdavinia M, 2018, J ALLERGY CLIN IMMUN, V142, P287, DOI 10.1016/j.jaci.2018.01.033; Mangin I, 2010, ANAEROBE, V16, P433, DOI 10.1016/j.anaerobe.2010.06.005; Manichanh C, 2006, GUT, V55, P205, DOI 10.1136/gut.2005.073817; Marchesi JR, 2016, GUT, V65, P330, DOI 10.1136/gutjnl-2015-309990; Martinez RM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146296; Metsala J, 2015, CLIN EXP ALLERGY, V45, P137, DOI 10.1111/cea.12356; Mitsou EK, 2008, ANAEROBE, V14, P94, DOI 10.1016/j.anaerobe.2007.11.002; Murray CS, 2005, CLIN EXP ALLERGY, V35, P741, DOI 10.1111/j.1365-2222.2005.02259.x; Nakayama J, 2011, FEMS IMMUNOL MED MIC, V63, P397, DOI 10.1111/j.1574-695X.2011.00872.x; Ouwehand AC, 2001, J ALLERGY CLIN IMMUN, V108, P144, DOI 10.1067/mai.2001.115754; Panzer AR, 2015, CURR OPIN RHEUMATOL, V27, P373, DOI 10.1097/BOR.0000000000000191; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Penders J, 2006, CLIN EXP ALLERGY, V36, P1602, DOI 10.1111/j.1365-2222.2006.02599.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Penders J, 2010, MICROBIOL-SGM, V156, P3298, DOI 10.1099/mic.0.042069-0; Ramakrishnan VR, 2018, J ALLERGY CLIN IMMUN, V142, P73, DOI 10.1016/j.jaci.2018.05.006; Risnes KR, 2011, AM J EPIDEMIOL, V173, P310, DOI 10.1093/aje/kwq400; Rodriguez B, 2011, FEMS MICROBIOL ECOL, V76, P133, DOI 10.1111/j.1574-6941.2010.01035.x; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Sepp E, 2005, CLIN EXP ALLERGY, V35, P1141, DOI 10.1111/j.1365-2222.2005.02315.x; Sjogren YM, 2009, CLIN EXP ALLERGY, V39, P518, DOI 10.1111/j.1365-2222.2008.03156.x; Songjinda P, 2007, BIOSCI BIOTECH BIOCH, V71, P2338, DOI 10.1271/bbb.70154; Stiemsma LT, 2016, CLIN SCI, V130, P2199, DOI 10.1042/CS20160349; Storro O, 2011, CLIN EXP ALLERGY, V41, P1545, DOI 10.1111/j.1365-2222.2011.03817.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Stsepetove J, 2007, FEMS IMMUNOL MED MIC, V51, P260, DOI 10.1111/j.1574-695X.2007.00306.x; Suzuki S, 2007, CLIN EXP ALLERGY, V37, P506, DOI 10.1111/j.1365-2222.2007.02676.x; Suzuki S, 2008, ASIAN PAC J ALLERGY, V26, P113; Ta Von, 2014, Pediatrics, V134 Suppl 3, pS141, DOI 10.1542/peds.2014-1817O; Tanaka M, 2017, FEMS MICROBIOL ECOL, V93, DOI 10.1093/femsec/fix099; Vael C, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-68; Vael Carl, 2008, BMC Pulm Med, V8, P19, DOI 10.1186/1471-2466-8-19; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Verhulst SL, 2008, J ASTHMA, V45, P828, DOI 10.1080/02770900802339734; Waligora-Dupriet AJ, 2011, ANAEROBE, V17, P91, DOI 10.1016/j.anaerobe.2011.04.003; Wampach L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00738; Wang HP, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0118-0; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Watanabe S, 2003, J ALLERGY CLIN IMMUN, V111, P587, DOI 10.1067/mai.2003.105; Wheeler ML, 2016, CELL HOST MICROBE, V19, P865, DOI 10.1016/j.chom.2016.05.003; Zeevi D, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0921-4; Zheng HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166026; Zuccotti G, 2015, ALLERGY, V70, P1356, DOI 10.1111/all.12700	97	99	104	9	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					467	485		10.1016/j.jaci.2018.09.025	http://dx.doi.org/10.1016/j.jaci.2018.09.025			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30600099	Bronze			2022-12-18	WOS:000457718700003
J	Bousquet, J; Schunemann, HJ; Hellings, PW; Arnavielhe, S; Bachert, C; Bedbrook, A; Bergmann, KC; Bosnic-Anticevich, S; Brozek, J; Calderon, M; Canonica, GW; Casale, TB; Chavannes, NH; Cox, L; Chrystyn, H; Cruz, AA; Dahl, R; De Carlo, G; Demoly, P; Devillier, P; Dray, G; Fletcher, M; Fokkens, WJ; Fonseca, J; Gonzalez-Diaz, SN; Grouse, L; Keil, T; Kuna, P; Larenas-Linnemann, D; Carlsen, KCL; Meltzer, EO; Mullol, J; Muraro, A; Naclerio, RN; Palkonen, S; Papadopoulos, NG; Passalacqua, G; Price, D; Ryan, D; Samolinski, B; Scadding, GK; Sheikh, A; Spertini, F; Valiulis, A; Valovirta, E; Walker, S; Wickman, M; Yorgancioglu, A; Haahtela, T; Zuberbier, T				Bousquet, Jean; Schunemann, Holger J.; Hellings, Peter W.; Arnavielhe, Sylvie; Bachert, Claus; Bedbrook, Anna; Bergmann, Karl-Christian; Bosnic-Anticevich, Sinthia; Brozek, Jan; Calderon, Moises; Canonica, G. Walter; Casale, Thomas B.; Chavannes, Niels H.; Cox, Linda; Chrystyn, Henry; Cruz, Alvaro A.; Dahl, Ronald; De Carlo, Giuseppe; Demoly, Pascal; Devillier, Phillipe; Dray, Gerard; Fletcher, Monica; Fokkens, Wytske J.; Fonseca, Joao; Gonzalez-Diaz, Sandra N.; Grouse, Lawrence; Keil, Thomas; Kuna, Piotr; Larenas-Linnemann, Desiree; Carlsen, Karin C. Lodrup; Meltzer, Eli O.; Mullol, Jaoquim; Muraro, Antonella; Naclerio, Robert N.; Palkonen, Susanna; Papadopoulos, Nikolaos G.; Passalacqua, Giovanni; Price, David; Ryan, Dermot; Samolinski, Boleslaw; Scadding, Glenis K.; Sheikh, Aziz; Spertini, Francois; Valiulis, Arunas; Valovirta, Erkka; Walker, Samantha; Wickman, Magnus; Yorgancioglu, Arzu; Haahtela, Tari; Zuberbier, Torsten		MASK Study Grp	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; conjunctivitis; Allergic Rhinitis and its Impact on Asthma; MACVIA-LR; information and communication technology; clinical decision support system	VISUAL ANALOG SCALE; FUROATE NASAL SPRAY; QUALITY-OF-LIFE; EUROPEAN INNOVATION PARTNERSHIP; IMPORTANT DIFFERENCE; DOUBLE-BLIND; INTRANASAL THERAPY; MOMETASONE FUROATE; OCULAR SYMPTOMS; ASTHMA	The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. Allergen exposure and the resulting symptoms vary, and treatment adjustment is required. Clinical decision support systems (CDSSs) might be beneficial for the assessment of disease control. CDSSs should be based on the best evidence and algorithms to aid patients and health care professionals to jointly determine treatment and its step-up or step-down strategy depending on AR control. Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR [fighting chronic diseases for active and healthy ageing]), one of the reference sites of the European Innovation Partnership on Active and Healthy Ageing, has initiated an allergy sentinel network (the MACVIA-ARIA Sentinel Network). A CDSS is currently being developed to optimize AR control. An algorithm developed by consensus is presented in this article. This algorithm should be confirmed by appropriate trials.	[Bousquet, Jean] Univ Hosp, Montpellier, France; [Bousquet, Jean; Bedbrook, Anna] European Innovat Partnership Act & Hlth Ageing Re, MAlad Chron VIeillissement Actif Languedoc Roussi, MACVIA LR, Montpellier, France; [Bousquet, Jean] INSERM, VIMA Ageing & Chron Dis Epidemiol & Publ Hlth App, Paris, France; [Bousquet, Jean] Univ Versailles St Quentin En Yvelines, Versailles, France; [Schunemann, Holger J.; Brozek, Jan] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada; [Schunemann, Holger J.; Brozek, Jan] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada; [Hellings, Peter W.] Katholieke Univ Leuven, Dept Microbiol & Immunol, Clin Immunol Lab, Leuven, Belgium; [Arnavielhe, Sylvie] Kyomed, Montpellier, France; [Bachert, Claus] Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium; [Bergmann, Karl-Christian; Zuberbier, Torsten] Charite Univ Med Berlin, Dept Dermatol, Allergy Ctr Charite, Berlin, Germany; [Bergmann, Karl-Christian; Zuberbier, Torsten] Global Allergy & Asthma European Network GA2LEN, Berlin, Germany; [Bosnic-Anticevich, Sinthia] Univ Sydney, Woolcock Inst Med Res, Glebe, NSW, Australia; [Bosnic-Anticevich, Sinthia] Sydney Local Hlth Dist, Glebe, NSW, Australia; [Calderon, Moises] Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp NHS, London, England; [Canonica, G. Walter; Passalacqua, Giovanni] Univ Genoa, IRCCS AOU San Martino IST, DIMI, Allergy & Resp Dis Clin, Genoa, Italy; [Casale, Thomas B.] Univ S Florida, Div Allergy Immunol, Tampa, FL USA; [Chavannes, Niels H.] Leiden Univ Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands; [Cox, Linda] Nova Southeastern Univ, Dept Med, Davie, FL USA; [Chrystyn, Henry] RiRL, Cambridge, England; [Cruz, Alvaro A.] Univ Fed Bahia, ProAR Nucleo Excelencia Asma, BR-41170290 Salvador, BA, Brazil; [Cruz, Alvaro A.; Yorgancioglu, Arzu] GARD Execut Comm, Salvador, Brazil; [Dahl, Ronald] Odense Univ Hosp, Dept Dermatol, Odense, Denmark; [Dahl, Ronald] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [De Carlo, Giuseppe; Palkonen, Susanna] EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium; [Demoly, Pascal] EPAR U707 INSERM, Paris, France; [Demoly, Pascal] Univ Paris 06, EPAR UMR S UPMC, Paris, France; [Demoly, Pascal] Montpellier Univ Hosp, Dept Resp Dis, Montpellier, France; [Devillier, Phillipe] Suresnes Univ Versailles St Quentin, Hop Foch, Lab Pharmacol Resp UPRES EA220, Suresnes, France; [Dray, Gerard] Ecole Mines, Ales, France; [Fletcher, Monica] Educ Hlth, Warwick, England; [Fokkens, Wytske J.] Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands; [Fonseca, Joao] Univ Porto, Ctr Res Hlth Technol & Informat Syst CINTESIS, Porto, Portugal; [Fonseca, Joao] Inst CUF Porto, Allergy Unit, Porto, Portugal; [Fonseca, Joao] Hosp CUF Porto, Porto, Portugal; [Fonseca, Joao] Univ Porto, Fac Med, Hlth Informat & Decis Sci Dept CIDES, Porto, Portugal; [Fonseca, Joao] Univ Porto, Fac Med, Porto, Portugal; [Gonzalez-Diaz, Sandra N.] Univ Autonoma Nuevo Leon, San Nicolas De Los Garza, NL, Mexico; [Grouse, Lawrence] Univ Washington, Sch Med, Fac Dept Neurol, Seattle, WA USA; [Keil, Thomas] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Kuna, Piotr] Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland; [Larenas-Linnemann, Desiree] Hosp Med Sur, Clin Alergia Asma Pediat, Mexico City, DF, Mexico; [Carlsen, Karin C. Lodrup] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, Karin C. Lodrup] Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway; [Meltzer, Eli O.] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; [Mullol, Jaoquim] IDIBAPS, Hosp Clin, Unitat Rinol & Clin Olfacte, Clin & Expt Resp Immunoallergy,Serv ORL, Barcelona, Spain; [Muraro, Antonella] Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy; [Naclerio, Robert N.] Univ Chicago, Med Ctr, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA; [Naclerio, Robert N.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Papadopoulos, Nikolaos G.] Univ Manchester, Royal Manchester Childrens Hosp, Inst Human Dev, Ctr Pediat & Child Hlth, Manchester M13 9PL, Lancs, England; [Papadopoulos, Nikolaos G.] Univ Athens, Athens Gen Childrens Hosp P&A Kyriakou, Dept Allergy, Pediat Clin 2, GR-10679 Athens, Greece; [Price, David] Univ Aberdeen, Acad Ctr Primary Care, Aberdeen AB9 1FX, Scotland; [Price, David] Res Real Life, Cambridge, England; [Ryan, Dermot] Univ Edinburgh, Allergy & Resp Res Grp, Edinburgh EH8 9YL, Midlothian, Scotland; [Samolinski, Boleslaw] Med Univ Warsaw, Dept Prevent Envinronm Hazards & Allergol, Warsaw, Poland; [Scadding, Glenis K.] UCL, Royal Natl TNE Hosp, London WC1E 6BT, England; [Sheikh, Aziz] Univ Edinburgh, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh EH8 9YL, Midlothian, Scotland; [Spertini, Francois] CHU Vaudois, Serv Immunol & Allergie, Lausanne, Switzerland; [Valiulis, Arunas] Vilnius Univ Clin Childrens Dis, Vilnius, Lithuania; [Valovirta, Erkka] Univ Turku, Dept Lung Dis & Clin Allergol, SF-20500 Turku, Finland; [Walker, Samantha] Asthma UK, London, England; [Wickman, Magnus] Sachs Childrens Hosp, Stockholm, Sweden; [Wickman, Magnus] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Yorgancioglu, Arzu] Celal Bayar Univ Manisa, Dept Pulmonol, Uncubozkoy Manisa, Turkey; [Haahtela, Tari] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; McMaster University; McMaster University; KU Leuven; Ghent University; Ghent University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Sydney; Woolcock Institute of Medical Research; Imperial College London; Royal Brompton Hospital; University of Genoa; IRCCS AOU San Martino IST; State University System of Florida; University of South Florida; Leiden University; Leiden University Medical Center (LUMC); Nova Southeastern University; Universidade Federal da Bahia; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite de Montpellier; CHU de Montpellier; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; IMT - Institut Mines-Telecom; IMT Mines Ales; University of Amsterdam; Academic Medical Center Amsterdam; Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidad Autonoma de Nuevo Leon; University of Washington; University of Washington Seattle; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; Medical University Lodz; Tecnologico de Monterrey; University of Oslo; University of Oslo; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Chicago; University of Chicago Medical Center; University of Chicago; Royal Manchester Children's Hospital; University of Manchester; National & Kapodistrian University of Athens; University of Aberdeen; University of Edinburgh; Medical University of Warsaw; University of London; University College London; University of Edinburgh; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Turku; Karolinska Institutet; University of Helsinki; Helsinki University Central Hospital	Bousquet, J (corresponding author), CHRU Arnaud Villeneuve, Dept Pneumol, 371 Ave Doyen Gaston, F-34295 Montpellier 5, France.	jean.bousquet@orange.fr	González-Díaz, Sandra Nora/H-3271-2018; Bergmann, Karl-Christian/AAA-4104-2019; Dray, Gerard/ACO-1836-2022; Ciprandi, Giorgio/G-7462-2012; Annesi-Maesano, Isabella/D-9173-2016; Rigla, Francisco Ródenas/L-5293-2014; Namazova-Baranova, Leyla/C-9485-2019; canonica, giorgio walter/ABF-2037-2020; Wagenman, Martin/B-2524-2012; Lambrecht, Bart N/K-2484-2014; Yorgancioglu, Arzu/AAC-7548-2020; Khaitov, Musa R/L-3369-2017; Demoly, Pascal/Y-9938-2019; Panzner, Petr/I-7034-2017; Custovic, Adnan/A-2435-2012; Chavannes, Niels/F-1148-2011; Khaitov, Musa/AAC-1516-2021; Caimmi, Davide/AAA-1277-2019; Rabe, Klaus F./AAW-6296-2021; Cox, Linda/AAP-1697-2021; Cruz, Alvaro A/I-1676-2012; Gemicioglu, Bilun/AAH-6927-2019; Price, David/H-2837-2019; Sunyer, Jordi/G-6909-2014; Bonini, Sergio/T-6594-2019; Barbara, C./AAF-3397-2020; DINH-XUAN, Anh Tuan/A-9691-2008; Hellings, Peter W/I-4068-2018; Bousquet, Jean/O-4221-2019; Nadif, Rachel/R-2876-2016; Fiocchi, Alessandro/K-9235-2016; Bosnic-Anticevich, Sinthia/AAD-2526-2021; Humbert, Marc/AAC-8459-2019; de Sousa, Jaime Correia/H-5607-2015; Fokkens, Wytske WJ/ABF-2185-2020; Romano, Antonino/D-3102-2017; Briggs, Andrew/ABA-9009-2020; Viegi, Giovanni/K-2746-2016; Kaidashev, Igor/L-2606-2019; Bachert, Claus/J-8825-2012; Kvedarienė, Violeta/GON-7937-2022; N.G., Papadopoulos/L-8670-2013; Masjedi, Mohammad Reza/J-9776-2017; molimard, mathieu/T-2762-2019; Fonseca, João A./B-7562-2008; Yusuf, M Osman/AAI-1142-2020; Ryan, Dermot/AAJ-2329-2021; O'Hehir, Robyn/H-3627-2011; Cucalin, Aleksandr/P-5678-2018; Namazova-Baranova, Leyla/C-9485-2019; Heinrich, Joachim/N-1720-2013; Bindslev-Jensen, Carsten/H-1877-2011; Forastiere, Francesco/J-9067-2016	González-Díaz, Sandra Nora/0000-0002-3612-0042; Ciprandi, Giorgio/0000-0001-7016-8421; Annesi-Maesano, Isabella/0000-0002-6340-9300; Rigla, Francisco Ródenas/0000-0003-3264-4735; Namazova-Baranova, Leyla/0000-0002-2209-7531; canonica, giorgio walter/0000-0001-8467-2557; Wagenman, Martin/0000-0002-9734-0241; Lambrecht, Bart N/0000-0003-4376-6834; Khaitov, Musa R/0000-0003-4961-9640; Demoly, Pascal/0000-0001-7827-7964; Panzner, Petr/0000-0002-1291-450X; Custovic, Adnan/0000-0001-5218-7071; Chavannes, Niels/0000-0002-8607-9199; Khaitov, Musa/0000-0003-4961-9640; Caimmi, Davide/0000-0003-4481-6194; Rabe, Klaus F./0000-0002-7020-1401; Cox, Linda/0000-0002-5258-6870; Cruz, Alvaro A/0000-0002-7403-3871; Gemicioglu, Bilun/0000-0001-5953-4881; Price, David/0000-0002-9728-9992; Sunyer, Jordi/0000-0002-2602-4110; Bonini, Sergio/0000-0003-0079-3031; Barbara, C./0000-0003-0915-4105; DINH-XUAN, Anh Tuan/0000-0001-8651-5176; Hellings, Peter W/0000-0001-6898-688X; Nadif, Rachel/0000-0003-4938-9339; Fiocchi, Alessandro/0000-0002-2549-0523; Bosnic-Anticevich, Sinthia/0000-0001-5077-8329; Humbert, Marc/0000-0003-0703-2892; de Sousa, Jaime Correia/0000-0001-6459-7908; Romano, Antonino/0000-0001-9742-9898; Briggs, Andrew/0000-0002-0777-1997; Viegi, Giovanni/0000-0002-1855-4410; Kaidashev, Igor/0000-0002-4708-0859; Kvedarienė, Violeta/0000-0002-6119-211X; N.G., Papadopoulos/0000-0002-4448-3468; Masjedi, Mohammad Reza/0000-0002-6871-382X; molimard, mathieu/0000-0002-4346-8346; Fonseca, João A./0000-0002-0887-8796; Yusuf, M Osman/0000-0002-8067-1204; Ryan, Dermot/0000-0002-4115-7376; Todo-Bom, Ana/0000-0002-1850-6689; Larenas Linnemann, Desiree/0000-0002-5713-5331; stelmach, rafael/0000-0002-5132-1934; Zhang, Luo/0000-0002-0910-9884; TRIGGIANI, MASSIMO/0000-0001-7318-2093; Raciborski, Filip/0000-0003-0562-0260; brightling, chris/0000-0002-9345-4903; O'Hehir, Robyn/0000-0002-3489-7595; BONINI, Matteo/0000-0002-3042-0765; yorgancioglu, arzu/0000-0002-4032-0944; Howarth, Peter/0000-0003-0619-7927; Dray, Gerard/0000-0003-1525-5682; Kuna, Piotr/0000-0003-2401-0070; Zar, Heather/0000-0002-9046-759X; Cucalin, Aleksandr/0000-0002-6808-5528; Sheikh, Aziz/0000-0001-7022-3056; Thijs, Carel/0000-0001-6646-5458; Valenta, Rudolf/0000-0001-5944-3365; Park, Hae-Sim/0000-0003-2614-0303; Maurer, Marcus/0000-0002-4121-481X; Burney, Peter/0000-0001-8635-5678; Yiallouros, Panayiotis/0000-0002-8339-9285; Zidarn, Mihaela/0000-0003-0515-5207; Johnston, Sebastian/0000-0003-3009-9200; El-Gamal, Yehia/0000-0002-8177-4520; Kleine-Tebbe, Joerg/0000-0002-2862-7353; Baigenzhin, Abay/0000-0002-7703-5004; Ivancevich, Juan Carlos/0000-0001-8713-6258; Namazova-Baranova, Leyla/0000-0002-7902-6427; Lau, Susanne/0000-0002-5189-4265; Heinrich, Joachim/0000-0002-9620-1629; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Schunemann, Holger/0000-0003-3211-8479; Zuberbier, Torsten/0000-0002-1466-8875; Popov, Todor/0000-0001-5052-5866; momas, isabelle/0000-0003-4344-3787; Bergmann, Karl-Christian/0000-0002-0306-9922; Pavord, Ian/0000-0002-4288-5973; Forastiere, Francesco/0000-0002-9162-5684	Actelion; Almirall; Meda; Merck; Merck Sharp Dohme; Novartis; Sanofi Aventis; Takeda; Teva; Uriach; AstraZeneca; Chiesi; GlaxoSmithKline; OM Pharma; Sanofi-Aventis; Schering- Plough; Research in Real Life; Mundipharma; ALK-Abello; Allergopharma; Allergy Therapeutics; Anallergo; Hal; Lofarma; Stallergenes; Thermo Fisher; Genentech; Circassia and Biomay; Boehringer Ingelheim; Cipla; Sanofi Pasteur MSD; Boehringer Ingelheim International; Stallergenes France; Air Liquide Sante International; Circassia; ThermoFisher Scientific; DBV; Menarini; MSD; Napp; Fundacao Ciencia e Tecnologia and Fundacao Calouste Gulbenkian; Aerocrine; Vitoria; European Union project MeDALL; European Union project iFAAM; Adamed; Pfizer; Polpharma; Lekam; Bayer; Celon Pharma; FAES; Sanofi; UCB; Senosiain; Carnot; Glenmark; EU MedALL; National and regional public funding applications; Church Dwight; Greer; Johnson Johnson; Mylan; Regeneron/Sanofi; Hartington Pharmaceuticals; Pierre-Fabre; Nestle; Abbvie; Amgen; UK National Health Service; British Lung Foundation; AKL Ltd; Respiratory Effectiveness Group; Zentiva; Kyorin; SkyePharma; Orion; European Union Social Fund; Lithuanian Ministry of Health; European Academy of Pediatrics; Microtest Dx; Ansell; Bayer Schering; Fujisawa; Henkel; Kryolan; Leti; Procter Gamble; Ranbaxy; Schering Plough; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	Actelion; Almirall(Almirall); Meda; Merck(Merck & Company); Merck Sharp Dohme(Merck & Company); Novartis(Novartis); Sanofi Aventis(Sanofi-Aventis); Takeda(Takeda Pharmaceutical Company Ltd); Teva(Teva Pharmaceutical Industries); Uriach; AstraZeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc); GlaxoSmithKline(GlaxoSmithKline); OM Pharma; Sanofi-Aventis(Sanofi-Aventis); Schering- Plough(Merck & CompanySchering Plough Corporation); Research in Real Life; Mundipharma; ALK-Abello; Allergopharma; Allergy Therapeutics; Anallergo; Hal(Horticulture Australia Limited); Lofarma; Stallergenes; Thermo Fisher; Genentech(Roche HoldingGenentech); Circassia and Biomay; Boehringer Ingelheim(Boehringer Ingelheim); Cipla; Sanofi Pasteur MSD; Boehringer Ingelheim International(Boehringer Ingelheim); Stallergenes France; Air Liquide Sante International; Circassia; ThermoFisher Scientific; DBV; Menarini(Menarini Group); MSD; Napp; Fundacao Ciencia e Tecnologia and Fundacao Calouste Gulbenkian; Aerocrine; Vitoria; European Union project MeDALL; European Union project iFAAM; Adamed; Pfizer(Pfizer); Polpharma; Lekam; Bayer(Bayer AG); Celon Pharma(Dexcel Pharma); FAES; Sanofi; UCB(UCB Pharma SA); Senosiain; Carnot; Glenmark; EU MedALL; National and regional public funding applications; Church Dwight; Greer; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Mylan; Regeneron/Sanofi(Regeneron); Hartington Pharmaceuticals; Pierre-Fabre; Nestle(Nestle SA); Abbvie(AbbVie); Amgen(Amgen); UK National Health Service; British Lung Foundation; AKL Ltd; Respiratory Effectiveness Group; Zentiva; Kyorin; SkyePharma; Orion; European Union Social Fund(European Commission); Lithuanian Ministry of Health; European Academy of Pediatrics; Microtest Dx; Ansell; Bayer Schering(Bayer AG); Fujisawa; Henkel; Kryolan; Leti; Procter Gamble(Procter & Gamble); Ranbaxy; Schering Plough(Merck & CompanySchering Plough Corporation); Asthma UK	J. Bousquet has received consulting fees from Actelion, Almirall, Meda, Merck, Merck Sharp Dohme, Novartis, Sanofi Aventis, Takeda, Teva, and Uriach; has received fees for participation in review activities from Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Meda, Merck, Merck Sharp Dohme, Novartis, OM Pharma, Sanofi-Aventis, Schering- Plough, Takeda, Teva, and Uriach; has received lecture fees from Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Meda, Merck, Merck Sharp Dohme, Novartis, OM Pharma, Sanofi- Aventis, Schering-Plough, Takeda, Teva, and Uriach; and has received payment for development of educational presentations from Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Meda, Merck, Merck Sharp Dohme, Novartis, OM Pharma, Sanofi- Aventis, Schering-Plough, Takeda, Teva, and Uriach. K.-C. Bergmann has received lecture fees from Novartis. S. Bosnic-Anticevich is a member of the Teva Pharmaceuticals Devices International Key Experts Panel, has received research support from Research in Real Life, and has received lecture fees and payment for developing educational presentations from Teva and Mundipharma. G. W. Canonica is on the Board for and has received consultancy and lecture fees from ALK-Abello, Allergopharma, Allergy Therapeutics, Anallergo, Hal, Lofarma, Stallergenes, and Thermo Fisher. T. B. Casale is Executive Vice President of the American Academy of Allergy, Asthma & Immunology (AAAAI). L. Cox has received consultancy fees from Genentech and Allergopharma; has received fees for participation in review activities from Circassia and Biomay; is on the ABAI Board; was on the AAAAI Board; and has received lecture fees from several regional, local, and state allergy meetings. A. A. Cruz is on the Meda Pharma Board, has received research support from GlaxoSmithKline, and has received lecture fees and travel support from Meda. R. Dahl has received lecture fees from Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, ALK-Abello, Cipla, Novartis, Meda, and Chiesi. G. De Carlo has received research support from Sanofi Pasteur MSD, Boehringer Ingelheim International, ALK-Abello, Almirall, Stallergenes France, Air Liquide Sante International, Novartis, GlaxoSmithKline, Mundipharma, and Chiesi. P. Demoly has received consultancy fees from ALK-Abello, Circassia, Stallergenes, ThermoFisher Scientific, DBV, and Chiesi and has received lecture fees from Menarini, AstraZeneca, GlaxoSmithKline, Allergopharma, and MSD. P. Devillier is on the Meda Pharma Board; has received consultancy fees from Stallergenes, ALK-Abello, and GlaxoSmithKline; has received lecture fees from Stallergenes and ALK-Abello; has received payment for manuscript preparation from Stallergenes; and has received travel support from Stallergenes and Meda. M. Fletcher has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Napp, and Teva and has received lecture fees from AstraZeneca, Boehringer Ingelheim, Napp,Novartis, and Teva. W. J. Fokkens has received research support from Meda and has received payment for developing a webcast on treatment of rhinitis for general practitioners. J. Fonseca is on the Boehringer Ingelheim and Novartis Boards; has received consultancy fees from Novartis; has received research support from Fundacao Ciencia e Tecnologia and Fundacao Calouste Gulbenkian; has received lecture fees from AstraZeneca, Aerocrine, Menarini, GlaxoSmithKline, MSD, and Vitoria; and has received travel support from AstraZeneca and Novartis. T. Keil has received research support from the European Union projects MeDALL and iFAAM. P.; Kuna has received lecture fees from Adamed, Allergopharma, Almirall, AstraZeneca, GlaxoSmithKline, Hal, Meda, Pfizer, Polpharma, Stallergenes, Lekam, and Bayer and has received lecture fees and is on the advisory board from Boehringer Ingelheim, Celon Pharma, Chiesi, FAES, MSD, Novartis, Polpharma, and Teva. D. Larenas-Linnemann has received consultancy fees from Boehringer Ingelheim, Meda, Pfizer, Mit Pharma, and Chiesi; has received research support from AstraZeneca, MSD, Novartis, Sanofi, UCB, GlaxoSmithKline, Pfizer, MEDA, TEVA, Senosiain, Carnot; has received lecture fees from AstraZeneca, MSD, Movartis, Sanofi, Pfizer, and Meda; has received payment for development of educational presentations from Glenmark; and has received travel support from ALK-Abello. K. C. Lodrup Carlsen has received research and travel support from EU MedALL, is on the Sanofi advisory board, has received research support from National and regional public funding applications. E. O. Meltzer has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Church & Dwight, GlaxoSmithKline, Greer, Johnson & Johnson, Meda, Mylan, Regeneron/Sanofi, and Teva; is self-employed; has received lecture fees from Greer, Meda, Merck, Mylan, Takeda, and Teva; and has received payment for developing educational presentations from Glenmark. J. Mullol is on the boards for Uriach, Meda, FAES, ALK-Abello, and Sanofi; has received research support from GlaxoSmithKline, Uriach, FAES, and Meda; and has received lecture fees from Uriach, Hartington Pharmaceuticals, Novartis, FAES, Menarini, MSD, Pierre-Fabre, and UCB. A. Muraro has received consultancy fees from Meda. R. N. Naclerio is on the Merck and Sanofi allergy advisory boards, has received consultancy fees from Teva, is employed by the University of Chicago, and has received research support from Meda. S. Palkonen is on the GlaxoSmithKline European Health Advisory Board; has received research support from Air Liquide Sante International, ALK-Abello, Almirall, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Chiesi, Mundipharma, Sanofi-Pasteur, and Stallergenes; has received travel support from Novartis; and declares that she regularly has dialogue with the funding partners listed above, who give unrestricted educational grants to the patient organization, EFA, for which she works as a Director. N. Papadopoulos has received research support from GlaxoSmithKline, Nestle, and Merck; has received payment for developing educational presentations from Abbvie, Sanofi, Menarini, and Meda; has received consultancy fees from GlaxoSmithKline, Abbvie, Novartis, Menarini, Meda, and ALK-Abello; and has received lecture fees from Allergopharma, Uriach, GlaxoSmithKline, Stallergenes, and MSD. D.; Price is on the boards for Aerocrine, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva; has received consultancy fees from Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, and Teva; has received research support from the UK National Health Service, British Lung Foundation, Aerocrine, AKL Ltd, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Eli Lilly, GlaxoSmithKline, Meda, Merck, Mundipharma, Napp, Novartis, Orion, Pfizer, Respiratory Effectiveness Group, Takeda, Teva, Zentiva; has received lecture fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, SkyePharma, Takeda, and Teva; has received payment for manuscript preparation from Mundipharma and Teva; has a patent with AKL Ltd; has received payment for developing educational presentations from GlaxoSmithKline and Novartis; has stock in AKL Ltd; has received travel support from Aerocrine, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva; has received funding for patient enrolment or completion of research from Almirall, Chiesi, Teva, and Zentiva; has served as a peer reviewer for grant committees for the Medical Research Council, Efficacy and Mechanism Evaluation Programme, and HTA; and is 80% owner of Research in Real Life, which receives unrestricted funding for investigator-initiated studies from Aerocrine, AKL Ltd, Almirall, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, and Zentiva. D. Ryan is on the Boards for Stallergenes and Uriach; has received consultancy fees from Meda; is employed by Optimum Patient Care and University of Edinburgh; has received lecture fees from Meda, Chiesi, Teva, AstraZeneca, and Boehringer Ingelheim; has received payment for developing educational presentation from Meda; and is Chairman of the European Academy of Allergy and Clinical Immunology (EAACI) Primary Care Interest Group. A. Valiulis is a board member without financial interest of the nonprofit organizations the European Academy of Paediatrics, European Paediatrc Association, European Confederation of Primary Care Paediatricians, Lithuanian Paediatric Society, and Lithuanian Paediatric Respiratory Society; has received research support from European Union Social Fund and Lithuanian Ministry of Health; has received travel support from the European Academy of Pediatrics; is Chairman of Executive Board of IPOKRaTES Lithuania Fund. E. Valovirta has received travel support from Stallergenes. M. Wickman has received research support and lecture fees from Thermo Fisher, has received consultancy fees from Thermo Fisher and Microtest Dx, and has received payment for developing educational presentations from Stallergenes. T. Zuberbier has received consultancy fees from Ansell, Bayer Schering, DST, FAES, Fujisawa, HAL, Henkel, Kryolan, Leti, Menarini, Merck, MSD, Novartis, Procter & Gamble, Ranbaxy, Sanofi-Aventis, Schering Plough, Stallergenes, Takeda, and UCB; is on the German Society for Allergy and Clinical Immunology Scientific Advisory Board; is head of the European Centre for Allergy Research Foundation; is a World Health Organization Initiative Allergic Rhinitis and its Impact on Asthma committee member; is a member of the World Allergy Organization Communications Council; and is Secretary General of the Global Allergy and Asthma European Network. The rest of the authors declare that they have no relevant conflicts of interest.	Anolik R, 2008, ANN ALLERG ASTHMA IM, V100, P264, DOI 10.1016/S1081-1206(10)60452-8; Auffinger BM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067408; Azevedo P, 2013, PRIM CARE RESP J, V22, P112, DOI 10.4104/pcrj.2013.00012; Baena-Cagnani CE, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0057-0; Berlin A, 2006, J BIOMED INFORM, V39, P656, DOI 10.1016/j.jbi.2005.12.003; Berner ES, 2009, CLIN DECISION SUPPOR; Bielory L, 2011, ALLERGY, V66, P686, DOI 10.1111/j.1398-9995.2010.02543.x; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Bird SB, 2001, ANN EMERG MED, V38, P639, DOI 10.1067/mem.2001.118012; Bourdel N, 2015, HUM REPROD UPDATE, V21, P136, DOI 10.1093/humupd/dmu046; Bourret Rodolphe, 2013, World Hosp Health Serv, V49, P25; Bousquet J, 2015, ALLERGY, V70, P1372, DOI 10.1111/all.12686; Bousquet J, 2014, EUR RESPIR J, V44, P304, DOI 10.1183/09031936.00014614; Bousquet J, 2012, INT ARCH ALLERGY IMM, V158, P216, DOI 10.1159/000332924; Bousquet J, 2009, ALLERGY, V64, P1516, DOI 10.1111/j.1398-9995.2009.02115.x; Bousquet J, 2016, EUR RESPIR J, V47, P1028, DOI 10.1183/13993003.01856-2015; Bousquet J, 2010, INT ARCH ALLERGY IMM, V153, P395, DOI 10.1159/000316351; Bousquet J, 2013, PRESSE MED, V42, P1558, DOI 10.1016/j.lpm.2013.11.002; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Bousquet PJ, 2007, INT ARCH ALLERGY IMM, V143, P163, DOI 10.1159/000099307; Bousquet PJ, 2010, J ALLERGY CLIN IMMUN, V126, P666, DOI 10.1016/j.jaci.2010.06.034; Bousquet PJ, 2013, INT ARCH ALLERGY IMM, V160, P393, DOI 10.1159/000342991; Bousquet PJ, 2009, J ALLERGY CLIN IMMUN, V123, P1349, DOI 10.1016/j.jaci.2009.02.033; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Carr W, 2012, J ALLERGY CLIN IMMUN, V129, P1282, DOI 10.1016/j.jaci.2012.01.077; Castillo M, 2015, COCHRANE DB SYST REV, V6; Church MK, 2010, ALLERGY, V65, P459, DOI 10.1111/j.1398-9995.2009.02325.x; Ciprandi G, 2011, CURR MED RES OPIN, V27, P1005, DOI 10.1185/03007995.2011.559580; del Cuvillo A, 2010, RHINOLOGY, V48, P201, DOI 10.4193/Rhin09.099; DeLoach LJ, 1998, ANESTH ANALG, V86, P102, DOI 10.1097/00000539-199801000-00020; Demoly P, 2013, CLIN EXP ALLERGY, V43, P881, DOI 10.1111/cea.12121; Demoly P, 2011, CLIN EXP ALLERGY, V41, P860, DOI 10.1111/j.1365-2222.2011.03734.x; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Demoly P, 2015, ALLERGY ASTHMA CL IM, V11, DOI 10.1186/s13223-015-0073-1; Demoly P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-29; Devillier P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-71; Emshoff R, 2011, PAIN, V152, P2277, DOI 10.1016/j.pain.2011.06.003; Esteitie R, 2010, ANN ALLERG ASTHMA IM, V105, P155, DOI 10.1016/j.anai.2010.05.017; Fokkens WJ, 2007, ALLERGY, V62, P1078, DOI 10.1111/j.1398-9995.2007.01522.x; Fonseca JA, 2010, ALLERGY, V65, P1042, DOI 10.1111/j.1398-9995.2009.02310.x; Frati F, 2014, MED SCI MONITOR, V20, P2151, DOI 10.12659/MSM.891206; Fromer LM, 2014, ALLERGY ASTHMA PROC, V35, P307, DOI 10.2500/aap.2014.35.3766; Gallagher EJ, 2002, AM J EMERG MED, V20, P287, DOI 10.1053/ajem.2002.33778; Gallagher EJ, 2001, ANN EMERG MED, V38, P633, DOI 10.1067/mem.2001.118863; Green Robin John, 2007, Prim Care Respir J, V16, P299; Hampel FC, 2010, ANN ALLERG ASTHMA IM, V105, P168, DOI 10.1016/j.anai.2010.06.008; Hellgren J, 2010, ALLERGY, V65, P776, DOI 10.1111/j.1398-9995.2009.02269.x; Hellings PW, 2013, ALLERGY, V68, P1, DOI 10.1111/all.12040; Hellings Peter W, 2012, Clin Transl Allergy, V2, P9; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Kelly AM, 1998, ACAD EMERG MED, V5, P1086, DOI 10.1111/j.1553-2712.1998.tb02667.x; Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205; Kenney P, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Kenney P, 2014, J ALLERGY CLIN IMMUN, V133, P1477, DOI 10.1016/j.jaci.2014.01.004; Kersten P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099485; Kersten P, 2012, J REHABIL MED, V44, P609, DOI 10.2340/16501977-0999; Khanna D, 2008, J RHEUMATOL, V35, P2339, DOI 10.3899/jrheum.080375; Klimek L, 2015, ALLERGY ASTHMA PROC, V36, P40, DOI 10.2500/aap.2015.36.3823; Lamb CE, 2006, CURR MED RES OPIN, V22, P1203, DOI 10.1185/030079906X112552; Larenas-Linnemann Desiree, 2014, Rev Alerg Mex, V61 Suppl 1, pS3; Larenas-Linnemann D, 2013, AM J RHINOL ALLERGY, V27, P495, DOI 10.2500/ajra.2013.27.3957; Lee JS, 2003, ACAD EMERG MED, V10, P1128, DOI 10.1197/S1069-6563(03)00372-5; Marple BF, 2007, OTOLARYNG HEAD NECK, V136, pS107, DOI 10.1016/j.otohns.2007.02.031; Matricardi PM, 2011, J ALLERGY CLIN IMMUN, V128, P791, DOI 10.1016/j.jaci.2011.03.049; Meltzer E, 2013, INT ARCH ALLERGY IMM, V161, P369, DOI 10.1159/000351404; Meltzer EO, 2013, ALLERGY ASTHMA PROC, V34, P301, DOI 10.2500/aap.2013.34.3676; Morais-Almeida M, 2013, ALLERGY, V68, P1278, DOI 10.1111/all.12221; Morais-Almeida M, 2013, ALLERGY, V68, P1150, DOI 10.1111/all.12207; Mullol J, 2015, ALLERGY, V70, P1, DOI 10.1111/all.12531; Mullol J, 2013, CLIN EXP ALLERGY, V43, P723, DOI 10.1111/cea.12081; Myles PS, 1999, ANESTH ANALG, V89, P1517, DOI 10.1097/00000539-199912000-00038; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nolte F, 2006, RESP MED, V100, P354, DOI 10.1016/j.rmed.2005.05.012; O'Byrne PM, 2010, EUR RESPIR J, V36, P269, DOI 10.1183/09031936.00124009; Ohta K, 2011, ALLERGY, V66, P1287, DOI 10.1111/j.1398-9995.2011.02676.x; Ohta K, 2013, J ASTHMA, V50, P514, DOI 10.3109/02770903.2013.786726; Padjas A, 2014, J ALLERGY CLIN IMMUN, V133, P777, DOI 10.1016/j.jaci.2013.08.029; Patel M, 2013, EXPERT REV RESP MED, V7, P451, DOI 10.1586/17476348.2013.837777; Reddel HK, 2015, EUR RESPIR J, V46, P622, DOI 10.1183/13993003.00853-2015; Roberts G, 2013, ALLERGY, V68, P1102, DOI 10.1111/all.12235; Rouve S, 2010, RHINOLOGY, V48, P285, DOI [10.4193/Rhin09.208, 10.4193/Rhino09.208]; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P19, DOI 10.1111/j.1365-2222.2007.02888.x; Scadding GK, 2015, ARCH DIS CHILD, V100, P576, DOI 10.1136/archdischild-2014-306300; Schatz M, 2010, ANN ALLERG ASTHMA IM, V104, P118, DOI 10.1016/j.anai.2009.11.063; Seidman MD, 2015, OTOLARYNG HEAD NECK, V152, P197, DOI 10.1177/0194599814562166; Seidman MD, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599814561600; Shao J, 2014, AM J RHINOL ALLERGY, V28, P131, DOI 10.2500/ajra.2014.28.4006; Tatar EC, 2012, AM J RHINOL ALLERGY, V26, pE37, DOI 10.2500/ajra.2012.26.3750; Thomas A, 2011, J ALLERGY CLIN IMMUN, V128, P915, DOI 10.1016/j.jaci.2011.07.014; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Turner RR, 2013, ALLERGY ASTHMA PROC, V34, P551, DOI 10.2500/aap.2013.34.3715; Valovirta E, 2008, CURR OPIN ALLERGY CL, V8, P1, DOI 10.1097/ACI.0b013e3282f3f42f; van der Leeuw S, 2015, NPJ PRIM CARE RESP M, V25, DOI 10.1038/npjpcrm.2014.107; Virchow J C, 2011, J Med Econ, V14, P305, DOI 10.3111/13696998.2011.576039; Vuurman EFPM, 2014, ALLERGY, V69, P906, DOI 10.1111/all.12418; Walker S, 2007, J ALLERGY CLIN IMMUN, V120, P381, DOI 10.1016/j.jaci.2007.03.034; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Wang C, 2015, J ALLERGY CLIN IMMUN, V135; Wei HQ, 2013, INT J MED SCI, V10, P1914, DOI 10.7150/ijms.7117; Zicari AM, 2013, CURR MED RES OPIN, V29, P415, DOI 10.1185/03007995.2013.779238; Zuberbier T, 2014, ALLERGY, V69, P1275, DOI 10.1111/all.12470	103	99	113	2	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					367	+		10.1016/j.jaci.2016.03.025	http://dx.doi.org/10.1016/j.jaci.2016.03.025			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27260321	Green Submitted, Green Accepted, hybrid, Green Published			2022-12-18	WOS:000380835800005
J	Saitoh, T; Akira, S				Saitoh, Tatsuya; Akira, Shizuo			Regulation of inflammasomes by autophagy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autophagy; host defense; inflammasome; inflammatory disorders; innate immunity; macrophages; organelle; pattern recognition receptors; reactive oxygen species; signal transduction	GENOME-WIDE ASSOCIATION; NLRP3 INFLAMMASOME; INNATE IMMUNITY; IL-1-BETA PRODUCTION; SELECTIVE AUTOPHAGY; NALP3 INFLAMMASOME; CROHN-DISEASE; GENE ATG16L1; ACTIVATION; RECOGNITION	Inflammasomes detect pathogen-associated molecular patterns to induce inflammatory innate immune responses and play a key role in host defense against infectious agents. However, inflammasomes are often wrongly activated by metabolites, amyloids, and environmental irritants. This induces massive inflammation, causing severe tissue damage, and results in the development of inflammatory diseases. Hence cellular machineries regulating both "activation'' and "inactivation'' of inflammasomes are definitely important. Recent studies have shown that autophagy, an intracellular degradation system associated with maintenance of cellular homeostasis, plays a key role in inflammasome inactivation. Notably, autophagy deficiency caused by gene mutation disrupts organelle elimination and thus induces aberrant activation of inflammasomes, leading to severe tissue damage. Here we review recent findings regarding the involvement of autophagy in the regulation of inflammasome activation and development of inflammatory disorders.	[Saitoh, Tatsuya] Univ Tokushima, Inst Enzyme Res, Dept Inflammat Biol, Tokushima 7708503, Japan; [Akira, Shizuo] Osaka Univ, World Premier Int Res Ctr, Immunol Frontier Res Ctr, Host Def Lab, Suita, Osaka 565, Japan; [Akira, Shizuo] Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Suita, Osaka 565, Japan	Tokushima University; Osaka University; Osaka University	Saitoh, T (corresponding author), Univ Tokushima, Inst Enzyme Res, Dept Inflammat Biol, Tokushima 7708503, Japan.	saitohtatsuya@tokushima-u.ac.jp	Akira, Shizuo/C-3134-2009		Japan Society for the Promotion of Science KAKENHI [15H01380, 26111514, 26713005]; Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology; Japan Foundation for Pediatric Research; LOTTE Foundation; Takeda Science Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Naito Foundation; Tokyo Biochemical Research Foundation	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology(Japan Agency for Medical Research and Development (AMED)); Japan Foundation for Pediatric Research; LOTTE Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Mochida Memorial Foundation for Medical and Pharmaceutical Research; Naito Foundation(Naito Memorial Foundation); Tokyo Biochemical Research Foundation	Supported in part by the Japan Society for the Promotion of Science KAKENHI (grant nos. 15H01380, 26111514, and 26713005); the Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology; a research grant of the Japan Foundation for Pediatric Research; a research grant of the LOTTE Foundation; a research grant of the Takeda Science Foundation; a research grant of the Mochida Memorial Foundation for Medical and Pharmaceutical Research; a research grant of the Naito Foundation; and a research grant of the Tokyo Biochemical Research Foundation (all to T.S.).	Abderrazak A, 2015, CIRCULATION, V131, P1061, DOI 10.1161/CIRCULATIONAHA.114.013730; Bronner DN, 2015, IMMUNITY, V43, P451, DOI 10.1016/j.immuni.2015.08.008; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; CLARK SL, 1957, J BIOPHYS BIOCHEM CY, V3, P349, DOI 10.1083/jcb.3.3.349; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398; Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Jounai N, 2007, P NATL ACAD SCI USA, V104, P14050, DOI 10.1073/pnas.0704014104; Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017; Khaminets A, 2016, TRENDS CELL BIOL, V26, P6, DOI 10.1016/j.tcb.2015.08.010; Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Konno H, 2013, CELL, V155, P688, DOI 10.1016/j.cell.2013.09.049; Ktistakis NT, 2016, TRENDS CELL BIOL; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Lassen KG, 2014, P NATL ACAD SCI USA, V111, P7741, DOI 10.1073/pnas.1407001111; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880; Lei Y, 2012, IMMUNITY, V36, P933, DOI 10.1016/j.immuni.2012.03.025; Liang QM, 2014, CELL HOST MICROBE, V15, P228, DOI 10.1016/j.chom.2014.01.009; Lim YM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5934; Lupfer C, 2013, NAT IMMUNOL, V14, P480, DOI 10.1038/ni.2563; Man SM, 2016, NAT REV IMMUNOL, V16, P7, DOI 10.1038/nri.2015.7; Meunier E, 2014, NATURE, V509, P366, DOI 10.1038/nature13157; Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Murthy A, 2014, NATURE, V506, P456, DOI 10.1038/nature13044; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; NOVIKOFF AB, 1959, J BIOPHYS BIOCHEM CY, V6, P136, DOI 10.1083/jcb.6.1.136; Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169; Ravindran R, 2016, NATURE, V531, P523, DOI 10.1038/nature17186; Razani B, 2012, CELL METAB, V15, P534, DOI 10.1016/j.cmet.2012.02.011; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; Shaw SY, 2013, ACS CHEM BIOL, V8, P2724, DOI 10.1021/cb400352d; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	51	99	103	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					28	36		10.1016/j.jaci.2016.05.009	http://dx.doi.org/10.1016/j.jaci.2016.05.009			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	27373323				2022-12-18	WOS:000379659100003
J	Hristova, M; Habibovic, A; Veith, C; Janssen-Heininger, YMW; Dixon, AE; Geiszt, M; van der Vliet, A				Hristova, Milena; Habibovic, Aida; Veith, Carmen; Janssen-Heininger, Yvonne M. W.; Dixon, Anne E.; Geiszt, Miklos; van der Vliet, Albert			Airway epithelial dual oxidase 1 mediates allergen-induced IL-33 secretion and activation of type 2 immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; redox signaling; H2O2; Src; epidermal growth factor receptor; IL-13	INNATE LYMPHOID-CELLS; HOUSE-DUST MITE; HYDROGEN-PEROXIDE; TH2 CYTOKINES; HOST-DEFENSE; ASTHMA; MIGRATION; MEMBERS; INFLAMMATION; INITIATION	Background: The IL-1 family member IL-33 plays a critical role in type 2 innate immune responses to allergens and is an important mediator of allergic asthma. The mechanisms by which allergens provoke epithelial IL-33 secretion are still poorly understood. Objective: Based on previous findings indicating involvement of the NADPH oxidase dual oxidase 1 (DUOX1) in epithelial wound responses, we explored the potential involvement of DUOX1 in allergen-induced IL-33 secretion and potential alterations in airways of asthmatic patients. Methods: Cultured human or murine airway epithelial cells or mice were subjected to acute challenge with Alternaria alternata or house dust mite, and secretion of IL-33 and activation of subsequent type 2 responses were determined. The role of DUOX1 was explored by using small interfering RNA approaches and DUOX1-deficient mice. Cultured nasal epithelial cells from healthy subjects or asthmatic patients were evaluated for DUOX1 expression and allergen-induced responses. Results: In vitro or in vivo allergen challenge resulted in rapid airway epithelial IL-33 secretion, which depended critically on DUOX1-mediated activation of epithelial epidermal growth factor receptor and the protease calpain-2 through a redox-dependent mechanism involving cysteine oxidation within epidermal growth factor receptor and the tyrosine kinase Src. Primary nasal epithelial cells from patients with allergic asthma were found to express increased DUOX1 and IL-33 levels and demonstrated enhanced IL-33 secretion in response to allergen challenge compared with values seen in nasal epithelial cells from nonasthmatic subjects. Conclusion: Our findings implicate epithelial DUOX1 as a pivotal mediator of IL-33-dependent activation of innate airway type 2 immune responses to common airborne allergens and indicate that enhanced DUOX1 expression and IL-33 secretion might present important contributing features of allergic asthma.	[Hristova, Milena; Habibovic, Aida; Veith, Carmen; Janssen-Heininger, Yvonne M. W.; van der Vliet, Albert] Univ Vermont, Dept Pathol & Lab Med, Vermont Lung Ctr, Burlington, VT 05405 USA; [Dixon, Anne E.] Univ Vermont, Dept Med, Vermont Lung Ctr, Burlington, VT 05405 USA; [Geiszt, Miklos] Semmelweis Univ, Dept Physiol, H-1085 Budapest, Hungary; [Geiszt, Miklos] Semmelweis Univ, Lendulet Peroxidase Enzyme Res Grp, H-1085 Budapest, Hungary	University of Vermont; University of Vermont; Semmelweis University; Semmelweis University	van der Vliet, A (corresponding author), Univ Vermont, Coll Med, Dept Pathol, 89 Beaumont Ave, Burlington, VT 05405 USA.	albert.van-der-vliet@uvm.edu			National Institutes of Health [R01 HL085646, ES021476, R01 HL060014]; IDeA-COBRE [P30 GM103532]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085646, R01HL060014, R01HL085464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES021476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103532] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); IDeA-COBRE; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health grants R01 HL085646 and ES021476 (to A.v.d.V.), R01 HL060014 (to Y.M.W.J.-H.), and IDeA-COBRE grant P30 GM103532.	Alcorn JF, 2008, J CELL SCI, V121, P1036, DOI 10.1242/jcs.019455; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Carta S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00123; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Cho DY, 2013, INT FORUM ALLERGY RH, V3, P376, DOI 10.1002/alr.21133; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; De Deken X, 2014, ANTIOXID REDOX SIGN, V20, P2776, DOI 10.1089/ars.2013.5602; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Dixon AE, 2009, CHEST, V136, P1324, DOI 10.1378/chest.08-1983; Donko A, 2010, FREE RADICAL BIO MED, V49, P2040, DOI 10.1016/j.freeradbiomed.2010.09.027; Enoksson M, 2011, J IMMUNOL, V186, P2523, DOI 10.4049/jimmunol.1003383; Evans JS, 2007, J NEUROCHEM, V103, P849, DOI 10.1111/j.1471-4159.2007.04815.x; Fink K, 2013, CELL RES, V23, P673, DOI 10.1038/cr.2013.47; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Gause WC, 2013, NAT REV IMMUNOL, V13, P607, DOI 10.1038/nri3476; Giannoni E, 2014, ANTIOXID REDOX SIGN, V20, P2011, DOI 10.1089/ars.2013.5525; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Gorissen SH, 2013, AM J RESP CELL MOL, V48, P337, DOI 10.1165/rcmb.2012-0393OC; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Gross Olaf, 2012, Immunity, V36, P388, DOI 10.1016/j.immuni.2012.01.018; Harper RW, 2005, FEBS LETT, V579, P4911, DOI 10.1016/j.febslet.2005.08.002; Hayakawa M, 2009, BIOCHEM BIOPH RES CO, V387, P218, DOI 10.1016/j.bbrc.2009.07.018; Hirakawa S, 2011, J IMMUNOL, V186, P4762, DOI 10.4049/jimmunol.1000791; Holgate ST, 2011, IMMUNOL REV, V242, P205, DOI 10.1111/j.1600-065X.2011.01030.x; Holtzman MJ, 2014, NAT REV IMMUNOL, V14, P686, DOI 10.1038/nri3739; Hristova M, 2014, REDOX BIOL, V2, P436, DOI 10.1016/j.redox.2013.12.030; Hristova M, 2012, AM J RESP CELL MOL, V46, P23, DOI 10.1165/rcmb.2011-0134OC; Hung LY, 2013, P NATL ACAD SCI USA, V110, P282, DOI 10.1073/pnas.1206587110; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703; Klomsiri C, 2010, METHOD ENZYMOL, V473, P77, DOI 10.1016/S0076-6879(10)73003-2; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lloyd CM, 2015, CURR OPIN IMMUNOL, V34, P52, DOI 10.1016/j.coi.2015.02.001; McSorley HJ, 2014, MUCOSAL IMMUNOL, V7, P1068, DOI 10.1038/mi.2013.123; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Muller L, 2013, JOVE-J VIS EXP, DOI 10.3791/50646; Muller L, 2013, J VIS EXP; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Paulsen CE, 2012, NAT CHEM BIOL, V8, P57, DOI 10.1038/nchembio.736; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Pulendran B, 2012, SCIENCE, V337, P431, DOI 10.1126/science.1221064; Ryu JH, 2013, J ALLERGY CLIN IMMUN, V131, P549, DOI 10.1016/j.jaci.2012.07.050; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sanos SL, 2013, IMMUNOL CELL BIOL, V91, P215, DOI 10.1038/icb.2013.3; Sham D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054391; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Smith DE, 2011, J LEUKOCYTE BIOL, V89, P383, DOI 10.1189/jlb.0810470; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Sonnenberg GF, 2015, NAT MED, V21, P698, DOI 10.1038/nm.3892; van der Vliet A, 2008, FREE RADICAL BIO MED, V44, P938, DOI 10.1016/j.freeradbiomed.2007.11.016; Voraphani N, 2014, MUCOSAL IMMUNOL, V7, P1175, DOI 10.1038/mi.2014.6; Wesley UV, 2007, J BIOL CHEM, V282, P3213, DOI 10.1074/jbc.M606533200; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; WU R, 1982, IN VITRO CELL DEV B, V18, P800	61	99	100	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1545	+		10.1016/j.jaci.2015.10.003	http://dx.doi.org/10.1016/j.jaci.2015.10.003			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26597162	Bronze, Green Accepted			2022-12-18	WOS:000376180200031
J	Suarez-Fueyo, A; Ramos, T; Galan, A; Jimeno, L; Wurtzen, PA; Marin, A; de Frutos, C; Blanco, C; Carrera, AC; Barber, D; Varona, R				Suarez-Fueyo, Abel; Ramos, Tania; Galan, Agustin; Jimeno, Lucia; Wurtzen, Peter A.; Marin, Alicia; de Frutos, Consolacion; Blanco, Carlos; Carrera, Ana C.; Barber, Domingo; Varona, Rosa			Grass tablet sublingual immunotherapy downregulates the T(H)2 cytokine response followed by regulatory T-cell generation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; regulatory T cells; allergic rhinitis; IgG(4); IgE; IL-4	ALLERGEN IMMUNOTHERAPY; IMMUNOGLOBULIN G4; TGF-BETA; POLLEN; IGE; ANTIBODIES; INHIBITION; ACTIVATION; EXPRESSION; TOLERANCE	Background: Sublingual administration of Phleum pratense allergen immunotherapy (SLIT) tablets is a clinically efficient treatment for grass pollen-induced rhinoconjunctivitis. This immunotherapy downregulates T(H)2 immune responses, induces tolerogenic pathways, and increases regulatory T cells. However, associated immune response markers of allergen desensitization remain undefined. Objective: We sought to characterize the kinetics of individual changes in the immunologic response to grass tablet SLIT. Methods: We evaluated the systemic effects of SLIT in a longitudinal analysis of humoral and cellular immune parameters in peripheral blood samples. Results: Grass tablet SLIT administration induced a 2-phase systemic humoral and cellular response. The T(H)2 response was initially exacerbated and detected as increased allergen-specific IgE (sIgE) and IgG(4) (sIgG(4)) levels and an increase in IL-4-producing cells, followed by downregulation of the T(H)2 response with a shift toward a T(H)1 cytokine profile. T cells with a regulatory phenotype were also elicited. Statistical correlations between immunologic measurements for each patient throughout therapy indicated that T(H)2 response downregulation and reduction of the immediate SLIT-induced IgE response were associated with increased allergen-specific IgG(4) synthesis early in therapy. T(H)2 response downregulation by month 4 correlated with increased frequency of CD4(+) T cells with a regulatory phenotype by 12 months. Conclusion: Changes in sIgE levels after therapy were linked to a specific IgG(4) response, and production of blocking antibodies correlated with T(H)2 response downregulation. Reduced IL-4(+) cell frequency was linked to an increase in the frequency of CD4(+) T cells with a regulatory phenotype. Changes in sIgE levels and reduced IL-4 and blocking antibody levels could thus be used as indicators of a patient's immune response to therapy.	[Suarez-Fueyo, Abel; Carrera, Ana C.; Varona, Rosa] Ctr Nacl Biotecnol CNB CSIC, Dept Immunol & Oncol, E-28049 Madrid, Spain; [Ramos, Tania; de Frutos, Consolacion; Blanco, Carlos] Hosp Univ La Princesa IP, Serv Alergia, Inst Invest Sanitaria Princesa, Madrid, Spain; [Galan, Agustin; Jimeno, Lucia; Marin, Alicia; Barber, Domingo] ALK Abello, Dept I D, Madrid, Spain; [Wurtzen, Peter A.] ALK Abello, Dept Immunol, Horsholm, Denmark	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); ALK-Abello AS; ALK-Abello AS	Varona, R (corresponding author), Ctr Nacl Biotecnol CNB CSIC, Dept Immunol & Oncol, Darwin 3,Campus Cantoblanco, E-28049 Madrid, Spain.	rvarona@cnb.csic.es	Blanco, Carlos/B-3895-2012; Barber, Domingo/Y-9516-2019; Suárez-Fueyo, Abel/D-1691-2013; Suarez Fueyo, Abel/E-5746-2017	Blanco, Carlos/0000-0002-2893-6594; Barber, Domingo/0000-0002-5488-5700; Suárez-Fueyo, Abel/0000-0002-8696-0197; Carrera, Ana/0000-0002-3999-5434; Alicia, Marin/0000-0001-6538-1383	Genoma Espana; Carlos III Institute, Spanish Ministry of Health	Genoma Espana; Carlos III Institute, Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government)	Supported by Genoma Espana. A.S.-F. was supported by a predoctoral fellowship from the Carlos III Institute, Spanish Ministry of Health.	Aalberse R, 2011, ALLERGY, V66, P28, DOI 10.1111/j.1398-9995.2011.02628.x; Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Allam JP, 2011, CURR OPIN ALLERGY CL, V11, P571, DOI 10.1097/ACI.0b013e32834cbaab; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Antunez C, 2008, PEDIAT ALLERG IMM-UK, V19, P210, DOI 10.1111/j.1399-3038.2007.00604.x; Beal AM, 2012, NAT IMMUNOL, V13, P77, DOI 10.1038/ni.2154; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calderon MA, 2012, ALLERGY, V67, P302, DOI 10.1111/j.1398-9995.2011.02761.x; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Fujimura T, 2010, INT ARCH ALLERGY IMM, V153, P378, DOI 10.1159/000316349; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Hadjur S, 2009, IMMUNOL LETT, V122, P37, DOI 10.1016/j.imlet.2008.11.001; Holm J, 2011, J ALLERGY CLIN IMMUN, V127, P1029, DOI 10.1016/j.jaci.2011.01.062; James LK, 2012, J ALLERGY CLIN IMMUN, V130, P663, DOI 10.1016/j.jaci.2012.04.006; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jimeno Nogales L, 1990, Int Arch Allergy Appl Immunol, V92, P175; Jutel M, 2011, ALLERGY, V66, P725, DOI 10.1111/j.1398-9995.2011.02589.x; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Lund G, 2012, J IMMUNOL METHODS, V383, P4, DOI 10.1016/j.jim.2012.05.021; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Nieminen K, 2009, INT ARCH ALLERGY IMM, V150, P370, DOI 10.1159/000226238; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Petersen AB, 2004, CLIN BIOCHEM, V37, P882, DOI 10.1016/j.clinbiochem.2004.06.010; Piconi S, 2010, J IMMUNOL, V185, P7723, DOI 10.4049/jimmunol.1002465; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Shamji MH, 2011, IMMUNOL ALLERGY CLIN, V31, P311, DOI 10.1016/j.iac.2011.03.005; Suphioglu C, 2000, CLIN EXP ALLERGY, V30, P1335, DOI 10.1046/j.1365-2222.2000.00955.x; Swamy RS, 2012, J ALLERGY CLIN IMMUN, V130, P215, DOI 10.1016/j.jaci.2012.04.021; van Neerven RJ, 2006, INT ARCH ALLERGY IMM, V141, P119, DOI 10.1159/000094714; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x; Wurtz O, 2004, INT IMMUNOL, V16, P501, DOI 10.1093/intimm/dxh050	37	99	102	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					130	+		10.1016/j.jaci.2013.09.043	http://dx.doi.org/10.1016/j.jaci.2013.09.043			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24290282				2022-12-18	WOS:000329105700018
J	Klemans, RJB; Otte, D; Knol, M; Knol, EF; Meijer, Y; Gmelig-Meyling, FHJ; Bruijnzeel-Koomen, CAFM; Knulst, AC; Pasmans, SGMA				Klemans, Rob J. B.; Otte, Dianne; Knol, Mirjam; Knol, Edward F.; Meijer, Yolanda; Gmelig-Meyling, Frits H. J.; Bruijnzeel-Koomen, Carla A. F. M.; Knulst, Andre C.; Pasmans, Suzanne G. M. A.			The diagnostic value of specific IgE to Ara h 2 to predict peanut allergy in children is comparable to a validated and updated diagnostic prediction model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Diagnostics; peanut allergy; food challenge; prediction model; validation; Ara h 2	SKIN PRICK TESTS; FOOD CHALLENGES; RECOMBINANT ALLERGENS; PROGNOSTIC MODEL; RULES; PREVALENCE; QUALITY; ANXIETY; STRESS; IMPACT	Background: A diagnostic prediction model for peanut allergy in children was recently published, using 6 predictors: sex, age, history, skin prick test, peanut specific immunoglobulin E (sIgE), and total IgE minus peanut sIgE. Objectives: To validate this model and update it by adding allergic rhinitis, atopic dermatitis, and sIgE to peanut components Ara h 1, 2, 3, and 8 as candidate predictors. To develop a new model based only on sIgE to peanut components. Methods: Validation was performed by testing discrimination (diagnostic value) with an area under the receiver operating characteristic curve and calibration (agreement between predicted and observed frequencies of peanut allergy) with the Hosmer-Lemeshow test and a calibration plot. The performance of the (updated) models was similarly analyzed. Results: Validation of the model in 100 patients showed good discrimination (88%) but poor calibration (P < .001). In the updating process, age, history, and additional candidate predictors did not significantly increase discrimination, being 94%, and leaving only 4 predictors of the original model: sex, skin prick test, peanut sIgE, and total IgE minus sIgE. When building a model with sIgE to peanut components, Ara h 2 was the only predictor, with a discriminative ability of 90%. Cutoff values with 100% positive and negative predictive values could be calculated for both the updated model and sIgE to Ara h 2. In this way, the outcome of the food challenge could be predicted with 100% accuracy in 59% (updated model) and 50%(Ara h 2) of the patients. Conclusions: Discrimination of the validated model was good; however, calibration was poor. The discriminative ability of Ara h 2 was almost comparable to that of the updated model, containing 4 predictors. With both models, the need for peanut challenges could be reduced by at least 50%. (J Allergy Clin Immunol 2013;131:157-63.)	[Klemans, Rob J. B.; Otte, Dianne; Knol, Edward F.; Bruijnzeel-Koomen, Carla A. F. M.; Knulst, Andre C.; Pasmans, Suzanne G. M. A.] Univ Med Ctr Utrecht, Dept Paediat Dermatol & Allergol, Utrecht, Netherlands; [Knol, Mirjam] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Meijer, Yolanda] Univ Med Ctr Utrecht, Dept Paediat Pulmonol, Utrecht, Netherlands; [Gmelig-Meyling, Frits H. J.] Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands; [Knol, Mirjam] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands; [Meijer, Yolanda; Pasmans, Suzanne G. M. A.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Ctr Paediat Allergol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Klemans, RJB (corresponding author), Univ Med Ctr Utrecht G02 124, Dept Dermatol & Allergol, POB 85-500, NL-3508 GA Utrecht, Netherlands.	r.j.b.klemans-3@umcutrecht.nl	Pasmans, Suzanne/AAI-6016-2021	Pasmans, Suzanne/0000-0003-1018-4475; Knulst, Andre/0000-0002-1056-3179; Knol, Edward/0000-0001-7368-9820	Thermo Fisher Scientific, Sweden; Thermo Fisher Scientific, The Netherlands; Thermo Fisher Scientific, Netherlands/Sweden	Thermo Fisher Scientific, Sweden; Thermo Fisher Scientific, The Netherlands; Thermo Fisher Scientific, Netherlands/Sweden	This study was partially funded by an unrestricted grant from Thermo Fisher Scientific, Sweden and The Netherlands.; A. Knulst has received research support from Thermo Fisher Scientific, Netherlands/Sweden. The rest of the authors declare that they have no relevant conflicts of interest.	Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO;2-X; Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Bleeker SE, 2003, J CLIN EPIDEMIOL, V56, P826, DOI 10.1016/S0895-4356(03)00207-5; Codreanu F, 2011, INT ARCH ALLERGY IMM, V154, P216, DOI 10.1159/000321108; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; DunnGalvin A, 2011, J ALLERGY CLIN IMMUN, V127, P633, DOI 10.1016/j.jaci.2010.12.004; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; King RM, 2009, ALLERGY, V64, P461, DOI 10.1111/j.1398-9995.2008.01843.x; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Kotz D, 2011, J ALLERGY CLIN IMMUN, V127, P623, DOI 10.1016/j.jaci.2010.11.021; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Roy KM, 2011, CLIN PEDIATR, V50, P1045, DOI 10.1177/0009922811412584; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Toll DB, 2008, J CLIN EPIDEMIOL, V61, P1085, DOI 10.1016/j.jclinepi.2008.04.008; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Zijlstra WT, 2010, PEDIAT ALLERG IMM-UK, V21, pE439, DOI 10.1111/j.1399-3038.2009.00929.x	33	99	101	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					157	163		10.1016/j.jaci.2012.08.010	http://dx.doi.org/10.1016/j.jaci.2012.08.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23026497				2022-12-18	WOS:000312961200020
J	Rezaei, N; Hedayat, M; Aghamohammadi, A; Nichols, KE				Rezaei, Nima; Hedayat, Mona; Aghamohammadi, Asghar; Nichols, Kim E.			Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunodeficiency; viral infection; malignancies; X-linked lymphoproliferative syndrome	LINKED LYMPHOPROLIFERATIVE-DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; HYPER-IGE SYNDROME; STEM-CELL TRANSPLANTATION; BARR-VIRUS INFECTION; DOMINANT EPIDERMODYSPLASIA-VERRUCIFORMIS; CHRONIC ENTEROVIRAL MENINGOENCEPHALITIS; MYELOKATHEXIS WHIM SYNDROME; T-LYMPHOCYTE DEVELOPMENT; SLAM-ASSOCIATED PROTEIN	Primary immunodeficiencies (PIDs) are commonly characterized by an increased susceptibility to specific infections and, in certain instances, a higher than usual incidence of malignancies. Although improved diagnosis and early treatment of PIDs have reduced early morbidity and mortality from infection, the development of cancer remains a significant cause of premature death. The emergence of cancer in patients with PIDs often results from impairments in the immune response that lead to weakened surveillance against oncogenic viruses, premalignant or malignant cells, or both. Here we review the clinical and biologic features of several PIDs associated with enhanced susceptibility to viral infections and cancer, including X-linked lymphoproliferative disease; IL-2-inducible T-cell kinase deficiency; epidermodysplasia verruciformis; warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; autosomal recessive hyper-IgE syndrome; X-linked agammaglobulinemia; and common variable immunodeficiency. It is of importance that we gain in-depth insights into the fundamental molecular nature of these unique PIDs to better understand the pathogenesis of virus-associated malignancies and to develop innovative therapeutic strategies. (J Allergy Clin Immunol 2011;127:1329-41.)	[Rezaei, Nima; Hedayat, Mona; Aghamohammadi, Asghar] Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Pediat Ctr Excellence, Tehran, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Mol Immunol Res Ctr, Tehran, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Dept Immunol, Sch Med, Tehran, Iran; [Rezaei, Nima] Univ Sheffield, Sch Med & Biomed Sci, Dept Infect & Immun, Sheffield, S Yorkshire, England; [Nichols, Kim E.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA	Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; University of Sheffield; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Rezaei, N (corresponding author), Childrens Med Ctr Hosp, Dr Qarib St,Keshavarz Blvd, Tehran 14194, Iran.	nicholsk@email.chop.edu; nicholsk@email.chop.edu	Nichols, Kim/E-9353-2016; Nichols, Kim/AAP-8592-2020; Rezaei, Nima/B-4245-2008	Nichols, Kim/0000-0002-5581-6555; Nichols, Kim/0000-0002-5581-6555; Rezaei, Nima/0000-0002-3836-1827; Aghamohammadi, Asghar/0000-0002-9454-1603	Tehran University of Medical Sciences; XLP Research Trust; Grundy Vision of Life Fund	Tehran University of Medical Sciences(Tehran University of Medical Sciences); XLP Research Trust; Grundy Vision of Life Fund	Supported in part by a grant from Tehran University of Medical Sciences (to N.R.), the XLP Research Trust (to K.E.N.), and the Grundy Vision of Life Fund (to K.E.N.).	Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; Anadolu R, 2001, J AM ACAD DERMATOL, V45, P296, DOI 10.1067/mjd.2001.114575; ANDROPHY EJ, 1985, ARCH DERMATOL, V121, P864, DOI 10.1001/archderm.121.7.864; Arai J, 2000, PEDIATR HEMAT ONCOL, V17, P171, DOI 10.1080/088800100276532; Atherly LO, 2006, J IMMUNOL, V176, P1571, DOI 10.4049/jimmunol.176.3.1571; Bachmann MF, 1997, J VIROL, V71, P7253, DOI 10.1128/JVI.71.10.7253-7257.1997; Balabanian K, 2005, BLOOD, V105, P2449, DOI 10.1182/blood-2004-06-2289; Balabanian K, 2008, J CLIN INVEST, V118, P1074, DOI 10.1172/JCI33187; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Belada D, 2010, LEUKEMIA RES, V34, pE232, DOI 10.1016/j.leukres.2010.01.024; Berg LJ, 2007, NAT REV IMMUNOL, V7, P479, DOI 10.1038/nri2091; Berg LJ, 2005, ANNU REV IMMUNOL, V23, P549, DOI 10.1146/annurev.immunol.22.012703.104743; Berthelot C, 2007, J AM ACAD DERMATOL, V56, P882, DOI 10.1016/j.jaad.2007.01.036; Booth C, 2011, BLOOD, V117, P53, DOI 10.1182/blood-2010-06-284935; Borkhardt A., 2010, 3 M CLIN IMM ALL IMM; Brandau O, 1999, HUM MOL GENET, V8, P2407, DOI 10.1093/hmg/8.13.2407; Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Chae KM, 2001, J AM ACAD DERMATOL, V44, P124, DOI 10.1067/mjd.2001.111337; Chang CH, 2010, KAOHSIUNG J MED SCI, V26, P206, DOI 10.1016/S1607-551X(10)70030-9; Chua I, 2008, CURR OPIN HEMATOL, V15, P368, DOI 10.1097/MOH.0b013e328302c7b6; Chung B, 2005, J IMMUNOL, V174, P3153, DOI 10.4049/jimmunol.174.6.3153; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; COOPER KD, 1990, J INVEST DERMATOL, V94, P769, DOI 10.1111/1523-1747.ep12874631; Cote JF, 2007, TRENDS CELL BIOL, V17, P383, DOI 10.1016/j.tcb.2007.05.001; de Oliveira WRP, 2003, J EUR ACAD DERMATOL, V17, P394, DOI 10.1046/j.1468-3083.2003.00703.x; de Oliveira WRP, 2003, J DERMATOL, V30, P203, DOI 10.1111/j.1346-8138.2003.tb00372.x; Desar IME, 2006, NETH J MED, V64, P136; Diaz GA, 2005, IMMUNOL REV, V203, P235, DOI 10.1111/j.0105-2896.2005.00226.x; Diaz GA, 2005, CURR ALLERGY ASTHM R, V5, P350, DOI 10.1007/s11882-005-0005-0; Dupre L, 2005, BLOOD, V105, P4383, DOI 10.1182/blood-2004-08-3269; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Falco M, 2004, EUR J IMMUNOL, V34, P1663, DOI 10.1002/eji.200424886; Felices M, 2008, J IMMUNOL, V180, P3007, DOI 10.4049/jimmunol.180.5.3007; Felices M, 2007, ADV IMMUNOL, V93, P145, DOI 10.1016/S0065-2776(06)93004-1; Forslund O, 2004, J INVEST DERMATOL, V123, P388, DOI 10.1111/j.0022-202X.2004.23205.x; Gasser S, 2007, ANN MED, V39, P457, DOI 10.1080/07853890701436773; Gatz SA, 2011, BONE MARROW TRANSPL, V46, P552, DOI 10.1038/bmt.2010.169; Gewirtzman A, 2008, CURR OPIN INFECT DIS, V21, P141, DOI 10.1097/QCO.0b013e3282f486c9; Giampieri S, 2004, BRIT J CANCER, V90, P2203, DOI 10.1038/sj.bjc.6601829; Gilmour KC, 2000, EUR J IMMUNOL, V30, P1691, DOI 10.1002/1521-4141(200006)30:6<1691::AID-IMMU1691>3.0.CO;2-K; Gorlin RJ, 2000, AM J MED GENET, V91, P368, DOI 10.1002/(SICI)1096-8628(20000424)91:5<368::AID-AJMG10>3.0.CO;2-9; Granados EL, 2002, J CLIN INVEST, V110, P1029, DOI 10.1172/JCI200215658; GRIERSON HL, 1991, AM J MED GENET, V40, P294, DOI 10.1002/ajmg.1320400309; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Gross TG, 1996, BONE MARROW TRANSPL, V17, P741; Gulino AV, 2004, BLOOD, V104, P444, DOI 10.1182/blood-2003-10-3532; Handisurya A, 2010, VACCINE, V28, P4837, DOI 10.1016/j.vaccine.2010.04.057; Hayashi J, 2002, INT J DERMATOL, V41, P817, DOI 10.1046/j.1365-4362.2002.01642.x; He YL, 2009, CANCER RES, V69, P7935, DOI 10.1158/0008-5472.CAN-09-0828; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Hislop AD, 2010, BLOOD, V116, P3249, DOI 10.1182/blood-2009-09-238832; Hu J, 2007, EUR J IMMUNOL, V37, P2892, DOI 10.1002/eji.200737311; Huck K, 2009, J CLIN INVEST, V119, P1350, DOI 10.1172/JCI37901; Idbaih A, 2008, J NEURO-ONCOL, V90, P133, DOI 10.1007/s11060-008-9644-z; Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443; Imashuku S, 2002, ANN HEMATOL, V81, P470, DOI 10.1007/s00277-002-0489-9; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Karrer S, 1999, BRIT J DERMATOL, V140, P935, DOI 10.1046/j.1365-2133.1999.02830.x; Kawai T, 2009, CURR OPIN HEMATOL, V16, P20, DOI 10.1097/MOH.0b013e32831ac557; Keresztes G, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-24; Khurana D, 2007, J IMMUNOL, V178, P3575, DOI 10.4049/jimmunol.178.6.3575; Krivan G, 2010, EUR J HAEMATOL, V84, P274, DOI 10.1111/j.1600-0609.2009.01368.x; Lankester AC, 2005, BONE MARROW TRANSPL, V36, P99, DOI 10.1038/sj.bmt.1705016; Lazarczyk M, 2008, J EXP MED, V205, P35, DOI 10.1084/jem.20071311; Lazarczyk M, 2009, MICROBIOL MOL BIOL R, V73, P348, DOI 10.1128/MMBR.00033-08; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; Lei JY, 2000, AM J DERMATOPATH, V22, P524, DOI 10.1097/00000372-200012000-00008; Leonard GD, 2004, LEUKEMIA LYMPHOMA, V45, P2521, DOI 10.1080/10428190400004463; LIESE JG, 1992, AM J DIS CHILD, V146, P335, DOI 10.1001/archpedi.1992.02160150075025; LINKA RM, 2010, AM SOC HEM M ORL FLA; Losi CG, 2005, J CLIN IMMUNOL, V25, P496, DOI 10.1007/s10875-005-5637-2; Lucas JA, 2002, J IMMUNOL, V168, P6142, DOI 10.4049/jimmunol.168.12.6142; LUTZNER MA, 1978, B CANCER, V65, P169; Ma CS, 2007, ANNU REV IMMUNOL, V25, P337, DOI 10.1146/annurev.immunol.25.022106.141651; MAJEWSKI S, 1990, J AM ACAD DERMATOL, V22, P423, DOI 10.1016/0190-9622(90)70058-P; Majewski S, 2006, INT J DERMATOL, V45, P192, DOI 10.1111/j.1365-4632.2006.02758.x; Marsh RA, 2010, BLOOD, V116, P1079, DOI 10.1182/blood-2010-01-256099; Martin D, 2008, ONCOGENE, V27, P1844, DOI [10.1038/sj.onc.1210817, 10.1038/onc.2009.351]; McDermott DF, 2009, PEDIATR DERMATOL, V26, P306, DOI 10.1111/j.1525-1470.2008.00853.x; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; Mellemkjaer L, 2002, CLIN EXP IMMUNOL, V130, P495, DOI 10.1046/j.1365-2249.2002.02004.x; Micali G, 2003, J AM ACAD DERMATOL, V48, pS9, DOI 10.1067/mjd.2003.111; Miller AT, 2002, J IMMUNOL, V168, P2163, DOI 10.4049/jimmunol.168.5.2163; Milone MC, 2005, BLOOD, V105, P994, DOI 10.1182/blood-2004-07-2965; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Minegishi Y, 2009, CURR OPIN IMMUNOL, V21, P487, DOI 10.1016/j.coi.2009.07.013; MISBAH SA, 1992, J CLIN IMMUNOL, V12, P266, DOI 10.1007/BF00918150; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nagy N, 2002, IMMUNOL LETT, V82, P141, DOI 10.1016/S0165-2478(02)00029-9; Nagy N, 2009, P NATL ACAD SCI USA, V106, P11966, DOI 10.1073/pnas.0905691106; Nichols KE, 2005, IMMUNOL REV, V203, P180, DOI 10.1111/j.0105-2896.2005.00230.x; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Nichols KE, 2005, NAT MED, V11, P340, DOI 10.1038/nm1189; O Atherly L, 2006, IMMUNITY, V25, P79, DOI 10.1016/j.immuni.2006.05.012; Onal IK, 2006, MED ONCOL, V23, P141, DOI 10.1385/MO:23:1:141; Orth G, 2005, J INVEST DERMATOL, V125, pXII, DOI 10.1111/j.0022-202X.2005.23811.x; Orth G, 2006, SEMIN IMMUNOL, V18, P362, DOI 10.1016/j.smim.2006.07.008; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Pasquier B, 2005, J EXP MED, V201, P695, DOI 10.1084/jem.20042432; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Prince Amanda L, 2009, Immunol Rev, V228, P115, DOI 10.1111/j.1600-065X.2008.00746.x; PURTILO DT, 1975, LANCET, V1, P936; Quartier P, 1999, J PEDIATR-US, V134, P589, DOI 10.1016/S0022-3476(99)70246-5; Quartier P, 2004, CLIN IMMUNOL, V110, P22, DOI 10.1016/j.clim.2003.10.007; Raeiszadeh M, 2006, CLIN EXP IMMUNOL, V146, P234, DOI 10.1111/j.1365-2249.2006.03209.x; Ramoz N, 2000, J INVEST DERMATOL, V114, P1148, DOI 10.1046/j.1523-1747.2000.00996.x; Ramoz N, 2002, NAT GENET, V32, P579, DOI 10.1038/ng1044; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Readinger JA, 2009, IMMUNOL REV, V228, P93, DOI 10.1111/j.1600-065X.2008.00757.x; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Renukaradhya GJ, 2008, BLOOD, V111, P5637, DOI 10.1182/blood-2007-05-092866; Revy P, 2005, ADV IMMUNOL, V87, P237, DOI 10.1016/S0065-2776(05)87007-5; Rezaei N, 2011, BRIT J HAEMATOL, V152, P13, DOI 10.1111/j.1365-2141.2010.08442.x; Rigaud S, 2006, NATURE, V444, P110, DOI 10.1038/nature05257; Ruusala A, 2004, FEBS LETT, V572, P159, DOI 10.1016/j.febslet.2004.06.095; Saelee P, 2009, ASIAN PAC J CANCER P, V10, P501; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schaeffer EM, 2000, J EXP MED, V192, P987, DOI 10.1084/jem.192.7.987; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Schmid JP, 2011, BLOOD, V117, P1522, DOI 10.1182/blood-2010-07-298372; Schuster V, 2001, BLOOD, V98, P1986, DOI 10.1182/blood.V98.6.1986; Shinozaki K, 2002, INT IMMUNOL, V14, P1215, DOI 10.1093/intimm/dxf084; Snow AL, 2009, J CLIN INVEST, V119, P2976, DOI 10.1172/JCI39518; Stepensky P, 2011, HAEMATOL-HEMATOL J, V96, P472, DOI 10.3324/haematol.2010.033910; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Su HC, 2010, CURR OPIN ALLERGY CL, V10, P515, DOI 10.1097/ACI.0b013e32833fd718; SULLIVAN JL, 1980, SCIENCE, V210, P543, DOI 10.1126/science.6158759; Sumegi J, 2000, BLOOD, V96, P3118; SUMEGI J, 2009, LYMPHOPROLIFERATIVE; Tabata Y, 2005, BLOOD, V105, P3066, DOI 10.1182/blood-2004-09-3651; Takahashi K, 2006, INT J ONCOL, V28, P321; Tangye SG, 2000, MOL IMMUNOL, V37, P493, DOI 10.1016/S0161-5890(00)00076-6; Tarzi MD, 2005, J ALLERGY CLIN IMMUN, V116, P1101, DOI 10.1016/j.jaci.2005.08.040; Tassone L, 2010, BLOOD, V116, P4870, DOI 10.1182/blood-2010-03-272096; Tchou I, 2001, J LEUKOCYTE BIOL, V70, P313; THORLEYLAWSON DA, 1982, CELL, V30, P415, DOI 10.1016/0092-8674(82)90239-2; Trottestam H, 2009, PEDIATR BLOOD CANCER, V52, P268, DOI 10.1002/pbc.21790; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; VANDERMEER JWM, 1993, LANCET, V341, P1439, DOI 10.1016/0140-6736(93)90883-I; Vohra S, 2010, INDIAN J DERMATOL VE, V76, P557, DOI 10.4103/0378-6323.69092; WESTON B, 1991, J PEDIATR-US, V118, P229, DOI 10.1016/S0022-3476(05)80488-3; WETZLER M, 1992, JAMA-J AM MED ASSOC, V267, P2179, DOI 10.1001/jama.267.16.2179; WETZLER M, 1990, AM J MED, V89, P663, DOI 10.1016/0002-9343(90)90187-I; Wheat WH, 2005, J EXP MED, V202, P479, DOI 10.1084/jem.20050381; Wintergerst U., PRIMARY IMMUNODEFICI, V2017, P245; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	154	99	103	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1329	U47		10.1016/j.jaci.2011.02.047	http://dx.doi.org/10.1016/j.jaci.2011.02.047			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21514636				2022-12-18	WOS:000291048500002
J	Teodosio, C; Garcia-Montero, AC; Jara-Acevedo, M; Sanchez-Munoz, L; Alvarez-Twose, I; Nunez, R; Schwartz, LB; Walls, AF; Escribano, L; Orfao, A				Teodosio, Cristina; Garcia-Montero, Andres C.; Jara-Acevedo, Maria; Sanchez-Munoz, Laura; Alvarez-Twose, Ivan; Nunez, Rosa; Schwartz, Lawrence B.; Walls, Andrew F.; Escribano, Luis; Orfao, Alberto			Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mastocytosis; immunophenotype; flow cytometry; KIT mutations	FLOW-CYTOMETRIC ANALYSIS; BONE-MARROW; KIT MUTATION; M-RAS; EXPRESSION; ACTIVATION; ANTIGENS; TRYPTASE; LEUKEMIA; DISEASE	Background: Systemic mastocytosis (SM) is a heterogeneous group of disorders with distinct clinical and biological behavior. Despite this, little is known about the immunophenotypic features of the distinct diagnostic categories of SM. Objective: To analyze the immunophenotypic characteristics of bone marrow (BM) mast cells (MCs) of different subtypes of SM. Methods: Bone marrow samples from 123 patients with different subtypes of SM and 92 controls were analyzed for a broad panel of immunophenotypic markers by flow cytometry. Results: Three clearly different maturation-associated immunophenotypic profiles were found for BMMCs in SM. These different profiles were associated with both genetic markers of the disease and its clinical behavior. BMMCs from poor-prognosis categories of SM (aggressive SM and MC leukemia) typically showed an immature phenotype with clonal involvement of all myeloid lineages by the D816V stem cell growth factor receptor gene (KIT) mutation. In turn, a mature activated versus resting BMMC immunophenotype was commonly found among patients with good-prognosis subtypes of SM depending on whether they carried (indolent SM and clonal MC activation disorders) or not (well differentiated SM) the D816V KIT mutation. Conclusion: Bone marrow MCs from SM show 3 different maturation-related immunophenotypic profiles that are associated with both the genetic markers of the disease and its clinical behavior. (J Allergy Clin Immunol 2010;125:719-26.)	[Teodosio, Cristina; Garcia-Montero, Andres C.; Jara-Acevedo, Maria; Orfao, Alberto] IBMCC CSIC USAL, Ctr Invest Canc, Serv Gen Citometria, Inst Biol Mol & Celular Cancer, Salamanca 37007, Spain; [Teodosio, Cristina; Garcia-Montero, Andres C.; Jara-Acevedo, Maria; Orfao, Alberto] Univ Salamanca, Dept Med, E-37008 Salamanca, Spain; [Sanchez-Munoz, Laura; Alvarez-Twose, Ivan; Escribano, Luis] Hosp Virgen Valle, KF Austen Lab, Ctr Estudios Mastocitosis Castilla Mancha, Toledo, OH USA; [Nunez, Rosa] Hosp Ramon & Cajal, Serv Hematol, E-28034 Madrid, Spain; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, Dept Internal Med, Richmond, VA 23284 USA; [Walls, Andrew F.] Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO9 4XY, Hants, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; Hospital Universitario Ramon y Cajal; Virginia Commonwealth University; University of Southampton	Orfao, A (corresponding author), IBMCC CSIC USAL, Ctr Invest Canc, Serv Gen Citometria, Inst Biol Mol & Celular Cancer, Avenida Univ Coimbra S-N,Campus Miguel Unamuno, Salamanca 37007, Spain.	orfao@usal.es	Orfao, Alberto/B-5801-2017; Montero, Andres/HGA-9093-2022; Garcia-Montero, Andres C/B-6558-2017; IBSAL, Secretaría/H-3719-2011	Garcia-Montero, Andres C/0000-0003-4360-1386; Alvarez-Twose, Ivan/0000-0002-1190-4473; Jara-Acevedo, Maria/0000-0001-7965-7512; Sanchez-Munoz, Laura/0000-0003-1757-7255; Teodosio, Cristina/0000-0002-2097-7199; Walls, Andrew/0000-0003-4803-4595	Fondo de Investigaciones Sanitarias of the Ministerio de Sanidad y Consumo of Spain [REMA G03/007, PI050726, PI061377, PI060529, RETICS RD06/0020/0035-FEDER]; Junta de Castilla y Leon [SAN/1778/2009]; Junta de Comunidades de Castilla La Mancha [FISCAM 2007/36]; Fundacion MMA; Fondo de Investigaciones Sanitarias/FEDER [CP03/00035]; Fundacao para a Ciencia e Tecnologia of Portugal [SFRH/BD/17545/2004]; National Institutes of Health [AI27517, AI077435]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077435, R01AI027517] Funding Source: NIH RePORTER; Medical Research Council [G0500729] Funding Source: researchfish; Asthma UK [06/026] Funding Source: researchfish; MRC [G0500729] Funding Source: UKRI	Fondo de Investigaciones Sanitarias of the Ministerio de Sanidad y Consumo of Spain(Instituto de Salud Carlos III); Junta de Castilla y Leon(Junta de Castilla y Leon); Junta de Comunidades de Castilla La Mancha(Junta de Comunidades de Castilla-La Mancha); Fundacion MMA; Fondo de Investigaciones Sanitarias/FEDER(Instituto de Salud Carlos IIIEuropean Commission); Fundacao para a Ciencia e Tecnologia of Portugal(Portuguese Foundation for Science and Technology); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by grants from the Fondo de Investigaciones Sanitarias of the Ministerio de Sanidad y Consumo of Spain (REMA G03/007, PI050726, PI061377, PI060529, and RETICS RD06/0020/0035-FEDER); Junta de Castilla y Leon (Grant SAN/1778/2009); Junta de Comunidades de Castilla La Mancha (FISCAM 2007/36), and Fundacion MMA. A.C.G.-M. is supported by a grant from Fondo de Investigaciones Sanitarias/FEDER (CP03/00035). C.T. is supported by a grant from the Fundacao para a Ciencia e Tecnologia of Portugal (SFRH/BD/17545/2004). L.B.S. is supported by grants from the National Institutes of Health (AI27517 and AI077435).; Disclosure of potential conflict of interest: L. B. Schwartz is on the speakers' bureau and is a consultant for Novartis/Genentech; is the inventor of the tryptase assay for Phadia; receives grant support from the NIH, GlaxoSmithKline, Novartis/Genentech, Pharming, and Ception; has provided legal consultation or expert witness testimony in cases related to anaphylaxis; is on the Board of Directors for AAFA and CIS; and is on the Program Directors' Board for the AAAAI. The rest of the authors have declared that they have no conflict of interest.	Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Akin C., 2004, Journal of Allergy and Clinical Immunology, V113, pS327, DOI 10.1016/j.jaci.2004.01.683; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Alfredsson J, 2005, CELL DEATH DIFFER, V12, P136, DOI 10.1038/sj.cdd.4401537; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Cervero C, 1999, AM J HEMATOL, V60, P191, DOI 10.1002/(SICI)1096-8652(199903)60:3<191::AID-AJH4>3.0.CO;2-Y; De Zen L, 2000, LEUKEMIA, V14, P1225, DOI 10.1038/sj.leu.2401824; Diaz-Agustin B, 1999, BRIT J HAEMATOL, V106, P400, DOI 10.1046/j.1365-2141.1999.01572.x; Escribano L, 1998, BLOOD, V91, P2731, DOI 10.1182/blood.V91.8.2731.2731_2731_2736; Escribano L, 2002, INT ARCH ALLERGY IMM, V127, P127, DOI 10.1159/000048183; Escribano L, 2001, LEUKEMIA RES, V25, P563, DOI 10.1016/S0145-2126(01)00050-9; Escribano L, 1998, CYTOMETRY, V34, P223, DOI 10.1002/(SICI)1097-0320(19981015)34:5<223::AID-CYTO3>3.0.CO;2-B; Escribano L, 2006, IMMUNOL ALLERGY CLIN, V26, P535, DOI 10.1016/j.iac.2006.05.008; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Guo X, 2006, ONCOGENE, V25, P4241, DOI 10.1038/sj.onc.1209452; Guo XC, 2005, ONCOGENE, V24, P2330, DOI 10.1038/sj.onc.1208441; Hartmann K, 2003, AM J PATHOL, V163, P819, DOI 10.1016/S0002-9440(10)63442-6; Henz BM, 2001, EXP DERMATOL, V10, P1, DOI 10.1034/j.1600-0625.2001.100101.x; Horny HP, 2007, PATHOBIOLOGY, V74, P121, DOI 10.1159/000101711; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Matarraz S, 2008, LEUKEMIA, V22, P1175, DOI 10.1038/leu.2008.49; Nunez-Lopez R, 2003, BRIT J HAEMATOL, V120, P257, DOI 10.1046/j.1365-2141.2003.04055.x; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; Orfao A, 1999, HAEMATOLOGICA, V84, P405; Orfao A, 1996, AM J PATHOL, V149, P1493; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; Pardanani A, 2004, LEUKEMIA RES, V28, P777, DOI 10.1016/j.leukres.2003.10.035; ROTTEM M, 1994, BLOOD, V84, P2489; Samorapoompichit P, 2006, HISTOPATHOLOGY, V48, P247, DOI 10.1111/j.1365-2559.2005.02314.x; Schernthaner GH, 2001, BLOOD, V98, P3784, DOI 10.1182/blood.V98.13.3784; Schernthaner GH, 2005, ALLERGY, V60, P1248, DOI 10.1111/j.1398-9995.2005.00865.x; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; Sotlar K, 2003, AM J PATHOL, V162, P737, DOI 10.1016/S0002-9440(10)63870-9; Sperr WR, 2001, LEUKEMIA RES, V25, P529, DOI 10.1016/S0145-2126(01)00041-8; Stelekati E, 2007, IMMUNOBIOLOGY, V212, P505, DOI 10.1016/j.imbio.2007.03.012; STEVENS EC, 2001, HEMATOPATHOLOGY, V116, P117; Tabernero MD, 2001, LEUKEMIA, V15, P406, DOI 10.1038/sj.leu.2402060; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2001, WHO CLASSIFICATION T, P291; Woolhiser MR, 2001, EUR J IMMUNOL, V31, P3298, DOI 10.1002/1521-4141(200111)31:11<3298::AID-IMMU3298>3.0.CO;2-U	42	99	102	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					719	726		10.1016/j.jaci.2009.10.020	http://dx.doi.org/10.1016/j.jaci.2009.10.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20061010				2022-12-18	WOS:000275883200031
J	Chinen, J; Buckley, RH				Chinen, Javier; Buckley, Rebecca H.			Transplantation immunology: Solid organ and bone marrow	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bone marrow transplantation; solid-organ transplantation; graft rejection; graft-versus-host disease	SEVERE COMBINED IMMUNODEFICIENCY; STEM-CELL TRANSPLANTATION; VERSUS-HOST-DISEASE; CHRONIC GRANULOMATOUS-DISEASE; IN-UTERO TRANSPLANTATION; WISKOTT-ALDRICH-SYNDROME; SINGLE-CENTER EXPERIENCE; CLASS-II DEFICIENCY; GENE-THERAPY; LUNG TRANSPLANTATION	Development of the field of organ and tissue transplantation has accelerated remarkably since the human MHC was discovered in 1967. Matching of donor and recipient for MHC antigens has been shown to have a significant positive effect on graft acceptance. The roles of the different components of the immune system involved in the tolerance or rejection of grafts and in graft-versus-host disease have been clarified. These components include antibodies, antigen-presenting cells, helper and cytotoxic T-cell subsets, immune cell-surface molecules, signaling mechanisms, and cytokines. The development of pharmacologic and biological agents that interfere with the alloimmune response has had a crucial role in the success of organ transplantation. Combinations of these agents work synergistically, leading to lower doses of immunosuppressive drugs and reduced toxicity. Reports of significant numbers of successful solid-organ transplantations include those of the kidneys, liver, heart, and lung. The use of bone marrow transplantation for hematologic diseases, particularly hematologic malignancies and primary immunodeficiencies, has become the treatment of choice in many of these conditions. Other sources of hematopoietic stem cells are also being used, and diverse immunosuppressive drug regimens of reduced intensity are being proposed to circumvent the mortality associated with the toxicity of these drugs. Gene therapy to correct inherited diseases by means of infusion of gene-modified autologous hematopoietic stem cells has shown efficacy in 2 forms of severe combined immunodeficiency, providing an alternative to allogeneic tissue transplantation. (J Allergy Clin Immunol 2010;125:S324-35.)	[Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Chinen, Javier] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Duke University; Baylor College of Medicine	Buckley, RH (corresponding author), Duke Univ, Med Ctr, Dept Pediat, 362 Jones Bldg,Campus Box 2898, Durham, NC 27710 USA.	BUCKL003@mc.duke.edu	Buckley, Rebecca/AAB-1578-2019		National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042951, R01AI047605] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	J. Chinen has declared that he has no conflict of interest. R. H. Buckley has received research support from the National Institute of Allergy and Infectious Diseases and is the Chair of the Medical Advisory Committee for the Immune Deficiency Foundation.	Adkins D, 2009, TRANSPLANTATION, V88, P198, DOI 10.1097/TP.0b013e3181abfbf7; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Al-Lamki RS, 2008, TRANSPLANTATION, V86, P1340, DOI 10.1097/TP.0b013e3181891d8b; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Appelbaum FR, 2007, NEW ENGL J MED, V357, P1472, DOI 10.1056/NEJMp078166; Atalar K, 2009, CURR OPIN ORGAN TRAN, V14, P23, DOI 10.1097/MOT.0b013e32831b70c2; Aurora P, 2008, J HEART LUNG TRANSPL, V27, P978, DOI 10.1016/j.healun.2008.06.018; BACH FH, 1967, SCIENCE, V156, P1506, DOI 10.1126/science.156.3781.1506; Balin SJ, 2009, TRANSPL INT, V22, P593, DOI 10.1111/j.1432-2277.2008.00816.x; Barrett AJ, 2008, BRIT J HAEMATOL, V142, P877, DOI 10.1111/j.1365-2141.2008.07260.x; Bertrand Y, 2002, BONE MARROW TRANSPL, V29, P759, DOI 10.1038/sj.bmt.1703531; BORTIN MM, 1977, JAMA-J AM MED ASSOC, V238, P591, DOI 10.1001/jama.238.7.591; Brennan DC, 2006, NEW ENGL J MED, V355, P1967, DOI 10.1056/NEJMoa060068; Broome CB, 1996, J PEDIATR-US, V128, P373, DOI 10.1016/S0022-3476(96)70285-8; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; BUCKLEY RH, 2006, PRIMARY IMMUNODEFICI, P669; Carnevale-Schianca F, 2009, BIOL BLOOD MARROW TR, V15, P749, DOI 10.1016/j.bbmt.2009.03.009; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Clatworthy MR, 2009, TRANSPLANTATION, V87, P1092, DOI 10.1097/TP.0b013e31819d3353; Coenen JJA, 2006, BLOOD, V107, P1018, DOI 10.1182/blood-2005-07-3032; Deeg HJ, 2006, SEMIN HEMATOL, V43, P24, DOI 10.1053/j.seminhematol.2005.09.003; Duplantier JE, 2001, CLIN IMMUNOL, V98, P313, DOI 10.1006/clim.2000.4994; Dwyre DM, 2008, VOX SANG, V95, P85, DOI 10.1111/j.1423-0410.2008.01073.x; Fernandez HF, 2009, CANCER CONTROL, V16, P153, DOI 10.1177/107327480901600207; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; Finke J, 2009, LANCET ONCOL, V10, P855, DOI 10.1016/S1470-2045(09)70225-6; Fishbein TM, 2009, NEW ENGL J MED, V361, P998, DOI 10.1056/NEJMra0804605; Flake AW, 1996, NEW ENGL J MED, V335, P1806, DOI 10.1056/NEJM199612123352404; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; GERRITSEN EJA, 1994, J PEDIATR-US, V125, P896, DOI 10.1016/S0022-3476(05)82004-9; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Goerner M, 2003, J HEMATOTH STEM CELL, V12, P309, DOI 10.1089/152581603322023043; Gratwohl A, 2005, BONE MARROW TRANSPL, V35, P869, DOI 10.1038/sj.bmt.1704892; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hertz MI, 2008, J HEART LUNG TRANSPL, V27, P937, DOI 10.1016/j.healun.2008.07.019; Holdsworth R, 2009, TISSUE ANTIGENS, V73, P95, DOI 10.1111/j.1399-0039.2008.01183.x; Hong JC, 2009, J AM COLL SURGEONS, V208, P682, DOI 10.1016/j.jamcollsurg.2009.01.023; Horowitz MM, 2008, BONE MARROW TRANSPL, V42, pS1, DOI 10.1038/bmt.2008.101; Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020; Kahan BD, 2009, TRANSPL P, V41, P1423, DOI 10.1016/j.transproceed.2009.05.001; Kahan BD, 1999, TRANSPLANT P, V31, p14S, DOI 10.1016/S0041-1345(98)02074-0; Kang EM, 2009, IMMUNOL RES, V43, P77, DOI 10.1007/s12026-008-8051-z; Karczewski J, 2008, TRANSPL P, V40, P3390, DOI 10.1016/j.transproceed.2008.07.125; KAUFFMAN HP, 1979, TRANSPL P, V8, P11; KISSMEYE F, 1966, LANCET, V2, P662, DOI 10.1016/S0140-6736(66)92829-7; KLEIN C, 1995, BLOOD, V85, P580; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006; Klein J, 2000, NEW ENGL J MED, V343, P782, DOI 10.1056/NEJM200009143431106; Knechtle SJ, 2009, SEMIN LIVER DIS, V29, P91, DOI 10.1055/s-0029-1192058; Knoll G, 2008, DRUGS, V68, P3, DOI 10.2165/00003495-200868001-00002; Koreth J, 2009, JAMA-J AM MED ASSOC, V301, P2349, DOI 10.1001/jama.2009.813; Kurtzberg J, 2009, CURR OPIN PEDIATR, V21, P22, DOI 10.1097/MOP.0b013e32832130bc; Li XC, 2009, IMMUNOL REV, V229, P271, DOI 10.1111/j.1600-065X.2009.00781.x; Ljungman P, 2006, BONE MARROW TRANSPL, V37, P439, DOI 10.1038/sj.bmt.1705265; Lucarelli G, 2002, BLOOD REV, V16, P81, DOI 10.1054/blre.2002.0192; Magee CC, 2004, ARCH INTERN MED, V164, P1373, DOI 10.1001/archinte.164.13.1373; Markert ML, 2008, J ALLERGY CLIN IMMUN, V121, P1063, DOI 10.1016/j.jaci.2007.12.1181; Markert ML, 2007, BLOOD, V109, P4539, DOI 10.1182/blood-2006-10-048652; MARSH SG, 2009, TISSUE ANTIGENS  JUN, P364; MARTIN PJ, 1987, ADV IMMUNOL, V40, P379, DOI 10.1016/S0065-2776(08)60243-6; Matesanz R, 2009, TRANSPL P, V41, P2297, DOI 10.1016/j.transproceed.2009.05.004; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; Mazzolari E, 2009, AM J HEMATOL, V84, P473, DOI 10.1002/ajh.21447; McGhee SA, 2009, IMMUNOL RES, V45, P37, DOI 10.1007/s12026-009-8108-7; MICKELSON EM, 1976, TRANSPLANTATION, V22, P294, DOI 10.1097/00007890-197609000-00011; MOWAT AP, 1987, TRANSPLANT P, V19, P3236; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; Ogawa H, 2002, TRANSPLANTATION, V74, P236, DOI 10.1097/00007890-200207270-00015; Onodera M, 1999, ACTA HAEMATOL-BASEL, V101, P89, DOI 10.1159/000040930; Orchard PJ, 2007, J PEDIATR-US, V151, P340, DOI 10.1016/j.jpeds.2007.04.054; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Padmanabhan A, 2009, VOX SANG, V97, P153, DOI 10.1111/j.1423-0410.2009.01183.x; Paramesh A, 2009, CLIN NEPHROL, V72, P55; Patel NC, 2009, J ALLERGY CLIN IMMUN, V124, P1062, DOI 10.1016/j.jaci.2009.08.041; Pidala J, 2009, BIOL BLOOD MARROW TR, V15, P881, DOI 10.1016/j.bbmt.2009.03.020; Pillai AA, 2009, WORLD J GASTROENTERO, V15, P4225, DOI 10.3748/wjg.15.4225; Qasim W, 2009, PEDIATRICS, V123, P836, DOI 10.1542/peds.2008-1191; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; REISNER Y, 1978, P NATL ACAD SCI USA, V75, P2933, DOI 10.1073/pnas.75.6.2933; ROWLEY S, 2008, PRINCIPLES PRACTICE, P1223; Sandmaier BM, 2007, BIOL BLOOD MARROW TR, V13, P87, DOI 10.1016/j.bbmt.2006.10.015; Santilli G, 2008, EXPERT OPIN BIOL TH, V8, P397, DOI [10.1517/14712598.8.4.397, 10.1517/14712598.8.4.397 ]; Sarzotti-Kelsoe M, 2009, BLOOD, V114, P1445, DOI 10.1182/blood-2009-01-199323; Sharathkumar A, 2002, J PEDIAT HEMATOL ONC, V24, P215, DOI 10.1097/00043426-200203000-00011; Shipley JL, 2009, EXP HEMATOL, V37, P649, DOI 10.1016/j.exphem.2009.04.002; SINDEL LJ, 1984, J ALLERGY CLIN IMMUN, V73, P829, DOI 10.1016/0091-6749(84)90455-X; Snanoudj R, 2006, TRANSPLANT INT, V19, P693, DOI 10.1111/j.1432-2277.2006.00332.x; Spellman S, 2008, BIOL BLOOD MARROW TR, V14, P37, DOI 10.1016/j.bbmt.2008.05.001; STARZL TE, 1987, TRANSPLANT P, V19, P3230; Thielke J, 2007, SEMIN NEPHROL, V27, P408, DOI 10.1016/j.semnephrol.2007.03.003; Throm RE, 2009, BLOOD, V113, P5104, DOI 10.1182/blood-2008-11-191049; Uchida J, 2008, TRANSPL P, V40, P2285, DOI 10.1016/j.transproceed.2008.06.018; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; Walters MC, 2001, BIOL BLOOD MARROW TR, V7, P665, DOI 10.1053/bbmt.2001.v7.pm11787529; Webber SA, 2006, LANCET, V368, P53, DOI 10.1016/S0140-6736(06)68969-1; Webster AC, 2005, BMJ-BRIT MED J, V331, P810, DOI 10.1136/bmj.38569.471007.AE; Wengler GS, 1996, LANCET, V348, P1484, DOI 10.1016/S0140-6736(96)09392-0; Zou YZ, 2009, CURR OPIN ORGAN TRAN, V14, P414, DOI 10.1097/MOT.0b013e32832d835e	106	99	103	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S324	S335		10.1016/j.jaci.2009.11.014	http://dx.doi.org/10.1016/j.jaci.2009.11.014			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176267	Green Accepted			2022-12-18	WOS:000280170600030
J	Agarwal, S; Mayer, L				Agarwal, Shradha; Mayer, Lloyd			Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunodeficiency; gastrointestinal disease; humoral immunodeficiency; inflammatory intestinal disease	COMMON VARIABLE IMMUNODEFICIENCY; X-LINKED AGAMMAGLOBULINEMIA; SELECTIVE IGA DEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; IMMUNOGLOBULIN-A DEFICIENCY; INFLAMMATORY-BOWEL-DISEASE; WISKOTT-ALDRICH-SYNDROME; CLASS-II DEFICIENCY; NODULAR LYMPHOID HYPERPLASIA; BONE-MARROW-TRANSPLANTATION	Primary humoral immune deficiencies are characterized by limited antibody responses secondary to either impaired B-lymphocyte development or B-cell responses to T-lymphocyte signals. Given that the gastrointestinal tract is the largest lymphoid organ in the body, it is not surprising that intestinal diseases are common in immunodeficiency. These gastrointestinal diseases can be classified into one of 4 groups, infection, malignancy, inflammatory, and autoimmune, and can mimic other known disease processes, such as inflammatory bowel disease and celiac sprue. The exact pathogenesis of these gastrointestinal disorders in the setting of systemic immunodeficiency is still under investigation. However, studies suggest that defects in antibody deficiency alone do not result in gastrointestinal disease but rather that defects in cellular immunity are also involved. Treatment is difficult given an already immunocompromised state, and often therapy with immunomodulators is required for more severe processes. (J Allergy Clin Immunol 2009;124:658-64.)	[Agarwal, Shradha; Mayer, Lloyd] Mt Sinai Sch Med, Div Clin Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Agarwal, S (corresponding author), Mt Sinai Sch Med, Div Clin Immunol, 1 Gustave L Levy Pl,Box 1089, New York, NY 10029 USA.	shradha.agarwal@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK072201] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK072201, P01 DK072201-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aalhotra RK, 2008, ARCH PATHOL LAB MED, V132, P847, DOI 10.1043/1543-2165(2008)132[847:PDGNCA]2.0.CO;2; AMMANN AJ, 1971, MEDICINE, V50, P223, DOI 10.1097/00005792-197105000-00004; Andersen P, 2005, BLOOD, V105, P511, DOI 10.1182/blood-2003-12-4359; Antachopoulos C, 2007, EUR J PEDIATR, V166, P1099, DOI 10.1007/s00431-007-0527-7; ASQUITH P, 1969, LANCET, V2, P129; Atarod Lida, 2003, Iran J Allergy Asthma Immunol, V2, P75; Aukrust P, 1996, BLOOD, V87, P674, DOI 10.1182/blood.V87.2.674.bloodjournal872674; Bachmeyer C, 2000, EUR J GASTROEN HEPAT, V12, P1033, DOI 10.1097/00042737-200012090-00013; Barton LL, 1998, CLIN PEDIATR, V37, P231, DOI 10.1177/000992289803700403; BEARD LJ, 1986, PEDIATR RES, V20, P937, DOI 10.1203/00006450-198610000-00006; BENBASSAT J, 1973, BMJ-BRIT MED J, V4, P762, DOI 10.1136/bmj.4.5895.762; BIENENSTOCK J, 1975, AM J VET RES, V36, P488; Bjoro K, 1999, J INTERN MED, V245, P517, DOI 10.1046/j.1365-2796.1999.00457.x; Bonhomme D, 2000, J IMMUNOL, V165, P4725, DOI 10.4049/jimmunol.165.8.4725; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Buckley RH, 2002, J ALLERGY CLIN IMMUN, V109, P747, DOI 10.1067/mai.2002.123617; Byrne MF, 2003, EUR J GASTROEN HEPAT, V15, P1051, DOI 10.1097/00042737-200309000-00019; CARDINALE F, 1995, ADV EXP MED BIOL, V371, P713; CASTELLANO G, 1992, J CLIN GASTROENTEROL, V15, P128, DOI 10.1097/00004836-199209000-00010; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Cataldo F, 1998, GUT, V42, P362, DOI 10.1136/gut.42.3.362; Cellier C, 2000, NEW ENGL J MED, V342, P1611, DOI 10.1056/NEJM200005253422113; Chua I, 2007, CLIN EXP IMMUNOL, V150, P306, DOI 10.1111/j.1365-2249.2007.03481.x; COLLIN P, 1992, SCAND J GASTROENTERO, V27, P367, DOI 10.3109/00365529209000089; Conley ME, 2000, CLIN REV ALLERG IMMU, V19, P183, DOI 10.1385/CRIAI:19:2:183; CONLEY ME, 1994, IMMUNOL REV, V138, P5, DOI 10.1111/j.1600-065X.1994.tb00844.x; CONLEY ME, 1981, NEW ENGL J MED, V305, P495, DOI 10.1056/NEJM198108273050905; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES C, 1987, J CLIN IMMUNOL, V7, P294, DOI 10.1007/BF00915550; Daniels JA, 2007, AM J SURG PATHOL, V31, P1800, DOI 10.1097/PAS.0b013e3180cab60c; Daniels JA, 2009, HUM PATHOL, V40, P484, DOI 10.1016/j.humpath.2008.09.008; Dimicoli S, 2003, BONE MARROW TRANSPL, V32, P733, DOI 10.1038/sj.bmt.1704211; Elnachef N, 2007, AM J GASTROENTEROL, V102, P1322, DOI 10.1111/j.1572-0241.2007.01141.x; Ermis F, 2008, INTERNAL MED, V47, P415, DOI 10.2169/internalmedicine.47.0535; FALCHUK KR, 1975, GASTROENTEROLOGY, V69, P503; FERRER JM, 1995, CLIN EXP IMMUNOL, V102, P286; FISCHER MB, 1993, J ALLERGY CLIN IMMUN, V92, P340, DOI 10.1016/0091-6749(93)90178-I; FISCHER MB, 1994, BLOOD, V84, P4234, DOI 10.1182/blood.V84.12.4234.bloodjournal84124234; Fogarty L, 1996, PEDIATR INFECT DIS J, V15, P553, DOI 10.1097/00006454-199606000-00021; Folwaczny C, 2002, ENDOSCOPY, V34, P840, DOI 10.1055/s-2002-34272; Fukushima K, 2008, HEPATOL RES, V38, P415, DOI 10.1111/j.1872-034X.2007.00281.x; GINSBERG A, 1970, AM J MED, V48, P787, DOI 10.1016/S0002-9343(70)80015-8; Goldacker S, 2005, CURR OPIN ALLERGY CL, V5, P504, DOI 10.1097/01.all.0000191888.97397.b3; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Hammarstrom L, 2000, CLIN EXP IMMUNOL, V120, P225, DOI 10.1046/j.1365-2249.2000.01131.x; Heneghan MA, 1997, J CLIN GASTROENTEROL, V25, P421, DOI 10.1097/00004836-199709000-00004; HERBST EW, 1994, CLIN EXP IMMUNOL, V95, P215; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; HEYWORTH MF, 1987, J EXP MED, V165, P1743, DOI 10.1084/jem.165.6.1743; HODGSON HJF, 1977, GUT, V18, P644, DOI 10.1136/gut.18.8.644; Holm AM, 2005, BLOOD, V105, P2887, DOI 10.1182/blood-2004-06-2423; Holm AM, 2003, J IMMUNOL, V170, P5772, DOI 10.4049/jimmunol.170.11.5772; HSIEH KH, 1988, ANN ALLERGY, V60, P429; Huang A, 2006, COLORECTAL DIS, V8, P637, DOI 10.1111/j.1463-1318.2006.01030.x; Iizuka M, 2001, J GASTROEN HEPATOL, V16, P951, DOI 10.1046/j.1440-1746.2001.t01-5-02379.x; JACOBSON KW, 1979, J ALLERGY CLIN IMMUN, V64, P516, DOI 10.1016/0091-6749(79)90061-7; JAMES SP, 1986, GASTROENTEROLOGY, V90, P283, DOI 10.1016/0016-5085(86)90922-4; Kalha Ishaan, 2004, Curr Gastroenterol Rep, V6, P377, DOI 10.1007/s11894-004-0053-y; Khodadad A, 2007, DIGEST DIS SCI, V52, P2977, DOI 10.1007/s10620-006-9736-6; KLEIN C, 1995, BLOOD, V85, P580; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; KLEMOLA T, 1988, J PEDIATR GASTR NUTR, V7, P537, DOI 10.1097/00005176-198807000-00010; Korponay-Szabo IR, 2003, GUT, V52, P1567, DOI 10.1136/gut.52.11.1567; Kutukculer N, 2003, J PEDIATR-US, V142, P194, DOI 10.1067/mpd.2003.41; Lai Ping So A, 1997, Semin Gastrointest Dis, V8, P22; LAVILLA P, 1993, CANCER, V72, P1528, DOI 10.1002/1097-0142(19930901)72:5<1528::AID-CNCR2820720506>3.0.CO;2-V; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; LEUNG DYM, 1991, J PEDIATR-US, V118, P633, DOI 10.1016/S0022-3476(05)83393-1; LEVER AML, 1984, LANCET, V2, P1062; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; Levy Y, 1998, P NATL ACAD SCI USA, V95, P13135, DOI 10.1073/pnas.95.22.13135; Luzi G, 2003, AM J GASTROENTEROL, V98, P118; MAGRATH IT, 1984, PATHOGENESIS LEUKEMI; MANN JG, 1970, AM J MED, V48, P357, DOI 10.1016/0002-9343(70)90066-5; Mannon PJ, 2006, GASTROENTEROLOGY, V131, P748, DOI 10.1053/j.gastro.2006.06.022; Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462; Meini A, 1996, ANN ALLERG ASTHMA IM, V77, P333, DOI 10.1016/S1081-1206(10)63329-7; MELLANDER L, 1986, J CLIN IMMUNOL, V6, P284, DOI 10.1007/BF00917328; MIRMADJLESSI SH, 1984, DIS COLON RECTUM, V27, P822, DOI 10.1007/BF02553947; MISBAH SA, 1992, J CLIN IMMUNOL, V12, P266, DOI 10.1007/BF00918150; Moss SF, 2007, HELICOBACTER, V12, P23, DOI 10.1111/j.1523-5378.2007.00539.x; Nos P, 2006, AM J GASTROENTEROL, V101, P2165, DOI 10.1111/j.1572-0241.2006.00763_5.x; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Ozgur TT, 2008, PEDIATR TRANSPLANT, V12, P910, DOI 10.1111/j.1399-3046.2008.00957.x; Oksenhendler E, 2008, CLIN INFECT DIS, V46, P1547, DOI 10.1086/587669; Onbasi Kevser, 2005, Turk J Gastroenterol, V16, P111; Piascik M, 2007, ADV MED SCI-POLAND, V52, P296; Quartier P, 2000, PEDIATR INFECT DIS J, V19, P1106, DOI 10.1097/00006454-200011000-00020; Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1; Razvi S, 2001, CLIN IMMUNOL, V101, P284, DOI 10.1006/clim.2001.5132; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; RICHMAN LK, 1977, J IMMUNOL, V119, P1515; ROSH JR, 1995, J PEDIATR-US, V126, P143, DOI 10.1016/S0022-3476(95)70519-8; Salcedo J, 1997, GUT, V41, P366, DOI 10.1136/gut.41.3.366; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; SAVILAHTI E, 1973, CLIN EXP IMMUNOL, V13, P395; Sawatzki M, 2007, DIGESTION, V75, P101, DOI 10.1159/000104728; SCHAFFER FM, 1989, P NATL ACAD SCI USA, V86, P8015, DOI 10.1073/pnas.86.20.8015; SPECTOR JI, 1974, JAMA-J AM MED ASSOC, V228, P334, DOI 10.1001/jama.228.3.334; STRANNEGARD O, 1982, CLIN IMMUNOL IMMUNOP, V25, P325, DOI 10.1016/0090-1229(82)90197-0; Sumazaki R, 1996, EUR J PEDIATR, V155, P532, DOI 10.1007/BF01957899; TEAHON K, 1994, GUT, V35, P1244, DOI 10.1136/gut.35.9.1244; Torgerson TR, 2007, J ALLERGY CLIN IMMUN, V120, P744, DOI 10.1016/j.jaci.2007.08.044; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TWOMEY JJ, 1970, ANN INTERN MED, V72, P499, DOI 10.7326/0003-4819-72-4-499; TWOMEY JJ, 1969, AM J MED, V47, P340, DOI 10.1016/0002-9343(69)90218-6; Ugazio A G, 1983, Birth Defects Orig Artic Ser, V19, P169; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; VANDERMEER JWM, 1993, LANCET, V341, P1439, DOI 10.1016/0140-6736(93)90883-I; Villalta D, 2007, ANN NY ACAD SCI, V1109, P212, DOI 10.1196/annals.1398.025; Villard J, 2001, MEDICINE, V80, P405, DOI 10.1097/00005792-200111000-00006; Vorechovsky I, 2000, J IMMUNOL, V164, P4408, DOI 10.4049/jimmunol.164.8.4408; WALCOTT DW, 1994, ANN ALLERGY, V72, P408; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1092, DOI 10.1016/j.jaci.2005.01.016; Washington K, 1996, AM J SURG PATHOL, V20, P1240, DOI 10.1097/00000478-199610000-00010; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Winkelstein JA, 2006, MEDICINE, V85, P193, DOI 10.1097/01.md.0000229482.27398.ad; Wood P, 2007, CLIN EXP IMMUNOL, V149, P410, DOI 10.1111/j.1365-2249.2007.03432.x; Zirkin HJ, 1996, HUM PATHOL, V27, P992, DOI 10.1016/S0046-8177(96)90232-4	121	99	102	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					658	664		10.1016/j.jaci.2009.06.018	http://dx.doi.org/10.1016/j.jaci.2009.06.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19665769	Green Accepted			2022-12-18	WOS:000270802800005
J	Ayuso, R; Grishina, G; Ibanez, MD; Blanco, C; Carrillo, T; Bencharitiwong, R; Sanchez, S; Nowak-Wegrzyn, A; Sampson, HA				Ayuso, Rosalia; Grishina, Galina; Dolores Ibanez, Maria; Blanco, Carlos; Carrillo, Teresa; Bencharitiwong, Ramon; Sanchez, Silvia; Nowak-Wegrzyn, Anna; Sampson, Hugh A.			Sarcoplasmic calcium-binding protein is an EF-hand-type protein identified as a new shrimp allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; Crustacea; shellfish; shrimp; recombinant; Lit v 4; sarcoplasmic calciunt-binding protein	AMINO-ACID-SEQUENCE; RECOMBINANT ALLERGENS; MOLECULAR CHARACTERIZATION; EMERGENCY-DEPARTMENT; FISH ALLERGY; TAIL MUSCLE; FOOD; TROPOMYOSIN; CHAIN; IMMUNOTHERAPY	Background: Shellfish allergy is a long-lasting disorder usually persisting throughout life. Despite its high prevalence, there is limited information about allergenic shrimp proteins. Objective: Characterization of shrimp allergens. Methods: Fifty-two adults and children with a history of immediate allergic reactions to shrimp and elevated serum IgE to shrimp were selected for this study. Tryptic digests from a 20-kd IgE-binding protein were analyzed by LC-MS/MS, identifying the protein as a sarcoplasmic-calcium-binding protein. cDNA encoding sarcoplasmic calcium-binding protein (SCP) from a shrimp cDNA library (Litopenaeus vannamei) was amplified by PCR, cloned into an expression vector, and sequenced. Recombinant SCP was tested with patients' sera. ELISA inhibition experiments determined the fraction of total shrimp IgE recognizing SCP. A functional assay with a rat basophilic leukemia cell line was used to determine the capacity for mediator release induced by SCP. Results: Immunoblotting demonstrated IgE binding by 31 of 52 (59.6%) of the sera to a 20-kd shrimp protein. The protein was identified as a SCP. Amplified cDNA encoding SCP was isolated and sequenced. Open reading frame translation provided the complete amino acid sequence of shrimp SCP. Recombinant SCP was recognized by serum IgE from 20 of 52 (38.4%) subjects, of whom 17 of 20 (85%) were children. ELISA inhibition of pooled sera IgE reactivity to BS extract using recombinant SCP was significant (as high as 79%). For some subjects, mediator release induced by recombinant SCP was higher than that induced by recombinant tropomyosin. Conclusion: We have identified and cloned a new shrimp allergen, Lit v 4.0101, an SCP, which appears to be of particular importance in the pediatric population. (J Allergy Clin Immunol 2009;124:114-20.)	[Ayuso, Rosalia; Grishina, Galina; Bencharitiwong, Ramon; Nowak-Wegrzyn, Anna; Sampson, Hugh A.] Mt Sinai Sch Med, Div Allergy & Immunol, New York, NY 10029 USA; [Dolores Ibanez, Maria] Mt Sinai Sch Med, Jaffe Food Allergy Res Inst, New York, NY 10029 USA; [Dolores Ibanez, Maria] Univ Nino Jesus, Hosp Infantil, Sect Allergy, Madrid, Spain; [Blanco, Carlos] Hosp Univ Princesa, Sect Allergy, Madrid, Spain; [Carrillo, Teresa] Hosp Univ Dr Negrin, Sect Allergy & Resp Dis, Las Palmas Gran Canaria, Spain; [Sanchez, Silvia] Fdn Jimenez Diaz, Allergy Sect, Madrid, Spain	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Hospital de La Princesa	Ayuso, R (corresponding author), Mt Sinai Sch Med, Div Allergy & Immunol, 1 Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	rosalia.ayuso@mssm.edu	Blanco, Carlos/B-3895-2012	Blanco, Carlos/0000-0002-2893-6594; Nowak-Wegrzyn, Anna/0000-0002-0960-9854	National Institute of Allergy and Infectious Diseases; National Institutes of Health [AI 059318]	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the Food Allergy Initiative. A.N.-W. is supported in part by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, grant no. AI 059318.	Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Ayuso R, 2008, J ALLERGY CLIN IMMUN, V122, P795, DOI 10.1016/j.jaci.2008.07.023; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; Gao Y, 2006, COMP BIOCHEM PHYS B, V144, P478, DOI 10.1016/j.cbpb.2006.04.007; Garcia-Orozco KD, 2007, INT ARCH ALLERGY IMM, V144, P23, DOI 10.1159/000102610; GOODMAN M, 1979, J MOL EVOL, V13, P331, DOI 10.1007/BF01731373; Hindley J, 2006, J ALLERGY CLIN IMMUN, V117, P1389, DOI 10.1016/j.jaci.2006.02.017; Hoffmann A, 1999, ALLERGY, V54, P446, DOI 10.1034/j.1398-9995.1999.00917.x; Kaul S, 2001, ALTEX-ALTERN TIEREXP, V18, P55; Kelly LE, 1997, INSECT BIOCHEM MOLEC, V27, P783, DOI 10.1016/S0965-1748(97)00062-3; Ledesma A, 2002, CLIN EXP ALLERGY, V32, P1476, DOI 10.1046/j.1365-2745.2002.01493.x; Leung PSC, 1998, MOL MAR BIOL BIOTECH, V7, P12; Liu Tzu-Hsuan, 2008, Pediatrics and Neonatology, V49, P58, DOI 10.1016/S1875-9572(08)60014-5; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; SHANTI KN, 1993, J IMMUNOL, V151, P5354; Shiomi K, 2008, INT ARCH ALLERGY IMM, V146, P91, DOI 10.1159/000113512; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Steckelbroeck S, 2008, J ALLERGY CLIN IMMUN, V121, P1323, DOI 10.1016/j.jaci.2008.04.008; Swoboda I, 2002, J IMMUNOL, V168, P4576, DOI 10.4049/jimmunol.168.9.4576; Swoboda I, 2007, J IMMUNOL, V178, P6290, DOI 10.4049/jimmunol.178.10.6290; TAKAGI T, 1984, J BIOCHEM, V95, P1603, DOI 10.1093/oxfordjournals.jbchem.a134773; TAKAGI T, 1984, J BIOCHEM-TOKYO, V96, P59, DOI 10.1093/oxfordjournals.jbchem.a134829; TAKAGI T, 1990, EUR J BIOCHEM, V192, P387, DOI 10.1111/j.1432-1033.1990.tb19239.x; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; WNUK W, 1983, EUR J BIOCHEM, V131, P177, DOI 10.1111/j.1432-1033.1983.tb07246.x; Yu CJ, 2003, J IMMUNOL, V170, P445, DOI 10.4049/jimmunol.170.1.445	30	99	115	5	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					114	120		10.1016/j.jaci.2009.04.016	http://dx.doi.org/10.1016/j.jaci.2009.04.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19523674				2022-12-18	WOS:000267909700014
J	Enriquez, R; Griffin, MR; Carroll, KN; Wu, PS; Cooper, WO; Gebretsadik, T; Dupont, WD; Mitchel, EF; Hartert, TV				Enriquez, Rachel; Griffin, Marie R.; Carroll, Kecia N.; Wu, Pingsheng; Cooper, William O.; Gebretsadik, Tebeb; Dupont, William D.; Mitchel, Edward F.; Hartert, Tina V.			Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pregnancy; medicaid database; outcomes; birth weight	WOMEN; ASSOCIATION; SEVERITY; RISK; MEDICATION; SYMPTOMS; THERAPY	Background: Asthma is a common condition during pregnancy. Objective: We sought to determine the effect of asthma on the rates of adverse pregnancy and fetal outcomes. Methods: We identified pregnancies among black and white women age 15 to 44 with singleton gestations enrolled in the Tennessee Medicaid program over a period of 9 consecutive years, from 1995to 2003, and used claims data to determine the relationship of maternal asthma and asthma exacerbations on pregnancy and infant outcomes. Results: Among the 140,299 pregnancies, 6.5% were in women with asthma. Among women with asthma, 23% had a hospital or emergency department visit (exacerbated asthma): 40% of black and 23% of white women received hospital or emergency, department care for asthma during pregnancy. After controlling for race and other covariates, birth weights among infants of women with asthma were, on average, 38 g lower, and among infants of women with exacerbated asthma they were, on average, 56 g lower. There were moderate, dose-dependent relationships between asthma alone and exacerbated asthma with hypertensive disorders of pregnancy, membrane-related disorders, preterm labor, anteparturn hemorrhage, and cesarean delivery. Maternal asthma was not associated with preterm birth or birth defects. Conclusion: Asthma is a risk factor for several common adverse outcomes of pregnancy, and poorly controlled asthma during pregnancy increases these risks. Clinical implications: It is possible that both maternal and infant outcomes could be improved in this population with appropriate asthma care, especially among black women.	Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Ctr Lung Res, Nashville, TN 37232 USA; Bureau TennCare Tennessee Medicaid, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN USA; Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA; Vanderbilt Univ, Sch Med, Div Gen Internal Med, Nashville, TN USA; Vanderbilt Univ, Sch Med, Div Gen Pediat, Nashville, TN USA; Vanderbilt Univ, Sch Med, Div Adolescent & Child, Hlth Res Unit, Nashville, TN USA; Vanderbilt Univ, Sch Med, Ctr Educ & Res Therapeut, Nashville, TN USA; Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN USA; Vanderbilt Univ, Sch Med, Gen Clin Res Ctr, Nashville, TN USA; Vanderbilt Univ, Sch Med, Meharry Vanderbilt Ctr Reducing Asthma Disparitie, Nashville, TN USA; Vet Affairs Tennessee Valley Hlth Care Syst, Clin Res Ctr Excellence, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Meharry Medical College; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Hartert, TV (corresponding author), Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Ctr Lung Res, T 1218 MCN, Nashville, TN 37232 USA.	Tina.Hariert@vanderbilt.edu	Dupont, William D./I-4430-2012		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010384] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001582] Funding Source: NIH RePORTER; AHRQ HHS [U18-HS10384] Funding Source: Medline; NCRR NIH HHS [MO1 RR00095] Funding Source: Medline; NHLBI NIH HHS [UO1 HL 72471] Funding Source: Medline; NIAID NIH HHS [KO8 AI01582] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acs N, 2005, J MATERN-FETAL NEO M, V18, P107, DOI 10.1080/14767050500198337; Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; [Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, P34, DOI 10.1016/j.jaci.2004.10.023; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; Chambers Karen, 2003, Case Manager, V14, P58, DOI 10.1016/j.casemgr.2003.09.003; Clifton VL, 2001, AM J RESP CRIT CARE, V164, P546, DOI 10.1164/ajrccm.164.4.2009119; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; Dombrowski MP, 2004, OBSTET GYNECOL, V103, P5, DOI 10.1097/01.AOG.0000103994.75162.16; Dombrowski MP, 2004, AM J OBSTET GYNECOL, V190, P737, DOI 10.1016/j.ajog.2003.09.071; Enriquez R, 2006, AM J OBSTET GYNECOL, V195, P149, DOI 10.1016/j.ajog.2006.01.065; Hartert TV, 2000, J AM GERIATR SOC, V48, P651, DOI 10.1111/j.1532-5415.2000.tb04723.x; Hartert TV, 2003, AM J OBSTET GYNECOL, V189, P1705, DOI 10.1016/S0002-9378(03)00857-3; Jadad AR, 2000, LANCET, V355, P119, DOI 10.1016/S0140-6736(99)02542-8; Kallen B, 2000, EUR J EPIDEMIOL, V16, P167, DOI 10.1023/A:1007678404911; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1486, DOI 10.2105/AJPH.84.9.1486; KRAMER MS, 1995, AM J EPIDEMIOL, V142, P1078, DOI 10.1093/oxfordjournals.aje.a117561; Kwon HL, 2003, ANN EPIDEMIOL, V13, P317, DOI 10.1016/S1047-2797(03)00008-5; Liu SL, 2001, AM J OBSTET GYNECOL, V184, P90, DOI 10.1067/mob.2001.108073; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Martel MJ, 2005, BMJ-BRIT MED J, V330, P230, DOI 10.1136/bmj.38313.624352.8F; Olesen C, 2001, RESPIRATION, V68, P256, DOI 10.1159/000050507; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; Pines JM, 2006, J ASTHMA, V43, P219, DOI 10.1080/02770900600567015; Piper J M, 1991, Paediatr Perinat Epidemiol, V5, P402, DOI 10.1111/j.1365-3016.1991.tb00726.x; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Schatz M, 2006, AM J OBSTET GYNECOL, V194, P120, DOI 10.1016/j.ajog.2005.06.028; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; Schatz M, 2004, J ALLERGY CLIN IMMUN, V113, P1040, DOI 10.1016/j.jaci.2004.03.017; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Sheiner E, 2005, J MATERN-FETAL NEO M, V18, P237, DOI 10.1080/14767050500260616; Tata LJ, 2007, AM J RESP CRIT CARE, V175, P991, DOI 10.1164/rccm.200611-1641OC; Triche EW, 2004, OBSTET GYNECOL, V104, P585, DOI 10.1097/01.AOG.0000136481.05983.91; Wen SW, 2001, ANN EPIDEMIOL, V11, P7, DOI 10.1016/S1047-2797(00)00077-6	33	99	102	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					625	630		10.1016/j.jaci.2007.05.044	http://dx.doi.org/10.1016/j.jaci.2007.05.044			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17658591				2022-12-18	WOS:000249505400022
J	Kattan, M; Gergen, PJ; Eggleston, P; Visness, CM; Mitchell, HE				Kattan, Meyer; Gergen, Peter J.; Eggleston, Peyton; Visness, Cynthia M.; Mitchell, Herman E.			Health effects of indoor nitrogen dioxide and passive smoking on urban asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; nitrogen dioxide; tobacco smoke; pollution; passive smoking	INNER-CITY CHILDREN; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; AIR-POLLUTION; RISK-FACTORS; PERSONAL EXPOSURE; PARENTAL SMOKING; LUNG-FUNCTION; ASSOCIATION; MORBIDITY	Background: Nitrogen dioxide (NO2) and environmental tobacco smoke (ETS) have been associated with adverse respiratory effects. Objective: We sought to assess the effect of NO2 and ETS on asthma morbidity among children in inner-city environments. Methods: Asthmatic children between the ages of 4 and 9 years had exposure to NO2 and ETS measured by using Palmes tubes in the home and urinary cotinine. A baseline interview and telephone assessments at 3, 6, and 9 months evaluated health service use, asthma symptoms, and peak flow rates. Results: Gas stoves were present in 87.8% of 469 homes. The median level of indoor NO2 was 29.8 ppb compared with the US national outdoor median of 18 ppb. Of 1444 children, 48% had urinary cotinine/creatinine ratios of greater than 30 ng/mg. The median level of the cotinine/creatinine ratio was 42.4 ng/mg in smoking homes compared with 18.0 ng/mg in nonsmoking homes. The relative risk for asthma symptoms with increased NO2 exposure was 1.75 (95% CI, 1.10-2.78) in children who did not have positive skin test responses. Higher NO2 exposure resulted in lower peak flows during colder months (relative risk, 1.46; 95% CI, 1.07-1.97). Higher ETS exposure in colder months was weakly associated with lower peak flows (relative risk, 1.21; 95% CI, 0.99-1.47). There was no effect of ETS exposure on symptoms or use of health care services. Conclusion: Higher levels of indoor NO2 are associated with increased asthma symptoms in nonatopic children and decreased peak flows.Clinical implications: Interventions to reduce NO2 exposure, such as venting of gas stoves, might help reduce asthma morbidity.	Univ Hosp Columbia & Cornell, Childrens Hosp New York Presbyterian, Dept Pediat, New York, NY 10032 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; Natl Inst Allergy & Infect Dis, Natl Inst Hlth, Div Allergy Immunol & Transplantat, Asthma Allergy & Inflammat Branch, Bethesda, MD USA; Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; Rho Fed Syst Div Inc, Chapel Hill, NC USA	NewYork-Presbyterian Hospital; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins Medicine	Kattan, M (corresponding author), Univ Hosp Columbia & Cornell, Childrens Hosp New York Presbyterian, Dept Pediat, 3959 Broadway, New York, NY 10032 USA.	meyer.kattan@mssm.edu			PHS HHS [A1-30779, UOI A1-30751, A1-30780, A1-30772, A1-30777, N01-A1-15105, A1-30752, A1-30773-01, A1-30756] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Belanger K, 2006, AM J RESP CRIT CARE, V173, P297, DOI 10.1164/rccm.200408-1123OC; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; COPAS JB, 1991, STATISTICIAN, V40, P51; DiFranza JR, 1996, PEDIATRICS, V97, P560; DUFF AL, 1993, PEDIATRICS, V92, P535; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681, DOI 10.1164/ajrccm.154.3.8810605; Farrow A, 1997, ARCH ENVIRON HEALTH, V52, P189, DOI 10.1080/00039899709602885; Garrett MH, 1998, AM J RESP CRIT CARE, V158, P891, DOI 10.1164/ajrccm.158.3.9701084; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Gergen PJ, 2002, J PEDIATR-US, V141, P631, DOI 10.1067/mpd.2002.127510; HENDERSON FW, 1989, AM REV RESPIR DIS, V140, P197, DOI 10.1164/ajrccm/140.1.197; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786, DOI 10.1164/ajrccm.151.6.7767521; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Just J, 2002, EUR RESPIR J, V20, P899, DOI 10.1183/09031936.02.00236902; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Klepeis NE, 2001, J EXPO ANAL ENV EPID, V11, P231, DOI 10.1038/sj.jea.7500165; Lee K, 1998, J AIR WASTE MANAGE, V48, P736, DOI 10.1080/10473289.1998.10463717; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Linaker CH, 2000, THORAX, V55, P930, DOI 10.1136/thorax.55.11.930; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36, DOI 10.1001/archpedi.155.1.36; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mitchell H, 1997, PEDIATR PULM, V24, P237; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; *NAT I MED, 2000, COMM ASS ASTHM IND A, P263; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; Ng TP, 2001, THORAX, V56, P596, DOI 10.1136/thorax.56.8.596; Pilotto LS, 1997, INT J EPIDEMIOL, V26, P788, DOI 10.1093/ije/26.4.788; Ponsonby AL, 2001, CLIN EXP ALLERGY, V31, P1205, DOI 10.1046/j.1365-2222.2001.01168.x; Robbins AS, 2002, ANN EPIDEMIOL, V12, P452, DOI 10.1016/S1047-2797(01)00278-2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Shima M, 2000, INT J EPIDEMIOL, V29, P862, DOI 10.1093/ije/29.5.862; Smith BJ, 2000, EUR RESPIR J, V16, P879, DOI 10.1183/09031936.00.16587900; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; *US EPA, 2003, 454R03005 EPA; *US EPA, 2004, NAT AMB AIR QU STAND; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016	41	99	101	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					618	624		10.1016/j.jaci.2007.05.014	http://dx.doi.org/10.1016/j.jaci.2007.05.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17582483				2022-12-18	WOS:000249505400021
J	Valero, A; Ferrer, M; Sastre, J; Navarro, AM; Monclus, L; Marti-Guadano, E; Herdman, M; Davila, I; del Cuvillo, A; Colas, C; Baro, E; Antepara, I; Alonso, J; Mullol, J				Valero, Antonio; Ferrer, Montse; Sastre, Joaquin; Navarro, Ana M.; Monclus, Laura; Marti-Guadano, Enrique; Herdman, Michael; Davila, Ignacio; del Cuvillo, Alfonso; Colas, Carlos; Baro, Eva; Antepara, Ignacio; Alonso, Jordi; Mullol, Joaquim			A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; severity criteria; ARIA; quality of life	QUALITY-OF-LIFE; HEALTH-STATUS; CLASSIFICATION; INTERMITTENT; PREVALENCE; VALIDATION	Background: Allergic Rhinitis and its Impact on Asthma (ARIA) differentiates mild from moderate/severe patients on the basis of 4 severity items. The high prevalence of moderate/severe patients suggests the need to differentiate between them. Objectives: To identify the categorization that maximizes discrimination between moderate and severe allergic rhinitis (AR) by using ARIA guidelines. Methods: Observational, cross-sectional study. Clinical characteristics, nasal symptoms (Total Symptom Score 4), and health-related quality of life (HRQL; Rhinoconjunctivitis Quality of Life Questionnaire and Short Form 12) were assessed. The association of severity items (sleep, daily activities/sport, work/school, and troublesome symptoms) with symptoms and HRQL was analyzed using linear regression models. ANOVA and effect sizes were used to assess differences in symptoms and HRQL among groups defined by the number of affected ARIA items. Results: Nontreated patients (N = 141) with moderate/severe AR were studied. All severity items showed a similar independent association with symptoms and HRQL scores, and there were no interaction effects, indicating that categorization of patients into moderate and severe could be based only on the number of items affected. Effect sizes were highest between patients with 4 affected ARIA items and those with 3, 2, or 1 affected item (effect sizes greater than 0.8 in all comparisons using Rhinoconjunctivitis Quality of Life Questionnaire and Short Form 12 Physical Composite Summary, and greater than 0.5 using the Total Symptom Score 4; P < .001). Conclusion: Using ARIA severity items, the criterion that best discriminates AR severity is considering moderate those with I to 3 affected items and severe those with 4. Clinical implications: Discrimination between patients with moderate and severe AR should help to obtain homogeneous populations for both research and clinical purposes.	Hosp Clin Barcelona, ICT, Serv Neumol & Alergia Resp, Unidad Alergia, Barcelona 08036, Spain; Inst Municipal Invest Med, Hlth Serv Res Unit, E-08003 Barcelona, Spain; Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain; Hosp EI Tomillar, Unidad Alergia, Seville, Spain; J Uriach & Co, Barcelona, Spain; Hosp Badalona Germans Trias & Pujol, Unidad Alergia, Badalona, Spain; 3D Hlth Res, Barcelona, Spain; Clin Dr Lobaton, Cadiz, Spain; Hosp Clin Lozano Blesa, Serv Alergia, Zaragoza, Spain; Hosp Basurto, Serv Alergia, Bilbao, Spain; IDIBAPS, Inst Invest Biomed August Pi Sunyer, Hosp Clin,Serv Otorinolaringol, Unitat Rinol Clin Olfacte, Barcelona, Spain; CIBER, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; Hospital Germans Trias i Pujol; Lozano Blesa University Clinical Hospital; Basurto Hospital; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red	Valero, A (corresponding author), Hosp Clin Barcelona, ICT, Serv Neumol & Alergia Resp, Unidad Alergia, C Villarroel 170, Barcelona 08036, Spain.	Valero@clinic.ub.es	2007, Secribsal/A-1556-2012; Ferrer, Montse/A-5510-2010; Del Cuvillo Bernal, Alfonso/G-7539-2011; Dávila, Ignacio/K-4453-2012; Ferrer, Marta/C-4319-2016; Herdman, Michael/AAI-7280-2020; Alonso, Jordi/A-5514-2010	Ferrer, Montse/0000-0001-9867-7391; Del Cuvillo Bernal, Alfonso/0000-0003-4332-0920; Dávila, Ignacio/0000-0001-8485-5513; Ferrer, Marta/0000-0001-8495-1302; Alonso, Jordi/0000-0001-8627-9636; Colas Sanz, Carlos/0000-0001-8959-6784				Bachert C, 2006, ALLERGY, V61, P693, DOI 10.1111/j.1398-9995.2006.01054.x; Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bousquet J, 2006, ALLERGY, V61, P1086, DOI 10.1111/j.1398-9995.2006.01144.x; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V117, P158, DOI 10.1016/j.jaci.2005.09.047; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x; Bousquet J, 2005, ALLERGY, V60, P788, DOI 10.1111/j.1398-9995.2005.00820.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Canonica GW, 2006, RESP MED, V100, P1706, DOI 10.1016/j.rmed.2006.03.039; Ciprandi G, 2005, ALLERGY, V60, P882, DOI 10.1111/j.1398-9995.2005.00602.x; Cohen J., 1988, STAT POWER ANAL BEHA; Demoly P, 2003, ALLERGY, V58, P672, DOI 10.1034/j.1398-9995.2003.t01-1-00202.x; Ferrer M, 1997, ANN INTERN MED, V127, P1072, DOI 10.7326/0003-4819-127-12-199712150-00003; Fonseca JA, 2004, ALLERGY, V59, P1198, DOI 10.1111/j.1398-9995.2004.00515.x; HOECKE H, 2006, ALLERGY, V61, P705; Hoogendoorn M, 2006, RESP MED, V100, P83, DOI 10.1016/j.rmed.2005.04.004; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; PEREIRA C, 2006, ALLERG IMMUNOL PARIS, V38, P186; Prenner BM, 2006, AM J MED, V119, P230, DOI 10.1016/j.amjmed.2005.06.015; RUTTENVANMOLKEN MP, 2006, CHEST, V130, P117; Soler R, 2004, REV CLIN ESP, V204, P131, DOI 10.1157/13058825; Van Hoecke H, 2006, J ALLERGY CLIN IMMUN, V118, P758, DOI 10.1016/j.jaci.2006.05.015; Vilagut Gemma, 2005, Gac Sanit, V19, P135, DOI 10.1157/13074370; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	26	99	102	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					359	365		10.1016/j.jaci.2007.04.006	http://dx.doi.org/10.1016/j.jaci.2007.04.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17531304				2022-12-18	WOS:000248654900021
J	Chang, TW; Shiung, YY				Chang, TW; Shiung, YY			Anti-IgE as a mast cell-stabilizing therapeutic agent	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; anti-IgE; mast cells; mast cell stabilizing; omalizumab; cromones; Fc epsilon RI; sensitivity; receptor density	FC-EPSILON-RI; SEASONAL ALLERGIC RHINITIS; HUMAN BASOPHILS; DISODIUM-CROMOGLYCATE; HIGH-AFFINITY; IN-VITRO; ACQUIRED-IMMUNITY; ARACHIDONIC-ACID; CROMOLYN SODIUM; DOWN-REGULATION	After nearly 20 years of development, humanized monoclonal anti-IgE antibodies have been shown in about 20 phase 11 and III clinical trials to be effective and safe in treating allergic asthma, perennial and seasonal allergic rhinitis, and allergic reactions to peanuts. Omalizumab has been approved in the United States, European Union, and several other countries for treating patients 12 years and older with moderate-to-severe allergic asthma. Although anti-IgE is often referred to as an IgE-neutralizing antibody and can block IgE's binding to high-affinity IgE Fc receptors (Fc epsilon RI) on mast cells and basophils, it has multiple immunoregulatory effects. One such effect is that as the result of depleting free IgE, Fc epsilon RI on mast cells and basophils is downregulated to less than 5% within a few weeks to a few months of anti-IgE treatment. This renders the mediator-packed inflammatory cells insensitive to allergen stimulation. Hence this therapeutic anti-IgE represents a new class of mast cell-stabilizing agents, reducing Fc epsilon RI density on mast cells and basophils and causing them to be insensitive to allergens. This mechanism contrasts with that of cromones, mast cell-stabilizing agents that retard Ca++ mobilization and the degranulation process, thus deflating the intracellular activation signal triggered by IgE-Fc epsilon RI aggregation.	Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu, Taiwan	Academia Sinica - Taiwan; National Tsing Hua University	Chang, TW (corresponding author), Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.	twchang@gate.sinica.edu.tw	Chang, Tse Wen/H-5955-2011					Abramson J, 2002, MOL IMMUNOL, V38, P1307, DOI 10.1016/S0161-5890(02)00080-9; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Austen KF, 2001, LEUKEMIA RES, V25, P511, DOI 10.1016/S0145-2126(01)00030-3; Babu KS, 2001, EXPERT OPIN BIOL TH, V1, P1049, DOI 10.1517/14712598.1.6.1049; Baghestanian M, 2002, INT ARCH ALLERGY IMM, V129, P228, DOI 10.1159/000066773; Befus AD, 1999, J IMMUNOL, V163, P947; Berger W, 2003, ANN ALLERG ASTHMA IM, V91, P182, DOI 10.1016/S1081-1206(10)62175-8; Bingham CO, 2000, J ALLERGY CLIN IMMUN, V105, pS527, DOI 10.1016/S0091-6749(00)90056-3; Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse W, 2001, CURR OPIN ALLERGY CL, V1, P105, DOI 10.1097/00130832-200102000-00017; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Castells MC, 2001, NAT IMMUNOL, V2, P436, DOI 10.1038/87749; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; CHANG TW, 1990, BIO-TECHNOL, V8, P122, DOI 10.1038/nbt0290-122; Church MK, 2002, CURR OPIN ALLERGY CL, V2, P419, DOI 10.1097/00130832-200210000-00009; Church MK, 1997, J ALLERGY CLIN IMMUN, V99, P155, DOI 10.1016/S0091-6749(97)70089-7; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVIS FM, 1993, SPRINGER SEMIN IMMUN, V15, P51; Edwards AM, 2005, J ALLERGY CLIN IMMUN, V115, P885, DOI 10.1016/j.jaci.2005.01.063; FUKUZUMI T, 1990, EXP HEMATOL, V18, P843; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Hashiguchi S, 2003, J BIOCHEM, V133, P43, DOI 10.1093/jb/mvg001; He SH, 1999, J PHARMACOL EXP THER, V291, P517; He SH, 2004, J PHARMACOL EXP THER, V309, P119, DOI 10.1124/jpet.103.061291; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IRANI AMA, 1994, ALLERGY PROC, V15, P303, DOI 10.2500/108854194778816472; Jutel M, 2005, CURR OPIN ALLERGY CL, V5, P365, DOI 10.1097/01.all.0000173784.81024.7a; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; KIRSHENBAUM AS, 1991, J IMMUNOL, V146, P1410; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V90, P13, DOI 10.1016/S1081-1206(10)61654-7; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V91, P154, DOI 10.1016/S1081-1206(10)62170-9; Leung Donald Y M, 2004, Novartis Found Symp, V257, P248; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Leynadier F, 2004, J ALLERGY CLIN IMMUN, V113, P360, DOI 10.1016/j.jaci.2003.11.020; Li L, 1999, ALLERGY, V54, P306, DOI 10.1034/j.1398-9995.1999.00086.x; Lunderius C, 2000, EUR J IMMUNOL, V30, P3396, DOI 10.1002/1521-4141(2000012)30:12<3396::AID-IMMU3396>3.0.CO;2-O; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan D, 2005, ANN NY ACAD SCI, V1050, P73, DOI 10.1196/annals.1313.009; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Machado DC, 1996, EUR J IMMUNOL, V26, P2972, DOI 10.1002/eji.1830261224; Malbec O, 2002, MOL IMMUNOL, V38, P1295, DOI 10.1016/S0161-5890(02)00078-0; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; McGill James I., 2004, International Ophthalmology, V25, P171, DOI 10.1007/s10792-004-1818-x; Mekori YA, 1999, J ALLERGY CLIN IMMUN, V104, P517, DOI 10.1016/S0091-6749(99)70316-7; MEKORI YA, 1994, J IMMUNOL, V153, P2194; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; Milgrom H, 2004, Minerva Pediatr, V56, P469; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Nabe T, 2004, EUR J PHARMACOL, V497, P97, DOI 10.1016/j.ejphar.2004.06.033; NAGLER A, 1995, CLIN EXP IMMUNOL, V100, P529; Nayak A, 2003, ALLERGY ASTHMA PROC, V24, P323; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Olsson N, 2004, SCAND J IMMUNOL, V59, P267, DOI 10.1111/j.0300-9475.2004.01397.x; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; Papadopoulos EJ, 2000, EUR J IMMUNOL, V30, P2355, DOI 10.1002/1521-4141(2000)30:8<2355::AID-IMMU2355>3.0.CO;2-#; Parikh V, 1998, J CARDIOVASC PHARM, V31, P779, DOI 10.1097/00005344-199805000-00018; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Saini SS, 1999, J IMMUNOL, V162, P5624; Siraganian RP, 2003, CURR OPIN IMMUNOL, V15, P639, DOI 10.1016/j.coi.2003.09.010; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Storms W, 2005, J ASTHMA, V42, P79, DOI 10.1081/JAS-52017; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; TABUCHI Y, 1994, AGENTS ACTIONS, V41, P21, DOI 10.1007/BF01986388; TSICOPOULOS A, 1988, INT J IMMUNOPHARMACO, V10, P227, DOI 10.1016/0192-0561(88)90053-7; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; VALENT P, 1992, ADV IMMUNOL, V52, P333, DOI 10.1016/S0065-2776(08)60879-2; Wang YH, 2005, ALLERGY, V60, P117, DOI 10.1111/j.1398-9995.2004.00641.x; Wedemeyer J, 2000, BRIT MED BULL, V56, P936, DOI 10.1258/0007142001903616; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; YANAGIDA M, 1995, BLOOD, V86, P3705, DOI 10.1182/blood.V86.10.3705.bloodjournal86103705; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; [No title captured]	94	99	106	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1203	1212		10.1016/j.jaci.2006.04.005	http://dx.doi.org/10.1016/j.jaci.2006.04.005			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750976				2022-12-18	WOS:000238332300001
J	[Anonymous]				[Anonymous]			Managing asthma during pregnancy: Recommendations for pharmacologic treatment - 2004 update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; beta(2)-agonists; cromolyn; infant; inhaled and oral corticosteroids; lactation; leukotriene modifiers; NAEPP; pregnancy; pharmacologic treatment; theophylline	DEVELOPMENTAL TOXICITY; PERINATAL OUTCOMES; PRENATAL EXPOSURE; GENERAL-PRACTICE; CLEFT-PALATE; THEOPHYLLINE; WOMEN; RATS; CORTICOSTEROIDS; HYDROCORTISONE											ABBOTT BD, 1992, TERATOLOGY, V45, P35, DOI 10.1002/tera.1420450104; ABBOTT BD, 1992, CHEMOSPHERE, V25, P75, DOI 10.1016/0045-6535(92)90483-8; ABBOTT BD, 1994, TOXICOL APPL PHARM, V128, P138, DOI 10.1006/taap.1994.1191; Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; Agarwal H S, 1998, Indian Pediatr, V35, P467; Alexander DJ, 1997, INHAL TOXICOL, V9, P477; Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; Baker ER, 1997, OBSTET GYNECOL, V89, P861, DOI 10.1016/S0029-7844(97)81432-9; BEAM WR, 1992, AM REV RESPIR DIS, V146, P1524, DOI 10.1164/ajrccm/146.6.1524; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; Carmichael SL, 1999, AM J MED GENET, V86, P242, DOI 10.1002/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO;2-U; Czeizel AE, 1997, TERATOLOGY, V56, P335, DOI 10.1002/(SICI)1096-9926(199711)56:5<335::AID-TERA7>3.0.CO;2-W; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; *DEP HHS NIH, 2004, 043279 NIH PUBL; *DEP HHS NIH, 2003, 025074 NIH PUBL; *DEP HHS NIH, 1997, 974051 NIH PUBL; *DEP HHS NIH, 1993, 933279 NIH PUBL; Dodic M, 1998, CLIN SCI, V94, P149, DOI 10.1042/cs0940149; Dombrowski M P, 1996, J Matern Fetal Med, V5, P310; Dombrowski MP, 2004, AM J OBSTET GYNECOL, V190, P737, DOI 10.1016/j.ajog.2003.09.071; HARRIS MW, 1992, FUND APPL TOXICOL, V19, P186, DOI 10.1016/0272-0590(92)90150-G; HART AD, 1990, BRIT J NUTR, V64, P339, DOI 10.1079/BJN19900036; HART AD, 1990, ANN NUTR METAB, V34, P297, DOI 10.1159/000177601; Jobe AH, 1998, AM J OBSTET GYNECOL, V178, P880, DOI 10.1016/S0002-9378(98)70518-6; Kallen B, 2000, EUR J EPIDEMIOL, V16, P167, DOI 10.1023/A:1007678404911; Kallen B, 1999, OBSTET GYNECOL, V93, P392, DOI 10.1016/S0029-7844(98)00454-2; Kwon HL, 2003, ANN EPIDEMIOL, V13, P317, DOI 10.1016/S1047-2797(03)00008-5; LAMB J, 1997, ENVIRON HEALTH PER S, V105, P1355; Leon D, 2002, J NEUROCHEM, V82, P625, DOI 10.1046/j.1471-4159.2002.01008.x; LINDSTROM P, 1990, FUND APPL TOXICOL, V14, P167, DOI 10.1016/0272-0590(90)90242-C; Murphy VE, 2002, J CLIN ENDOCR METAB, V87, P1660, DOI 10.1210/jc.87.4.1660; NEFF RK, 1990, CHEST, V97, P1266, DOI 10.1378/chest.97.5.1266; Norjavaara E, 2003, J ALLERGY CLIN IMMUN, V111, P736, DOI 10.1067/mai.2003.1340; PARK JM, 1990, SOUTHERN MED J, V83, P1487, DOI 10.1097/00007611-199012000-00031; Park-Wyllie L, 2000, TERATOLOGY, V62, P385, DOI 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; RAYBURN WF, 1994, AM J OBSTET GYNECOL, V171, P770, DOI 10.1016/0002-9378(94)90095-7; Robert E, 1994, Int J Risk Saf Med, V6, P75, DOI 10.3233/JRS-1994-6201; Rodriguez-Pinilla E, 1998, TERATOLOGY, V58, P2, DOI 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4; Rotschild A, 1997, PEDIATR PULM, V23, P76; SAKAMOTO MK, 1991, ANAT REC, V230, P121, DOI 10.1002/ar.1092300112; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Schatz M, 2003, J ALLERGY CLIN IMMUN, V112, P283, DOI 10.1067/mai.2003.1516; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Shibata M, 2000, METHOD FIND EXP CLIN, V22, P101, DOI 10.1358/mf.2000.22.2.796072; STENIUSAARNIALA B, 1995, CHEST, V107, P642, DOI 10.1378/chest.107.3.642; SteniusAarniala BSM, 1996, THORAX, V51, P411, DOI 10.1136/thx.51.4.411; TANGALAKIS K, 1992, EXP PHYSIOL, V77, P709, DOI 10.1113/expphysiol.1992.sp003637; UNO H, 1994, HORM BEHAV, V28, P336, DOI 10.1006/hbeh.1994.1030; Watanabe Chiaki, 1995, Congenital Anomalies, V35, P133, DOI 10.1111/j.1741-4520.1995.tb00307.x; Wendel PJ, 1996, AM J OBSTET GYNECOL, V175, P150, DOI 10.1016/S0002-9378(96)70265-X; Wilton LV, 2002, DRUG SAFETY, V25, P213, DOI 10.2165/00002018-200225030-00006; Wilton LV, 1998, BRIT J OBSTET GYNAEC, V105, P882, DOI 10.1111/j.1471-0528.1998.tb10234.x; WISE LD, 1991, TERATOLOGY, V44, P507, DOI 10.1002/tera.1420440505	54	99	102	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					34	46		10.1016/j.jaci.2004.10.023	http://dx.doi.org/10.1016/j.jaci.2004.10.023			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS					2022-12-18	WOS:000226267000005
J	Kawai, K; Tsuno, NH; Kitayama, J; Okaji, Y; Yazawa, K; Asakage, M; Hori, N; Watanabe, T; Takahashi, K; Nagawa, H				Kawai, K; Tsuno, NH; Kitayama, J; Okaji, Y; Yazawa, K; Asakage, M; Hori, N; Watanabe, T; Takahashi, K; Nagawa, H			Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD4; epigallocatechin gallate; gp120; lymphocyte	GREEN TEA; DOWN-MODULATION; SOLUBLE CD4; T-CELLS; ANTIGEN; INHIBITION; COMPLEX; (-)-EPIGALLOCATECHIN-3-GALLATE; PHOSPHORYLATION; ANTIOXIDANT	Background: Epigallocatechin gallate (EGCG), the major component of tea polyphenol, has been reported to have various physiologic modulatory activities. Several reports also have shown that catechin has a protective effect against HIV infection, part of which is mediated by inhibiting virions to bind to the target cell surface. Objective: We investigated the effect of EGCG on the expression of CD4 molecules and on its ability to bind gp120, an envelope protein of HIV-1. Methods: Peripheral blood CD4(+) T cells were incubated in the presence of EGCG, and the expression of CD4 was evaluated by means of flow cytometry. The effect of EGCG on the antibody binding to CD4 was investigated by using a sandwich ELISA, and the effect on the gp120 binding to CD4 was analyzed by means of flow cytometry. Results: EGCG efficiently inhibited binding of anti-CD4 antibody to its corresponding antigen. This effect was mediated by the direct binding of EGCG to the CD4 molecule, with consequent inhibition of antibody binding, as well as gp120 binding. Conclusion: The present results suggest a potential preventive effect of EGCG on HIV-1 infection by modulating binding to CD4.	Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Transfus Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Kawai, K (corresponding author), Univ Tokyo, Dept Surg Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							ACRES RB, 1986, J BIOL CHEM, V261, P6210; Amarowicz R, 2000, NAHRUNG, V44, P60, DOI [10.1002/(SICI)1521-3803(20000101)44:1&lt;60::AID-FOOD60&gt;3.0.CO;2-L, 10.1002/(SICI)1521-3803(20000101)44:1<60::AID-FOOD60>3.3.CO;2-C]; BENKIRANE M, 1994, EMBO J, V13, P5559, DOI 10.1002/j.1460-2075.1994.tb06893.x; BENKIRANE M, 1995, J VIROL, V69, P6904, DOI 10.1128/JVI.69.11.6904-6910.1995; Briant L, 1996, J IMMUNOL, V156, P3994; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Chow HHS, 2001, CANCER EPIDEM BIOMAR, V10, P53; CRISE B, 1992, J VIROL, V66, P2296, DOI 10.1128/JVI.66.4.2296-2301.1992; ENNEN J, 1994, P NATL ACAD SCI USA, V91, P7207, DOI 10.1073/pnas.91.15.7207; Fassina G, 2002, AIDS, V16, P939, DOI 10.1097/00002030-200204120-00020; FURUKAWA S, 1991, CLIN EXP IMMUNOL, V86, P134; Garofalo T, 1998, J BIOL CHEM, V273, P35153, DOI 10.1074/jbc.273.52.35153; GELEZIUNAS R, 1994, FASEB J, V8, P593, DOI 10.1096/fasebj.8.9.8005387; Grunewald RW, 2000, NEPHROL DIAL TRANSPL, V15, P71, DOI 10.1093/ndt/15.1.71; Harada S, 1999, BIOL PHARM BULL, V22, P1122; Huang ZW, 1997, BIOPOLYMERS, V43, P367, DOI 10.1002/(SICI)1097-0282(1997)43:5<367::AID-BIP3>3.0.CO;2-T; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Kono K, 1994, Kansenshogaku Zasshi, V68, P1518; Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025; LOU FQ, 1989, CHINESE MED J-PEKING, V102, P579; Maeda-Yamamoto M, 1999, J AGR FOOD CHEM, V47, P2350, DOI 10.1021/jf9811525; MOREL I, 1993, BIOCHEM PHARMACOL, V45, P13, DOI 10.1016/0006-2952(93)90371-3; Nakamura K, 1996, J IMMUNOL, V157, P5339; Nakane H, 1989, Nucleic Acids Symp Ser, P115; PAUZA CD, 1990, J EXP MED, V172, P1035, DOI 10.1084/jem.172.4.1035; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; REDDY MM, 1990, J CLIN MICROBIOL, V28, P1744, DOI 10.1128/JCM.28.8.1744-1746.1990; RIVAS A, 1988, J IMMUNOL, V140, P2912; SAKIHAMA T, 1995, IMMUNOL TODAY, V16, P581, DOI 10.1016/0167-5699(95)80081-6; Sartippour MR, 2002, J NUTR, V132, P2307, DOI 10.1093/jn/132.8.2307; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SYMONS JA, 1991, CLIN IMMUNOL IMMUNOP, V60, P72, DOI 10.1016/0090-1229(91)90113-O; Tomozawa S, 1999, BRIT J CANCER, V81, P1274, DOI 10.1038/sj.bjc.6694262; Valcic S, 1996, ANTI-CANCER DRUG, V7, P461, DOI 10.1097/00001813-199606000-00011; Yamaguchi K, 2002, ANTIVIR RES, V53, P19, DOI 10.1016/S0166-3542(01)00189-9; Yang CS, 1997, NATURE, V389, P134, DOI 10.1038/38154; ZHAO BL, 1992, ACTA PHARM SINIC, V13, P9	39	99	115	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					951	957		10.1016/S0091-6749(03)02007-4	http://dx.doi.org/10.1016/S0091-6749(03)02007-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610487				2022-12-18	WOS:000186553300019
J	Profita, M; Sala, A; Bonanno, A; Riccobono, L; Siena, L; Melis, MR; Di Giorgi, R; Mirabella, F; Gjomarkaj, M; Bonsignore, G; Vignola, AM				Profita, M; Sala, A; Bonanno, A; Riccobono, L; Siena, L; Melis, MR; Di Giorgi, R; Mirabella, F; Gjomarkaj, M; Bonsignore, G; Vignola, AM			Increased prostaglandin E-2 concentrations and cyclooxygenase-2 expression in asthmatic subjects with sputum eosinophilia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alveolar macrophages; apoptosis; inflammation; granulocyte-macrophage colony stimulating factor; lipopolysaccharides	INHALED PGE(2); ACID RELEASE; INFLAMMATION; INDUCTION; APOPTOSIS; ENDOTOXIN; ALLERGEN; PROTEIN	Background: Prostaglandin E-2 (PGE(2)) is known to be produced within human airways, but it is not clear whether in airway diseases it can play a deleterious or a beneficial role. Recently it has been reported that PGE(2) can enhance eosinophil survival in vitro. in Objective: To evaluate whether the concentrations of PGE(2) asthmatic airways correlate with the number of eosinophils and can be responsible for eosinophil-enhanced survival and to identify the cyclooxygenase isoform contributing to the synthesis of PGE(2) by cells present in asthmatic airways. Methods: Reversed-phase high-performance liquid chromatography and/or specific radioimmunoassay was used to measure PGE(2) concentrations in induced sputum supernatants from 14 control and 30 asthmatic subjects. Correlations between concentrations of PGE(2) and the number of eosinophils in induced sputum were evaluated. Expression of cyclooxygenase-2 (COX-2) in induced sputum cells was determined by immunocytochemistry, and the effect of COX-2 inhibition on PGE(2) production was evaluated with the use of radiolabeled arachidonic acid. The effects on eosinophil apoptosis by PGE(2) or induced sputum supernatants were studied by using peripheral blood eosinophils obtained by negative immunomagnetic selection. Results: PGE(2) concentrations resulted in elevated samples from asthmatic subjects and directly correlated with the percentage of eosinophils and the concentrations of eosinophilic cationic protein. Immunostaining for COX-2 showed enhanced expression in macrophages of asthmatic subjects when compared with control subjects, and the use of a specific COX-2 inhibitor provided evidence that PGE(2) synthesis was the result of COX-2 enzymatic activity in asthma-induced sputum cells. Supernatant from induced sputum of asthmatic subjects with high eosinophil counts caused a decreased apoptosis of peripheral blood eosinophils when compared with control subjects, and immunoprecipitation of PGE(2) significantly reverted this phenomenon, suggesting that PGE(2) was present in biologically relevant concentrations in induced sputum. Conclusions: The results obtained suggest that COX-2 expression in alveolar macrophages from asthmatic subjects may contribute to enhanced eosinophil survival through an increased PGE(2) production.	Univ Milan, Ctr Cardiopulm Pharmacol, Dept Pharmacol Sci, I-20133 Milan, Italy; Italian Natl Res Council, Inst Lung Pathophysiol, Palermo, Italy; Univ Palermo, Clin Pneumol, Palermo, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Palermo	Sala, A (corresponding author), Univ Milan, Ctr Cardiopulm Pharmacol, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.		bonanno, anna/F-7613-2015; Profita, Mirella/AAY-3165-2020; Bonanno, Anna/AAV-9474-2020; Profita, Mirella/AFU-7423-2022; Sala, Angelo/H-5478-2019; Riccobono, Loredana/F-7950-2015; Profita, Mirella/D-8957-2018	bonanno, anna/0000-0003-3448-283X; Riccobono, Loredana/0000-0002-0012-3591; Profita, Mirella/0000-0002-7821-8283; Sala, Angelo/0000-0001-9290-0257; SIENA, LIBORIA/0000-0002-3182-9503; Melis, Mario Raphael/0000-0002-5418-6301				ARMOUR CL, 1989, EUR J PHARMACOL, V165, P215, DOI 10.1016/0014-2999(89)90715-2; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; Eldridge MW, 2000, J TOXICOL ENV HEAL A, V61, P27, DOI 10.1080/00984100050116762; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Gencay M, 2001, AM J RESP CRIT CARE, V163, P1097, DOI 10.1164/ajrccm.163.5.2003162; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; Needleman P, 1997, J RHEUMATOL, V24, P6; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905, DOI 10.1164/ajrccm.160.6.9903114; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; POWELL WS, 1980, PROSTAGLANDINS, V20, P947, DOI 10.1016/0090-6980(80)90144-6; Profita M, 2000, AM J PHYSIOL-CELL PH, V279, pC1249, DOI 10.1152/ajpcell.2000.279.4.C1249; Profita M, 1999, J ALLERGY CLIN IMMUN, V103, P159, DOI 10.1016/S0091-6749(99)70540-3; Profita M, 2000, J ALLERGY CLIN IMMUN, V105, P711, DOI 10.1067/mai.2000.105122; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SAMUELSSON B, 1987, DRUGS, V33, P2, DOI 10.2165/00003495-198700331-00003; Santini G, 2001, CLIN PHARMACOL THER, V70, P475, DOI 10.1067/mcp.2001.119213; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Taha R, 2000, AM J RESP CRIT CARE, V161, P636, DOI 10.1164/ajrccm.161.2.9811063; TAKENAKA M, 1995, INT ARCH ALLERGY IMM, V108, P247, DOI 10.1159/000237160; Vigano T, 1997, AM J RESP CRIT CARE, V155, P864, DOI 10.1164/ajrccm.155.3.9117018; Vignola AM, 2000, APOPTOSIS, V5, P473, DOI 10.1023/A:1009661406440; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110	30	99	101	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					709	716		10.1016/S0091-6749(03)01889-X	http://dx.doi.org/10.1016/S0091-6749(03)01889-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564348				2022-12-18	WOS:000185831200009
J	Zambrano, JC; Carper, HT; Rakes, GP; Patrie, J; Murphy, DD; Platts-Mills, TAE; Hayden, FG; Gwaltney, JM; Hatley, TK; Owens, AM; Heymann, PW				Zambrano, JC; Carper, HT; Rakes, GP; Patrie, J; Murphy, DD; Platts-Mills, TAE; Hayden, FG; Gwaltney, JM; Hatley, TK; Owens, AM; Heymann, PW			Experimental rhinovirus challenges in adults with mild asthma: Response to infection in relation to IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; rhinovirus; viral infections; IgE; allergic inflammation; eosinophils; eosinophil cationic protein; expired nitric oxide; intracellular adhesion molecule-1	EXPIRED NITRIC-OXIDE; CHILDHOOD ASTHMA; AIRWAY-OBSTRUCTION; VIRAL-INFECTIONS; SERUM IGE; COLDS; EXACERBATIONS; CHILDREN; REACTIVITY; ALLERGENS	Background: Although most children and young adults with asthma are atopic, exacerbations of asthma are frequently associated with viral respiratory tract infections, especially those caused by rhinovirus (HRV). Objective: Young atopic adults with mild asthma were evaluated before and during an experimental HRV infection to test the hypothesis that airway inflammation before virus inoculation may be a risk factor for an adverse response to HRV. Methods: Experimental HRV infections were evaluated in 16 allergic volunteers with mild asthma and 9 nonatopic control patients (age, 18 to 30 years). Before virus inoculation, each participant was screened with tests for lung function, prick skin tests for sensitization to common aeroallergens, measurements of total serum IgE, and serum neutralizing antibodly to rhinovirus-16 (the serotype used for inoculation). The response to infection was monitored for 21 days by using symptom diary cards, tests for lung function, and markers of airway inflammation in nasal washes, blood, and expired air. Results: During the infection, asthmatic patients had cumulative upper and lower respiratory tract symptom scores that were significantly greater over the course of 21 days than scores from the control patients. At baseline, the asthmatic patients also had increased sensitivity to methacholine and significantly lower values for FEV1 (percent predicted) than the control patients (geometric mean and intraquartile values: 87% [79% to 91%] for the asthmatic patients and 101% [90% to 104%] for the control patients, P < .03). Among the patients with mild asthma, 6 had levels of total serum IgE that were substantially elevated (range, 371 to 820 IU/mL) compared with 10 who had lower levels (range, 29 to 124 IU/mL). Those with high levels of IgE had significantly greater lower respiratory tract symptom scores during the initial 4 days of the infection than the low IgE group. They also had higher total blood eosinophil counts at baseline, increased eosinophil cationic protein in their nasal washes (>200 ng/mL), and augmented levels of expired nitric oxide at baseline and during peak cold symptoms. In contrast, levels of soluble intracellular adhesion molecule-1 in nasal wash supernatants from the asthmatic patients with high IgE were diminished, both at baseline and during the infection. Conclusions: The reduced lung function and increased markers of inflammation observed before virus inoculation in the asthmatic patients who had high levels of total serum IgE may be risk factors for an adverse response to infections with HRV.	Univ Virginia, Dept Pediat, Charlottesville, VA 22908 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA; Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Heymann, PW (corresponding author), Univ Virginia, Dept Pediat, POB 800386, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X	NCRR NIH HHS [M01 RR00847] Funding Source: Medline; NIAID NIH HHS [AI20565, 1P01 AI50989] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050989, R01AI020565, R37AI020565] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1997, NIH PUBLICATION; Avila PC, 2000, J ALLERGY CLIN IMMUN, V105, P923, DOI 10.1067/mai.2000.106214; BARDIN PG, 1994, CLIN EXP ALLERGY, V24, P457, DOI 10.1111/j.1365-2222.1994.tb00934.x; BARDIN PG, 1995, INT ARCH ALLERGY IMM, V107, P127, DOI 10.1159/000236951; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse WW, 2000, J ALLERGY CLIN IMMUN, V105, P889, DOI 10.1067/mai.2000.106378; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Cameron C. A., 1998, REGRESSION ANAL COUN; Crater SE, 1999, AM J RESP CRIT CARE, V159, P806, DOI 10.1164/ajrccm.159.3.9805103; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; DUFF AL, 1993, PEDIATRICS, V92, P535; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Gern JE, 2000, J ALLERGY CLIN IMMUN, V106, P201, DOI 10.1067/mai.2000.108604; Grunberg K, 1999, AM J RESP CRIT CARE, V160, P1375; GWALTNEY JM, 1980, J INFECT DIS, V142, P811, DOI 10.1093/infdis/142.6.811; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976; Hocking RR, 1996, METHODS APPL LINEAR; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Leigh R, 2000, J ALLERGY CLIN IMMUN, V106, P593; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PAPADOPOULAS NG, 2000, THORAX, V57, P328; PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Riccio MM, 1996, J ALLERGY CLIN IMMUN, V97, P1252, DOI 10.1016/S0091-6749(96)70193-8; SAS Institute Inc, 1997, SAS STAT SOFTW CHANG; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SPECTOR SL, 1983, PROVOCATIVE CHALLENG, V1, P137; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; WINTHER B, 1984, ACTA OTO-LARYNGOL, P19; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	36	99	106	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1008	1016		10.1067/mai.2003.1396	http://dx.doi.org/10.1067/mai.2003.1396			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743565				2022-12-18	WOS:000182904500015
J	Helm, RM; Furuta, GT; Stanley, JS; Ye, JH; Cockrell, G; Connaughton, C; Simpson, P; Bannon, GA; Burks, AW				Helm, RM; Furuta, GT; Stanley, JS; Ye, JH; Cockrell, G; Connaughton, C; Simpson, P; Bannon, GA; Burks, AW			A neonatal swine model for peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						animal model; peanut allergy; food allergy	EARLY-WEANED PIGS; PROTEIN INGESTION; IMMUNE-RESPONSES; MURINE MODEL; PIGLETS; SENSITIZATION; INTERLEUKIN-5; EXPRESSION; INDUCTION; ANTIGEN	Background: Peanut allergy represents a significant health threat in the United States. The factors contributing to the severity of the allergic response and the immunopathogenic mechanisms underlying peanut allergy remain to be completely characterized. As yet, no animal model has been developed that will completely mimic the physical, immunologic, and histologic features of food allergy. Objective: The purpose of this investigation was to develop a neonatal pig model of peanut allergy that would mimic the allergic symptoms and the immunologic and histologic profile of human peanut allergy. Methods: Newborn piglets sensitized intraperitoneally with peanut extract and cholera toxin were orally challenged repeatedly with peanut meal. Physical symptoms, including emesis, lethargy, diarrhea, and respiratory distress, were monitored to determine the allergic response. Immunologic assessment was conducted through use of skin testing and the antigenic response to peanut proteins. Histologically, tissues derived from the esophagus, stomach, small intestine, and colon were assessed for morphologic changes after the oral challenge. Results: Peanut-sensitized pigs responded with physical symptoms that mimicked those seen in double-blinded, placebo-controlled. oral food challenges to peanuts in children and adults. Skin testing suggested an TgE-mediated response; this was confirmed by a negative passive cutaneous anaphylaxis response of heat-treated sera obtained from peanut-sensitized animals. Damage to villi of the small intestine was similar to that seen in endoscopically obtained tissue specimens from certain food-allergic individuals. Conclusion: The neonatal pig model of peanut allergy mimics the physical and immunologic characteristics of peanut allergy in human beings. The model will be useful for determining IgE-mediated mechanisms and conducting endoscopic histologic assessment of tissues and immunotherapeutic intervention strategies with repeated allergen challenges.	Univ Arkansas Med Sci, Arkansas Childrens Hosp, Inst Res,Div Allergy Immunol, Dept Pediat, Little Rock, AR 72201 USA; Harvard Univ, Childrens Hosp, Sch Med, Combined Program Pediat Gastroenterol Nutr, Boston, MA 02115 USA; Univ Arkansas Med Sci, Arkansas Childrens Hosp, Inst Res, CARE, Little Rock, AR 72201 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72201 USA	Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Harvard University; Boston Children's Hospital; Harvard Medical School; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Helm, RM (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Hosp, Inst Res,Div Allergy Immunol, Dept Pediat, Slot 512-13, Little Rock, AR 72201 USA.				NIDDK NIH HHS [P30-DK40561] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVING K, 1991, ACTA PHYSIOL SCAND, V143, P93, DOI 10.1111/j.1748-1716.1991.tb09204.x; BAILEY M, 1994, INT ARCH ALLERGY IMM, V103, P183, DOI 10.1159/000236625; BAILEY M, 1993, INT ARCH ALLERGY IMM, V101, P266, DOI 10.1159/000236456; BARRATT MEJ, 1978, CLIN EXP IMMUNOL, V31, P305; BARRIGA OO, 1984, VET PARASITOL, V16, P343, DOI 10.1016/0304-4017(84)90052-9; BOCK SA, 1993, PEDIATRICS, V93, P683; Buchanan BB, 1997, P NATL ACAD SCI USA, V94, P5372, DOI 10.1073/pnas.94.10.5372; Dearman RJ, 2000, FOOD CHEM TOXICOL, V38, P351, DOI 10.1016/S0278-6915(99)00159-3; del Val G, 1999, J ALLERGY CLIN IMMUN, V103, P690, DOI 10.1016/S0091-6749(99)70244-7; DREAU D, 1994, J ANIM SCI, V72, P2090, DOI 10.2527/1994.7282090x; FORNHEM C, 1995, EUR RESPIR J, V8, P1100, DOI 10.1183/09031936.95.08071100; Fornhem C, 1996, BRIT J PHARMACOL, V118, P989, DOI 10.1111/j.1476-5381.1996.tb15497.x; HANKINS CC, 1992, J ANIM SCI, V70, P3096, DOI 10.2527/1992.70103096x; HEPPELL LMJ, 1989, RES VET SCI, V47, P257, DOI 10.1016/S0034-5288(18)31216-5; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; KLEBOSA F, 1990, AM J VET RES, V51, P1407; LI DF, 1991, J ANIM SCI, V69, P3299; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 1999, J IMMUNOL, V162, P3045; MARINARO M, 1995, J IMMUNOL, V155, P4621; Mitchell HW, 1999, J APPL PHYSIOL, V86, P932, DOI 10.1152/jappl.1999.86.3.932; MURTAUGH MP, 1994, VET IMMUNOL IMMUNOP, V43, P37, DOI 10.1016/0165-2427(94)90118-X; REES AS, 1989, VET IMMUNOL IMMUNOP, V23, P171, DOI 10.1016/0165-2427(89)90119-0; Salmon H, 1999, VET IMMUNOL IMMUNOP, V72, P143, DOI 10.1016/S0165-2427(99)00127-0; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SNIDER DP, 1994, J IMMUNOL, V153, P647; Sylvin H, 2000, IMMUNOGENETICS, V51, P59, DOI 10.1007/s002510050009; TEIGE T, 1997, ACTA VET SCAND, V18, P210; TELEMO E, 1991, SCAND J IMMUNOL, V34, P689, DOI 10.1111/j.1365-3083.1991.tb01593.x; Vandezande LM, 1999, CLIN EXP ALLERGY, V29, P652, DOI [10.1046/j.1365-2222.1999.00514.x, 10.1046/j.1365-2222.1999.00511.x]; Wilkie B, 1999, VET IMMUNOL IMMUNOP, V72, P231, DOI 10.1016/S0165-2427(99)00136-1; WILSON AD, 1989, RES VET SCI, V46, P180, DOI 10.1016/S0034-5288(18)31142-1	33	99	109	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					136	142		10.1067/mai.2002.120551	http://dx.doi.org/10.1067/mai.2002.120551			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799380				2022-12-18	WOS:000173739300023
J	Hamilos, DL; Leung, DYM; Muro, S; Kahn, AM; Hamilos, SS; Thawley, SE; Hamid, QA				Hamilos, DL; Leung, DYM; Muro, S; Kahn, AM; Hamilos, SS; Thawley, SE; Hamid, QA			GR beta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; sinusitis; glucocorticoid; steroid resistance; receptor	GLUCOCORTICOID RECEPTOR-BETA; CHRONIC HYPERPLASTIC SINUSITIS; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; TISSUE EOSINOPHILIA; RESISTANT ASTHMA; MECHANISMS; ISOFORM; ASSOCIATION	Background: Nasal polyposis disease is an inflammatory disorder with intense eosinophilic infiltration of respiratory mucosa that is often difficult to control with topical steroids. Recent evidence suggests that overexpression of the glucocorticoid receptor splice variant GR beta in inflammatory cells might contribute to steroid insensitivity in diseases such as asthma. Objective: The purposes of this investigation were to determine whether nasal polyp (NP) inflammatory cells overexpress GR beta and to examine whether GR beta overexpression is associated with insensitivity to the potent topical steroid fluticasone propionate (FP). Methods: Biopsies were obtained from 10 subjects with NPs before and 4 weeks after treatment with intranasal FP. Middle turbinates biopsies from 6 healthy, nonallergic subjects served as normal controls. Biopsies were immunostained for inflammatory cell markers as well as GR beta and probed for various cytokine mRNA. The anti-inflammatory response to FP was examined in relation to pretreatment levels of GR beta expression. Results: The total numbers of inflammatory cells were increased in NPs. The percentage of inflammatory cells expressing GR beta was also increased (40.5% +/- 19.2% vs 16.1% +/- 4.0%, P = .009). GR beta expression in NPs was almost exclusive to T lymphocytes, eosinophils, and macrophages. An inverse correlation was observed between the baseline inflammatory cell GR beta expression and the reduction after FP treatment in EG2-positive eosinophils, CD4-positive T lymphocytes, endothelial VCAM-1 expression, and IL-4 mRNA-positive cells. NPs that were "FP-insensitive" in terms of suppression of eosinophil numbers (major basic protein-positive) had a significantly greater percentage of GR beta -positive inflammatory cells, a higher ratio of GR beta -positive/GR alpha -positive cells, and increased numbers of GR beta -positive eosinophils and macrophages in comparison with those that were "FP-sensitive" "FP-insensitive" NPs also demonstrated a higher percentage of IL-5-positive inflammatory cells expressing GR beta before and after FP treatment. Conclusion: GR beta expression appears to be a marker of steroid insensitivity in NPs. Expression of GR beta by NP inflammatory cells, particularly T cells and eosinophils, might render them resistant to suppression by topical steroids and thereby contribute to persistent NP inflammation.	Washington Univ, Sch Med, Dept Med, Div Allergy & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Otolaryngol Ear Nose & Throat Surg, St Louis, MO 63110 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Pathol, Montreal, PQ, Canada	Washington University (WUSTL); Washington University (WUSTL); National Jewish Health; McGill University; McGill University	Hamilos, DL (corresponding author), Washington Univ, Sch Med, Dept Med, Div Allergy & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.							ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; BOURKE GJ, 1985, INTERPRETATION USES; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V105, P211, DOI 10.1016/S0091-6749(00)90068-X; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1999, J ALLERGY CLIN IMMUN, V103, P79, DOI 10.1016/S0091-6749(99)70529-4; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Holmberg K, 1997, ANN ALLERG ASTHMA IM, V78, P270, DOI 10.1016/S1081-1206(10)63180-8; Honda M, 2000, GASTROENTEROLOGY, V118, P859, DOI 10.1016/S0016-5085(00)70172-7; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung DYM, 1998, ANN NY ACAD SCI, V840, P735, DOI 10.1111/j.1749-6632.1998.tb09612.x; Leung DYM, 2000, AM J RESP CRIT CARE, V162, P1; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; Oakley RH, 1999, J BIOL CHEM, V274, P27857, DOI 10.1074/jbc.274.39.27857; Simon HU, 1997, J IMMUNOL, V158, P3902; Sousa AR, 1999, J ALLERGY CLIN IMMUN, V104, P565, DOI 10.1016/S0091-6749(99)70325-8; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; Spahn JD, 1996, J IMMUNOL, V157, P2654; TANAKA Y, 1994, J INVEST DERMATOL, V103, P589, DOI 10.1111/1523-1747.ep12396899; Walsh GM, 1997, J ALLERGY CLIN IMMUN, V100, P208, DOI 10.1016/S0091-6749(97)70226-4	23	99	110	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					59	68						10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447383				2022-12-18	WOS:000170171200008
J	Taylor, SL; Hefle, SL				Taylor, SL; Hefle, SL			Will genetically modified foods be allergenic?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						biotechnology; allergy; food; sequence homology; digestion; exposure; classification; heat stability	BETA-LACTOGLOBULIN; HYPERSENSITIVITY REACTIONS; BACILLUS-THURINGIENSIS; DOUBLE-BLIND; HUMAN-MILK; IDENTIFICATION; SENSITIVITY; EXPOSURE; CHILDREN; INFANTS	Foods produced through agricultural biotechnology, including such staples as corn, soybeans, canola, and potatoes, are already reaching the consumer marketplace. Agricultural biotechnology offers the promise to produce crops with improved agronomic characteristics (eg, insect resistance, herbicide tolerance, disease resistance, and climatic tolerance) and enhanced consumer benefits (eg, better taste and texture, longer shelf life, and more nutritious). Certainly, the products of agricultural biotechnology should be subjected to a careful and complete safety assessment before commercialization. Because the genetic modification ultimately results in the introduction of new proteins into the food plant, the safety, including the potential allergenicity, of the newly introduced proteins must be assessed. Although most allergens are proteins, only a few of the many proteins found in foods are allergenic under the typical circumstances of exposure. The potential allergenicity of the introduced proteins call be evaluated by focusing on the source of the gene, the sequence homology of the newly introduced protein to known allergens, the expression level of the novel protein in the modified crop, the functional classification of the novel protein, the reactivity of the novel protein with IgE from the serum of individuals with known allergies to the source of the transferred genetic material, and various physicochemical properties of the newly introduced protein, such as heat stability and digestive stability. Few products of agricultural biotechnology (and none of the current products) will involve the transfer of genes from known allergenic sources, Applying such criteria provides reasonable assurance that the newly introduced protein has limited capability to become an allergen.	Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Taylor, SL (corresponding author), 143 Food Ind Complex, Lincoln, NE 68583 USA.		Taylor, Steve L./V-1341-2019					Aalberse RC, 1997, ENVIRON TOXICOL PHAR, V4, P55, DOI 10.1016/S1382-6689(97)10042-4; ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Beever D. E., 2000, Nutrition Abstracts and Reviews. Series B, Livestock Feeds and Feeding, V70, P175; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; Betz FS, 2000, REGUL TOXICOL PHARM, V32, P156, DOI 10.1006/rtph.2000.1426; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; *FAO UN, 1995, REP FAO TECHN CONS F; *FAO WHO CONS, 2000, SAF ASP GEN MOD FOOD; *FAO WHO CONS, 1996, 61 FAOWHO CONS; Fukushima Y, 1997, AM J CLIN NUTR, V65, P30, DOI 10.1093/ajcn/65.1.30; Harrison LA, 1996, J NUTR, V126, P728, DOI 10.1093/jn/126.3.728; HEFTE SL, 1996, CRIT REV FOOD SCI S, V36, pS69; HOST A, 1990, CLIN EXP ALLERGY, V20, P383, DOI 10.1111/j.1365-2222.1990.tb02798.x; Houben GF, 1997, ENVIRON TOXICOL PHAR, V4, P127, DOI 10.1016/S1382-6689(97)10053-9; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; *IFT, 2000, FOOD TECHNOL, V54, P62; IFT, 2000, FOOD TECHNOL, V54, P61; *IFT, 2000, FOOD TECHNOL, V54, P124; Knippels LMJ, 1999, FOOD CHEM TOXICOL, V37, P881, DOI 10.1016/S0278-6915(99)00064-2; Knippels LMJ, 1998, CLIN EXP ALLERGY, V28, P368, DOI 10.1046/j.1365-2222.1998.00242.x; MACHTINGER S, 1986, J ALLERGY CLIN IMMUN, V77, P341, DOI 10.1016/S0091-6749(86)80115-4; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165, DOI 10.1080/10408399609527763; Moneret-Vautrin D A, 1995, Allerg Immunol (Paris), V27, P2; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; Rance F, 1998, J ALLERGY CLIN IMMUN, V101, pS88; Redenbaugh K., 1992, SAFETY ASSESSMENT GE, P267; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; SORVA R, 1994, J ALLERGY CLIN IMMUN, V93, P787, DOI 10.1016/0091-6749(94)90259-3; Taylor SL, 1997, ENVIRON TOXICOL PHAR, V4, P121, DOI 10.1016/S1382-6689(97)10052-7; Taylor SL, 1996, CRIT REV FOOD SCI, V36, pS91, DOI 10.1080/10408399609527761; Underwood BA, 1994, RETINOIDS BIOL CHEM, P217; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253, DOI 10.1136/adc.58.4.253; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Wal JM, 1998, INT DAIRY J, V8, P413, DOI 10.1016/S0958-6946(98)00064-8; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303	43	99	105	4	121	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					765	771		10.1067/mai.2001.114241	http://dx.doi.org/10.1067/mai.2001.114241			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344340	Bronze			2022-12-18	WOS:000168812300001
J	Minshall, E; Chakir, J; Laviolette, M; Molet, S; Zhu, Z; Olivenstein, R; Elias, JA; Hamid, Q				Minshall, E; Chakir, J; Laviolette, M; Molet, S; Zhu, Z; Olivenstein, R; Elias, JA; Hamid, Q			IL-11 expression is increased in severe asthma: Association with epithelial cells and eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						severe asthma; IL-11; airway remodeling; airways inflammation; collagen deposition	GROWTH-FACTOR-BETA; MESSENGER-RNA; SUBEPITHELIAL FIBROSIS; BRONCHIAL BIOPSIES; INTERLEUKIN-11; CYTOKINE; AIRWAYS; LUNG; IDENTIFICATION; LOCALIZATION	Background: IL-11 is a pleiotropic cytokine produced by a variety of stromal cells. Targeted overexpression of this cytokine in mice results in a remodeling of the airways and the development of airway hyperresponsiveness and airway obstruction. Objectives: Because these alterations mimic important pathologic and physiologic changes in the airways of some asthmatic patients, we investigated the expression of IL-11 messenger RNA (mRNA) within the airways of patients with mild to severe asthma and nonasthmatic control subjects. Methods: Fiberoptic bronchoscopy to obtain bronchial biopsy specimens was performed on patients with mild (n = 13), moderate (n = 10), and severe (n = 9) asthma and on nonasthmatic control subjects (n = 9). Results: These patients differed in their extent of airway fibrosis with types I and III collagens being noted in greater quantities in the biopsy specimens from the severe and moderate asthmatics than in those from controls (P <.05), IL-11 mRNA expression was observed in the epithelial and subepithelial layers of asthmatic and nonasthmatic control subjects. The number of cells within the epithelium and subepithelium expressing IL-11 mRNA was greater in those with moderate and severe asthma compared with mild asthma and nonasthmatic subjects (P <.001). There were also greater numbers of IL-11 mRNA-positive cells within the subepithelium in severe com pared with moderate asthma (P <.001). Immunostaining for IL-11 within the airway tissues confirmed translation of the mRNA into IL-11-immunoreactive protein in airway epithelial cells. Colocalization of IL-11 mRNA and immunoreactivity with resident inflammatory cells demonstrated that this cytokine was also expressed by major basic protein-positive eosinophils. Conclusion: These results suggest that IL-11 is involved in the chronic remodeling seen in asthmatic airways and is associated with increasing severity of the disease.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Hop Laval, Ste Foy, PQ, Canada; Montreal Chest Res Inst, Montreal, PQ, Canada; Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06510 USA	McGill University; Laval University; McGill University; Yale University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; ELIAS JA, 1994, J BIOL CHEM, V269, P22261; ELIAS JA, 1994, J IMMUNOL, V152, P2421; GIAID A, 1993, LANCET, V341, P1550; HAMID Q, 1992, BLOOD, V80, P1496; Hill GR, 1998, J CLIN INVEST, V102, P115, DOI 10.1172/JCI3132; Huang J, 1999, AM J RESP CRIT CARE, V160, P725, DOI 10.1164/ajrccm.160.2.9809040; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, 1994, AM J RESP CRIT CARE, V150, pS6, DOI 10.1164/ajrccm/150.5_Pt_2.S6; Lacy P, 1998, BLOOD, V91, P2508, DOI 10.1182/blood.V91.7.2508.2508_2508_2516; Leng SX, 1997, J IMMUNOL, V159, P2161; MAIER R, 1993, J BIOL CHEM, V268, P21527; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; MOQBEL R, 1995, J IMMUNOL, V155, P4939; Nilsen EM, 1998, GUT, V42, P635, DOI 10.1136/gut.42.5.635; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; ROCHE WR, 1989, LANCET, V1, P520; Rochester CL, 1996, J IMMUNOL, V156, P4449; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Trepicchio WL, 1996, J IMMUNOL, V157, P3627; Trepicchio WL, 1997, J IMMUNOL, V159, P5661; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHENG T, 1994, J IMMUNOL, V153, P4742	34	99	113	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				232	238		10.1016/S0091-6749(00)90070-8	http://dx.doi.org/10.1016/S0091-6749(00)90070-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669841				2022-12-18	WOS:000085402200005
J	Harding, SM				Harding, SM			Gastroesophageal reflux and asthma: Insight into the association	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; gastroesophageal reflux; microaspiration	GASTRO-ESOPHAGEAL REFLUX; INDUCED BRONCHOCONSTRICTION; RESPIRATORY SYMPTOMS; SURGICAL-TREATMENT; DOUBLE-BLIND; THERAPY; OMEPRAZOLE; DISEASE; PREVALENCE; ACIDIFICATION	Gastroesophageal reflux (GER) is a potential trigger of asthma. GER symptoms are more prevalent in asthma patients compared with control populations, with a prevalence of approximately 75%, GER symptoms are associated with respiratory symptoms and inhaler use. GER may also occur without esophageal symptoms, Abnormal esophageal acid contact times are also more prevalent in patients with asthma compared with control populations, with a prevalence of 80%, Pathophysiologic mechanisms of esophageal acid-induced bronchoconstriction include a vagally mediated reflex, heightened bronchial reactivity, and microaspiration. Esophageal acid may increase minute ventilation without evidence of bronchoconstriction, Esophageal acid is associated with the release of substance P in the bronchial mucosa, resulting in airway edema. Medical antireflux therapy with proton pump inhibitors results in asthma symptom improvement in approximately 70% of patients, similar to surgical results, Predictors of asthma response include the presence of regurgitation, proximal acid reflux, esophagitis healing with therapy, reflux-associated respiratory symptoms, or nocturnal asthma, Management of GER in adult patients with asthma should include a 3-month trial of high-dose proton pump inhibitor while monitoring asthma outcome, GER should be considered as a potential asthma trigger: in all patients,	Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Harding, SM (corresponding author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, 215 Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA.							Boeree MJ, 1998, EUR RESPIR J, V11, P1070, DOI 10.1183/09031936.98.11051070; Campo S, 1997, DIGEST DIS SCI, V42, P1184, DOI 10.1023/A:1018841704897; DEMEESTER TR, 1990, ANN SURG, V211, P337, DOI 10.1097/00000658-199003000-00005; DEVAULT KR, 1995, ARCH INTERN MED, V155, P2165, DOI 10.1001/archinte.155.20.2165; DIMARINO AJ, 1982, DIGEST DIS SCI, V27, P1063, DOI 10.1007/BF01391441; EKSTROM T, 1989, THORAX, V44, P19, DOI 10.1136/thx.44.1.19; EKSTROM T, 1988, EUR J CLIN PHARMACOL, V35, P353, DOI 10.1007/BF00561363; ElSerag HB, 1997, GASTROENTEROLOGY, V113, P755, DOI 10.1016/S0016-5085(97)70168-9; Field SK, 1996, CHEST, V109, P316, DOI 10.1378/chest.109.2.316; Field SK, 1998, CHEST, V114, P275, DOI 10.1378/chest.114.1.275; Field SK, 1998, AM J RESP CRIT CARE, V157, P1058, DOI 10.1164/ajrccm.157.4.9707094; Field SK, 1999, CHEST, V115, P848, DOI 10.1378/chest.115.3.848; FORD GA, 1994, POSTGRAD MED J, V70, P350, DOI 10.1136/pgmj.70.823.350; GASTAL OL, 1994, CHEST, V106, P1793, DOI 10.1378/chest.106.6.1793; Hamamoto J, 1997, J APPL PHYSIOL, V82, P738, DOI 10.1152/jappl.1997.82.3.738; Harding SM, 1996, AM J MED, V100, P395, DOI 10.1016/S0002-9343(97)89514-9; Harding SM, 1999, LUNG BIOL HEALTH DIS, V129, P139; Harding SM, 1997, CHEST, V111, P1389, DOI 10.1378/chest.111.5.1389; HARDING SM, 1995, CHEST, V108, P1220, DOI 10.1378/chest.108.5.1220; Harding SM, 1999, CHEST, V115, P654, DOI 10.1378/chest.115.3.654; Harding SM, 1995, AM J RESP CRIT CARE, V151, pA589; HERVE P, 1986, AM REV RESPIR DIS, V134, P986, DOI 10.1164/arrd.1986.134.5.986; HUBERT D, 1988, J ALLERGY CLIN IMMUN, V81, P1168, DOI 10.1016/0091-6749(88)90886-X; Hunter JG, 1996, ANN SURG, V223, P673, DOI 10.1097/00000658-199606000-00006; IRWIN RS, 1993, CHEST, V103, P1662, DOI 10.1378/chest.103.6.1662; JACK CIA, 1995, THORAX, V50, P201, DOI 10.1136/thx.50.2.201; Johnson WE, 1996, ARCH SURG-CHICAGO, V131, P489; KJELLEN G, 1981, EUR J RESPIR DIS, V62, P87; LARRAIN A, 1991, CHEST, V99, P1330, DOI 10.1378/chest.99.6.1330; Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8; Lodi U, 1997, CHEST, V111, P65, DOI 10.1378/chest.111.1.65; MANSFIELD LE, 1981, ANN ALLERGY, V47, P431; MANSFIELD LE, 1978, ANN ALLERGY, V41, P224; MATON PN, 1991, NEW ENGL J MED, V324, P965; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MEIER JH, 1994, DIGEST DIS SCI, V39, P2127, DOI 10.1007/BF02090360; MITTAL RK, 1995, GASTROENTEROLOGY, V109, P601, DOI 10.1016/0016-5085(95)90351-8; Mittal RK, 1997, NEW ENGL J MED, V336, P924, DOI 10.1056/NEJM199703273361306; O'CONNELL S, 1990, Gastroenterology, V98, pA97; O'Connor JB, 1998, GASTROENTEROLOGY, V114, pA244; PERRIN-FAYOLLE M, 1980, Poumon et le Coeur, V36, P225; PERRINFAYOLLE M, 1989, CHEST, V96, P40, DOI 10.1378/chest.96.1.40; ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304; Sant'Ambrogio FB, 1998, J APPL PHYSIOL, V84, P1299, DOI 10.1152/jappl.1998.84.4.1299; SCHAN CA, 1994, CHEST, V106, P731, DOI 10.1378/chest.106.3.731; SCHINDLBECK NE, 1988, JAMA-J AM MED ASSOC, V260, P3156, DOI 10.1001/jama.260.21.3156; Schnatz PF, 1996, AM J GASTROENTEROL, V91, P1715; SONTAG SJ, 1990, GASTROENTEROLOGY, V99, P613, DOI 10.1016/0016-5085(90)90945-W; SONTAG SJ, 1992, GUT, V33, P872, DOI 10.1136/gut.33.7.872; SONTAG SJ, 1991, DYSPHAGIA, V6, P62; Spivak H, 1998, GASTROENTEROLOGY, V114, pA1428, DOI 10.1016/S0016-5085(98)85812-5; TAN WC, 1990, AM REV RESPIR DIS, V141, P1394, DOI 10.1164/ajrccm/141.6.1394; Teichtahl H, 1996, AUST NZ J MED, V26, P671, DOI 10.1111/j.1445-5994.1996.tb02938.x; TUCHMAN DN, 1984, GASTROENTEROLOGY, V87, P872; Vincent D, 1997, EUR RESPIR J, V10, P2255, DOI 10.1183/09031936.97.10102255; WESSELING G, 1993, CHEST, V104, P1733, DOI 10.1378/chest.104.6.1733; WRIGHT RA, 1990, GASTROENTEROLOGY, V99, P71, DOI 10.1016/0016-5085(90)91231-T	57	99	107	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				251	259		10.1016/S0091-6749(99)70360-X	http://dx.doi.org/10.1016/S0091-6749(99)70360-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452738				2022-12-18	WOS:000082364800007
J	Sherrill, DL; Stein, R; Halonen, M; Holberg, CJ; Wright, A; Martinez, FD				Sherrill, DL; Stein, R; Halonen, M; Holberg, CJ; Wright, A; Martinez, FD			Total serum IgE and its association with asthma symptoms and allergic sensitization among children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin test; wheeze phenotypes; epidemiology; longitudinal; IgE; allergy	SKIN-TEST REACTIVITY; COMMUNITY POPULATION-SAMPLE; HISPANIC WHITE FAMILIES; LONGITUDINAL DATA; RESPONSIVENESS; SENSITIVITY; INFANTS; ATOPY; LIFE; AGE	Background: Asthma and wheezing during childhood are associated with elevated total serum IgE and with allergic sensitization to local aeroallergens. However, little is known about the longitudinal relationship between total serum IgE and the development of wheezing and allergic sensitization during childhood. Objective: The purpose of our investigation was to determine the relationship between total serum IgE and the development of wheezing and allergic sensitization in childhood. Methods: Our study subjects were participants in the Tucson Children's Respiratory Study who underwent an IgE measurement in at Least 1 of 3 surveys (at years 1, 6, and 11) and complete allergy skin tests during the latter 2 surveys. The children's phenotypes were categorized on the basis of skin test response (never, early, and late) and wheezing status (never, early, late, and persistent). Repeated-measures analyses were used, allowing subjects to be included who had unequal numbers of IgE observations (a total of 263 boys and 277 girls). Results: We found that total serum IgE levels track with age: subjects with high serum IgE levels less than 1 year old continued to have high IgE levels at ages 6 and 11 years, Both persistent wheezing and early sensitization were associated with high serum IgE levels at all ages. Boys who had late or persistent wheezing or who were sensitized early or late had high serum IgE le,els as early as age 9 months, whereas only girls with persistent wheezing and early sensitization had elevated IgE levels at that age. Children who wheezed only in the first Sears of life and not after tie, those with early wheezing) had serum IgE levels that were not different from those of nonwheezing children. Conclusion: On the basis of these findings we conclude that although total serum IgE tracks with age, children who are predisposed to persistent wheezing and early sensitization to local aeroallergens already have high levels of IgE at age 9 months. This suggests that the predisposition to respond to environmental stimuli through high levels of IgE precede early allergic sensitization, indicating that there may be a common defect in the development of the immune system involving IgE production and early allergic sensitization.	Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ 85724 USA	University of Arizona	Sherrill, DL (corresponding author), Univ Arizona, Coll Med, Resp Sci Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA.		Stein, Renato Tetelbom/K-2568-2014	Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [R01 HL56177, HL14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136, R01HL056177] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKER V, 1992, ALLERGY, V47, P484, DOI 10.1111/j.1398-9995.1992.tb00669.x; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; FREIDHOFF LR, 1993, INT ARCH ALLERGY IMM, V100, P355, DOI 10.1159/000236438; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; HEYMANN PW, 1995, INT ARCH ALLERGY IMM, V107, P380, DOI 10.1159/000237043; Holberg CJ, 1996, AM J RESP CRIT CARE, V154, P144, DOI 10.1164/ajrccm.154.1.8680670; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; JONES RH, 1991, BIOMETRICS, V47, P161, DOI 10.2307/2532504; Jones RH, 1993, LONGITUDINAL DATA SE; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, AM J HUM GENET, V55, P555; Park T, 1997, STAT MED, V16, P1859, DOI 10.1002/(SICI)1097-0258(19970830)16:16<1859::AID-SIM593>3.0.CO;2-3; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P418; SIMMS DG, 1981, BRIT MED J, V282, P2086; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8	26	99	102	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					28	36		10.1016/S0091-6749(99)70110-7	http://dx.doi.org/10.1016/S0091-6749(99)70110-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400836				2022-12-18	WOS:000081738900005
J	Heederik, D; Venables, KM; Malmberg, P; Hollander, A; Karlsson, AS; Renstrom, A; Doekes, G; Nieuwenhijsen, M; Gordon, S				Heederik, D; Venables, KM; Malmberg, P; Hollander, A; Karlsson, AS; Renstrom, A; Doekes, G; Nieuwenhijsen, M; Gordon, S			Exposure-response relationships for work-related sensitization in workers exposed to rat urinary allergens: Results from a pooled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						laboratory animal allergy; sensitization; allergen exposure; rat urinary allergens	LABORATORY-ANIMAL ALLERGY; IGE; AEROALLERGENS; SYMPTOMS; SAMPLE; DUST; AGE; SEX	Background: Recent studies in a few industries have shown that the likelihood of IgE-mediated sensitization increases with increasing exposure. The shape of the exposure-response relationships and modification by age, sex, and smoking habit has hardly been studied. Objective: The purpose of this study was to determine exposure sensitization relationships for rat sensitization and to evaluate the influence of atopy, smoking habits, and sex. Methods: Data from 3 cross-sectional studies in The Netherlands, the United Kingdom, and Sweden were used and involved 1062 animal laboratory workers. Selection criteria were harmonized, and this resulted in a study population of 650 animal laboratory workers (60.6% female) with less than 4 years of exposure. Air allergen levels were assessed previously and converted on the basis of an interlaboratory allergen analysis comparison. Available sera were analyzed for the presence of specific antibodies against common allergens (house dust mite, cat, dog, and grass and birch pollen) and work-related allergens (rat and mouse urinary proteins). Questionnaire items on work-related respiratory symptoms, hours worked with rats per week, job performed, smoking habits, and sex were used in this analysis Results: The prevalence of work-related sensitization to rat urinary allergens (IgE >0.7 KU/L) was 9.7% (n = 63), Thirty-six of the sensitized workers had work-related symptoms (asthma or rhinitis). Two hundred forty-eight workers (38.2%) mere atopic (defined as specific IgE to 1 of the common allergens), The sensitization rate increased with increasing air allergen exposure. Atopic workers exposed to low levels of allergen had a more than 3-fold increased sensitization risk compared with nonexposed atopic workers. For atopic subjects, the risk increased little with increasing exposure, whereas for nonatopic subjects, a steadily increasing risk was observed. Smoking and sex did not modify the sensitization risk. Conclusion: Rat urinary allergen-sensitization risk increased with increasing exposure intensity. Workers who mere atopic had a clearly elevated sensitization risk at Low allergen exposure levels.	Wageningen Univ & Res Ctr, Environm & Occupat Hlth Grp, Dept Environm Sci, NL-6700 AE Wageningen, Netherlands; Imperial Coll Sch Med, Natl Heart & Lung Inst, Dept Occupat & Environm Med, London, England; Natl Inst Working Life, Dept Occupat Med, Solna, Sweden	Wageningen University & Research; Imperial College London	Heederik, D (corresponding author), Wageningen Univ & Res Ctr, Environm & Occupat Hlth Grp, Dept Environm Sci, POB 238, NL-6700 AE Wageningen, Netherlands.		Tuluc, Petronel/C-2527-2011	Heederik, Dick/0000-0002-4550-1437				BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; Bryant DH, 1995, MED J AUSTRALIA, V163, P415, DOI 10.5694/j.1326-5377.1995.tb124657.x; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; DEGROOT H, 1990, ANN ALLERGY, V65, P97; DOEKES G, 1996, OCCUP ENVIRON MED, V57, P567; GORDON S, 1993, J ALLERGY CLIN IMMUN, V92, P298, DOI 10.1016/0091-6749(93)90173-D; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; Hollander A, 1996, J ALLERGY CLIN IMMUN, V98, P545, DOI 10.1016/S0091-6749(96)70088-X; HOLLANDER A, 1997, J ALLERGY CLIN IMMUN, V99, P286; HOLLANDER A, 1998, IN PRESS ALLERGY; Kerkhof M, 1996, ALLERGY, V51, P770, DOI 10.1111/j.1398-9995.1996.tb04465.x; Kruize H, 1997, OCCUP ENVIRON MED, V54, P830, DOI 10.1136/oem.54.11.830; NEWMANTAYLOR A, 1977, LANCET, V2, P847; NIEUWENHUIJSEN M, 1994, OCCUP ENVIRON MED, V51, P593, DOI 10.1136/oem.51.9.593; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; RENSTROM A, 1994, ALLERGY, V49, P548, DOI 10.1111/j.1398-9995.1994.tb01127.x; RENSTROM A, 1995, EUR RESPIR J, V8, P1514; RENSTROM A, 1998, EUR RESPIR J, V9, P1205; RENSTROM A, 1998, IN PRESS ALLERGY; TEE RD, 1992, CLIN EXP ALLERGY, V22, P233, DOI 10.1111/j.1365-2222.1992.tb03078.x; Thompson ML, 1998, OCCUP ENVIRON MED, V55, P272, DOI 10.1136/oem.55.4.272; VENABLES KM, 1988, BRIT J IND MED, V45, P667	22	99	102	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					678	684		10.1016/S0091-6749(99)70242-3	http://dx.doi.org/10.1016/S0091-6749(99)70242-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200019				2022-12-18	WOS:000079723900023
J	Tovey, E; Marks, G				Tovey, E; Marks, G			Methods and effectiveness of environmental control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergen avoidance; allergen exposure; aeroallergens; allergens; risk factors; mites; cats	HOUSE-DUST-MITE; FEL-D-I; VENTILATED HEALTHY HOMES; INNER-CITY CHILDREN; ALLERGENS DER-I; CAN-F-I; ASTHMATIC-CHILDREN; COCKROACH ALLERGEN; BENZYL BENZOATE; GRASS-POLLEN	In recent years the role of allergen exposure and atopy, and the interaction between them in the clinical expression of allergic disease, has been examined in a quantitative manner in epidemiologic studies. Such analyses suggest that avoidance of exposure to domestic allergens is a critical element in integrated strategies for both the prevention and the management of asthma. The promise of primary intervention in high-risk infants, as shown in the Isle of White study, has been confirmed in a recent study in Japan, and at least 4 similar trials are in progress. Applying these principles to the management of symptoms in patients with chronic asthma has proved more difficult, and it is likely that many earlier studies were poorly designed to test the hypothesis that allergen avoidance was clinically useful. Recent studies with patients moved to high altitudes during seasonal reductions in mite exposure and randomized controlled interventions in houses have all shown improvements in clinical manifestations of asthma. These recent trials have also demonstrated something that was less certain-that massive reductions in domestic allergen exposure can be achieved and that people mill adopt the significant changes to their domestic environment and lifestyles if the risks and benefits are known. In the future, it seems likely that better study designs, as well as improvements in methods to monitor exposure and clinical outcomes, mill provide further support for the role of allergen avoidance in the prevention and management of asthma.	Univ Sydney, Inst Resp Med, Dept Med, Sydney, NSW 2006, Australia	University of Sydney	Tovey, E (corresponding author), Univ Sydney, Inst Resp Med, Dept Med, Rm 461,DO6, Sydney, NSW 2006, Australia.		Marks, Guy B./F-5058-2013; Tovey, Euan R/G-8604-2017	Marks, Guy B./0000-0002-8976-8053; Tovey, Euan R/0000-0002-1802-7266				Adilah N, 1997, NEW ZEAL MED J, V110, P438; ALTOUNYAN REC, 1970, DISODIUM CHROMOGLYCA, P43; *AM LUNG ASS, 1997, RES AIR CLIN DEV TYP; ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; ANDERSON M, 1995, EXP LUNG RES, V21, P187, DOI 10.3109/01902149509031753; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 1998, AM J RESP CRIT CARE, V157, P1900, DOI 10.1164/ajrccm.157.6.9603034; Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; Bahir A, 1997, ANN ALLERG ASTHMA IM, V78, P506, DOI 10.1016/S1081-1206(10)63239-5; Becker AB, 1997, EUR RESPIR J, V10, P1203, DOI 10.1183/09031936.97.10061203; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; Benckhuijsen J, 1996, PEDIATR PULM, V22, P147, DOI 10.1002/(SICI)1099-0496(199609)22:3<147::AID-PPUL2>3.0.CO;2-M; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; BISCHOFF ERC, 1995, J ALLERGY CLIN IMMUN, V95, P263; Bjornsdottir U. S., 1997, Journal of Allergy and Clinical Immunology, V99, pS389; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; Bollinger ME, 1998, J ALLERGY CLIN IMMUN, V101, P124, DOI 10.1016/S0091-6749(98)70203-9; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CABRERA P, 1995, J ALLERGY CLIN IMMUN, V95, P635, DOI 10.1016/S0091-6749(95)70328-4; CALL RS, 1994, J ALLERGY CLIN IMMUN, V94, P1065, DOI 10.1016/0091-6749(94)90125-2; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARDANO G, 1663, OPERA OMINA HIERONYM; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Chang JH, 1996, ANN ALLERG ASTHMA IM, V77, P187, DOI 10.1016/S1081-1206(10)63253-X; CHANYEUNG M, 1988, CHEST, V93, P407, DOI 10.1378/chest.93.2.407; CHANYEUNG M, 1998, AM J RESP CRIT CARE, V157, pA12; CHAPMAN M, 1998, 30 YEARS IGE, P53; Chew FT, 1996, ACTA PAEDIATR JAPON, V38, P483; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; COLLOFF MJ, 1995, CLIN EXP ALLERGY, V25, P1061, DOI 10.1111/j.1365-2222.1995.tb03252.x; COLLOFF MJ, 1994, CLIN EXP ALLERGY, V24, P94, DOI 10.1111/j.1365-2222.1994.tb00202.x; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; Crane J, 1998, ALLERGY, V53, P755, DOI 10.1111/j.1398-9995.1998.tb03971.x; Custovic A, 1998, J ALLERGY CLIN IMMUN, V101, pS81; CUSTOVIC A, 1995, CLIN EXP ALLERGY, V25, P312, DOI 10.1111/j.1365-2222.1995.tb01048.x; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1243, DOI 10.1111/j.1365-2222.1996.tb00520.x; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; de Blay F, 1998, ALLERGY, V53, P411, DOI 10.1111/j.1398-9995.1998.tb03914.x; De Lucca SD, 1998, J ALLERGY CLIN IMMUN, V101, pS168; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)70307-5; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622, DOI 10.2307/3433608; Duffy DL, 1998, AM J RESP CRIT CARE, V157, P840, DOI 10.1164/ajrccm.157.3.9702070; Edwards DA, 1998, J APPL PHYSIOL, V85, P379, DOI 10.1152/jappl.1998.85.2.379; Egmar AC, 1998, PEDIATR ALLERGY IMMU, V9, P31, DOI 10.1111/j.1399-3038.1998.tb00297.x; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; ELLINGSON AR, 1995, J ALLERGY CLIN IMMUN, V96, P473, DOI 10.1016/S0091-6749(95)70289-X; FELL P, 1992, LANCET, V340, P788, DOI 10.1016/0140-6736(92)92327-C; Fletcher AM, 1996, CLIN EXP ALLERGY, V26, P1051, DOI 10.1111/j.1365-2222.1996.tb00643.x; Frederick JM, 1998, J ALLERGY CLIN IMMUN, V101, pS26; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Frey AH, 1996, ANN ALLERG ASTHMA IM, V77, P460, DOI 10.1016/S1081-1206(10)63350-9; GELBER L, 1991, Journal of Allergy and Clinical Immunology, V87, P233, DOI 10.1016/0091-6749(91)91659-H; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HAMMARQUIST C, 1998, HOUSE DUST MITE CONT; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; HARVING H, 1991, ALLERGY, V46, P33, DOI 10.1111/j.1398-9995.1991.tb00647.x; HARVING H, 1994, ALLERGY, V49, P713, DOI 10.1111/j.1398-9995.1994.tb02092.x; HEGARTY JM, 1995, RESP MED, V89, P279, DOI 10.1016/0954-6111(95)90088-8; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; Horak F, 1995, Wien Med Wochenschr, V145, P1; HTUT T, 1998, AM J RESP CRIT CARE, V157, pA624; JOOMA OF, 1995, S AFR MED J, V85, P1002; Juliusson S., 1997, Journal of Allergy and Clinical Immunology, V99, pS388; Kainka E, 1997, Pneumologie, V51, P2; Kemp TJ, 1996, BMJ-BRIT MED J, V313, P916, DOI 10.1136/bmj.313.7062.916; KLEIN GL, 1988, CLIN REV ALLERG, V6, P3; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Leopold SS, 1925, J AMER MED ASSOC, V84, P731, DOI 10.1001/jama.1925.02660360013006; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38, DOI 10.1080/00039896.1995.9955011; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Mahmic A, 1998, ALLERGY, V53, P976, DOI 10.1111/j.1398-9995.1998.tb03799.x; MANJRA A, 1994, S AFR MED J, V84, P278; MARKS GB, 1995, CLIN EXP ALLERGY, V25, P114, DOI 10.1111/j.1365-2222.1995.tb01015.x; Marks GB, 1995, CLIN EXP ALLERGY, V25, P1190, DOI 10.1111/j.1365-2222.1995.tb03043.x; MARKS GB, 1999, IN PRESS ALLERGY; MASSEY D, 1998, ANN ALLERGY, V61, P229; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; McLaughlin T, 1998, J ALLERGY CLIN IMMUN, V101, pS167; Meijer GG, 1995, PEDIATR ALLERGY IMMU, V6, P187, DOI 10.1111/j.1399-3038.1995.tb00283.x; Meijer GG, 1996, AM J RESP CRIT CARE, V154, P881, DOI 10.1164/ajrccm.154.4.8887579; Mistrello G, 1998, J MED ENTOMOL, V35, P143, DOI 10.1093/jmedent/35.2.143; MITAKAKIS TZ, 1998, P 6 INT C AER 1998 P; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Munir AKM, 1996, ALLERGY, V51, P36; *NAT AIR FILT ASS, 1996, NAFA GUID AIR FILTR; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; *NIH, 1997, 2 NIH; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; OLIVER J, 1995, INT ARCH ALLERGY IMM, V107, P452, DOI 10.1159/000237078; OSWALD H, 1994, BRIT MED J, V309, P95, DOI 10.1136/bmj.309.6947.95; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; PEARSON D, 1995, MITES ASTHMA DOMESTI, V2; Peat JK, 1998, CLIN EXP ALLERGY, V28, P261; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PERONI DG, 1995, ALLERGY, V50, P925, DOI 10.1111/j.1398-9995.1995.tb02500.x; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Piacentini GL, 1998, CLIN EXP ALLERGY, V28, P561, DOI 10.1046/j.1365-2222.1998.00260.x; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PlattsMills TAE, 1996, J ALLERGY CLIN IMMUN, V98, pS297, DOI 10.1016/S0091-6749(96)80115-1; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PRAHL P, 1992, ALLERGY, V47, P362, DOI 10.1111/j.1398-9995.1992.tb02072.x; PRICE EC, 1990, AM J PRIMATOL, V20, P1, DOI 10.1002/ajp.1350200102; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; Rebmann H, 1996, ALLERGY, V51, P876; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P7, DOI 10.1159/000237495; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; SAKAGUCHI M, 1992, ALLERGY, V47, P55, DOI 10.1111/j.1398-9995.1992.tb02250.x; SALVAGGIO JE, 1994, J ALLERGY CLIN IMMUN, V94, P304, DOI 10.1053/ai.1994.v94.a56009; Sarpong SB, 1996, ANN ALLERG ASTHMA IM, V76, P257, DOI 10.1016/S1081-1206(10)63437-0; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SENSI LG, 1994, CLIN EXP ALLERGY, V24, P377, DOI 10.1111/j.1365-2222.1994.tb00250.x; Siebers RW, 1996, J ALLERGY CLIN IMMUN, V98, P853, DOI 10.1016/S0091-6749(96)70141-0; Simpson A, 1998, ALLERGY, V53, P602, DOI 10.1111/j.1398-9995.1998.tb03936.x; SOLDATOV D, 1995, J ALLERGY CLIN IMMUN, V95, P263; Sporik R, 1998, J ALLERGY CLIN IMMUN, V101, P451, DOI 10.1016/S0091-6749(98)70352-5; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; SQUILLACE SP, 1992, OTOLARYNG HEAD NECK, V107, P831, DOI 10.1177/019459989210700603.2; Strachan D, 1997, BRIT MED J, V314, P518, DOI 10.1136/bmj.314.7079.518; Strachan DP, 1996, BRIT MED J, V312, P1195; TOVEY E, 1993, MED J AUSTRALIA, V158, P579, DOI 10.5694/j.1326-5377.1993.tb121900.x; TOVEY E, 1996, UPDATE LONG LASTING, P32; Tovey ER, 1997, J ALLERGY CLIN IMMUN, V100, P464, DOI 10.1016/S0091-6749(97)70136-2; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1994, J ALLERGY CLIN IMMUN, V93, P1072, DOI 10.1016/S0091-6749(94)70058-3; TOVEY ER, 1992, EXP APPL ACAROL, V16, P181, DOI 10.1007/BF01201500; TOVEY ER, 1997, ASTHMA, P1883; van Leeuwen W S, 1924, Proc R Soc Med, V17, P19; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; vanderHeide S, 1997, CLIN EXP ALLERGY, V27, P627, DOI 10.1111/j.1365-2222.1997.tb01189.x; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544, DOI 10.1016/S1081-1206(10)63214-0; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WALSHAW MJ, 1986, Q J MED, V58, P199; Weiss ST, 1998, J ALLERGY CLIN IMMUN, V101, P720, DOI 10.1016/S0091-6749(98)70300-8; WENTZ PE, 1990, J ALLERGY CLIN IMMUN, V85, P94, DOI 10.1016/0091-6749(90)90228-V; WICKMAN M, 1993, AM REV RESPIR DIS, V148, P58, DOI 10.1164/ajrccm/148.1.58; Wickman M, 1996, ALLERGY, V51, P511, DOI 10.1111/j.1398-9995.1996.tb04658.x; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P199; Woodcock A, 1998, THORAX, V53, pS47, DOI 10.1136/thx.53.2008.S47; WOODFOLK JA, 1995, J ALLERGY CLIN IMMUN, V96, P325, DOI 10.1016/S0091-6749(95)70051-X; ZOCK JP, 1995, CLIN EXP ALLERGY, V25, P549, DOI 10.1111/j.1365-2222.1995.tb01093.x; [No title captured]; 1993, INDOOR ALLERGENS ASS	167	99	102	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				179	191		10.1016/S0091-6749(99)70488-4	http://dx.doi.org/10.1016/S0091-6749(99)70488-4			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949306	Bronze			2022-12-18	WOS:000078630100001
J	Martinez, FD; Stern, DA; Wright, AL; Taussig, LM; Halonen, M				Martinez, FD; Stern, DA; Wright, AL; Taussig, LM; Halonen, M			Differential immune responses to acute lower respiratory illness in early life and subsequent development of persistent wheezing and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory sounds; IgE; eosinophils; infant; childhood asthma; virus diseases; respiratory tract infections	EOSINOPHIL CATIONIC PROTEIN; BLOOD MONONUCLEAR-CELLS; VIRUS-SPECIFIC IGE; SYNCYTIAL VIRUS; SERUM IGE; INFECTION; INFANTS; BRONCHIOLITIS; EPIDEMIOLOGY; CHILDREN	Background: Recent epidemiologic evidence suggests that 2 wheezing syndromes coexist in early life: transient wheezing, limited to early childhood, and persistent wheezing, which starts in early childhood and persists beyond that age. Objective: Whether the nature of the immune response occurring during acute lower respiratory illnesses (LRIs) in infancy differs between these 2 groups of wheezers has yet to be determined. Methods: We compared total serum IgE levels and peripheral blood eosinophil counts obtained during the acute phase of the first LRI with those obtained during the convalescent phase or with well-baby samples in persistent (n = 49) and transient early wheezers (n = 88), as well as in children who had only nonwheezing LRIs (n = 43) during the first 3 years of life. Results: Total serum IgE Levels were significantly higher (P = .008) during the acute phase compared with the convalescent phase of the LRI in persistent wheezers, a response not observed in transient early wheezers (P = .7). Peripheral blood eosinophil counts were significantly reduced during the acute phase of the LRI (P = .009) in transient early wheezers, a response not observed among persistent wheezers (P = .7). Acute responses in children who had nonwheezing LRIs only were similar to those seen in transient early wheezers. Conclusion: Alterations in acute immune response to viral infection may be detected at the time of the first wheezing episode in subjects who will go on to have persistent wheezing symptoms.	Univ Arizona, Hlth Sci Ctr, Resp Sci Ctr, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences	Martinez, FD (corresponding author), Univ Arizona, Hlth Sci Ctr, Resp Sci Ctr, POB 245030, Tucson, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL-14136, R01 HL-56177] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136, R01HL056177] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBEE RA, 1985, CHEST, V87, pS21, DOI 10.1378/chest.87.1.21S; BASS DA, 1980, J CLIN INVEST, V65, P1265, DOI 10.1172/JCI109789; BUI RHD, 1987, J PEDIATR-US, V110, P87; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; GARDNER PS, 1970, BMJ-BRIT MED J, V1, P327, DOI 10.1136/bmj.1.5692.327; GAROFALO R, 1994, PEDIAT ALLERGY IMMUN, V5, P1111; Gibson PG, 1998, AM J RESP CRIT CARE, V158, P36, DOI 10.1164/ajrccm.158.1.9705031; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; KIMPEN JLL, 1992, PEDIATR RES, V32, P160, DOI 10.1203/00006450-199208000-00007; Koller DY, 1997, J ALLERGY CLIN IMMUN, V99, P752, DOI 10.1016/S0091-6749(97)80007-3; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Pohunek P., 1997, European Respiratory Journal Supplement, V10, p160S; Reijonen TM, 1997, PEDIATR PULM, V23, P397, DOI 10.1002/(SICI)1099-0496(199706)23:6<397::AID-PPUL1>3.0.CO;2-G; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Toms GL, 1996, ARCH DIS CHILD, V74, P126, DOI 10.1136/adc.74.2.126; UNETSU DT, 1997, P SOC EXP BIOL MED, V215, P11; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	23	99	101	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				915	920		10.1016/S0091-6749(98)70328-8	http://dx.doi.org/10.1016/S0091-6749(98)70328-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847431				2022-12-18	WOS:000077690700007
J	Sabroe, RA; Francis, DM; Barr, RM; Black, AK; Greaves, MW				Sabroe, RA; Francis, DM; Barr, RM; Black, AK; Greaves, MW			Anti-Fc epsilon RI autoantibodies land basophil histamine releasability in chronic idiopathic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil releasability; basophils; Fc epsilon RI; chronic idiopathic urticaria; histamine; IgE; autoantibody	AFFINITY IGE RECEPTOR; MAST-CELL ACTIVATION; RELEASE; SERUM; SKIN	Background: Circulating functional autoantibodies to the high-affinity IgE receptor (Fc epsilon RI) or to IgE have been found in approximately one third of patients with chronic idiopathic urticaria (CIU). Objective: We sought to compare basophil histamine release and basophil numbers in patients with CIU with and without autoantibodies. Methods: Basophil histamine release to the anti-Fc epsilon RI mAb 2237, anti-IgE, and formyl-methionyl-leucyl-phenylalanine (fMLP); basophil numbers; and total cellular histamine were measured in 26 patients with CIU and 18 healthy control subjects. Twelve patients were classified as having functional anti-Fc epsilon RI and/or anti-IgE autoantibodies on the basis of their serum-evoked histamine release from the basophils of 2 healthy donors. Results: 2237 and anti-lgE, but not fMLP, released less histamine from basophils of patients with CIU than from those of control subjects. Mean +/- SEM maximum histamine release to 2237 from basophils of control subjects and patients with CIU with and without autoantibodies was 38.5% +/- 5.0%, 17.9% +/- 6.0% (P = .01), and 1.0% +/- 0.3% (P<.0001), respectively. Similar results were obtained with anti-IgE, which is dependent on and cross-links cell bound IgE, and 2237, which directly cross-links the IgE receptor. The mean +/- SEM basophil counts for control subjects and patients with CIU without and with autoantibodies were 52 +/- 7, 34 +/- 9 (P=.04), and 5 +/- 1 (P<.0001) x 10(6) cells/L, respectively, and similar changes were found in measurements of total cellular histamine. Conclusion: Patients with autoantibodies have both markedly reduced basophil numbers and basophil histamine release to factors acting through Fc epsilon RI, which indicates either a residual pool of functionally distinct basophils or may be a consequence of desensitization of the Fc epsilon RI pathway.	United Med & Dent Sch Guys & St Thomas, St Thomas Hosp, St Johns Inst Dermatol, Professorial Unit, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sabroe, RA (corresponding author), United Med & Dent Sch Guys & St Thomas, St Thomas Hosp, St Johns Inst Dermatol, Professorial Unit, London SE1 7EH, England.							ANSELMINO LM, 1989, J ALLERGY CLIN IMMUN, V84, P907, DOI 10.1016/0091-6749(89)90388-6; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BULL HA, 1993, J INVEST DERMATOL, V100, P305, DOI 10.1111/1523-1747.ep12469895; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; Grattan CEH, 1997, CLIN EXP ALLERGY, V27, P1417, DOI 10.1111/j.1365-2222.1997.tb02986.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GREAVES MW, 1974, CLIN ALLERGY, V4, P265, DOI 10.1111/j.1365-2222.1974.tb01384.x; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MARONE G, 1994, J ALLERGY CLIN IMMUN, V94, P1293, DOI 10.1016/0091-6749(94)90345-X; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; O'Donnell BF, 1998, BRIT J DERMATOL, V138, P101; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROBINSON TW, 1966, BRIT J DERMATOL, V78, P472, DOI 10.1111/j.1365-2133.1966.tb12252.x; RORSMAN H, 1961, ACTA ALLERGOL, V16, P185, DOI 10.1111/j.1398-9995.1961.tb02894.x; RORSMAN H, 1962, ACTA ALLERGOL, V17, P168, DOI 10.1111/j.1398-9995.1962.tb02937.x; SHALIT M, 1995, CLIN EXP ALLERGY, V25, P896, DOI 10.1111/j.1365-2222.1995.tb00033.x; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SMITH CH, 1995, J ALLERGY CLIN IMMUN, V96, P360, DOI 10.1016/S0091-6749(95)70055-2; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Yamaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1279, DOI 10.1016/S0091-6749(96)70196-3; Zuberbier T, 1996, ALLERGY, V51, P24, DOI 10.1111/j.1398-9995.1996.tb04545.x; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	34	99	105	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				651	658		10.1016/S0091-6749(98)70283-0	http://dx.doi.org/10.1016/S0091-6749(98)70283-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802375	Bronze			2022-12-18	WOS:000076600400017
J	Go, ES; Ballas, ZK				Go, ES; Ballas, ZK			Anti-pneumococcal antibody response in normal subjects: A meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunodeficiency; antibody; pneumococcal vaccine; anti-polysaccharide antibody; Streptococcus pneumoniae; meta-analysis; antibody deficiency	POLYSACCHARIDE VACCINE; HODGKINS-DISEASE; CAPSULAR POLYSACCHARIDE; IMMUNE-RESPONSE; STREPTOCOCCUS-PNEUMONIAE; CHILDREN; ADULTS; DEFICIENCY; IMMUNODEFICIENCY; INFECTIONS	Background: The diagnosis of anti-polysaccharide antibody deficiency is based on the presence of normal serum immunoglobulin levels and the lack of specific antibody response to polysaccharide antigens, such as the pneumococcal vaccine. However, a normal response to pneumococcal vaccine is not well defined. ''Modified meta-analysis'' was undertaken in an attempt to define the normal antibody response to pneumococcal vaccine. Methods: Studies identified by a MEDLINE search were selected Data of the normal control groups, rather than the patient groups, were collated for analysis. Results: Twenty-three studies fulfilled the selection criteria. Prevaccination antibody titers, postvaccination titers, and post- to prevaccination titer. ratios varied widely. On the basis of weighted mean ratios, serotype 8 appeared to be the most antigenic. It appeared that normal subjects do not mount a response of even a twofold increase in antibody titer to all the serotypes present in the vaccine. Moreover; no minimal absolute antibody level that could be of diagnostic value, either before or after vaccination, was evident. Conclusion: Response to pneumococcal vaccine among normal subjects varies widely. Better designed and prospective studies are needed to define the parameters of a normal antibody response to pneumococcal vaccine so that uniform guidelines of interpretation can be formulated.	UNIV IOWA HOSP & CLIN,DEPT INTERNAL MED,IOWA CITY,IA 52242	University of Iowa				Ballas, Zuhair/0000-0001-5569-1230; Knaack, Aaron/0000-0001-7712-1415				ADDIEGO JE, 1980, LANCET, V2, P450; AMBROSINO DM, 1987, NEW ENGL J MED, V316, P790, DOI 10.1056/NEJM198703263161306; AMMANN AJ, 1980, P SOC EXP BIOL MED, V164, P312; AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; BARRETT DJ, 1981, REV INFECT DIS, V3, pS179; BEAM TR, 1980, JAMA-J AM MED ASSOC, V244, P2621; BIRGENS HS, 1983, SCAND J HAEMATOL, V30, P324; BORGONO JM, 1978, P SOC EXP BIOL MED, V157, P148, DOI 10.3181/00379727-157-40010; BROOME CV, 1991, NEW ENGL J MED, V325, P1506, DOI 10.1056/NEJM199111213252109; CHAPEL HM, 1994, BRIT MED J, V308, P581, DOI 10.1136/bmj.308.6928.581; CHUDWIN DS, 1987, CLIN IMMUNOL IMMUNOP, V44, P114, DOI 10.1016/0090-1229(87)90057-2; COOPER MD, 1968, AM J MED, V44, P499, DOI 10.1016/0002-9343(68)90051-X; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; FIEBACH N, 1994, ARCH INTERN MED, V154, P2545, DOI 10.1001/archinte.154.22.2545; FINE MJ, 1994, ARCH INTERN MED, V154, P2666, DOI 10.1001/archinte.1994.00420230051007; FREDERIKSEN B, 1989, EUR J HAEMATOL, V43, P45; GIEBINK GS, 1980, J INFECT DIS, V141, P404, DOI 10.1093/infdis/141.3.404; GIEBINK GS, 1986, J INFECT DIS, V154, P590, DOI 10.1093/infdis/154.4.590; Goldblatt D, 1993, Immunodeficiency, V4, P47; HOSEA SW, 1981, LANCET, V1, P804; HUSTON DP, 1991, J ALLERGY CLIN IMMUN, V87, P1, DOI 10.1016/0091-6749(91)90203-Z; KOSKELA M, 1981, J CLIN PATHOL, V34, P93, DOI 10.1136/jcp.34.1.93; KOSKELA M, 1986, PEDIATR INFECT DIS J, V5, P45, DOI 10.1097/00006454-198601000-00009; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; LAWRENCE EM, 1983, AM J DIS CHILD, V137, P846, DOI 10.1001/archpedi.1983.02140350024007; LAZARUS HM, 1980, AM J MED, V69, P419, DOI 10.1016/0002-9343(80)90014-5; LEE CJ, 1991, CRIT REV MICROBIOL, V18, P89, DOI 10.3109/10408419109113510; MCMAHON BJ, 1993, AM J MED, V95, P589, DOI 10.1016/0002-9343(93)90354-R; MINOR DR, 1979, ANN INTERN MED, V90, P887, DOI 10.7326/0003-4819-90-6-887; MOSIER DE, 1982, IMMUNOL TODAY, V3, P217, DOI 10.1016/0167-5699(82)90095-0; MUFSON MA, 1985, J INFECT DIS, V151, P749, DOI 10.1093/infdis/151.4.749; MUFSON MA, 1984, P SOC EXP BIOL MED, V177, P220, DOI 10.3181/00379727-177-41934; MUSHER DM, 1986, J INFECT DIS, V154, P245, DOI 10.1093/infdis/154.2.245; MUSHER DM, 1990, J INFECT DIS, V161, P728, DOI 10.1093/infdis/161.4.728; PIROVINO M, 1984, HEPATOLOGY, V4, P946, DOI 10.1002/hep.1840040527; ROGHMANN KJ, 1987, J GERONTOL, V42, P265, DOI 10.1093/geronj/42.3.265; RUBEN FL, 1985, J INFECT DIS, V151, P845, DOI 10.1093/infdis/151.5.845; SANDERS LAM, 1993, J ALLERGY CLIN IMMUN, V91, P110, DOI 10.1016/0091-6749(93)90303-W; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIBER GR, 1978, NEW ENGL J MED, V299, P442, DOI 10.1056/NEJM197808312990903; SIBER GR, 1989, PEDIATR INFECT DIS J, V8, pS84; SIMBERKOFF MS, 1980, J LAB CLIN MED, V96, P363; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SORENSEN UBS, 1984, ACTA PATH MICRO IM C, V92, P351; Spika J S, 1990, Infect Dis Clin North Am, V4, P11; SULLIVAN JL, 1978, LANCET, V1, P178; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; WINSTON DJ, 1983, ARCH INTERN MED, V143, P1735, DOI 10.1001/archinte.143.9.1735; 1989, MMWR-MORBID MORTAL W, V38, P64; 1989, MMWR-MORBID MORTAL W, V38, P73	50	99	101	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					205	215		10.1016/S0091-6749(96)70244-0	http://dx.doi.org/10.1016/S0091-6749(96)70244-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765836				2022-12-18	WOS:A1996VA69200025
J	Vrtala, S; Susani, M; Sperr, WR; Valent, P; Laffer, S; Dolecek, C; Kraft, D; Valenta, R				Vrtala, S; Susani, M; Sperr, WR; Valent, P; Laffer, S; Dolecek, C; Kraft, D; Valenta, R			Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, PHl p 2, Phl p 5)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant timothy grass pollen allergens; Phl p 1; Phl p 2; Phl p 5; high level expression in E-coli; histamine release	BASOPHILS; BINDING	Background: Grass pollen allergens belong to the potent elicitors of type I allergy. Approximately 40% of allergic individuals display IgE reactivity with grass pollen allergens. In previous studies we have reported the complementary DNA cloning and expression in Escherichia coli of three of the most relevant timothy grass pollen allergens: Phl p 1, Phl 2, and Phl p 5. Objective: To achieve high level expression of immunologically active timothy grass pollen allergens in E. coli, the cDNAs were inserted into expression plasmids. Methods: The three recombinant grass pollen allergens were expressed at high levels in E. coli as recombinant nonfusion proteins, purified by conventional protein by conventional protein chemical methods and tested for their IgE-binding capacity by immunoblot and ELISA, as well as in histamine release assays. Results: Milligram amounts of pure recombinant allergens were obtained from cultured E. coli. IgE binding to purified recombinant Phl p 1, Phl p 2, and Phl p 5 could be demonstrated by immunoblot and ELISA. With ELISAs the percentage of grass pollen-specific IgE directed against the individual recombinant allergens induced dose-dependent and specific histamine release from patients' blood basophils. Conclusion: Purified recombinant timothy grass pollen allergens useful tools for diagnosis and therapy of grass pollen allergy.	UNIV VIENNA,AKH,INST GEN & EXPTL PATHOL,A-1090 VIENNA,AUSTRIA; INST MOLEC BIOL,SALZBURG,AUSTRIA; UNIV VIENNA,AKH,DEPT HAEMATOL & HAEMOSTASEOL,VIENNA,AUSTRIA	University of Vienna; University of Vienna			Valent, Peter/B-8533-2016; Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019; Test, PV/U-9451-2019; Sperr, Mast/V-4767-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243				ANSARI AA, 1989, BIOCHEMISTRY-US, V28, P8665, DOI 10.1021/bi00447a058; BOUSQUET J, 1994, ACI NEWS, V6, P54; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; Sambrook J, 1989, MOL CLONING LAB MANU; SCHEINER O, 1992, RECOMBINANT ALLERGEN, P115; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUSANI M, UNPUB HIGH LEVEL EXP; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1993, VACCINES93 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P37; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VRTALA S, 1993, J IMMUNOL, V151, P4773; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x	20	99	102	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					781	787		10.1016/S0091-6749(96)80156-4	http://dx.doi.org/10.1016/S0091-6749(96)80156-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613635				2022-12-18	WOS:A1996UA97500009
J	SMITH, DL; SMITH, JG; WONG, SW; DESHAZO, RD				SMITH, DL; SMITH, JG; WONG, SW; DESHAZO, RD			NETHERTONS SYNDROME - A SYNDROME OF ELEVATED IGE AND CHARACTERISTIC SKIN AND HAIR FINDINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NETHERTONS SYNDROME; ICHTHYOSIS LINEARIS CIRCUMFLEXA; TRICHORRHEXIS INVAGINATA; IGE; ATOPY	ICHTHYOSIS LINEARIS CIRCUMFLEXA; COMEL	Netherton's syndrome is a rare symptom complex characterized by greatly elevated IgE levels with atopic manifestations, an ichthyotic skin disorder (ichthyosis linearis circumflexa and/or congenital lamellar ichthyosis), and the characteristic hail abnormality trichorrhexis invaginata. It may be confused with atopic dermatitis but does not respond to topical corticosteroid treatment Netherton's syndrome is therefore of considerable importance to allergists. In this article we report the results of the clinical and immunologic evaluation of a previously unreported patient who responded to treatment with 12% ammonium lactate lotion and management of his allergic disease. Furthermore, we have reviewed the English literature and compared the findings in our patient with those of 43 other reported patients. Our patient shared the features of other previously reported patients with this disorder. We conclude that this disease should be included among the other disorders with elevated IgE. Patients may benefit from evaluation and treatment of their allergic symptoms and topical skin treatment with ammonium lactate.	UNIV SO ALABAMA, DEPT MED, MOBILE, AL USA; UNIV SO ALABAMA, DEPT PATHOL, MOBILE, AL USA	University of South Alabama; University of South Alabama								ALTMAN J, 1969, ARCH DERMATOL, V100, P550, DOI 10.1001/archderm.100.5.550; BORZYSKOWSKI M, 1976, CLIN EXP DERMATOL, V1, P337, DOI 10.1111/j.1365-2230.1976.tb01440.x; BRODIN MB, 1980, CUTIS, V26, P185; BUCKLEY RH, 1989, IMMUNOLOGIC DISORDER, P316; BUCKLEY RH, 1993, ALLERGY PRINCIPLES P, P1007; BUSTOS JAQ, 1977, LANCET, V2, P403; BUXMAN M, 1986, J AM ACAD DERMATOL, V15, P1253, DOI 10.1016/S0190-9622(86)70299-5; CAPUTO R, 1984, ARCH DERMATOL, V120, P220, DOI 10.1001/archderm.120.2.220; CHANG A, 1990, ACTA DERM-VENEREOL, V70, P147; COMEL M, 1949, Dermatologica, V98, P133; DUVINA PL, 1978, ITAL GEN REV DERMATO, V16, P113; FRENK E, 1972, ARCH DERMATOL FORSCH, V245, P42, DOI 10.1007/BF00596151; GREENE SL, 1985, J AM ACAD DERMATOL, V13, P329, DOI 10.1016/S0190-9622(85)70170-3; Greig D, 1982, Australas J Dermatol, V23, P27, DOI 10.1111/j.1440-0960.1982.tb00235.x; GROSS TP, 1987, AM J MED, V83, P797, DOI 10.1016/0002-9343(87)90919-3; GUPTA AK, 1986, ARCH DERMATOL, V122, P1199, DOI 10.1001/archderm.122.10.1199; HAUSSER I, 1989, ARCH DERMATOL RES, V281, P165, DOI 10.1007/BF00456387; HERSLE K, 1972, ACTA DERM-VENEREOL, V52, P298; HINTNER H, 1980, HAUTARZT, V31, P428; ITO M, 1984, J INVEST DERMATOL, V83, P1, DOI 10.1111/1523-1747.ep12261618; JONES SK, 1986, BRIT J DERMATOL, V114, P741, DOI 10.1111/j.1365-2133.1986.tb04885.x; JUDGE MR, 1992, BRIT J DERMATOL, V127, P91, DOI 10.1111/j.1365-2133.1992.tb08038.x; JULIUS CE, 1971, ARCH DERMATOL, V104, P422, DOI 10.1001/archderm.104.4.422; KASSIS V, 1986, CUTIS, V38, P175; KLEIN E, 1979, J SURG ONCOL, V11, P85, DOI 10.1002/jso.2930110202; KRAFCHIK BR, 1992, PEDIATR DERMATOL, V9, P157, DOI 10.1111/j.1525-1470.1992.tb01231.x; KRAFCHIK BR, 1983, INT J DERMATOL, V22, P459, DOI 10.1111/j.1365-4362.1983.tb02173.x; KUBLER HC, 1987, GEBURTSH FRAUENHEILK, V47, P742, DOI 10.1055/s-2008-1036037; MARSHALL JAMES, 1961, S AFRICAN MED JOUR, V35, P221; MARTEN RH, 1973, P ROY SOC MED, V66, P624; MENNE T, 1985, ARCH DERMATOL, V121, P451, DOI 10.1001/archderm.1985.01660040025006; MEVORAH B, 1974, DERMATOLOGICA, V149, P193, DOI 10.1159/000251520; MURPHY GM, 1989, J ROY SOC MED, V82, P683, DOI 10.1177/014107688908201118; NAGATA T, 1980, DERMATOLOGICA, V161, P51, DOI 10.1159/000250330; NETHERTON EW, 1958, ARCH DERMATOL, V78, P483, DOI 10.1001/archderm.1958.01560100059009; PLANTIN P, 1991, ANN DERMATOL VENER, V118, P525; PORTER PS, 1968, ARCH DIS CHILD, V43, P319, DOI 10.1136/adc.43.229.319; SALAMON T, 1969, FOLIA MED FACULT MED, V4, P81; SMITH DL, 1992, MANUAL CLIN LABORATO, P202; STANKLER L, 1967, BRIT J DERMATOL, V79, P187, DOI 10.1111/j.1365-2133.1967.tb11475.x; STEVANOVIC DV, 1969, BRIT J DERMATOL, V81, P851, DOI 10.1111/j.1365-2133.1969.tb15956.x; THORNE EG, 1975, ARCH DERMATOL FORSCH, V253, P177, DOI 10.1007/BF00582069; TRAUPE H, 1985, EUR J PEDIATR, V143, P166, DOI 10.1007/BF00442128; WALRAVENS PA, 1976, LANCET, V1, P488; WEHR RF, 1988, J AM ACAD DERMATOL, V19, P140, DOI 10.1016/S0190-9622(88)80234-2; WILKINSON RD, 1964, ARCH DERMATOL, V89, P46, DOI 10.1001/archderm.1964.01590250052010; ZINA AM, 1979, DERMATOLOGICA, V158, P404, DOI 10.1159/000250790; ZINNEMAN HH, 1963, J CLIN ENDOCR METAB, V23, P996, DOI 10.1210/jcem-23-10-996	48	99	100	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				116	123		10.1016/S0091-6749(95)70159-1	http://dx.doi.org/10.1016/S0091-6749(95)70159-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822652	Bronze			2022-12-18	WOS:A1995QC31200015
J	LIN, KL; HSIEH, KH; THOMAS, WR; CHIANG, BL; CHUA, KY				LIN, KL; HSIEH, KH; THOMAS, WR; CHIANG, BL; CHUA, KY			CHARACTERIZATION OF DER-P-V-ALLERGEN, CDNA ANALYSIS, AND IGE-MEDIATED REACTIVITY TO THE RECOMBINANT PROTEIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DERMATOPHAGOIDES PTERONYSSINUS; CDNA SEQUENCE; RECOMBINANT ALLERGEN (DER P V)	DUST MITE ALLERGEN; DERMATOPHAGOIDES-PTERONYSSINUS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; MESSENGER-RNA; DNA; EXTRACTS; CLONING; TRANSLATION; COMPONENTS	A lambda gt11 library for cDNA from Dermatophagoides pteronyssinus was screened by plaque immunoassay, and a number of related clones that produced IgE-binding proteins were isolated. Their sequences were homologous to that of a cDNA described previously which contained a reading frame encoding a 17 kd polypeptide and which as determined by serologic analysis corresponded to a protein with relative molecular mass of 14 kd in mite extracts. The cDNA from the lambda gt11 clones was truncated so if was used to obtain longer clones from a lambda gt10 library. Analysis of the sequence of these clones showed that the allergen now designated Der p V is produced from a 132-residue polypeptide, which has a putative 19-residue leader peptide and a 213-residue mature protein. This would have a molecular weight of 14 kd, corresponding to that found in mite extracts. IgE binding studies with the lambda gt11 clone and a fusion of the mature sequence in a pGEX construct showed that it reacted with 50% of allergic sera. Further studies with skin tests indicated that it caused reactions in about 60% of patients with asthma and 29% of chose with allergic rhinitis alone.	NATL TAIWAN UNIV,COLL MED,GRAD INST IMMUNOL,SECT 1,TAIPEI 10016,TAIWAN; NATL TAIWAN UNIV,COLL MED,GRAD INST MICROBIOL,SECT 1,TAIPEI 10016,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PEDIAT,SECT 1,TAIPEI 10016,TAIWAN; WESTERN AUSTRALIAN RES INST CHILD HLTH,PERTH,WA,AUSTRALIA	National Taiwan University; National Taiwan University; National Taiwan University; Telethon Kids Institute; University of Western Australia				CHIANG, BOR-LUEN/0000-0002-6705-0286				BENYAJATI C, 1983, CELL, V33, P125, DOI 10.1016/0092-8674(83)90341-0; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; CHUA KY, 1993, INT ARCH ALLERGY IMM, V101, P364, DOI 10.1159/000236478; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; FLETCHER TS, 1978, P NATL ACAD SCI USA, V75, P5609, DOI 10.1073/pnas.75.11.5609; FORD SA, 1989, CLIN EXP ALLERGY, V20, P27; GREENE WK, 1990, INT ARCH ALLER A IMM, V92, P30, DOI 10.1159/000235220; HEIJNE GV, 1983, EUR J BIOCHEM, V133, P17; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEWART GA, 1992, IMMUNOLOGY, V75, P29; STEWART GA, 1987, INT ARCH ALLER A IMM, V83, P384, DOI 10.1159/000234373; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127, DOI 10.1159/000234488; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; YASEUDA H, 1993, CLIN EXP ALLERGY, V23, P384; 1988, WHO B, V66, P769	30	99	110	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				989	996		10.1016/0091-6749(94)90117-1	http://dx.doi.org/10.1016/0091-6749(94)90117-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798547				2022-12-18	WOS:A1994PY23000007
J	ALVAREZCUESTA, E; CUESTAHERRANZ, J; PUYANARUIZ, J; CUESTAHERRANZ, C; BLANCOQUIROS, A				ALVAREZCUESTA, E; CUESTAHERRANZ, J; PUYANARUIZ, J; CUESTAHERRANZ, C; BLANCOQUIROS, A			MONOCLONAL ANTIBODY-STANDARDIZED CAT EXTRACT IMMUNOTHERAPY - RISK-BENEFIT EFFECTS FROM A DOUBLE-BLIND PLACEBO STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; MONOCLONAL ANTIBODIES; CAT; FEL D-I ANTIGEN	FEL-D-I; ENVIRONMENTAL-CONTROL; CLADOSPORIUM-HERBARUM; INDUCED ASTHMA; DUST MITES; ALLERGEN; RESPONSES; CHILDREN; TRIAL; RESPONSIVENESS	Twenty-eight patients (14 in an active treatment group and 14 in a placebo group) with rhinoconjunctivitis and asthma caused by cat hypersensitivity took part in a placebo-controlled, randomized, double-blind study to evaluate the risk-benefit quotient of the maintenance dose corresponding to 13.2 mug Fel d I antigen. The cat extract was biologically standardized and quantified with monoclonal antibodies (100 biological units. 33 mug of Fel d I antigen, 650 mug of albumin, and 99 mug of Fel d Bd/K30 antigen). After 1 year of treatment, the systemic reactions to cat extract immunotherapy were mild and infrequent. Improvement was observed in the active treatment group in comparison with the placebo group in the medication-symptoms score (p < 0.001); in skin prick test (p < 0.001), conjunctival provocation test (p < 0.001), and allergen bronchoprovocation test (p < 0.05) results, and in nonspecific bronchial hyperreactivity measured with methacholine, which was not statistically significant. This study demonstrates the favorable risk-benefit quotient of the dose of 13.2 mug of Fel d I antigen, which may serve as a future reference in defining the optimum dose and appropriate proportion of antigens that should be administered in cat extract immunotherapy.	HOSP RAMON & CAJAL,MADRID,SPAIN; HOSP UNIV VALLADOLID,VALLADOLIDAD,SPAIN	Hospital Universitario Ramon y Cajal; Universidad de Valladolid								BALDO BA, 1983, ALLERGY, V38, P535, DOI 10.1111/j.1398-9995.1983.tb04137.x; Barber D, 1990, REV ESP ALERGOL IMMU, V5, P125; BERTELSEN A, 1989, ALLERGY, V44, P330, DOI 10.1111/j.1398-9995.1989.tb00454.x; BOUSQUET J, 1985, 3RD P P EHRL SEM REG, P291; BOUSQUET J, 1990, 46TH POSTGR ED COURS, P183; BRIGHTON WD, 1979, CLIN ALLERGY, V9, P591, DOI 10.1111/j.1365-2222.1979.tb00484.x; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1987, ANN M EAACI ALLERGEN, P65; COCKCROFT DW, 1985, ANN ALLERGY, V55, P527; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; DREBORG S K G, 1991, Journal of Allergy and Clinical Immunology, V87, P169, DOI 10.1016/0091-6749(91)91404-H; DUFFORT O, 1987, INT ARCH ALLER A IMM, V84, P339, DOI 10.1159/000234447; DUFFORT O, 1988, IMMUNOL LETT, V17, P71, DOI 10.1016/0165-2478(88)90104-6; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; FERNANDEZCALDAS E, 1992, MED CLIN N AM, V76, P935, DOI 10.1016/S0025-7125(16)30333-9; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; KRILIS S, 1908, INT ARCH ALLER A IMM, V66, P252; LOMBARDERO M, 1986, ALLERGOL IMMUNOPATH, V14, P189; LOMBARDERO M, 1988, J IMMUNOL METHODS, V108, P71, DOI 10.1016/0022-1759(88)90404-8; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MARTIN S, 1992, ALLERGY, V47, P129; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P320; PIPKORN U, 1988, ALLERGY, V43, P81, DOI 10.1111/j.1398-9995.1988.tb00398.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; RUDOLPH R, 1983, 11 P INT C ALL CLIN, P437; SARSFIELD JK, 1976, ARCH DIS CHILD, V51, P186, DOI 10.1136/adc.51.3.186; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; Tiffeneau R, 1958, Acta Allergol Suppl (Copenh), V5, P187; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; WAHN U, 1988, J ALLERGY CLIN IMMUN, V82, P360, DOI 10.1016/0091-6749(88)90007-3; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; ZUIDEMA P, 1969, RESPIRATION, VS 26, P141, DOI 10.1159/000192648; 1983, VET SERVICES MARKET, V2; 1989, ALLERGY S10, V44, P22; 1983, B EUR PHYSIOPATHOL R, V19, P495; 1983, VET SERVICES MARKET, V1, P140; 1988, ALLERGY S6, V43, P9	48	99	101	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					556	566		10.1016/S0091-6749(94)70067-2	http://dx.doi.org/10.1016/S0091-6749(94)70067-2			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	8151058	Bronze			2022-12-18	WOS:A1994ND14000002
J	RAPHAEL, G; RAPHAEL, MH; KALINER, M				RAPHAEL, G; RAPHAEL, MH; KALINER, M			GUSTATORY RHINITIS - A SYNDROME OF FOOD-INDUCED RHINORRHEA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											RAPHAEL, G (corresponding author), NIAID,ALLERG DIS SECT,CLIN INVEST LAB,BLDG 10,11C207,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1987, J ALLERGY CLIN IMMUN, V79, P138; BUSINCO L, 1986, ANN ALLERGY, V57, P213; COLE P, 1984, AM REV RESPIR DIS, V129, P351; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; HEINER DC, 1983, ANN ALLERGY, V51, P273; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBLAD L, 1983, ACTA OTO-LARYNGOL, V96, P479, DOI 10.3109/00016488309132734; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; OGLE KA, 1980, ANN ALLERGY, V44, P273; OGLE KA, 1977, ANN ALLERGY, V39, P8; OLSON LG, 1987, AM REV RESPIR DIS, V135, P356; PATOW CA, 1984, EAR NOSE THROAT J, V63, P78; RAPHAEL GD, 1986, J ALLERGY CLIN IMMUN, V77, P239; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SYABBALO NC, 1985, B EUR PHYSIOPATH RES, V21, P507; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; WIDDICOMBE JG, 1982, NOSE UPPER AIRWAY PH, P215; 1984, DHEW NIH842442 PUBL, P52	22	99	99	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					110	115		10.1016/0091-6749(89)90484-3	http://dx.doi.org/10.1016/0091-6749(89)90484-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2643657	Green Submitted			2022-12-18	WOS:A1989T041900015
J	LOCKEY, RF; TURKELTAUB, PC; BAIRDWARREN, IA; OLIVE, CA; OLIVE, ES; PEPPE, BC; BUKANTZ, SC				LOCKEY, RF; TURKELTAUB, PC; BAIRDWARREN, IA; OLIVE, CA; OLIVE, ES; PEPPE, BC; BUKANTZ, SC			THE HYMENOPTERA VENOM STUDY-1, 1979-1982 - DEMOGRAPHICS AND HISTORY-STING DATA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JAMES A HALEY VET ADM MED CTR,TAMPA,FL 33612; US FDA,OFF BIOL RES & REVIEW,ALLERGEN PROD LAB,BETHESDA,MD 20014	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; US Food & Drug Administration (FDA)	LOCKEY, RF (corresponding author), UNIV S FLORIDA,VET ADM HOSP,COLL MED,DEPT MED,DIV ALLERGY & IMMUNOL,VAR 111D,TAMPA,FL 33612, USA.		turkeltaub, paul/U-7729-2019; turkeltaub, paul/AAG-6160-2019	turkeltaub, paul/0000-0002-7350-1469				BARR SE, 1971, ANN ALLERGY, V29, P49; GERGEN PJ, 1986, DHHS PHS861685 PUBL; GRANT JA, 1983, J ALLERGY CLIN IMMUN, V72, P399, DOI 10.1016/0091-6749(83)90506-7; HARVEY P, 1984, MED J AUSTRALIA, V140, P209, DOI 10.5694/j.1326-5377.1984.tb103996.x; HUBER P, 1983, MONOGR ALLERGY, V18, P147; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; MOSBECH H, 1983, ALLERGY, V38, P195, DOI 10.1111/j.1398-9995.1983.tb01606.x; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; PARRISH HM, 1963, AM J MED SCI, V245, P129; RAMIREZ DA, 1981, ANN ALLERGY, V47, P435; ROBERTSTHOMSON PJ, 1985, ASIAN PAC J ALLERGY, V3, P161; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SETTIPANE GA, 1978, CLIN ALLERGY, V8, P259, DOI 10.1111/j.1365-2222.1978.tb03222.x; 1965, JAMA, V193, P115; UNPUB DEATHS ACCIDEN	15	99	99	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				370	381		10.1016/0091-6749(88)90008-5	http://dx.doi.org/10.1016/0091-6749(88)90008-5			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170986				2022-12-18	WOS:A1988Q322900008
J	BEER, DJ; ROCKLIN, RE				BEER, DJ; ROCKLIN, RE			HISTAMINE-INDUCED SUPPRESSOR-CELL ACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT MED,DIV ALLERGY,BOSTON,MA 02111; BOSTON UNIV,SCH MED,EVANS MEM DEPT CLIN RES,PULM MED SECT,BOSTON,MA 02118	Tufts Medical Center; Tufts University; Boston University					NHLBI NIH HHS [HL-00898] Funding Source: Medline; NIAID NIH HHS [AI-16362] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL000898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016362] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; AVELLA J, 1978, LANCET, V1, P624; BEER DJ, 1982, CELL IMMUNOL, V69, P101, DOI 10.1016/0008-8749(82)90054-5; BEER DJ, 1982, J CLIN INVEST, V70, P393, DOI 10.1172/JCI110629; BEER DJ, 1982, NEW ENGL J MED, V306, P454, DOI 10.1056/NEJM198202253060804; BEER DJ, 1983, ADV INTERNAL MED, V28, P225; BOURNE HR, 1971, SCIENCE, V173, P743, DOI 10.1126/science.173.3998.743; BRODER S, 1978, NEW ENGL J MED, V299, P1335, DOI 10.1056/NEJM197812142992404; BRODER S, 1980, J ALLERGY CLIN IMMUN, V65, P239, DOI 10.1016/0091-6749(80)90150-5; CANONICA GW, 1979, J IMMUNOL, V123, P2669; CHENSUE SW, 1981, J IMMUNOL, V127, P363; CHENSUE SW, 1980, J EXP MED, V151, P1398, DOI 10.1084/jem.151.6.1398; DAMAN LA, 1977, LANCET, V1, P1087; DAMLE NK, 1981, J CLIN IMMUNOL, V1, P241, DOI 10.1007/BF00915143; DY M, 1982, TRANSPLANT P, V14, P575; DY M, 1981, J EXP MED, V153, P293, DOI 10.1084/jem.153.2.293; DY M, 1983, J IMMUNOL, V130, P2443; EPSTEIN WL, 1979, J PATHOL, V127, P207, DOI 10.1002/path.1711270408; FAUCI AS, 1979, ANTIBODY PRODUCTION; GAROVOY MR, 1983, J IMMUNOL, V130, P357; GERSHON RK, 1971, J IMMUNOL, V106, P1524; GERSHON RK, 1971, J IMMUNOL, V106, P1532; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; HEBERT J, 1980, CELL IMMUNOL, V54, P49, DOI 10.1016/0008-8749(80)90188-4; HEBERT J, 1981, CELL IMMUNOL, V58, P366, DOI 10.1016/0008-8749(81)90230-6; HOFSTETTER M, 1983, J IMMUNOL, V130, P1376; HOFSTETTER M, 1982, IMMUNOLOGY, V46, P477; JORIZZO JL, 1980, ANN INTERN MED, V92, P192, DOI 10.7326/0003-4819-92-2-192; LIMA M, 1981, CELL IMMUNOL, V64, P324, DOI 10.1016/0008-8749(81)90484-6; MARTINEZ JD, 1979, J ALLERGY CLIN IMMUN, V64, P485, DOI 10.1016/0091-6749(79)90057-5; MATLOFF SM, 1983, J ALLERGY CLIN IMMUN, V72, P359, DOI 10.1016/0091-6749(83)90500-6; MAUDSLEY DV, 1973, NATURE-NEW BIOL, V245, P148, DOI 10.1038/newbio245148a0; MELMON KL, 1981, AM J MED, V71, P100, DOI 10.1016/0002-9343(81)90264-3; NORLUND JJ, 1980, CELL IMMUNOL, V56, P273; NORLUND JJ, 1975, J IMMUNOL, V114, P1486; NORLUND JJ, 1980, CELL IMMUNOL, V56, P258; NORLUND JJ, J INVEST DERMATOL; OKITA N, 1981, J CLIN ENDOCR METAB, V53, P1002, DOI 10.1210/jcem-53-5-1002; OKITA N, 1981, J CLIN ENDOCR METAB, V52, P523, DOI 10.1210/jcem-52-3-523; OKITA N, 1980, J CLIN ENDOCR METAB, V51, P316, DOI 10.1210/jcem-51-2-316; OSBAND ME, 1981, LANCET, V1, P636; OSBAND ME, 1981, NEW ENGL J MED, V304, P146, DOI 10.1056/NEJM198101153040304; OTTESEN EA, 1978, CLIN EXP IMMUNOL, V33, P38; OWEN DAA, 1977, GEN PHARMACOL, V8, P141, DOI 10.1016/0306-3623(77)90043-X; PLAUT M, 1973, J IMMUNOL, V111, P389; PLAUT M, 1982, PHARM HISTAMINE RECE, P392; REINHERZ EL, 1979, NEW ENGL J MED, V301, P1018, DOI 10.1056/NEJM197911083011902; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; REINHERZ EL, 1980, J IMMUNOL, V124, P1301; ROCKLIN RE, 1979, CELL IMMUNOL, V44, P404, DOI 10.1016/0008-8749(79)90015-7; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROCKLIN RE, 1977, J IMMUNOL, V118, P1734; ROCKLIN RE, 1983, CELL IMMUNOL, V76, P243, DOI 10.1016/0008-8749(83)90367-2; ROCKLIN RE, 1978, CELL IMMUNOL, V37, P162, DOI 10.1016/0008-8749(78)90184-3; ROCKLIN RE, 1976, J CLIN INVEST, V57, P1051, DOI 10.1172/JCI108347; ROCKLIN RE, 1980, CELL IMMUNOL, V51, P226, DOI 10.1016/0008-8749(80)90255-5; ROCKLIN RE, 1981, J CLIN IMMUNOL, V1, P73, DOI 10.1007/BF00915479; ROCKLIN RE, 1983, CELL IMMUNOL, V77, P92, DOI 10.1016/0008-8749(83)90009-6; ROCKLIN RE, INT J IMMUNOPHARMACO; SCHECHTER B, 1977, INT J CANCER, V20, P239, DOI 10.1002/ijc.2910200212; SHEARER GM, 1972, J EXP MED, V136, P1302, DOI 10.1084/jem.136.5.1302; STASZAK C, 1980, CELL IMMUNOL, V54, P351, DOI 10.1016/0008-8749(80)90215-4; TERRY WD, 1980, NEW ENGL J MED, V203, P1174; THOMAS Y, 1981, CELL IMMUNOL, V59, P268, DOI 10.1016/0008-8749(81)90408-1; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; Waldmann T A, 1977, Prog Clin Immunol, V3, P155; WEINSTOCK JV, 1982, INFECT IMMUN, V35, P465, DOI 10.1128/IAI.35.2.465-470.1982; WEINSTOCK JV, 1983, J IMMUNOL, V130, P423; WEINSTOCK JV, 1981, J IMMUNOL, V127, P1906; WOLFE JD, 1979, J ALLERGY CLIN IMMUN, V63, P208; ZARLING JM, 1980, CANCER IMMUNOL IMMUN, V7, P243	74	99	99	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					439	452		10.1016/0091-6749(84)90353-1	http://dx.doi.org/10.1016/0091-6749(84)90353-1			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6231338	Bronze			2022-12-18	WOS:A1984SM08900004
J	BURROWS, B; HALONEN, M; LEBOWITZ, MD; KNUDSON, RJ; BARBEE, RA				BURROWS, B; HALONEN, M; LEBOWITZ, MD; KNUDSON, RJ; BARBEE, RA			THE RELATIONSHIP OF SERUM IMMUNOGLOBULIN-E, ALLERGY SKIN-TESTS, AND SMOKING TO RESPIRATORY DISORDERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BURROWS, B (corresponding author), UNIV ARIZONA,COLL MED,HLTH SCI CTR,DIV RESP SCI,WESTEND LABS,TUCSON,AZ 85724, USA.			Halonen, Marilyn/0000-0001-9606-935X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1977, AM REV RESPIR DIS, V115, P195; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; HALONEN M, 1982, J ALLERGY CLIN IMMUN, V69, P221, DOI 10.1016/0091-6749(82)90103-8; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LEBOWITZ MD, 1977, INT J EPIDEMIOL, V6, P107, DOI 10.1093/ije/6.2.107; LEHRER SB, 1980, AM REV RESPIR DIS, V121, P168; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; NELSON DC, 1973, J APPL PHYSIOL, V35, P304, DOI 10.1152/jappl.1973.35.2.304; REINHERZ EL, 1980, NEW ENGL J MED, V303, P370, DOI 10.1056/NEJM198008143030704; SCHOPFER K, 1979, NEW ENGL J MED, V300, P835, DOI 10.1056/NEJM197904123001506; SILVERMAN NA, 1975, CLIN EXP IMMUNOL, V22, P285; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215; 1971, 1ST P NHLI EP WORKSH	18	99	99	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	3					199	204		10.1016/0091-6749(82)90042-2	http://dx.doi.org/10.1016/0091-6749(82)90042-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG384	7108071				2022-12-18	WOS:A1982PG38400007
J	TAYLOR, SL; BUSSE, WW; SACHS, MI; PARKER, JL; YUNGINGER, JW				TAYLOR, SL; BUSSE, WW; SACHS, MI; PARKER, JL; YUNGINGER, JW			PEANUT OIL IS NOT ALLERGENIC TO PEANUT-SENSITIVE INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,DEPT FOOD SCI,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED,ALLERGY SECT,MADISON,WI 53706; MAYO CLIN & MAYO FDN,MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,MAYO GRAD SCH MED,ALLERG DIS RES LAB,ROCHESTER,MN 55901	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Mayo Clinic; Mayo Clinic	TAYLOR, SL (corresponding author), UNIV WISCONSIN,INST FOOD RES,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-585] Funding Source: Medline; NIAID NIH HHS [AI-00343, AI-11483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P477, DOI 10.1016/0091-6749(76)90191-3; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; LUSAS EW, 1979, J AM OIL CHEM SOC, V56, P425, DOI 10.1007/BF02671530; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Orange RP, 1978, ALLERGY PRINCIPLES P, P563; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; SPEER F, 1978, FOOD ALLERGY, P140; TATTRIE NH, 1973, J I CAN SCI TECHNOL, V6, P289; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P55; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; 1979, FED REG 75990, V44	15	99	103	2	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	5					372	375		10.1016/0091-6749(81)90135-4	http://dx.doi.org/10.1016/0091-6749(81)90135-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MQ454	7299001				2022-12-18	WOS:A1981MQ45400005
J	KOZAK, PP; CUMMINS, LH; GILLMAN, SA				KOZAK, PP; CUMMINS, LH; GILLMAN, SA			ADMINISTRATION OF ERYTHROMYCIN TO PATIENTS ON THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter																		ORCUTT JJ, 1977, CLIN CHEM, V23, P599; WEINBERGER M, 1976, J ALLERGY CLIN IMMUN, V57, P262	2	99	99	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	2					149	151		10.1016/0091-6749(77)90042-2	http://dx.doi.org/10.1016/0091-6749(77)90042-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR448	874213	Bronze			2022-12-18	WOS:A1977DR44800011
J	NARASBHAT, K; ARROYAVE, CM; MARNEY, SR; STEVENSON, DD; TAN, EM				NARASBHAT, K; ARROYAVE, CM; MARNEY, SR; STEVENSON, DD; TAN, EM			PLASMA HISTAMINE CHANGES DURING PROVOKED BRONCHOSPASM IN ASTHMATIC-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037	Scripps Research Institute								BEALL GN, 1963, J ALLERGY, V34, P8, DOI 10.1016/0021-8707(63)90080-7; BEALL GN, 1960, J CLIN INVEST, V39, P676, DOI 10.1172/JCI104083; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BHAT KN, 1975, CLIN RES, V23, pA345; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; CHIESA A, 1975, AM REV RESPIR DIS, V111, P148; Code CF, 1939, AM J PHYSIOL, V127, P78, DOI 10.1152/ajplegacy.1939.127.1.78; DEGARA PF, 1951, J ALLERGY, V22, P429, DOI 10.1016/0021-8707(51)90146-3; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; HASTIE R, 1971, CLIN EXP IMMUNOL, V8, P45; HOWARTH E, 1937, J HYG LOND, V37, P234; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; Katz G, 1941, J AMER MED ASSOC, V117, P1782, DOI 10.1001/jama.1941.02820470030008; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MATHISON DA, 1973, POSTGRAD MED, V54, P105, DOI 10.1080/00325481.1973.11713614; MATHISON DA, 1973, JAMA-J AM MED ASSOC, V224, P1134, DOI 10.1001/jama.224.8.1134; PATTERSON R, 1975, 5TH ANN WORKSH ASTHM; ROSE B, 1950, J CLIN INVEST, V29, P1113, DOI 10.1172/JCI102348; SCHILD HO, 1956, HISTAMINE CIBA F S, P138; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; STECHSCHULTE DJ, 1975, J IMMUNOL, V111, P1585	23	99	99	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	6					647	656		10.1016/0091-6749(76)90176-7	http://dx.doi.org/10.1016/0091-6749(76)90176-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP077	993479	Bronze			2022-12-18	WOS:A1976CP07700003
J	Shields, AM; Burns, SO; Savic, S; Richter, AG				Shields, Adrian M.; Burns, Siobhan O.; Savic, Sinisa; Richter, Alex G.		UK PIN COVID-19 Consortium	COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; primary immunodeficiency; secondary immunodeficiency		Background: As of November 2020, severe acute respiratory syndrome coronavirus 2 has resulted in 55 million infections worldwide and more than 1.3 million deaths from coronavirus disease 2019 (COVID-19). Outcomes following severe acute respiratory syndrome coronavirus 2 infection in individuals with primary immunodeficiency (PID) or symptomatic secondary immunodeficiency (SID) remain uncertain. Objectives: We sought to document the outcomes of individuals with PID or symptomatic SID following COVID-19 in the United Kingdom. Methods: At the start of the COVID-19 pandemic, the United Kingdom Primary Immunodeficiency Network established a registry of cases to collate the nationwide outcomes of COVID-19 in individuals with PID or symptomatic SID and determine risk factors associated with morbidity and mortality from COVID-19 in these patient groups. Results: A total of 100 patients had been enrolled by July 1, 2020, 60 with PID, 7 with other inborn errors of immunity including autoinflammatory diseases and C1 inhibitor deficiency, and 33 with symptomatic SID. In individuals with PID, 53.3% (32 of 60) were hospitalized, the infection-fatality ratio was 20.0% (12 of 60), the case-fatality ratio was 31.6% (12 of 38), and the inpatient mortality was 37.5% (12 of 32). Individuals with SID had worse outcomes than those with PID; 75.8% (25 of 33) were hospitalized, the infection-fatality ratio was 33.3% (11 of 33), the case-fatality ratio was 39.2% (11 of 28), and inpatient mortality was 44.0% (11 of 25). Conclusions: In comparison to the general population, adult patients with PID and symptomatic SID display greater morbidity and mortality from COVID-19. This increased risk & nbsp; must be reflected in public health guidelines to adequately protect vulnerable patients from exposure to the virus.& nbsp;	[Shields, Adrian M.; Richter, Alex G.] Univ Birmingham, Clin Immunol Serv, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England; [Burns, Siobhan O.] UCL, Inst Immun & Transplantat, London, England; [Burns, Siobhan O.] Royal Free London NHS Fdn Trust, Dept Immunol, London, England; [Savic, Sinisa] Leeds Teaching Hosp NHS Trust, Dept Clin Immunol & Allergy, St Jamess Univ Hosp, Leeds, W Yorkshire, England	University of Birmingham; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; Saint James's University Hospital; University of Leeds	Richter, AG (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England.	a.g.richter@bham.ac.uk	Elkhalifa, Shuayb Kamal/ABA-2650-2020	Elkhalifa, Shuayb Kamal/0000-0002-6292-6795; Bahal, Sameer/0000-0002-5541-3705; Shields, Adrian/0000-0001-5345-2156; Savic, Sinisa/0000-0001-7910-0554	UK Primary Immunodeficiency Network (UK PIN); Immunodeficiency patient community within the United Kingdom	UK Primary Immunodeficiency Network (UK PIN); Immunodeficiency patient community within the United Kingdom	We are grateful to the UK Primary Immunodeficiency Network (UK PIN), its members, and the Immunodeficiency patient community within the United Kingdom for their support of this study.	Aries JA, 2020, BRIT J HAEMATOL, V190, pE64, DOI 10.1111/bjh.16852; Cook G, 2020, BRIT J HAEMATOL, V190, pE83, DOI 10.1111/bjh.16874; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Glynn JR, 2020, LANCET INFECT DIS, V20, P1123, DOI 10.1016/S1473-3099(20)30311-X; Howden D, 2020, DECLINING CASE FATAL; Meyts I, 2021, J ALLERGY CLIN IMMUN, V147, P520, DOI 10.1016/j.jaci.2020.09.010; Oke J., 2020, GLOBAL COVID 19 CASE; Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013; United Kingdom Primary Immunodeficiency Network, COVID 19 UK PIN UPDA; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4	11	98	98	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					870	+		10.1016/j.jaci.2020.12.620	http://dx.doi.org/10.1016/j.jaci.2020.12.620		MAR 2021	7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	33338534	Bronze, Green Submitted, Green Published			2022-12-18	WOS:000631762400008
J	Laguna-Goya, R; Utrero-Rico, A; Talayero, P; Lasa-Lazaro, M; Ramirez-Fernandez, A; Naranjo, L; Segura-Tudela, A; Cabrera-Marante, O; de Frias, ER; Garcia-Garcia, R; Fernandez-Ruiz, M; Aguado, JM; Martinez-Lopez, J; Lopez, EA; Catalan, M; Serrano, A; Paz-Artal, E				Laguna-Goya, Rocio; Utrero-Rico, Alberto; Talayero, Paloma; Lasa-Lazaro, Maria; Ramirez-Fernandez, Angel; Naranjo, Laura; Segura-Tudela, Alejandro; Cabrera-Marante, Oscar; Rodriguez de Frias, Edgar; Garcia-Garcia, Rocio; Fernandez-Ruiz, Mario; Maria Aguado, Jose; Martinez-Lopez, Joaquin; Ana Lopez, Elena; Catalan, Mercedes; Serrano, Antonio; Paz-Artal, Estela			IL-6-based mortality risk model for hospitalized patients with COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; IL-6; mortality risk; predictive model		Background: Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic. Because the severity of the disease is highly variable, predictive models to stratify patients according to their mortality risk are needed. Objective: Our aim was to develop a model able to predict the risk of fatal outcome in patients with COVID-19 that could be used easily at the time of patients' arrival at the hospital. Methods: We constructed a prospective cohort with 611 adult patients in whom COVID-19 was diagnosed between March 10 and April 12, 2020, in a tertiary hospital in Madrid, Spain. The analysis included 501 patients who had been discharged or had died by April 20, 2020. The capacity of several biomarkers, measured at the beginning of hospitalization, to predict mortality was assessed individually. Those biomarkers that independently contributed to improve mortality prediction were included in a multivariable risk model. Results: High IL-6 level, C-reactive protein level, lactate dehydrogenase (LDH) level, ferritin level, D-dimer level, neutrophil count, and neutrophil-to-lymphocyte ratio were all predictive of mortality (area under the curve >0.70), as were low albumin level, lymphocyte count, monocyte count, and ratio of peripheral blood oxygen saturation to fraction of inspired oxygen (SpO(2)/FiO(2)). A multivariable mortality risk model including the SpO(2)/FiO(2) ratio, neutrophil-to-lymphocyte ratio, LDH level, IL-6 level, and age was developed and showed high accuracy for the prediction of fatal outcome (area under the curve 0.94). The optimal cutoff reliably classified patients (including patients with no initial respiratory distress) as survivors and nonsurvivors with 0.88 sensitivity and 0.89 specificity. Conclusion: This mortality risk model allows early risk stratification of hospitalized patients with COVID-19 before the appearance of obvious signs of clinical deterioration, and it can be used as a tool to guide clinical decision making.	[Laguna-Goya, Rocio; Utrero-Rico, Alberto; Talayero, Paloma; Lasa-Lazaro, Maria; Ramirez-Fernandez, Angel; Naranjo, Laura; Segura-Tudela, Alejandro; Cabrera-Marante, Oscar; Rodriguez de Frias, Edgar; Serrano, Antonio; Paz-Artal, Estela] Hosp Univ 12 Octubre, Dept Immunol, Madrid, Spain; [Garcia-Garcia, Rocio] Hosp Univ 12 Octubre, Dept Pneumol, Madrid, Spain; [Fernandez-Ruiz, Mario; Maria Aguado, Jose] Hosp Univ 12 Octubre, Unit Infect Dis, Madrid, Spain; [Martinez-Lopez, Joaquin] Hosp Univ 12 Octubre, Dept Hematol, Madrid, Spain; [Ana Lopez, Elena] Hosp Univ 12 Octubre, Dept Biochem, Madrid, Spain; [Catalan, Mercedes] Hosp Univ 12 Octubre, Intens Care Unit, Madrid, Spain; [Laguna-Goya, Rocio; Utrero-Rico, Alberto; Talayero, Paloma; Lasa-Lazaro, Maria; Ramirez-Fernandez, Angel; Naranjo, Laura; Segura-Tudela, Alejandro; Cabrera-Marante, Oscar; Rodriguez de Frias, Edgar; Fernandez-Ruiz, Mario; Maria Aguado, Jose; Martinez-Lopez, Joaquin; Serrano, Antonio; Paz-Artal, Estela] Sanitaria Hosp 12 Octubre Imasl2, Inst Invest, Madrid, Spain; [Maria Aguado, Jose; Martinez-Lopez, Joaquin] Dept Med, Madrid, Spain; [Martinez-Lopez, Joaquin] Ctr Nacl Invest Oncol, Madrid, Spain; [Paz-Artal, Estela] Univ Complutense Madrid, Dept Immunol Ophthalmol & ENT, Madrid, Spain; [Martinez-Lopez, Joaquin] CIBERONC, Madrid, Spain	Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre; Complutense University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Laguna-Goya, R (corresponding author), Hosp 12 Octubre, Serv Inmunol, Avda Cordoba S-N, Madrid 28041, Spain.	rocio.laguna@salud.madrid.org	Talayero, Paloma/AAA-8781-2019; martinez, joaquin/AAN-6939-2020; Naranjo, Laura/AAE-2302-2022	Talayero, Paloma/0000-0003-0327-0092; martinez, joaquin/0000-0001-7908-0063; Naranjo, Laura/0000-0001-9295-1468; Laguna Goya, Rocio/0000-0003-4265-8567; Segura Tudela, Alejandro/0000-0002-5506-0153; Serrano, Antonio/0000-0003-1993-640X	Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation [COV20/00181, JR19/00049, CP18/00073]; European Development Regional Fund A Way to Achieve Europe, Operative Program Intelligent Growth 2014-2020; Rio Hortega research contract [CM19/00120, CM19/00092]	Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation(Instituto de Salud Carlos IIIMinistry of Science and Innovation, Spain (MICINN)Spanish Government); European Development Regional Fund A Way to Achieve Europe, Operative Program Intelligent Growth 2014-2020; Rio Hortega research contract	Supported by the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 research call COV20/00181), and cofinanced by the European Development Regional Fund A Way to Achieve Europe, Operative Program Intelligent Growth 2014-2020. R.L.G. and O.C.M. each hold a Rio Hortega research contract (CM19/00120 and CM19/00092, respectively). P.T. holds a Juan Rodes research contract (JR19/00049), and M.F.R. holds a Miguel Servet research contract (CP18/00073), all from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation. The funder of this study had no role in the study design, data collection, data analysis, interpretation of the data, or writing of the report. R.L.G. had full access to all the data and final responsibility to submit for publication. A.U.R. also had access to all the raw data.	Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948; Bime C, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2697-x; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Fernandez-Ruiz M, 2021, J MED VIROL, V93, P831, DOI 10.1002/jmv.26308; Gu X., 2020, LANCET, V395, P506, DOI [10.1016/S0140-6736(20)30183-5, DOI 10.1016/S0140-6736(20)30183-5]; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Klopfenstein T, 2020, MED MALADIES INFECT, V50, P397, DOI 10.1016/j.medmal.2020.05.001; Lei F, 2020, HEPATOLOGY, V72, P389, DOI 10.1002/hep.31301; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Moons KGM, 2015, ADV ANAT PATHOL, V22, P303, DOI 10.1097/PAP.0000000000000072; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617; Richardson S., 2020, JAMA-J AM MED ASSOC, V323, P22, DOI [10.1001/jama.2020.7681, 10.1001/ jama.2020.6775, DOI 10.1001/JAMA.2020.6775]; Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529; Wang K, 2020, CLIN INFECT DIS, V71, P2079, DOI 10.1093/cid/ciaa538; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Yan L, 2020, NAT MACH INTELL, V2, P283, DOI 10.1038/s42256-020-0180-7; Zhang J, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104392; Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zou XJ, 2020, CRIT CARE MED, V48, pE657, DOI 10.1097/CCM.0000000000004411; Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6	26	98	103	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					799	+		10.1016/j.jaci.2020.07.009	http://dx.doi.org/10.1016/j.jaci.2020.07.009			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32710975	Green Published, Bronze			2022-12-18	WOS:000582395800010
J	Gustafson, CE; Kim, C; Weyand, CM; Goronzy, JJ				Gustafson, Claire E.; Kim, Chulwoo; Weyand, Cornelia M.; Goronzy, Jorg J.			Influence of immune aging on vaccine responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Vaccination; antibody; T cells; T-cell receptor; recall response; age	T-CELL RESPONSES; ZOSTER SUBUNIT VACCINE; HERPES-ZOSTER; ANTIBODY-RESPONSE; VIRAL-INFECTION; OLDER-ADULTS; PNEUMOCOCCAL VACCINE; B-CELLS; AGED 65; MEMORY	INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participationin Learning Process: Thecorematerial for these activities can be read in this issue of the Journal or online at the JACI Web site: www.jacionline.org. The accompanying tests may only be submitted online at www.jacionline.org. Fax or other copies will not be accepted. Date of Original Release: May 2020. Credit may be obtained for these courses until April 30, 2021. Copyright Statement: Copyright (C) 2020-2021. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The AmericanAcademy ofAllergy, Asthma& Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuingmedical education for physicians. TheAAAAI designates this journal-based CME activity for a maximumof 1.00AMA PRACategory 1 Credit (TM). Physicians should claim only the credit commensurate with the extent of their participation in the activity. List of Design Committee Members: Claire E. Gustafson, PhD, Chulwoo Kim, PhD, Cornelia M. Weyand, MD, PhD, and J_org J. Goronzy, MD, PhD (authors); Zuhair K. Ballas, MD (editor) Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: The authors declare that they have no relevant conflicts of interest. Z. K. Ballas (editor) disclosed no relevant financial relationships. Activity Objectives: 1. To understand the differences in vaccine responses based on age and how older adults respond to various types of vaccines. 2. To understand age-related defects in T cells and how that affects primary vaccine response. 3. To discuss ways in which aging affects the functionality of the B-cell compartment. 4. To understand different vaccination strategies that can be used to overcome deficiencies of vaccine responses in the aging immune system.	[Gustafson, Claire E.; Kim, Chulwoo; Weyand, Cornelia M.; Goronzy, Jorg J.] Stanford Univ, Div Rheumatol & Immunol, Sch Med, Dept Med, Stanford, CA 94305 USA; [Gustafson, Claire E.; Kim, Chulwoo; Weyand, Cornelia M.; Goronzy, Jorg J.] Vet Adm Healthcare Syst, Dept Med, Palo Alto, CA USA	Stanford University	Goronzy, JJ (corresponding author), Stanford Univ, Dept Med, Div Immunol & Rheumatol, CCSR Bdg,Rm 2225,269 Campus Dr West, Stanford, CA 94305 USA.	jgoronzy@stanford.edu	Weyand, Cornelia/AAH-3343-2021; Kim, Chulwoo/AAL-8854-2021	Kim, Chulwoo/0000-0001-5736-8170; Gustafson, Claire/0000-0002-1437-6709; Goronzy, Jorg/0000-0001-7670-1856	National Institutes of Health [R01 AI108906, R01 AI108891, R01 AG045779, U19 AI057266, R01 AI129191]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health (grant no. R01 AI108906 to C.M.W., grant nos. R01 AI108891, R01 AG045779, U19 AI057266, and R01 AI129191 to J.J.G., and Irene Diamond/AFAR Postdoctoral Transition Award to C.E.G.) and with resources and the use of facilities at the Palo Alto Veterans Administration Healthcare System. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Adler H, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00004-17; Akondy RS, 2017, NATURE, V552, P362, DOI 10.1038/nature24633; Alanio C, 2010, BLOOD, V115, P3718, DOI 10.1182/blood-2009-10-251124; Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155; Bains I, 2009, BLOOD, V113, P5480, DOI 10.1182/blood-2008-10-184184; Becklund BR, 2016, SCI REP-UK, V6, DOI 10.1038/srep30842; Bentebibel SE, 2016, SCI REP-UK, V6, DOI 10.1038/srep26494; Blackman MA, 2011, CURR OPIN IMMUNOL, V23, P537, DOI 10.1016/j.coi.2011.05.005; Cancro MP, 2020, ANNU REV IMMUNOL, V38, P315, DOI 10.1146/annurev-immunol-092419-031130; Cao WQ, 2020, J CLIN INVEST, V130, P3422, DOI 10.1172/JCI132417; Chlibek R, 2016, VACCINE, V34, P863, DOI 10.1016/j.vaccine.2015.09.073; Choi YS, 2013, J IMMUNOL, V190, P4014, DOI 10.4049/jimmunol.1202963; Chua Joel V, 2010, Aging health, V6, P169, DOI 10.2217/ahe.10.5; Cirelli KM, 2019, CELL, V177, P1153, DOI 10.1016/j.cell.2019.04.012; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Crotty S, 2004, SEMIN IMMUNOL, V16, P197, DOI 10.1016/j.smim.2004.02.008; Cui WG, 2011, IMMUNITY, V35, P792, DOI 10.1016/j.immuni.2011.09.017; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095; den Braber I, 2012, IMMUNITY, V36, P288, DOI 10.1016/j.immuni.2012.02.006; Di Benedetto S, 2015, BIOGERONTOLOGY, V16, P631, DOI 10.1007/s10522-015-9563-2; DiazGranados CA, 2016, CLIN INFECT DIS, V62, P1092, DOI 10.1093/cid/ciw085; Djennad A, 2018, ECLINICALMEDICINE, V6, P42, DOI 10.1016/j.eclinm.2018.12.007; Dolfi DV, 2013, J LEUKOCYTE BIOL, V93, P825, DOI 10.1189/jlb.0912438; Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011; Dugan HL, 2020, CELL IMMUNOL, V348, DOI 10.1016/j.cellimm.2019.103998; Egorov ES, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01618; Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368; Fang FQ, 2016, CELL REP, V14, P1218, DOI 10.1016/j.celrep.2016.01.002; Frasca D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219545; Frasca D, 2017, CELL IMMUNOL, V321, P68, DOI 10.1016/j.cellimm.2017.04.007; Frasca D, 2016, VACCINE, V34, P2834, DOI 10.1016/j.vaccine.2016.04.023; Frasca D, 2010, VACCINE, V28, P8077, DOI 10.1016/j.vaccine.2010.10.023; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Gil A, 2015, J VIROL, V89, P4102, DOI 10.1128/JVI.03020-14; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Goronzy JJ, 2019, NAT REV IMMUNOL, V19, P573, DOI 10.1038/s41577-019-0180-1; Goronzy JJ, 2018, J LEUKOCYTE BIOL, V104, P691, DOI 10.1002/JLB.1RI0418-160R; Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135; Grant EJ, 2016, CURR OPIN VIROL, V16, P132, DOI 10.1016/j.coviro.2016.01.016; Grasse M, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0081-0; Gustafson CE, 2019, AGING CELL, V18, DOI 10.1111/acel.12879; Gustafson CE, 2018, CLIN SCI, V132, P1925, DOI 10.1042/CS20171157; Hagen M, 2020, GERONTOLOGY, V66, P105, DOI 10.1159/000501963; Hao Y, 2011, BLOOD, V118, P1294, DOI 10.1182/blood-2011-01-330530; Heaney JLJ, 2015, J GERONTOL A-BIOL, V70, P1578, DOI 10.1093/gerona/glv085; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Hendriks J, 2005, J IMMUNOL, V175, P1665, DOI 10.4049/jimmunol.175.3.1665; Henry C, 2019, CELL HOST MICROBE, V25, P357, DOI 10.1016/j.chom.2019.01.002; Herati RS, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag2152; Herati RS, 2014, J IMMUNOL, V193, P3528, DOI 10.4049/jimmunol.1302503; Hu B, 2019, AGING CELL, V18, DOI 10.1111/acel.12957; Jha V, 2019, VACCINES, V7; Jiang J, 2011, AGEING RES REV, V10, P422, DOI 10.1016/j.arr.2011.02.001; Jin J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1808; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Ju CH, 2018, CLIN IMMUNOL, V193, P70, DOI 10.1016/j.clim.2018.01.011; Kalia V, 2010, IMMUNITY, V32, P91, DOI 10.1016/j.immuni.2009.11.010; Kaml M, 2006, VACCINE, V24, P6808, DOI 10.1016/j.vaccine.2006.06.037; Kang IS, 2004, J IMMUNOL, V173, P673, DOI 10.4049/jimmunol.173.1.673; Kim C, 2019, CELL REP, V29, P2202, DOI 10.1016/j.celrep.2019.10.044; Kim C, 2018, CELL REP, V25, P2148, DOI 10.1016/j.celrep.2018.10.074; Kityo C, 2018, J CLIN INVEST, V128, P2763, DOI 10.1172/JCI97377; Krishnamoorthy V, 2017, IMMUNITY, V47, P481, DOI 10.1016/j.immuni.2017.09.001; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Levin MJ, 2008, J INFECT DIS, V197, P825, DOI 10.1086/528696; Levin MJ, 2003, J INFECT DIS, V188, P1336, DOI 10.1086/379048; Levin MJ, 2018, J CLIN INVEST, V128, P4429, DOI [10.1172/JCI121484, 10.1172/jci121484]; Li GJ, 2012, NAT MED, V18, P1518, DOI 10.1038/nm.2963; Li MD, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0165-8; Ling GS, 2018, SCIENCE, V360, P558, DOI 10.1126/science.aao4555; Link A, 2007, NAT IMMUNOL, V8, P1255, DOI 10.1038/ni1513; Livingston KA, 2013, J IMMUNOL METHODS, V390, P18, DOI 10.1016/j.jim.2013.01.001; Mannick JB, 2018, SCI TRANSL MED, V10; Marraco SAF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3700; Marshall HD, 2011, IMMUNITY, V35, P633, DOI 10.1016/j.immuni.2011.08.016; Marttila S, 2011, EXP GERONTOL, V46, P1000, DOI 10.1016/j.exger.2011.09.004; Masters AR, 2017, CLIN EXP IMMUNOL, V187, P6, DOI 10.1111/cei.12851; Masters AR, 2019, J GERONTOL A-BIOL, V74, P1734, DOI 10.1093/gerona/glz029; Masters April R, 2018, Immunohorizons, V2, P155, DOI 10.4049/immunohorizons.1700062; McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005; Middleton DR, 2017, J IMMUNOL, V199, P598, DOI 10.4049/jimmunol.1700026; Miller JD, 2008, IMMUNITY, V28, P710, DOI 10.1016/j.immuni.2008.02.020; Monath TP, 2005, HUM VACCINES, V1, P207, DOI 10.4161/hv.1.5.2221; Montgomery RR, 2017, CLIN EXP IMMUNOL, V187, P26, DOI 10.1111/cei.12863; Morrison VA, 2015, CLIN INFECT DIS, V60, P900, DOI 10.1093/cid/ciu918; Moskowitz DM, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag0192; Musher DM, 2016, HUM VACC IMMUNOTHER, V12, P331, DOI 10.1080/21645515.2015.1098794; Nakaya HI, 2015, IMMUNITY, V43, P1186, DOI 10.1016/j.immuni.2015.11.012; Nguyen THO, 2018, J LEUKOCYTE BIOL, V103, P321, DOI 10.1189/jlb.5MA0517-207R; Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x; Nipper AJ, 2018, CLIN IMMUNOL, V193, P80, DOI 10.1016/j.clim.2018.02.003; Nunez IA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185666; Okoye AA, 2015, J IMMUNOL, V195, P4292, DOI 10.4049/jimmunol.1500609; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Pallikkuth S, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000257; Park S, 2011, INFECT IMMUN, V79, P314, DOI 10.1128/IAI.00768-10; Parker AR, 2019, VACCINE, V37, P1350, DOI [10.1016/j.vaccine.2019.01.035, 10.1016/j.vaccine.2019.01.]; Patrick M, 2019, CELL IMMUNOL, V345, DOI 10.1016/j.cellimm.2019.103989; Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097; Pekalski ML, 2013, J IMMUNOL, V190, P2554, DOI 10.4049/jimmunol.1202914; Phalke S, 2018, CURR OPIN IMMUNOL, V55, P75, DOI 10.1016/j.coi.2018.09.007; Phipps JP, 2019, J INFECT DIS, V219, P323, DOI 10.1093/infdis/jiy506; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Qi Q, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005892; Qi Q, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1725; Qi Q, 2014, P NATL ACAD SCI USA, V111, P13139, DOI 10.1073/pnas.1409155111; Quinn KM, 2018, CELL REP, V23, P3512, DOI 10.1016/j.celrep.2018.05.057; Rane S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2003949; Reynaldi A, 2019, P NATL ACAD SCI USA, V116, P3974, DOI 10.1073/pnas.1811634116; Rossey I, 2014, VACCINE, V32, P6130, DOI 10.1016/j.vaccine.2014.08.063; Roukens AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027753; Rubtsov AV, 2011, BLOOD, V118, P1305, DOI 10.1182/blood-2011-01-331462; Sant S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01453; Sarkar S, 2008, J EXP MED, V205, P625, DOI 10.1084/jem.20071641; Sarkar S, 2018, J IMMUNOL, V201, P3641, DOI 10.4049/jimmunol.1800906; Schenkein JG, 2008, VACCINE, V26, P5521, DOI 10.1016/j.vaccine.2008.07.071; Schmader KE, 2010, J AM GERIATR SOC, V58, P1634, DOI 10.1111/j.1532-5415.2010.03021.x; Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678; Schulz AR, 2015, J IMMUNOL, V195, P4699, DOI 10.4049/jimmunol.1500598; Schwarz TF, 2018, HUM VACC IMMUNOTHER, V14, P1370, DOI 10.1080/21645515.2018.1442162; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Smith NL, 2018, CELL, V174, P117, DOI 10.1016/j.cell.2018.05.029; Snook JP, 2018, SCI IMMUNOL, V3; Su LF, 2013, IMMUNITY, V38, P373, DOI 10.1016/j.immuni.2012.10.021; Sukumar M, 2013, J CLIN INVEST, V123, P4479, DOI 10.1172/JCI69589; Sullivan NL, 2018, J VIROL, V92, DOI 10.1128/JVI.00269-18; Suzuki M, 2017, LANCET INFECT DIS, V17, P313, DOI [10.1016/S1473-3099(17)30049-X, 10.1016/s1473-3099(17)30049-x]; Tan MP, 2015, CLIN EXP IMMUNOL, V180, P255, DOI 10.1111/cei.12570; Thome JJC, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah6506; Thompson HL, 2019, AGING CELL, V18, DOI 10.1111/acel.12865; Tseng HF, 2016, J INFECT DIS, V213, P1872, DOI 10.1093/infdis/jiw047; Tubo NJ, 2013, CELL, V153, P785, DOI 10.1016/j.cell.2013.04.007; Van Damme P, 2019, J VIRAL HEPATITIS, V26, P1066, DOI 10.1111/jvh.13125; van den Berg SPH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00082; Van Epps P, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-14; van Panhuys N, 2014, IMMUNITY, V41, P63, DOI 10.1016/j.immuni.2014.06.003; van Werkhoven CH, 2015, CLIN INFECT DIS, V61, P1835, DOI 10.1093/cid/civ686; Wagar LE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023698; Wagner A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28111-8; Weinberg A, 2019, J VIROL, V93, DOI 10.1128/JVI.00305-19; Weinberg A, 2017, J IMMUNOL, V199, P604, DOI 10.4049/jimmunol.1700290; Weinberger B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01035; Weyand CM, 2018, CELL METAB, V28, P185, DOI 10.1016/j.cmet.2018.07.014; White JT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11291; Whiting CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133627; Wieten RW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149871; Wong MT, 2015, CELL REP, V11, P1822, DOI 10.1016/j.celrep.2015.05.022; Yanes RE, 2019, CLIN IMMUNOL, V207, P58, DOI 10.1016/j.clim.2019.07.003; Ye ZD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05552-3; Zens KD, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85832	151	98	99	3	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2020	145	5					1309	1321		10.1016/j.jaci.2020.03.017	http://dx.doi.org/10.1016/j.jaci.2020.03.017			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	LK7TB	32386655	Green Published, Bronze			2022-12-18	WOS:000531063400001
J	Salimi, M; Stoger, L; Liu, W; Go, SM; Pavord, I; Klenerman, P; Ogg, G; Xue, LZ				Salimi, Maryam; Stoger, Linda; Liu, Wei; Go, Simei; Pavord, Ian; Klenerman, Paul; Ogg, Graham; Xue, Luzheng			Cysteinyl leukotriene E-4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D-2 and epithelial cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cell; leukotriene E-4; prostaglandin D2; IL-25; IL-33; IL-2; thymic stromal lymphopoietin; atopic dermatitis	GM-CSF; RECEPTOR; EXPRESSION; MONTELUKAST; EOSINOPHIL; ASTHMA; INFLAMMATION; INHALATION; SURVIVAL; DISEASE	Background: Group 2 innate lymphoid cells (ILC2s) are a potential innate source of type 2 cytokines in the pathogenesis of allergic conditions. Epithelial cytokines (IL-33, IL-25, and thymic stromal lymphopoietin [TSLP]) and mast cell mediators (prostaglandin D-2 [PGD(2)]) are critical activators of ILC2s. Cysteinyl leukotrienes (cysLTs), including leukotriene (LT) C-4, LTD4, and LTE4, are metabolites of arachidonic acid and mediate inflammatory responses. Their role in human ILC2s is still poorly understood. Objectives: We sought to determine the role of cysLTs and their relationship with other ILC2 stimulators in the activation of human ILC2s. Methods: For ex vivo studies, fresh blood from patients with atopic dermatitis and healthy control subjects was analyzed with flow cytometry. For in vitro studies, ILC2s were isolated and cultured. The effects of cysLTs, PGD(2), IL-33, IL-25, TSLP, and IL-2 alone or in combination on ILC2s were defined by using chemotaxis, apoptosis, ELISA, Luminex, quantitative RT-PCR, and flow cytometric assays. The effect of endogenous cysLTs was assessed by using human mast cell supernatants. Results: Human ILC2s expressed the LT receptor CysLT1, levels of which were increased in atopic subjects. CysLTs, particularly LTE4, induced migration, reduced apoptosis, and promoted cytokine production in human ILC2s in vitro. LTE4 enhanced the effect of PGD(2), IL-25, IL-33, and TSLP, resulting in increased production of type 2 and other proinflammatory cytokines. The effect of LTE4 was inhibited by montelukast, a CysLT(1) antagonist. Interestingly, addition of IL-2 to LTE4 and epithelial cytokines significantly amplified ILC2 activation and upregulated expression of the receptors for IL-33 and IL-25. Conclusion: CysLTs, particularly LTE4, are important contributors to the triggering of human ILC2s in inflammatory responses, particularly when combined with other ILC2 activators.	[Salimi, Maryam; Ogg, Graham] Univ Oxford, John Radcliffe Hosp, NIHR Biomed Res Ctr, Weatherall Inst Mol Med,MRC Human Immunol Unit, Oxford, England; [Stoger, Linda; Liu, Wei; Go, Simei; Pavord, Ian; Xue, Luzheng] Univ Oxford, Nuffield Dept Med, Resp Med Unit, Oxford, England; [Stoger, Linda; Xue, Luzheng] Univ Oxford, Core Translat Immunol Lab, Oxford NIHR Biomed Res Ctr, Oxford, England; [Klenerman, Paul] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Translat Gastroenterol Unit, Oxford, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford	Xue, LZ (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Resp Med Unit, Headley Way, Oxford OX3 9DU, England.	luzheng.xue@ndm.ox.ac.uk		Ogg, Graham/0000-0002-3097-045X; Go, Simei/0000-0002-4793-1967; klenerman, paul/0000-0003-4307-9161	Wellcome Trust [WT109965MA]; MRC [CF7720]; NIHR Biomedical Research Centre Programme; NIHR Senior Fellowship; Oxford Martin School; British Medical Association; MRC [MC_UU_12010/5, MC_U137881017] Funding Source: UKRI; Medical Research Council [MC_UU_12010/5, MC_U137881017, G1000800h] Funding Source: researchfish; National Institute for Health Research [NF-SI-0515-10005] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Biomedical Research Centre Programme(National Institute for Health Research (NIHR)); NIHR Senior Fellowship; Oxford Martin School; British Medical Association; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the Wellcome Trust (WT109965MA to P.K.), the MRC (CF7720 to G.O.), the NIHR Biomedical Research Centre Programme (to L.X. and G.O.), the NIHR Senior Fellowship (to P.K.), the Oxford Martin School (to P.K.), and the British Medical Association (The James Trust 2011 to G.O., P.K., and L.X.).	Arm JP, 2004, ALLERGY ASTHMA PROC, V25, P37; Bautz F, 2001, BLOOD, V97, P3433, DOI 10.1182/blood.V97.11.3433; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Caldenhoven E, 1998, STEM CELLS, V16, P397, DOI 10.1002/stem.160397; Capella GL, 2001, EUR J DERMATOL, V11, P209; Capra V, 2007, MED RES REV, V27, P469, DOI 10.1002/med.20071; Carucci JA, 1998, ARCH DERMATOL, V134, P785, DOI 10.1001/archderm.134.7.785; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; FAULER J, 1993, BRIT J DERMATOL, V128, P627, DOI 10.1111/j.1365-2133.1993.tb00256.x; Foster HR, 2016, SCI REP-UK, V6, DOI 10.1038/srep20461; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Henkels KM, 2011, FEBS LETT, V585, P159, DOI 10.1016/j.febslet.2010.11.031; Hon KLE, 2005, J DERMATOL TREAT, V16, P15, DOI 10.1080/09546630510026328; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Lee E, 1999, AM J RESP CRIT CARE, V160, P2079, DOI 10.1164/ajrccm.160.6.9903136; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; Liao B, 2015, ALLERGY, V70, P1169, DOI 10.1111/all.12667; Loppow D, 2007, EUR J MED RES, V12, P556; Lynch KR, 1999, NATURE, V399, P789; Macfarlane AJ, 2000, AM J RESP CRIT CARE, V161, P1553, DOI 10.1164/ajrccm.161.5.9906068; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Mullol J, 2010, J BIOL REG HOMEOS AG, V24, P403; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Parmentier CN, 2012, J ALLERGY CLIN IMMUN, V129, P1136, DOI 10.1016/j.jaci.2012.01.057; Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240; Rabinovitch N, 2012, IMMUNOL ALLERGY CLIN, V32, P433, DOI 10.1016/j.iac.2012.06.012; Roediger B, 2015, J ALLERGY CLIN IMMUN, V136, P1653, DOI 10.1016/j.jaci.2015.03.043; SALA A, 1990, J BIOL CHEM, V265, P21771; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wojno EDT, 2015, MUCOSAL IMMUNOL, V8, P1313, DOI 10.1038/mi.2015.21; Woszczek G, 2008, J ALLERGY CLIN IMMUN, V121, P215, DOI 10.1016/j.jaci.2007.09.013; Xue L, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Xue LZ, 2015, J ALLERGY CLIN IMMUN, V135, P1358, DOI 10.1016/j.jaci.2014.09.006; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Xue LZ, 2012, J IMMUNOL, V188, P694, DOI 10.4049/jimmunol.1102474	46	98	101	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1090	+		10.1016/j.jaci.2016.12.958	http://dx.doi.org/10.1016/j.jaci.2016.12.958			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28115217	Green Published, hybrid			2022-12-18	WOS:000412172900020
J	Canani, RB; Di Costanzo, M; Bedogni, G; Amoroso, A; Cosenza, L; Di Scala, C; Granata, V; Nocerino, R				Canani, Roberto Berni; Di Costanzo, Margherita; Bedogni, Giorgio; Amoroso, Antonio; Cosenza, Linda; Di Scala, Carmen; Granata, Viviana; Nocerino, Rita			Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow's milk allergy: 3-year randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eczema; urticaria; asthma; rhinoconjunctivitis; atopic march; food allergy; gut microbiota; probiotics	INFANT NUTRITIONAL INTERVENTION; FOOD ALLERGY; NATURAL-HISTORY; BIRTH COHORT; DIAGNOSIS; ALLERGENICITY; MANAGEMENT; RATIONALE; ASTHMA; LIFE	Background: Children with cow's milk allergy (CMA) have an increased risk of other allergic manifestations (AMs). Objective: We performed a parallel-arm randomized controlled trial to test whether administration of an extensively hydrolyzed casein formula (EHCF) containing the probiotic Lactobacillus rhamnosus GG (LGG) can reduce the occurrence of other AMs in children with CMA. Methods: Children with IgE-mediated CMA were randomly allocated to the EHCF or EHCF+LGG groups and followed for 36 months. The main outcome was occurrence of at least 1 AM (eczema, urticaria, asthma, and rhinoconjunctivitis). The secondary outcome was tolerance acquisition, which was defined as the negativization of a double-blind food challenge results at 12, 24, and 36 months. AMs were diagnosed according to standardized criteria. Tolerance acquisition was evaluated every 12 months. Results: A total of 220 children (147 boys [67%]) with a median age of 5.0 months (interquartile range, 3.0-8.0 months) were randomized; 110 children were placed in the EHCF group, and 110 children were placed in the EHCF+LGG group. In the complete case analysis the absolute risk difference for the occurrence of at least 1 AM over 36 months was -0.23 (95% CI, -0.36 to -0.10; P < .001), and the absolute risk difference for the acquisition of cow's milk tolerance was 0.20 (95% CI, 0.05-0.35; P < .01) at 12 months, 0.24 (95% CI, 0.08-0.41; P < .01) at 24 months, and 0.27 (95% CI, 0.11-0.43; P < .001) at 36 months. In the sensitivity analysis the effect size of the main outcome was virtually unchanged when the occurrence of AMs was assigned to all 27 missing children. Conclusions: EHCF+LGG reduces the incidence of other AMs and hastens the development of oral tolerance in children with IgE-mediated CMA.	[Canani, Roberto Berni; Di Costanzo, Margherita; Amoroso, Antonio; Cosenza, Linda; Di Scala, Carmen; Granata, Viviana; Nocerino, Rita] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Canani, Roberto Berni] Univ Naples Federico II, European Lab Invest Food Induced Dis, Naples, Italy; [Canani, Roberto Berni; Bedogni, Giorgio; Amoroso, Antonio; Nocerino, Rita] Univ Naples Federico II, CEINGE Adv Biotechnol, Naples, Italy; [Bedogni, Giorgio] Liver Res Ctr Basovizza, Clin Epidemiol Unit, Trieste, Italy	University of Naples Federico II; University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Naples Federico II	Canani, RB (corresponding author), Univ Naples Federico II, CEINGE Adv Biotechnol, European Lab Invest Food Induced Dis,Pediat Sect, Pediat Allergy Unit,Dept Translat Med Sci, Via S Pansini 5, I-80131 Naples, Italy.	berni@unina.it	Canani, Roberto Berni/AAC-4810-2022; Nocerino, Rita/ABD-8087-2020; Bedogni, Giorgio/K-1911-2018; NOCERINO, RITA/AAC-1966-2022	Canani, Roberto Berni/0000-0002-5169-9574; Bedogni, Giorgio/0000-0002-1495-9306; NOCERINO, RITA/0000-0003-4681-546X; Di Costanzo, Margherita/0000-0002-8985-770X	Italian Ministry of Health [PE-2011-02348447]; Mead Johnson Nutrition (Evansville, Ind)	Italian Ministry of Health(Ministry of Health, Italy); Mead Johnson Nutrition (Evansville, Ind)	Supported in part by the Italian Ministry of Health (grant PE-2011-02348447) and an unrestricted grant from Mead Johnson Nutrition (Evansville, Ind) devoted to the Department of Translational Medical Science of the University of Naples "Federico II." However, the Italian Ministry of Health and Mead Johnson Nutrition had no influence on (1) the study design; (2) the collection, analysis, and interpretation of the data; (3) the writing of the manuscript; or (4) the decision to submit the manuscript for publication.	Alduraywish SA, 2016, ALLERGY, V71, P77, DOI 10.1111/all.12784; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Caffarelli C, 2002, CLIN EXP ALLERGY, V32, P74, DOI 10.1046/j.0022-0477.2001.01262.x; Canani RB, 2016, ISME J, V10, P742, DOI 10.1038/ismej.2015.151; Canani RB, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0070-8; Canani RB, 2014, J ACAD NUTR DIET, V114, P1432, DOI 10.1016/j.jand.2014.03.018; Canani RB, 2013, J PEDIATR-US, V163, P771, DOI 10.1016/j.jpeds.2013.03.008; Canani RB, 2012, J ALLERGY CLIN IMMUN, V129, P580, DOI 10.1016/j.jaci.2011.10.004; de Groot H, 2007, BMJ-BRIT MED J, V335, P985, DOI 10.1136/bmj.39365.617905.BE; Fiocchi A, 2010, PEDIAT ALLERG IMM-UK, V21, P1, DOI [10.1111/j.1399-3038.2010.01068.x, 10.1097/WOX.0b013e3181defeb9]; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hardin JW, 2012, GEN LINEAR MODELS EX, V3rd; Koletzko S, 2012, J PEDIATR GASTR NUTR, V55, P221, DOI 10.1097/MPG.0b013e31825c9482; Licciardi Paul V, 2011, ISRN Allergy, V2011, P869647, DOI 10.5402/2011/869647; Liu AH, 2015, J ALLERGY CLIN IMMUN, V136, P860, DOI 10.1016/j.jaci.2015.08.012; Luyt D, 2014, CLIN EXP ALLERGY, V44, P642, DOI 10.1111/cea.12302; McBride D, 2012, PEDIAT ALLERG IMM-UK, V23, P230, DOI 10.1111/j.1399-3038.2011.01254.x; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Ovcinnikova O, 2015, CLINICOECONOMIC OUTC, V7, P145, DOI 10.2147/CEOR.S75071; Paparo L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0252-z; Rabe-Hesketh S, 2012, MULTILEVEL LONGITUDI; RAGNO V, 1993, EUR J PEDIATR, V152, P760, DOI 10.1007/BF01953996; Shi YH, 2015, SCI REP-UK, V5, DOI 10.1038/srep17651; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; von Berg A, 2016, ALLERGY, V71, P210, DOI 10.1111/all.12790; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; von Berg A, 2013, J ALLERGY CLIN IMMUN, V131, P1565, DOI 10.1016/j.jaci.2013.01.006; Weinmann T, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2555-y; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060	36	98	101	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1906	+		10.1016/j.jaci.2016.10.050	http://dx.doi.org/10.1016/j.jaci.2016.10.050			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28043872	Green Accepted, hybrid			2022-12-18	WOS:000402724600021
J	Romano, A; Gaeta, F; Valluzzi, RL; Maggioletti, M; Zaffiro, A; Caruso, C; Quaratino, D				Romano, Antonino; Gaeta, Francesco; Valluzzi, Rocco Luigi; Maggioletti, Michela; Zaffiro, Alessandra; Caruso, Cristiano; Quaratino, Donato			IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cephalosporin allergy; cross-reactivity; skin tests; tolerability	SELECTIVE IMMEDIATE HYPERSENSITIVITY; BETA-LACTAM ANTIBIOTICS; ALLERGIC REACTIONS; TYPE-1 HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; PENICILLINS; CEFAZOLIN; DIAGNOSIS; CEFTRIAXONE; CEFUROXIME	Background: Studies regarding the cross-reactivity and tolerability of alternative cephalosporins in large samples of subjects with an IgE-mediated hypersensitivity to cephalosporins are lacking. Objective: We sought to evaluate the possibility of using alternative cephalosporins in subjects with cephalosporin allergy who especially require them. Methods: One hundred two subjects with immediate reactions to cephalosporins and positive skin test results to the responsible drugs underwent serum specific IgE assays with cefaclor and skin tests with different cephalosporins. Subjects were classified in 4 groups: group A, positive responses to 1 or more of ceftriaxone, cefuroxime, cefotaxime, cefepime, cefodizime, and ceftazidime; group B, positive responses to aminocephalosporins; group C, positive responses to cephalosporins other than those belonging to the aforementioned groups; and group D, positive responses to cephalosporins belonging to 2 different groups. Group A subjects underwent challenges with cefaclor, cefazolin, and ceftibuten; group B participants underwent challenges with cefuroxime axetil, ceftriaxone, cefazolin, and ceftibuten; and group C and D subjects underwent challenges with some of the aforementioned cephalosporins selected on the basis of their patterns of positivity. Results: There were 73 subjects in group A, 13 in group B, 7 in group C, and 9 in group D. Challenges with alternative cephalosporins (ceftibuten in 101, cefazolin in 96, cefaclor in 82, and cefuroxime axetil and ceftriaxone in 22 subjects) were well tolerated. Conclusions: Cephalosporin hypersensitivity does not seem to be a class hypersensitivity. Subjects with cephalosporin allergy who especially require alternative cephalosporins might be treated with compounds that have side-chain determinants different from those of the responsible cephalosporins and have negative pretreatment skin test responses.	[Romano, Antonino; Gaeta, Francesco; Valluzzi, Rocco Luigi; Maggioletti, Michela; Caruso, Cristiano] Complesso Integrato Columbus, Allergy Unit, I-00168 Rome, Italy; [Romano, Antonino] IRCCS Oasi Maria SS, Troina, Italy; [Zaffiro, Alessandra; Quaratino, Donato] IDI IRCCS, Ambulatorio Allergol, Capranica, Italy	IRCCS Oasi Maria SS	Romano, A (corresponding author), Complesso Integrato Columbus, Unita Allergol, Via G Moscati 31, I-00168 Rome, Italy.	antoninoromano@h-columbus.it	Valluzzi, Rocco Luigi/Q-3879-2019; caruso, cristiano/AAR-9502-2020; Gaeta, Francesco/AAC-7107-2020; Romano, Antonino/D-3102-2017	Valluzzi, Rocco Luigi/0000-0003-0029-6254; caruso, cristiano/0000-0001-7631-029X; Gaeta, Francesco/0000-0003-2942-7633; Romano, Antonino/0000-0001-9742-9898	(Italian) Ministry for University, Scientific and Technological Research	(Italian) Ministry for University, Scientific and Technological Research	Supported by the (Italian) Ministry for University, Scientific and Technological Research.	Antunez C, 2006, J ALLERGY CLIN IMMUN, V117, P404, DOI 10.1016/j.jaci.2005.10.032; Atanaskovic-Markovic M, 2005, ALLERGY, V60, P1454, DOI 10.1111/j.1398-9995.2005.00912.x; Baldo BA, 1999, CLIN EXP ALLERGY, V29, P744; Blanca M, 2009, ALLERGY, V64, P183, DOI [10.1111/j.1398-9995.2008.01924.x, 10.1111/j.1398-9995.2008.01916.x]; BRAVO CM, 1995, ALLERGY, V50, P359, DOI 10.1111/j.1398-9995.1995.tb01160.x; Brockow K, 2002, ALLERGY, V57, P45; Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350; Demoly P, 2000, ALLERGY, V55, P418, DOI 10.1034/j.1398-9995.2000.00605.x; Dickson SD, 2013, CLIN REV ALLERG IMMU, V45, P131, DOI 10.1007/s12016-013-8367-x; Empedrad R, 2003, J ALLERGY CLIN IMMUN, V112, P629, DOI 10.1067/mai.2003.1690; Gaig P, 1999, ALLERGY, V54, P901, DOI 10.1034/j.1398-9995.1999.00261.x; Gueant JL, 2006, CURR PHARM DESIGN, V12, P3335, DOI 10.2174/138161206778194060; Hasdenteufel F, 2007, ANN PHARMACOTHER, V41, P1069, DOI 10.1345/aph.1K050; Hasdenteufel F, 2012, CURR CLIN PHARMACOL, V7, P15, DOI 10.2174/157488412799218815; IGEA JM, 1992, ANN ALLERGY, V68, P515; Macy E, 2015, J ALLERGY CLIN IMMUN, V135, P745, DOI 10.1016/j.jaci.2014.07.062; Moreno E, 2007, J INVEST ALLERG CLIN, V17, P52; Orhan F, 2004, ALLERGY, V59, P239, DOI 10.1046/j.1398-9995.2003.00376.x; Pichichero ME, 1998, J PEDIATR-US, V132, P137, DOI 10.1016/S0022-3476(98)70499-8; Pichichero ME, 2014, ANN ALLERG ASTHMA IM, V112, P404, DOI 10.1016/j.anai.2014.02.005; Pipet A, 2011, CLIN EXP ALLERGY, V41, P1602, DOI 10.1111/j.1365-2222.2011.03846.x; Romano A, 2005, ALLERGY, V60, P1545, DOI 10.1111/j.1398-9995.2005.00932.x; Romano A, 2005, CLIN EXP ALLERGY, V35, P1234, DOI 10.1111/j.1365-2222.2005.02317.x; Romano A, 2014, ALLERGY, V69, P806, DOI 10.1111/all.12390; Romano A, 1998, J ALLERGY CLIN IMMUN, V101, P564, DOI 10.1016/S0091-6749(98)70368-9; Romano A, 1999, J ALLERGY CLIN IMMUN, V104, P1113, DOI 10.1016/S0091-6749(99)70100-4; Romano A, 2000, ALLERGY, V55, P415, DOI 10.1034/j.1398-9995.2000.00589.x; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Romano A, 2001, ALLERGY, V56, P84, DOI 10.1034/j.1398-9995.2001.00921.x; Romano A, 2000, J ALLERGY CLIN IMMUN, V106, P1177; ROMANO A, 1997, INT J IMMUNOPATHO S2, V10, P187; Romano A, 2008, PEDIATRICS, V122, P521, DOI 10.1542/peds.2007-3178; Romano A, 2012, J ALLERGY CLIN IMMUN, V129, P1166, DOI 10.1016/j.jaci.2011.12.995; Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047; Romano A, 2010, J ALLERGY CLIN IMMUN, V126, P994, DOI 10.1016/j.jaci.2010.06.052; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Solensky R, 2012, J ALLERGY CLIN IMMUN, V130, P1442, DOI 10.1016/j.jaci.2012.08.021; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Somech R, 2009, INT ARCH ALLERGY IMM, V150, P205, DOI 10.1159/000222672; Testi S, 2010, J INVEST ALLERG CLIN, V20, P171; Warrington RJ, 1996, J ALLERGY CLIN IMMUN, V98, P460, DOI 10.1016/S0091-6749(96)70171-9; Weber EA, 1996, J ALLERGY CLIN IMMUN, V98, P849, DOI 10.1016/S0091-6749(96)70138-0	42	98	99	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					685	+		10.1016/j.jaci.2015.03.012	http://dx.doi.org/10.1016/j.jaci.2015.03.012			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25930196				2022-12-18	WOS:000360913300021
J	Bonnelykke, K; Vissing, NH; Sevelsted, A; Johnston, SL; Bisgaard, H				Bonnelykke, Klaus; Vissing, Nadja Hawwa; Sevelsted, Astrid; Johnston, Sebastian L.; Bisgaard, Hans			Association between respiratory infections in early life and later asthma is independent of virus type	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Child; asthma; virus; bacteria; respiratory tract infection	SYNCYTIAL-VIRUS; CHILDHOOD ASTHMA; VIRAL-INFECTIONS; RISK; WHEEZE; ALLERGY; INFANCY; SENSITIZATION; BRONCHIOLITIS; VARIANTS	Background: Lower respiratory tract infections in the first years of life are associated with later asthma, and this observation has led to a focus on the potential causal role of specific respiratory viruses, such as rhinoviruses and respiratory syncytial virus, in asthma development. However, many respiratory viruses and bacteria trigger similar respiratory symptoms and it is possible that the important risk factors for asthma are the underlying susceptibility to infection and the exaggerated reaction to such triggers rather than the particular triggering agent. Objective: We sought to study the association between specific infections in early life and development of asthma later in childhood. Methods: Three hundred thirteen children were followed prospectively in the Copenhagen Prospective Studies of Asthma in Childhood2000 high-risk birth cohort. Nine respiratory virus types (respiratory syncytial virus, rhinoviruses, other picornaviruses, coronaviruses 229E and OC43, parainfluenza viruses 1-3, influenza viruses AH1, AH3, and B, human metapneumovirus, adenoviruses, and bocavirus) and 3 pathogenic airway bacteria (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis) were identified in airway secretions sampled during episodes of troublesome lung symptoms in the first 3 years of life. Asthma was determined by age 7 years. Results: In unadjusted analyses, all viruses and pathogenic bacteria identified during episodes of troublesome lung symptoms were associated with increased risk of asthma by age 7 years with similar odds ratios for all viruses and pathogenic bacteria. After adjustment for the frequency of respiratory episodes, the particular triggers were no longer associated with asthma. Conclusion: The number of respiratory episodes in the first years of life, but not the particular viral trigger, was associated with later asthma development. This suggests that future research should focus on the susceptibility and exaggerated response to lower respiratory tract infections in general rather than on the specific triggering agent.	[Bonnelykke, Klaus; Vissing, Nadja Hawwa; Sevelsted, Astrid; Bisgaard, Hans] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen Prospect Studies Asthma Childhood, DK-2820 Gentofte, Denmark; [Bonnelykke, Klaus; Vissing, Nadja Hawwa; Sevelsted, Astrid; Bisgaard, Hans] Univ Copenhagen, Gentofte Hosp, Danish Pediat Asthma Ctr, DK-2820 Gentofte, Denmark; [Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, MRC, Airway Dis Infect Sect, London SW7 2AZ, England; [Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Asthma UK Ctr Allerg Mech Asthma, London SW7 2AZ, England; [Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Ctr Resp Infect, London SW7 2AZ, England	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; Imperial College London; Imperial College London; University of London; King's College London; Imperial College London	Bisgaard, H (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen Prospect Studies Asthma Childhood, Denmark Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Johnston, Sebastian Lennox/I-2423-2012; Bisgaard, Hans/N-4761-2016	Johnston, Sebastian Lennox/0000-0003-3009-9200; Bisgaard, Hans/0000-0003-4131-7592; sevelsted, astrid/0000-0001-7117-2334; Bonnelykke, Klaus/0000-0003-2003-1018	Lundbeck Foundation [R16-A1694]; Ministry of Health [903516]; Danish Council for Strategic Research [0603-00280B]; Danish Council for Independent Research; Capital Region Research Foundation; Thermo Fischer Scientific Inc; ERC [233015]; Chair from Asthma UK [CH11SJ]; MRC Centre Grant [G1000758]; Predicta FP7 Collaborative Project grant [260895]; National Institutes of Health; European Research Council; Novo Nordisk; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish; Medical Research Council [G1000758] Funding Source: researchfish; Asthma UK [CH11SJ] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Ministry of Health; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Capital Region Research Foundation; Thermo Fischer Scientific Inc; ERC(European Research Council (ERC)European Commission); Chair from Asthma UK; MRC Centre Grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Predicta FP7 Collaborative Project grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Research Council(European Research Council (ERC)European Commission); Novo Nordisk(Novo Nordisk); Lundbeck Foundation(Lundbeckfonden); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) is funded by private and public research funds all listed on www.copsac.com. The Lundbeck Foundation (grant no. R16-A1694); the Ministry of Health (grant no. 903516); the Danish Council for Strategic Research (grant no. 0603-00280B); the Danish Council for Independent Research and the Capital Region Research Foundation have provided core support for COPSAC. Thermo Fischer Scientific Inc sponsored the IgE analyses. No pharmaceutical company was involved in the study. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript. S. L. Johnston is supported by ERC FP7 Advanced grant 233015, a Chair from Asthma UK (CH11SJ), MRC Centre Grant G1000758, and Predicta FP7 Collaborative Project grant 260895. H. Bisgaard is employed by the Capital Region of Denmark, which has received funding from the Lundbeck Foundation and has received or has grants pending from the European Research Council, National Institutes of Health, and Novo Nordisk and has received compensation for providing expert testimony from the European Medicines Agency. The rest of the authors declare that they have no relevant conflicts of interest.	Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2012, J ALLERGY CLIN IMMUN, V130, P531, DOI 10.1016/j.jaci.2011.10.047; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Bonnelykke K, 2010, PEDIAT ALLERG IMM-UK, V21, P954, DOI 10.1111/j.1399-3038.2010.01073.x; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Chawes BLK, 2012, J ALLERGY CLIN IMMUN, V130, P354, DOI 10.1016/j.jaci.2012.04.045; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Goetghebuer T, 2004, PEDIATR PULM, V38, P321, DOI 10.1002/ppul.20069; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kuehni CE, 2009, AM J RESP CRIT CARE, V179, P1079, DOI 10.1164/rccm.200904-0567ED; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; McBride JT, 1999, J PEDIATR-US, V135, pS28; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Paganelli R, 1998, ALLERGY, V53, P763; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Skytt N, 2012, J ALLERGY CLIN IMMUN, V130, P403, DOI 10.1016/j.jaci.2012.04.043; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stensballe LG, 2006, PEDIATRICS, V118, pE1360, DOI 10.1542/peds.2006-0907; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC	31	98	103	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					81	U164		10.1016/j.jaci.2015.02.024	http://dx.doi.org/10.1016/j.jaci.2015.02.024			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25910716	Bronze, Green Published, Green Submitted			2022-12-18	WOS:000357542200009
J	Konradsen, JR; Fujisawa, T; van Hage, M; Hedlin, G; Hilger, C; Kleine-Tebbe, J; Matsui, EC; Roberts, G; Ronmark, E; Platts-Mills, TAE				Konradsen, Jon R.; Fujisawa, Takao; van Hage, Marianne; Hedlin, Gunilla; Hilger, Christiane; Kleine-Tebbe, Joerg; Matsui, Elizabeth C.; Roberts, Graham; Ronmark, Eva; Platts-Mills, Thomas A. E.			Allergy to furry animals: New insights, diagnostic approaches, and challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Molecular-based allergy diagnostics; allergy; allergens; furry animals; cats; dogs; allergic asthma; allergic rhinitis; pork-cat syndrome	FEL-D-I; DOG LIPOCALIN ALLERGEN; MODIFIED TH2 RESPONSE; RED MEAT ALLERGY; CAT ALLERGEN; INHALANT ALLERGENS; CHILDHOOD ASTHMA; IGE ANTIBODIES; IMMUNOLOGICAL CHARACTERIZATION; MOLECULAR CHARACTERIZATION	The prevalence of allergy to furry animals has been increasing, and allergy to cats, dogs, or both is considered a major risk factor for the development of asthma and rhinitis. An important step forward in the diagnosis of allergy to furry animals has been made with the introduction of molecular-based allergy diagnostics. A workshop on furry animals was convened to provide an up-to-date assessment of our understanding of (1) the exposure and immune response to the major mammalian allergens, (2) the relationship of these responses (particularly those to specific proteins or components) to symptoms, and (3) the relevance of these specific antibody responses to current or future investigation of patients presenting with allergic diseases. In this review research results discussed at the workshop are presented, including the effect of concomitant exposures from other allergens or microorganisms, the significance of the community prevalence of furry animals, molecular-based allergy diagnostics, and a detailed discussion of cat and dog components.	[Konradsen, Jon R.; Hedlin, Gunilla] Karolinska Inst, Dept Womens & Childrens Hlth, S-10401 Stockholm, Sweden; [Konradsen, Jon R.; Hedlin, Gunilla] Karolinska Inst, Ctr Allergy Res, S-10401 Stockholm, Sweden; [Konradsen, Jon R.; Hedlin, Gunilla] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, SE-17176 Stockholm, Sweden; [Fujisawa, Takao] Mie Natl Hosp, Inst Clin Res, Tsu, Mie, Japan; [van Hage, Marianne] Karolinska Inst, Clin Immunol & Allergy Unit, Dept Med, Stockholm, Sweden; [van Hage, Marianne] St Gorans Univ Hosp, S-11281 Stockholm, Sweden; [Hilger, Christiane] CRP Sante, Lab Immunogenet & Allergol, Luxembourg, Luxembourg; [Kleine-Tebbe, Joerg] Allergy & Asthma Ctr Westend, Outpatient Clin & Res Unit, Berlin, Germany; [Matsui, Elizabeth C.] Johns Hopkins Sch Med, Div Pediat Allergy Immunol, Baltimore, MD USA; [Roberts, Graham] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England; [Roberts, Graham] Univ Southampton, Fac Med, Human Dev & Hlth Acad Unit, Southampton SO9 5NH, Hants, England; [Roberts, Graham] Univ Southampton, Fac Med, Clin & Expt Sci Acad Unit, Southampton SO9 5NH, Hants, England; [Roberts, Graham] Univ Hosp Southampton NHS Fdn Trust, NIHR Resp Biomed Res Unit, Southampton, Hants, England; [Ronmark, Eva] Umea Univ, Dept Publ Hlth & Clin Med, Occupat & Environm Med, S-90187 Umea, Sweden; [Platts-Mills, Thomas A. E.] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Saint Goran's Hospital; Luxembourg Institute of Health; Johns Hopkins University; Johns Hopkins Medicine; University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Umea University; University of Virginia	Konradsen, JR (corresponding author), Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Q2 04, SE-17176 Stockholm, Sweden.	jon.konradsen@karolinska.se	Konradsen, Jon/AAD-5620-2021; van Hage, Marianne/A-9678-2017	Konradsen, Jon/0000-0001-7745-8624; van Hage, Marianne/0000-0003-3091-1596; Hilger, Christiane/0000-0001-9455-5442; Kleine-Tebbe, Joerg/0000-0002-2862-7353; Matsui, Elizabeth/0000-0001-8134-5593; Platts-Mills, Thomas/0000-0002-1263-329X	Thermo Fisher Scientific; Novartis; Hycor Biomedical; ALK-Abello; US Environmental Protection Agency's Science Advisory Board; National Institutes of Health; Medical Research Council [G0900453, G0400473] Funding Source: researchfish; MRC [G0400473, G0900453] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565] Funding Source: NIH RePORTER	Thermo Fisher Scientific; Novartis(Novartis); Hycor Biomedical; ALK-Abello; US Environmental Protection Agency's Science Advisory Board; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	J. R. Konradsen has received travel support from Thermo Fisher Scientific, research support from Novartis, and payment for lectures from Novartis, Thermo Fisher, and Meda. M. van Hage has received consultancy fees from Hycor Biomedical and lecture fees from Thermo Fisher Scientific, Novartis, and ALK-Abello. G. Hedlin has received lecture fees from Thermo Fisher. C. Hilger, J. Kleine-Tebbe, and E. Ronmark have received travel support from Thermo Fisher Scientific. E. C. Matsui has received travel support from Thermo Fisher, is on the US Environmental Protection Agency's Science Advisory Board, and has received research support from the National Institutes of Health. G. Roberts has received research support from Thermo Fisher in the form of providing assay reagents. T. A. E. Platts-Mills has received travel support from Phadia and research support from Thermo Fisher. T. Fujisawa declares no relevant conflicts of interest.	Abdel-Moein KA, 2011, VECTOR-BORNE ZOONOT, V11, P627, DOI 10.1089/vbz.2010.0272; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; Almqvist C, 2010, PAEDIATR PERINAT EP, V24, P171, DOI 10.1111/j.1365-3016.2010.01095.x; Andersson M, 2013, PEDIATRICS, V132, pE435, DOI 10.1542/peds.2013-0741; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bergstrom SE, 2010, RESP MED, V104, P180, DOI 10.1016/j.rmed.2009.09.021; Borres MP, 2011, PEDIAT ALLERG IMM-UK, V22, P454, DOI 10.1111/j.1399-3038.2011.01197.x; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Bulone V, 1998, EUR J BIOCHEM, V253, P202, DOI 10.1046/j.1432-1327.1998.2530202.x; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; Canonica GW, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-17; Caponetto P, 2013, J ALLER CL IMM-PRACT, V1, P302, DOI 10.1016/j.jaip.2013.01.007; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Cornmins SP, 2012, AM J RESP CRIT CARE, V185, P723, DOI 10.1164/rccm.201111-2017OC; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; DANDEU JP, 1993, J CHROMATOGR-BIOMED, V621, P23, DOI 10.1016/0378-4347(93)80072-C; Dharmage SC, 2012, CURR ALLERGY ASTHM R, V12, P413, DOI 10.1007/s11882-012-0288-x; Drouet M, 2001, Allerg Immunol (Paris), V33, P163; Earle CD, 2007, J ALLERGY CLIN IMMUN, V119, P428, DOI 10.1016/j.jaci.2006.11.004; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Emara M, 2011, J BIOL CHEM, V286, P13033, DOI 10.1074/jbc.M111.220657; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Erwin EA, 2014, ANN ALLERG ASTHMA IM, V112, P545, DOI 10.1016/j.anai.2014.03.007; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Gregoire C, 1996, J BIOL CHEM, V271, P32951, DOI 10.1074/jbc.271.51.32951; Gronlund H, 2008, CLIN EXP ALLERGY, V38, P1275, DOI 10.1111/j.1365-2222.2008.03003.x; Gronlund H, 2009, J ALLERGY CLIN IMMUN, V123, P1189, DOI 10.1016/j.jaci.2009.03.011; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Hamsten C, 2013, J ALLERGY CLIN IMMUN, V132, P1431, DOI 10.1016/j.jaci.2013.07.050; Heinzerling LM, 2009, ALLERGY, V64, P1498, DOI 10.1111/j.1398-9995.2009.02093.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hilger C, 1997, ALLERGY, V52, P179, DOI 10.1111/j.1398-9995.1997.tb00972.x; Hilger C, 2014, J ALLERGY CLIN IMMUN, V133, P759, DOI 10.1016/j.jaci.2013.04.034; Hilger C, 2012, CURR ALLERGY ASTHM R, V12, P438, DOI 10.1007/s11882-012-0283-2; Hilger C, 2012, J ALLERGY CLIN IMMUN, V129, P1149, DOI 10.1016/j.jaci.2011.10.017; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; IUIS Allergen Nomenclature Sub Committee, 2014, ALL NOM; JANOSSY G, 1976, CLIN EXP IMMUNOL, V26, P108; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; Kim J, 2011, J KOREAN MED SCI, V26, P1165, DOI 10.3346/jkms.2011.26.9.1165; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KLEINETEBBE J, 1993, INT ARCH ALLERGY IMM, V100, P256, DOI 10.1159/000236421; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; Konradsen JR, 2014, PEDIAT ALLERG IMM-UK, V25, P187, DOI 10.1111/pai.12198; Lascombe MB, 2000, J BIOL CHEM, V275, P21572, DOI 10.1074/jbc.M002854200; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Liccardi G, 2012, CURR ALLERGY ASTHM R, V12, P429, DOI 10.1007/s11882-012-0280-5; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; Linneberg A, 2003, ALLERGY, V58, P21, DOI 10.1034/j.1398-9995.2003.23639.x; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Madhurantakam C, 2010, J MOL BIOL, V401, P68, DOI 10.1016/j.jmb.2010.05.043; Mandhane PJ, 2009, J ALLERGY CLIN IMMUN, V124, P745, DOI 10.1016/j.jaci.2009.06.038; Mattsson L, 2010, CLIN EXP ALLERGY, V40, P1276, DOI 10.1111/j.1365-2222.2010.03533.x; Mattsson L, 2009, J ALLERGY CLIN IMMUN, V123, P362, DOI 10.1016/j.jaci.2008.11.021; McBride D, 2012, PEDIAT ALLERG IMM-UK, V23, P230, DOI 10.1111/j.1399-3038.2011.01254.x; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Morisset M, 2012, ALLERGY, V67, P609, DOI 10.1111/j.1398-9995.2012.02799.x; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Nicholas C, 2010, ANN ALLERG ASTHMA IM, V105, P228, DOI 10.1016/j.anai.2010.06.019; Niitsuma T, 2004, J INVEST ALLERG CLIN, V14, P221; Nilsson OB, 2012, ALLERGY, V67, P751, DOI 10.1111/j.1398-9995.2012.02826.x; Nordlund B, 2012, ALLERGY, V67, P661, DOI 10.1111/j.1398-9995.2012.02797.x; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Olivieri M, 2012, J ALLERGY CLIN IMMUN, V129, P420, DOI 10.1016/j.jaci.2011.10.044; Ownby DR, 2013, INDOOR AIR, V23, P219, DOI 10.1111/ina.12016; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Parviainen S, 2013, SCAND J IMMUNOL, V77, P171, DOI 10.1111/sji.12023; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Patelis A, 2012, J ALLERGY CLIN IMMUN, V130, P397, DOI 10.1016/j.jaci.2012.03.046; Peng RD, 2011, J ALLERGY CLIN IMMUN, V128, P390, DOI 10.1016/j.jaci.2011.04.050; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Phillips JF, 2009, J ALLERGY CLIN IMMUN, V123, P513, DOI 10.1016/j.jaci.2008.09.019; Platts-Mills JA, 2005, J ALLERGY CLIN IMMUN, V116, P384, DOI 10.1016/j.jaci.2005.05.012; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Portnoy JM, 2012, ANN ALLERG ASTHMA IM, V109, P229, DOI 10.1016/j.anai.2012.02.015; Posthumus J, 2013, J ALLERGY CLIN IMMUN, V131, P923, DOI 10.1016/j.jaci.2012.12.665; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Roberts G, 2012, CLIN EXP ALLERGY, V42, P1501, DOI 10.1111/j.1365-2222.2012.04074.x; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Ronmark E, 2003, PEDIAT ALLERG IMM-UK, V14, P91, DOI 10.1034/j.1399-3038.2003.00042.x; Saarelainen S, 2008, CLIN EXP ALLERGY, V38, P374, DOI 10.1111/j.1365-2222.2007.02895.x; Sabbah A, 1994, Allerg Immunol (Paris), V26, P173; SABBAH A, 1994, ALLERG IMMUNOL PARIS, V26, P177; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Schmitz R, 2013, INT ARCH ALLERGY IMM, V162, P263, DOI 10.1159/000353344; Sheehan WJ, 2009, ANN ALLERG ASTHMA IM, V102, P125, DOI 10.1016/S1081-1206(10)60242-6; Smith W, 2004, CLIN EXP ALLERGY, V34, P1732, DOI 10.1111/j.1365-2222.2004.02090.x; Smith W, 2011, INT ARCH ALLERGY IMM, V156, P159, DOI 10.1159/000322879; Sohy C, 2005, ALLERGY, V60, P541, DOI 10.1111/j.1398-9995.2005.00742.x; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; Vartiainen E, 2002, J ALLERGY CLIN IMMUN, V109, P643, DOI 10.1067/mai.2002.123307; Virtanen T, 2012, CLIN EXP ALLERGY, V42, P494, DOI 10.1111/j.1365-2222.2011.03903.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warm K, 2012, J ALLERGY CLIN IMMUN, V129, P136, DOI 10.1016/j.jaci.2011.08.033; Wegienka G, 2011, CLIN EXP ALLERGY, V41, P979, DOI 10.1111/j.1365-2222.2011.03747.x; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V117, P213, DOI 10.1016/j.jaci.2005.09.040; Wisniewski JA, 2013, CLIN EXP ALLERGY, V43, P1160, DOI 10.1111/cea.12169	122	98	102	3	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					616	625		10.1016/j.jaci.2014.08.026	http://dx.doi.org/10.1016/j.jaci.2014.08.026			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25282018	Bronze			2022-12-18	WOS:000351065000004
J	Harvima, IT; Levi-Schaffer, F; Draber, P; Friedman, S; Polakovicova, I; Gibbs, BF; Blank, U; Nilsson, G; Maurer, M				Harvima, Ilkka T.; Levi-Schaffer, Francesca; Draber, Petr; Friedman, Sheli; Polakovicova, Iva; Gibbs, Bernhard F.; Blank, Ulrich; Nilsson, Gunnar; Maurer, Marcus			Molecular targets on mast cells and basophils for novel therapies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; basophil; mediator; receptor; signaling protein; survival protein; drug; therapy	FC-EPSILON-RI; THYMIC STROMAL LYMPHOPOIETIN; TYROSINE KINASE INHIBITOR; AIRWAY SMOOTH-MUSCLE; HISTAMINE H-4 RECEPTOR; CRTH2 ANTAGONIST OC000459; PROSTAGLANDIN D SYNTHASE; HIGH-AFFINITY; SIGLEC-F; IN-VITRO	Mast cells and basophils (MCs/Bs) play a crucial role in type I allergy, as well as in innate and adaptive immune responses. These cells mediate their actions through soluble mediators, some of which are targeted therapeutically by, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists. Recently, considerable progress has been made in developing new drugs that target additional MC/B mediators or receptors, such as serine proteinases, histamine 4-receptor, 5-lipoxygenase-activating protein, 15-lipoxygenase-1, prostaglandin D-2, and proinflammatory cytokines. Mediator production can be abrogated by the use of inhibitors directed against key intracellular enzymes, some of which have been used in clinical trials (eg, inhibitors of spleen tyrosine kinase, phosphatidylinositol 3-kinase, Bruton tyrosine kinase, and the protein tyrosine kinase KIT). Reduced MC/B function can also be achieved by enhancing Src homology 2 domain-containing inositol 5' phosphatase 1 activity or by blocking sphingosine-1-phosphate. Therapeutic interventions in mast cell-associated diseases potentially include drugs that either block ion channels and adhesion molecules or antagonize antiapoptotic effects on B-cell lymphoma 2 family members. MCs/Bs express high-affinity IgE receptors, and blocking their interactions with IgE has been a prime goal in antiallergic therapy. Surface-activating receptors, such as CD48 and thymic stromal lymphopoietin receptors, as well as inhibitory receptors, such as CD300a, Fc gamma RIIb, and endocannabinoid receptors, hold promising therapeutic possibilities based on preclinical studies. The inhibition of activating receptors might help prevent allergic reactions from developing, although most of the candidate drugs are not sufficiently cell specific. In this review recent advances in the development of novel therapeutics toward different molecules of MCs/Bs are presented.	[Harvima, Ilkka T.] Univ Eastern Finland, Dept Dermatol, Kuopio, Finland; [Harvima, Ilkka T.] Univ Eastern Finland, Canc Ctr Eastern Finland, Kuopio, Finland; [Harvima, Ilkka T.] Kuopio Univ Hosp, Kuopio 70029, Finland; [Levi-Schaffer, Francesca; Friedman, Sheli] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res,Dept Pharmacol & Expt Therapeut, Jerusalem, Israel; [Draber, Petr; Polakovicova, Iva] Acad Sci Czech Republ, Inst Mol Genet, Dept Signal Transduct, Prague, Czech Republic; [Gibbs, Bernhard F.] Univ Kent, Medway Sch Pharm, Canterbury CT2 7NZ, Kent, England; [Blank, Ulrich] INSERM, UMRS 699, Paris, France; [Blank, Ulrich] Univ Paris Diderot, Sorbonne Paris Cite, Lab Excellence, INFLAMEX, Paris, France; [Nilsson, Gunnar] Karolinska Inst, Dept Med, Stockholm, Sweden; [Maurer, Marcus] Charite, Allergie Ctr, Dept Dermatol & Allergy, Berlin, Germany	University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Hebrew University of Jerusalem; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Kent; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Harvima, IT (corresponding author), Kuopio Univ Hosp, Dept Dermatol, POB 100, Kuopio 70029, Finland.	ilkka.harvima@kuh.fi	Maurer, Marcus/ABG-2174-2020; Polakovicova, Iva/AAF-6990-2019; Draber, Petr/E-1119-2018; Sumbayev, Vadim/HCH-7696-2022	Maurer, Marcus/0000-0002-4121-481X; Draber, Petr/0000-0002-3986-2025; Blank, Ulrich/0000-0002-2661-2983; Levi-Schaffer, Francesca/0000-0003-0620-2810; Nilsson, Gunnar/0000-0001-6795-5512; Polakovicova, Iva/0000-0002-4505-9896	COST Action BM1007 "Mast cells and Basophils: targets for innovative therapies"; Cancer Center of Eastern Finland; VTR funding of Kuopio University Hospital; Israel Science Foundation [213/05]; MAARS (Microbes in Allergy and Autoimmunity Related to the Skin) EU 7th framework [HEALTH-F2-2011-261366]; Aimwell Charitable Trust (London, United Kingdom); Ministry of Education of the Czech Republic [COST CZ LD12073]; Czech Science foundation [14-00703S, 14-09807S, P302/12/G101]; Institute of Molecular Genetics ASCR [RVO 68378050]; Faculty of Science, Charles University, Prague; French National Research Agency [ANR-12-ISV3-0006-01]; Investissements d'Avenir programme [ANR-11-IDEX-0005-02]; Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX	COST Action BM1007 "Mast cells and Basophils: targets for innovative therapies"; Cancer Center of Eastern Finland; VTR funding of Kuopio University Hospital; Israel Science Foundation(Israel Science Foundation); MAARS (Microbes in Allergy and Autoimmunity Related to the Skin) EU 7th framework; Aimwell Charitable Trust (London, United Kingdom); Ministry of Education of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Czech Science foundation(Grant Agency of the Czech Republic); Institute of Molecular Genetics ASCR; Faculty of Science, Charles University, Prague; French National Research Agency(French National Research Agency (ANR)); Investissements d'Avenir programme(French National Research Agency (ANR)); Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX	Supported by the COST Action BM1007 "Mast cells and Basophils: targets for innovative therapies.'' I.T.H. was supported, in part, by the Cancer Center of Eastern Finland and VTR funding of Kuopio University Hospital. F.L.-S.' s research is supported, in part, by grants from the Israel Science Foundation (grant 213/05); the MAARS (Microbes in Allergy and Autoimmunity Related to the Skin) EU 7th framework (grant no. HEALTH-F2-2011-261366); and the Aimwell Charitable Trust (London, United Kingdom). P.D. and I.P. were supported, in part, by project COST CZ LD12073 from Ministry of Education of the Czech Republic and grants 14-00703S, 14-09807S, and P302/12/G101 from the Czech Science foundation and by the Institute of Molecular Genetics ASCR (RVO 68378050). I.P. was supported in part by the Faculty of Science, Charles University, Prague. U.B is supported by the French National Research Agency (ANR-12-ISV3-0006-01), the Investissements d'Avenir programme ANR-11-IDEX-0005-02, Sorbonne Paris Cite, Laboratoire d'excellence INFLAMEX.	Ackermann L, 1998, ARCH DERMATOL RES, V290, P353, DOI 10.1007/s004030050317; Aizawa H, 2002, J ALLERGY CLIN IMMUN, V109, P176, DOI 10.1067/mai.2002.120550; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; ALOE L, 1993, AGENTS ACTIONS, V39, pC145, DOI 10.1007/BF01972748; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Astrakhan A, 2007, NAT IMMUNOL, V8, P522, DOI 10.1038/ni1452; Baba Y, 2008, NAT IMMUNOL, V9, P81, DOI 10.1038/ni1546; Bachelet I, 2005, J IMMUNOL, V175, P7989, DOI 10.4049/jimmunol.175.12.7989; Bachelet I, 2006, J ALLERGY CLIN IMMUN, V117, P1314, DOI 10.1016/j.jaci.2006.04.031; Barnes N, 2012, CLIN EXP ALLERGY, V42, P38, DOI 10.1111/j.1365-2222.2011.03813.x; Ben Efraim AHN, 2013, ALLERGY, V68, P397, DOI 10.1111/all.12092; Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Blunt MD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00226; Blunt MD, 2012, CURR OPIN PHARMACOL, V12, P444, DOI 10.1016/j.coph.2012.02.015; Blunt MD, 2013, FRONT IMMUNOL, V3, P1; Borner C, 2008, MOL PHARMACOL, V73, P1013, DOI 10.1124/mol.107.042945; Borner C, 2007, J LEUKOCYTE BIOL, V81, P336, DOI 10.1189/jlb.0306224; Bounab Y, 2013, CURR OPIN IMMUNOL, V25, P313, DOI 10.1016/j.coi.2013.04.001; Braselmann S, 2006, J PHARMACOL EXP THER, V319, P998, DOI 10.1124/jpet.106.109058; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Bruhns P, 2005, CURR OPIN IMMUNOL, V17, P662, DOI 10.1016/j.coi.2005.09.012; Busse WW, 2013, J ALLERGY CLIN IMMUN, V131, P339, DOI 10.1016/j.jaci.2012.10.013; Cady CT, 2010, IMMUNOL LETT, V130, P57, DOI 10.1016/j.imlet.2009.12.001; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Caughey GH, 2007, IMMUNOL REV, V217, P141, DOI 10.1111/j.1600-065X.2007.00509.x; Cemerski S, 2012, IMMUNOL LETT, V143, P34, DOI 10.1016/j.imlet.2012.01.008; Chang BY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3400; Chang TW, 2006, J ALLERGY CLIN IMMUN, V117, P1203, DOI 10.1016/j.jaci.2006.04.005; Cho JY, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-154; Comeau MR, 2010, MUCOSAL IMMUNOL, V3, P138, DOI 10.1038/mi.2009.134; Corren J, 2009, CLIN EXP ALLERGY, V39, P788, DOI 10.1111/j.1365-2222.2009.03214.x; Crivellato E, 2010, INT ARCH ALLERGY IMM, V151, P89, DOI 10.1159/000235998; D'Cruz OJ, 2013, ONCOTARGETS THER, V6, P161, DOI 10.2147/OTT.S33732; D'Orleans-Juste P, 2008, VASC PHARMACOL, V49, P51, DOI 10.1016/j.vph.2008.06.007; Dahlen SE, 2004, THORAX, V59, P453, DOI 10.1136/thx.2004.026641; Davi Giovanni, 2012, Handb Exp Pharmacol, P261, DOI 10.1007/978-3-642-29423-5_11; Di Capite J, 2009, J ALLERGY CLIN IMMUN, V124, P1014, DOI 10.1016/j.jaci.2009.08.030; Di Girolamo N, 2000, Dev Immunol, V7, P131, DOI 10.1155/2000/82708; Di Girolamo N, 2006, J IMMUNOL, V177, P2638, DOI 10.4049/jimmunol.177.4.2638; Eklund KK, 2003, ANN MED, V35, P362, DOI 10.1080/07853890310001339; Ekoff M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039117; Ekoff M, 2011, ADV EXP MED BIOL, V716, P47, DOI 10.1007/978-1-4419-9533-9_4; El-Agamy DS, 2012, EUR J PHARMACOL, V680, P115, DOI 10.1016/j.ejphar.2012.01.039; Elishmereni M, 2011, ALLERGY, V66, P376, DOI 10.1111/j.1398-9995.2010.02494.x; Elishmereni M, 2011, INT J BIOCHEM CELL B, V43, P25, DOI 10.1016/j.biocel.2010.09.001; Ellmeier W, 2011, FEBS J, V278, P1990, DOI 10.1111/j.1742-4658.2011.08073.x; Evans EK, 2013, J PHARMACOL EXP THER, V346, P219, DOI 10.1124/jpet.113.203489; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Falcone FH, 2011, CLIN EXP ALLERGY, V41, P939, DOI 10.1111/j.1365-2222.2011.03781.x; Falkencrone S, 2013, ALLERGY, V68, P614, DOI 10.1111/all.12143; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; Farid SS, 2012, IMMUNOPHARM IMMUNOT, V34, P721, DOI 10.3109/08923973.2011.589453; Fischer M, 2006, J CLIN INVEST, V116, P2748, DOI 10.1172/JCI24274; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Foster JG, 2012, PHARMACOL REV, V64, P1027, DOI 10.1124/pr.110.004051; Foussias G, 2000, BIOCHEM BIOPH RES CO, V278, P775, DOI 10.1006/bbrc.2000.3866; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Giacomin PR, 2012, J IMMUNOL, V189, P4371, DOI 10.4049/jimmunol.1200691; Gibbs BF, 2012, EXP DERMATOL, V21, P884, DOI 10.1111/exd.12018; Gibbs BF, 2012, FRONT BIOSCI-LANDMRK, V17, P430, DOI 10.2741/3936; Gotlib J, 2010, BLOOD, V116; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; Gulliksson M, 2007, BBA-MOL CELL BIOL L, V1771, P1156, DOI 10.1016/j.bbalip.2007.06.001; Gulliksson M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012360; Gutzmer Ralf, 2011, Front Biosci (Schol Ed), V3, P985; Guyer BJ, 2006, ALLERGY ASTHMA PROC, V27, P208, DOI 10.2500/aap.2006.27.2861; Haddon DJ, 2009, J IMMUNOL, V183, P228, DOI 10.4049/jimmunol.0900427; Hagiyama M, 2013, BRIT J DERMATOL, V168, P771, DOI 10.1111/bjd.12108; Hallgren J, 2001, BIOCHEMISTRY-US, V40, P7342, DOI 10.1021/bi001988c; Halova I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00119; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Hart TK, 2002, CLIN EXP IMMUNOL, V130, P93, DOI 10.1046/j.1365-2249.2002.01973.x; Harvima IT, 2011, ACTA DERM-VENEREOL, V91, P644, DOI 10.2340/00015555-1197; He AN, 2013, CURR PHARM DESIGN, V19, P1114; He LP, 2005, J BIOL CHEM, V280, P10997, DOI 10.1074/jbc.M411797200; Hognauer K, 2008, CHEMMEDCHEM, V3, P1027, DOI 10.1002/cmdc.200800037; Hofstra CL, 2003, J PHARMACOL EXP THER, V305, P1212, DOI 10.1124/jpet.102.046581; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Hollins F, 2008, J IMMUNOL, V181, P2772, DOI 10.4049/jimmunol.181.4.2772; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Horak F, 2012, ALLERGY, V67, P1572, DOI 10.1111/all.12042; Hudson SA, 2011, J CLIN IMMUNOL, V31, P1045, DOI 10.1007/s10875-011-9589-4; Hudson SA, 2009, J PHARMACOL EXP THER, V330, P608, DOI 10.1124/jpet.109.152439; Humbert M, 2009, ALLERGY, V64, P1194, DOI 10.1111/j.1398-9995.2009.02122.x; Huttunen M, 2005, BRIT J DERMATOL, V152, P1149, DOI 10.1111/j.1365-2133.2005.06428.x; Jeon SG, 2009, CLIN EXP ALLERGY, V39, P908, DOI 10.1111/j.1365-2222.2009.03211.x; Jogie-Brahim S, 2004, J ALLERGY CLIN IMMUN, V113, P1086, DOI 10.1016/j.jaci.2004.02.032; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Joo M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/503128; Juurikivi A, 2005, ANN RHEUM DIS, V64, P1126, DOI 10.1136/ard.2004.029835; Kajiwara D, 2011, EUR J PHARMACOL, V667, P389, DOI 10.1016/j.ejphar.2011.05.041; Kalesnikoff J, 2002, J IMMUNOL, V168, P4737, DOI 10.4049/jimmunol.168.9.4737; Kamo A, 2014, J INVEST DERMATOL, V134, P546, DOI 10.1038/jid.2013.351; Karasuyama H, 2011, ALLERGY, V66, P1133, DOI 10.1111/j.1398-9995.2011.02613.x; Karlberg M, 2010, J IMMUNOL, V185, P2555, DOI 10.4049/jimmunol.0903656; Karra L, 2009, CURR OPIN IMMUNOL, V21, P708, DOI 10.1016/j.coi.2009.09.010; Kaur D, 2012, CHEST, V142, P76, DOI 10.1378/chest.11-1782; KAZIMIERCZAK W, 1981, AGENTS ACTIONS, V11, P96, DOI 10.1007/BF01991468; Kenna TJ, 2013, NAT REV RHEUMATOL, V9, P375, DOI 10.1038/nrrheum.2012.205; Kent SE, 2013, CLIN EXP ALLERGY, V43, P177, DOI 10.1111/cea.12002; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; Kiwamoto T, 2011, CLIN EXP ALLERGY, V41, P116, DOI 10.1111/j.1365-2222.2010.03571.x; Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005; KLEINETEBBE J, 1990, AGENTS ACTIONS, V30, P137, DOI 10.1007/BF01969020; Kneidinger M, 2008, BLOOD, V111, P3097, DOI 10.1182/blood-2007-08-104372; Krause K, 2013, ALLERGY, V68, P921, DOI 10.1111/all.12171; Krishna MT, 2001, J ALLERGY CLIN IMMUN, V107, P1039, DOI 10.1067/mai.2001.115631; Kubavat AH, 2013, AM J THER, V20, P154, DOI 10.1097/MJT.0b013e318254259b; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; Laidlaw TM, 2012, CLIN EXP ALLERGY, V42, P1313, DOI 10.1111/j.1365-2222.2012.03982.x; Lau AHY, 2003, EUR J PHARMACOL, V464, P229, DOI 10.1016/S0014-2999(03)01430-4; Lee KS, 2006, FASEB J, V20, P455, DOI 10.1096/fj.05-5045com; Levi-Schaffer F, 2009, J INVEST DERMATOL, V129, P2549, DOI 10.1038/jid.2009.256; Lieberman JA, 2013, CURR ALLERGY ASTHM R, V13, P78, DOI 10.1007/s11882-012-0316-x; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Lin LH, 2012, IMMUNOL RES, V52, P276, DOI 10.1007/s12026-012-8339-x; Lippert U, 2004, J INVEST DERMATOL, V123, P116, DOI 10.1111/j.0022-202X.2004.22721.x; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Luskova P, 2004, CURR PHARM DESIGN, V10, P1727, DOI 10.2174/1381612043384538; MacGlashan D, 2011, INT IMMUNOPHARMACOL, V11, P475, DOI 10.1016/j.intimp.2010.12.018; Malaviya R, 2001, IMMUNOL REV, V179, P16, DOI 10.1034/j.1600-065X.2001.790102.x; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; Maryanoff BE, 2010, AM J RESP CRIT CARE, V181, P247, DOI 10.1164/rccm.200904-0627OC; MASINI E, 1982, AGENTS ACTIONS, V12, P85, DOI 10.1007/BF01965111; Masuda ES, 2008, PULM PHARMACOL THER, V21, P461, DOI 10.1016/j.pupt.2007.06.002; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Merighi S, 2010, BIOCHEM PHARMACOL, V79, P471, DOI 10.1016/j.bcp.2009.09.009; Messingham KN, 2012, GIORN ITAL DERMAT V, V147, P251; Migalovich-Sheikhet H, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00238; Mohammad RM, 2007, CLIN CANCER RES, V13, P2226, DOI 10.1158/1078-0432.CCR-06-1574; Moiseeva EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061579; Moiseeva EP, 2012, CELL MOL LIFE SCI, V69, P2751, DOI 10.1007/s00018-012-0948-y; Montuschi P, 2010, CLIN EXP ALLERGY, V40, P1732, DOI 10.1111/j.1365-2222.2010.03630.x; Mori S, 2003, J PHARMACOL SCI, V92, P420; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Munitz A, 2007, AM J RESP CRIT CARE, V175, P911, DOI 10.1164/rccm.200605-695OC; Munitz A, 2006, J ALLERGY CLIN IMMUN, V118, P1082, DOI 10.1016/j.jaci.2006.07.041; Munoz S, 2003, J IMMUNOL, V170, P5590, DOI 10.4049/jimmunol.170.11.5590; Na HJ, 2012, CYTOKINE, V57, P169, DOI 10.1016/j.cyto.2011.10.007; Nabe T, 2011, PROSTAG OTH LIPID M, V95, P27, DOI 10.1016/j.prostaglandins.2011.05.001; Nakahashi-Oda C, 2012, J EXP MED, V209, P1493, DOI 10.1084/jem.20120096; Ng SW, 2008, J BIOL CHEM, V283, P31348, DOI 10.1074/jbc.M804942200; Norman P, 2011, EXPERT OPIN THER PAT, V21, P1773, DOI 10.1517/13543776.2011.629606; Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P1153, DOI 10.1016/j.jaci.2012.04.039; Nutku-Bilir E, 2008, AM J RESP CELL MOL, V38, P121, DOI 10.1165/rcmb.2007-0154OC; Oh SY, 2007, J ALLERGY CLIN IMMUN, V119, P123, DOI 10.1016/j.jaci.2006.08.029; Ohsawa Y, 2012, ALLERGY, V67, P1014, DOI 10.1111/j.1398-9995.2012.02854.x; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Oskeritzian CA, 2008, BLOOD, V111, P4193, DOI 10.1182/blood-2007-09-115451; Pacher P, 2011, PROG LIPID RES, V50, P193, DOI 10.1016/j.plipres.2011.01.001; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Patel DD, 2013, ANN RHEUM DIS, V72, P116, DOI 10.1136/annrheumdis-2012-202371; Paul C, 2010, AM J HEMATOL, V85, P921, DOI 10.1002/ajh.21894; Peter B, 2014, J LEUKOCYTE BIOL, V95, P95, DOI 10.1189/jlb.1112609; PETERS SP, 1982, J IMMUNOL, V129, P797; Philip G, 2009, J ALLERGY CLIN IMMUN, V124, P942, DOI 10.1016/j.jaci.2009.07.006; Piliponsky AM, 2003, BLOOD, V101, P1898, DOI 10.1182/blood-2002-05-1488; Pini A, 2012, CURR DRUG TARGETS, V13, P984, DOI 10.2174/138945012800675786; Proft T, 2009, CELL MOL LIFE SCI, V66, P613, DOI 10.1007/s00018-008-8477-4; Pullen NA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00117; Putney J W Jr, 2001, Mol Interv, V1, P84; Rafi A, 2010, ALLERGY ASTHMA PROC, V31, P76, DOI 10.2500/aap.2010.31.3304; Rai G, 2010, J MED CHEM, V53, P7392, DOI 10.1021/jm1008852; Randis TM, 2008, EUR J IMMUNOL, V38, P1215, DOI 10.1002/eji.200838266; Riccaboni M, 2010, DRUG DISCOV TODAY, V15, P517, DOI 10.1016/j.drudis.2010.05.001; Rice KD, 1998, CURR PHARM DESIGN, V4, P381; Rocha-De-Souza CM, 2008, INFECT IMMUN, V76, P4489, DOI 10.1128/IAI.00270-08; Rudin CM, 2012, CLIN CANCER RES, V18, P3163, DOI 10.1158/1078-0432.CCR-11-3090; Ryan JJ, 2008, DRUG NEWS PERSPECT, V21, P89, DOI 10.1358/dnp.2008.21.2.1188195; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Sabato V, 2012, CYTOM PART B-CLIN CY, V82B, P132, DOI 10.1002/cyto.b.21003; Salcedo Carolina, 2013, Front Biosci (Elite Ed), V5, P178; Samson MT, 2003, J IMMUNOL, V170, P4953, DOI 10.4049/jimmunol.170.10.4953; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; Schneider E, 2010, EUR CYTOKINE NETW, V21, P142, DOI 10.1684/ecn.2010.0197; Schroeder JT, 2011, IMMUNOL REV, V242, P144, DOI 10.1111/j.1600-065X.2011.01023.x; Schuligoi R, 2010, PHARMACOLOGY, V85, P372, DOI 10.1159/000313836; Sheinkopf LE, 2008, ALLERGY ASTHMA PROC, V29, P530, DOI 10.2500/aap.2008.29.3160; Shi ZG, 2012, RECENT PAT ANTI-CANC, V7, P74, DOI 10.2174/157489212798357976; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Shiraishi Y, 2013, J IMMUNOL, V190, P539, DOI 10.4049/jimmunol.1202049; Simhadri VR, 2012, BLOOD, V119, P2799, DOI 10.1182/blood-2011-08-372425; Simmons DL, 2013, CURR OPIN PHARMACOL, V13, P426, DOI 10.1016/j.coph.2013.02.008; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Skov L, 2008, J IMMUNOL, V181, P669, DOI 10.4049/jimmunol.181.1.669; Smith LD, 2013, FUTURE MED CHEM, V5, P1423, DOI 10.4155/fmc.13.112; Smolen JS, 2013, ANN RHEUM DIS, V72, P482, DOI 10.1136/annrheumdis-2012-202469; So L, 2012, BIOCHEM J, V442, P465, DOI 10.1042/BJ20112092; Soucek L, 2011, NEOPLASIA, V13, P1093, DOI 10.1593/neo.11980; SPIEGELBERG HL, 1986, J IMMUNOL, V136, P131; Stenton GR, 2013, BRIT J PHARMACOL, V168, P1506, DOI 10.1111/bph.12039; Stenton GR, 2013, BRIT J PHARMACOL, V168, P1519, DOI 10.1111/bph.12038; Stevens WW, 2007, J IMMUNOL METHODS, V327, P63, DOI 10.1016/j.jim.2007.07.011; Straumann A, 2013, ALLERGY, V68, P375, DOI 10.1111/all.12096; Sugawara K, 2013, J ALLERGY CLIN IMMUN, V132, P182, DOI 10.1016/j.jaci.2013.01.002; Sugawara K, 2012, J ALLERGY CLIN IMMUN, V129, P726, DOI 10.1016/j.jaci.2011.11.009; Sumbayev VV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034259; Sumbayev VV, 2009, EUR J IMMUNOL, V39, P3511, DOI 10.1002/eji.200939370; SUMMERS R, 1981, J ALLERGY CLIN IMMUN, V67, P456, DOI 10.1016/0091-6749(81)90099-3; Suttle MM, 2012, CLIN EXP IMMUNOL, V169, P311, DOI 10.1111/j.1365-2249.2012.04618.x; Tabrizi Mohammad, 2010, Inflammation & Allergy Drug Targets, V9, P229; Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113; Takezawa R, 2006, MOL PHARMACOL, V69, P1413, DOI 10.1124/mol.105.021154; Tateno H, 2007, MOL CELL BIOL, V27, P5699, DOI 10.1128/MCB.00383-07; TEDESCHI A, 1991, ALLERGY, V46, P626, DOI 10.1111/j.1398-9995.1991.tb00634.x; Thurmond RL, 2004, J PHARMACOL EXP THER, V309, P404, DOI 10.1124/jpet.103.061754; Tremaine WJ, 2002, ALIMENT PHARM THERAP, V16, P407, DOI 10.1046/j.1365-2036.2002.01194.x; Tristano AG, 2009, INT IMMUNOPHARMACOL, V9, P1, DOI 10.1016/j.intimp.2008.09.010; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Le TA, 2011, INT ARCH ALLERGY IMM, V155, P31, DOI 10.1159/000318679; Ugajin T, 2011, AM J PATHOL, V179, P775, DOI 10.1016/j.ajpath.2011.04.023; Ustun C, 2011, LEUKEMIA RES, V35, P1143, DOI 10.1016/j.leukres.2011.05.006; Vega-Ruiz A, 2009, LEUKEMIA RES, V33, P1481, DOI [10.1016/j.leukres.2009.05.005, 10.1016/j.leukres.2008.12.020]; Verstovsek S, 2006, LEUKEMIA RES, V30, P1365, DOI 10.1016/j.leukres.2006.04.005; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Weinblatt ME, 2013, J RHEUMATOL, V40, P369, DOI 10.3899/jrheum.120923; Weller K, 2009, J INVEST DERMATOL, V129, P2723, DOI 10.1038/jid.2009.134; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wulff Heike, 2010, Expert Rev Clin Pharmacol, V3, P385, DOI 10.1586/ecp.10.11; Xiang Z, 2006, ALLERGY, V61, P1040, DOI 10.1111/j.1398-9995.2006.01024.x; Yahiro E, 2013, CURR PHARM DESIGN, V19, P3065; Yang WD, 2006, J IMMUNOL, V176, P1238, DOI 10.4049/jimmunol.176.2.1238; Yokoi H, 2006, ALLERGY, V61, P769, DOI 10.1111/j.1398-9995.2006.01133.x; Yokoi H, 2008, J ALLERGY CLIN IMMUN, V121, P499, DOI 10.1016/j.jaci.2007.10.004; Yoshino T, 2007, EUR J PHARMACOL, V560, P225, DOI 10.1016/j.ejphar.2007.01.012; Zhang F, 2011, CLIN EXP IMMUNOL, V164, P256, DOI 10.1111/j.1365-2249.2011.04328.x; Zhang K, 2004, J ALLERGY CLIN IMMUN, V114, P321, DOI 10.1016/j.jaci.2004.03.058; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255; Zhao W, 2006, J IMMUNOL, V177, P694, DOI 10.4049/jimmunol.177.1.694; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	239	98	100	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					530	544		10.1016/j.jaci.2014.03.007	http://dx.doi.org/10.1016/j.jaci.2014.03.007			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24767877	Bronze			2022-12-18	WOS:000341372400004
J	McGarvey, LP; Butler, CA; Stokesberry, S; Polley, L; McQuaid, S; Abdullah, H; Ashraf, S; McGahon, MK; Curtis, TM; Arron, J; Choy, D; Warke, TJ; Bradding, P; Ennis, M; Zholos, A; Costello, RW; Heaney, LG				McGarvey, Lorcan P.; Butler, Claire A.; Stokesberry, Susan; Polley, Liam; McQuaid, Stephen; Abdullah, Hani'ah; Ashraf, Sadaf; McGahon, Mary K.; Curtis, Tim M.; Arron, Joe; Choy, David; Warke, Tim J.; Bradding, Peter; Ennis, Madeleine; Zholos, Alexander; Costello, Richard W.; Heaney, Liam G.			Increased expression of bronchial epithelial transient receptor potential vanilloid 1 channels in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ion channel; sensory; asthma; irritant; chemical; exacerbation; cough	MESSENGER-RNA EXPRESSION; CAPSAICIN RECEPTORS; TRP CHANNELS; ACTIVATION; PROTEIN; LOCALIZATION; RESPONSES; RELEASE; COUGH; ALPHA	Background: The airway epithelium is exposed to a range of physical and chemical irritants in the environment that are known to trigger asthma. Transient receptor potential (TRP) cation channels play a central role in sensory responses to noxious physical and chemical stimuli. Recent genetic evidence suggests an involvement of transient receptor potential vanilloid 1 (TRPV1), one member of the vanilloid subfamily of TRP channels, in the pathophysiology of asthma. The functional expression of TRPV1 on airway epithelium has yet to be elucidated. Objective: In this study we examined the molecular, functional, and immunohistochemical expression of TRPV1 in asthmatic and healthy airways. Methods: Bronchial biopsy specimens and bronchial brushings were obtained from healthy volunteers (n = 18), patients with mild-to-moderate asthma (n = 24), and patients with refractory asthma (n = 22). Cultured primary bronchial epithelial cells from patients with mild asthma (n = 4), nonasthmatic coughers (n = 4), and healthy subjects (n = 4) were studied to investigate the functional role of TRPV1. Results: Quantitative immunohistochemistry revealed significantly more TRPV1 expression in asthmatic patients compared with healthy subjects, with the greatest expression in patients with refractory asthma (P = .001). PCR and Western blotting analysis confirmed gene and protein expression of TRPV1 in cultured primary bronchial epithelial cells. Patch-clamp electrophysiology directly confirmed functional TRPV1 expression in all 3 groups. In functional assays the TRPV1 agonist capsaicin induced dose-dependent IL-8 release, which could be blocked by the antagonist capsazepine. Reduction of external pH from 7.4 to 6.4 activated a capsazepine-sensitive outwardly rectifying membrane current. Conclusions: Functional TRPV1 channels are present in the human airway epithelium and overexpressed in the airways of patients with refractory asthma. These channels might represent a novel therapeutic target for the treatment of uncontrolled asthma.	[McGarvey, Lorcan P.; Butler, Claire A.; Stokesberry, Susan; Polley, Liam; Abdullah, Hani'ah; Warke, Tim J.; Ennis, Madeleine; Heaney, Liam G.] Queens Univ Belfast, Ctr Infect & Immun, Belfast BT9 7AB, Antrim, North Ireland; [Ashraf, Sadaf; McGahon, Mary K.; Curtis, Tim M.; Zholos, Alexander] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast BT9 7AB, Antrim, North Ireland; [McQuaid, Stephen] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland; [Arron, Joe; Choy, David] Genentech Inc, San Francisco, CA 94080 USA; [Bradding, Peter] Univ Leicester, Dept Infect Immun & Inflammat, Inst Lung Hlth, Leicester LE1 7RH, Leics, England; [Zholos, Alexander] Taras Shevchenko Kiev Natl Univ, Inst Biol, Kiev, Ukraine; [Costello, Richard W.] Royal Coll Surgeons Ireland, Educ & Res Ctr, Dept Resp Otolaryngol & Mol Med, Dublin 2, Ireland	Queens University Belfast; Queens University Belfast; Roche Holding; Genentech; University of Leicester; Ministry of Education & Science of Ukraine; Taras Shevchenko National University Kiev; Royal College of Surgeons - Ireland	McGarvey, LP (corresponding author), Queens Univ Belfast, Ctr Infect & Immun, Belfast City Hosp, Level 8,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	l.mcgarvey@qub.ac.uk	Zholos, Alexander/A-7017-2011; Ennis, Madeleine/GZG-4070-2022; Curtis, Tim/AEU-9750-2022	Zholos, Alexander/0000-0002-4320-149X; Choy, David/0000-0003-1351-6113; Curtis, Tim/0000-0003-1543-2781; Arron, Joseph/0000-0001-7677-9979; Bradding, Peter/0000-0001-8403-0319; Costello, Richard/0000-0003-1179-6692	Northern Ireland Chest Heart & Stroke Association; Higher Education Authority (North South Research Programme); Genentech, South San Francisco, California; Biotechnology and Biological Sciences Research Council [BB/I026359/1] Funding Source: researchfish; British Heart Foundation [PG/11/99/29207] Funding Source: researchfish; BBSRC [BB/I026359/1] Funding Source: UKRI	Northern Ireland Chest Heart & Stroke Association; Higher Education Authority (North South Research Programme); Genentech, South San Francisco, California(Roche HoldingGenentech); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	S.S. was supported by a grant from the Northern Ireland Chest Heart & Stroke Association, and L. P. was supported by a grant from the Higher Education Authority (North South Research Programme). Work in Leicester and Belfast was supported in part by grants from Genentech, South San Francisco, California.	Agopyan N, 2004, AM J PHYSIOL-LUNG C, V286, pL563, DOI 10.1152/ajplung.00299.2003; Agopyan N, 2003, TOXICOL APPL PHARM, V192, P21, DOI 10.1016/S0041-008X(03)00259-X; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; [Anonymous], 2008, EUR RESPIR J, V31, P1; Banner KH, 2011, PHARMACOL THERAPEUT, V130, P371, DOI 10.1016/j.pharmthera.2011.03.005; British Thoracic Society Scottish Intercollegiate Guidelines Network, 2008, Thorax, V63 Suppl 4, piv1, DOI 10.1136/thx.2008.097741; Bessac Bret F, 2010, Proc Am Thorac Soc, V7, P269, DOI 10.1513/pats.201001-004SM; Brichtling CE, 2000, AM J RESP CRIT CARE, V162, P878, DOI 10.1164/ajrccm.162.3.9909064; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Butler CA, 2010, AM J RESP CRIT CARE, pA2490, DOI DOI 10.1164/AJRCCM-CONFERENCE.2010.181.1_MEETINGABSTRACTS.A2490; Cantero-Recasens G, 2010, J BIOL CHEM, V285, P27532, DOI 10.1074/jbc.C110.159491; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; Dhaka A, 2009, J NEUROSCI, V29, P153, DOI 10.1523/JNEUROSCI.4901-08.2009; Doherty GM, 2003, CLIN EXP ALLERGY, V33, P1221, DOI 10.1046/j.1365-2222.2003.01752.x; Doherty MJ, 2000, THORAX, V55, P643, DOI 10.1136/thorax.55.8.643; Geppetti P, 2004, BRIT J PHARMACOL, V141, P1313, DOI 10.1038/sj.bjp.0705768; Groneberg DA, 2004, AM J RESP CRIT CARE, V170, P1276, DOI 10.1164/rccm.200402-174OC; Guo YF, 2008, ACTA BIOCH BIOPH SIN, V40, P426, DOI 10.1111/j.1745-7270.2008.00418.x; HATHAWAY TJ, 1993, AM REV RESPIR DIS, V148, P1233, DOI 10.1164/ajrccm/148.5.1233; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jia YL, 2007, BBA-MOL BASIS DIS, V1772, P915, DOI 10.1016/j.bbadis.2007.01.013; Karai LJ, 2004, J BIOL CHEM, V279, P16377, DOI 10.1074/jbc.M310891200; Lazzeri M, 2004, EUR UROL, V46, P792, DOI 10.1016/j.eururo.2004.08.007; Ma J, 2012, AM J PHYSIOL-GASTR L, V303, pG635, DOI 10.1152/ajpgi.00097.2012; McGarvey LPA, 1998, THORAX, V53, P738, DOI 10.1136/thx.53.9.738; Mitchell JE, 2005, EXP LUNG RES, V31, P295, DOI 10.1080/01902140590918803; Nilius B, 2007, BBA-MOL BASIS DIS, V1772, P805, DOI 10.1016/j.bbadis.2007.02.002; Olah Z, 2002, J BIOL CHEM, V277, P35752, DOI 10.1074/jbc.M201551200; Otsuguro KI, 2008, J BIOL CHEM, V283, P10026, DOI 10.1074/jbc.M707306200; Paredi P, 2002, AM J RESP CRIT CARE, V165, P181, DOI 10.1164/ajrccm.165.2.2103053; Sachs D, 2002, PAIN, V96, P89, DOI 10.1016/S0304-3959(01)00433-X; Seki N, 2006, RHINOLOGY, V44, P128; Szigeti C, 2012, NEUROSCIENCE, V201, P320, DOI 10.1016/j.neuroscience.2011.10.058; Uceyler N, 2010, NEUROLOGY, V74, P1806, DOI 10.1212/WNL.0b013e3181e0f7b3; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Veronesi B, 2000, TOXICOL APPL PHARM, V169, P66, DOI 10.1006/taap.2000.9040; Vriens J, 2009, MOL PHARMACOL, V75, P1262, DOI 10.1124/mol.109.055624; Wang Z, 2011, MOL VIS, V17, P3137; Watanabe N, 2008, INT ARCH ALLERGY IMM, V146, P28, DOI 10.1159/000126057; Yamamoto Y, 2005, AUTON NEUROSCI-BASIC, V117, P62, DOI 10.1016/j.autneu.2004.11.003	43	98	102	1	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					704	+		10.1016/j.jaci.2013.09.016	http://dx.doi.org/10.1016/j.jaci.2013.09.016			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24210884	Green Accepted			2022-12-18	WOS:000332397600011
J	Peters, RL; Dharmage, SC; Gurrin, LC; Koplin, JJ; Ponsonby, AL; Lowe, AJ; Tang, MLK; Tey, D; Robinson, M; Hill, D; Czech, H; Thiele, L; Osborne, NJ; Allen, KJ				Peters, Rachel L.; Dharmage, Shyamali C.; Gurrin, Lyle C.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Lowe, Adrian J.; Tang, Mimi L. K.; Tey, Dean; Robinson, Marnie; Hill, David; Czech, Helen; Thiele, Leone; Osborne, Nicholas J.; Allen, Katrina J.		HealthNuts Study	The natural history and clinical predictors of egg allergy in the first 2 years of life: A prospective, population-based cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg allergy; skin prick test; allergen-specific IgE; oral food challenge; natural history; resolution; baked egg; filaggrin	ORAL FOOD CHALLENGES; SKIN-TEST REACTIVITY; IGE LEVELS; CHILDREN; MILK; PREVALENCE; ANTIBODIES; RESOLUTION; TOLERANCE; VALIDITY	Background: There is a paucity of data examining the natural history of and risk factors for egg allergy persistence, the most common IgE-mediated food allergy in infants. Objective: We aimed to assess the natural history of egg allergy and identify clinical predictors for persistent egg allergy in a population-based cohort. Methods: The HealthNuts study is a prospective, population-based cohort study of 5276 infants who underwent skin prick tests to 4 allergens, including egg. Infants with a detectable wheal were offered hospital-based oral food challenges (OFCs) to egg, irrespective of skin prick test wheal sizes. Infants with challenge-confirmed raw egg allergy were offered baked egg OFCs at age 1 year and follow-up at age 2 years, with repeat OFCs to raw egg. Results: One hundred forty infants with challenge-confirmed egg allergy at age 1 year participated in the follow-up. Egg allergy resolved in 66 (47%) infants (95% CI, 37% to 56%) by 2 years of age; however, resolution was lower in children with baked egg allergy at age 1 year compared with baked egg tolerance (13% and 56%, respectively; adjusted odds ratio, 5.27; 95% CI, 1.36-20.50; P=.02). In the subgroup of infants who were tolerant to baked egg at age 1 year, frequent ingestion of baked egg (>= 5 times per month) compared with infrequent ingestion (0-4 times per month) increased the likelihood of tolerance (adjusted odds ratio, 3.52; 95% CI, 1.38-8.98; P=.009). Mutation in the filaggrin gene was not associated with the resolution of either egg allergy or egg sensitization at age 2 years. Conclusion: Phenotyping of egg allergy (baked egg tolerant vs allergic) should be considered in the management of this allergy because it has prognostic implications and eases dietary restrictions. Randomized controlled trials for egg oral immunotherapy should consider stratifying at baseline by the baked egg subphenotype to account for the differential rate of tolerance development.	[Peters, Rachel L.; Dharmage, Shyamali C.; Gurrin, Lyle C.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Lowe, Adrian J.; Tang, Mimi L. K.; Tey, Dean; Hill, David; Czech, Helen; Thiele, Leone; Allen, Katrina J.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Peters, Rachel L.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Tang, Mimi L. K.; Tey, Dean; Osborne, Nicholas J.; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Dharmage, Shyamali C.; Gurrin, Lyle C.; Lowe, Adrian J.; Osborne, Nicholas J.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3052, Australia; [Tang, Mimi L. K.; Tey, Dean; Robinson, Marnie; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Osborne, Nicholas J.] Univ Exeter, Sch Med, European Ctr Environm & Human Hlth, Truro, England; [Allen, Katrina J.] Univ Manchester, Manchester M13 9PL, Lancs, England	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Exeter; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Tang, Mimi/ABD-8350-2020; Matheson, Melanie C/O-4721-2015; Allen, Katrina/I-4361-2018; Tey, Dean/U-4525-2019; Osborne, Nicholas/D-2086-2011; Ponsonby, Anne-Louise/AAE-4351-2019	Tang, Mimi/0000-0002-3839-5293; Matheson, Melanie C/0000-0002-5822-3499; Allen, Katrina/0000-0002-1921-4493; Osborne, Nicholas/0000-0002-6700-2284; Gurrin, Lyle/0000-0001-7052-1969; Lowe, Adrian/0000-0002-4691-8162; Koplin, Jennifer/0000-0002-7576-5142; Peters, Rachel/0000-0002-2411-6628; Ponsonby, Anne-Louise/0000-0002-6581-3657	National Health & Medical Research Council (NHMRC) of Australia; Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government; Australian Egg Corporation Ltd.; NHMRC	National Health & Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government; Australian Egg Corporation Ltd.(Australian Eggs); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health & Medical Research Council (NHMRC) of Australia, the Ilhan Food Allergy Foundation, AnaphylaxiStop, the Charles and Sylvia Viertel Medical Research Foundation, the Victorian Government's Operational Infrastructure Support Program, and the Australian Egg Corporation Ltd. K.J.A. is a Viertel Senior Medical Research Fellow. R.L.P. is an Australian Postgraduate Award scholar. L.C.G., A.J.L., A.-L.P., J.J.K., and S.C.D. hold NHMRC awards.	Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Clark A, 2011, CLIN EXP ALLERGY, V41, P706, DOI 10.1111/j.1365-2222.2011.03697.x; Dieguez MC, 2009, CLIN EXP ALLERGY, V39, P1575, DOI 10.1111/j.1365-2222.2009.03299.x; FORD RPK, 1982, ARCH DIS CHILD, V57, P649, DOI 10.1136/adc.57.9.649; Kato Y, 2000, BIOSCI BIOTECH BIOCH, V64, P198, DOI 10.1271/bbb.64.198; Kim J, 2009, ASIAN PAC J ALLERGY, V27, P107; Konstantinou GN, 2008, J ALLERGY CLIN IMMUN, V122, P414, DOI 10.1016/j.jaci.2008.05.032; Konstantinou GN, 2012, IMMUNOL ALLERGY CLIN, V32, P151, DOI 10.1016/j.iac.2011.11.003; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V130, P473, DOI 10.1016/j.jaci.2012.06.006; Lieberman JA, 2012, J ALLERGY CLIN IMMUN, V129, P1682, DOI 10.1016/j.jaci.2012.04.007; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; Montesinos E, 2010, PEDIAT ALLERG IMM-UK, V21, P634, DOI 10.1111/j.1399-3038.2009.00940.x; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P234, DOI 10.1097/ACI.0b013e32832b88e7; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127; Peters RL, 2013, J ALLERGY CLIN IMMUN, V132, P874, DOI 10.1016/j.jaci.2013.05.038; Roberts G, 2000, CLIN EXP ALLERGY, V30, P1495, DOI 10.1046/j.1365-2222.2000.00960.x; Roches AD, 2006, ALLERGY, V61, P900, DOI 10.1111/j.1398-9995.2006.01134.x; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; Tan HTT, 2012, J ALLERGY CLIN IMMUN, V130, P1211, DOI 10.1016/j.jaci.2012.07.022; Venter C, 2008, ALLERGY, V63, P354, DOI 10.1111/j.1398-9995.2007.01570.x; Wood RA, 2003, PEDIATRICS, V111, P1631	28	98	98	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					485	+		10.1016/j.jaci.2013.11.032	http://dx.doi.org/10.1016/j.jaci.2013.11.032			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24373356				2022-12-18	WOS:000332397100024
J	Greil, J; Rausch, T; Giese, T; Bandapalli, OR; Daniel, V; Bekeredjian-Ding, I; Stutz, AM; Drees, C; Roth, S; Ruland, J; Korbel, JO; Kulozik, AE				Greil, Johann; Rausch, Tobias; Giese, Thomas; Bandapalli, Obul R.; Daniel, Volker; Bekeredjian-Ding, Isabelle; Stuetz, Adrian M.; Drees, Christoph; Roth, Susanne; Ruland, Juergen; Korbel, Jan O.; Kulozik, Andreas E.			Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Whole-exome sequencing; systematic variant categorization; caspase recruitment domain 11 (CARD11); severe combined immunodeficiency; T cell; B cell; nuclear factor kappa B; infection	NF-KAPPA-B; ACTIVATION; CARMA1; FAMILY; ASSOCIATION; REQUIREMENT; IMMUNOLOGY; MUTATIONS; ANTIGEN; INNATE	Background: Primary immunodeficiencies represent model diseases for the mechanistic understanding of the human innate and adaptive immune response. They are clinically highly relevant per se because in patients with severe combined immunodeficiency (SCID), infections caused by opportunistic pathogens are typically life-threatening early in life. Objectives: We aimed at defining and functionally characterizing a novel form of SCID in an infant of consanguineous parents who presented with life-threatening Pneumocystis jirovecii pneumonia using a comprehensive immunologic and whole-exome genetic diagnostic strategy. Methods: Analysis of leukocyte subpopulations was performed by using multicolor flow cytometry and was combined with stimulation tests for T-cell function. The search for a disease-causing mutation was performed with diagnostic whole-exome sequencing and systematic variant categorization. Reconstitution assays were used for validating the loss-offunction mutation. Results: The novel entity of SCID was characterized by agammaglobulinemia and profoundly deficient T-cell function despite quantitatively normal T and B lymphocytes. Genetic analysis revealed a single pathogenic homozygous nonsense mutation of the caspase recruitment domain 11 (CARD11) gene. In reconstitution assays we demonstrated that the patient-derived truncated CARD11 protein is defective in antigen receptor signaling and nuclear factor kappa B activation. Conclusion: We show that an inactivating CARD11 mutation links defective nuclear factor kB signaling to a novel cause of autosomal recessive SCID.	[Greil, Johann; Bandapalli, Obul R.; Kulozik, Andreas E.] Heidelberg Univ, Dept Pediat Oncol Hematol & Immunol, D-69120 Heidelberg, Germany; [Rausch, Tobias; Stuetz, Adrian M.; Korbel, Jan O.] EMBL, Genome Biol Unit, D-69117 Heidelberg, Germany; [Giese, Thomas; Daniel, Volker] Heidelberg Univ, Inst Immunol, Heidelberg, Germany; [Bekeredjian-Ding, Isabelle] Heidelberg Univ, Dept Infect Dis Med Microbiol & Hyg, Heidelberg, Germany; [Bekeredjian-Ding, Isabelle] Univ Clin Bonn, IMMIP, Bonn, Germany; [Drees, Christoph; Roth, Susanne; Ruland, Juergen] Tech Univ Munich, Klinikum Rechts Isar, Inst Klin Chem & Pathobiochem, D-80290 Munich, Germany	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Bonn; Technical University of Munich	Korbel, JO (corresponding author), EMBL, Genome Biol Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	jan.korbel@embl-heidelberg.de; andreas.kulozik@med.uni-heidelberg.de	Bandapalli, Obul Reddy/A-8668-2012; Kulozik, Andreas/AAO-2432-2020; Korbel, Jan O/G-6470-2012; Rausch, Tobias/H-6511-2019; Ruland, Jürgen/Q-6680-2018; Bekeredjian-Ding, Isabelle/I-6197-2013	Bandapalli, Obul Reddy/0000-0002-1132-1745; Korbel, Jan O/0000-0002-2798-3794; Rausch, Tobias/0000-0001-5773-5620; Ruland, Jürgen/0000-0002-8381-3597; Bekeredjian-Ding, Isabelle/0000-0001-6646-5888; Stuetz, Adrian/0000-0001-7650-3470	Dietmar Hopp Stiftung; German Research Foundation (DFG) SFB; DFG [KO 4037/1-1, BE3841/2-1]; Deutsche Forschungsgemeinschaft (German Research Association)	Dietmar Hopp Stiftung; German Research Foundation (DFG) SFB(German Research Foundation (DFG)); DFG(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (German Research Association)(German Research Foundation (DFG))	Supported by the Dietmar Hopp Stiftung and the German Research Foundation (DFG) SFB grants (to J.R.). J.O.K. was supported by an Emmy Noether Fellowship (KO 4037/1-1) from the DFG. I.B.-D. was supported by DFG grant BE3841/2-1. Disclosure of potential conflict of interest: I. Bekeredjian-Ding has received grants from Deutsche Forschungsgemeinschaft (German Research Association). The rest of the authors declare that they have no relevant conflicts of interest.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Asan, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r95; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Blonska M, 2011, CELL RES, V21, P55, DOI 10.1038/cr.2010.182; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Daniel V, 1996, CLIN EXP IMMUNOL, V104, P4, DOI 10.1046/j.1365-2249.1996.d01-640.x; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hara H, 2009, TRENDS IMMUNOL, V30, P234, DOI 10.1016/j.it.2009.03.002; Hoischen A, 2010, NAT GENET, V42, P483, DOI 10.1038/ng.581; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Isakov N, 1998, ADV IMMUNOL, V69, P183, DOI 10.1016/S0065-2776(08)60608-2; Jiang CY, 2012, IMMUNOL REV, V246, P141, DOI 10.1111/j.1600-065X.2012.01110.x; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lalonde E, 2010, HUM MUTAT, V31, P918, DOI 10.1002/humu.21293; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158; McCully RR, 2008, MOL CELL BIOL, V28, P5668, DOI 10.1128/MCB.00418-08; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013; Shaw AS, 2009, NAT REV IMMUNOL, V9, P47, DOI 10.1038/nri2473; Shinohara H, 2005, J EXP MED, V202, P1423, DOI 10.1084/jem.20051591; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tampella G, 2011, J INVEST ALLERG CLIN, V21, P348; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	35	98	104	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1376	U194		10.1016/j.jaci.2013.02.012	http://dx.doi.org/10.1016/j.jaci.2013.02.012			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23561803	Bronze			2022-12-18	WOS:000318912200015
J	Harpsoe, MC; Basit, S; Bager, P; Wohlfahrt, J; Benn, CS; Nohr, EA; Linneberg, A; Jess, T				Harpsoe, Maria C.; Basit, Saima; Bager, Peter; Wohlfahrt, Jan; Benn, Christine Stabell; Nohr, Ellen A.; Linneberg, Allan; Jess, Tine			Maternal obesity, gestational weight gain, and risk of asthma and atopic disease in offspring: A study within the Danish National Birth Cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Obesity; pre-pregnancy BMI; gestational weight gain; asthma; wheezing; atopy	BODY-MASS INDEX; PREPREGNANCY OBESITY; DIAGNOSTIC-CRITERIA; NONATOPIC ASTHMA; YOUNG-CHILDREN; PREGNANCY; ASSOCIATION; PREVALENCE; OVERWEIGHT; LEPTIN	Background: High pre-pregnancy body mass index (BMI) and excessive gestational weight gain (GWG) are suggested to influence risk of asthma and atopic disease in offspring. Objective: We examined the effect of BMI and GWG on risk of asthma, wheezing, atopic eczema (AE), and hay fever in children during the first 7 years of life. Methods: This was a cohort study of 38,874 mother-child pairs from the Danish National Birth Cohort (enrollment 1996-2002) with information from the 16th week of pregnancy and at age 6 months, 18 months, and 7 years of the child. Odds ratios (ORs) with 95% CIs were calculated by logistic regression with adjustment for potential confounders. Results: During the first 7 years of life, 10.4% of children developed doctor-diagnosed asthma, 25.8% AE, and 4.6% hay fever. Maternal BMI and to a lesser extent GWG were associated with doctor-diagnosed asthma ever. In particular, BMI >= 35 (adjusted OR, 1.87; 95% CI, 0.95-3.68) and GWG >= 25 kg (adjusted OR, 1.97; 95% CI, 1.38-2.83) were associated with current severe asthma at age 7 years. Maternal BMI was also associated with wheezing in offspring, with the strongest association observed between BMI >= 35 and late-onset wheezing (adjusted OR, 1.87; 95% CI, 1.28-2.73). Maternal BMI and GWG were not associated with AE or hay fever. Conclusions: Maternal obesity during pregnancy was associated with increased risk of asthma and wheezing in offspring but not with AE and hay fever, suggesting that pathways may be nonallergic. (J Allergy Clin Immunol 2013; 131:1033-40.)	[Harpsoe, Maria C.; Basit, Saima; Bager, Peter; Wohlfahrt, Jan; Jess, Tine] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; [Benn, Christine Stabell] Statens Serum Inst, Res Ctr Vitamins & Vaccines CVIVA, Bandim Hlth Project, DK-2300 Copenhagen, Denmark; [Nohr, Ellen A.] Aarhus Univ, Dept Publ Hlth, Epidemiol Sect, Aarhus, Denmark; [Linneberg, Allan] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark	Statens Serum Institut; Statens Serum Institut; Aarhus University; University of Copenhagen	Harpsoe, MC (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen, Denmark.	rrh@ssi.dk	Bager, Peter/R-3310-2019	Bager, Peter/0000-0002-3577-8459; Linneberg, Allan/0000-0002-0994-0184	Female Research Leader grant from the Danish Council of Independent Research [09-066323]; ERC Starting Grant [ERC-2009-StG-243149]	Female Research Leader grant from the Danish Council of Independent Research; ERC Starting Grant	Supported by a Female Research Leader grant (no. 09-066323) from the Danish Council of Independent Research to T.J. and by an ERC Starting Grant (ERC-2009-StG-243149) to C. S. B. The funding source had no role in the project.	Akinbami LJ, 2005, PEDIATRICS, V115, P1254, DOI 10.1542/peds.2004-0897; Bendixen H, 2004, OBES RES, V12, P1464, DOI 10.1038/oby.2004.183; Benn CS, 2003, ACTA DERM-VENEREOL, V83, P347; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brenninkmeijer EEA, 2008, BRIT J DERMATOL, V158, P754, DOI 10.1111/j.1365-2133.2007.08412.x; Das UN, 2001, NUTRITION, V17, P953, DOI 10.1016/S0899-9007(01)00672-4; De Sario M, 2006, J ASTHMA, V43, P633, DOI 10.1080/02770900600878974; Donini LM, 2012, J NUTR HEALTH AGING, V16, P89, DOI 10.1007/s12603-011-0073-x; Flegal KM, 2007, JAMA-J AM MED ASSOC, V298, P2028, DOI 10.1001/jama.298.17.2028; Greene N, 2011, EPIDEMIOLOGY, V22, P815, DOI 10.1097/EDE.0b013e31822939fd; Guler N, 2004, J ALLERGY CLIN IMMUN, V114, P254, DOI 10.1016/j.jaci.2004.03.053; Haberg SE, 2009, PAEDIATR PERINAT EP, V23, P352, DOI 10.1111/j.1365-3016.2009.01034.x; Herberth G, 2011, ALLERGY, V66, P1065, DOI 10.1111/j.1398-9995.2011.02587.x; Hersoug LG, 2007, ALLERGY, V62, P1205, DOI 10.1111/j.1398-9995.2007.01506.x; Huber LRB, 2007, MATERN CHILD HLTH J, V11, P137, DOI 10.1007/s10995-006-0157-0; *I MED, 1990, NUTR PREGN 2; Institute of Medicine (Subcommittees on Nutritional Status and Weight Gain During Pregnancy and Dietary Intake and Nutrient Supplements During Pregnancy Committee on Nutritional Status During Pregnancy and Lactation Food and Nutrition Board), 1990, NUTR PREGN 1; Jacobsen TN, 2010, EUR J EPIDEMIOL, V25, P349, DOI 10.1007/s10654-010-9448-2; Kastorini CM, 2012, MATURITAS, V72, P220, DOI 10.1016/j.maturitas.2012.04.012; Kozyrskyj AL, 2011, CURR OPIN ALLERGY CL, V11, P400, DOI 10.1097/ACI.0b013e328349b166; Kumar R, 2010, PEDIAT ALLER IMM PUL, V23, P183, DOI 10.1089/ped.2010.0032; Lihn AS, 2004, MOL CELL ENDOCRINOL, V219, P9, DOI 10.1016/j.mce.2004.03.002; Lowe A, 2011, J ALLERGY CLIN IMMUN, V128, P1107, DOI 10.1016/j.jaci.2011.08.025; Mahabir S, 2007, NUTR J, V6, DOI 10.1186/1475-2891-6-3; Martino D, 2011, CHEST, V139, P640, DOI 10.1378/chest.10-1800; Michel G, 2006, EUR RESPIR J, V28, P1124, DOI 10.1183/09031936.06.00008406; Miller JE, 2001, AM J EPIDEMIOL, V154, P245, DOI 10.1093/aje/154.3.245; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nagel G, 2009, PEDIAT ALLERG IMM-UK, V20, P81, DOI 10.1111/j.1399-3038.2008.00740.x; Noal RB, 2011, OBES REV, V12, P93, DOI 10.1111/j.1467-789X.2010.00741.x; Nohr EA, 2006, EPIDEMIOLOGY, V17, P413, DOI 10.1097/01.ede.0000220549.14177.60; Nohr EA, 2005, THESIS U AARHUS; Nohr EA, 2008, AM J CLIN NUTR, V87, P1750, DOI 10.1093/ajcn/87.6.1750; Nysom K, 2001, INT J OBESITY, V25, P177, DOI 10.1038/sj.ijo.0801515; Ogden CL, 2007, GASTROENTEROLOGY, V132, P2087, DOI 10.1053/j.gastro.2007.03.052; Oliveti JF, 1996, AM J EPIDEMIOL, V143, P570; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Patel SP, 2012, J EPIDEMIOL COMMUN H, V66, P809, DOI 10.1136/jech.2011.133777; Rasmussen KM, 2009, WEIGHT GAIN DURING PREGNANCY: REEXAMINING THE GUIDELINES, P1; Reichman NE, 2008, MATERN CHILD HLTH J, V12, P725, DOI 10.1007/s10995-007-0292-2; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Rusconi F, 2007, AM J RESP CRIT CARE, V175, P16, DOI 10.1164/rccm.200512-1978OC; Scholtens S, 2010, INT J OBESITY, V34, P606, DOI 10.1038/ijo.2009.194; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Shore SA, 2007, J APPL PHYSIOL, V102, P516, DOI 10.1152/japplphysiol.00847.2006; Siega-Riz AM, 2004, NUTR REV, V62, pS105, DOI 10.1111/j.1753-4887.2004.tb00079.x; Sood A, 2006, THORAX, V61, P300, DOI 10.1136/thx.2004.031468; Tanaka K, 2011, J ASTHMA, V48, P804, DOI 10.3109/02770903.2011.611956; The ISAAC Steering Committee, 1998, PHAS 2 MOD INT STUD; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; Visness CM, 2010, J ASTHMA, V47, P822, DOI 10.3109/02770903.2010.489388; Visscher TLS, 2006, OBESITY, V14, P2054, DOI 10.1038/oby.2006.240; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; WHO, 2000, OB PREV MAN GLOB EP; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x	58	98	99	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1033	1040		10.1016/j.jaci.2012.09.008	http://dx.doi.org/10.1016/j.jaci.2012.09.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23122630				2022-12-18	WOS:000317187200010
J	Nwaru, BI; Takkinen, HM; Niemela, O; Kaila, M; Erkkola, M; Ahonen, S; Haapala, AM; Kenward, MG; Pekkanen, J; Lahesmaa, R; Kere, J; Simell, O; Veijola, R; Ilonen, J; Hyoty, H; Knip, M; Virtanen, SM				Nwaru, Bright I.; Takkinen, Hanna-Mari; Niemela, Onni; Kaila, Minna; Erkkola, Maijaliisa; Ahonen, Suvi; Haapala, Anna-Maija; Kenward, Michael G.; Pekkanen, Juha; Lahesmaa, Riitta; Kere, Juha; Simell, Olli; Veijola, Riitta; Ilonen, Jorma; Hyoty, Heikki; Knip, Mikael; Virtanen, Suvi M.			Timing of infant feeding in relation to childhood asthma and allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic rhinitis; atopic eczema; atopic sensitization; breast-feeding; complementary foods; children	SOLID FOOD INTRODUCTION; ATOPIC-DERMATITIS; IMMUNE-SYSTEM; RISK; SENSITIZATION; CHILDREN; ECZEMA; AGE; METAANALYSIS; ASSOCIATION	Background: Emerging evidence questions current recommendations on the timing of infant feeding for the prevention of childhood allergies. The evidence for asthma is inconclusive. Objective: We sought to investigate the associations between the duration of breast-feeding and timing of introduction of complementary foods and the development of asthma and allergies by the age of 5 years. Methods: Data were analyzed for 3781 consecutively born children. The dietary exposures were categorized into thirds and analyzed as time-dependent variables. Asthma, allergic rhinitis, and atopic eczema end points were assessed by using the International Study of Asthma and Allergies in Childhood questionnaire, whereas IgE antibodies were analyzed from serum samples at the age of 5 years. Cox proportional hazard and logistic regressions were used for the analyses. Results: The median duration of exclusive and total breast-feeding was 1.4 months (interquartile range, 0.2-3.5 months) and 7.0 months (interquartile range, 4.0-11.0 months), respectively. Total breast-feeding of 9.5 months or less was associated with an increased risk of nonatopic asthma. Introduction of wheat, rye, oats, or barley at 5 to 5.5 months was inversely associated with asthma and allergic rhinitis, whereas introduction of other cereals at less than 4.5 months increased the risk of atopic eczema. Introduction of egg at 11 months or less was inversely associated with asthma, allergic rhinitis, and atopic sensitization, whereas introduction of fish at 9 months or less was inversely associated with allergic rhinitis and atopic sensitization. Conclusion: Early introduction of wheat, rye, oats, and barley cereals; fish; and egg (respective to the timing of introduction of each food) seems to decrease the risk of asthma, allergic rhinitis, and atopic sensitization in childhood. Longer duration of total breast-feeding, rather than its exclusivity, was protective against the development of nonatopic but not atopic asthma, suggesting a potential differing effect of breast-feeding on different asthma phenotypes. (J Allergy Clin Immunol 2013;131:78-86.)	[Nwaru, Bright I.; Takkinen, Hanna-Mari; Ahonen, Suvi; Virtanen, Suvi M.] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland; [Niemela, Onni] Seinajoki Cent Hosp, Dept Lab Med, Tampere, Finland; [Niemela, Onni] Seinajoki Cent Hosp, Med Res Unit, Tampere, Finland; [Kaila, Minna; Knip, Mikael; Virtanen, Suvi M.] Tampere Univ Hosp, Dept Pediat, Tampere, Finland; [Kaila, Minna] Univ Helsinki, Hjelt Inst, FIN-00014 Helsinki, Finland; [Erkkola, Maijaliisa] Univ Helsinki, Dept Food & Environm Sci, Div Nutr, FIN-00014 Helsinki, Finland; [Ahonen, Suvi; Virtanen, Suvi M.] Pirkanmaa Hosp Dist, Ctr Sci, Tampere, Finland; [Haapala, Anna-Maija] Fimlab Med Labs, Tampere, Finland; [Kenward, Michael G.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England; [Pekkanen, Juha] Natl Inst Hlth & Welf, Environm Epidemiol Unit, Kuopio, Finland; [Pekkanen, Juha] Univ Eastern Finland, Sch Publ Hlth & Clin Nutr, Kuopio, Finland; [Lahesmaa, Riitta] Univ Turku, Turku Ctr Biotechnol, SF-20500 Turku, Finland; [Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Kere, Juha] Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; [Kere, Juha; Knip, Mikael] Folkhalsan Res Ctr, Helsinki, Finland; [Simell, Olli] Univ Turku, Dept Pediat, SF-20500 Turku, Finland; [Veijola, Riitta] Univ Oulu, Dept Pediat, Oulu, Finland; [Ilonen, Jorma] Univ Turku, Immunogenet Lab, SF-20500 Turku, Finland; [Ilonen, Jorma] Univ Eastern Finland, Dept Clin Microbiol, Kuopio, Finland; [Hyoty, Heikki] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland; [Hyoty, Heikki] Pirkanmaa Hosp Dist, Fimlab Ltd, Tampere, Finland; [Knip, Mikael] Univ Helsinki, Childrens Hosp, FIN-00014 Helsinki, Finland; [Knip, Mikael] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; [Virtanen, Suvi M.] Natl Inst Hlth & Welf, Nutr Unit, Dept Lifestyle & Participat, Helsinki, Finland	Tampere University; Seinajoki Central Hospital; Seinajoki Central Hospital; Tampere University; Tampere University Hospital; University of Helsinki; University of Helsinki; Pirkanmaa Hospital District; University of London; London School of Hygiene & Tropical Medicine; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Turku; Karolinska Institutet; University of Helsinki; Folkhalsan Research Center; University of Turku; University of Oulu; University of Turku; University of Eastern Finland; Tampere University; Pirkanmaa Hospital District; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare	Nwaru, BI (corresponding author), 33014 Univ Tampere, Sch Hlth Sci, Tampere, Finland.	bright.nwaru@uta.fi	Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008; Knip, Mikael/AAL-3773-2020; Virtanen, Suvi/AAP-1922-2021; Erkkola, Maijaliisa/J-5539-2018	Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Kaila, Minna/0000-0002-9645-4925; Knip, Mikael/0000-0003-0474-0033; Ilonen, Jorma/0000-0002-9973-2062; Erkkola, Maijaliisa/0000-0002-6966-1523; Virtanen, Suvi/0000-0001-8928-0878; Nwaru, Bright/0000-0002-2876-6089; Hyoty, Heikki/0000-0003-0370-4145	Academy of Finland [44105, 48724, 80846, 201988, 126813, 129492]; Prevaller Consortium; Foundation for Pediatric Research; Tampere Tuberculosis Foundation; Juho Vainio Foundation; Yrjo Jahnsson Foundation; Medical Research Funds, Turku; Oulu University Hospital; Tampere University Hospital; Juvenile Diabetes Research Foundation; Novo Nordisk Foundation; EU Biomed 2 Program [BMH4-CT98-3314]; Pirkanmaan Sairaanhoitopiiri, Tampere, Finland; Tuberkuloosisaatio, Tampere, Finland; University of Helsinki; Ministry of Social Affairs and Health; University of Tampere; Academy of Finland; Sigrid Juselius Foundation	Academy of Finland(Academy of Finland); Prevaller Consortium; Foundation for Pediatric Research; Tampere Tuberculosis Foundation; Juho Vainio Foundation; Yrjo Jahnsson Foundation; Medical Research Funds, Turku; Oulu University Hospital; Tampere University Hospital; Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); EU Biomed 2 Program; Pirkanmaan Sairaanhoitopiiri, Tampere, Finland; Tuberkuloosisaatio, Tampere, Finland; University of Helsinki; Ministry of Social Affairs and Health; University of Tampere; Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation)	Supported by the Academy of Finland (grants 44105, 48724, 80846, 201988, 126813, and 129492); the Prevaller Consortium; the Foundation for Pediatric Research; the Tampere Tuberculosis Foundation; the Juho Vainio Foundation; the Yrjo Jahnsson Foundation; Medical Research Funds, Turku; Oulu and Tampere University Hospitals; the Juvenile Diabetes Research Foundation; the Novo Nordisk Foundation; and the EU Biomed 2 Program (BMH4-CT98-3314).; M. Kaila has received research support from Pirkanmaan Sairaanhoitopiiri, Tampere, Finland, and Tuberkuloosisaatio, Tampere, Finland. M. Erkkola has received research support from the University of Helsinki and the Ministry of Social Affairs and Health, lecture fees from the University of Tampere, and payment for the development of educational presentations from Helsinki Metropolia University of Applied Sciences. J. Kere has received research support from the Academy of Finland and the Sigrid Juselius Foundation and is employed by the Karolinska Institute. The rest of the other authors declare that they have no relevant conflicts of interest.	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bailey M, 2005, P NUTR SOC, V64, P451, DOI 10.1079/PNS2005452; Baker SS, 2000, PEDIATRICS, V106, P346; Chuang CH, 2011, PEDIAT ALLERG IMM-UK, V22, P43, DOI 10.1111/j.1399-3038.2010.01007.x; Dreskin SC, 2010, CLIN IMMUNOL, V137, P366, DOI 10.1016/j.clim.2010.08.009; Duncan JM, 2008, CURR OPIN ALLERGY CL, V8, P398, DOI 10.1097/ACI.0b013e32830d82ed; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Fiocchi A, 2006, ANN ALLERG ASTHMA IM, V97, P10, DOI 10.1016/S1081-1206(10)61364-6; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Haahtela T, 2008, ALLERGY, V63, P634, DOI 10.1111/j.1398-9995.2008.01712.x; Hesselmar B, 2010, ACTA PAEDIATR, V99, P1861, DOI 10.1111/j.1651-2227.2010.01939.x; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Joseph CLM, 2011, J ALLERGY CLIN IMMUN, V127, P1203, DOI 10.1016/j.jaci.2011.02.018; Kajosaari M, 1991, Adv Exp Med Biol, V310, P453; Knutsen AP, 2010, ALLERGY, V65, P1367, DOI 10.1111/j.1398-9995.2010.02382.x; Kramer MS, 2007, BMJ-BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051; Kupila A, 2001, DIABETOLOGIA, V44, P290, DOI 10.1007/s001250051616; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Ludvigsson JF, 2005, PEDIAT ALLERG IMM-UK, V16, P201, DOI 10.1111/j.1399-3038.2005.00257.x; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Miyake Y, 2009, PEDIATR ALLERGY IMMU, V20, P234, DOI 10.1111/j.1399-3038.2008.00778.x; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Newburg DS, 2005, J NUTR, V135, P1308, DOI 10.1093/jn/135.5.1308; Nwaru BI, 2010, PEDIATRICS, V125, P50, DOI 10.1542/peds.2009-0813; Nwaru BI, 2011, CLIN RESPIR J, V5, P211, DOI 10.1111/j.1752-699X.2010.00222.x; Pekkanen J, 2012, EUR J EPIDEMIOL, V27, P281, DOI 10.1007/s10654-012-9649-y; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Prescott SL, 2005, MED J AUSTRALIA, V182, P464, DOI 10.5694/j.1326-5377.2005.tb06787.x; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; Silvers KM, 2009, MATERN CHILD NUTR, V5, P243, DOI 10.1111/j.1740-8709.2008.00169.x; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; Virtanen SM, 2006, DIABETOLOGIA, V49, P1512, DOI 10.1007/s00125-006-0236-1; Virtanen SM, 2011, DIABETIC MED, V28, P965, DOI 10.1111/j.1464-5491.2011.03294.x; Virtanen SM, 2010, BRIT J NUTR, V103, P266, DOI 10.1017/S0007114509991541; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; White SR, 2010, EUR RESPIR J, V35, P925, DOI 10.1183/09031936.00164809; Yang YW, 2009, BRIT J DERMATOL, V161, P373, DOI 10.1111/j.1365-2133.2009.09049.x; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353; Zutavern A, 2008, PEDIATRICS, V121, pE44, DOI 10.1542/peds.2006-3553	46	98	107	0	57	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					78	86		10.1016/j.jaci.2012.10.028	http://dx.doi.org/10.1016/j.jaci.2012.10.028			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23182171				2022-12-18	WOS:000312961200009
J	Savenije, OEM; Kerkhof, M; Koppelman, GH; Postma, DS				Savenije, Olga E. M.; Kerkhof, Marjan; Koppelman, Gerard H.; Postma, Dirkje S.			Predicting who will have asthma at school age among preschool children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; prediction; preschool; children; episodic wheeze; multiple-trigger wheeze	WHEEZING RHINOVIRUS ILLNESSES; OBSTRUCTIVE AIRWAYS DISEASE; 1ST 6 YEARS; LUNG-FUNCTION; CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; HIGH-RISK; GENOMEWIDE ASSOCIATION; MEDICAL LITERATURE; USERS GUIDES	It is difficult to distinguish at preschool age whether a wheezing child will or will not have asthma at school age. A prediction rule for asthma in preschool children might help to determine a prognosis and to study improvements in treatment and prevention. This review discusses (1) the development and use of clinical prediction rules, (2) the European Respiratory Society Task Force classification of wheeze at preschool age, (3) published prediction rules developed to identify preschool children who will have asthma at school age, and (4) recommendations to improve asthma prediction. Prediction rules are currently created more frequently, yet their clinical use remains low. The classification of episodic wheeze and multiple-trigger wheeze in preschool children shows conflicting results as to whether episodic wheeze and multiple-trigger wheeze differ in clinical features and has limited value in predicting asthma at school age. Clearly, more studies are needed to confirm this. Currently available prediction rules aiming to identify preschool children having asthma at school age are of modest clinical value. Prediction can be improved by more precise definitions and measures and, ultimately, by more knowledge of pathophysiologic mechanisms. In the future, biomarkers and genomic risk profiles to develop personalized medicine might further improve asthma prediction, treatment, and prevention. (J Allergy Clin Immunol 2012;130:325-31.)	[Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, GRIAC Res Inst, NL-9700 RB Groningen, Netherlands; [Savenije, Olga E. M.; Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, GRIAC Res Inst, NL-9700 RB Groningen, Netherlands; [Savenije, Olga E. M.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat, NL-9700 RB Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, NL-9700 RB Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen	Postma, DS (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, GRIAC Res Inst, POB 30-001, NL-9700 RB Groningen, Netherlands.	d.s.postma@umcg.nl	Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252	ZonMw AGIKO fund [92003555]; University Medical Center Groningen; Dutch Asthma Foundation [3.4.01.26, 3.2.06.022, 3.2.09.081JU]; ZonMw Netherlands [912-03-031]; Ministry of the Environment; Chiesi; AstraZeneca; Nycomed	ZonMw AGIKO fund; University Medical Center Groningen; Dutch Asthma Foundation; ZonMw Netherlands(Netherlands Organization for Health Research and DevelopmentNetherlands Government); Ministry of the Environment(Ministry of the Environment, Japan); Chiesi(Chiesi Pharmaceuticals Inc); AstraZeneca(AstraZeneca); Nycomed	O.E.M.S. was supported by a ZonMw AGIKO fund (grant no. 92003555) and the University Medical Center Groningen. The Prevention and Incidence of Asthma and Mite Allergy study was supported by the Dutch Asthma Foundation (grants 3.4.01.26, 3.2.06.022 , and 3.2.09.081JU), the ZonMw Netherlands (grant 912-03-031), and the Ministry of the Environment.; G. H. Koppelman has received research support from the Dutch Asthma Foundation. D. S. Postma has consultant arrangements with Nycomed, GlaxoSmithKline, AstraZeneca, and Chiesi and has received research support from Chiesi, AstraZeneca, and Nycomed. The rest of the authors declare that they have no relevant conflicts of interest.	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bacharier LB, 2009, J ALLERGY CLIN IMMUN, V123, P1077, DOI 10.1016/j.jaci.2008.12.1120; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Bhatt JM, 2011, PAEDIATR RESPIR REV, V12, P70, DOI 10.1016/j.prrv.2010.09.001; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bottema RWB, 2010, J ALLERGY CLIN IMMUN, V126, P338, DOI 10.1016/j.jaci.2010.04.024; Bottema RW, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brand PLP, 2011, RESP MED, V105, P1588, DOI 10.1016/j.rmed.2011.07.017; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Carlsen KCL, 2010, ALLERGY, V65, P1134, DOI 10.1111/j.1398-9995.2010.02344.x; Casey BM, 2001, NEW ENGL J MED, V344, P467, DOI 10.1056/NEJM200102153440701; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Caudri D, 2010, THORAX, V65, P801, DOI 10.1136/thx.2009.126912; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, pe1, DOI DOI 10.1016/HACI.2010.10.050; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P390, DOI 10.1016/j.jaci.2010.10.050; Davies BR, 2011, ARCH DIS CHILDHOOD-E, V96, P61, DOI 10.1136/adc.2009.171272; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Ducharme FM, 2011, PAEDIATR RESPIR REV, V12, P170, DOI 10.1016/j.prrv.2011.02.007; Dupuy AV, 2011, J ASTHMA, V48, P1015, DOI 10.3109/02770903.2011.626481; Eysink PED, 2005, BRIT J GEN PRACT, V55, P125; Frank PI, 2008, BRIT MED J, V336, P1423, DOI 10.1136/bmj.39568.623750.BE; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532, DOI 10.1016/j.jaci.2011.06.037; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, pe1; Haland G, 2009, PEDIAT ALLERG IMM-UK, V20, P254, DOI 10.1111/j.1399-3038.2008.00781.x; Heianza Y, 2011, LANCET, V378, P147, DOI 10.1016/S0140-6736(11)60472-8; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Kappelle L, 2012, EUR J PEDIAT; Kotaniemi-Syrjanen A, 2011, J ALLERGY CLIN IMMUN, V128, pe1; Kotaniemi-Syrjanen A, 2008, PEDIATR INT, V50, P506, DOI 10.1111/j.1442-200X.2008.02620.x; Kotaniemi-Syrjanen A, 2011, J ALLERGY CLIN IMMUN, V128, P1111, DOI 10.1016/j.jaci.2011.07.028; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Leonardi NA, 2011, J ALLERGY CLIN IMMUN, V127, P1466, DOI 10.1016/j.jaci.2011.03.001; Maguire JL, 2011, PEDIATRICS, V128, pE666, DOI 10.1542/peds.2011-0043; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2011, J ALLERGY CLIN IMMUN, V128, P939, DOI 10.1016/j.jaci.2011.09.020; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Matricardi PM, 2010, EUR RESPIR J, V35, P701, DOI 10.1183/09031936.00163709; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Meyers DA, 2010, J ALLERGY CLIN IMMUN, V126, P439, DOI 10.1016/j.jaci.2010.07.012; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Morales E, 2012, AM J RESP CRIT CARE, V185, P937, DOI 10.1164/rccm.201105-0870OC; Papi A, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-39; Reijmerink NE, 2009, ALLERGY, V64, P898, DOI 10.1111/j.1398-9995.2009.01939.x; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Roberts G, 2009, J ALLERGY CLIN IMMUN, V124, P911, DOI 10.1016/j.jaci.2009.09.034; Rodriguez-Martinez CE, 2011, PEDIATR PULM, V46, P1175, DOI 10.1002/ppul.21493; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schultz A, 2010, ACTA PAEDIATR, V99, P56, DOI 10.1111/j.1651-2227.2009.01508.x; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sonnappa S, 2011, EUR RESPIR J, V38, P1431, DOI 10.1183/09031936.00164910; Sonnappa S, 2010, J ALLERGY CLIN IMMUN, V126, P519, DOI 10.1016/j.jaci.2010.04.018; Spycher BD, 2010, CLIN EXP ALLERGY, V40, P1130, DOI 10.1111/j.1365-2222.2010.03541.x; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Toll DB, 2008, J CLIN EPIDEMIOL, V61, P1085, DOI 10.1016/j.jclinepi.2008.04.008; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; van Aalderen WMC, 2011, EUR J PEDIATR, V170, P709, DOI 10.1007/s00431-010-1319-z; van de Kant KDG, 2012, PEDIAT ALLERG IMM-UK, V23, P259, DOI 10.1111/j.1399-3038.2011.01244.x; van der Zalm MM, 2011, AM J RESP CRIT CARE, V183, P262, DOI 10.1164/rccm.200905-0716OC; van Wonderen KE, 2010, EUR RESPIR J, V36, P48, DOI 10.1183/09031936.00154409; von Jagwitz M, 2011, J ALLERGY CLIN IMMUN, V128, P50, DOI 10.1016/j.jaci.2011.03.005; von Mutius E, 2011, J ALLERGY CLIN IMMUN, V127, P1513, DOI 10.1016/j.jaci.2011.04.026; Weiss ST, 2012, J ALLERGY CLIN IMMUN, V129, P327, DOI 10.1016/j.jaci.2011.12.971; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647	77	98	101	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					325	331		10.1016/j.jaci.2012.05.007	http://dx.doi.org/10.1016/j.jaci.2012.05.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22704537				2022-12-18	WOS:000307002200010
J	Busse, WW; Morgan, WJ; Taggart, V; Togias, A				Busse, William W.; Morgan, Wayne J.; Taggart, Virginia; Togias, Alkis			Asthma outcomes workshop: Overview	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma clinical research; National Institutes of Health asthma initiatives; standardizing outcomes		Background: Asthma clinical research will highly benefit from standardization of major outcomes in terms of definition and assessment methodology. This will permit useful comparisons across interventional or observational studies and will allow more effective data sharing. Objective: National Institutes of Health (NIH) institutes and the Agency for Healthcare Research and Quality convened a workshop involving 7 expert subcommittees to propose which asthma outcomes should be assessed with standardized methodology in future asthma clinical research studies. Methods: Each subcommittee utilized comprehensive literature reviews and expert opinion to compile a list of asthma outcomes and classified them as either core (required in future studies), supplemental (to be used according to study aims and standardized), or emerging (requiring validation and standardization). This work was discussed at an NIH-organized workshop in March 2010 and finalized in September 2011. Results: Outcomes for study participant characterization, as well as for prospective clinical trial intervention and observational studies, were proposed for adults and children, and methodologies for outcome collection and reporting were determined. Furthermore, the workshop identified areas in which new outcomes or instruments for their measurement need to be developed and validated. Conclusions: Standardized outcomes for clinical research in asthma have been proposed. Participating NIH institutes and other federal agencies will consider these recommendations in future clinical research initiatives in asthma. (J Allergy Clin Immunol 2012; 129: S1-8.)	[Togias, Alkis] NIAID, DAIT, NIH, Bethesda, MD 20892 USA; [Busse, William W.] Univ Wisconsin, Madison, WI 53706 USA; [Morgan, Wayne J.] Univ Arizona, Phoenix, AZ USA; [Taggart, Virginia] NHLBI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wisconsin System; University of Wisconsin Madison; University of Arizona; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Togias, A (corresponding author), NIAID, DAIT, NIH, 6610 Rockledge Dr, Bethesda, MD 20892 USA.	togiasa@niaid.nih.gov			National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Environmental Health Sciences; Agency for Healthcare Research and Quality; Merck Childhood Asthma Network; Robert Wood Johnson Foundation; US Environmental Protection Agency; National Institutes of Health (NIAID); National Institutes of Health (NHLBI); NIH-NHLBI CARE Network; Cystic Fibrosis Network	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Merck Childhood Asthma Network; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); US Environmental Protection Agency(United States Environmental Protection Agency); National Institutes of Health (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH-NHLBI CARE Network; Cystic Fibrosis Network	The Asthma Outcomes workshop was funded by contributions from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; the Agency for Healthcare Research and Quality; and the Merck Childhood Asthma Network, as well as by a grant from the Robert Wood Johnson Foundation. Contributions from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; and the US Environmental Protection Agency funded the publication of this article and all other articles in this supplement.; Disclosure of potential conflict of interest: W. W. Busse is on the Advisory Board for Centocor and Merck; is a consultant for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, Genentech, and Boehringer Ingelheim; is on the Actelion Date Safety Monitoring Board; and has received research support from the National Institutes of Health (NIAID and NHLBI). W. J. Morgan is a consultant for Genentech, Novartis, and the Cystic Fibrosis Foundation; has received research support from the NIH-NHLBI CARE Network and the Cystic Fibrosis Network; and is a speaker for Phadia. The rest of the authors declare that they have no relevant conflicts of interest.	Akinbami LJ, 2011, ASTHMA PREVALENCE HL; [American Educational Research Association American Psychological Association National Council on Measurement in Education], 1999, STAND ED PSYCH TEST; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST	3	98	98	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3		S			S1	S8		10.1016/j.jaci.2011.12.985	http://dx.doi.org/10.1016/j.jaci.2011.12.985			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	901OL	22386504	Green Accepted, Bronze			2022-12-18	WOS:000300976600001
J	Hussaarts, L; van der Vlugt, LEPM; Yazdanbakhsh, M; Smits, HH				Hussaarts, Leonie; van der Vlugt, Lucien E. P. M.; Yazdanbakhsh, Maria; Smits, Hermelijn H.			Regulatory B-cell induction by helminths: Implications for allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory B cells; IL-10; regulatory T cells; helminths; allergy; asthma	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; B10 CELLS; T-CELLS; INFLAMMATION; MICE; IL-10; INFECTION; INITIATION; RESPONSES; SUBSET	Chronic helminth infections are often associated with a reduced prevalence of inflammatory disorders, including allergic diseases. Helminths influence the host immune system by downregulating T-cell responses; the cytokine IL-10 appears to play a central role in this process. Over the last decade, evidence has emerged toward a new regulatory cell type: IL-10-producing B cells, capable of regulating immunity and therefore termed regulatory B cells. Initially, regulatory B cells have been described in autoimmunity models where they dampen inflammation, but recently they were also found in several helminth infection models. Importantly, regulatory B cells have recently been identified in humans, and it has been suggested that patients suffering from autoimmunity have an impaired regulatory B-cell function. As such, it is of therapeutic interest to study the conditions in which IL-10-producing B cells can be induced. Chronic helminth infections appear to hold promise in this context as emerging evidence suggests that helminth-induced regulatory B cells strongly suppress allergic inflammation. In this review, we will discuss the conditions under which regulatory B cells are present, leading to a state of tolerance, as well as the conditions where their absence or functional impairment leads to exacerbated disease. We will summarize their phenotypic characteristics and their mechanisms of action and elaborate on possible mechanisms whereby regulatory B cells can be induced or expanded, as this may open novel avenues for the treatment of inflammatory diseases, such as allergic asthma. (J Allergy Clin Immunol 2011;128:733-9.)	[Hussaarts, Leonie; van der Vlugt, Lucien E. P. M.; Yazdanbakhsh, Maria; Smits, Hermelijn H.] Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Smits, HH (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, POB 9600, NL-2300 ZA Leiden, Netherlands.	H.H.Smits@lumc.nl	Yazdanbakhsh, Maria/AAI-3996-2020; Smits, Hermelijn/V-4216-2018	Yazdanbakhsh, Maria/0000-0002-7666-1441; Smits, Hermelijn/0000-0001-9279-2890	Dutch Organization for Scientific Research (NWO); ZONMW-VENI [016.066.093]; Netherlands Asthma Foundation (NAF) [10.072]	Dutch Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); ZONMW-VENI; Netherlands Asthma Foundation (NAF)	This work was supported by the Dutch Organization for Scientific Research (NWO), ZONMW-VENI 016.066.093 (HHS), the Netherlands Asthma Foundation (NAF), grant no. 10.072 (LEPMV).	Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Blair PA, 2009, J IMMUNOL, V182, P3492, DOI 10.4049/jimmunol.0803052; Bouaziz JD, 2010, EUR J IMMUNOL, V40, P2686, DOI 10.1002/eji.201040673; Carter NA, 2011, J IMMUNOL, V186, P5569, DOI 10.4049/jimmunol.1100284; Correale J, 2008, ANN NEUROL, V64, P187, DOI 10.1002/ana.21438; Correale J, 2009, J IMMUNOL, V183, P5999, DOI 10.4049/jimmunol.0900897; Evans JG, 2007, J IMMUNOL, V178, P7868, DOI 10.4049/jimmunol.178.12.7868; Everts B, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000667; Gray M, 2007, P NATL ACAD SCI USA, V104, P14080, DOI 10.1073/pnas.0700326104; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Madan R, 2009, J IMMUNOL, V183, P2312, DOI 10.4049/jimmunol.0900185; Mann MK, 2007, J IMMUNOL, V178, P3447, DOI 10.4049/jimmunol.178.6.3447; Matsushita T, 2008, J CLIN INVEST, V118, P3420, DOI 10.1172/JCI36030; Matsushita T, 2010, J IMMUNOL, V185, P2240, DOI 10.4049/jimmunol.1001307; Nakashima H, 2010, J IMMUNOL, V184, P4637, DOI 10.4049/jimmunol.0901719; Neves P, 2010, IMMUNITY, V33, P777, DOI 10.1016/j.immuni.2010.10.016; Noh J, 2010, CELL IMMUNOL, V264, P143, DOI 10.1016/j.cellimm.2010.05.013; Ronet C, 2010, J IMMUNOL, V184, P886, DOI 10.4049/jimmunol.0901114; Sayi A, 2011, J IMMUNOL, V186, P878, DOI 10.4049/jimmunol.1002269; Smits HH, 2007, J ALLERGY CLIN IMMUN, V120, P932, DOI 10.1016/j.jaci.2007.06.009; Sugimoto K, 2007, GASTROENTEROLOGY, V133, P124, DOI 10.1053/j.gastro.2007.03.112; Watanabe R, 2010, J IMMUNOL, V184, P4801, DOI 10.4049/jimmunol.0902385; Wilson MS, 2010, EUR J IMMUNOL, V40, P1682, DOI 10.1002/eji.200939721; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yang M, 2010, J IMMUNOL, V184, P3321, DOI 10.4049/jimmunol.0902551	27	98	108	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					733	739		10.1016/j.jaci.2011.05.012	http://dx.doi.org/10.1016/j.jaci.2011.05.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21684587				2022-12-18	WOS:000296538100005
J	Leung, DYM; Gao, PS; Grigoryev, DN; Rafaels, NM; Streib, JE; Howell, MD; Taylor, PA; Boguniewicz, M; Canniff, J; Armstrong, B; Zaccaro, DJ; Schneider, LC; Hata, TR; Hanifin, JM; Beck, LA; Weinberg, A; Barnes, KC				Leung, Donald Y. M.; Gao, Pei-Song; Grigoryev, Dmitry N.; Rafaels, Nicholas M.; Streib, Joanne E.; Howell, Michael D.; Taylor, Patricia A.; Boguniewicz, Mark; Canniff, Jennifer; Armstrong, Brian; Zaccaro, Daniel J.; Schneider, Lynda C.; Hata, Tissa R.; Hanifin, Jon M.; Beck, Lisa A.; Weinberg, Adriana; Barnes, Kathleen C.			Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-gamma response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; infection; eczema herpeticum; IFNG; IFNGR1	VACCINIA VIRUS; SMALLPOX VACCINATION; GENE POLYMORPHISM; INTERFERON; CELLS; POPULATION; PROMOTER; RISK; RNA; TUBERCULOSIS	Background: The basis for increased susceptibility of patients with atopic dermatitis (AD) to develop disseminated viral skin infections such as eczema herpeticum (AD with a history of eczema herpeticum, ADEH(+)) is poorly understood. Objective: We sought to determine whether subjects with AD prone to disseminated viral skin infections have defects in their IFN responses. Methods: GeneChip profiling was used to identify differences in gene expression of PBMCs from patients with ADEH(+) compared with patients with AD without a history of eczema herpeticum (ADEH(-)) and nonatopic controls. Key differences in protein expression were verified by enzyme-linked immunosorbent spot assay and/or ELISA. Clinical relevance was further demonstrated by a mouse model of disseminated viral skin infection and genetic association analysis for genetic variants in IFNG and IFNGR1 and ADEH among 435 cases and controls. Results: We demonstrate by global gene expression analysis selective transcriptomic changes within the IFN superfamily of PBMCs from subjects with ADEH(+) reflecting low IFN-gamma and IFN-gamma receptor gene expression. IFN-gamma protein production was also significantly lower in patients with ADEH(+) (n = 24) compared with patients with ADEH(-) (n = 20) and nonatopic controls (n 5 20). IFN-gamma receptor knockout mice developed disseminated viral skin infection after epicutaneous challenge with vaccinia virus. Genetic variants in IFNG and IFNGR1 single nucleotide polymorphisms (SNPs) were significantly associated with ADEH (112 cases, 166 controls) and IFN-gamma production: a 2-SNP (A-G) IFNGR1 haplotype (rs10457655 and rs7749390) showed the strongest association with a reduced risk of ADEH+ (13.2% ADEH+ vs 25.5% ADEH -; P = .00057). Conclusion: Patients with ADEH(+) have reduced IFN-gamma production, and IFNG and IFNGR1 SNPs are significantly associated with ADEH(+) and may contribute to an impaired immune response to herpes simplex virus. (J Allergy Clin Immunol 2011;127:965-73.)	[Leung, Donald Y. M.; Streib, Joanne E.; Howell, Michael D.; Taylor, Patricia A.; Boguniewicz, Mark] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Leung, Donald Y. M.; Boguniewicz, Mark; Canniff, Jennifer; Weinberg, Adriana] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Gao, Pei-Song; Grigoryev, Dmitry N.; Rafaels, Nicholas M.; Barnes, Kathleen C.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; [Armstrong, Brian; Zaccaro, Daniel J.] Rho Inc, Chapel Hill, NC USA; [Schneider, Lynda C.] Childrens Hosp Boston, Boston, MA USA; [Hata, Tissa R.] UCSD Med Ctr, San Diego, CA USA; [Hanifin, Jon M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Beck, Lisa A.] Univ Rochester, Dept Dermatol, Med Ctr, Rochester, NY 14627 USA	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Johns Hopkins University; Johns Hopkins Medicine; Rho; Harvard University; Boston Children's Hospital; University of California System; University of California San Diego; Oregon Health & Science University; University of Rochester	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St,Room K926I, Denver, CO 80206 USA.	leungd@njhealth.org	Grigoryev, Dmitry/C-9422-2015	Grigoryev, Dmitry/0000-0002-1849-1763	National Center for Research Resources [UL1 RR02580]; Atopic Dermatitis Vaccinia Network; National Institutes of Health/National Institute of Allergy and Infectious Diseases [N01 AI40029, N01 AI40030, N01 AI40033]; NIAMS [AR41256]; Edelstein Family Foundation; Mary Beryl Patch Turnbull Scholar Program; National Institutes of Health (NIH); Astellas; Novartis; National Eczema Association; Centocor, Inc.; Sanofi-Aventis; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Atopic Dermatitis Vaccinia Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Edelstein Family Foundation; Mary Beryl Patch Turnbull Scholar Program; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Astellas(Astellas Pharmaceuticals); Novartis(Novartis); National Eczema Association; Centocor, Inc.(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Sanofi-Aventis(Sanofi-Aventis); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Clinical Translational Scientific Award from the National Center for Research Resources, UL1 RR02580, and the Atopic Dermatitis Vaccinia Network, National Institutes of Health/National Institute of Allergy and Infectious Diseases contracts N01 AI40029, N01 AI40030, and N01 AI40033. D.Y.M.L. was supported in part by NIAMS grant AR41256 and the Edelstein Family Foundation. K. C. B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program.; Disclosure of potential conflict of interest: M. Boguniewicz receives research support from the National Institutes of Health (NIH). L. C. Schneider receives research support from Astellas and Novartis. L. A. Beck has consultant arrangements with Regeneron and receives research support from the NIH/National Institute of Allergy and Infectious Diseases, the National Eczema Association, and Centocor, Inc. K. C. Barnes receives research support from the NIH and Sanofi-Aventis. The rest of the authors declare that they have no relevant conflicts of interest.	AMEGADZIE BY, 1991, J BIOL CHEM, V266, P13712; Baran W, 2008, BIOMARKERS, V13, P52, DOI 10.1080/13547500701610273; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136; Dobbs ME, 2005, J VIROL, V79, P14546, DOI 10.1128/JVI.79.23.14546-14554.2005; ESTEBAN M, 1984, VIROLOGY, V134, P40, DOI 10.1016/0042-6822(84)90270-8; Fauci AS, 2002, NEW ENGL J MED, V346, P1319, DOI 10.1056/NEJM200204253461711; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Grigoryev DN, 2010, J ALLERGY CLIN IMMUN, V125, P153, DOI 10.1016/j.jaci.2009.10.024; Grigoryev DN, 2004, CRIT CARE, V8, P440, DOI 10.1186/cc2901; He J, 2010, SCAND J IMMUNOL, V71, P452, DOI 10.1111/j.1365-3083.2010.02393.x; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Howell MD, 2009, J INVEST DERMATOL, V129, P2668, DOI 10.1038/jid.2009.120; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Hussein YM, 2009, J INVEST ALLERG CLIN, V19, P292; Jugessur A, 2008, GENET EPIDEMIOL, V32, P413, DOI 10.1002/gepi.20314; KLOTZBUCHER A, 1990, VIROLOGY, V179, P487, DOI 10.1016/0042-6822(90)90322-I; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; Madsen BE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000384; Matsuda A, 2007, INVEST OPHTH VIS SCI, V48, P583, DOI 10.1167/iovs.06-0991; MELKOVA Z, 1994, VIROLOGY, V198, P731, DOI 10.1006/viro.1994.1087; Moses AE, 2002, NEW ENGL J MED, V346, P1287, DOI 10.1056/NEJMicm010892; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Sallakci N, 2007, TUBERCULOSIS, V87, P225, DOI 10.1016/j.tube.2006.10.002; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; Takahashi N, 2005, HUM MOL GENET, V14, P3149, DOI 10.1093/hmg/ddi347; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584; van de Wetering D, 2010, MOL IMMUNOL, V47, P1023, DOI 10.1016/j.molimm.2009.11.016; Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668; Weinberg A, 2009, CLIN VACCINE IMMUNOL, V16, P1176, DOI 10.1128/CVI.00342-08	33	98	99	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					965	U210		10.1016/j.jaci.2011.02.010	http://dx.doi.org/10.1016/j.jaci.2011.02.010			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21458658	Green Accepted			2022-12-18	WOS:000289055800018
J	Simon, D; Hoesli, S; Roth, N; Staedler, S; Yousefi, S; Simon, HU				Simon, Dagmar; Hoesli, Susanne; Roth, Nina; Staedler, Simon; Yousefi, Shida; Simon, Hans-Uwe			Eosinophil extracellular DNA traps in skin diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ECP; eosinophils; eosinophil extracellular traps; DNA; skin disease	MAJOR BASIC-PROTEIN; MITOCHONDRIAL-DNA; CATIONIC PROTEIN; HOST-DEFENSE; MECHANISM; RELEASE	Background: In the skin, eosinophils are found in a broad spectrum of diseases, including infectious diseases. Objective: In this study, we investigated whether eosinophil extracellular traps, structures containing DNA in association with eosinophil granule proteins able to bind and kill bacteria, are present in the skin under various pathologic conditions. Methods: Immunofluorescence staining was performed on sections of paraformaldehyde-fixed and paraffin-embedded skin biopsy tissues of 25 different eosinophilic skin diseases by using propidium iodide and an antibody to eosinophil cationic protein. Slides were evaluated by laser scanning microscopy. Results: Eosinophils releasing DNA together with eosinophil cationic protein were detected in infectious skin diseases such as ectoparasitosis and larva migrans. Further, we observed the extracellular DNA structures in allergic/reactive diseases (Wells syndrome, hypereosinophilic syndrome, positive reaction of atopy patch test, allergic contact dermatitis, drug hypersensitivity) and in autoimmune diseases (bullous pemphigoid, pemphigus foliaceus, dermatitis herpetiformis). The average number of eosinophils releasing DNA in the skin was usually below 10%, although in Wells syndrome the proportion was up to 30%. In areas with clusters of eosinophils, up to 50% of the eosinophils were seen to generate eosinophil extracellular traps. Conclusion: Eosinophil extracellular traps are seen in both infectious and noninfectious inflammatory skin diseases and are particularly common in Wells syndrome. (J Allergy Clin Immunol 2011;127:194-9.)	[Simon, Dagmar; Roth, Nina; Staedler, Simon] Univ Hosp Bern, Inselspital, Dept Dermatol, CH-3010 Bern, Switzerland; [Hoesli, Susanne; Yousefi, Shida; Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern	Simon, D (corresponding author), Univ Hosp Bern, Inselspital, Dept Dermatol, CH-3010 Bern, Switzerland.	dagmar.simon@insel.ch	Yousefi, Shida/AAU-7986-2020; Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-7410-2020; Simon, Hans-Uwe/AAU-5079-2020	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736; 	Stanley Thomas Johnson Foundation; Swiss National Foundation	Stanley Thomas Johnson Foundation; Swiss National Foundation(Swiss National Science Foundation (SNSF))	Supported by grants from the Stanley Thomas Johnson Foundation (D. S.) and the Swiss National Foundation (S.Y., H.-U.S.)	Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; FRIGAS E, 1991, EUR RESPIR J, V4, pS123; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050; KROEGEL C, 1987, LANCET, V1, P1380; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Simon D, 2006, EXP DERMATOL, V15, P441, DOI 10.1111/j.0906-6705.2006.00428.x; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010; Simon D, 2010, J ALLERGY CLIN IMMUN, V126, P3, DOI 10.1016/j.jaci.2010.01.055; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855	15	98	100	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					194	199		10.1016/j.jaci.2010.11.002	http://dx.doi.org/10.1016/j.jaci.2010.11.002			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211654				2022-12-18	WOS:000285917300028
J	Haczku, A; Panettieri, RA				Haczku, Angela; Panettieri, Reynold A., Jr.			Social stress and asthma: The role of corticosteroid insensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway inflammation; psychosocial stress corticosteroids; innate immune system	SURFACTANT PROTEIN-D; ALLERGIC AIRWAY INFLAMMATION; BROWN-NORWAY RATS; INFLUENZA VIRAL-INFECTION; DIVERSE NOCUOUS AGENTS; NECROSIS-FACTOR-ALPHA; GLUCOCORTICOID-RECEPTOR; MOLECULAR-MECHANISMS; DENDRITIC CELLS; T-CELLS	Psychosocial stress alters susceptibility to infectious and systemic illnesses and may enhance airway inflammation in asthma by modulating immune cell function through neural and hormonal pathways. Stress activates the hypothalamic-pituitary-adrenal axis. Release of endogenous glucocorticoids, as a consequence, may play a prominent role in altering the airway immune homeostasis. Despite substantial corticosteroid and catecholamine plasma levels, chronic psychosocial stress evokes asthma exacerbations. Animal studies suggest that social stress induces corticosteroid insensitivity that in part may be a result of impaired glucocorticoid receptor expression and/or function. Such mechanisms likely promote and amplify airway inflammation in response to infections, allergen, or irritant exposure. This review discusses evidence of an altered corticosteroid responsive state as a consequence of chronic psychosocial stress. Elucidation of the mechanisms of stress-induced impairment of glucocorticoid responsiveness and immune homeostasis may identify novel therapeutic targets that could improve asthma management. (J Allergy Clin Immunol 2010;125:550-8.)	[Haczku, Angela] Univ Penn, Translat Res Labs, Pulm Allergy & Crit Care Div, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Haczku, A (corresponding author), Univ Penn, Translat Res Labs, Pulm Allergy & Crit Care Div, Dept Med, 125 S 31st St, Philadelphia, PA 19104 USA.	haczku@mail.med.upenn.edu	panettieri, reynold/AAG-9485-2019; HACZKU, ANGELA/A-8486-2013	HACZKU, ANGELA/0000-0002-1301-4941	NIH [R01A1055593, R01HL076646]; Mind, Body, Brain, and Health Initiative; Sepracor; NIH-NHLBI; AstraZeneca; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [RC1ES018505] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mind, Body, Brain, and Health Initiative; Sepracor; NIH-NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AstraZeneca(AstraZeneca); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	A.H. receives grant support from NIH R01A1055593. R01HL076646, and ALA Cl. R.A.P. is supported by the Mind, Body, Brain, and Health Initiative.; Disclosure of potential conflict of interest: A. Haczku receives research support from Sepracor. R. A. Panettieri receives research support from the NIH-NHLBI and AstraZeneca.	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Adcock IM, 2008, CURR ALLERGY ASTHM R, V8, P171, DOI 10.1007/s11882-008-0028-4; ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; Agarwal SK, 2001, CLIN EXP ALLERGY, V31, P25, DOI 10.1046/j.1365-2222.2001.01005.x; Ashwell JD, 1996, STEM CELLS, V14, P490, DOI 10.1002/stem.140490; Atochina EN, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-15; Avitsur R, 2005, BRAIN BEHAV IMMUN, V19, P311, DOI 10.1016/j.bbi.2004.09.005; Avitsur R, 2003, J LEUKOCYTE BIOL, V74, P507, DOI 10.1189/jlb.0303090; Avitsur R, 2002, J NEUROIMMUNOL, V124, P54, DOI 10.1016/S0165-5728(02)00010-3; Avitsur R, 2002, J NEUROIMMUNOL, V132, P66, DOI 10.1016/S0165-5728(02)00310-7; Avitsur R, 2001, HORM BEHAV, V39, P247, DOI 10.1006/hbeh.2001.1653; BADOUX A, 1994, ANN ALLERGY, V72, P229; Bailey MT, 2009, J IMMUNOL, V182, P7888, DOI 10.4049/jimmunol.0800891; BAILEY MT, 2006, AM J RESP CRIT CARE, V175, pA237; Barnes PJ, 2005, EUR RESPIR J, V25, P552, DOI 10.1183/09031936.05.00117504; BEGGS PJ, 1995, ARCH ENVIRON HEALTH, V50, P87, DOI 10.1080/00039896.1995.9940884; Berin MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/ajrcmb.24.4.4360; Bhandare R, 2010, AM J RESP CELL MOL, V42, P9, DOI 10.1165/rcmb.2009-0239RC; Bowers SL, 2008, BRAIN BEHAV IMMUN, V22, P105, DOI 10.1016/j.bbi.2007.07.012; Breslin MB, 2001, MOL ENDOCRINOL, V15, P1381, DOI 10.1210/me.15.8.1381; BURNSTEIN KL, 1991, STEROIDS, V56, P52, DOI 10.1016/0039-128X(91)90124-E; Cao Y, 2004, J ALLERGY CLIN IMMUN, V113, P439, DOI 10.1016/j.jaci.2003.11.031; Chen E, 2007, BRAIN BEHAV IMMUN, V21, P993, DOI 10.1016/j.bbi.2007.03.009; Chida Y, 2007, AM J RESP CRIT CARE, V175, P316, DOI 10.1164/rccm.200607-898OC; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V105, P211, DOI 10.1016/S0091-6749(00)90068-X; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1993, J BIOL CHEM, V268, P2976; Damera G, 2009, PULM PHARMACOL THER, V22, P353, DOI 10.1016/j.pupt.2008.12.006; Datti F, 2002, PHYSIOL BEHAV, V77, P79, DOI 10.1016/S0031-9384(02)00811-9; DeVries AC, 2003, PHYSIOL BEHAV, V79, P399, DOI 10.1016/S0031-9384(03)00152-5; Dobbs CM, 1996, J IMMUNOL, V157, P1870; Eells JB, 2006, NEUROSCIENCE, V140, P1117, DOI 10.1016/j.neuroscience.2005.12.065; Eisenbarth SC, 2003, CURR OPIN IMMUNOL, V15, P620, DOI 10.1016/j.coi.2003.09.003; Engler H, 2005, J NEUROIMMUNOL, V163, P110, DOI 10.1016/j.jneuroim.2005.03.002; Engler H, 2004, J NEUROIMMUNOL, V148, P106, DOI 10.1016/j.jneuroim.2003.11.011; Forsythe P, 2004, AM J RESP CRIT CARE, V169, P220, DOI 10.1164/rccm.200307-979OC; Geng CD, 2005, BIOCHEMISTRY-US, V44, P7395, DOI 10.1021/bi047485e; Geng CD, 2004, MOL ENDOCRINOL, V18, P912, DOI 10.1210/me.2003-0157; Georen S, 2005, ACTA OTO-LARYNGOL, V125, P378, DOI 10.1080/00016480410025261; GOULD CL, 1987, AVIAT SPACE ENVIR MD, V58, P983; Gross KL, 2009, MOL CELL ENDOCRINOL, V300, P7, DOI 10.1016/j.mce.2008.10.001; HACZKU A, 1995, IMMUNOLOGY, V85, P598; Haczku A, 1997, IMMUNOLOGY, V91, P176, DOI 10.1046/j.1365-2567.1997.d01-2221.x; Haczku A, 1996, IMMUNOLOGY, V88, P247, DOI 10.1111/j.1365-2567.1996.tb00011.x; HACZKU A, 1995, IMMUNOLOGY, V85, P591; Haczku A, 2002, AM J PHYSIOL-LUNG C, V283, pL755, DOI 10.1152/ajplung.00062.2002; Haczku A, 2001, AM J RESP CELL MOL, V25, P45, DOI 10.1165/ajrcmb.25.1.4391; Haczku A., 2008, AM J RESP CRIT CARE, V177, pA64; Haczku A, 2008, J ALLERGY CLIN IMMUN, V122, P861, DOI 10.1016/j.jaci.2008.10.014; Haczku A, 2006, J IMMUNOL, V176, P3557, DOI 10.4049/jimmunol.176.6.3557; Haczku Angela, 1998, Acta Microbiologica et Immunologica Hungarica, V45, P19; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327, DOI 10.1165/ajrcmb.23.3.3796; HERMANN G, 1994, J NEUROIMMUNOL, V49, P25, DOI 10.1016/0165-5728(94)90177-5; HERMANN G, 1995, J NEUROIMMUNOL, V56, P179, DOI 10.1016/0165-5728(94)00145-E; Hortobagyi L, 2008, J ALLERGY CLIN IMMUN, V122, P521, DOI 10.1016/j.jaci.2008.05.002; ISENBERG SA, 1992, PSYCHOSOM MED, V54, P192, DOI 10.1097/00006842-199203000-00006; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Joachim RA, 2004, PSYCHOSOM MED, V66, P564, DOI 10.1097/01.psy.0000132878.08780.93; Joachim RA, 2003, PSYCHOSOM MED, V65, P811, DOI 10.1097/01.PSY.0000088582.50468.A3; Joachim RA, 2007, J NEUROIMMUNOL, V182, P55, DOI 10.1016/j.jneuroim.2006.09.010; Joachim RA, 2006, NEUROIMMUNOMODULAT, V13, P43, DOI 10.1159/000094394; KALINYAK JE, 1987, J BIOL CHEM, V262, P10441; Kandel ER, 1998, AM J PSYCHIAT, V155, P457, DOI 10.1176/ajp.155.4.457; Kierstein S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-85; Klinsey SG, 2007, BRAIN BEHAV IMMUN, V21, P458, DOI 10.1016/j.bbi.2006.11.001; KOLBE J, 1994, CHEST, V106, pS211, DOI 10.1378/chest.106.4_Supplement.211S; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LEHRER PM, 1993, J ASTHMA, V30, P5, DOI 10.3109/02770909309066375; Lin CW, 2002, MOL PHARMACOL, V62, P297, DOI 10.1124/mol.62.2.297; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/ajrccm.165.8.2109065; Louahed J, 2001, BLOOD, V97, P1035, DOI 10.1182/blood.V97.4.1035; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; Marshall GD, 2000, ALLERGY ASTHMA PROC, V21, P241, DOI 10.2500/108854100778248917; Marshall GD, 2004, ANN ALLERG ASTHMA IM, V93, pS11, DOI 10.1016/S1081-1206(10)61482-2; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; MILLER BD, 1987, J ALLERGY CLIN IMMUN, V80, P481, DOI 10.1016/0091-6749(87)90080-7; MILLER BD, 1994, J AM ACAD CHILD PSY, V33, P1236, DOI 10.1097/00004583-199411000-00004; Miller Bruce D, 2003, Adv Psychosom Med, V24, P131, DOI 10.1159/000073785; Miller G, 2009, ANNU REV PSYCHOL, V60, P501, DOI 10.1146/annurev.psych.60.110707.163551; Miller GE, 2009, J ALLERGY CLIN IMMUN, V123, P824, DOI 10.1016/j.jaci.2008.12.019; Okuyama Kaori, 2007, Allergol Int, V56, P29, DOI 10.2332/allergolint.O-06-435; Panettieri RA, 2008, J ALLERGY CLIN IMMUN, V121, P607, DOI 10.1016/j.jaci.2008.01.006; Panettieri RA, 2009, ALLERGY ASTHMA PROC, V30, P519, DOI 10.2500/aap.2009.30.3281; Panettieri RA, 2009, ALLERGY ASTHMA PROC, V30, P103, DOI 10.2500/aap.2009.30.3202; Penna G, 2002, HUM IMMUNOL, V63, P1164, DOI 10.1016/S0198-8859(02)00755-3; Pincus-Knackstedt MK, 2006, J IMMUNOL, V177, P8484, DOI 10.4049/jimmunol.177.12.8484; Powell ND, 2009, BRAIN BEHAV IMMUN, V23, P225, DOI 10.1016/j.bbi.2008.09.010; Pujols L, 2007, CURR ALLERGY ASTHM R, V7, P93, DOI 10.1007/s11882-007-0005-3; Quan N, 2003, J NEUROIMMUNOL, V137, P51, DOI 10.1016/S0165-5728(03)00042-0; Quan N, 2001, J NEUROIMMUNOL, V115, P36, DOI 10.1016/S0165-5728(01)00273-9; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Rosenkranz MA, 2005, P NATL ACAD SCI USA, V102, P13319, DOI 10.1073/pnas.0504365102; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Selye H, 1936, NATURE, V138, P32, DOI 10.1038/138032a0; Selye H, 1998, J NEUROPSYCH CLIN N, V10, P230; Silverman ES, 2004, J ALLERGY CLIN IMMUN, V114, P747, DOI 10.1016/j.jaci.2004.06.055; Sims MW, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-13; Sonoda J, 2005, NEUROIMMUNOMODULAT, V12, P375, DOI 10.1159/000091131; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Subramanian SV, 2007, INT J EPIDEMIOL, V36, P569, DOI 10.1093/ije/dym007; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; Vig RS, 2006, ANN NY ACAD SCI, V1088, P65, DOI 10.1196/annals.1366.023; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2007, CHEST, V132, p757S, DOI 10.1378/chest.07-1904; Wright RJ, 2006, CLIN CHEST MED, V27, P413, DOI 10.1016/j.ccm.2006.04.003; Yeh WY, 2009, SOC SCI MED, V68, P1407, DOI 10.1016/j.socscimed.2009.01.031; Zupkovitz G, 2006, MOL CELL BIOL, V26, P7913, DOI 10.1128/MCB.01220-06	116	98	106	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					550	558		10.1016/j.jaci.2009.11.005	http://dx.doi.org/10.1016/j.jaci.2009.11.005			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20153032	Green Accepted			2022-12-18	WOS:000275883200007
J	Foliaki, S; Pearce, N; Bjorksten, B; Mallol, J; Montefort, S; von Mutius, E				Foliaki, Sunia; Pearce, Neil; Bjorksten, Bengt; Mallol, Javier; Montefort, Stephen; von Mutius, Erika		Int Study Asthma Allergies Childho	Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis, and eczema in children 6 and 7 years old: International Study of Asthma and Allergies in Childhood Phase III	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antibiotics; ISAAC; asthma; rhinoconjunctivitis; eczema	EARLY-LIFE EXPOSURE; WORLDWIDE VARIATIONS; BIRTH COHORT; SUBSEQUENT DEVELOPMENT; ATOPIC SENSITIZATION; 1ST YEAR; PREVALENCE; INFECTIONS; ASSOCIATION; DISEASE	Background: Phase III of the International Study of Asthma and Allergies in Childhood measured the global prevalence of symptoms of asthma, rhinoconjunctivitis, and eczema in children. Objective: To investigate the associations between the use of antibiotics in the first year of life and symptoms of asthma, rhinoconjunctivitis, and eczema in children 6 and 7 years old. Methods: Parents or guardians of children 6 and 7 years old completed written questionnaires on current symptoms and possible risk factors. Prevalence odds ratios (ORs) were estimated by using logistic regression. Results: A total of 193,412 children from 71 centers in 29 countries participated. Reported use of antibiotics in the first year of life was associated with an increased risk of current asthma symptoms (wheezing in the previous 12 months) with an OR (adjusted for sex, region of the world, language, and per capita gross national income) of 1.96 (95% CI, 1.85-2.07); this fell to 1.70 (1.60-1.80) when adjusted for other risk factors for asthma. Similar associations were observed for severe asthma symptoms (OR, 1.82; 95% CI, 1.67-1.98), and asthma ever (OR, 1.94; 95% CI, 1.83-2.06). Use of antibiotics in the first year of life was also associated, but less strongly, with increased risks of current symptoms of rhinoconjunctivitis (OR, 1.56; 95% CI, 1.46-1.66) and eczema (OR, 1.58; 95% CI, 1.33-1.51). Conclusion: There is an association between antibiotic use in the first year of life and current symptoms of asthma, rhinoconjunctivitis, and eczema in children 6 and 7 years old. Further research is required to determine whether the observed associations are causal or are a result of confounding by indication or reverse causation. (J Allergy Clin Immunol 2009;124:982-9.)	[Foliaki, Sunia; Pearce, Neil] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; [Bjorksten, Bengt] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Mallol, Javier] Univ Santiago Chile, Dept Pediat & Resp Med, Santiago, Chile; [Montefort, Stephen] Univ Malta, Dept Med, Msida, Malta; [von Mutius, Erika] Univ Munich, Dr von Haunersches Univ Childrens Hosp, Munich, Germany	Massey University; Karolinska Institutet; Universidad de Santiago de Chile; University of Malta; University of Munich	Pearce, N (corresponding author), Massey Univ, Ctr Publ Hlth Res, Wellington Campus,Private Box 756, Wellington, New Zealand.	n.e.pearce@massey.ac.nz	Anderson, Hugh R/A-7417-2016; Steriu, Andreea/AAQ-5127-2021; Garcia-Almaraz, Roberto/G-8506-2018; Masjedi, Mohammad Reza/J-9776-2017; Ellwood, Philippa/G-7555-2015; Forastiere, Francesco/J-9067-2016	Steriu, Andreea/0000-0002-2998-8644; Garcia-Almaraz, Roberto/0000-0001-5828-1771; Masjedi, Mohammad Reza/0000-0002-6871-382X; Ellwood, Philippa/0000-0002-1994-4023; Forastiere, Francesco/0000-0002-9162-5684; von Mutius, Erika/0000-0002-8893-4515; Mallol, Javier/0000-0003-2528-8672; Garcia-Marcos, Luis/0000-0002-0925-3851; , Sunia/0000-0002-3238-5940; Pearce, Neil/0000-0002-9938-7852	New Zealand Health Research Council; Center for Public Health Research, Massey University; Airsonett	New Zealand Health Research Council(Health Research Council of New Zealand); Center for Public Health Research, Massey University; Airsonett	Disclosure of potential conflict of interest: S. Foliaki has received research support from the New Zealand Health Research Council and the Center for Public Health Research, Massey University. E. von Mutius has consulted for GlaxoSmithKline, UCB, and ProtectImmun and has received research support from Airsonett. The rest of the authors have declared that they have no conflict of interest.	Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Bjorksten B, 2006, CLIN EXP ALLERGY, V36, P1215, DOI 10.1111/j.1365-2222.2006.02579.x; BJORKSTEN B, 2006, ASTHMA PREVENTION; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Douwes J, 2008, INT J EPIDEMIOL, V37, P570, DOI 10.1093/ije/dyn077; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Ellwood P, 2005, INT J TUBERC LUNG D, V9, P10; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Kummeling I, 2008, CLIN EXP ALLERGY, V38, P1249, DOI 10.1111/j.1365-2222.2008.03047.x; Kummeling I, 2007, PEDIATRICS, V119, pE225, DOI 10.1542/peds.2006-0896; Kusel MMH, 2008, CLIN EXP ALLERGY, V38, P1921, DOI 10.1111/j.1365-2222.2008.03138.x; Lowe A, 2009, LANCET, V373, P120, DOI 10.1016/S0140-6736(09)60030-1; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; MARTINEZ SR, 1999, ITINERA GEOBOT, V12, P5; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Mendall MA, 1998, EUR J GASTROEN HEPAT, V10, P59, DOI 10.1097/00042737-199801000-00011; Pearce N, 2004, ENVIRON HEALTH PERSP, V112, P1047, DOI 10.1289/ehp.6927; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; Tantisira KG, 2001, RESP RES, V2, P324, DOI 10.1186/rr81; Voor T, 2005, CLIN EXP ALLERGY, V35, P153, DOI 10.1111/j.1365-2222.2005.02157.x; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Wickens K, 2008, CLIN EXP ALLERGY, V38, P1318, DOI 10.1111/j.1365-2222.2008.03024.x; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Wjst M, 2001, EUR J MED RES, V6, P263; Xu BZ, 1999, INT J EPIDEMIOL, V28, P723, DOI 10.1093/ije/28.4.723	36	98	107	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					982	989		10.1016/j.jaci.2009.08.017	http://dx.doi.org/10.1016/j.jaci.2009.08.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895986				2022-12-18	WOS:000272108000016
J	Marenholz, I; Kerscher, T; Bauerfeind, A; Esparza-Gordillo, J; Nickel, R; Keil, T; Lau, S; Rohde, K; Wahn, U; Lee, YA				Marenholz, Ingo; Kerscher, Tamara; Bauerfeind, Anja; Esparza-Gordillo, Jorge; Nickel, Renate; Keil, Thomas; Lau, Susanne; Rohde, Klaus; Wahn, Ulrich; Lee, Young-Ae			An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Genetic prediction; interaction; asthma; eczema; food sensitization; filaggrin; mutations; subphenotype; prevention; pulmonary function	1ST 6 YEARS; ATOPIC-DERMATITIS; NATURAL COURSE; DUST-MITE; RISK; ASSOCIATION; ALLERGENS; EXPOSURE; INFANCY; BIRTH	Background: Asthma prediction in early infancy is essential for the development of new preventive strategies. Loss-of-function mutations in the filaggrin gene (FLG) were identified as risk factors for eczema and associated asthma. Objective: We evaluated the utility of the FLG mutations for the prediction of asthma. Methods: Eight hundred seventy-one individuals of the prospective German Multicenter Allergy Study cohort were genotyped for 3 FLG mutations. Information on asthma, eczema, and food sensitization was available from birth to 13 years of age. Pulmonary function was measured from 7 to 13 years of age. The predictive value of the FLG mutations and of atopic phenotypes in infancy was assessed for asthma. Results: In infants with eczema and sensitization to food allergens, the FLG mutations predicted childhood asthma with a positive predictive value of 100% (95% CI, 65.5% to 100%). This subgroup was characterized by a significant decrease in pulmonary function until puberty and represented 8.1% of all asthmatic children and 19.1% of patients with asthma after infantile eczema. We found a strong synergistic interaction between the FLG-null alleles and early food sensitization in the disease transition from eczema to asthma (relative excess risk due to interaction, 2.64; 95% CI, 1.70-3.98; P = .00040). Conclusion: FLG mutations and food sensitization represent 2 distinct mechanisms interacting in the pathogenesis of asthma. In infants with eczema and food sensitization, genotyping of the FLG mutations allows the prediction of asthma before the onset of symptoms. Our findings might facilitate the development of early subgroup-specific interventions to prevent the progression from eczema to asthma. (J Allergy Clin Immunol 2009;123:911-6.)	[Keil, Thomas; Lee, Young-Ae] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Marenholz, Ingo; Kerscher, Tamara; Bauerfeind, Anja; Esparza-Gordillo, Jorge; Rohde, Klaus; Lee, Young-Ae] Max Delbruck Ctr Mol Med, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Lee, YA (corresponding author), Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany.	yolee@mdc-berlin.de			German Ministry for Education and Research through the Clinical Research Group for Allergy; German National Genome Research Network; European Union; Global Allergy and Asthma European Network	German Ministry for Education and Research through the Clinical Research Group for Allergy; German National Genome Research Network; European Union(European Commission); Global Allergy and Asthma European Network	Supported by grants from the German Ministry for Education and Research through the Clinical Research Group for Allergy and the German National Genome Research Network, the European Union through a Marie-Curie fellowship to J.E.-G., and the Global Allergy and Asthma European Network.	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Assmann SF, 1996, EPIDEMIOLOGY, V7, P286, DOI 10.1097/00001648-199605000-00012; Berg AO, 2005, ANN INTERN MED, V143, P355, DOI 10.7326/0003-4819-143-5-200509060-00011; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Bottema RWB, 2008, EUR RESPIR J, V32, P593, DOI 10.1183/09031936.00162407; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Danov Z, 2007, CURR OPIN ALLERGY CL, V7, P174, DOI 10.1097/ACI.0b013e32801d216a; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Grody WW, 2003, ANNU REV MED, V54, P473, DOI 10.1146/annurev.med.54.101601.152127; Guerra S, 2008, ANNU REV MED, V59, P327, DOI 10.1146/annurev.med.59.060406.213232; Halonen M, 2006, ALLERGY ASTHMA PROC, V27, P328, DOI 10.2500/aap.2006.27.2888; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kulig M, 1999, J PEDIATR-US, V134, P453, DOI 10.1016/S0022-3476(99)70203-9; Lal S, 2007, EUR J GASTROEN HEPAT, V19, P321, DOI 10.1097/MEG.0b013e328013e9a8; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P1624, DOI 10.1111/j.1365-2222.2007.02822.x; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Melen E, 2008, ENVIRON HEALTH PERSP, V116, P1077, DOI 10.1289/ehp.11117; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Nickel R, 2002, CLIN EXP ALLERGY, V32, P1274, DOI 10.1046/j.1365-2745.2002.01482.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943	37	98	101	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					911	916		10.1016/j.jaci.2009.01.051	http://dx.doi.org/10.1016/j.jaci.2009.01.051			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348926	Bronze			2022-12-18	WOS:000265058600020
J	Garcia-Laorden, MI; Sole-Violan, J; de Castro, FR; Aspa, J; Briones, ML; Garcia-Saavedra, A; Rajas, O; Blanquer, J; Caballero-Hidalgo, A; Marcos-Ramos, JA; Hernandez-Lopez, J; Rodriguez-Gallego, C				Garcia-Laorden, M. Isabel; Sole-Violan, Jordi; de Castro, Felipe Rodriguez; Aspa, Javier; Briones, M. Luisa; Garcia-Saavedra, Ayoze; Rajas, Olga; Blanquer, Jose; Caballero-Hidalgo, Araceli; Marcos-Ramos, J. Alberto; Hernandez-Lopez, Javier; Rodriguez-Gallego, Carlos			Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						community-acquired pneumonia; sepsis; mannose-binding lectin; mannose-binding lectin-associated serine protease 2; primary immunodeficiency	COMMUNITY-ACQUIRED PNEUMONIA; PHASE-I SAFETY; L-FICOLIN; CLASSICAL PATHWAY; MODULATING FACTOR; INNATE IMMUNITY; CANARY-ISLANDS; DEFICIENT MICE; POLYMORPHISMS; INFECTION	Background: Community-acquired pneumonia (CAP) is the leading cause of death from infection in developed countries. Mannose-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) deficiencies are common primary immunodeficiencies the clinical penetrance of which remains controversial. MBL is a serum lectin that mediates phagocytosis and activates the lectin pathway of complement involving MASP-2. Objective: We sought to evaluate the significance of MBL deficiency (O/O genotypes) and insufficiency (O/O plus XA/O genotypes), as well as MASP-2 deficiency (D105G mutation), in the susceptibility to and severity and outcome of CAP in adults. Methods: MBL and MASP-2 serum levels, as well as lectin pathway activity with regard to MBL2 and MASP2 genotypes, were measured in healthy control subjects. For susceptibility, 848 patients with CAP, 1447 healthy control subjects, and a control group of 519 patients without relevant infectious diseases were studied in a case-control study. Severity and outcome were evaluated in a prospective study of the 848 patients. Results: We found similar frequencies of MBL2 and MASP2 alleles and genotypes among patients and control subjects. However, in a multivariate analysis MBL insufficiency was associated with the development of the most severe forms of sepsis (P = .007), acute respiratory failure (P = .009), multiorgan dysfunction syndrome (P = .036), intensive care unit admission (P = .020), and death (P = .003). Conclusion: Our large study suggests that MBL plays a redundant role in human defenses against primary infection, at least in adults with CAP, and provides, for the first time, evidence that MBL insufficiency predisposes to higher severity and fatal outcome in patients with CAP, irrespective of the causal microorganisms.	[Garcia-Laorden, M. Isabel; Garcia-Saavedra, Ayoze; Hernandez-Lopez, Javier; Rodriguez-Gallego, Carlos] Hosp Univ Gran Canaria Dr Negrin, Serv Inmunol, Dept Immunol, Las Palmas Gran Canaria 35010, Spain; [Sole-Violan, Jordi; Marcos-Ramos, J. Alberto] Hosp Univ Gran Canaria Dr Negrin, Intens Care Unit, Las Palmas Gran Canaria 35010, Spain; [de Castro, Felipe Rodriguez] Hosp Univ Gran Canaria Dr Negrin, Resp Dis Serv, Las Palmas Gran Canaria 35010, Spain; [Caballero-Hidalgo, Araceli] Hosp Univ Gran Canaria Dr Negrin, Res Unit, Las Palmas Gran Canaria 35010, Spain; [Aspa, Javier; Rajas, Olga] Hosp Univ Princesa, Resp Dis Serv, Madrid, Spain; [Briones, M. Luisa] Hosp Clin & Univ Valencia, Intens Care Unit, Valencia, Spain	Hospital de La Princesa; Hospital Clinic Universitari de Valencia	Rodriguez-Gallego, C (corresponding author), Hosp Univ Gran Canaria Dr Negrin, Serv Inmunol, Dept Immunol, Barranco Balleria S-N, Las Palmas Gran Canaria 35010, Spain.	jrodgal@gobiernodecanarias.org	García-Laorden, M. Isabel/B-3649-2019; de Castro, Felipe Rodriguez/R-8416-2019; RODRIGUEZ-GALLEGO, CARLOS/AAB-7516-2022	Briones, Maria Luisa/0000-0002-2815-4234; Rodriguez-Gallego, Carlos/0000-0002-4344-8644; Rodriguez de Castro, Felipe/0000-0002-6812-2739; Marcos-Ramos, Jose Alberto/0000-0002-6478-5586				BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brouwer N, 2006, MOL IMMUNOL, V43, P2051, DOI 10.1016/j.molimm.2006.01.003; Brown JS, 2002, P NATL ACAD SCI USA, V99, P16969, DOI 10.1073/pnas.012669199; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Casanova JL, 2004, J EXP MED, V199, P1295, DOI 10.1084/jem.20040537; Dommett RM, 2006, TISSUE ANTIGENS, V68, P193, DOI 10.1111/j.1399-0039.2006.00649.x; Fidler KJ, 2004, INTENS CARE MED, V30, P1438, DOI 10.1007/s00134-004-2303-8; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fraser DA, 2006, J LEUKOCYTE BIOL, V80, P107, DOI 10.1189/jlb.1105683; Garcia-Laorden MI, 2006, J ALLERGY CLIN IMMUN, V118, P1383, DOI 10.1016/j.jaci.2006.08.004; Garcia-Laorden MI, 2001, GENES IMMUN, V2, P292, DOI 10.1038/sj.gene.6363778; Garcia-Laorden MI, 2003, J RHEUMATOL, V30, P740; Garred P, 2003, J INFECT DIS, V188, P1394, DOI 10.1086/379044; Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; Gomi K, 2004, CHEST, V126, P95, DOI 10.1378/chest.126.1.95; Gong MN, 2007, CRIT CARE MED, V35, P48, DOI 10.1097/01.CCM.0000251132.10689.F3; Gordon AC, 2006, SHOCK, V25, P88, DOI 10.1097/01.shk.0000186928.57109.8d; Hellemann D, 2007, HUM MOL GENET, V16, P3071, DOI 10.1093/hmg/ddm265; Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943; Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x; Jonsson G, 2006, J IMMUNOL, V177, P722, DOI 10.4049/jimmunol.177.1.722; Krarup A, 2005, INFECT IMMUN, V73, P1052, DOI 10.1128/IAI.73.2.1052-1060.2005; Kronborg G, 2002, J INFECT DIS, V185, P1517, DOI 10.1086/340216; Kuraya M, 2005, IMMUNOBIOLOGY, V209, P689, DOI 10.1016/j.imbio.2004.11.001; Liu Y, 2005, J IMMUNOL, V175, P3150, DOI 10.4049/jimmunol.175.5.3150; Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Moens L, 2006, HUM IMMUNOL, V67, P605, DOI 10.1016/j.humimm.2006.04.014; Moller-Kristensen M, 2006, J IMMUNOL, V176, P1769, DOI 10.4049/jimmunol.176.3.1769; Nadesalingam J, 2005, J IMMUNOL, V175, P1785, DOI 10.4049/jimmunol.175.3.1785; Nau R, 2002, CLIN MICROBIOL REV, V15, P95, DOI 10.1128/CMR.15.1.95-110.2002; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Perez-Castellano M, 2006, CLIN EXP IMMUNOL, V145, P228, DOI 10.1111/j.1365-2249.2006.03140.x; Petersen KA, 2006, J CLIN IMMUNOL, V26, P465, DOI 10.1007/s10875-006-9037-z; Roos A, 2004, EUR J IMMUNOL, V34, P2589, DOI 10.1002/eji.200324401; Roy S, 2002, LANCET, V359, P1569, DOI 10.1016/S0140-6736(02)08516-1; Seyfarth J, 2005, HUM MOL GENET, V14, P2859, DOI 10.1093/hmg/ddi318; Shi L, 2004, J EXP MED, V199, P1379, DOI 10.1084/jem.20032207; Stengaard-Pedersen K, 2003, NEW ENGL J MED, V349, P554, DOI 10.1056/NEJMoa022836; Stuart LM, 2005, J IMMUNOL, V174, P3220, DOI 10.4049/jimmunol.174.6.3220; Sutherland AM, 2005, CRIT CARE MED, V33, P638, DOI [10.1097/01.CCM.0000156242.44356.C5, 10.1097/01.ccm.0000156242.44356.c5]; Valdimarsson H, 2004, SCAND J IMMUNOL, V59, P97, DOI 10.1111/j.0300-9475.2004.01357.x; Verdu P, 2006, HUM MOL GENET, V15, P2650, DOI 10.1093/hmg/ddl193; Vincent JL, 2004, CRIT CARE MED, V32, pS209, DOI 10.1097/01.CCM.0000126124.41743.86	46	98	102	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					368	374		10.1016/j.jaci.2008.05.037	http://dx.doi.org/10.1016/j.jaci.2008.05.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18582923	Bronze			2022-12-18	WOS:000258426300025
J	Klunker, S; Saggar, LR; Seyfert-Margolis, V; Asare, AL; Casale, TB; Durham, SR; Francis, JN				Klunker, Sven; Saggar, Lavina R.; Seyfert-Margolis, Vicki; Asare, Adam L.; Casale, Thomas B.; Durham, Stephen R.; Francis, James N.		Immune Tolerance Network Grp	Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; immunotherapy; omalizumab; anti-IgE; IgEfacilitated allergen binding; ragweed	GRASS-POLLEN IMMUNOTHERAPY; T-CELLS; MONOCLONAL-ANTIBODY; ATOPIC PATIENTS; BEE VENOM; RESPONSES; SERUM; BASOPHILS; ASTHMA; VACCINATION	Background: The combination of anti-IgE (omalizumab) therapy with ragweed injection immunotherapy for seasonal allergic rhinitis results in a significant reduction in systemic side effects and enhanced efficacy compared with immunotherapy alone. One proposed mechanism of immunotherapy is to induce regulatory antibodies that inhibit facilitated antigen presentation. Objectives: We sought to determine whether the combination protocol has a cumulative effect on inhibition of facilitated antigen presentation both during and after discontinuation of treatment. Methods: Ragweed allergen immunotherapy with and without omalizumab therapy was tested in a 4-arm, double-blind, placebo-controlled study. Flow cytometry was used to detect serum inhibitory activity for IgE-facilitated CD23-dependent allergen binding to B cells as a surrogate marker for facilitated antigen presentation. Serum ragweed-specific IgG4 was measured by means of ELISA. Results: Immunotherapy alone resulted in partial inhibition of allergen-IgE binding after 5 to 19 weeks of treatment compared with baseline (P <.01). Complete inhibition of allergen-specific IgE binding was observed in both treatment groups receiving omalizumab (P <.001). Allergen-specific IgG4 levels were only increased after immunotherapy (P <.05), both in the presence and absence of anti-IgE treatment. Combined treatment resulted in the induction of long-lasting inhibitory antibody function for up to 42 weeks compared with either treatment alone. Conclusion: Ragweed immunotherapy induced serum regulatory antibodies that partially blocked binding of allergen-IgE complexes to B cells. Additional treatment with anti-IgE, by directly blocking IgE binding to CD23, completely inhibited allergen-IgE binding. Clinical implications: The combination of ragweed immunotherapy and anti-IgE resulted in prolonged inhibition of allergen-IgE binding compared with either treatment alone, events that might contribute to enhanced efficacy.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London SW3 6LY, England; Immune Tolerance Network, San Francisco, CA USA; Creighton Univ, Sch Med, Omaha, NE 68178 USA	Imperial College London; Immune Tolerance Network; Creighton University	Francis, JN (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, Dovehouse St, London SW3 6LY, England.	james.francis@imperial.ac.uk	Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377; Asare, Adam/0000-0002-9299-3518	MRC [G0200485, G0601303] Funding Source: UKRI; Medical Research Council [G0200485, G0601303] Funding Source: Medline; Medical Research Council [G0400503B] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Bodtger U, 2005, INT ARCH ALLERGY IMM, V136, P340, DOI 10.1159/000084227; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; DEMEULEMESTER C, 1986, IMMUNOLOGY, V57, P617; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; *GEN INC, 2006, XOL OM SUBC US; Hamelmann E, 2003, CURR OPIN ALLERGY CL, V3, P501, DOI 10.1097/01.all.0000104455.09202.52; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; KIMURA I, 1985, CLIN ALLERGY, V15, P1, DOI 10.1111/j.1365-2222.1985.tb02248.x; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Marshall JD, 2003, NUCLEIC ACIDS RES, V31, P5122, DOI 10.1093/nar/gkg700; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; van Neerven RJJ, 2004, CLIN EXP ALLERGY, V34, P420, DOI 10.1111/j.1365-2222.2004.01899.x; van Neerven RJJ, 2001, INT ARCH ALLERGY IMM, V124, P400, DOI 10.1159/000053770; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERHEIJDEN FL, 1995, CLIN EXP IMMUNOL, V99, P289; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x	38	98	102	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					688	695		10.1016/j.jaci.2007.05.034	http://dx.doi.org/10.1016/j.jaci.2007.05.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17631952				2022-12-18	WOS:000249505400031
J	Almqvist, C; Garden, F; Xuan, W; Mihrshahi, S; Leeder, SR; Oddy, W; Webb, K; Marks, GB				Almqvist, Catarina; Garden, Frances; Xuan, Wei; Mihrshahi, Seema; Leeder, Steve R.; Oddy, Wendy; Webb, Karen; Marks, Guy B.		CAPS Team	Omega-3 and omega-6 fatty acid exposure from early life does not affect atopy and asthma at age 5 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy and immunology; birth cohort; child; eczema; omega-3 fatty acids; omega-6 fatty acids; primary prevention	CHILDHOOD ASTHMA; DIETARY; PREVENTION; CHILDREN; RISK; FISH	Background: The Childhood Asthma Prevention Study was a randomized controlled trial conducted in children with a family history of asthma in whom omega-3 fatty acid supplementation and restriction of dietary omega-6 fatty acids did not prevent asthma, eczema, or atopy at age 5 years. Objective: We sought to examine the relation of all measures of omega-3 and omega-6 polyunsaturated fatty acids with outcomes at age 5 years in the whole birth cohort, regardless of randomization group. Methods: Plasma fatty acids were measured at 18 months, 3 years, and 5 years. Compliance with the fatty acid supplements was estimated every 6 months. Dietary intake was assessed at 18 months by means of weighed-food record and at 3 years by means of food-frequency questionnaire. At age 5 years, 516 children were examined for wheeze and eczema (questionnaire) and atopy (skin prick tests, n = 488). Multiple logistic regression was used to evaluate associations between exposures and outcomes. Results: Plasma levels of omega-3 or omega-6 fatty acids were not associated with wheeze, eczema, or atopy at age 5 years (P = .11-.96). Overall, fatty acid exposure, measured as plasma levels, dietary intake, and compliance with supplements, was not associated with any respiratory or allergic outcomes (P =.35-.59). Conclusion: This observational analysis of the cohort, using the full range of observed variation in omega-3 and omega-6 fatty acid exposure, supports the negative findings of the randomized controlled trial. Clinical implications: Modification of dietary polyunsaturated fatty acids in early childhood is not helpful in preventing atopy and asthma.	Woolcock Inst Med Res, Sydney, NSW, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; Karolinska Inst, Astrid Lindgren Childrens Hosp, Dept Woman & Child Hlth, Stockholm, Sweden; New S Wales Dept Hlth, Sydney, NSW, Australia; Childrens Hosp Westmead, Sydney, NSW, Australia; Curtin Univ Technol, Telethon Inst Child Hlth Res, Perth, WA 6001, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Sydney; Karolinska Institutet; University of Sydney; Curtin University; Telethon Kids Institute; University of Western Australia	Almqvist, C (corresponding author), Woolcock Inst Med Res, PO Box M77,Missenden Rd, Camperdown, NSW 2050, Australia.	calmqvist@woolcock.org.au	Mihrshahi, Seema/AAW-1854-2020; Mihrshahi, Seema/A-9877-2009; Marks, Guy B./F-5058-2013	Mihrshahi, Seema/0000-0002-2394-5432; Mihrshahi, Seema/0000-0001-6567-9884; Marks, Guy B./0000-0002-8976-8053				Bolte G, 2006, CLIN EXP ALLERGY, V36, P293, DOI 10.1111/j.1365-2222.2006.02441.x; Broadfield EC, 2004, CLIN EXP ALLERGY, V34, P1232, DOI 10.1111/j.1365-2222.2004.02032.x; Department of Health and Aging National Health and Medical Research Council, 2006, NUTR REF VAL AUSTR N, VN35; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Hodge L, 1996, MED J AUSTRALIA, V164, P137, DOI 10.5694/j.1326-5377.1996.tb122010.x; Hodge L, 1998, EUR RESPIR J, V11, P361, DOI 10.1183/09031936.98.11020361; KIRSCH CM, 1988, CLIN ALLERGY, V18, P177, DOI 10.1111/j.1365-2222.1988.tb02857.x; Mann N. J., 2003, Nutrition & Dietetics, V60, P42; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; Nagakura T, 2000, EUR RESPIR J, V16, P861, DOI 10.1183/09031936.00.16586100; PARM J, 1988, THORAX, V43, P84, DOI 10.1136/thx.43.2.84; PEAT JK, 1992, EUR RESPIR J, V5, P921; Trak-Fellermeier MA, 2004, EUR RESPIR J, V23, P575, DOI 10.1183/09031936.04.00074404; WEBB K, 2005, NUTR DIET, V62, P189; Woods RK, 2004, THORAX, V59, P105, DOI 10.1136/thorax.2003.009498; WOODS RK, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858	17	98	100	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1438	1444		10.1016/j.jaci.2007.01.046	http://dx.doi.org/10.1016/j.jaci.2007.01.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17379291	Bronze			2022-12-18	WOS:000247232800020
J	Graudenz, GS; Landgraf, RG; Jancar, S; Tribess, A; Fonseca, SG; Fae, KC; Kalil, J				Graudenz, Gustavo Silveira; Landgraf, Richardt G.; Jancar, Sonia; Tribess, Arlindo; Fonseca, Simone G.; Fae, Kellen Cristhina; Kalil, Jorge			The role of allergic rhinitis in nasal responses to sudden temperature changes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						indoor air quality; environmental illness; air conditioning; inflammatory mediators	SICK BUILDING SYNDROME; OFFICE BUILDINGS; RESPIRATORY SYMPTOMS; RISK-FACTORS; EOSINOPHIL; INVOLVEMENT; CHALLENGE; SYSTEMS; WORKERS	Background: Air conditioning-induced rhinitis in allergic individuals is a common epidemiologic finding, but its physiopathology,is still controversial. The aim of this study was to describe and compare the effects of experimental air conditioning temperature changes on the nasal mucosa of individuals with persistent allergic rhinitis compared with a control group. Methods: A case-control challenge study was performed in a laboratory of thermal comfort with experimental twin challenge chambers set at a 12 C difference in temperature. A group of 32 patients with persistent allergic rhinitis and a group of 16 control subjects were exposed for 30 minutes, 3 times alternately in each chamber. Nasal symptom scores were recorded and nasal samples collected before, immediately after, and 24 and 48 hours after the challenge. Results: The rhinitis group showed a higher symptom score, epithelial shedding, percentage of eosinophils, total inflammatory cells, leukotriene C-4, eosinophil cationic protein, albumin, and tryptase levels compared with controls. There was also a significant increase in symptom score, total cells recovered, percentage of eosinophils, epithelial shedding, albumin, myeloperoxidase, and soluble intercellular adhesion molecule 1 in both groups compared with baseline levels. Conclusion: Sudden temperature changes led to a more pronounced inflammatory nasal response in the rhinitis group with the recruitment and activation of eosinophils. Clinical implications: Persistent allergic rhinitis is a risk factor for developing sudden temperature change-related rhinitis even in the absence of allergen exposure.	State Univ Sao Paulo, Div Immunol & Clin Allergy, Dept Internal Med, Sao Paulo, Brazil; State Univ Sao Paulo, Dept Mech Engn, Polytech Inst, Sao Paulo, Brazil; Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, Sao Paulo, Brazil; Millennium Inst, Inst Immunol Invest, Sao Paulo, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade de Sao Paulo	Graudenz, GS (corresponding author), Av Dr Eneas Carvalho Aguiar 44-9 Andar Bloco 2, BR-05403002 Sao Paulo, Brazil.	gustavog@usp.br	KALIL, JORGE/C-8029-2012; FONSECA, SIMONE GONÇALVES/U-9278-2019; Jancar, Sonia/C-5153-2012; Landgraf, Richardt/F-7146-2012; Tribess, Arlindo/K-6329-2013	KALIL, JORGE/0000-0001-8415-4274; Jancar, Sonia/0000-0001-7983-3459; Landgraf, Richardt/0000-0001-7774-7880; Tribess, Arlindo/0000-0001-9908-9233				American Society of Heating Refrigerating and Air-Conditioning Engineers, 2001, ASHRAE 64; Bardana EJ, 1997, ANN ALLERG ASTHMA IM, V79, P283, DOI 10.1016/S1081-1206(10)63017-7; Bonini S, 2001, ANN ALLERG ASTHMA IM, V87, P48, DOI 10.1016/S1081-1206(10)62341-1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BROOKS SM, 1994, J ALLERGY CLIN IMMUN, V94, P344, DOI 10.1053/ai.1994.v94.a56013; CHURCH MK, 2003, MIDDLETONS ALLERGY P, P190; Galvão Clóvis Eduardo Santos, 2004, Sao Paulo Med. J., V122, P204, DOI 10.1590/S1516-31802004000500005; Gentile DA, 2003, ANN ALLERG ASTHMA IM, V91, P270, DOI 10.1016/S1081-1206(10)63529-6; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Gilain L, 2000, Ann Otolaryngol Chir Cervicofac, V117, P91; Graudenz GS, 2005, INDOOR AIR, V15, P62, DOI 10.1111/j.1600-0668.2004.00324.x; Graudenz GS, 2002, CHEST, V122, P729, DOI 10.1378/chest.122.2.729; Haxel BR, 2004, AM J RHINOL, V18, P93, DOI 10.1177/194589240401800205; Howarth Peter H, 2005, J Allergy Clin Immunol, V115, pS387, DOI 10.1016/j.jaci.2004.12.017; Howarth Peter H, 2005, J Allergy Clin Immunol, V115, pS414, DOI 10.1016/j.jaci.2004.12.1134; Kuwahara Y, 2001, ALLERGY, V56, P224, DOI 10.1034/j.1398-9995.2001.056003224.x; LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P327, DOI 10.1053/ai.1994.v94.a56012; LIGHT IM, 1980, AVIAT SPACE ENVIR MD, V51, P1100; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P900, DOI 10.1016/0091-6749(88)90032-2; Mendell MJ, 1996, EPIDEMIOLOGY, V7, P583, DOI 10.1097/00001648-199611000-00004; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; Mendell MJ, 2003, AM J IND MED, V43, P630, DOI 10.1002/ajim.10211; Menzies D, 1996, AM J PUBLIC HEALTH, V86, P1629, DOI 10.2105/AJPH.86.11.1629; Menzies D, 1997, NEW ENGL J MED, V337, P1524, DOI 10.1056/NEJM199711203372107; Menzies D, 1999, OCCUP ENVIRON MED, V56, P397, DOI 10.1136/oem.56.6.397; MIDDLETON J, 2003, MIDDLETONS ALLERGY P, P1391; MION O, 1998, P ISIAN C IT; Ooi PL, 1997, INT J EPIDEMIOL, V26, P1243, DOI 10.1093/ije/26.6.1243; Robertson A, 1986, Occup Health (Lond), V38, P78; Sanico AM, 1998, CLIN EXP ALLERGY, V28, P92; Schneider T, 1999, SCAND J WORK ENV HEA, V25, P574, DOI 10.5271/sjweh.483; Terada N, 2001, AM J RESP CRIT CARE, V164, P575, DOI 10.1164/ajrccm.164.4.2009046; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; Watanabe K, 1998, ANN OTO RHINOL LARYN, V107, P564, DOI 10.1177/000348949810700704; Webster R O, 1978, Inflammation, V3, P129, DOI 10.1007/BF00910734	35	98	102	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1126	1132		10.1016/j.jaci.2006.07.005	http://dx.doi.org/10.1016/j.jaci.2006.07.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088139				2022-12-18	WOS:000244282300019
J	Lee, KS; Kim, SR; Park, SJ; Park, HS; Min, KH; Jin, SM; Lee, MK; Kim, UH; Lee, YC				Lee, Kyung Sun; Kim, So Ri; Park, Seoung Ju; Park, Hee Sun; Min, Kyung Hoon; Jin, Sun Mi; Lee, Moon Kyu; Kim, Uh Hyun; Lee, Yong Chul			Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappa B and hypoxia-inducible factor 1 alpha in allergic airway disease of mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; HIF-1 alpha; NF-kappa B; oxidative stress; peroxisome proliferator activated receptor gamma	ENDOTHELIAL GROWTH-FACTOR; PPAR-GAMMA; SIGNAL-TRANSDUCTION; ASTHMA; INFLAMMATION; ALPHA; EXPRESSION; AGONISTS; CELLS; HYPERRESPONSIVENESS	Background: Reactive oxygen species (ROSs) play a crucial role in the pathogenesis of airway inflammation. Peroxisome proliferator activated receptor (PPAR)-gamma is also involved in airway inflammation. We have demonstrated that the administration of PPAR gamma agonists or adenovirus carrying PPAR gamma cDNA (AdPPAR gamma) reduced bronchial inflammation and airway hyperresponsiveness. However, the effects of PPAR gamma on ROS generation in conditions associated with airway inflammation have not been clarified. Objective: This study aimed to investigate the effects of the PPAR gamma on ROS generation in allergic airway disease of mice. Methods: We have used a female C57BL/6 mouse model for allergic airway disease to determine the role of PPAR gamma. Results: In this study with an ovalbumin-induced murine model of allergic airway disease, the increased ROS generation and the increased expression of T(H)2 cell cytokines, adhesion molecules, chemokines, and vascular endothelial growth factor in lungs after ovalbumin inhalation were significantly reduced by the administration of PPAR gamma agonists or AdPPAR gamma. We also showed that the increased nuclear factor-kappa B and hypoxia-inducible factor let levels in nuclear protein extracts of lung tissues after ovalbumin inhalation were decreased by the administration of PPAR gamma agonists or AdPPAR gamma. Conclusion: These results indicate that the effects of PPAR gamma ire mediated by the modulation of ROS generation and activation of redox-sensitive transcription factor nuclear factor-kappa B and HIF-1 alpha in allergic airway disease of mice. Clinical implications: Thus, these findings provide a pivotal molecular mechanism for the use of PPAR gamma agonists to prevent and/or treat asthma and other airway inflammatory disorders.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju 561180, South Korea; Chonbuk Natl Univ, Sch Med, Airway Remodeling Lab, Jeonju 561180, South Korea; Chonbuk Natl Univ, Sch Med, Res Ctr Allerg Immune Dis, Jeonju 561180, South Korea; Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561180, South Korea; Chonbuk Natl Univ, Sch Med, Cardiovasc Res Inst, Jeonju 561180, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Endocrinol & Metab, Seoul, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Sungkyunkwan University (SKKU); Samsung Medical Center	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, San 2-20,Geumam Dong, Jeonju 561180, South Korea.	leeyc@chonbuk.ac.kr	Kim, So Ri/AAS-1630-2021; Park, Seoungju/D-4444-2014	Kim, So Ri/0000-0002-6074-9158; 				Adam L, 1999, J BIOL CHEM, V274, P26337, DOI 10.1074/jbc.274.37.26337; Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen K, 2004, HYPERTENSION, V44, P655, DOI 10.1161/01.HYP.0000144400.49062.6b; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Cho YS, 2004, J ALLERGY CLIN IMMUN, V114, P429, DOI 10.1016/j.jaci.2004.04.004; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Collino M, 2006, EUR J PHARMACOL, V530, P70, DOI 10.1016/j.ejphar.2005.11.049; Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Gelman L, 1999, CELL MOL LIFE SCI, V55, P932, DOI 10.1007/s000180050345; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Harper R, 2001, AM J RESP CELL MOL, V25, P178, DOI 10.1165/ajrcmb.25.2.4471; HULSMANN AR, 1994, AM J RESP CRIT CARE, V149, P519, DOI 10.1164/ajrccm.149.2.8306055; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; KOHEI H, 2004, J ALLERGY CLIN IMMUN, V112, P882; Konturek PC, 2003, SCAND J GASTROENTERO, V38, P468, DOI 10.1080/00365520310002904; Kota BP, 2005, PHARMACOL RES, V51, P85, DOI 10.1016/j.phrs.2004.07.012; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee KS, 2005, FASEB J, V19, P1033, DOI 10.1096/fj.04-3309fje; Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039; Lee M, 2002, BIOCHEM J, V366, P937, DOI 10.1042/BJ20020453; Lee YC, 2004, FASEB J, V18, P1917, DOI 10.1096/fj.04-2212fje; Lee YC, 2001, J ALLERGY CLIN IMMUN, V107, P1106, DOI 10.1067/mai.2001.115628; Mehta JL, 2003, ARTERIOSCL THROM VAS, V23, P2203, DOI 10.1161/01.ATV.0000094411.98127.5F; Mori A, 1999, J ALLERGY CLIN IMMUN, V103, pS429, DOI 10.1016/S0091-6749(99)70158-2; Nishida S, 2002, FREE RADICAL RES, V36, P601, DOI 10.1080/10715760210872; OWEN S, 1991, NEW ENGL J MED, V325, P586; Rahman I, 1997, THORAX, V52, P565, DOI 10.1136/thx.52.6.565; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Semenza CL, 2001, PEDIATR RES, V49, P614, DOI 10.1203/00006450-200105000-00002; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Sivarajah A, 2003, AM J NEPHROL, V23, P267, DOI 10.1159/000072088; Stutz AM, 1999, J IMMUNOL, V163, P4383; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Trifilieff A, 2003, BRIT J PHARMACOL, V139, P163, DOI 10.1038/sj.bjp.0705232; Verhasselt V, 1999, J IMMUNOL, V162, P2569; Villegas I, 2004, EUR J PHARMACOL, V505, P195, DOI 10.1016/j.ejphar.2004.10.020; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Zhang MJ, 2002, FREE RADICAL BIO MED, V32, P454, DOI 10.1016/S0891-5849(01)00825-5	54	98	101	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					120	127		10.1016/j.jaci.2006.03.021	http://dx.doi.org/10.1016/j.jaci.2006.03.021			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815147				2022-12-18	WOS:000239184800015
J	Conus, S; Bruno, A; Simon, HU				Conus, S; Bruno, A; Simon, HU			Leptin is an eosinophil survival factor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; eosinophils; inflammation; leptin; signal transduction	COLONY-STIMULATING FACTOR; CYTOCHROME-C RELEASE; IMMUNE-RESPONSE; IN-VITRO; APOPTOSIS; ACTIVATION; PROTEIN; INFLAMMATION; NEUTROPHIL; EXPRESSION	Background: Leptin regulates food intake, as well as metabolic, endocrine, and immune functions. It exerts proliferative and antiapoptotic activities in a variety of cell types, including T cells. Leptin also stimulates macrophages and neutrophils, and its production is increased during inflammation. Objective: We sought to examine the expression of leptin receptors on eosinophils and the effect of recombinant leptin on proapoptotic pathways in these cells. Methods: The presence of leptin receptor was examined by means of RT-PCR and immunofluorescence analysis in freshly isolated blood eosinophils and tissue eosinophils. The effect of recombinant leptin on apoptotic pathways in eosinophils was studied by using flow cytometric, immunoblotting, and immunofluorescence techniques. Results: Human eosinophils express leptin surface receptors under in vitro and in vivo conditions, and leptin delays apoptosis of mature eosinophils in vitro. The antiapoptotic effects of leptin were concentration dependent and blocked by an anti-leptin receptor mAb. The efficacy of leptin to block eosinophil apoptosis was similar to that of GM-CSF. Leptin delayed the cleavage of Bax, as well as the mitochondrial release of cytochrome c and second mitochondria-derived activator of caspase, suggesting that it blocks proapoptotic pathways proximal to mitochondria in eosinophils. Using pharmacological inhibitors, we obtained evidence that leptin initiates a signaling cascade involving phosphatidylinositol-3-OH kinase and mitogen-activated protein kinase-dependent pathways in eosinophils. Conclusion: Leptin is a survival cytokine for human eosinophils, a finding with potential pathologic relevance in allergic and parasitic diseases.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Bruno, Andreina/AAX-8151-2020; Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				Adachi T, 2000, J IMMUNOL, V165, P2198, DOI 10.4049/jimmunol.165.4.2198; Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Altznauer F, 2003, J ALLERGY CLIN IMMUN, V112, P1185, DOI 10.1016/j.jaci.2003.09.045; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Baumann R, 2004, EUR J IMMUNOL, V34, P2268, DOI 10.1002/eji.200424863; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Cohen SL, 1996, NATURE, V382, P589, DOI 10.1038/382589a0; Daschner M, 1998, J AM SOC NEPHROL, V9, P1074; Dewson G, 2001, BLOOD, V98, P2239, DOI 10.1182/blood.V98.7.2239; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Faggioni R, 2001, FASEB J, V15, P2565, DOI 10.1096/fj.01-0431rev; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; Fujioka K, 1999, JAMA-J AM MED ASSOC, V282, P1517, DOI 10.1001/jama.282.16.1517; Fujita Y, 2002, CLIN EXP IMMUNOL, V128, P21, DOI 10.1046/j.1365-2249.2002.01797.x; Gao G, 2000, J CELL BIOCHEM, V80, P53; Goren I, 2003, DIABETES, V52, P2821, DOI 10.2337/diabetes.52.11.2821; Guler N, 2004, J ALLERGY CLIN IMMUN, V114, P254, DOI 10.1016/j.jaci.2004.03.053; Heinisch IVWM, 2001, J ALLERGY CLIN IMMUN, V108, P21, DOI 10.1067/mai.2001.116864; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; Kim GS, 2003, J BIOL CHEM, V278, P21920, DOI 10.1074/jbc.M204598200; Kimata H, 2002, ALLERGY, V57, P179, DOI 10.1034/j.1398-9995.2002.1n3549.x; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Machida K, 2005, AM J PHYSIOL-LUNG C, V288, pL860, DOI 10.1152/ajplung.00131.2004; Najib S, 2002, CELL IMMUNOL, V220, P143, DOI 10.1016/S0008-8749(03)00027-3; Ogawa K, 2003, CLIN EXP IMMUNOL, V131, P436, DOI 10.1046/j.1365-2249.2003.02090.x; Pinho V, 2005, J LEUKOCYTE BIOL, V77, P800, DOI 10.1189/jlb.0704386; Plotz SG, 1998, J ALLERGY CLIN IMMUN, V102, P1037, DOI 10.1016/S0091-6749(98)70344-6; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Russo VC, 2004, ENDOCRINOLOGY, V145, P4103, DOI 10.1210/en.2003-1767; Simon HU, 2000, J IMMUNOL, V165, P4069, DOI 10.4049/jimmunol.165.7.4069; Simon HU, 2000, ALLERGY, V55, P910, DOI 10.1034/j.1398-9995.2000.055010910.x; Simon HU, 2001, IMMUNOL REV, V179, P156, DOI 10.1034/j.1600-065X.2001.790115.x; Simon HU, 1997, J IMMUNOL, V158, P3902; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536, DOI 10.1016/S0091-6749(97)70147-7; Zarkesh-Esfahani H, 2004, J IMMUNOL, V172, P1809, DOI 10.4049/jimmunol.172.3.1809	43	98	107	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1228	1234		10.1016/j.jaci.2005.09.003	http://dx.doi.org/10.1016/j.jaci.2005.09.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337450				2022-12-18	WOS:000235687000009
J	Hunger, RE; Hunziker, T; Buettiker, U; Braathen, LR; Yawalkar, N				Hunger, RE; Hunziker, T; Buettiker, U; Braathen, LR; Yawalkar, N			Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NECROSIS-FACTOR-ALPHA; INTRAVENOUS IMMUNOGLOBULIN; INFLIXIMAB		Univ Bern, Dept Dermatol, Inselspital, CH-3010 Bern, Switzerland	University of Bern	Hunger, RE (corresponding author), Univ Bern, Dept Dermatol, Inselspital, CH-3010 Bern, Switzerland.							Fischer M, 2002, BRIT J DERMATOL, V146, P707, DOI 10.1046/j.1365-2133.2002.46833.x; Lebwohl M, 2003, LANCET, V361, P1197, DOI 10.1016/S0140-6736(03)12954-6; Nassif A, 2004, J INVEST DERMATOL, V123, P850, DOI 10.1111/j.0022-202X.2004.23439.x; PAQUET P, 1994, ARCH DERMATOL, V130, P605, DOI 10.1001/archderm.130.5.605; Prins C, 2003, DERMATOLOGY, V207, P96, DOI 10.1159/000070957; Van Den Brande JMH, 2003, GASTROENTEROLOGY, V124, P1774, DOI 10.1016/S0016-5085(03)00382-2; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Wolff K, 2003, ARCH DERMATOL, V139, P85, DOI 10.1001/archderm.139.1.85	8	98	104	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					923	924		10.1016/j.jaci.2005.06.029	http://dx.doi.org/10.1016/j.jaci.2005.06.029			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210071				2022-12-18	WOS:000235686600031
J	Matsui, EC; Simons, E; Rand, C; Butz, A; Buckley, TJ; Breysse, P; Eggleston, PA				Matsui, EC; Simons, E; Rand, C; Butz, A; Buckley, TJ; Breysse, P; Eggleston, PA			Airborne mouse allergen in the homes of inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mouse allergen; inner-city asthma; particulate matter; Mus m 1	SKIN-TEST SENSITIVITY; EXPOSURE; SENSITIZATION; PREVALENCE; CATS	Background: Airborne mouse allergen has not previously been measured in inner-city homes, and its relationship to settled dust mouse allergen levels is unknown. Objective: To quantify airborne and settled dust Mus m 1 levels in homes of inner-city patients with asthma and to identify risk factors for mouse allergen exposure. Methods: One hundred inner-city school-age children with asthma in Baltimore underwent skin testing to a panel of aeroallergens, and their homes were inspected by a trained technician. Air and settled dust were sampled in the child's bedroom. Mus m 1, particulate matter smaller than 10 microns (PM10), and particulate matter smaller than 2.5 microns were quantified in air samples, and Mus m 1 was quantified in settled dust samples. Results: Mus m 1 was detected in settled dust samples from 100% of bedrooms. Airborne mouse allergen was detected in 48 of 57 (84%) bedrooms, and the median airborne mouse allergen concentration was 0.03 ng/m(3). The median PM10 concentration was 48 mug/m(3). Airborne and settled dust mouse allergen levels were moderately correlated (r = .52; P < .0001), and airborne Mus m 1 and PM10 levels were weakly correlated (r =.29; P = .03). Having cracks or holes in doors or walls, evidence of food remains in the kitchen, and mouse infestation were all independently associated with having detectable airborne mouse allergen. Conclusion: Airborne mouse allergen concentrations in many inner-city homes may be similar to those found in animal facilities, where levels are sufficiently high to elicit symptoms in sensitized individuals. Exposed food remains, cracks and holes in doors or walls, and evidence of mouse infestation appear to be risk factors for having detectable airborne Mus m 1.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Matsui, EC (corresponding author), Johns Hopkins Univ Hosp, Dept Pediat, 600 N Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	ematsui@jhmi.edu	Buckley, Timothy/AAS-7516-2021	Matsui, Elizabeth/0000-0001-8134-5593	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL058942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL058942] Funding Source: Medline; NIEHS NIH HHS [ES09606] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Korpi A, 2004, J ALLERGY CLIN IMMUN, V113, P677, DOI 10.1016/j.jaci.2003.11.039; Lewis RD, 1998, AM IND HYG ASSOC J, V59, P606, DOI 10.1080/15428119891010776; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Matsui EC, 2004, ANN ALLERG ASTHMA IM, V93, P171, DOI 10.1016/S1081-1206(10)61471-8; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Mitchell H, 1997, PEDIATR PULM, V24, P237; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; Swartz LJ, 2004, ENVIRON RES, V95, P156, DOI 10.1016/j.envres.2003.08.003; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60, DOI 10.1016/S1081-1206(10)62324-1	16	98	98	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					358	363		10.1016/j.jaci.2004.11.007	http://dx.doi.org/10.1016/j.jaci.2004.11.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696095				2022-12-18	WOS:000227043600024
J	Basehore, MJ; Howard, TD; Lange, LA; Moore, WC; Hawkins, GA; Marshik, PL; Harkins, MS; Meyers, DA; Bleecker, ER				Basehore, MJ; Howard, TD; Lange, LA; Moore, WC; Hawkins, GA; Marshik, PL; Harkins, MS; Meyers, DA; Bleecker, ER			A comprehensive evaluation of IL4 variants in ethnically diverse populations: Association of total serum IgE levels and asthma in white subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IgE; IL4; single nucleotide polymorphism; haplotypes; association	INTERLEUKIN-4 PROMOTER POLYMORPHISM; IMMUNOGLOBULIN-E LEVELS; POSITIONAL CLONING; SUSCEPTIBILITY LOCI; GENE-CLUSTER; LINKAGE; ATOPY; REACTIVITY; REGION; HYPERRESPONSIVENESS	Background: The role of variation in the IL4 gene in asthma and allergy susceptibility is controversial. This cytokine is important in IgE isotype switching and the regulation of allergic inflammation; however, published studies have not delineated the specific role of variation in this gene in allergic disorders. Objective: We sought to identify single nucleotide polymorphisms (SNPs) in IL4 and to evaluate the association of SNPs and haplotypes with asthma and allergic phenotypes (total serum IgE) in white, African American, and Hispanic asthmatic populations. Methods: Sixteen individuals were resequenced, and 19 SNPs were identified; 2 novel and 17 SNPs were previously reported. Eleven of the SNPs were used to evaluate association in the 3 groups. Results: Nine polymorphisms were associated with total serum IgE levels in white subjects (.0012 less than or equal to P less than or equal to .034), and 5 of these were also associated with asthma in this population (.010 less than or equal to P less than or equal to .031). Three common haplotypes were observed, and all were associated with either high or low serum IgE levels in white subjects (.00008 less than or equal to P less than or equal to .004). Inspection of the haplotypes revealed that 3017 G/T in intron 2 was the only SNP concordant with serum IgE levels (G allele with lower levels and T allele with higher levels). Conclusions: After a comprehensive genetic evaluation, our data suggest that the 3017 G/T variant or the haplotype it identifies influences IL4's ability to modulate total serum IgE levels. Inconsistencies with previously reported IL4 associations might be due to population differences in allele frequencies, the extent of linkage disequilibrium with this SNP or haplotype, or both.	Wake Forest Univ, Sch Med, Med Genet Sect,Ctr Human Genomics, Dept Pediat,Sect Pulm Crit Care Allergy & Immunol, Winston Salem, NC 27157 USA; Univ New Mexico, Sch Pharm, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA	Wake Forest University; University of New Mexico; University of New Mexico	Howard, TD (corresponding author), Wake Forest Univ, Sch Med, Med Genet Sect,Ctr Human Genomics, Dept Pediat,Sect Pulm Crit Care Allergy & Immunol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	tdhoward@wfubmc.edu			NHLBI NIH HHS [U01-HL49602] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049602] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHATHAM M, 1982, CHEST, V82, P15, DOI 10.1378/chest.82.1.15; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Dizier MH, 1999, GENET EPIDEMIOL, V16, P84, DOI 10.1002/(SICI)1098-2272(1999)16:1<84::AID-GEPI7>3.0.CO;2-D; Dolganov G, 1996, BLOOD, V87, P3316, DOI 10.1182/blood.V87.8.3316.bloodjournal8783316; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Green LE, 2001, AM J HUM GENET, V69, P514; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; Howard TD, 1999, CLIN EXP ALLERGY, V29, P86; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1016/j.jaci.2003.08.033; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; KRUGLYAK L, SNP ANAL; Kruse S, 1999, IMMUNOLOGY, V96, P365; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; LEWONTIN RC, 1967, AM J HUM GENET, V19, P681; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Lonjou C, 2000, P NATL ACAD SCI USA, V97, P10942, DOI 10.1073/pnas.97.20.10942; MAK TW, 1998, HDB IMMUNE RESPONSE; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Marx N, 2002, CIRC RES, V90, P703, DOI 10.1161/01.RES.0000014225.20727.8F; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ober C, 2000, CLIN CHEST MED, V21, P245, DOI 10.1016/S0272-5231(05)70264-1; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Suzuki I, 2000, CLIN EXP ALLERGY, V30, P1746, DOI 10.1046/j.1365-2222.2000.00983.x; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; Wiesch DG, 1999, J ALLERGY CLIN IMMUN, V104, P895, DOI 10.1016/S0091-6749(99)70065-5; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; 2003, SEATTLESNPS NHLBI PR	51	98	108	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					80	87		10.1016/j.jaci.2004.05.035	http://dx.doi.org/10.1016/j.jaci.2004.05.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241348				2022-12-18	WOS:000222534300012
J	Iwasaki, M; Saito, K; Takemura, M; Sekikawa, K; Fuji, H; Yamada, Y; Wada, H; Mizuta, K; Seishima, M; Ito, Y				Iwasaki, M; Saito, K; Takemura, M; Sekikawa, K; Fuji, H; Yamada, Y; Wada, H; Mizuta, K; Seishima, M; Ito, Y			TNF-alpha contributes to the development of allergic rhinitis in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TNF-alpha; TNF-alpha-deficient mice; adhesion molecule; allergic rhinitis; IgE	TUMOR-NECROSIS-FACTOR; EOTAXIN MESSENGER-RNA; ADHESION MOLECULES; AIRWAY HYPERRESPONSIVENESS; ENDOTHELIAL-CELLS; NASAL-MUCOSA; MAST-CELLS; TH2 CELLS; INDUCTION; ASTHMA	Background: Allergic rhinitis is an inflammation involving T(H)2-type cytokine production, with pathologic eosinophil infiltration in the nasal mucosa. Although TNF-alpha is thought to be a pro-inflammatory cytokine, the relationship between TNF-alpha and allergic rhinitis has not been clarified. Objectives: The role of TNF-alpha in a murine model of ovalbumin (OVA)-sensitized allergic rhinitis was investigated by using mice deficient in the gene encoding TNF-alpha (TNF-alpha(-/-) mice). Methods: Both wild-type (TNF-alpha(+/+)) and TNF-alpha(-/-) mice were sensitized with OVA by means of intraperitoneal injection. They were then challenged with intranasal OVA, and various allergic responses were assessed. Results: The production of OVA-specific IgE in the serum (P < .05) and the frequency of sneezes (P < .05) and nasal rubs (P < .05) decreased significantly in TNF-&alpha;(-/-) mice after OVA sensitization compared with that in TNF-&alpha;(+/+) mice (P < .05). The mRNA expression of IL-4, IL-10, and eotaxin in nasal mucosa in TNF-alpha(-/-) mice was also significantly suppressed compared with that in TNF-alpha(+/+) mice after OVA sensitization (P < .05). Furthermore, the expression of both endothelial-leukocyte adhesion molecule 1 and vascular cell adhesion molecule 1 mRNA in the nasal mucosa was significantly suppressed (P < .05), although intercellular adhesion molecule 1 mRNA expression did not decrease significantly in TNF-alpha(-/-) mice compared with that in TNF-alpha(+/+) mice after OVA sensitization. In addition, the effect of TNF-alpha on endothelial-leukocyte adhesion molecule 1 and vascular cell adhesion molecule 1 expression by means of Western blot analysis was compatible with the mRNA results. Pathologically, eosinophil infiltration in nasal mucosa was significantly restricted in TNF-alpha(-/-) mice compared with in TNF-alpha(+/+) mice after OVA sensitization (P < .05). Conclusion: TNF-&alpha; is necessary for antigen-specific IgE production and for the induction of T(H)2-type cytokines and chemokines. Furthermore, TNF-&alpha; might be important for the expression of adhesion molecules to recruit eosinophils to the allergic inflammatory site. We conclude that the lack of TNF-&alpha; inhibited the development of allergic rhinitis.	NIMH, LNT, Bethesda, MD 20892 USA; Gifu Univ, Sch Med, Dept Otorhinolaryngol, Gifu 500, Japan; Gifu Univ, Sch Med, Dept Clin Lab Med, Gifu 500, Japan; Natl Inst Anim Hlth, Dept Immunol, Tsukuba, Ibaraki 305, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Gifu University; Gifu University; National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan	Saito, K (corresponding author), NIMH, LNT, Bldg 10 Room 3D42,MSC 1262,10 Ctr Dr, Bethesda, MD 20892 USA.							Artis D, 1999, J EXP MED, V190, P953, DOI 10.1084/jem.190.7.953; BACHERT C, 1995, INT ARCH ALLERGY IMM, V107, P106, DOI 10.1159/000236945; Barnes PJ, 2002, ANNU REV PHARMACOL, V42, P81, DOI 10.1146/annurev.pharmtox.42.111901.111143; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BRADDING P, 1995, CLIN EXP ALLERGY, V25, P406, DOI 10.1111/j.1365-2222.1995.tb01071.x; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1993, J IMMUNOL, V151, P3853; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V105, P211, DOI 10.1016/S0091-6749(00)90068-X; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; DEL PG, 1988, J IMMUNOL, V140, P4193; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Hohki G, 1997, BIOCHEM BIOPH RES CO, V241, P136, DOI 10.1006/bbrc.1997.7785; Kanehiro A, 2001, AM J RESP CRIT CARE, V164, P2229, DOI 10.1164/ajrccm.164.12.2012059; Lambert AL, 2001, EXP LUNG RES, V27, P617, DOI 10.1080/019021401753181863; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; MASINOVSKY B, 1990, J IMMUNOL, V145, P2886; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Neurath MF, 1997, EUR J IMMUNOL, V27, P1743, DOI 10.1002/eji.1830270722; OHMORI H, 1995, IMMUNOL LETT, V47, P127, DOI 10.1016/0165-2478(95)00084-I; Okano M, 1999, ALLERGY, V54, P593, DOI 10.1034/j.1398-9995.1999.00063.x; Rudmann DG, 2000, AM J PHYSIOL-LUNG C, V279, pL1047, DOI 10.1152/ajplung.2000.279.6.L1047; Taniguchi T, 1997, LAB INVEST, V77, P647; Terada N, 2000, CLIN EXP ALLERGY, V30, P348; Thomas PS, 2001, IMMUNOL CELL BIOL, V79, P132, DOI 10.1046/j.1440-1711.2001.00980.x; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; UEDA A, 1990, CELL IMMUNOL, V128, P31, DOI 10.1016/0008-8749(90)90004-B; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; Watanabe M, 1996, Arerugi, V45, P1127; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	33	98	106	2	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					134	140		10.1067/mai.2003.1554	http://dx.doi.org/10.1067/mai.2003.1554			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847490				2022-12-18	WOS:000184010600021
J	Kerschenlohr, K; Decard, S; Przybilla, B; Wollenberg, A				Kerschenlohr, K; Decard, S; Przybilla, B; Wollenberg, A			Atopy patch test reactions show a rapid influx of inflammatory dendritic epidermal cells in patients with extrinsic atopic dermatitis and patients with intrinsic atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; Langerhans cells; inflammatory dendritic epidermal cells; atopy patch test	FC-EPSILON-RI; LANGERHANS CELLS; HUMAN SKIN; IN-SITU; ECZEMA; IGE; RECEPTOR; AEROALLERGEN; REACTIVITY; EXPRESSION	Background: Normal human skin harbors a single epidermal dendritic cell (DC) population, the CD1a(.+++)CD11b(-) Langerhans cells. In many chronic inflammatory skin diseases, the epidermal DC pool bears a second population, the CD1a(+)CD11b(+++) inflammatory dendritic epidermal cells (IDECs). Immunophenotypic, ultrastructural, and functional aspects of IDECs have been investigated in chronic untreated skin lesions of intrinsic and extrinsic atopic dermatitis (AD), contact dermatitis (CD), and psoriasis, but little is known about freshly induced early skin lesions. Objective: We sought to characterize enumerative and immunophenotypic changes in the epidermal DC pool during the development of eczematous skin lesions. Methods: The atopy patch test with aeroallergens and food-protein allergens and a conventional patch test with standard-series haptens were performed as models for early skin lesions of extrinsic and intrinsic AD and CD, respectively. After 72 hours, epidermal cell suspensions were prepared, analyzed in a standardized flow cytometric technique, and compared with the results obtained from chronic lesions. Results: The migration of IDECs into the epidermis occurs within 72 hours and is thus an early event. It continues in chronic AD, but not in chronic CD, lesions. The specific upregulation of FcepsilonRI, especially on IDECs, occurs later during formation of extrinsic but not intrinsic AD lesions. LCs were negative for CD36 in patch test lesions, whereas in chronic skin lesions, LCs expressed CD36. Conclusion: The DC alteration during skin lesion formation can be subdivided into early and late events, with the influx of IDECs as an early event and the alteration of the DC phenotype as a late event.	Univ Munich, Dept Dermatol & Allergy, D-80337 Munich, Germany	University of Munich	Wollenberg, A (corresponding author), Univ Munich, Dept Dermatol & Allergy, Frauenlobstr 9-11, D-80337 Munich, Germany.							BAADSGAARD O, 1989, J INVEST DERMATOL, V92, P190, DOI 10.1111/1523-1747.ep12276718; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Billmann-Eberwein C, 2002, SKIN PHARMACOL APPL, V15, P100, DOI 10.1159/000049396; Brand CU, 1999, ARCH DERMATOL RES, V291, P65, DOI 10.1007/s004030050385; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; COOPER KD, 1991, IMMUNOLOGICAL PHARM, V4, P119; Cumberbatch M, 1997, ARCH DERMATOL RES, V289, P277, DOI 10.1007/s004030050193; Darsow U, 1996, BRIT J DERMATOL, V135, P182, DOI 10.1111/j.1365-2133.1996.tb01144.x; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; Darsow U, 1999, J AM ACAD DERMATOL, V40, P187, DOI 10.1016/S0190-9622(99)70186-6; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; de Bruin-Weller MS, 1999, ALLERGY, V54, P784, DOI 10.1034/j.1398-9995.1999.00097.x; Eckert F, 1991, HDB ATOPIC DERMATITI, P127; ENK AH, 1993, J IMMUNOL, V150, P3698; Grewe M, 1998, J IMMUNOL, V161, P415; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P195, DOI 10.1016/S0091-6749(03)70068-2; Kimber I, 1992, J INVEST DERMATOL, V99, p48S; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1987, CLIN IMMUNOL IMMUNOP, V42, P328, DOI 10.1016/0090-1229(87)90021-3; Morhenn VB, 1999, J AM ACAD DERMATOL, V41, P687, DOI 10.1016/S0190-9622(99)70002-2; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Oppel T, 2000, BRIT J DERMATOL, V143, P1193, DOI 10.1046/j.1365-2133.2000.03887.x; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P379, DOI 10.1159/000237609; RISKE F, 1991, J BIOL CHEM, V266, P11245; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Schuller E, 2001, ARCH DERMATOL RES, V293, P448, DOI 10.1007/s004030100263; TAYLOR RS, 1991, J IMMUNOL, V147, P3794; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Wiithrich B, 1983, AKTUEL DERMATOL, V9, P1; Wittmann M, 1999, BLOOD, V94, P1717, DOI 10.1182/blood.V94.5.1717.417k21_1717_1726; Wollenberg A, 2000, ALLERGY, V55, P205, DOI 10.1034/j.1398-9995.2000.00115.x; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; Wollenberg A, 2002, ATOPIC DERMATITIS, P267; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; WOLLENBERG A, 1999, ARCH DERMATOL RES, V291, P153	41	98	100	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					869	874		10.1067/mai.2003.1347	http://dx.doi.org/10.1067/mai.2003.1347			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704371				2022-12-18	WOS:000182258500031
J	Simons, FER; Prenner, BM; Finn, A				Simons, FER; Prenner, BM; Finn, A		Desloratadine Study Grp	Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						desloratadine; H-1-antihistamine; perennial allergic rhinitis; persistent allergic rhinitis	REDUCES NASAL CONGESTION; CETIRIZINE; EBASTINE; LORATADINE; THERAPY; PLACEBO	The evidence base for the use of HI-antihistamines in the treatment of perennial allergic rhinitis is considerably smaller than it is in the treatment of seasonal allergic rhinitis. Objective: We hypothesized that desloratadine, a new, nonsedating selective HI-antihistamine, would be efficacious and safe in the treatment of perennial allergic rhinitis. Methods: In a multicenter, randomized, placebo-controlled, double-blind, parallel-group study, 676 patients with symptomatic perennial allergic rhinitis were randomly assigned to 4 weeks of treatment with either 5 mg of desloratadine once daily or placebo. Efficacy was assessed by using a morning-evening instantaneous total symptom score (TSS), which was composed of scores for 4 individual nasal symptoms (rhinorrhea, itching, sneezing, and postnasal drip) and 3 individual nonnasal symptoms (itching eyes, watering eyes, and itching of the ears or palate). Secondary outcome measures included a morning-evening reflective TSS, total nasal and nonnasal symptoms scores, and individual symptom scores. Safety evaluations, including 12-lead electrocardiograms, were performed. Results: Six hundred thirty-four patients completed the study. Desloratadine consistently diminished perennial allergic rhinitis symptoms, reducing the morning-evening instantaneous TSS (P =.005), the morning-evening reflective TSS (P =.007), the morning-evening reflective total nonnasal score (P =.023), and the individual nasal symptom scores for rhinorrhea, nasal itching, sneezing, and postnasal drip/drainage (P =.05 to P.013) during weeks 1 through 4. Improvement in symptoms was observed after the first dose. Dropouts, and the type and frequency of adverse events (headache, viral infection, pharyngitis, and upper respiratory tract infection), were similar in both treatment groups. No clinically significant changes in QTc intervals were observed. Conclusions: Desloratadine rapidly and safely reduced the symptoms of perennial allergic rhinitis, and its efficacy did not diminish during 4 weeks of treatment.	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3T 2N2, Canada; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Allergy Associated Med Grp Inc, San Diego, CA USA; Urticaria Ctr Charleston, Charleston, SC USA	University of Manitoba; University of California System; University of California San Diego	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							Bachert C, 1998, ALLERGY, V53, P969, DOI 10.1111/j.1398-9995.1998.tb03798.x; Bachert C, 2001, ALLERGY, V56, P14, DOI 10.1034/j.1398-9995.2001.00102.x; Bellioni P., 1996, Rhinology (Utrecht), V34, P101; Bousquet J, 1999, ALLERGY, V54, P562, DOI 10.1034/j.1398-9995.1999.00984.x; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P309, DOI 10.1016/S0091-6749(96)70155-0; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BRUTTMANN G, 1989, J ALLERGY CLIN IMMUN, V83, P411, DOI 10.1016/0091-6749(89)90127-9; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V105, P211, DOI 10.1016/S0091-6749(00)90068-X; Ciprandi G, 2001, ALLERGY, V56, P1068, DOI 10.1034/j.1398-9995.2001.00191.x; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P463, DOI 10.1016/S1081-1206(10)63152-3; FROLUND L, 1990, ALLERGY, V45, P254; Geha RS, 2001, J ALLERGY CLIN IMMUN, V107, P752, DOI 10.1067/mai.2001.114239; GROSSMAN J, 1994, ANN ALLERGY, V73, P141; Howarth Peter, 2002, Clin Allergy Immunol, V17, P179; Kreutner W, 2000, ARZNEIMITTEL-FORSCH, V50, pE345; MANSMANN HC, 1992, ANN ALLERGY, V68, P348; Meltzer EO, 2001, CLIN DRUG INVEST, V21, P25, DOI 10.2165/00044011-200121010-00004; Murris-Espin M, 1998, ANN ALLERG ASTHMA IM, V80, P399, DOI 10.1016/S1081-1206(10)62991-2; Nayak AS, 2001, ALLERGY, V56, P1077, DOI 10.1034/j.1398-9995.2001.00082.x; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; SIMONS FER, 2002, CLIN PHARMACOKINET S, V41, P1; VALLES CP, 1991, ANN ALLERGY, V67, P615; Wilson A, 2000, CLIN EXP ALLERGY, V30, P833	23	98	103	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					617	622		10.1067/mai.2003.168	http://dx.doi.org/10.1067/mai.2003.168			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642846				2022-12-18	WOS:000181639500027
J	Horak, F; Stubner, UP; Zieglmayer, R; Harris, AG				Horak, F; Stubner, UP; Zieglmayer, R; Harris, AG			Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						desloratadine; antihistamine; nasal obstruction; seasonal allergic rhinitis; allergen exposure; rhinomanometry	MUCOSAL BLOOD-FLOW; RECEPTOR ANTAGONISTS; ATOPIC PATIENTS; EFFICACY; CETIRIZINE; CHALLENGE; SYMPTOMS; SAFETY; LORATADINE; MANAGEMENT	Background: Unlike many antihistamines, desloratadine can reduce nasal congestion in patients with seasonal allergic rhinitis (SAR). Objective: We compared the effects of 5 mg of desloratadine and placebo on nasal airflow and SAR symptoms, including nasal congestion, in response to grass pollen in an allergen-exposure unit. Methods: In a randomized, double-blind, placebo-controlled, crossover trial, 47 subjects with histories of SAR received desloratadine or placebo every morning for 7 days and, after a 10-day washout period, were crossed over to the other treatment arm for 7 days. Subjects underwent a 6-hour allergen exposure on day 7 of each treatment period. Nasal airflow and nasal secretion weights were measured before and every 30 minutes during allergen exposure; SAR symptoms (including nasal congestion) were scored before exposure and every 15 minutes thereafter. Results: Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P < .02). Individual and combined SAR symptom severity scores, including nasal congestion and sneezing, were significantly lower with desloratadine than with placebo (all P less than or equal to .003). Within 30 minutes of allergen exposure, less severely decreased nasal airflow (P < .02), less nasal secretions (P < .001), and less severe symptoms, including nasal congestion (P < .002), rhinorrhea, and sneezing, occurred with desloratadine compared with placebo, and this continued throughout (0-6 hours) allergen exposure. Desloratadine was well tolerated, with an adverse event profile similar to that of placebo. Conclusion: In subjects with allergen-induced SAR symptoms, desloratadine significantly reduced the severity of nasal obstruction and accompanying complaints of nasal congestion and other SAR symptoms compared with the effects of placebo.	Univ Vienna, AKH Vienna, ENT Clin, A-1090 Vienna, Austria; Schering Plough Corp, Kenilworth, NJ 07033 USA	University of Vienna; Merck & Company; Schering Plough Corporation	Horak, F (corresponding author), Univ Vienna, AKH Vienna, ENT Clin, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.			Harris, Alan/0000-0002-6618-2092				*AM AC ALL ASTHM I, 2001, ALL REP; ANDERSSON KE, 1984, ANN OTO RHINOL LARYN, V93, P179, DOI 10.1177/000348948409300216; Bachert C, 2001, ALLERGY, V56, P14, DOI 10.1034/j.1398-9995.2001.00102.x; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; BROIDE D, 1995, ALLERGY, V50, P31, DOI 10.1111/j.1398-9995.1995.tb04261.x; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P163, DOI 10.1016/S1081-1206(10)63104-3; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; Geha RS, 2001, J ALLERGY CLIN IMMUN, V107, P752, DOI 10.1067/mai.2001.114239; Gentile DA, 2000, IMMUNOL ALLERGY CLIN, V20, P355, DOI 10.1016/S0889-8561(05)70152-1; HORAK F, 1993, ALLERGY, V48, P226, DOI 10.1111/j.1398-9995.1993.tb00720.x; Horak F, 2001, INT ARCH ALLERGY IMM, V125, P73, DOI 10.1159/000053799; Horak F, 1998, ALLERGY, V53, P849, DOI 10.1111/j.1398-9995.1998.tb03990.x; HORAK F, 1987, WIEN KLIN WOCHENSCHR, V99, P509; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kreutner W, 2000, ARZNEIMITTEL-FORSCH, V50, pE345; *MED EC COMP, 2000, 2000 PHYS DESK REF N; Meltzer EO, 1998, J ALLERGY CLIN IMMUN, V102, P39, DOI 10.1016/S0091-6749(98)70053-3; Meltzer EO, 2001, CLIN DRUG INVEST, V21, P25, DOI 10.2165/00044011-200121010-00004; PIPKORN U, 1982, ALLERGY, V37, P129, DOI 10.1111/j.1398-9995.1982.tb01886.x; Schmidt BMW, 1999, J CLIN PHARMACOL, V39, P1062, DOI 10.1177/00912709922011836; SMALL P, 1991, ANN ALLERGY, V67, P520; Wang DY, 1996, ACTA OTO-LARYNGOL, V116, P91, DOI 10.3109/00016489609137720; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P61, DOI 10.1046/j.1365-2222.2001.00964.x	24	98	102	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					956	961		10.1067/mai.2002.124657	http://dx.doi.org/10.1067/mai.2002.124657			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063524				2022-12-18	WOS:000176442700010
J	Scheurer, S; Pastorello, EA; Wangorsch, A; Kastner, M; Haustein, D; Vieths, S				Scheurer, S; Pastorello, EA; Wangorsch, A; Kastner, M; Haustein, D; Vieths, S			Recombinant allergens Pro av 1 and Pru av 4 and a newly identified lipid transfer protein in the in vitro diagnosis of cherry allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; cherry; lipid transfer protein; Pru av 1; Pru av 4; birth pollinosis; cross-reactivity	PEACH PRUNUS-PERSICA; MAJOR ALLERGEN; MOLECULAR-CLONING; CROSS-REACTIVITY; POLLEN ALLERGEN; APPLE ALLERGEN; IGE; CLEAVAGE; ISOFORMS; FAMILY	Background: In central and northern Europe food allergy to fruits of the Rosaceae family is strongly associated with birch pollinosis because of the existence of IgE cross-reactive homologous allergens in birch pollen and food. By contrast, in the Mediterranean population allergic reactions to these fruits frequently are not related to birch pollen allergy and are predominantly elicited by lipid transfer proteins (LTPs), Objective: We sought to determine the prevalence of IgE sensitization to the recombinant cherry allergens Pru av 1 and Pru av 4 in comparison with cherry extract within a representative group of patients who were allergic to cherries recruited in Germany and to compare the relevance of IgE to cherry LTPs in Italian patients. Methods: Recombinant Pru av 1 and rPru av 4 were available from earlier studies. The cDNA of the cherry LTPs was obtained by using a PCR-cloning strategy. The protein was expressed in Escherichia coli and purified by means of metal chelate affinity chromatography. Sera from 101 German patients with birch pollinosis and oral allergy syndrome to cherry and sera from 7 Italian patients with cherry allergy were investigated by using enzyme allergosorbent tests for IgE reactivity with cherry extract, rPru av 1, rPru av 4, and the recombinant cherry LTP. Inhibition experiments were performed to compare the IgE reactivity of natural and recombinant cherry LTPs and to investigate potential cross-reactivity with birch pollen allergens, Results: The LTP from cherry comprises 91 amino acids and a 26 amino acid signal peptide, The mature cherry LTP shows high amino acid sequence identity with allergenic LTPs from peach (Pru p 3, 88%), apricot (Pru ar 3, 86%), and maize (Zea m 14, 59%) and displays no IgE cross-reactivity with birch pollen. The IgE prevalences in the German patients were as follows: LTP, 3 of 101 (3%); rPru av 1, 97 of 101 (96.0%); rPru av 4, 16 of 101 (16.2%); and cherry extract, 98 of 101 (97%), All 7 Italian patients had IgE against the cherry LTP. Conclusions: Recombinant allergens are useful tools for a more accurate in vitro IgE-based diagnosis of cherry allergy, Taken together, they mimic the allergenic activity of cherry extract, having slightly higher biologic activity. Sensitization to the cherry LTP is relevant for a minority of patients recruited in Germany, but our data indicate that it may be a major allergen in Italy.	Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany; Osped Maggiore, Ist Ric, Div Gen Med 3, Allergy Ctr, Milan, Italy; Carratere Sci, Milan, Italy; Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany	Paul Ehrlich Institute; Paul Ehrlich Institute	Scheurer, S (corresponding author), Paul Ehrlich Inst, Dept Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.		Scheurer, Stephan/A-6509-2019; PASTORELLO, ELIDE ANNA/E-3897-2017	Scheurer, Stephan/0000-0002-2859-562X; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Caballero T, 1998, J INVEST ALLERG CLIN, V8, P6; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Duro G, 1997, INT ARCH ALLERGY IMM, V112, P348, DOI 10.1159/000237479; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; Inschlag C, 1998, INT ARCH ALLERGY IMM, V116, P22, DOI 10.1159/000023920; Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1; KARAMLOO F, 2000, IN PRESS J CHROMAT B; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1998, ALLERGY, V53, P48, DOI 10.1111/j.1398-9995.1998.tb04960.x; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V105, P371, DOI 10.1016/S0091-6749(00)90090-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 1999, BIOL CHEM, V380, P1315, DOI 10.1515/BC.1999.167; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; SCHEUER S, 2001, IN PRESS J CHROMAT B; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; VIETHS S, 2000, REGULATORY CONTROL S, P159	34	98	99	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					724	731		10.1067/mai.2001.113864	http://dx.doi.org/10.1067/mai.2001.113864			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295665	Bronze			2022-12-18	WOS:000168190100028
J	Kalish, RS; Askenase, PW				Kalish, RS; Askenase, PW			Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: Implications for allergies, asthma, and autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T lymphocytes; CD8+; delayed hypersensitivity; allergic contact dermatitis; drug eruptions; asthma	RESTRICTED ANTIGEN PRESENTATION; BETA-LACTAM ANTIBIOTICS; CLASS-II MOLECULES; CONTACT SENSITIVITY; INTERFERON-GAMMA; PERIPHERAL-BLOOD; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; LYMPHOKINE PRODUCTION; TOLUENE DIISOCYANATE	Delayed-type hypersensitivity (DTH) is defined as the recruitment of T cells into tissues to be activated by antigen-presenting cells to produce cytokines that mediate Local inflammation. CD8+ T cells are now known to mediate DTH responses in allergic contact dermatitis, drug eruptions, asthma, and autoimmune diseases. This inflammatory effector capability of CD8+ cytotoxic T cells was previously poorly recognized, but there is now considerable evidence that these diseases may be mediated by CD8+ DTH. The difference between CD8+ T cells and CD4+ T cells mediating DTH relates to the molecular mechanisms by which antigens are processed and presented to the T cells. Antigens external to the cell are phagocytosed and processed for presentation on MHC class II molecules (eg, HLA-DR) to CD4+ T cells. In contrast, internal cytoplasmic antigens are processed by the endogenous pathway for presentation on MHC class I molecules (eg, HLA-A, -B, and -C) to CD8+ T cells, External allergens can also enter the endogenous pathway to be presented to CD8+ T cells. These include many contact sensitizers, chemical and protein respiratory allergens, viral antigens, metabolic products of drugs, and autoantigens. The resulting CD8+ T-cell response explains the role of CD8+ T-cell DTH mechanisms in allergic contact dermatitis, asthma, drug eruptions, and autoimmune diseases.	SUNY Stony Brook, Hlth Sci Ctr, Dept Dermatol, Stony Brook, NY 11794 USA; Yale Univ, Sch Med, New Haven, CT USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Yale University	Kalish, RS (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Dermatol, Stony Brook, NY 11794 USA.				NHLBI NIH HHS [94 HL-08-1] Funding Source: Medline; NIAID NIH HHS [AI-11077, AI-12211] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012211, R01AI012211, R01AI011077] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANETT FC, 1984, SPONDYLOARTHROPATHIE, P297; Baer H, 1986, Clin Dermatol, V4, P152, DOI 10.1016/0738-081X(86)90074-X; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BODMER H, 1994, SCIENCE, V263, P1284, DOI 10.1126/science.7510069; Bouloc A, 1998, J INVEST DERMATOL, V111, P44, DOI 10.1046/j.1523-1747.1998.00236.x; BOUR H, 1995, EUR J IMMUNOL, V25, P3006, DOI 10.1002/eji.1830251103; BYCK JS, 1968, ANAL BIOCHEM, V25, P123, DOI 10.1016/0003-2697(68)90086-9; Cavani A, 1998, J INVEST DERMATOL, V111, P621, DOI 10.1046/j.1523-1747.1998.00334.x; CHER DJ, 1987, J IMMUNOL, V138, P3688; CLAESEN M, 1982, DRUG METAB DISPOS, V10, P667; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; Coyle AJ, 1996, ANN NY ACAD SCI, V796, P97, DOI 10.1111/j.1749-6632.1996.tb32571.x; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; CRESSWELL P, 1990, NATURE, V343, P593, DOI 10.1038/343593a0; CRIBB AE, 1990, MOL PHARMACOL, V38, P744; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; Dai WJ, 1997, J IMMUNOL, V158, P5297; Doherty PC, 1996, CURR TOP MICROBIOL, V206, P1; DUPUIS G, 1982, ALLERGIC CONTACT DER, P47; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; HAHN S, 1995, IMMUNOL REV, V146, P57, DOI 10.1111/j.1600-065X.1995.tb00684.x; HEHMKE B, 1995, DIABETES, V44, P1414, DOI 10.2337/diabetes.44.12.1414; HERTL M, 1993, J INVEST DERMATOL, V101, P794, DOI 10.1111/1523-1747.ep12371697; HERTL M, 1993, BRIT J DERMATOL, V128, P619, DOI 10.1111/j.1365-2133.1993.tb00255.x; Hohler T, 1996, HUM IMMUNOL, V51, P49, DOI 10.1016/S0198-8859(96)00156-5; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; Jiang XS, 1997, J IMMUNOL, V158, P287; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; KALISH RS, 1994, J ALLERGY CLIN IMMUN, V94, P465, DOI 10.1016/0091-6749(94)90202-X; KALISH RS, 1989, J INVEST DERMATOL, V92, P46, DOI 10.1111/1523-1747.ep13070998; KALISH RS, 1990, J IMMUNOL, V145, P3706; KALISH RS, 1994, J CLIN INVEST, V93, P2039, DOI 10.1172/JCI117198; KAPSENBERG ML, 1992, J INVEST DERMATOL, V98, P59, DOI 10.1111/1523-1747.ep12494841; KHAN IU, 1992, DRUG METAB DISPOS, V20, P620; KURTJONES EA, 1985, P NATL ACAD SCI USA, V82, P1204, DOI 10.1073/pnas.82.4.1204; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Landau Louis I., 1996, Current Opinion in Pediatrics, V8, P3, DOI 10.1097/00008480-199602000-00002; LEHNER T, 1982, IMMUNOLOGY, V47, P581; Liu TM, 1997, J IMMUNOL, V159, P5364; LOFSTROM A, 1986, ACTA DERM-VENEREOL, V66, P200; MA J, 1994, J INVEST DERMATOL, V103, P42, DOI 10.1111/1523-1747.ep12389535; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376, DOI 10.5271/sjweh.1383; MARGOLIS RJ, 1983, J INVEST DERMATOL, V81, P403, DOI 10.1111/1523-1747.ep12522001; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MILLS KHG, 1986, IMMUNOL TODAY, V7, P260, DOI 10.1016/0167-5699(86)90006-X; MORNBURG F, 1998, ADV IMMUNOL, V68, P191; Moulon C, 1998, J INVEST DERMATOL, V111, P360, DOI 10.1046/j.1523-1747.1998.00306.x; MUNK ME, 1995, EUR RESPIR J, V8, pS668; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NOBLE A, 1995, J IMMUNOL, V155, P2928; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; Padovan E, 1997, EUR J IMMUNOL, V27, P1303, DOI 10.1002/eji.1830270602; Park HS, 1997, CLIN EXP ALLERGY, V27, P1145; Peakman M, 1996, DIABETES CARE, V19, P1177, DOI 10.2337/diacare.19.11.1177; Penzotti JE, 1997, ARTHRITIS RHEUM, V40, P1316, DOI 10.1002/art.17; Pichler WJ, 1997, INT ARCH ALLERGY IMM, V113, P177, DOI 10.1159/000237539; REINHERZ EL, 1979, J IMMUNOL, V123, P2894; Reveille John D., 1998, Current Opinion in Rheumatology, V10, P187, DOI 10.1097/00002281-199805000-00007; Ridgway WM, 1998, CLIN IMMUNOL IMMUNOP, V86, P3, DOI 10.1006/clin.1997.4449; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; RODRIGUEZ GM, 1992, J IMMUNOL, V149, P2894; ROMAGNOLI P, 1991, EMBO J, V10, P1303, DOI 10.1002/j.1460-2075.1991.tb07648.x; SCHMIDT RJ, 1990, ARCH DERMATOL RES, V282, P56, DOI 10.1007/BF00505646; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SHULTZ LD, 1975, IMMUNOGENETICS, V1, P570; SINIGAGLIA F, 1985, J IMMUNOL, V135, P3929; Smith KJ, 1997, DERMATOLOGY, V195, P145, DOI 10.1159/000245718; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; SPIELBERG SP, 1984, FED PROC, V43, P2308; Stanciu LA, 1997, J ALLERGY CLIN IMMUN, V100, P373, DOI 10.1016/S0091-6749(97)70251-3; STERKERS G, 1984, EUR J IMMUNOL, V14, P125, DOI 10.1002/eji.1830140205; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; Su HC, 1998, J IMMUNOL, V160, P5007; SuarezPinzon W, 1996, DIABETES, V45, P1350, DOI 10.2337/diabetes.45.10.1350; SUGIHARA S, 1995, J IMMUNOL, V155, P1619; SUNDAY M E, 1980, Journal of Immunology, V125, P1601; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; Tang HW, 1997, INT IMMUNOL, V9, P679, DOI 10.1093/intimm/9.5.679; TAPPER H, 1990, BIOCHEM J, V272, P407, DOI 10.1042/bj2720407; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; THOMSON G, 1995, CRIT REV CL LAB SCI, V32, P183, DOI 10.3109/10408369509084684; TONNESEN MG, 1983, J INVEST DERMATOL, V80, P282, DOI 10.1111/1523-1747.ep12534652; Wahlstrom J, 1998, CLIN EXP IMMUNOL, V112, P1; Wang B, 1996, EUR J IMMUNOL, V26, P1762, DOI 10.1002/eji.1830260815; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001; Ying S, 1997, J IMMUNOL, V158, P3539; Yurovsky VV, 1998, AM J RESP CELL MOL, V18, P370, DOI 10.1165/ajrcmb.18.3.2935; Zanni MP, 1998, TRENDS PHARMACOL SCI, V19, P308, DOI 10.1016/S0165-6147(98)01227-9; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	100	98	103	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				192	199		10.1016/S0091-6749(99)70489-6	http://dx.doi.org/10.1016/S0091-6749(99)70489-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949307				2022-12-18	WOS:000078630100002
J	Busse, WW				Busse, WW			Inflammation in asthma: The cornerstone of the disease and target of therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; etiology; inflammation mediators; drug therapy; glucocorticoids; inhalation drug administration	BRONCHOALVEOLAR LAVAGE FLUID; NITRIC-OXIDE SYNTHASE; HUMAN-LUNG FRAGMENTS; MAST-CELLS; NEDOCROMIL SODIUM; ALLERGEN CHALLENGE; GLUCOCORTICOIDS INHIBIT; INHALED CORTICOSTEROIDS; DISODIUM-CROMOGLYCATE; AIRWAY INFLAMMATION	Asthma is a chronic disease associated with variable levels of airflow obstruction. Considerable evidence has been obtained to show that airway inflammation is a major factor in the pathogenesis of asthma in associated bronchial hyperresponsiveness, and in the level of disease severity. The inflammatory pattern in asthma is multicellular in nature, with mast cells, neutrophils, eosinophils, T lymphocytes, and epithelial cells participating in the response. Furthermore, it is known that mediators, cytokines, and chemokines from these cells contribute to the orchestration of the inflammatory process. Because airway inflammation appears to be a critical etiologic feature of asthma, it has become the target of therapy In this review the features of airway inflammation will be examined, and the effect of therapeutic agents on markers of airway injury will be discussed. Establishing, understanding, and finally controlling the features of airway inflammation have given insight to disease pathogenesis and the effectiveness of various treatments. The integral role of inhaled corticosteroids in modifying the complex inflammatory component of asthma will be explored, with special focus on the high degree of efficacy associated with this treatment-vis-a-vis other therapeutic agents-in preventing or blocking specific proinflammatory markers.	Univ Wisconsin, Dept Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin, Dept Med, J5-220 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.							AALBERS R, 1993, AM REV RESPIR DIS, V147, P76, DOI 10.1164/ajrccm/147.1.76; BAIGELMAN W, 1983, AM J MED, V75, P929, DOI 10.1016/0002-9343(83)90871-9; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADDING P, 1995, J IMMUNOL, V155, P297; BRUIJNZEEL PLB, 1990, BRIT J PHARMACOL, V99, P798, DOI 10.1111/j.1476-5381.1990.tb13009.x; BRUIJNZEEL PLB, 1989, BRIT J PHARMACOL, V96, P631, DOI 10.1111/j.1476-5381.1989.tb11862.x; BURKE C, 1992, EUR RESPIR J, V5, P73; CASTELLS M, 1995, FASEB J, V9, pA1047; CHURCH MK, 1983, BRIT J PHARMACOL, V78, P671, DOI 10.1111/j.1476-5381.1983.tb09419.x; COHAN VL, 1989, AM REV RESPIR DIS, V140, P951, DOI 10.1164/ajrccm/140.4.951; Devalia J. L., 1994, European Respiratory Journal, V7, p98S; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EVANS PM, 1993, J ALLERGY CLIN IMMUN, V91, P643, DOI 10.1016/0091-6749(93)90270-P; FLINT KC, 1985, CLIN SCI, V68, P427, DOI 10.1042/cs0680427; HABER P, 1989, RESPIRATION, V55, P44; HOAG JE, 1991, ANN ALLERGY, V66, P53; Holgate ST, 1997, CIBA F SYMP, V206, P5; Holtzman MJ, 1996, AM J RESP CELL MOL, V14, P316, DOI 10.1165/ajrcmb.14.4.8600934; HUI KP, 1991, THORAX, V46, P184, DOI 10.1136/thx.46.3.184; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; Jaffar ZH, 1996, EUR RESPIR J, V9, P456, DOI 10.1183/09031936.96.09030456; JAMES DG, 1995, CLIN EXP ALLERGY, V25, P389, DOI 10.1111/j.1365-2222.1995.tb01067.x; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KITA H, 1991, J ALLERGY CLIN IMMUN, V87, P70, DOI 10.1016/0091-6749(91)90214-9; KWON OJ, 1994, IMMUNOLOGY, V81, P389; KWON OJ, 1995, AM J RESP CELL MOL, V12, P488, DOI 10.1165/ajrcmb.12.5.7537968; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAMAS AM, 1991, J IMMUNOL, V147, P254; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MARQUARDT DL, 1986, AM REV RESPIR DIS, V133, P1105; MIESFELD RL, 1990, AM REV RESPIR DIS, V141, pS11; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MUZOZ NM, 1997, AM J RESP CRIT CARE, V155, P1398; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OHEHIR RE, 1989, DRUGS, V37, P23, DOI 10.2165/00003495-198900371-00006; PEARCE FL, 1982, J IMMUNOL, V128, P2481; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; ROBINSON DS, 1993, THORAX, V48, P845, DOI 10.1136/thx.48.8.845; ROCHE WR, 1991, CLIN EXP ALLERGY, V21, P545, DOI 10.1111/j.1365-2222.1991.tb00845.x; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1990, AM REV RESPIR DIS S, V141, P59; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442, DOI 10.1164/ajrccm.155.2.9032176; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; Simon HU, 1997, J IMMUNOL, V158, P3902; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; SVENDSEN UG, 1989, J ALLERGY CLIN IMMUN, V84, P224, DOI 10.1016/0091-6749(89)90329-1; TANIGUCHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P507, DOI 10.1016/0091-6749(93)90074-P; THOMSON NC, 1989, RESP MED, V83, P269, DOI 10.1016/S0954-6111(89)80195-7; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; WALLEN N, 1991, J IMMUNOL, V147, P3490; WEERSINK EJM, 1994, RESP MED, V88, P103, DOI 10.1016/0954-6111(94)90021-3; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; WOOLLEY MJ, 1994, AM J RESP CELL MOL, V11, P600, DOI 10.1165/ajrcmb.11.5.7946389	78	98	99	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	2				S17	S22		10.1016/S0091-6749(98)70002-8	http://dx.doi.org/10.1016/S0091-6749(98)70002-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	133CT	9798720				2022-12-18	WOS:000076669400004
J	JUNG, T; LACK, G; SCHAUER, U; UBERUCK, W; RENZ, H; GELFAND, EW; RIEGER, CHL				JUNG, T; LACK, G; SCHAUER, U; UBERUCK, W; RENZ, H; GELFAND, EW; RIEGER, CHL			DECREASED FREQUENCY OF INTERFERON-GAMMA-PRODUCING AND INTERLEUKIN-2-PRODUCING CELLS IN PATIENTS WITH ATOPIC DISEASES MEASURED AT THE SINGLE-CELL LEVEL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPY; T CELL; CYTOKINE; SINGLE CELL ASSAY; FLOW CYTOMETRY	COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; T-CELLS; IGE SYNTHESIS; BECLOMETHASONE DIPROPIONATE; PERIPHERAL-BLOOD; DERMATITIS; CLONES; ASTHMA; IL-4	Background: Recently, diminished interferon-gamma (IFN-gamma) and increased interleukin (IL)-4 production in peripheral blood mononuclear cells (PBMCs)) from atopic patients have been described by several groups, measured as total cytokine content in culture supernatants. These studies suggested a predominance of T-H2-like cells producing large amounts of IL-4 in atopic patients. It is not clear whether the reported cytokine imbalances are the result of an alteration in the distribution of specific T-cell subsets or whether intrinsic dysregulation in cytokine production is a characteristic of atopic individuals. Objective: This study examined the production of IFN-gamma, IL-4, and IL-2 in PBMCs from atopic patients at the single cell level with the use of freshly isolated lymphocytes. Methods: We recently described a flow cytometric assay in which three-color analysis was used to study the production of a cytokine of interest in a T-cell subpopulation defined by two cell surface markers. PBMCs fram 23 atopic patients and 14 control subjects were stimulated with phorbol ester and ionomycin for 5 hours. PBMCs from seven patients and seven control subjects were also cultured with immobilized anti-CD3 antibodies for 24 hours Cells were fixed made permeable, and stained for intracellular cytokines in combination with cell surface markers CD3, CD8, and CD45RO. Cytokine;producing cells were analyzed by gating on T-cell subsets. Results: IFN-gamma-producing cells were significantly decreased (p < 0.05) in CD4+ T cells but not in CD8+ T cells of atopic patients. CD45RO+ and CD45RO- T cells showed a decreased proportion of IFN-gamma-producing cells (p < 0.05 and p < 0.01, respectively). IL-2-production was diminished in all T-cell subsets (p < 0.01). The number of IL-4-producing cells was not elevated and such cells were exclusively found in the CD45RO+ T cells. Analysis of culture supernatants of sorted CD45RO+ T cells for IL-4 and IFN-gamma production confirmed these results. Conclusion: Out findings provide evidence that a reduced IFN-gamma production in atopic patients is due to an intrinsic defect selectively found in the CD4+ T cells Because IL-2 production was markedly decreased but IL-4 production was unchanged, our data demonstrate a deficiency in the ability of atopic T cells to produce T-H1-like cytokines on stimulation with phorbol ester; ionomycin, or anti-CD3 monoclonal antibodies.	NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO USA; RUHR UNIV BOCHUM, KINDERKLIN, BOCHUM, GERMANY	National Jewish Health; Ruhr University Bochum	JUNG, T (corresponding author), UNIV GOTTINGEN, DEPT DERMATOL, V SIEBOLD STR 3, D-37075 GOTTINGEN, GERMANY.			Lack, Gideon/0000-0001-7350-4021	NIAID NIH HHS [AI-29704] Funding Source: Medline; PHS HHS [AL-26490] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029704] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; AKBAR AN, 1991, EUR J IMMUNOL, V21, P2517, DOI 10.1002/eji.1830211031; ANDERSSON U, 1990, EUR J IMMUNOL, V20, P1591, DOI 10.1002/eji.1830200727; Beverley P C, 1992, Semin Immunol, V4, P35; BROWN PH, 1993, THORAX, V48, P967, DOI 10.1136/thx.48.10.967; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DOI S, 1994, CLIN EXP ALLERGY, V24, P854, DOI 10.1111/j.1365-2222.1994.tb01808.x; DURHAM SR, 1992, J IMMUNOL, V148, P2390; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; HANIFIN JM, 1984, ANN ALLERGY, V386, P395; JUJO K, 1993, J ALLERGY CLIN IMMUN, V91, P1206, DOI 10.1016/0091-6749(93)90324-9; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; JUNG K, 1993, ARCH DERMATOL RES, V285, P135, DOI 10.1007/BF01112915; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; JUNG T, 1994, J IMMUNOL, V152, pA109; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; LEUNG DYM, 1993, CLIN REV ALLERG, V11, P447; LEUNG DYM, 1992, PEDIATR RES, V33, pS56; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MAGGI E, 1992, J IMMUNOL, V148, P2142; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PELTZ G, 1991, IMMUNOL REV, V123, P23, DOI 10.1111/j.1600-065X.1991.tb00604.x; PETERSEN CM, 1992, EXP CELL RES, V201, P160, DOI 10.1016/0014-4827(92)90360-K; POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; REINHOLD U, 1990, CLIN EXP IMMUNOL, V79, P374; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMANO MF, 1992, CELL IMMUNOL, V139, P91, DOI 10.1016/0008-8749(92)90102-U; ROTH MD, 1994, J EXP MED, V179, P857, DOI 10.1084/jem.179.3.857; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SCHAUER U, 1991, CLIN EXP IMMUNOL, V83, P25; SCHAUER U, 1991, CLIN EXP IMMUNOL, V86, P440; SCHWINZER R, 1992, J IMMUNOL, V148, P1322; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TRASK DM, 1988, J INVEST DERMATOL, V90, P526, DOI 10.1111/1523-1747.ep12461047; van Kooten C, 1992, Eur Cytokine Netw, V3, P289; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WIERENGA EA, 1991, J IMMUNOL, V147, P2942	44	98	99	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					515	527		10.1016/S0091-6749(95)70296-2	http://dx.doi.org/10.1016/S0091-6749(95)70296-2			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560664	Bronze			2022-12-18	WOS:A1995TA09500013
J	KOTSES, H; BERNSTEIN, IL; BERNSTEIN, DI; REYNOLDS, RVC; KORBEE, L; WIGAL, JK; GANSON, E; STOUT, C; CREER, TL				KOTSES, H; BERNSTEIN, IL; BERNSTEIN, DI; REYNOLDS, RVC; KORBEE, L; WIGAL, JK; GANSON, E; STOUT, C; CREER, TL			A SELF-MANAGEMENT PROGRAM FOR ADULT ASTHMA .1. DEVELOPMENT AND EVALUATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADULT ASTHMA; SELF-MANAGEMENT; BEHAVIORAL CONTROL; ENVIRONMENTAL CHANGE	CHILDHOOD ASTHMA; EDUCATION; BEHAVIOR; EFFICACY; QUALITY; SCALE	Background: We developed and evaluated a self-management program for adult asthma. In developing the program, we considered questions of format and behavior control. The for-mat we selected included components known to be effective in educational settings. We regulated asthma management behavior through the introduction of environmental cues. Methods: Seventy-six subjects, whose asthma was generally under medical control, were assigned randomly to either a treatment group or a waiting-list control group. Those in the treatment group were exposed to a 7-week program that incorporated proven features of providing effective training and establishing behavioral control. Subsequently, subjects in the control group received the treatment. Short-term evaluation of the treatment was made after the subjects in the experimental group were trained but before the control subjects were trained. Long-term evaluation was conducted after both groups of subjects were trained. Results: Over the short term, self-management training led to fewer. asthma symptoms and physician visits and improvement in asthma management skills and cognitive abilities. Over the long term, self-management training was related to lower asthma attack frequency, reduced medication use, improvement in cognitive measures, and increased use of self-management skills. Conclusions: The program improved asthma management in patients whose conditions were already under good medical control. The effects of the program were apparent a year after the conclusion of self-management training.	OHIO UNIV,DEPT PSYCHOL,ATHENS,OH 45701; CTR ALLERGY & ASTHMA,CINCINNATI,OH	University System of Ohio; Ohio University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032538] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32538] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BAUMAN AE, 1989, PATIENT EDUC COUNS, V14, P217, DOI 10.1016/0738-3991(89)90034-7; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; Beck A.T., 1967, DEPRESSION CLIN EXPT; BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; BURNS RBP, 1983, J ASTHMA, V20, P105, DOI 10.3109/02770908309077073; Byrne D., 1971, ATTRACTION PARADIGM; CHAIKEN S, 1973, J PERS SOC PSYCHOL, V34, P605; COOPER J, 1984, ANNU REV PSYCHOL, V35, P395, DOI 10.1146/annurev.ps.35.020184.002143; CREER TL, 1992, PEDIATR ASTHMA ALLER, V6, P21, DOI 10.1089/pai.1992.6.21; CREER TL, 1992, PEDIATR ASTHMA ALLER, V6, P143, DOI 10.1089/pai.1992.6.143; CREER TL, 1989, J ASTHMA, V26, P17, DOI 10.3109/02770908909073226; CREER TL, 1981, DEV EVALUATION SELF, V2; CREER TL, 1991, HDB CLIN PSYCHOL MED, P497; CREER TL, 1991, HDB ASTHMA SELF MAN; KAPLAN RM, 1984, J CHRON DIS, V37, P85, DOI 10.1016/0021-9681(84)90050-X; Kazdin A., 1992, RES DESIGN CLIN PSYC; KOTSES H, 1990, J ASTHMA, V27, P375, DOI 10.3109/02770909009073354; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MARION RJ, 1985, ANN ALLERGY, V54, P31; MOLDOFSKY H, 1979, CAN MED ASSOC J, V120, P669; MULHAUSER I, 1991, J INT MED, V230, P157; RINGSBERG KC, 1990, EUR RESPIR J, V3, P33; SNYDER SE, 1987, J ASTHMA, V24, P153, DOI 10.3109/02770908709070931; STARK J E, 1977, British Journal of Diseases of the Chest, V71, P225, DOI 10.1016/S0007-0971(77)80020-X; TAITEL MS, IN PRESS J ALLERGY C; TEHAN N, 1989, J ADOLESCENT HEALTH, V10, P513, DOI 10.1016/0197-0070(89)90014-4; TOBIN DL, 1987, ANN ALLERGY, V59, P273; WIGAL J K, 1990, Pediatric Asthma Allergy and Immunology, V4, P17, DOI 10.1089/pai.1990.4.17; WRIGHT BM, 1959, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.5159.1041; 1987, AM REV RESPIR DIS, V136, P225	31	98	98	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					529	540		10.1016/S0091-6749(95)70315-2	http://dx.doi.org/10.1016/S0091-6749(95)70315-2			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852669				2022-12-18	WOS:A1995QH69700005
J	BLAINEY, AD; TOPPING, MD; OLLIER, S; DAVIES, RJ				BLAINEY, AD; TOPPING, MD; OLLIER, S; DAVIES, RJ			ALLERGIC RESPIRATORY-DISEASE IN GRAIN WORKERS - THE ROLE OF STORAGE MITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST BARTHOLOMEWS HOSP,COLL MED,DEPT RESP MED,LONDON EC1A 7BE,ENGLAND; OCCUPAT MED & HYG LABS,LONDON,ENGLAND	University of London; Queen Mary University London								ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P166, DOI 10.1016/0091-6749(84)90281-1; ARMITAGE P, 1971, STATISTICAL METHODS; BENNETT J, 1988, BRIT J DIS CHEST, V82, P268, DOI 10.1016/0007-0971(88)90067-8; BENNETT J, 1985, THORAX, V40, P695; BLAINEY AD, 1988, THORAX, V43, P697, DOI 10.1136/thx.43.9.697; BRODER I, 1979, AM REV RESPIR DIS, V119, P193; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHANYEUNG M, 1980, AM REV RESPIR DIS, V121, P329; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTES JE, 1979, LUNG FUNCTION; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; DARKE CS, 1976, THORAX, V31, P294, DOI 10.1136/thx.31.3.294; DOPICO GA, 1977, AM REV RESPIR DIS, V115, P915; DOPICO GA, 1982, CHEST, V81, P55, DOI 10.1378/chest.81.1.55; DOSMAN JA, 1980, AM REV RESPIR DIS, V121, P11; FLEISS JL, 1979, J CHRON DIS, V32, P69, DOI 10.1016/0021-9681(79)90015-8; GRIFFIN P, 1989, J ALLERGY CLIN IMMUN, V84, P108, DOI 10.1016/0091-6749(89)90184-X; GRIFFITHS DA, 1971, ANN APPL BIOL, V82, P180; HAPKE EJ, 1968, THORAX, V23, P451, DOI 10.1136/thx.23.5.451; LACEY J, 1980, OCCUPATIONAL PULMONA; MINK JT, 1980, CHEST, V77, P28, DOI 10.1378/chest.77.1.28; PEPYS J, 1975, CLIN ASPECTS IMMUNOL; Service M. W, 1980, GUIDE MED ENTOMOLOGY; TERHO EO, 1985, ALLERGY, V40, P23, DOI 10.1111/j.1398-9995.1985.tb04150.x; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; WRAITH DG, 1979, CLIN ALLERGY, V9, P454	26	98	99	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					296	303		10.1016/0091-6749(89)90411-9	http://dx.doi.org/10.1016/0091-6749(89)90411-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2778235				2022-12-18	WOS:A1989AR19900004
J	BARNES, PJ				BARNES, PJ			NEUROPEPTIDES IN THE LUNG - LOCALIZATION, FUNCTION, AND PATHOPHYSIOLOGIC IMPLICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BARNES, PJ (corresponding author), BROMPTON HOSP, INST CARDIOTHORAC, DEPT CLIN PHARMACOL, FULHAM RD, LONDON SW3 6HP, ENGLAND.			Barnes, Peter/0000-0002-5122-4018				ANDERSSON P, 1977, ACTA PHARMACOL TOX, V41, P444; ANDERSSON RGG, 1983, EUR J RESPIR DIS, V64, P141; BARNES PJ, 1984, LANCET, V1, P112; BARNES PJ, 1984, THORAX, V39, P561, DOI 10.1136/thx.39.8.561; BARNES PJ, 1984, AM REV RESPIR DIS, V130, P162; BARNES PJ, 1986, ARCH INT PHARMACOD T, V280, P208; BARNES PJ, 1986, J PHYSIOL-LONDON, V374, pP48; BARNES PJ, 1986, BRIT J PHARMACOL, V88, P741, DOI 10.1111/j.1476-5381.1986.tb16246.x; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1986, BRIT J PHARMACOL, V89, P157, DOI 10.1111/j.1476-5381.1986.tb11131.x; BARNES PJ, IN PRESS BR J PHARM; BARNES PJ, IN PRESS AM REV RESP; BARNES PJ, IN PRESS TIPS; BARNES PJ, IN PRESS CURRENT TOP; BORSON DB, 1984, J APPL PHYSIOL, V57, P457, DOI 10.1152/jappl.1984.57.2.457; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; BUNGAARD A, 1983, EUR J RESPIR DI S128, V64, P427; CAMERON AR, 1983, Q J EXP PHYSIOL CMS, V68, P413, DOI 10.1113/expphysiol.1983.sp002735; CARSTAIRS JR, 1986, J PHARMACOL EXP THER, V239, P249; CASTAIRS JR, 1986, EUR J PHARMACOL, V127, P295, DOI 10.1016/0014-2999(86)90380-8; CHEUNG A, 1985, THORAX, V40, P889, DOI 10.1136/thx.40.12.889; CHRISTOFIDES ND, 1984, ENDOCRINOLOGY, V115, P1958, DOI 10.1210/endo-115-5-1958; COLES SJ, 1981, AM REV RESPIR DIS, V124, P531; COLES SJ, 1984, J APPL PHYSIOL, V57, P1323, DOI 10.1152/jappl.1984.57.5.1323; COSTA M, 1982, BRIT MED BULL, V38, P247, DOI 10.1093/oxfordjournals.bmb.a071768; DEY RD, 1981, CELL TISSUE RES, V220, P231; DIAMOND L, 1983, AM REV RESPIR DIS, V128, P827; DIAMOND L, 1980, SCIENCE, V208, P185, DOI 10.1126/science.7361114; EKBLAD E, 1985, BRIT J PHARMACOL, V86, P241, DOI 10.1111/j.1476-5381.1985.tb09455.x; FOREMAN JC, 1983, J PHYSIOL-LONDON, V335, P449, DOI 10.1113/jphysiol.1983.sp014543; FULLER RW, 1985, J APPL PHYSIOL, V58, P1080, DOI 10.1152/jappl.1985.58.4.1080; FULLER RW, IN PRESS J APPL PHYS; FULLER RW, IN PRESS AM REV RESP; GHATEI MA, 1982, ENDOCRINOLOGY, V111, P1248, DOI 10.1210/endo-111-4-1248; GREENBERG B, 1985, THORAX, V40, P715; HAMASAKI Y, 1983, J APPL PHYSIOL, V54, P1607, DOI 10.1152/jappl.1983.54.6.1607; HAMASAKI Y, 1981, CLIN RES, V29, pA550; IRVIN GG, 1982, J APPL PHYSL RESPIRA, V52, P562; ITO Y, 1982, J PHYSIOL-LONDON, V330, P497, DOI 10.1113/jphysiol.1982.sp014355; KARLSSON JA, 1984, LIFE SCI, V35, P2681, DOI 10.1016/0024-3205(84)90038-9; KARLSSON JA, 1984, ACTA PHYSIOL SCAND, V122, P589, DOI 10.1111/j.1748-1716.1984.tb07548.x; LAITINEN A, 1985, HISTOCHEMISTRY, V82, P313, DOI 10.1007/BF00494059; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAITINEN LA, 1983, THORAX, V38, P531, DOI 10.1136/thx.38.7.531; LAITINEN LA, IN PRESS AM REV RESP; LAUWERYNS JM, 1985, J NEUROL SCI, V67, P81, DOI 10.1016/0022-510X(85)90024-3; LAZARUS SC, 1986, AM J PHYSIOL, V61, P1322; LEE CM, 1982, N-S ARCH PHARMACOL, V318, P281, DOI 10.1007/BF00501166; LEROUX P, 1984, ENDOCRINOLOGY, V114, P1506, DOI 10.1210/endo-114-5-1506; LUNDBERG JM, 1984, PEPTIDES, V5, P593, DOI 10.1016/0196-9781(84)90090-1; LUNDBERG JM, 1981, ACTA PHYSIOL SCAND, P1; LUNDBERG JM, 1984, CELL TISSUE RES, V235, P251; LUNDBERG JM, 1983, ACTA PHYSIOL SCAND, V119, P243, DOI 10.1111/j.1748-1716.1983.tb07334.x; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P477, DOI 10.1111/j.1748-1716.1982.tb07171.x; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; LUNDBERG JM, 1985, EUR J PHARMACOL, V108, P315, DOI 10.1016/0014-2999(85)90456-X; LUNDBERG JM, 1983, ACTA PHYSIOL SCAND, V119, P49, DOI 10.1111/j.1748-1716.1983.tb07304.x; MATSUZAKI Y, 1980, SCIENCE, V210, P1252, DOI 10.1126/science.6254154; MICHOUD MC, 1985, AM REV RESPIR DIS, V131, P284; MORICE A, 1983, LANCET, V2, P1225; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; NANDIWADA PA, 1985, J APPL PHYSIOL, V58, P1723, DOI 10.1152/jappl.1985.58.5.1723; NATHANSON I, 1983, J APPL PHYSIOL, V55, P1844, DOI 10.1152/jappl.1983.55.6.1844; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; PACK RJ, 1984, EUR J RESPIR DIS, V65, P559; PALMER JB, IN PRESS J APPL PHYS; PALMER JB, 1986, AM REV RESPIR DIS, V133, pA91; PALMER JB, 1985, AM REV RESPIR DIS, V131, P282; PALMER JBD, 1986, THORAX, V41, P663, DOI 10.1136/thx.41.9.663; PALMER JBD, 1985, THORAX, V40, P713; PARTANEN M, IN PRESS CELL TISSUE; PAYAN DG, 1984, J IMMUNOL, V132, P1601; PEATFIELD AC, 1983, AM REV RESPIR DIS, V128, P89, DOI 10.1164/arrd.1983.128.1.89; PEATFIELD AC, 1983, J PHYSIOL-LONDON, V342, P335, DOI 10.1113/jphysiol.1983.sp014854; POLAK JM, 1982, EXP LUNG RES, V3, P313, DOI 10.3109/01902148209069660; RICHARDSON JB, 1981, LUNG, V159, P315, DOI 10.1007/BF02713931; ROBBERECHT P, 1981, BIOCHIM BIOPHYS ACTA, V678, P76, DOI 10.1016/0304-4165(81)90049-0; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; SAID SI, 1984, PEPTIDES, V5, P143, DOI 10.1016/0196-9781(84)90197-9; SAID SI, 1982, EXP LUNG RES, V3, P343, DOI 10.3109/01902148209069662; SHEPPARD MN, 1984, THORAX, V39, P326, DOI 10.1136/thx.39.5.326; SZAREK JL, 1984, AM REV RESPIR DIS, V129, P243; TANAKA DT, 1984, J APPL PHYSIOL, V57, P1551, DOI 10.1152/jappl.1984.57.5.1551; TATEMOTO K, 1984, PEPTIDES, V5, P151, DOI 10.1016/0196-9781(84)90198-0; THEODORSSONNORHEIM E, 1985, ACTA PHYSIOL SCAND, V124, P129, DOI 10.1111/j.1748-1716.1985.tb07642.x; UDDMAN R, 1979, ORL J OTO-RHINO-LARY, V41, P221, DOI 10.1159/000275461; UDDMAN R, 1984, ARCH OTO-RHINO-LARYN, V239, P145, DOI 10.1007/BF00463555; UNDEM BJ, 1983, EUR J PHARMACOL, V88, P247, DOI 10.1016/0014-2999(83)90012-2; VENUGOPALAN CS, 1981, PHYSIOLOGIST, V24, P83; WORTHEN GS, 1985, J APPL PHYSIOL, V59, P1098, DOI 10.1152/jappl.1985.59.4.1098	90	98	101	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					285	295		10.1016/0091-6749(87)90143-6	http://dx.doi.org/10.1016/0091-6749(87)90143-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	3546463				2022-12-18	WOS:A1987G179100001
J	VANMETRE, TE; MARSH, DG; ADKINSON, NF; FISH, JE; KAGEYSOBOTKA, A; NORMAN, PS; RADDEN, EB; ROSENBERG, GL				VANMETRE, TE; MARSH, DG; ADKINSON, NF; FISH, JE; KAGEYSOBOTKA, A; NORMAN, PS; RADDEN, EB; ROSENBERG, GL			DOSE OF CAT (FELIS-DOMESTICUS) ALLERGEN-1 (FEL-D-1) THAT INDUCES ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV HOSP,ALLERGY CLIN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine					NIAID NIH HHS [AI-18374, AI-10304, AI-11936] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018374] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1976, MANUAL CLIN IMMUNOLO; ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; ANDERSON MC, 1981, J IMMUNOL, V127, P972; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BROWN PR, 1984, INT ARCH ALLER A IMM, V74, P67, DOI 10.1159/000233518; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DURHAM OC, 1946, J ALLERGY, V17, P79, DOI 10.1016/0021-8707(46)90025-1; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; FRASER DA, 1973, SIZING METHODOLOGY I, P163; GRAFF-LONNEVIG V, 1984, Journal of Allergy and Clinical Immunology, V73, P139; HEDLIN G, 1984, Journal of Allergy and Clinical Immunology, V73, P139; LOWENSTEIN H, 1980, REGULATORY CONTROL S, P75; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P320; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; Siegel S., 1956, NONPARAMETRIC STAT B; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SUDIN B, 1985, J ALLERGY CLIN IMMUN, V75, P163; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1977, J ALLERGY CLIN IMMUN, V59, P341, DOI 10.1016/0091-6749(77)90058-6; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3	27	98	98	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				62	75		10.1016/0091-6749(86)90116-8	http://dx.doi.org/10.1016/0091-6749(86)90116-8			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3722635				2022-12-18	WOS:A1986D299600011
J	VANMETRE, TE; ADKINSON, NF; AMODIO, FJ; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; MARDINEY, MR; NORMAN, PS; ROSENBERG, GL				VANMETRE, TE; ADKINSON, NF; AMODIO, FJ; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; MARDINEY, MR; NORMAN, PS; ROSENBERG, GL			A COMPARISON OF IMMUNOTHERAPY SCHEDULES FOR INJECTION TREATMENT OF RAGWEED POLLEN HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV HOSP,ALLERGY CLIN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine					NCRR NIH HHS [5MOIRR35-20] Funding Source: Medline; NIAID NIH HHS [AI 11936-05] Funding Source: Medline; NCPDCID CDC HHS [3 P50 AL 10304-0851 ACIRC] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCPDCID CDC HHS		CONNELL JT, 1967, ANN ALLERGY, V25, P239; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; HIRSCH SR, 1979, J ALLERGY CLIN IMMUN, V63, P167; HIRSCH SR, 1981, J ALLERGY CLIN IMMUN, V68, P133, DOI 10.1016/0091-6749(81)90172-X; HIRSCH SR, 1981, 37TH P ANN M AM AC A, P33; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; KELLY JF, 1980, J ALLERGY CLIN IMMUN, V65, P50, DOI 10.1016/0091-6749(80)90176-1; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; Lieberman P, 1974, Adv Intern Med, V19, P391; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; MELAM HL, 1970, J ALLERGY, V46, P292, DOI 10.1016/0021-8707(70)90069-9; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V62, P314, DOI 10.1016/0091-6749(78)90164-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1979, J ALLERGY CLIN IMMUN, V63, P167; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; NORMAN PS, 1973, RECENT ADV IMMUNOTHE; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; Sherman WB, 1941, J IMMUNOL, V40, P289; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3	36	98	98	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	2					181	193		10.1016/0091-6749(82)90098-7	http://dx.doi.org/10.1016/0091-6749(82)90098-7			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NC581	7056949				2022-12-18	WOS:A1982NC58100004
J	Balmes, JR				Balmes, John R.			Household air pollution from domestic combustion of solid fuels and health	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Household air pollution; indoor air pollution; biomass smoke; solid fuel; global burden of disease	OBSTRUCTIVE PULMONARY-DISEASE; FINE PARTICULATE MATTER; LUNG-CANCER RISK; BIOMASS FUEL; RESPIRATORY SYMPTOMS; WOOD SMOKE; CHRONIC-BRONCHITIS; OXIDATIVE STRESS; BLOOD-PRESSURE; TOBACCO-SMOKE	Inefficient cooking and heating with solid fuels in poorly ventilated homes are a major source of exposure to indoor air pollution in developing countries. Household air pollution from cooking and heating with solid fuels also is an important contributor to outdoor air pollution. The combustion of organically derived solid fuel is qualitatively similar to the burning of tobacco in terms of emissions of particulate matter and gases, and the mechanisms by which solid fuel smoke causes adverse health effects in human subjects are likely similar. The public health effect of domestic cooking and heating with solid fuels is great. The World Health Organization estimates that there are 3.8 million deaths globally per year attributable to household air pollution. This estimate is based on the strength of the evidence, primarily meta-analyses of epidemiologic studies of acceptable scientific quality, although for cardiovascular disease, the evidence is more inferential. The greatest burden of household air pollution-related premature deaths is in children with pneumonia exposed to biomass smoke. The greatest estimated burden in adults is cardiovascular disease, but chronic obstructive pulmonary disease and lung cancer are important causes of disability and premature death in women, who are the primary cooks and tend not to smoke tobacco in developing countries. Research gaps and opportunities for interventions to reduce effects of solid fuel smoke on public health are identified.	[Balmes, John R.] Univ Calif San Francisco, Dept Med, Div Occupat & Environm Med, Box 0843, San Francisco, CA 94143 USA; [Balmes, John R.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley	Balmes, JR (corresponding author), Univ Calif San Francisco, Dept Med, Div Occupat & Environm Med, Box 0843, San Francisco, CA 94143 USA.	john.balmes@ucsf.edu						Addo-Yobo EOD, 2007, PLOS MED, V4, P355, DOI 10.1371/journal.pmed.0040070; Agrawal S, 2012, J ASTHMA, V49, P355, DOI 10.3109/02770903.2012.663030; Albalak R, 1999, THORAX, V54, P1004, DOI 10.1136/thx.54.11.1004; Amaral AFS, 2018, AM J RESP CRIT CARE, V197, P595, DOI 10.1164/rccm.201701-0205OC; [Anonymous], 2010, HOUS US SOL FUELS HI; Arku RE, 2018, ENVIRON RES, V160, P499, DOI 10.1016/j.envres.2017.10.026; Balakrishnan K, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-77; Balmes JR, 2018, AM J RESP CRIT CARE, V197, P547, DOI 10.1164/rccm.201801-0033ED; Barregard L, 2008, OCCUP ENVIRON MED, V65, P319, DOI 10.1136/oem.2006.032458; Bates D, 2013, J STAT SOFTW, V52, P1, DOI 10.18637/jss.v052.i05; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; Bruce N, 2015, THORAX, V70, P433, DOI 10.1136/thoraxjnl-2014-206625; Burnett RT, 2014, ENVIRON HEALTH PERSP, V122, P397, DOI 10.1289/ehp.1307049; Pena MB, 2015, HYPERTENSION, V65, P1134, DOI 10.1161/HYPERTENSIONAHA.114.04840; Caballero A, 2008, CHEST, V133, P343, DOI 10.1378/chest.07-1361; Chapman RS, 2005, BMJ-BRIT MED J, V331, P1050, DOI 10.1136/bmj.38628.676088.55; Chen F, 2018, ENVIRON POLLUT, V232, P329, DOI 10.1016/j.envpol.2017.08.072; Cheng LL, 2015, J TRANSL INTERN MED, V3, P126, DOI 10.1515/jtim-2015-0012; Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529; Diette GB, 2012, GLOB HEART, V7, P265, DOI 10.1016/j.gheart.2012.06.016; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ezzati M, 2001, ENVIRON HEALTH PERSP, V109, P481, DOI 10.2307/3454706; FAGBULE D, 1994, ANN TROP PAEDIATR, V14, P15, DOI 10.1080/02724936.1994.11747686; Fandino-Del-Rio M, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2179-x; Forchhammer L, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-7; Gordon S, 2017, LANCET RESP MED, V5, P918, DOI 10.1016/S2213-2600(17)30393-4; Hosgood HD, 2011, INT J EPIDEMIOL, V40, P719, DOI 10.1093/ije/dyq259; Hu GP, 2010, CHEST, V138, P20, DOI 10.1378/chest.08-2114; Jacobson MZ, 2001, NATURE, V409, P695, DOI 10.1038/35055518; Kurmi OP, 2010, THORAX, V65, P221, DOI 10.1136/thx.2009.124644; Kurmi OP, 2012, EUR RESPIR J, V40, P1228, DOI 10.1183/09031936.00099511; Lam NL, 2018, INDOOR AIR, V28, P218, DOI 10.1111/ina.12433; Lam NL, 2012, J TOXICOL ENV HEAL B, V15, P396, DOI 10.1080/10937404.2012.710134; Lee A, 2015, ANN GLOB HEALTH, V81, P368, DOI 10.1016/j.aogh.2015.08.006; Lee MS, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-18; McCarthy CE, 2016, AM J PHYSIOL-LUNG C, V311, pL1222, DOI 10.1152/ajplung.00183.2016; Mehra D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052889; Migliaccio CT, 2010, INHAL TOXICOL, V22, P104, DOI 10.3109/08958370903008870; Mondal NK, 2018, MOL CELL BIOCHEM, V447, P63, DOI 10.1007/s11010-018-3293-0; Mortimer K, 2017, LANCET, V389, P167, DOI 10.1016/S0140-6736(16)32507-7; Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1; Noonan CW, 2017, ENVIRON HEALTH PERSP, V125, DOI [10.1289/EHP849, 10.1289/ehp849]; Fernandes AGO, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0235-6; Po JYT, 2011, THORAX, V66, P232, DOI 10.1136/thx.2010.147884; Pokhrel AK, 2010, ENVIRON HEALTH PERSP, V118, P558, DOI 10.1289/ehp.0901032; Pope CA, 2009, CIRCULATION, V120, P941, DOI 10.1161/CIRCULATIONAHA.109.857888; Pope D, 2015, ENVIRON HEALTH PERSP, V123, P285, DOI 10.1289/ehp.1408200; Ramirez-Venegas A, 2006, AM J RESP CRIT CARE, V173, P393, DOI 10.1164/rccm.200504-568OC; Raspanti GA, 2016, ENVIRON RES, V147, P141, DOI 10.1016/j.envres.2016.02.008; Regalado J, 2006, AM J RESP CRIT CARE, V174, P901, DOI 10.1164/rccm.200503-479OC; Riddervold IS, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-12; Rivera RM, 2008, INT J TUBERC LUNG D, V12, P972; Romieu I, 2009, AM J RESP CRIT CARE, V180, P649, DOI 10.1164/rccm.200810-1556OC; Rylance J, 2015, AM J RESP CELL MOL, V52, P584, DOI 10.1165/rcmb.2014-0188OC; Rylance J, 2013, AM J PHYSIOL-LUNG C, V304, pL571, DOI 10.1152/ajplung.00416.2012; Sehlstedt M, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-21; Siddharthan T, 2018, AM J RESP CRIT CARE, V197, P611, DOI 10.1164/rccm.201709-1861OC; Smith KR, 2014, ANNU REV PUBL HEALTH, V35, P185, DOI 10.1146/annurev-publhealth-032013-182356; Smith KR, 2013, ANNU REV PUBL HEALTH, V34, P159, DOI 10.1146/annurev-publhealth-031912-114404; Smith KR, 2011, LANCET, V378, P1717, DOI 10.1016/S0140-6736(11)60921-5; Smith KR, 2010, ENVIRON HEALTH PERSP, V118, P1643, DOI 10.1289/ehp.1002517; Smith-Sivertsen T, 2009, AM J EPIDEMIOL, V170, P211, DOI 10.1093/aje/kwp100; Snider G, 2018, ENVIRON INT, V117, P116, DOI 10.1016/j.envint.2018.04.048; Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X; Stanaway JD, 2018, LANCET, V392, P1923, DOI 10.1016/s0140-6736(18)32225-6; Stockfelt L, 2013, INHAL TOXICOL, V25, P417, DOI 10.3109/08958378.2013.798387; Stockfelt L, 2012, INHAL TOXICOL, V24, P47, DOI 10.3109/08958378.2011.633281; Sumpter C, 2013, TROP MED INT HEALTH, V18, P101, DOI 10.1111/tmi.12013; Thacher JD, 2013, RESP MED, V107, P1845, DOI 10.1016/j.rmed.2013.09.009; Unosson J, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-20; Vork KL, 2007, ENVIRON HEALTH PERSP, V115, P1394, DOI 10.1289/ehp.10155; Wallwork RS, 2017, AM J EPIDEMIOL, V185, P30, DOI 10.1093/aje/kww157; Warwick H., 2004, SMOKE KILLER KITCHEN; Whitehouse AL, 2018, SCI TOTAL ENVIRON, V635, P405, DOI 10.1016/j.scitotenv.2018.04.125; Wong GWK, 2013, LANCET RESP MED, V1, P386, DOI 10.1016/S2213-2600(13)70073-0; World Health Organization, CHRON OBSTR PULM DIS; World Health Organization, HOUS AIR POLL HLTH; Young BN, 2019, INDOOR AIR, V29, P130, DOI 10.1111/ina.12507; Zelikoff JT, 2002, J TOXICOL ENV HEAL B, V5, P269, DOI 10.1080/10937400290070062; Zhou YM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001621	80	97	98	11	77	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					1979	1988		10.1016/j.jaci.2019.04.016	http://dx.doi.org/10.1016/j.jaci.2019.04.016			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	31176380	Bronze			2022-12-18	WOS:000470113200001
J	Asarnoj, A; Hamsten, C; Waden, K; Lupinek, C; Andersson, N; Kull, I; Curin, M; Anto, J; Bousquet, J; Valenta, R; Wickman, M; van Hage, M				Asarnoj, Anna; Hamsten, Carl; Waden, Konrad; Lupinek, Christian; Andersson, Niklas; Kull, Inger; Curin, Mirela; Anto, Josep; Bousquet, Jean; Valenta, Rudolf; Wickman, Magnus; van Hage, Marianne			Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: ABAMSE/MeDALL study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen; Barn/Children Allergy/Asthma Milieu Stockholm Epidemiologic; birth cohort; cat; children; dog; IgE; ISAC technology; microarray; pet; sensitization; Can f 1; Can f 5; Fel d 1; prediction	FEL D 1; IGE; DIAGNOSIS; ASTHMA; POPULATION; LIPOCALIN; INHALANT; PATTERNS; CHILDREN; HEALTH	Background: Sensitization to individual cat and dog allergen molecules can contribute differently to development of allergy to these animals. Objective: We sought to investigate the association between sensitization patterns to cat and dog allergen molecules during childhood and symptoms to these furry animals up to age 16 years. Methods: Data from 779 randomly collected children from the Barn/Children Allergy/Asthma Milieu Stockholm Epidemiologic birth cohort at 4, 8, and 16 years were used. IgE levels to cat and dog were determined by using ImmunoCAP, and levels to allergen molecules were determined by using an allergen chip based on ISAC technology (Mechanisms for the Development of Allergy chip). Allergy was defined as reported rhinitis, conjunctivitis, or asthma at exposure to cat or dog. Results: Cross-sectionally, IgE to Fel d 1 and cat extract had similar positive predictive values for cat allergy. IgE to Can f 1 showed a higher positive predictive value for dog allergy than dog extract IgE. Sensitizations to Fel d 1 and Can f 1 in childhood were significantly associated with symptoms to cat or dog at age 16 years. Polysensitization to 3 or more allergen molecules from cat or dog was a better longitudinal predictor of cat or dog symptoms than results of IgE tests with cat or dog allergen extract, respectively. Cross-sectionally, cat/dog-polysensitized children had higher IgE levels and more frequent symptoms to cat and dog than monosensitized children. Conclusions: Sensitization to Fel d 1 and Can f 1 in childhood and polysensitization to either cat or dog allergen molecules predict cat and dog allergy cross-sectionally and longitudinally significantly better than IgE to cat or dog extract.	[Asarnoj, Anna; Hamsten, Carl; Waden, Konrad; van Hage, Marianne] Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, L2 04, S-17176 Stockholm, Sweden; [Asarnoj, Anna; Hamsten, Carl; Waden, Konrad; van Hage, Marianne] Univ Hosp, Stockholm, Sweden; [Asarnoj, Anna] Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Hamsten, Carl] Karolinska Inst, Ctr Inflammatory Dis, Stockholm, Sweden; [Andersson, Niklas; Kull, Inger; Wickman, Magnus] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Wickman, Magnus] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Kull, Inger; Wickman, Magnus] Soder Sjukhuset, Sachs Childrens Hosp, Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Stockholm South Gen Hosp, Dept Clin Sci & Educ, Stockholm, Sweden; [Lupinek, Christian; Curin, Mirela; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Anto, Josep] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Anto, Josep] Hosp del Mar, Res Inst, IMIM, Barcelona, Spain; [Anto, Josep] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Anto, Josep] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Bousquet, Jean] Hop Arnaud de Villeneuve, Univ Hosp Montpellier, Villejuif, France	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Medical University of Vienna; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Universite de Montpellier; CHU de Montpellier	Asarnoj, A (corresponding author), Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, L2 04, S-17176 Stockholm, Sweden.; Asarnoj, A (corresponding author), Karolinska Univ Hosp, S-17176 Stockholm, Sweden.	anna.asarnoj@ki.se	Anto, J M/H-2676-2014; Lupinek, Christian/I-3311-2019; Bousquet, Jean/O-4221-2019; van Hage, Marianne/A-9678-2017; Asarnoj, Anna/ABC-4112-2020; Andersson, Niklas/AAN-1633-2020	Anto, J M/0000-0002-4736-8529; Lupinek, Christian/0000-0002-8612-8245; van Hage, Marianne/0000-0003-3091-1596; Andersson, Niklas/0000-0001-9785-7462; Kull, Inger/0000-0001-6096-3771; Curin, Mirela/0000-0003-2575-4127; Valenta, Rudolf/0000-0001-5944-3365; Asarnoj, Anna/0000-0002-0797-2369	Swedish Asthma and Allergy Association's Research Foundation; Foundation for Health Care Sciences and Allergy Research; Centre for Allergy Research (CfA); Stockholm County Council; Swedish Research Council; Swedish Heart-Lung Foundation; Center for Inflammatory Diseases, Karolinska Institutet; Swedish Cancer and Allergy Foundation; Konsul Th C Bergs Foundation; King Gustaf V Research Foundation; Swedish Society of Medicine; Magnus Bergvall Foundation; Karolinska Institutet; Austrian Science Fund (FWF) [F4605]; European Commission [261357]	Swedish Asthma and Allergy Association's Research Foundation; Foundation for Health Care Sciences and Allergy Research; Centre for Allergy Research (CfA); Stockholm County Council(Stockholm County Council); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Center for Inflammatory Diseases, Karolinska Institutet; Swedish Cancer and Allergy Foundation; Konsul Th C Bergs Foundation; King Gustaf V Research Foundation; Swedish Society of Medicine; Magnus Bergvall Foundation; Karolinska Institutet(Karolinska Institutet); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); European Commission(European CommissionEuropean Commission Joint Research Centre)	Supported by the Swedish Asthma and Allergy Association's Research Foundation, the Foundation for Health Care Sciences and Allergy Research, the Centre for Allergy Research (CfA), Stockholm County Council, the Swedish Research Council, the Swedish Heart-Lung Foundation, the Center for Inflammatory Diseases, Karolinska Institutet, the Swedish Cancer and Allergy Foundation, the Konsul Th C Bergs Foundation, the King Gustaf V Research Foundation, the Swedish Society of Medicine, the Magnus Bergvall Foundation and Karolinska Institutet, the Austrian Science Fund (FWF project F4605), and the European Commission's Seventh Framework 29 Program MeDALL under grant agreement no. 261357.	Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Asarnoj A, 2008, CLIN EXP ALLERGY, V38, P1507, DOI 10.1111/j.1365-2222.2008.03046.x; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Canonica GW, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-17; Curin M, 2014, J ALLERGY CLIN IMMUN, V133, P918, DOI 10.1016/j.jaci.2013.10.058; Curin M, 2011, INT ARCH ALLERGY IMM, V154, P258, DOI 10.1159/000321113; Gronlund H, 2008, CLIN EXP ALLERGY, V38, P1275, DOI 10.1111/j.1365-2222.2008.03003.x; Gronlund H, 2010, INT ARCH ALLERGY IMM, V151, P265, DOI 10.1159/000250435; Hales BJ, 2013, J ALLER CL IMM-PRACT, V1, P656, DOI 10.1016/j.jaip.2013.08.008; Hales BJ, 2013, J ALLERGY CLIN IMMUN, V1, pe1; Hamilton RG, 2010, IMMUNOL RES, V47, P273, DOI 10.1007/s12026-009-8160-3; KLEINETEBBE J, 1993, INT ARCH ALLERGY IMM, V100, P256, DOI 10.1159/000236421; Konradsen JR, 2014, PEDIAT ALLERG IMM-UK, V25, P187, DOI 10.1111/pai.12198; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Mattsson L, 2009, J ALLERGY CLIN IMMUN, V123, P362, DOI 10.1016/j.jaci.2008.11.021; Nilsson OB, 2014, METHODS, V66, P86, DOI 10.1016/j.ymeth.2013.09.002; Nivenius E, 2012, CLIN EXP ALLERGY, V42, P58, DOI 10.1111/j.1365-2222.2011.03858.x; Nordlund B, 2012, ALLERGY, V67, P661, DOI 10.1111/j.1398-9995.2012.02797.x; Patelis A, 2012, J ALLERGY CLIN IMMUN, V130, P397, DOI 10.1016/j.jaci.2012.03.046; Prosperi MCF, 2014, PEDIAT ALLERG IMM-UK, V25, P71, DOI 10.1111/pai.12139; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Schmitz R, 2013, INT ARCH ALLERGY IMM, V162, P263, DOI 10.1159/000353344; Smith W, 2004, CLIN EXP ALLERGY, V34, P1732, DOI 10.1111/j.1365-2222.2004.02090.x; Tillander H, 2014, J ALLERGY CLIN IMMUN, V133, P580, DOI 10.1016/j.jaci.2013.09.009; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5	28	97	99	4	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					813	+		10.1016/j.jaci.2015.09.052	http://dx.doi.org/10.1016/j.jaci.2015.09.052			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26686472	Green Accepted			2022-12-18	WOS:000371897500025
J	Eggel, A; Baravalle, G; Hobi, G; Kim, B; Buschor, P; Forrer, P; Shin, JS; Vogel, M; Stadler, BM; Dahinden, CA; Jardetzky, TS				Eggel, Alexander; Baravalle, Guenther; Hobi, Gabriel; Kim, Beomkyu; Buschor, Patrick; Forrer, Patrik; Shin, Jeoung-Sook; Vogel, Monique; Stadler, Beda M.; Dahinden, Clemens A.; Jardetzky, Theodore S.			Accelerated dissociation of IgE-Fc epsilon RI complexes by disruptive inhibitors actively desensitizes allergic effector cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; basophils; mast cells; IgE; Fc epsilon RI alpha; designed ankyrin repeat proteins; inhibitors	HIGH-AFFINITY RECEPTOR; HUMAN BASOPHILS; IN-VITRO; MONOCLONAL-ANTIBODIES; DOWN-REGULATION; ALPHA-SUBUNIT; BINDING-SITE; OMALIZUMAB; ASTHMA; EXPRESSION	Background: The remarkably stable interaction of IgE with its high-affinity receptor Fc epsilon RI on basophils and mast cells is critical for the induction of allergic hypersensitivity reactions. Because of the exceptionally slow dissociation rate of IgE-Fc epsilon RI complexes, such allergic effector cells permanently display allergen-specific IgE on their surface and immediately respond to allergen challenge by releasing inflammatory mediators. We have recently described a novel macromolecular inhibitor that actively promotes the dissociation of IgE from Fc epsilon RI through a molecular mechanism termed facilitated dissociation. Objective: Here we assessed the therapeutic potential of this non-immunoglobulin-based IgE inhibitor E2_79, a designed ankyrin repeat protein (DARPin), as well as a novel engineered biparatopic DARPin bi53_79, and directly compared them with the established anti-IgE antibody omalizumab. Methods: IgE-Fc epsilon RI complex dissociation was analyzed in vitro by using recombinant proteins in ELISA and surface plasmon resonance, ex vivo by using human primary basophils with flow cytometry, and in vivo by using human Fc epsilon RI alpha-chain transgenic mice in a functional passive cutaneous anaphylaxis test. Results: We show that E2_79-mediated removal of IgE from primary human basophils fully abrogates IgE-dependent cell activation and release of proinflammatory mediators ex vivo. Furthermore, we report that omalizumab also accelerates the dissociation of IgE from Fc epsilon eRI, although much less efficiently than E2_79. Using the biparatopic IgE targeting approach, we further improved the disruptive potency of E2_79 by approximately 100-fold and show that disruptive IgE inhibitors efficiently prevent passive cutaneous anaphylaxis in mice expressing the human Fc epsilon RI alpha-chain. Conclusion: Our findings highlight the potential of such novel IgE inhibitors as important diagnostic and therapeutic tools for management of allergic diseases.	[Eggel, Alexander; Hobi, Gabriel; Buschor, Patrick; Vogel, Monique; Stadler, Beda M.; Dahinden, Clemens A.] Univ Bern, Inst Immunol, CH-3012 Bern, Switzerland; [Baravalle, Guenther; Shin, Jeoung-Sook] Univ Calif San Francisco, Sandler Asthma Basic Res Ctr, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Kim, Beomkyu; Jardetzky, Theodore S.] Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; [Forrer, Patrik] Mol Partners AG, Zurich, Switzerland	University of Bern; University of California System; University of California San Francisco; Stanford University	Eggel, A (corresponding author), Inst Immunol, Sahlihaus 2, Bern, Switzerland.	alexander.eggel@iib.unibe.ch	Kim, Beomkyu/AAM-7220-2020; Eggel, Alexander/J-8177-2019	Eggel, Alexander/0000-0001-8746-3339; Forrer, Patrik/0000-0002-9717-0991	Fondation Acteria; Swiss National Science Foundation Ambizione grant [PZ00P3_148185]; Swiss National Science Foundation [310030_127350]; National Institutes of Health [AI-18939]; American Asthma Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI038972, R37AI038972, R37AI018939, R01AI018939] Funding Source: NIH RePORTER	Fondation Acteria; Swiss National Science Foundation Ambizione grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Asthma Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a grant from the Fondation Acteria (to A. E.), a Swiss National Science Foundation Ambizione grant (PZ00P3_148185, to A. E.), a Swiss National Science Foundation grant (310030_127350, to C. A. D.), a National Institutes of Health research grant (AI-18939), and an American Asthma Foundation Senior Investigator Award (to T.S.J.).	Baumann MJ, 2010, IMMUNOL LETT, V133, P78, DOI 10.1016/j.imlet.2010.07.005; Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Casale TB, 2009, J ALLERGY CLIN IMMUN, V123, P770, DOI 10.1016/j.jaci.2009.02.016; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Cochran JR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000276; Cox L, 2011, J ALLERGY CLIN IMMUN, V128, P210, DOI 10.1016/j.jaci.2011.04.010; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Eggel A, 2011, ALLERGY, V66, P961, DOI 10.1111/j.1398-9995.2011.02546.x; Eggel A, 2009, J MOL BIOL, V393, P598, DOI 10.1016/j.jmb.2009.08.014; FungLeung WP, 1996, J EXP MED, V183, P49, DOI 10.1084/jem.183.1.49; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Holdom MD, 2011, NAT STRUCT MOL BIOL, V18, P571, DOI 10.1038/nsmb.2044; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Kim B, 2012, NATURE, V491, P613, DOI 10.1038/nature11546; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KNUTTIMULLER JM, 1986, ALLERGY, V41, P457, DOI 10.1111/j.1398-9995.1986.tb00327.x; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; KURIMOTO Y, 1991, EUR J IMMUNOL, V21, P361, DOI 10.1002/eji.1830210217; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MacGlashan DW, 2007, J LEUKOCYTE BIOL, V82, P1003, DOI 10.1189/jlb.0207103; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Mendonsa SD, 2004, ANAL CHEM, V76, P5387, DOI 10.1021/ac049857v; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Nakamura GR, 2002, P NATL ACAD SCI USA, V99, P1303, DOI 10.1073/pnas.022635599; Nakamura GR, 2001, BIOCHEMISTRY-US, V40, P9828, DOI 10.1021/bi0109360; Nechansky A, 1997, HYBRIDOMA, V16, P441, DOI 10.1089/hyb.1997.16.441; Nechansky A, 1998, FEBS LETT, V441, P225, DOI 10.1016/S0014-5793(98)01558-0; RISKE F, 1991, J BIOL CHEM, V266, P11245; Roovers RC, 2011, INT J CANCER, V129, P2013, DOI 10.1002/ijc.26145; Rudolf MP, 2000, J IMMUNOL, V165, P813, DOI 10.4049/jimmunol.165.2.813; Saini SS, 1999, J IMMUNOL, V162, P5624; Stamos J, 2004, STRUCTURE, V12, P1289, DOI 10.1016/j.str.2004.04.015; Tschopp CM, 2006, BLOOD, V108, P2290, DOI 10.1182/blood-2006-03-010348; Valent P, 2004, METHODS, V32, P265, DOI 10.1016/j.ymeth.2003.08.006; Wiegand TW, 1996, J IMMUNOL, V157, P221; Wright JD, 1998, PROTEIN ENG, V11, P421, DOI 10.1093/protein/11.6.421; Zheng L, 2008, BIOCHEM BIOPH RES CO, V375, P619, DOI 10.1016/j.bbrc.2008.08.055; ZURCHER AW, 1995, IMMUNOL LETT, V46, P49, DOI 10.1016/0165-2478(95)00014-V	45	97	102	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1709	+		10.1016/j.jaci.2014.02.005	http://dx.doi.org/10.1016/j.jaci.2014.02.005			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24642143	Green Accepted			2022-12-18	WOS:000336672500025
J	Massoud, AH; Yona, M; Xue, D; Chouiali, F; Alturaihi, H; Ablona, A; Mourad, W; Piccirillo, CA; Mazer, BD				Massoud, Amir H.; Yona, Madelaine; Xue, Di; Chouiali, Fazila; Alturaihi, Haydar; Ablona, Aidan; Mourad, Walid; Piccirillo, Ciriaco A.; Mazer, Bruce D.			Dendritic cell immunoreceptor: A novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intravenous immunoglobulin; dendritic cells; regulatory T cells; immune modulation; asthma	VASOACTIVE-INTESTINAL-PEPTIDE; ANTIINFLAMMATORY ACTIVITY; AIRWAY HYPERRESPONSIVENESS; MURINE MODEL; IVIG; ANTIGEN; AUTOIMMUNE; INFLAMMATION; DEFICIENCY; ACTIVATION	Background: Intravenous immunoglobulin (IVIg) is a polyclonal IgG preparation with potent immunomodulating properties. Our laboratory demonstrated that IVIg significantly increases numbers of forkhead box protein 3-positive regulatory T (Treg) cells through generation of tolerogenic dendritic cells (DCs) in an allergic airways disease model. Objective: We sought to investigate potential receptors on DCs mediating these events. Methods: C57BL/6 mice were either sensitized to ovalbumin (OVA) intraperitoneally or through adoptive transfer of OVA-primed DCs and then challenged with intranasal OVA. IVIg was fractionated into sialic acid-enriched IVIg (SA-IVIg) and sialic acid-depleted IVIg (non-SA-IVIg). Dendritic cell immunoreceptor (DCIR) constructs in CHO cells or on DCs were examined by using fluorescent microscopy and flow cytometry. Results: Administration of SA-IVIg, but not non-SA-IVIg, to OVA-sensitized and OVA-challenged mice induced Treg cells and attenuated airway hyperresponsiveness (AHR) and inflammation comparably with IVIg. Bone marrow-derived dendritic cells cultured with SA-IVIg or IVIg adoptively transferred to mice before OVA challenge induced Treg cells and inhibited AHR. IVIg-treated bone marrow-derived dendritic cells from Fc gamma receptor knockout mice inhibited AHR, suggesting IVIg's action was not caused by Fc gamma receptor-mediated events. Fluorescently labeled IVIg or SA-IVIg bound DCs and colocalized specifically to the C-type lectin DCIR. IVIg binding to DCIR induced phosphorylation of Src homology domain 2-containing protein tyrosine phosphatase (SHP) 2 and Src homology domain 2-containing inositol phosphatase 1 (SHIP-1) and internalization of IVIg into DCs. Inhibition of IVIg binding to DCIR by small interfering RNA completely blocked induction of Treg cells. Inhibition of SHP-2 or abrogation of IgG internalization through clatherin inhibitors rendered IVIg ineffective. Conclusions: IVIg alleviates allergic airways disease through interaction of SA-IgG with DCIR. DCIR is a novel receptor for IVIg, mediating interaction of innate and adaptive immunity in tolerogenic responses.	[Massoud, Amir H.; Yona, Madelaine; Xue, Di; Chouiali, Fazila; Ablona, Aidan; Mazer, Bruce D.] McGill Univ, Meakins Christie Labs, Dept Pediat, Div Allergy & Immunol,Res Inst,Hlth Ctr, Montreal, PQ H2X 2P2, Canada; [Massoud, Amir H.; Yona, Madelaine; Xue, Di; Chouiali, Fazila; Ablona, Aidan; Mazer, Bruce D.] McGill Univ, Dept Med, Montreal, PQ H2X 2P2, Canada; [Massoud, Amir H.; Alturaihi, Haydar; Mourad, Walid] Univ Montreal, Inst Rech, Hop St Luc, Dept Immunol & Microbiol, Montreal, PQ, Canada; [Piccirillo, Ciriaco A.] McGill Univ, Res Inst, Dept Microbiol & Immunol, Ctr Hlth, Montreal, PQ H2X 2P2, Canada	McGill University; McGill University; Hydro-Quebec; Universite de Montreal; McGill University	Mazer, BD (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain, Montreal, PQ H2X 2P2, Canada.	bruce.mazer@mcgill.ca	Massoud, Amir Hossein/AAO-2940-2021	Mourad, Walid/0000-0002-1859-9387	Talecris and Grifols Bio-therapeutics (Clinical Investigation Program); Canadian Institutes for Health Research (CIHR) [ISO115295, MOP67211]; Research Institute of the McGill University Health Center (RI-MUHC); Montreal Chest Institute; Strauss Family Foundation; Fonds de Recherche en Sante du Quebec (FRSQ)	Talecris and Grifols Bio-therapeutics (Clinical Investigation Program); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Research Institute of the McGill University Health Center (RI-MUHC); Montreal Chest Institute; Strauss Family Foundation; Fonds de Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec)	Supported by Talecris and Grifols Bio-therapeutics (Clinical Investigation Program) and the Canadian Institutes for Health Research (CIHR grants ISO115295 [to B. D. M.] and MOP67211 [to C. A. P.]), The Research Institute of the McGill University Health Center (RI-MUHC), the Montreal Chest Institute, and the Strauss Family Foundation. A. H. M. was the recipient of a Fonds de Recherche en Sante du Quebec (FRSQ) Student Scholarship. B. D. M. is a Chercheur National of the FRSQ. C. A. P. holds a CIHR Canada Research Chair.	Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Anthony RM, 2012, ANN NY ACAD SCI, V1253, P170, DOI 10.1111/j.1749-6632.2011.06305.x; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Aslam R, 2012, BLOOD, V120, P2127, DOI 10.1182/blood-2012-02-413526; Aubin E, 2011, CLIN IMMUNOL, V141, P273, DOI 10.1016/j.clim.2011.06.009; Bayry J, 2003, BLOOD, V101, P758, DOI 10.1182/blood-2002-05-1447; Brooks R, 2010, J IMMUNOL, V184, P3582, DOI 10.4049/jimmunol.0902844; Costa N, 2013, J CLIN IMMUNOL, V33, P349, DOI 10.1007/s10875-012-9816-7; Cousens LP, 2013, J CLIN IMMUNOL, V33, pS43, DOI 10.1007/s10875-012-9762-4; De Groot AS, 2008, BLOOD, V112, P3303, DOI 10.1182/blood-2008-02-138073; Delgado M, 2006, ANN NY ACAD SCI, V1070, P233, DOI 10.1196/annals.1317.020; Ephrem A, 2008, BLOOD, V111, P715, DOI 10.1182/blood-2007-03-079947; Fujikado N, 2008, NAT MED, V14, P176, DOI 10.1038/nm1697; Gelfand EW, 2012, NEW ENGL J MED, V367, P2015, DOI 10.1056/NEJMra1009433; Gonzalez-Rey E, 2006, BLOOD, V107, P3632, DOI 10.1182/blood-2005-11-4497; Gunnarsson P, 2010, INFLAMM RES, V59, P89, DOI 10.1007/s00011-009-0071-1; Hsu TL, 2009, J BIOL CHEM, V284, P34479, DOI 10.1074/jbc.M109.065961; Kasermann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037243; Kanazawa N, 2002, J INVEST DERMATOL, V118, P261, DOI 10.1046/j.0022-202x.2001.01633.x; Kanazawa N, 2007, J DERMATOL SCI, V45, P77, DOI 10.1016/j.jdermsci.2006.09.001; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kaufman GN, 2011, CLIN EXP ALLERGY, V41, P718, DOI 10.1111/j.1365-2222.2010.03663.x; Koya T, 2009, AM J RESP CELL MOL, V41, P271, DOI 10.1165/rcmb.2008-0256OC; Lambert AA, 2008, BLOOD, V112, P1299, DOI 10.1182/blood-2008-01-136473; Lambert AA, 2011, BLOOD, V117, P6589, DOI 10.1182/blood-2011-01-331363; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Massoud AH, 2012, J ALLERGY CLIN IMMUN, V129, P1656, DOI 10.1016/j.jaci.2012.02.050; Meyer-Wentrup F, 2008, BLOOD, V111, P4245, DOI 10.1182/blood-2007-03-081398; Olivito B, 2010, CLIN EXP RHEUMATOL, V28, pS93; Proulx DP, 2009, IMMUNOL LETT, V124, P18, DOI 10.1016/j.imlet.2009.03.012; Scallon BJ, 2007, MOL IMMUNOL, V44, P1524, DOI 10.1016/j.molimm.2006.09.005; Seite JF, 2010, BLOOD, V116, P1698, DOI 10.1182/blood-2009-12-261461; Shalaby KH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-82; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Takai T, 2005, J CLIN IMMUNOL, V25, P1, DOI 10.1007/s10875-005-0353-8; Tsurikisawa N, 2012, J RHEUMATOL, V39, P1019, DOI 10.3899/jrheum.110981; van Die I, 2010, GLYCOBIOLOGY, V20, P2, DOI 10.1093/glycob/cwp140; Vani J, 2008, AUTOIMMUN REV, V7, P440, DOI 10.1016/j.autrev.2008.04.011; Wu XX, 2012, J IMMUNOL, V189, P3497, DOI 10.4049/jimmunol.1201006; Yamazaki S, 2008, J IMMUNOL, V181, P6923, DOI 10.4049/jimmunol.181.10.6923	43	97	101	0	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					853	+		10.1016/j.jaci.2013.09.029	http://dx.doi.org/10.1016/j.jaci.2013.09.029			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24210883	Bronze			2022-12-18	WOS:000332397600030
J	Konradsen, JR; James, A; Nordlund, B; Reinius, LE; Soderhall, C; Melen, E; Wheelock, A; Carlsen, KCL; Lidegran, M; Verhoek, M; Boot, RG; Dahlen, B; Dahlen, SE; Hedlin, G				Konradsen, Jon R.; James, Anna; Nordlund, Bjorn; Reinius, Lovisa E.; Soderhall, Cilla; Melen, Erik; Wheelock, Asa; Carlsen, Karin C. Lodrup; Lidegran, Marika; Verhoek, Marri; Boot, Rolf G.; Dahlen, Barbro; Dahlen, Sven Erik; Hedlin, Gunilla			The chitinase-like protein YKL-40: A possible biomarker of inflammation and airway remodeling in severe pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; inflammation; airway remodeling; chitinases; imaging; genes	PROBLEMATIC SEVERE ASTHMA; SEVERE CHILDHOOD ASTHMA; CHILDREN; CHITOTRIOSIDASE; LUNG; CHI3L1; CT	Background: Problematic severe childhood asthma includes a subgroup of patients who are resistant to therapy. The specific mechanisms involved are unknown, and novel biomarkers are required to facilitate treatment and diagnosis of therapy-resistant asthma. The chitinase-like protein YKL-40 has been related to asthma and airway remodeling. Objectives: To compare serum YKL-40 levels in children with severe, therapy-resistant asthma (n 5 34), children with controlled persistent asthma (n = 39), and healthy controls (n = 27), and to investigate correlations with biomarkers of inflammation and airway remodeling. Methods: The study protocol included questionnaires, measurement of exhaled nitric oxide in exhaled air, blood sampling for inflammatory biomarkers, and high-resolution computed tomography of the lungs to identify bronchial wall thickening (therapy-resistant only). Serum YKL-40 levels were measured by ELISA, and all asthmatic children were genotyped for a CHI3L1 promoter single nucleotide polymorphism (rs4950928). Results: Serum YKL-40 levels were significantly higher in children with therapy-resistant asthma than in healthy children (19.2 ng/mL vs 13.8 ng/mL, P = .03). Among children with severe, therapy-resistant asthma, YKL-40 levels correlated with fraction of exhaled nitric oxide in exhaled air (r = 0.48, P = .004), blood neutrophils (r = 0.63, P < .001), and bronchial wall thickening on high-resolution computed tomography (r = 0.45, P = .01). Following adjustment for CHI3L1 genotype, significantly greater levels of YKL-40 were found in children with therapy-resistant asthma than in children with controlled asthma. Conclusions: YKL-40 levels are increased in children with severe, therapy-resistant asthma compared to healthy children, and also compared to children with controlled asthma following correction for genotype.	[Konradsen, Jon R.; Nordlund, Bjorn; Lidegran, Marika; Hedlin, Gunilla] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, SE-17176 Stockholm, Sweden; [Konradsen, Jon R.; Nordlund, Bjorn; Hedlin, Gunilla] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Konradsen, Jon R.; James, Anna; Nordlund, Bjorn; Reinius, Lovisa E.; Dahlen, Barbro; Dahlen, Sven Erik; Hedlin, Gunilla] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [James, Anna; Melen, Erik; Dahlen, Sven Erik] Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden; [Reinius, Lovisa E.; Soderhall, Cilla] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Melen, Erik] Sachs Children & Youth Hosp, Stockholm, Sweden; [Wheelock, Asa] Karolinska Inst, Dept Med, Resp Med Unit, Stockholm, Sweden; [Carlsen, Karin C. Lodrup] Oslo Univ Hosp, Dept Pediat, Oslo, Norway; [Carlsen, Karin C. Lodrup] Univ Oslo, Oslo, Norway; [Verhoek, Marri; Boot, Rolf G.] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands; [Dahlen, Barbro] Karolinska Univ Hosp, Dept Med, Div Resp Med & Allergy Res, Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Oslo; University of Oslo; University of Amsterdam; Academic Medical Center Amsterdam; Karolinska Institutet; Karolinska University Hospital	Konradsen, JR (corresponding author), Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, H1 02, SE-17176 Stockholm, Sweden.	jon.konradsen@karolinska.se	Reinius, Lovisa/C-4555-2014; Konradsen, Jon/AAD-5620-2021; Nordlund, Björn/AAF-6037-2019; James, Anna/AAY-9937-2021; Wheelock, Åsa/B-7904-2017; Söderhäll, Cilla/E-3940-2012	Reinius, Lovisa/0000-0001-5029-0120; Konradsen, Jon/0000-0001-7745-8624; Nordlund, Björn/0000-0001-9888-1659; Wheelock, Åsa/0000-0002-8013-2745; Söderhäll, Cilla/0000-0002-8397-3080; Boot, Rolf/0000-0002-7031-3390	Swedish Heart-Lung Foundation; Swedish MRC; Swedish Asthma and Allergy Foundation; Novartis; Meda; Stockholm County Council Research Funds; Nigaard Pharmaceuticals; Freemason Child House Foundation in Stockholm; Konsul Th. C. Bergh's Foundation; Swedish Asthma and Allergy Association's Research Foundation; Centre for Allergy Research at Karolinska Institutet; Pediatric Research Foundation of Astrid Lindgren Children's Hospital; Thermo Fisher Scientific	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Swedish Asthma and Allergy Foundation; Novartis(Novartis); Meda; Stockholm County Council Research Funds; Nigaard Pharmaceuticals; Freemason Child House Foundation in Stockholm; Konsul Th. C. Bergh's Foundation; Swedish Asthma and Allergy Association's Research Foundation; Centre for Allergy Research at Karolinska Institutet(Karolinska Institutet); Pediatric Research Foundation of Astrid Lindgren Children's Hospital; Thermo Fisher Scientific	B. Dahlen is a Board member for Actelion DMC; has received one or more grants from or has one or more grants pending with the Swedish Heart-Lung Foundation, the Swedish MRC, and the Swedish Asthma and Allergy Foundation; and has received one or more payments for lecturing from or is on the speakers' bureau for Novartis and for Meda. S. E. Dahlen has been supported by one or more grants from the Swedish MRC, the Swedish Heart-Lung Foundation, and the Stockholm County Council Research Funds; has consultancy arrangements with GSK & AZ Respiratory; and has received one or more payments for lecturing from or is on the speakers' bureau for Nigaard Pharmaceuticals. J. R. Konradsen has received grants from the Freemason Child House Foundation in Stockholm, the Konsul Th. C. Bergh's Foundation, the Swedish Asthma and Allergy Association's Research Foundation, the Centre for Allergy Research at Karolinska Institutet, the Pediatric Research Foundation of Astrid Lindgren Children's Hospital, and the Swedish Heart-Lung Foundation; and has received payment for lecturing from Novartis and Thermo Fisher Scientific. K. C. Lodrup Carlsen has received one or more public grants, has received or has one or more grants pending with the Kloster Foundation, and has received one or more payments for lecturing from or is on the speakers' bureau for GSK. The rest of the authors declare that they have no relevant conflicts of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; Bara I, 2012, AM J RESP CRIT CARE, V185, P715, DOI 10.1164/rccm.201105-0915OC; Bargagli E, 2010, RESPIRATION, V79, P437, DOI 10.1159/000277664; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigg HF, 2006, J BIOL CHEM, V281, P21082, DOI 10.1074/jbc.M601153200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Bussink AP, 2007, GENETICS, V177, P959, DOI 10.1534/genetics.107.075846; Carlsen KCL, 2011, EUR RESPIR J, V37, P432, DOI 10.1183/09031936.00091410; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Cunningham J, 2011, ANN ALLERG ASTHMA IM, V106, P381, DOI 10.1016/j.anai.2011.01.030; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; de Blic J, 2007, J ALLERGY CLIN IMMUN, V119, P808, DOI 10.1016/j.jaci.2006.12.657; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2010, PEDIAT ALLER IMM PUL, V23, P131, DOI 10.1089/ped.2010.0021; Gavala ML, 2013, CLIN EXP ALLERGY, V43, P187, DOI 10.1111/cea.12032; Global Initiative for Asthma (GINA), 2012, GLOB STRAT ASTHM MAN; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Konradsen JR, 2011, PEDIAT ALLERG IMM-UK, V22, P9, DOI 10.1111/j.1399-3038.2010.01098.x; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Letuve S, 2008, J IMMUNOL, V181, P5167, DOI 10.4049/jimmunol.181.7.5167; Marchac V, 2002, AM J ROENTGENOL, V179, P1245, DOI 10.2214/ajr.179.5.1791245; Melen E, 2012, J INTERN MED, V272, P108, DOI 10.1111/j.1365-2796.2012.02555.x; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; Otsuka K, 2012, RESPIRATION, V83, P507, DOI 10.1159/000330840; POLGAR G, 1979, AM REV RESPIR DIS, V120, P625; Schoonhoven A, 2007, CLIN CHIM ACTA, V381, P136, DOI 10.1016/j.cca.2007.02.042; Seibold MA, 2008, J ALLERGY CLIN IMMUN, V122, P944, DOI 10.1016/j.jaci.2008.08.023; Tang H, 2010, EUR RESPIR J, V35, P757, DOI 10.1183/09031936.00034409; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; Tercelj M, 2009, SCAND J CLIN LAB INV, V69, P575, DOI 10.1080/00365510902829362; Volck B, 1998, P ASSOC AM PHYSICIAN, V110, P351; Zhao XZ, 2007, AM J HUM GENET, V80, P12, DOI 10.1086/510438	37	97	100	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					328	+		10.1016/j.jaci.2013.03.003	http://dx.doi.org/10.1016/j.jaci.2013.03.003			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23628340	Bronze			2022-12-18	WOS:000322631700009
J	Li, DQ; Zhang, LL; Pflugfelder, SC; De Paiva, CS; Zhang, XB; Zhao, GQ; Zheng, XF; Su, ZT; Qu, YLW				Li, De-Quan; Zhang, Lili; Pflugfelder, Stephen C.; De Paiva, Cintia S.; Zhang, Xiaobo; Zhao, Guiqiu; Zheng, Xiaofen; Su, Zhitao; Qu, Yangluowa			Short ragweed pollen triggers allergic inflammation through Toll-like receptor 4-dependent thymic stromal lymphopoietin/OX40 ligand/OX40 signaling pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; pollen; conjunctivitis; Toll-like receptor; thymic stromal lymphopoietin; innate immunity	AIRWAY EPITHELIAL-CELLS; ADAPTIVE IMMUNE-RESPONSES; EXPERIMENTAL DRY EYE; INNATE IMMUNITY; CORNEAL INFLAMMATION; OCULAR SURFACE; MOUSE MODEL; CONJUNCTIVITIS; EXPRESSION; ACTIVATION	Background: Allergic diseases affect a large population. Pollen, an ubiquitous allergen, is the trigger of seasonal rhinitis, conjunctivitis, and asthma, as well as an exacerbating factor of atopic dermatitis. However, the underlying mechanism by which pollen induces thymic stromal lymphopoietin (TSLP)-triggered allergic inflammation through epithelial innate immunity is largely unknown. Objective: We sought to explore whether short ragweed (SRW) pollen induces TSLP/OX40 ligand (OX40L)/OX40 signaling through Toll-like receptor (TLR) 4-dependent pathways in patients with allergic disease. Methods: Three models were used for this study, a well-characterized murine model of allergic conjunctivitis induced by SRW pollen, a topical challenge model on the murine ocular surface, and a culture model of primary human corneal epithelium exposed to aqueous extract of defatted SRW pollen (SRWe). Results: The topical challenges with SRW pollen generated typical allergic conjunctivitis in BALB/c mice. Clinical signs, stimulated TSLP/OX40L/OX40 signaling, and T(H)2 cytokine levels in the ocular mucosa and draining cervical lymph nodes were significantly reduced or eliminated in TLR4-deficient (Tlr4-d) or myeloid differentiation primary response gene 88 (MyD88) knockout (MyD88(-/-)) mice compared with those seen in their wild-type littermates. SRWe stimulated TSLP production by ocular epithelia in wild-type but not Tlr4-d or MyD88(-/-) mice. SRWe-stimulated TSLP was blocked by TLR4 antibody and nuclear factor kappa B inhibitor in murine and human corneal epithelia. Conclusion: For the first time, we have shown that SRW pollen, acting as a functional TLR4 agonist, initiates TLR4-dependent TSLP/OX40L/OX40 signaling, which triggers T(H)2-dominant allergic inflammation. These findings shed light on the understanding of mucosal epithelial innate immunity and create new therapeutic targets to cure allergic diseases. (J Allergy Clin Immunol 2011;128:1318-25.)	[Li, De-Quan; Zhang, Lili; Pflugfelder, Stephen C.; De Paiva, Cintia S.; Zhang, Xiaobo; Zheng, Xiaofen; Su, Zhitao; Qu, Yangluowa] Baylor Univ, Cullen Eye Inst, Dept Ophthalmol, Ocular Surface Ctr, Houston, TX 77030 USA; [Zhang, Lili; Zhao, Guiqiu] Qingdao Univ, Coll Med, Dept Ophthalmol, Affiliated Hosp, Qingdao 266071, Peoples R China	Baylor College of Medicine; Baylor University; Qingdao University	Li, DQ (corresponding author), Baylor Univ, Cullen Eye Inst, Dept Ophthalmol, Ocular Surface Ctr, 6565 Fannin St,NC-205, Houston, TX 77030 USA.	dequanl@bcm.tmc.edu	De Paiva, Cintia/AAH-8354-2021	De Paiva, Cintia/0000-0002-9057-5494	Department of Defense CDMRP PRMRP [FY06 PR064719]; National Institutes of Health [EY11915]; Research to Prevent Blindness; Oshman Foundation; William Stamps Farish Fund; Department of Defense; NATIONAL EYE INSTITUTE [R01EY011915] Funding Source: NIH RePORTER	Department of Defense CDMRP PRMRP; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Oshman Foundation; William Stamps Farish Fund; Department of Defense(United States Department of Defense); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Supported by Department of Defense CDMRP PRMRP grant FY06 PR064719 (DQL), National Institutes of Health grant EY11915 (SCP), an unrestricted grant from Research to Prevent Blindness, the Oshman Foundation, and the William Stamps Farish Fund.r D.-Q. Li receives research support from the Department of Defense. S. C. Pflugfelder receives research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2000, J ENDOTOXIN RES, V6, P383, DOI 10.1177/09680519000060050901; Buc M, 2009, ARCH IMMUNOL THER EX, V57, P331, DOI 10.1007/s00005-009-0039-4; Chen Z, 2004, STEM CELLS, V22, P355, DOI 10.1634/stemcells.22-3-355; Chung SH, 2011, CLIN EXP IMMUNOL, V164, P275, DOI 10.1111/j.1365-2249.2011.04368.x; De Paiva CS, 2006, EXP EYE RES, V83, P526, DOI 10.1016/j.exer.2006.02.004; De Paiva CS, 2005, STEM CELLS, V23, P63, DOI 10.1634/stemcells.2004-0093; Fasciano S, 2006, CURR MED CHEM, V13, P1389, DOI 10.2174/092986706776872916; Groneberg DA, 2003, ALLERGY, V58, P1101, DOI 10.1046/j.1398-9995.2003.00326.x; Johnson AC, 2005, INVEST OPHTH VIS SCI, V46, P589, DOI 10.1167/iovs.04-1077; Johnson AC, 2008, J BIOL CHEM, V283, P3988, DOI 10.1074/jbc.M707264200; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Kim HS, 2004, EXP EYE RES, V79, P41, DOI 10.1016/j.exer.2004.02.015; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Kumar A, 2006, CURR MOL MED, V6, P327, DOI 10.2174/156652406776894572; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Li DQ, 2010, INVEST OPHTH VIS SCI, V51, P5623, DOI 10.1167/iovs.09-4992; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Lowe B, 2003, ANAL BIOCHEM, V315, P95, DOI 10.1016/S0003-2697(02)00695-4; Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145; Ma P, 2009, INVEST OPHTH VIS SCI, V50, P2702, DOI 10.1167/iovs.08-3074; Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507; Matsuda A, 2010, INVEST OPHTH VIS SCI, V51, P151, DOI 10.1167/iovs.09-4183; Miller LS, 2007, SEMIN IMMUNOPATHOL, V29, P15, DOI 10.1007/s00281-007-0061-8; Mishra KP, 2009, IMMUNOBIOLOGY, V214, P27, DOI 10.1016/j.imbio.2008.04.001; Nemeth K, 2010, P NATL ACAD SCI USA, V107, P5652, DOI 10.1073/pnas.0910720107; Niederkorn JY, 2008, CURR OPIN ALLERGY CL, V8, P472, DOI 10.1097/ACI.0b013e32830edbcb; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Rassa JC, 2002, P NATL ACAD SCI USA, V99, P2281, DOI 10.1073/pnas.042355399; RENZ H, 1993, J IMMUNOL, V151, P1907; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Solomon, 2000, Am J Ophthalmol, V130, P688, DOI 10.1016/S0002-9394(00)00755-8; Song XJ, 2003, INVEST OPHTH VIS SCI, V44, P4223, DOI 10.1167/iovs.02-1319; Stern ME, 2005, INVEST OPHTH VIS SCI, V46, P3239, DOI 10.1167/iovs.05-0138; Stern ME, 2005, CURR OPIN ALLERGY CL, V5, P446, DOI 10.1097/01.all.0000182547.60595.64; Tsuji RF, 2003, CLIN EXP ALLERGY, V33, P249, DOI 10.1046/j.1365-2222.2003.01575.x; Le TA, 2011, INT ARCH ALLERGY IMM, V155, P31, DOI 10.1159/000318679; Wang RF, 2008, ONCOGENE, V27, P181, DOI 10.1038/sj.onc.1210906; Wollenberg A, 2007, CLIN REV ALLERG IMMU, V33, P35, DOI 10.1007/s12016-007-0032-9; Yoon KC, 2007, INVEST OPHTH VIS SCI, V48, P2561, DOI 10.1167/iovs.07-0002; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106; Zheng XF, 2010, INVEST OPHTH VIS SCI, V51, P3076, DOI 10.1167/iovs.09-4122	44	97	101	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1318	+		10.1016/j.jaci.2011.06.041	http://dx.doi.org/10.1016/j.jaci.2011.06.041			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21820713	Green Accepted			2022-12-18	WOS:000298342700023
J	Boyce, JA; Assa'ad, A; Burks, AW; Jones, SM; Sampson, HA; Wood, RA; Plaut, M; Cooper, SF; Fenton, MJ; Arshad, SH; Bahna, SL; Beck, LA; Byrd-Bredbenner, C; Camargo, CA; Eichenfield, L; Furuta, GT; Hanifin, JM; Jones, C; Kraft, M; Levy, BD; Lieberman, P; Luccioli, S; McCall, KM; Schneider, LC; Simon, RA; Simons, FER; Teach, SJ; Yawn, BP; Schwaninger, JM				Boyce, Joshua A.; Assa'ad, Amal; Burks, A. Wesley; Jones, Stacie M.; Sampson, Hugh A.; Wood, Robert A.; Plaut, Marshall; Cooper, Susan F.; Fenton, Matthew J.; Arshad, S. Hasan; Bahna, Sami L.; Beck, Lisa A.; Byrd-Bredbenner, Carol; Camargo, Carlos A., Jr.; Eichenfield, Lawrence; Furuta, Glenn T.; Hanifin, Jon M.; Jones, Carol; Kraft, Monica; Levy, Bruce D.; Lieberman, Phil; Luccioli, Stefano; McCall, Kathleen M.; Schneider, Lynda C.; Simon, Ronald A.; Simons, F. Estelle R.; Teach, Stephen J.; Yawn, Barbara P.; Schwaninger, Julie M.			Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Plaut, Marshall; Cooper, Susan F.; Fenton, Matthew J.; Schwaninger, Julie M.] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Boyce, Joshua A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy,Dept Med, Boston, MA 02115 USA; [Assa'ad, Amal] Univ Cincinnati, Div Allergy & Immunol, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Div Allergy & Immunol, Dept Pediat, Arkansas Childrens Hosp, Little Rock, AR 72205 USA; [Sampson, Hugh A.] Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Dept Pediat, New York, NY USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD USA; [Arshad, S. Hasan] Univ Southampton, Sch Med, Southampton, Hants, England; [Arshad, S. Hasan] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England; [Arshad, S. Hasan] Southampton Univ Hosp NHS Trust, Southampton, Hants, England; [Bahna, Sami L.] Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Allergy & Immunol Sect, Shreveport, LA 71105 USA; [Beck, Lisa A.] Univ Rochester, Dept Dermatol, Med Ctr, Rochester, NY 14627 USA; [Byrd-Bredbenner, Carol] Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08903 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Dept Med, Div Rheumatol Allergy & Immunol,Massachusetts Gen, Boston, MA USA; [Eichenfield, Lawrence] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Eichenfield, Lawrence] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Eichenfield, Lawrence] Rady Childrens Hosp, Div Pediat & Adolescent Dermatol, San Diego, CA USA; [Furuta, Glenn T.] Childrens Hosp Denver, Sect Pediat Gastroenterol Hepatol & Nutr, Digest Hlth Inst, Aurora, CO USA; [Furuta, Glenn T.] Univ Colorado, Dept Pediat, Denver Sch Med, Aurora, CO USA; [Furuta, Glenn T.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Hanifin, Jon M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Jones, Carol] Allergy & Asthma Network Mothers Asthmat, Mclean, VA USA; [Kraft, Monica] Duke Univ, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA; [Levy, Bruce D.] Brigham & Womens Hosp, Partners Asthma Ctr, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Levy, Bruce D.] Harvard Univ, Sch Med, Boston, MA USA; [Lieberman, Phil] Univ Tennessee, Dept Med, Div Allergy & Immunol, Coll Med, Memphis, TN 38104 USA; [Luccioli, Stefano] US FDA, Off Food Addit Safety, College Pk, MD USA; [McCall, Kathleen M.] Childrens Hosp Orange Cty, Orange, CA USA; [Schneider, Lynda C.] Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Simon, Ronald A.] Scripps Clin, Div Allergy Asthma & Immunol, San Diego, CA USA; [Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Pediat, Winnipeg, MB, Canada; [Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Child Hlth & Immunol, Winnipeg, MB, Canada; [Teach, Stephen J.] Childrens Natl Med Ctr, Div Emergency Med, Washington, DC 20010 USA; [Yawn, Barbara P.] Olmsted Med Ctr, Dept Res, Rochester, MN USA; [Yawn, Barbara P.] Univ Minnesota, Sch Med, Dept Family & Community Hlth, Minneapolis, MN 55455 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Duke University; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Rochester; Rutgers State University New Brunswick; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health; Oregon Health & Science University; Duke University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Tennessee System; University of Tennessee Health Science Center; US Food & Drug Administration (FDA); Childrens Hospital of Orange County; Harvard University; Boston Children's Hospital; Scripps Research Institute; University of Manitoba; University of Manitoba; Children's National Health System; Olmsted Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Fenton, MJ (corresponding author), NIAID, Div Allergy Immunol & Transplantat, NIH, 6610 Rockledge Dr,Room 3105, Bethesda, MD 20892 USA.	fentonm@niaid.nih.gov	Byrd-Bredbenner, Carol/F-8064-2015; Camargo, Carlos A./C-2145-2008	Byrd-Bredbenner, Carol/0000-0002-8010-3987; Camargo, Carlos A./0000-0002-5071-7654	National Institutes of Health; GlaxoSmithKline; Food Allergy and Anaphylaxis Network, Gerber, Mead Johnson; Dyax Corp; Food Allergy and Anaphylaxis Network, Mead Johnson; National Peanut Board; Food Allergy Initiative; National Institutes of Health (Division of Receipt and Referral, National Institute of Allergy and Infectious Diseases, National Center for Complementary and Alternative Medicine); Phadia AB; Genentech; National Institutes of Health (National Institute of Allergy and Infectious Diseases); National Institute of Health Research, UK; American Academy of Allergy, Asthma, and Immunology; National Eczema Association; US Department of Agriculture; Canned Food Alliance; New Jersey Department of Health and Senior Services; Dey; Novartis; Astellas; Ferndale; Johnson Johnson; Sinclair; Stiefel; Therapeutics Inc.; American Gastrointestinal Association; ALZA; Astellas Pharma US, Inc; Asubio Pharmaceuticals, Inc; Centocor, Inc; Corgentech; Nucryst Pharmaceuticals; Seattle Genetics; Shionogi USA; Merck; Sepracor; Dey Laboratories; Schering-Plough; AstraZenica; TEVA; Pfizer; MEDA; Alcon; Intelliject; US Food and Drug Administration; AllerGen; Canadian Allergy; Asthma and Immunology Foundation/Anaphylaxis Canada; Canadian Institutes of Health Research; AstraZeneca Foundation; Aventis; Child Health Center Board; CNMC Research Advisory Council; National Association of Chain Drug Stores Foundation; National Institutes of Health (National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute); Novartis/Genentech; Robert Woods Johnson Foundation; US Centers for Disease Control and Prevention; US Public Health Service; Washington, DC, Department of Health	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); Food Allergy and Anaphylaxis Network, Gerber, Mead Johnson; Dyax Corp; Food Allergy and Anaphylaxis Network, Mead Johnson; National Peanut Board; Food Allergy Initiative; National Institutes of Health (Division of Receipt and Referral, National Institute of Allergy and Infectious Diseases, National Center for Complementary and Alternative Medicine)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)NIH National Center for Complementary & Alternative Medicine); Phadia AB(Phadia); Genentech(Roche HoldingGenentech); National Institutes of Health (National Institute of Allergy and Infectious Diseases)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Health Research, UK(National Institute for Health Research (NIHR)); American Academy of Allergy, Asthma, and Immunology; National Eczema Association; US Department of Agriculture(United States Department of Agriculture (USDA)); Canned Food Alliance; New Jersey Department of Health and Senior Services; Dey; Novartis(Novartis); Astellas(Astellas Pharmaceuticals); Ferndale; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Sinclair; Stiefel; Therapeutics Inc.; American Gastrointestinal Association; ALZA; Astellas Pharma US, Inc(Astellas Pharmaceuticals); Asubio Pharmaceuticals, Inc; Centocor, Inc; Corgentech; Nucryst Pharmaceuticals; Seattle Genetics; Shionogi USA; Merck(Merck & Company); Sepracor; Dey Laboratories; Schering-Plough(Merck & CompanySchering Plough Corporation); AstraZenica(AstraZeneca); TEVA(Teva Pharmaceutical Industries); Pfizer(Pfizer); MEDA; Alcon(Novartis); Intelliject; US Food and Drug Administration; AllerGen; Canadian Allergy; Asthma and Immunology Foundation/Anaphylaxis Canada; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); AstraZeneca Foundation(AstraZeneca); Aventis(Sanofi-Aventis); Child Health Center Board; CNMC Research Advisory Council; National Association of Chain Drug Stores Foundation; National Institutes of Health (National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)NIH National Heart Lung & Blood Institute (NHLBI)); Novartis/Genentech(Roche HoldingGenentech); Robert Woods Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); US Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Washington, DC, Department of Health	J. A. Boyce has served on the Advisory Board of GlaxoSmithKline. He has served as a consultant and/or speaker for Altana, GlaxoSmithKline, and Merck. He has received funding/grant support from the National Institutes of Health.; A. Assa'ad holds, or is listed as an inventor on, US patent application #10/566903, entitled "Genetic markers of food allergy." She has served as a consultant for GlaxoSmithKline and as a speaker for the American College of Allergy, Asthma, and Immunology, the North East Allergy Society, the Virginia Allergy Society, the New England Allergy Society, and the American Academy of Pediatrics. Dr Assa'ad has received funding/grant support from GlaxoSmithKline.; A. W. Burks holds, or is listed as an inventor on, multiple US patents related to food allergy. He owns stock in Allertein and MastCell, Inc, and is a minority stockholder in Dannon Co Probiotics. He has served as a consultant for ActoGeniX NV, McNeil Nutritionals, Mead Johnson, and Novartis. He has served on the speaker's bureau for EpiPen/Dey, LP, and has served on the data monitoring committee for Genentech. He has served on an expert panel for Nutricia. Dr Burks has received funding/grant support from the Food Allergy and Anaphylaxis Network, Gerber, Mead Johnson, and the National Institutes of Health.; S. M. Jones has served as a speaker and grant reviewer and has served on the medical advisory committee for the Food Allergy and Anaphylaxis Network. She has received funding/grant support from Dyax Corp, the Food Allergy and Anaphylaxis Network, Mead Johnson, the National Peanut Board, and the National Institutes of Health.; H. A. Sampson holds, or is listed as an inventor on, multiple US patents related to food allergy. He owns stock in Allertein Therapeutics. He is the immediate past president of the American Academy of Allergy, Asthma, and Immunology. He has served as a consultant for Allertein Therapeutics, the American Academy of Allergy, Asthma, and Immunology, the Food Allergy Initiative, and Schering Plough. He has received funding/grant support for research projects from the Food Allergy Initiative, the National Institutes of Health (Division of Receipt and Referral, National Institute of Allergy and Infectious Diseases, National Center for Complementary and Alternative Medicine), and Phadia AB. He is a co-owner of Herbal Spring, LLC.; R. A. Wood has served as a speaker/advisory board member for GlaxoSmithKline, Merck, and Dey. He has received funding/grant support from Genentech and the National Institutes of Health (National Institute of Allergy and Infectious Diseases).; S. H. Arshad has received funding/grant support from the National Institutes of Health and the National Institute of Health Research, UK.; S. L. Bahna has received funding/grant support from Genentech.; L. A. Beck has received funding/grant support from the American Academy of Allergy, Asthma, and Immunology, the National Eczema Association, and the National Institutes of Health.; C. Byrd-Bredbenner owns stock in Johnson & Johnson. She has received funding/grant support from the US Department of Agriculture, the Canned Food Alliance, and the New Jersey Department of Health and Senior Services.; C. A. Camargo Jr has consulted for Dey and Novartis. He has received funding/grant support from a variety of government agencies and not-for-profit research foundations, as well as Dey and Novartis.; L. Eichenfield has received funding/grant support from a variety of not-for-profit foundations, as well as Astellas, Ferndale, Johnson & Johnson, Novartis, Sinclair, Stiefel, and Therapeutics Inc.; G. T. Furuta has served as a consultant and/or speaker to Ception Therapeutics and TAP. He has received funding/grant support from the American Gastrointestinal Association and the National Institutes of Health.; J. M. Hanifin has served as served as a consultant for ALZA, Anesiva, Inc, Barrier Therapeutics, Inc, Milliken & Company, Nordic Biotech, Novartis Pharmaceuticals Corporation, Shionogi USA, Taisho Pharmaceutical R&D, Inc, Teikoku Pharma USA, Inc, UCB, York Pharma, ZARS, Inc, and ZymoGenetics. He has served as an investigator or received research funding from ALZA, Astellas Pharma US, Inc, Asubio Pharmaceuticals, Inc, Centocor, Inc, Corgentech, Novartis, Nucryst Pharmaceuticals, Seattle Genetics, and Shionogi USA.; M. Kraft has served as a consultant and/or speaker for Astra-Zeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Sepracor. She has received funding/grant support from Genentech, GlaxoSmithKline, the National Institutes of Health and Novartis.; B. D. Levy holds, or is listed as an inventor on, US patent applications #20080064746 entitled "Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases" and #20080096961 entitled "Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma." He owns stock in Resolvyx Pharmaceuticals. He has served as a consultant for Bayer Healthcare and Resolvyx Pharmaceuticals. Dr Levy has received funding/grant support from the National Institutes of Health.; P. Lieberman has served as a consultant and/or speaker to Dey Laboratories, Novartis, Schering-Plough, AstraZenica, Merck, TEVA, Pfizer, MEDA, Alcon, Genentech, Intelliject, and the Food Allergy and Anaphylaxis Network. He is past president of the American Academy of Allergy, Asthma, and Immunology.; L. C. Schneider has served as a consultant/clinical advisor for the Food Allergy Initiative. She has received funding/grant support from a variety of not-for-profit research foundations, as well as Novartis and the National Institutes of Health.; R. A. Simon has served as a speaker for Dey Laboratories, Genentech, GlaxoSmithKline, Merck, Novartis, and the US Food and Drug Administration.; F. E. R. Simons holds a patent on "Fast-disintegrating epinephrine tablets for sublingual administration." She is a past-president of the American Academy of Allergy, Asthma, and Immunology and of the Canadian Society of Allergy and Clinical Immunology. She is a member of the advisory boards of Dey, Intelliject, and ALK-Abello. She has received funding/grant support from AllerGen, the Canadian Allergy, Asthma and Immunology Foundation/Anaphylaxis Canada, and the Canadian Institutes of Health Research.; S. J. Teach has served as a speaker for AstraZeneca. He has received funding/grant support from the AstraZeneca Foundation, Aventis, the Child Health Center Board, the CNMC Research Advisory Council, the National Association of Chain Drug Stores Foundation, the National Institutes of Health (National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute), Novartis/Genentech, the Robert Woods Johnson Foundation, the US Centers for Disease Control and Prevention, the US Public Health Service, and the Washington, DC, Department of Health.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007	1	97	116	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1105	1118		10.1016/j.jaci.2010.10.008	http://dx.doi.org/10.1016/j.jaci.2010.10.008			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ		Green Accepted, Green Submitted			2022-12-18	WOS:000284947800005
J	Allam, JP; Wurtzen, PA; Reinartz, M; Winter, J; Vrtala, S; Chen, KW; Valenta, R; Wenghoefer, M; Appel, T; Gros, E; Niederhagen, B; Bieber, T; Lund, K; Novak, N				Allam, Jean-Pierre; Wuertzen, Peter A.; Reinartz, Markus; Winter, Jochen; Vrtala, Susanne; Chen, Kuan-Wei; Valenta, Rudolf; Wenghoefer, Matthias; Appel, Thorsten; Gros, Eva; Niederhagen, Bernd; Bieber, Thomas; Lund, Kaare; Novak, Natalija			Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta 1 and IL-10-producing properties	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; oral mucosa; Langerhans cells; Phl p 5; tolerance	MATURE DENDRITIC CELLS; HIGH-AFFINITY RECEPTOR; SUBLINGUAL IMMUNOTHERAPY; IMMUNOLOGICAL CHANGES; TOLERANCE; EFFICACY; SAFETY; PHARMACOKINETICS; MACROPINOCYTOSIS; MECHANISMS	Background: Sublingual immunotherapy (SLIT) is safe and effective as treatment of allergic rhinitis and mild asthma. Oral mucosal Langerhans cells (oLCs) play a central role. However, little is known about allergen binding by oLCs during mucosal allergen resorption and its impact on oLC functions. Objective: Binding of Phl p 5 to oLCs was studied in a standardized ex vivo model to investigate mechanisms important for SLIT. Methods: Human oral mucosal biopsies were incubated with the grass pollen allergen Phl p 5. Migration, binding of Phl p 5, phenotype and cytokine production, and T-cell priming of Phl p 5-binding oLCs were analyzed. Results: Significant uptake required more than 5 minutes, and dose-dependent binding of Phl p 5 to oLCs was saturated at 100 mg/mL Phl p 5. Furthermore, Phl p 5 significantly increased the migratory capacity of oLCs but attenuated their maturation and strongly promoted the release of TGF-b1 and IL-10 by oLCs themselves as well as by cocultured T cells. Conclusion: Oral mucosal Langerhans cells bind Phlp5 in a dose-dependent and time-dependent manner, leading to an increased production of tolerogenic cytokines and an enhanced migratory capacity but decelerated maturation of oLCs. (J Allergy Clin Immunol 2010;126:638-45.)	[Novak, Natalija] Univ Bonn, Dept Dermatol & Allergy, D-53127 Bonn, Germany; [Reinartz, Markus] Univ Bonn, Kekule Inst Organ Chem & Biochem, D-5300 Bonn, Germany; [Winter, Jochen] Univ Bonn, Dept Periodontol Operat & Prevent Dent, D-5300 Bonn, Germany; [Wenghoefer, Matthias; Appel, Thorsten; Niederhagen, Bernd] Univ Bonn, Dept Oral & Maxillofacial Plast Surg, D-5300 Bonn, Germany; [Wuertzen, Peter A.; Lund, Kaare] Med Univ Vienna, Dept Expt Immunol, ALK Abello Horsholm, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Vrtala, Susanne; Chen, Kuan-Wei; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol, Dept Pathophysiol, Vienna, Austria	University of Bonn; University of Bonn; University of Bonn; University of Bonn; ALK-Abello AS; Medical University of Vienna; Medical University of Vienna	Novak, N (corresponding author), Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53127 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de		Chen, Kuan-Wei/0000-0001-5899-5766; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243	Deutsche Forschungsgemeinschaft (DFG) [KFO 208 TPA1, SFB704 TPA4, NO454/5-2]; BONFOR; University of Bonn and ALK-Abello, Horsholm, Denmark	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); BONFOR; University of Bonn and ALK-Abello, Horsholm, Denmark	Supported by grants from the Deutsche Forschungsgemeinschaft (DFG KFO 208 TPA1, SFB704 TPA4) and a BONFOR grant of the University of Bonn and ALK-Abello, Horsholm, Denmark. N. N. is supported by a Heisenberg-Professorship of the DFG NO454/5-2.	Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Allam JP, 2008, ALLERGY, V63, P720, DOI 10.1111/j.1398-9995.2007.01611.x; Allam JP, 2008, J ALLERGY CLIN IMMUN, V121, P368, DOI 10.1016/j.jaci.2007.09.045; Allam JP, 2006, ALLERGY, V61, P166, DOI 10.1111/j.1398-9995.2005.00965.x; Allam JP, 2004, J INVEST DERMATOL, V123, P676, DOI 10.1111/j.0022-202X.2004.23428.x; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Allan S, 2009, NAT REV IMMUNOL, V9, P7, DOI 10.1038/nri2481; Bagnasco M, 2005, INT ARCH ALLERGY IMM, V138, P197, DOI 10.1159/000088719; Bagnasco M, 2001, CLIN EXP ALLERGY, V31, P54, DOI 10.1046/j.1365-2222.2001.00999.x; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bordignon V, 2006, ANN ALLERG ASTHMA IM, V97, P158, DOI 10.1016/S1081-1206(10)60006-3; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Duraisingham SS, 2009, J IMMUNOL, V183, P2242, DOI 10.4049/jimmunol.0900474; Durham SR, 2007, J ALLERGY CLIN IMMUN, V119, P792, DOI 10.1016/j.jaci.2007.02.034; Jacobs JJL, 2006, EXP DERMATOL, V15, P432, DOI 10.1111/j.0906-6705.2006.00420.x; Jonuleit H, 2003, J IMMUNOL, V171, P6323, DOI 10.4049/jimmunol.171.12.6323; Jotwani R, 2001, J IMMUNOL, V167, P4693, DOI 10.4049/jimmunol.167.8.4693; Kato M, 2000, INT IMMUNOL, V12, P1511, DOI 10.1093/intimm/12.11.1511; Kildsgaard J, 2007, ANN ALLERG ASTHMA IM, V98, P366, DOI 10.1016/S1081-1206(10)60884-8; Kraft S, 1998, J IMMUNOL, V161, P1000; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Malling HJ, 2006, J INVEST ALLERG CLIN, V16, P162; Mascarell L, 2008, J ALLERGY CLIN IMMUN, V122, P603, DOI 10.1016/j.jaci.2008.06.034; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Morelli AE, 2005, J IMMUNOL, V175, P7905, DOI 10.4049/jimmunol.175.12.7905; Noirey N, 2000, J ALLERGY CLIN IMMUN, V105, P1194, DOI 10.1067/mai.2000.106545; Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Razafindratsita A, 2007, J ALLERGY CLIN IMMUN, V120, P278, DOI 10.1016/j.jaci.2007.04.009; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Steinman RM, 2007, EUR J IMMUNOL, V37, pS53, DOI 10.1002/eji.200737400; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Takahara K, 2004, INT IMMUNOL, V16, P819, DOI 10.1093/intimm/dxh084; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	36	97	102	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					638	U5		10.1016/j.jaci.2010.04.039	http://dx.doi.org/10.1016/j.jaci.2010.04.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20584546				2022-12-18	WOS:000281512500034
J	Rudders, SA; Banerji, A; Vassallo, MF; Clark, S; Camargo, CA				Rudders, Susan A.; Banerji, Aleena; Vassallo, Milo F.; Clark, Sunday; Camargo, Carlos A., Jr.			Trends in pediatric emergency department visits for food-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY; PREVALENCE		[Rudders, Susan A.] Childrens Hosp, Div Allergy & Immunol, Boston, MA 02115 USA; [Rudders, Susan A.; Vassallo, Milo F.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Banerji, Aleena; Vassallo, Milo F.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Clark, Sunday] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA	Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rudders, SA (corresponding author), Childrens Hosp, Div Allergy & Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	ccamargo@partners.org	Banerji, Aleena/ABG-1245-2021; Clark, Sunday/AAA-5458-2021; Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007512] Funding Source: NIH RePORTER; NIAID NIH HHS [T32-AI-007512] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRANUM AM, 2009, PEDIATRICS, V1549, P55; BRANUM AM, 2008, FOOD ALLERGY U S CHI, V28, P2010; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Keil T, 2008, CLIN EXP ALLERGY, V38, P1252, DOI 10.1111/j.1365-2222.2008.03048.x; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Sampson HA, 2000, BRIT MED BULL, V56, P925, DOI 10.1258/0007142001903607; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x	9	97	100	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					385	388		10.1016/j.jaci.2010.05.018	http://dx.doi.org/10.1016/j.jaci.2010.05.018			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20621344				2022-12-18	WOS:000281203800026
J	Lin, J; Bardina, L; Shreffler, WG; Andreae, DA; Ge, YC; Wang, JL; Bruni, FM; Fu, ZY; Han, YS; Sampson, HA				Lin, Jing; Bardina, Ludmilla; Shreffler, Wayne G.; Andreae, Doerthe A.; Ge, Yongchao; Wang, Julie; Bruni, Francesca M.; Fu, Zhiyan; Han, Youngshin; Sampson, Hugh A.			Development of a novel peptide microarray for large-scale epitope mapping of food allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epitope mapping; peptide microarray; allergy; milk allergen	IGG-BINDING EPITOPES; SEQUENTIAL EPITOPES; MEMBRANE SUPPORTS; KAPPA-CASEIN; MILK; IDENTIFICATION; PERSISTENT; CHILDREN; PROTEIN; ALPHA(S1)-CASEIN	Background: The peptide microarray is a novel assay that facilitates high-throughput screening of peptides with a small quantity of sample. Objective: We sought to use overlapping peptides of milk allergenic proteins as a model system to establish a reliable and sensitive peptide microarray-based immunoassay for large-scale epitope mapping of food allergens. Methods: A milk peptide microarray was developed by using commercially synthesized peptides (20-mers, 3 offset) covering the primary sequences of alpha(s1)-casein, alpha(s2)-casein, beta-casein, kappa-casein, and beta-lactoglobulin. Conditions for printing and immunolabeling were optimized using a serum pool of 5 patients with milk allergy. Reproducibility of the milk peptide microarray was evaluated using replicate arrays immunolabeled with the serum pool, whereas specificity and sensitivity were assessed by using serial dilution of the serum pool and a peptide inhibition assay. Results: Our results show that epitopes identified by the peptide microarray were mostly consistent with those identified previously by SPOT membrane technology, but with specific binding to a few newly identified epitopes of milk allergens. Data from replicate arrays were reproducible (r >= 0.92) regardless of printing lots, immunolabeling, and serum pool batches. Using the serially diluted serum pool, we confirmed that IgE antibody binding detected in the array was specific. Peptide inhibition of IgE binding to the same peptide and overlapping peptides further confirmed the specificity of the array. Conclusion: A reliable peptide microarray was established for large-scale IgE epitope mapping of milk allergens, and this robust technology could be applied for epitope mapping of other food allergens. (J Allergy Clin Immunol 2009;124:315-22.)	[Lin, Jing; Ge, Yongchao] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Bruni, Francesca M.] Univ Verona, I-37100 Verona, Italy; [Han, Youngshin] Sungkyunkwan Univ, Sch Med, Seoul, South Korea	Icahn School of Medicine at Mount Sinai; University of Verona; Sungkyunkwan University (SKKU)	Lin, J (corresponding author), Mt Sinai Sch Med, Dept Neurol, Box 1198, New York, NY 10029 USA.	jing.s.lin@mssm.edu	Lin, Jing/C-8877-2010; Ge, Yongchao/AAG-9317-2021	Ge, Yongchao/0000-0001-6448-5703	Korean Government (MOEHRD) [KRF-2006-214-C00099]; National Institute of Allergy and Infectious Diseases [AI-44236]; National Center for Research Resources [MO1-RR-00071]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044236, U19AI044236] Funding Source: NIH RePORTER	Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Y.H. was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD; KRF-2006-214-C00099). H.A.S. and J.L. were supported in part by a grant from National Institute of Allergy and Infectious Diseases (AI-44236). Studies were Supported in part by grants from the National Institute of Allergy and Infectious Diseases (AI-44236) and the National Center for Research Resources (MO1-RR-00071).	Beyer K, 2005, J ALLERGY CLIN IMMUN, V116, P704, DOI 10.1016/j.jaci.2005.05.007; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; BISCHOFF SC, 2003, FOOD ALLERGY ADVERSE; Busse PJ, 2002, INT ARCH ALLERGY IMM, V129, P93, DOI 10.1159/000065178; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Cocco RR, 2003, J ALLERGY CLIN IMMUN, V112, P433, DOI 10.1067/mai.2003.1617; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; FU Z, 2008, POSTSTRUCTURAL GENOM; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Han N, 2008, ALLERGY, V63, P198, DOI 10.1111/j.1398-9995.2007.01539.x; Harwanegg C, 2003, CLIN EXP ALLERGY, V33, P7, DOI 10.1046/j.1365-2222.2003.01550.x; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; Kim TE, 2002, EXP MOL MED, V34, P152, DOI 10.1038/emm.2002.22; Lin J, 2006, INT ARCH ALLERGY IMM, V141, P91, DOI 10.1159/000094535; MacBeath G, 2000, SCIENCE, V289, P1760; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Mehl A, 2005, ALLERGY, V60, P1034, DOI 10.1111/j.1398-9995.2005.00806.x; Panicker RC, 2004, COMB CHEM HIGH T SCR, V7, P547; REINEKE U, 2006, MICRO NANOTECHNOLOGI, P161; Sampson HA, 2005, ALLERGY, V60, P19, DOI 10.1111/j.1398-9995.2005.00853.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shin DS, 2005, J BIOCHEM MOL BIOL, V38, P517; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T	34	97	108	2	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					315	322		10.1016/j.jaci.2009.05.024	http://dx.doi.org/10.1016/j.jaci.2009.05.024			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19577281	Green Accepted, Bronze			2022-12-18	WOS:000268860400019
J	Bousquet, PJ; Combescure, C; Klossek, JM; Daures, JP; Bousquet, J				Bousquet, Philippe-Jean; Combescure, Christophe; Klossek, Jean-Michel; Daures, Jean-Pierre; Bousquet, Jean			Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; Allergic Rhinitis and Its Impact on Asthma; visual analog scale; pragmatic cluster randomized clinical trial	QUALITY-OF-LIFE; FUROATE NASAL SPRAY; FLUTICASONE PROPIONATE; SYMPTOM SEVERITY; ASTHMA; DESLORATADINE; BUDESONIDE; EFFICACY; COLLABORATION; GUIDELINES	Background: Most patients with allergic rhinitis consult in primary care. A simple test is needed to evaluate globally the severity of allergic rhinitis to assess the efficacy of treatment. Objective: This study compared the responsiveness of visual analog scale (VAS) scores between baseline and treatment with the 2 gold-standard outcomes (symptom score and quality of life). Five hundred eighty-six subjects were included, all with allergic rhinitis caused by grass pollens and all seen in primary care. Methods: A randomized, multicenter, open-label parallel study was designed to compare 2 therapeutic strategies in patients with allergic rhinitis. The disease-specific Rhinoconjunctivitis Quality of Life Questionnaire total score, the symptom score, and the VAS score (0-10 cm) were all self-assessed by the patient before and after 2 weeks of treatment. Receiver operating characteristic curves and cost function were used to assess VAS cutoff scores and to distinguish between patients with no clinical improvement and patients with improvement in symptoms, quality of life, or both. Results: The optimal cutoff in VAS score change separating the patients without improvement from those with improvement is 0.30 cm. By using the cost of false-positive and false-negative results, a difference of more than 1 cm is significant. However, when patients show an improvement in both symptoms and Rhinoconjunctivitis Quality of Life Questionnaire scores, the median improvement on the VAS is 7 cm. Conclusions: A VAS, when used for a global evaluation of rhinitis, is highly responsive to change during the treatment of a large number of patients in a cluster randomized pragmatic trial. (J Allergy Clin Immunol 2009;123:1349-54.)	[Bousquet, Philippe-Jean; Bousquet, Jean] Hop Arnaud Villeneuve, Serv Malad Resp, F-34275 Montpellier 5, France; [Bousquet, Philippe-Jean; Combescure, Christophe; Daures, Jean-Pierre] Grp Hosp Univ Caremeau, Dept Epidemiol Clin Biostat Sante Publ & Informat, Nimes, France; [Klossek, Jean-Michel] CHU Poitiers, Poitiers, France	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Nimes; CHU Poitiers; Universite de Poitiers	Bousquet, PJ (corresponding author), Hop Arnaud Villeneuve, Serv Malad Resp, 371 Ave Doyen Gaston Giraud, F-34275 Montpellier 5, France.	jean.bousquet@inserm.fr	Bousquet, Philippe Jean/AAW-8608-2021; Bousquet, Jean/O-4221-2019	Bousquet, Philippe Jean/0000-0002-0217-5483; 	Sixth EU Framework program for research [FOOD-CT-2004-506378]	Sixth EU Framework program for research	Members of the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN). Supported by the Sixth EU Framework program for research, contract no. FOOD-CT-2004-506378.	Bachert C, 2004, J ALLERGY CLIN IMMUN, V114, P838, DOI 10.1016/j.jaci.2004.05.070; Baena-Cagnani CE, 2003, INT ARCH ALLERGY IMM, V130, P307, DOI 10.1159/000070218; BANOV CH, 1994, ANN ALLERGY, V73, P240; Beeh KM, 2004, RESP MED, V98, P591, DOI 10.1016/j.rmed.2004.01.004; Berger WE, 2002, ANN ALLERG ASTHMA IM, V89, P485, DOI 10.1016/S1081-1206(10)62086-8; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2008, ALLERGY, V63, P633; Bousquet J, 2008, ALLERGY, V63, P1, DOI 10.1111/j.1398-9995.2007.01594.x; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BOUSQUET J, 2009, IMPROVEMENT IN PRESS; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Ciprandi G, 2002, ALLERGY, V57, P586, DOI 10.1034/j.1398-9995.2002.03228.x; Day J, 1998, J ALLERGY CLIN IMMUN, V102, P902, DOI 10.1016/S0091-6749(98)70326-4; DEBLAY F, 1993, J ALLERGY CLIN IMMUN, V92, P255, DOI 10.1016/0091-6749(93)90169-G; Dokic D, 2005, Prilozi, V26, P113; DRUMMOND C, 2004, ROC ANAL ARTIFICIAL, P19; Fokkens WJ, 2007, ALLERGY, V62, P1078, DOI 10.1111/j.1398-9995.2007.01522.x; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V102, P16, DOI 10.1016/S0091-6749(98)70048-X; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; Juniper EF, 1997, J ALLERGY CLIN IMMUN, V99, pS742, DOI 10.1016/S0091-6749(97)90000-2; Kaiser HB, 2007, J ALLERGY CLIN IMMUN, V119, P1430, DOI 10.1016/j.jaci.2007.02.022; LANGLEY GB, 1985, RHEUMATOL INT, V5, P145, DOI 10.1007/BF00541514; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391, DOI 10.1164/ajrccm.162.4.9912033; MATRICARDI PM, 1994, J ALLERGY CLIN IMMUN, V93, P68, DOI 10.1016/0091-6749(94)90234-8; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; Meltzer EO, 2006, ANN ALLERG ASTHMA IM, V96, P363, DOI 10.1016/S1081-1206(10)61249-5; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Numminen J, 2003, RHINOLOGY, V41, P65; Pradalier A, 2007, ALLERGY, V62, P1331, DOI 10.1111/j.1398-9995.2007.01374.x; Roberts G, 2003, J ALLERGY CLIN IMMUN, V111, P491, DOI 10.1067/mai.2003.138; Ryan D, 2008, ALLERGY, V63, P981, DOI 10.1111/j.1398-9995.2008.01653.x; Senti G, 2007, ANN ALLERG ASTHMA IM, V98, P134, DOI 10.1016/S1081-1206(10)60685-0; Shedden Arthur, 2005, Treat Respir Med, V4, P439, DOI 10.2165/00151829-200504060-00007; Simola M, 1997, CLIN OTOLARYNGOL, V22, P260, DOI 10.1046/j.1365-2273.1997.00033.x; SPECTOR S, 1990, ANN ALLERGY, V64, P300; Spector SL, 2003, ANN ALLERG ASTHMA IM, V91, P105, DOI 10.1016/S1081-1206(10)62160-6; Stern MA, 1998, ANN ALLERG ASTHMA IM, V81, P354, DOI 10.1016/S1081-1206(10)63128-6; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Van Cauwenberge P, 2000, CLIN EXP ALLERGY, V30, P891; van Weel C, 2008, ALLERGY, V63, P1005, DOI 10.1111/j.1398-9995.2008.01655.x; Vasar M, 2008, ALLERGY ASTHMA PROC, V29, P313, DOI 10.2500/aap.2008.29.3126; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Weintraub JM, 2001, ALLERGY, V56, P243, DOI 10.1034/j.1398-9995.2001.056003243.x; WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x	47	97	103	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1349	1354		10.1016/j.jaci.2009.02.033	http://dx.doi.org/10.1016/j.jaci.2009.02.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19368963	Bronze			2022-12-18	WOS:000266799100028
J	Leigh, R; Oyelusi, W; Wiehler, S; Koetzler, R; Zaheer, RS; Newton, R; Proud, D				Leigh, Richard; Oyelusi, Wale; Wiehler, Shahina; Koetzler, Rommy; Zaheer, Raza S.; Newton, Robert; Proud, David			Human rhinovirus infection enhances airway epithelial cell production of growth factors involved in airway remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human rhinovirus; asthma; airway remodeling; airway epithelial cell; vascular endothelial growth factor amphiregulin; activin A; milogen-activated protein kinase; nuclear factor kappa B; I kappa B kinase	IN-VITRO; EOSINOPHILIC INFLAMMATION; FACTOR VEGF; MAST-CELLS; KAPPA-B; ASTHMA; VIVO; EXPRESSION; INDUCTION; STIMULATION	Background: Childhood human rhinovirus (HRV) infections are associated with an increased risk of asthma. We reasoned that HRV infections might be important in the pathogenesis of airway remodeling, thereby providing a mechanism by which these children are at risk of asthma. Objective: We sought to determine whether HRV infection of airway epithelial cells regulates production of growth factors associated with airway remodeling and to determine whether vascular endothelial growth factor (VEGF) was upregulated in airways during HRV-induced natural colds. Methods: Cultured human airway epithelial cells were infected with HRV. Amphiregulin, activin A, and VEGF protein levels were assayed by means of ELISA, and VEGF mRNA was quantified by using real-time RT-PCR. Pharmacologic inhibitors were used to assess the role of mitogen-activated protein kinase and nuclear factor kappa B pathways. Nasal lavage samples from subjects with confirmed natural HRV infections were assayed for VEGF protein and compared with baseline levels and with control levels. Results: HRV infection upregulated amphiregulin, activin A, and VEGF protein levels compared with control media (P <.05). VEGF gene expression was maximally induced 3 hours after infection. HRV-induced generation of VEGF was regulated by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2 pathways but did not depend on nuclear factor kappa B activation. In subjects with HRV infections, VEGF levels during peak cold symptoms were significantly higher than at baseline (P = .005) or in control subjects (P < .01). Conclusion: HRV-16 infection upregulates amphiregulin, activin A, and VEGF in airway epithelial cells, and HRV infections in vivo upregulate airway VEGF production.	[Leigh, Richard; Oyelusi, Wale] Univ Calgary, Airway Inflammat Res Grp, Dept Med, Inst Infect Immun & Inflammat, Calgary, AB T2N 1N4, Canada; [Leigh, Richard; Oyelusi, Wale; Wiehler, Shahina; Koetzler, Rommy; Zaheer, Raza S.; Proud, David] Univ Calgary, Inst Infect Immun & Inflammat, Dept Physiol & Biophys, Calgary, AB T2N 1N4, Canada; [Newton, Robert] Univ Calgary, Inst Infect Immun & Inflammat, Dept Cell Biol & Anat, Calgary, AB T2N 1N4, Canada	University of Calgary; University of Calgary; University of Calgary	Leigh, R (corresponding author), Room 228,Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rleigh@uclagary.ca	Newton, Robert/C-6814-2012	Newton, Robert/0000-0002-4919-8498				Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cho SH, 2003, J IMMUNOL, V170, P4045, DOI 10.4049/jimmunol.170.8.4045; De Silva D, 2006, J MED VIROL, V78, P666, DOI 10.1002/jmv.20591; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; Feltis BN, 2006, AM J RESP CRIT CARE, V173, P1201, DOI 10.1164/rccm.200507-1105OC; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Ip WK, 2007, IMMUNOLOGY, V122, P532, DOI 10.1111/j.1365-2567.2007.02668.x; Le AV, 2007, J IMMUNOL, V178, P7310, DOI 10.4049/jimmunol.178.11.7310; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee CG, 2000, AM J RESP CELL MOL, V23, P662, DOI 10.1165/ajrcmb.23.5.4188; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Newton R, 2007, J PHARMACOL EXP THER, V321, P734, DOI 10.1124/jpet.106.118125; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Pohunek P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/j.1399-3038.2005.00239.x; Proud D, 2004, J IMMUNOL, V172, P4637, DOI 10.4049/jimmunol.172.7.4637; Psarras S, 2006, J ALLERGY CLIN IMMUN, V117, P291, DOI 10.1016/j.jaci.2005.11.005; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Saglani S, 2007, CURR OPIN ALLERGY CL, V7, P83; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Sanders SP, 2001, J ALLERGY CLIN IMMUN, V107, P235, DOI 10.1067/mai.2001.112028; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simcock DE, 2007, AM J RESP CRIT CARE, V176, P146, DOI 10.1164/rccm.200701-042OC; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Wang L, 2003, CHEST, V123, p356S, DOI 10.1378/chest.123.3_suppl.356S-a; Wang SW, 2005, J ALLERGY CLIN IMMUN, V115, P287, DOI 10.1016/j.jaci.2004.11.037; Wang XM, 2006, J IMMUNOL, V177, P6859, DOI 10.4049/jimmunol.177.10.6859; Wiehler S, 2007, AM J PHYSIOL-LUNG C, V293, pL505, DOI 10.1152/ajplung.00066.2007; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	33	97	101	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1238	1245		10.1016/j.jaci.2008.01.067	http://dx.doi.org/10.1016/j.jaci.2008.01.067			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18355907				2022-12-18	WOS:000255961700025
J	Hammad, H; Lambrecht, BN				Hammad, Hamida; Lambrecht, Bart N.			Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; asthma; inflammation; tolerance	THYMIC STROMAL LYMPHOPOIETIN; CD4(+) T-CELLS; INHALED ANTIGEN; TH2 RESPONSES; MOUSE MODEL; IN-VIVO; IMMUNE-RESPONSES; IL-12 PRODUCTION; TGF-BETA; LUNG	Dendritic cells (DCs) are crucial in determining the outcome of antigen encounter and integrating signals derived from the antigen, its inflammatory context, and the host environment into a signal that can be read by naive T cells in the lymphoid tissues and by effector T cells in peripheral tissues. Airway DC subsets, however, induce different types of immune responses, with plasmacytoid DCs promoting tolerance and myelloid DCs inducing immunity. We also propose that airway DCs are not only crucial for sensitization to inhaled antigens, leading to allergy, but also play a crucial role in established inflammation and therefore represent a therapeutic target to prevent the development of airway diseases.	Erasmus Univ, Ctr Med, Dept Pulm Med, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam	Hammad, H (corresponding author), Erasmus Univ, Ctr Med, Dept Pulm Med, Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	H.Hammad@erasmusmc.nl	Lambrecht, Bart N/K-2484-2014; Hammad, Hamida/J-9391-2015	Lambrecht, Bart N/0000-0003-4376-6834; Hammad, Hamida/0000-0003-3762-8603				Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Doganci A, 2005, CLIN REV ALLERG IMMU, V28, P257, DOI 10.1385/CRIAI:28:3:257; Edwan JH, 2004, J IMMUNOL, V172, P5016, DOI 10.4049/jimmunol.172.8.5016; Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fallarino F, 2004, J IMMUNOL, V173, P3748, DOI 10.4049/jimmunol.173.6.3748; Gordon JR, 2005, J IMMUNOL, V175, P1516, DOI 10.4049/jimmunol.175.3.1516; Hammad H, 2004, CLIN EXP ALLERGY, V34, P1834, DOI 10.1111/j.1365-2222.2004.02133.x; Hammad H, 2003, EUR CYTOKINE NETW, V14, P219; Hammad H, 2003, J IMMUNOL, V171, P3936, DOI 10.4049/jimmunol.171.8.3936; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Hessel EM, 2005, J EXP MED, V202, P1563, DOI 10.1084/jem.20050631; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jakubzick C, 2006, J IMMUNOL, V176, P3578, DOI 10.4049/jimmunol.176.6.3578; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Koya T, 2006, AM J RESP CRIT CARE, V173, P42, DOI 10.1164/rccm.200505-783OC; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; Kuipers H, 2004, J LEUKOCYTE BIOL, V76, P1028, DOI 10.1189/jlb.0604325; Kuipers H, 2003, J IMMUNOL, V171, P3645, DOI 10.4049/jimmunol.171.7.3645; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Marsland BJ, 2005, IMMUNITY, V22, P493, DOI 10.1016/j.immuni.2005.02.010; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Oflazoglu E, 2004, EUR J IMMUNOL, V34, P3326, DOI 10.1002/eji.200425197; Oriss TB, 2005, J IMMUNOL, V174, P854, DOI 10.4049/jimmunol.174.2.854; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038; Scherf W, 2005, EUR J IMMUNOL, V35, P198, DOI 10.1002/eji.200425209; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Stock P, 2004, EUR J IMMUNOL, V34, P1817, DOI 10.1002/eji.200324623; Sung SSJ, 2006, J IMMUNOL, V176, P2161, DOI 10.4049/jimmunol.176.4.2161; Swanson KA, 2004, J IMMUNOL, V173, P4875, DOI 10.4049/jimmunol.173.8.4875; Takano K, 2005, J HISTOCHEM CYTOCHEM, V53, P611, DOI 10.1369/jhc.4A6539.2005; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Wang JS, 2006, J CLIN INVEST, V116, P414, DOI 10.1172/JCI26631; Watanabe N, 2005, BLOOD, V105, P4749, DOI 10.1182/blood-2004-09-3622; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	46	97	104	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					331	336		10.1016/j.jaci.2006.03.041	http://dx.doi.org/10.1016/j.jaci.2006.03.041			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890754				2022-12-18	WOS:000239877700005
J	Karagiannidis, C; Hense, G; Martin, C; Epstein, M; Ruckert, B; Mantel, PY; Menz, G; Uhlig, S; Blaser, K; Schmidt-Weber, CB				Karagiannidis, C; Hense, G; Martin, C; Epstein, M; Ruckert, B; Mantel, PY; Menz, G; Uhlig, S; Blaser, K; Schmidt-Weber, CB			Activin A is an acute allergen-responsive cytokine and provides a link to TGF-beta-mediated airway remodeling in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; fibrosis; tolerance; suppression; allergy	HUMAN LUNG FIBROBLASTS; GROWTH-FACTOR-BETA; BRONCHOALVEOLAR LAVAGE FLUID; REGULATORY T-CELLS; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; PULMONARY-FIBROSIS; PROLIFERATION; EXPRESSION; INFLAMMATION	Background: Allergic asthma typically shows activated, allergen-specific CD4(+) T cells in the early phase and airway remodeling in the late phase of the disease. Although TGF-beta plays a crucial role in airway remodeling, it is only marginally induced in CD4(+) T cells in the early allergen-dependent activation of the immune system. Objective: To elucidate the transition between early- and late-phase events, we investigated the role of activin A, a close family member of TGF-beta. Methods: Activin A and TGF-beta(1) levels were measured systemically in the serum and in CD4(+) T cells of asthmatic patients, as well as locally in the lung. Results: Activin A serum levels were increased in patients with severe asthma compared with levels in patients with moderate asthma and healthy control subjects, whereas all patients showed significantly increased TGF-beta(1) serum levels independent of disease severity. In T cells only patients with moderate asthma showed increased activin A mRNA expression, whereas TGF-beta(1) expression was equal to that seen in healthy subjects. Accordingly, ovalburnin sensitization in a mouse model of allergic asthma could induce activin A mRNA expression, but not TGF-beta(1) expression, in the lung. Immunohistochemistry of mice and human specimens revealed an abundant expression of activin A by infiltrating lymphocytes and structural cells of the lung. Although TGF-beta(1) more potently enhanced proliferation and Smad 2/3-dependent reporter genes in fibroblasts, activin A was capable of inducing TGF-beta(1) and vice versa. Conclusion: Activin A provides a link between acute allergenspecific T-cell responses and chronic TGF-beta(1)-mediated airway remodeling in asthma.	Swiss Inst Allergy & Asthma Res, SIAF, CH-7270 Davos, Switzerland; Res Ctr, Borstel, Germany; Univ Vienna, Dept Dermatol, Vienna, Austria; Hochgebirgsklin Davos Wolfgang, Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; Forschungszentrum Borstel; University of Vienna	Schmidt-Weber, CB (corresponding author), Swiss Inst Allergy & Asthma Res, SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	csweber@siaf.unizh.ch	Schmidt-Weber, Carsten B./AAU-1621-2021; Uhlig, Stefan/A-7290-2014; Mantel, Pierre-Yves/N-3065-2015	Schmidt-Weber, Carsten B./0000-0002-3203-8084; Uhlig, Stefan/0000-0003-2332-1280; Mantel, Pierre-Yves/0000-0001-9526-9309; Epstein, Michelle/0000-0002-4755-0224	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Abe M, 2002, J LEUKOCYTE BIOL, V72, P347; Abe Y, 2004, GROWTH FACTORS, V22, P105, DOI 10.1080/08977190410001704688; Batra V, 2004, CLIN EXP ALLERGY, V34, P437, DOI 10.1111/j.1365-2222.2004.01885.x; Bergeron A, 2003, EUR RESPIR J, V22, P69, DOI 10.1183/09031936.03.00014703; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Cho SH, 2003, J IMMUNOL, V170, P4045, DOI 10.4049/jimmunol.170.8.4045; Chung KF, 1999, EUR RESPIR J, V13, P1198; FINE A, 1987, J BIOL CHEM, V262, P3897; Funaba M, 2000, MOL ENDOCRINOL, V14, P1583, DOI 10.1210/me.14.10.1583; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; Hedger MP, 2000, CYTOKINE, V12, P595, DOI 10.1006/cyto.1999.0597; Hughes RD, 2003, EUR J GASTROEN HEPAT, V15, P127, DOI 10.1097/00042737-200302000-00004; Jones KL, 2004, J ENDOCRINOL, V182, P69, DOI 10.1677/joe.0.1820069; Jones KL, 2004, MOL CELL ENDOCRINOL, V225, P119, DOI 10.1016/j.mce.2004.07.010; Karagiannidis C, 2005, SCAND J IMMUNOL, V61, P187, DOI 10.1111/j.0300-9475.2005.01546.x; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kokturk N, 2003, J ASTHMA, V40, P887, DOI 10.1081/JAS-120023580; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P567, DOI 10.1111/j.1365-2222.2004.1917.x; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Mojtabavi N, 2002, J IMMUNOL, V169, P4788, DOI 10.4049/jimmunol.169.9.4788; Moustakas A, 2001, J CELL SCI, V114, P4359; Ohga E, 1996, BIOCHEM BIOPH RES CO, V228, P391, DOI 10.1006/bbrc.1996.1672; Ohga E, 2000, LIFE SCI, V66, P1603, DOI 10.1016/S0024-3205(00)00480-X; Ota F, 2003, ARTHRITIS RHEUM, V48, P2442, DOI 10.1002/art.11249; Pachot A, 2005, CLIN IMMUNOL, V114, P61, DOI 10.1016/j.clim.2004.08.015; Pangas SA, 2000, TRENDS ENDOCRIN MET, V11, P309, DOI 10.1016/S1043-2760(00)00294-0; Phillips DJ, 2000, BIOESSAYS, V22, P689, DOI 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Rosendahl A, 2002, AM J RESP CELL MOL, V27, P160, DOI 10.1165/ajrcmb.27.2.4779; Schmidt-Weber Carsten B, 2002, Curr Allergy Asthma Rep, V2, P259, DOI 10.1007/s11882-002-0028-8; Schmidt-Weber CB, 2004, CURR OPIN IMMUNOL, V16, P709, DOI 10.1016/j.coi.2004.09.008; Schramm C, 2003, J IMMUNOL, V170, P1313, DOI 10.4049/jimmunol.170.3.1313; Shav-Tal Y, 2002, STEM CELLS, V20, P493, DOI 10.1634/stemcells.20-6-493; Smith C, 2004, J AM COLL CARDIOL, V44, P369, DOI 10.1016/j.jacc.2004.03.069; Tanaka H, 2001, INFLAMM RES, V50, P616, DOI 10.1007/PL00000243; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Wohlfahrt JG, 2003, INT ARCH ALLERGY IMM, V131, P272, DOI 10.1159/000072139; Xu YD, 2003, AM J PHYSIOL-LUNG C, V285, pL527, DOI 10.1152/ajplung.00298.2002; Yndestad A, 2004, CIRCULATION, V109, P1379, DOI 10.1161/01.CIR.0000120704.97934.41	42	97	99	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					111	118		10.1016/j.jaci.2005.09.017	http://dx.doi.org/10.1016/j.jaci.2005.09.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387593				2022-12-18	WOS:000235687100018
J	Kattan, M; Stearns, SC; Crain, EF; Stout, JW; Gergen, PJ; Evans, R; Visness, CM; Gruchalla, RS; Morgan, WJ; O'Connor, GT; Mastin, JP; Mitchell, HE				Kattan, M; Stearns, SC; Crain, EF; Stout, JW; Gergen, PJ; Evans, R; Visness, CM; Gruchalla, RS; Morgan, WJ; O'Connor, GT; Mastin, JP; Mitchell, HE			Cost-effectiveness of a home-based environmental intervention for inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inner city; cost-effectiveness; asthma intervention; allergen mitigation	UNITED-STATES; ILLNESS; TRENDS	Background: Exposure to indoor allergens contributes to increased asthma morbidity. The Inner-City Asthma Study, a randomized trial involving home environmental allergen and irritant remediation among children aged 6 through 11 years with moderate-to-severe asthma, successfully reduced asthma symptoms. A cost-effectiveness analysis can help stakeholders to evaluate the potential costs and benefits of adopting such a program. Objective: We sought to assess the cost-effectiveness of the environmental intervention of the Inner-City Asthma Study. Methods: Incremental cost-effectiveness ratios for a 2-year study period were calculated. Health outcome was measured as symptom-free days. Resource use measures included ambulatory visits, hospitalizations, and pharmaceutical use. CIs were obtained by using bootstrapping. Results: The intervention, which cost $1469 per family, led to statistically significant reductions in symptom days, unscheduled clinic visits, and use of beta-agonist inhalers. Over the year of the intervention and a year of follow-up, the intervention cost was $27.57 per additional symptom-free day (95% CI, $7.46-$67.42). Subgroup analysis showed that targeting the intervention to selected high-risk subgroups did not reduce the incremental cost-effectiveness ratio. Conclusions: A targeted home-based environmental intervention improved health and reduced service use in inner-city children with moderate-to-severe asthma. The intervention is cost-effective when the aim is to reduce asthma symptom days and the associated costs.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Univ N Carolina, Dept Hlth Policy & Adm, Chapel Hill, NC USA; Albert Einstein Coll Med, Jacobi Med Ctr, Dept Pediat Emergency Med, Bronx, NY 10467 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; NIAID, Asthma Allergy Inflammat Branch, Div Allergy Immunol Transplantat, NIH, Bethesda, MD 20892 USA; Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Rho Inc, Chapel Hill, NC USA; Univ Texas, SW Med Ctr Dallas, Dept Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75235 USA; Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ USA; Boston Univ, Sch Med, Boston, MA 02215 USA; Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA	Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; Jacobi Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Northwestern University; Northwestern University; Rho; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Arizona; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kattan, M (corresponding author), Mt Sinai Sch Med, Dept Pediat, Box 1202B,1 Gustave L Levy Pl, New York, NY 10029 USA.	meyer.kattan@mssm.edu		O'Connor, George/0000-0002-6476-3926	NIAID NIH HHS [AI-39900, AI-39901, AI-39789, AI-39902, AI-39785, AI-39776, AI-39769, AI-39761] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI039785, U01AI039789, U01AI039902, U01AI039761, U01AI039900, U01AI039776, U01AI039901, U01AI039769] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chaudhary MA, 1996, STAT MED, V15, P1447; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287, DOI 10.1001/archpedi.154.3.287; Paltiel AD, 2001, J ALLERGY CLIN IMMUN, V108, P39, DOI 10.1067/mai.2001.116289; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; STEIN REK, 1987, LANCET, V2, P1506; Sullivan SD, 2003, J ALLERGY CLIN IMMUN, V112, P1229, DOI 10.1016/j.jaci.2003.09.025; Sullivan SD, 2002, J ALLERGY CLIN IMMUN, V110, P576, DOI 10.1067/mai.2002.128009; Wang Li Yan, 2005, Prev Chronic Dis, V2, pA11; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304	14	97	100	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1058	1063		10.1016/j.jaci.2005.07.032	http://dx.doi.org/10.1016/j.jaci.2005.07.032			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275376	Bronze			2022-12-18	WOS:000235686700017
J	Portengen, L; Preller, L; Tielen, M; Doekes, G; Heederik, D				Portengen, L; Preller, L; Tielen, M; Doekes, G; Heederik, D			Endotoxin exposure and atopic sensitization in adult pig farmers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxins; hypersensitivity; IgE; allergens; adult; occupational exposure; epidemiology	RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; LUNG-FUNCTION; HOUSE-DUST; ASTHMA; ALLERGY; ENVIRONMENT; PREVALENCE; CHILDREN; INDUSTRY	Background: Recent studies have reported a low prevalence of atopic sensitization and respiratory allergy in children growing up on farms. Objectives: We sought to evaluate the dose-response relationship between endotoxin and atopic sensitization in adult farmers and to assess the effect on respiratory health outcomes. Methods: Data on endotoxin exposure and serum IgE levels were available for 162 pig farmers from a cross-sectional, case-control study, with case selection on the basis of respiratory symptoms. Exposure to endotoxin was modeled in detail, and respiratory health effects were assessed during a medical examination. Exploratory analysis was done by using nonparametric modeling and was followed by classical parametric regression. Results: IgE to one or more common allergens was detected in sera from 28 (17%) farmers. The average (geometric mean) total serum IgE levels was 37 lU/mL (geometric SD, 4 IU/mL). A strong inverse relationship was found between endotoxin and sensitization to common allergens for exposures of 75 ng/m(3) or less, with an odds ratio of 0.03 (95% CI, 0.0-0.34) for a 2-fold increase in endotoxin. For endotoxin exposure of greater than 75 ng/m(3), the association was weak (odds ratio, 1.2 [95% Cl, 0.38-3.6]). No association was found between endotoxin exposure and total serum IgE levels. Endotoxin was associated with increased airway hyperresponsiveness to histamine and lower lung function in sensitized farmers, without evidence of a nonlinear relationship. Conclusions: The prevalence of atopic sensitization in adult pig farmers is low. Endotoxin or related exposures might protect from sensitization, even in an adult working population exposed to high levels of endotoxin, but is a risk factor for increased airway hyperresponsiveness and low lung function.	Univ Utrecht, IRAS, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Dept Herd Hlth & Reprod, NL-3508 TD Utrecht, Netherlands; TNO Chem, Food & Chem Risk Anal, Zeist, Netherlands	Utrecht University; Utrecht University; Netherlands Organization Applied Science Research	Portengen, L (corresponding author), Univ Utrecht, IRAS, POB 80176, NL-3508 TD Utrecht, Netherlands.	L.Portengen@iras.uu.nl		Heederik, Dick/0000-0002-4550-1437				BIERSTEKER K, 1974, TIJDSCHR SOC GENEESK, V52, P158; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2003, CLIN EXP ALLERGY, V33, P409, DOI 10.1046/j.1365-2222.2003.01650.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Cormier Y, 2000, EUR RESPIR J, V15, P560, DOI 10.1034/j.1399-3003.2000.15.22.x; Doekes G, 1996, OCCUP ENVIRON MED, V53, P63, DOI 10.1136/oem.53.1.63; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Filipiak B, 2001, CLIN EXP ALLERGY, V31, P1829, DOI 10.1046/j.1365-2222.2001.01246.x; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Hastie T.J., 1990, GEN ADDITIVE MODELS; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; HOLLANDER A, 1993, AM IND HYG ASSOC J, V54, P647, DOI 10.1202/0002-8894(1993)054<0647:IAEITA>2.0.CO;2; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499, DOI 10.1164/ajrccm.158.5.9803055; Johnson CC, 2002, CURR OPIN ALLERGY CL, V2, P133, DOI 10.1097/00130832-200204000-00009; Kauffmann F, 2002, CLIN EXP ALLERGY, V32, P379, DOI 10.1046/j.1365-2222.2002.01325.x; Kerkhof M, 1996, ALLERGY, V51, P770, DOI 10.1111/j.1398-9995.1996.tb04465.x; Kilpelainen M, 2002, ALLERGY, V57, P1130, DOI 10.1034/j.1398-9995.2002.23341.x; Koppelman GH, 2003, CLIN EXP ALLERGY, V33, P170, DOI 10.1046/j.1365-2222.2003.01591.x; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Preller L, 1996, EUR RESPIR J, V9, P1407, DOI 10.1183/09031936.96.09071407; PRELLER L, 1995, ANN OCCUP HYG, V39, P545, DOI 10.1093/annhyg/39.5.545; Preller L, 1995, SCAND J WORK ENV HEA, V21, P504, DOI 10.5271/sjweh.67; PRELLER L, 1995, OCCUP ENVIRON MED, V52, P654, DOI 10.1136/oem.52.10.654; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305, DOI 10.1164/ajrccm.163.2.ed2000a; Simpson JCG, 1999, ANN OCCUP HYG, V43, P107, DOI 10.1093/annhyg/43.2.107; Vogelzang PFJ, 1997, INT ARCH OCC ENV HEA, V70, P327, DOI 10.1007/s004200050226; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15, DOI 10.1164/ajrccm.157.1.9703087; Wahba G., 1990, SPLINE MODELS OBSERV; Wouters IM, 2002, OCCUP ENVIRON MED, V59, P106, DOI 10.1136/oem.59.2.106; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x; Zock JP, 1998, OCCUP ENVIRON MED, V55, P823, DOI 10.1136/oem.55.12.823	41	97	100	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					797	802		10.1016/j.jaci.2004.11.046	http://dx.doi.org/10.1016/j.jaci.2004.11.046			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806001	Green Published			2022-12-18	WOS:000228373400020
J	Akin, C; Metcalfe, DD				Akin, C; Metcalfe, DD			The biology of Kit in disease and the application of pharmacogenetics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Kit; c-kit; tyrosine kinase; mastocytosis; mast cells; mutations; pharmacogenetics; imatinib; tyrosine kinase inhibitors	GASTROINTESTINAL STROMAL TUMORS; STEM-CELL FACTOR; KINASE INHIBITOR STI571; BLOOD MONONUCLEAR-CELLS; PROTOONCOGENE C-KIT; HUMAN MAST-CELL; ABL TYROSINE KINASE; IMATINIB MESYLATE; WILD-TYPE; V-KIT	C-kit encodes a transmembrane protein with intrinsic tyrosine kinase activity, which functions as the receptor for stem cell factor. It is expressed on a variety of cell types, including mast cells, hematopoietic progenitor cells, melanocytes, germ cells, and gastrointestinal pacemaker cells. Mutations resulting in alteration of Kit function are associated with diseases involving each of these cells. Recent development of tyrosine kinase inhibitors led to their evaluation as novel therapies for diseases associated with Kit activation. This review will discuss the pathobiology of Kit in human disease, with a particular emphasis on implications for potential targeted treatment strategies in mast cell disease.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Akin, C (corresponding author), Univ Michigan, 4220-D MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	cemakin@med.umich.edu		Akin, Cem/0000-0001-6301-4520	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000513, ZIAAI000513] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abu-Duhier FM, 2003, BRIT J HAEMATOL, V120, P464, DOI 10.1046/j.1365-2141.2003.04108.x; Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; Akin C, 2003, EXP HEMATOL, V31, P686, DOI 10.1016/S0301-472X(03)00112-7; Akin C, 2003, LEUKEMIA RES, V27, P877, DOI 10.1016/S0145-2126(03)00093-6; Akin C, 2000, BLOOD, V96, p747A; ANDREJAUSKASBUCHDUNGER E, 1992, CANCER RES, V52, P5353; BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Beghini A, 2001, CANCER, V92, P657, DOI 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Buttner C, 1998, J INVEST DERMATOL, V111, P1227, DOI 10.1046/j.1523-1747.1998.00414.x; Capdeville R, 2003, SEMIN HEMATOL, V40, P15; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; Driancourt MA, 2000, REV REPROD, V5, P143, DOI 10.1530/revreprod/5.3.143; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Fumo G, 2004, BLOOD, V103, P1078, DOI 10.1182/blood-2003-07-2477; GALLI SJ, 1993, AM J PATHOL, V142, P965; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gotlib J, 2003, BLOOD, V102, p425A; Hasan S, 2003, J NATL MED ASSOC, V95, P722; Heinrich MC, 2002, J CLIN ONCOL, V20, P1692, DOI 10.1200/JCO.2002.20.6.1692; HERBST R, 1995, ONCOGENE, V10, P369; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hongyo T, 2000, CANCER RES, V60, P2345; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; IWAMOTO T, 1992, EXP CELL RES, V200, P410, DOI 10.1016/0014-4827(92)90189-F; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kato M, 2004, CANCER RES, V64, P801, DOI 10.1158/0008-5472.CAN-03-2532; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; Kitayama H, 1996, BLOOD, V88, P995; Klion AD, 2004, BLOOD, V103, P473, DOI 10.1182/blood-2003-08-2798; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Lasota J, 2000, AM J PATHOL, V157, P1091, DOI 10.1016/S0002-9440(10)64623-8; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Mekori YA, 2001, J CLIN IMMUNOL, V21, P171, DOI 10.1023/A:1011083031272; Miettinen M, 2002, EUR J CANCER, V38, pS39, DOI 10.1016/S0959-8049(02)80602-5; Montone KT, 1997, MODERN PATHOL, V10, P939; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NAKATA Y, 1995, BRIT J HAEMATOL, V91, P661, DOI 10.1111/j.1365-2141.1995.tb05364.x; Neckers L, 2003, CURR MED CHEM, V10, P733, DOI 10.2174/0929867033457818; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Ohashi A, 1996, MELANOMA RES, V6, P25, DOI 10.1097/00008390-199602000-00004; OKADA S, 1991, BLOOD, V78, P1706; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Robson ME, 2004, CLIN CANCER RES, V10, P1250, DOI 10.1158/1078-0432.CCR-03-0110; Rossi P, 2003, ANDROLOGIA, V35, P71, DOI 10.1046/j.1439-0272.2003.00539.x; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; SPRITZ RA, 1994, J INVEST DERMATOL, V103, pS137; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Tsao AS, 2003, CANCER, V98, P2483, DOI 10.1002/cncr.11812; TSUJIMURA T, 1991, BLOOD, V78, P1942; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; VALENT P, 1992, BLOOD, V80, P2237; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Wehrle-Haller B, 2003, PIGM CELL RES, V16, P287, DOI 10.1034/j.1600-0749.2003.00055.x; Worobec AS, 1998, CANCER, V83, P2120, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Yavuz AS, 2002, BLOOD, V100, P661, DOI 10.1182/blood-2002-01-0203; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	82	97	99	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					13	19		10.1016/j.jaci.2004.04.046	http://dx.doi.org/10.1016/j.jaci.2004.04.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241338				2022-12-18	WOS:000222534300002
J	Craig, TJ; McCann, JL; Gurevich, F; Davies, MJ				Craig, Timothy J.; McCann, Jeffrey L.; Gurevich, Faina; Davies, Michael J.			The correlation between allergic rhinitis and sleep disturbance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; antihistamines; inflammation; intranasal corticosteroids; leukotriene receptor antagonists; nasal congestion; nighttime symptoms; performance impairment; quality of life; sedation; sleep	QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; RECEPTOR BINDING-AFFINITY; INFLAMMATORY MEDIATORS; STEROID RESPONSIVENESS; DAYTIME SOMNOLENCE; NOCTURNAL ASTHMA; NASAL CONGESTION; DOUBLE-BLIND; SUBSTANCE-P	Nasal congestion, a common symptom related to allergic rhinitis (AR), often is associated with poor sleep quality, leading to decreased learning ability, decreased productivity at work or school, and a reduced quality of life. The release of inflammatory mediators and activation of inflammatory cells results in nasal congestion, causing disrupted sleep and subsequent daytime somnolence. Therefore it is important to treat AR with medications that improve congestive symptoms without exacerbating sedation. Second-generation antihistamines and anticholinergic drugs are well tolerated but have little effect on congestion and therefore are limited in their ability to reduce AR-associated daytime somnolence. However, intranasal corticosteroids reduce congestion, improve sleep and sleep problems, and reduce daytime sleepiness, fatigue, and inflammation. Recently, montelukast, a leukotriene receptor antagonist, has joined the approved therapies for AR. Montelukast significantly improves both daytime and nighttime symptoms. AR treatment should endeavor to improve daytime and nighttime symptoms, sleep, and productivity, thereby improving quality of life. (J Allergy Clin Immunol 2004; 114: S139-45.)	[Craig, Timothy J.; McCann, Jeffrey L.; Gurevich, Faina; Davies, Michael J.] Penn State Univ, Coll Med, Dept Med, Allergy Sect, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania State University - University Park	Craig, TJ (corresponding author), Care of Sweetman L, Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53202 USA.				GlaxoSmithKline; Schering; BI; Genentech; AstraZeneca; Glaxo; Merck; Novartis; Pfizer	GlaxoSmithKline(GlaxoSmithKline); Schering; BI; Genentech(Roche HoldingGenentech); AstraZeneca(AstraZeneca); Glaxo; Merck(Merck & Company); Novartis(Novartis); Pfizer(Pfizer)	T. J. Craig has received grants-research support from GlaxoSmithKline, Schering, BI. Genentech, AstraZeneca, Glaxo, Merck, Schering, Novartis, and Pfizer support the PAAA, of which Dr Craig is the president. J. L. McCann-none disclosed. F. Gurevich-none disclosed. M. J. Davies-none disclosed.	Aoyagi M, 1999, INT ARCH ALLERGY IMM, V120, P95, DOI 10.1159/000053604; Arimura A, 2001, J PHARMACOL EXP THER, V298, P411; ASANO K, 1995, J ALLERGY CLIN IMMUN, V96, P643, DOI 10.1016/S0091-6749(95)70263-6; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Calhoun WJ, 2003, CHEST, V123, p399S, DOI 10.1378/chest.123.3_suppl.399S; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; Flemons WW, 1997, J ALLERGY CLIN IMMUN, V99, pS750, DOI 10.1016/S0091-6749(97)70123-4; Golden S, 2000, ANN ALLERG ASTHMA IM, V85, P53, DOI 10.1016/S1081-1206(10)62434-9; Howarth PH, 1997, ALLERGY, V52, P12, DOI 10.1111/j.1398-9995.1997.tb04878.x; Hughes K, 2003, ALLERGY, V58, P380, DOI 10.1034/j.1398-9995.2003.00093.x; Juniper EF, 2003, J ALLERGY CLIN IMMUN, V111, P484, DOI 10.1067/mai.2003.137; Juniper EF, 1998, CLIN EXP ALLERGY, V28, P34; Kessler RC, 2001, ANN ALLERG ASTHMA IM, V87, P289, DOI 10.1016/S1081-1206(10)62242-9; Kraft M, 1999, J ALLERGY CLIN IMMUN, V103, P66, DOI 10.1016/S0091-6749(99)70527-0; Krouse HJ, 2002, OTOLARYNG HEAD NECK, V126, P607, DOI 10.1067/mhn.2002.125300; LAVIE P, 1981, ACTA OTO-LARYNGOL, V92, P529, DOI 10.3109/00016488109133292; Lieb K, 2002, NEUROPSYCHOPHARMACOL, V27, P1041, DOI 10.1016/S0893-133X(02)00369-X; McColley SA, 1997, CHEST, V111, P170, DOI 10.1378/chest.111.1.170; MCNICHOLAS WT, 1982, AM REV RESPIR DIS, V126, P625; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P242, DOI 10.1016/0091-6749(92)90078-G; Meltzer EO, 2000, ANN ALLERG ASTHMA IM, V84, P176, DOI 10.1016/S1081-1206(10)62750-0; Milgrom H, 1999, ANN ALLERG ASTHMA IM, V83, P105, DOI 10.1016/S1081-1206(10)62620-8; Mullington JM, 2001, ANN NY ACAD SCI, V933, P201; Naclerio R, 1999, J ALLERGY CLIN IMMUN, V103, pS382, DOI 10.1016/S0091-6749(99)70216-2; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592, DOI 10.1016/S1081-1206(10)61891-1; Nayak AS, 2001, ALLERGY, V56, P1077, DOI 10.1034/j.1398-9995.2001.00082.x; Nguyen KL, 2003, ANN ALLERG ASTHMA IM, V91, P38, DOI 10.1016/S1081-1206(10)62056-X; Nimmagadda SR, 1997, AM J RESP CRIT CARE, V155, P87, DOI 10.1164/ajrccm.155.1.9001294; Numata T, 1999, ANN OTO RHINOL LARYN, V108, P467, DOI 10.1177/000348949910800509; OKUDA M, 1988, ANN ALLERGY, V60, P537; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; RAJAKULASINGAM K, 1993, THORAX, V48, P324, DOI 10.1136/thx.48.4.324; RUBINSTEIN I, 1995, LARYNGOSCOPE, V105, P175, DOI 10.1288/00005537-199502000-00012; RUNDCRANTZ H, 1969, ACTA OTO-LARYNGOL, V68, P435, DOI 10.3109/00016486909121582; Saengpanich S, 2002, LARYNGOSCOPE, V112, P47, DOI 10.1097/00005537-200201000-00009; Spaeth J, 1996, ALLERGY, V51, P893; Tamaoki J, 1997, J ALLERGY CLIN IMMUN, V99, P233, DOI 10.1016/S0091-6749(97)70102-7; Tanner LA, 1999, AM J MANAG CARE, V5, pS235; Tashiro M, 2002, LIFE SCI, V72, P409, DOI 10.1016/S0024-3205(02)02276-2; Thompson AK, 2000, ANN ALLERG ASTHMA IM, V85, P338, DOI 10.1016/S1081-1206(10)62543-4; van Adelsberg J, 2003, ANN ALLERG ASTHMA IM, V90, P214, DOI 10.1016/S1081-1206(10)62144-8; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Weiler JM, 2000, ANN INTERN MED, V132, P354, DOI 10.7326/0003-4819-132-5-200003070-00004; White M, 1999, J ALLERGY CLIN IMMUN, V103, pS378, DOI 10.1016/S0091-6749(99)70215-0; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V102, P598, DOI 10.1016/S0091-6749(98)70275-1; Young T, 1997, J ALLERGY CLIN IMMUN, V99, pS757, DOI 10.1016/S0091-6749(97)70124-6	51	97	102	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		2004	114	5		S			S139	S145		10.1016/j.jaci.2004.08.044	http://dx.doi.org/10.1016/j.jaci.2004.08.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V17HV	15536445				2022-12-18	WOS:000207929200003
J	Aihara, Y; Takahashi, Y; Kotoyori, T; Mitsuda, T; Ito, R; Aihara, M; Ikezawa, Z; Yokota, S				Aihara, Y; Takahashi, Y; Kotoyori, T; Mitsuda, T; Ito, R; Aihara, M; Ikezawa, Z; Yokota, S			Frequency of food-dependent, exercise-induced anaphylaxis in Japanese junior-high-school students	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epidemiology; food-dependent, exercise-induced anaphylaxis; frequency; questionnaire; junior-high-school student	PHYSICAL ALLERGY; FORM	Background: Food-dependent, exercise-induced anaphylaxis (FEIAn) is classified among the physical allergies. The pathophysiology of FEIAn remains unknown, as does the frequency of FEIAn in the general population. Objective: We sought to study the epidemiology of FEIAn, especially its frequency in junior-high-school students in Yokohama, Japan. Methods: A questionnaire asking about the occurrence of FEIAn in school students was sent to all 145 public junior-high-school nurses in Yokohama. Results: One hundred thirty-two junior-high-school nurses responded to the questionnaire, and 13 (11 boys and 2 girls) cases of FEIAn among 76,229 junior-high-school students were reported. In addition, 24 (12 boys and 12 girls) subjects with exercise-induced anaphylaxis (ElAn) were detected. From this survey, the frequency of FEIAn was 0.017% in this population, and its frequency was significantly higher in boys than in girls (P < .05). The frequency of ElAn was 0.031%, and there was no difference according to sex. Only one third of junior-high-school nurses had any knowledge of FEIAn. We also performed provocation tests in 5 of the 13 cases with FEIAn after obtaining informed consent from the students and their parents and were able to confirm the diagnosis. Conclusion: This study showed that FEIAn and ElAn are relatively rare diseases among junior-high-school students in Yokohama. To avoid serious outcomes, we believe it is important that not only physicians but also school nurses and teachers of physical education be aware of these diseases.	Yokohama City Univ, Med Ctr, Dept Pediat, Minami Ku, Yokohama, Kanagawa 2320024, Japan; Yokohama City Univ, Sch Med, Dept Pediat, Yokohama, Kanagawa 232, Japan; Yokohama City Univ, Sch Med, Dept Dermatol, Yokohama, Kanagawa 232, Japan	Yokohama City University; Yokohama City University; Yokohama City University	Aihara, Y (corresponding author), Yokohama City Univ, Med Ctr, Dept Pediat, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.							AIHARA M, 1999, ENV DERMATOL, V6, P247; Aihara Y, 2001, J ALLERGY CLIN IMMUN, V107, P1100, DOI 10.1067/mai.2001.115627; BRUCE R A, 1963, Pediatrics, V32, P742; BUCHBINDER EM, 1983, JAMA-J AM MED ASSOC, V250, P2973, DOI 10.1001/jama.250.21.2973; Caffarelli C, 1996, J ALLERGY CLIN IMMUN, V98, P762, DOI 10.1016/S0091-6749(96)70125-2; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Drebotg S, 1989, ALLERGY S10, V44, P22; FUKUTOMI O, 1992, ANN ALLERGY, V68, P438; GRANT JA, 1985, ANN ALLERGY, V54, P35; Hanakawa Y, 1998, BRIT J DERMATOL, V138, P898; Harada S, 2000, Arerugi, V49, P1066; Hosoi S, 1997, Arerugi, V46, P1025; JUJI F, 1994, ANN ALLERGY, V72, P452; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; Morita E, 2000, BRIT J DERMATOL, V143, P1059, DOI 10.1046/j.1365-2133.2000.03844.x; ROMANO A, 1995, ALLERGY, V50, P817, DOI 10.1111/j.1398-9995.1995.tb05055.x; Romano A, 1997, INT ARCH ALLERGY IMM, V113, P505, DOI 10.1159/000237629; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P479, DOI 10.1016/S0091-6749(85)80021-X; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840; Tanaka S, 1994, Asia Pac J Public Health, V7, P26	24	97	101	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1035	1039		10.1067/mai.2001.119914	http://dx.doi.org/10.1067/mai.2001.119914			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742285				2022-12-18	WOS:000172938400023
J	Bacon, AS; Ahluwalia, P; Irani, AM; Schwartz, LB; Holgate, ST; Church, MK; McGill, JI				Bacon, AS; Ahluwalia, P; Irani, AM; Schwartz, LB; Holgate, ST; Church, MK; McGill, JI			Tear and conjunctival changes during the allergen-induced early- and late-phase responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; conjunctivitis; histamine; tryptase; eosinophil cationic protein; mast cell; basophil; eosinophil; T cell; E-selectin; intercellular adhesion molecule 1; vascular adhesion molecule 1	MAST-CELL NUMBERS; ADHESION MOLECULES; MEDIATOR RELEASE; INFLAMMATORY MEDIATORS; CHALLENGE; EXPRESSION; HISTAMINE; MUCOSA; SKIN; PROVOCATION	Background: Allergic eye disease is common, but little is known about the underlying disease mechanisms. Conjunctival allergen challenge causes symptoms similar to those of seasonal allergic conjunctivitis and is a useful model to study. Objective: We have used allergen challenge to investigate the course of the ocular response, tear inflammatory mediators, tissue adhesion protein expression, and cellular infiltration. Methods: Eighteen atopic patients and 4 nonatopic control subjects were challenged with extracted mixed grass or Dermatophagoides pteronyssinus in one eye and control vehicle in the other. The clinical response was recorded, and tears mere collected over a 6-hour period. Conjunctival biopsy specimens mere taken from the challenged eye at 6 or 24 hours. Results: An early-phase response (maximal at 20 minutes) showed a significant increase in tear histamine and tryptase levels, reducing to control levels again by 40 minutes. At 6 hours, a late-phase response occurred with increased symptoms, a second peak of tear histamine and eosinophil cationic protein but not tryptase, upregulation of the adhesion molecules E-selectin and intercellular adhesion molecule, and a cellular infiltrate of mast cells, neutrophils, eosinophils, macrophages, and basophils, with T cells increased only in bulbar biopsy specimens. Conclusions: The early peaks of tear histamine plus tryptase indicate that the mast cell is responsible for the early-phase response, but basophils may be involved in the late-phase response. Both tear and biopsy findings underline the significance of the late-phase response as the transition between a type I response and clinical disease.	Southampton Univ Hosp, Southampton Eye Unit, Southampton SO16 6YD, Hants, England; Virginia Commonwealth Univ, Dept Pediat, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23284 USA; Southampton Univ Hosp, Resp Cell & Mol Biol Res Div, Southampton SO16 6YD, Hants, England	University of Southampton; Virginia Commonwealth University; Virginia Commonwealth University; University of Southampton	McGill, JI (corresponding author), Southampton Univ Hosp, Southampton Eye Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.				NIAMS NIH HHS [AR45441] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045441] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84, DOI 10.1001/archopht.1990.01070030090035; Allansmith M R, 1970, Surv Ophthalmol, V14, P367; ALLANSMITH MR, 1986, SURV OPHTHALMOL, V30, P229, DOI 10.1016/0039-6257(86)90119-0; Anderson DF, 1997, CLIN EXP ALLERGY, V27, P1060, DOI 10.1111/j.1365-2222.1997.tb01258.x; Bacon AS, 1998, INVEST OPHTH VIS SCI, V39, P322; BADDELEY SM, 1995, CLIN EXP ALLERGY, V25, P41, DOI 10.1111/j.1365-2222.1995.tb01001.x; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; BISGAARD H, 1985, ALLERGY, V40, P417, DOI 10.1111/j.1398-9995.1985.tb02680.x; Blackley C. H., 1873, EXPT RES CAUSES NATU, P77; BONINI S, 1990, J ALLERGY CLIN IMMUN, V86, P869, DOI 10.1016/S0091-6749(05)80148-4; BONINI S, 1989, ALLERGOLOGIE, V12, P158; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P1227, DOI 10.1016/0091-6749(93)90327-C; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Costa JJ, 1998, LUNG BIOL HEALTH DIS, V117, P111; DART JKG, 1986, T OPHTHAL SOC UK, V105, P513; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; HELLEBOID L, 1991, INVEST OPHTH VIS SCI, V32, P2281; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; IRANI AMA, 1990, J ALLERGY CLIN IMMUN, V86, P34, DOI 10.1016/S0091-6749(05)80120-4; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; KARI O, 1985, GRAEF ARCH CLIN EXP, V223, P60, DOI 10.1007/BF02150945; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; MAJCHEL AM, 1992, J ALLERGY CLIN IMMUN, V90, P85, DOI 10.1016/S0091-6749(06)80014-X; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MORGAN SJ, 1991, J ALLERGY CLIN IMMUN, V87, P111, DOI 10.1016/0091-6749(91)90221-9; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PESHKIN NM, 1932, J ALLERGY, V3, P20; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PROUD D, 1990, J ALLERGY CLIN IMMUN, V85, P896, DOI 10.1016/0091-6749(90)90075-F; SEAL DV, 1986, BRIT J OPHTHALMOL, V70, P122, DOI 10.1136/bjo.70.2.122; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; WALLS AF, 1990, CLIN EXP ALLERGY, V20, P581, DOI 10.1111/j.1365-2222.1990.tb03153.x	42	97	100	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					948	954		10.1067/mai.2000.110930	http://dx.doi.org/10.1067/mai.2000.110930			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080719				2022-12-18	WOS:000167865200021
J	Gibson, PG; Saltos, N; Borgas, T				Gibson, PG; Saltos, N; Borgas, T			Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; sputum; eosinophil; mast cell; airway responsiveness; inflammation; corticosteroid	BRONCHIAL RESPONSIVENESS; INDUCED SPUTUM; T-CELLS; EPITHELIAL-CELLS; INFLAMMATION; SYMPTOMS; ADHESION; MACROPHAGES; BIOPSIES; FLUID	Background: The relationship between airway inflammation and asthma severity in corticosteroid-treated asthma is unclear. Objectives: Our purpose was to characterize the inflammatory cell profile of the airway lumen and epithelium in corticosteroid-treated asthma and to relate these findings to clinical and physiologic markers of asthma severity. Methods: Adults (n = 20) with asthma received standardized high-dose inhaled corticosteroid therapy with beclomethasone 2000 mu g per day For 8 weeks, Airway responsiveness to methacholine and hypertonic (4.5%) saline solution was then assessed, followed by sputum induction and, 1 week later, bronchoscopy with bronchoalveolar lavage and bronchial brush biopsy to assess inflammatory cells. Results: Clinical asthma severity was associated with airway hyperresponsiveness. Metachromatic cells were the main granulocyte present in bronchial blush biopsy specimens and correlated with airway responsiveness to saline solution (r = -0.75), methacholine (r = -0.74), peak flow variability (r = 0.59), and clinical asthma severity (r = 0.57). Eosinophils were the main granulocyte present in sputum and correlated with airway responsiveness to saline solution (r = -0.63) but not with other clinical markers of asthma severity. Bronchoalveolar lavage cell counts were not related to clinical asthma severity. Conclusions: In asthmatic patients treated with corticosteroids, the dominant inflammatory effector cell in the epithelium is the metachromatic cell, and in sputum it is the eosinophil. These cells correlate with the degree of airway hyperresponsiveness. Clinical asthma severity correlates with airway responsiveness and epithelial metachromatic cells. Induced sputum eosinophils and airway responsiveness to hypertonic saline solution may be useful markers of airway inflammation for clinical practice.	John Hunter Hosp, Dept Resp Med, Airways Res Ctr, Newcastle, NSW 2310, Australia	John Hunter Hospital	Gibson, PG (corresponding author), John Hunter Hosp, Dept Resp Med, Airways Res Ctr, Locked Bag 1,Hunter Mail Ctr, Newcastle, NSW 2310, Australia.		gibson, peter/G-6194-2014	gibson, peter/0000-0001-5865-489X				Baroody FM, 1998, AM J RESP CRIT CARE, V157, P899, DOI 10.1164/ajrccm.157.3.97-07060; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; Burke-Gaffney A, 1998, AM J RESP CELL MOL, V19, P408, DOI 10.1165/ajrcmb.19.3.3179; Chanez P, 1998, EUR RESPIR J, V11, p26S; CORRIGAN CJ, 1988, LANCET, V1, P1129; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80, DOI 10.1164/ajrccm/148.1.80; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; Godard P, 1998, EUR RESPIR J, V11, p2S; GOLDSTEIN RA, 1985, AM REV RESPIR DIS, V132, P180; IREDALE MJ, 1994, CLIN EXP ALLERGY, V24, P940, DOI 10.1111/j.1365-2222.1994.tb02725.x; Jeffery PK, 1996, EUR RESPIR J, V9, P1583, DOI 10.1183/09031936.96.09081583; KANAI N, 1994, AM J RESP CRIT CARE, V150, P1094, DOI 10.1164/ajrccm.150.4.7921442; Karlsson MG, 1996, VIRCHOWS ARCH, V429, P49; KELSEN SG, 1992, AM J RESP CELL MOL, V7, P66, DOI 10.1165/ajrcmb/7.1.66; *NAT ASTHM CAMP, 1996, ASTHM MAN HDB; OByrne PM, 1997, LANCET, V349, P818, DOI 10.1016/S0140-6736(05)61745-X; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Riise GC, 1996, EUR RESPIR J, V9, P1665, DOI 10.1183/09031936.96.09081665; ROBINSON DS, 1993, THORAX, V48, P26, DOI 10.1136/thx.48.1.26; SMITH CM, 1989, J ALLERGY CLIN IMMUN, V84, P781, DOI 10.1016/0091-6749(89)90309-6; Smith TJ, 1996, IMMUNOL TODAY, V17, P60, DOI 10.1016/0167-5699(96)80580-9; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; TIISALA S, 1995, EUR J IMMUNOL, V25, P411, DOI 10.1002/eji.1830250216; Twaddell SH, 1996, EUR RESPIR J, V9, P2104, DOI 10.1183/09031936.96.09102104; Veen JCCMI, 1996, EUR RESPIR J, V9, P2441, DOI 10.1183/09031936.96.09122441; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	32	97	98	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					752	759		10.1067/mai.2000.105319	http://dx.doi.org/10.1067/mai.2000.105319			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756226				2022-12-18	WOS:000086604100014
J	Koenig, JQ				Koenig, JQ			Air pollution and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; air pollution; pulmonary function; airway inflammation; bronchial hyperresponsiveness	EMERGENCY ROOM VISITS; PULMONARY-FUNCTION CHANGES; RESPIRATORY HEALTH; OZONE EXPOSURE; BRONCHIAL RESPONSIVENESS; ALLERGIC SENSITIZATION; OCCUPATIONAL ASTHMA; INHALED ALLERGEN; CHILDHOOD ASTHMA; SULFURIC-ACID	Asthma is a disease syndrome that has captured a great deal of attention for several years. One of the perplexing aspects to asthma is that the prevalence is increasing in most industrialized countries. The reasons for this widespread increase are largely unknown. Another aspect of industrialization is the persistence of air pollution in urban areas. Because much air pollution is due to vehicles, no solution appears in sight. The topic of this article is the association between air pollution and various signs and symptoms of asthma, Air pollution is convincingly associated with many signs of asthma aggravation. These include pulmonary function decrements, increased bronchial hyperresponsiveness, visits to emergency departments, hospital admissions, increased medication use and symptom reporting, inflammatory changes, interactions between air pollution and allergen challenges, and immune system changes. With the exception of exposure to environmental tobacco smoke, common air pollutants have not been shown to cause asthma, It seems prudent for clinicians to counsel their patients about the potential risks of asthma aggravation from common outdoor air pollutants.	Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Koenig, JQ (corresponding author), Univ Washington, Dept Environm Hlth, Box 357234, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES 07033] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson HR, 1998, THORAX, V53, P842, DOI 10.1136/thx.53.10.842; Anuszewski J, 1998, J EXPO ANAL ENV EPID, V8, P483; Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Ball BA, 1996, J ALLERGY CLIN IMMUN, V98, P563, DOI 10.1016/S0091-6749(96)70090-8; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; Baur X, 1996, LUNG, V174, P23; CASTELLSAGUE J, 1995, THORAX, V50, P1051, DOI 10.1136/thx.50.10.1051; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771, DOI 10.1136/oem.55.11.771; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.2307/3434265; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633, DOI 10.1164/ajrccm.154.3.8810598; FOLINSBEE LJ, 1992, TOXICOL IND HEALTH, V8, P273; Forsberg B, 1998, EUR RESPIR J, V12, P900, DOI 10.1183/09031936.98.12040900; Gordian ME, 1996, ENVIRON HEALTH PERSP, V104, P290, DOI 10.2307/3432887; HALKEN S, 1995, ALLERGY, V50, P97; HANLEY QS, 1992, AM REV RESPIR DIS, V145, P326, DOI 10.1164/ajrccm/145.2_Pt_1.326; HASSELBLAD V, 1989, J AIR WASTE MANAGE, V67, P1535; HATCH GE, 1995, AM J CLIN NUTR S, V61, P625; Hiltermann TJN, 1997, AM J RESP CRIT CARE, V156, P1765, DOI 10.1164/ajrccm.156.6.9704127; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; Kinney PL, 1996, ENVIRON HEALTH PERSP, V104, P170, DOI 10.2307/3432785; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; KOENIG JQ, 1991, J TOXICOL-CLIN TOXIC, V29, P401, DOI 10.3109/15563659109000366; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; KOENIG JQ, 1992, TOXICOL IND HEALTH, V8, P285; Korrick SA, 1998, ENVIRON HEALTH PERSP, V106, P93, DOI 10.2307/3433784; KREIT JW, 1989, J APPL PHYSIOL, V66, P217, DOI 10.1152/jappl.1989.66.1.217; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.2307/3433245; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; PANTAZOPOULOU A, 1995, ENVIRON RES, V69, P31, DOI 10.1006/enrs.1995.1022; Peters A, 1996, AM J EPIDEMIOL, V144, P570, DOI 10.1093/oxfordjournals.aje.a008967; POPE CA, 1991, AM REV RESPIR DIS, V144, P668, DOI 10.1164/ajrccm/144.3_Pt_1.668; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546, DOI 10.1093/oxfordjournals.aje.a117470; Rusznak C, 1996, THORAX, V51, P1105, DOI 10.1136/thx.51.11.1105; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24, DOI 10.1164/ajrccm.154.1.8680687; SCHWARTZ J, 1994, AM J CLIN NUTR, V59, P110, DOI 10.1093/ajcn/59.1.110; Segala C, 1998, EUR RESPIR J, V11, P677; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; SIOUTAS C, 1995, INHAL TOXICOL, V7, P633, DOI 10.3109/08958379509014470; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654, DOI 10.1164/ajrccm.155.2.9032209; THURSTON GD, 1997, AM J RESP CRIT CARE, V155, pA426; TRENGA CA, IN PRESS ARCH ENV HL; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401, DOI 10.1164/ajrccm.151.5.7735592; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Yang W, 1997, INHAL TOXICOL, V9, P15, DOI 10.1080/089583797198385; ZWICK H, 1991, AM REV RESPIR DIS, V144, P1075, DOI 10.1164/ajrccm/144.5.1075	52	97	99	4	25	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				717	722		10.1016/S0091-6749(99)70280-0	http://dx.doi.org/10.1016/S0091-6749(99)70280-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518814				2022-12-18	WOS:000083281200001
J	Majori, M; Corradi, M; Caminati, A; Cacciani, G; Bertacco, S; Pesci, A				Majori, M; Corradi, M; Caminati, A; Cacciani, G; Bertacco, S; Pesci, A			Predominant T-H1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic obstructive pulmonary disease; peripheral blood; lymphocytes; cytokines	ACTIVATED LYMPHOCYTES-T; TUMOR-NECROSIS-FACTOR; CHRONIC-BRONCHITIS; INTERFERON-GAMMA; EPITHELIAL-CELLS; BRONCHOALVEOLAR LAVAGE; FLOW-CYTOMETRY; IFN-GAMMA; TH2; EXPRESSION	Background: Previous studies have provided evidence for an inflammatory process in the large airways of subjects with chronic obstructive pulmonary disease (COPD), consisting predominantly of activated T cells. No data are available on the T-H1/T-H2 T-cell cytokine pattern in this disease, Objective: We sought to characterize the T-H1/T-H2 T-cell. cytokine pattern in subjects with COPD. Methods: We examined the IFN-gamma and IL-4 expression in peripheral blood CD4+ and CD8+ T cells from 20 patients with COPD and 25 control subjects by using a flow cytometric method of intracellular cytokine detection. We also examined the expression of? surface activation markers (CD25 and HLA-DR) on peripheral blood CD4+ and CD8+ T cells. Results: There was an increased percentage of IFN-gamma-producing cells(30.3% [range, 12.9% to 60.4%] vs 19.1% [range, 4% to 31.2%], P = .003) and a decreased percentage of IL-4-producing cells ( 4.55% [range, 0.6% to 11.3%] vs 9.5% [2.1% to 21.3%], P = .0008) among peripheral blood CD4+ T cells from the patients with COPD compared with control subjects. There was no significant difference between the 2 groups in the percentage of peripheral blood CD8+ T cells producing IFN-gamma or IL-4 or in the percentage of peripheral blood CD4+ and CD8+ T cells expressing CD25 and HLA-DR. Conclusion: These findings provide evidence for a T-H1-like immune response of peripheral blood CD4+ T cells in subjects with COPD.	Univ Parma, Ist Clin Malattie Apparato Resp, I-43100 Parma, Italy; Azienda Osped, Parma, Italy	University of Parma; University of Parma; University Hospital of Parma	Pesci, A (corresponding author), Univ Parma, Ist Clin Malattie Apparato Resp, Via Rasori 10, I-43100 Parma, Italy.		Caminati, Antonella/L-8743-2019	Majori, Maria/0000-0001-7453-7247; corradi, massimo/0000-0002-2808-4184				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BROD SA, 1991, J IMMUNOL, V147, P810; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CHATELAIN R, 1992, J IMMUNOL, V148, P1182; DOHERTY TM, 1995, CURR OPIN IMMUNOL, V7, P400; FOURNIER M, 1989, AM REV RESPIR DIS, V140, P737, DOI 10.1164/ajrccm/140.3.737; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; LeCam L, 1996, INT ARCH ALLERGY IMM, V111, P372, DOI 10.1159/000237395; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; MATSUBA K, 1989, EUR RESPIR J, V2, P834; MATSUSE T, 1992, AM REV RESPIR DIS, V146, P177, DOI 10.1164/ajrccm/146.1.177; MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P5654, DOI 10.1073/pnas.83.15.5654; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Mueller R, 1996, RESP MED, V90, P79, DOI 10.1016/S0954-6111(96)90202-4; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852, DOI 10.1164/ajrccm.155.3.9117016; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PETERSEN CM, 1992, EXP CELL RES, V201, P160, DOI 10.1016/0014-4827(92)90360-K; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; POBER JS, 1986, J IMMUNOL, V137, P1893; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301, DOI 10.1164/ajrccm/147.2.301; Saetta M, 1997, AM J RESP CRIT CARE, V156, P1633, DOI 10.1164/ajrccm.156.5.9701081; Sakkas LI, 1998, CLIN DIAGN LAB IMMUN, V5, P430, DOI 10.1128/CDLI.5.4.430-437.1998; SAUNDERS NA, 1994, AM J RESP CELL MOL, V11, P147, DOI 10.1165/ajrcmb.11.2.8049075; SCOTT P, 1991, J IMMUNOL, V147, P3149; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; vanRoon JAG, 1997, ANN RHEUM DIS, V56, P656, DOI 10.1136/ard.56.11.656; von Hertzen LC, 1998, ANN MED, V30, P27, DOI 10.3109/07853899808999382; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012	38	97	105	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				458	462		10.1016/S0091-6749(99)70471-9	http://dx.doi.org/10.1016/S0091-6749(99)70471-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069880				2022-12-18	WOS:000079175700015
J	Meltzer, EO; Jalowayski, AA; Orgel, HA; Harris, AG				Meltzer, EO; Jalowayski, AA; Orgel, HA; Harris, AG			Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; intranasal glucocorticosteroid; mometasone furoate nasal spray; nasal cytology; mucociliary clearance; rhinomanometry; olfaction; inflammatory mediators; nasal lavage	INTRANASAL FLUTICASONE PROPIONATE; EOSINOPHIL CATIONIC PROTEIN; BECLOMETHASONE DIPROPIONATE; MEDIATOR RELEASE; ANTIGEN CHALLENGE; MAST-CELLS; PRETREATMENT; HISTAMINE; SYMPTOMS; TRYPTASE	Background: Efficacy of topical nasal steroid therapy for allergic rhinitis is usually evaluated by patient and clinician assessments of subjective symptom changes in diaries and at clinical interviews. Objective: We sought to complement the subjective measures with objective measures of nasal cytology, biochemistry, and function. Methods: In this double-blind, randomized study patients with seasonal allergic rhinitis (SAR) 12 years of age or older received 200 mu g mometasone furoate nasal spray (n = 80) or placebo spray (n = 41) once daily for 2 weeks, Subjective assessments by clinician and patient comprised symptom/sign scores and overall therapeutic response evaluations. Objective measures included nasal cytology, nasal biochemistry, nasal airway resistance (NAR), mucociliary clearance, and olfactory functions. Results: Mometasone furoate produced a significantly greater decrease than placebo in subjective measures of SAR for total symptom score (-46% vs 30%, p < 0.05), total nasal score (-47% vs 30%, p < 0.024), individual nasal symptom scores, and overall therapeutic response. The objective measures of eosinophil, basophil, and neutrophil counts and mucociliary clearance were significantly better in mometasone furoate- than in placebo-treated patients. Similarly, within-treatment statistically significant improvements were produced by mometasone furoate but not by placebo sprays for levels of eosinophilic cationic protein, tryptase and albumin, NAR, and odor identification. Significant positive correlations were found bem een NAR and nasal stuffiness and between eosinophils, basophils, and neutrophils and both eosinophilic cationic protein and albumin. Conclusion: Subjective measures of SAR were significantly improved in the mometasone furoate group by comparison with placebo-treated patients. Objective assessments supported the subjective findings because within-treatment measures were frequently significantly improved after mometasone furoate treatment but not after placebo treatment.	Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Schering Plough Corp, Integrated Therapeut Grp, Kenilworth, NJ 07033 USA	University of California System; University of California San Diego; Merck & Company; Schering Plough Corporation	Meltzer, EO (corresponding author), 9610 Granite Ridge Dr,Suite B, San Diego, CA 92123 USA.			Harris, Alan/0000-0002-6618-2092				AlvaradoValdes CA, 1997, CLIN THER, V19, P273, DOI 10.1016/S0149-2918(97)80115-4; ANDERSEN I, 1974, AM REV RESPIR DIS, V110, P301, DOI 10.1164/arrd.1974.110.3.301; APTER AJ, 1995, ANN ALLERG ASTHMA IM, V75, P311; Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; BENDE M, 1997, ISOT ACH 19 M, P182; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; Brannan MD, 1996, J ALLERGY CLIN IMMUN, V97, P62; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; Bronsky EA, 1996, J ALLERGY CLIN IMMUN, V97, P915, DOI 10.1016/S0091-6749(96)80065-0; CAIN WS, 1988, LARYNGOSCOPE, V98, P83; COWART BJ, 1993, J ALLERGY CLIN IMMUN, V91, P747, DOI 10.1016/0091-6749(93)90194-K; Davies RJ, 1997, CLIN THER, V19, P27; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153, DOI 10.1016/S1081-1206(10)63502-8; ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551; Fokkens WJ, 1997, ALLERGY, V52, P29, DOI 10.1111/j.1398-9995.1997.tb04819.x; GARRELDS IM, 1995, EUR J PHARMACOL, V275, P295, DOI 10.1016/0014-2999(95)00049-Q; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; HANSEL FK, 1966, ANN ALLERGY, V24, P564; HERBERT JR, 1996, ALLERGY, V51, P569; HILBERG O, 1995, ALLERGY, V50, P683, DOI 10.1111/j.1398-9995.1995.tb02586.x; JULIUSSON S, 1993, CLIN EXP ALLERGY, V23, P591, DOI 10.1111/j.1365-2222.1993.tb00899.x; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; Klimek L, 1997, J ALLERGY CLIN IMMUN, V100, P158, DOI 10.1016/S0091-6749(97)70218-5; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; Levenson T, 1996, ALLERGY ASTHMA PROC, V17, P157, DOI 10.2500/108854196779165021; LOZEWICZ S, 1992, J ALLERGY CLIN IMMUN, V89, P951, DOI 10.1016/0091-6749(92)90217-P; MACKAY IS, 1983, J LARYNGOL OTOL, V97, P43, DOI 10.1017/S0022215100093786; MALMBERG H, 1979, ALLERGY, V34, P389, DOI 10.1111/j.1398-9995.1979.tb02008.x; Mandl M, 1997, ANN ALLERG ASTHMA IM, V79, P370, DOI 10.1016/S1081-1206(10)63030-X; MELTZER EO, 1994, J ALLERGY CLIN IMMUN, V94, P708, DOI 10.1016/0091-6749(94)90178-3; Meltzer EO, 1997, J ALLERGY CLIN IMMUN, V99, pS815, DOI 10.1016/S0091-6749(97)80041-3; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V91, P298; MELTZER EO, 1995, ANN ALLERG ASTHMA IM, V74, P406; Meltzer EO, 1988, AM J RHINOL, V2, P47, DOI DOI 10.2500/105065888781693212; MUNCH E, 1981, CLIN ALLERGY, V11, P303, DOI 10.1111/j.1365-2222.1981.tb01598.x; MUNK ZM, 1994, PEDIATR ASTHMA ALLER, V8, P39, DOI 10.1089/pai.1994.8.39; MURRAY AB, 1969, J ALLERGY, V43, P1, DOI 10.1016/0021-8707(69)90014-8; Mygind N, 1996, CLIN EXP ALLERGY, V26, P2, DOI 10.1111/j.1365-2222.1996.tb00652.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; Naclerio RM, 1997, ALLERGY, V52, P7, DOI 10.1111/j.1398-9995.1997.tb04816.x; Naclerio RM, 1993, ALLERGIC NONALLERGIC, P114; NATHAN RA, 1991, ANN ALLERGY, V67, P332; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; PEDERSEN B, 1994, ALLERGY, V49, P855, DOI 10.1111/j.1398-9995.1994.tb00787.x; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; Prenner BM, 1996, J ALLERGY CLIN IMMUN, V98, P302, DOI 10.1016/S0091-6749(96)70154-9; PROUD D, 1992, J ALLERGY CLIN IMMUN, V89, P1098, DOI 10.1016/0091-6749(92)90293-B; RUTLAND J, 1981, THORAX, V36, P654, DOI 10.1136/thx.36.9.654; SCADDING GK, 1994, BRIT J CLIN PHARMACO, V38, P447, DOI 10.1111/j.1365-2125.1994.tb04381.x; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHNEIDER RA, 1960, J APPL PHYSIOL, V15, P914, DOI 10.1152/jappl.1960.15.5.914; SIEGEL SC, 1982, J ALLERGY CLIN IMMUN, V69, P345, DOI 10.1016/0091-6749(82)90144-0; SVENSSON C, 1995, J ALLERGY CLIN IMMUN, V96, P239, DOI 10.1016/S0091-6749(95)70013-7; THERATTIL J, 1997, ANN ALLERG ASTHMA IM, V78, P129; WANG D, 1995, ALLERGY, V50, P147	60	97	104	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					39	49		10.1016/S0091-6749(98)70053-3	http://dx.doi.org/10.1016/S0091-6749(98)70053-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679846				2022-12-18	WOS:000074909500008
J	Blanco, C; Quiralte, J; Castillo, R; Delgado, J; Arteaga, C; Barber, D; Carrillo, T				Blanco, C; Quiralte, J; Castillo, R; Delgado, J; Arteaga, C; Barber, D; Carrillo, T			Anaphylaxis after ingestion of wheat flour contaminated with mites	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; acetylsalicylic acid intolerance; dust mites; food hypersensitivity; storage mites; wheat flour	DERMATOPHAGOIDES; ANTIBODIES; ALLERGENS; EPITOPES	Background: Anaphylaxis after ingestion of flours contaminated with mites has been recently reported. Objective: The study was designed to determine whether flour-induced reactions in the absence of food sensitivity may result from mite contamination. Methods: Patients with systemic reactions after ingestion of foods containing wheat flour and without food sensitivities were included in a prospective study. The flours were examined microscopically, and major Dermatophagoides allergens were quantified by monoclonal antibody techniques. Skin prick tests and IgE determinations to mites and hours were performed. Single-blind, placebo-controlled oral challenges were also performed. Results: Sixteen patients were included in our protocol. They showed respiratory allergies to dust mites (100%) and intolerance to acetylsalicylic acid (87%). Microscopic examination of four flours implicated in allergic reactions revealed a high degree of mite contamination: Dermatophagoides farinae in one case and Thyreophagus entomophagus in three cases. Our patients' skin test and specific IgE responses to the flours implicated in the reactions were positive. ri high level of Der 2 was found in the flour infested by D. farinae. Three of six food challenges with contaminated flours resulted in systemic reactions. Good tolerance to control flours was shown in our patients. Conclusion: Ingestion of foods contaminated with mites may induce systemic anaphylactic reactions in patients with respiratory allergy to mites.	ALERGIA & IMMUNOL ABELLO,MADRID,SPAIN		Blanco, C (corresponding author), HOSP NUESTRA SENORA PINO,FAC CIENCIAS MED & SALUD,SECT ALLERGY,C ANGEL GUIMERA 93,LAS PALMAS 35005,SPAIN.		IBIS, ALERGICAS/C-1733-2016; Barber, Domingo/Y-9516-2019; Blanco, Carlos/B-3895-2012	Barber, Domingo/0000-0002-5488-5700; Blanco, Carlos/0000-0002-2893-6594				Barber D, 1996, J ALLERGY CLIN IMMUN, V97, P963, DOI 10.1016/S0091-6749(96)80071-6; CASTILLO S, 1995, J ALLERGY CLIN IMMUN, V95, P304; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; ERBEN AM, 1993, J ALLERGY CLIN IMMUN, V92, P846, DOI 10.1016/0091-6749(93)90062-K; GUERIN B, 1995, CLIN REV ALLERG IMMU, V13, P107; HORN N, 1987, INT ARCH ALLER A IMM, V83, P404, DOI 10.1159/000234376; KRANTZ GW, 1975, MANUAL ACAROLOGY; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; Platts-Mills TA, 1993, ALLERGY PRINCIPLES P, P469; Quiralte J, 1996, J ALLERGY CLIN IMMUN, V98, P678, DOI 10.1016/S0091-6749(96)70102-1; SCALA G, 1995, ALLERGY, V50, P517, DOI 10.1111/j.1398-9995.1995.tb01189.x; SPIEGEL WA, 1995, ANN ALLERG ASTHMA IM, V74, P56; TRINDER P, 1954, BIOCHEM J, V57, P301, DOI 10.1042/bj0570301; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P881; VANHAGEHAMSTEN M, 1992, EXP APPL ACAROL, V16, P117, DOI 10.1007/BF01201495	15	97	99	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					308	313		10.1016/S0091-6749(97)70047-2	http://dx.doi.org/10.1016/S0091-6749(97)70047-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058685				2022-12-18	WOS:A1997WM42200006
J	Miyazawa, H; Fukamachi, H; Inagaki, Y; Reese, G; Daul, CB; Lehrer, SB; Inouye, S; Sakaguchi, M				Miyazawa, H; Fukamachi, H; Inagaki, Y; Reese, G; Daul, CB; Lehrer, SB; Inouye, S; Sakaguchi, M			Identification of the first major allergen of a squid (Todarodes pacificus)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; squid shrimp; tropomyosin; food allergy	SHRIMP ALLERGEN; TROPOMYOSIN; CRUSTACEA; HYPERSENSITIVITY; POLLEN	Background: In Japan squid is an important seafood, and some patients with food allergies are sensitive to squid. There has been no report, however, describing the major allergens of squid. Objective: To characterize squid allergens, we isolated a major allergen from the Pacific flying squid (Todarodes pacificus) and compared it with a major allergen from a shrimp (Penaeus orientalis). Methods: The major squid and shrimp allergens were isolated by column chromatography on diethylaminoethyl-Sepharose (Pharmacia, Uppsala, Sweden), hydroxylapatite, and Sephacryl S-300 (Pharmacia). The IgE reactivity of the isolated allergens was assessed by immunoblotting. The cross-reactivity between the squid and shrimp allergens was examined by use of mouse polyclonal and monoclonal antibodies to the major allergens. Amino acid sequence analyses of the isolated allergens were done. Results: The isolated squid allergen is a 38 kd, heat-stable protein. IgE antibody binding to the purified squid allergen was demonstrated by immunoblotting. Cross-reactivity between major squid and shrimp allergens was demonstrated with sera from patients allergic to squid or shrimp or with allergen-specific monoclonal antibodies. The amino acid sequence analysis of the major squid allergen showed a marked homology with tropomyosin from blood fluke planorbid (Biomphalaria glabrata), which is a common vector snail of Schistosoma mansoni. Conclusion: This 38 kd protein is a major allergen of the squid, Todarodes pacificus, and is believed to be squid muscle protein tropomyosin. We named it Tod p 1 according to International Union of Immunological Societies allergen nomenclature regulation.	NATL INST HLTH & NUTR, DEPT EPIDEMIOL, SHINJUKU KU, TOKYO 162, JAPAN; KYORIN UNIV, DEPT MED TECHNOL, TOKYO, JAPAN; KIRIN BREWERY CO LTD, PHARMACEUT RES LAB, TAKASAKI, GUMMA, JAPAN; TULANE UNIV, MED CTR, DEPT MED, NEW ORLEANS, LA 70112 USA	National Institute of Health & Nutrition - Japan; Kyorin University; Kirin Brewery Company Limited; Tulane University			Inouye, Sharon/R-7216-2019					CARRILLO T, 1992, ANN ALLERGY, V68, P483; DAUL C B, 1991, Journal of Allergy and Clinical Immunology, V87, P192, DOI 10.1016/0091-6749(91)91497-H; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; DAUL CB, 1993, CLIN REV ALLERG, V11, P201; DESPOMMIER DD, 1987, PARASITE LIFE CYCLES, P72; ERIKSSON NE, 1989, ALLERGY, V44, P305, DOI 10.1111/j.1398-9995.1989.tb00451.x; HALMEPURO L, 1987, INT ARCH ALLER A IMM, V84, P165, DOI 10.1159/000234418; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; KOSHTE VL, 1989, J ALLERGY CLIN IMMUN, V84, P174, DOI 10.1016/0091-6749(89)90322-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; LEHRER SB, 1986, ANN ALLERGY, V57, P267; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; Miyake T, 1987, JPN J PEDIAT ALLERGY, V1, P14; MIYAZAWA H, 1988, J ALLERGY CLIN IMMUN, V82, P407, DOI 10.1016/0091-6749(88)90013-9; MUSMAND JJ, 1993, CLIN EXP ALLERGY, V23, P722, DOI 10.1111/j.1365-2222.1993.tb00359.x; NAGPAL S, 1989, J ALLERGY CLIN IMMUN, V83, P26, DOI 10.1016/0091-6749(89)90474-0; ONEIL CE, 1985, ANN ALLERGY, V55, P374; SAKAGUCHI M, 1990, ALLERGY, V45, P309, DOI 10.1111/j.1398-9995.1990.tb00501.x; SAMPSON HA, 1993, ALLERGY PRINCIPLES P, P1661; SHANTI KN, 1993, J IMMUNOL, V151, P5354; *STAT BUR MAN COOR, 1993, ANN REP FAM INC EXP, P290; TAKAHASHI Y, 1993, ALLERGY, V48, P94, DOI 10.1111/j.1398-9995.1993.tb00692.x; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803	24	97	107	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				948	953		10.1016/S0091-6749(96)80011-X	http://dx.doi.org/10.1016/S0091-6749(96)80011-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939158	Bronze			2022-12-18	WOS:A1996VU76400011
J	Graft, D; Aaronson, D; Chervinsky, P; Kaiser, H; Melamed, J; Pedinoff, A; Rosen, JP; Schenkel, EJ; Vandewalker, ML; Keim, A; Jensen, PK; Nolop, K; MesarinaWicki, B				Graft, D; Aaronson, D; Chervinsky, P; Kaiser, H; Melamed, J; Pedinoff, A; Rosen, JP; Schenkel, EJ; Vandewalker, ML; Keim, A; Jensen, PK; Nolop, K; MesarinaWicki, B			A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mometasone furoate; seasonal allergic rhinitis; ragweed; prophylaxis; intranasal corticosteroids	BECLOMETHASONE DIPROPIONATE; REACTIVITY; THERAPY	Background: Topical nasal corticosteroids have become a mainstay of treatment for the symptoms of seasonal allergic rhinitis (SAR), it is likely that topical corticosteroids, by, blocking an initial influx of inflammatory cells in the nasal mucosa induced by aa aeroallergens, may have a preventive effect on nasal allergy symptoms when administered before the pollen season. Objective: This study was designed to assess the efficacy and safety of an 8-week course of mometasone furoate nasal spray (MFNS), 200 mu g once daily, in the treatment of SAR compared with beclomethasone dipropionate aqueous nasal spray (BDP), 168 mu g twice daily, and placebo vehicle, when treatment is initiated before the anticipated-onset of the ragweed season. Methods: Three hundred forty-nine patients with SAR to ragweed pollen from nine centers in the Northeast and Midwest of the United States were randomized to one of the three intranasal study medications (MFNS, 200 mu g once daily BDP, 168 mu g twice daily or placebo, vehicle), starting 4 week before the estimated start of the ragweed season. Results: The proportion of ''minimal symptom'' days (total nasal symptom score less than or equal to 2) was statistically significantly higher in both the MFNS and BDP groups when compared with the placebo vehicle group (p < 0.01). The two active treatment groups were not statistically significantly different from each other. MFNS and BDP displayed a similar safety profile that did nor differ from placebo. Conclusions: This suggests that MFNS, 200 mu g (once daily), is a useful therapy in the prophylactic treatment of SAR.	SCHERING PLOUGH CORP, RES INST, KENILWORTH, NJ 07033 USA; PK NICOLLET CLIN, MINNEAPOLIS, MN USA; AARONSON ASTHMA & ALLERGY ASSOCIATES, DES PLAINES, IL USA; CTR ASTHMA & ALLERGY, N DARTMOUTH, MA USA; CERTIFIED ALLERGY CONSULTANTS, CHELMSFORD, MA USA; PRINCETON ALLERGY & ASTHMA ASSOCIATES, PRINCETON, NJ USA; PEDIAT ALLERGY ASSOCIATES, W HARTFORD, CT USA; CLIN RES OZARKS, ROLLA, MO USA	Merck & Company; Schering Plough Corporation								ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; APTER AJ, 1994, J ALLERGY CLIN IMMUN, V94, P732, DOI 10.1016/0091-6749(94)90181-3; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BOUSQUET J, 1993, ALLERGY, V48, P327, DOI 10.1111/j.1398-9995.1993.tb02401.x; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; BRATTSAND R, 1982, J STEROID BIOCHEM, V16, P779, DOI 10.1016/0022-4731(82)90035-8; BRONSKY E, 1995, ALLERGY S, V50, P191; CONNELL JT, 1968, J ALLERGY, V41, P101; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRETICOS PS, 1995, ASTHMA RHINITIS, P1394; DEWECK AL, 1989, ALLERGOLOGIE, V12, P85; MABRY RL, 1992, SOUTH MED J, V85, P149, DOI 10.1097/00007611-199202000-00008; MANN MC, 1992, CHEST, V102, P1342, DOI 10.1378/chest.102.5.1342; MELTZER EO, 1992, AM J ASTHMA ALLERGY, V6, P13; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NUUTINEN J, 1987, Rhinology (Utrecht), V25, P121; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; Prenner BM, 1996, J ALLERGY CLIN IMMUN, V98, P302, DOI 10.1016/S0091-6749(96)70154-9; RATNER P, 1993, J ALLERGY CLIN IMMUN, V91, P194; ROSENTHAL D, 1988, CURR THER RES CLIN E, V44, P790; SCHLEIMER RP, 1993, ASTHMA, P375; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414; 1994, EUR J ALLERGY CLIN I, V49, P1	26	97	107	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					724	731		10.1016/S0091-6749(96)70119-7	http://dx.doi.org/10.1016/S0091-6749(96)70119-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876546				2022-12-18	WOS:A1996VM66500003
J	Heilman, DK; Jones, RT; Swanson, MC; Yunginger, JW				Heilman, DK; Jones, RT; Swanson, MC; Yunginger, JW			A prospective, controlled study showing that rubber gloves are the major contributor to latex aeroallergen levels in the operating room	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural rubber latex allergy; aeroallergens; latex gloves; operating room	DISPOSABLE MEDICAL GLOVES	Background: Although protocols have been published for reducing natural rubber later exposure in medical environments, there are no objective data documenting their effectiveness. Objective: We prospectively studied the impact of a single intervention, substitution of low-allergen-containing latex gloves for high-allergen-containing Inter gloves, on Inter aeroallergen levels in a single operating room (OR). Methods: We sampled OR air on 52 consecutive days, including 33 surgery days and 19 nonsurgery days. On each surgery day all personnel wore either high-allergen gloves (n = 18 days) or low-allergen gloves (n = 15 days). Latex aeroallergen levels (in nanograms per cubic meter) and extractable latex glove allergen contents (in allergen units per milliliter) were measured by inhibition immunoassays. An on-site study monitor recorded the number of gloves used, the total time spent by all patients in the OR each day (OR time), and the total time of all procedures for each day (operating procedure time). Results: Latex aeroallergen levels during low-allergen glove rise days (mean, 1.1 ng/m(3) median, 0.9 ng/m(3); range, 0.1 to 3.5 ng/m(3)) were significantly lower than on high-allergen glove use days (mean, 13.7 ng/m(3); median, 77 ng/m(3); range, 2.2 to 56.4 ng/m(3)) (p < 0.001) but not significantly different from that on nonsurgery days (mean, 0.6 median median, 0.3 ng/m(3) range, 0.1 to 3.6 ng/m(3)). Latex aeroallergen levels were strongly correlated with the total number of gloves used on designated high-allergen glove days (r = 0.66, p = 0.003). There was no appreciable day-to-day carryover of latex aeroallergen. Conclusions: The substitution of low-allergen-containing latex gloves for high-allergen-containing latex gloves can reduce levels of latex aeroallergen by more than 10-fold in an OR environment.	MAYO CLIN & MAYO FDN,DEPT PEDIAT & ADOLESCENT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO GRAD SCH MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic								ASA R, 1994, MAT MANAG HLTH C JUN, P28; BABAK ME, 1992, MAYO CLIN P, V67, P1075; HOLZMAN RS, 1993, ANESTH ANALG, V76, P635; JONES RT, 1994, ANN ALLERGY, V73, P321; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3	10	97	103	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					325	330		10.1016/S0091-6749(96)70157-4	http://dx.doi.org/10.1016/S0091-6749(96)70157-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757210				2022-12-18	WOS:A1996VC99500012
J	Nelson, RP; DiNicolo, R; FernandezCaldas, E; Seleznick, MJ; Lockey, RF; Good, RA				Nelson, RP; DiNicolo, R; FernandezCaldas, E; Seleznick, MJ; Lockey, RF; Good, RA			Allergen-specific IgE levels and mite allergen exposure in children with acute asthma first seen in an emergency department and in nonasthmatic control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acute asthma; IgE; emergency department; dermatophagoides pteronyssinus; storage mites	INNER-CITY CHILDREN; DER-P-I; RISK-FACTORS; ALEUROGLYPHUS-OVATUS; INHALANT ALLERGENS; CHANGING PATTERNS; CROSS-REACTIVITY; UNITED-STATES; SKIN-TEST; MORTALITY	Background: Sensitization to allergens has been shown to be a risk factor for Objective: The purpose of this study was to evaluate the prevalence of specific IgE to common aeroallergens in children with asthma first seen in the emergency department and in control subjects. Methods: fifty-four children, aged 3 to 16 years (mean age, 8.34 years) who visited the emergency department for treatment of acute bronchospasm or other illness, were evaluated. specific IgE to seven common aeroallergens and four common storage mites was determined. Group I consisted of 29 patients who had acute bronshocpasm and histories of recurrent asthma. Group II consisted of 25 control subjects who had no clinical history of atopic disease. Groups I and II were compared for differences in the prevalence of positive RAST responses to the 11 allergens tested. Dust samples were collected from 17 homes of subjects in group I and from 13 homes of subjects in group II and were analyzed for levels of Der p 1 and Der f 1. Results: Statistically significant differences in the prevalence of positive RAST results between groups I and Ii were found in response to: Dermatophagoides pteronyssinus, 89.6% versus 36% (p = 0.0001); Blattella germanica, 45.8% versus 9.5% (p = 0.0002); Chortoglyphus arcuatus, 46.4% versus 0% (p = 0.0001); and Lepidoglyphus destructor, 32.1% versus 0% (p = 0.0019). Mean specific IgE levels, expressed as percent of the total counts bound, were significantly higher in group I compared with group II only in response to D. pteronyssinus, samples revealed no significant differences between the two groups, except for a higher concentration of Der f 1 in the sofas of subjects in group II. Conclusion: Sensitization to D. pteronyssinus, storage mites, and, to a lesser extent, to A. tenuis and B. germanica is associated with acute childhood asthma that requires emergency treatment in Florida.	UNIV S FLORIDA, COLL MED, ALL CHILDRENS HOSP, TAMPA, FL USA; JAMES A HALEY VET HOSP, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Nelson, RP (corresponding author), UNIV S FLORIDA, ALL CHILDRENS HOSP, COLL MED, 801 6TH ST S, ACH 699, ST PETERSBURG, FL 33701 USA.							BAUMAN A, 1990, MED J AUSTRALIA, V153, P366, DOI 10.5694/j.1326-5377.1990.tb136973.x; BUIST AS, 1989, J ALLERGY CLIN IMMUN, V84, P275, DOI 10.1016/0091-6749(89)90408-9; BUKANTZ SC, 1990, HOSP PRACT, V25, P10; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CRAIN EF, 1994, PEDIATRICS, V94, P356; DUFF AL, 1993, PEDIATRICS, V92, P535; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FERNANDEZCALDAS E, 1993, J INVEST ALLERG CLIN, V3, P245; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERGEN P, 1986, J ALLERGY CLIN IMMUN, V77, P161; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PHILLIPS JW, 1989, ANN ALLERGY, V63, P503; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; PUERTA L, 1993, CLIN EXP ALLERGY, V23, P117, DOI 10.1111/j.1365-2222.1993.tb00306.x; SILTON RP, 1991, J ALLERGY CLIN IMMUN, V88, P595, DOI 10.1016/0091-6749(91)90153-F; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stanaland BE, 1996, J ALLERGY CLIN IMMUN, V97, P1045, DOI 10.1016/S0091-6749(96)70256-7; STANALAND BE, 1994, J ALLERGY CLIN IMMUN, V94, P452, DOI 10.1016/0091-6749(94)90200-3; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; 1990, MMWR-MORBID MORTAL W, V39, P493	33	97	100	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					258	263		10.1016/S0091-6749(96)70148-3	http://dx.doi.org/10.1016/S0091-6749(96)70148-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757201				2022-12-18	WOS:A1996VC99500003
J	Nielsen, L; Johnsen, CR; Mosbech, H; Poulsen, LK; Malling, HJ				Nielsen, L; Johnsen, CR; Mosbech, H; Poulsen, LK; Malling, HJ			Antihistamine premedication in specific cluster immunotherapy: A double-blind, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; immunotherapy; side effects; antihistamine; pretreatment	DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; SYSTEMIC REACTIONS; POLLEN EXTRACTS; POSITION PAPER; REDUCTION; SAFETY	Background: Specific immunotherapy treatment in allergic diseases involves a risk of systemic side effects. A double-blind, placebo-controlled study was performed in 45 patients allergic to pollen to determine whether pretreatment with loratadine could reduce the number and severity of systemic reactions during the dose-increase phase of cluster immunotherapy. Methods: The patients received cluster immunotherapy with a standardized birch (Betula verrucosa) oi grass (Phleum pratense) pollen extract adsorbed to aluminum hydroxide. The immunotherapy schedule involved seven visits and 14 injections to reach a maintenance dose of 100,000 standardized quality units. Loratadine, 10 mg, or placebo tablets were administered 2 hours before the first injection at each visit. Results: A total of 720 injections were given (309 injections in 21 patients receiving loratadine and 411 injections in 24 patients receiving placebo). The median numbers of injections to reach maintenance dose were 15 (range, 14 to 18) in the loratadine group and 16 (range 14 to 23) in the placebo group (p = 0.037). The numbers of patients with systemic reactions were seven (33%) ann 19 (79%) in the loratadine and placebo groups, respectively (p = 0.002). Twenty-five reductions caused by systemic reactions were observed in the placebo group in contrast to nine in the loratadine group (p = 0.047). No life-threatening systemic reactions were observed in either group. Systemic reactions were, however, more severe in the placebo group, mainly because of a significantly higher incidence of urticaria (10 vs 1, p = 0.022). Conclusion: Pretreatment with loratadine seems to reduce both the number and severity of systemic reactions in specific cluster immunotherapy.			Nielsen, L (corresponding author), NATL UNIV HOSP,MED DEPT TTA 7511,ALLERGY UNIT,TAGENSVEJ 20,DK-2200 COPENHAGEN N,DENMARK.		Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X				BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEJJAOUI A, 1992, J ALLERGY CLIN IMMUN, V89, P925, DOI 10.1016/0091-6749(92)90214-M; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; JARISCH R, 1988, ARB P EHRLICH I BUND, V82, P163; LOWENSTEIN H, 1980, P 1 INT P ERL SEM RE, P122; MALLING HJ, 1993, ALLERGY, V48, P9; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; NORUSIS MJ, 1990, SPSS PC PLUS STAT 4; OSTERBALLE O, 1982, ALLERGY, V37, P553, DOI 10.1111/j.1398-9995.1982.tb02340.x; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; TABAR AI, 1993, ALLERGY, V48, P450, DOI 10.1111/j.1398-9995.1993.tb00743.x; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; VANCAUWENBERGE PB, 1992, DRUG INVEST, V4, P283; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Walter SD, 1992, BIOMETRICS, V48, P656; WANTKE F, 1993, J ALLERGY CLIN IMMUN, V92, P497, DOI 10.1016/0091-6749(93)90132-Y; WEKKELI M, 1989, WIEN KLIN WOCHENSCHR, V101, P639	20	97	101	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1207	1213		10.1016/S0091-6749(96)70186-0	http://dx.doi.org/10.1016/S0091-6749(96)70186-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648014				2022-12-18	WOS:A1996VD60700006
J	KROEGEL, C; LIU, MC; HUBBARD, WC; LICHTENSTEIN, LM; BOCHNER, BS				KROEGEL, C; LIU, MC; HUBBARD, WC; LICHTENSTEIN, LM; BOCHNER, BS			BLOOD AND BRONCHOALVEOLAR EOSINOPHILS IN ALLERGIC SUBJECTS AFTER SEGMENTAL ANTIGEN CHALLENGE - SURFACE PHENOTYPE, DENSITY HETEROGENEITY, AND PROSTANOID PRODUCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHOALVEOLAR EOSINOPHILS; PHENOTYPE; HYPODENSE EOSINOPHILS; PLATELET ACTIVATING FACTOR; PROSTANOID GENERATION		Eosinophil infiltration into the airways has been implicated in the pathophysiology of asthma. To improve our understanding of the function of eosinophils in asthma, we have compared the phenotype and function of eosinophils obtained simultaneously from blood and bronchoalveolar lavage (BAL) of allergic subjects 19 hours after segmental lung allergen challenge. Eosinophils were purified by discontinuous density gradient centrifugation, and their distribution at various layers was quantitated. Eosinophils at the 1.080 to 1.085 gm/ml interfaces from blood and BAL (purity > 70%) were analyzed by immunofluorescence and flow cytometry for several surface markers including adhesion-activation antigens. Eosinophils in BAL from antigen-challenged sites were markedly increased compared with control diluent-challenged BAL sites (0.3% +/- 1% vs 28.1% +/- 9.7%, n = 12, p < 0.002), and a greater percentage were hypodense (specific gravity < 1.080 gm/ml) than in peripheral blood (51.3 +/- 5.3 vs 19.0 +/- 4.4, n = 15, p < 0.01). In vitro, resting and activated BAL eosinophils biosynthesized less thromboxane B-2 than blood eosinophils. Although both BAL and blood eosinophils expressed similar levels of Fc gamma RII (CD32), CD11a, and CD45, resting levels of Mo-1 (CD11b) were upregulated on BAL eosinophils (mean fluorescence intensity 316% +/- 48% of blood eosinophils, n = 5, p < 0.05). Blood eosinophils stimulated in vitro with 1 mu mol/L platelet activating factor or N-formyl-methionyl-leucyl-phenylalanine achieved levels of CD11b expression similar to those of BAL eosinophils. In contrast, CD11b expression on BAL eosinophils could not be further increased. These results confirm that antigen challenge of the lower airways promotes eosinophil infiltration in the lung. Because these eosinophils are of lower density express maximal amounts of CD11b, and are less responsive than peripheral blood eosinophils, we conclude that eosinophils undergo activation during this recruitment process, which may be followed by a state of decreased responsiveness.	JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine					NIAID NIH HHS [AI27429] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027429] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; AIZAWA T, 1990, ANN ALLERGY, V64, P287; BAIGELMAN W, 1983, AM J MED, V75, P929, DOI 10.1016/0002-9343(83)90871-9; BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BURROWS B, 1980, AM REV RESPIR DIS, V122, P709, DOI 10.1164/arrd.1980.122.5.709; CAPRON M, 1984, J IMMUNOL, V132, P462; CAULFIELD JP, 1990, AM J PATHOL, V137, P27; CONNELL JT, 1968, J ALLERGY, V41, P1, DOI 10.1016/0021-8707(68)90002-6; CZECH W, 1993, J ALLERGY CLIN IMMUN, V91, P157; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V133, P855; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FILLEY WV, 1982, LANCET, V2, P11; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; HARTNELL A, 1990, IMMUNOLOGY, V69, P264; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KAUFFMAN HF, 1987, J ALLERGY CLIN IMMUN, V79, P611, DOI 10.1016/S0091-6749(87)80157-4; KHALIFE J, 1986, J IMMUNOL, V137, P1659; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KLOPROGGE E, 1989, J ALLERGY CLIN IMMUN, V83, P393, DOI 10.1016/0091-6749(89)90124-3; KOH YY, 1991, AM REV RESPIR DIS, V143, P83; KROEGEL C, 1989, FEBS LETT, V243, P41, DOI 10.1016/0014-5793(89)81214-1; KROEGEL C, 1991, J ALLERGY CLIN IMMUN, V88, P114, DOI 10.1016/0091-6749(91)90308-B; KROEGEL C, 1993, IMMUNOLOGY, V78, P279; KROEGEL C, 1992, CLIN INVESTIGATOR, V70, P447; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LIU MC, 1988, PROSTAGLANDINS, V35, P67, DOI 10.1016/0090-6980(88)90275-4; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LOWELL FC, 1967, J AMER MED ASSOC, V202, P875, DOI 10.1001/jama.202.9.875; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; NEELEY SP, 1993, AM J RESP CELL MOL, V8, P633, DOI 10.1165/ajrcmb/8.6.633; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PARWARESCH MR, 1976, VIRCHOWS ARCH B, V21, P57; PINCUS SH, 1981, BLOOD, V58, P1175; PRIN L, 1986, CLIN EXP IMMUNOL, V63, P249; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; SCHLEIMER RP, 1993, EOSINOPHILS ALLERGY, P99; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SHULT PA, 1988, J ALLERGY CLIN IMMUN, V81, P429, DOI 10.1016/0091-6749(88)90912-8; SPRY CJF, 1971, CELL TISSUE KINET, V4, P351, DOI 10.1111/j.1365-2184.1971.tb01545.x; SPRY CJF, 1976, CLIN EXP IMMUNOL, V24, P423; VIRCHOW JC, 1993, AM REV RESPIR DIS, V147, pA821; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; WINQVIST I, 1982, IMMUNOLOGY, V47, P531; YUKAWA T, 1989, IMMUNOLOGY, V68, P140	56	97	108	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					725	734		10.1016/0091-6749(94)90252-6	http://dx.doi.org/10.1016/0091-6749(94)90252-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163782				2022-12-18	WOS:A1994NH49700005
J	MOSER, M; CRAMERI, R; BRUST, E; SUTER, M; MENZ, G				MOSER, M; CRAMERI, R; BRUST, E; SUTER, M; MENZ, G			DIAGNOSTIC-VALUE OF RECOMBINANT ASPERGILLUS-FUMIGATUS ALLERGEN I/A FOR SKIN TESTING AND SEROLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ASPERGILLUS FUMIGATUS ALLERGY; RECOMBINANT ALLERGEN; SKIN TEST; ELISA	EXTRACELLULAR ALKALINE PROTEASE; BRONCHOPULMONARY ASPERGILLOSIS; IGE-BINDING; NUCLEOTIDE-SEQUENCE; TOXIN RESTRICTOCIN; MAJOR ALLERGEN; ANTIGENS; ANTIBODIES; STANDARDIZATION; EXPRESSION	Background: We report a clinical study comparing the recombinant Aspergillus fumigatus allergen I/a (rAsp f I/a) to two commercial A. fumigatus extracts in skin prick tests, intrademal tests, and serologic assays. Methods: Patients with allergic bronchopulmonary aspergillosis and A. fumigatus-allergic patients with asthma, and control subjects, including allergic patients with asthma without allery to A. fumigatus and healthy subjects, were investigated. Results: All patients with allergic bronchopulmonary aspergillosis (n = 15) reacted to skin prick tests with the commercial extracts, and eight were sensitized to rAsp f I/a. Of 10 patients with well-characterized A. fumigatus-allergic asthma nine showed positive skin prick test results to at least one of the commercial extracts, and five reacted to rAsp f I/a. There was a strong correlation between skin test reactivity to rAsp f I/a and rAsp f I/a-specific serum IgE as determined by an antigen-specific ELISA. The healthy control subjects (n = 7) and allergic patients with asthma without A. fumigatus allergy (n = 6) did not react in skin prick and intradermal tests to rAsp f I/a, nor did they have detectable amounts of rAsp f I/a-specific IgE. In addition, patients with allergic bronchopulmonary aspergillosis showed significant elevated levels of rAsp f I/a-specific IgG, and IgG, but no significant differences in rAsp f I/a-specific serum IgA levels when compared with the healthy control subjects. Conclusions: The data show that rAsp f I/a is a major allergen with biologic relevance in some A. fumigatus-allergic individuals as evaluated by skin prick tests, intradermal tests, or serologic methods. Furthermore, no discrepancies were observed between skin test results and rAsp f I/a-specific IgE. Hence the correlation between rAsp f I/a skin test results and serologic data indicates the potential of recombinant allergens for clinical applications and diagnosis of allergies.	HOCHGEBIRGSKLIN DAVOS WOLFGANG, DEPT PNEUMOL 2, CH-7265 DAVOS, SWITZERLAND; SWISS INST ALLERGY & ASTHMA RES, DAVOS, SWITZERLAND	Swiss Institute of Allergy & Asthma Research								[Anonymous], 1989, ALLERGY S10, V10, P1; ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; BARDANA E. J, 1980, CRC CRIT REV CLIN LA, V13, P21; BUTLER JE, 1992, J IMMUNOL METHODS, V150, P77, DOI 10.1016/0022-1759(92)90066-3; Butler JE, 1991, IMMUNOCHEMISTRY SOLI, P173; CONDE FP, 1989, EUR J BIOCHEM, V178, P795, DOI 10.1111/j.1432-1033.1989.tb14511.x; DREBORG S, 1992, ALLERGY, V47, P291, DOI 10.1111/j.1398-9995.1992.tb02055.x; ENDO Y, 1983, J BIOL CHEM, V258, P2662; FAUX JA, 1992, THORAX, V47, P48, DOI 10.1136/thx.47.1.48; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; FREW AJ, 1992, CLIN EXP ALLERGY, V22, P881, DOI 10.1111/j.1365-2222.1992.tb02058.x; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P645, DOI 10.1016/0091-6749(84)90223-9; GREENBERGER PA, 1988, ALLERGY PRINCIPLES P, P1219; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JATONOGAY K, 1992, FEMS MICROBIOL LETT, V92, P163, DOI 10.1111/j.1574-6968.1992.tb05253.x; KAUFFMAN HF, 1984, J ALLERGY CLIN IMMUN, V73, P567, DOI 10.1016/0091-6749(84)90512-8; KAUFFMAN HF, 1980, INT ARCH ALLER A IMM, V62, P252, DOI 10.1159/000232521; KAUFFMAN HF, 1985, INT ARCH ALLER A IMM, V76, P168, DOI 10.1159/000233685; KOLLER DY, 1992, ALLERGY, V47, P58, DOI 10.1111/j.1398-9995.1992.tb02251.x; KURUP VP, 1986, J ALLERGY CLIN IMMUN, V78, P1166, DOI 10.1016/0091-6749(86)90267-8; LAMY B, 1991, NUCLEIC ACIDS RES, V19, P1001, DOI 10.1093/nar/19.5.1001; LESER C, 1992, J ALLERGY CLIN IMMUN, V90, P589, DOI 10.1016/0091-6749(92)90131-K; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P18, DOI 10.1016/0091-6749(86)90109-0; LONGBOTTOM JL, 1989, INT ARCH ALLER A IMM, V88, P185, DOI 10.1159/000234780; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P9, DOI 10.1016/0091-6749(86)90108-9; MONOD M, 1991, J MED MICROBIOL, V35, P23, DOI 10.1099/00222615-35-1-23; MOSER M, 1992, J IMMUNOL, V149, P454; MULLBACHER A, 1984, P NATL ACAD SCI-BIOL, V81, P3835, DOI 10.1073/pnas.81.12.3835; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1987, J ALLERGY CLIN IMMUN, V80, P663, DOI 10.1016/0091-6749(87)90285-5; PIECHURA JE, 1983, IMMUNOLOGY, V49, P657; PLATTSMILLS TAE, 1991, J ALLERGY CLIN IMMUN, V87, P621, DOI 10.1016/0091-6749(91)90379-3; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEINER O, 1992, INT ARCH ALLERGY IMM, V98, P93, DOI 10.1159/000236170; SCHONHEYDER H, 1984, INT ARCH ALLER A IMM, V74, P262, DOI 10.1159/000233555; SCHWARTZ HJ, 1978, J ALLERGY CLIN IMMUN, V62, P9, DOI 10.1016/0091-6749(78)90065-9; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VIJAY HM, 1978, INT ARCH ALLER A IMM, V56, P517, DOI 10.1159/000232067; VILLAREJIO MR, 1974, J BACTERIOL, V110, P171; WALLENBECK I, 1991, ALLERGY, V46, P372, DOI 10.1111/j.1398-9995.1991.tb00601.x; WALLENBECK I, 1984, INT ARCH ALLER A IMM, V73, P166, DOI 10.1159/000233459; WILLIAMS PB, 1992, J ALLERGY CLIN IMMUN, V89, P738, DOI 10.1016/0091-6749(92)90382-C; 1991, J ALLERGY CLIN IMMUN, V88, P427	47	97	102	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				1	11		10.1016/0091-6749(94)90227-5	http://dx.doi.org/10.1016/0091-6749(94)90227-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	7508461				2022-12-18	WOS:A1994MT78100001
J	ROBINSON, BWS; VENAILLE, TJ; MENDIS, AHW; MCALEER, R				ROBINSON, BWS; VENAILLE, TJ; MENDIS, AHW; MCALEER, R			ALLERGENS AS PROTEASES - AN ASPERGILLUS-FUMIGATUS PROTEINASE DIRECTLY INDUCES HUMAN EPITHELIAL-CELL DETACHMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									QUEEN ELIZABETH II MED CTR,STATE HLTH LABS,MYCOL SECT,NEDLANDS,WA 6009,AUSTRALIA	University of Western Australia	ROBINSON, BWS (corresponding author), UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT MED,NEDLANDS,WA 6009,AUSTRALIA.		Robinson, Bruce/N-1900-2014					COHEN BL, 1973, J GEN MICROBIOL, V77, P521, DOI 10.1099/00221287-77-2-521; DONALDSON JC, 1978, ANN INTERN MED, V88, P656, DOI 10.7326/0003-4819-88-5-656; GERTLER A, 1971, BIOCHIM BIOPHYS ACTA, V235, P378, DOI 10.1016/0005-2744(71)90217-8; GLIMP RA, 1981, CHEST, V80, P85, DOI 10.1378/chest.80.1.85; GROUTAS WC, 1987, MED RES REV, V7, P227, DOI 10.1002/med.2610070205; HENDERSON AH, 1968, THORAX, V23, P501, DOI 10.1136/thx.23.5.501; HORSFIELD K, 1977, THORAX, V32, P250, DOI 10.1136/thx.32.3.250; KOTHARY MH, 1984, INFECT IMMUN, V43, P320, DOI 10.1128/IAI.43.1.320-325.1984; KURUP VP, 1986, J ALLERGY CLIN IMMUN, V78, P1166, DOI 10.1016/0091-6749(86)90267-8; LEUNG PSC, 1988, INT ARCH ALLER A IMM, V85, P416, DOI 10.1159/000234544; MENDIS AHW, 1990, IMMUNOL CELL BIOL, V68, P95, DOI 10.1038/icb.1990.14; MILLMAN M, 1985, ANN ALLERGY, V54, P294; PRINGLE JR, 1975, METHOD CELL BIOL, P282; RICKETTI AJ, 1984, CHEST, V86, P773, DOI 10.1378/chest.86.5.773; SCHONHEYDER H, 1984, INT ARCH ALLER A IMM, V74, P262, DOI 10.1159/000233555; SCHONHEYDER H, 1984, INT ARCH ALLER A IMM, V73, P231, DOI 10.1159/000233473; STEWART GA, 1989, LANCET, V2, P154, DOI 10.1016/S0140-6736(89)90203-1; STIKSA G, 1984, EUR J RESPIR DIS, V65, P278; VENAILLE TJ, 1989, IMMUNOL CELL BIOL, V67, P359, DOI 10.1038/icb.1989.52	19	97	99	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					726	731		10.1016/S0091-6749(05)80176-9	http://dx.doi.org/10.1016/S0091-6749(05)80176-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229838				2022-12-18	WOS:A1990EJ63100004
J	BOUSQUET, J; HEJJAOUI, A; DHIVERT, H; CLAUZEL, AM; MICHEL, FB				BOUSQUET, J; HEJJAOUI, A; DHIVERT, H; CLAUZEL, AM; MICHEL, FB			IMMUNOTHERAPY WITH A STANDARDIZED DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT .3. SYSTEMIC REACTIONS DURING THE RUSH PROTOCOL IN PATIENTS SUFFERING FROM ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BOUSQUET, J (corresponding author), CHU MONTPELLIER, HOP LAIGUELONGUE, MALADIES RESP CLIN, F-34059 MONTPELLIER, FRANCE.		Bousquet, Jean/O-4221-2019					AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ANDERSON JA, 1986, J ALLERGY CLIN IMMUN, V77, P271, DOI 10.1016/S0091-6749(86)80103-8; [Anonymous], 1986, BMJ-BRIT MED J, V293, P948; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, 1985, REGULATORY CONTROL S, P291; BOUSQUET J, 1986, 12 P INT C ALL CLIN, P397; BURROWS B, 1977, AM REV RESPIR DIS, V115, P195; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; Dreborg S, 1987, THESIS LINKOPING U; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; HEJJAOUI A, 1985, REV FR ALLERGOL, V25, P29, DOI 10.1016/S0335-7457(85)80029-0; LESSOF M, 1983, P INT ALLERGY WORKSH, P1; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; PARRISH HM, 1963, AM J MED SCI, V245, P129; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; VANARSDEL PP, 1957, J ALLERGY, V28, P251, DOI 10.1016/0021-8707(57)90130-2; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x	29	97	100	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					797	802		10.1016/0091-6749(89)90017-1	http://dx.doi.org/10.1016/0091-6749(89)90017-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2708740				2022-12-18	WOS:A1989U342000014
J	DURHAM, SR; GRANEEK, BJ; HAWKINS, R; TAYLOR, AJN				DURHAM, SR; GRANEEK, BJ; HAWKINS, R; TAYLOR, AJN			THE TEMPORAL RELATIONSHIP BETWEEN INCREASES IN AIRWAY RESPONSIVENESS TO HISTAMINE AND LATE ASTHMATIC RESPONSES INDUCED BY OCCUPATIONAL AGENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP, INST CARDIOTHORAC, DEPT OCCUPAT MED, FULHAM RD, LONDON SW3 6HP, ENGLAND	Royal Brompton Hospital								BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BURGE PS, 1979, CLIN ALLERGY, V9, P185, DOI 10.1111/j.1365-2222.1979.tb01540.x; BURGE PS, 1982, EUR J RESPIR DIS, V63, P65; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1985, CLIN INVEST MED, V8, pA44; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GUERIN C, 1980, POUMON COEUR, V36, P393; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; LAITINEN LA, 1976, AM REV RESPIR DIS, V113, pA194; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; OBRIEN IM, 1979, CLIN ALLERGY, V9, P7, DOI 10.1111/j.1365-2222.1979.tb01517.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; TATTERSFIELD AE, 1981, THORAX, V36, P561, DOI 10.1136/thx.36.8.561; VENGE P, 1982, ALLERGY, V37, P55, DOI 10.1111/j.1398-9995.1982.tb04117.x	26	97	97	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					398	406		10.1016/0091-6749(87)90161-8	http://dx.doi.org/10.1016/0091-6749(87)90161-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	3819221				2022-12-18	WOS:A1987G179100016
J	BRICKMAN, CM; TSOKOS, GC; BALOW, JE; LAWLEY, TJ; SANTAELLA, M; HAMMER, CH; FRANK, MM				BRICKMAN, CM; TSOKOS, GC; BALOW, JE; LAWLEY, TJ; SANTAELLA, M; HAMMER, CH; FRANK, MM			IMMUNOREGULATORY DISORDERS ASSOCIATED WITH HEREDITARY ANGIOEDEMA .1. CLINICAL MANIFESTATIONS OF AUTOIMMUNE-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,BETHESDA,MD 20205; NIADDKD,KIDNEY DIS SECT,BETHESDA,MD 20205; NCI,KIDNEY DIS BRANCH,BETHESDA,MD 20205; NCI,DERMATOL BRANCH,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360				AGNELLO V, 1978, MEDICINE, V57, P1; Bennett P.H., 1967, B RHEUM DIS, V17, P453; BLOCH KJ, 1965, MEDICINE, V44, P187, DOI 10.1097/00005792-196505000-00001; BORSOS T, 1961, J IMMUNOL, V87, P310; BORSOS T, 1963, J IMMUNOL, V91, P851; CARROLL MC, 1984, NATURE, V307, P237, DOI 10.1038/307237a0; DAVIS AE, 1985, COMPLEMENT, V2, P20; DONALDSON VH, 1977, ANN INTERN MED, V86, P312, DOI 10.7326/0003-4819-86-3-312; DONALDSON WH, 1980, AM J MED, V35, P37; FARID NR, 1981, ENDOCR REV, V2, P50, DOI 10.1210/edrv-2-1-50; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1980, CLIN IMMUNOLOGY, P262; GAITHER TA, 1974, J IMMUNOL, V113, P547; GIGLI I, 1968, J IMMUNOL, V100, P1154; GOODMAN MG, 1982, J EXP MED, V156, P912, DOI 10.1084/jem.156.3.912; GREENSPAN JS, 1974, ORAL SURG ORAL MED O, V37, P217, DOI 10.1016/0030-4220(74)90417-4; GROVE AS, 1968, AMER J ROENTGENOL RA, V102, P109, DOI 10.2214/ajr.102.1.109; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HARMON CE, 1982, CLIN RHEUM DIS, V8, P121; HERSEY P, 1983, CLIN EXP IMMUNOL, V52, P551; Hory B, 1983, Rev Med Interne, V4, P57, DOI 10.1016/S0248-8663(83)80043-5; HOSEA SW, 1980, ANN INTERN MED, V93, P809, DOI 10.7326/0003-4819-93-6-809; KIJLSTRA A, 1979, J IMMUNOL, V123, P640; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MOUTSOPOULOS HM, 1980, ANN INTERN MED, V92, P212, DOI 10.7326/0003-4819-92-2-212; PICKERING RJ, 1971, J PEDIATR-US, V78, P30, DOI 10.1016/S0022-3476(71)80261-5; PLAZA J, 1973, POSTGRAD MED J, V53, P627; PRIETO L, 1983, MED CLIN-BARCELONA, V80, P149; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; SCHREIBER AD, 1972, J CLIN INVEST, V51, P575, DOI 10.1172/JCI106846; SEIGNALET C, 1979, CLIN ALLERGY, V9, P527, DOI 10.1111/j.1365-2222.1979.tb02517.x; STASTNY P, 1979, J CLIN INVEST, V63, P124, DOI 10.1172/JCI109265; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TERASAKI PI, DHEW NIH74545 PUBL, P54; THEOFILOPOULOS AN, 1976, J CLIN INVEST, V57, P169, DOI 10.1172/JCI108257; TUFFANELLI DL, 1977, ARCH DERMATOL, V113, P374, DOI 10.1001/archderm.1977.01640030120024; UNGER B, 1981, BMJ-BRIT MED J, V282, P768; WALPORT MJ, 1984, CLIN RHEUMATIC DISEA, P3; WOOD PHN, 1970, P ROY SOC MED, V63, P189, DOI 10.1177/003591577006300232; ZUBLER RH, 1976, J IMMUNOL, V116, P232	40	97	98	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					749	757		10.1016/0091-6749(86)90424-0	http://dx.doi.org/10.1016/0091-6749(86)90424-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3084606				2022-12-18	WOS:A1986C390300022
J	RICKETTI, AJ; GREENBERGER, PA; PATTERSON, R				RICKETTI, AJ; GREENBERGER, PA; PATTERSON, R			SERUM IGE AS AN IMPORTANT AID IN MANAGEMENT OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	PHS HHS [11759] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HOEHNE JH, 1973, CHEST, V63, P177, DOI 10.1378/chest.63.2.177; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; KUMAR L, 1971, J ALLERGY CLIN IMMUN, V48, P305, DOI 10.1016/0091-6749(71)90032-7; PATTERSON R, 1974, INT ARCH ALLER A IMM, V46, P150, DOI 10.1159/000231119; PEPYS J, 1969, MONOGRAPHS ALLERGY, V4; POSEY WC, 1978, J ALLERGY CLIN IMMUN, V62, P340, DOI 10.1016/0091-6749(78)90134-3; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SCHWARTZ HJ, 1978, J ALLERGY CLIN IMMUN, V62, P9, DOI 10.1016/0091-6749(78)90065-9; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; WANG JLF, 1979, AM REV RESPIR DIS, V120, P87	12	97	98	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					68	71		10.1016/0091-6749(84)90089-7	http://dx.doi.org/10.1016/0091-6749(84)90089-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6429230				2022-12-18	WOS:A1984SZ64800010
J	NORDLEE, JA; TAYLOR, SL; JONES, RT; YUNGINGER, JW				NORDLEE, JA; TAYLOR, SL; JONES, RT; YUNGINGER, JW			ALLERGENICITY OF VARIOUS PEANUT PRODUCTS AS DETERMINED BY RAST INHIBITION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,INST FOOD RES,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT FOOD SCI,MADISON,WI 53706; MAYO CLIN & MAYO FDN,MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,MAYO GRAD SCH MED,ALLERG DIS RES LAB,ROCHESTER,MN 55901	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Mayo Clinic; Mayo Clinic								AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; BASHA SMM, 1979, PLANT PHYSIOL, V63, P301, DOI 10.1104/pp.63.2.301; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; CHERRY J P, 1971, Journal American Peanut Research and Education Association Incorporated, V3, P63; CHERRY J P, 1975, Peanut Science, V2, P57, DOI 10.3146/i0095-3679-2-2-7; CHERRY JP, 1973, J AGR FOOD CHEM, V21, P656, DOI 10.1021/jf60188a022; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P477, DOI 10.1016/0091-6749(76)90191-3; COLLINS JL, 1981, J FOOD SCI, V46, P445, DOI 10.1111/j.1365-2621.1981.tb04881.x; DAWSON R, 1971, ANAL BIOCHEM, V41, P305, DOI 10.1016/0003-2697(71)90147-3; DIXON WJ, 1969, INTRO STATISTICAL AN, P222; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; Johns CO, 1916, J BIOL CHEM, V28, P77; JOHNSON P, 1950, BIOCH BIOPHYS ACTA, V5, P375; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSAS EW, 1979, J AM OIL CHEM SOC, V56, P245; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MCWATTERS KH, 1980, J FOOD SCI, V45, P831, DOI 10.1111/j.1365-2621.1980.tb07460.x; MCWATTERS KH, 1978, CEREAL CHEM, V55, P853; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; TATTRIE NH, 1973, J I CAN SCI TECHNOL, V6, P289; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; TOMBS MP, 1965, BIOCHEM J, V96, P119, DOI 10.1042/bj0960119; YAMADA T, 1979, AGR BIOL CHEM TOKYO, V43, P2549, DOI 10.1080/00021369.1979.10863847; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778	26	97	103	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	5					376	382		10.1016/0091-6749(81)90136-6	http://dx.doi.org/10.1016/0091-6749(81)90136-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MQ454	7299002	Green Published			2022-12-18	WOS:A1981MQ45400006
J	RUFFIN, RE; FITZ GERALD, JD; REBUCK, AS				RUFFIN, RE; FITZ GERALD, JD; REBUCK, AS			COMPARISON OF BRONCHODILATOR ACTIVITY OF SCH-1000 AND SALBUTAMOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV, DEPT MED, HAMILTON 16, ONTARIO, CANADA	McMaster University								ALTOUNYA.RE, 1966, P ROY SOC MED, VS 59, P56; [Anonymous], 1965, LANCET, V1, P775; ENGELHARDT A, 1975, POSTGRAD MED J, V51, P82; GOODMAN LS, 1975, PHARMACOL BASIS, P514; GROSS NJ, 1975, AM REV RESPIR DIS, V112, P823; LAHDENSUO A, 1973, SCAND J CLIN LAB INV, V31, P16; MACDONALD AG, 1967, BRIT J ANAESTH, V39, P919, DOI 10.1093/bja/39.12.919; PETRIE GR, 1975, BRIT MED J, V1, P430, DOI 10.1136/bmj.1.5955.430; POPPIUS H, 1973, BMJ-BRIT MED J, V4, P134, DOI 10.1136/bmj.4.5885.134; RUFFIN RE, UNPUBLISHED DATA; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; STORMS WW, 1975, AM REV RESPIR DIS, V111, P419; VINCENT NJ, 1970, J APPL PHYSIOL, V29, P236, DOI 10.1152/jappl.1970.29.2.236; VLAGOPOULOS T, 1975, J ALLERGY CLIN IMMUN, V55, P99	14	97	97	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					136	141		10.1016/0091-6749(77)90215-9	http://dx.doi.org/10.1016/0091-6749(77)90215-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	137922	Bronze			2022-12-18	WOS:A1977CV62200007
J	SPITZ, E; SHEFFER, AL; AUSTEN, KF; GELFAND, EW				SPITZ, E; SHEFFER, AL; AUSTEN, KF; GELFAND, EW			SERUM IGE IN CLINICAL IMMUNOLOGY AND ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AMMANN AJ, 1969, NEW ENGL J MED, V281, P469, DOI 10.1056/NEJM196908282810904; AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P53, DOI 10.1016/0019-2791(69)90178-5; BAZARAL M, 1971, J IMMUNOL, V107, P794; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; BERGLUND G, 1968, ACTA PAEDIATR SCAND, V57, P89, DOI 10.1111/j.1651-2227.1968.tb04658.x; CALLERAME ML, 1971, J ALLERGY, V47, P187, DOI 10.1016/S0091-6749(71)80464-5; CONNELL JT, 1968, J ALLERGY, V41, P1, DOI 10.1016/0021-8707(68)90002-6; CONNELL JT, 1969, J ALLERGY, V43, P22, DOI 10.1016/0021-8707(69)90017-3; COOMBS RRA, 1968, LANCET, V1, P1115; DIGEORGE AM, 1968, IMMUNOL DEFICIENCY, V4, P116; FUDENBERG H, 1971, PEDIATRICS, V47, P927; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GOETZL EJ, 1970, BIOCHEMISTRY-US, V9, P1267, DOI 10.1021/bi00807a031; HEINER DC, 1970, J ALLERGY, V45, P30, DOI 10.1016/0021-8707(70)90014-6; HENDERSON LL, 1971, J ALLERGY CLIN IMMUN, V48, P361, DOI 10.1016/0091-6749(71)90082-0; HOGARTHSCOTT RS, 1969, CLIN EXP IMMUNOL, V5, P619; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; ISHIZAKA T, 1971, Federation Proceedings, V30, P654; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON AFO, 1970, CLIN EXP IMMUNOL, V6, P43; JOHANSSON SG, 1968, LANCET, V1, P1118; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KAY AB, 1971, J IMMUNOL, V107, P899; LEVEY RH, 1971, LANCET, V2, P571; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; NEWCOMB RW, 1969, J ALLERGY, V43, P292, DOI 10.1016/0021-8707(69)90150-6; NORDBRING F, 1969, Scandinavian Journal of Infectious Diseases, V1, P99; OGAWA M, 1969, NEW ENGL J MED, V281, P1217, DOI 10.1056/NEJM196911272812204; ORANGE RP, 1971, J EXP MED, V134, pS136; ROSENBERG EB, 1970, NEW ENGL J MED, V283, P1148, DOI 10.1056/NEJM197011192832107; ROWE DS, 1969, B WORLD HEALTH ORGAN, V40, P613; ROWE DS, 1970, INT ARCH ALLER A IMM, V39, P1; SCHWARTZ DP, 1971, NEW ENGL J MED, V284, P513, DOI 10.1056/NEJM197103112841002; SCHWARTZ RH, 1966, AM J DIS CHILD, V111, P408, DOI 10.1001/archpedi.1966.02090070106015; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WIDE L, 1967, LANCET, V2, P1105	40	97	98	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	6					337	+		10.1016/0091-6749(72)90132-7	http://dx.doi.org/10.1016/0091-6749(72)90132-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6593	4623555				2022-12-18	WOS:A1972M659300003
J	Reese, SE; Xu, CJ; den Dekker, HT; Lee, MK; Sikdar, S; Ruiz-Arenas, C; Merid, SK; Rezwan, FI; Page, CM; Ullemar, V; Melton, PE; Oh, SS; Yang, IV; Burrows, K; Soderhall, C; Jima, DD; Gao, L; Arathimos, R; Kupers, LK; Wielscher, M; Rzehak, P; Lahti, J; Laprise, C; Madore, AM; Ward, J; Bennett, BD; Wang, TY; Bell, DA; Vonk, JM; Haberg, SE; Zhao, SS; Karlsson, R; Hollams, E; Hu, DL; Richards, AJ; Bergstrom, A; Sharp, GC; Felix, JF; Bustamante, M; Gruzieva, O; Maguire, RL; Gilliland, F; Baiz, N; Nohr, EA; Corpeleijn, E; Sebert, S; Karmaus, W; Grote, V; Kajantie, E; Magnus, MC; Ortqvist, AK; Eng, C; Liu, AH; Kull, I; Jaddoe, VWV; Sunyer, J; Kere, J; Hoyo, C; Annesi-Maesano, I; Arshad, SH; Koletzko, B; Brunekreef, B; Binder, EB; Raikkonen, K; Reischl, E; Holloway, JW; Jarvelin, MR; Snieder, H; Kazmi, N; Breton, CV; Murphy, SK; Pershagen, G; Anto, JM; Relton, CL; Schwartz, DA; Burchard, EG; Huang, RC; Nystad, WC; Almqvist, C; Henderson, AJ; Melen, E; Duijts, L; Koppelman, GH; London, SJ				Reese, Sarah E.; Xu, Cheng-Jian; den Dekker, Herman T.; Lee, Mi Kyeong; Sikdar, Sinjini; Ruiz-Arenas, Carlos; Merid, Simon K.; Rezwan, Faisal, I; Page, Christian M.; Ullemar, Vilhelmina; Melton, Phillip E.; Oh, Sam S.; Yang, Ivana, V; Burrows, Kimberley; Soderhall, Cilla; Jima, Dereje D.; Gao, Lu; Arathimos, Ryan; Kupers, Leanne K.; Wielscher, Matthias; Rzehak, Peter; Lahti, Jari; Laprise, Catherine; Madore, Anne-Marie; Ward, James; Bennett, Brian D.; Wang, Tianyuan; Bell, Douglas A.; Vonk, Judith M.; Haberg, Siri E.; Zhao, Shanshan; Karlsson, Robert; Hollams, Elysia; Hu, Donglei; Richards, Adam J.; Bergstrom, Anna; Sharp, Gemma C.; Felix, Janine F.; Bustamante, Mariona; Gruzieva, Olena; Maguire, Rachel L.; Gilliland, Frank; Baiz, Nour; Nohr, Ellen A.; Corpeleijn, Eva; Sebert, Sylvain; Karmaus, Wilfried; Grote, Veit; Kajantie, Eero; Magnus, Maria C.; Ortqvist, Anne K.; Eng, Celeste; Liu, Andrew H.; Kull, Inger; Jaddoe, Vincent W. V.; Sunyer, Jordi; Kere, Juha; Hoyo, Cathrine; Annesi-Maesano, Isabella; Arshad, Syed Hasan; Koletzko, Berthold; Brunekreef, Bert; Binder, Elisabeth B.; Raikkonen, Katri; Reischl, Eva; Holloway, John W.; Jarvelin, Marjo-Riitta; Snieder, Harold; Kazmi, Nabila; Breton, Carrie, V; Murphy, Susan K.; Pershagen, Goran; Maria Anto, Josep; Relton, Caroline L.; Schwartz, David A.; Burchard, Esteban G.; Huang, Rae-Chi; Nystad, WeRae-Che; Almqvist, Catarina; Henderson, A. John; Melen, Erik; Duijts, Liesbeth; Koppelman, Gerard H.; London, Stephanie J.		BIOS Consortium	Epigenome-wide meta-analysis of DNA methylation and childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epigenetics; methylation; asthma; childhood; newborn; drug development	PRENATAL ARSENIC EXPOSURE; GENE-EXPRESSION; COHORT PROFILE; CORD BLOOD; ASSOCIATION; EPIGENETICS; PREGNANCY; RISK; CONSORTIUM; DISCOVERY	Background: Epigenetic mechanisms, including methylation, can contribute to childhood asthma. Identifying DNA methylation profiles in asthmatic patients can inform disease pathogenesis. Objective: We sought to identify differential DNA methylation in newborns and children related to childhood asthma. Methods: Within the Pregnancy And Childhood Epigenetics consortium, we performed epigenome-wide meta-analyses of school-age asthma in relation to CpG methylation (Illumina450K) in blood measured either in newborns, in prospective analyses, or cross-sectionally in school-aged children. We also identified differentially methylated regions. Results: In newborns (8 cohorts, 668 cases), 9 CpGs (and 35 regions) were differentially methylated (epigenome-wide significance, false discovery rate < 0.05) in relation to asthma development. In a cross-sectional meta-analysis of asthma and methylation in children (9 cohorts, 631 cases), we identified 179 CpGs (false discovery rate < 0.05) and 36 differentially methylated regions. In replication studies of methylation in other tissues, most of the 179 CpGs discovered in blood replicated, despite smaller sample sizes, in studies of nasal respiratory epithelium or eosinophils. Pathway analyses highlighted enrichment for asthma-relevant immune processes and overlap in pathways enriched both in newborns and children. Gene expression correlated with methylation at most loci. Functional annotation supports a regulatory effect on gene expression at many asthma-associated CpGs. Several implicated genes are targets for approved or experimental drugs, including IL5RA and KCNH2. Conclusion: Novel loci differentially methylated in newborns represent potential biomarkers of risk of asthma by school age. Cross-sectional associations in children can reflect both risk for and effects of disease. Asthma-related differential methylation in blood in children was substantially replicated in eosinophils and respiratory epithelium.	[Reese, Sarah E.; Lee, Mi Kyeong; Sikdar, Sinjini; Ward, James; Bennett, Brian D.; Wang, Tianyuan; Bell, Douglas A.; Zhao, Shanshan; London, Stephanie J.] NIEHS, Div Intramural Res, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA; [Xu, Cheng-Jian] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Xu, Cheng-Jian; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp, Groningen, Netherlands; [Xu, Cheng-Jian; Vonk, Judith M.; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Groningen, Netherlands; [Kupers, Leanne K.; Vonk, Judith M.; Corpeleijn, Eva; Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [den Dekker, Herman T.; Felix, Janine F.; Jaddoe, Vincent W. V.] Erasmus MC, Univ Med Ctr Rotterdam, Dept Epidemiol, Rotterdam, Netherlands; [den Dekker, Herman T.; Duijts, Liesbeth] Erasmus MC, Univ Med Ctr Rotterdam, Dept Pediat, Div Resp Med & Allergol, Rotterdam, Netherlands; [den Dekker, Herman T.; Felix, Janine F.; Jaddoe, Vincent W. V.] Erasmus MC, Univ Med Ctr Rotterdam, Generat R Study Grp, Rotterdam, Netherlands; [Felix, Janine F.; Jaddoe, Vincent W. V.] Erasmus MC, Univ Med Ctr Rotterdam, Dept Pediat, Rotterdam, Netherlands; [Duijts, Liesbeth] Erasmus MC, Univ Med Ctr Rotterdam, Dept Pediat, Div Neonatol, Rotterdam, Netherlands; [Ruiz-Arenas, Carlos; Bustamante, Mariona; Sunyer, Jordi; Maria Anto, Josep] CIBERESP, Madrid, Spain; [Ruiz-Arenas, Carlos; Bustamante, Mariona; Sunyer, Jordi; Maria Anto, Josep] ISGlobal, Barcelona, Spain; [Ruiz-Arenas, Carlos; Bustamante, Mariona; Sunyer, Jordi; Maria Anto, Josep] UPF, Barcelona, Spain; [Merid, Simon K.; Bergstrom, Anna; Gruzieva, Olena; Pershagen, Goran; Melen, Erik] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Ullemar, Vilhelmina; Karlsson, Robert; Ortqvist, Anne K.; Almqvist, Catarina] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Soderhall, Cilla] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden; [Rezwan, Faisal, I; Holloway, John W.] Univ Southampton, Fac Med, Human Dev & Hlth, Southampton, Hants, England; [Arshad, Syed Hasan; Holloway, John W.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England; [Page, Christian M.] Norwegian Inst Publ Hlth, Ctr Fertil & Hlth, Oslo, Norway; [Page, Christian M.] Oslo Univ Hosp, Oslo Ctr Biostat & Epidemiol, Oslo, Norway; [Melton, Phillip E.] Univ Western Australia, Fac Hlth & Med Sci, Curtin UWA Ctr Genet Origins Hlth & Dis, Crawley, WA, Australia; [Melton, Phillip E.] Curtin Univ, Sch Pharm & Biomed Sci, Bentley, WA, Australia; [Oh, Sam S.; Hu, Donglei; Eng, Celeste; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Yang, Ivana, V; Richards, Adam J.; Schwartz, David A.] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA; [Burrows, Kimberley; Kupers, Leanne K.; Sharp, Gemma C.; Magnus, Maria C.; Relton, Caroline L.; Henderson, A. John] Univ Bristol, Bristol Med Sch, Dept Populat Hlth Sci, Bristol, Avon, England; [Burrows, Kimberley; Arathimos, Ryan; Kupers, Leanne K.; Sharp, Gemma C.; Magnus, Maria C.; Kazmi, Nabila; Relton, Caroline L.] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Bristol, Avon, England; [Arathimos, Ryan; Kazmi, Nabila] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Sharp, Gemma C.] Univ Bristol, Bristol Dent Sch, Bristol, Avon, England; [Soderhall, Cilla; Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden; [Jima, Dereje D.] North Carolina State Univ, Bioinformat Res Ctr, Raleigh, NC 27695 USA; [Jima, Dereje D.; Hoyo, Cathrine] North Carolina State Univ, Ctr Human Hlth & Environm, Raleigh, NC 27695 USA; [Maguire, Rachel L.] North Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA; [Gao, Lu; Gilliland, Frank; Breton, Carrie, V] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA; [Wielscher, Matthias; Jarvelin, Marjo-Riitta] Imperial Coll London, Sch Publ Hlth, MRC PHE Ctr Environm & Hlth, Dept Epidemiol & Biostat, London, England; [Sebert, Sylvain] Imperial Coll London, Sch Publ Hlth, Dept Genom Complex Dis, London, England; [Rzehak, Peter; Grote, Veit; Koletzko, Berthold] Ludwig Maximilians Univ Munchen LMU, Dr von Hauner Childrens Hosp, Div Metab & Nutr Med, Munich, Germany; [Lahti, Jari; Raikkonen, Katri] Univ Helsinki, Dept Psychol & Logoped, Helsinki, Finland; [Lahti, Jari] Univ Helsinki, Helsinki Coll Adv Studies, Helsinki, Finland; [Laprise, Catherine] Univ Quebec Chicoutimi, Ctr Integre Univ Sante & Serv Sociaux Saguenay, Saguenay, PQ, Canada; [Laprise, Catherine; Madore, Anne-Marie] Univ Quebec Chicoutimi, Dept Sci Fondamentales, Saguenay, PQ, Canada; [Haberg, Siri E.; Magnus, Maria C.; Nystad, WeRae-Che] Norwegian Inst Publ Hlth, Div Mental & Phys Hlth, Oslo, Norway; [Hollams, Elysia; Huang, Rae-Chi] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Bergstrom, Anna; Gruzieva, Olena; Pershagen, Goran] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden; [Bustamante, Mariona] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Barcelona, Spain; [Maguire, Rachel L.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA; [Murphy, Susan K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA; [Baiz, Nour; Annesi-Maesano, Isabella] INSERM, IPLESP, Epidemiol Allerg & Resp Dis Dept, Paris, France; [Baiz, Nour; Annesi-Maesano, Isabella] UPMC, Sorbonne Univ, Paris, France; [Nohr, Ellen A.] Univ Southern Denmark, Dept Clin Res, Res Unit Gynaecol & Obstet, Odense, Denmark; [Sebert, Sylvain; Jarvelin, Marjo-Riitta] Univ Oulu, Bioctr Oulu, Oulu, Finland; [Sebert, Sylvain; Jarvelin, Marjo-Riitta] Univ Oulu, Ctr Life Course Hlth Res, Fac Med, Oulu, Finland; [Karmaus, Wilfried] Univ Memphis, Sch Publ Hlth, Div Epidemiol Biostat & Environm Hlth, Memphis, TN 38152 USA; [Kajantie, Eero] Natl Inst Hlth & Welf, Chron Dis Prevent Unit, Helsinki, Finland; [Kajantie, Eero] Oulu Univ Hosp, MRC Oulu, Dept Obstet & Gynaecol, Oulu, Finland; [Kajantie, Eero] Univ Oulu, Oulu, Finland; [Kajantie, Eero] Helsinki Univ Cent Hosp, Hosp Children & Adolescents, Helsinki, Finland; [Kajantie, Eero] Univ Helsinki, Helsinki, Finland; [Liu, Andrew H.] Childrens Hosp Colorado, Aurora, CO USA; [Kull, Inger; Melen, Erik] Soder Sjukhuset, Sachs Childrens Hosp, Stockholm, Sweden; [Sunyer, Jordi; Maria Anto, Josep] Hosp Mar Med Res Inst IMIM, Barcelona, Spain; [Kere, Juha] Kings Coll London, Dept Med & Mol Genet, London, England; [Arshad, Syed Hasan] David Hide Asthma & Allergy Res Ctr, Newport, Wight, England; [Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Binder, Elisabeth B.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA; [Binder, Elisabeth B.] Max Planck Inst Psychiat, Munich, Germany; [Reischl, Eva] Helmholtz Zentrum Muenchen, Inst Epidemiol 2, Res Unit Mol Epidemiol, Munich, Germany; [Murphy, Susan K.] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA; [Hoyo, Cathrine; Almqvist, Catarina] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Pediat Allergy & Pulmonol Unit, Stockholm, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Groningen; University of Groningen; University of Groningen; University of Groningen; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; ISGlobal; Pompeu Fabra University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; University of Southampton; University of Southampton; Norwegian Institute of Public Health (NIPH); University of Oslo; University of Western Australia; Curtin University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Bristol; University of Bristol; University of Bristol; University of Bristol; Karolinska Institutet; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of Southern California; Imperial College London; Imperial College London; University of Munich; University of Helsinki; University of Helsinki; University of Quebec; University of Quebec Chicoutimi; University of Quebec; University of Quebec Chicoutimi; Norwegian Institute of Public Health (NIPH); Telethon Kids Institute; University of Western Australia; Stockholm County Council; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Duke University; Duke University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Southern Denmark; University of Oulu; University of Oulu; University of Memphis; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Children's Hospital Colorado; Sodersjukhuset Hospital; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of London; King's College London; Utrecht University; Utrecht University; Utrecht University Medical Center; Emory University; Max Planck Society; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Duke University; Karolinska Institutet; Karolinska University Hospital	London, SJ (corresponding author), NIEHS, POB 12233,MD A3-05, Res Triangle Pk, NC 27709 USA.	london2@niehs.nih.gov	London, Stephanie/C-3734-2019; Lahti, Jari/P-7987-2018; Melton, Phillip/A-5012-2013; Relton, Caroline/AAC-5904-2019; Xu, Cheng-Jian/G-9144-2018; Wielscher, Matthias/GLS-8316-2022; Kere, Juha/A-9179-2008; Bustamante, Mariona/ABB-9142-2021; Koppelman, Gerard/AAG-9187-2020; Rezwan, Faisal I/E-8905-2017; Anto, J M/H-2676-2014; Örtqvist, Anne Kristina/P-6618-2019; Holloway, John W/B-5424-2009; Kere, Juha/AAX-9117-2021; Grote, Veit/ABH-9605-2020; Sharp, Gemma/U-1294-2019; Zhao, Shanshan/AFM-7084-2022; Annesi-Maesano, Isabella/D-9173-2016; Lee, Mi Kyeong/C-3046-2017; Bell, Douglas A/C-7687-2019; Sunyer, Jordi/G-6909-2014	London, Stephanie/0000-0003-4911-5290; Lahti, Jari/0000-0002-4310-5297; Melton, Phillip/0000-0003-4026-2964; Xu, Cheng-Jian/0000-0003-1586-4672; Wielscher, Matthias/0000-0003-4138-1383; Kere, Juha/0000-0003-1974-0271; Bustamante, Mariona/0000-0003-0127-2860; Rezwan, Faisal I/0000-0001-9921-222X; Anto, J M/0000-0002-4736-8529; Holloway, John W/0000-0001-9998-0464; Kere, Juha/0000-0003-1974-0271; Grote, Veit/0000-0001-7168-2385; Sharp, Gemma/0000-0003-2906-4035; Zhao, Shanshan/0000-0002-5828-4881; Annesi-Maesano, Isabella/0000-0002-6340-9300; Lee, Mi Kyeong/0000-0002-3036-3684; Bell, Douglas A/0000-0001-7700-0840; Sunyer, Jordi/0000-0002-2602-4110; Ruiz-Arenas, Carlos/0000-0002-6014-3498; Gao, Lu/0000-0002-2206-5476; Kebede Merid, Simon/0000-0001-5974-7676; Koppelman, Gerard/0000-0001-8567-3252; Murphy, Susan/0000-0001-8298-7272; Raikkonen, Katri/0000-0003-3124-3470; Hollams, Elysia/0000-0002-3481-6396; Laprise, Catherine/0000-0001-5526-9945; Jima, Dereje/0000-0002-7784-1612; Relton, Caroline/0000-0003-2052-4840; Corpeleijn, Eva/0000-0002-2974-3305; Page, Christian Magnus/0000-0002-1897-3666; Burrows, Kimberley/0000-0002-3208-0389; Ward, James/0000-0002-9510-2848	Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences; BBSRC [BB/I025263/1] Funding Source: UKRI; MRC [G0401540, MC_UU_00011/5, MC_UU_12013/2] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL132321, R33HL120770, R01HL097163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES049019, ZIAES046008] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences. See supplemental materials in this article's Online Repository at www.jacionline.org for complete funding information for individual studies.	Andrews SV, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0107-z; Arathimos R, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0414-7; Arshad SH, 2017, J ALLERGY CLIN IMMUN, V139, P415, DOI 10.1016/j.jaci.2016.12.002; Bakulski KM, 2016, EPIGENETICS-US, V11, P354, DOI 10.1080/15592294.2016.1161875; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bento AP, 2014, NUCLEIC ACIDS RES, V42, pD1083, DOI 10.1093/nar/gkt1031; Bisgaard H, 2007, PEDIATR PULM, V42, P723, DOI 10.1002/ppul.20644; Bonder MJ, 2017, NAT GENET, V49, P131, DOI 10.1038/ng.3721; Breeze CE, 2016, CELL REP, V17, P2137, DOI 10.1016/j.celrep.2016.10.059; Chen W, 2017, J ALLERGY CLIN IMMUN, V140, P571, DOI 10.1016/j.jaci.2016.11.030; Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; DeVries A, 2017, J ALLERGY CLIN IMMUN, V140, P534, DOI 10.1016/j.jaci.2016.10.041; DeVries A, 2016, ANN AM THORAC SOC, V13, pS48, DOI 10.1513/AnnalsATS.201507-420MG; Edwards DRV, 2013, HUM GENET, V132, P323, DOI 10.1007/s00439-012-1246-3; Felix JF, 2018, INT J EPIDEMIOL, V47, P22, DOI 10.1093/ije/dyx190; Ferland C, 2001, J LEUKOCYTE BIOL, V69, P772; Fox CS, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002695; Gref A, 2017, AM J RESP CRIT CARE, V195, P1373, DOI 10.1164/rccm.201605-1026OC; Gunawardhana LP, 2014, EPIGENETICS-US, V9, P1302, DOI 10.4161/epi.33066; Guxens M, 2012, INT J EPIDEMIOL, V41, P930, DOI 10.1093/ije/dyr054; Han B, 2011, AM J HUM GENET, V88, P586, DOI 10.1016/j.ajhg.2011.04.014; Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86; Joehanes R, 2016, CIRC-CARDIOVASC GENE, V9, P436, DOI 10.1161/CIRCGENETICS.116.001506; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Joubert BR, 2016, AM J HUM GENET, V98, P680, DOI 10.1016/j.ajhg.2016.02.019; Joubert BR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10577; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Laprise C, 2014, GENES IMMUN, V15, P247, DOI 10.1038/gene.2014.12; Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161; Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825; Leslie R, 2014, BIOINFORMATICS, V30, P185, DOI 10.1093/bioinformatics/btu273; MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Murphy TM, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0163-4; Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501; Nicodemus-Johnson J, 2016, AM J RESP CRIT CARE, V193, P376, DOI 10.1164/rccm.201506-1243OC; Pedersen BS, 2012, BIOINFORMATICS, V28, P2986, DOI 10.1093/bioinformatics/bts545; Peters TJ, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-6; Psaty BM, 2013, EPIDEMIOLOGY, V24, P346, DOI 10.1097/EDE.0b013e31828b2cbb; Rager JE, 2014, ENVIRON MOL MUTAGEN, V55, P196, DOI 10.1002/em.21842; Rastogi D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02164; Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361; Rice K, 2018, J R STAT SOC A STAT, V181, P205, DOI 10.1111/rssa.12275; Rojas D, 2015, TOXICOL SCI, V143, P97, DOI 10.1093/toxsci/kfu210; Sachs RE, 2017, JAMA-J AM MED ASSOC, V318, P2421, DOI 10.1001/jama.2017.17535; Sharma S, 2014, THORAX, V69, P481, DOI 10.1136/thoraxjnl-2014-205166; Sharp GC, 2017, HUM MOL GENET, V26, P4067, DOI 10.1093/hmg/ddx290; Teschendorff AE, 2018, NAT REV GENET, V19, P129, DOI 10.1038/nrg.2017.86; Tost J, 2018, J ALLERGY CLIN IMMUN, V142, P715, DOI 10.1016/j.jaci.2018.07.009; Weiss ST, 2011, AM J RESP CRIT CARE, V184, P631, DOI 10.1164/rccm.201103-0485ED; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Wjst M, 2013, CURR OPIN ALLERGY CL, V13, P112, DOI 10.1097/ACI.0b013e32835c1674; Wu MC, 2018, METHODS MOL BIOL, V1708, P303, DOI 10.1007/978-1-4939-7481-8_16; Xu CJ, 2018, LANCET RESP MED, V6, P379, DOI 10.1016/S2213-2600(18)30052-3; Xu CJ, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3452-1; Yandell M, 2012, NAT REV GENET, V13, P329, DOI 10.1038/nrg3174; Yang IV, 2017, J ALLERGY CLIN IMMUN, V139, P1478, DOI 10.1016/j.jaci.2016.07.036; Yang IV, 2017, AM J RESP CRIT CARE, V195, P829, DOI 10.1164/rccm.201608-1558LE; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zhernakova DV, 2017, NAT GENET, V49, P139, DOI 10.1038/ng.3737	63	96	99	0	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2062	2074		10.1016/j.jaci.2018.11.043	http://dx.doi.org/10.1016/j.jaci.2018.11.043			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30579849	Green Accepted, Green Published, Green Submitted, hybrid			2022-12-18	WOS:000470113200012
J	Fleischer, DM; Sicherer, S; Greenhawt, M; Campbell, D; Chan, E; Muraro, A; Halken, S; Katz, Y; Ebisawa, M; Eichenfield, L; Sampson, H; Lack, G; Du Toit, G; Roberts, G; Bahnson, H; Feeney, M; Hourihane, J; Spergel, J; Young, M; As'aad, A; Allen, K; Prescott, S; Kapur, S; Saito, H; Agache, I; Akdis, CA; Arshad, H; Beyer, K; Dubois, A; Eigenmann, P; Fernandez-Rivas, M; Grimshaw, K; Hoffman-Sommergruber, K; Host, A; Lau, S; O'Mahony, L; Mills, C; Papadopoulos, N; Venter, C; Agmon-Levin, N; Kessel, A; Antaya, R; Drolet, B; Rosenwasser, L				Fleischer, David M.; Sicherer, Scott; Greenhawt, Matthew; Campbell, Dianne; Chan, Edmond; Muraro, Antonella; Halken, Susanne; Katz, Yitzhak; Ebisawa, Motohiro; Eichenfield, Lawrence; Sampson, Hugh; Lack, Gideon; Du Toit, George; Roberts, Graham; Bahnson, Henry; Feeney, Mary; Hourihane, Jonathan; Spergel, Jonathan; Young, Michael; As'aad, Amal; Allen, Katrina; Prescott, Susan; Kapur, Sandeep; Saito, Hirohisa; Agache, Ioana; Akdis, Cezmi A.; Arshad, Hasan; Beyer, Kirsten; Dubois, Anthony; Eigenmann, Philippe; Fernandez-Rivas, Monserrat; Grimshaw, Kate; Hoffman-Sommergruber, Karin; Host, Arne; Lau, Susanne; O'Mahony, Liam; Mills, Clare; Papadopoulos, Nikolaus; Venter, Carina; Agmon-Levin, Nancy; Kessel, Aaron; Antaya, Richard; Drolet, Beth; Rosenwasser, Lanny		LEAP Study Team	Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy prevention; complementary feeding; peanut allergy	FOOD ALLERGY; NUTRITIONAL INTERVENTIONS; CHILDREN; PREVALENCE; DISEASE	The purpose of this brief communication is to highlight emerging evidence to existing guidelines regarding potential benefits of supporting early, rather than delayed, peanut introduction during the period of complementary food introduction in infants. This document should be considered as interim guidance based on consensus among the following organizations: American Academy of Allergy, Asthma & Immunology, American Academy of Pediatrics, American College of Allergy, Asthma & Immunology, Australasian Society of Clinical Immunology and Allergy, Canadian Society of Allergy and Clinical Immunology, European Academy of Allergy and Clinical Immunology, Israel Association of Allergy and Clinical Immunology, Japanese Society for Allergology, Society for Pediatric Dermatology, and World Allergy Organization. More formal guidelines regarding early-life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases-sponsored Working Group and the European Academy of Allergy and Clinical Immunology.	[Sampson, Hugh; Lack, Gideon; Feeney, Mary; Rosenwasser, Lanny] WAO, Milwaukee, WI USA; [Bahnson, Henry] Rho Fed Syst Div Inc, Chapel Hill, NC USA		Fleischer, DM (corresponding author), Childrens Hosp Colorado, 13123 E 16th Ave,B518, Aurora, CO 80045 USA.	david.fleischer@childrenscolorado.org	O'Mahony, Liam/AAG-5838-2019; Eigenmann, Philippe/A-6569-2017; Agache, Ioana/AAP-7403-2020; Allen, Katrina/I-4361-2018; Akdis, Cezmi/AAV-4844-2020	O'Mahony, Liam/0000-0003-4705-3583; Eigenmann, Philippe/0000-0003-1738-1826; Allen, Katrina/0000-0002-1921-4493; Akdis, Cezmi/0000-0001-8020-019X; Ebisawa, Motohiro/0000-0003-4117-558X; Campbell, Dianne/0000-0002-0907-6963; Lau, Susanne/0000-0002-5189-4265; Chan, Edmond/0000-0003-2947-1175; Halken, Susanne/0000-0003-0161-8278; Spergel, Jonathan/0000-0002-4658-5353; Roberts, Graham/0000-0003-2252-1248; Saito, Hirohisa/0000-0002-6630-8337; Du Toit, George/0000-0002-0321-2928; Lack, Gideon/0000-0001-7350-4021				Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; Amoah AS, 2013, J ALLERGY CLIN IMMUN, V132, P639, DOI 10.1016/j.jaci.2013.04.023; ASCIA, ASCIA INF FEED ADV; Chan ES, 2013, PAED CHILD HEALT-CAN, V18, P545, DOI 10.1093/pch/18.10.545; de Silva D, 2014, ALLERGY, V69, P581, DOI 10.1111/all.12334; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fleischer DM, 2013, J ALLER CL IMM-PRACT, V1, P29, DOI 10.1016/j.jaip.2012.09.003; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Muraro A, 2014, ALLERGY, V69, P590, DOI 10.1111/all.12398; Nwaru BI, 2014, ALLERGY, V69, P62, DOI 10.1111/all.12305; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Soller L, 2012, J ALLERGY CLIN IMMUN, V130, P986, DOI 10.1016/j.jaci.2012.06.029; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x	14	96	101	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					258	261		10.1016/j.jaci.2015.06.001	http://dx.doi.org/10.1016/j.jaci.2015.06.001			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	26100082	Green Published			2022-12-18	WOS:000359004900005
J	Macy, E; Contreras, R				Macy, Eric; Contreras, Richard			Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adverse drug reaction; allergy; cephalosporin; Clostridium difficile; death; hemolytic anemia; hospitalized; oral; outpatient; nephropathy; parenteral; serious cutaneous adverse reaction; Stevens-Johnson syndrome	PENICILLIN ALLERGY; ANAPHYLAXIS; HYPERSENSITIVITY; PREVALENCE; SAFETY	Background: Few studies have provided population-based, route-specific data on allergy to cephalosporin or incidence of serious adverse drug reactions (ADRs). Objective: We investigated the incidence of new reports of cephalosporin-associated "allergy" and serious ADRs. Methods: We identified all members of the Kaiser Permanente Southern California health plan given cephalosporins (from January 1, 2010, through December 31, 2012), all new reports of cephalosporin-associated allergy, and all serious ADRs. Results: There were 622,456 health plan members exposed to 901,908 courses of oral cephalosporins and 326,867 members exposed to 487,630 courses of parenteral cephalosporins over the 3-year study period. New reports of allergy to cephalosporin were more frequent among women (0.56%; 95% CI, 0.54% to 0.57%) than among men (0.43%; 95% CI, 0.41% to 0.44%) per course (P <.0001). The most frequent serious cephalosporin-associated ADRs were Clostridium difficile infection within 90 days (0.91%), nephropathy within 30 days (0.15%), and all-cause death within 1 day (0.10%). None correlated with history of drug allergy. Physician-documented cephalosporin-associated anaphylaxis occurred with 5 oral exposures (95% CI, 1/1,428,571-1/96,154) and 8 parenteral exposures (95% CI, 1/200,000-1/35,971) (P = .0761). There were 3 documented cephalosporin-associated serious cutaneous adverse reactions (95% CI, 0-1 in 217,291). All were associated with the use of another antibiotic at the same time as cephalosporin. Conclusions: Cephalosporins are widely and safely used, even in individuals with a history of penicillin allergy. Physician-documented cephalosporin-associated anaphylaxis and serious cutaneous adverse reactions are rare compared with C difficile infection within 90 days, nephropathy within 30 days, and all-cause death within 1 day.	[Macy, Eric] Univ Calif San Diego, San Diego Med Ctr, So Calif Permanente Med Grp, Dept Allergy, San Diego, CA 92103 USA; [Contreras, Richard] Kaiser Permanente Hlth Care Program, Dept Res & Evaluat, Pasadena, CA USA	Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of California System; University of California San Diego; Kaiser Permanente	Macy, E (corresponding author), Kaiser Permanente, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	eric.m.macy@kp.org		Macy, Eric/0000-0002-5857-9444	ALK Abello, Inc; BioMarin	ALK Abello, Inc; BioMarin	Disclosure of potential conflict of interest: The Southern California Permanente Medical Group and the Kaiser Permanente Health Care Program employ the authors. E. Macy has received a research grant from ALK Abello, Inc, is a member of a clinical trial safety and monitoring committee for BioMarin Pharmaceutical, Inc, and has received participation fees from BioMarin. R. Contreras declares that he has no relevant conflicts of interest.	ALANIS A, 1983, MED CLIN N AM, V67, P113, DOI 10.1016/S0025-7125(16)31227-5; Campbell RL, 2012, J ALLERGY CLIN IMMUN, V129, P748, DOI 10.1016/j.jaci.2011.09.030; Grgurevic I, 2008, ACTA DERMATOVENER CR, V16, P133; Hunziker T, 1997, ALLERGY, V52, P388, DOI 10.1111/j.1398-9995.1997.tb01017.x; Johannes CB, 2007, DRUG SAFETY, V30, P705, DOI 10.2165/00002018-200730080-00007; Kaufman DW, 2003, PHARMACOEPIDEM DR S, V12, P195; Lagace -Wiens P, 2012, EXPERT OPIN DRUG SAF, V11, P381, DOI 10.1517/14740338.2012.643866; Lee P, 2007, J ANTIMICROB CHEMOTH, V60, P1172, DOI 10.1093/jac/dkm315; Lode H, 2010, AM J MED, V123, pS26, DOI 10.1016/j.amjmed.2010.02.004; Longstreth KL, 2004, PHARMACOTHERAPY, V24, P808, DOI 10.1592/phco.24.8.808.36069; Macy E, 2014, CLIN REV ALLERG IMMU, V47, P46, DOI 10.1007/s12016-013-8369-8; Macy E, 2014, J ALLERGY CLIN IMMUN, V133, P790, DOI 10.1016/j.jaci.2013.09.021; Macy E, 2013, J ALLER CL IMM-PRACT, V1, P258, DOI 10.1016/j.jaip.2013.02.002; Macy E, 2012, ANN ALLERG ASTHMA IM, V108, P88, DOI 10.1016/j.anai.2011.11.006; Macy Eric, 2011, Perm J, V15, P31; Macy E, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.01.034; Mitropoulos IF, 2007, DIAGN MICR INFEC DIS, V57, p67S, DOI 10.1016/j.diagmicrobio.2006.12.002; Mulla ZD, 2007, INT ARCH ALLERGY IMM, V144, P128, DOI 10.1159/000103224; Ren XH, 2012, EXPERT OPIN DRUG SAF, V11, P689, DOI 10.1517/14740338.2012.699037; Seltsam A, 2000, INTENS CARE MED, V26, P1390, DOI 10.1007/s001340000598; Sheikh A, 2001, CLIN EXP ALLERGY, V31, P1571, DOI 10.1046/j.1365-2222.2001.01203.x; Solensky R, 2003, CLIN REV ALLERG IMMU, V24, P201, DOI 10.1385/CRIAI:24:3:201; Alonso MAT, 2011, INT ARCH ALLERGY IMM, V156, P212, DOI 10.1159/000322997; Tong JE, 2007, PEDIATR NEPHROL, V22, P306, DOI 10.1007/s00467-006-0318-9; VANDERKLAUW MM, 1993, BRIT J CLIN PHARMACO, V35, P400; Viraraghavan Roopa, 2002, Adverse Drug Reactions and Toxicological Reviews, V21, P101; Yoon SY, 2013, ALLERGY, V68, P938, DOI 10.1111/all.12182; Zhang Q, 2007, METHOD INFORM MED, V46, P516, DOI 10.1160/ME0374	28	96	95	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					745	U261		10.1016/j.jaci.2014.07.062	http://dx.doi.org/10.1016/j.jaci.2014.07.062			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25262461	Bronze			2022-12-18	WOS:000351065000022
J	Raedler, D; Ballenberger, N; Klucker, E; Bock, A; Otto, R; da Costa, OP; Holst, O; Illig, T; Buch, T; von Mutius, E; Schaub, B				Raedler, Diana; Ballenberger, Nikolaus; Klucker, Elisabeth; Boeck, Andreas; Otto, Ragna; da Costa, Olivia Prazeres; Holst, Otto; Illig, Thomas; Buch, Thorsten; von Mutius, Erika; Schaub, Bianca			Identification of novel immune phenotypes for allergic and nonallergic childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma phenotypes; immune-regulatory mechanisms; innate immunity; linear discriminant analysis; peripheral blood mononuclear cells; regulatory T cells; transcriptomics	REGULATORY T-CELLS; INFLAMMATION; EXPRESSION; RECEPTOR; CD93	Background: Childhood asthma is classified into allergic asthma (AA) and nonallergic asthma (NA), yet both are treated identically, with only partial success. Objective: We sought to identify novel immune phenotypes for childhood AA and NA. Methods: The Clinical Asthma Research Association cohort study includes 275 steroid-naive 4-to 15-year-old German children (healthy control subjects [HCs], patients with AA, and patients with NA). In PBMCs both quantitative and functional analysis of regulatory T (Treg) and T(H)17 cells (flow cytometry/Treg cell suppression) before/after anti-CD3/CD28, lipid A, and peptidoglycan stimulation were performed. Cytokines and gene expression, as assessed by using Luminex or transcriptomics/quantitative real-time RT-PCR, were analyzed by means of regression analysis. Linear discriminant analysis was applied to discriminate between phenotypes. Results: The 3 phenotypes were immunologically well discriminated by means of microarray and protein analysis with linear discriminant analysis. Patients with AA were characterized by increased Treg cells compared with those in HCs but not those in patients with NA. Treg cells from patients with AA, but not patients with NA, significantly suppressed IL5, IL-13, and IFN-gamma secretion. Patients with AA had decreased expression of chloride intracellular channel 4 (CLIC4) and tuberous sclerosis 1 (TSC1), important innate immunity regulators. Patients with NA were characterized by increased proinflammatory IL-1 beta levels, neutrophil counts, and IL-17-shifted immunity. In parallel, expressions of anti-inflammatory IL37, proline-serine-threonine phosphatase-interacting protein 2 (PSTPIP2), and the neutrophil-associated genes CD93, triggering receptor expressed on myeloid cells 1 (TREM1), and regulator of G-protein signaling 13 (RGS13) were increased in patients with NA. A shared T(H)2 immunity was present in both asthma phenotypes. Conclusion: Novel immune-regulatory mechanisms in childhood asthma identified increased Treg cells in patients with AA compared with those in HCs but not those in NA and decreased innate immunity genes for patients with AA, the first potentially indicating a counterregulatory mechanism to suppress cytokines yet not sufficient to control allergic inflammation. Very distinctly, patients with NA showed an IL-17-shifted proinflammatory immunity, promoting neutrophil inflammation and less functional Treg cells. Identification of these unique pathways provides a profound basis for future strategies for individualized prediction of asthma development, disease course, and prevention.	[Raedler, Diana; Ballenberger, Nikolaus; Klucker, Elisabeth; Boeck, Andreas; Otto, Ragna; von Mutius, Erika; Schaub, Bianca] Ludwig Maximilians Univ Munchen, Univ Childrens Hosp Munich, German Ctr Lung Res DZL, Dept Pulm & Allergy, D-80337 Munich, Germany; [da Costa, Olivia Prazeres; Buch, Thorsten] TUM Munich, Inst Med Microbiol Immunol & Hyg, Munich, Germany; [Holst, Otto] Res Ctr Borstel, Leibniz Ctr Med & Biosci, Div Struct Biochem, Borstel, Germany; [Illig, Thomas] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Epidemiol, Neuherberg, Germany; [Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, Hannover, Germany; [Illig, Thomas] German Ctr Lung Res DZL, Hannover, Germany	University of Munich; Technical University of Munich; Forschungszentrum Borstel; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Hannover Medical School	Schaub, B (corresponding author), Ludwig Maximilians Univ Munchen, Univ Childrens Hosp Munich, Lindwurmstr 4, D-80337 Munich, Germany.	Bianca.Schaub@med.uni-muenchen.de	Schaub, Bianca/B-9935-2019; Buch, Thorsten/P-1659-2019	Schaub, Bianca/0000-0003-1652-8873; Buch, Thorsten/0000-0002-2236-9074; von Mutius, Erika/0000-0002-8893-4515	German Research Foundation (DFG) [TRR 22/2, TRR 22/3, SFB-TR22]; GPA; WAO; GlaxoSmithKline; Forschungsstipendium fur Klinische Pneumologie; FoFoLe [839]; German Centre for Lung Research (DZL), Comprehensive Pneumology Centre in Munich (CPC-M)	German Research Foundation (DFG)(German Research Foundation (DFG)); GPA; WAO; GlaxoSmithKline(GlaxoSmithKline); Forschungsstipendium fur Klinische Pneumologie; FoFoLe; German Centre for Lung Research (DZL), Comprehensive Pneumology Centre in Munich (CPC-M)	Supported by the German Research Foundation (DFG, TRR 22/2 and 22/3, SFB-TR22; to D.R., N.B., E.K., A.B., B.S., O.P.d.C., and T.B.), GPA, WAO (to B.S.), a grant from GlaxoSmithKline, Forschungsstipendium fur Klinische Pneumologie 2013 (D.R.), FoFoLe Reg.Nr. 839 (DR), and the German Centre for Lung Research (DZL) as part of the Comprehensive Pneumology Centre in Munich (CPC-M; to D.R., B.S., and E.v.M.).	Agache I, 2012, ALLERGY, V67, P835, DOI 10.1111/j.1398-9995.2012.02832.x; [Anonymous], 2011, DTSCH ARZTEBL INT, V10, P192; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Bohlson SS, 2005, J IMMUNOL, V175, P1239, DOI 10.4049/jimmunol.175.2.1239; Chitu V, 2009, BLOOD, V114, P2497, DOI 10.1182/blood-2009-02-204925; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Craig TJ, 2010, ALLERGY ASTHMA PROC, V31, P96, DOI 10.2500/aap.2010.31.3310; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Development Core Team, 2005, R LANG ENV STAT COMP; Dhimolea E, 2010, MABS-AUSTIN, V2, P3, DOI 10.4161/mabs.2.1.10328; Drews AC, 2009, ALLERGY, V64, P1597, DOI 10.1111/j.1398-9995.2009.02057.x; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Gallelli L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/104315; Greenfeder S, 2001, RESP RES, V2, P71, DOI 10.1186/rr41; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; He GA, 2011, EUR J IMMUNOL, V41, P1221, DOI 10.1002/eji.201041266; Hsu HC, 2008, NAT IMMUNOL, V9, P166, DOI 10.1038/ni1552; Kim G, 2011, P NATL ACAD SCI USA, V108, P16493, DOI 10.1073/pnas.1113711108; Kleinewietfeld M, 2009, BLOOD, V113, P827, DOI 10.1182/blood-2008-04-150524; Lee JH, 2007, CLIN EXP IMMUNOL, V148, P53, DOI 10.1111/j.1365-2249.2007.03329.x; Lin YL, 2008, ALLERGY, V63, P67, DOI 10.1111/j.1398-9995.2007.01526.x; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Louten J, 2009, J ALLERGY CLIN IMMUN, V123, P1004, DOI 10.1016/j.jaci.2009.04.003; Newcomb DC, 2013, CURR OPIN IMMUNOL, V25, P755, DOI 10.1016/j.coi.2013.08.002; Papadopoulos NG, 2012, ALLERGY, V67, P976, DOI 10.1111/j.1398-9995.2012.02865.x; Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schenk M, 2007, J CLIN INVEST, V117, P3097, DOI 10.1172/JCI30602; Steinberger P, 2002, J LEUKOCYTE BIOL, V71, P133; Thunberg S, 2010, ALLERGY, V65, P311, DOI 10.1111/j.1398-9995.2009.02218.x; TSUKAGOSHI H, 1994, J ALLERGY CLIN IMMUN, V93, P464, DOI 10.1016/0091-6749(94)90355-7; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wang XS, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-391; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297	37	96	102	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					81	91		10.1016/j.jaci.2014.07.046	http://dx.doi.org/10.1016/j.jaci.2014.07.046			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25226851				2022-12-18	WOS:000347298200010
J	Van Eyck, L; Hershfield, MS; Pombal, D; Kelly, SJ; Ganson, NJ; Moens, L; Frans, G; Schaballie, H; De Hertogh, G; Dooley, J; Bossuyt, X; Wouters, C; Liston, A; Meyts, I				Van Eyck, Lien, Jr.; Hershfield, Michael S.; Pombal, Diana; Kelly, Susan J.; Ganson, Nancy J.; Moens, Leen; Frans, Glynis; Schaballie, Heidi; De Hertogh, Gert; Dooley, James; Bossuyt, Xavier; Wouters, Carine; Liston, Adrian; Meyts, Isabelle			Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MACROPHAGES		[Van Eyck, Lien, Jr.; Pombal, Diana; Dooley, James; Liston, Adrian] VIB, Dept Immunol & Microbiol, Autoimmune Genet Lab, Leuven, Belgium; [Van Eyck, Lien, Jr.; Pombal, Diana; Dooley, James; Liston, Adrian] Univ Leuven, Leuven, Belgium; [Hershfield, Michael S.; Kelly, Susan J.; Ganson, Nancy J.] Duke Univ, Med Ctr, Durham, NC USA; [Moens, Leen; Frans, Glynis; Bossuyt, Xavier] Univ Leuven, Dept Immunol & Microbiol, Expt Lab Immunol, Leuven, Belgium; [Schaballie, Heidi; Wouters, Carine; Meyts, Isabelle] Univ Hosp Leuven, Dept Immunol & Microbiol, Dept Pediat, Leuven, Belgium; [De Hertogh, Gert] Univ Leuven, Dept Pathol, Leuven, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Duke University; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven	Van Eyck, L (corresponding author), VIB, Dept Immunol & Microbiol, Autoimmune Genet Lab, Leuven, Belgium.	Isabelle.Meyts@uzleuven.be	Bossuyt, Xavier/B-2085-2019; Liston, Adrian/G-8606-2013; Meyts, Isabelle/Z-3295-2019	Bossuyt, Xavier/0000-0001-6856-8485; Liston, Adrian/0000-0002-6272-4085; Dooley, James/0000-0003-3154-4708; Wouters, Carine/0000-0002-6426-8845				Arredondo-Vega FX, 2002, BLOOD, V99, P1005, DOI 10.1182/blood.V99.3.1005; Danso-Abeam D, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-79; DiCarlo J, 2014, BIOL BLOOD MARROW TR, V20, P361, DOI 10.1016/j.bbmt.2013.11.026; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; HERSHFIELD MS, 1982, J BIOL CHEM, V257, P6380; Malamut G, 2010, AM J GASTROENTEROL, V105, P2262, DOI 10.1038/ajg.2010.214; Mercalli A, 2013, IMMUNOLOGY, V140, P179, DOI 10.1111/imm.12126; Segel R, 2014, NEW ENGL J MED, V371, P481, DOI 10.1056/NEJMc1405506; Zavialov AV, 2010, J LEUKOCYTE BIOL, V88, P279, DOI 10.1189/jlb.1109764; Zavialov AV, 2010, J BIOL CHEM, V285, P12367, DOI 10.1074/jbc.M109.083527; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361	11	96	98	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					283	+		10.1016/j.jaci.2014.10.010	http://dx.doi.org/10.1016/j.jaci.2014.10.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25457153	Green Published, hybrid			2022-12-18	WOS:000347298200041
J	Camargo, CA; Ganmaa, D; Sidbury, R; Erdenedelger, K; Radnaakhand, N; Khandsuren, B				Camargo, Carlos A., Jr.; Ganmaa, D.; Sidbury, Robert; Erdenedelger, Kh.; Radnaakhand, N.; Khandsuren, B.			Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Randomized controlled trial; vitamin D; nutritional supplement; atopic dermatitis; winter; children; Mongolia	SERUM 25-HYDROXYVITAMIN D; ANTIMICROBIAL PEPTIDE EXPRESSION; ECZEMA PREVALENCE; ALLERGIC DISEASE; SCHOOLCHILDREN; SEVERITY; LESIONS; ASTHMA; BIRTH; FOOD	Background: Epidemiologic and preclinical data, and a small randomized trial in Boston, suggest that vitamin D supplementation may improve winter-related atopic dermatitis (AD). Objective: To determine the effect of vitamin D supplementation on winter-related AD. Methods: We performed a randomized, double-blind, placebo-controlled trial of Mongolian children with winter-related AD (clinicaltrials.gov identifier: NCT00879424). Baseline eligibility included age 2 to 17 years, AD score 10 to 72 using the Eczema Area and Severity Index (EASI), and winter-related AD (eg, history of AD worsening during the fall-to-winter transition). Subjects were enrolled in Ulaanbaatar during winter and randomly assigned to oral cholecalciferol (1000 IU/day) versus placebo for 1 month. All children and parents received emollient and patient education about AD and basic skin care. The main outcomes were changes in EASI score and in Investigator's Global Assessment. Results: The 107 enrolled children had a mean age of 9 years (SD 5), and 59% were male. Their median age of AD onset was 3 months (interquartile range 2 months to 1 year) and mean EASI score at baseline 21 (SD 9). One-month follow-up data were available for 104 (97%) children. Compared with placebo, vitamin D supplementation for 1 month produced a clinically and statistically significant improvement in EASI score (adjusted mean change: -6.5 vs -3.3, respectively; P = .04). Moreover, change in Investigator's Global Assessment favored vitamin D over placebo (P = .03). There were no adverse effects in either group. Conclusion: Vitamin D supplementation improved winter-related AD among Mongolian children, a population likely to have vitamin D deficiency in winter.	[Camargo, Carlos A., Jr.; Ganmaa, D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA; [Camargo, Carlos A., Jr.; Ganmaa, D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Ganmaa, D.; Erdenedelger, Kh.; Radnaakhand, N.; Khandsuren, B.] Hlth Sci Univ Mongolia, Ulaanbaatar, Mongolia; [Erdenedelger, Kh.; Khandsuren, B.] Natl Dermatol Ctr, Ulaanbaatar, Mongolia; [Sidbury, Robert] Seattle Childrens Hosp, Seattle, WA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Mongolian National University of Medical Sciences; Seattle Children's Hospital	Camargo, CA (corresponding author), Massachusetts Gen Hosp, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	ccamargo@partners.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	Massachusetts General Hospital in Boston	Massachusetts General Hospital in Boston	This trial was supported by Massachusetts General Hospital in Boston. Study agents and packaging were provided by Ddrops Company (Toronto, Ontario, Canada). Neither sponsor had any role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; nor in the preparation, review, or approval of the manuscript.	Amestejani M, 2012, J DRUGS DERMATOL, V11, P327; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Bikle DD, 2004, J INVEST DERMATOL, V122, P984, DOI 10.1111/j.0022-202X.2004.22424.x; Bischoff-Ferrari HA, 2010, OSTEOPOROSIS INT, V21, P1121, DOI 10.1007/s00198-009-1119-3; Borzutzky A, 2013, EXPERT REV CLIN IMMU, V9, P751, DOI 10.1586/1744666X.2013.816493; Byremo G, 2006, ALLERGY, V61, P1403, DOI 10.1111/j.1398-9995.2006.01209.x; Chiu YE, 2013, J AM ACAD DERMATOL, V69, P40, DOI 10.1016/j.jaad.2013.01.010; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hata TR, 2014, J EUR ACAD DERMATOL, V28, P781, DOI 10.1111/jdv.12176; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Holick MF, 2011, J INVEST MED, V59, P872, DOI 10.2310/JIM.0b013e318214ea2d; Institute of Medicine, 2011, DIETARY REFERENCE IN; Javanbakht MH, 2011, J DERMATOL TREAT, V22, P144, DOI 10.3109/09546630903578566; Jones AP, 2012, PEDIATRICS, V130, pE1128, DOI 10.1542/peds.2012-1172; Kusunoki T, 1999, J ALLERGY CLIN IMMUN, V103, P1148, DOI 10.1016/S0091-6749(99)70191-0; Kuzume K, 2007, PEDIATR ALLERGY IMMU, V18, P281, DOI 10.1111/j.1399-3038.2006.00526.x; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Lim HW, 2005, J AM ACAD DERMATOL, V52, P868, DOI 10.1016/j.jaad.2005.03.015; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Mansbach JM, 2009, PEDIATRICS, V124, P1404, DOI 10.1542/peds.2008-2041; Miyake Y, 2010, EUR RESPIR J, V35, P1228, DOI 10.1183/09031936.00100609; Muehleisen B, 2013, J ALLERGY CLIN IMMUN, V131, P324, DOI 10.1016/j.jaci.2012.12.1562; Oren E, 2008, J ALLERGY CLIN IMMUN, V121, P533, DOI 10.1016/j.jaci.2007.11.005; Osborne NJ, 2012, J ALLERGY CLIN IMMUN, V129, P865, DOI 10.1016/j.jaci.2012.01.037; Peroni DG, 2011, BRIT J DERMATOL, V164, P1078, DOI 10.1111/j.1365-2133.2010.10147.x; Rich-Edwards JW, 2011, AM J CLIN NUTR, V94, P578, DOI 10.3945/ajcn.110.008771; Samochocki Z, 2013, J AM ACAD DERMATOL, V69, P238, DOI 10.1016/j.jaad.2013.03.014; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Sidbury R, 2008, BRIT J DERMATOL, V159, P245, DOI 10.1111/j.1365-2133.2008.08601.x; Silverberg JI, 2013, J INVEST DERMATOL, V133, P1752, DOI 10.1038/jid.2013.19; Simpson EL, 2012, J ALLERGY CLIN IMMUN, V130, P137, DOI 10.1016/j.jaci.2012.01.075; Tolppanen AM, 2013, EPIDEMIOLOGY, V24, P310, DOI [10.1097/EDE.0b013e318280dd5e, 10.1097/EDE.obo13e318280dd5e]; Vahavihu K, 2010, BRIT J DERMATOL, V163, P321, DOI 10.1111/j.1365-2133.2010.09767.x; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Won C H, 2004, J Dermatolog Treat, V15, P30, DOI 10.1080/09546630310020812	39	96	101	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					831	U420		10.1016/j.jaci.2014.08.002	http://dx.doi.org/10.1016/j.jaci.2014.08.002			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25282565				2022-12-18	WOS:000343155700008
J	Kim, SR; Kim, DI; Kang, MR; Lee, KS; Park, SY; Jeong, JS; Lee, YC				Kim, So Ri; Kim, Dong Im; Kang, Mi Ran; Lee, Kyung Sun; Park, Seung Yong; Jeong, Jae Seok; Lee, Yong Chul			Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor kappa B activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchial asthma; endoplasmic reticulum stress; phenylbutyric acid; Toll-like receptor 4; IL-10; nuclear factor kappa B	UNFOLDED PROTEIN RESPONSE; REGULATES IL-17 EXPRESSION; TRANSCRIPTION FACTOR; ER STRESS; AIRWAY HYPERRESPONSIVENESS; SODIUM PHENYLBUTYRATE; SIGNALING PATHWAYS; VIRAL-INFECTION; GENE-EXPRESSION; MURINE MODEL	Background: Despite many studies on endoplasmic reticulum (ER) stress in patients with various inflammatory diseases, there is scarce information on ER stress in patients with bronchial asthma. Objective: In this study we aimed to elucidate the role of ER stress in the pathogenesis of bronchial asthma. Methods: Using mice sensitized with ovalbumin (OVA) and LPS and challenged with OVA (OVA(LPS)-OVA mice), as well as mice sensitized and challenged with OVA (OVA-OVA mice), we investigated whether ER stress is involved in the pathogenesis of bronchial asthma. Moreover, we also determined the levels of ER stress markers in blood and bronchoalveolar lavage fluid from asthmatic patients. Results: The OVA(LPS)-OVA mice showed that the expression of ER stress markers and the protein levels of unfolded protein response-related markers in lung tissue were significantly increased after OVA challenge. Moreover, we found that ER stress markers in PBMCs and bronchoalveolar lavage fluid from human asthmatic patients were dramatically increased compared with those from healthy control subjects. In OVA(LPS-)OVA mice 4-phenylbutyric acid (4-PBA), a chemical chaperone, significantly reduced the increases in ER stress, nuclear translocation of nuclear factor kappa B, inflammatory cytokine levels, dendritic cell infiltration, Toll-like receptor 4 expression, airway inflammation, and bronchial hyperresponsiveness, whereas it further enhanced the increase in IL-10 levels. Additionally, the established asthmatic features of OVA-OVA mice were substantially attenuated by 4-PBA administered after completion of OVA challenge. Conclusion: These results indicate that ER stress might be implicated in the pathogenesis of bronchial asthma at least in part through modulation of nuclear factor kappa B activation.	[Kim, So Ri; Kim, Dong Im; Kang, Mi Ran; Lee, Kyung Sun; Park, Seung Yong; Jeong, Jae Seok; Lee, Yong Chul] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Dept Internal Med,Biomed Res Inst, Res Inst Clin Med,Res Ctr Pulm Disorders,Med Sch, Jeonju 561180, South Korea	Jeonbuk National University; Jeonbuk National University Hospital	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, San 2-20, Jeonju 561180, South Korea.	leeyc@jbnu.ac.kr	Kim, So Ri/AAS-1630-2021; Jeong, Jae Seok/GXH-8417-2022	Kim, So Ri/0000-0002-6074-9158; Jeong, Jae Seok/0000-0002-4635-8302	Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [A084144, A121931, A111992]; Biomedical Research Institute, Chonbuk National University Hospital	Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea; Biomedical Research Institute, Chonbuk National University Hospital	Supported by the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (grants A084144, A121931 [to Y.C.L.], and A111992 [to S.R.K.]) and the fund of the Biomedical Research Institute, Chonbuk National University Hospital.	Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Blomkalns AL, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-4; Borish L, 1998, J ALLERGY CLIN IMMUN, V101, P293, DOI 10.1016/S0091-6749(98)70238-6; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Brusilow S W, 1996, Adv Pediatr, V43, P127; Carducci MA, 2001, CLIN CANCER RES, V7, P3047; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Endo M, 2006, J IMMUNOL, V176, P6245, DOI 10.4049/jimmunol.176.10.6245; Franco A, 2010, CELL IMMUNOL, V266, P1, DOI 10.1016/j.cellimm.2010.09.006; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Haldar P, 2007, J ALLERGY CLIN IMMUN, V119, P1043, DOI 10.1016/j.jaci.2007.02.042; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hampton RY, 2000, CURR BIOL, V10, pR518, DOI 10.1016/S0960-9822(00)00583-2; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; Hosoi T, 2010, CLIN SCI, V118, P19, DOI 10.1042/CS20080680; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Inden M, 2007, J NEUROCHEM, V101, P1491, DOI 10.1111/j.1471-4159.2006.04440.x; Iwakoshi NN, 2007, J EXP MED, V204, P2267, DOI 10.1084/jem.20070525; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kelsen SG, 2008, AM J RESP CELL MOL, V38, P541, DOI 10.1165/rcmb.2007-0221OC; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim SR, 2007, J IMMUNOL, V179, P6820, DOI 10.4049/jimmunol.179.10.6820; Kim SR, 2005, MOL PHARMACOL, V68, P1568, DOI 10.1124/mol.105.017160; Kincaid MM, 2007, ANTIOXID REDOX SIGN, V9, P2373, DOI 10.1089/ars.2007.1817; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; Marahatta A, 2012, J CHROMATOGR B, V903, P118, DOI 10.1016/j.jchromb.2012.07.004; Martinon F, 2011, CURR OPIN IMMUNOL, V23, P35, DOI 10.1016/j.coi.2010.10.016; Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857; Mauad T, 2008, CURR OPIN PULM MED, V14, P31, DOI 10.1097/MCP.0b013e3282f19846; Mercuri E, 2004, NEUROMUSCULAR DISORD, V14, P130, DOI 10.1016/j.nmd.2003.11.006; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Ono K, 2009, PARKINSONISM RELAT D, V15, P649, DOI 10.1016/j.parkreldis.2009.03.002; Park SJ, 2009, J IMMUNOL, V183, P3259, DOI 10.4049/jimmunol.0900231; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Poppek D, 2006, ANTIOXID REDOX SIGN, V8, P173, DOI 10.1089/ars.2006.8.173; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Richardson CE, 2010, NATURE, V463, P1092, DOI 10.1038/nature08762; Ricobaraza A, 2009, NEUROPSYCHOPHARMACOL, V34, P1721, DOI 10.1038/npp.2008.229; Robinson DS, 2009, CLIN EXP ALLERGY, V39, P1314, DOI 10.1111/j.1365-2222.2009.03301.x; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Said EA, 2010, NAT MED, V16, P452, DOI 10.1038/nm.2106; Shirtcliffe P, 2011, CURR OPIN PULM MED, V17, P72, DOI 10.1097/MCP.0b013e328341f181; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Smith JA, 2008, EUR J IMMUNOL, V38, P1194, DOI 10.1002/eji.200737882; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tateda C, 2008, J PLANT RES, V121, P603, DOI 10.1007/s10265-008-0185-5; Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359; Toth Ambrus, 2007, Cardiovascular & Hematological Disorders - Drug Targets, V7, P205, DOI 10.2174/187152907781745260; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Tsokos M, 2002, VIRCHOWS ARCH, V441, P494, DOI 10.1007/s00428-002-0666-1; Urade R, 2009, BIOFACTORS, V35, P326, DOI 10.1002/biof.45; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wiley JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009135; Xu Y, 2006, NAT REV IMMUNOL, V6, P261, DOI 10.1038/nri1804; Zerfaoui M, 2009, J LEUKOCYTE BIOL, V86, P1385, DOI 10.1189/jlb.0309183; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203	70	96	102	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1397	+		10.1016/j.jaci.2013.08.041	http://dx.doi.org/10.1016/j.jaci.2013.08.041			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	24161747	Bronze			2022-12-18	WOS:000327538200019
J	Otani, IM; Anilkumar, AA; Newbury, RO; Bhagat, M; Beppu, LY; Dohil, R; Broide, DH; Aceves, SS				Otani, Iris M.; Anilkumar, Arjun A.; Newbury, Robert O.; Bhagat, Monica; Beppu, Lisa Y.; Dohil, Ranjan; Broide, David H.; Aceves, Seema S.			Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; pediatric; eosinophils; mast cells; IL-5; IL-9	PLACEBO-CONTROLLED TRIAL; ELIMINATION DIET; DOUBLE-BLIND; IN-VITRO; CHILDREN; MEPOLIZUMAB; EXPRESSION; SURVIVAL; ADULTS	Background: Eosinophilic esophagitis (EoE) is a clinicopathologic entity of increasing worldwide prevalence. IL-5 is essential for eosinophil trafficking, and anti-IL-5 therapy decreases esophageal eosinophilia. EoE is associated with prominent mast cell infiltration. Objective: We investigated whether anti-IL-5 (mepolizumab) treatment reduced esophageal mast cell accumulation in biopsy specimens from pediatric patients with EoE from a previous randomized anti-IL-5 trial. Methods: A subanalysis was completed for children treated with 0.55, 2.5, or 10 mg/kg mepolizumab monthly for 12 weeks followed by no treatment until week 24. Quantitative immunochemistry was used to assess the numbers of eosinophils, tryptase-positive mast cells, IL-9(+) cells, and mast cell-eosinophil couplets before and after treatment. Results: Forty-three biopsy specimens had adequate tissue for paired analysis. Forty percent of subjects responded to anti-IL-5 (defined as <15 eosinophils per high-power field [hpf] after mepolizumab therapy), and 77% of all subjects had decreased numbers of mast cells after anti-IL-5. In responders epithelial mast cell numbers decreased from 62 to 19 per hpf (P < .001), were significantly lower than in nonresponders after therapy (P < .05), and correlated with eosinophil numbers (r = 0.75, P < .0001). Mast cells and eosinophils were found in couplets before therapy, and these were significantly decreased only in responders after anti-IL-5 (P < .001). Esophageal eosinophils comprised the majority of cells that made the mast cell growth factor IL-9. IL-9(+) cell numbers decreased from 102 to 71 per hpf (P < .001) after anti-IL-5. Conclusions: Pediatric patients with EoE had significantly fewer mast cells, IL-9(+) cells, and mast cell-eosinophil couplets in the esophageal epithelium after anti-IL-5 therapy. Because eosinophils were one source of IL-9, they might support esophageal mastocytosis.	[Otani, Iris M.; Anilkumar, Arjun A.; Bhagat, Monica; Beppu, Lisa Y.; Broide, David H.; Aceves, Seema S.] Univ Calif San Diego, Rady Childrens Hosp, Div Allergy & Immunol, La Jolla, CA 92093 USA; [Newbury, Robert O.] Univ Calif San Diego, Rady Childrens Hosp, Div Pathol, La Jolla, CA 92093 USA; [Dohil, Ranjan] Univ Calif San Diego, Rady Childrens Hosp, Div Gastroenterol, La Jolla, CA 92093 USA; [Newbury, Robert O.; Beppu, Lisa Y.; Dohil, Ranjan; Aceves, Seema S.] Univ Calif San Diego, Rady Childrens Hosp, Dept Pediat, La Jolla, CA 92093 USA; [Otani, Iris M.; Anilkumar, Arjun A.; Bhagat, Monica; Broide, David H.; Aceves, Seema S.] Univ Calif San Diego, Rady Childrens Hosp, Dept Med, La Jolla, CA 92093 USA	Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego	Aceves, SS (corresponding author), Univ Calif San Diego, Dept Pediat, Div Allergy & Immunol, 9500 Gilman Dr,MC 0635, La Jolla, CA 92093 USA.	saceves@ucsd.edu		Broide, David/0000-0001-8405-9090	GlaxoSmithKline; National Institutes of Health/National Institute of Allergy and Infectious Disease [AI092135, AI38425, AI70535, AI72115]; National Institutes of Health (NIH); Department of Defense; NIH/National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070535, R01AI072115, R01AI038425, R01AI092135, R37AI038425] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); National Institutes of Health/National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a research grant from GlaxoSmithKline (to S. S. A.) and National Institutes of Health/National Institute of Allergy and Infectious Disease grants AI092135 (to S. S. A.), AI38425, AI70535, and AI72115 (to D.H.B.).; Disclosure of potential conflict of interest: D. H. Broide has received grants from the National Institutes of Health (NIH) and the Department of Defense and has consultant arrangements with Ambit and Guidepoint. S. S. Aceves has received grants from GlaxoSmithKline and the NIH/National Institute of Allergy and Infectious Diseases, has a patent with Meritage Pharma for Oral Viscous Budesonide, has stock/stock options with Meritage Pharma, and has received travel support from the NIH as a member of the NIH CIMG Study Section. The rest of the authors declare that they have no relevant conflicts of interest.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Blatman KSH, 2011, J ALLERGY CLIN IMMUN, V127, P1307, DOI 10.1016/j.jaci.2010.12.1118; Dahl C, 2004, ALLERGY, V59, P1087, DOI 10.1111/j.1398-9995.2004.00606.x; Dohil R, 2010, GASTROENTEROLOGY, V139, P418, DOI 10.1053/j.gastro.2010.05.001; Elishmereni M, 2011, ALLERGY, V66, P376, DOI 10.1111/j.1398-9995.2010.02494.x; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Gounni AS, 2000, BLOOD, V96, P2163; Jones TG, 2009, J IMMUNOL, V183, P5251, DOI 10.4049/jimmunol.0901471; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kagalwalla AF, 2012, J ALLERGY CLIN IMMUN, V129, P1387, DOI 10.1016/j.jaci.2012.03.005; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Ochi H, 2000, P NATL ACAD SCI USA, V97, P10509, DOI 10.1073/pnas.180318697; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Wilson TM, 2011, J ALLERGY CLIN IMMUN, V128, P1086, DOI 10.1016/j.jaci.2011.05.032	27	96	109	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1576	+		10.1016/j.jaci.2013.02.042	http://dx.doi.org/10.1016/j.jaci.2013.02.042			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23623266	Bronze, Green Accepted			2022-12-18	WOS:000320532800017
J	Takabayashi, T; Kato, A; Peters, AT; Suh, LA; Carter, R; Norton, J; Grammer, LC; Tan, BK; Chandra, RK; Conley, DB; Kern, RC; Fujieda, S; Schleimer, RP				Takabayashi, Tetsuji; Kato, Atsushi; Peters, Anju T.; Suh, Lydia A.; Carter, Roderick; Norton, James; Grammer, Leslie C.; Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.; Fujieda, Shigeharu; Schleimer, Robert P.			Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; mast cells; tryptase; chymase; carboxypeptidase A3 (CPA3)	EPITHELIAL-CELLS; GENE-EXPRESSION; INFLAMMATION; ACTIVATION; EOSINOPHILS; MEDIATORS; ACCUMULATION; IMMUNITY; RELEASE; ASTHMA	Background: Although chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) is characterized by T(H)2 inflammation, the role of mast cells is poorly understood. Objective: The objective of this study was to investigate the presence, localization, and phenotype of mast cells in patients with CRS. Methods: We collected nasal tissue and nasal lavage fluid from patients with CRS and control subjects. We analyzed mRNA for the mast cell proteases tryptase, chymase, and carboxypeptidase A3 by using real-time PCR and measured mast cell protease proteins by using ELISA, immunohistochemistry, and immunofluorescence. Results: Tryptase mRNA was significantly increased in nasal polyps (NPs) from patients with CRSwNP (P < .001) compared with uncinate tissue from patients with CRS or control subjects. Tryptase protein was also elevated in NPs and in nasal lavage fluids from patients with CRSwNP. Immnohistochemistry showed increased numbers of mast cells in epithelium and glands but not within the lamina propria in NPs. The mast cells detected in the epithelium in NPs were characterized by the expression of tryptase and carboxypeptidase A3 but not chymase. Mast cells expressing all the 3 proteases were abundant within the glandular epithelium of NPs but were not found in normal glandular structures. Conclusions: Herein we demonstrated a unique localization of mast cells within the glandular epithelium of NPs and showed that mast cells in NPs have distinct phenotypes that vary by tissue location. Glandular mast cells and the diverse subsets of mast cells detected may contribute to the pathogenesis of CRSwNP. (J Allergy Clin Immunol 2012;130:410-20.)	[Takabayashi, Tetsuji; Kato, Atsushi; Peters, Anju T.; Suh, Lydia A.; Carter, Roderick; Norton, James; Grammer, Leslie C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA; [Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA; [Takabayashi, Tetsuji; Fujieda, Shigeharu] Univ Fukui, Div Otorhinolaryngol Head & Neck Surg, Dept Sensory & Locomotor Med, Fukui 910, Japan	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Fukui	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, 240 E Huron, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu		Chandra, Rakesh/0000-0002-3612-0026; Kato, Atsushi/0000-0001-9144-3138; Grammer, Leslie/0000-0001-6860-2014	National Institutes of Health [R37HL068546-27, R01HL078860, RO1AI072570]; Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by National Institutes of Health grants R37HL068546-27, R01HL078860, and RO1AI072570 and the Ernest S. Bazley Trust.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Ali MS, 2005, ACTA OTO-LARYNGOL, V125, P618, DOI 10.1080/00016480510027538; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Beaven MA, 2009, EUR J IMMUNOL, V39, P11, DOI 10.1002/eji.200838899; Blatman KSH, 2011, J ALLERGY CLIN IMMUN, V127, P1307, DOI 10.1016/j.jaci.2010.12.1118; Boyce JA, 2007, IMMUNOL REV, V217, P168, DOI 10.1111/j.1600-065X.2007.00512.x; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Choi YH, 2011, J BIOL CHEM, V286, P34199, DOI 10.1074/jbc.M111.247684; Di Lorenzo G, 2001, INT ARCH ALLERGY IMM, V125, P164, DOI 10.1159/000053811; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Ediger D, 2005, CLIN EXP ALLERGY, V35, P319, DOI 10.1111/j.1365-2222.2005.02194.x; ENERBACK L, 1989, INT ARCH ALLER A IMM, V88, P209, DOI 10.1159/000234788; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80, DOI 10.1164/ajrccm/148.1.80; Hamilos Daniel L, 2007, Clin Allergy Immunol, V20, P1; Hsieh FH, 2005, P NATL ACAD SCI USA, V102, P14380, DOI 10.1073/pnas.0503948102; Hunter DD, 1998, NEUROSCIENCE, V83, P591, DOI 10.1016/S0306-4522(97)00324-2; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kowalski ML, 2005, ALLERGY, V60, P631, DOI 10.1111/j.1398-9995.2005.00753.x; Kowalski ML, 2002, ALLERGY, V57, P493, DOI 10.1034/j.1398-9995.2002.13508.x; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; Maintz L, 2011, ALLERGY, V66, P862, DOI 10.1111/j.1398-9995.2011.02550.x; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; NADEL JA, 1991, RESPIRATION, V58, P3; Otsuka H, 1998, J ALLERGY CLIN IMMUN, V102, P757, DOI 10.1016/S0091-6749(98)70015-6; Patou J, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-11; Pawankar R, 2005, CHEM IMMUNOL ALLERGY, V87, P111, DOI 10.1159/000087639; Perez-Novo CA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-75; Piliponsky AM, 2002, MOL IMMUNOL, V38, P1369, DOI 10.1016/S0161-5890(02)00090-1; Polzehl D, 2006, ALLERGY, V61, P1275, DOI 10.1111/j.1398-9995.2006.01132.x; Price KS, 2003, AM J RESP CELL MOL, V28, P420, DOI 10.1165/rcmb.2002-0155OC; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Schwartz Lawrence B, 2006, Methods Mol Biol, V315, P53; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; Tancowny BP, 2010, IMMUNOLOGY, V131, P220, DOI 10.1111/j.1365-2567.2010.03296.x; TOS M, 1977, ARCH OTOLARYNGOL, V103, P407; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Verbruggen K, 2009, INT ARCH ALLERGY IMM, V148, P87, DOI 10.1159/000155739; Weller CL, 2005, J EXP MED, V201, P1961, DOI 10.1084/jem.20042407; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	48	96	96	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					410	+		10.1016/j.jaci.2012.02.046	http://dx.doi.org/10.1016/j.jaci.2012.02.046			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22534535	Green Accepted			2022-12-18	WOS:000307002200022
J	Caubet, JC; Bencharitiwong, R; Moshier, E; Godbold, JH; Sampson, HA; Nowak-Wegrzyn, A				Caubet, Jean Christoph; Bencharitiwong, Ramon; Moshier, Erin; Godbold, James H.; Sampson, Hugh A.; Nowak-Wegrzyn, Anna			Significance of ovomucoid- and ovalbumin-specific IgE/IgG(4) ratios in egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg; egg white; ovalbumin; ovomucoid; egg allergy; food allergy; children; hypersensitivity; IgE; IgG(4); IgE/IgG(4) ratio	IMMUNOLOGICAL CHANGES; ORAL IMMUNOTHERAPY; ATOPIC-DERMATITIS; IMMUNOGLOBULIN-G; IGG4 ANTIBODIES; IGE ANTIBODIES; MILK-PROTEINS; FOOD ALLERGY; COWS MILK; CHILDREN	Background: The role of specific IgG(4) antibodies in natural tolerance acquisition remains a matter of debate; the specific IgE/IgG(4) ratio might add value to the measurement of absolute amounts of IgE for assessing the ongoing status of egg reactivity. Objective: We sought to determine the significance of IgG(4) antibodies to ovalbumin (OVA) and ovomucoid (OVM) in egg-allergic children. Methods: One hundred seven egg-allergic children (mean age 6.9 years; range 1.6-18.6 years) were challenged to baked egg. The outcomes of the challenges were related to the level of specific IgE and IgG(4) to OVM and OVA, component IgE/IgG(4) ratios, and mediator release in a functional assay based on the rat basophil leukemia cell line. Results: Baked egg-reactive children had significantly higher OVA and OVM ratios of IgE/IgG(4) and mediator release in the rat basophil leukemia-based assay than did tolerant children (P < .05 for both). The OVA- and OVM-specific IgE/IgG(4) ratios and mediator release were correlated. In the receiver operating characteristic analysis, the areas under the curve for a logistic regression model including specific IgE and IgG(4) to OVA and OVM were significantly greater compared with the areas under the curve for egg white-specific IgE and OVM-specific IgE. Conclusions: The balance between IgE and IgG(4) to OVA and OVM has functional consequences. A model that includes the interactions between IgE and IgG(4) to OVA and OVM accurately predicts reactivity to baked egg and warrants further investigation. (J Allergy Clin Immunol 2012; 129: 739-47.)	[Caubet, Jean Christoph; Bencharitiwong, Ramon; Moshier, Erin; Godbold, James H.; Sampson, Hugh A.; Nowak-Wegrzyn, Anna] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY 10028 USA	Icahn School of Medicine at Mount Sinai	Nowak-Wegrzyn, A (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY 10028 USA.	anna.nowak-wegrzyn@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) [AI 059318]; National Center for Research Resources (NCRR) [CTSA ULI RR 029887, RR026134, UL1RR029887]; NIH/NIAID [AI44236, AI066738]; Food Allergy Initiative; National Institute of Allergy and Infectious Diseases-National Institutes of Health; HAL Allergy; Novartis vaccines; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI059318, U19AI066738] Funding Source: NIH RePORTER	National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Initiative; National Institute of Allergy and Infectious Diseases-National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); HAL Allergy(HAL Allergy Group); Novartis vaccines; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	A. N.-W. was supported in part by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) grant no. AI 059318.; The project was supported in part by grant no. CTSA ULI RR 029887 from the National Center for Research Resources (NCRR), a component of the NIH. H. A. S. was funded in part by grants from the NIH/NIAID (grant nos. AI44236 and AI066738) and the NCRR (grant no. RR026134). J. H. G. was supported by award number UL1RR029887 from the NCRR. The article's contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCRR or the NIH.; H. A. Sampson has consultant arrangements with Allertein Therapeutics, LLC; is on the advisory board for Immusan T, receives research support from the Food Allergy Initiative and the National Institute of Allergy and Infectious Diseases-National Institutes of Health, is a consultant/scientific advisor for the Food Allergy Initiative, is a medical advisor for the Food Allergy and Anaphylaxis Network, is a scientific advisor for the University of Nebraska-Food Allergy Research and Resource Program, and is 45% owner of Herb Springs, LLC. A. Nowak Wegrzyn receives royalties from UpToDate, is a Data Safety Materials Board member for a clinical trial for Merck, is on the speakers' bureau for Thermofisher Scientific, and receives research support from HAL Allergy, Novartis vaccines, and the Food Allergy Initiative. The rest of the authors declare that they have no relevant conflicts of interest.	AALBERSE RC, 1983, J IMMUNOL, V130, P722; Ahrens B, 2010, ALLERGY, V65, P1554, DOI 10.1111/j.1398-9995.2010.02429.x; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Ando H, 2008, J ALLERGY CLIN IMMUN, V122, P583, DOI 10.1016/j.jaci.2008.06.016; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Antunez C, 2008, PEDIAT ALLERG IMM-UK, V19, P210, DOI 10.1111/j.1399-3038.2007.00604.x; Benhamou AH, 2010, ALLERGY, V65, P283, DOI 10.1111/j.1398-9995.2009.02251.x; BOCEK P, 1995, EUR J IMMUNOL, V25, P2948, DOI 10.1002/eji.1830251035; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Clark A, 2011, CLIN EXP ALLERGY, V41, P706, DOI 10.1111/j.1365-2222.2011.03697.x; Cooke SK, 1997, J IMMUNOL, V159, P2026; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; GERMANO P, 1993, INT J CLIN LAB RES, V23, P206, DOI 10.1007/BF02592310; HOST A, 1992, ALLERGY, V47, P218, DOI 10.1111/j.1398-9995.1992.tb00654.x; HUSBY S, 1988, APMIS, V96, P1; ISHIZAKA A, 1990, CLIN EXP IMMUNOL, V79, P392; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kemp AS, 2007, PEDIAT ALLERG IMM-UK, V18, P696, DOI 10.1111/j.1399-3038.2007.00679.x; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; Konstantinou GN, 2008, J ALLERGY CLIN IMMUN, V122, P414, DOI 10.1016/j.jaci.2008.05.032; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Loisel S, 2007, CRIT REV ONCOL HEMAT, V62, P34, DOI 10.1016/j.critrevonc.2006.11.010; Nowak-Wegrzyn AH, 2009, J ALLERGY CLIN IMMUN, V123, P949, DOI 10.1016/j.jaci.2009.01.070; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Reimann C, 2008, STAT DATA ANAL EXPLA; Roches AD, 2006, ALLERGY, V61, P900, DOI 10.1111/j.1398-9995.2006.01134.x; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; Ruiter B, 2007, CLIN EXP ALLERGY, V37, P1103, DOI 10.1111/j.1365-2222.2007.02749.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Shek LPC, 2005, ALLERGY, V60, P912, DOI 10.1111/j.1398-9995.2005.00705.x; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Stapel SO, 2008, ALLERGY, V63, P793, DOI 10.1111/j.1398-9995.2008.01705.x; Tay SS, 2007, CLIN EXP ALLERGY, V37, P1512, DOI 10.1111/j.1365-2222.2007.02802.x; Teuber SS, 2007, CURR OPIN ALLERGY CL, V7, P257, DOI 10.1097/ACI.0b013e3281667645; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Tomicic S, 2009, PEDIAT ALLERG IMM-UK, V20, P35, DOI 10.1111/j.1399-3038.2008.00738.x; Uermosi C, 2010, J ALLERGY CLIN IMMUN, V126, P375, DOI 10.1016/j.jaci.2010.05.040; Vance GHS, 2004, CLIN EXP ALLERGY, V34, P1542, DOI 10.1111/j.1365-2222.2004.02058.x; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, P576, DOI 10.1016/j.jaci.2010.12.1116; Vickery BP, 2010, ANN ALLERG ASTHMA IM, V105, P444, DOI 10.1016/j.anai.2010.09.030; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	53	96	99	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					739	747		10.1016/j.jaci.2011.11.053	http://dx.doi.org/10.1016/j.jaci.2011.11.053			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22277199	Bronze			2022-12-18	WOS:000301189300019
J	Matricardi, PM; Kuna, P; Panetta, V; Wahn, U; Narkus, A				Matricardi, Paolo Maria; Kuna, Piotr; Panetta, Valentina; Wahn, Ulrich; Narkus, Annemie			Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-analyses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Seasonal allergic rhinitis; allergen-specific immunotherapy; allergen-specific subcutaneous immunotherapy; nasal corticosteroids; antihistamines; leukotriene antagonists	FUROATE NASAL SPRAY; GRASS-POLLEN IMMUNOTHERAPY; PLACEBO-CONTROLLED TRIAL; SHORT-TERM IMMUNOTHERAPY; MOLECULAR STANDARDIZED GRASS; DOUBLE-BLIND; FOLLOW-UP; HAY-FEVER; PRESEASONAL INJECTIONS; RESPIRATORY ALLERGY	Background: Allergen-specific subcutaneous immunotherapy (SCIT) of seasonal allergic rhinitis (SAR) is usually considered a "second-line," slow-acting, disease-modifying treatment. Objective: We sought to test whether SCIT is as effective as antisymptomatic treatment in the control of symptoms in patients with SAR in the first year of treatment. Methods: We reviewed meta-analyses with 5 or more randomized, double-blind, placebo-controlled trials of SCIT or antisymptomatic treatment in patients with SAR. We then selected trials measuring the total nasal symptom score (TNSS), the total symptom score (TSS), or both during the first pollen season after treatment initiation. Efficacy was determined as the percentage reduction in TSSs and TNSSs obtained with active treatment compared with placebo (relative clinical impact [RCI]) and the standardized mean difference (SMD) of treatment verses placebo (effect size [ES]). Results: The weighted mean RCI of SCIT on TNSSs (-34.7% +/- 6.8%) was higher than those of mometasone (-31.7% +/- 16.7%, P < .00001) and montelukast (-6.3% +/- 3.0%, P < .00001). The weighted mean RCI of SCIT on TSSs (-32.9% +/- 12.7%) was higher than that of desloratadine (-12.0% +/- 5.1%, P < .00001). The overall ES of SCIT in terms of TNSSs (SMD, -0.94; 95% CI, -1.45 to -0.43) was similar to that of mometasone (SMD, -0.47; 95% CI, -0.63 to -0.32; P > .05) and higher than that of montelukast (SMD, -0.24; 95% CI, -0.33 to -0.16; P < .05). The overall ES of SCIT in terms of TSSs (SMD, -0.86; 95% CI, -1.17 to -0.55) was comparable with that of desloratadine (SMD, -1.00; 95% CI, -1.68 to -0.32; P > .05). Conclusions: Our data provide indirect but consistent evidence that SCIT is at least as potent as pharmacotherapy in controlling the symptoms of SAR as early as the first season of treatment. (J Allergy Clin Immunol 2011;128:791-9.)	[Matricardi, Paolo Maria; Panetta, Valentina; Wahn, Ulrich] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Kuna, Piotr] Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland; [Narkus, Annemie] Allergopharma Joachim Ganzer KG, Reinbek, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Medical University Lodz; Allergopharma	Matricardi, PM (corresponding author), Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	paolo.matricardi@charite.de		Kuna, Piotr/0000-0003-2401-0070	Allergopharma; German Research Foundation; Allergopharma-Nexter	Allergopharma; German Research Foundation(German Research Foundation (DFG)); Allergopharma-Nexter	P. M. Matricardi receives honoraria from Allergopharma and Meda Pharma and receives research support from Allergopharma and the German Research Foundation. P. Kuna has consultant arrangements with ALK-Abello and receives lecture fees from Allergopharma-Nexter. The rest of the authors have declared that they have no conflict of interest.	Balda BR, 1998, ALLERGY, V53, P740; Benninger M, 2010, ANN ALLERG ASTHMA IM, V104, P13, DOI 10.1016/j.anai.2009.11.020; Berkowitz RB, 1999, ALLERGY, V54, P64, DOI 10.1034/j.1398-9995.1999.00713.x; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; Brewczynski PZ, 1999, ALLERGOLOGIE, V22, P411; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; Bruggenjurgen B, 2008, ANN ALLERG ASTHMA IM, V101, P316, DOI 10.1016/S1081-1206(10)60498-X; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Canonica GW, 2007, ALLERGY, V62, P359, DOI 10.1111/j.1398-9995.2006.01277.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Ciprandi G, 2004, CLIN EXP ALLERGY, V34, P958, DOI 10.1111/j.1365-2222.2004.01960.x; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cyr MM, 2005, INT ARCH ALLERGY IMM, V138, P209, DOI 10.1159/000088721; DAMATO G, 1995, CLIN EXP ALLERGY, V25, P149, DOI 10.1111/j.1365-2222.1995.tb01020.x; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Ferrer M, 2005, J INVEST ALLERG CLIN, V15, P283; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Gawchik S, 2003, ANN ALLERG ASTHMA IM, V90, P416, DOI 10.1016/S1081-1206(10)61826-1; Giovannini M, 2005, Eur Ann Allergy Clin Immunol, V37, P69; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Hebert JR, 1996, ALLERGY, V51, P569; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V85, P606, DOI 10.1016/0091-6749(90)90100-I; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kaiser HB, 2007, J ALLERGY CLIN IMMUN, V119, P1430, DOI 10.1016/j.jaci.2007.02.022; Klimek L, 2005, OTOLARYNG HEAD NECK, V133, P538, DOI 10.1016/j.otohns.2005.07.020; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Meltzer EO, 2006, ANN ALLERG ASTHMA IM, V96, P363, DOI 10.1016/S1081-1206(10)61249-5; Meltzer EO, 1998, J ALLERGY CLIN IMMUN, V102, P39, DOI 10.1016/S0091-6749(98)70053-3; Meltzer EO, 2001, CLIN DRUG INVEST, V21, P25, DOI 10.2165/00044011-200121010-00004; Meltzer EO, 1999, J ALLERGY CLIN IMMUN, V104, P107, DOI 10.1016/S0091-6749(99)70121-1; MERINEY DK, 1986, ANN ALLERGY, V56, P34; Mirone C, 2004, CLIN EXP ALLERGY, V34, P1408, DOI 10.1111/j.1365-2222.2004.02056.x; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592, DOI 10.1016/S1081-1206(10)61891-1; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; Penagos M, 2008, ALLERGY, V63, P1280, DOI 10.1111/j.1398-9995.2008.01808.x; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743; Ratner P, 2005, INT ARCH ALLERGY IMM, V138, P312, DOI 10.1159/000088869; Ratner PH, 2006, J ALLERGY CLIN IMMUN, V118, P1142, DOI 10.1016/j.jaci.2006.07.050; Rodrigo GJ, 2006, ANN ALLERG ASTHMA IM, V96, P779, DOI 10.1016/S1081-1206(10)61339-7; Stuck BA, 2003, ALLERGY, V58, P1195, DOI 10.1034/j.1398-9995.2003.00162.x; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; van Adelsberg J, 2003, ANN ALLERG ASTHMA IM, V90, P214, DOI 10.1016/S1081-1206(10)62144-8; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Wahn U, 2003, J ALLERGY CLIN IMMUN, V111, P763, DOI 10.1067/mai.2003.1384; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson AM, 2002, CLIN EXP ALLERGY, V32, P1504, DOI 10.1046/j.1365-2745.2002.01509.x; Zenner HP, 1997, J ALLERGY CLIN IMMUN, V100, P23, DOI 10.1016/S0091-6749(97)70190-8	59	96	97	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					791	U473		10.1016/j.jaci.2011.03.049	http://dx.doi.org/10.1016/j.jaci.2011.03.049			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21620452				2022-12-18	WOS:000296538100015
J	Ushio, H; Ueno, T; Kojima, Y; Komatsu, M; Tanaka, S; Yamamoto, A; Ichimura, Y; Ezaki, J; Nishida, K; Komazawa-Sakon, S; Niyonsaba, F; Ishii, T; Yanagawa, T; Kominami, E; Ogawa, H; Okumura, K; Nakano, H				Ushio, Hiroko; Ueno, Takashi; Kojima, Yuko; Komatsu, Masaaki; Tanaka, Satoshi; Yamamoto, Akitsugu; Ichimura, Yoshinobu; Ezaki, Junji; Nishida, Keigo; Komazawa-Sakon, Sachiko; Niyonsaba, Francois; Ishii, Tetsuro; Yanagawa, Toru; Kominami, Eiki; Ogawa, Hideoki; Okumura, Ko; Nakano, Hiroyasu			Crucial role for autophagy in degranulation of mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; autophagy; CD63; degranulation; p62; light chain 3 (LC3)	UNCONVENTIONAL SECRETION; EXOCYTOSIS; PROTEIN; IMMUNE; RESPONSES; EFFECTOR; DISEASE; ACB1; P62	Background: Autophagy plays a crucial role in controlling various biological responses including starvation, homeostatic turnover of long-lived proteins, and invasion of bacteria. However, a role for autophagy in development and/or function of mast cells is unknown. Objective: To investigate a role for autophagy in mast cells, we generated bone marrow-derived mast cells (BMMCs) from mice lacking autophagy related gene (Atg) 7, an essential enzyme for autophagy induction. Methods: Bone marrow-derived mast cells were generated from bone marrow cells of control and IFN-inducible Atg7-deficient mice, and morphologic and functional analyses were performed. Results: We found that conversion of type I to type II light chain (LC3)-II, a hallmark of autophagy, was constitutively induced in mast cells under full nutrient conditions, and LC3-II localized in secretory granules of mast cells. Although deletion of Atg7 did not impair the development of BMMCs, Atg7(-/-) BMMCs showed severe impairment of degranulation, but not cytokine production on FceRI cross-linking. Intriguingly, LC3-II but not LC3-I was co-localized with CD63, a secretory lysosomal marker, and was released extracellularly along with degranulation in Atg7(+/+) but not Atg7(-/-) BMMCs. Moreover, passive cutaneous anaphylaxis reactions were severely impaired in mast cell-deficient WBB6F1-W/W-V mice reconstituted with Atg7(-/-) BMMCs compared with Atg7(+/+) BMMCs. Conclusion: These results suggest that autophagy is not essential for the development but plays a crucial role in degranulation of mast cells. Thus, autophagy might be a potential target to treat allergic diseases in which mast cells are critically involved. (J Allergy Clin Immunol 2011;127:1267-76.)	[Ushio, Hiroko; Niyonsaba, Francois; Ogawa, Hideoki; Okumura, Ko] Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Tokyo 1138421, Japan; [Ueno, Takashi; Ezaki, Junji; Kominami, Eiki] Juntendo Univ, Sch Med, Dept Biochem, Tokyo 1138421, Japan; [Kojima, Yuko] Juntendo Univ, Sch Med, Div Biomed Imaging Res, Tokyo 1138421, Japan; [Komazawa-Sakon, Sachiko; Okumura, Ko; Nakano, Hiroyasu] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; [Komatsu, Masaaki; Ichimura, Yoshinobu] Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Tokyo, Japan; [Komatsu, Masaaki] Japan Sci & Technol Corp, PREST, Kawaguchi, Saitama, Japan; [Tanaka, Satoshi] Okayama Univ, Dept Immunochem, Div Pharmaceut Sci, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan; [Yamamoto, Akitsugu] Nagahama Inst Biosci & Technol, Dept Cell Biol, Fac Biosci, Nagahama, Japan; [Nishida, Keigo] RIKEN Res Ctr Allergy & Immunol, Lab Cytokine Signaling, Yokohama, Kanagawa, Japan; [Ishii, Tetsuro; Yanagawa, Toru] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 305, Japan	Juntendo University; Juntendo University; Juntendo University; Juntendo University; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); Okayama University; RIKEN; University of Tsukuba	Ushio, H (corresponding author), Juntendo Univ, Sch Med, Atopy Res Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	hushio@juntendo.ac.jp; hnakano@juntendo.ac.jp	Yanagawa, Toru/GYU-6448-2022; TANAKA, Satoshi/B-1624-2011; Komatsu, Masaaki/B-8321-2011; Tanaka, Satoshi/H-6800-2019; Ushio, Hiroko/K-5718-2013	Yanagawa, Toru/0000-0003-0868-2563; TANAKA, Satoshi/0000-0002-3468-7694; Komatsu, Masaaki/0000-0001-7672-7722; Tanaka, Satoshi/0000-0002-3468-7694; Nakano, Hiroyasu/0000-0003-4843-1427; Komazawa-Sakon, Sachiko/0000-0002-6244-1974	Ministry of Education, Culture, Sports, Science and Technology, Japan; Japan Society for the Promotion of Science; Promotion and Mutual Aid Corporation for Private Schools of Japan; MEXT, Japan; Takeda Science Foundation; Astellas Foundation for Research on Metabolic Disorders; Grants-in-Aid for Scientific Research [23659404] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Promotion and Mutual Aid Corporation for Private Schools of Japan(Promotion and Mutual Aid Corporation for Private Schools of Japan); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Astellas Foundation for Research on Metabolic Disorders; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by grants-in-aid for the "High-Tech Research Center'' Project for Private Universities; a matching fund subsidy from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and Scientific Research (B) and (C) from the Japan Society for the Promotion of Science; the Science Research Promotion Fund from the Promotion and Mutual Aid Corporation for Private Schools of Japan; Scientific Research on Innovative Areas; MEXT, Japan; the Takeda Science Foundation; and the Astellas Foundation for Research on Metabolic Disorders.	Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Cadwell K, 2009, CURR TOP MICROBIOL, V335, P141, DOI 10.1007/978-3-642-00302-8_7; Duran JM, 2010, J CELL BIOL, V188, P527, DOI 10.1083/jcb.200911154; Dvorak AM, 2005, J HISTOCHEM CYTOCHEM, V53, P1043, DOI 10.1369/jhc.5R6647.2005; Ebato C, 2008, CELL METAB, V8, P325, DOI 10.1016/j.cmet.2008.08.009; Fader CM, 2009, CELL DEATH DIFFER, V16, P70, DOI 10.1038/cdd.2008.168; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Jung HS, 2008, CELL METAB, V8, P318, DOI 10.1016/j.cmet.2008.08.013; Kamijo S, 2009, J IMMUNOL, V183, P6087, DOI 10.4049/jimmunol.0901039; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Logan MR, 2003, J ALLERGY CLIN IMMUN, V111, P923, DOI 10.1067/mai.2003.1573; Malaviya R, 2001, IMMUNOL REV, V179, P16, DOI 10.1034/j.1600-065X.2001.790102.x; Manjithaya R, 2010, J CELL BIOL, V188, P537, DOI 10.1083/jcb.200911149; Menager MM, 2007, NAT IMMUNOL, V8, P257, DOI 10.1038/ni1431; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Miyoshi Hiroyuki, 2004, Methods Mol Biol, V246, P429; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617; Nishida K, 2005, J CELL BIOL, V170, P115, DOI 10.1083/jcb.200501111; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Puri N, 2008, P NATL ACAD SCI USA, V105, P2580, DOI 10.1073/pnas.0707854105; Stappenbeck TS, 2010, MUCOSAL IMMUNOL, V3, P8, DOI 10.1038/mi.2009.121; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Supajatura V, 2001, J IMMUNOL, V167, P2250, DOI 10.4049/jimmunol.167.4.2250; Tiwari N, 2008, BLOOD, V111, P3665, DOI 10.1182/blood-2007-07-103309	34	96	100	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1267	U282		10.1016/j.jaci.2010.12.1078	http://dx.doi.org/10.1016/j.jaci.2010.12.1078			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21333342				2022-12-18	WOS:000290018600023
J	Zimmermann, M; Koreck, A; Meyer, N; Basinski, T; Meiler, F; Simone, B; Woehrl, S; Moritz, K; Eiwegger, T; Schmid-Grendelmeier, P; Kemeny, L; Akdis, CA				Zimmermann, Maya; Koreck, Andrea; Meyer, Norbert; Basinski, Tomasz; Meiler, Flurina; Simone, Burgler; Woehrl, Stefan; Moritz, Katharina; Eiwegger, Thomas; Schmid-Grendelmeier, Peter; Kemeny, Lajos; Akdis, Cezmi A.			TNF-like weak inducer of apoptosis (TWEAK) and TNF-alpha cooperate in the induction of keratinocyte apoptosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human primary keratinocytes; eczema formation; atopic dermatitis; psoriasis; TNF-alpha; TNF-like weak inducer of apoptosis; TNF receptors; Fn14; apoptosis	TRAIL-INDUCED APOPTOSIS; SENSITIZE TUMOR-CELLS; FUNCTIONAL EXPRESSION; ADENOCARCINOMA CELLS; MULTIPLE PATHWAYS; ATOPIC-DERMATITIS; NECROSIS; RECEPTOR; DEATH; INHIBITION	Background: Activation of skin keratinocytes followed by their apoptotic death leads to eczema and spongiosis formations in patients with atopic dermatitis (AD). TNF-like weak inducer of apoptosis (TWEAK) binds to its receptor, fibroblast growth factor-inducible 14 (Fn14), and controls many cellular activities, including proliferation, migration, differentiation, apoptosis, angiogenesis, and inflammation. Objective: The aim of the study was to investigate the role of TWEAK and Fn14 in the formation of eczema in patients with AD. Methods: Primary keratinocytes were isolated from nonlesional skin from patients with AD and psoriasis and from normal skin of healthy donors. Apoptosis analysis was performed by using annexin V/7-aminoactinomycin D and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling staining. The expression and regulation of TWEAK, TNF-alpha, Fn14, TNF receptor (TNFR) 1, and TNFR2 were measured by means of RT-PCR, flow cytometric analysis, and ELISA. TWEAK and Fn14 expression of lesional AD and psoriatic skin and normal control skin was analyzed by using immunohistochemistry and immunofluorescence. Results: TWEAK and TNF-alpha cooperate in the induction of apoptosis in primary keratinocytes obtained from patients with AD, patients with psoriasis, and healthy subjects and in artificial skin equivalents. TNFR1 and Fn14 were the main receptors involved. TWEAK upregulates TNF-alpha expression in primary keratinocytes, whereas TNF-alpha did not affect the expression of TWEAK and its receptors. High TWEAK expression was observed in AD lesions but not in psoriatic lesions or normal skin. Fn14 was highly expressed in the lesional skin of patients with AD and patients with psoriasis and in healthy control skin. Conclusion: The high expression of TWEAK in lesional AD skin contributes to the difference in keratinocyte apoptosis and lesional formation between AD and psoriasis. (J Allergy Clin Immunol 2011;127:200-7.)	[Zimmermann, Maya; Meyer, Norbert; Basinski, Tomasz; Meiler, Flurina; Simone, Burgler; Eiwegger, Thomas; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland; [Koreck, Andrea; Kemeny, Lajos] Univ Szeged, Dept Dermatol & Allergol, Szeged, Hungary; [Kemeny, Lajos] Hungarian Acad Sci, Dermatol Res Grp, Szeged, Hungary; [Woehrl, Stefan; Moritz, Katharina] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Eiwegger, Thomas] Med Univ Vienna, Dept Pediat, Vienna, Austria; [Schmid-Grendelmeier, Peter] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; [Basinski, Tomasz] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Szeged University; Hungarian Academy of Sciences; Medical University of Vienna; Medical University of Vienna; University of Zurich; University Zurich Hospital; Wroclaw Medical University	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; Kemeny, Lajos/ABF-1339-2021; Wöhrl, Stefan/B-6954-2013	Akdis, Cezmi/0000-0001-8020-019X; Kemeny, Lajos/0000-0002-2119-9501; Wöhrl, Stefan/0000-0002-6324-0007; Eiwegger, Thomas/0000-0002-2914-7829	Swiss National Science Foundation [32118226]; Global Allergy Asthma European Network (GA2LEN); Christine Kuhne Center for Allergy Research and Education (CK-CARE); OTKA [NK77434, TAMOP 4.2.2-08/1]; Novartis; Swiss National Science Foundation; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research; Stallergenes	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Global Allergy Asthma European Network (GA2LEN); Christine Kuhne Center for Allergy Research and Education (CK-CARE); OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Novartis(Novartis); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research; Stallergenes	The authors' laboratory is supported by Swiss National Science Foundation grant 32118226, the Global Allergy Asthma European Network (GA2LEN), the Christine Kuhne Center for Allergy Research and Education (CK-CARE), and the OTKA NK77434 and TAMOP 4.2.2-08/1 grants.; C. A. Akdis receives research support from Novartis, Stallergenes, the Swiss National Science Foundation, the Global Allergy and Asthma European Network, and the Christine Kuhne Center for Allergy Research; is a fellow and interest group member of the American Academy of Allergy, Asthma & Immunology; is vice president of the European Academy of Allergy and Clinical Immunology; and is an ex-committee member WP leader for GA2LEN. The rest of the authors have declared that they have no conflict of interest.	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Basinski TM, 2009, J ALLERGY CLIN IMMUN, V124, P74, DOI 10.1016/j.jaci.2009.04.019; Bover LC, 2007, J IMMUNOL, V178, P8183, DOI 10.4049/jimmunol.178.12.8183; Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017; Burkly LC, 2007, CYTOKINE, V40, P1, DOI 10.1016/j.cyto.2007.09.007; Chacon MR, 2006, CYTOKINE, V33, P129, DOI 10.1016/j.cyto.2005.12.005; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Diessenbacher P, 2008, J INVEST DERMATOL, V128, P1134, DOI 10.1038/sj.jid.5701141; Fulda S, 2000, CANCER RES, V60, P3947; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Ho DH, 2004, CANCER RES, V64, P8968, DOI 10.1158/0008-5472.CAN-04-1879; Jin L, 2004, J INVEST DERMATOL, V122, P1175, DOI 10.1111/j.0022-202X.2004.22419.x; Kawakita T, 2005, INT J ONCOL, V26, P87; Kawakita T, 2004, BIOCHEM BIOPH RES CO, V318, P726, DOI 10.1016/j.bbrc.2004.04.084; Klunker S, 2003, J IMMUNOL, V171, P1078, DOI 10.4049/jimmunol.171.2.1078; Kralisch S, 2008, ATHEROSCLEROSIS, V199, P440, DOI 10.1016/j.atherosclerosis.2007.10.022; KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354; Krueger G, 2005, J AM ACAD DERMATOL, V53, pS94, DOI 10.1016/j.jaad.2005.04.035; Leverkus M, 2000, CANCER RES, V60, P553; Meyer N, 2010, J ALLERGY CLIN IMMUN, V125, P858, DOI 10.1016/j.jaci.2010.01.016; Nagasawa M, 2008, AM J HEMATOL, V83, P222, DOI 10.1002/ajh.21082; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373; Park MC, 2008, SCAND J RHEUMATOL, V37, P173, DOI 10.1080/03009740801898608; Perper SJ, 2006, J IMMUNOL, V177, P2610, DOI 10.4049/jimmunol.177.4.2610; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; TREFZER U, 1991, J INVEST DERMATOL, V97, P911, DOI 10.1111/1523-1747.ep12491668; Vince JE, 2008, J CELL BIOL, V182, P171, DOI 10.1083/jcb.200801010; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wicovsky A, 2009, CELL DEATH DIFFER, V16, P1445, DOI 10.1038/cdd.2009.80; Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107; Yanaba K, 2009, J RHEUMATOL, V36, P1657, DOI 10.3899/jrheum.081310; Yilmaz MI, 2009, CLIN J AM SOC NEPHRO, V4, P1716, DOI 10.2215/CJN.02760409	38	96	104	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					200	U324		10.1016/j.jaci.2010.11.005	http://dx.doi.org/10.1016/j.jaci.2010.11.005			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211655				2022-12-18	WOS:000285917300029
J	Melen, E; Himes, BE; Brehm, JM; Boutaoui, N; Klanderman, BJ; Sylvia, JS; Lasky-Su, J				Melen, Erik; Himes, Blanca E.; Brehm, John M.; Boutaoui, Nadia; Klanderman, Barbara J.; Sylvia, Jody S.; Lasky-Su, Jessica			Analyses of shared genetic factors between asthma and obesity in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Association; asthma; body mass index; children; genetics; genome-wide association study; obesity; polymorphism; single nucleotide polymorphism	GENOME-WIDE ASSOCIATION; BODY-MASS INDEX; MANAGEMENT PROGRAM CAMP; CHILDHOOD ASTHMA; INSULIN-RESISTANCE; SEQUENCE VARIANTS; FTO GENE; RISK; POPULATION; POLYMORPHISMS	Background: Epidemiologic studies consistently show associations between asthma and obesity. Shared genetics might account for this association. Objective: We sought to identify genetic variants associated with both asthma and obesity. Methods: On the basis of a literature search, we identified genes from (1) genome-wide association studies (GWASs) of body mass index (BMI; n = 17 genes), (2) GWASs of asthma (n = 14), and (3) candidate gene studies of BMI and asthma (n = 7). We used GWAS data from the Childhood Asthma Management Program to analyze associations between single nucleotide polymorphisms (SNPs) in these genes and asthma (n = 359 subjects) and BMI (n = 537). Results: One top BMI GWAS SNP from the literature, rs10938397 near glucosamine-6-phosphate deaminase 2 (GNPDA2), was associated with both BMI (P = 4 x 10(-4)) and asthma (P = .03). Of the top asthma GWAS SNPs and the candidate gene SNPs, none was found to be associated with both BMI and asthma. Gene-based analyses that included all available SNPs in each gene found associations (P < .05) with both phenotypes for several genes: neuronal growth regulator 1 (NEGR1); roundabout, axon guidance receptor, homolog 1 (ROBO1); diacylglycerol kinase, gamma (DGKG); Fas apoptotic inhibitory molecule 2 (FAIM2); fat mass and obesity associated (FTO); and carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 (CHST8) among the BMI GWAS genes; interleukin 1 receptor-like 1/interleukin 18 receptor 1 (IL1RL1/IL18R1), dipeptidyl-peptidase 10 (DPP10), phosphodiesterase 4D (PDE4D), V-myb myeloblastosis viral oncogene homolog (MYB), PDE10A, IL33, and especially protein tyrosine phosphatase, receptor type D (PTPRD) among the asthma GWAS genes; and protein kinase C, alpha (PRKCA) among the BMI and asthma candidate genes. Conclusions: SNPs within several genes showed associations to BMI and asthma at a genetic level, but none of these associations were significant after correction for multiple testing. Our analysis of known candidate genes reveals some evidence for shared genetics between asthma and obesity, but other shared genetic determinants are likely to be identified in novel loci. (J Allergy Clin Immunol 2010;126:631-7.)	[Melen, Erik; Himes, Blanca E.; Brehm, John M.; Boutaoui, Nadia; Klanderman, Barbara J.; Sylvia, Jody S.; Lasky-Su, Jessica] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; [Melen, Erik; Himes, Blanca E.; Brehm, John M.; Boutaoui, Nadia; Klanderman, Barbara J.; Sylvia, Jody S.; Lasky-Su, Jessica] Brigham & Womens Hosp, Boston, MA 02115 USA; [Melen, Erik] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Himes, Blanca E.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA USA; [Himes, Blanca E.] Childrens Hosp, Informat Program, Boston, MA 02115 USA; [Himes, Blanca E.] Partners Ctr Personalized Genet Med, Boston, MA USA; [Brehm, John M.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Harvard University; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital	Melen, E (corresponding author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	erik.melen@ki.se			National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health [U01 HL075419, U01 HL065899, P01 HL083069, R01 HL086601, T32 HL07427]; Asthma Clinical Research Network (ACRN), NHLBI [U01 HL51510, U01 HL51834, U01 HL51831, U01 HL51845, U01 HL51843, M01 RR00079, M01 RR03186]; National Library of Medicine [T15 LM007092];  [KHL096840A]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186, M01RR000079] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427, R00HL096840, K12HL089990, P01HL083069, K99HL096840, R01HL086601, U01HL065899, U01HL075419] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007092] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Asthma Clinical Research Network (ACRN), NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Supported by the KHL096840A awarded to J. L. S. In addition, the Childhood Asthma Management Program Genetic Ancillary Study is supported by grants U01 HL075419, U01 HL065899, P01 HL083069, R01 HL086601, and T32 HL07427 from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health. We also acknowledge the Asthma Clinical Research Network (ACRN) investigators and research teams supported by grants U01 HL51510, U01 HL51834, U01 HL51831, U01 HL51845, U01 HL51843, M01 RR00079, and M01 RR03186 from the NHLBI. E. M. is supported by a post doc grant from the Swedish Heart Lung Foundation, the Swedish Fulbright Commission and Riksbankens Jubileumsfond, the Erik R_ onnberg's scholarship for research on early childhood diseases. B. E. H. is supported by a National Library of Medicine training grant (T15 LM007092).	Castro-Giner F, 2009, EUR RESPIR J, V33, P1003, DOI 10.1183/09031936.00140608; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Fox CS, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S18; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Ge DL, 2008, GENOME RES, V18, P640, DOI 10.1101/gr.071571.107; Gloria-Bottini F, 2007, INT J OBESITY, V31, P392, DOI 10.1038/sj.ijo.0803396; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Herbert A, 2006, SCIENCE, V312, P279, DOI 10.1126/science.1124779; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hindorff LA, CATALOG PUBLISHED GE; Kim TH, 2008, CLIN EXP ALLERGY, V38, P1727, DOI 10.1111/j.1365-2222.2008.03082.x; Koren S, 2007, BEST PRACT RES CL EN, V21, P621, DOI 10.1016/j.beem.2007.08.004; Lasky-Su J, 2008, AM J HUM GENET, V82, P849, DOI 10.1016/j.ajhg.2008.01.018; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Liu YG, 2005, INT ARCH ALLERGY IMM, V137, P263, DOI 10.1159/000086340; Liu YJ, 2008, HUM MOL GENET, V17, P1803, DOI 10.1093/hmg/ddn072; Loos RJF, 2008, NAT GENET, V40, P768, DOI 10.1038/ng.140; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, pe4; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Matricardi PM, 2007, CLIN EXP ALLERGY, V37, P476, DOI 10.1111/j.1365-2222.2007.02664.x; Miscio G, 2004, J MOL MED, V82, P459, DOI 10.1007/s00109-004-0544-1; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Murphy A, 2009, AM J HUM GENET, V85, P87, DOI 10.1016/j.ajhg.2009.06.011; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rankinen T, 2006, OBESITY, V14, P529, DOI 10.1038/oby.2006.71; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Scholtens S, 2010, INT J OBESITY, V34, P606, DOI 10.1038/ijo.2009.194; Scuteri A, 2007, PLOS GENET, V3, P1200, DOI 10.1371/journal.pgen.0030115; Shyur SD, 2008, EUR J HUM GENET, V16, P1283, DOI 10.1038/ejhg.2008.79; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Szczepankiewicz A, 2009, J ASTHMA, V46, P53, DOI 10.1080/02770900802460514; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Thomsen SF, 2007, ALLERGY, V62, P1199, DOI 10.1111/j.1398-9995.2007.01480.x; Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287; Zhao JH, 2009, OBESITY, V17, P2254, DOI 10.1038/oby.2009.159	42	96	98	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					631	U43		10.1016/j.jaci.2010.06.030	http://dx.doi.org/10.1016/j.jaci.2010.06.030			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816195	Green Accepted, Green Submitted			2022-12-18	WOS:000281512500033
J	Kajiwara, N; Sasaki, T; Bradding, P; Cruse, G; Sagara, H; Ohmori, K; Saito, H; Ra, C; Okayama, Y				Kajiwara, Naoki; Sasaki, Tomomi; Bradding, Peter; Cruse, Glenn; Sagara, Hironori; Ohmori, Kazumitsu; Saito, Hirohisa; Ra, Chisei; Okayama, Yoshimichi			Activation of human mast cells through the platelet-activating factor receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; histamine; human lung mast cells; human peripheral blood-derived mast cells; human skin mast cells; platelet-activating factor receptor	GENE-EXPRESSION PROFILES; RELEASE; RESPONSES; 1-ACYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; IDENTIFICATION; PROLIFERATION; ANAPHYLAXIS; HISTAMINE; PATHWAYS; TRYPTASE	Background: In human subjects platelet-activating factor (PAF) concentrations are markedly increased in the plasma after anaphylactic reactions, and these correlate strongly with the severity of the response. The mechanism for the systemic spread of mast cell (MC) activation in anaphylaxis is often assumed to relate to the hematogenous spread of allergen, but this is implausible, and amplification mechanisms need to be considered. Objective: We have investigated the ability of PAF to induce human MC degranulation using skin, lung, and peripheral blood (PB) derived cultured MCs and the signaling pathways activated in PB-derived MCs in response to PAF. Methods: The expression of PAF receptor was investigated by means of RT-PCR and Western blot analysis. Cell-signaling pathways in PB-derived MCs in response to PAF were investigated by analyzing the effect of various inhibitors and the silencing of phospholipase C (PLC) mRNA on PAF-mediated histamine release. Results: We show for the first time that PAF induces histamine release from human lung MCs and PB-derived MCs but not skin MCs. Activation of PAF receptor coupled G(alpha i) leads to degranulation through PLC gamma 1 and PLC beta 2 activation in human MCs. PAF-induced degranulation was rapid, being maximal at 5 seconds, and was partially dependent on extracellular Ca2+. Conclusion: Our findings provide a mechanism whereby PAF mediates an amplification loop for MC activation in the generation of anaphylaxis. (J Allergy Clin Immunol 2010;125:1137-45.)	[Okayama, Yoshimichi] Nihon Univ, Grad Sch Med Sci, Div Mol Cell Immunol & Allergol, Adv Med Res Ctr,Itabashi Ku, Tokyo 1738610, Japan; [Bradding, Peter; Cruse, Glenn] Glenfield Gen Hosp, Dept Resp Med, Leicester LE3 9QP, Leics, England; [Sagara, Hironori] Dokkyo Med Univ, Koshigaya Hosp, Dept Resp Med, Saitama, Japan; [Ohmori, Kazumitsu] Nihon Univ, Grad Sch Med Sci, Dept Surg, Tokyo 1738610, Japan; [Saito, Hirohisa] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo, Japan	Nihon University; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Dokkyo Medical University; Nihon University; National Center for Child Health & Development - Japan	Okayama, Y (corresponding author), Nihon Univ, Grad Sch Med Sci, Div Mol Cell Immunol & Allergol, Adv Med Res Ctr,Itabashi Ku, 30-1 Oyaguchikami Machi, Tokyo 1738610, Japan.	yokayama@med.nihon-u.ac.jp	Okayama, Yoshimichi/AAG-4352-2021; Cruse, Glenn/B-4597-2012; Cruse, Glenn/AAZ-1093-2021	Cruse, Glenn/0000-0002-7511-0082; Saito, Hirohisa/0000-0002-6630-8337; Bradding, Peter/0000-0001-8403-0319	Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government [20591195, 20790700]; Nihon University; National Institute of Biomedical Innovation [ID05-24]	Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Nihon University; National Institute of Biomedical Innovation(National Institute of Biomedical Innovation)	Supported in part by Grants-in-Aid for Scientific Research (C) programs of the Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government (project no. 20591195, awarded to Y.O.); a Grant-in-Aid for Young Scientists (B) program of the Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government (project no. 20790700, awarded to N.K.); the Nihon University Joint Research Grant for 2008 (awarded to Y.O.); a grant from the National Institute of Biomedical Innovation (project ID05-24, awarded to H. S. and Y.O.); and the Matching Fund Subsidy for Private Universities from the Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government (awarded to C. R.).	Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Baker JG, 2007, TRENDS PHARMACOL SCI, V28, P374, DOI 10.1016/j.tips.2007.06.011; Bansal G, 2008, J IMMUNOL, V181, P7882, DOI 10.4049/jimmunol.181.11.7882; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; BRADDING P, 1995, J IMMUNOL, V155, P297; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brown SL, 2006, J IMMUNOL, V177, P3242, DOI 10.4049/jimmunol.177.5.3242; CHURCH MK, 1995, ASTHMA RHINITIS, P209; Deo DD, 2004, J BIOL CHEM, V279, P3497, DOI 10.1074/jbc.M304497200; Honda Z, 2002, J BIOCHEM, V131, P773, DOI 10.1093/oxfordjournals.jbchem.a003164; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Jeziorska M, 1997, J PATHOL, V182, P115, DOI 10.1002/(SICI)1096-9896(199705)182:1<115::AID-PATH806>3.0.CO;2-9; Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453; Jiang YF, 2006, J IMMUNOL, V177, P2755, DOI 10.4049/jimmunol.177.5.2755; Karasawa K, 2006, BBA-MOL CELL BIOL L, V1761, P1359, DOI 10.1016/j.bbalip.2006.06.017; Kashiwakura J, 2004, J IMMUNOL, V173, P5247, DOI 10.4049/jimmunol.173.8.5247; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Kim YJ, 2004, MOL CELL BIOL, V24, P9986, DOI 10.1128/MCB.24.22.9986-9999.2004; Kuehn HS, 2007, IMMUNOL LETT, V113, P59, DOI 10.1016/j.imlet.2007.08.007; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Ng SW, 2008, J BIOL CHEM, V283, P31348, DOI 10.1074/jbc.M804942200; Nilsson G, 2000, IMMUNOLOGY, V99, P314, DOI 10.1046/j.1365-2567.2000.00972.x; Okayama Yoshimichi, 2008, Allergol Int, V57, P197, DOI 10.2332/allergolint.R-08-163; Okumura S, 2003, BLOOD, V102, P2547, DOI 10.1182/blood-2002-12-3929; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; Petersen LJ, 1997, J ALLERGY CLIN IMMUN, V99, P640, DOI 10.1016/S0091-6749(97)70026-5; SCHLEIMER RP, 1986, J IMMUNOL, V136, P3006; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SEYFRIED CE, 1992, GENOMICS, V13, P832, DOI 10.1016/0888-7543(92)90162-L; Sugo T, 2006, BIOCHEM BIOPH RES CO, V341, P1078, DOI 10.1016/j.bbrc.2006.01.069; THOMAS G, 1990, CLIN EXP ALLERGY, V20, P377, DOI 10.1111/j.1365-2222.1990.tb02797.x; Tkaczyk C, 2003, J BIOL CHEM, V278, P48474, DOI 10.1074/jbc.M301350200; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; TRIGGIANI M, 1990, J IMMUNOL, V144, P4773; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030	40	96	101	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1137	1145		10.1016/j.jaci.2010.01.056	http://dx.doi.org/10.1016/j.jaci.2010.01.056			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392487				2022-12-18	WOS:000277686700025
J	Pongracic, JA; O'Connor, GT; Muilenberg, ML; Vaughn, B; Gold, DR; Kattan, M; Morgan, WJ; Gruchalla, RS; Smartt, E; Mitchell, HE				Pongracic, Jacqueline A.; O'Connor, George T.; Muilenberg, Michael L.; Vaughn, Ben; Gold, Diane R.; Kattan, Meyer; Morgan, Wayne J.; Gruchalla, Rebecca S.; Smartt, Ernestine; Mitchell, Herman E.			Differential effects of outdoor versus indoor fungal spores on asthma morbidity in inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; inner city; airborne fungi; indoor fungi; outdoor fungi; fungal allergens; children	RESIDENTIAL CHARACTERISTICS; ENVIRONMENTAL INTERVENTION; ASPERGILLUS-FUMIGATUS; RESPIRATORY SYMPTOMS; URBAN COMMUNITIES; HOUSE DUST; 1ST YEAR; F-I; ALLERGENS; EXPOSURE	Background: Although sensitization to fungal allergens is prevalent in inner-city children with asthma, the relationship between fungal exposure and morbidity is poorly understood. Objective: We examined relationships between fungal sensitization, exposure, and asthma morbidity in inner-city children. Methods: Participants were 5 to 11 years old and enrolled in the Inner-City Asthma Study. This report includes the subset of children with at least 1 positive skin test (PST) response to a fungal allergen extract; for these children, indoor and outdoor airborne culturable fungi levels were measured at baseline and throughout the 2-year study. Asthma morbidity measures were collected prospectively. The primary outcome was symptom days per 2 weeks. Results: At baseline, children with a PST response to a fungal allergen extract had significantly more symptom days compared with those without a PST response to any fungal allergen extract (6.3 vs 5.7 days per 2 weeks, P = .04). During the study, increases in total fungal exposure and indoor Penicillium species exposure were associated with increases in symptom days and asthma-related unscheduled visits. Indoor exposures to total fungi and to Penicillium species were associated with significant increases in unscheduled visits, even after controlling for outdoor fungal levels. Adverse effects associated with exposure to a specific fungus were stronger among children with PST responses to that fungal allergen extract compared with those seen in children with negative skin test responses. Conclusion: Outdoor fungal exposure is primarily associated with increased asthma symptoms and increased risk of exacerbations in this population. (J Allergy Clin Immunol 2010;125:593-9.)	[Pongracic, Jacqueline A.] Northwestern Univ, Feinburg Sch Med, Childrens Mem Hosp, Chicago, IL 60611 USA; [O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Muilenberg, Michael L.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA; [Vaughn, Ben; Mitchell, Herman E.] Rho Inc, Chapel Hill, NC USA; [Gold, Diane R.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Kattan, Meyer] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Morgan, Wayne J.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Gruchalla, Rebecca S.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Smartt, Ernestine] NIAID, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Boston University; University of Massachusetts System; University of Massachusetts Amherst; Rho; Harvard University; Brigham & Women's Hospital; Columbia University; University of Arizona; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Pongracic, JA (corresponding author), 2300 Childrens Plaza,60, Chicago, IL 60614 USA.	j-pongracic@northwestern.edu		O'Connor, George/0000-0002-6476-3926	National Institute of Allergy and Infectious Diseases [AI/ES-39769, AI/ES-39900, AI/ES39902, AI/ES-39789, AI/ES-39901, AI/ES-39761, AI/ES-39785, AI/ES-39776]; National Institutes of Environmental Health Sciences; National Institutes of Health, Department of Health and Human Services; National Center for Research Resources, National Institutes of Health, Department of Health and Human Services [M01 RR00533]; National Institute of Allergy and Infectious Diseases and the Food Allergy Project; National Institutes of Health; US Environmental Protection Agency; Novartis; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI039769, U01AI039776, U01AI039761, U01AI039902, U01AI039789, U01AI039785, U01AI039900, U01AI039901] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of Allergy and Infectious Diseases and the Food Allergy Project(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency(United States Environmental Protection Agency); Novartis(Novartis); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI/ES-39769, AI/ES-39900, AI/ES39902, AI/ES-39789, AI/ES-39901, AI/ES-39761, AI/ES-39785, and AI/ES-39776 from the National Institute of Allergy and Infectious Diseases and the National Institutes of Environmental Health Sciences. National Institutes of Health, Department of Health and Human Services, and by grant M01 RR00533 front the National Center for Research Resources, National Institutes of Health, Department of Health and Human Services.; Disclosure of potential conflict of interest: J. A. Pongracic receives research support front the National Institute of Allergy and Infectious Diseases and the Food Allergy Project. G. T. O'Connor is a consultant for Sepracor, Inc, and Pulmatrix, Inc. M. L. Muilenberg receives research support from the National Institutes of Health. B. Vaughn is employed by Rho, Inc. D. R. Gold receives grant support from the National Institutes of Health and the US Environmental Protection Agency. W. J. Morgan is a consultant for the Cystic Fibrosis Foundation and Genentech. Inc, and receives grant support from the National Institutes of Health. R. S. Gruchalla is a consultant for GlaxoSmithKline, receives research support front Novartis, and is on the Board of Directors for ABAI. H. E. Mitchell is employed by Rho, Inc, and receives research support from the National Institute of Allergy and Infectious Diseases and the National Institutes of Environmental Health Sciences. The rest of the authors have declared that they have no conflict of interest.	ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; BEAUMONT F, 1985, ANN ALLERGY, V55, P740; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Cruz P, 2008, MYCOLOGIA, V100, P683, DOI 10.3852/08-022; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633, DOI 10.1164/ajrccm.154.3.8810598; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781, DOI 10.1289/ehp.021100781; Gergen PJ, 2002, J PEDIATR-US, V141, P631, DOI 10.1067/mpd.2002.127510; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; *HLTH COMM DAMP IN, 2004, DAMP IND SPAC HLTH; Hoekstra E.S., 2004, INTRO FOOD AIRBORNE, V7th ed.; HOLST PE, 1983, NEW ZEAL MED J, V96, P718; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38, DOI 10.1080/00039896.1995.9955011; LITTLE SA, 1993, CLIN EXP ALLERGY, V23, P835, DOI 10.1111/j.1365-2222.1993.tb00261.x; McDevitt JJ, 2007, AEROBIOLOGIA, V23, P35, DOI 10.1007/s10453-006-9047-6; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; O'Connor GT, 2004, J ALLERGY CLIN IMMUN, V114, P599, DOI 10.1016/j.jaci.2004.05.064; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Peters JL, 2008, ANN ALLERG ASTHMA IM, V100, P364, DOI 10.1016/S1081-1206(10)60600-X; PLATT SD, 1989, BRIT MED J, V298, P1673, DOI 10.1136/bmj.298.6689.1673; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; SU HJ, 1992, APPL ENVIRON MICROB, V58, P181, DOI 10.1128/AEM.58.1.181-186.1992; Turyk M, 2006, J ASTHMA, V43, P453, DOI 10.1080/02770900600758333; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	37	96	99	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					593	599		10.1016/j.jaci.2009.10.036	http://dx.doi.org/10.1016/j.jaci.2009.10.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20132971	Green Accepted			2022-12-18	WOS:000275883200013
J	Enomoto, Y; Orihara, K; Takamasu, T; Matsuda, A; Gon, Y; Saito, H; Ra, C; Okayama, Y				Enomoto, Yukinori; Orihara, Kanami; Takamasu, Tetsuya; Matsuda, Akio; Gon, Yasuhiro; Saito, Hirohisa; Ra, Chisei; Okayama, Yoshimichi			Tissue remodeling induced by hypersecreted epidermal growth factor and amphiregulin in the airway after an acute asthma attack	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Amphiregulin; bronchial asthma; bronchial epithelial cells; epidermal growth factor; tissue remodeling	BREAST-CANCER CELLS; EPITHELIAL-CELLS; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; MUCIN PRODUCTION; GENE-EXPRESSION; GOBLET CELL; PROLIFERATION; REPAIR; LEUKOTRIENES	Background: Epidermal growth factor receptor ligands, such as epidermal growth factor (EGF) and amphiregulin, may play key roles in tissue remodeling in asthma. However, the kinetics of EGF and amphiregulin secretion in the airway after an acute asthma attack and the effect of prolonged airway exposure to these ligands on airway remodeling are unknown. Objective: To measure the EGF and amphiregulin concentrations in sputa obtained from patients with asthma under various conditions, and to examine the effects of EGF and amphiregulin on the proliferation or differentiation of airway structural cells. Methods: Epidermal growth factor and amphiregulin levels were measured by ELISA in sputum specimens collected from 14 hospitalized children with asthma during an acute asthma attack, 13 stable outpatients with asthma, 8 healthy control children, and 7 children with respiratory tract infections. The effects of EGF and amphiregulin on the proliferation and/or differentiation of normal human bronchial epithelial cells (NHBE), bronchial smooth muscle cells (BSMC), and normal human lung fibroblasts (NHLF) were examined. Results: The sputum levels of EGF were significantly higher for about a week after an acute asthma attack compared with the levels in stable subjects with asthma and control subjects. In contrast, upregulation of amphiregulin in the sputa of patients with asthma was observed only during the acute attack. EGF caused proliferation of NHBE, BSMC, and NHLF, whereas amphiregulin induced proliferation of only NHBE. Prolonged exposure of NHBE to EGF and amphiregulin induced mucous cell metaplasia in an IL-13-independent manner. Conclusion: Acute asthma attacks are associated with hypersecretion of EGF and amphiregulin in the airway. Recurrent acute attacks may aggravate airway remodeling. (J Allergy Clin Immunol 2009;124:913-20.)	[Okayama, Yoshimichi] Nihon Univ, Grad Sch Med Sci, Div Mol Cell Immunol & Allergol, Adv Med Res Ctr,Itabashi Ku, Tokyo 1738610, Japan; [Enomoto, Yukinori] Yokohama City Univ, Dept Environm Immunodermatol, Sch Med, Kanagawa, Japan; [Orihara, Kanami; Matsuda, Akio; Saito, Hirohisa] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo, Japan; [Takamasu, Tetsuya] Kanagawa Childrens Med Ctr, Dept Allergy, Kanagawa, Japan	Nihon University; Yokohama City University; National Center for Child Health & Development - Japan	Okayama, Y (corresponding author), Nihon Univ, Grad Sch Med Sci, Div Mol Cell Immunol & Allergol, Adv Med Res Ctr,Itabashi Ku, 30-1 Oyaguchikami Machi, Tokyo 1738610, Japan.	yokayama@med.nihon-u.ac.jp	Okayama, Yoshimichi/AAG-4352-2021	Saito, Hirohisa/0000-0002-6630-8337; Orihara, Kanami/0000-0002-2652-4529	Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government [18604009, 20591195]; Nihon University Joint Research; National Institute of Biomedical Innovation [ID05-24]	Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Nihon University Joint Research; National Institute of Biomedical Innovation(National Institute of Biomedical Innovation)	Supported in part by Grants-in-Aid for Scientific Research (C) programs of the Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government (project nos. 18604009 and 20591195, awarded to Y.O.), the Nihon University Joint Research Grant for 2008 (awarded to YO), a grant from the National Institute of Biomedical Innovation (project no. ID05-24, awarded to H.S. and Y.O.), and the Matching Fund Subsidy for Private Universities from the Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government (to C.R).	ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; BARROW RE, 1993, LUNG, V171, P335, DOI 10.1007/BF00165699; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035, DOI 10.1164/ajrccm.160.3.9902064; Casalino-Matsuda SM, 2006, AM J RESP CELL MOL, V34, P581, DOI 10.1165/rcmb.2005-0386OC; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Dorscheid DR, 2001, AM J PHYSIOL-LUNG C, V281, pL982, DOI 10.1152/ajplung.2001.281.4.L982; Ediger TL, 2000, J PHARMACOL EXP THER, V294, P1076; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Gilmore JL, 2008, BREAST CANCER RES TR, V110, P493, DOI 10.1007/s10549-007-9748-8; Hamilton LM, 2005, EUR RESPIR J, V25, P978, DOI 10.1183/09031936.05.00098604; Hartl D, 2008, J BIOL CHEM, V283, P33472, DOI 10.1074/jbc.M805574200; Holgate Stephen T, 2008, Allergol Int, V57, P1, DOI 10.2332/allergolint.R-07-154; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; MCDOWELL EM, 1984, VIRCHOWS ARCH B, V45, P197, DOI 10.1007/BF02889865; Ogawa Y, 2006, J ALLERGY CLIN IMMUN, V118, P789, DOI 10.1016/j.jaci.2006.08.009; Okumura S, 2005, J ALLERGY CLIN IMMUN, V115, P272, DOI 10.1016/j.jaci.2004.10.004; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Phipps S, 2004, AM J RESP CELL MOL, V31, P626, DOI 10.1165/rcmb.2004-0193OC; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; Schuger L, 1996, DEVELOPMENT, V122, P1759; Shao MXG, 2005, J IMMUNOL, V175, P4009, DOI 10.4049/jimmunol.175.6.4009; Streicher KL, 2007, MOL CANCER RES, V5, P847, DOI 10.1158/1541-7786.MCR-06-0427; Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399; WILLEY JC, 1985, J CELL PHYSIOL, V124, P207, DOI 10.1002/jcp.1041240206; Willmarth NE, 2006, J BIOL CHEM, V281, P37728, DOI 10.1074/jbc.M606532200; Wilson KJ, 2009, PHARMACOL THERAPEUT, V122, P1, DOI 10.1016/j.pharmthera.2008.11.008; Wolff GS, 2007, BIOL REPROD, V77, P53, DOI 10.1095/biolreprod.106.057984; Yoshisue H, 2007, J ALLERGY CLIN IMMUN, V119, P132, DOI 10.1016/j.jaci.2006.08.028; Zhen GH, 2007, AM J RESP CELL MOL, V36, P244, DOI 10.1165/rcmb.2006-0180OC	33	96	99	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					913	920		10.1016/j.jaci.2009.08.044	http://dx.doi.org/10.1016/j.jaci.2009.08.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895983				2022-12-18	WOS:000272108000006
J	Srivastava, KD; Qu, CF; Zhang, TF; Goldfarb, J; Sampson, HA; Li, XM				Srivastava, Kamal D.; Qu, Chunfeng; Zhang, Tengfei; Goldfarb, Joseph; Sampson, Hugh A.; Li, Xiu-Min			Food Allergy Herbal Formula-2 silences peanut-induced anaphylaxis for a prolonged posttreatment period via IFN-gamma-producing CD8(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; murine model; anaphylaxis; IgE; T(H)2; cytokines; CD8; T cells; traditional Chinese herbal medicine	INTERFERON-GAMMA; IN-VIVO; MURINE MODEL; INHIBIT IGE; IMMUNOTHERAPY; INDUCTION; CHILDREN; RESPONSES; EPIDEMIC; IMMUNITY	Background: Food allergy is a serious and sometimes fatal condition for which there is no cure. We previously reported that Food Allergy Herbal Formula (FAHF)-2) protected peanut-allergic mice against anaphylactic reactions as long as 4 weeks posttherapy. This formula is now in clinical trials in the United States. Objective: We sought to determine whether FAHF-2-mediated protection could be extended long-term and explored the mechanisms underlying its persistent immunomodulatory effects. Methods: Peanut-allergic mice received FAHF-2 daily orally by gavage tier 7 weeks, and then received 7 oral peanut challenges at intervals of 4 to 10 weeks over a period of 36 weeks. For mechanistic studies, some mice received CD4(+) or CD8(+) T-cell-depleting antibodies or IFN-gamma-neutralizing antibodies. Anaphylactic symptoms, body temperatures, and plasma histamine levels were recorded after each challenge, and peanut-specific immunoglobulin levels and cytokine profiles of splenocytes, mesenteric lymph node cells, and purified CD4(+) and CD8(+) T cells were determined. Results: Food Allergy Herbal Formula-2 treatment protected mice from anaphylaxis for more than 36 weeks after discontinuing treatment. Peanut-specific IgE levels were reduced as much as 50%, whereas IgG(2a) levels were increased as much as 60%, and these effects persisted over time. T(H)2 cytokine production by CD4(+) T cells from FAHF-2-treated mice was reduced as much as 75%, whereas CD8(+) T-cell IFN-gamma production was markedly increased by as much as 85% at the final challenge. Neutralization of INF-gamma and depletion of CD8(+) T cells markedly attenuated FAHF-2 efficacy. Conclusions: Food Allergy Herbal Formula-2 provides long-term protection from anaphylaxis by inducing a beneficial shift in allergen-specific immune responses mediated largely by elevated CD8(+) T-cell IFN-gamma production. (J Allergy Clin Immunol 2009;123:443-51.)	[Srivastava, Kamal D.; Qu, Chunfeng; Zhang, Tengfei; Sampson, Hugh A.; Li, Xiu-Min] Mt Sinai Sch Med, Dept Pediat, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Goldfarb, Joseph] Mt Sinai Sch Med, Dept Pharmacol & Syst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Li, XM (corresponding author), Mt Sinai Sch Med, Dept Pediat, Jaffe Food Allergy Inst, 1 Gustuve L Levy Pl, New York, NY 10029 USA.	xin-min.li@mssm.edu	li, xiu/GXV-1745-2022		Food Allergy Initiative and by National Institutes of Health;  [AT001495-01A1]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001495] Funding Source: NIH RePORTER	Food Allergy Initiative and by National Institutes of Health; ; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by the Food Allergy Initiative and by National Institutes of Health grant #AT001495-01A1 awarded to X: M.L.	Arora S, 2006, INFECT IMMUN, V74, P4339, DOI 10.1128/IAI.01989-05; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; HARTY JT, 1992, P NATL ACAD SCI USA, V89, P11612, DOI 10.1073/pnas.89.23.11612; Hauer AC, 1998, CYTOKINE, V10, P627, DOI 10.1006/cyto.1997.0337; Isolauri E, 2004, CLIN EXP ALLERGY, V34, P1007, DOI 10.1111/j.1365-2222.2004.01999.x; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kattan JD, 2008, PHYTOTHER RES, V22, P651, DOI 10.1002/ptr.2357; Kirshenbaum AS, 1998, EXP HEMATOL, V26, P245; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lewkowich IP, 2002, EUR J IMMUNOL, V32, P3536, DOI 10.1002/1521-4141(200212)32:12<3536::AID-IMMU3536>3.0.CO;2-U; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; MacDonald TT, 2000, INFLAMM BOWEL DIS, V6, P116, DOI 10.1097/00054725-200005000-00008; Nagata S, 2000, J IMMUNOL, V165, P5315, DOI 10.4049/jimmunol.165.9.5315; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Netea MG, 2005, EUR J CLIN INVEST, V35, P718, DOI 10.1111/j.1365-2362.2005.01564.x; O'Connell EJ, 2004, ALLERGY, V59, P7, DOI 10.1111/j.1398-9995.2004.00563.x; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Pene J, 2006, J IMMUNOL, V177, P5006, DOI 10.4049/jimmunol.177.8.5006; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Saini SS, 1999, J IMMUNOL, V162, P5624; Salagianni M, 2007, J IMMUNOL, V178, P4771, DOI 10.4049/jimmunol.178.8.4771; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; The State Pharmacopoeia Commission of P.R. China, 2005, PHARM PEOPL REP CHIN; Thomas MJ, 2002, J IMMUNOL, V168, P216, DOI 10.4049/jimmunol.168.1.216; US Food and Drug Administration, 2004, GUID IND BOT DRUG PR; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x; Wells JW, 2007, J ALLERGY CLIN IMMUN, V119, P226, DOI 10.1016/j.jaci.2006.09.004; WILLIAMS RO, 1993, CLIN EXP IMMUNOL, V92, P323, DOI 10.1111/j.1365-2249.1993.tb03399.x	37	96	100	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					443	451		10.1016/j.jaci.2008.12.1107	http://dx.doi.org/10.1016/j.jaci.2008.12.1107			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203662				2022-12-18	WOS:000263495000024
J	De Olano, DG; Alvarez-Twose, I; Esteban-Lopez, MI; Sanchez-Munoz, L; Durana, MDAD; Vega, A; Garcia-Montero, A; Gonzalez-Mancebo, E; Belver, T; Herrero-Gil, MD; Fernandez-Rivas, M; Orfao, A; de la Hoz, B; Castells, MC; Escribano, L				De Olano, David Gonzalez; Alvarez-Twose, Ivan; Esteban-Lopez, Maria I.; Sanchez-Munoz, Laura; Durana, Maria D. Alonso Diaz; Vega, Arantza; Garcia-Montero, Andres; Gonzalez-Mancebo, Eloina; Belver, Teresa; Herrero-Gil, Maria D.; Fernandez-Rivas, Montserrat; Orfao, Alberto; de la Hoz, Belen; Castells, Mariana C.; Escribano, Luis			Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; effectiveness; Hymenoptera; immunotherapy; mastocytosis; safety; skin lesion; tryptase; venom	MAST-CELL DISEASE; URTICARIA PIGMENTOSA; SPANISH NETWORK; SERUM TRYPTASE; BONE-MARROW; STING ANAPHYLAXIS; ALLERGY; CRITERIA; REMA	Background: Anaphylaxis after Hymenoptera sting has been described in patients with mastocytosis. Venom immunotherapy (VIT) is a safe and effective way to treat patients with Hymenoptera anaphylaxis, but few studies have addressed its usefulness in patients with systemic mastocytosis. Objective: To study the effectiveness and safety of VIT in patients with systemic mastocytosis having anaphylaxis after Hymenoptera sting. Methods: A total of 21 mastocytosis patients-4 women (19%) and 17 men (81%) with a median age of 50 years (range, 29-74 years)-with Hymenoptera sting anaphylaxis who were treated with VIT and followed for a median of 52 months (range, 2-250 months) were studied. Results: In 18 of 21 patients-16 of them lacking skin involvement-anaphylaxis was the presenting symptom. Six patients (29%) experienced adverse reactions during VIT, 3 during initiation and 3 during maintenance. Twelve patients (57%) were restung while undergoing VIT; 9 (75%) presented local reactions and 3 (25%) systemic reactions, 1 of which required intubation. The Hymenoptera specific IgE decreased from 4.15 kU/L (range, 0.44-100 kU/L) before immunotherapy to 1.2 kU/L (range, 0.34-69.4 kU/L) after 4 years (P<.003). Conclusion: Venom immunotherapy is effective to treat IgE-mediated Hymenoptera anaphylaxis in patients with mastocytosis. Its use is recommended despite a relatively high risk of adverse reactions during the build-up phase because it provides protection from anaphylaxis in around 3/4 of the patients.	[De Olano, David Gonzalez; Gonzalez-Mancebo, Eloina] Hosp Fuenlabrada, Allergy Unit, Madrid, Spain; [Alvarez-Twose, Ivan; Sanchez-Munoz, Laura; Escribano, Luis] Hosp Virgen Valle, Ctr Estudios Mastocitosis Castilla Mancha, Toledo, Spain; [Esteban-Lopez, Maria I.; Herrero-Gil, Maria D.] Gen Hosp, Dept Allergy, Madrid, Spain; [Durana, Maria D. Alonso Diaz] Fdn Hosp Alcoron, Allergy Unit, Madrid, Spain; [Vega, Arantza] Hosp Guadalajara, Dept Allergy, Guadalajara, Spain; [Garcia-Montero, Andres; Orfao, Alberto] Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, E-37008 Salamanca, Spain; [Belver, Teresa] Hosp La Paz, Dept Allergy, Madrid, Spain; [Fernandez-Rivas, Montserrat] Hosp Clin San Carlos, Dept Allergy, Madrid, Spain; [de la Hoz, Belen] Hosp Ramon & Cajal, Dept Allergy, Madrid, Spain; [Castells, Mariana C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Allergy & Immunol Dept, Cambridge, MA 02138 USA; [De Olano, David Gonzalez; Alvarez-Twose, Ivan; Orfao, Alberto; de la Hoz, Belen; Escribano, Luis] Hosp Virgen Valle, Red Espanola Mastocitosis, Toledo, Spain	Hospital Universitario Fuenlabrada; Complejo Hospitalario de Toledo; Alcorcon Foundation University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Hospital Universitario La Paz; Hospital Clinico San Carlos; Hospital Universitario Ramon y Cajal; Harvard University; Brigham & Women's Hospital; Complejo Hospitalario de Toledo	Escribano, L (corresponding author), Hosp Virgen Valle, Ctr Estudios Mastocitosis Castilla La Mancha, Planta 3, Carretera Cobisa S-N, E-45071 Toledo, Spain.	lescribanom@sescam.jccm.es	2008, Ibsal/A-1268-2012; Orfao, Alberto/B-5801-2017; Montero, Andres/HGA-9093-2022; de la Hoz, Belen/AAA-8067-2019; Garcia-Montero, Andres C/B-6558-2017	de la Hoz, Belen/0000-0002-5127-8702; Garcia-Montero, Andres C/0000-0003-4360-1386; Sanchez-Munoz, Laura/0000-0003-1757-7255; Alvarez-Twose, Ivan/0000-0002-1190-4473				Akin C., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80711-X; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Caruso B, 2007, ALLERGY, V62, P561, DOI 10.1111/j.1398-9995.2007.01353.x; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; Dubois AEJ, 2004, CURR OPIN ALLERGY CL, V4, P291, DOI 10.1097/01.all.0000136756.20701.f8; Eich-Wanger C, 1998, CLIN EXP ALLERGY, V28, P1292, DOI 10.1046/j.1365-2222.1998.00411.x; Elberink JNGO, 1997, J ALLERGY CLIN IMMUN, V99, P153, DOI 10.1016/S0091-6749(97)70314-2; ENGLER RJM, 1994, J ALLERGY CLIN IMMUN, V94, P556, DOI 10.1016/0091-6749(94)90213-5; Escribano L, 1998, BLOOD, V91, P2731, DOI 10.1182/blood.V91.8.2731.2731_2731_2736; Escribano L, 2004, CYTOM PART B-CLIN CY, V58B, P1, DOI 10.1002/cyto.b.10072; ESTEBAN MI, 2004, ALERGOL INMUNOL CLIN, V19, P316; Fernandez FG, 2004, AM J TRANSPLANT, V4, P319, DOI 10.1111/j.1600-6143.2004.00333.x; Florian S, 2005, INT ARCH ALLERGY IMM, V136, P273, DOI 10.1159/000083954; Fricker M, 1997, J ALLERGY CLIN IMMUN, V100, P11, DOI 10.1016/S0091-6749(97)70188-X; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P727, DOI 10.1016/0091-6749(86)90418-5; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; HAMILTON RG, 1993, J ALLERGY CLIN IMMUN, V92, P651, DOI 10.1016/0091-6749(93)90007-3; Horny HP, 1998, AM J SURG PATHOL, V22, P1132, DOI 10.1097/00000478-199809000-00013; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; Kim DC, 2003, ALLERGY ASTHMA PROC, V24, P175; KORS JW, 1993, J INTERN MED, V233, P255, DOI 10.1111/j.1365-2796.1993.tb00984.x; Krishna MT, 2001, LANCET, V357, P1527, DOI 10.1016/S0140-6736(00)04677-8; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; Mosbech H, 2000, ALLERGY, V55, P1005, DOI 10.1034/j.1398-9995.2000.00587.x; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1993, ALLERGY          S14, V48, P36; MULLER UR, 1983, J ALLERGY CLIN IMMUN, V72, P685, DOI 10.1016/0091-6749(83)90630-9; Rueff F, 2006, CURR OPIN ALLERGY CL, V6, P284, DOI 10.1097/01.all.0000235903.10548.63; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; Severino MG, 2006, ALLERGY, V61, P860, DOI 10.1111/j.1398-9995.2006.01077.x; SIERRA E, 2003, SESIONES INTERHOSPIT, P247; Sonneck K, 2007, INT ARCH ALLERGY IMM, V142, P158, DOI 10.1159/000096442; SOTLAR K, 2002, AM J PATHOL, V81, P677; Sperr WR, 2001, LEUKEMIA RES, V25, P529, DOI 10.1016/S0145-2126(01)00041-8; Straumann F, 2000, INT ARCH ALLERGY IMM, V123, P268, DOI 10.1159/000024453; Valent F, 2001, IMMUNOL REV, V179, P74, DOI 10.1034/j.1600-065X.2001.790108.x; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; van Halteren HK, 1997, J ALLERGY CLIN IMMUN, V100, P767, DOI 10.1016/S0091-6749(97)70271-9; Wein M, 1998, J ALLERGY CLIN IMMUN, V101, P432, DOI 10.1016/S0091-6749(98)70263-5	44	96	98	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					519	526		10.1016/j.jaci.2007.11.010	http://dx.doi.org/10.1016/j.jaci.2007.11.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18177694				2022-12-18	WOS:000253337800036
J	Woodfolk, JA				Woodfolk, Judith A.			T-cell responses to allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergens; T(H)1; T(H)2; effector memory T cells; central memory T cells; regulatory T cells; LPS; lipid antigens; immunostimulatory DNA sequences; T-cell epitopes; peptide vaccines	THYMIC STROMAL LYMPHOPOIETIN; HOUSE-DUST MITE; CHEMOKINE RECEPTOR EXPRESSION; FOSTERS IMMUNE PRIVILEGE; MUGWORT POLLEN ALLERGEN; MODIFIED TH2 RESPONSE; AIRWAY INFLAMMATION; ATOPIC-DERMATITIS; DENDRITIC CELLS; IN-VIVO	The allergic response in human beings is engineered by CD4(+) T lymphocytes, which secrete T(H)2 cytokines in response to activation by allergen-derived peptides. Although T(H)2 cells have been well characterized, defining the properties of allergen-specific T cells has proved challenging in human beings because of their low frequency within the T-cell repertoire. However, recent studies have provided insight into the molecular signature of long-lived human memory T(H)2 cells, which are allergen-specific. T-cell responses directed against allergens develop in early life and are heavily influenced by the type and dose of allergen, and possibly coexposure to microbial products. These responses are susceptible to suppression by regulatory T cells. This article highlights recent advances in the characterization of allergen-specific memory T(H)2 cells and discusses the heterogeneous nature of regulatory T cells and possible mechanisms of action. The relevance of T-cell epitope mapping studies to understanding the unique nature of T-cell responses to different allergens, as well as to peptide vaccine development, is reviewed. Experimental techniques and approaches for analyzing allergen-specific T cells and identifying novel T-cell epitopes are described that may lead to new T-cell-based therapies.	Univ Virginia, Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Woodfolk, JA (corresponding author), Univ Virginia, Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070364, R01AI052196] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI-070364, R01 AI-52196] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; Abraham JH, 2005, J ALLERGY CLIN IMMUN, V116, P431, DOI 10.1016/j.jaci.2005.05.015; Adkins B, 2002, J IMMUNOL, V169, P4998, DOI 10.4049/jimmunol.169.9.4998; Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Andrew DP, 2001, J IMMUNOL, V166, P103, DOI 10.4049/jimmunol.166.1.103; Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; Bocek P, 2004, J EXP MED, V199, P1619, DOI 10.1084/jem.20032014; Bohle B, 1998, J IMMUNOL, V160, P2022; Bohle B, 2005, CLIN EXP ALLERGY, V35, P367, DOI 10.1111/j.1365-2222.2005.02180.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Cardona ID, 2006, J ALLERGY CLIN IMMUN, V117, P688, DOI 10.1016/j.jaci.2005.11.037; Chen L, 2006, BIOL BLOOD MARROW TR, V12, P160, DOI 10.1016/j.bbmt.2005.10.027; Cochran JR, 2002, PEDIATR PULM, V34, P267, DOI 10.1002/ppul.10161; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Custovic A, 2001, CURR OPIN ALLERGY CL, V1, P133; Delespesse G, 1998, VACCINE, V16, P1415, DOI 10.1016/S0264-410X(98)00101-7; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; EPSTEIN MM, 2005, PHARMACOL THERAPEUT, V109, P107; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Erwin EA, 2005, INDOOR AIR, V15, P33, DOI 10.1111/j.1600-0668.2005.00355.x; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Francis JN, 2005, CURR OPIN ALLERGY CL, V5, P537, DOI 10.1097/01.all.0000191234.97760.88; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P728, DOI 10.1046/j.1365-2222.2002.01374.x; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4&lt;1211::AID-IMMU1211&gt;3.0.CO;2-R; Grakoui A, 1999, J IMMUNOL, V162, P1923; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hales BJ, 1997, CLIN EXP ALLERGY, V27, P868, DOI 10.1111/j.1365-2222.1997.tb01226.x; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P349, DOI 10.1067/mai.2001.117461; Hessel EM, 2005, J EXP MED, V202, P1563, DOI 10.1084/jem.20050631; HIGGINS JA, 1994, J ALLERGY CLIN IMMUN, V93, P891, DOI 10.1016/0091-6749(94)90383-2; Immonen A, 2005, J IMMUNOL, V175, P3614, DOI 10.4049/jimmunol.175.6.3614; Ishida T, 2006, CANCER RES, V66, P5716, DOI 10.1158/0008-5472.CAN-06-0261; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; Kircher MF, 2002, J ALLERGY CLIN IMMUN, V109, P517, DOI 10.1067/mai.2002.121945; Kondo M, 2005, J INVEST ALLERG CLIN, V15, P107; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2000, J IMMUNOL, V164, P2937, DOI 10.4049/jimmunol.164.6.2937; Leckie Maggie J, 2003, Am J Respir Med, V2, P245; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee I, 2005, J EXP MED, V201, P1037, DOI 10.1084/jem.20041709; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LELLEM A, 2001, J EXP MED, V194, P847; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Macaubas C, 2006, J IMMUNOL, V176, P5069, DOI 10.4049/jimmunol.176.8.5069; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Mark PG, 1996, CLIN EXP ALLERGY, V26, P1316, DOI 10.1111/j.1365-2222.1996.tb00529.x; Marsden VS, 2006, INT ARCH ALLERGY IMM, V139, P63, DOI 10.1159/000090000; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; Mathur M, 1999, AM J RESP CRIT CARE, V159, P580, DOI 10.1164/ajrccm.159.2.9712018; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Mojtabavi N, 2002, J IMMUNOL, V169, P4788, DOI 10.4049/jimmunol.169.9.4788; Nagata K, 1999, J IMMUNOL, V162, P1278; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OBRIEN RM, 1994, J ALLERGY CLIN IMMUN, V93, P628, DOI 10.1016/S0091-6749(94)70074-5; Okano M, 2004, CLIN EXP ALLERGY, V34, P770, DOI 10.1111/j.1365-2222.2004.1948.x; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Platts-Mills JA, 2005, J ALLERGY CLIN IMMUN, V116, P384, DOI 10.1016/j.jaci.2005.05.012; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 2003, CLIN EXP ALLERGY, V33, P566, DOI 10.1046/j.1365-2222.2003.01659.x; Prescott SL, 1998, J IMMUNOL, V160, P4730; Reefer AJ, 2007, J ALLERGY CLIN IMMUN, V119, pS238, DOI 10.1016/j.jaci.2006.12.605; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Rivino L, 2004, J EXP MED, V200, P725, DOI 10.1084/jem.20040774; Russano AM, 2006, J ALLERGY CLIN IMMUN, V117, P1178, DOI 10.1016/j.jaci.2006.01.001; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; SANTAMARIA LF, 1995, INT ARCH ALLERGY IMM, V107, P359, DOI 10.1159/000237032; Seneviratne SL, 2002, J CLIN INVEST, V110, P1283, DOI 10.1172/JCI200215753; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Shevach EM, 2006, IMMUNITY, V25, P195, DOI 10.1016/j.immuni.2006.08.003; Shirai T, 2006, J ALLERGY CLIN IMMUN, V118, P622, DOI 10.1016/j.jaci.2006.05.005; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Smith WA, 2001, J ALLERGY CLIN IMMUN, V107, P985, DOI 10.1067/mai.2001.114652; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spiegelberg HL, 2002, CURR OPIN MOL THER, V4, P64; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Sugimoto T, 2004, J EXP MED, V199, P535, DOI 10.1084/jem.20031368; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Takahama H, 2002, HUM IMMUNOL, V63, P558, DOI 10.1016/S0198-8859(02)00406-8; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Vailes LD, 2002, J ALLERGY CLIN IMMUN, V110, P757, DOI 10.1067/mai.2002.129035; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wang YF, 2006, J ALLERGY CLIN IMMUN, V118, P143, DOI 10.1016/j.jaci.2006.03.020; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woodfolk JA, 2006, CURR PHARM DESIGN, V12, P2349, DOI 10.2174/138161206777698936; Woodfolk JA, 2000, J IMMUNOL, V165, P4379, DOI 10.4049/jimmunol.165.8.4379; Woodfolk Judith A, 2006, Expert Rev Clin Immunol, V2, P309, DOI 10.1586/1744666X.2.2.309; Wynn TA, 2005, NAT IMMUNOL, V6, P1069, DOI 10.1038/ni1105-1069; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; YSSEL H, 1992, J IMMUNOL, V148, P738; Yurovsky VV, 1998, AM J RESP CELL MOL, V18, P370, DOI 10.1165/ajrcmb.18.3.2935; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	124	96	100	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					280	294		10.1016/j.jaci.2006.11.008	http://dx.doi.org/10.1016/j.jaci.2006.11.008			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291848				2022-12-18	WOS:000244327900002
J	Bacsi, A; Choudhury, BK; Dharajiya, N; Sur, S; Boldogh, I				Bacsi, Attila; Choudhury, Barun K.; Dharajiya, Nilesh; Sur, Sanjiv; Boldogh, Istvan			Subpollen particles: Carriers of allergenic proteins and oxidases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						subpollen particles; oxidative stress; inflammation	OXIDATIVE STRESS; POLLEN ALLERGENS; BIRCH; INFLAMMATION; SUPEROXIDE; MECHANISM; RELEASE; DEATH; TREE	Background: Pollen is known to induce allergic asthma in atopic individuals, although only a few inhaled pollen grains penetrate into the lower respiratory tract. Objective: We sought to provide evidence that subpollen particles (SPPs) of respirable size, possessing both antigenic and redox properties, are released from weed pollen grains and to test their role in allergic airway inflammation. Methods: The release of SPPs was analyzed by means of microscopic imaging and flow cytometry. The redox properties of SPPs and the SPP-mediated oxidative effect on epithelial cells were determined by using redox-sensitive probes and specific inhibitors. Western blotting and amino acid sequence analysis were used to examine the protein components of the SPP. The allergenic properties of the SPP were determined in a murine model of experimental asthma. Results: Ragweed pollen grains released 0.5 to 4.5 mu m of SPPs on hydration. These contained Amb a 1, along with other allergenic proteins of ragweed pollen, and possessed nicotinamide adenine dinucleotide (reduced) or nicotinamide adenine dinucleotide phosphate (reduced) [NAD(P)H] oxidase activity. The SPPs significantly increased the levels of reactive oxygen species (ROS) in cultured cells and induced allergic airway inflammation in the experimental animals. Pretreatment of the SPPs with NAD(P)H oxidase inhibitors attenuated their capacity to increase ROS levels in the airway epithelial cells and subsequent airway inflammation. Conclusions: The allergenic potency of SPPs released from ragweed pollen grains is mediated in tandem by ROS generated by intrinsic NAD(P)H oxidases and antigenic proteins. Clinical implications: Severe clinical symptoms associated with seasonal asthma might be explained by immune responses to inhaled SPPs carrying allergenic proteins and ROS-producing NAD(P)H oxidases.	Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Dept Internal Med, Med Branch, Div Allergy Pulm Immunol Crit Care & Sleep, Galveston, TX USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Boldogh, I (corresponding author), Univ Texas, Med Branch, Dept Microbiol & Immunol, 3-170 Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	sboldogh@utmb.edu		Bacsi, Attila/0000-0002-2311-2975	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI062885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01HV28184, R01-HL07163-01, N01-HV28184] Funding Source: Medline; NIAID NIH HHS [P01 AI062885, P01 AI062885-02, P01AI062885-01, P01 AI062885-01] Funding Source: Medline; NIEHS NIH HHS [ES066676, P30 ES006676] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bacsi A, 2005, J ALLERGY CLIN IMMUN, V116, P836, DOI 10.1016/j.jaci.2005.06.002; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Burge HA, 2002, J ALLERGY CLIN IMMUN, V110, P544, DOI 10.1067/mai.2002.128674; Das A, 2005, J BIOL CHEM, V280, P35272, DOI 10.1074/jbc.M505526200; Day JP, 2002, APPL ENVIRON MICROB, V68, P37, DOI 10.1128/AEM.68.1.37-45.2002; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Frahry G, 2001, PLANTA, V212, P175, DOI 10.1007/s004250000376; Grote M, 2003, J ALLERGY CLIN IMMUN, V111, P1017, DOI 10.1067/mai.2003.1452; Grote M, 1999, INT ARCH ALLERGY IMM, V118, P1, DOI 10.1159/000024024; Grote M, 2000, J ALLERGY CLIN IMMUN, V105, P1140, DOI 10.1067/mai.2000.107044; Henricks PAJ, 2001, PULM PHARMACOL THER, V14, P409, DOI 10.1006/pupt.2001.0319; Kawasaki T, 2006, P NATL ACAD SCI USA, V103, P230, DOI 10.1073/pnas.0509875103; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Lam E, 2001, NATURE, V411, P848, DOI 10.1038/35081184; LIOCHEV SI, 1995, ARCH BIOCHEM BIOPHYS, V318, P408, DOI 10.1006/abbi.1995.1247; Liszkay A, 2003, PLANTA, V217, P658, DOI 10.1007/s00425-003-1028-1; Menetrez MY, 2001, J AIR WASTE MANAGE, V51, P1436, DOI 10.1080/10473289.2001.10464365; Powell CS, 2004, AM J PHYSIOL-LUNG C, V286, pL826, DOI 10.1152/ajplung.00119.2003; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Roberts G, 2004, THORAX, V59, P752, DOI 10.1136/thx.2003.008722; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; Schappi GF, 1999, ALLERGY, V54, P478, DOI 10.1034/j.1398-9995.1999.00838.x; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Taylor PE, 2004, CLIN EXP ALLERGY, V34, P1591, DOI 10.1111/j.1365-2222.2004.02078.x; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; VanGestelen P, 1997, PLANT PHYSIOL, V115, P543, DOI 10.1104/pp.115.2.543; VANZANDWIJK N, 1995, J CELL BIOCHEM, P24; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Wark PAB, 2002, CLIN EXP ALLERGY, V32, P1750, DOI 10.1046/j.1365-2222.2002.01556.x; Zhang SQ, 2001, TRENDS PLANT SCI, V6, P520, DOI 10.1016/S1360-1385(01)02103-3	33	96	100	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					844	850		10.1016/j.jaci.2006.07.006	http://dx.doi.org/10.1016/j.jaci.2006.07.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030236	Green Submitted, Green Accepted			2022-12-18	WOS:000241434200010
J	Triggiani, M; Granata, F; Giannattasio, G; Marone, G				Triggiani, M; Granata, F; Giannattasio, G; Marone, G			Secretory phospholipases A(2) in inflammatory and allergic diseases: Not just enzymes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						secretory phospholipases A(2); arachidonic acid; inflammation; cytokines; chemokines; asthma	GROUP-II PHOSPHOLIPASE-A2; GROUP-V; GROUP-X; PROSTAGLANDIN D-2; ARACHIDONIC-ACID; SELECTIVE INHIBITOR; MESANGIAL CELLS; RECEPTOR; ACTIVATION; GENERATION	Secretory phospholipases A(2) (sPLA(2)s) are molecules released in plasma and biologic fluids of patients with systemic inflammatory, autoimmune, and allergic diseases. Several sPLA(2) isoforms are expressed and released by such human inflammatory cells as neutrophils, eosinophils, basophils, T cells, monocytes, macrophages, and mast cells. Certain sPLA(2)s release arachidonic acid, thereby providing the substrate for the biosynthesis of proinflammatory eicosanoids. However, there are other mechanisms by which sPLA(2)S might participate in the synthesis of lipid mediators. Interestingly, sPLA(2)s activate inflammatory cells through mechanisms unrelated to their enzymatic activity. Several sPLA(2)S induce degranulation of mast cells and eosinophils and activate exocytosis in macrophages. Furthermore, sPLA(2)S promote cytokine and chemokine production from macrophages, neutrophils, eosinophils, monocytes, and endothelial cells. Some of these effects are mediated by the binding of sPLA(2)S to specific receptors expressed on effector cells. Thus sPLA(2)S might play important roles in the initiation and amplification of the inflammatory reaction. Selective inhibitors of sPLA(2)s and specific antagonists of sPLA(2) receptors might prove useful in the treatment of allergic and autoimmune diseases, such as bronchial asthma and rheumatoid arthritis.	Univ Naples Federico II, Div Clin Immunol & Allergy, Ctr Basic & Clin Immunol Res, I-80131 Naples, Italy	University of Naples Federico II	Marone, G (corresponding author), Univ Naples Federico II, Div Clin Immunol & Allergy, Ctr Basic & Clin Immunol Res, Via Pansini 5, I-80131 Naples, Italy.	marone@unina.it	Triggiani, Massimo/K-8271-2016	Triggiani, Massimo/0000-0001-7318-2093				ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Beck GC, 2003, BIOCHEM BIOPH RES CO, V300, P731, DOI 10.1016/S0006-291X(02)02920-0; Beck S, 2003, J BIOL CHEM, V278, P29799, DOI 10.1074/jbc.M211763200; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Bowton DL, 2005, J ASTHMA, V42, P65, DOI 10.1081/JAS-200044748; Bowton DL, 1997, AM J RESP CRIT CARE, V155, P421, DOI 10.1164/ajrccm.155.2.9032172; Bradley JD, 2005, J RHEUMATOL, V32, P417; Chilton FH, 1996, J EXP MED, V183, P2235, DOI 10.1084/jem.183.5.2235; De Marino V, 1999, INT ARCH ALLERGY IMM, V118, P200, DOI 10.1159/000024066; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Fenard D, 2001, MOL PHARMACOL, V60, P341, DOI 10.1124/mol.60.2.341; Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773; Gambero A, 2002, BIOCHEM PHARMACOL, V63, P65, DOI 10.1016/S0006-2952(01)00841-3; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Granata F, 2005, J IMMUNOL, V174, P464, DOI 10.4049/jimmunol.174.1.464; Hamaguchi K, 2003, BBA-MOL CELL BIOL L, V1635, P37, DOI 10.1016/j.bbalip.2003.10.004; Hanasaki K, 2002, PROSTAG OTH LIPID M, V68-9, P71, DOI 10.1016/S0090-6980(02)00022-9; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; Hundley TR, 1998, J PHARMACOL EXP THER, V284, P847; Jo EJ, 2004, J IMMUNOL, V173, P6433, DOI 10.4049/jimmunol.173.10.6433; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; Masuda S, 2005, FEBS J, V272, P655, DOI 10.1111/j.1742-4658.2004.04489.x; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; NAKANO T, 1990, J BIOL CHEM, V265, P12745; Offer S, 2005, AM J PHYSIOL-LUNG C, V288, pL523, DOI 10.1152/ajplung.00199.2004; Park DW, 2003, J IMMUNOL, V170, P2093, DOI 10.4049/jimmunol.170.4.2093; Peilot H, 2000, J BIOL CHEM, V275, P22895, DOI 10.1074/jbc.M002783200; Perrin-Cocon L, 2004, EUR J IMMUNOL, V34, P2293, DOI 10.1002/eji.200324797; Portielje JEA, 2005, CANCER IMMUNOL IMMUN, V54, P37, DOI 10.1007/s00262-004-0574-0; Ramoner R, 2005, BLOOD, V105, P3583, DOI 10.1182/blood-2004-08-3001; Rizzo MT, 2000, BLOOD, V96, P3809, DOI 10.1182/blood.V96.12.3809.h8003809_3809_3815; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; Seeds MC, 2000, AM J RESP CELL MOL, V23, P37, DOI 10.1165/ajrcmb.23.1.4034; Silliman CC, 2002, AM J PHYSIOL-CELL PH, V283, pC1102, DOI 10.1152/ajpcell.00608.2001; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Snyder DW, 1999, J PHARMACOL EXP THER, V288, P1117; STADEL JM, 1994, AM J RESP CELL MOL, V11, P108, DOI 10.1165/ajrcmb.11.1.8018333; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Tessier C, 2002, FEBS LETT, V520, P111, DOI 10.1016/S0014-5793(02)02779-5; Tomita Y, 2004, J PHARMACOL SCI, V96, P144, DOI 10.1254/jphs.FP0040314; Triggiani M, 2003, J IMMUNOL, V170, P3279, DOI 10.4049/jimmunol.170.6.3279; Triggiani M, 2002, EUR J IMMUNOL, V32, P67, DOI 10.1002/1521-4141(200201)32:1<67::AID-IMMU67>3.0.CO;2-3; Triggiani M, 2000, J IMMUNOL, V164, P4908, DOI 10.4049/jimmunol.164.9.4908; UHL W, 1997, PHOSPHOLIPASE A2 BAS; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; van der Helm HA, 2000, BBA-MOL CELL BIOL L, V1484, P215, DOI 10.1016/S1388-1981(00)00021-4; Villarrubia VG, 2004, MED CLIN-BARCELONA, V123, P749, DOI 10.1157/13069312	57	96	101	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1000	1006		10.1016/j.jaci.2005.08.011	http://dx.doi.org/10.1016/j.jaci.2005.08.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275367				2022-12-18	WOS:000235686700008
J	Rosenzweig, SD; Holland, SM				Rosenzweig, SD; Holland, SM			Phagocyte immunodeficiencies and their infections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic granulomatous disease; leukocyte adhesion deficiency; IFN-gamma; IFN-gamma receptor; E-selectin; Aspergillus species; mycobacteria species; Staphylococcus aureus; IL-12; granuloma	LEUKOCYTE ADHESION DEFICIENCY; INTERFERON-GAMMA-RECEPTOR; CHRONIC GRANULOMATOUS-DISEASE; BONE-MARROW-TRANSPLANTATION; MYCOBACTERIAL; INTERLEUKIN-12; SUSCEPTIBILITY; PATIENT; MUTATION; MAC-1	Primary immunodeficiencies (PIDs) primarily affecting the phagocytes (neutrophils and macrophages) typically predispose patients to infections. However, one of the most clinically important features of these disorders is their relatively narrow spectrum of disease-specific infections. Invasive aspergillosis in the absence of immune suppression is essentially seen only in chronic granulomatous disease; disseminated nontuberculous mycobacterial infection in the absence of immune suppression is seen predominantly in patients with defects of the IFN-gamma/IL-12 axis. In contrast, infections that are relatively common in some of the PIDs affecting the lymphoid system (Pneumocystis jiroveci and Streptococcus pneumoniae) are extremely uncommon in PIDs affecting phagocytes. Therefore careful attention to the microbiology laboratory early in the course of evaluation of a patient with recurrent infections and suspected of having a PID will help steer the workup in the appropriate direction. Over the last few years, there have been major advances in the molecular and cellular understandings of PIDs affecting phagocytes. As the field of PIDs becomes broader and more clinical and molecular definition becomes available, it is increasingly important to be able to identify likely pathways for investigation early in the evaluation. Here we have updated some of the more rapidly evolving aspects of PIDs affecting phagocytes, with a special emphasis on the associated microbiology.	Host Def Lab, Bethesda, MD 20892 USA; Hosp Juan P Garrahan, Buenos Aires, DF, Argentina	Hospital de Pediatria Doctor Juan Garrahan	Holland, SM (corresponding author), Host Def Lab, 10 Ctr Dr,MSC 1886,Bldg 10,Room 11N103, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646, Z01AI000646, ZIAAI000647, Z01AI000647] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alon R, 2003, BLOOD, V101, P4437, DOI 10.1182/blood-2002-11-3427; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bauer TR, 2004, PEDIATR RES, V55, P363, DOI 10.1203/01.PDR.0000111287.74989.1B; Bauer TR, 1998, BLOOD, V91, P1520, DOI 10.1182/blood.V91.5.1520.1520_1520_1526; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; DeLisser HM, 1999, BLOOD, V94, P884, DOI 10.1182/blood.V94.3.884.415a14_884_894; Doffinger R, 2004, CLIN INFECT DIS, V38, pE10, DOI 10.1086/380453; Dorman SE, 2000, CYTOKINE GROWTH F R, V11, P321, DOI 10.1016/S1359-6101(00)00010-1; Dorman SE, 1999, J PEDIATR-US, V135, P640, DOI 10.1016/S0022-3476(99)70064-8; Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901; Dorman SE, 2002, CLIN INFECT DIS, V35, P390, DOI 10.1086/341416; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Etzioni A, 1998, J ALLERGY CLIN IMMUN, V102, P323, DOI 10.1016/S0091-6749(98)70104-6; Etzioni A, 2000, BLOOD, V95, P3641, DOI 10.1182/blood.V95.11.3641.011a52g_3641_3643; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; Fieschi C, 2003, J EXP MED, V197, P527, DOI 10.1084/jem.20021769; Fischer A, 1988, Immunodefic Rev, V1, P39; FISCHER A, 1994, BLOOD, V83, P1149; Fleisher TA, 1999, CLIN IMMUNOL, V90, P425, DOI 10.1006/clim.1998.4654; Gallin JI, 2003, NEW ENGL J MED, V348, P2416, DOI 10.1056/NEJMoa021931; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; Hoflich C, 2004, BLOOD, V103, P673, DOI 10.1182/blood-2003-04-1065; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; Holland S M, 2000, Adv Intern Med, V45, P431; Holland SM, 1998, J INFECT DIS, V178, P1095, DOI 10.1086/515670; Holland SM, 2000, MICROBES INFECT, V2, P1579, DOI 10.1016/S1286-4579(00)01314-9; Horwitz ME, 2003, BLOOD, V102, P2692, DOI 10.1182/blood-2003-04-1268; Horwitz ME, 2001, NEW ENGL J MED, V344, P881, DOI 10.1056/NEJM200103223441203; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Jouanguy E, 1999, NAT GENET, V21, P370, DOI 10.1038/7701; Kinashi T, 2004, BLOOD, V103, P1033, DOI 10.1182/blood-2003-07-2499; KISHIMOTO TK, 1989, J BIOL CHEM, V264, P3588; Kuijpers TW, 1997, J CLIN INVEST, V100, P1725, DOI 10.1172/JCI119697; LEDEIST F, 1989, BLOOD, V74, P512; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Lublin M, 2002, ANN SURG, V235, P383, DOI 10.1097/00000658-200203000-00010; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/88289; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Picard C, 2002, AM J HUM GENET, V70, P336, DOI 10.1086/338625; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Repo H, 1999, ANN MED, V31, P156, DOI 10.3109/07853899909115974; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Segal BH, 1998, MEDICINE, V77, P345, DOI 10.1097/00005792-199809000-00004; Seger RA, 2002, BLOOD, V100, P4344, DOI 10.1182/blood-2002-02-0583; THOMAS C, 1995, BLOOD, V86, P1629, DOI 10.1182/blood.V86.4.1629.bloodjournal8641629; Uzel G, 2001, CLIN IMMUNOL, V100, P270, DOI 10.1006/clim.2001.5078; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; Vowells SJ, 1996, J PEDIATR-US, V128, P104, DOI 10.1016/S0022-3476(96)70437-7; Williams DA, 2000, BLOOD, V96, P1646; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	58	96	104	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					620	626		10.1016/j.jaci.2004.02.001	http://dx.doi.org/10.1016/j.jaci.2004.02.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100664				2022-12-18	WOS:000220956600006
J	Esch, RE				Esch, RE			Manufacturing and standardizing fungal allergen products	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen standardization; fungal extracts	EXTRACTS	The importance of fungal allergen products in the practice of clinical allergy is frequently underestimated. A wide variety of fungal species have been demonstrated to elicit allergic symptoms and to sensitize patients. The quality of fungal allergen preparations might have a significant effect on the specificity and sensitivity of diagnostic tests. Varying degrees of cross-reactivity have been shown among fungal genera, and the clinical relevance of this cross-reactivity has been neither fully appreciated nor applied to clinical practice. In addition, an increasing number of potentially new fungal allergen sources for which commercial extracts are not available are being identified. Manufacturers of allergen products have the formidable task of providing quality fungal allergen extracts that are routinely used for specific allergy diagnosis and treatment in the clinic. Currently there are no standardized fungal allergen products available in the United States because of inherent difficulties with manufacturing and standardizing fungal extracts. Without intervention, progress will not be forthcoming.	Greer Labs Inc, Lenoir, NC 28645 USA		Esch, RE (corresponding author), Greer Labs Inc, 639 Nuway Circle,POB 800, Lenoir, NC 28645 USA.							AAS K, 1980, ALLERGY, V35, P443, DOI 10.1111/j.1398-9995.1980.tb01791.x; [Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; AUKRUST L, 1985, Allergy (Copenhagen), V40, P43, DOI 10.1111/j.1398-9995.1985.tb02641.x; Esch RE, 1991, REGULATORY CONTROL S, P171; Hauck PR, 2001, CLIN REV ALLERG IMMU, V21, P93, DOI 10.1385/CRIAI:21:2-3:93; HELM RM, 1988, J ALLERGY CLIN IMMUN, V81, P651, DOI 10.1016/0091-6749(88)91035-4; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; ILI JT, 2003, ANN ALLERGY, V90, P1; KORDASH TR, 1993, ANN ALLERGY, V71, P240; MORROW MB, 1964, ANN ALLERGY, V22, P575; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; Nissen D, 1998, ANN ALLERG ASTHMA IM, V81, P247, DOI 10.1016/S1081-1206(10)62821-9; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P773, DOI 10.1016/0091-6749(93)90197-N; PRINCE HE, 1961, ANN ALLERGY, V19, P259; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; STERINGER I, 1987, INT ARCH ALLER A IMM, V84, P190, DOI 10.1159/000234422; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; Vijay HM, 1999, ALLERGENS ALLERGEN I, P133; WAHL R, 1989, ANN ALLERGY, V63, P527; Weber RW, 2001, CLIN REV ALLERG IMMU, V21, P153, DOI 10.1385/CRIAI:21:2-3:153; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4	22	96	97	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					210	215		10.1016/j.jaci.2003.11.024	http://dx.doi.org/10.1016/j.jaci.2003.11.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767431				2022-12-18	WOS:000188885700003
J	Mempel, M; Rakoski, J; Ring, J; Ollert, M				Mempel, M; Rakoski, J; Ring, J; Ollert, M			Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DOUBLE-BLIND; POLLEN; RHINOCONJUNCTIVITIS; ANTIBODIES		Tech Univ Munich, Dept Dermatol & Allergol, D-80802 Munich, Germany; Tech Univ Munich, Clin Res Div Mol & Clin Allergotoxicol, D-80802 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy GSF TUM, Neuherberg, Germany	Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mempel, M (corresponding author), Tech Univ Munich, Dept Dermatol & Allergol, Biedersteiner Str 29, D-80802 Munich, Germany.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152; Ollert, Markus W./0000-0002-8055-0103				EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; GALL H, 1994, J ALLERGY CLIN IMMUN, V94, P70, DOI 10.1016/0091-6749(94)90073-6; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; VOCKS E, 1993, ALLERGY, V48, P168, DOI 10.1111/j.1398-9995.1993.tb00708.x; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x	9	96	99	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1406	1409		10.1067/mai.2003.1497	http://dx.doi.org/10.1067/mai.2003.1497			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789247				2022-12-18	WOS:000183424700035
J	Juniper, EF; Rohrbaugh, T; Meltzer, EO				Juniper, EF; Rohrbaugh, T; Meltzer, EO			A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						quality of life; rhinitis; rhinoconjunctivitis; nocturnal; questionnaire; measurement; health status	OF-LIFE; HEALTH-STATUS; RHINITIS; VERSION	Background: Many patients with rhinoconjunctivitis experience symptoms at night and these interfere with getting a good night's sleep. Objective: The aim of this study was to develop the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) to measure the functional problems that are most troublesome to patients with nocturnal allergic rhinoconjunctivitis (NAR). Methods: After generating a list of 256 potentially important items, 132 patients with NAR identified the items that were most troublesome. The top scoring 16 items are included in the NRQLQ in four domains (sleep problems, symptoms during sleep time, symptoms on waking and practical problems). The NRQLQ asks patients to recall their experiences during the previous week and score each item on a 7-point scale. Results: One hundred and six patients with NAR participated in a 3 week validation study. This showed the NRQLQ to have good reliability (ICC = 0.87) and responsiveness (responsiveness index = 0.93). For both cross-sectional and longitudinal construct validity correlations between the NRQLQ and other measures of health status were close to a priori predictions. Conclusions: The NRQLQ has strong evaluative and discriminative measurement properties and can be used with confidence in both clinical practice and clinical trials to measure the functional impairments that are most troublesome to patients with nocturnal allergic rhinoconjunctivitis. (J Allergy Clin Immunol 2003;111:484-90.).	McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Rohrbaugh Associates Inc, Newtown, PA USA; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA	McMaster University	Juniper, EF (corresponding author), 20 Marcuse Fields, Bosham PO18 8NA, W Sussex, England.							BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; deGraafintVeld T, 1996, J ALLERGY CLIN IMMUN, V98, P508, DOI 10.1016/S0091-6749(96)70083-0; Feinstein AR, 1987, CLINIMETRICS, P141, DOI DOI 10.2307/J.CTT1XP3VBC.13; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; GUYATT GH, 1992, J CLIN EPIDEMIOL, V45, P1341, DOI 10.1016/0895-4356(92)90194-R; Guyatt GH, 2002, J CLIN EPIDEMIOL, V55, P900, DOI 10.1016/S0895-4356(02)00435-3; Hays R.D., 1992, MEASURING FUNCTIONIN, P235; JUNIPER EF, 1993, J ALLERGY CLIN IMMUN, V92, P66, DOI 10.1016/0091-6749(93)90039-I; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163, DOI 10.1016/S0091-6749(98)70380-X; Juniper EF, 1997, J CLIN EPIDEMIOL, V50, P233, DOI 10.1016/S0895-4356(96)00377-0; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Juniper EF, 1995, QUALITY LIFE PHARMAC, P49; REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007	15	96	106	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					484	490		10.1067/mai.2003.137	http://dx.doi.org/10.1067/mai.2003.137			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642826				2022-12-18	WOS:000181639500007
J	Polosa, R; Puddicombe, SM; Krishna, MT; Tuck, AB; Howarth, PH; Holgate, ST; Davies, DE				Polosa, R; Puddicombe, SM; Krishna, MT; Tuck, AB; Howarth, PH; Holgate, ST; Davies, DE			Expression of c-erbB receptors and ligands in the bronchial epithelium of asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial epithelium; erbB receptor; epidermal growth factor; transforming growth factor alpha; phosphorylation; wound repair	EPIDERMAL GROWTH-FACTOR; FACTOR-ALPHA; CELL-PROLIFERATION; AIRWAY EPITHELIUM; MUCOSAL BIOPSIES; INJURY; REPAIR; LUNG; HETERODIMERIZATION; INDUCTION	Background: The c-erbB family of receptor tyrosine kinases act in a combinatorial fashion to regulate cell behavior. Disturbances in this system have been associated with neoplastic and inflammatory diseases. Objectives: Although expression of the epidermal growth factor receptor (EGFR; c-erbB1) is increased in the bronchial epithelium in asthma, there is no information on expression of other members of the c-erbB receptor and ligand family that can modulate EGFR function. Methods: Immunohistochemistry was used to compare expression of EGFR, c-erbB2, c-erbB3, epidermal growth factor, heparin-binding epidermal growth factor-like growth factor, and transforming growth factor a in bronchial biopsy specimens from normal and asthmatic subjects. Scrape-wounded monolayers of 16HBE 14o(-) cells were used as an in vitro model of damage and repair. Changes in EGFR, c-erbB2, and cerbB3 distribution were measured by means of immunocytochemistry, whereas tyrosine phosphorylation was measured by means of immunoprecipitation and Western blotting. Results: Although epithelial staining for the EGFR was significantly increased in asthmatic epithelium (P <.001), there was no difference in staining for the other receptors and ligands studied. In scrape-wounded epithelial monolayers, tyrosine phosphorylation of EGFR, c-erbB2, and c-erbB3 occurred immediately after damage; however, only EGFR showed a change in expression in response to damage. Conclusions: Even though EGFR levels are increased in asthma, this is not linked to changes in expression of its activating ligands or other c-erbB receptors. Because bronchial epithelial cells respond to physical damage through activation of several c-erbB family members, the shift in favor of increased EGFR levels in asthma may lead to altered epithelial function by influencing the number and type of heterodimeric signaling complexes, assuming sufficient ligand availability.	Southampton Gen Hosp, Sch Med, Div Resp Cell & Mol Biol, Southampton SO16 6YD, Hants, England	University of Southampton	Davies, DE (corresponding author), Southampton Gen Hosp, Sch Med, Div Resp Cell & Mol Biol, RCMB 810,D Level Ctr Block, Southampton SO16 6YD, Hants, England.		Davies, Donna E/H-2993-2012	Howarth, Peter/0000-0003-0619-7927; Davies, Donna/0000-0002-5117-2991				ANTONIADES HN, 1993, AM J PATHOL, V142, P1099; Barsky SH, 1998, JNCI-J NATL CANCER I, V90, P1198, DOI 10.1093/jnci/90.16.1198; Baughman RP, 1999, SARCOIDOSIS VASC DIF, V16, P57; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Davies DE, 1999, ALLERGY, V54, P771; Davies DE, 2001, CURR OPIN ALLERGY CL, V1, P67, DOI 10.1097/00130832-200102000-00012; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214, DOI 10.1164/ajrccm.150.1.7912988; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; ERJEFALT JS, 1995, CELL TISSUE RES, V281, P305, DOI 10.1007/BF00583399; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hardie WD, 1999, PEDIATR DEVEL PATHOL, V2, P415, DOI 10.1007/s100249900144; Hoffmann P, 1997, GUT, V41, P195, DOI 10.1136/gut.41.2.195; HURD S, 1992, EUR RESPIR J, V5, P115; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; MADTES DK, 1994, AM J RESP CELL MOL, V11, P540, DOI 10.1165/ajrcmb.11.5.7524566; McCarthy DW, 1996, J INVEST DERMATOL, V106, P49, DOI 10.1111/1523-1747.ep12327214; MONTEFORT S, 1992, THORAX, V47, P499, DOI 10.1136/thx.47.7.499; NANNEY LB, 1986, J INVEST DERMATOL, V86, P260, DOI 10.1111/1523-1747.ep12285389; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324, DOI 10.1164/ajrccm.162.6.2001041; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; RUSCH V, 1993, CANCER RES, V53, P2379; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Sundaresan S, 1998, ENDOCRINOLOGY, V139, P4756, DOI 10.1210/en.139.12.4756; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; VanWinkle LS, 1997, AM J PATHOL, V151, P443; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819	33	96	100	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					75	81		10.1067/mai.2002.120274	http://dx.doi.org/10.1067/mai.2002.120274			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799369				2022-12-18	WOS:000173739300012
J	Bellinghausen, I; Brand, U; Steinbrink, K; Enk, AH; Knop, J; Saloga, J				Bellinghausen, I; Brand, U; Steinbrink, K; Enk, AH; Knop, J; Saloga, J			Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: Differences from hydrocortisone-treated dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; IL-10; hydrocortisone; T(H)1/T(H)2; allergy	INTERLEUKIN-12 PRODUCTION; CORTICOSTEROIDS INHIBIT; CYTOKINE PRODUCTION; IMMUNE-RESPONSE; HUMAN MONOCYTES; TH2 RESPONSES; HELPER CELLS; IN-VITRO; ANTIGEN; GLUCOCORTICOIDS	Background. Dendritic cells (DCs) are able to induce human allergic T(H)1 responses as well as T(H)2 responses. Objective: In this study, we examined the effect of anti-inflammatory agents such as IL-10 and hydrocortisone (HC) on the accessory function of DCs and the resulting T-cell response, especially that of T(H)2 cells. Methods: Naive and memory CD4(+) T cells from atopic donors were stimulated with autologous allergen-pulsed DCs generated from CD14(+) monocytes by culture with GM-CSF/IL-4 and fully matured with IL-1 beta, TNF-alpha and PGE(2) in the presence or absence of IL-10 or HC. Results: IL-10-treated DCs, and, to a lesser extent, HC-treated DCs showed a decreased expression of MHC II molecules, the costimulatory molecule CD86, and the DC-specific marker CD83, as well as a strongly reduced IL-12 secretion. Consequently, T-cell proliferation was reduced after stimulation with IL-10- or HC-treated DCs alike. However, pretreatment of DCs with IL-10 inhibited the production of T(H)1 and T(H)2 cytokines by T cells, whereas HC-treated DCs inhibited production of IFN-gamma but induced an increased release of IL-4 and no change in IL-5. Both effects were long-lasting; cytokine production remained low (which was due not to enhanced. hyporesponsiveness) or even apoptosis but to functional hy increased after restimulation with fully matured DCs. Conclusion: These data indicate that IL-10- or HC-treated DCs differ in their ability to influence human allergic T-cell responses. This has major implications for therapeutic strategies. aiming at the downregulation of proallergic T(H)2 responses.	Univ Mainz, Hautklin, Dept Dermatol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Bellinghausen, I (corresponding author), Univ Mainz, Hautklin, Dept Dermatol, Langenbeckstr 1, D-55131 Mainz, Germany.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akdis CA, 1997, EUR J IMMUNOL, V27, P2351, DOI 10.1002/eji.1830270933; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bellinghausen I, 2000, J ALLERGY CLIN IMMUN, V105, P988, DOI 10.1067/mai.2000.105526; Blotta MH, 1997, J IMMUNOL, V158, P5589; Braun CM, 1997, J ALLERGY CLIN IMMUN, V100, P400, DOI 10.1016/S0091-6749(97)70255-0; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CAUX C, 1994, INT IMMUNOL, V6, P1177, DOI 10.1093/intimm/6.8.1177; de Jong EC, 1999, J LEUKOCYTE BIOL, V66, P201, DOI 10.1002/jlb.66.2.201; DEL PG, 1993, J IMMUNOL, V150, P353; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Fong L, 2001, J IMMUNOL, V166, P4254, DOI 10.4049/jimmunol.166.6.4254; Frieri M, 1999, ALLERGY ASTHMA PROC, V20, P147, DOI 10.2500/108854199778553082; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Kalinski P, 1997, J IMMUNOL, V159, P28; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; Kelsall BL, 1996, ANN NY ACAD SCI, V795, P116, DOI 10.1111/j.1749-6632.1996.tb52660.x; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Liu LM, 1998, INT IMMUNOL, V10, P1017, DOI 10.1093/intimm/10.8.1017; MALEFYT RD, 1991, J EXP MED, V174, P915; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Palucka K, 1999, J CLIN IMMUNOL, V19, P12, DOI 10.1023/A:1020558317162; Piemonti L, 1999, J IMMUNOL, V162, P6473; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Rieser C, 1997, J EXP MED, V186, P1603, DOI 10.1084/jem.186.9.1603; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Schuler G, 1995, ADV EXP MED BIOL, V378, P43; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Steinbrink K, 1999, BLOOD, V93, P1634, DOI 10.1182/blood.V93.5.1634.405k11_1634_1642; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Vieira PL, 1998, J IMMUNOL, V161, P5245; Visser J, 1998, BLOOD, V91, P4255, DOI 10.1182/blood.V91.11.4255.411a03_4255_4264; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; WILLEMS F, 1994, EUR J IMMUNOL, V24, P1007, DOI 10.1002/eji.1830240435	39	96	101	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					242	249		10.1067/mai.2001.117177	http://dx.doi.org/10.1067/mai.2001.117177			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496241				2022-12-18	WOS:000170584600013
J	Katelaris, CH; Carrozzi, FM; Burke, TV; Byth, K				Katelaris, CH; Carrozzi, FM; Burke, TV; Byth, K			A springtime Olympics demands special consideration for allergic athletes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pollen counts; athletes; allergic rhinoconjunctivitis; olympics; paralympics; asthma	QUALITY-OF-LIFE; HAY-FEVER; QUESTIONNAIRE; ASTHMA	Background: The Sydney Olympic and Paralympic Games will be held in September-October 2000, which is early to midspring in the southern hemisphere. Pollen-sensitive athletes may encounter problems with allergic symptoms triggered by pollen exposure, thus compromising their ability to attain peak performance. Objective: We sought to monitor pollen levels at the major Olympic venues to provide information for allergic athletes and their team doctors in order to adequately prepare them for Olympic competition. Methods: We performed aerobiologic monitoring of the major Olympic venues to provide a profile of the most prevalent pollen species appearing during the spring. In the second part of this study, we surveyed a population of elite Australian athletes from Olympic sports to ascertain the prevalence of allergic rhinoconjunctivitis, to investigate the major allergens involved in sensitization, and to conduct a pilot study to assess the effect of allergic rhinoconjunctivitis on quality of life. Results: The pollen counts obtained at the 3 major sites were high over the period of Olympic competition. Tree pollens appeared from July, and grasses appeared from early September and peaked in the second week of October, the beginning of Paralympic competition. A relatively small number of pollen varieties comprise the majority of the total pollen count. Two hundred fourteen athletes (61% male; mean age, 21 +/- 16 years) representing 12 Olympic sports participated in the study. Fifty-six percent gave a symptom history consistent with allergic rhinoconjunctivitis, 41% had symptoms of allergic rhinoconjunctivitis and a positive test response to any one allergen, and 29% had seasonal allergic rhinoconjunctivitis (a positive history and at least one positive skin prick test response to a seasonal allergen). Athletes from aquatic sports were more likely to have symptoms than those from other sports, Symptom scores were higher and quality of life ratings were poorer in allergic compared with nonallergic athletes over the spring period, Conclusion: Olympic team managers and medical officers need to adequately prepare Olympic athletes for the possibility of exposure to high pollen levels in the weeks leading up to this most important sporting event. Symptoms of pollen sensitivity, such as rhinoconjunctivitis and exacerbation of asthma, could be devastating to athletes expecting peak performance, Potential Olympic athletes should be screened for the possibility of pollen allergy and have medical programs with permitted medication tailored to meet their needs. This may involve preventative therapy with meditation, such as intranasal corticosteroid sprays or immunotherapy programs, if symptoms are particularly severe. The newer nonsedating antihistamines are the treatment of choice fur acute intermittent symptoms, Appropriate management will ensure that the allergic athlete will safely perform to maximum ability with permitted medication during the Spring 2000 Olympic Games in Sydney.	Westmead Hosp, ICPMR, Dept Clin Immunol & Allergy, Sydney, NSW 2145, Australia; Westmead Hosp, Westmead Millennium Inst, Sydney, NSW 2145, Australia	University of Sydney; University of Sydney; Westmead Institute for Medical Research	Katelaris, CH (corresponding author), Westmead Hosp, ICPMR, Dept Clin Immunol & Allergy, Sydney, NSW 2145, Australia.			Byth Wilson, Karen/0000-0002-1253-6393				BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; Carrozzi FM, 1998, ASIAN PAC J ALLERGY, V16, P149; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DAVIES RR, 1973, CLIN ALLERGY, V3, P477, DOI 10.1111/j.1365-2222.1973.tb01332.x; FITCH KD, 1984, J ALLERGY CLIN IMMUN, V73, P722, DOI 10.1016/0091-6749(84)90314-2; HELBLING A, 1990, SCHWEIZ MED WSCHR, V120, P231; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646, DOI 10.1016/S0091-6749(98)70173-3; HOPPER JL, 1995, AUST J PUBLIC HEALTH, V19, P120; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; TAUDORF E, 1988, INT ARCH ALLER A IMM, V86, P225, DOI 10.1159/000234576; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1994, ALLERGY S19, V49, P5	12	96	97	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					260	266		10.1067/mai.2000.108603	http://dx.doi.org/10.1067/mai.2000.108603			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932068				2022-12-18	WOS:000088708100007
J	Bleecker, ER; Welch, MJ; Weinstein, SF; Kalberg, C; Johnson, M; Edwards, L; Rickard, KA				Bleecker, ER; Welch, MJ; Weinstein, SF; Kalberg, C; Johnson, M; Edwards, L; Rickard, KA			Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fluticasone propionate; asthma; inhaled corticosteroids; leukotriene modifiers; zafirlukast	PITUITARY-ADRENAL AXIS; TO-MODERATE ASTHMA; ANTILEUKOTRIENE THERAPIES; TRIAMCINOLONE ACETONIDE; CORTICOSTEROIDS; PREDNISONE; EFFICACY; PLACEBO	Background: Few studies have compared the efficacy of inhaled corticosteroids and leukotriene modifiers for the treatment of persistent asthma. Objective: Our purpose was to compare the efficacy of a low dose of inhaled fluticasone propionate (FP) with that of oral zafirlukast in the treatment of persistent asthma previously treated with short-acting beta(2)-agonists alone. Methods: A 12-week, randomized, double-blind, double-dummy, multicenter study was conducted in 451 patients aged 12 years and older with asthma who were symptomatic on short-acting beta(2)-agonists alone. After an 8- to 14-day run-in period; patients were randomized to treatment with FP 88 pg twice daily or zafirlukast 20 mg twice daily. Results: Treatment with FP was more effective than treatment with zafirlukast in increasing morning FEV1 (by 0.42 L vs 0.20 L over baseline, P < .001), morning peak expiratory flow (by 49.94 L/min vs 11.68 L/min over baseline, P < .001), and evening PEF (by 38.91 L/min vs 10.50 L/min over baseline, P < .001). Statistically significant differences between the two treatments in FEV1 were noted after the first observation (week 4) and in morning and evening peak expiratory flow by week 2, Mean change in percentage of symptom-free days was greater with FP than with zafirlukast (28.5% of days vs 15.6% of days, P < .001) and FP significantly increased the percentage of rescue-free days by 40.4% of days compared with 24.2% of days with zafirlukast (P < .001). Treatment with FP significantly reduced albuterol use by 2.39 puffs per day compared with 1.45 puffs per day (P < .001) and increased the percentage of nights with no awakenings by 21.2% of nights compared with 8.0% of nights with zafirlukast (P < .001). Conclusion: The clinical effectiveness of a low dose of FP as first-line therapy in patients with persistent asthma who are symptomatic on Pz-agonists alone is superior to that of zafirlukast.	Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Allergy & Asthma Med Grp, San Diego, CA USA; Allergy & Asthma Specialists Med Grp, Huntington Beach, CA USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	University System of Maryland; University of Maryland Baltimore; GlaxoSmithKline	Bleecker, ER (corresponding author), Univ Maryland, Sch Med, Room 119,108 N Green St, Baltimore, MD 21201 USA.			Edwards, Lisa/0000-0002-4867-2151				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; Busse W, 1999, AM J RESP CRIT CARE, V159, pA628; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 1998, AM J RESP CRIT CARE, V158, P1697, DOI 10.1164/ajrccm.158.6.15860; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Fish JE, 1997, CLIN THER, V19, P675, DOI 10.1016/S0149-2918(97)80092-6; Li JTC, 1999, J ALLERGY CLIN IMMUN, V103, P622, DOI 10.1016/S0091-6749(99)70234-4; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Nathan RA, 1998, J ALLERGY CLIN IMMUN, V102, P935, DOI 10.1016/S0091-6749(98)70331-8; *NIH, 1997, NIH PUBL; Polgar G, 1971, PULMONARY FUNCTION T; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; Sorkness CA, 1999, CLIN THER, V21, P353, DOI 10.1016/S0149-2918(00)88292-2; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; Wasserman SI, 1996, J ASTHMA, V33, P265, DOI 10.3109/02770909609055367; Wenzel SE, 1998, AM J RESP CRIT CARE, V158, P1699, DOI 10.1164/ajrccm.158.6.15861	20	96	98	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1123	1129		10.1067/mai.2000.106043	http://dx.doi.org/10.1067/mai.2000.106043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856145				2022-12-18	WOS:000087781800012
J	van Ree, R; van Leeuwen, WA; Bulder, I; Bond, J; Aalberse, RC				van Ree, R; van Leeuwen, WA; Bulder, I; Bond, J; Aalberse, RC			Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cat allergy; diagnostics; Fel d 1; cat albumin; recombinant allergens	D-I; MONOCLONAL-ANTIBODIES; SEQUENCE-ANALYSIS; MAJOR ALLERGEN; SERUM-ALBUMIN; HUMAN IGE; BINDING; IMMUNOREACTIVITY; PURIFICATION; EXTRACTS	Background: Current diagnostics and therapeutics for cat allergy are based on cat epithelial extracts originating from highly variable source materials, This gives rise to several problems: variability of allergen composition, contamination with house dust mite allergens, and potential transfer of pathogenic agents. Objective: The aim of this study was to investigate the feasibility of replacing cat epithelial extracts with purified natural or recombinant allergens. Methods: Sera (n = 509) were selected on the basis of a positive cat RAST result and tested in a RAST for IgE reactivity to purified Fel d 1, cat albumin (CA), or both. The analysis was performed with both natural and recombinant allergens, In addition, some sera were further analyzed by means of immunoblotting, A serum pool was used for cat RAST inhibition with purified natural and recombinant allergens as inhibitors. Results: Natural and recombinant Fel d 1 caused very similar results: 94.1% and 96.1% positive test results, respectively. In general, the negative sera were low responders to cat extract. The addition of CA (16.7% positive sera) resulted in a decrease in the number of discrepencies between purified allergens and whole extract to 2.8%. Only for 2% of all sera, sensitization to cat was largely explained by IgE reactivity to CA. IgE reactivity to Fel d 1 accounts for 886 of the total IgE response to cat allergens, as was demonstrated by RAST, with Fel d 1 concentrations nearing saturation, Recombinant Fel d 1 performed equally well in the RAST analysis. Recombinant CA was succesfully expressed in the yeast Pichia pastoris, and its immune reactivity closely resembled that of its natural counterpart. Conclusion: Natural and recombinant Fel d 1 and CA are good candidates for replacing ill-defined cat dander extracts in diagnostics for cat allergy, Although CA is not essential for the vast majority of cat-sensitized patients, some subjects are selectively sensitized to this serum protein.	Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Expt & Clin Immunol Lab, NL-1105 AZ Amsterdam, Netherlands; ImmuLog Pharmaceut Corp, Waltham, MA USA	University of Amsterdam; Academic Medical Center Amsterdam	van Ree, R (corresponding author), Dept Allergy, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; BOND JF, 1993, MOL IMMUNOL, V30, P1529, DOI 10.1016/0161-5890(93)90461-J; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; GOUBRAN BH, 1996, IMMUNOLOGY, V88, P340; Hilger C, 1997, ALLERGY, V52, P179, DOI 10.1111/j.1398-9995.1997.tb00972.x; Hilger C, 1996, GENE, V169, P295, DOI 10.1016/0378-1119(95)00851-9; KEATING KM, 1995, MOL IMMUNOL, V32, P287, DOI 10.1016/0161-5890(94)00140-V; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; ROGERS BL, 1993, MOL IMMUNOL, V30, P559, DOI 10.1016/0161-5890(93)90030-F; SLUNT JB, 1995, J ALLERGY CLIN IMMUN, V95, P1221, DOI 10.1016/S0091-6749(95)70079-X; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; van Ree R, 1999, ALLERGY CLIN IMMUNOL, V11, P55; vanderVeen MJ, 1996, J ALLERGY CLIN IMMUN, V98, P1028, DOI 10.1016/S0091-6749(96)80187-4; VANMILLIGEN FJ, 1992, INT ARCH ALLERGY IMM, V99, P63, DOI 10.1159/000236337; VANREE R, 1994, ALLERGY, V49, P254; vanRee R, 1997, ALLERGY, V52, P795; VANREE R, 1997, REGULATORY CONTROL S, P174; VANREE R, 1993, REGULATORY CONTROL S, P127; VANTHOF W, 1993, ALLERGY, V48, P255	23	96	101	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1223	1230		10.1016/S0091-6749(99)70017-5	http://dx.doi.org/10.1016/S0091-6749(99)70017-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589005				2022-12-18	WOS:000084289200017
J	Taha, RA; Minshall, EM; Miotto, D; Shimbara, A; Luster, A; Hogg, JC; Hamid, QA				Taha, RA; Minshall, EM; Miotto, D; Shimbara, A; Luster, A; Hogg, JC; Hamid, QA			Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and nonasthmatic individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokines; allergic inflammation; peripheral airways; eotaxin; monocyte chemotactic protein-4; eosinophils	ATOPIC ASTHMA; MESSENGER-RNA; RECEPTOR CCR3; BRONCHIAL BIOPSIES; EOSINOPHILS; CELLS; LYMPHOCYTES; MCP-4; INTERLEUKIN-5; INFLAMMATION	Background: Although an eosinophilic infiltrate has been observed in the small airways of asthmatic individuals, the mechanisms responsible for cellular recruitment in the lung periphery remain to be clarified, Eotaxin and monocyte chemotactic protein (MCP)-4 are 2 eosinophil-associated chemokines shown to be upregulated at sites of allergic inflammation. However, their expression within the small airways of asthmatic individuals remains to be elucidated, Objective: We sought to determine the expression of eotaxin and,MCP-4 in the peripheral airways and parenchyma of lungs of subjects vith asthma and to assess their relationship to the numbers of resident eosinophils. Methods: We examined surgically resected lung tissue from 6 asthmatic and 10 nonasthmatic subjects for the presence of eotaxin and MCP-4 mRNA. by in situ hybridization, Chemokine mRNA expression was examined with respect to the numbers of eosinophils within the airways, as detected by immunocytochemistry for major basic protein. Results: Numbers of chemokine mRNA-positive cells were significantly increased in the large and small airways of asthmatic subjects compared with nonasthmatic subjects, Although eotaxin and MCP-4 mRNA were widely expressed in the lungs of subjects with asthma, their expression was particularly evident within the bronchial epithelium and inflammatory cells. In the airways of the asthmatic individuals, the expression of eotaxin mRNA was significantly correlated to the numbers of eosinophils present. Conclusion: There is an increased expression of eotaxin and MCP-4 mRNA within the peripheral airways of lungs of asthmatic subjects, suggesting that these chemokines contribute to the small airways and peripheral lung inflammation in asthma.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Harvard Univ, Sch Med, Boston, MA USA; Univ British Columbia, Pulm Res Lab, Vancouver, BC, Canada	McGill University; Harvard University; Harvard Medical School; University of British Columbia	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; FRIGAS E, 1991, EUR RESPIR J, V4, pS123; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Laberge S, 1997, AM J RESP CELL MOL, V17, P193, DOI 10.1165/ajrcmb.17.2.2750; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lefort J, 1996, J CLIN INVEST, V97, P1117, DOI 10.1172/JCI118505; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Minshall EM, 1998, J ALLERGY CLIN IMMUN, V101, P386, DOI 10.1016/S0091-6749(98)70252-0; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Moqbel R, 1996, ADV EXP MED BIOL, V409, P287; Petering H, 1998, J IMMUNOL, V160, P555; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SEKIZAWA K, 1986, AM REV RESPIR DIS, V133, P593; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447, DOI 10.1164/ajrccm.157.2.9611043; Wright ED, 1998, J OTOLARYNGOL, V27, P281; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	31	96	99	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				476	483		10.1016/S0091-6749(99)70474-4	http://dx.doi.org/10.1016/S0091-6749(99)70474-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069883	Bronze			2022-12-18	WOS:000079175700018
J	Wilson, AM; McFarlane, LC; Lipworth, BJ				Wilson, AM; McFarlane, LC; Lipworth, BJ			Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hpothalamic-pituitary-adrenal axis; cortisol; adrenocorticotrophic hormone; intranasal corticosteroids; fluticasone propionate; beclomethasone dipropionate; triamcinolone acetonide	AQUEOUS NASAL SPRAY; INHALED FLUTICASONE PROPIONATE; SEASONAL ALLERGIC RHINITIS; HEALTHY-VOLUNTEERS; BECLOMETHASONE; SUPPRESSION; BUDESONIDE; SINGLE	Background: Intranasal corticosteroids are regarded as the first-line treatment for allergic rhinitis, but few studies have directly compared their systemic effects. Objective: We sought to compare the hypothalamic-pituitary-adrenal (HPA)-axis suppression with three intranasal corticosteroids in terms of basal and dynamic adrenocortical activity. Methods: Sixteen healthy volunteers (mean age, 30.7 years) were studied in a single-blind, randomized, four-way crossover study comparing placebo with 200 mu g/day fluticasone propionate (FP), 220 mu g/day triamcinolone acetonide (TAA), anti 336 mu g/day beclomethasone dipropionate (BDP), After 4 days or treatment, an overnight urine collection was taken for cortisol and creatinine excretion starting at 10 PM (14 hours after the fourth dose), and blood was taken for serum cortisol at 8 AM (24 hours after the fourth dose) and after stimulation with adrenocorticotrophic hormone (ACTH) (0.5 mu g). Results: For overnight urinary cortisol excretion compared with placebo (20.8 nmol), there was a significant (p < 0.05) degree of suppression with FP (11.8 nmol) but not with TAA (16.0 nmol) or BDP (16.5 nmol). In terms of fold difference (95% CI for difference) from placebo, this amounted to 1.75-fold (1.01 to 3.03) for FP (43% suppression), 1.30-fold (0.75 to 2.25) for TAA (23% suppression), and 1.26-fold (0.73 to 2.18) for BDP (21% suppression). There was also a trend towards suppression of overnight, urinary cortisol/creatinine excretion, but this was not statistically significant (placebo, 5.2 nmol/mmol; TAA, 5.0 nmol/mmol; BDP, 4.3 nmol/mmol; and FP, 4.3 nmol/mmol). Values for serum cortisol before and after ACTH stimulation showed no significant suppression. Conclusion: Suppression of overnight urinary cortisol occurred dth intranasal FP (43%), TAA (23%), and BDP (21%), although this was only statistically significant with FP. None of the drugs were associated with blunting of the response to ACTH stimulation. Further studies are indicated to establish whether the systemic effects of inhaled and intraanasal corticosteroids are additive.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.							Bernstein DI, 1996, J ALLERGY CLIN IMMUN, V97, P749, DOI 10.1016/S0091-6749(96)80151-5; Boorsma M, 1996, EUR RESPIR J, V9, P1427, DOI 10.1183/09031936.96.09071427; BRANNAN MD, 1995, CLIN THER, V17, P637, DOI 10.1016/0149-2918(95)80040-9; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; Bronsky EA, 1996, J ALLERGY CLIN IMMUN, V97, P915, DOI 10.1016/S0091-6749(96)80065-0; BROWN PH, 1991, RESP MED, V85, P511, DOI 10.1016/S0954-6111(06)80269-6; Clark DJ, 1997, THORAX, V52, P55, DOI 10.1136/thx.52.1.55; ENGLISH AF, 1994, AM J RESP CRIT CAR S, V149, pA212; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; GRAHNEN A, 1994, BRIT J CLIN PHARMACO, V38, P521, DOI 10.1111/j.1365-2125.1994.tb04393.x; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; Howland WC, 1996, J ALLERGY CLIN IMMUN, V98, P32, DOI 10.1016/S0091-6749(96)70223-3; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; Lipworth BJ, 1996, BRIT J CLIN PHARMACO, V42, P697, DOI 10.1046/j.1365-2125.1996.00493.x; LIPWORTH BJ, 1987, RHINOLOGY, V25, P77; Lonnebo A, 1996, EUR J CLIN PHARMACOL, V49, P459; MCINTYRE HD, 1995, THORAX, V50, P1280, DOI 10.1136/thx.50.12.1280; MYGIND N, 1993, ALLERGY, V48, P476, DOI 10.1111/j.1398-9995.1993.tb01103.x; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; Rasmuson S, 1996, CLIN ENDOCRINOL, V44, P151, DOI 10.1046/j.1365-2265.1996.600482.x; Thorsson L, 1997, BRIT J CLIN PHARMACO, V43, P155, DOI 10.1046/j.1365-2125.1997.d01-1425.x; VANAS A, 1991, ANN ALLERGY, V67, P156; Wilson AM, 1997, AM J RESP CRIT CARE, V156, P1274, DOI 10.1164/ajrccm.156.4.97-03029; WURTHWEIN G, 1992, PHARM ZELT WISSENSCH, V137, P161	24	96	99	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				470	474		10.1016/S0091-6749(98)70354-9	http://dx.doi.org/10.1016/S0091-6749(98)70354-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564799				2022-12-18	WOS:000073113500008
J	Patchett, K; Lewis, S; Crane, J; Fitzharris, P				Patchett, K; Lewis, S; Crane, J; Fitzharris, P			Cat allergen (Fel d 1) levels on school children's clothing and in primary school classrooms in Wellington, New Zealand	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cat; Fel d 1; schools; allergen; clothing; carpet	HOUSE-DUST MITE; ASTHMATIC-CHILDREN; INHALANT ALLERGENS; CHILDHOOD ASTHMA; D-I; EXPOSURE; HOMES; RISK; SENSITIZATION; ANTIBODIES	Background: New Zealand has a high prevalence of the major allergic diseases including asthma, rhinitis, and eczema, and cat ownership is common, with more than 50% of homes containing a cat. Objective: The study was designed to examine the levels of cat allergen (Fel d 1) in the primary school environment, both on floors and on children's clothing. Methods: We collected and analyzed dust samples from 11 school classrooms and from 202 children's garments using vacuum sampling and two-site monoclonal antibody ELISA, respectively. Environmental variables were identified by questionnaire. Results: The geometric mean level of Fel d 1 in classrooms was 2.61 mu/gm (95% confidence interval, 1.28 to 3.84); however, seven classrooms had a floor sample with Fel d 1 greater than 8 mu g/m(2). Carpeted floor levels at 2.21 mu g/gm (1.28 to 3.84) were considerably higher than those on uncarpeted floors, at 0.33 mu g/gm (0.1 to 1.14). Floor levels and pupil cat ownership rates were positively correlated (r(2) = 0.93, p = 0.0003). Children from homes with cats carried allergen on their clothes (mean Fel d 1, 6.10 mu g per garment compared with non-cat owners (0.72 mu g per garment). Wool and polyester garments contained more Fel d 1 than cotton clothing. Girls' clothing had significantly higher levels of allergen than did that of boys, even after controlling for cat status and fabric differences. Conclusions: Carpeting should be discouraged in environments such as schools and child care centers, where children spend considerable time. Transport of Fel d 1 on clothing from the domestic to the school environment is a major source of classroom cat allergen.	Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, Wellington S, New Zealand	University of Otago	Fitzharris, P (corresponding author), Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, POB 7343, Wellington S, New Zealand.							ASHER MI, 1988, AM REV RESPIR DIS, V138, P524, DOI 10.1164/ajrccm/138.3.524; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164, DOI 10.1111/j.1365-2222.1994.tb03323.x; DELACOURT C, 1994, ALLERGY, V49, P843, DOI 10.1111/j.1398-9995.1994.tb00785.x; DYBENDAL T, 1994, ALLERGY, V49, P210, DOI 10.1111/j.1398-9995.1994.tb02651.x; ENBERG RN, 1993, ANN ALLERGY, V70, P471; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LUCZYNSKA CM, 1994, RESP MED, V88, P723, DOI 10.1016/S0954-6111(05)80193-3; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; PATCHETT K, 1996, THESIS U OTAGO WELLI; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1982, NEW ZEAL MED J, V95, P533; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Siebers RW, 1996, J ALLERGY CLIN IMMUN, V98, P853, DOI 10.1016/S0091-6749(96)70141-0; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1992, CLIN EXP ALLERGY, V23, P279; WARNER JA, 1993, CLIN EXP ALLERGY, V23, P279, DOI 10.1111/j.1365-2222.1993.tb00323.x	21	96	96	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				755	759		10.1016/S0091-6749(97)70269-0	http://dx.doi.org/10.1016/S0091-6749(97)70269-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438482				2022-12-18	WOS:000071353600006
J	SanchezBorges, M; CaprilesHulett, A; FernandezCaldas, E; SuarezChacon, R; Caballero, F; Castillo, S; Sotillo, E				SanchezBorges, M; CaprilesHulett, A; FernandezCaldas, E; SuarezChacon, R; Caballero, F; Castillo, S; Sotillo, E			Mite-contaminated foods as a cause of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	51st Annual Meeting of the American-Academy-of-Allergy-and-Immunology	FEB 24-MAR 01, 1995	NEW YORK, NY	Amer Acad Allergy & Immunol		anaphylaxis; mites; Dermatophagoides farinae; wheat flour; food allergy	HOUSE-DUST MITES; TROPICAL ENVIRONMENT; ALLERGIC REACTIVITY; DERMATOPHAGOIDES; DISEASE; IGG	Background: Although insect and arthropod contamination of certain foods has been recognized for many Sears, allergic manifestations caused by ingestion of mite allergens have only rarely been reported. Objective: The purpose of this study is to present clinical observations in patients who experienced acute anaphylaxis after eating mite-contaminated foods, Methods: Thirty atopic subjects who were first seen with systemic anaphylaxis precipitated by the ingestion of wheat-containing foods underwent skin prick tests with inhalant and food extracts, as well as with uncontaminated and mite-contaminated wheat flour, Flour samples were examined michoscopically for identification and counting of mites, Der p 1 and Der f 1 levels were quantitated by using immunochemical methods. Results: The most common symptoms were breathlessness, angioedema, wheezing, and rhinorrhea, which started between 10 and 240 minutes after eating. Abundant mites sere present in the flour obtained from 25 patients; Suidasia spp. mites were found in grated bread from the other two patients. Positive pride test responses to Dermatophagoides farinae- and mite-contaminated flour and negative skin test responses to wheat extract, other food extracts, and uncontaminated wheat flour were found in all patients. Skin test responses were positive in volunteers with mite allergy even after heating Lire mite-contaminated flour at 100 degrees C. Screening of 35 unselected flour samples demonstrated the presence of mites in 13 of them (37.1%). Conclusions: Systemic anaphylaxis can occur after the ingestion of heated or unheated mite-contaminated foods. This problem may be mure prevalent in tropical and subtropical countries than previously recognized.	CTR MED DOCENTE LA TRINIDAD,SERV IMMUNOL,CARACAS,VENEZUELA; MINIST HLTH,INST ONCOL & HEMATOL,SERV IMMUNOL,CARACAS,VENEZUELA; IETI SA,CBF,RES LAB,MADRID,SPAIN									ARLIAN LG, 1983, J MED ENTOMOL, V20, P99, DOI 10.1093/jmedent/20.1.99; ARLIAN LG, 1989, IMMUNOL CLIN N AM, V9, P2; Blanco C., 1996, Journal of Allergy and Clinical Immunology, V97, P363, DOI 10.1016/S0091-6749(96)80939-0; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; ERBEN AM, 1993, J ALLERGY CLIN IMMUN, V92, P846, DOI 10.1016/0091-6749(93)90062-K; FERNANDEZCALDAS E, 1991, ALLERGEN IMMUNOTHERA, P69; FRIERI M, 1994, 50 ANN M AM AC ALL I; HAGEL I, 1993, INT ARCH ALLERGY IMM, V101, P209, DOI 10.1159/000236521; HUGHES AM, 1961, MIN AGR FISH TECHNIC, V9; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LYNCH NR, 1984, J ALLERGY CLIN IMMUN, V73, P229, DOI 10.1016/S0091-6749(84)80012-3; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; LYNCH NR, 1984, CLIN ALLERGY, V14, P233, DOI 10.1111/j.1365-2222.1984.tb02202.x; MATSUMOTO T, 1996, INT ARCH ALLERGY IMM, V109, P2; PHILLIPS JK, 1984, INSECT MANAGEMENT FO; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1992, ASTHMA BASIC MECH CL, P515; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; SANCHEZBORGES M, 1991, PROGR ALLERGY CLIN I, P333; SOLIMAN MY, 1986, AM REV RESPIR DIS, V134, P962, DOI 10.1164/arrd.1986.134.5.962; SPIEGEL WA, 1995, ANN ALLERG ASTHMA IM, V74, P56; Stevenson DD, 1992, ALLERGY, P1747; *WHO, 1988, B WHO, V66; [No title captured]	26	96	99	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				738	743		10.1016/S0091-6749(97)80005-X	http://dx.doi.org/10.1016/S0091-6749(97)80005-X			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215239				2022-12-18	WOS:A1997XH19300004
J	Ryan, JJ				Ryan, JJ			Interleukin-4 and its receptor: Essential mediators of the allergic response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											Ryan, JJ (corresponding author), NIAID,IMMUNOL LAB,NIH,BLDG 10,BETHESDA,MD 20892, USA.							ELLIS E, 1992, MERCK MANUAL DIAGNOS, P646; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; TEPPER R, 1994, RES IMMUNOL, V144, P633; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845	8	96	101	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				1	5						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003204				2022-12-18	WOS:A1997WD06100001
J	Kane, GC; Pollice, M; Kim, CJ; Cohn, J; Dworski, RT; Murray, JJ; Sheller, JR; Fish, JE; Peters, SP				Kane, GC; Pollice, M; Kim, CJ; Cohn, J; Dworski, RT; Murray, JJ; Sheller, JR; Fish, JE; Peters, SP			A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SAC of the lung; bronchoalveolar lavage; leukotriene B-4; cysteinyl leukotrienes; 5-lipoxygenase; zileuton; eosinophil; neutrophil; IgE-mediated inflammation	AIRWAY INFLAMMATION; ALLERGEN CHALLENGE; PATHO-PHYSIOLOGY; LEUKOTRIENES; ASTHMA; IMMEDIATE; MEDIATORS; RHINITIS; RELEASE; RECRUITMENT	Background: Segmental antigen challenge (SAC) and bronchoalveolar lavage (BAL) have been proven useful for investigating IgE-mediated lung inflammation in volunteers with allergies. Objective: This model was used to evaluate the pulmonary antiinflammatory effects of an experimental 5-lipoxygenase inhibitor (zileuton) in subjects allergic to ragweed. We hypothesized that decreased generation of leukotrienes by inhibition of the 5-lipoxygenase pathway of arachidonic acid metabolism would diminish the subsequent inflammatory response resulting from antigen challenge. Methods: Ten subjects with allergies received zileuton or placebo, 600 mg administered orally four times a day for 8 days, and then underwent bronchoscopy, BAL of a control segment, and SAC in the contralateral lung followed by BAL of the challenged segment 24 hours later in a double-blind, placebo-controlled, crossover protocol. Urinary excretion of leukotriene E(4) induced by antigen challenge plus total and differential cell counts and the amount of total protein, albumin, urea, and eosinophil cationic protein in BAL fluid were determined. Results: A significant inhibition of leukotriene production (approximately 86%) was observed in subjects receiving zileuton. In addition, there was a statistically significant increase in eosinophils after antigen challenge (0.6 +/- 0.2 x 10(4) eosinophils/ml increasing to 49.0 +/- 25.0 x 10(4)) in subjects receiving placebo, whereas the influx of eosinophils in subjects receiving zileuton was not statistically different from baseline (1.1 +/- 0.7 x 10(4) eosinophils/ml increasing to 16.5 +/- 4.1 x 10(4); analysis of variance for repeated measures with post hoc comparisons). Conclusion: Treatment with zileuton altered the inflammatory response after antigen challenge. Products of the 5-lipoxygenase pathway appear to be important in recruiting eosinophils to the lung after SAC.	CHUNG ANG UNIV, COLL PHARM, SEOUL 156756, SOUTH KOREA; ABBOTT LABS, IMMUNOSCI VENTURE, ABBOTT PK, IL 60064 USA; VANDERBILT UNIV, MED CTR, DEPT MED, DIV ALLERGY & IMMUNOL, NASHVILLE, TN USA; VANDERBILT UNIV, MED CTR, DEPT MED, DIV PULM & CRIT CARE MED, NASHVILLE, TN USA	Chung Ang University; Abbott Laboratories; Vanderbilt University; Vanderbilt University	Kane, GC (corresponding author), JEFFERSON MED COLL, DEPT MED, DIV PULM & CRIT CARE MED, 805 COLL BLDG, 1025 WALNUT ST, PHILADELPHIA, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 24509] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAY MA, 1983, BRIT MED BULL, V39, P249, DOI 10.1093/oxfordjournals.bmb.a071828; CHANEY AL, 1962, CLIN CHEM, V8, P130; COLLINS DS, 1993, AM REV RESPIR DIS, V147, P677, DOI 10.1164/ajrccm/147.3.677; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DUPUIS R, 1992, J ALLERGY CLIN IMMUN, V89, P850, DOI 10.1016/0091-6749(92)90441-4; FAWCETT JK, 1960, J CLIN PATHOL, V13, P156, DOI 10.1136/jcp.13.2.156; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, ANN INTERN MED, V119, P10595; KIM CJ, 1994, PROSTAGLANDINS, V47, P393, DOI 10.1016/0090-6980(94)90056-6; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; KOH YY, 1993, AM J RESP CELL MOL, V8, P493, DOI 10.1165/ajrcmb/8.5.493; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM S, 1991, J ALLERGY CLIN IMMUN, V87, P842, DOI 10.1016/0091-6749(91)90131-7; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LIU MC, 1993, AM REV RESPIR DIS, V147, pA521; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; RUBIN P, 1991, AGENT ACTION SUPPL, V35, P103; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SHAVER JR, IN PRESS AM J RESPIR; SMITH DL, 1993, AM REV RESPIR DIS, V148, P523, DOI 10.1164/ajrccm/148.2.523; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; TAGARI P, 1989, CLIN CHEM, V35, P388; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450	31	96	96	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					646	654		10.1016/S0091-6749(96)70310-X	http://dx.doi.org/10.1016/S0091-6749(96)70310-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621850	Bronze			2022-12-18	WOS:A1996TW08700010
J	PINCUS, DJ; SZEFLER, SJ; ACKERSON, LM; MARTIN, RJ				PINCUS, DJ; SZEFLER, SJ; ACKERSON, LM; MARTIN, RJ			CHRONOTHERAPY OF ASTHMA WITH INHALED STEROIDS - THE EFFECT OF DOSAGE TIMING ON DRUG EFFICACY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; INHALED STEROIDS; CHRONOTHERAPY; DOSE TIMING; TRIAMCINOLONE ACETONIDE	BECLOMETHASONE DIPROPIONATE; DOSING FREQUENCY; BUDESONIDE; TWICE; CHILDREN; MILD	Background: Studies in asthma with systemic corticosteroids given at 3:00 PM have shown a superior therapeutic benefit compared with dosing at other time points. Objective: The study was designed to compare beneficial and systemic effects of 800 mu g of inhaled triamcinolone once daily at 3:00 PM (QD group) versus 200 mu g conventional four times a day dosing (QID group). Methods: Efficacy outcome measures included forced expiratory volume in I second (FEV(1)), peak expiratory pow rates, bronchial responsiveness, and use of beta-agonist. Systemic effects were blood eosinophil and cortisol levels, 24-hour urinary cortisol, and evaluation for oral candidiasis and dysphonia. Results: The baseline FEV(1) was comparable in the two groups: QD = 67% +/- 2% and QID = 66% +/- 2% of predicted value. After 4 weeks of treatment, FEV(1) increased similarly in the QD group to 77% +/- 4% and in the QID group to 74% +/- 4% of predicted value. Likewise, the improvement in morning and evening peak expiratory flow rates was nor significantly different between the groups. Both QD and QID groups experienced comparable daily decrements in beta-agonist use. The systemic responses to the two regimens as assessed by eosinophil count, morning serum cortisol, and 24-hour urinary cortisol were also comparable. Conclusions: The single daily administration of inhaled triamcinolone at 3:00 PM has no increased systemic effects and produces similar improvement in efficacy variables. A dosing strategy based on once daily dosing should increase compliance of inhaled steroid use in the clinical setting.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,PULM & CRIT CARE SECT,DENVER,CO	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	PINCUS, DJ (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,ROOM J116,DENVER,CO 80206, USA.				NHLBI NIH HHS [HL 36577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYD FJ, 1974, JAMA-J AM MED ASSOC, V230, P263, DOI 10.1001/jama.230.2.263; BARTOSZEK M, 1987, CLIN PHARMACOL THER, V42, P424, DOI 10.1038/clpt.1987.173; BEAM WR, 1992, AM REV RESPIR DIS, V146, P1524, DOI 10.1164/ajrccm/146.6.1524; BOYD G, 1985, CLIN ALLERGY, V15, P383, DOI 10.1111/j.1365-2222.1985.tb03007.x; DAHL R, 1982, EUR J RESPIR DIS, V63, P268; MALO JL, 1989, AM REV RESPIR DIS, V140, P624, DOI 10.1164/ajrccm/140.3.624; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; MOHIUDDIN AA, 1990, AM REV RESPIR DIS, V142, P1153, DOI 10.1164/ajrccm/142.5.1153; MUNCH EP, 1982, EUR J RESPIR DIS, V63, P143; NICHOLS T, 1965, J CLIN ENDOCR METAB, V25, P343, DOI 10.1210/jcem-25-3-343; REINBERG A, 1974, CHRONOBIOLOGIA, V1, P333; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; WILLEY RF, 1982, BRIT J DIS CHEST, V76, P61, DOI 10.1016/0007-0971(82)90009-2; 1975, CHEST, V67, P583	15	96	99	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1172	1178		10.1016/S0091-6749(95)70073-0	http://dx.doi.org/10.1016/S0091-6749(95)70073-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797785				2022-12-18	WOS:A1995RD30900004
J	SILVIUDAN, F; MCPHILLIPS, S; WARRINGTON, RJ				SILVIUDAN, F; MCPHILLIPS, S; WARRINGTON, RJ			THE FREQUENCY OF SKIN-TEST REACTIONS TO SIDE-CHAIN PENICILLIN DETERMINANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PENICILLINS; SEMISYNTHETICS; IMMEDIATE HYPERSENSITIVITY SKIN TESTS	GOOD TOLERANCE; HYPERSENSITIVITY REACTIONS; ALLERGY; AMOXYCILLIN; ANTIBODIES; CHILDREN	Background: Skin testing for immediate hyper sensitivity to penicillins is usually carried out with reagents prepared from benzylpenicillin, and it is believed that side-chain-specific rections to semisynthetic derivatives are rare. Because some experimental and clinical data suggest that antibodies can be induced to immunogenic epitopes on the side chains of penicillins, we looked for side-chain-specific reactions to skin testing in patients with a history of allergy to penicillins or semisynthetic penicillins. Methods: One hundred twelve patients with a clinical history of allergic reactions to penicillins and other semisynthetic penicillins were skin tested an average of 4.9 +/- 0.7 years after their reactions with the major and minor determinants of benzylpenicillin and minor determinant mixtures of ampicillin, amoxicillin, or cloxacillin. Results: In these patients the most common clinical reactions were urticaria and angioedema (36.6%) and exanthema (48.8%). It was found that 21 cases (18.8%) still exhibited immediate hypersensitivity reactions on skin testing. But of these 21 patients, skin test reactivity was limited in 47.6% to the semisynthetic penicillin reagents derived from ampicillin, amoxicillin, or cloxacillin; that is, skin tests were negative with the benzylpenicillin derivatives. Ampicillin and amoxicillin were the semisynthetic beta-lactams causing most clinical reactions (24.1% and 33.9%, respectively), and ampicillin was the most common penicillin derivative to which skin test reactivity occurred (38.1%), other than the benzylpenicillin derivatives (52.3%). Conclusions: IgE antibodies appear therefore to discriminate between benzylpenicillin and ampicillin or other semisynthetic penicillins in a significant proportion of patients allergic to penicillin. Although it has not been proved that side-chain-specific skin reactivity implies the presence of clinically significant immediate hypersensitivity to semisynthetic penicillins, it is possible that side-chain-specific reagents may be required to exclude possible immediate hypersensitivity to the penicillins in patients who reacted to these antibiotics clinically.	HLTH SCI CTR,ALLERGY & CLIN IMMUNOL SECT,GC319-820 SHERBROOK ST,WINNIPEG R3A 1R9,MB,CANADA; UNIV MANITOBA,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba								BLANCA M, 1990, CLIN EXP ALLERGY, V20, P475, DOI 10.1111/j.1365-2222.1990.tb03139.x; BLANCA M, 1988, ALLERGY, V43, P508, DOI 10.1111/j.1398-9995.1988.tb01628.x; BLANCA M, 1989, J ALLERGY CLIN IMMUN, V83, P270; BROWN BC, 1964, JAMA-J AM MED ASSOC, V189, P599; BUNDGAARD H, 1976, J PHARM PHARMACOL, V9, P725; CHANDRA RK, 1980, ARCH DIS CHILD, V55, P587; CHOPRA R, 1989, CAN MED ASSOC J, V140, P921; DEHAAN P, 1985, INT ARCH ALLER A IMM, V76, P42, DOI 10.1159/000233659; DEWDNEY JM, 1907, ANTIGENS, P73; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; LEVINE BB, 1966, J CLIN INVEST, V45, P1895, DOI 10.1172/JCI105494; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; MOSS RB, 1984, J PEDIATR-US, V104, P460, DOI 10.1016/S0022-3476(84)81117-8; SAXON A, 1983, REV INFECT DIS, V5, P5368; SOGN DD, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90358-5; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; STEWART GT, 1967, LANCET, V1, P177; VANDELLEN RG, 1971, J ALLERGY CLIN IMMUN, V67, P230; WARRINGTON RJ, 1978, CAN MED ASSOC J, V11, P787; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x	23	96	99	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					694	701		10.1016/0091-6749(93)90188-L	http://dx.doi.org/10.1016/0091-6749(93)90188-L			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454791				2022-12-18	WOS:A1993KU20300001
J	WANDERER, AA; GRANDEL, KE; WASSERMAN, SI; FARR, RS				WANDERER, AA; GRANDEL, KE; WASSERMAN, SI; FARR, RS			CLINICAL CHARACTERISTICS OF COLD-INDUCED SYSTEMIC REACTIONS IN ACQUIRED COLD URTICARIA SYNDROMES - RECOMMENDATIONS FOR PREVENTION OF THIS COMPLICATION AND A PROPOSAL FOR A DIAGNOSTIC CLASSIFICATION OF COLD URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO; UNIV CALIF SAN DIEGO,MED CTR,DEPT MED,DIV ALLERGY,SAN DIEGO,CA 92103	National Jewish Health; National Jewish Health; University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017268, P50AI020476] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34617] Funding Source: Medline; NIAID NIH HHS [AI20476, AI17268] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson P C, 1967, Mo Med, V64, P916; BACK O, 1978, ACTA DERM-VENEREOL, V58, P369; BERMAN BA, 1983, CUTIS, V31, P20; BLACKMAN N S, 1959, N Y State J Med, V59, P2614; BURNS MR, 1983, ANN INTERN MED, V98, P1025, DOI 10.7326/0003-4819-98-6-1025_3; CHANG TW, 1965, J AMER MED ASSOC, V193, P848, DOI 10.1001/jama.1965.03090100094041; Costanzi J J, 1967, Clin Exp Immunol, V2, P167; CZARNETZKI BM, 1981, BRIT J DERMATOL, V104, P83, DOI 10.1111/j.1365-2133.1981.tb01716.x; Duke WW, 1924, J AMER MED ASSOC, V83, P3, DOI 10.1001/jama.1924.02660010007002; EADY RA, 1981, CLIN EXP DERMATOL, V6, P335; FITZPATRICK TB, 1963, ARCH DERMATOL, V87, P495; FRANK L, 1964, ARCH DERMATOL, V90, P246; Gay M W, 1970, Cutis, V6, P1104; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; Harris KE, 1929, HEART-J STUD CIRC, V14, P305; HAUPTMANN G, 1975, SCAND J HAEMATOL, V15, P22; HIGHET AS, 1979, BRIT J DERMATOL, V101, P51, DOI 10.1111/j.1365-2133.1979.tb15292.x; Horton BT, 1936, J AMER MED ASSOC, V107, P1263, DOI 10.1001/jama.1936.02770420001001; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; INOUE S, 1980, J ALLERGY CLIN IMMUN, V66, P299, DOI 10.1016/0091-6749(80)90025-1; JUHLIN L, 1961, JAMA-J AM MED ASSOC, V177, P371, DOI 10.1001/jama.1961.73040320001004; KAPLAN AP, 1984, J ALLERGY CLIN IMMUN, V73, P453, DOI 10.1016/0091-6749(84)90354-3; KAPLAN AP, 1981, NEW ENGL J MED, V305, P1074, DOI 10.1056/NEJM198110293051808; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P438; KOBACKER JL, 1935, JAMA-J AM MED ASSOC, V105, P662; LEIGH IM, 1974, T ST JOHNS HOSP DERM, V60, P40; MCGOVERN JP, 1948, J ALLERGY, V19, P408, DOI 10.1016/0021-8707(48)90038-0; MILLER DA, 1968, AM J MED, V44, P68, DOI 10.1016/0002-9343(68)90238-6; MOROZ LA, 1971, IMMUNOLOGICAL DISEAS, P459; MULLER SA, 1961, ARCH DERMATOL, V83, P930, DOI 10.1001/archderm.1961.01580120042009; NEITTAANMAKI H, 1984, J AM ACAD DERMATOL, V11, P483, DOI 10.1016/S0190-9622(84)70196-4; RAWNSLEY HM, 1968, ARCH DERMATOL, V98, P12, DOI 10.1001/archderm.98.1.12; RITZMANN SE, 1961, ARCH INTERN MED, V107, P754, DOI 10.1001/archinte.1961.03620050120014; SARKANY I, 1965, P ROY SOC MED, V58, P622, DOI 10.1177/003591576505800826; SARKANY I, 1971, BRIT J DERMATOL, V85, P46; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; SIGAL C, 1964, CAN MED ASSOC J, V91, P609; SOTER NA, 1977, J ALLERGY CLIN IMMUN, V59, P294, DOI 10.1016/0091-6749(77)90050-1; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129; TING S, 1985, J ALLERGY CLIN IMMUN, V75, P421, DOI 10.1016/0091-6749(85)90081-8; VELOU A, 1964, J Indian Med Assoc, V43, P401; VILLACORTE GV, 1970, J ALLERGY, V45, P122; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WANDERER AA, 1983, ARCH DERMATOL, V119, P145, DOI 10.1001/archderm.119.2.145; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WU LYF, 1983, ANN ALLERGY, V50, P271	46	96	96	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				417	423		10.1016/0091-6749(86)90027-8	http://dx.doi.org/10.1016/0091-6749(86)90027-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	3760401				2022-12-18	WOS:A1986E114800008
J	NOVEY, HS; HABIB, M; WELLS, ID				NOVEY, HS; HABIB, M; WELLS, ID			ASTHMA AND IGE ANTIBODIES INDUCED BY CHROMIUM AND NICKEL SALTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,COLL MED,DEPT MED,ORANGE,CA 92668	University of California System; University of California Irvine								BIDSTRUP P L, 1956, Br J Ind Med, V13, P260; BRETZA J, 1983, AM J MED, V74, P945, DOI 10.1016/0002-9343(83)90787-8; CROMWELL O, 1979, CLIN ALLERGY, V9, P109, DOI 10.1111/j.1365-2222.1979.tb01529.x; Joulfs H, 1932, LANCET, V2, P182; MCCONNELL LH, 1973, ANN INTERN MED, V78, P888, DOI 10.7326/0003-4819-78-6-888; MURPHY RLH, 1976, BRONCHIAL ASTHMA MEC, P517; NOVEY HS, 1980, CLIN ALLERGY, V10, P721, DOI 10.1111/j.1365-2222.1980.tb02157.x; PEPYS J, 1972, Clinical Allergy, V2, P197, DOI 10.1111/j.1365-2222.1972.tb01283.x; PEPYS J, 1980, J ALLERGY CLIN IMMUN, V66, P179, DOI 10.1016/0091-6749(80)90036-6; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1979, CLIN ALLERGY, V9, P99, DOI 10.1111/j.1365-2222.1979.tb01528.x; Smith AR, 1931, J AMER MED ASSOC, V97, P0095, DOI 10.1001/jama.1931.02730020023008; WIDE L, 1969, ACTA ENDOCRINOL-COP, VS 63, P207	13	96	100	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					407	412		10.1016/0091-6749(83)90507-9	http://dx.doi.org/10.1016/0091-6749(83)90507-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6413567				2022-12-18	WOS:A1983RN33000012
J	SHEFFER, AL; FEARON, DT; AUSTEN, KF				SHEFFER, AL; FEARON, DT; AUSTEN, KF			CLINICAL AND BIOCHEMICAL EFFECTS OF STANOZOLOL THERAPY FOR HEREDITARY ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NIADDK NIH HHS [AM-05577] Funding Source: Medline; NIAID NIH HHS [AI-07722, AI-10356] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; ARNOLD A, 1959, P SOC EXP BIOL MED, V102, P184; BOLCH SH, 1971, AM J OBSTET GYNECOL, V111, P1107; DAVIS PJ, 1974, JOHNS HOPKINS MED J, V135, P391; DECK HP, 1963, EXP MOL PATHOL S2, V2, P115; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GIGLI I, 1968, J IMMUNOL, V100, P1154; GOULD DJ, 1978, LANCET, V1, P770; HOSEA SW, 1980, ANN INTERN MED, V93, P809, DOI 10.7326/0003-4819-93-6-809; HOWARD RP, 1962, J CLIN ENDOCR METAB, V22, P43, DOI 10.1210/jcem-22-1-43; KEELE DK, 1967, AM J DIS CHILD, V113, P422, DOI 10.1001/archpedi.1967.02090190068004; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; Osler W, 1888, AM J MED SCI, V95, P362; PITTS JS, 1978, J LAB CLIN MED, V92, P501; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; Rosse W F, 1976, Trans Assoc Am Physicians, V89, P122; RUDDY S, 1967, J IMMUNOL, V99, P1162; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; SHEFFER AL, 1977, ANN INTERN MED, V86, P306, DOI 10.7326/0003-4819-86-3-306; SHEFFER AL, 1979, J ALLERGY CLIN IMMUN, V64, P275, DOI 10.1016/0091-6749(79)90144-1; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; WESTABY D, 1977, LANCET, V2, P261	23	96	97	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					181	187		10.1016/0091-6749(81)90181-0	http://dx.doi.org/10.1016/0091-6749(81)90181-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	6790595				2022-12-18	WOS:A1981MG54400003
J	HAGY, GW; SETTIPANE, GA				HAGY, GW; SETTIPANE, GA			RISK-FACTORS FOR DEVELOPING ASTHMA AND ALLERGIC RHINITIS - 7-YEAR FOLLOW-UP-STUDY OF COLLEGE-STUDENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROWN UNIV,DIV BIOL & MED SCI,PROVIDENCE,RI 02912; RHODE ISLAND HOSP,DEPT MED,DIV ALLERGY,PROVIDENCE,RI 02902	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital								BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; Higgins Michael D, COMMUNICATION; SMITH JM, 1971, J ALLERGY, V47, P23, DOI 10.1016/S0091-6749(71)80314-7	5	96	97	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	2					330	336		10.1016/0091-6749(76)90139-1	http://dx.doi.org/10.1016/0091-6749(76)90139-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	CA661	947983	Bronze			2022-12-18	WOS:A1976CA66100011
J	SOBOTKA, AK; VALENTINE, MD; BENTON, AW; LICHTENSTEIN, LM				SOBOTKA, AK; VALENTINE, MD; BENTON, AW; LICHTENSTEIN, LM			ALLERGY TO INSECT STINGS .1. DIAGNOSIS OF LGE-MEDIATED HYMENOPTERA SENSITIVITY BY VENOM-INDUCED HISTAMINE-RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; PENN STATE UNIV, UNIVERSITY PK, PA USA	Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park								ARBESMAN CE, 1965, J ALLERGY, V36, P147, DOI 10.1016/0021-8707(65)90163-2; BENSON RL, 1930, J ALLERGY, V1, P105; BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; BERNTON HS, 1965, J ALLERGY, V36, P315, DOI 10.1016/0021-8707(65)90038-9; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; DIRKS TF, 1972, TOXICON, V10, P381, DOI 10.1016/0041-0101(72)90062-1; FOUBERT EL, 1958, J ALLERGY, V29, P13, DOI 10.1016/0021-8707(58)90050-9; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; LANGLOIS C, 1965, J ALLERGY, V36, P12, DOI 10.1016/0021-8707(65)90028-6; LANGLOIS C, 1965, J ALLERGY, V36, P109, DOI 10.1016/0021-8707(65)90160-7; LEVINE MI, 1971, J AMER MED ASSOC, V217, P964, DOI 10.1001/jama.1971.03190070072024; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1966, J IMMUNOL, V97, P203; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MUELLER HL, 1971, IMMUNOLOGICAL DISEAS; PARISH HM, 1965, AM J MED SCI, V245, P129; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SHULMAN S, 1966, J IMMUNOL, V96, P29; 1965, JAMA, V193, P109	24	96	96	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	3					170	184		10.1016/0091-6749(74)90005-0	http://dx.doi.org/10.1016/0091-6749(74)90005-0			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S3550	4130686				2022-12-18	WOS:A1974S355000005
J	GALANT, SP; BULLOCK, J; WONG, D; MAIBACH, HI				GALANT, SP; BULLOCK, J; WONG, D; MAIBACH, HI			INHIBITORY EFFECT OF ANTI-ALLERGY DRUGS ON ALLERGEN AND HISTAMINE INDUCED WHEAL AND FLARE RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SO CALIF, MED CTR, LOS ANGELES, CA 90007 USA; UNIV CALIF, SAN FRANCISCO, CA 94122 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of California System; University of California San Francisco								BAIN WA, 1948, LANCET, V252, P964, DOI 10.1016/S0140-6736(48)91644-4; BECKER EL, 1948, J ALLERGY, V19, P317, DOI 10.1016/0021-8707(48)90112-9; BLACKLEY C, 1873, EXPERIMENTAL RESEARC; COLLINS JA, 1960, APPL THER, V2, P609; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; FEINBERG AR, 1958, J ALLERGY, V29, P358, DOI 10.1016/0021-8707(58)90041-8; FEINBERG SM, 1951, J ALLERGY, V22, P195, DOI 10.1016/0021-8707(51)90015-9; GALANT S, 1972, ANN ALLERGY, V30, P53; HAUGE HE, 1965, ACTA ALLERGOL, V20, P496, DOI 10.1111/j.1398-9995.1965.tb03084.x; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MAIBACH HI, 1963, ARCH DERMATOL, V87, P743, DOI 10.1001/archderm.1963.01590180071015; MOSKO MM, 1950, J ALLERGY, V21, P242, DOI 10.1016/0021-8707(50)90132-8; NYFORS A, 1970, ACTA ALLERGOL, V25, P53, DOI 10.1111/j.1398-9995.1970.tb01381.x; ORANGE RP, 1971, J EXP MED, V134, pS136; SHELDON J M, 1951, Ann Allergy, V9, P45; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P56; SHERMAN WB, 1968, HYPERSENSITIVITY MEC, P144; Snedecor G.W., 1980, STAT METHODS, V7; STANWORT.DR, 1965, IMMUNOLOGY, V8, P323; TUFT L, 1936, J ALLERGY, V7, P238; WOLFE HI, 1964, J ALLERGY, V35, P271, DOI 10.1016/0021-8707(64)90016-4	21	96	96	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	1					11	21		10.1016/0091-6749(73)90003-1	http://dx.doi.org/10.1016/0091-6749(73)90003-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O5651	4118408				2022-12-18	WOS:A1973O565100002
J	Galvan-Roman, JM; Rodriguez-Garcia, SC; Roy-Vallejo, E; Marcos-Jimenez, A; Sanchez-Alonso, S; Fernandez-Diaz, C; Alcaraz-Serna, A; Mateu-Albero, T; Rodriguez-Cortes, P; Sanchez-Cerrillo, I; Esparcia, L; Martinez-Fleta, P; Lopez-Sanz, C; Gabrie, L; Guerola, LD; Suarez-Fernandez, C; Ancochea, J; Canabal, A; Albert, P; Rodriguez-Serrano, DA; Aguilar, JM; del Arco, C; de los Santos, I; Garcia-Fraile, L; de la Camara, R; Serra, JM; Ramirez, E; Alonso, T; Landete, P; Soriano, JB; Martin-Gayo, E; Torres, AF; Cruz, NDZ; Garcia-Vicuna, R; Cardenoso, L; Sanchez-Madrid, F; Alfranca, A; Munoz-Calleja, C; Gonzalez-Alvaro, I				Maria Galvan-Roman, Jose; Rodriguez-Garcia, Sebastian C.; Roy-Vallejo, Emilia; Marcos-Jimenez, Ana; Sanchez-Alonso, Santiago; Fernandez-Diaz, Carlos; Alcaraz-Serna, Ana; Mateu-Albero, Tamara; Rodriguez-Cortes, Pablo; Sanchez-Cerrillo, Ildefonso; Esparcia, Laura; Martinez-Fleta, Pedro; Lopez-Sanz, Celia; Gabrie, Ligia; del Campo Guerola, Luciana; Suarez-Fernandez, Carmen; Ancochea, Julio; Canabal, Alfonso; Albert, Patricia; Rodriguez-Serrano, Diego A.; Mariano Aguilar, Juan; del Arco, Carmen; de los Santos, Ignacio; Garcia-Fraile, Lucio; de la Camara, Rafael; Maria Serra, Jose; Ramirez, Esther; Alonso, Tamara; Landete, Pedro; Soriano, Joan B.; Martin-Gayo, Enrique; Fraile Torres, Arturo; Zurita Cruz, Nelly Daniela; Garcia-Vicuna, Rosario; Cardenoso, Laura; Sanchez-Madrid, Francisco; Alfranca, Arantzazu; Munoz-Calleja, Cecilia; Gonzalez-Alvaro, Isidoro		REINMUN-COVID Grp	IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; IL-6; tocilizumab; invasive mechanical ventilation		Background: Patients with coronavirus disaese 2019 (COVID-19) can develop a cytokine release syndrome that eventually leads to acute respiratory distress syndrome requiring invasive mechanical ventilation (IMV). Because IL-6 is a relevant cytokine in acute respiratory distress syndrome, the blockade of its receptor with tocilizumab (TCZ) could reduce mortality and/or morbidity in severe COVID-19. Objective: We sought to determine whether baseline IL-6 serum levels can predict the need for IMV and the response to TCZ. Methods: A retrospective observational study was performed in hospitalized patients diagnosed with COVID-19. Clinical information and laboratory findings, including IL-6 levels, were collected approximately 3 and 9 days after admission to be matched with preadministration and postadministration of TCZ. Multivariable logistic and linear regressions and survival analysis were performed depending on outcomes: need for IMV, evolution of arterial oxygen tension/fraction of inspired oxygen ratio, or mortality. Results: One hundred forty-six patients were studied, predominantly males (66%); median age was 63 years. Forty-four patients (30%) required IMV, and 58 patients (40%) received treatment with TCZ. IL-6 levels greater than 30 pg/mL was the best predictor for IMV (odds ratio, 7.1; P < .001). Early administration of TCZ was associated with improvement in oxygenation (arterial oxygen tension/fraction of inspired oxygen ratio) in patients with high IL-6 (P = .048). Patients with high IL-6 not treated with TCZ showed high mortality (hazard ratio, 4.6; P = .003), as well as those with low IL-6 treated with TCZ (hazard ratio, 3.6; P = .016). No relevant serious adverse events were observed in TCZ-treated patients. Conclusions: Baseline IL-6 greater than 30 pg/mL predicts IMV requirement in patients with COVID-19 and contributes to establish an adequate indication for TCZ administration.	[Maria Galvan-Roman, Jose; Roy-Vallejo, Emilia; Rodriguez-Cortes, Pablo; Suarez-Fernandez, Carmen; de los Santos, Ignacio; Garcia-Fraile, Lucio] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Internal Med Serv, Madrid, Spain; [Rodriguez-Garcia, Sebastian C.; Fernandez-Diaz, Carlos; Garcia-Vicuna, Rosario; Gonzalez-Alvaro, Isidoro] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Rheumatol Serv, Madrid, Spain; [Marcos-Jimenez, Ana; Sanchez-Alonso, Santiago; Alcaraz-Serna, Ana; Mateu-Albero, Tamara; Sanchez-Cerrillo, Ildefonso; Esparcia, Laura; Martinez-Fleta, Pedro; Lopez-Sanz, Celia; Gabrie, Ligia; del Campo Guerola, Luciana; Martin-Gayo, Enrique; Sanchez-Madrid, Francisco; Alfranca, Arantzazu; Munoz-Calleja, Cecilia] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Immunol Serv, Madrid, Spain; [Ancochea, Julio; Alonso, Tamara; Landete, Pedro; Soriano, Joan B.] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Serv Pneumol, Madrid, Spain; [Canabal, Alfonso; Albert, Patricia; Rodriguez-Serrano, Diego A.] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Intens Care Unit, Madrid, Spain; [Mariano Aguilar, Juan; del Arco, Carmen] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Emergency Serv, Madrid, Spain; [de la Camara, Rafael] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Hematol Serv, Madrid, Spain; [Maria Serra, Jose; Ramirez, Esther] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Hosp Pharm Serv, Madrid, Spain; [Fraile Torres, Arturo; Zurita Cruz, Nelly Daniela; Cardenoso, Laura] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Microbiol Serv, Madrid, Spain; [Sanchez-Madrid, Francisco] Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Cardiovasc CIB, Madrid, Spain	Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; CIBER - Centro de Investigacion Biomedica en Red; CIBERCV	Gonzalez-Alvaro, I (corresponding author), Hosp Univ Princesa, Inst Invest Sanitaria Princesa IIS IP, Rheumatol Serv, C Diego de Leon 62, Madrid 28006, Spain.	isidoro.ga@ser.es	Marcos-Jiménez, Ana/AAD-1761-2022; de VicuÃa, Rosario Garcia/ABD-7892-2020; de la Camara, Rafael/B-2106-2009; I, Sanchez-Cerrillo/AAC-1150-2021; Fraile, Lucio Jesus García-Fraile/ABG-6690-2021; Gayo, Enrique Martin/AAK-4273-2021; Rodriguez-Garcia, Sebastián C/AAJ-4913-2020; Sanchez-Madrid, Francisco/M-7889-2016; Arco Galan, Carmen Del/I-2300-2018	Marcos-Jiménez, Ana/0000-0002-7606-3580; de VicuÃa, Rosario Garcia/0000-0001-9096-3780; de la Camara, Rafael/0000-0002-8189-5779; I, Sanchez-Cerrillo/0000-0001-7262-1234; Fraile, Lucio Jesus García-Fraile/0000-0002-2512-6107; Rodriguez-Garcia, Sebastián C/0000-0002-7773-151X; Ancochea, julio/0000-0001-7451-4133; Galvan Roman, Jose Maria/0000-0001-9260-8141; Bautista Hernandez, Azucena/0000-0002-5731-7282; De Los Santos Gil, Ignacio/0000-0001-7073-5211; Canabal Berlanga, Alfonso/0000-0001-7021-3456; Landete, Pedro/0000-0002-9631-9408; Lopez Sanz, Celia/0000-0001-7203-0290; Alfranca, Arantzazu/0000-0002-3732-5816; Aguilar Mulet, Juan Mariano/0000-0002-8306-5218; Montes, Nuria/0000-0001-9526-2772; Rodriguez Serrano, Diego Anibal/0000-0003-1841-2751; Garcia Castillo, Elena/0000-0002-4190-6533; Martinez-Fleta, Pedro/0000-0001-6107-0262; Sanchez-Madrid, Francisco/0000-0001-5303-0762; ALONSO PEREZ, TAMARA/0000-0002-6312-4575; Martin-Gayo, Enrique/0000-0002-2619-6086; Arco Galan, Carmen Del/0000-0002-4609-6963	Spanish Ministry of Economy, Industry and Competitiveness (MINECO); Instituto de Salud Carlos III [RD16/0011/0012, PI18/0371, PI19/00549, SAF2017-82886-R]; European Regional Development Fund; La Caixa Banking Foundation [HR17-00016]; "Fondos Supera COVID19'' by Banco de Santander; CRUE	Spanish Ministry of Economy, Industry and Competitiveness (MINECO)(Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund(European Commission); La Caixa Banking Foundation(La Caixa Foundation); "Fondos Supera COVID19'' by Banco de Santander; CRUE	This study was funded by Spanish Ministry of Economy, Industry and Competitiveness (MINECO) and Instituto de Salud Carlos III (grant nos. RD16/0011/0012 and PI18/0371 to I.G.A., grant no. PI19/00549 to A.A., and grant no. SAF2017-82886-R to F.S.-M.) and co-funded by the European Regional Development Fund. The study was also funded by "La Caixa Banking Foundation'' (grant no. HR17-00016 to F.S.-M.) and "Fondos Supera COVID19'' by Banco de Santander and CRUE. None of these sponsors have had any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.	[Anonymous], 2020, ROCH PROV UPD PHAS 3; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Borrega JG, 2019, HEMASPHERE, V3, DOI 10.1097/HS9.0000000000000191; ClinicalTrials.gov, 2020, SEARCH COVID19 TOCIL; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; De Luna G, 2020, AM J HEMATOL, V95, P876, DOI 10.1002/ajh.25833; European Medicines Agency, 2013, ROACTEMRA INN TOCILI; Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028; Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Luo P, 2020, J MED VIROL, V92, P814, DOI 10.1002/jmv.25801; Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; Pires-Neto RC, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.05.013; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529; SEVERINGHAUS JW, 1979, J APPL PHYSIOL, V46, P599, DOI 10.1152/jappl.1979.46.3.599; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; The Spanish Agency for Medicine and Health Products [Agencia Espa~nola de Medicamentos y Productos Sanitarios (AEMPS)], TREATMENTS AVAILABLE; Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786; Waterer GW, 2020, AM J RESP CRIT CARE, V201, P1324, DOI 10.1164/rccm.202004-1153ED; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954; Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907	31	95	98	2	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					72	+		10.1016/j.jaci.2020.09.018	http://dx.doi.org/10.1016/j.jaci.2020.09.018		JAN 2021	17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	33010257	Bronze, Green Published			2022-12-18	WOS:000613645900010
J	Pontali, E; Volpi, S; Antonucci, G; Castellaneta, M; Buzzi, D; Tricerri, F; Angelelli, A; Caorsi, R; Feasi, M; Calautti, F; Castagnola, E; Rollandi, GA; Ravelli, A; Cassola, G; Gattorno, M				Pontali, Emanuele; Volpi, Stefano; Antonucci, Giancarlo; Castellaneta, Marco; Buzzi, Davide; Tricerri, Francesca; Angelelli, Alessia; Caorsi, Roberta; Feasi, Marcello; Calautti, Francesca; Castagnola, Elio; Rollandi, Gian Andrea; Ravelli, Angelo; Cassola, Giovanni; Gattorno, Marco			Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Pontali, Emanuele; Antonucci, Giancarlo; Castellaneta, Marco; Buzzi, Davide; Tricerri, Francesca; Feasi, Marcello; Calautti, Francesca; Rollandi, Gian Andrea; Cassola, Giovanni] Ente Osped Osped Galliera, Genoa, Italy; [Volpi, Stefano; Angelelli, Alessia; Caorsi, Roberta; Castagnola, Elio; Ravelli, Angelo; Gattorno, Marco] IRCCS G Gaslini, Genoa, Italy	Ente Ospedaliero Ospedali Galliera; University of Genoa; IRCCS Istituto Giannina Gaslini	Gattorno, M (corresponding author), IRCCS G Gaslini, Genoa, Italy.	marcogattorno@gaslini.org	Volpi, Stefano/O-3717-2014; Gattorno, Marco/AAL-2974-2020; Caorsi, Roberta/K-8608-2016	Volpi, Stefano/0000-0002-7129-868X; Gattorno, Marco/0000-0003-0704-1916; Caorsi, Roberta/0000-0003-0131-7846; Pontali, Emanuele/0000-0002-1085-0442				Eloseily EM, 2020, ARTHRITIS RHEUMATOL, V72, P326, DOI 10.1002/art.41103; HENDERSON LA, 2020, ARTHRITIS RHEUM 1003, DOI DOI 10.1002/ART; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhang YL, 2020, ANN INTERN MED, V173, P402, DOI 10.7326/L20-0227; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	8	95	101	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					213	+		10.1016/j.jaci.2020.05.002	http://dx.doi.org/10.1016/j.jaci.2020.05.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32437739	Green Published, Bronze			2022-12-18	WOS:000579170500033
J	Peters, MC; Kerr, S; Dunican, EM; Woodruff, PG; Fajt, ML; Levy, BD; Israel, E; Phillips, BR; Mauger, DT; Comhair, SA; Erzurum, SC; Johansson, MW; Jarjour, NN; Coverstone, AM; Castro, M; Hastie, AT; Bleecker, ER; Wenzel, SE; Fahy, JV				Peters, Michael C.; Kerr, Sheena; Dunican, Eleanor M.; Woodruff, Prescott G.; Fajt, Merritt L.; Levy, Bruce D.; Israel, Elliot; Phillips, Brenda R.; Mauger, David T.; Comhair, Suzy A.; Erzurum, Serpil C.; Johansson, Mats W.; Jarjour, Nizar N.; Coverstone, Andrea M.; Castro, Mario; Hastie, Annette T.; Bleecker, Eugene R.; Wenzel, Sally E.; Fahy, John V.		Natl Heart Lung Blood Inst Severe	Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; type 2 inflammation; steroid resistance; biomarkers	GENE-EXPRESSION; INDUCED SPUTUM; CELLS; MEPOLIZUMAB; PHENOTYPES; SEVERITY	Background: Airway type 2 inflammation is usually corticosteroid sensitive, but the role of type 2 inflammation as a mechanism of asthma in patients receiving high-dose inhaled corticosteroids (ICSs) is uncertain. Objective: We sought to determine whether airway type 2 inflammation persists in patients treated with ICSs and to evaluate the clinical features of patients with steroid-resistant airway type 2 inflammation. Methods: We used quantitative PCR to generate a composite metric of type 2 cytokine gene expression (type 2 gene mean [T2GM]) in induced sputum cells from healthy control subjects, patients with severe asthma receiving ICSs (n = 174), and patients with nonsevere asthma receiving ICSs (n = 85). We explored relationships between asthma outcomes and T2GM values and the utility of noninvasive biomarkers of airway T2GM. Results: Sputum cell T2GM values in asthmatic patients were significantly increased and remained high after treatment with intramuscular triamcinolone. We used the median T2GM value as a cutoff to classify steroid-treated type 2-low and steroid-resistant type 2-high (srT2-high) subgroups. Compared with patients with steroid-treated type 2-low asthma, those with srT2-high asthma were older and had more severe asthma. Blood eosinophil cell counts predicted srT2-high asthma when body mass index was less than 40 kg/m(2) but not when it was 40 kg/m(2) or greater, whereas blood IgE levels strongly predicted srT2-high asthma when age was less than 34 years but not when it was 34 years or greater. Conclusion: Despite ICS therapy, many asthmatic patients have persistent airway type 2 inflammation(srT2-highasthma), andthese patients are older and have more severe disease. Body weight and age modify the performance of blood-based biomarkers of airway type 2 inflammation.	[Peters, Michael C.; Kerr, Sheena; Dunican, Eleanor M.; Woodruff, Prescott G.; Fahy, John V.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA; [Peters, Michael C.; Kerr, Sheena; Dunican, Eleanor M.; Woodruff, Prescott G.; Fahy, John V.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA USA; [Fajt, Merritt L.; Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Dept Med, Pulm Allergy & Crit Care Med Div, Pittsburgh, PA 15260 USA; [Levy, Bruce D.; Israel, Elliot] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Levy, Bruce D.; Israel, Elliot] Harvard Med Sch, Boston, MA USA; [Phillips, Brenda R.; Mauger, David T.] Penn State Univ, Dept Publ Hlth Sci, Div Stat & Bioinformat, Hershey, PA USA; [Comhair, Suzy A.; Erzurum, Serpil C.] Cleveland Clin Cleveland, Dept Pathobiol, Cleveland, OH USA; [Johansson, Mats W.] Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; [Jarjour, Nizar N.] Univ Wisconsin, Sch Med, Sect Pulm & Crit Care Med, Madison, WI 53706 USA; [Coverstone, Andrea M.] Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, MO 63130 USA; [Castro, Mario] Washington Univ, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63130 USA; [Castro, Mario] Washington Univ, Dept Med, Dept Pediat, St Louis, MO 63130 USA; [Hastie, Annette T.; Bleecker, Eugene R.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Cleveland Clinic Foundation; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Wake Forest University; Wake Forest Baptist Medical Center	Fahy, JV (corresponding author), Univ Calif San Francisco, Hlth Sci East, Rm 1307,513 Parnassus Ave, San Francisco, CA 94131 USA.	John.Fahy@ucsf.edu	Peters, Michael/AAO-6544-2020	Peters, Michael/0000-0003-1854-4447; Wenzel, Sally/0000-0002-4242-0164; Johansson, Mats/0000-0001-5699-978X	National Institutes of Health [PO1 HL107201, R01 HL080414, U19, AI077439, U10 HL109146, U10 HL109164, U10 HL109172, U10 HL109086, U10 HL109250, U10 HL109168, U10HL109257, U10 HL109152, K23 HL138303, K12 HL119997-04]; Parker B. Francis Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448, UL1TR002345] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL119997, R01HL080414, K23HL138303, U10HL109168, U10HL109086, P01HL107202, U10HL109146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parker B. Francis Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (PO1 HL107201, R01 HL080414, U19, AI077439, U10 HL109146, U10 HL109164, U10 HL109172, U10 HL109086, U10 HL109250, U10 HL109168, U10HL109257, U10 HL109152, K23 HL138303, and K12 HL119997-04) and by grants from the Parker B. Francis Foundation.	Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Cai ZJ, 1999, WHO TECH REP SER, V887, P1; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Gaga M, 2009, EUR RESPIR REV, V18, P58, DOI 10.1183/09059180.00001009; Gershman NH, 1996, EUR RESPIR J, V9, P2448, DOI 10.1183/09031936.96.09122448; Gonem S, 2016, LANCET RESP MED, V4, P699, DOI 10.1016/S2213-2600(16)30179-5; Jagger A, 2014, GERONTOLOGY, V60, P130, DOI 10.1159/000355303; Kaur M, 2014, INT IMMUNOPHARMACOL, V23, P581, DOI 10.1016/j.intimp.2014.10.008; Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Peters MC, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0651-4; Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Phipatanakul W, 2017, AM J RESP CRIT CARE, V195, P1439, DOI 10.1164/rccm.201607-1453OC; Risse PA, 2011, AM J PHYSIOL-LUNG C, V300, pL958, DOI 10.1152/ajplung.00247.2010; Rossios C, 2018, J ALLERGY CLIN IMMUN, V141, P560, DOI 10.1016/j.jaci.2017.02.045; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Seys SF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0524-y; StataCorp, 2014, STAT STAT SOFTW REL; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	30	95	97	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					104	+		10.1016/j.jaci.2017.12.1009	http://dx.doi.org/10.1016/j.jaci.2017.12.1009			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29524537	Green Accepted, Bronze			2022-12-18	WOS:000454918300017
J	Chipps, BE; Lanier, B; Milgrom, H; Deschildre, A; Hedlin, G; Szefler, SJ; Kattan, M; Kianifard, F; Ortiz, B; Haselkorn, T; Iqbal, A; Rosen, K; Trzaskoma, B; Busse, WW				Chipps, Bradley E.; Lanier, Bob; Milgrom, Henry; Deschildre, Antoine; Hedlin, Gunilla; Szefler, Stanley J.; Kattan, Meyer; Kianifard, Farid; Ortiz, Benjamin; Haselkorn, Tmirah; Iqbal, Ahmar; Rosen, Karin; Trzaskoma, Benjamin; Busse, William W.			Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergy; asthma; IgE; omalizumab; pediatric	EXHALED NITRIC-OXIDE; ANTI-IGE; INHALED CORTICOSTEROIDS; AIRWAY INFLAMMATION; SAFETY; ADOLESCENTS; CHILDHOOD; LIFE; TOLERABILITY; MALIGNANCY	Asthma is one of the most common chronic diseases of childhood. Allergen sensitization and high frequencies of comorbid allergic diseases are characteristic of severe asthma in children. Omalizumab, an anti-IgE mAb, is the first targeted biologic therapeutic approved for the treatment of moderate-to-severe persistent allergic asthma (AA) that remains uncontrolled despite high-dose inhaled corticosteroids plus other controller medications. Since its initial licensing for use in adults and adolescents 12 years of age and older, the clinical efficacy, safety, and tolerability of omalizumab have been demonstrated in several published clinical trials in children aged 6 to less than 12 years with moderate-to-severe AA. These studies supported the approval of the pediatric indication (use in children aged >= 6 years) by the European Medicines Agency in 2009 and the US Food and Drug Administration in 2016. After this most recent change in licensing, we review the outcomes from clinical trials in children with persistent AA receiving omalizumab therapy and observational studies from the past 7 years of clinical experience in Europe. Data sources were identified by using PubMed in 2016. Guidelines and management recommendations and materials from the recent US Food and Drug Administration's Pediatric Advisory Committee meeting are also reviewed.	[Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, 5609 J St,Suite C, Sacramento, CA 95819 USA; [Lanier, Bob] Univ North Texas, Dept Pediat, Ft Worth, TX USA; [Milgrom, Henry] Natl Jewish Hlth, Denver, CO USA; [Deschildre, Antoine] Ctr Hosp Reg Univ Lille, Pneumol Pediat, Lille, France; [Hedlin, Gunilla] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Hedlin, Gunilla] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Hedlin, Gunilla] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Szefler, Stanley J.] Childrens Hosp Colorado, Dept Pediat, Breathing Inst, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Aurora, CO USA; [Kattan, Meyer] Columbia Univ, Med Ctr, Pediat Pulm Div, New York, NY USA; [Kianifard, Farid; Ortiz, Benjamin] Novartis Pharmaceut, E Hanover, NJ USA; [Haselkorn, Tmirah; Iqbal, Ahmar; Rosen, Karin; Trzaskoma, Benjamin] Genentech Inc, San Francisco, CA USA; [Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Div Allergy Pulm & Crit Care, Dept Med, Madison, WI 53706 USA	University of North Texas System; University of North Texas Denton; National Jewish Health; Universite de Lille - ISITE; CHU Lille; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Columbia University; Novartis; Roche Holding; Genentech; University of Wisconsin System; University of Wisconsin Madison	Chipps, BE (corresponding author), Capital Allergy & Resp Dis Ctr, 5609 J St,Suite C, Sacramento, CA 95819 USA.	bchipps@capitalallergy.com		Szefler, Stanley/0000-0002-6911-3199; Ortiz, Benjamin/0000-0001-6950-5582	Genentech; Merck; Novartis; GlaxoSmithKline; Sepracor; Sanofi-Aventis; ALK-Abello; TEVA; Stallergenes; MSD; MEDA; Chiesi	Genentech(Roche HoldingGenentech); Merck(Merck & Company); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); Sepracor; Sanofi-Aventis(Sanofi-Aventis); ALK-Abello; TEVA(Teva Pharmaceutical Industries); Stallergenes; MSD; MEDA; Chiesi(Chiesi Pharmaceuticals Inc)	B. E. Chipps serves as a consultant for AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, and Novartis. B, Lanier serves as a consultant for Novartis and Genentech. H. Milgrom receives grant support from Genentech, Merck, Novartis, GlaxoSmithKline, Sepracor, and Sanofi-Aventis; serves on the advisory board for Genentech, Merck, and Novartis; and receives payments for lectures from Genentech, Merck, and Novartis. A. Deschildre reports personal fees from Novartis, ALK-Abello, TEVA, GlaxoSmithKline, Stallergenes, MSD, MEDA, and Chiesi. S. J. Szefler serves as a consultant for Roche, AstraZeneca, Aerocrine, Daiichi Sankyo, Boehringer Ingelheim, Merck, Genentech, Novartis, and GlaxoSmithKline and receives grant support from GlaxoSmithKline. M. Kattan serves on the Advisory Board for Novartis. F. Kianifard is an employee of Novartis. B. Ortiz is an employee for Novartis and holds stock in Novartis. T. Haselkorn serves as a consultant for Genentech and Novartis. A. Iqbal is an employee of Genentech and holds stock in GlaxoSmithKline and Pfizer. K. Rosen is an employee of Genentech and holds stock in Genentech. B. Trzaskoma is an employee of Genentech. W. W. Busse serves as a consultant for Novartis, Genentech, GlaxoSmithKline, Genentech, Roche, Pfizer, Merck, Boehringer Ingelheim, Sanofi, AstraZeneca, Takeda, Aerocrine, 3M, PrEP Biopharm, and Teva and serves as a member for the DSMB for Boston Scientific and Circassia. The rest of the authors declare that they have no relevant conflicts of interest.	Agrawal DK, 2010, CURR ALLERGY ASTHM R, V10, P39, DOI 10.1007/s11882-009-0081-7; Akinbami Lara J, 2011, Natl Health Stat Report, P1; [Anonymous], 2016, XOLAIR OMALIZUMAB PE; [Anonymous], 2010, OMALIZUMAB TREATMENT; Baena-Cagnani CE, 2015, CURR OPIN ALLERGY CL, V15, P267, DOI 10.1097/ACI.0000000000000161; Berger W, 2003, ANN ALLERG ASTHMA IM, V91, P182, DOI 10.1016/S1081-1206(10)62175-8; Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247, DOI 10.1016/S1081-1206(10)61221-5; Brodlie M, 2012, ARCH DIS CHILD, V97, P604, DOI 10.1136/archdischild-2011-301570; Busse W, 2012, J ALLERGY CLIN IMMUN, V129, P983, DOI 10.1016/j.jaci.2012.01.033; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Canadian Agency for Drugs and Technologies in Health, 2015, PCSK9 INH MON ANT TR; Chipps BE, 2012, J ALLERGY CLIN IMMUN, V130, P332, DOI 10.1016/j.jaci.2012.04.014; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Corren J, 2009, CLIN EXP ALLERGY, V39, P788, DOI 10.1111/j.1365-2222.2009.03214.x; Cover RA, 2000, J ALLERGY CLIN IMMUN, V106, P651; de Groot EP, 2015, ACTA PAEDIATR, V104, P916, DOI 10.1111/apa.13059; Deschildre A, 2015, EUR RESPIR J, V46, P856, DOI 10.1183/09031936.00008115; Deschildre A, 2013, EUR RESPIR J, V42, P1224, DOI 10.1183/09031936.00149812; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; European Medicines Agency (EMA), 2016, XOL OM SUMM PROD CHA; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Faria R, 2014, VALUE HEALTH, V17, P772, DOI 10.1016/j.jval.2014.07.009; FDA drug safety communication, 2014, FDA APPR LAB CHANG A; Fernandez C, 2005, P AM THORAC SOC, V2, pA359; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fleming L, 2015, EUR RESPIR J, V46, P1322, DOI 10.1183/13993003.00780-2015; Global Asthma Network, 2014, GLOB ASTHM REP; Global Initiative for Asthma, 2021, GLOB STRAT ASTHM MAN; Haselkorn T, 2010, PEDIAT ALLERG IMM-UK, V21, P1157, DOI 10.1111/j.1399-3038.2010.01065.x; Hedlin G, 2010, EUR RESPIR J, V36, P196, DOI 10.1183/09031936.00104809; Hill DA, 2014, ALLERGY, V69, P674, DOI 10.1111/all.12375; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate ST, 2011, J ALLERGY CLIN IMMUN, V128, P495, DOI 10.1016/j.jaci.2011.06.052; Hossny E, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0117-0; Humbert M, 2014, J ALLER CL IMM-PRACT, V2, P525, DOI 10.1016/j.jaip.2014.03.010; Kulus M, 2010, CURR MED RES OPIN, V26, P1285, DOI 10.1185/03007991003771338; Lang A, 2008, ALLERGY, V63, P1054, DOI 10.1111/j.1398-9995.2008.01672.x; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Lemanske RF, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e55; Li J, 2015, J ALLERGY CLIN IMMUN, V135, P289, DOI 10.1016/j.jaci.2014.09.017; Lieberman PL, 2016, J ALLERGY CLIN IMMUN, V138, P913, DOI 10.1016/j.jaci.2016.03.030; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Milgrom H, 2011, CURR MED RES OPIN, V27, P163, DOI 10.1185/03007995.2010.539502; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; National Asthma Education and Prevention Program Third Expert Panel on the Diagnosis and Management of Asthma, 2007, 3 NAT HEART LUNG BLO; National Institute for Health and Care Excellence, 2013, OM TREAT SEV PERS AL; Novartis Pharmaceuticals Corporation, 2000, DAT FIL STUD 010; Novartis Pharmaceuticals UK Ltd, 2010, XOL OM SINGL TECHN A; Papadopoulos NG, 2012, ALLERGY, V67, P976, DOI 10.1111/j.1398-9995.2012.02865.x; Pearson WS, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.140139; Rodrigo GJ, 2015, PEDIAT ALLERG IMM-UK, V26, P551, DOI 10.1111/pai.12405; Samitas K, 2015, EUR RESPIR REV, V24, P594, DOI 10.1183/16000617.00001715; Silkoff PE, 2004, PEDIATRICS, V113, pE308, DOI 10.1542/peds.113.4.e308; Stempel DA, 2016, NEW ENGL J MED, V374, P1822, DOI 10.1056/NEJMoa1511049; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; US Food and Drug Administration (FDA), 2016, XOL OM US PRESCR INF; US Food and Drug Administration (FDA), 2015, XOL OM US PRESCR INF; Xia Y, 2013, THER ADV DRUG SAF, V4, P254, DOI 10.1177/2042098613504124	64	95	98	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1431	1444		10.1016/j.jaci.2017.03.002	http://dx.doi.org/10.1016/j.jaci.2017.03.002			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	28477722	hybrid			2022-12-18	WOS:000400465300003
J	Bowatte, G; Lodge, CJ; Knibbs, LD; Lowe, AJ; Erbas, B; Dennekamp, M; Marks, GB; Giles, G; Morrison, S; Thompson, B; Thomas, PS; Hui, JN; Perret, JL; Abramson, MJ; Walters, H; Matheson, MC; Dharmage, SC				Bowatte, Gayan; Lodge, Caroline J.; Knibbs, Luke D.; Lowe, Adrian J.; Erbas, Bircan; Dennekamp, Martine; Marks, Guy B.; Giles, Graham; Morrison, Stephen; Thompson, Bruce; Thomas, Paul S.; Hui, Jennie; Perret, Jennifer L.; Abramson, Michael J.; Walters, Haydn; Matheson, Melanie C.; Dharmage, Shyamali C.			Traffic-related air pollution exposure is associated with allergic sensitization, asthma, and poor lung function in middle age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; allergic sensitization; asthma; Glutathione S-Transferase genes; respiratory function	S-TRANSFERASE P1; PARTICULATE; GENES; POLLUTANTS; SMOKING; ADULTS; ATOPY; FLOW	Background: Traffic-related air pollution (TRAP) exposure is associated with allergic airway diseases and reduced lung function in children, but evidence concerning adults, especially in low-pollution settings, is scarce and inconsistent. Objectives: We sought to determine whether exposure to TRAP in middle age is associated with allergic sensitization, current asthma, and reduced lung function in adults, and whether these associations are modified by variants in Glutathione S-Transferase genes. Methods: The study sample comprised the proband 2002 laboratory study of the Tasmanian Longitudinal Health Study. Mean annual residential nitrogen dioxide (NO2) exposure was estimated for current residential addresses using a validated land use regression model. Associations between TRAP exposure and allergic sensitization, lung function, current wheeze, and asthma (n = 1405) were investigated using regression models. Results: Increased mean annual NO2 exposure was associated with increased risk of atopy (adjusted odds ratio [aOR], 1.14; 95% CI, 1.02-1.28 per 1 interquartile range increase in NO2 [2.2 ppb]) and current wheeze (aOR, 1.14; 1.02-1.28). Similarly, living less than 200 m from a major road was associated with current wheeze (aOR, 1.38; 95% CI, 1.06-1.80) and atopy (aOR, 1.26; 95% CI, 0.99-1.62), and was also associated with having significantly lower prebronchodilator and postbronchodilator FEV1 and prebronchodilator forced expiratory flow at 25% to 75% of forced vital capacity. We found evidence of interactions between living less than 200 m from a major road and GSTT1 polymorphism for atopy, asthma, and atopic asthma. Overall, carriers of the GSTT1 null genotype had an increased risk of asthma and allergic outcomes if exposed to TRAP. Conclusions: Even relatively low TRAP exposures confer an increased risk of adverse respiratory and allergic outcomes in genetically susceptible individuals.	[Bowatte, Gayan; Lodge, Caroline J.; Lowe, Adrian J.; Perret, Jennifer L.; Matheson, Melanie C.; Dharmage, Shyamali C.] Univ Melbourne, Sch Populat & Global Hlth, Allergy & Lung Hlth Unit, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia; [Knibbs, Luke D.] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia; [Erbas, Bircan] La Trobe Univ, Sch Psychol & Publ Hlth, Dept Publ Hlth, Melbourne, Vic, Australia; [Dennekamp, Martine; Abramson, Michael J.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Marks, Guy B.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia; [Marks, Guy B.] Univ New South Wales, South Western Sydney Clin Sch, Sydney, NSW, Australia; [Giles, Graham] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia; [Morrison, Stephen] Royal Brisbane Hosp, Brisbane, Qld, Australia; [Thompson, Bruce] Alfred Hosp, Melbourne, Vic, Australia; [Thomas, Paul S.] Univ New South Wales, Inflammat & Infect Res Ctr, Fac Med, Sydney, NSW, Australia; [Hui, Jennie] Univ Western Australia, Busselton Populat Med Res Inst, Perth, WA, Australia; [Hui, Jennie] Univ Western Australia, Sch Populat Hlth, Perth, WA, Australia; [Hui, Jennie] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA, Australia; [Hui, Jennie] Sir Charles Gairdner Hosp, PathWest Lab Med WA, Perth, WA, Australia; [Walters, Haydn] Univ Tasmania, Sch Med, NHMRC CRE, Hobart, Tas, Australia; [Dharmage, Shyamali C.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia	University of Melbourne; University of Queensland; La Trobe University; Monash University; University of Sydney; Woolcock Institute of Medical Research; University of New South Wales Sydney; Cancer Council Victoria; Royal Brisbane & Women's Hospital; Florey Institute of Neuroscience & Mental Health; University of New South Wales Sydney; University of Western Australia; University of Western Australia; University of Western Australia; University of Tasmania; Murdoch Children's Research Institute	Dharmage, SC (corresponding author), Univ Melbourne, Allergy & Lung Hlth Unit, Ctr Epidemiol & Biostat, Sch Populat & Global Hlth, L3,207 Bouverie St, Carlton, Vic 3053, Australia.	s.dharmage@unimelb.edu.au	Lodge, Caroline J/E-9688-2014; Marks, Guy B./F-5058-2013; Morrison, Stephen C/H-7936-2013; Abramson, Michael/AAQ-2671-2020; WALTERS, Eugene/AAL-2264-2021; Hui, Jennie/A-9543-2013; Matheson, Melanie C/O-4721-2015; Knibbs, Luke/C-7865-2012	Marks, Guy B./0000-0002-8976-8053; Abramson, Michael/0000-0002-9954-0538; Hui, Jennie/0000-0002-1653-2496; Matheson, Melanie C/0000-0002-5822-3499; Bowatte, Gayan/0000-0002-9577-9752; Walters, Eugene/0000-0002-0993-4374; Dennekamp, Martine/0000-0001-8069-2892; Thompson, Bruce/0000-0002-5885-0652; Lodge, Caroline/0000-0002-2342-3888; Knibbs, Luke/0000-0002-0399-2370	Centre for Air Quality and Health Research and Evaluation (CAR), a National Health & Medical Research Council Centre of Research Excellence, Australia	Centre for Air Quality and Health Research and Evaluation (CAR), a National Health & Medical Research Council Centre of Research Excellence, Australia	This study was supported by the Centre for Air Quality and Health Research and Evaluation (CAR), a National Health & Medical Research Council Centre of Research Excellence, Australia.	Anderson HR, 2013, AIR QUAL ATMOS HLTH, V6, P47, DOI 10.1007/s11869-011-0144-5; Beckerman B, 2008, ATMOS ENVIRON, V42, P275, DOI 10.1016/j.atmosenv.2007.09.042; Bedada GB, 2007, INT J HYG ENVIR HEAL, V210, P691, DOI 10.1016/j.ijheh.2006.11.005; Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613; Bowatte G, 2015, ALLERGY, V70, P245, DOI 10.1111/all.12561; Brandt EB, 2015, CURR OPIN PEDIATR, V27, P724, DOI 10.1097/MOP.0000000000000286; Brauer Michael, 2010, Proc Am Thorac Soc, V7, P111, DOI 10.1513/pats.200908-093RM; Brunst KJ, 2013, J ALLERGY CLIN IMMUN, V131, P592, DOI 10.1016/j.jaci.2012.10.042; Carlsten C, 2016, THORAX, V71, P35, DOI 10.1136/thoraxjnl-2015-207399; Castro-Giner F, 2009, ENVIRON HEALTH PERSP, V117, P1919, DOI 10.1289/ehp.0900589; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Fuertes E, 2013, J ALLERGY CLIN IMMUN, V132, P342, DOI 10.1016/j.jaci.2013.03.007; Goodrich GG, 2009, MUTAT RES-GEN TOX EN, V674, P55, DOI 10.1016/j.mrgentox.2008.10.009; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Heinrich J, 2005, ENVIRON RES, V98, P240, DOI 10.1016/j.envres.2004.08.004; Hong YC, 2007, ENVIRON HEALTH PERSP, V115, P430, DOI 10.1289/ehp.9531; Hwang BF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052715; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Karner AA, 2010, ENVIRON SCI TECHNOL, V44, P5334, DOI 10.1021/es100008x; Knibbs LD, 2014, ENVIRON RES, V135, P204, DOI 10.1016/j.envres.2014.09.011; LAST JA, 1994, ENVIRON HEALTH PERSP, V102, P179, DOI 10.2307/3432236; Le Moual Nicole, 2013, Presse Med, V42, pe317, DOI 10.1016/j.lpm.2013.06.010; McCunney RJ, 2005, J OCCUP ENVIRON MED, V47, P1285, DOI 10.1097/01.jom.0000188561.75578.bf; Melen E, 2008, ENVIRON HEALTH PERSP, V116, P1077, DOI 10.1289/ehp.11117; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Minelli C, 2011, AM J EPIDEMIOL, V173, P603, DOI 10.1093/aje/kwq403; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nawrot TS, 2009, ATMOS ENVIRON, V43, P4595, DOI 10.1016/j.atmosenv.2009.06.010; NELSON HS, 1983, ANN ALLERGY, V51, P411; Peden DB, 2015, CLIN EXP ALLERGY, V45, P3, DOI 10.1111/cea.12414; Perret JL, 2013, AM J RESP CRIT CARE, V187, P42, DOI 10.1164/rccm.201205-0788OC; Pujades-Rodriguez Mar, 2009, BMC Pulm Med, V9, P42, DOI 10.1186/1471-2466-9-42; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Schroer KT, 2009, J PEDIATR-US, V154, P401, DOI 10.1016/j.jpeds.2008.08.040; Textor J, 2011, EPIDEMIOLOGY, V22, P745, DOI 10.1097/EDE.0b013e318225c2be; Velsor LW, 1997, AM J PHYSIOL-LUNG C, V273, pL1265, DOI 10.1152/ajplung.1997.273.6.L1265; Wharton C, 2006, AUST NZ J PUBL HEAL, V30, P105, DOI 10.1111/j.1467-842X.2006.tb00100.x; Wu WD, 2012, FREE RADICAL BIO MED, V53, P721, DOI 10.1016/j.freeradbiomed.2012.05.037; Wu WQ, 2013, SCI REP-UK, V3, DOI 10.1038/srep01352; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015	40	95	96	2	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					122	+		10.1016/j.jaci.2016.05.008	http://dx.doi.org/10.1016/j.jaci.2016.05.008			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27372567	Bronze			2022-12-18	WOS:000393996800014
J	Weiler, JM; Brannan, JD; Randolph, CC; Hallstrand, TS; Parsons, J; Silvers, W; Storms, W; Zeiger, J; Bernstein, DI; Blessing-Moore, J; Greenhawt, M; Khan, D; Lang, D; Nicklas, RA; Oppenheimer, J; Portnoy, JM; Schuller, DE; Tilles, SA; Wallace, D				Weiler, John M.; Brannan, John D.; Randolph, Christopher C.; Hallstrand, Teal S.; Parsons, Jonathan; Silvers, William; Storms, William; Zeiger, Joanna; Bernstein, David I.; Blessing-Moore, Joann; Greenhawt, Matthew; Khan, David; Lang, David; Nicklas, Richard A.; Oppenheimer, John; Portnoy, Jay M.; Schuller, Diane E.; Tilles, Stephen A.; Wallace, Dana			Exercise-induced bronchoconstriction update-2016	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exercise-induced bronchoconstriction; exercise-induced bronchospasm; exercise-induced asthma; exercise-induced bronchoconstriction pathogenesis; diagnosis; differential diagnosis and therapy; nonpharmacologic; pharmacologic	VOCAL-CORD DYSFUNCTION; EUCAPNIC VOLUNTARY HYPERVENTILATION; LEUKOTRIENE-RECEPTOR ANTAGONIST; HYPERPNEA-INDUCED BRONCHOCONSTRICTION; FINE PARTICULATE MATTER; CROSS-COUNTRY SKIERS; LONG-ACTING BETA(2)-AGONISTS; INHALED IPRATROPIUM BROMIDE; ARTERIAL PLASMA HISTAMINE; CLINICAL IMMUNOLOGY EAACI	The first practice parameter on exercise-induced bronchoconstriction (EIB) was published in 2010. This updated practice parameter was prepared 5 years later. In the ensuing years, there has been increased understanding of the pathogenesis of EIB and improved diagnosis of this disorder by using objective testing. At the time of this publication, observations included the following: dry powder mannitol for inhalation as a bronchial provocation test is FDA approved however not currently available in the United States; if baseline pulmonary function test results are normal to near normal (before and after bronchodilator) in a person with suspected EIB, then further testing should be performed by using standardized exercise challenge or eucapnic voluntary hyperpnea (EVH); and the efficacy of nonpharmaceutical interventions (omega-3 fatty acids) has been challenged. The workgroup preparing this practice parameter updated contemporary practice guidelines based on a current systematic literature review. The group obtained supplementary literature and consensus expert opinions when the published literature was insufficient. A search of the medical literature on PubMed was conducted, and search terms included pathogenesis, diagnosis, differential diagnosis, and therapy (both pharmaceutical and nonpharmaceutical) of exercise-induced bronchoconstriction or exercise-induced asthma (which is no longer a preferred term); asthma; and exercise and asthma. References assessed as relevant to the topic were evaluated to search for additional relevant references. Published clinical studies were appraised by category of evidence and used to document the strength of the recommendation. The parameter was then evaluated by Joint Task Force reviewers and then by reviewers assigned by the parent organizations, as well as the general membership. Based on this process, the parameter can be characterized as an evidence-and consensus-based document.						Hallstrand, Teal/0000-0002-5059-6872; Brannan, John/0000-0001-7243-7998	TEVA; GlaxoSmithKline; AstraZeneca; Merck; National Institutes of Health (NIH); Amgen; Genentech/Novartis; Circassia; Meda; Mylan; Sanofi; Sunovion; Bausch Lomb; Johnson Johnson; Novartis; Pearl Therapeutics; Genentech; Pfizer; Allergy Therapeutics; Alcon; Agency for Healthcare Research Quality [1K08HS024599-01]; American College of Allergy, Asthma, and Immunology; Reach MD; Thermo Fisher Scientific; California Society for Allergy and Immunology; Allergy and Asthma Network; New England Society for Allergy; UCLA/Harbor Heiner Lectureship; Medscape; Western Michigan School of Medicine; Canadian Society of Allergy and Clinical Immunology; Pennsylvania Society for Allergy and Immunology; NIH; Quintiles; PRA; UpToDate; Annals of Allergy; Pulmonary & Allergy Associates Atlantic Health System; Thermo Fisher; NIAID; Astellas	TEVA(Teva Pharmaceutical Industries); GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Merck(Merck & Company); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amgen(Amgen); Genentech/Novartis(Roche HoldingGenentech); Circassia; Meda; Mylan; Sanofi; Sunovion; Bausch Lomb; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Novartis(Novartis); Pearl Therapeutics; Genentech(Roche HoldingGenentech); Pfizer(Pfizer); Allergy Therapeutics; Alcon(Novartis); Agency for Healthcare Research Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); American College of Allergy, Asthma, and Immunology; Reach MD; Thermo Fisher Scientific; California Society for Allergy and Immunology; Allergy and Asthma Network; New England Society for Allergy; UCLA/Harbor Heiner Lectureship; Medscape; Western Michigan School of Medicine; Canadian Society of Allergy and Clinical Immunology; Pennsylvania Society for Allergy and Immunology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Quintiles; PRA; UpToDate; Annals of Allergy; Pulmonary & Allergy Associates Atlantic Health System; Thermo Fisher; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Astellas(Astellas Pharmaceuticals)	J. Weiler is employed by CompleWare and has stock/stock options with CompleWare and ICRC. J. D. Brannan has received royalties from Pharmaxis. C. C. Randolph is a member of the American College of Asthma, Allergy & Immunology Board of Regents; has consultant arrangements with Genentech; has received payment for lectures from TEVA, GlaxoSmithKline, AstraZeneca, and Merck; has received travel support from TEVA; and owns an eucapnic voluntary hyperpnea machine purchased from Richard Rosenthal. T. S. Hallstrand has received grants from the National Institutes of Health (NIH), has consultant arrangements with Genentech, has received payment for lectures from Teva, GlaxoSmithKline, AstraZeneca, and Merck; has received travel support from Teva; and owns a eucapnic voluntary hyperpnoea testing machine purchased from Richard Rosenthal. W. Silvers has received payment for lectures from Teva. W. Storms has consultant arrangements with Amgen, AstraZeneca, Bausch & Lomb, Merck, Sunovion, and TEVA; has received grants from Amgen, Genentech/Novartis, GlaxoSmithKline, Circassia, Meda, Mylan, Sanofi, Sunovion, and TEVA; and has received payment for lectures from AstraZeneca, Genentech/Novartis, Bausch & Lomb, Merck, Sunovion, and TEVA. D. I. Bernstein is a member of the American Board of Allergy and Immunology; has consultant arrangements with TEVA, Circassia, and Merck; has received grants from Merck, TEVA, Johnson & Johnson, Novartis, Pearl Therapeutics, Genentech, Pfizer, GlaxoSmithKline, Allergy Therapeutics, and Amgen; has received payment for lectures from AstraZeneca and Merck; and has received payment for development of educational presentations from AstraZeneca. J. Blessing-Moore has received travel support from the American Academy of Allergy, Asthma & Immunology and has received payment for lectures from AstraZeneca, Merck, Genentech/Novartis, Alcon, and Mylan. M. Greenhawt has received a grant from the Agency for Healthcare Research Quality (1K08HS024599-01, Career Development Award); has received travel support from the National Institute of Allergy and Infectious Diseases and the Joint Taskforce on Allergy Practice Parameters; is on the scientific advisory council for the National Peanut Board; has consultant arrangements with Adamis Pharmaceutical, Canadian Transportation Agency, Nutricia, Nestle/Gerber, and Aimmune; is an Associate Editor for the Annals of Allergy, Asthma, and Immunology; and has received payment for lectures from the American College of Allergy, Asthma, and Immunology, Reach MD, Thermo Fisher Scientific, California Society for Allergy and Immunology, the Allergy and Asthma Network, New England Society for Allergy, UCLA/Harbor Heiner Lectureship, Medscape, Western Michigan School of Medicine, Canadian Society of Allergy and Clinical Immunology, and the Pennsylvania Society for Allergy and Immunology. D. Khan has consultant arrangements with Aimmune; has received grants from the NIH, has received payment for lectures from Genentech, and has received royalties from UpToDate. D. Lang has consultant arrangements with Genentech/Novartis, Adamis, Merck, Meda, GlaxoSmithKline, and AstraZeneca; has received grants from Genentech/Novartis and Merck; and has received payment for lectures from Genentech/Novartis. J.; Oppenheimer has consultant arrangements with GlaxoSmithKline, Mylan, and Meda; has received fees for participation in review activities from Quintiles and PRA; has received money from UpToDate and Annals of Allergy; is a member of the American Board of Allergy and Immunology; and is employed by the Pulmonary & Allergy Associates Atlantic Health System. J. M. Portnoy has received payment for lectures from Mylan and Thermo Fisher. D. Schuller declares that she has no relevant conflicts of interest. S. Tilles received grant support from Merck, Genentech, Novartis, Teva, Mylan, NIAID, Circassia, Astellas, and AstraZeneca. D. Wallace has consultant arrangements with Neohealth, Sanofi, Allergan, and Kaleo and has received payment for lectures from Mylan and MEDA. The rest of the authors declare that they have no relevant conflicts of interest.	Abu-Hasan M, 2005, ANN ALLERG ASTHMA IM, V94, P366, DOI 10.1016/S1081-1206(10)60989-1; Achouh L, 2008, EUR RESPIR J, V32, P513, DOI 10.1183/09031936.00005408; Ahmed T, 1999, AM J RESP CRIT CARE, V160, P576, DOI 10.1164/ajrccm.160.2.9812076; AITKEN ML, 1985, AM REV RESPIR DIS, V131, P357; Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518; AlShati M, 2012, ANN ALLERG ASTHMA IM, V109, P282, DOI 10.1016/j.anai.2012.07.022; Anderson GP, 2006, CLIN REV ALLERG IMMU, V31, P119, DOI 10.1385/CRIAI:31:2:119; ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; Anderson SD, 2008, J ALLERGY CLIN IMMUN, V122, P225, DOI 10.1016/j.jaci.2008.05.001; Anderson SD, 2006, CLIN REV ALLERG IMMU, V31, P163, DOI 10.1385/CRIAI:31:2:163; Anderson SD, 2013, IMMUNOL ALLERGY CLIN, V33, P363, DOI 10.1016/j.iac.2013.02.006; Anderson SD, 2012, BRIT J SPORT MED, V46, P391, DOI 10.1136/bjsports-2011-090810; Anderson SD, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-120; Anderson SD, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-4; ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1991, CHEST, V100, P1254, DOI 10.1378/chest.100.5.1254; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Anderson SD, 2002, J ALLERGY CLIN IMMUN, V109, P771, DOI 10.1067/mai.2002.123644; Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; ANDERSON SD, 1992, THORAX, V47, P748, DOI 10.1136/thx.47.9.748; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P472; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; [Anonymous], 2007, J ALLERGY CLIN IMMUN, V120, pS94, DOI 10.1016/j.jaci.2007.09.029; [Anonymous], 2002, GUID IND EX IN PRESS; Argyros GJ, 1996, CHEST, V109, P1520, DOI 10.1378/chest.109.6.1520; ARGYROS GJ, 1993, AM REV RESPIR DIS, V147, P1419, DOI 10.1164/ajrccm/147.6_Pt_1.1419; Aziz I, 1998, EUR RESPIR J, V12, P580, DOI 10.1183/09031936.98.12030580; Babb TG, 2008, AM J RESP CRIT CARE, V178, P116, DOI 10.1164/rccm.200706-875OC; Baki A, 2002, ARCH DIS CHILD, V86, P38, DOI 10.1136/adc.86.1.38; Balkissoon R, 2012, SEMIN RESP CRIT CARE, V33, P595, DOI 10.1055/s-0032-1326959; BARDAGI S, 1993, AM REV RESPIR DIS, V147, P1112, DOI 10.1164/ajrccm/147.5.1112; BARNES PJ, 1981, THORAX, V36, P726, DOI 10.1136/thx.36.10.726; BARNES PJ, 1981, J ALLERGY CLIN IMMUN, V68, P411, DOI 10.1016/0091-6749(81)90193-7; BEIL M, 1978, RESPIRATION, V35, P78, DOI 10.1159/000193863; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822, DOI 10.1164/arrd.1987.135.4.822; Ben-Dov I, 2008, ISR MED ASSOC J, V10, P579; Bent JP, 1996, ANN OTO RHINOL LARYN, V105, P169, DOI 10.1177/000348949610500301; Bernard A, 2009, PEDIATRICS, V124, P1110, DOI 10.1542/peds.2009-0032; BESLEY DC, 1982, AM HEART J, V103, P332, DOI 10.1016/0002-8703(82)90270-8; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; BIANCO S, 1988, LANCET, V2, P252; Bikov A, 2010, J ASTHMA, V47, P1057, DOI 10.1080/02770903.2010.512690; Bisgaard H, 2000, PEDIATR PULM, V29, P221, DOI 10.1002/(SICI)1099-0496(200003)29:3<221::AID-PPUL11>3.3.CO;2-G; BITTLEMAN DB, 1994, CHEST, V106, P615, DOI 10.1378/chest.106.2.615; Bjornsdottir US, 2000, ANN ALLERG ASTHMA IM, V85, P387; Blake K, 2006, PHARMACOTHERAPY, V26, p148S, DOI 10.1592/phco.26.9part2.148S; BONER AL, 1989, PEDIATR PULM, V6, P81, DOI 10.1002/ppul.1950060205; BONER AL, 1994, AM J RESP CRIT CARE, V149, P935, DOI 10.1164/ajrccm.149.4.7908246; Bonini M, 2013, AM J RESP CRIT CARE, V188, P1407, DOI 10.1164/rccm.201307-1323OC; Bougault V, 2010, CHEST, V138, p31S, DOI 10.1378/chest.09-1689; Boulet LP, 2015, NEW ENGL J MED, V372, P641, DOI 10.1056/NEJMra1407552; BOULET LP, 1989, J ALLERGY CLIN IMMUN, V83, P882, DOI 10.1016/0091-6749(89)90101-2; Brannan JD, 2006, EUR RESPIR J, V27, P944, DOI 10.1183/09031936.06.00078205; Brannan JD, 2003, EUR RESPIR J, V22, P491, DOI 10.1183/09031936.03.00113403; Brannan JD, 2001, AM J RESP CRIT CARE, V163, P1420, DOI 10.1164/ajrccm.163.6.2006019; Brannan JD, 2015, CHEST, V147, P397, DOI 10.1378/chest.14-1214; Brannan JD, 2010, CHEST, V138, p11S, DOI 10.1378/chest.10-0231; Brockow K, 2015, J ALLERGY CLIN IMMUN, V135, P977, DOI 10.1016/j.jaci.2014.08.024; Bronsky EA, 2002, ANN ALLERG ASTHMA IM, V89, P407, DOI 10.1016/S1081-1206(10)62043-1; Bronsky EA, 1997, CLIN PHARMACOL THER, V62, P556, DOI 10.1016/S0009-9236(97)90051-5; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Brummel NE, 2009, J ASTHMA, V46, P683, DOI 10.1080/02770900902972178; BRUTSCHE M, 1995, ALLERGY, V50, P905, DOI 10.1111/j.1398-9995.1995.tb02497.x; Buckner K, 2013, IMMUNOL ALLERGY CLIN, V33, P35, DOI 10.1016/j.iac.2012.10.012; Cabral ALB, 1999, AM J RESP CRIT CARE, V159, P1819, DOI 10.1164/ajrccm.159.6.9805093; Cai YQ, 2003, AM J RESP CELL MOL, V29, P683, DOI 10.1165/rcmb.2002-0174OC; Carbonnelle S, 2002, BIOMARKERS, V7, P464, DOI 10.1080/13547500210166612; Carlsen KH, 2008, ALLERGY, V63, P492, DOI 10.1111/j.1398-9995.2008.01663.x; Carlsen KH, 2008, ALLERGY, V63, P387, DOI 10.1111/j.1398-9995.2008.01662.x; CARLSEN KH, 1995, EUR RESPIR J, V8, P1852, DOI 10.1183/09031936.95.08111852; Carlsen KH, 2000, RESP MED, V94, P750, DOI 10.1053/rmed.2000.0809; Carraro S, 2005, J ALLERGY CLIN IMMUN, V115, P764, DOI 10.1016/j.jaci.2004.10.043; Silva MJCD, 2015, ANN ALLERG ASTHMA IM, V115, P277, DOI 10.1016/j.anai.2015.07.009; Chemery L, 2002, REV MAL RESPIR, V19, P641; Choi IS, 2012, ALLERGY ASTHMA IMMUN, V4, P192, DOI 10.4168/aair.2012.4.4.192; Chong LK, 2003, BRIT J PHARMACOL, V138, P512, DOI 10.1038/sj.bjp.0705050; CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605; Chuang ML, 2006, INT J CARDIOL, V108, P117, DOI 10.1016/j.ijcard.2005.02.022; CLEE MD, 1984, BRIT J DIS CHEST, V78, P180, DOI 10.1016/0007-0971(84)90120-7; Cockcroft D, 2009, ANN ALLERG ASTHMA IM, V103, P363, DOI 10.1016/S1081-1206(10)60353-5; Cohen HA, 1997, ARCH PEDIAT ADOL MED, V151, P367, DOI 10.1001/archpedi.1997.02170410041005; COMIS A, 1993, EUR RESPIR J, V6, P523; Coreno A, 2000, J ALLERGY CLIN IMMUN, V106, P500; CORRIS PA, 1983, AM REV RESPIR DIS, V128, P991; Couillard S, 2014, CHEST, V145, P794, DOI 10.1378/chest.13-1413; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dahlen B, 2002, J ALLERGY CLIN IMMUN, V109, P789, DOI 10.1067/mai.2002.123306; DALONZO GE, 1987, CHEST, V92, P57, DOI 10.1378/chest.92.1.57; DAVIES CTM, 1975, J APPL PHYSIOL, V38, P373, DOI 10.1152/jappl.1975.38.3.373; Davis Beth E, 2003, Can Respir J, V10, P23; Davis MS, 2003, J APPL PHYSIOL, V94, P2545, DOI 10.1152/japplphysiol.00018.2003; Davis RS, 2007, J ALLERGY CLIN IMMUN, V119, P1329, DOI 10.1016/j.jaci.2007.04.007; DAVISKAS E, 1995, EUR RESPIR J, V8, P742; DAVISKAS E, 1991, RESP PHYSIOL, V84, P115, DOI 10.1016/0034-5687(91)90023-C; De Baets F, 2005, PEDIATR PULM, V39, P301, DOI 10.1002/ppul.20185; de Benedictis FM, 2006, EUR RESPIR J, V28, P291, DOI 10.1183/09031936.06.00020606; de Benedictis FM, 1998, ANN ALLERG ASTHMA IM, V80, P352, DOI 10.1016/S1081-1206(10)62982-1; Dempsey JA, 2008, CHEST, V134, P613, DOI 10.1378/chest.07-2730; Dickinson JW, 2006, BRIT J SPORT MED, V40, P179, DOI 10.1136/bjsm.2005.022764; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Driessen JMM, 2011, PEDIATR PULM, V46, P849, DOI 10.1002/ppul.21447; Drotar DE, 1998, ANN ALLERG ASTHMA IM, V80, P31, DOI 10.1016/S1081-1206(10)62935-3; Du Toit G, 2007, PEDIATR ALLERGY IMMU, V18, P455, DOI 10.1111/j.1399-3038.2007.00599.x; DUFFY P, 1991, CHEST, V99, P1374, DOI 10.1378/chest.99.6.1374; Duong M, 2008, CHEST, V133, P404, DOI 10.1378/chest.07-2048; Duong M, 2012, J ALLERGY CLIN IMMUN, V130, P535, DOI 10.1016/j.jaci.2012.02.051; Edelman JM, 2000, ANN INTERN MED, V132, P97, DOI 10.7326/0003-4819-132-2-200001180-00002; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; ELIASSON AH, 1992, CHEST, V102, P347, DOI 10.1378/chest.102.2.347; ELLIS EF, 1984, J ALLERGY CLIN IMMUN, V73, P690, DOI 10.1016/0091-6749(84)90307-5; ESCHENBACHER WL, 1985, AM REV RESPIR DIS, V131, P894; Fahey JT, 2005, PEDIATR PULM, V39, P51, DOI 10.1002/ppul.20076; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P879, DOI 10.1164/ajrccm.152.3.7663799; FDA Drug Safety Communication, NEW WARN US GAD BAS, DOI 12031841/http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm.; Ferrari M, 2000, RESPIRATION, V67, P510, DOI 10.1159/000067465; Ferrari M, 2002, RESPIRATION, V69, P509, DOI 10.1159/000066458; Ferrari M, 2008, BRIT J SPORT MED, V42, P845, DOI 10.1136/bjsm.2006.034983; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; FINNERTY JP, 1993, EUR RESPIR J, V6, P1132; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; Fitch KD, 2008, J ALLERGY CLIN IMMUN, V122, P254, DOI 10.1016/j.jaci.2008.07.003; Flaherty KR, 2001, AM J RESP CRIT CARE, V164, P425, DOI 10.1164/ajrccm.164.3.2005110; Fonkalsrud EW, 2002, ANN SURG, V236, P304, DOI 10.1097/00000658-200209000-00007; Ford CN, 2005, JAMA-J AM MED ASSOC, V294, P1534, DOI 10.1001/jama.294.12.1534; FRANK MJ, 1983, EUR HEART J, V4, P155, DOI 10.1093/eurheartj/4.suppl_F.155; Freed AN, 1999, AM J RESP CRIT CARE, V159, P1101, DOI 10.1164/ajrccm.159.4.9802072; FREED AN, 1994, EUR RESPIR J, V7, P1308, DOI 10.1183/09031936.94.07071308; FREED AN, 1995, J CLIN INVEST, V96, P1221, DOI 10.1172/JCI118155; Freed AN, 2003, AM J RESP CRIT CARE, V167, P1102, DOI 10.1164/rccm.200201-055OC; Garcia R, 2001, J INVEST ALLERG CLIN, V11, P176; Gessler EM, 2002, AM J OTOLARYNG, V23, P386, DOI 10.1053/ajot.2002.126322; GHOSH SK, 1991, THORAX, V46, P242, DOI 10.1136/thx.46.4.242; Giannini D, 1996, CHEST, V110, P1452, DOI 10.1378/chest.110.6.1452; Global Initiative for Asthma, 2007, NHLBI WHO WORKSH REP; GODFREY S, 1975, PEDIATRICS, V56, P851; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1975, PEDIATRICS, V56, P930; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; Goldberg S, 2012, ALLERGY ASTHMA PROC, V33, P416, DOI 10.2500/aap.2012.33.3586; Gossage JR, 1998, AM J RESP CRIT CARE, V158, P643, DOI 10.1164/ajrccm.158.2.9711041; Gotshall RW, 2000, MED SCI SPORT EXER, V32, P1815, DOI 10.1097/00005768-200011000-00001; Gronnerod TA, 2000, RESP MED, V94, P661, DOI 10.1053/rmed.2000.0789; Grzelewski T, 2009, DRUGS, V69, P1533, DOI 10.2165/11316720-000000000-00000; Gulliksson M, 2006, ALLERGY, V61, P1473, DOI 10.1111/j.1398-9995.2006.01213.x; HABY MM, 1995, EUR RESPIR J, V8, P729; Haden James R, 2003, Adv Psychosom Med, V24, P72, DOI 10.1159/000073781; HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135; Hallstrand TS, 2007, J ALLERGY CLIN IMMUN, V119, P1092, DOI 10.1016/j.jaci.2007.01.005; Hallstrand TS, 2013, IMMUNOL ALLERGY CLIN, V33, P423, DOI 10.1016/j.iac.2013.02.010; Hallstrand TS, 2012, PULM PHARMACOL THER, V25, P432, DOI 10.1016/j.pupt.2012.02.004; Hallstrand TS, 2010, CURR OPIN ALLERGY CL, V10, P60, DOI 10.1097/ACI.0b013e32833489c3; Hallstrand TS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008583; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Hallstrand TS, 2002, J PEDIATR-US, V141, P343, DOI 10.1067/mpd.2002.125729; Hammo AH, 1999, ANN ALLERG ASTHMA IM, V82, P574, DOI 10.1016/S1081-1206(10)63169-9; Hancox RJ, 1999, EUR RESPIR J, V14, P283, DOI 10.1034/j.1399-3003.1999.14b08.x; Hancox RJ, 2000, RESP MED, V94, P767, DOI 10.1053/rmed.2000.0820; Hancox RJ, 2002, AM J RESP CRIT CARE, V165, P1068, DOI 10.1164/ajrccm.165.8.200111-091bc; Haney S, 2005, RESP MED, V99, P566, DOI 10.1016/j.rmed.2004.10.014; Haney S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-19; Haney S, 2006, CLIN REV ALLERG IMMU, V31, P181, DOI 10.1385/CRIAI:31:2:181; Hanks CD, 2012, PHYSICIAN SPORTSMED, V40, P28, DOI 10.3810/psm.2012.05.1962; HarrisEze AO, 1996, AM J RESP CRIT CARE, V154, P994, DOI 10.1164/ajrccm.154.4.8887597; HARTLEY JPR, 1981, CLIN SCI, V61, P151, DOI 10.1042/cs0610151; Haverkamp HC, 2007, J ALLERGY CLIN IMMUN, V120, P39, DOI 10.1016/j.jaci.2007.03.013; Haverkamp HC, 2005, J APPL PHYSIOL, V99, P1843, DOI 10.1152/japplphysiol.01399.2004; Hayes MJ, 1996, AM J RESP CRIT CARE, V154, P1277, DOI 10.1164/ajrccm.154.5.8912736; Heimdal JH, 2006, LARYNGOSCOPE, V116, P52, DOI 10.1097/01.mlg.0000184528.16229.ba; Helenius I, 2000, J ALLERGY CLIN IMMUN, V106, P444, DOI 10.1067/mai.2000.107749; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125, DOI 10.1136/bjsm.32.2.125; Helenius IJ, 1997, THORAX, V52, P157, DOI 10.1136/thx.52.2.157; HENDRICKSON CD, 1994, LUNG, V172, P1; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; Hofstra WB, 1997, THORAX, V52, P739, DOI 10.1136/thx.52.8.739; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Holley AB, 2012, J ASTHMA, V49, P614, DOI 10.3109/02770903.2012.697955; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; HOOPER RG, 1995, CHEST, V107, P317, DOI 10.1378/chest.107.2.317; Hull James H, 2009, BMC Pulm Med, V9, P29, DOI 10.1186/1471-2466-9-29; Ichinose M, 1996, AM J RESP CRIT CARE, V153, P936, DOI 10.1164/ajrccm.153.3.8630576; Iikura Y, 1996, CLIN EXP ALLERGY, V26, P38; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; Jack S, 2004, AM J RESP CRIT CARE, V170, P118, DOI 10.1164/rccm.200207-720OC; Johnson M, 2006, J ALLERGY CLIN IMMUN, V117, P18, DOI 10.1016/j.jaci.2005.11.012; Jonasson G, 2000, PEDIATR ALLERGY IMMU, V11, P120, DOI 10.1034/j.1399-3038.2000.00067.x; Jones COH, 1996, THORAX, V51, P1134, DOI 10.1136/thx.51.11.1134; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Kanazawa H, 2002, CHEST, V122, P166, DOI 10.1378/chest.122.1.166; Kanazawa H, 2008, J ALLERGY CLIN IMMUN, V121, P390, DOI 10.1016/j.jaci.2007.09.026; Kang MJ, 2008, PHARMACOGENET GENOM, V18, P551, DOI 10.1097/FPC.0b013e3282fe94c5; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; KATTAN M, 1978, J PEDIATR-US, V92, P718, DOI 10.1016/S0022-3476(78)80135-8; Kelly KD, 2001, EUR RESPIR J, V17, P39, DOI 10.1183/09031936.01.17100390; KEMP JP, 1994, AM J RESP CRIT CARE, V150, P1612, DOI 10.1164/ajrccm.150.6.7952623; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Kent SE, 2014, ALLERGY ASTHMA PROC, V35, P126, DOI 10.2500/aap.2014.35.3723; Kersten ETG, 2012, PEDIATR PULM, V47, P27, DOI 10.1002/ppul.21511; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; Kim JH, 2008, CLIN EXP ALLERGY, V38, P51, DOI 10.1111/j.1365-2222.2007.02874.x; Kippelen P, 2013, RESP MED, V107, P1837, DOI 10.1016/j.rmed.2013.09.020; Kippelen P, 2013, IMMUNOL ALLERGY CLIN, V33, P299, DOI 10.1016/j.iac.2013.02.002; Kippelen P, 2010, MED SCI SPORT EXER, V42, P1853, DOI 10.1249/MSS.0b013e3181da4f7d; Kippelen P, 2010, MED SCI SPORT EXER, V42, P273, DOI 10.1249/MSS.0b013e3181b541b1; KIVITY S, 1988, J ALLERGY CLIN IMMUN, V81, P1155, DOI 10.1016/0091-6749(88)90884-6; KIVITY S, 1990, CHEST, V97, P1083, DOI 10.1378/chest.97.5.1083; Knopfli BH, 2005, MED SCI SPORT EXER, V37, P354, DOI 10.1249/01.MSS.0000155436.31581.90; Koh MS, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002739.pub3; KONIG P, 1987, J ALLERGY CLIN IMMUN, V79, P64, DOI 10.1016/S0091-6749(87)80018-0; Koumbourlis AC, 2004, PEDIATR PULM, V38, P339, DOI 10.1002/ppul.20062; Kukafka DS, 1998, CHEST, V114, P1613, DOI 10.1378/chest.114.6.1613; Kunz LIZ, 2006, PULM PHARMACOL THER, V19, P286, DOI 10.1016/j.pupt.2005.04.011; KUZEMKO JA, 1989, RESP MED, V83, P11, DOI 10.1016/S0954-6111(89)80245-8; Lai Y, 2014, J ALLERGY CLIN IMMUN, V133, P1448, DOI 10.1016/j.jaci.2013.08.052; Lai Y, 2010, J BIOL CHEM, V285, P41491, DOI 10.1074/jbc.M110.153338; Lai YL, 1999, N-S ARCH PHARMACOL, V360, P597, DOI 10.1007/s002109900090; LAKIN RC, 1984, CHEST, V86, P499, DOI 10.1378/chest.86.3.499; Langdeau JB, 2009, RESP MED, V103, P401, DOI 10.1016/j.rmed.2008.09.023; Larsson J, 2011, J APPL PHYSIOL, V110, P1029, DOI 10.1152/japplphysiol.00978.2010; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440, DOI 10.1164/arrd.1983.128.3.440; Lazarinis N, 2014, THORAX, V69, P130, DOI 10.1136/thoraxjnl-2013-203557; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Lehnigk B, 1998, EUR RESPIR J, V11, P617; Lin RY, 2008, J ASTHMA, V45, P931, DOI 10.1080/02770900802395504; Lipworth BJ, 2012, CHEST, V141, P607, DOI 10.1378/chest.11-1748; LOCKHART A, 1994, CHEST, V106, P244, DOI 10.1378/chest.106.1.244; Lopes WA, 2009, ALLERGOL IMMUNOPATH, V37, P175, DOI 10.1016/j.aller.2009.03.001; Madhuban AA, 2011, J ASTHMA, V48, P275, DOI 10.3109/02770903.2011.555035; MAGNUSSEN H, 1992, RESPIRATION, V59, P42; MAGNUSSEN H, 1988, CHEST, V93, P937, DOI 10.1378/chest.93.5.937; Mak JCW, 2000, MOL PHARMACOL, V57, P857; Malmberg LP, 2009, PEDIAT ALLERG IMM-UK, V20, P673, DOI 10.1111/j.1399-3038.2009.00858.x; Mandell DL, 2003, INT J PEDIATR OTORHI, V67, P999, DOI 10.1016/S0165-5876(03)00178-2; Manjra AI, 2009, J ASTHMA, V46, P156, DOI 10.1080/02770900802538251; MANNING PJ, 1993, AM REV RESPIR DIS, V148, P950, DOI 10.1164/ajrccm/148.4_Pt_1.950; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; Mannix ET, 2003, J ASTHMA, V40, P349, DOI 10.1081/JAS-120018634; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; MARCINIUK DD, 1994, J APPL PHYSIOL, V77, P963, DOI 10.1152/jappl.1994.77.2.963; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Matsuo H, 2008, ALLERGY, V63, P233, DOI 10.1111/j.1398-9995.2007.01504.x; Matsuo H, 2005, J IMMUNOL, V175, P8116, DOI 10.4049/jimmunol.175.12.8116; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; MCFADDEN ER, 1985, J CLIN INVEST, V76, P1007, DOI 10.1172/JCI112052; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; McFadden ER, 1996, AM J RESP CRIT CARE, V153, P942, DOI 10.1164/ajrccm.153.3.8630577; McGraw DW, 2007, J CLIN INVEST, V117, P1391, DOI 10.1172/JCI30489; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; MCKENZIE DC, 1994, MED SCI SPORT EXER, V26, P951; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; Meyer FJ, 2002, THORAX, V57, P473, DOI 10.1136/thorax.57.6.473; Meyer T, 2004, BRIT J SPORT MED, V38, P622, DOI 10.1136/bjsm.2003.007815; Mickleborough TD, 2007, INT J SPORTS MED, V28, P456, DOI 10.1055/s-2006-924583; Mickleborough TD, 2006, CHEST, V129, P39, DOI 10.1378/chest.129.1.39; Mickleborough TD, 2005, MED SCI SPORT EXER, V37, P904, DOI 10.1249/01.mss.0000166949.11296.2b; Mickleborough TD, 2003, AM J RESP CRIT CARE, V168, P1181, DOI 10.1164/rccm.200303-373OC; Mickleborough TD, 2013, RESP MED, V107, P1152, DOI 10.1016/j.rmed.2013.04.010; Moloney ED, 2003, RESP MED, V97, P1; Molphy J, 2014, J ASTHMA, V51, P44, DOI 10.3109/02770903.2013.838256; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; Morris MJ, 1999, CHEST, V116, P1676, DOI 10.1378/chest.116.6.1676; Mountjoy M, 2015, J ALLERGY CLIN IMMUN, V136, P588, DOI 10.1016/j.jaci.2015.01.041; NALINE E, 1989, AM REV RESPIR DIS, V140, P679, DOI 10.1164/ajrccm/140.3.679; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nelson JA, 1998, NEW ENGL J MED, V339, P141, DOI 10.1056/NEJM199807163390301; NEWNHAM DM, 1993, RESP MED, V87, P439, DOI 10.1016/0954-6111(93)90070-G; Nielsen EW, 2013, MED SCI SPORT EXER, V45, P2030, DOI 10.1249/MSS.0b013e318298b19a; O'Byrne PM, 2009, J ALLERGY CLIN IMMUN, V124, P1217, DOI 10.1016/j.jaci.2009.08.047; O'Byrne PM, 2000, AM J RESP CRIT CARE, V161, pS68, DOI 10.1164/ajrccm.161.supplement_1.ltta-14; O'Sullivan S, 1998, EUR RESPIR J, V12, P345, DOI 10.1183/09031936.98.12020345; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; Ofir D, 2008, AM J RESP CRIT CARE, V177, P622, DOI 10.1164/rccm.200707-1064OC; Oyefara BI, 2007, ALLERGY ASTHMA PROC, V28, P64, DOI 10.2500/aap.2007.28.2951; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Parker JM, 2000, J ASTHMA, V37, P275, DOI 10.3109/02770900009055450; PARM J, 1988, THORAX, V43, P84, DOI 10.1136/thx.43.2.84; Parsons JP, 2007, MED SCI SPORT EXER, V39, P1487, DOI 10.1249/mss.0b013e3180986e45; Parsons JP, 2013, AM J RESP CRIT CARE, V187, P1016, DOI 10.1164/rccm.201303-0437ST; Parsons JP, 2005, CHEST, V128, P3966, DOI 10.1378/chest.128.6.3966; Passalacqua Giovanni, 2002, Clin Allergy Immunol, V17, P65; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PATEL KR, 1986, EUR J RESPIR DIS, V69, P256; PATEL KR, 1986, BRIT J CLIN PHARMACO, V21, P231, DOI 10.1111/j.1365-2125.1986.tb05181.x; Patel NJ, 2004, OTOLARYNG HEAD NECK, V130, P686, DOI 10.1016/j.otohns.2004.01.003; Peachell P, 2006, CLIN REV ALLERG IMMU, V31, P131, DOI 10.1385/CRIAI:31:2:131; Pearlman D, 2006, ANN ALLERG ASTHMA IM, V97, P382, DOI 10.1016/S1081-1206(10)60805-8; Pearlman D, 2009, PEDIATR PULM, V44, P429, DOI 10.1002/ppul.20962; Pearlman DS, 2006, ANN ALLERG ASTHMA IM, V97, P98, DOI 10.1016/S1081-1206(10)61377-4; Pearlman DS, 1999, J PEDIATR-US, V134, P273, DOI 10.1016/S0022-3476(99)70449-X; Pedersen L, 2008, MED SCI SPORT EXER, V40, P1567, DOI 10.1249/MSS.0b013e31875719a; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Perkins PJ, 2002, CHEST, V122, P1988, DOI 10.1378/chest.122.6.1988; Peroni DG, 2002, PEDIAT ALLERG IMM-UK, V13, P434, DOI 10.1034/j.1399-3038.2002.02078.x; Peroni DG, 2002, EUR RESPIR J, V20, P104, DOI 10.1183/09031936.02.00234902; Peters HPF, 1999, ALIMENT PHARM THERAP, V13, P1015; Peterson KA, 2009, DIGEST DIS SCI, V54, P564, DOI 10.1007/s10620-008-0396-6; Philip G, 2007, CHEST, V132, P875, DOI 10.1378/chest.07-0550; Philip G, 2007, J ASTHMA, V44, P213, DOI 10.1080/02770900701209806; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; Pohjantahti H, 2005, SCAND J MED SCI SPOR, V15, P324, DOI 10.1111/j.1600-0838.2004.00423.x; POPPIUS H, 1986, EUR J RESPIR DIS, V68, P319; Powell DM, 2000, ARCH OTOLARYNGOL, V126, P29, DOI 10.1001/archotol.126.1.29; Prandota Joseph, 2002, Am J Ther, V9, P317, DOI 10.1097/00045391-200207000-00009; Price OJ, 2015, EXPERT REV RESP MED, V9, P369, DOI 10.1586/17476348.2015.1036032; Price OJ, 2015, J ALLER CL IMM-PRACT, V3, P243, DOI 10.1016/j.jaip.2014.10.012; Raissy HH, 2008, PHARMACOTHERAPY, V28, P287, DOI 10.1592/phco.28.3.287; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Randolph C, 2013, CURR ALLERGY ASTHM R, V13, P662, DOI 10.1007/s11882-013-0380-x; Randolph CC, 2006, MED SCI SPORT EXER, V38, P2053, DOI 10.1249/01.mss.0000235357.31932.43; Rastogi D, 2004, PEDIATR PULM, V37, P50, DOI 10.1002/ppul.10363; Reindl I, 1996, CARDIOLOGY, V91, P37; Reiss TF, 1997, THORAX, V52, P1030, DOI 10.1136/thx.52.12.1030; Richter GT, 2008, ARCH OTOLARYNGOL, V134, P75, DOI 10.1001/archoto.2007.17; Ringsberg KC, 1999, J ALLERGY CLIN IMMUN, V103, P601, DOI 10.1016/S0091-6749(99)70231-9; Roca J, 1997, EUR RESPIR J, V10, P2662; Romberg K, 2011, RESP MED, V105, P31, DOI 10.1016/j.rmed.2010.07.012; ROSSING TH, 1982, J APPL PHYSIOL, V52, P1119, DOI 10.1152/jappl.1982.52.5.1119; Rundell KW, 2008, J ALLERGY CLIN IMMUN, V122, P238, DOI 10.1016/j.jaci.2008.06.014; Rundell KW, 2008, J STRENGTH COND RES, V22, P2, DOI 10.1519/JSC.0b013e31815ef98b; Rundell KW, 2006, INHAL TOXICOL, V18, P541, DOI 10.1080/08958370600685640; Rundell KW, 2007, INHAL TOXICOL, V19, P133, DOI 10.1080/08958370601051727; Rundell KW, 2015, COMPR PHYSIOL, V5, P579, DOI 10.1002/cphy.c130013; Rundell KW, 2013, CURR SPORT MED REP, V12, P41, DOI 10.1249/JSR.0b013e318281e471; Rundell KW, 2005, BRIT J SPORT MED, V39, P232, DOI 10.1136/bjsm.2004.014282; Rundell KW, 2004, MED SCI SPORT EXER, V36, P405, DOI 10.1249/01.MSS.0000117118.77267.BF; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2003, INHAL TOXICOL, V15, P237, DOI 10.1080/08958370304502; Rundell KW, 2003, CHEST, V123, P468, DOI 10.1378/chest.123.2.468; Rundell KW, 2003, MED SCI SPORT EXER, V35, P18, DOI 10.1097/00005768-200301000-00004; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; Sallaoui Ridha, 2009, BMC Pulm Med, V9, P8, DOI 10.1186/1471-2466-9-8; Sano F, 1998, PEDIAT ALLERG IMM-UK, V9, P181, DOI 10.1111/j.1399-3038.1998.tb00370.x; Sarria B, 2002, AM J PHYSIOL-LUNG C, V283, pL1125, DOI 10.1152/ajplung.00084.2002; SCHACHTER EN, 1982, ANN ALLERGY, V49, P146; Schatz M, 2004, PEDIATR PULM, V37, P523, DOI 10.1002/ppul.20018; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; SCHOEFFEL RE, 1983, AUST NZ J MED, V13, P157, DOI 10.1111/j.1445-5994.1983.tb02672.x; SCHWARTZ HJ, 1995, J ALLERGY CLIN IMMUN, V95, P917, DOI 10.1016/S0091-6749(95)70139-7; Scola AM, 2004, BRIT J PHARMACOL, V141, P163, DOI 10.1038/sj.bjp.0705599; Scollo M, 2000, AM J RESP CRIT CARE, V161, P1047, DOI 10.1164/ajrccm.161.3.9905043; SEALE JP, 1977, AUST NZ J MED, V7, P270, DOI 10.1111/j.1445-5994.1977.tb03685.x; SHEFFER AL, 1984, J ALLERGY CLIN IMMUN, V73, P699, DOI 10.1016/0091-6749(84)90309-9; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P419, DOI 10.1136/adc.47.253.419; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Simpson AJ, 2013, J APPL PHYSIOL, V115, P1450, DOI 10.1152/japplphysiol.00716.2013; Simpson AJ, 2015, MED SCI SPORT EXER, V47, P2005, DOI 10.1249/MSS.0000000000000646; SMITH CM, 1988, CHEST, V94, P709, DOI 10.1378/chest.94.4.709; SMITH RJH, 1995, ANN OTO RHINOL LARYN, V104, P537, DOI 10.1177/000348949510400707; SMYTH RJ, 1986, PEDIATRICS, V77, P692; Spooner C, 2003, COCHRANE DB SYST REV, P4, DOI DOI 10.1002/14651858.CD002307; Stadelmann K, 2011, MED SCI SPORT EXER, V43, P375, DOI 10.1249/MSS.0b013e3181f1c0b1; Stelmach I, 2008, J ALLERGY CLIN IMMUN, V121, P383, DOI 10.1016/j.jaci.2007.09.007; Stensrud T, 2007, MED SCI SPORT EXER, V39, P1681, DOI 10.1249/mss.0b013e31813738ac; Stickland MK, 2012, MED SCI SPORT EXER, V44, P383, DOI 10.1249/MSS.0b013e31822fb73a; Storms W, 2004, RESP MED, V98, P1051, DOI 10.1016/j.rmed.2004.05.008; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1999, RESP MED, V93, P719, DOI 10.1016/S0954-6111(99)90039-2; Sue-Chu M, 2002, EUR RESP J S38, V20, p410s; Suh DI, 2011, PEDIATR PULM, V46, P1007, DOI 10.1002/ppul.21468; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57; TABKA Z, 1988, CHEST, V94, P81, DOI 10.1378/chest.94.1.81; Tahan F, 2008, J ASTHMA, V45, P161, DOI 10.1080/02770900701847068; Tan RA, 2002, ANN ALLERG ASTHMA IM, V89, P226, DOI 10.1016/S1081-1206(10)61948-5; Tanaka H, 2001, J AM COLL CARDIOL, V37, P153, DOI 10.1016/S0735-1097(00)01054-8; Tarran Robert, 2004, Proc Am Thorac Soc, V1, P42, DOI 10.1513/pats.2306014; Taylor-Clark TE, 2008, BRIT J PHARMACOL, V154, P1359, DOI 10.1038/bjp.2008.196; Tecklenburg SL, 2007, RESP MED, V101, P1770, DOI 10.1016/j.rmed.2007.02.014; Tecklenburg-Lund S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013487; Thio BJ, 2001, PEDIATR PULM, V32, P115; Tilles SA, 2003, CURR ALLERGY ASTHM R, V3, P467, DOI 10.1007/s11882-003-0056-z; Tilles SA, 2013, ANN ALLERG ASTHMA IM, V111, P342, DOI 10.1016/j.anai.2013.07.025; Tilles SA, 2010, ANN ALLERG ASTHMA IM, V104, P361, DOI 10.1016/j.anai.2009.12.008; Timmer W, 2002, J CLIN PHARMACOL, V42, P297, DOI 10.1177/00912700222011328; TULLETT WM, 1985, THORAX, V40, P41, DOI 10.1136/thx.40.1.41; Ucok K, 2004, LUNG, V182, P265, DOI 10.1007/s00408-004-2503-6; van Leeuwen JC, 2013, IMMUNOL ALLERGY CLIN, V33, P381, DOI 10.1016/j.iac.2013.02.007; Van Rensen ELJ, 2002, AM J RESP CRIT CARE, V165, P1275, DOI 10.1164/rccm.2110092; VanHaitsma TA, 2010, INT J SPORTS MED, V31, P231, DOI 10.1055/s-0030-1247592; VanSchoor J, 1997, AM J RESP CRIT CARE, V155, P875, DOI 10.1164/ajrccm.155.3.9117020; Vidal C, 2001, ANN ALLERG ASTHMA IM, V86, P655, DOI 10.1016/S1081-1206(10)62294-6; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; Vilsvik J, 2001, RESP MED, V95, P484, DOI 10.1053/rmed.2001.1074; Visser R, 2015, PEDIATR PULM, V50, P1178, DOI 10.1002/ppul.23144; Wasfi YS, 2011, ALLERGY ASTHMA PROC, V32, P453, DOI 10.2500/aap.2011.32.3482; Weiler JM, 2005, ANN ALLERG ASTHMA IM, V94, P65, DOI 10.1016/S1081-1206(10)61288-4; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; Weiler JM, 2000, J ALLERGY CLIN IMMUN, V106, P267, DOI 10.1067/mai.2000.108605; Weiler JM, 2007, J ALLERGY CLIN IMMUN, V119, P1349, DOI 10.1016/j.jaci.2007.02.041; Weiler JM, 2014, J ALLER CL IMM-PRACT, V2, P275, DOI 10.1016/j.jaip.2013.11.001; Weiler John M, 2010, Ann Allergy Asthma Immunol, V105, pS1, DOI 10.1016/j.anai.2010.09.021; Weinberger M, 2006, ARCH DIS CHILD, V91, P543, DOI 10.1136/adc.2006.095000; Weinberger M, 2007, PEDIATRICS, V120, P855, DOI 10.1542/peds.2007-0078; Weinberger M, 2009, PEDIATR CLIN N AM, V56, P33, DOI 10.1016/j.pcl.2008.10.015; Weinberger MM, 2008, J ALLERGY CLIN IMMUN, V121, P269, DOI 10.1016/j.jaci.2007.08.062; Weiner P, 1998, RESP MED, V92, P1071, DOI 10.1016/S0954-6111(98)90357-2; White KM, 2008, ANN ALLERG ASTHMA IM, V100, P171, DOI 10.1016/S1081-1206(10)60429-2; WIEBICKE W, 1988, PEDIATR PULM, V4, P225, DOI 10.1002/ppul.1950040407; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003; WILSON BA, 1994, EUR RESPIR J, V7, P2174, DOI 10.1183/09031936.94.07122174; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; WOOLLEY M, 1990, CHEST, V97, P39, DOI 10.1378/chest.97.1.39; Wraight JM, 2003, EUR RESPIR J, V21, P810, DOI 10.1183/09031936.03.00067503; Wright RA, 1996, DIGEST DIS SCI, V41, P921, DOI 10.1007/BF02091531; Yates DH, 1996, AM J RESP CRIT CARE, V154, P1603, DOI 10.1164/ajrccm.154.6.8970342; ZIELINSKI J, 1977, RESPIRATION, V34, P31, DOI 10.1159/000193773; [No title captured]	421	95	99	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1292	+		10.1016/j.jaci.2016.05.029	http://dx.doi.org/10.1016/j.jaci.2016.05.029			40	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27665489				2022-12-18	WOS:000389542700006
J	Werfel, T; Heratizadeh, A; Niebuhr, M; Kapp, A; Roesner, LM; Karch, A; Erpenbeck, VJ; Losche, C; Jung, T; Krug, N; Badorrek, P; Hohlfeld, JM				Werfel, Thomas; Heratizadeh, Annice; Niebuhr, Margarete; Kapp, Alexander; Roesner, Lennart Matthias; Karch, Annika; Erpenbeck, Veit J.; Loesche, Christian; Jung, Thomas; Krug, Norbert; Badorrek, Philipp; Hohlfeld, Jens M.			Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; inhalant allergen; grass pollen; environmental challenge chamber; exposure	ALLERGEN INHALATION CHALLENGE; BARRIER IMPAIRMENT; DENDRITIC CELLS; T-CELLS; ECZEMA; SENSITIZATION; ACTIVATION; SKIN; KERATINOCYTES; AEROALLERGENS	Background: It has frequently been speculated that pruritus and skin lesions develop after topical exposure to aeroallergens in sensitized patients with atopic dermatitis (AD). Objective: We sought to study cutaneous reactions to grass pollen in adult patients with AD with accompanying clear IgE sensitization to grass allergen in an environmental challenge chamber using a monocenter, double-blind, placebo-controlled study design. Methods: Subjects were challenged on 2 consecutive days with either 4000 pollen grains/m(3) of Dactylis glomerata pollen or clean air. The severity of AD was assessed at each study visit up to 5 days after challenge by (objective) scoring of AD (SCORAD). Additionally, air-exposed and non-air-exposed skin areas were each scored using local SCORAD scoring and investigator global assessments. Levels of a series of serum cytokines and chemokines were determined by using a Luminex-based immunoassay. The primary end point of the study was the change in objective SCORAD scores between prechallenge and postchallenge values. Results: Exposure to grass pollen induced a significant worsening of AD. A pronounced eczema flare-up of air-exposed rather than covered skin areas occurred. In grass pollen-exposed subjects a significantly higher increase in CCL17, CCL22, and IL-4 serum levels was observed. Conclusions: This study demonstrates that controlled exposure to airborne allergens of patients with a so-called extrinsic IgE-mediated form of AD induced a worsening of cutaneous symptoms.	[Werfel, Thomas; Heratizadeh, Annice; Niebuhr, Margarete; Kapp, Alexander; Roesner, Lennart Matthias] Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, D-30625 Hannover, Germany; [Karch, Annika] Hannover Med Sch, Inst Biostat, D-30625 Hannover, Germany; [Erpenbeck, Veit J.; Loesche, Christian; Jung, Thomas] Novartis Pharma AG, Basel, Switzerland; [Krug, Norbert; Badorrek, Philipp; Hohlfeld, Jens M.] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Krug, Norbert; Hohlfeld, Jens M.] Biomed Res Endstage & Obstruct Lung Res BREATH, Hannover, Germany	Hannover Medical School; Hannover Medical School; Novartis; Fraunhofer Gesellschaft	Heratizadeh, A (corresponding author), Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Carl Neuberg St 1, D-30625 Hannover, Germany.	heratizadeh.annice@mh-hannover.de	Werfel, Thomas/B-6921-2012; Roesner, Lennart/K-1074-2019	Roesner, Lennart/0000-0001-6651-0458; Hohlfeld, Jens/0000-0003-2646-6186; Kapp, Alexander/0000-0002-1748-6276; Badorrek, Philipp/0000-0003-2490-0583; Loesche, Christian/0000-0001-6505-0349	Novartis Pharma AG [PJMR005 2111]	Novartis Pharma AG	Supported by Novartis Pharma AG (grant no. PJMR005 2111).	Akdis CA, 2003, CLIN EXP ALLERGY, V33, P1618, DOI 10.1111/j.1365-2222.2003.01803.x; Badorrek P, 2012, ANN ALLERG ASTHMA IM, V109, P208, DOI 10.1016/j.anai.2012.06.019; Bieber T, 2009, CURR ALLERGY ASTHM R, V9, P291, DOI 10.1007/s11882-009-0041-2; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Boralevi F, 2008, ALLERGY, V63, P205, DOI 10.1111/j.1398-9995.2007.01556.x; Brinkman L, 1997, CLIN EXP ALLERGY, V27, P1043, DOI 10.1111/j.1365-2222.1997.tb01256.x; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Fortugno P, 2012, HUM MOL GENET, V21, P4187, DOI 10.1093/hmg/dds243; Heratizadeh A, 2011, BRIT J DERMATOL, V164, P316, DOI 10.1111/j.1365-2133.2010.10090.x; Heratizadeh A, 2011, CURR ALLERGY ASTHM R, V11, P284, DOI 10.1007/s11882-011-0202-y; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Hohlfeld JM, 2010, CLIN EXP ALLERGY, V40, P998, DOI 10.1111/j.1365-2222.2010.03498.x; Jinnestal CL, 2014, INT J DERMATOL, V53, P27, DOI 10.1111/ijd.12198; Kramer U, 2005, J INVEST DERMATOL, V124, P514, DOI 10.1111/j.0022-202X.2005.23625.x; Krug N, 2003, CLIN EXP ALLERGY, V33, P1667, DOI 10.1111/j.1365-2222.2003.01810.x; Kwon YS, 2010, EXP DERMATOL, V19, P246, DOI 10.1111/j.1600-0625.2009.00971.x; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Oppel T, 2000, BRIT J DERMATOL, V143, P1193, DOI 10.1046/j.1365-2133.2000.03887.x; Orange AP, 1997, PEDIAT ALLERG IMM-UK, V8, P28, DOI 10.1111/j.1399-3038.1997.tb00139.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Rho NK, 2004, BRIT J DERMATOL, V151, P119, DOI 10.1111/j.1365-2133.2004.06027.x; Ring J, 2012, CHEM IMMUNOL ALLERGY, V96, P24, DOI 10.1159/000331807; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Rost GA, 1928, ARCH DERMATOL SYPHIL, V155, P297; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Schoefer Y, 2008, ALLERGY, V63, P81, DOI 10.1111/j.1398-9995.2007.01517.x; Sharquie IK, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-54; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P326, DOI 10.1016/j.jaci.2010.11.024; Storm van Leeuwen W, 1929, KLIN WOCHENSCHR, V8, P986; TUFT L, 1950, J ALLERGY, V21, P181, DOI 10.1016/0021-8707(50)90125-0; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; Turjanmaa K, 2005, CURR OPIN ALLERGY CL, V5, P425, DOI 10.1097/01.all.0000182538.63273.a3; Walker WF, 1923, AM J PUBLIC HEALTH, V13, P897, DOI 10.2105/AJPH.13.11.897-a; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Werfel T, 1998, ALLERGY, V53, P731; Werfel T, 2007, ALLERGY, V62, P723, DOI 10.1111/j.1398-9995.2007.01429.x; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x	40	95	100	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					96	U196		10.1016/j.jaci.2015.04.015	http://dx.doi.org/10.1016/j.jaci.2015.04.015			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	26044854	Bronze			2022-12-18	WOS:000357542200011
J	Stanic, B; van de Veen, W; Wirz, OF; Ruckert, B; Morita, H; Sollner, S; Akdis, CA; Akdis, M				Stanic, Barbara; van de Veen, Willem; Wirz, Oliver F.; Rueckert, Beate; Morita, Hideaki; Soellner, Stefan; Akdis, Cezmi A.; Akdis, Muebeccel			IL-10-overexpressing B cells regulate innate and adaptive immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-10 overexpression; regulatory B cells; immune regulation; anti-inflammatory effects; immunoregulatory capacity	GENE-EXPRESSION; INTERLEUKIN-10; SUBSET; MICE; INDUCTION; RECEPTOR; COLITIS; HELIOS; ALPHA; IGG4	Background: Distinct human IL-10-producing B-cell subsets with immunoregulatory properties have been described. However, the broader spectrum of their direct cellular targets and suppressive mechanisms has not been extensively studied, particularly in relation to direct and indirect IL-10-mediated functions. Objective: The aim of the study was to investigate the effects of IL-10 overexpression on the phenotype and immunoregulatory capacity of B cells. Methods: Primary human B cells were transfected with hIL-10, and IL-10-overexpressing B cells were characterized for cytokine and immunoglobulin production by means of specific ELISA and bead-based assays. Antigen presentation, costimulation capacity, and transcription factor signatures were analyzed by means of flow cytometry and quantitative RT-PCR. Effects of IL-10-overexpresing B cells on Toll-like receptor-triggered cytokine release from PBMCs, LPS-triggered maturation of monocyte-derived dendritic cells, and tetanus toxoid-induced PBMC proliferation were assessed in autologous cocultures. Results: IL-10-overexpressing B cells acquired a prominent immunoregulatory profile comprising upregulation of suppressor of cytokine signaling 3 (SOCS3), glycoprotein A repetitions predominant (GARP), the IL-2 receptor alpha chain (CD25), and programmed cell death 1 ligand 1 (PD-L1). Concurrently, their secretion profile was characterized by a significant reduction in levels of proinflammatory cytokines (TNF-alpha, IL-8, and macrophage inflammatory protein 1 alpha) and augmented production of anti-inflammatory IL-1 receptor antagonist and vascular endothelial growth factor. Furthermore, IL-10 overexpression was associated with a decrease in costimulatory potential. IL-10-overexpressing B cells secreted less IgE and potently suppressed proinflammatory cytokines in PBMCs, maturation of monocyte-derived dendritic cells (rendering their profile to regulatory phenotype), and antigen-specific proliferation in vitro. Conclusion: Our data demonstrate an essential role for IL-10 in inducing an immunoregulatory phenotype in B cells that exerts substantial anti-inflammatory and immunosuppressive functions.	[Stanic, Barbara; van de Veen, Willem; Wirz, Oliver F.; Rueckert, Beate; Morita, Hideaki; Soellner, Stefan; Akdis, Cezmi A.; Akdis, Muebeccel] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich	Akdis, M (corresponding author), Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdism@siaf.uzh.ch	Wirz, Oliver/U-7914-2019; Akdis, Cezmi/AAV-4844-2020; Morita, Hideaki/S-2214-2016; Morita, Hideaki/ADL-2008-2022	Wirz, Oliver/0000-0003-0377-6464; Akdis, Cezmi/0000-0001-8020-019X; Morita, Hideaki/0000-0003-0928-8322; van de Veen, Willem/0000-0001-9951-6688	Swiss National Science Foundation [320030-125249/1, 32-188226, 320030-140772]; Christine Kuhne-Center for Allergy Research and Education (CK-CARE); European Commission [261357]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne-Center for Allergy Research and Education (CK-CARE); European Commission(European CommissionEuropean Commission Joint Research Centre)	Supported by the Swiss National Science Foundation (grant no. 320030-125249/1, 32-188226, 320030-140772), the Christine Kuhne-Center for Allergy Research and Education (CK-CARE), and the European Commission's Seventh Framework Programme (grant agreement no. 261357 MeDALL).	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Anderson AC, 2004, J IMMUNOL, V173, P828, DOI 10.4049/jimmunol.173.2.828; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Dass S, 2007, ARTHRITIS RHEUM, V56, P2715, DOI 10.1002/art.22811; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Dovat S, 2005, J IMMUNOL, V175, P3508, DOI 10.4049/jimmunol.175.6.3508; Fife BT, 2009, NAT IMMUNOL, V10, P1185, DOI 10.1038/ni.1790; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Getnet D, 2010, MOL IMMUNOL, V47, P1595, DOI 10.1016/j.molimm.2010.02.001; Gillan V, 2005, INT IMMUNOL, V17, P373, DOI 10.1093/intimm/dxh217; Goetz M, 2007, INFLAMM BOWEL DIS, V13, P1365, DOI 10.1002/ibd.20215; Himmel ME, 2013, J IMMUNOL, V190, P2001, DOI 10.4049/jimmunol.1201379; Hussaarts L, 2011, J ALLERGY CLIN IMMUN, V128, P733, DOI 10.1016/j.jaci.2011.05.012; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jung M, 2004, EUR J IMMUNOL, V34, P481, DOI 10.1002/eji.200324323; Kabei K, 2014, TRANSPL IMMUNOL; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kurosawa A, 2012, GENE, V492, P305, DOI 10.1016/j.gene.2011.11.003; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Mangan NE, 2004, J IMMUNOL, V173, P6346, DOI 10.4049/jimmunol.173.10.6346; Matsushita T, 2008, J CLIN INVEST, V118, P3420, DOI 10.1172/JCI36030; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Mizoguchi A, 1997, J EXP MED, V186, P1749, DOI 10.1084/jem.186.10.1749; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morel AS, 1997, EUR J IMMUNOL, V27, P26, DOI 10.1002/eji.1830270105; Schioppa T, 2011, P NATL ACAD SCI USA, V108, P10662, DOI 10.1073/pnas.1100994108; Smallie T, 2010, J EXP MED, V207, P2081, DOI 10.1084/jem.20100414; Stockis J, 2009, EUR J IMMUNOL, V39, P3315, DOI 10.1002/eji.200939684; Tamassia N, 2010, FASEB J, V24, P1365, DOI 10.1096/fj.09-145573; Tanaka T, 2012, IMMUNOTHERAPY-UK, V4, P87, DOI [10.2217/IMT.11.147, 10.2217/imt.11.147]; Tangye SG, 2009, EUR J IMMUNOL, V39, P2065, DOI 10.1002/eji.200939531; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Wang R, 2009, P NATL ACAD SCI USA, V106, P13439, DOI 10.1073/pnas.0901965106; Williams L, 2002, J LEUKOCYTE BIOL, V72, P800; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yang M, 2010, J IMMUNOL, V184, P3321, DOI 10.4049/jimmunol.0902551; Zolotukhin I., 2011, J GENET SYNDR GENE T, V2	45	95	99	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					771	U299		10.1016/j.jaci.2014.07.041	http://dx.doi.org/10.1016/j.jaci.2014.07.041			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25240783				2022-12-18	WOS:000351065000025
J	Lee, YN; Frugoni, F; Dobbs, K; Walter, JE; Giliani, S; Gennery, AR; Al-Herz, W; Haddad, E; LeDeist, F; Bleesing, JH; Lauren, AH; Pai, SY; Nelson, RP; El-Ghoneimy, DH; El-Feky, RA; Reda, SM; Hossny, E; Soler-Palacin, P; Fuleihan, RL; Patel, NC; Massaad, MJ; Geha, RS; Puck, JM; Palma, P; Cancrini, C; Chen, K; Vihinen, M; Alt, FW; Notarangelo, LD				Lee, Yu Nee; Frugoni, Francesco; Dobbs, Kerry; Walter, Jolan E.; Giliani, Silvia; Gennery, Andrew R.; Al-Herz, Waleed; Haddad, Elie; LeDeist, Francoise; Bleesing, Jack H.; Henderson, Lauren A.; Pai, Sung-Yun; Nelson, Robert P.; El-Ghoneimy, Dalia H.; El-Feky, Reem A.; Reda, Shereen M.; Hossny, Elham; Soler-Palacin, Pere; Fuleihan, Ramsay L.; Patel, Niraj C.; Massaad, Michel J.; Geha, Raif S.; Puck, Jennifer M.; Palma, Paolo; Cancrini, Caterina; Chen, Karin; Vihinen, Mauno; Alt, Frederick W.; Notarangelo, Luigi D.			A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Recombination-activating gene 1; V(D)J recombination; severe combined immune deficiency; Omenn syndrome; autoimmunity; genotype-phenotype correlation; immune repertoire	COMBINED IMMUNE-DEFICIENCY; B-CELL; RAG MUTATIONS; IMMUNODEFICIENCY; REPERTOIRE; SPECTRUM; DEFECTS; REVEALS; DISEASE; LENGTH	Background: The recombination-activating gene (RAG) 1/2 proteins play a critical role in the development of T and B cells by initiating the VDJ recombination process that leads to generation of a broad T-cell receptor (TCR) and B-cell receptor repertoire. Pathogenic mutations in the RAG1/2 genes result in various forms of primary immunodeficiency, ranging from T 2 B 2 severe combined immune deficiency to delayed-onset disease with granuloma formation, autoimmunity, or both. It is not clear what contributes to such heterogeneity of phenotypes. Objective: We sought to investigate the molecular basis for phenotypic diversity presented in patients with various RAG1 mutations. Methods: We have developed a flow cytometry-based assay that allows analysis of RAG recombination activity based on green fluorescent protein expression and have assessed the induction of the Ighc locus rearrangements in mouse Rag1(-/-) pro-B cells reconstituted with wild-type or mutant human RAG1 (hRAG1) using deep sequencing technology. Results: Here we demonstrate correlation between defective recombination activity of hRAG1 mutant proteins and severity of the clinical and immunologic phenotype and provide insights on the molecular mechanisms accounting for such phenotypic diversity. Conclusions: Using a sensitive assay to measure the RAG1 activity level of 79 mutations in a physiologic setting, we demonstrate correlation between recombination activity of RAG1 mutants and the severity of clinical presentation and show that RAG1 mutants can induce specific abnormalities of the VDJ recombination process.	[Lee, Yu Nee; Frugoni, Francesco; Dobbs, Kerry; Walter, Jolan E.; Henderson, Lauren A.; Massaad, Michel J.; Geha, Raif S.; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Div Immunol, Boston, MA USA; [Lee, Yu Nee; Frugoni, Francesco; Dobbs, Kerry; Walter, Jolan E.; Henderson, Lauren A.; Massaad, Michel J.; Geha, Raif S.; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Manton Ctr Orphan Dis Res, Boston, MA USA; [Walter, Jolan E.] Massachusetts Gen Hosp Children, Div Pediat Allergy Immunol, Boston, MA USA; [Giliani, Silvia] Univ Brescia, A Nocivelli Inst Mol Med, Pediat Clin, Brescia, Italy; [Giliani, Silvia] Genet Sect, Dept Pathol Spedali Civili, Brescia, Italy; [Gennery, Andrew R.] NHS Fdn Trust, Newcastle Upon Tyne Hosp, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait; [Haddad, Elie; LeDeist, Francoise] Univ Montreal, Dept Pediat, CHU St Justine Res Ctr, Montreal, PQ H3C 3J7, Canada; [Haddad, Elie; LeDeist, Francoise] Univ Montreal, Dept Microbiol Infectiol & Immunol, CHU St Justine Res Ctr, Montreal, PQ, Canada; [Bleesing, Jack H.] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA; [Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Nelson, Robert P.] Indiana Univ, Sch Med, Div Hematol & Oncol, Indianapolis, IN USA; [El-Ghoneimy, Dalia H.; El-Feky, Reem A.; Reda, Shereen M.; Hossny, Elham] Ain Shams Univ, Dept Pediat Allergy & Immunol, Childrens Hosp, Fac Med, Cairo, Egypt; [Soler-Palacin, Pere] Vall Hebron Univ Hosp, Paediat Infect Dis & Immunodeficiencies Unit, Barcelona, Spain; [Fuleihan, Ramsay L.] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Patel, Niraj C.] Levine Childrens Hosp, Carolinas Med Ctr, Immunol Clin, Charlotte, NC USA; [Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Puck, Jennifer M.] UCSF Benioff Childrens Hosp, San Francisco, CA USA; [Palma, Paolo; Cancrini, Caterina] Bambino Gesu Pediat Hosp, DPUO, Univ Dept Pediat, Rome, Italy; [Palma, Paolo; Cancrini, Caterina] Univ Roma Tor Vergata, Sch Med, Rome, Italy; [Chen, Karin] Univ Utah, Dept Pediat, Div Allergy Immunol & Rheumatol, Salt Lake City, UT USA; [Vihinen, Mauno] Lund Univ, Dept Expt Med Sci, S-22100 Lund, Sweden; [Alt, Frederick W.] Boston Childrens Hosp, Howard Hughes Med Inst, Program Cellular & Mol Med, Boston, MA USA; [Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Brescia; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Kuwait University; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Cincinnati Children's Hospital Medical Center; Harvard University; Boston Children's Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; Egyptian Knowledge Bank (EKB); Ain Shams University; Hospital Universitari Vall d'Hebron; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Carolinas Medical Center; University of California System; University of California San Francisco; IRCCS Bambino Gesu; University of Rome Tor Vergata; Utah System of Higher Education; University of Utah; Lund University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Alt, FW (corresponding author), Boston Childrens Hosp, Program Mol & Cellular Med, Karp Res Bldg,9th Floor,One Blackfan Circle, Boston, MA 02115 USA.	alt@enders.tch.harvard.edu; luigi.notarangelo@childrens.harvard.edu	Palma, Paolo/K-3379-2016; Notarangelo, Luigi D/F-9718-2016; Palma, Paolo/AAK-9275-2020; El-Ghoneimy, Dalia/ABG-6141-2021; Haddad, Elie/AAQ-4971-2020; Pai, Sung-Yun/AAH-7762-2019; Soler-Palacin, Pere/N-2373-2014; Vihinen, Mauno/A-8452-2012; Giliani, Silvia/AAX-8843-2020; Lee, Yu Nee/T-2360-2017	Notarangelo, Luigi D/0000-0002-8335-0262; Palma, Paolo/0000-0002-3066-4719; Pai, Sung-Yun/0000-0002-0158-8147; Soler-Palacin, Pere/0000-0002-0346-5570; Vihinen, Mauno/0000-0002-9614-7976; Giliani, Silvia/0000-0001-8137-4642; Dobbs, Kerry/0000-0002-3432-3137; Haddad, Elie/0000-0003-2446-6879; cancrini, caterina/0000-0001-8410-9617; Lee, Yu Nee/0000-0001-8648-5253; Hossny, Elham/0000-0001-6876-6318; Frugoni, Francesco/0000-0002-1769-8121	National Institutes of Health [U54AI082973, 1P01AI076210-01A1]; March of Dimes [1-FY-13-500]; Jeffrey Modell Foundation; Translational Research Program [TRP 2009 042809]; Dubai Harvard Foundation for Medical Research; Manton Foundation; March of Dimes; National Institutes of Health (NIH); National Institute of Allergy and Infectious Disease; Translational Investigator Service Award from Boston Children's Hospital; Baxter; CSL Behring; Octapharma; NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, K08AI103035, R01AI105776, U54AI082973] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); Jeffrey Modell Foundation; Translational Research Program; Dubai Harvard Foundation for Medical Research; Manton Foundation; March of Dimes(March of Dimes); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Translational Investigator Service Award from Boston Children's Hospital; Baxter; CSL Behring; Octapharma; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health grants U54AI082973 (to L.D.N.) and 1P01AI076210-01A1 (to L.D.N., F. W. A., and R. S. G.). F. W. A is an investigator of the Howard Hughes Medical Institute. This work received additionally contributions from the March of Dimes (grant 1-FY-13-500 to L.D.N.), the Jeffrey Modell Foundation (to L.D.N.), the Translational Research Program grant TRP 2009 042809 (to L.D.N.), the Dubai Harvard Foundation for Medical Research (to L.D.N. and R. S. G.), and the Manton Foundation (to Y.N.L. and L.D.N.).; Y.N. Lee has received research support from the Manton Foundation and the March of Dimes and is employed by Boston Children's Hospital. F. Frugoni, J. Puck, and F. Alt have received research support from the National Institutes of Health (NIH). J. E. Walter is employed by Massachusetts General Hospital and receives research support from the National Institute of Allergy and Infectious Disease. L. A. Henderson has received travel support from the American College of Rheumatology and the American Academy of Pediatrics. S.-Y. Pai is employed by Boston Children's Hospital and receives research support from the Translational Investigator Service Award from Boston Children's Hospital. P. Soler-Palacin has consultant arrangements with CSL Behring; has provided expert testimony on behalf of CSL Behring; has received research support from Baxter, CSL Behring, and Octapharma; has received payment for lectures from CSL Behring; and has received travel support from the European Society of Immunodeficiencies. R. S. Geha has received research support from the NIH and the Dubai Harvard Foundation for Medical Research. L. D. Notarangelo has received research support from the NIH, the Jeffrey Modell Foundation, the March of Dimes, the Dubai Harvard Foundation for Medical Research, and the Manton Foundation; has board memberships with the Program in Molecular and Cellular Medicine and Pediatric University Hospital "Meyer" in Florence, Italy; is employed by Boston Children's Hospital; and has received royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	Alamyar E., 2012, IMMUNOME RES, V8, P26, DOI [DOI 10.1007/978-1-61779-842-9_32, 10.4172/1745-7580.1000056, DOI 10.4172/1745-7580.1000056]; Alt FW, 2013, CELL, V152, P417, DOI 10.1016/j.cell.2013.01.007; Asai E, 2011, CLIN IMMUNOL, V138, P172, DOI 10.1016/j.clim.2010.11.005; Avila EM, 2010, PEDIATRICS, V126, pE1248, DOI 10.1542/peds.2009-3171; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Cassani B, 2010, J ALLERGY CLIN IMMUN, V125, P209, DOI 10.1016/j.jaci.2009.10.023; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Couedel C, 2010, J CLIN INVEST, V120, P1337, DOI 10.1172/JCI41305; Dalal I, 2011, CLIN IMMUNOL, V140, P284, DOI 10.1016/j.clim.2011.04.011; De Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Ehl S, 2005, J CLIN INVEST, V115, P3140, DOI 10.1172/JCI25221; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Giblin W, 2009, BLOOD, V113, P2965, DOI 10.1182/blood-2008-07-165167; Guo CG, 2011, NATURE, V477, P424, DOI 10.1038/nature10495; Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated; Henderson LA, 2013, J ALLERGY CLIN IMMUN, V132, P969, DOI 10.1016/j.jaci.2013.06.032; Ivanov II, 2005, J IMMUNOL, V174, P7773, DOI 10.4049/jimmunol.174.12.7773; Kuijpers TW, 2011, BLOOD, V117, P5892, DOI 10.1182/blood-2011-01-329052; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Mainville CA, 2001, J VIROL, V75, P1816, DOI 10.1128/JVI.75.4.1816-1823.2001; Muljo SA, 2003, NAT IMMUNOL, V4, P31, DOI 10.1038/ni870; Olatubosun A, 2012, HUM MUTAT, V33, P1166, DOI 10.1002/humu.22102; Pasic S, 2009, ACTA PAEDIATR, V98, P1062, DOI 10.1111/j.1651-2227.2009.01250.x; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; Rogosch T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00176; Safaeil S, 2011, IRAN J ALLERGY ASTHM, V10, P129, DOI 010.02/ijaai.129132; Schatz DG, 2011, ANNU REV GENET, V45, P167, DOI 10.1146/annurev-genet-110410-132552; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Sobacchi C, 2006, HUM MUTAT, V27, P1174, DOI 10.1002/humu.20408; TSUKADA S, 1990, J IMMUNOL, V144, P4053; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Wang CL, 2010, P NATL ACAD SCI USA, V107, P1518, DOI 10.1073/pnas.0913939107; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wong SY, 2008, J IMMUNOL, V181, P4124, DOI 10.4049/jimmunol.181.6.4124; Yin FF, 2009, NAT STRUCT MOL BIOL, V16, P499, DOI 10.1038/nsmb.1593; Yu XM, 2014, J ALLERGY CLIN IMMUN, V133, P1109, DOI 10.1016/j.jaci.2013.11.018; Zemlin M, 2005, MOL IMMUNOL, V42, P789, DOI 10.1016/j.molimm.2004.07.049; Zhang JY, 2005, PEDIATRICS, V116, pE445, DOI 10.1542/peds.2005-0369	43	95	97	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1099	+		10.1016/j.jaci.2013.10.007	http://dx.doi.org/10.1016/j.jaci.2013.10.007			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24290284	Green Published, Green Accepted			2022-12-18	WOS:000333531700021
J	Kolly, L; Busso, N; von Scheven-Gete, A; Bagnoud, N; Moix, I; Holzinger, D; Simon, G; Ives, A; Guarda, G; So, A; Morris, MA; Hofer, M				Kolly, Laeticia; Busso, Nathalie; von Scheven-Gete, Annette; Bagnoud, Nathaliane; Moix, Isabelle; Holzinger, Dirk; Simon, Gregoire; Ives, Annette; Guarda, Greta; So, Alexander; Morris, Michael A.; Hofer, Michael			Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL-1 beta production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Periodic fever; aphthous stomatitis; pharyngitis; cervical adenitis syndrome; recurrent fever; autoinflammatory disease; interleukine-1 beta; inflammasome	MULTISYSTEM INFLAMMATORY DISEASE; JUVENILE IDIOPATHIC ARTHRITIS; PFAPA SYNDROME; AUTOINFLAMMATORY DISEASES; CIAS1 MUTATIONS; INTERLEUKIN-1-BETA; ACTIVATION; MOSAICISM; MECHANISM; BLOCKADE	Background: The exact pathogenesis of the pediatric disorder periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome is unknown. Objectives: We hypothesized that PFAPA might be due to dysregulated monocyte IL-1 beta production linked to genetic variants in proinflammatory genes. Methods: Fifteen patients with PFAPA syndrome were studied during and outside a febrile episode. Hematologic profile, inflammatory markers, and cytokine levels were measured in the blood. The capacity of LPS-stimulated PBMCs and monocytes to secrete IL-1 beta was assessed by using ELISA, and active IL-1 beta secretion was visualized by means of Western blotting. Real-time quantitative PCR was performed to assess cytokine gene expression. DNA was screened for variants of the MEFV, TNFRSF1A, MVK, and NLRP3 genes in a total of 57 patients with PFAPA syndrome. Results: During a febrile attack, patients with PFAPA syndrome revealed significantly increased neutrophil counts, erythrocyte sedimentation rates, and C-reactive protein, serum amyloid A, myeloid-related protein 8/14, and S100A12 levels compared with those seen outside attacks. Stimulated PBMCs secreted significantly more IL-1 beta during an attack (during a febrile episode, 575 +/- 88 pg/mL; outside a febrile episode, 235 +/- 56 pg/mL; P < .001), and this was in the mature active p17 form. IL-1 beta secretion was inhibited by ZYVAD, a caspase inhibitor. Similar results were found for stimulated monocytes (during a febrile episode, 743 +/- 183 pg/mL; outside a febrile episode, 227 +/- 92 pg/mL; P < .05). Genotyping identified variants in 15 of 57 patients, with 12 NLRP3 variants, 1 TNFRSF1A variant, 4 MEFV variants, and 1 MVK variant. Conclusion: Our data strongly suggest that IL-1 beta monocyte production is dysregulated in patients with PFAPA syndrome. Approximately 20% of them were found to have NLRP3 variants, suggesting that inflammasome-related genes might be involved in this autoinflammatory syndrome.	[Kolly, Laeticia; Busso, Nathalie; Bagnoud, Nathaliane; Simon, Gregoire; Ives, Annette; So, Alexander] Univ Lausanne, Univ Lausanne Hosp, DAL, Rheumatol Serv, CH-1015 Lausanne, Switzerland; [von Scheven-Gete, Annette; Hofer, Michael] Univ Lausanne, Univ Lausanne Hosp, Dept Pediat, Pediat Rheumatol Romande Unit, CH-1015 Lausanne, Switzerland; [von Scheven-Gete, Annette; Hofer, Michael] Univ Hosp Geneva, Dept Pediat, Geneva, Switzerland; [Holzinger, Dirk] Univ Munster, Inst Immunol, Munster, Germany; [Holzinger, Dirk] Univ Childrens Hosp Munster, Dept Gen Pediat, Munster, Germany; [Moix, Isabelle; Morris, Michael A.] Univ Hosp Geneva, Genet Med Serv, Geneva, Switzerland; [Guarda, Greta] Univ Lausanne, Inst Biochem, CH-1015 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Munster; University of Munster; University of Geneva; University of Lausanne	Hofer, M (corresponding author), CHU Vaudois, Serv Pediat, CH-1011 Lausanne, Switzerland.	michael.hofer@chuv.ch	Morris, Michael/AAD-2458-2022	Morris, Michael/0000-0002-9660-505X; Holzinger, Dirk/0000-0002-8062-8820; Guarda, Greta/0000-0001-9243-6116; Ives, Annette/0000-0002-7407-960X	Swiss National Science Foundation [FN 310030-130085/1]; Novartis Foundation; Jean and Linette Warnery Foundation; German Ministry of Education and Research (BMBF project AID-NET); Swiss National Science Foundation; Novartis; Bundesministerium fur Bildung und Forschung; University of Lausanne; Swiss National Foundation; Menarini	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis Foundation(Novartis); Jean and Linette Warnery Foundation; German Ministry of Education and Research (BMBF project AID-NET)(Federal Ministry of Education & Research (BMBF)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis(Novartis); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); University of Lausanne; Swiss National Foundation(Swiss National Science Foundation (SNSF)); Menarini(Menarini Group)	Supported by a grant from the Swiss National Science Foundation (FN 310030-130085/1), the Novartis Foundation, the Jean and Linette Warnery Foundation, and the German Ministry of Education and Research (BMBF project AID-NET).; Disclosure of potential conflict of interest: N. Busso has received grants from the Swiss National Science Foundation. I. Moix has received grants from Novartis. D. Holzinger has received grants from Bundesministerium fur Bildung und Forschung. G. Guarda is employed by and has received grants from the University of Lausanne. A. So serves on advisory boards for Novartis AG and Menarini, has received grants from the Swiss National Foundation, has received payment for lectures/service on speakers' bureaus from Menarini, and has received payment for development of educational presentations from Novartis. M. A. Morris has received grants from Novartis. M. Hofer has received grants from the Novartis Foundation, has board membership with Novartis and Bristol-Myers-Squibb, and has received travel expenses from Pfizer. The rest of the authors declare that they have no relevant conflicts of interest.	Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 2007, ARTHRITIS RHEUM-US, V56, P1273, DOI 10.1002/art.22491; Arostegui JI, 2010, ARTHRITIS RHEUM-US, V62, P1158, DOI 10.1002/art.27342; Booth DR, 2001, QJM-INT J MED, V94, P527, DOI 10.1093/qjmed/94.10.527; Brown KL, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-65; Cochard M, 2010, RHEUMATOLOGY, V49, P1984, DOI 10.1093/rheumatology/keq187; Delaloye J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000480; Foell D, 2005, J IMMUNOL, V175, P3459, DOI 10.4049/jimmunol.175.6.3459; Frosch M, 2009, ARTHRITIS RHEUM-US, V60, P883, DOI 10.1002/art.24349; Gattorno M, 2008, ARTHRITIS RHEUM, V58, P1505, DOI 10.1002/art.23437; Gattorno M, 2007, ARTHRITIS RHEUM, V56, P3138, DOI 10.1002/art.22842; Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137; Hofer M, 2006, BEST PRACT RES CL RH, V20, P627, DOI 10.1016/j.berh.2006.04.001; Hoffman HM, 2010, CURR ALLERGY ASTHM R, V10, P229, DOI 10.1007/s11882-010-0109-z; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Ives A, 2011, SCIENCE, V331, P775, DOI 10.1126/science.1199326; Kastner DL, 2010, CELL, V140, P784, DOI 10.1016/j.cell.2010.03.002; Lachmann HJ, 2011, ARTHRITIS RHEUM-US, V63, P314, DOI 10.1002/art.30105; Lachmann HJ, 2009, J EXP MED, V206, P1029, DOI 10.1084/jem.20082481; Long SS, 1999, J PEDIATR-US, V135, P1, DOI 10.1016/S0022-3476(99)70316-1; Loock J, 2010, J ALLERGY CLIN IMMUN, V125, P500, DOI 10.1016/j.jaci.2009.10.066; Marek-Yagel D, 2009, J RHEUMATOL, V36, P2372, DOI 10.3899/jrheum.090250; Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720; Pelagatti MA, 2011, ARTHRITIS RHEUM-US, V63, P1141, DOI 10.1002/art.30237; Pontillo A, 2011, AM J GASTROENTEROL, V106, P539, DOI 10.1038/ajg.2010.474; Schoultz I, 2009, AM J GASTROENTEROL, V104, P1180, DOI 10.1038/ajg.2009.29; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Shinar Y, 2012, ANN RHEUM DIS; Stojanov S, 2006, EUR CYTOKINE NETW, V17, P90; Stojanov S, 2011, P NATL ACAD SCI USA, V108, P7148, DOI 10.1073/pnas.1103681108; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512; Tasher D, 2006, ARCH DIS CHILD, V91, P981, DOI 10.1136/adc.2005.084731; Thomas KT, 1999, J PEDIATR-US, V135, P15, DOI 10.1016/S0022-3476(99)70321-5; Ting TV, 2007, PEDIATR NEUROL, V36, P338, DOI 10.1016/j.pediatrneurol.2006.12.008; Toplak N, 2012, ANN RHEUM DIS, V71, P1177, DOI 10.1136/annrheumdis-2011-200549; Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725; Verma D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034977	38	95	97	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1635	1643		10.1016/j.jaci.2012.07.043	http://dx.doi.org/10.1016/j.jaci.2012.07.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23006543				2022-12-18	WOS:000320532800024
J	Ziska, LH; Beggs, PJ				Ziska, Lewis H.; Beggs, Paul J.			Anthropogenic climate change and allergen exposure: The role of plant biology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Climate change; aerobiology; pollen; allergen; allergic rhinitis; asthma; exposure	RAGWEED AMBROSIA-ARTEMISIIFOLIA; DIESEL EXHAUST PARTICLES; BIRCH POLLEN SEASONS; LONG-TERM TRENDS; COMMON RAGWEED; GRASS-POLLEN; ATMOSPHERIC CO2; AIR-POLLUTION; ASTHMA; IMPACTS	Accumulation of anthropogenic gases, particularly CO2, is likely to have 2 fundamental effects on plant biology. The first is an indirect effect through Earth's increasing average surface temperatures, with subsequent effects on other aspects of climate, such as rainfall and extreme weather events. The second is a direct effect caused by CO2-induced stimulation of photosynthesis and plant growth. Both effects are likely to alter a number of fundamental aspects of plant biology and human health, including aerobiology and allergic diseases, respectively. This review highlights the current and projected effect of increasing CO2 and climate change in the context of plants and allergen exposure, emphasizing direct effects on plant physiologic parameters (eg, pollen production) and indirect effects (eg, fungal sporulation) related to diverse biotic and abiotic interactions. Overall, the review assumes that future global mitigation efforts will be limited and suggests a number of key research areas that will assist in adapting to the ongoing challenges to public health associated with increased allergen exposure. (J Allergy Clin Immunol 2012; 129: 27-32.)	[Ziska, Lewis H.] ARS, USDA, Beltsville, MD 20705 USA; [Beggs, Paul J.] Macquarie Univ, Fac Sci, Dept Geog & Environm, Sydney, NSW 2109, Australia	United States Department of Agriculture (USDA); Macquarie University	Ziska, LH (corresponding author), ARS, USDA, 10300 Baltimore Ave, Beltsville, MD 20705 USA.	lewis.ziska@ars.usda.gov		Beggs, Paul/0000-0001-9949-1783				Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; American Academy of Allergy Asthma & Immunology, ASTHM STAT; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Arbor Day Foundation, 2006 ARB HARD ZON MA; Ariano R, 2010, ANN ALLERG ASTHMA IM, V104, P215, DOI 10.1016/j.anai.2009.12.005; Bass DJ, 2000, AEROBIOLOGIA, V16, P107, DOI DOI 10.1023/A:1007696112953; Beggs PJ, 2010, INT J ENV RES PUB HE, V7, P3006, DOI 10.3390/ijerph7083006; Beggs PJ, 2008, AIR QUAL ATMOS HLTH, V1, P119, DOI 10.1007/s11869-008-0013-z; Beggs PJ, 2005, ENVIRON HEALTH PERSP, V113, P915, DOI 10.1289/ehp.7724; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; Beggs PJ, 2011, INT PUBLIC HLTH, V2, P377; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Bradley BA, 2010, TRENDS ECOL EVOL, V25, P310, DOI 10.1016/j.tree.2009.12.003; Burch M, 2002, INT J BIOMETEOROL, V46, P107, DOI 10.1007/s00484-002-0127-1; Burr ML, 1999, CLIN EXP ALLERGY, V29, P735; Buters JTM, 2008, INT ARCH ALLERGY IMM, V145, P122, DOI 10.1159/000108137; Cecchi L, 2010, ALLERGY, V65, P1073, DOI 10.1111/j.1398-9995.2010.02423.x; Centers for Disease Control and Prevention, ALL HAY FEV; Cleland EE, 2007, TRENDS ECOL EVOL, V22, P357, DOI 10.1016/j.tree.2007.04.003; Clements DR, 2011, WEED RES, V51, P227, DOI 10.1111/j.1365-3180.2011.00850.x; Clot Bernard, 2003, Aerobiologia, V19, P227, DOI 10.1023/B:AERO.0000006572.53105.17; Corden J.M., 2001, AEROBIOLOGIA, V17, P127, DOI [10.1023/A, DOI 10.1023/A:1010876917512, 10.1023/A:1010876917512]; Corden Julie M., 2003, Aerobiologia, V19, P191, DOI 10.1023/B:AERO.0000006529.51252.2f; Costello A, 2009, LANCET, V373, P1693, DOI [10.1016/S0140-6736(09)60935-1, 10.1016/S0140-6736(09)60929-6]; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; D'Amato G, 2008, J ALLERGY CLIN IMMUN, V121, P537, DOI 10.1016/j.jaci.2007.10.046; Damialis A, 2007, ATMOS ENVIRON, V41, P7011, DOI 10.1016/j.atmosenv.2007.05.009; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Ebi KL, 2008, ENVIRON HEALTH PERSP, V116, P1449, DOI 10.1289/ehp.11463; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; Emberlin J, 1997, GRANA, V36, P29, DOI 10.1080/00173139709362586; Emberlin J, 1999, CLIN EXP ALLERGY, V29, P347, DOI 10.1046/j.1365-2222.1999.00369.x; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Fourier J.-B.J., 1827, MEMOIRES LACAD MIE R, VVII, P570; Frei T, 2008, INT J BIOMETEOROL, V52, P667, DOI 10.1007/s00484-008-0159-2; Frenguelli G, 2002, Monaldi Arch Chest Dis, V57, P141; Galan C, 2005, INT J BIOMETEOROL, V49, P184, DOI 10.1007/s00484-004-0223-5; Garcia-Mozo H, 2006, ANN AGR ENV MED, V13, P209; George K, 2009, OECOLOGIA, V159, P637, DOI 10.1007/s00442-008-1238-0; Hansen J, 2006, P NATL ACAD SCI USA, V103, P14288, DOI 10.1073/pnas.0606291103; Jacob DJ, 2009, ATMOS ENVIRON, V43, P51, DOI 10.1016/j.atmosenv.2008.09.051; Rodriguez-Rajo FJ, 2010, AEROBIOLOGIA, V26, P1, DOI 10.1007/s10453-009-9138-2; Kiehl J, 2011, SCIENCE, V331, P158, DOI 10.1126/science.1199380; Kiss L, 2007, BIOCONTROL SCI TECHN, V17, P535, DOI 10.1080/09583150701311705; Klironomos JN, 1997, CAN J BOT, V75, P1670, DOI 10.1139/b97-880; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Ladeau SL, 2006, FUNCT ECOL, V20, P541, DOI 10.1111/j.1365-2435.2006.01133.x; Levetin E, 2008, CURR ALLERGY ASTHM R, V8, P418, DOI 10.1007/s11882-008-0081-z; Miller-Rushing AJ, 2008, TREE PHYSIOL, V28, P659, DOI 10.1093/treephys/28.4.659; Mohan JE, 2006, P NATL ACAD SCI USA, V103, P9086, DOI 10.1073/pnas.0602392103; Motta AC, 2006, INT ARCH ALLERGY IMM, V139, P294, DOI 10.1159/000091600; Namork E, 2006, TOXICOL LETT, V165, P71, DOI 10.1016/j.toxlet.2006.01.016; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Quest Diagnostics Health Trends, QUEST DIAGN HLTH TRE; Rasmussen Alix, 2002, Aerobiologia, V18, P253, DOI 10.1023/A:1021321615254; Reid CE, 2009, ECOHEALTH, V6, P458, DOI 10.1007/s10393-009-0261-x; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Singer BD, 2005, FUNCT PLANT BIOL, V32, P667, DOI 10.1071/FP05039; Stach A, 2007, J INVEST ALLERG CLIN, V17, P39; Suarez-Cervera M, 2008, ANN ALLERG ASTHMA IM, V101, P57, DOI 10.1016/S1081-1206(10)60836-8; Suphioglu C, 1998, INT ARCH ALLERGY IMM, V116, P253, DOI 10.1159/000023953; Tashpulatov AS, 2004, INT ARCH ALLERGY IMM, V134, P1, DOI 10.1159/000077527; Thuiller W, 2003, GLOBAL CHANGE BIOL, V9, P1353, DOI 10.1046/j.1365-2486.2003.00666.x; Wan SQ, 2002, AM J BOT, V89, P1843, DOI 10.3732/ajb.89.11.1843; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279, DOI 10.1016/S1081-1206(10)62009-1; Wolf J, 2010, ENVIRON HEALTH PERSP, V118, P1223, DOI 10.1289/ehp.0901867; Ziska LH, 2007, GLOBAL CHANGE BIOL, V13, P266, DOI 10.1111/j.1365-2486.2006.01264.x; Ziska L.H., 2010, WEED BIOL CLIMATE CH, P248; Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893; Ziska LH, 2004, OECOLOGIA, V139, P454, DOI 10.1007/s00442-004-1526-2; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53; Ziska LH, 2002, FUNCT PLANT BIOL, V29, P1365, DOI 10.1071/FP02039	75	95	97	5	66	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					27	32		10.1016/j.jaci.2011.10.032	http://dx.doi.org/10.1016/j.jaci.2011.10.032			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22104602				2022-12-18	WOS:000298634000004
J	Moreira, AP; Cavassani, KA; Hullinger, R; Rosada, RS; Fong, DJ; Murray, L; Hesson, DP; Hogaboam, CM				Moreira, Ana Paula; Cavassani, Karen A.; Hullinger, Rikki; Rosada, Rogerio S.; Fong, Daniel J.; Murray, Lynne; Hesson, Dave P.; Hogaboam, Cory M.			Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; Aspergillus fumigatus; fungal-induced allergic airway disease; pentraxins; serum amyloid P component; macrophage; airway remodeling	LONG PENTRAXIN PTX3; C-REACTIVE PROTEIN; IFN-GAMMA; PERIBRONCHIAL FIBROSIS; PULMONARY INFLAMMATION; TYPE-2 INFLAMMATION; EPITHELIAL-CELLS; INNATE IMMUNITY; SEVERE ASTHMA; IN-VITRO	Background: Aspergillus fumigatus conidia aggravate asthmatic responses. Lung macrophages normally kill fungal conidia, but the presence of type 2 cytokines during asthma contributes to the alternative (or M2) activation of these cells, which secrete proallergic factors and exhibit impaired innate immunity. Objective: Considering that pentraxins modulate macrophage function, we examined the effect of C-reactive protein (CRP) and serum amyloid P (SAP) in an experimental model of A fumigatus-induced allergic airway disease. Methods: The effects of SAP and CRP on M2 macrophage differentiation were examined in vitro, and the in vivo effects of these pentraxins were analyzed in the asthma model. Results: SAP inhibited the generation of M2 markers, such as arginase and the chitinase Ym-1, through an Fc gamma R-dependent mechanism in cultured macrophages. This effect correlated with a decrease in signal transducer and activator of transcription 6 (STAT6) phosphorylation in SAP-treated M2 macrophages. In vivo treatment with SAP significantly decreased methacholine-induced bronchial resistance, mucus cell metaplasia, the number of "found in inflammatory zone 1" (FIZZ1)-positive cells in the lungs, and collagen deposition compared with the control group. CRP had a modest effect on M2 differentiation, and in vivo treatment with CRP had a minor effect or exacerbated A fumigatus-induced lung disease. Finally, the adoptive transfer of SAP-pretreated M2 macrophages into allergic mice significantly attenuated disease when compared with nontransferred or M2-transferred control groups. Conclusions: These findings demonstrate that SAP is a potent inhibitor of M2 macrophage differentiation and represents a novel therapy in A fumigatus-induced allergic disease. (J Allergy Clin Immunol 2010;126:712-21.)	[Moreira, Ana Paula; Cavassani, Karen A.; Hullinger, Rikki; Rosada, Rogerio S.; Fong, Daniel J.; Hogaboam, Cory M.] Univ Michigan, Dept Pathol, Sch Med, Program Immunol, Ann Arbor, MI 48109 USA; [Murray, Lynne; Hesson, Dave P.] Promedior Inc, Malvern, PA USA	University of Michigan System; University of Michigan	Hogaboam, CM (corresponding author), Univ Michigan, Dept Pathol, Sch Med, Program Immunol, Room 4057,BSRB,109 Zina Pitcher Rd, Ann Arbor, MI 48109 USA.	anapaula@umich.edu; hogaboam@med.umich.edu	Hogaboam, Cory M./AAI-1433-2021; Rosada, Rogerio/B-1396-2010; Murray, Lynne/AAB-1793-2020; hogaboam, cory/M-3578-2014	Hogaboam, Cory M./0000-0003-3366-4850; Murray, Lynne/0000-0003-4879-966X; 	Promedior	Promedior	Disclosure of potential conflict of interest: A. P. Moreira, K. A. Cavassani, R. Hullinger, R. S. Rosada, D. J. Fong, and C. M. Hogaboam have received research support from Promedior. L. Murray is an employee of MedImmune and was previously employed by Promedior. D. P. Hesson has declared that he has no conflict of interest.	Albanesi C, 2007, J IMMUNOL, V179, P984, DOI 10.4049/jimmunol.179.2.984; Alexis NE, 2001, AM J PHYSIOL-LUNG C, V280, pL369; Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x; Billiau A, 2009, CYTOKINE GROWTH F R, V20, P97, DOI 10.1016/j.cytogfr.2009.02.004; Blease K, 2001, J IMMUNOL, V167, P6583, DOI 10.4049/jimmunol.167.11.6583; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Blease K, 2001, INFLAMM RES, V50, P552, DOI 10.1007/PL00000233; Blease K, 2000, J IMMUNOL, V165, P2603, DOI 10.4049/jimmunol.165.5.2603; Blease K, 2000, J IMMUNOL, V165, P1564, DOI 10.4049/jimmunol.165.3.1564; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; Dong L, 2008, J ASTHMA, V45, P648, DOI 10.1080/02770900802126941; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; Haudek SB, 2008, P NATL ACAD SCI USA, V105, P10179, DOI 10.1073/pnas.0804910105; Hirschfield GM, 2003, QJM-INT J MED, V96, P793, DOI 10.1093/qjmed/hcg134; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Homer RJ, 2006, AM J PHYSIOL-LUNG C, V291, pL502, DOI 10.1152/ajplung.00364.2005; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Lee AM, 2004, AM J PHYSIOL-LUNG C, V286, pL1255, DOI 10.1152/ajplung.00451.2003; Lee CG, 2009, YONSEI MED J, V50, P22, DOI 10.3349/ymj.2009.50.1.22; Lu JH, 2008, NATURE, V456, P989, DOI 10.1038/nature07468; Manfredi AA, 2008, CURR OPIN IMMUNOL, V20, P538, DOI 10.1016/j.coi.2008.05.004; Mantovani A, 2008, J CLIN IMMUNOL, V28, P1, DOI 10.1007/s10875-007-9126-7; Martin K, 2009, DEMENT GERIATR COGN, V27, P451, DOI 10.1159/000216840; Mavropoulos A, 2005, BLOOD, V105, P282, DOI 10.1182/blood-2004-07-2782; Melgert BN, 2010, AM J RESP CELL MOL, V42, P595, DOI 10.1165/rcmb.2009-0016OC; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Nair MG, 2009, J EXP MED, V206, P937, DOI 10.1084/jem.20082048; Nair MG, 2005, INFECT IMMUN, V73, P385, DOI 10.1128/IAI.73.1.385-394.2005; Nair MG, 2003, IMMUNOL LETT, V85, P173, DOI 10.1016/S0165-2478(02)00225-0; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000393; Pilling D, 2003, J IMMUNOL, V171, P5537, DOI 10.4049/jimmunol.171.10.5537; Pilling D, 2007, J IMMUNOL, V179, P4035, DOI 10.4049/jimmunol.179.6.4035; Schuh JM, 2003, EUR J IMMUNOL, V33, P3080, DOI 10.1002/eji.200323917; SCHULTZ RM, 1987, TOXICOL PATHOL, V15, P333, DOI 10.1177/019262338701500311; Sehra S, 2003, J IMMUNOL, V171, P2080, DOI 10.4049/jimmunol.171.4.2080; Singh PP, 2006, MICROBES INFECT, V8, P541, DOI 10.1016/j.micinf.2005.08.007; SIRIPONT J, 1988, CELL IMMUNOL, V117, P239, DOI 10.1016/0008-8749(88)90115-3; Sun Y, 2008, LUNG, V186, P375, DOI 10.1007/s00408-008-9099-1; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Valstar DL, 2006, ARCH TOXICOL, V80, P561, DOI 10.1007/s00204-006-0081-5; Vercelli D, 2003, J CLIN INVEST, V111, P1815, DOI 10.1172/JCI200318908; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	45	95	108	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					712	U75		10.1016/j.jaci.2010.06.010	http://dx.doi.org/10.1016/j.jaci.2010.06.010			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20673988				2022-12-18	WOS:000282510000004
J	Kinoshita, H; Takai, T; Le, TA; Kamijo, S; Wang, XL; Ushio, H; Hara, M; Kawasaki, J; Vu, AT; Ogawa, T; Gunawan, H; Ikeda, S; Okumura, K; Ogawa, H				Kinoshita, Hirokazu; Takai, Toshiro; Le, Tuan Anh; Kamijo, Seiji; Wang, Xiao Ling; Ushio, Hiroko; Hara, Mutsuko; Kawasaki, Junko; Vu, Anh Tuan; Ogawa, Takasuke; Gunawan, Hendra; Ikeda, Shigaku; Okumura, Ko; Ogawa, Hideoki			Cytokine milieu modulates release of thymic stromal lymphopoietin from human keratinocytes stimulated with double-stranded RNA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; keratinocyte; double-stranded RNA; cytokine milieu; atopic dermatitis; viral exposure; viral infection; vicious cycle; promotion and blockade	INNATE IMMUNE-RESPONSE; HUMAN EPITHELIAL-CELLS; ATOPIC-DERMATITIS; DENDRITIC CELLS; VACCINIA VIRUS; CUTTING EDGE; T-CELLS; INFLAMMATION; INDUCE; EXPRESSION	Background: Thymic stromal lymphopoietin (TSLP) plays a key role in allergic diseases, such as atopic dermatitis (AD) and asthma. TSLP is highly expressed by keratinocytes in skin lesions of patients with AD, but environmental triggers for its release from keratinocytes with endogenous factors are not well understood. Patients with AD, in whom allergic sensitization is already established, are susceptible to viral dissemination. Objectives: We investigated TSLP's release from primary human keratinocytes stimulated with a Toll-like receptor (TLR) 3 ligand, polyinosinic-polycytidylic acid, which mimics viral double-stranded RNA (dsRNA), and its modulation by cytokines. Methods: Primary human keratinocytes were stimulated with TLR ligands, cytokines, or both. TSLP released into culture supernatants was measured by means of ELISA. Results: Stimulation of keratinocytes with dsRNA induced release of TSLP and upregulated gene expression of TSLP and other cytokines and chemokines. The release of TSLP was enhanced by the addition of IL-4, IL-13, and/or TNF-alpha. With or without the T(H)2/TNF cytokines, the dsRNA-induced release of TSLP was upregulated by IFN-alpha and IFN-beta and suppressed by IFN-gamma, TGF-beta, or IL-17. Conclusions: The effect of the TLR3 ligand on keratinocytes suggests contribution of viral dsRNA to skin inflammations under the influence of a cytokine milieu. The results imply that viral dsRNA and a T(H)2 cytokine milieu might promote T(H)2-type inflammation through an induction of TSLP expression, suggesting that a vicious cycle exists between AD with T(H)2-type inflammation and viral infections and a possible blockade of this cycle by other cytokine milieus provided by cells, such as T(H)1, regulatory T, and T(H)7 cells. (J Allergy Clin Immunol 2009;123:179-86.)	[Takai, Toshiro] Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan; [Kinoshita, Hirokazu; Le, Tuan Anh; Kawasaki, Junko; Vu, Anh Tuan; Ogawa, Takasuke; Gunawan, Hendra; Ikeda, Shigaku] Juntendo Univ, Sch Med, Dept Dermatol, Tokyo 1138421, Japan; [Okumura, Ko] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan	Juntendo University; Juntendo University; Juntendo University	Takai, T (corresponding author), Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	t-takai@Juntendo.ac.jp	Gunawan, Hendra/ABA-5503-2021; Ushio, Hiroko/K-5718-2013; Takai, Toshiro/K-5690-2013	Takai, Toshiro/0000-0001-8363-0355; Gunawan, Hendra/0000-0002-6924-0833				Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Clark RA, 2006, J IMMUNOL, V176, P4431, DOI 10.4049/jimmunol.176.7.4431; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HARADA M, 2008, AM J RESP CELL MOL B; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kikuchi Y, 2006, INT ARCH ALLERGY IMM, V141, P322, DOI 10.1159/000095458; Kikuchi Y, 2006, J IMMUNOL, V177, P1609, DOI 10.4049/jimmunol.177.3.1609; Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Lebre MC, 2003, J INVEST DERMATOL, V120, P990, DOI 10.1046/j.1523-1747.2003.12245.x; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; MacDonald AS, 2008, J EXP MED, V205, P13, DOI 10.1084/jem.20072665; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ogawa Hideoki, 1993, Journal of Dermatological Science, V5, P197, DOI 10.1016/0923-1811(93)90767-J; Olesen AB, 2003, ACTA DERM-VENEREOL, V83, P445, DOI 10.1080/00015550310014997; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Scott JE, 2007, J ALLERGY CLIN IMMUN, V120, P1382, DOI 10.1016/j.jaci.2007.08.004; Segre JA, 2006, J CLIN INVEST, V116, P1150, DOI 10.1172/JCI28521; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Teraki Y, 2000, BRIT J DERMATOL, V143, P373, DOI 10.1046/j.1365-2133.2000.03665.x; Tohyama M, 2005, BIOCHEM BIOPH RES CO, V335, P505, DOI 10.1016/j.bbrc.2005.07.105; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Xu WF, 2007, NAT IMMUNOL, V8, P294, DOI 10.1038/ni1434; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	44	95	104	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					179	186		10.1016/j.jaci.2008.10.008	http://dx.doi.org/10.1016/j.jaci.2008.10.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19056108				2022-12-18	WOS:000262793900030
J	Litonjua, AA; Gold, DR				Litonjua, Augusto A.; Gold, Diane R.			Asthma and obesity: Common early-life influences in the inception of disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; atopy; obesity; diet; microbial flora; prenatal exposures; early-life factors	TUMOR-NECROSIS-FACTOR; ADIPOSE-TISSUE DEVELOPMENT; VITAMIN-D-RECEPTOR; BODY-MASS INDEX; POLYUNSATURATED FATTY-ACIDS; LOW-BIRTH-WEIGHT; QUALITY-OF-LIFE; 1ST 2 YEARS; CHILDHOOD ASTHMA; CORD BLOOD	The respective prevalences of both asthma and obesity have seen a significant rise in the past few decades. Although the association between these 2 conditions has been found in many studies from different areas around the world, the exact mechanisms for how this association arises remains unresolved. Because both asthma and obesity appear to have their beginnings in early childhood, common exposures that predispose individuals to both these conditions may explain how they are associated. These exposures include common genetic predictors, prenatal exposure to specific nutrients and overall maternal nutrition, patterns of colonization of the neonatal and infant gut, birth weight and infant weight gain, sedentary behaviors, and levels of adipokines in early life.	[Litonjua, Augusto A.; Gold, Diane R.] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; [Litonjua, Augusto A.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Dept Med, Boston, MA 02115 USA; [Litonjua, Augusto A.; Gold, Diane R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University	Litonjua, AA (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	augusto.litonjua@channing.harvard.edu		Litonjua, Augusto/0000-0003-0422-5875				Ackermann C, 2007, EXPERT OPIN THER TAR, V11, P1369, DOI 10.1517/14728222.11.11.1369; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Ailhaud G, 2004, Obes Rev, V5, P21, DOI 10.1111/j.1467-789X.2004.00121.x; Ailhaud G, 2006, PROG LIPID RES, V45, P203, DOI 10.1016/j.plipres.2006.01.003; Aoki Takeshi, 2006, J Hum Genet, V51, P677, DOI 10.1007/s10038-006-0007-3; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Benyshek DC, 2007, COLLEGIUM ANTROPOL, V31, P11; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; Brooks AM, 2001, ARCH PEDIAT ADOL MED, V155, P401, DOI 10.1001/archpedi.155.3.401; Budge Helen, 2005, Birth Defects Research, V75, P193, DOI 10.1002/bdrc.20044; Calvani M, 2006, PEDIAT ALLERG IMM-UK, V17, P94, DOI 10.1111/j.1399-3038.2005.00367.x; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Cani PD, 2007, DIABETOLOGIA, V50, P2374, DOI 10.1007/s00125-007-0791-0; Cani PD, 2007, CURR OPIN CLIN NUTR, V10, P729, DOI 10.1097/MCO.0b013e3282efdebb; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S, DOI 10.1093/ajcn/80.6.1717S; Centers for Disease Control and Prevention, 2007, OV OB; Corbalan MS, 2002, CLIN GENET, V61, P305; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; Dekker MJ, 2007, METABOLISM, V56, P332, DOI 10.1016/j.metabol.2006.10.015; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Devereux G, 2007, CLIN EXP ALLERGY, V37, P1000, DOI 10.1111/j.1365-2222.2007.02757.x; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Devereux G, 2006, NAT REV IMMUNOL, V6, P869, DOI 10.1038/nri1958; Devereux G, 2006, AM J RESP CRIT CARE, V174, P499, DOI 10.1164/rccm.200512-1946OC; DORNER G, 1994, HORM METAB RES, V26, P213, DOI 10.1055/s-2007-1001668; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Edwards CA, 2002, BRIT J NUTR, V88, pS11, DOI [10.1079/BJN2002625, 10.1079/BJNBJN2002580]; Ellison JA, 2006, BRIT J DERMATOL, V155, P532, DOI 10.1111/j.1365-2133.2006.07400.x; Eriksson J, 2003, INT J OBESITY, V27, P722, DOI 10.1038/sj.ijo.0802278; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Feary J, 2007, THORAX, V62, P466, DOI 10.1136/thx.2006.073866; Field AE, 2005, OBES RES, V13, P163, DOI 10.1038/oby.2005.21; Flaherman V, 2006, ARCH DIS CHILD, V91, P334, DOI 10.1136/adc.2005.080390; Fogarty A, 2000, CLIN EXP ALLERGY, V30, P615, DOI 10.1046/j.1365-2222.2000.00766.x; Fogarty A, 2003, CLIN EXP ALLERGY, V33, P1355, DOI 10.1046/j.1365-2222.2003.01777.x; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Galan P, 2005, EUR J CLIN NUTR, V59, P1181, DOI 10.1038/sj.ejcn.1602230; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; GALLI E, 1994, BRIT J DERMATOL, V130, P752, DOI 10.1111/j.1365-2133.1994.tb03413.x; Gillis L, 2005, CAN J DIET PRACT RES, V66, P237, DOI 10.3148/66.4.2005.237; Gold DR, 2006, J ALLERGY CLIN IMMUN, V117, P931, DOI 10.1016/j.jaci.2005.12.1322; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Grundberg E, 2004, EUR J ENDOCRINOL, V150, P323, DOI 10.1530/eje.0.1500323; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Haley NM, 2008, THORAX, V63, P89, DOI 10.1136/thx.2007.084350; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; Hamid YH, 2005, DIABETOLOGIA, V48, P445, DOI 10.1007/s00125-004-1659-1; Hoffjan S, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-14; Howard TD, 2000, J ALLERGY CLIN IMMUN, V105, pS477, DOI 10.1016/S0091-6749(00)90046-0; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; ICHIHARA S, 2007, CELL MOL LIFE S 1222; Ishiyama-Shigemoto S, 1999, DIABETOLOGIA, V42, P98, DOI 10.1007/s001250051120; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Jebb SA, 2007, OBES REV, V8, P93, DOI 10.1111/j.1467-789X.2007.00326.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kimlin M, 2007, J PHOTOCH PHOTOBIO B, V89, P139, DOI 10.1016/j.jphotobiol.2007.09.008; Kimmons Joel E, 2006, MedGenMed, V8, P3; Kimmons Joel E, 2006, MedGenMed, V8, P59; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Lago F, 2007, NAT CLIN PRACT RHEUM, V3, P716, DOI 10.1038/ncprheum0674; Lavoie KL, 2006, RESP MED, V100, P648, DOI 10.1016/j.rmed.2005.08.001; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; LIEL Y, 1988, CALCIFIED TISSUE INT, V43, P199, DOI 10.1007/BF02555135; Litonjua AA, 2006, CURR OPIN PULM MED, V12, P12, DOI 10.1097/01.mcp.0000198068.50457.95; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Litonjua AA, 2006, AM J CLIN NUTR, V84, P903, DOI 10.1093/ajcn/84.4.903; LONG SS, 1977, J PEDIATR-US, V91, P298, DOI 10.1016/S0022-3476(77)80836-6; Lucas SR, 2006, PAEDIATR RESPIR REV, V7, P233, DOI 10.1016/j.prrv.2006.08.001; Mai XM, 2005, PEDIAT ALLERG IMM-UK, V16, P380, DOI 10.1111/j.1399-3038.2005.00290.x; Maritz GS, 2005, EARLY HUM DEV, V81, P763, DOI 10.1016/j.earlhumdev.2005.07.002; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; Martorell R, 2001, J NUTR, V131, p874S, DOI 10.1093/jn/131.3.874S; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Massiera F, 2003, J LIPID RES, V44, P271, DOI 10.1194/jlr.M200346-JLR200; McCarthy A, 2007, AM J CLIN NUTR, V86, P907, DOI 10.1093/ajcn/86.4.907; McDevitt H, 2002, ARTHRITIS RES THER, V4, pS141, DOI 10.1186/ar570; McKeever TM, 2004, AM J RESP CRIT CARE, V170, P725, DOI 10.1164/rccm.200405-611PP; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Miwa K, 2004, CIRC J, V68, P542, DOI 10.1253/circj.68.542; Moore YF, 2004, IMMUNOGENETICS, V56, P1, DOI 10.1007/s00251-004-0661-6; Mori Y, 1999, BIOCHEM BIOPH RES CO, V258, P138, DOI 10.1006/bbrc.1999.0607; Murray CS, 2005, CLIN EXP ALLERGY, V35, P741, DOI 10.1111/j.1365-2222.2005.02259.x; Nepomnyaschy L, 2006, AM J PUBLIC HEALTH, V96, P1604, DOI 10.2105/AJPH.2005.079400; Neuhouser ML, 2001, J NUTR, V131, P2184, DOI 10.1093/jn/131.8.2184; Newson RB, 2004, J ALLERGY CLIN IMMUN, V114, P531, DOI 10.1016/j.jaci.2004.05.010; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; PACKER L, 1991, AM J CLIN NUTR, V53, pS1050, DOI 10.1093/ajcn/53.4.1050S; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Parikh SJ, 2004, J CLIN ENDOCR METAB, V89, P1196, DOI 10.1210/jc.2003-031398; Parsons TJ, 1999, INT J OBESITY, V23, pS1; Parsons TJ, 2001, BRIT MED J, V323, P1331, DOI 10.1136/bmj.323.7325.1331; Pearson PJK, 2004, THORAX, V59, P652, DOI 10.1136/thx.2004.022616; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Prentice A, 2004, NUTR REV, V62, pS98, DOI 10.1111/j.1753-4887.2004.tb00095.x; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Randolph AG, 2005, AM J RESP CRIT CARE, V172, P687, DOI 10.1164/rccm.200501-122OC; Rankinen T, 2006, OBESITY, V14, P529, DOI 10.1038/oby.2006.71; Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Rothenbacher D, 2007, CLIN EXP ALLERGY, V37, P1143, DOI 10.1111/j.1365-2222.2007.02759.x; Sachdev HS, 2005, AM J CLIN NUTR, V82, P456, DOI 10.1093/ajcn/82.2.456; Saint-Pierre P, 2006, ALLERGY, V61, P79, DOI 10.1111/j.1398-9995.2005.00953.x; Salam MT, 2005, J ASTHMA, V42, P513, DOI 10.1081/JAS-200067619; Salsberry PJ, 2005, PEDIATRICS, V116, P1329, DOI 10.1542/peds.2004-2583; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaheen SO, 2004, EUR RESPIR J, V24, P292, DOI 10.1183/09031936.04.00117803; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83, DOI 10.1093/oxfordjournals.aje.a115646; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Silverman EK, 2003, J ALLERGY CLIN IMMUN, V112, P870, DOI 10.1016/S0091-6749(03)02023-2; Snethen JA, 2007, JOGNN-J OBST GYN NEO, V36, P501, DOI [10.1111/J.1552-6909.2007.00181.x, 10.1111/j.1552-6909.2007.00181.x]; Snijder MB, 2005, J CLIN ENDOCR METAB, V90, P4119, DOI 10.1210/jc.2005-0216; Sookoian SC, 2005, OBES RES, V13, P2122, DOI 10.1038/oby.2005.263; Spear BA, 2007, PEDIATRICS, V120, pS254, DOI 10.1542/peds.2007-2329F; Stettler N, 2005, CIRCULATION, V111, P1897, DOI 10.1161/01.CIR.0000161797.67671.A7; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Tantisira KG, 2001, THORAX, V56, P64; Taveras EM, 2006, PEDIATR PULM, V41, P643, DOI 10.1002/ppul.20427; Taylor PD, 2007, EXP PHYSIOL, V92, P287, DOI 10.1113/expphysiol.2005.032854; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turner S, 2008, THORAX, V63, P234, DOI 10.1136/thx.2006.064642; van Gent R, 2007, J ALLERGY CLIN IMMUN, V119, P591, DOI 10.1016/j.jaci.2006.11.007; Vickers MH, 2007, CURR DRUG TARGETS, V8, P923; Viner RM, 2005, BRIT MED J, V330, P1354, DOI 10.1136/bmj.38453.422049.E0; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Wang TN, 2004, CLIN EXP ALLERGY, V34, P184, DOI 10.1111/j.1365-2222.2004.01867.x; Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Weiss ST, 1997, CIBA F SYMP, V206, P244; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Weiss ST, 1997, CIBA FOUND S, V206, P53; Weyermann M, 2006, CLIN CHEM, V52, P2095, DOI 10.1373/clinchem.2006.071019; Willers SM, 2007, THORAX, V62, P773, DOI 10.1136/thx.2006.074187; Wjst M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-60; Wortsman J, 2000, AM J CLIN NUTR, V72, P690, DOI 10.1093/ajcn/72.3.690; Wu Q, 2006, OBES REV, V7, P201, DOI 10.1111/j.1467-789X.2006.00232.x; Yang WJ, 2007, EPIDEMIOL REV, V29, P49, DOI 10.1093/epirev/mxm004; Yu G, 1996, ACTA PAEDIATR, V85, P679, DOI 10.1111/j.1651-2227.1996.tb14124.x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	152	95	100	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1075	1084		10.1016/j.jaci.2008.03.005	http://dx.doi.org/10.1016/j.jaci.2008.03.005			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18378287				2022-12-18	WOS:000255961700001
J	Brown, SJ; Relton, CL; Liao, HH; Zhao, YW; Sandilands, A; Wilson, IJ; Burn, J; Reynolds, NJ; McLean, WHI; Cordell, HJ				Brown, Sara J.; Relton, Caroline L.; Liao, Haihui; Zhao, Yiwei; Sandilands, Aileen; Wilson, Ian J.; Burn, John; Reynolds, Nick J.; McLean, W. H. Irwin; Cordell, Heather J.			Filaggrin null mutations and childhood atopic eczema: A population-based case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; seasonal rhinitis; atopic eczema; complex trait; filaggrin; ichthyosis vulgaris; skin barrier function	OF-FUNCTION MUTATIONS; ICHTHYOSIS VULGARIS; GENE PREDISPOSE; RARE MUTATIONS; EARLY-ONSET; DERMATITIS; SEVERITY; CHILDREN; PREVALENCE; VALIDATION	Background: Null mutations within the filaggrin gene (FLG) are associated with moderate-to-severe atopic eczema; their role in mild-to-moderate eczema in the general population is unknown. Objective: We sought to investigate the significance of 5 common FLG null mutations in childhood atopic eczema in an unselected population cohort. Methods: Eight hundred eleven English children aged 7 to 9 years were screened for FLG mutations. Eczema cases were defined by using United Kingdom diagnostic criteria and skin examination. Asthma and seasonal rhinitis cases were defined by parental questionnaire. Association between phenotype and genotype was investigated using Fisher exact test and logistic regression analysis. Results: The 12-month period prevalence of atopic eczema was 24.2% (95% CI, 21.2% to 27.2%), with 96% (115/120) of cases having mild-to-moderate disease. The combined null genotype (carriage of >= 1 FLG mutations) was significantly associated with atopic eczema (P = 1.2 x 10(-4)). The odds ratio (OR) for individuals carrying 2 null mutations was 26.9 (95% CI, 3.3-217.1), but heterozygote carriers showed no significant increase in risk (OR, 1.2; 95% CI, 0.7-1.9). Eight of 190 eczema cases (4.2%) carried 2 FLG null mutations and thus might be attributed to filaggrin deficiency. Asthma in the context of eczema showed significant association with the FLG null mutations (P = 7.1 x 10(-4)). There was no association of FLG with asthma independent of eczema (P =.15) and no association with seasonal rhinitis (P = .66). Conclusion: FLG null mutations are significantly associated with mild-to-moderate atopic eczema in childhood, with a recessive pattern of inheritance.	[Brown, Sara J.; Wilson, Ian J.; Burn, John; Cordell, Heather J.] Univ Newcastle, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; [Brown, Sara J.; Reynolds, Nick J.] Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Relton, Caroline L.] Univ Newcastle, Sch Clin Med Sci Child Hlth, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; [Liao, Haihui; Zhao, Yiwei; Sandilands, Aileen; McLean, W. H. Irwin] Univ Dundee, Ninewells Hosp, Human Genet Unit, Epithelial Genet Grp, Dundee DD1 4HN, Scotland; [Reynolds, Nick J.] Univ Newcastle, Inst Celullar Med, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; University of Dundee; Newcastle University - UK	Brown, SJ (corresponding author), Univ Newcastle, Inst Human Genet, Int Ctr Life, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	sara.brown@ncl.ac.uk	McLean, William HI/C-6352-2009; Relton, Caroline/AAC-5904-2019; Brown, Sara J/AAF-7095-2019	Brown, Sara J/0000-0002-3232-5251; McLean, William Henry Irwin/0000-0001-5539-5757; Reynolds, Nick/0000-0002-6484-825X; Burn, John/0000-0002-9823-2322; Cordell, Heather/0000-0002-1879-5572; Relton, Caroline/0000-0003-2052-4840; Wilson, Ian/0000-0001-6893-2873	Medical Research Council [G0700314] Funding Source: Medline; Wellcome Trust [074524] Funding Source: Medline; MRC [G0700314] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Angus VC, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-21; Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Brown S, 2006, BMJ-BRIT MED J, V332, P584, DOI 10.1136/bmj.332.7541.584; BROWN SJ, 2007, J INVEST DERMATOL; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chamlin SL, 2005, J INVEST DERMATOL, V125, P1106, DOI 10.1111/j.0022-202X.2005.23911.x; Charman CR, 2005, ARCH DERMATOL, V141, P1146, DOI 10.1001/archderm.141.9.1146; Chase DS, 1998, J MED GENET, V35, P413, DOI 10.1136/jmg.35.5.413; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; MANABE M, 1991, DIFFERENTIATION, V48, P43, DOI 10.1111/j.1432-0436.1991.tb00241.x; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Oranje AP, 2007, BRIT J DERMATOL, V157, P645, DOI 10.1111/j.1365-2133.2007.08112.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Shamssain M, 2007, PEDIAT ALLERG IMM-UK, V18, P149, DOI 10.1111/j.1399-3038.2006.00498.x; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Stemmler S, 2007, J INVEST DERMATOL, V127, P722, DOI 10.1038/sj.jid.5700579; Taieb Alain, 2006, J Allergy Clin Immunol, V117, P378, DOI 10.1016/j.jaci.2005.11.038; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; WELLS RS, 1966, BRIT MED J, V1, P947, DOI 10.1136/bmj.1.5493.947; Williams HC, 1996, BRIT J DERMATOL, V135, P12; Williams HC, 2000, ATOPIC DERMATITIS EP, P41, DOI 10.1017/CBO9780511545771.005; Wolkerstorfer A, 1999, ACTA DERM-VENEREOL, V79, P356	36	95	101	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					940	946		10.1016/j.jaci.2008.01.013	http://dx.doi.org/10.1016/j.jaci.2008.01.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18313126	Green Accepted			2022-12-18	WOS:000254884000019
J	Leguy-Seguin, V; Jolimoy, G; Coudert, B; Pernot, C; Dalac, S; Vabres, P; Collet, E				Leguy-Seguin, Vanessa; Jolimoy, Genevieve; Coudert, Bruno; Pernot, Corine; Dalac, Sophie; Vabres, Pierre; Collet, Evelyne			Diagnostic and predictive value of skin testing in platinum salt hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						drug hypersensitivity; platinum salts; anaphylaxis; patch tests; prick tests; intradermal test	CARBOPLATIN HYPERSENSITIVITY; OXALIPLATIN; CISPLATIN; ANAPHYLAXIS; ALLERGY	Background: Hypersensitivity reactions to platinum salts are potentially lethal adverse events in chemotherapy, and often require its discontinuation. Several preventive procedures have been proposed: premedication, desensitization regimens, or replacement with a different platinum salt. Objective: We therefore assessed the value of skin tests with platinum salts. A positive result would confirm their responsibility in hypersensitivity reaction, whereas a negative result would identify candidates for continuation of therapy using a different platinum salt. Methods: Patch tests, prick tests, and intradermal tests with cisplatin, carboplatin, and oxaliplatin were performed in 21 patients. Results: Skin tests were positive in 14 of 21 cases. Prick tests were positive in 5 cases with the suspected platinum salt. Intradermal tests were positive in 12 of 19 cases, always when the hypersensitivity occurred less than 2 hours after infusion. Cross-reactions were observed in 4 cases. Delayed readings of skin tests at 24 hours and 48 hours were positive in 3 patients. Patch tests were negative in all the 21 patients tested. Replacement with another platinum salt was performed in 13 patients using one that gave a negative skin test. A relapse of symptoms occurred in 1 patient. Conclusion: Intradermal tests are particularly indicated for the diagnosis of immediate hypersensitivity reaction. Their good negative predictive value allows safe retreatment by detecting a potential cross-reaction. Clinical implications: The frequency of cross-reactions among cisplatin, carboplatin, and oxaliplatin has not been clearly established. Skin tests allow different platinum salts to be given and avoid discontinuation of chemotherapy.	Univ Hosp, Dept Dermatol, F-21079 Dijon, France; Univ Hosp, Dept Pharmacol, F-21079 Dijon, France; Univ Hosp, Dept Pharm, F-21079 Dijon, France	CHU Dijon Bourgogne; CHU Dijon Bourgogne; CHU Dijon Bourgogne	Collet, E (corresponding author), Univ Hosp, Dept Dermatol, 2 Bd Marechal de Lattre de Tassigny,BP 77908, F-21079 Dijon, France.	ecollet@chu-dijon.fr	Vabres, Pierre/V-3850-2019; Vabres, Pierre/D-3906-2011	Vabres, Pierre/0000-0001-8693-3183; Vabres, Pierre/0000-0001-8693-3183; Coudert, Bruno/0000-0001-9445-2216				Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Basu Rimpa, 2002, Int J Clin Oncol, V7, P365, DOI 10.1007/s101470200056; BEGAUD B, 1985, THERAPIE, V40, P111; Dizon DS, 2002, GYNECOL ONCOL, V84, P378, DOI 10.1006/gyno.2001.6519; Garufi C, 2003, ANN ONCOL, V14, P497, DOI 10.1093/annonc/mdg092; Gottlieb MJ, 1998, J ALLERGY CLIN IMMUN, V101, pS139; KHAN A, 1975, CANCER RES, V35, P2766; Lenz G, 2003, ANTI-CANCER DRUG, V14, P731, DOI 10.1097/01.cad.0000092785.37568.ca; Maindrault-Goebel F, 2005, EUR J CANCER, V41, P2262, DOI 10.1016/j.ejca.2005.06.021; Markman M, 1999, J CLIN ONCOL, V17, P1141, DOI 10.1200/JCO.1999.17.4.1141; Markman M, 2003, J CLIN ONCOL, V21, P4611, DOI 10.1200/JCO.2003.05.539; Markman M, 2003, GYNECOL ONCOL, V89, P514, DOI 10.1016/S0090-8258(03)00155-0; Menczer J, 1999, EUR J GYNAECOL ONCOL, V20, P214; Petit-Laurent F, 2000, GASTROEN CLIN BIOL, V24, P851; Porzio G, 2002, EUR J GYNAECOL ONCOL, V23, P335; Santini D, 2001, ANN ONCOL, V12, P132, DOI 10.1023/A:1008366223918; Sliesoraitis S, 2005, INT J GYNECOL CANCER, V15, P13, DOI 10.1111/j.1048-891x.2005.14401.x; SOOD AK, 1995, GYNECOL ONCOL, V57, P131, DOI 10.1006/gyno.1995.1111; Taylor AJN, 1999, AM J RESP CRIT CARE, V160, P435; Thomas RR, 2003, CANCER-AM CANCER SOC, V97, P2301, DOI 10.1002/cncr.11379; WEIDMANN B, 1994, CANCER, V73, P2218, DOI 10.1002/1097-0142(19940415)73:8<2218::AID-CNCR2820730830>3.0.CO;2-1; Zanotti KM, 2001, J CLIN ONCOL, V19, P3126, DOI 10.1200/JCO.2001.19.12.3126; ZWEIZIG S, 1994, GYNECOL ONCOL, V53, P121, DOI 10.1006/gyno.1994.1098	23	95	99	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					726	730		10.1016/j.jaci.2006.11.640	http://dx.doi.org/10.1016/j.jaci.2006.11.640			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17258305				2022-12-18	WOS:000244925000028
J	Stevenson, DD; Simon, RA				Stevenson, Donald D.; Simon, Ronald A.			Selection of patients for aspirin desensitization treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						aspirin; ASA desensitization; asthma; nasal polyps	EXACERBATED RESPIRATORY-DISEASE		Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA; Scripps Clin, Dept Med, La Jolla, CA USA; Scripps Res Inst, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Stevenson, DD (corresponding author), Scripps Clin, Div Allergy Asthma & Immunol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Stevensn.donald@Scrippshealth.org						Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330, DOI 10.1016/S1081-1206(10)61150-7	3	95	99	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					801	804		10.1016/j.jaci.2006.06.019	http://dx.doi.org/10.1016/j.jaci.2006.06.019			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030229	Bronze			2022-12-18	WOS:000241434200003
J	Schatz, M; Zeiger, RS; Vollmer, WM; Mosen, D; Apter, AJ; Stibolt, TB; Leong, A; Johnson, MS; Mendoza, G; Cook, EF				Schatz, Michael; Zeiger, Robert S.; Vollmer, William M.; Mosen, David; Apter, Andrea J.; Stibolt, Thomas B.; Leong, Albin; Johnson, Michael S.; Mendoza, Guillermo; Cook, E. Francis			Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma control; beta-agonists; administrative data; asthma population management	HEALTH-CARE UTILIZATION; RISK; HOSPITALIZATION; ASSOCIATION; SYMPTOMS	Background: Asthma control has been defined clinically by using validated tools, but an asthma control scale using administrative data has not been reported. Objective: We sought to validate a beta-agonist asthma control scale derived from administrative data. Methods: Surveys that included validated asthma symptom and control tools were completed by a random sample of 2250 health maintenance organization members aged 18 to 56 years with persistent asthma. Linked computerized pharmacy data provided beta-agonist canister and oral corticosteroid dispensings. The proposed 4-level asthma control scale was based on the number of short-acting beta-agonist canisters dispensed in 12 months. Construct validity and predictive validity were assessed. Results: For construct validity, factor analysis showed significant loading of the beta-agonist scale on the symptom control factor, and the beta-agonist scale was significantly related to the validated asthma control and symptom scales (r = 0.31, P < .0001). For predictive validity, each progressive level of the proposed P-agonist control scale was associated with an increased risk of subsequent asthma hospitalizations or emergency department visits and oral corticosteroid use, independent of prior use. Conclusion: A scale based on the number of beta-agonists dispensed in a 1-year period and derived from administrative data reflects asthma symptom control over that period of time. This scale can help identify patients who are at risk for future acute asthma health care use. Clinical implications: This information can he used in population management and by clinicians to assess long-term asthma control and identify patients who need intervention to prevent future morbidity.	Dept Allergy, San Diego, CA USA; Dept Allergy, Sacramento, CA USA; Dept Allergy, Vacaville, CA USA; Ctr Hlth Res, Portland, OR USA; Care Management Inst, Kaiser Permanete Med Care Program, Oakland, CA USA; Univ Penn, Sch Med, Dept Pulm & Crit Care Med, Div Allergy Immunol, Philadelphia, PA 19104 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Kaiser Permanente; University of Pennsylvania; Harvard University; Harvard T.H. Chan School of Public Health	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	michael.x.schatz@kp.org	Leong, Albin/AAF-7215-2019	Zeiger, Robert/0000-0001-5788-5063				Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; BAYLISS MS, 1999, ASTHMA OUTCOMES MONI; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Global Initiative for Asthma, 2002, GLOB STRAT ASTHM MAN; Grana J, 1997, Am J Med Qual, V12, P113, DOI 10.1177/0885713X9701200205; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Lieu TA, 1998, AM J RESP CRIT CARE, V157, P1173, DOI 10.1164/ajrccm.157.4.9708124; Magadle R, 2002, CHEST, V121, P329, DOI 10.1378/chest.121.2.329; *NAT COMM QUAL ASS, 2002, HEDIS 2002, V2; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 1991, NIH PUBL, V91- 3642; Schatz M, 2005, CHEST, V128, P1968, DOI 10.1378/chest.128.4.1968; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P1049, DOI 10.1016/j.jaci.2005.02.008; Schatz M, 2004, AM J MANAG CARE, V10, P25; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P564, DOI 10.1016/j.jaci.2004.12.005; Senthilselvan A, 2005, CHEST, V127, P1242, DOI 10.1378/chest.127.4.1242; Stahl E, 2000, RESP MED, V94, P735, DOI 10.1053/rmed.2000.0814; Streiner DL, 2000, HLTH MEASUREMENT SCA; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Vollmer WM, 2004, ANN ALLERG ASTHMA IM, V93, P409, DOI 10.1016/S1081-1206(10)61406-8; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127	24	95	96	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					995	1000		10.1016/j.jaci.2006.01.053	http://dx.doi.org/10.1016/j.jaci.2006.01.053			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675324				2022-12-18	WOS:000237436300004
J	Aceves, SS; Dohil, R; Newbury, RO; Bastian, JF				Aceves, SS; Dohil, R; Newbury, RO; Bastian, JF			Topical viscous budesonide suspension for treatment of eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GASTROINTESTINAL DISORDERS		Univ Calif San Diego, Dept Pediat, La Jolla, CA USA; Univ Calif San Diego, Div Pediat Gastroenterol, San Diego, CA USA; Childrens Hosp, Div Pathol, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Children's Hospital Los Angeles	Aceves, SS (corresponding author), Immunol Childrens Hosp, Div Allergy, 3020 Childrens Way MC-5114, San Diego, CA 92123 USA.							Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Guajardo JR, 2002, J PEDIATR-US, V141, P576, DOI 10.1067/mpd.2002.127663; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Teitelbaum JE, 2002, GASTROENTEROLOGY, V122, P1216, DOI 10.1053/gast.2002.32998	7	95	114	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					705	706		10.1016/j.jaci.2005.05.011	http://dx.doi.org/10.1016/j.jaci.2005.05.011			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159647				2022-12-18	WOS:000235686500037
J	Jarvis, D; Luczynska, C; Chinn, S; Potts, J; Sunyer, J; Janson, C; Svanes, C; Kunzli, N; Leynaert, B; Heinrich, J; Kerkhof, M; Ackermann-Liebrich, U; Anto, MM; Cerveri, I; de Marco, R; Gislason, T; Neukirch, F; Vermeire, P; Wjst, M; Burney, P				Jarvis, D; Luczynska, C; Chinn, S; Potts, J; Sunyer, J; Janson, C; Svanes, C; Kunzli, N; Leynaert, B; Heinrich, J; Kerkhof, M; Ackermann-Liebrich, U; Anto, MM; Cerveri, I; de Marco, R; Gislason, T; Neukirch, F; Vermeire, P; Wjst, M; Burney, P			Change in prevalence of IgE sensitization and mean total IgE with age and cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ECRHS; atopy; total IgE; cohort	RESPIRATORY-HEALTH-SURVEY; SKIN-TEST REACTIVITY; 8 YEARS APART; HAY-FEVER; SERUM IGE; IMMUNOGLOBULIN-E; INCREASING PREVALENCE; COPENHAGEN ALLERGY; ASTHMA; ATOPY	Background: Cross-sectional studies show that the prevalence of IgE sensitization is lower in older age groups than younger age groups. This could reflect either a decrease in sensitization with aging or a higher prevalence of sensitization in more recent birth cohorts. Objective: To assess change in IgE sensitization and mean total IgE in young adults as they age. Methods: Serum specific IgE to common allergens and total IgE were measured on 2 occasions about 9 years apart in 6371 young adults living in 28 centers, mainly in Western Europe, who took part in the European Community Respiratory Health Survey II. Outcomes were analyzed by using generalized estimating equations, and adjustments were made for differences between laboratory measures on the 2 occasions. Results: Overall, there was no net change in the prevalence of sensitization to at least 1 of house dust mite, grass, or cat (net change per 10 years of follow-up, -0.1%; 95% CI, -1.7% to 1.5%), although there was a fall in mean total IgE (ratio of geometric mean total IgE, 0.86; 95% CI, 0.79 to 0.93). There was evidence that sensitization to at least 1 allergen was higher in more recent cohorts, and this was largely explained by a higher prevalence of sensitization to grass. Conclusion: The disease burden associated with IgE sensitization in adults, and particularly with IgE sensitization to grass, is likely to continue to increase for some time despite current evidence that the increase in allergy seen in children may have ceased.	Univ London Kings Coll, Dept Publ Hlth Sci, London SE1 3QD, England; Univ Pompeu Fabra, Inst Municipal Invest Med, Barcelona, Spain; Univ Uppsala, S-75105 Uppsala, Sweden; Haukeland Hosp, Dept Med, Dept Thorac Med, Bergen, Norway; Univ So Calif, Keck Sch Med, Div Environm Hlth, Dept Prevent Med, Los Angeles, CA 90089 USA; Inst Natl Sante & Rech Med Epidemiol, Paris, France; GSF Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Univ Groningen, Dept Hlth Sci, Groningen, Netherlands; Univ Basel, Int Social & Prevent Med, CH-4003 Basel, Switzerland; Univ Pavia, Ist Ricovero & Curea Carattere Sci San Matteo, Div Resp Dis, Pavia, Italy; Univ Verona, Div Epidemiol & Stat, Dept Med & Publ Hlth, I-37100 Verona, Italy; Univ Hosp, Dept Allergy Resp Med & Sleep, Reykjavik, Iceland; Univ Antwerp, Antwerp, Belgium	University of London; King's College London; Pompeu Fabra University; Uppsala University; University of Bergen; Haukeland University Hospital; University of Southern California; Institut National de la Sante et de la Recherche Medicale (Inserm); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Groningen; University of Basel; University of Pavia; University of Verona; Landspitali National University Hospital; University of Antwerp	Jarvis, D (corresponding author), Univ London Kings Coll, Dept Publ Hlth Sci, 42 Weston St, London SE1 3QD, England.	deborah.jarvis@kcl.ac.uk	de Marco, Roberto/A-5470-2008; Svanes, Cecilie/N-7556-2017; Kerkhof, Marjan/A-8846-2008; Leynaert, Benedicte/N-5251-2018; Sunyer, Jordi/G-6909-2014; Kuenzli, Nino/F-7195-2014; Heinrich, Joachim/N-1720-2013; SESM, SESM/C-1440-2008; Jarvis, Deborah/E-6494-2011	Svanes, Cecilie/0000-0001-8512-5192; Sunyer, Jordi/0000-0002-2602-4110; Kuenzli, Nino/0000-0001-8360-080X; Heinrich, Joachim/0000-0002-9620-1629; Cerveri, Isa/0000-0003-0337-043X; Burney, Peter/0000-0001-8635-5678; Jarvis, Deborah/0000-0002-1753-3896; Leynaert, Benedicte/0000-0001-5045-2492	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER; NCRR NIH HHS [2 S07 RR05521-28] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Broadfield E, 2002, J ALLERGY CLIN IMMUN, V109, P969, DOI 10.1067/mai.2002.124772; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CRIQUI MH, 1990, ANN ALLERGY, V64, P308; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Gassner-Bachmann M, 2000, DEUT MED WOCHENSCHR, V125, P924, DOI 10.1055/s-2000-6778; GERRARD JW, 1980, ANN ALLERGY, V44, P261; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Kosunen TU, 2002, CLIN EXP ALLERGY, V32, P373, DOI 10.1046/j.1365-2222.2002.01330.x; Krause TG, 2002, LANCET, V360, P691, DOI 10.1016/S0140-6736(02)09841-0; Linneberg A, 2002, CLIN EXP ALLERGY, V32, P1702, DOI 10.1046/j.1365-2222.2002.01537.x; Linneberg A, 2000, ALLERGY, V55, P767, DOI 10.1034/j.1398-9995.2000.00672.x; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; ORYSZCZYN M, 1990, ANN ALLERGY, V67, P355; ORYSZCZYN MP, 1995, AM J RESP CRIT CARE, V151, P663; Ronchetti R, 2003, CLIN EXP ALLERGY, V33, P1232, DOI 10.1046/j.1365-2222.2003.01746.x; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; *STAT CORP, 2003, STAT STAT SOFTW REL; Sunyer J, 1999, EUR RESPIR J, V14, P885, DOI 10.1034/j.1399-3003.1999.14d26.x; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	31	95	96	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					675	682		10.1016/j.jaci.2005.05.009	http://dx.doi.org/10.1016/j.jaci.2005.05.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159642				2022-12-18	WOS:000235686500032
J	Kull, I; Bohme, M; Wahlgren, CF; Nordvall, L; Pershagen, G; Wickman, M				Kull, I; Bohme, M; Wahlgren, CF; Nordvall, L; Pershagen, G; Wickman, M			Breast-feeding reduces the risk for childhood eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; allergy march; BAMSE; breast-feeding; children; eczema; sensitization	ATOPIC-DERMATITIS; ALLERGIC DISEASE; BIRTH COHORT; ASTHMA; CHILDREN; LIFE; ASSOCIATION; ONSET; AGE	Background: The evidence for a preventive effect of breast-feeding on the development of eczema in childhood remains controversial. Objective: To investigate the effect of breast-feeding in various phenotypes of eczema to 4 years. Methods: A birth cohort of 4089 children made up the study base. Data on breast-feeding, allergic symptoms, and potential confounders were obtained from questionnaires when the children were 2 months and 1, 2, and 4 years old. At 4 years, blood specific IgE was analyzed. Children with symptoms of eczema and asthma during the period of breast-feeding were excluded in most analyses on risk assessment of eczema and asthma, respectively, to avoid disease-related modification of exposure. Results: Exclusive breast-feeding for >= 4 months reduced the risk for eczema at the age of 4 years (odds ratio [OR], 0.78; 95% CI, 0.63-0.96) irrespective of combination with asthma, sensitization to common allergens, or parental allergic disease. This decreased risk was most evident for children with onset of eczema during the first 2 years persisting to 4 years (OR, 0.59; 95% CI, 0.45-0.77). Among children with early-onset eczema, irrespective of persistency, followed by late onset of asthma or early-onset asthma irrespective of persistency, followed by late-onset eczema to 4 years, a protective effect of breast-feeding was also seen (OR, 0.48: 95% CI, 0.30-0.76). Conclusion: Breast-feeding 4 months or more reduces the risk for eczema and onset of the allergy march to age 4.	Karolinska Hosp, Dept Occupat & Environm Hlth, SE-17176 Stockholm, Sweden; Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden; Karolinska Univ Hosp, Inst Med, Dept Med Dermatol & Venereol Unit, Stockholm, Sweden; Karolinska Inst, Stockholm, Sweden; Univ Uppsala, Dept Woman & Child Hlth, S-75105 Uppsala, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Uppsala University	Kull, I (corresponding author), Karolinska Hosp, Dept Occupat & Environm Hlth, SE-17176 Stockholm, Sweden.	inger.kull@sll.se		Kull, Inger/0000-0001-6096-3771; Pershagen, Goran/0000-0002-9701-1130				Benn CS, 2004, AM J EPIDEMIOL, V160, P217, DOI 10.1093/aje/kwh208; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P159, DOI 10.1046/j.1365-2222.2002.01343.x; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Karlsson H, 2002, INFECT IMMUN, V70, P6688, DOI 10.1128/IAI.70.12.6688-6696.2002; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Kurukulaaratchy RJ, 2004, PEDIATRICS, V113, P345, DOI 10.1542/peds.113.2.345; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Manickasingham SR, 2003, EUR J IMMUNOL, V33, P101, DOI 10.1002/immu.200390001; Miyake Y, 2003, CLIN EXP ALLERGY, V33, P312, DOI 10.1046/j.1365-2222.2003.t01-1-01607.x; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Prescott SL, 2003, CURR OPIN ALLERGY CL, V3, P125, DOI 10.1097/01.all.0000064776.57552.32; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Wickman M, 2005, ALLERGY, V60, P650, DOI 10.1111/j.1398-9995.2004.00764.x	22	95	106	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					657	661		10.1016/j.jaci.2005.04.028	http://dx.doi.org/10.1016/j.jaci.2005.04.028			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159639	Bronze			2022-12-18	WOS:000235686500029
J	Meyers, DA; Postma, DS; Stine, OC; Koppelman, GH; Ampleford, EJ; Jongepier, H; Howard, TD; Bleecker, ER				Meyers, DA; Postma, DS; Stine, OC; Koppelman, GH; Ampleford, EJ; Jongepier, H; Howard, TD; Bleecker, ER			Genome screen for asthma and bronchial hyperresponsiveness: Interactions with passive smoke exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						smoking; bronchial hyperresponsiveness; asthma; lung function; linkage; genome-wide sereen	ENVIRONMENTAL TOBACCO-SMOKE; WIDE SEARCH; RESPIRATORY SYMPTOMS; CHROMOSOME 5Q31-Q33; SUSCEPTIBILITY LOCI; LINKAGE ANALYSIS; LUNG-FUNCTION; SERUM IGE; GENE; RESPONSIVENESS	Background: Asthma is a common respiratory disease caused by the interaction of genetic susceptibility and exposure to various environmental factors. Passive smoke exposure, characterized by parental smoking, has been shown to be a risk factor for the development of atopy and asthma. Objective: We sought to perform a genome-wide linkage screen for asthma and bronchial hyperresponsiveness (BHR) and to determine the influence of passive tobacco smoke exposure during childhood on the results of genetic linkage studies to investigate gene-environment interactions. Methods: A genome-wide linkage screen for asthma and BHR was performed in 200 families ascertained through a parent with asthma. Analyses were performed separately for the entire sample and for the smoking-exposed and nonexposed families. Results: For asthma and BHR, the strongest evidence for linkage was observed for chromosomes 3p and 5q. The families in which the children were exposed to passive smoking accounted for the evidence for linkage of BHR to 5q (P < .001), but evidence for linkage to 3p was found in both sets of families. Similar results were observed for asthma. However, there was no observed difference in the frequency of asthma or BHR in the offspring from the smoke-exposed compared with the nonexposed families. Conclusion: The results from this study demonstrate that the influence of susceptibility genes for a common disease such as asthma might not be apparent unless there is the appropriate exposure to environmental stimuli, such as passive exposure to cigarette smoke. This approach should be useful for identification of asthma susceptibility genes.	Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Pediat, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA; Univ Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	Wake Forest University; Wake Forest University; Wake Forest University; University of Groningen; University System of Maryland; University of Maryland Baltimore	Meyers, DA (corresponding author), Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Pediat, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dmeyers@wfubmc.edu	Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066393, R01HL048341] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 66393, R01 HL 48341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; Carey VJ, 1996, AM J RESP CRIT CARE, V153, P356, DOI 10.1164/ajrccm.153.1.8542143; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DEVRIES K, 1962, INT ARCH ALLERGY, V20, P63; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Ehrlich F, 1906, BIOCHEM Z, V1, P8; Gilliland FD, 2003, AM J EPIDEMIOL, V157, P861, DOI 10.1093/aje/kwg037; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; HIRSCHHORN JN, 2005, J CLIN ENDOCR METAB, V87, P4438; Howard TD, 2002, J ALLERGY CLIN IMMUN, V110, P743, DOI 10.1067/mai.2002.128723; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097, DOI 10.1164/ajrccm.162.6.2004178; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MORTON NE, 1956, AM J HUM GENET, V8, P80; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; PEAT JK, 1993, EUR RESPIR J, V6, P662; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Wright AL, 2002, CLIN REV ALLERG IMMU, V22, P33, DOI 10.1385/CRIAI:22:1:033; XU J, 2001, AM J HUM GENET, V69, P1271; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Young S, 2000, PEDIATR PULM, V29, P331, DOI 10.1002/(SICI)1099-0496(200005)29:5<331::AID-PPUL1>3.0.CO;2-A	39	95	97	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1169	1175		10.1016/j.jaci.2005.01.070	http://dx.doi.org/10.1016/j.jaci.2005.01.070			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940130				2022-12-18	WOS:000229815400010
J	Satinover, SM; Reefer, AJ; Pomes, A; Chapman, MD; Platts-Mills, TAE; Woodfolk, JA				Satinover, SM; Reefer, AJ; Pomes, A; Chapman, MD; Platts-Mills, TAE; Woodfolk, JA			Specific IgE and IgG antibody-binding patterns to recombinant cockroach allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach; asthma; allergens; troponryosin; IgE antibody; IgG antibody; multiplex	INNER-CITY CHILDREN; FLOW-CYTOMETRIC ASSAY; AMERICAN COCKROACH; HOUSE-DUST; DERMATOPHAGOIDES-PTERONYSSINUS; BLATTELLA-GERMANICA; MOLECULAR-CLONING; MAJOR ALLERGEN; RISK-FACTORS; ASTHMA	Background: The specificity of serum antibody responses to different cockroach allergens has not been studied. Objective: We sought to quantitate serum IgE and IgG antibodies to a panel of purified cockroach allergens among cockroach-sensitized subjects. Methods: IgE antibodies to recombinant cockroach allergens (rBla g 1, rBla g 2, rBla g 4, rBla g 5, and rPer a 7) were measured in sera containing IgE antibodies to Blattella germanica extract (n = 118) by using a streptavidin CAP assay and a multiplex flow cytometric assay. Specific IgG antibodies were determined by using radioimmuno-precipitation techniques. Results: Specific IgE antibodies measured by means of CAP assay and multiplex assay were strongly correlated (r = 0.8, P < .001). The sum of IgE antibodies (in international units per milliliter) against all 5 allergens equated to IgE antibodies to cockroach extract. Although the prevalence of IgE antibodies was highest for rBla g 2 (54.4%) and rBla g 5 (37.4%), patterns of IgE antibody binding were unique to each subject. Surprisingly, only 16% of cockroach-sensitized subjects with IgE antibodies to house dust mite exhibited IgE antibody binding to cockroach tropomyosin (rPer a 7). Specific IgE antibodies were associated with increased IgG antibody levels, although detection of IgG in the absence of IgE was not uncommon. Conclusion: The techniques described offer a new approach for defining the hierarchy of purified allergens. IgE antibodies directed against 5 allergens constitute the majority of the IgE antibody repertoire for cockroach. Such distinct, patterns of IgE-IgG responsiveness to different cockroach allergens highlight the complexity of B-cell responses to environmental allergens.	Univ Virginia, Asthma & Allerg Dis Ctr, Div Allergy, Charlottesville, VA 22908 USA	University of Virginia	Woodfolk, JA (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, Div Allergy, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu	Pomés, Anna/H-7010-2019	Pomés, Anna/0000-0002-8729-1829; Platts-Mills, Thomas/0000-0002-1263-329X; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, R01AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Arruda L K, 2001, Curr Allergy Asthma Rep, V1, P466, DOI 10.1007/s11882-001-0035-1; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Asturias JA, 1999, J IMMUNOL, V162, P4342; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; ERWIN EA, 2005, IN PRESS J ALLERGY C; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; HULETT AC, 1979, ANN ALLERGY, V42, P160; Jeong KY, 2003, ALLERGY, V58, P1059, DOI 10.1034/j.1398-9995.2003.00167.x; Lal G, 2004, CLIN DIAGN LAB IMMUN, V11, P272, DOI 10.1128/CDLI.11.2.272-279.2004; Lee CS, 2004, CLIN EXP ALLERGY, V34, P354, DOI 10.1111/j.1365-2222.2004.01878.x; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Melen E, 1999, J ALLERGY CLIN IMMUN, V103, P859, DOI 10.1016/S0091-6749(99)70430-6; Pickering JW, 2002, CLIN DIAGN LAB IMMUN, V9, P872, DOI 10.1128/CDLI.9.4.872-876.2002; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2002, EUR J BIOCHEM, V269, P3086, DOI 10.1046/j.1432-1033.2002.02990.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; vanWijnen JH, 1997, ALLERGY, V52, P460, DOI 10.1111/j.1398-9995.1997.tb01030.x; Wu CH, 1997, MOL IMMUNOL, V34, P1, DOI 10.1016/S0161-5890(97)00009-6; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937; Wu CH, 2000, ALLERGY, V55, P1179, DOI 10.1034/j.1398-9995.2000.00604.x; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4	34	95	99	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					803	809		10.1016/j.jaci.2005.01.018	http://dx.doi.org/10.1016/j.jaci.2005.01.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806002				2022-12-18	WOS:000228373400021
J	Liu, Z; Kim, J; Sypek, JP; Wang, IM; Horton, H; Oppenheim, FG; Bochner, BS				Liu, Z; Kim, J; Sypek, JP; Wang, IM; Horton, H; Oppenheim, FG; Bochner, BS			Gene expression profiles in human nasal polyp tissues studied by means of DNA microarray	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyp; sinus; DNA microarray; gene expression; statherin; prolactin-induced protein; lactoferrin; deleted in malignant brain tumor 1; Clara cell 10-kd protein	CHRONIC SINUSITIS; LACTOFERRIN; GLUCOCORTICOIDS; DIFFERENTIATION; IDENTIFICATION; APOPTOSIS; PROTEINS; RHINITIS; NUMBER; GROWTH	Background: Nasal polyposis (NP) is a chronic inflammatory disease of the sinuses. Its pathogenesis is unknown. DNA microarray analysis allows simultaneous measurement of expression of thousands of genes in the same tissue sample and might help to identify gene alterations in various disorders. Objective: We sought to screen for disease-related genes in NP by using DNA microarrays and to validate the altered expression of selected genes at the mRNA and protein level. Methods: Expression microarrays containing approximately 10,500 genes were used to compare individual gene profiles of NP samples (n = 10) and normal mucosal samples obtained from sphenoid sinuses in patients undergoing pituitary surgery (n = 4). Four of the 5 most upregulated, and the single most downregulated, genes were retested by means of quantitative RT-PCR and immunohistochemistry in a different set of NP and normal mucosal samples obtained from the ethmoid and sphenoid sinuses. Results: Compared with normal sinus tissue, 192 genes were upregulated at least 2-fold, and 156 genes were downregulated by at least 50% in NP samples (approximately 3% of genes evaluated). Four of the top 5 overexpressed genes (statherin, 48.0-fold; prolactin-induced protein [PIP], 24.9-fold; lactoferrin, 26.6-fold; and deleted in malignant brain tumor 1 [DMBT1], 30.3-fold) and the most underexpressed gene (Clara cell 10-kd protein [CC10], -20.1-fold) were selected and retested by means of quantitative RT-PCR and immunohistochemical staining. Quantitative RT-PCR and immunohistochemical staining confirmed the differential expression of all except statherin in NP tissue. Conclusion: DNA microarrays can provide new insight into the possible pathophysiologic processes involved in NP.	Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Dept Med, Baltimore, MD USA; Wyeth Ayerst Res, Inflammat, Cambridge, MA USA; Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02215 USA	Johns Hopkins University; Pfizer; Boston University	Bochner, BS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, 5501 Hopkins Bayview Circle,Rm 2B-71, Baltimore, MD 21224 USA.	bbochner@jhmi.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE007652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005672, U01DE014950, R37DE005672] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE14950, DE07652, DE05672] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguila A, 2001, FEMS IMMUNOL MED MIC, V31, P145, DOI 10.1111/j.1574-695X.2001.tb00511.x; Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; Bernstein JM, 1997, J ALLERGY CLIN IMMUN, V99, P165, DOI 10.1016/S0091-6749(97)70091-5; Bikker FJ, 2002, J BIOL CHEM, V277, P32109, DOI 10.1074/jbc.M203788200; Boers JE, 1999, AM J RESP CRIT CARE, V159, P1585, DOI 10.1164/ajrccm.159.5.9806044; BRATLUND B, 1996, J WORLD PREHIST, V10, P1, DOI 10.1007/BF02226070; Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81, DOI 10.1046/j.1365-2036.1996.22164025.x; Burgel PR, 2000, J ALLERGY CLIN IMMUN, V106, P705, DOI 10.1067/mai.2000.109823; Caputo E, 2000, J BIOL CHEM, V275, P7935, DOI 10.1074/jbc.275.11.7935; CAYETHOMASEN P, 1995, ACTA OTO-LARYNGOL, V115, P76, DOI 10.3109/00016489509133351; Chen LC, 2001, J IMMUNOL, V167, P3025, DOI 10.4049/jimmunol.167.6.3025; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Cole AM, 1999, INFECT IMMUN, V67, P3267, DOI 10.1128/IAI.67.7.3267-3275.1999; Fritz SB, 2003, J ALLERGY CLIN IMMUN, V112, P1057, DOI 10.1016/j.jaci.2003.09.042; FUKAMI M, 1993, EUR ARCH OTO-RHINO-L, V250, P133; Gaubin M, 1999, J IMMUNOL, V162, P2631; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Hayashida S, 2000, AM J PHYSIOL-LUNG C, V279, pL452, DOI 10.1152/ajplung.2000.279.3.L452; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646, DOI 10.1164/ajrccm.159.2.9806064; Hill AA, 2001, GENOME BIOL, V2; Jang YJ, 2002, EUR ARCH OTO-RHINO-L, V259, P465, DOI 10.1007/s00405-002-0500-z; KAKOI H, 1987, ACTA OTO-LARYNGOL, V103, P137, DOI 10.3109/00016488709134709; LAMKIN MS, 1993, CRIT REV ORAL BIOL M, V4, P251, DOI 10.1177/10454411930040030101; Leprini A, 1992, Acta Otorhinolaryngol Ital, V12, P475; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mollenhauer J, 2000, CANCER RES, V60, P1704; Mollenhauer J, 2002, GENE CHROMOSOME CANC, V35, P164, DOI 10.1002/gcc.10096; NOMORI H, 1994, VIRCHOWS ARCH, V424, P517; Oshika E, 1998, PEDIATR RES, V43, P305, DOI 10.1203/00006450-199803000-00001; Pawankar R, 2003, CURR OPIN ALLERGY CL, V3, P1, DOI 10.1097/01.all.0000053260.61007.d6; Podolsky Daniel K., 2000, Journal of Gastroenterology, V35, P69; Roca-Ferrer J, 2000, J ALLERGY CLIN IMMUN, V106, P1053, DOI 10.1067/mai.2000.110476; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P930, DOI 10.1164/ajrccm.160.3.9803113; SHIU RPC, 1985, J BIOL CHEM, V260, P1307; Singh G, 2000, ANN NY ACAD SCI, V923, P43; STIEMA PLE, 1997, NASAL POLYPS RELATIO; Temple R, 2001, AM J RESP CELL MOL, V25, P425, DOI 10.1165/ajrcmb.25.4.4456; Thomas LL, 2002, J IMMUNOL, V169, P993, DOI 10.4049/jimmunol.169.2.993; Thornton DJ, 2001, GLYCOBIOLOGY, V11, P969, DOI 10.1093/glycob/11.11.969; Watelet JB, 2004, ALLERGY, V59, P54, DOI 10.1046/j.1398-9995.2003.00364.x; WONSIEWICZ M, 1988, TEXT ATLAS HISTOLOGY; Wurmbach E, 2002, NEUROCHEM RES, V27, P1027, DOI 10.1023/A:1020900720328	43	95	107	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					783	790		10.1016/j.jaci.2004.04.052	http://dx.doi.org/10.1016/j.jaci.2004.04.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480316				2022-12-18	WOS:000224439100010
J	Laouini, D; Kawamoto, S; Yalcindag, A; Bryce, P; Mizoguchi, E; Oettgen, H; Geha, RS				Laouini, D; Kawamoto, S; Yalcindag, A; Bryce, P; Mizoguchi, E; Oettgen, H; Geha, RS			Epicutaneous sensitization with superantigen induces allergic skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; superantigens; skin inflammation; cytokines; staphylococcal enterotoxin B; in vivo animal models	STAPHYLOCOCCAL-ENTEROTOXIN-B; T-CELLS; ATOPIC-DERMATITIS; MURINE MODEL; IFN-GAMMA; EXPRESSION; HYPERRESPONSIVENESS; EOSINOPHILIA; ACTIVATION; CYTOKINES	Background: Atopic dermatitis (AD) is characterized by skin infiltration with eosinophils and lymphocytes and expression of Th-2 cytokines in acute skin lesions. The skin of patients with AD is frequently colonized with enterotoxin-secreting strains of Staphylococcus aureus. Staphylococcal enterotoxins have been implicated in the exacerbations of the inflammatory skin lesions in patients with AD. Objective: We sought to determine whether epicutaneous (EC) sensitization of mice with staphylococcal enterotoxin B (SEB) results in allergic skin inflammation. Methods: BALB/c mice were EC-sensitized with SEB. Their skin was examined for allergic inflammation and cytokine expression, and their splenocytes were examined for cylokine secretion in response to SEB. Results: EC sensitization with SEB elicited a local, cutaneous, inflammatory response characterized by dermal infiltration with eosinophils and mononuclear cells and increased mRNA expression of the Th-2 cytokine IL-4 but not of the Th-1 cytokine IFN-gamma. EC-sensitized mice mounted a systemic Th-2 response to SEB evidenced by elevated total and SEB-specific IgG1 and IgE. Although EC sensitization with SEB resulted in selective depletion of SEB-specific T-cell receptor Vbeta8+ cells from the spleen and sensitized skin, splenoeytes from SEB-sensitized mice secreted relatively more IL-4 and less IFN-gamma than did saline-sensitized controls, consistent with Th-2 skewing of the systemic immune response to the superantigen. Conclusion: These results suggest that EC exposure to super-antigens skews the immune response toward Th-2 cells, leading to allergic skin inflammation and increased IgE synthesis that are characteristic of AD.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol,Immunopathol Unit, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard University; Massachusetts General Hospital	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave,Enders 8, Boston, MA 02115 USA.		Yalcindag, Ali/GLU-9728-2022; Laouini, Dhafer/Q-6535-2019; Kawamoto, Seiji/F-3423-2015	Yalcindag, Ali/0000-0002-5752-0360; Laouini, Dhafer/0000-0003-1222-4880; Kawamoto, Seiji/0000-0002-2056-4802	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 47417] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akdis M, 1999, J IMMUNOL, V163, P466; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Breuer K, 2000, ALLERGY, V55, P551, DOI 10.1034/j.1398-9995.2000.00432.x; Campbell DE, 1997, CLIN EXP IMMUNOL, V107, P392, DOI 10.1111/j.1365-2249.1997.278-ce1172.x; CARDELL S, 1993, EUR J IMMUNOL, V23, P523, DOI 10.1002/eji.1830230234; Chou MC, 1997, IMMUNOL LETT, V55, P85, DOI 10.1016/S0165-2478(97)02689-8; Ebtekar M, 1996, SCAND J IMMUNOL, V43, P391, DOI 10.1046/j.1365-3083.1996.d01-55.x; Florquin S, 1996, J AUTOIMMUN, V9, P609, DOI 10.1006/jaut.1996.0080; GONZALO JA, 1992, EUR J IMMUNOL, V22, P1007, DOI 10.1002/eji.1830220420; HAMEL ME, 1995, INT IMMUNOL, V7, P1065, DOI 10.1093/intimm/7.7.1065; HOIDEN I, 1993, SCAND J IMMUNOL, V38, P515; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; JANEWAY CA, 1991, ADV IMMUNOL, V50, P1; KONIG B, 1995, INT ARCH ALLERGY IMM, V106, P124, DOI 10.1159/000236832; LAGOO AS, 1994, J IMMUNOL, V152, P1641; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1995, J INVEST DERMATOL, V105, pS37, DOI 10.1111/1523-1747.ep12315250; LEUNG DYM, 1992, SPRINGER SEMIN IMMUN, V13, P427; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; Neuber K, 1996, ACTA DERM-VENEREOL, V76, P214; SOLAGA J, 1996, J INVEST DERMATOL, V106, P982; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; YAGI JJ, 1990, J IMMUNOL, V144, P892; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153	30	95	102	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					981	987		10.1016/j.jaci.2003.07.007	http://dx.doi.org/10.1016/j.jaci.2003.07.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610492				2022-12-18	WOS:000186553300023
J	Casale, TB; Blaiss, MS; Gelfand, E; Gilmore, T; Harvey, PD; Hindmarch, I; Simons, FER; Spangler, DL; Szefler, SJ; Terndrup, TE; Waldman, SA; Weiler, J; Wong, DE				Casale, TB; Blaiss, MS; Gelfand, E; Gilmore, T; Harvey, PD; Hindmarch, I; Simons, FER; Spangler, DL; Szefler, SJ; Terndrup, TE; Waldman, SA; Weiler, J; Wong, DE		Antihistamine Impairment Rou	First do no harm: Managing antihistamine impairment in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; antihistamines; cetirizine; fexofenadine; loratadine; desloratadine; sedation; drowsiness; impairment	ENVIRONMENTAL EXPOSURE UNIT; QUALITY-OF-LIFE; 2ND-GENERATION ANTIHISTAMINES; DRIVING PERFORMANCE; MEDICATION USE; 120 MG; FEXOFENADINE; CETIRIZINE; EFFICACY; SAFETY	Antihistamines are effective medications that have been used for decades in the management of allergic rhinitis; however, they may be administered or selected in an inappropriate fashion and may be the source of drug-related morbidity. Our objective is to present relevant background information and an expert consensus statement on the use of antihistamines in treatment of allergic rhinitis. In July 2002, 14 experts in allergy, clinical immunology, pharmacology, and impairment assessment were invited to participate in a roundtable conference to present current concepts and develop a consensus statement on the clinical management of allergic rhinitis with antihistamines. Many of the antihistamines used to treat allergic rhinitis, as well as the disease itself, may produce sedation, impairment, and reduced quality of life. Allergic rhinitis is more appropriately managed with the relatively nonimpairing second-generation antihistamines (eg, Ioratadine, desloratadine, cetirizine, and fexofenadine), because older agents (eg, diphenhydramine, chlorpheniramine, and brompheniramine) produce sedation and impairment and worsen sleep architecture. Although there is some debate surrounding the varying degrees of efficacy of second-generation antihistamines, it is known that some agents may produce varying levels of drowsiness or impairment, especially at higher than recommended doses. The differences with regard to safety among the second-generation antihistamines are smaller than are the differences between the first and second generations. A nonsedating, nonimpairing (even at higher than recommended doses), second-generation antihistamine is preferred for all patients, particularly those with a higher risk for the development of adverse effects. We recommend that primary care and specialist physicians, nurse practitioners, physician assistants, pharmacists, and all other health professionals involved in the diagnosis and treatment of allergic rhinitis follow this consensus document and share this information with patients for whom antihistamine therapy is recommended. In addition, further epidemiologic studies on the effects of antihistamines should be performed.	Creighton Univ, Dept Med, Sch Med, Omaha, NE 68131 USA; Univ Tennessee, Ctr Hlth Sci, Div Clin Immunol, Memphis, TN 38163 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Washington, Seattle, WA 98195 USA; Grp Hlth Permanente, Seattle, WA USA; Univ Surrey, Med Res Ctr, New York, NY USA; Mt Sinai Sch Med, Dept Psychiat, New York, NY USA; Univ Manitoba, Dept Pediat & Child Hlth, Sect Allergy & Clin Immunol, Winnipeg, MB, Canada; Childrens Med Network Atlanta, Sect Allergy, Atlanta, GA USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Natl Jewish Med & Res Ctr, Dept Pharmacol, Denver, CO USA; Univ Alabama Birmingham, Dept Emergency Med, Birmingham, AL USA; Ctr Disaster Preparedness, Birmingham, AL USA; Thomas Jefferson Univ, Dept Med & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Mol Pharmacol, Philadelphia, PA 19107 USA; Univ Iowa, Iowa City, IA USA; Iowa Clin Res Corp, Iowa City, IA USA; Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; Johns Hopkins Univ, Dept Psychiat, Baltimore, MD USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Baltimore, MD USA	Creighton University; University of Tennessee System; University of Tennessee Health Science Center; National Jewish Health; University of Washington; University of Washington Seattle; Icahn School of Medicine at Mount Sinai; University of Manitoba; National Jewish Health; National Jewish Health; University of Alabama System; University of Alabama Birmingham; Jefferson University; Jefferson University; University of Iowa; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Casale, TB (corresponding author), Creighton Univ, Dept Med, Sch Med, 601 N 30th St,Suite 5850, Omaha, NE 68131 USA.	tbcasale@creighton.edu	Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377; Waldman, Scott/0000-0001-6619-175X; terndrup, thomas/0000-0003-4376-2593				*AM AC ALL ASTHM I, 2002, ALL DIS PROM BEST PR, V1; [Anonymous], 2002, Med Lett Drugs Ther, V44, P27; Berkowitz RB, 2002, ANN ALLERG ASTHMA IM, V89, P38, DOI 10.1016/S1081-1206(10)61909-6; Blaiss MS, 2000, ALLERGY ASTHMA PROC, V21, P7, DOI 10.2500/108854100778248953; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Burton WN, 2001, J OCCUP ENVIRON MED, V43, P64, DOI 10.1097/00043764-200101000-00013; Day JH, 1998, J ALLERGY CLIN IMMUN, V101, P638, DOI 10.1016/S0091-6749(98)70172-1; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P533, DOI 10.1016/S1081-1206(10)63062-1; DOGAN AS, 2001, J NUCL MED S, V42, pS143; DuBuske LM, 1996, J ALLERGY CLIN IMMUN, V98, pS307, DOI 10.1016/S0091-6749(96)80116-3; DuBuske LM, 1999, CLIN THER, V21, P281, DOI 10.1016/S0149-2918(00)88286-7; DUBUSKE LM, 2001, CLIN APPL IMMUNOL RE, V1, P277; Finkle WD, 2002, ANN ALLERG ASTHMA IM, V89, P244, DOI 10.1016/S1081-1206(10)61950-3; GENGO FM, 1987, ANN ALLERGY, V59, P53; Gilmore TM, 1996, AM J IND MED, V30, P234; Handley D A, 1998, Expert Opin Investig Drugs, V7, P1045, DOI 10.1517/13543784.7.7.1045; HIDNMARCH I, 2002, CLIN EXP ALERGY REV, V2, P26; Horak F, 2001, INT ARCH ALLERGY IMM, V125, P73, DOI 10.1159/000053799; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; Mann RD, 2000, BRIT MED J, V320, P1184, DOI 10.1136/bmj.320.7243.1184; *NAT COUNC PAT INF, 2002, ATT BEL OV THE COUNT; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; Nicholson AN, 2000, AVIAT SPACE ENVIR MD, V71, P2; Nicholson AN, 1998, AVIAT SPACE ENVIR MD, V69, P166; OHANLON JF, 1995, ALLERGY, V50, P234, DOI 10.1111/j.1398-9995.1995.tb01140.x; Philpot EE, 2000, ALLERGY ASTHMA PROC, V21, P15, DOI 10.2500/108854100778249033; PRATT CM, 1994, AM J CARDIOL, V73, P346, DOI 10.1016/0002-9149(94)90006-X; Rossoff LJ, 1997, AM J MANAGED CARE S9, V3, pS8; Shamsi Z, 2000, HUM PSYCHOPHARM CLIN, V15, pS3, DOI 10.1002/1099-1077(200010)15:1+<::AID-HUP247>3.0.CO;2-S; Simons FER, 2001, J ALLERGY CLIN IMMUN, V107, P526, DOI 10.1067/mai.2001.113080; Storms W, 1997, J ALLERGY CLIN IMMUN, V99, pS820, DOI 10.1016/S0091-6749(97)80042-5; Vermeeren A, 2002, J PSYCHOPHARMACOL, V16, P57, DOI 10.1177/026988110201600104; Waldman SA, 2002, ANN ALLERG ASTHMA IM, V89, P7, DOI 10.1016/S1081-1206(10)61904-7; Weiler JM, 2000, ANN INTERN MED, V132, P354, DOI 10.7326/0003-4819-132-5-200003070-00004; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; 2001, MED LETT DRUGS THER, V43, P35; 1998, AVIAT SPACE ENV MED, V69, P166	41	95	98	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					S835	S842		10.1067/mai.2003.1550	http://dx.doi.org/10.1067/mai.2003.1550			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743547				2022-12-18	WOS:000182904500045
J	George, M; Freedman, TG; Norfleet, AL; Feldman, HI; Apter, AJ				George, M; Freedman, TG; Norfleet, AL; Feldman, HI; Apter, AJ			Qualitative research-enhanced understanding of patients' beliefs: Results of focus groups with low-income, urban, African American adults with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MEDICAL LITERATURE; USERS GUIDES; HEALTH-CARE; XXIII	Background: Qualitative research is an important research methodology for understanding the health beliefs and attitudes of patients. These beliefs and attitudes have been proposed as partial explanations for low adherence to medical therapy and the consequent high burden of morbidity from asthma among low-income urban minorities. Objective: The purpose of this study was to explore barriers to adherence to inhaled corticosteroids (ICSs), health beliefs regarding asthma and its treatment, and opinions about providers and clinical research among low-income groups. Methods: Three focus groups were conducted with 15 low-income, urban, African American adults with persistent asthma. These focus group sessions were audiotaped, transcribed verbatim, and coded by using qualitative analytic techniques. Results: Health beliefs that influenced adherence included patients' reliance on their assessment of asthma control over that of the health provider and concern over the adverse effects of ICS therapy. Adherence was also adversely affected by social obligations and insurers' approval policies and restricted formularies. Although mistrust of the medical establishment was evident, members generally expressed a willingness to participate in nonpharmacologic clinical research and the belief that research was beneficial. However, they had strong preferences for where the research should be conducted. Conclusions: Although barriers exist to ICS adherence in patient populations, many of these can be addressed during patient-clinician interactions. Qualitative research is an important tool for formulating hypotheses for improving ICS adherence that can then be tested in the future by using quantitative research methods.	Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Univ Penn, Gen Clin Res Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.			George, Maureen/0000-0001-9234-7842	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004337] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00040] Funding Source: Medline; NHLBI NIH HHS [HL04337-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams S, 1997, SOC SCI MED, V45, P189, DOI 10.1016/S0277-9536(96)00333-4; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Bach PB, 2002, JAMA-J AM MED ASSOC, V287, P2106, DOI 10.1001/jama.287.16.2106; Boulet LP, 1998, CHEST, V113, P587, DOI 10.1378/chest.113.3.587; Cook DJ, 2001, CHEST, V120, p469S, DOI 10.1378/chest.120.6_suppl.469S; Diette GB, 1999, ARCH INTERN MED, V159, P2697, DOI 10.1001/archinte.159.22.2697; Freedman TG, 1998, SOC SCI MED, V47, P941, DOI 10.1016/S0277-9536(98)00167-1; Giacomini MK, 2000, JAMA-J AM MED ASSOC, V284, P478, DOI 10.1001/jama.284.4.478; Giacomini MK, 2000, JAMA-J AM MED ASSOC, V284, P357, DOI 10.1001/jama.284.3.357; GUBA EG, 1981, ECTJ-EDUC COMMUN TEC, V29, P75; Hand CH, 1996, J ASTHMA, V33, P331, DOI 10.3109/02770909609055374; HARDING JM, 1985, J ROY COLL GEN PRACT, V35, P226; *I MED, 2002, UN TREATM CONFR RAC; Krueger R.A., 2015, FOCUS GROUPS PRACTIC; Krugman Paul, 2002, NY TIMES MAGAZI 1020, P62; Munro JF, 1996, J ASTHMA, V33, P313, DOI 10.3109/02770909609055372; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; OSMAN LM, 1993, THORAX, V48, P827, DOI 10.1136/thx.48.8.827; Sateren WB, 2002, J CLIN ONCOL, V20, P2109, DOI 10.1200/JCO.2002.08.056; 1997, PUBLICATION NIH	20	95	96	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					967	973		10.1067/mai.2003.1459	http://dx.doi.org/10.1067/mai.2003.1459			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743559				2022-12-18	WOS:000182904500009
J	Marks, GB; Ng, K; Zhou, J; Toelle, BG; Xuan, W; Belousova, EG; Britton, WJ				Marks, GB; Ng, K; Zhou, J; Toelle, BG; Xuan, W; Belousova, EG; Britton, WJ			The effect of neonatal BCG vaccination on atopy and asthma at age 7 to 14 years: An historical cohort study in a community with a very low prevalence of tuberculosis infection and a high prevalence of atopic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; immune deviation; cytokines; bacille Calmette-Guerin	ALLERGIC SENSITIZATION; CHILDREN; ASSOCIATION; RESPONSES; ENTRY	Background: There are conflicting reports on the effect of BCG vaccination on the subsequent development of atopy and asthma. There are no data on the effects of neonatal BCG vaccination on cytokine responses of lymphocytes that are exposed in vitro to allergens. Objectives: We sought to test the hypothesis that neonatal BCG vaccination or, alternatively, evidence of an immunologic memory of this vaccination is associated with a reduced prevalence of allergic sensitization, asthma, eczema, and hay fever during childhood. Methods: An historical cohort study was conducted among 7-to 14-year-old children who were born in 2 districts in Sydney, Australia, and whose mothers were born in southeast Asia. One district had routinely administered BCG vaccination to infants born to overseas-born mothers and the other had not. Eligible subjects were identified from birth registers. Consenting subjects completed questionnaires, performed spirometric and airway hyperresponsiveness testing, and had allergen skin prick testing and tuberculin skin testing. Blood was collected to measure total serum IgE levels and for in vitro lymphocyte culture in the presence of an extract of house dust mite, the dominant allergen in this region, and purified protein derivative of Mycobacterium tuberculosis (tuberculin). IL-4, IL-5, IL10, and IFN-gamma were measured in the culture supernatant. Results: The cohort included 309 BCG-vaccinated subjects and 442 non-BCG-vaccinated subjects. BCG-vaccinated subjects did not have a lower rate of allergic sensitization than nonvaccinated subjects. However, among the subgroup of subjects with a family history of rhinitis or eczema, BCG vaccination was associated with a lower prevalence of current asthma (defined as recent wheezing plus airway hyperresponsiveness; relative risk, 0.46; 95% CI, 0.22-0.95). BCG vaccination was also associated with lower levels of allergen-stimulated IL-10 production in vitro. Among the BCG-vaccinated subjects, the 44 (14.3%) who had tuberculin skin test reaction sizes of 5 mm or greater and the 31 (18.3%) who demonstrated an in vitro IFN-gamma response to purified protein derivative of M tuberculosis did not have lower rates of allergic sensitization and, overall, did not have a lower prevalence of allergic disease than tuberculin skin test or IFN-gamma nonreactors. Conclusion: We conclude that neonatal BCG vaccination has an effect on T-cell allergen responsiveness 7 to 14 years after vaccination and that among a subgroup of subjects with an inherited predisposition to allergic disease, this is associated with clinically relevant beneficial effects. The findings of this study encourage the view that external influences on the immune system in the neonatal period have consequences that extend into later childhood and influence the expression of asthma. Genetic factors are likely to modify the effect of those external factors. (J Allergy Clin Immunoll 2003;111:541-9.).	Woolcook Inst Med Res, ZA-2050 Johannesburg, NSW, South Africa; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Centenary Inst Canc Med & Cell Biol, Sydney, NSW, Australia	University of Sydney; University of Sydney; Centenary Institute	Marks, GB (corresponding author), Woolcook Inst Med Res, POB M77,Missenden Rd Post Off, ZA-2050 Johannesburg, NSW, South Africa.		Toelle, Brett G/B-1531-2008; Marks, Guy B./F-5058-2013	Toelle, Brett G/0000-0002-7375-0019; Marks, Guy B./0000-0002-8976-8053; Britton, Warwick/0000-0001-6721-9646				Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Alperstein G, 1996, AUST NZ J PUBL HEAL, V20, P123, DOI 10.1111/j.1753-6405.1996.tb01805.x; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Haby MM, 2000, PEDIATR PULM, V30, P377, DOI 10.1002/1099-0496(200011)30:5<377::AID-PPUL3>3.0.CO;2-3; Hogg C, 1997, CLIN EXP ALLERGY, V27, P1237; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Jenmalm MC, 1999, PEDIATR ALLERGY IMMU, V10, P168, DOI 10.1034/j.1399-3038.1999.00016.x; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; *NAT TB ADV COMM C, 2001, COMMUN DIS INTELL, V25, P1; PEAT JK, 1995, MED J AUSTRALIA, V163, P22, DOI 10.5694/j.1326-5377.1995.tb126083.x; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Pouchot J, 1997, ANN INTERN MED, V126, P210, DOI 10.7326/0003-4819-126-3-199702010-00005; QUANJER PH, 1995, PEDIATR PULM, V19, P135, DOI 10.1002/ppul.1950190209; Sander B, 1995, IMMUNOLOGY, V86, P512; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; Wong GWK, 2001, THORAX, V56, P770, DOI 10.1136/thorax.56.10.770; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	27	95	99	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					541	549		10.1067/mai.2003.171	http://dx.doi.org/10.1067/mai.2003.171			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642835				2022-12-18	WOS:000181639500016
J	Gavrovic-Jankulovic, M; Cirkovic, T; Vuckovic, O; Atanaskovic-Markovic, M; Petersen, A; Gojgic, G; Burazer, L; Jankov, RM				Gavrovic-Jankulovic, M; Cirkovic, T; Vuckovic, O; Atanaskovic-Markovic, M; Petersen, A; Gojgic, G; Burazer, L; Jankov, RM			Isolation and biochemical characterization of a thaumatin-like kiwi allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen purification; antifungal activity; food allergen; kiwi fruit; pathogenesis-related protein; thaumatin-like protein	PATHOGENESIS-RELATED PROTEINS; BET V 1; CROSS-REACTIVITY; RECOMBINANT ALLERGENS; MAJOR ALLERGEN; APPLE ALLERGEN; FRUIT ALLERGY; BIRCH; IDENTIFICATION; CLASSIFICATION	Background: Kiwi fruit allergy, as well as its association with hypersensitivity to other foods and to pollen, has been extensively reported in the last few years. Several IgE-binding components have been detected in kiwi extract, but only one 30-kd allergen has been isolated; it was identified as actinidin (Act c 1). Recently, we have reported a 24-kd kiwi protein to be a potential major allergen in a group of patients with oral allergy syndrome (OAS). Objective: The aim of this study was to purify and characterize the 24-kd kiwi allergen biochemically. Methods: Seven polysensitized patients with OAS to kiwi were used in this study. The kiwi allergen was isolated by using a combination of gel permeation, ion exchange, and immobilized metal ion affinity chromatography. Its biochemical characterization included determination of its isoelectric point, molecular weight, N-terminal sequencing, concanavalin A-binding ability, digestibility in simulated gastric fluid, and antifungal activity. Western blotting, 2-dimensional PAGE immunoblotting, and skin prick tests were performed to characterize the isolated protein immunochemically. Results: All 7 patients recognized the isolated 24-kd kiwi protein as an allergen. The isolated protein consisted of 2 isoforms with isoelectric points of 9.4 and 9.5 migrated as one protein band of 20 kd after SDS-PAGE under nonreducing conditions or at 24 kd under reducing conditions. The partial N-terminal sequence revealed that it is a thaumatin-like protein (TLP) with concanavalin A-binding ability. The protein showed antifungal activity toward Saccharomyces carlsbergensis, and Candida albicans. The protein was degraded by the simulated gastric fluid within 1 minute. Both isoforms bound IgE from a pool of sera in a 2-dimensional PAGE inummoblot. The TLP elicited positive skin prick test responses in 4 (80%) of 5 patients with OAS. Conclusion: This study reported isolation and full characterization of a new kiwi allergen, TLP (isoelectric points of 9.4 and 9.5 and molecular weight of 24 kd), which belongs to the family of pathogenesis-related proteins. The isolated protein expressed antifungal activity toward S carlsbergensis and C albicans.	Univ Belgrade, Fac Chem, Dept Biochem, YU-11000 Belgrade, Yugoslavia; Inst Immunol & Virol Torlak, Dept Allergol, Belgrade, Yugoslavia; Univ Belgrade, Childrens Hosp, Dept Allergol, Belgrade, Yugoslavia; Res Ctr Borstel, Borstel, Germany	University of Belgrade; University of Belgrade; Forschungszentrum Borstel	Gavrovic-Jankulovic, M (corresponding author), Univ Belgrade, Fac Chem, Dept Biochem, Studentski Trg 16, YU-11000 Belgrade, Yugoslavia.		Gavrovic-Jankulovic, Marija/AAE-4077-2022; Cirkovic Velickovic, Tanja/R-6751-2016; Gojgic-Cvijovic, Gordana/F-8620-2017	Gavrovic-Jankulovic, Marija/0000-0002-8591-4391; Cirkovic Velickovic, Tanja/0000-0003-2559-5234; Gojgic-Cvijovic, Gordana/0000-0001-5598-0585				Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Amsterdam D., 1996, ANTIBIOTICS LAB MED, P52; Becker WM, 2001, J CHROMATOGR B, V756, P131, DOI 10.1016/S0378-4347(01)00098-6; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; CUSACK M, 1988, PHYTOCHEMISTRY, V27, P3817, DOI 10.1016/0031-9422(88)83024-3; FilsLycaon BR, 1996, PLANT PHYSIOL, V111, P269, DOI 10.1104/pp.111.1.269; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Fu TJ, 2002, ANN NY ACAD SCI, V964, P99; GALL H, 1994, J ALLERGY CLIN IMMUN, V94, P70, DOI 10.1016/0091-6749(94)90073-6; Gavrovic-Jankulovic M, 2000, J INVEST ALLERG CLIN, V10, P361; GAVROVICJANKULO.M, 2002, IN PRESS J INVEST AL; HARLOW E, 1988, ANTIBODIES LAB MANUA, P473; HSICH LS, 1995, J ALLERGY CLIN IMMUN, V96, P960; Hubbard TJP, 1999, NUCLEIC ACIDS RES, V27, P254, DOI 10.1093/nar/27.1.254; Inschlag C, 1998, INT ARCH ALLERGY IMM, V116, P22, DOI 10.1159/000023920; Jensen-Jarolim E, 1998, INT ARCH ALLERGY IMM, V116, P103, DOI 10.1159/000023932; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU D, 1994, P NATL ACAD SCI USA, V91, P1888, DOI 10.1073/pnas.91.5.1888; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLING HJ, 1993, ALLERGY, V48, P9; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; Pastorello EA, 2001, J CHROMATOGR B, V756, P71, DOI 10.1016/S0378-4347(01)00072-X; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V101, P531, DOI 10.1016/S0091-6749(98)70360-4; Pressey R, 1997, PHYTOCHEMISTRY, V44, P1241, DOI 10.1016/S0031-9422(96)00667-X; Rudeschko O, 1998, J INVEST ALLERG CLIN, V8, P78; Salcedo G, 1999, CLIN EXP ALLERGY, V29, P1158, DOI 10.1046/j.1365-2222.1999.00629.x; Sanchez-Monge R, 2000, J ALLERGY CLIN IMMUN, V106, P190, DOI 10.1067/mai.2000.107599; Scheurer S, 2001, J ALLERGY CLIN IMMUN, V107, P724, DOI 10.1067/mai.2001.113864; Steinhart H, 2001, ALLERGY, V56, P9, DOI 10.1034/j.1398-9995.2001.00902.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Vieths S, 2001, ALLERGY, V56, P78, DOI 10.1034/j.1398-9995.2001.00923.x; VOCKS E, 1993, ALLERGY, V48, P168, DOI 10.1111/j.1398-9995.1993.tb00708.x; Voitenko V, 1997, ALLERGY, V52, P136, DOI 10.1111/j.1398-9995.1997.tb00967.x; Wurms K, 1999, J SCI FOOD AGR, V79, P1448, DOI [10.1002/(SICI)1097-0010(199908)79:11<1448::AID-JSFA381>3.3.CO;2-V, 10.1002/(SICI)1097-0010(199908)79:11&lt;1448::AID-JSFA381&gt;3.0.CO;2-3]; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171; Yun DJ, 1997, P NATL ACAD SCI USA, V94, P7082, DOI 10.1073/pnas.94.13.7082	44	95	100	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					805	810		10.1067/mai.2002.128947	http://dx.doi.org/10.1067/mai.2002.128947			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417892				2022-12-18	WOS:000179082500018
J	Malo, JL; Chan-Yeung, M				Malo, JL; Chan-Yeung, M			Occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; occupational asthma; irritant-induced asthma; reactive airways dysfunction syndrome	AIRWAYS DYSFUNCTION SYNDROME; EXHALED NITRIC-OXIDE; HLA CLASS-II; TOLUENE DIISOCYANATE; BRONCHIAL HYPERRESPONSIVENESS; IGE ANTIBODIES; ADULT ASTHMA; CEDAR ASTHMA; EXPOSURE; APPRENTICES	The workplace can be responsible for approximately one in 10 cases of adult-onset asthma. Two types of occupational asthma (OA) are distinguished by whether they arise after a latency period that is necessary for acquiring sensitization or as a result of acute exposure to irritant materials (irritant-induced asthma). The pathophysiology of OA with a latency period is similar to that of nonoccupational asthma, whereas the mechanism of irritant-induced asthma is still uncertain. HLA haplotypes and other genetic polymorphisms have been found to be associated with OA. According to various sources of data, the overall frequency of OA has remained stable in the last 10 years, although the frequency of causal agents vary. Registers of causal occupations and agents have been issued on Web sites (eg, www.asmanet.com). Improved sampling methods have shown that the degree of exposure plays a key role in the onset of the disease, whereas prospective data collected in high-risk workplaces have also identified personal risk factors (eg, atopy, smoking, and rhinoconjunctivitis). A diagnosis of OA should no longer be based on a compatible history only but should be confirmed by means of objective testing. Once the diagnosis is confirmed, the worker should be removed from exposure, and satisfactory compensation programs should be offered, the most important being retraining programs with financial compensations because affected workers are generally young. The cost-effectiveness of prevention programs in high-risk workforces should be assessed.	Hop Sacre Coeur, Dept Resp Med, Montreal, PQ H4J 1C5, Canada; Univ British Columbia, Vancouver Gen Hosp, Dept Med, Vancouver, BC V5Z 1M9, Canada	Universite de Montreal; University of British Columbia	Malo, JL (corresponding author), Hop Sacre Coeur, Dept Resp Med, 5400 W Gouin Blvd, Montreal, PQ H4J 1C5, Canada.							AGLUS RM, 1991, ANN OCCUP HYG, V35, P129; ARCHAMBAULT S, IN PRESS JALLERGY CL; Balboni A, 1996, EUR RESPIR J, V9, P207, DOI 10.1183/09031936.96.09020207; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; BECKLAKE MR, 1999, ASTHMA WORKPLACE, P27; BENTLEY A M, 1991, Journal of Allergy and Clinical Immunology, V87, P246, DOI 10.1016/0091-6749(91)91710-B; Bernstein DI, 1999, ASTHMA WORKPLACE, P145; Bernstein IL, 1999, ASTHMA WORKPLACE; Bernstein JA, 1999, J ALLERGY CLIN IMMUN, V103, P1153, DOI 10.1016/S0091-6749(99)70192-2; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; BOULET LP, 1994, EUR RESPIR J, V7, P1567, DOI 10.1183/09031936.94.07091567; Burge PS, 1999, ASTHMA WORKPLACE, P193; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P655, DOI 10.1016/0091-6749(79)90031-9; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; Cartier A, 1999, ASTHMA WORKPLACE, P211; Chan-Yeung M, 1999, AM J RESP CRIT CARE, V159, P1434, DOI 10.1164/ajrccm.159.5.9807007; Chan-Yeung M, 1999, ASTHMA WORKPLACE, P129; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; CHANYEUNG M, 1980, J ALLERGY CLIN IMMUN, V65, P333, DOI 10.1016/0091-6749(80)90209-2; CHITANO P, 1994, EUR J PHARM-ENVIRON, V270, P167, DOI 10.1016/0926-6917(94)90059-0; COTE J, 1990, AM REV RESPIR DIS, V141, P373, DOI 10.1164/ajrccm/141.2.373; DALFONSO S, 1997, 12 INT HIST WORKSH C, P167; DEWITTE JD, 1994, EUR RESPIR J, V7, P969; FABBRI LM, 1988, AM REV RESPIR DIS, V137, P1494, DOI 10.1164/ajrccm/137.6.1494; FINOTTO S, 1991, BRIT J IND MED, V48, P116; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301, DOI 10.1136/oem.54.5.301; FREW A, 1993, J ALLERGY CLIN IMMUN, V92, P466, DOI 10.1016/0091-6749(93)90126-Z; FREW AJ, 1995, AM J RESP CRIT CARE, V151, P340, DOI 10.1164/ajrccm.151.2.7842189; FREW AJ, 1993, J ALLERGY CLIN IMMUN, V91, P219; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P12, DOI 10.1016/0091-6749(94)90228-3; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841, DOI 10.1164/ajrccm.155.6.9196084; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899, DOI 10.1164/ajrccm.163.4.2008011; Gautrin D, 1999, ASTHMA WORKPLACE, P565; GAUTRIN D, IN PRESS EUR RESP J; Graham C, 1997, REGUL TOXICOL PHARM, V26, P296, DOI 10.1006/rtph.1997.1170; Grammer L, 1998, CHEST, V114, P1199, DOI 10.1378/chest.114.4.1199; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Heederik D, 1999, OCCUP ENVIRON MED, V56, P735, DOI 10.1136/oem.56.11.735; HEEDERIK D, 1999, ASTHMA WORKPLACE, P377; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; Home C, 2000, EUR RESPIR J, V15, P911, DOI 10.1034/j.1399-3003.2000.15e17.x; Houba R, 1998, AM J IND MED, V34, P529, DOI 10.1002/(SICI)1097-0274(199812)34:6&lt;529::AID-AJIM1&gt;3.0.CO;2-I; Jajosky R A, 1999, MMWR CDC Surveill Summ, V48, P1; Johnson AR, 2000, AM J RESP CRIT CARE, V162, P2058, DOI 10.1164/ajrccm.162.6.9805079; Karjalainen A, 2000, AM J IND MED, V37, P451, DOI 10.1002/(SICI)1097-0274(200005)37:5&lt;451::AID-AJIM1&gt;3.0.CO;2-U; KAROL MH, 1980, CLIN ALLERGY, V10, P101, DOI 10.1111/j.1365-2222.1980.tb02086.x; KERWIN EM, 1993, J ALLERGY CLIN IMMUN, V91, P235; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137, DOI 10.1164/ajrccm.154.1.8680669; Lemiere C, 1996, AM J RESP CRIT CARE, V154, P329, DOI 10.1164/ajrccm.154.2.8756802; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; LESAGE J, 1999, ASTHMA WORKPLACE, P257; Liss GM, 2000, AM J RESP CRIT CARE, V162, P112, DOI 10.1164/ajrccm.162.1.9906108; LOW B, 1988, TISSUE ANTIGENS, V31, P224, DOI 10.1111/j.1399-0039.1988.tb02085.x; MAESTRELLI P, 1993, J ALLERGY CLIN IMMUN, V91, P220; Malo JL, 2000, CHEST, V118, P1232, DOI 10.1378/chest.118.5.1232; Malo JL, 1996, AM J RESP CRIT CARE, V153, P953, DOI 10.1164/ajrccm.153.3.8630579; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1988, AM REV RESPIR DIS, V138, P807, DOI 10.1164/ajrccm/138.4.807; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P1121, DOI 10.1016/0091-6749(93)90313-5; Mapp CE, 2000, EUR RESPIR J, V16, P570, DOI 10.1034/j.1399-3003.2000.016003570.x; MAPP CE, 1990, EUR J PHARMACOL, V180, P113, DOI 10.1016/0014-2999(90)90598-Z; McDonald JC, 2000, OCCUP ENVIRON MED, V57, P823, DOI 10.1136/oem.57.12.823; MCDONALD JC, 1995, BMJ-BRIT MED J, P325; Meredith S, 1996, THORAX, V51, P435, DOI 10.1136/thx.51.4.435; Monso E, 2000, AM J RESP CRIT CARE, V161, P1508, DOI 10.1164/ajrccm.161.5.9906113; Moscato G, 1999, CHEST, V115, P249, DOI 10.1378/chest.115.1.249; MOSCATO G, 1995, J ALLERGY CLIN IMMUN, V96, P295; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; PEPYS J, 1999, ASTHMA WORKPLACE, P5; Perfetti L, 1998, CHEST, V114, P398, DOI 10.1378/chest.114.2.398; PERRIN B, 1991, J ALLERGY CLIN IMMUN, V87, P630, DOI 10.1016/0091-6749(91)90381-W; REED CE, 1999, ASTHMA WORKPLACE, P235; Rihs HP, 1997, AM J IND MED, V32, P522, DOI 10.1002/(SICI)1097-0274(199711)32:5<522::AID-AJIM13>3.0.CO;2-4; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169, DOI 10.1164/ajrccm/145.1.169; SHIRAKAWA T, 1990, THORAX, V45, P267, DOI 10.1136/thx.45.4.267; Tarlo S M, 1998, Can Respir J, V5, P289; Tarlo SM, 1997, AM J IND MED, V32, P517, DOI 10.1002/(SICI)1097-0274(199711)32:5<517::AID-AJIM12>3.0.CO;2-5; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; Tarlo SM, 2000, CHEST, V118, P1309, DOI 10.1378/chest.118.5.1309; Taylor AJN, 1999, AM J RESP CRIT CARE, V160, P435; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; VENABLES KM, 1994, EUR RESPIR J, V7, P768, DOI 10.1183/09031936.94.07040768; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219, DOI 10.1164/ajrccm.151.1.7812558	91	95	99	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					317	328		10.1067/mai.2001.116432	http://dx.doi.org/10.1067/mai.2001.116432			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544449				2022-12-18	WOS:000171215400001
J	Vliagoftis, H; Befus, AD; Hollenberg, MD; Moqbel, R				Vliagoftis, H; Befus, AD; Hollenberg, MD; Moqbel, R			Airway epithelial cells release eosinophil survival-promoting factors (GM-CSF) after stimulation of proteinase-activated receptor 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inflammation; lung; inflammatory mediators; cell surface molecules; protease-activated receptor 2; GM-CSF; eotaxin; corticosteroids	BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE; THROMBIN RECEPTOR; ENDOTHELIAL-CELLS; INDUCED SPUTUM; EXPRESSION; ASTHMA; INFLAMMATION; TRYPTASE; TRYPSIN	Background: Epithelium is considered an active participant in allergic inflammation. Proteinase-activated receptor (PAR) 2 is expressed in a variety of cell types, including epithelial cells, and has been implicated in inflammation. Objective: PAR-2-mediated activation of airway epithelial cells induces the release of mediators that could promote eosinophil survival and mediate eosinophil recruitment. Methods: PAR-2-activating peptides were used to activate the human airway epithelial cell line A549. as well as primary cultures of small airway epithelial cells (SAECs), Human peripheral blood eosinophils were cultured in the presence or absence of epithelial cell supernatants. Survival was assessed by using an Annexin V apoptosis detection kit. GM-CSF and eotaxin were measured by using ELISA. Results: Eosinophils undergo apoptosis in the absence of growth factors. Supernatants from PAR-2-activated A549 epithelial cells increased eosinophil survival. Supernatants from resting SAECs also increased eosinophil survival, but supernatants From PAR-2-activated SAECs showed a greater effect. The effect of PAR-2-activated epithelial cell supernatants on eosinophil survival was completely inhibited by a neutralizing anti-GM-CSF antibody but not an anti-IL-5 antibody. Resting A549 cells did not release any detectable GMCSF, whereas PAR-2-activated cells released 35 pg/10(6) cells. Resting SAECs released 754.3 pg/10(6) cells of GM-CSF, which was further increased to 1360.5 pg/106 cells after PAR-2-mediated activation. Budesonide inhibited this PAR-2 effect. PAR-2-activated epithelial cells also released eotaxin. Conclusion: PAR-2-mediated activation of airway epithelial cells induced release of GM-CSF, which promoted eosinophil survival and activation. It also induced release of eotaxin, which could mediate eosinophil recruitment to the airways.	Univ Alberta, Dept Med, Pulm Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada	University of Alberta; University of Calgary	Vliagoftis, H (corresponding author), Univ Alberta, Dept Med, Pulm Res Grp, HMRC 574, Edmonton, AB T6G 2S2, Canada.		Hollenberg, Morley/AFV-6966-2022; Befus, Dean/C-5561-2009; Vliagoftis, Harissis/C-6480-2013	Befus, Dean/0000-0002-1611-2897; Vliagoftis, Harissis/0000-0002-5029-855X				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; Bissonnette E Y, 1998, Can Respir J, V5, P23; Bohm SK, 1996, BIOCHEM J, V314, P1009; Cairns JA, 1996, J IMMUNOL, V156, P275; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Grunberg K, 1999, CLIN EXP ALLERGY, V29, P65; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P90, DOI 10.1046/j.1365-2222.1999.00016.x; Howells GL, 1997, J CELL SCI, V110, P881; Hwa JJ, 1996, CIRC RES, V78, P581, DOI 10.1161/01.RES.78.4.581; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; King C, 1998, J IMMUNOL, V161, P3645; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; Koyama S, 1999, EUR RESPIR J, V13, P820, DOI 10.1183/09031936.99.13482099; Krishna MT, 1998, EUR RESPIR J, V11, P1294, DOI 10.1183/09031936.98.11061294; KWON OJ, 1995, AM J RESP CELL MOL, V12, P488, DOI 10.1165/ajrcmb.12.5.7537968; Lacy P, 1998, BLOOD, V91, P2508, DOI 10.1182/blood.V91.7.2508.2508_2508_2516; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V97, P153, DOI 10.1016/S0091-6749(96)80215-6; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Meagher LC, 1996, J IMMUNOL, V156, P4422; Molinari JF, 1996, AM J RESP CRIT CARE, V154, P649, DOI 10.1164/ajrccm.154.3.8810600; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Pizzichini MMM, 1998, AM J RESP CRIT CARE, V158, P1178, DOI 10.1164/ajrccm.158.4.9712082; Reibman J, 2000, J IMMUNOL, V165, P1618, DOI 10.4049/jimmunol.165.3.1618; Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x; Schechter NM, 1998, J CELL PHYSIOL, V176, P365, DOI 10.1002/(SICI)1097-4652(199808)176:2<365::AID-JCP15>3.0.CO;2-2; Vitalis TZ, 1998, EUR RESPIR J, V11, P664; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Yao PM, 1998, AM J RESP CELL MOL, V18, P813, DOI 10.1165/ajrcmb.18.6.2984; Yao PM, 1996, J BIOL CHEM, V271, P15580, DOI 10.1074/jbc.271.26.15580; Yasuoka S, 1997, AM J RESP CELL MOL, V16, P300, DOI 10.1165/ajrcmb.16.3.9070615	47	95	100	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					679	685		10.1067/mai.2001.114245	http://dx.doi.org/10.1067/mai.2001.114245			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295658				2022-12-18	WOS:000168190100021
J	Vanden Burgt, JA; Busse, WW; Martin, RJ; Szefler, SJ; Donnell, D				Vanden Burgt, JA; Busse, WW; Martin, RJ; Szefler, SJ; Donnell, D			Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chlorofluorocarbon propellant; hydrofluoroalkane propellant; QVAR; inhaled corticosteroids; beclomethasone; fluticasone; budesonide; efficacy; safety	METERED-DOSE INHALER; 400 MU-G; SMALL AIRWAYS; LUNG DEPOSITION; HFA-BDP; DIPROPIONATE; CHLOROFLUOROCARBON; INFLAMMATION; FORMULATION; PHARMACOKINETICS	Chlorofluorocarbon (CFC)-containing inhalers are gradually being phased out and replaced with hydrofluoroalkane (HFA)-based alternatives, The reformulation provided the opportunity to improve the inhalation technology and physical characteristics of corticosteroid formulations. QVAR contains HFA-beclomethasone dipropionate (HFA-BDP) with the steroid in solution rather than suspension, which, in combination with improved inhaler technology, produces an extrafine aerosol with a mass median aerodynamic diameter of 1.1 mum (smaller than the 3.5-4.0 mum found with CFC-BDP). It mas predicted and demonstrated that the smaller particle size of QVAR would be deposited in the lung to a greater extent than that found with CFC-BDP, particularly in the small airway, a major site of inflammation. Increased lung deposition of QVAR permits a reduction in dosage relative to CFC-BDP, Clinical evidence confirms that adult and elderly patients required approximately. half the dose of QVAR to achieve the same degree of asthma control as with CFC-BDP. In longterm assessments, patients taking CFC-BDP could he snitched to QVAR at half the daily dose without exacerbation of their asthma symptoms, QVAR was associated with a low overall incidence of side effects and, at the maximum recommended dose of 640 mug/d, caused no more adrenal suppression than 672 mug/d CFC-BDP.	3M Pharmaceut, St Paul, MN USA; Univ Wisconsin, Sch Med, Allergy & Immunol Dept, Madison, WI USA; Natl Jewish Med & Res Ctr, Div Clin Pharmacol Immunopharmacol, Denver, CO USA; Natl Jewish Med & Res Ctr, Div Pulm, Denver, CO USA	3M; University of Wisconsin System; University of Wisconsin Madison; National Jewish Health; National Jewish Health	Vanden Burgt, JA (corresponding author), 3M Co, St Paul, MN 55144 USA.	javandenburgt@mmm.com						ALEXANDER DJ, 1995, J AEROSOL MED, V8, pS29; Ayres JG, 1999, RESP MED, V93, P27, DOI 10.1016/S0954-6111(99)90073-2; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; Carroll N, 1996, PATHOL RES PRACT, V192, P238, DOI 10.1016/S0344-0338(96)80227-5; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Cohen R, 1999, AM J RESP CRIT CARE, V159, pA631; CONWAY JH, 1999, EUR RESPIR J, V14, pS196; CRIPPS AL, 1997, J AEROSOL MED, V10, pPD6; Davies RJ, 1998, RESP MED, V92, P23, DOI 10.1016/S0954-6111(98)90214-1; Dekhuijzen PNR, 2000, RESP MED, V94, P627, DOI 10.1053/rmed.2000.0791; Demedts M, 1999, INT J CLIN PRACT, V53, P331; Demedts M, 2000, CURR THER RES CLIN E, V61, P120, DOI 10.1016/S0011-393X(00)80009-0; *DIV PULM ALL DRUG, 1994, POINTS CONS CLIN DEV; DOLOVICH MB, 2000, AM J RESP CRIT CARE, V161, pA33; DONNELL D, 1995, EUR J CLIN PHARMACOL, V48, P473; Evans DJ, 1998, THORAX, V53, P629, DOI 10.1136/thx.53.8.629; FOSTER L, 1998, AM J RESP CRIT CARE, V157, pA638; Gabrio BJ, 1999, INT J PHARMACEUT, V186, P3, DOI 10.1016/S0378-5173(99)00133-7; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Gross G, 1999, CHEST, V115, P343, DOI 10.1378/chest.115.2.343; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; Hampel F, 2000, J ASTHMA, V37, P389, DOI 10.3109/02770900009055464; Harrison LI, 1999, J PHARM PHARMACOL, V51, P263, DOI 10.1211/0022357991772439; Harrison LI, 1996, J PHARM PHARMACOL, V48, P596, DOI 10.1111/j.2042-7158.1996.tb05980.x; Harrison LI, 1999, J PHARM PHARMACOL, V51, P1235, DOI 10.1211/0022357991776967; HAYMAN G, 1995, BRIT J CLIN PRACT, P2; Heald DL, 1998, J ALLERGY CLIN IMMUN, V101, pS9; JUNE DS, 1994, PHARM TECHNOL, V18, P40; JUNIPER EF, 1999, EUR RESPIR J, V14, pS523; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; LEACH C, 1997, EUR RESPIR REV, V7, P35; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Leach CL, 1998, RESP MED, V92, P3, DOI 10.1016/S0954-6111(98)90211-6; Leach CL, 1999, AM J RESP CRIT CARE, V159, pA116; LEACH CL, 2000, AM J RESP CRIT CARE, V161, pA34; LIPWORTH BJ, 1993, PHARMACOL THERAPEUT, V58, P173, DOI 10.1016/0163-7258(93)90049-J; Lipworth BJ, 2000, RESP MED, V94, pS21, DOI 10.1016/S0954-6111(00)80137-7; Marshall BG, 2000, EUR RESPIR J, V15, P764, DOI 10.1034/j.1399-3003.2000.15d22.x; Martin RJ, 1998, AM J RESP CRIT CARE, V157, pS188, DOI 10.1164/ajrccm.157.5.rsaa-4; Matthys H, 1998, RESP MED, V92, P17, DOI 10.1016/S0954-6111(98)90213-X; Mitchell JP, 1999, J AEROSOL MED, V12, P255, DOI 10.1089/jam.1999.12.255; *MONTR PROT, 1994, FED REGISTER, V59, P56276; *NAT HEART LUNG BL, 1997, NIH PUBL; *NAT HEART LUNG BL, 1995, NIH PUBL; Newman SP, 1998, CHEST, V113, P957, DOI 10.1378/chest.113.4.957; Pedersen S, 1996, RESP MED, V90, P69, DOI 10.1016/S0954-6111(96)90201-2; Rahman S, 2000, AM J RESP CRIT CARE, V161, pA177; Ramsdell JW, 1999, CHEST, V115, P945, DOI 10.1378/chest.115.4.945; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; Shaw RJ, 1999, RESP MED, V93, P149, DOI 10.1016/S0954-6111(99)90000-8; SHIM C, 1987, CHEST, V91, P207, DOI 10.1378/chest.91.2.207; Soria I., 1997, European Respiratory Journal Supplement, V10, p237S; Struijs A, 1997, NETH J MED, V50, P233, DOI 10.1016/S0300-2977(96)00081-2; Thompson PJ, 1998, RESP MED, V92, P33, DOI 10.1016/S0954-6111(98)90215-3; Thorsson L, 1998, EUR RESPIR J, V12, P1340, DOI 10.1183/09031936.98.12061340; Vignola AM, 1998, AM J RESP CRIT CARE, V157, pS184, DOI 10.1164/ajrccm.157.5.rsaa-3	58	95	96	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1210	1226		10.1067/mai.2000.111582	http://dx.doi.org/10.1067/mai.2000.111582			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER					2022-12-18	WOS:000165930300033
J	Williams, PB; Barnes, JH; Szeinbach, SL; Sullivan, TJ				Williams, PB; Barnes, JH; Szeinbach, SL; Sullivan, TJ			Analytic precision and accuracy of commercial immunoassays for specific IgE: Establishing a standard	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						specific IgE; laboratory tests; allergy; standardization; precision; accuracy; quantitation; diagnosis	PERFORMANCE-CHARACTERISTICS; INVITRO ASSAYS	Background: Different laboratory assays are used to detect and measure specific IgE antibodies. No standard exists to assess their analytic performance. Objective: We sought to analyze reported specific IgE results from different laboratories on the same serum samples for their accuracy and precision. Methods: Blinded serum samples (26) containing variable levels of specific IgE to 17 common aeroallergens were sent on 3 different occasions through normal channels to 6 laboratories that used 5 different test procedures. Six samples were presented as a dilution series. Laboratory-assay performance was assessed by analyzing the reported results (n = 12,708) by using ordinary least squares regression with slope coefficients, the t statistic, SEs, confidence intervals, and R-2 values, These were compared with a theoretic ideal assay as the reference. Results: Analysis revealed that one system used in two different laboratories performed nearly as well as the ideal standard, with an overall average slope (0.97; range, 0.91-1.01), SE (0.05; range, 0.02-0.16), R-2 value (93%; range, 0.64-0.99), and coefficient of variation (10.3%; range, 6%-14%). Extensive variability was observed in the other 4 laboratory-assay systems with respect to overall average slope (0.76; range, 0.11-1.24), SE (0.19; range, 0.03-0.95), R-2 value (53%; range, 0.00-0.98), and coefficient of variation (19%; range, 5%-49%). For some specific allergens, some laboratories-assays were not able to detect serial dilutions of the same sample. Conclusions: One commercial system used in two different laboratories performed nearly as well as the ideal standard. Four of the laboratories-assays for specific IgE antibodies demonstrated substandard overall performance with multiple instances of poor precision and accuracy, particularly for certain allergens, such as weeds and molds.	Univ Missouri, Sch Med, Kansas City, MO 64108 USA; IBT Reference Lab, Lenexa, KS USA; Univ Mississippi, Sch Business Adm, University, MS 38677 USA; Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA; Emory Univ, Sch Med, Dept Med, Div Allergy & Immunol, Atlanta, GA USA	University of Missouri System; University of Missouri Kansas City; University of Mississippi; University System of Ohio; Ohio State University; Emory University	Williams, PB (corresponding author), 11840 Woodland Rd, Olathe, KS 66061 USA.							*COLL AM PATH, 1994, INT COMP PROGR SE DI; COSTONGS GMPJ, 1995, EUR J CLIN CHEM CLIN, V33, P295; DOLEN WK, 1995, ANN ALLERG ASTHMA IM, V75, P81; *FOOD DRUG ADM, 1999, HHS PUBL; JOHANSSON SGO, 1988, CLIN REV ALLERG, V6, P93; JOHNSON S, 1972, ECONOMETRIC METHODS, P8; KELSO JM, 1991, ANN ALLERGY, V67, P511; KIRK RE, 1999, EXPT DESIGN PROCEDUR, P113; *NAT COMM CLIN LAB, 1996, 1LA20P NCCLS; PETERMAN JH, 1991, IMMUNOCHEMISTRY SOLI, P47; Selner JC, 1999, ANN ALLERG ASTHMA IM, V82, P407, DOI 10.1016/S1081-1206(10)62714-7; WIDE L, 1967, LANCET, V2, P1105; WILLIAMS PB, 1992, ANN ALLERGY, V69, P48; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35	14	95	104	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1221	1230		10.1067/mai.2000.105219	http://dx.doi.org/10.1067/mai.2000.105219			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856158				2022-12-18	WOS:000087781800025
J	Zuraw, BL; Herschbach, J				Zuraw, BL; Herschbach, J			Detection of C1 inhibitor mutations in patients with hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; C1 inhibitor; serpin; single-stranded conformational polymorphism; mutation; complement system	HUMAN C1BAR INHIBITOR; ANGIONEUROTIC-EDEMA; GENE; ALPHA-1-ANTITRYPSIN; DEFICIENCY; DELETION; REPEAT; SITE; GEL	Background: Hereditary angioedema (HAE) results from a deficiency in the functional level of C1 inhibitor caused by mutations in the C1 inhibitor gene, The mutations responsible for HAE have been shown to be heterogeneous. Objective: Because the identification of C1 inhibitor mutations may depend, in part, on the technique used to screen for mutations, we screened the entire C1 inhibitor coding region to identify mutations in a cohort of patients with HAE. Methods: By using single-stranded conformational polymorphism analysis, 24 subjects with HAE from 16 different kindreds were screened fur C1 inhibitor polymorphisms. C1 inhibitor mutations were identified by sequencing the exons containing identified polymorphisms. Results: Ail 24 subjects with NAE had identifiable polymorphisms, involving exons 2, 3, 4, 5, or 8, Fourteen different C1 inhibitor mutations were identified: 8 missense, 1 nonsense, 4 frameshift, and 1 small deletion mutations. No large deletions or duplications were found. Nine of the 14 mutations represent newly recognized C1 inhibitor mutations, 6 of which involve exon 4. Conclusions: Single-stranded conformational polymorphism is an effective approach for identifying new mutations in HAE, Elucidation of the range of C1 inhibitor mutations causing HAE is important for both defining which residues are required Fur C1 inhibitor secretion or function and providing the basis For future studies to define the relationship between the Ct inhibitor genotype and disease severity.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zuraw, BL (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Zuraw, Bruce/0000-0003-0640-6768	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036220] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI36220] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIGA T, 1990, GENOMICS, V8, P607, DOI 10.1016/0888-7543(90)90246-Q; ARIGA T, 1989, J CLIN INVEST, V83, P1888, DOI 10.1172/JCI114095; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; BERTENSHAW R, 1991, AM J HUM GENET, V48, P741; BISSLER JJ, 1994, P NATL ACAD SCI USA, V91, P9622, DOI 10.1073/pnas.91.20.9622; Bissler JJ, 1997, P ASSOC AM PHYSICIAN, V109, P164; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; CARTER PE, 1991, EUR J BIOCHEM, V197, P301, DOI 10.1111/j.1432-1033.1991.tb15911.x; CICARDI M, 1987, J CLIN INVEST, V80, P1640, DOI 10.1172/JCI113252; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CURIEL DT, 1990, MOL CELL BIOL, V10, P47, DOI 10.1128/MCB.10.1.47; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DAVIS AE, 1993, COMPLEMENT TODAY, V1, P133; DONALDSON VH, 1985, J CLIN INVEST, V75, P124, DOI 10.1172/JCI111664; DONALDSON VH, 1992, J LAB CLIN MED, V119, P330; FRANGI D, 1992, FEBS LETT, V301, P34, DOI 10.1016/0014-5793(92)80204-T; FRANGI D, 1991, J CLIN INVEST, V88, P755, DOI 10.1172/JCI115373; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PARAD RB, 1990, P NATL ACAD SCI USA, V87, P6786, DOI 10.1073/pnas.87.17.6786; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SKRIVER K, 1989, J BIOL CHEM, V264, P3066; SMITH TJ, 1995, J MOL GRAPHICS, V13, P122, DOI 10.1016/0263-7855(94)00019-O; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STOPPALYONNET D, 1991, AM J HUM GENET, V49, P1055; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; Tosi M, 1998, IMMUNOBIOLOGY, V199, P358, DOI 10.1016/S0171-2985(98)80040-5; Verpy E, 1996, AM J HUM GENET, V59, P308; VERPY E, 1995, J CLIN INVEST, V95, P350, DOI 10.1172/JCI117663	30	95	97	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					541	546		10.1067/mai.2000.104780	http://dx.doi.org/10.1067/mai.2000.104780			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719305	Bronze			2022-12-18	WOS:000088946700021
J	Teuber, SS; Jarvis, KC; Dandekar, AM; Peterson, WR; Ansari, AA				Teuber, SS; Jarvis, KC; Dandekar, AM; Peterson, WR; Ansari, AA			Identification and cloning of a complementary DNA encoding a vicilin-like proprotein, Jug r 2, from English walnut kernel (Juglans regia) a major food allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; cDNA cloning; recombinant walnut allergen; walnut allergy; vicilin; 7S globulin	VIGNA-UNGUICULATA SEEDS; STORAGE PROTEINS; BETA-CONGLYCININ; CDNA; GENES; PURIFICATION; EXPRESSION; SEQUENCE; BINDING; MEMBERS	Background: Walnuts and other tree nuts are important food-allergen sources that have the potential to be associated sith Life-threatening, IgE-mediated systemic reactions in some individuals. Objective: The purpose of this study was to characterize a complementary (c)DNA clone encoding one of the walnut food allergens. Methods: A cDNA expression library prepared from walnut somatic embryo was screened for IgE reactivity with patient serum. A reactive clone of 2060 bp, which encoded a protein of 593 amino acids in length, was subcloned by excision into the pGEX expression vector. IgE-binding inhibition experiments were performed. Results: A recombinant fusion protein was induced and shown to bind serum IgE from 9 of 15 patients tested, thus identifying a major allergen. This clone, named Jug r 2, exhibited significant homology with genes encoding the vicilin group of seed proteins. An IgE-binding inhibition experiment suggested that the encoded protein undergoes posttranslational modification into at least one major polypeptide (47 kd) and possibly several others, which is similar to the vicilin-like proteins characterized in cocoa bean (Theobroma cacao) and cottonseed (Gossypium hirsutum). N-terminal sequencing of the 47-kd band, Jug r 2, identified it as a mature protein obtained from the precursor. A second IgE-binding inhibition experiment showed that there is minimal or no cross-reactivity between Jug r 2 and pea vicilin, peanut proteins, or cacao proteins. Conclusion: Jug r 2 is the third vicilin food allergen identified in addition to vicilins from soy and peanut. The availability of recombinant food allergens should help advance studies on the immunopathogenesis and possible treatment of IgE-mediated food hypersensitivity.	Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Dept Internal Med, Davis, CA 95616 USA; Vet Affairs No Calif Hlth Care Syst, Pleasant Hill, CA USA; Univ Calif Davis, Dept Pomol, Davis, CA 95616 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	University of California System; University of California Davis; University of California System; University of California Davis; Emory University	Teuber, SS (corresponding author), Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Dept Internal Med, 1 Shields Ave,TB 192, Davis, CA 95616 USA.			Dandekar, Abhaya/0000-0001-7925-4086	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035747] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35747] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Becker WM, 1997, INT ARCH ALLERGY IMM, V113, P118, DOI 10.1159/000237522; BORROTO K, 1987, PLANT MOL BIOL, V8, P113, DOI 10.1007/BF00025323; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; CHLAN CA, 1986, PLANT MOL BIOL, V7, P475, DOI 10.1007/BF00020331; DOYLE JJ, 1986, J BIOL CHEM, V261, P9228; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gomes VM, 1997, J AGR FOOD CHEM, V45, P4110, DOI 10.1021/jf960942g; HARADA JJ, 1989, PLANT CELL, V1, P415, DOI 10.1105/tpc.1.4.415; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LYCETT GW, 1983, NUCLEIC ACIDS RES, V11, P2367, DOI 10.1093/nar/11.8.2367; MACEDO MLR, 1995, BRAZ J MED BIOL RES, V28, P183; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; OGAWA T, 1995, BIOSCI BIOTECH BIOCH, V59, P831, DOI 10.1271/bbb.59.831; Osborne T. B., 1924, VEGETABLE PROTEINS; Sales MP, 1996, BRAZ J MED BIOL RES, V29, P319; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SCHREIBER RA, 1989, MAYO CLIN PROC, V64, P1381, DOI 10.1016/S0025-6196(12)65380-4; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SPENCER ME, 1992, PLANTA, V186, P567, DOI 10.1007/BF00198037; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; Teuber SS, 1998, J ALLERGY CLIN IMMUN, V101, P807, DOI 10.1016/S0091-6749(98)70308-2; WATSON MD, 1988, BIOCHEM J, V251, P857, DOI 10.1042/bj2510857; YOULE RJ, 1979, J AGR FOOD CHEM, V27, P500, DOI 10.1021/jf60223a017; ZAK DL, 1976, J AGR FOOD CHEM, V24, P483, DOI 10.1021/jf60205a056; 1996, WALNUT MARKETING BOA	27	95	106	0	22	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1311	1320		10.1016/S0091-6749(99)70029-1	http://dx.doi.org/10.1016/S0091-6749(99)70029-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589017	Bronze			2022-12-18	WOS:000084289200029
J	Beasley, R; Pearce, N; Crane, J; Burgess, C				Beasley, R; Pearce, N; Crane, J; Burgess, C			beta-agonists: What is the evidence that their use increases the risk of asthma morbidity and mortality?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; epidemiology; mortality; morbidity; beta-agonist	NEAR-FATAL ASTHMA; REGULAR INHALED SALBUTAMOL; LONG-TERM TREATMENT; BRONCHIAL RESPONSIVENESS; MILD ASTHMA; NEW-ZEALAND; AIRWAY RESPONSIVENESS; BRONCHODILATOR SUBSENSITIVITY; PRESCRIBED FENOTEROL; INDUCED BRONCHOCONSTRICTION	In this article, studies that have examined the effects on morbidity and mortality of beta-agonist drugs are reviewed. With regard to morbidity, there is considerable evidence that the regular use of beta-agonist drugs as a class could potentially lead to worsening asthma control because of the effects on bronchial hyperresponsiveness, the development of tolerance and reduced protection against provoking stimuli, an increased allergen load, and masking of the symptoms of deteriorating asthma. Despite these effects, the short-acting beta-agonist drugs albuterol and terbutaline and the long-acting beta-agonist drugs salmeterol and formoterol have, in general, not been associated with a significant worsening of asthma control or an increased frequency of severe attacks. In contrast, there is evidence that the regular use of isoproterenol and fenoterol may lead to worsening asthma control. With regard to deaths, available evidence indicates that the high-dose preparations of isoproterenol and fenoterol are associated with increased mortality and were the major causes of the epidemics of asthma mortality observed in some countries. The increased risk of death associated with isoproterenol and fenoterol is probably the result of both long-term effects with their regular use leading to worsening asthma control and acute effects resulting from their overuse in the situation of a life-threatening attack of asthma. In contrast, the use of the short-acting beta-agonists albuterol and terbutaline is not associated with an increased risk of mortality. Although this lark of risk may also apply to formoterol and salmeterol, in the absence of sufficient studies specifically addressing the risk of death, this remains uncertain.	Wellington Sch Med, Dept Med, Wellington, New Zealand	University of Otago	Beasley, R (corresponding author), Wellington Sch Med, Dept Med, POB 7343, Wellington, New Zealand.			Pearce, Neil/0000-0002-9938-7852; Beasley, Richard/0000-0003-0337-406X				BEACH JR, 1993, PULM PHARMACOL, V6, P155, DOI 10.1006/pulp.1993.1020; BEAGLEHOLE R, 1987, NEW ZEAL MED J, V100, P231; BEASLEY R, 1991, AUST NZ J MED, V21, P753, DOI 10.1111/j.1445-5994.1991.tb01385.x; BEASLEY R, 1994, CLIN EXP ALLERGY, V24, P660, DOI 10.1111/j.1365-2222.1994.tb00970.x; BEASLEY R, 1993, THORAX, V48, P1093, DOI 10.1136/thx.48.11.1093; BEASLEY R, 1991, NEW ENGL J MED, V325, P205; BENSON RL, 1948, J ALLERGY, V19, P129, DOI 10.1016/0021-8707(48)90101-4; BOOTH H, 1993, THORAX, V48, P1121, DOI 10.1136/thx.48.11.1121; Bremner P, 1996, CHEST, V109, P957, DOI 10.1378/chest.109.4.957; BREMNER P, 1994, CLIN PHARMACOL THER, V56, P302, DOI 10.1038/clpt.1994.141; BREMNER P, 1992, THORAX, V47, P814, DOI 10.1136/thx.47.10.814; BRITTAIN RT, 1976, PHARMACOL THER PT B, V2, P423, DOI 10.1016/0306-039X(76)90001-5; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Cockcroft DW, 1997, THORAX, V52, P845, DOI 10.1136/thx.52.10.845; COCKCROFT DW, 1993, BRONCHIAL ASTHMA MEC, P32; COLLINS JM, 1969, BRIT J PHARMACOL, V36, P35, DOI 10.1111/j.1476-5381.1969.tb08301.x; CRANE J, 1989, THORAX, V44, P136, DOI 10.1136/thx.44.2.136; CRANE J, 1989, LANCET, V1, P917; Cried CP, 1993, EUR RESPIR J, V6, p426S; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; ERNST P, 1993, AM REV RESPIR DIS, V148, P75, DOI 10.1164/ajrccm/148.1.75; FINKELSTEIN FN, 1994, NEW ENGL J MED, V331, P1314; Fox N, 1931, ARCHIV OTOLARYNGOL, V13, P73; FRASER P M, 1971, British Journal of Diseases of the Chest, V65, P71, DOI 10.1016/0007-0971(71)90008-8; Galgiani JV, 1939, J AMER MED ASSOC, V112, P1929, DOI 10.1001/jama.1939.02800190043011; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; GREENBERG MJ, 1967, BMJ-BRIT MED J, V1, P563, DOI 10.1136/bmj.1.5539.563; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HENSLEY MJ, 1992, MED J AUSTRALIA, V157, P568; HIGGINS RM, 1987, LANCET, V2, P863; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; HORWITZ RI, 1991, CHEST, V100, P1586, DOI 10.1378/chest.100.6.1586; HUNNICUTT LF, 1941, T PACIFIC COAST OTOL, V26, P53; INMAN WHW, 1969, LANCET, V2, P279; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; Johansson F, 1996, CLIN REV ALLERG IMMU, V14, P57, DOI 10.1007/BF02772203; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; KIELY DG, 1995, THORAX, V50, P1062, DOI 10.1136/thx.50.10.1062; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAI CKW, 1989, AM REV RESPIR DIS, V140, P917, DOI 10.1164/ajrccm/140.4.917; LIN RY, 1993, CHEST, V103, P221, DOI 10.1378/chest.103.1.221; LIPWORTH BJ, 1989, AM REV RESPIR DIS, V140, P586, DOI 10.1164/ajrccm/140.3.586; LOWELL FC, 1949, NEW ENGL J MED, V240, P45, DOI 10.1056/NEJM194901132400201; MACONOCHIE JG, 1994, BRIT J CLIN PHARMACO, V37, P199, DOI 10.1111/j.1365-2125.1994.tb04261.x; Mann RD, 1996, J CLIN EPIDEMIOL, V49, P247, DOI 10.1016/0895-4356(95)00555-2; MATSUI T, 1996, 32 ANN M JAP SOC PAE, P161; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; MCDEVITT DG, 1974, BRIT J PHARMACOL, V50, P335, DOI 10.1111/j.1476-5381.1974.tb09608.x; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; MITCHELL EA, 1989, THORAX, V44, P81, DOI 10.1136/thx.44.2.81; MITSUI S, 1986, SINO JPN J ALLERGOL, V3, P249; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; MUGGE A, 1985, KLIN WOCHENSCHR, V63, P26, DOI 10.1007/BF01537483; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; Newhouse MT, 1996, CHEST, V110, P595, DOI 10.1378/chest.110.3.595; NEWNHAM DM, 1995, THORAX, V50, P497, DOI 10.1136/thx.50.5.497; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PALMER JBD, 1994, NEW ENGL J MED, V331, P1314; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PEARCE N, 1992, NEW ENGL J MED, V327, P355; Pearce N, 1998, EPIDEMIOL REV, V20, P173, DOI 10.1093/oxfordjournals.epirev.a017979; PEARCE N, 1994, JAMA-J AM MED ASSOC, V271, P822, DOI 10.1001/jama.271.11.822; PEARCE N, 1998, ASTHMA EPIDEMIOLOGY; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; PerrinFayolle M, 1996, CLIN REV ALLERG IMMU, V14, P139, DOI 10.1007/BF02772208; RAES M, 1989, J ALLERGY CLIN IMMUN, V84, P874, DOI 10.1016/0091-6749(89)90382-5; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; SACKETT DL, 1990, LANCET, V335, P46; SEARS MR, 1994, DRUG SAFETY, V11, P259, DOI 10.2165/00002018-199411040-00005; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHOVLIN CL, 1990, LANCET, V336, P1258, DOI 10.1016/0140-6736(90)92878-L; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SOMERS VK, 1989, J APPL PHYSIOL, V67, P2101, DOI 10.1152/jappl.1989.67.5.2101; SPEIZER FE, 1968, BRIT MED J, V1, P3359; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; STOLLEY PD, 1978, PREV MED, V7, P319; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; Tan KS, 1997, AM J RESP CRIT CARE, V156, P28, DOI 10.1164/ajrccm.156.1.9610113; Taylor DA, 1997, AM J RESP CRIT CARE, V156, P1731, DOI 10.1164/ajrccm.156.6.9703047; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; Templeton AGB, 1998, PULM PHARMACOL THER, V11, P1, DOI 10.1006/pupt.1998.0110; TOWN GI, 1991, NEW ZEAL MED J, V104, P3; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VANMETRE TE, 1969, J ALLERGY, V43, P101, DOI 10.1016/0021-8707(69)90130-0; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; WAALKENS HJ, 1991, THORAX, V46, P499, DOI 10.1136/thx.46.7.499; WAGNER J, 1973, RES EXP MED, V162, P49; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; WALLE UK, 1993, BRIT J CLIN PHARMACO, V35, P413, DOI 10.1111/j.1365-2125.1993.tb04159.x; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; Williams C, 1998, THORAX, V53, P7, DOI 10.1136/thx.53.1.7; WINDOM HH, 1990, NEW ZEAL MED J, V103, P205; WINSOR T, 1975, MICROVASC RES, V9, P261, DOI 10.1016/0026-2862(75)90063-1; WONG CS, 1994, AM J RESP CRIT CARE, V150, P1268, DOI 10.1164/ajrccm.150.5.7952551; Yates DH, 1996, AM J RESP CRIT CARE, V154, P1603, DOI 10.1164/ajrccm.154.6.8970342; YATES DH, 1995, AM J RESP CRIT CARE, V152, P1170, DOI 10.1164/ajrccm.152.4.7551366	112	95	97	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	2	S			S18	S30		10.1016/S0091-6749(99)70270-8	http://dx.doi.org/10.1016/S0091-6749(99)70270-8			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	233GX	10452785				2022-12-18	WOS:000082419400003
J	Johnson, M				Johnson, M			Development of fluticasone propionate and comparison with other inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fluticasone propionate; inhaled corticosteroids; structure-activity relationships; asthma	GLUCOCORTICOIDS; STEROIDS; RECEPTOR	Fluticasone propionate (FP) is a trifluorinated glucocorticoid based on the androstane nucleus. It was selected for development from structure-activity relationships (topical anti-inflammatory, cutaneous vasoconstriction, and hypothalamic-pituitary-adrenal axis suppression) of a series of 17 beta-carbothioates. FP is 3-, 300-, and 1000-fold more lipophilic than beclomethasone dipropionate, budesonide, and triamcinolone acetonide, respectively. FP has an absolute affinity (K-D) for the glucocorticoid receptor of 0.5 nmol/L; and a relative receptor affinity 1.5-fold higher than beclomethasone-17-monopropionate (17-BMP) and mometasone furoate, 3-fold higher than budesonide, and 20-fold higher than flunisolide and triamcinolone acetonide, The rate of association of FP with the receptor is faster and the rate of dissociation slower than other corticosteroids. The resulting half-life of the FP active steroid-receptor complex is >10 hours, compared with approximately 5, 7.5, and 4 hours for budesonide, 17-BMP, and triamcinolone acetonide, respectively. FP has high selectivity for the glucocorticoid receptor, with little or no activity at other steroid receptors, FP is more potent than beclomethasone dipropionate, budesonide, triamcinolone acetonide, and mometasone furoate in inhibiting human T-cell migration and proliferation, inhibiting CD4+ T-cell cytokine and basophil histamine release, attenuating adhesion molecule expression, stimulating inflammatory cell apoptosis, and inducing cellular antiprotease release. In asthma patients. FP decreases the number of CD3+, CD4+, CD8+, and CD25+ T cells, mast cells, and eosinophils in bronchial biopsies, in addition to suppressing CD1a-dendritic and IgE+ cells and HL-DR FP, therefore, has a good pharmacologic profile for a topical steroid,vith increased intrinsic glucocorticoid potency and potent anti-inflammatory activity.	Glaxo Wellcome Res & Dev Ltd, Int Med Affairs, Uxbridge UB11 1BT, Middx, England	GlaxoSmithKline	Johnson, M (corresponding author), Glaxo Wellcome Res & Dev Ltd, Int Med Affairs, Stockley Pk W, Uxbridge UB11 1BT, Middx, England.							ABBINANTENISSEN JM, 1994, AM J RESP CRIT CARE, V149, pA869; ADCOCK IM, 1996, INT RESP FORUM, P25; ADLER KB, 1996, INT RESP FORUM, P18; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; Bickel CA, 1997, J ALLERGY CLIN IMMUN, V99, P1632; BOOTH H, 1993, EUR RESP J S17, V6, pS584; CRUIKSHANK W, 1996, INT RESP FORUM, P19; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; DERENDORF H, 1993, J CLIN PHARMACOL, V33, P115, DOI 10.1002/j.1552-4604.1993.tb03930.x; ENGLISH AF, 1994, AM J RESP CRIT CAR S, V149, pA212; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; HOGGER P, 1995, EUR RESPIR J, V8, pS303; HOGGER P, 1994, EUR RESP J S18, V7, pS382; Hogger P, 1993, EUR RESP J S17, V6, p584S; JOHNSON M, 1995, INT ARCH ALLERGY IMM, V107, P439, DOI 10.1159/000237073; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; KITA H, 1996, INT RESP FORUM, P17; MCKENZIE AW, 1962, ARCH DERMATOL, V86, P611, DOI 10.1001/archderm.1962.01590110047006; MOLLER GM, 1996, INT RESP FORUM, P16; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; PHILLIPPS GH, 1994, J MED CHEM, V37, P3717, DOI 10.1021/jm00048a008; PHILLIPS GH, 1976, MECHANISMS TOPICAL C, P1; TONELLI G, 1965, ENDOCRINOLOGY, V77, P625, DOI 10.1210/endo-77-4-625; Umland SP, 1996, J ALLERGY CLIN IMMUN, V97, P423; VANDENBOSCH JMM, 1993, BIOPHARM DRUG DISPOS, V14, P455, DOI 10.1002/bdd.2510140511; WARNER JA, IN PRESS AM J RESP C; WEEKS CM, 1973, J AM CHEM SOC, V95, P2865, DOI 10.1021/ja00790a021; ZENKER N, 1958, J BIOL CHEM, V231, P695	29	95	104	0	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	2	S			S434	S439		10.1016/S0091-6749(98)70155-1	http://dx.doi.org/10.1016/S0091-6749(98)70155-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZK101	9563368				2022-12-18	WOS:000073285000002
J	Irani, AMA; Huang, C; Xia, HZ; Kepley, C; Nafie, A; Fouda, ED; Craig, S; Zweiman, B; Schwartz, LB				Irani, AMA; Huang, C; Xia, HZ; Kepley, C; Nafie, A; Fouda, ED; Craig, S; Zweiman, B; Schwartz, LB			Immunohistochemical detection of human basophils in late-phase skin reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; mast cell; tryptase; Factor VII; endothelial cell	HISTAMINE-RELEASING-FACTOR; FC-EPSILON-RI; HUMAN MAST-CELLS; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; EOSINOPHIL GRANULE PROTEINS; EPIDERMAL LANGERHANS CELLS; MAJOR BASIC-PROTEIN; ACTIVATING FACTOR; MEDIATOR RELEASE; GROWTH-FACTORS	Background: Human basophils are difficult to detect with classic histochemical stains at sites of allergic inflammation. The 2D7 anti-basophil monoclonal antibody was used to identify basophils in skin during the late-phase response to a cutaneous allergen challenge. Methods: The 2D7 monoclonal antibody was used on protease-digested sections of skin biopsy specimens obtained 6 and 24 hours after an allergen or buffer challenge. The skin chamber technique was used to compare buffer- and allergen-challenged sites at 6 hours, and intradermal injection of allergen was used to compare allergen-challenged sites at 6 and 24 hours. Results: Dramatic increases in the numbers of 2D7(+) cells and in tissue staining by 2D7 were observed Ci hours after allergen challenge compared with buffer challenge. Histamine levels in skin chamber fluid varied with 2D7(+) cell concentrations. By 24 hours, 2D7(+) cells and tissue staining appeared to diminish but were still detectable in the allergen-challenged sites. Basophils localized primarily in and around blood vessels, whereas mast cells remained mostly in the superficial dermis. Mast cells were 2D7(-) in both the allergen and buffer-challenged skin. Metachromatic staining of 2D7(+) basophils with toluidine blue was absent in these tissue sections. Conclusions: The 2D7 monoclonal antibody provides a mole sensitive and precise marker than histochemical staining for human basophil involvement during the late-phase response to an allergen challenge. Basophil infiltration was observed al: 6 tours only after allergen challenge and persisted at similar levels by 24 hours.	Virginia Commonwealth Univ, Dept Pediat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA; Virginia Commonwealth Univ, Dept Anat, Richmond, VA USA; Al Azhar Univ, Dept Internal Med, Cairo, Egypt; Univ Penn, Dept Internal Med, Philadelphia, PA 19104 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Egyptian Knowledge Bank (EKB); Al Azhar University; University of Pennsylvania	Irani, AMA (corresponding author), Virginia Commonwealth Univ, Dept Pediat, POB 980-225, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI020487, U01AI034631, R01AI014332, R01AI020487, R37AI020487] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34631, AI-20487, AI-14332] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; ACKERMAN SJ, 1983, J EXP MED, V158, P946, DOI 10.1084/jem.158.3.946; Agis H, 1996, LEUKEMIA LYMPHOMA, V22, P187, DOI 10.3109/10428199609051750; ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; ALAM R, 1992, AM J RESP CELL MOL, V7, P427, DOI 10.1165/ajrcmb/7.4.427; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; BISCHOFF SC, 1992, BLOOD, V79, P2662; BODGER MP, 1987, BLOOD, V69, P1414; BURGI B, 1994, EUR J IMMUNOL, V24, P1583, DOI 10.1002/eji.1830240720; BUTTERFIELD JH, 1990, LAB INVEST, V62, P77; CASOLARO V, 1990, AM REV RESPIR DIS, V142, P1108, DOI 10.1164/ajrccm/142.5.1108; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHOI KL, 1987, IMMUNOL RES, V6, P145, DOI 10.1007/BF02918088; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DJUKANOVIC R, 1992, J ALLERGY CLIN IMMUN, V90, P175, DOI 10.1016/0091-6749(92)90069-E; Dvorak AM, 1996, CLIN EXP ALLERGY, V26, P281; ELLATI SG, 1994, J INVEST DERMATOL, V102, P803, DOI 10.1111/1523-1747.ep12378589; FUREDER W, 1995, ANN HEMATOL, V70, P251; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; HIRAI K, 1988, J IMMUNOL, V141, P3958; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; HIRAI K, 1993, J IMMUNOL, V150, P1503; IRANI AA, 1995, MAST CELL PROTEASES, P127; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; JAMES JM, 1993, J ALLERGY CLIN IMMUN, V91, P1155, DOI 10.1016/0091-6749(93)90318-A; KEPLEY C, 1994, J IMMUNOL METHODS, V175, P1, DOI 10.1016/0022-1759(94)90326-3; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; Koshino T, 1996, J ASTHMA, V33, P89, DOI 10.3109/02770909609054536; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; KUNA P, 1993, J IMMUNOL, V150, P1932; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MARUYAMA N, 1994, AM J RESP CRIT CARE, V150, P1086, DOI 10.1164/ajrccm.150.4.7921441; MASSEY WA, 1989, J IMMUNOL, V143, P1875; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MAYER P, 1989, BLOOD, V74, P613; NILSSON G, 1993, IMMUNOLOGY, V79, P325; Petersen LJ, 1996, J ALLERGY CLIN IMMUN, V98, P790, DOI 10.1016/S0091-6749(96)70128-8; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SCHULMAN ES, 1988, J CLIN INVEST, V81, P918, DOI 10.1172/JCI113403; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SHALIT M, 1988, J IMMUNOL, V141, P821; SHALIT M, 1990, J ALLERGY CLIN IMMUN, V86, P117, DOI 10.1016/S0091-6749(05)80131-9; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; TEDESCHI A, 1995, J IMMUNOL, V155, P2652; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WEBER M, 1995, J IMMUNOL, V154, P4166; XIA HZ, 1995, J IMMUNOL, V154, P5472; ZEIGER RS, 1993, J ALLERGY CLIN IMMUN, V91, P723, DOI 10.1016/0091-6749(93)90191-H; ZWEIMAN B, 1991, J ALLERGY CLIN IMMUN, V87, P984, DOI 10.1016/0091-6749(91)90421-J	63	95	96	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					354	362		10.1016/S0091-6749(98)70248-9	http://dx.doi.org/10.1016/S0091-6749(98)70248-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525452	hybrid			2022-12-18	WOS:000072593900013
J	Munir, AKM; Kjellman, NIM; Bjorksten, B				Munir, AKM; Kjellman, NIM; Bjorksten, B			Exposure to indoor allergens in early infancy and sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						high-risk children; indoor allergens; ELISA; sensitization	DUST MITE ALLERGENS; DER-P-I; CAN-F-I; FEL-D-I; ASTHMATIC-CHILDREN; ENVIRONMENTAL-FACTORS; HOMES; CHILDHOOD; RISK	Background: Indoor allergens play a major role both in sensitization and as triggers of asthma in children, The relationship between allergen exposure and sensitization to cats, dogs, and mites was studied prospectively in 100 newborn babies with a history of allergy in both parents. Methods: Skin prick tests were done dth Dermatophagoides pteronyssinus, D. farinae, and cat and dog allergens in all the children at 6 and 18 months of age and in 86 children at 5 Sears of age, Dust samples were collected from the homes during infancy and at 5 Sears, The parents of the children responded to a questionnaire focused on environmental factors that could influence indoor allergen levels, In addition, dust samples were collected from the day-care centers of the sensitized children. The allergen levels were determined by ELISA. Results: The levels of the major cat allergen, Fel d 1, varied from 0.02 mu g to 6.8 mu g/gm (geometric mean [GM], 0.4 mu g/gm) during infancy and less than 0.02 mu g to 13 mu g/gm dust (GM, 0.12 mu g/gm) at age 5 years, Dog allergen, Can f 1, levels ranged from 0.18 mu g to 590 mu g/gm (GM, 3.1 mu g/gm) in infancy and 0.09 mu g to 13 mu g/gm at age 5 years (GM, 0.6 mu g/gm). Eleven children (13%) were sensitive to cats, and three were sensitive to dogs at 5 years of age, They had been exposed to similar levels of allergen as the nonsensitized children. The levels of mite allergen (Der p 1 + Der f 1) at age 1 par varied from less than 0.02 mu g to 1 mu g/gm dust (GM, 0.12 mu g/gm) and at age 5 Sears from less than 0.02 mu g to 3.5 mu g/gm (GM, 0.05 mu g/gm) dust, Only two homes contained mite allergen levels greater than 2 mu g/gm dust. The levels were less than 0.3 mu g/gm dust in all but one sample from the day-care centers. Only one child was sensitized to mites at age 5 years. The mite allergen level was less than 0.1 mu/gm at home, and he did not attend a day-care center. Conclusions: The findings indicate that exposure to low levels of indoor allergens in early childhood is associated with a low incidence of sensitization, However, levels well below currently suggested threshold levels may cause sensitization in children with a family history of allergy, We suggest that a fixed threshold risk level for allergic sensitization may not be appropriate in all climates.	LINKOPING UNIV HOSP,DEPT HLTH & ENVIRONM,DIV PEDIAT,S-58185 LINKOPING,SWEDEN	Linkoping University								AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1111/j.1365-2222.1996.tb00607.x; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; CALL RS, 1993, J ALLERGY CLIN IMMUN, V91, P172; DREBORG S, 1987, CLIN ALLERGY, V17, P537, DOI 10.1111/j.1365-2222.1987.tb02050.x; DREBORG S, 1995, ALLERGY, V50, P188, DOI 10.1111/j.1398-9995.1995.tb05079.x; DREBORG S, 1990, RESPIRATORY ALLERGY, V2, P185; DREBORG S, 1985, ALLERGY S4, V40, P55; EHNERT B, 1993, J ALLERGY CLIN IMMUN, V91, P324; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Lau-Schadendorf S, 1989, J ALLERGY CLIN IMMUN, V84, P718; MUNIR AKM, 1994, ALLERGY, V49, P508, DOI 10.1111/j.1398-9995.1994.tb01121.x; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; MUNIR AKM, 1995, ALLERGY, V50, P55, DOI 10.1111/j.1398-9995.1995.tb02483.x; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; MUNIR AKM, 1994, THESIS U LINKOPING L; MUNIR AKM, 1994, PEDIATR ALLERGY IMMU, V5, P136; PAULI G, 1993, CLIN EXP ALLERGY, V23, P606, DOI 10.1111/j.1365-2222.1993.tb00901.x; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1995, 51 AAAI ANN M NEW YO, P111; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; WAHN U, 1995, P 1 16 EUR C ALL CLI, P281; Warner AM, 1996, PEDIAT ALLERG IMM-UK, V7, P61, DOI 10.1111/j.1399-3038.1996.tb00108.x; Warner J, 1990, PEDIATR ALLERGY IMMU, V1, P79; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8; WOODFOLK JA, 1992, ANN ALLERGY, V69, P273	32	95	95	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					177	181		10.1016/S0091-6749(97)70221-5	http://dx.doi.org/10.1016/S0091-6749(97)70221-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275137	Bronze, Green Submitted			2022-12-18	WOS:A1997XR35100006
J	Bousquet, J; Duchateau, J; Pignat, JC; Marquis, P; Mariz, S; Ware, JE; Valentin, B; Burtin, B				Bousquet, J; Duchateau, J; Pignat, JC; Marquis, P; Mariz, S; Ware, JE; Valentin, B; Burtin, B			Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cetirizine; perennial rhinitis; quality of life; SF-36 questionnaire	HEALTH SURVEY QUESTIONNAIRE; OF-LIFE; MEDICAL OUTCOMES; VALIDITY; TERFENADINE; CARE	Background and aim: Perennial allergic rhinitis impairs social life, but it is not known whether quality of life may be improved when patients are treated with an H-1-blocker. A randomized, double-blind, placebo-controlled study was carried out with cetirizine to assess the effect of this drug on quality of life. Methods: Two hundred seventy-four patients with perennial allergic rhinitis were tested. Quality of life was measure by using the Medical Outcome Study Short-Form Health Survey (SF-36) questionnaire. After a 2-week run-in period, cetirizine, 10 mg once daily, (136 patients) or placebo (138 patients) was given for the next 6 weeks. The SF-36 questionnaire was administered after the run-in period (at the start of treatment) and after 1 and 6 weeks of treatment. Symptom-medication scores were measure daily during the study. Results: After the run-in period (baseline), there were no significant differences between the cetirizine and placebo groups in terms of symptoms or quality-of-life scores. After 6 weeks of treatment, percentage of days without rhinitis or with only mild rhinitis symptoms was significantly greater in the cetirizine group in comparison with the placebo group (p < 0.001, Mann-Whitney U test). All of the nine quality-of-life dimensions were significantly improved (from p = 0.01 to p < 0.0001, Mann-Whitney U test) after 1 and 6 weeks of cetirizine treatment compared with placebo. There was no improvement in the placebo group. Conclusions: This study is the first to demonstrate that an H-1-blocker, cetirizine, can improve quality of life for patients with perennial allergic rhinitis.	HOP UNIV ST PIERRE, SERV IMMUNOL & TRANSFUS, B-1000 BRUSSELS, BELGIUM; HOP CROIX ROUSSE, F-69317 LYON, FRANCE; MAPI, LYON, FRANCE; UCB PHARMA LTD, WATFORD, HERTS, ENGLAND; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; UCB BIOPROD SA, PHARMACEUT SECTOR, BRAINE LALLEUD, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; CHU Lyon; UCB Pharma SA; Tufts Medical Center; UCB Pharma SA	Bousquet, J (corresponding author), HOP ARNAUD VILLENEUVE, SERV MALAD RESP, F-34295 MONTPELLIER 05, FRANCE.		Bousquet, Jean/O-4221-2019					Aaronson N K, 1992, Qual Life Res, V1, P349, DOI 10.1007/BF00434949; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; BROOKS CD, 1990, CLIN EXP ALLERGY, V20, P21, DOI 10.1111/j.1365-2222.1990.tb02770.x; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; JUNIPER EF, 1993, J ALLERGY CLIN IMMUN, V92, P66, DOI 10.1016/0091-6749(93)90039-I; MANSMANN HC, 1992, ANN ALLERGY, V68, P348; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; RIHOUX JP, 1987, ANN ALLERGY, V59, P235; Stewart A., 1992, MED OUTCOMES STUDY A; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; WALKER SR, 1987, QUALITY LIFE ASSESSM, P169; Ware J.E., 1993, LINC RI QUAL METR IN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; 1994, BIOSTATISTICAL METHO	20	95	99	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					309	316		10.1016/S0091-6749(96)70155-0	http://dx.doi.org/10.1016/S0091-6749(96)70155-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757208				2022-12-18	WOS:A1996VC99500010
J	BURROWS, B; SEARS, MR; FLANNERY, EM; HERBISON, P; HOLDAWAY, MD				BURROWS, B; SEARS, MR; FLANNERY, EM; HERBISON, P; HOLDAWAY, MD			RELATIONS OF BRONCHIAL RESPONSIVENESS TO ALLERGY SKIN-TEST REACTIVITY, LUNG-FUNCTION, RESPIRATORY SYMPTOMS, AND DIAGNOSES IN 13-YEAR-OLD NEW-ZEALAND CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BRONCHIAL RESPONSIVENESS; ALLERGY SKIN TESTS; LUNG FUNCTION	SERUM IGE LEVELS; HOUSE-DUST MITE; AUSTRALIAN SCHOOLCHILDREN; AIRWAY RESPONSIVENESS; PULMONARY-FUNCTION; HAY-FEVER; CHILDHOOD ASTHMA; 2 POPULATIONS; METHACHOLINE; ATOPY	Background: Many factors have been found to relate univariately to bronchial responsiveness (BR), but their independent relationships are often unclear because many are interrelated Objective: The purpose of this study was to present a multivariate analysis of the closeness of the association of various factors that are related univariately to BR, including allergy skin tests. Methods: The results of methacholine challenge were transformed into a continuous variable (BRindex), which has a nearly Gaussian distribution. With stepwise multiple regression, the closeness of the association of the independent variables with BRindex was evaluated. Results: Of the 11 skin tests applied, four showed independent relationships to BRindex (mite, cat, dog, and Aspergillus species). The sizes of these skin test reactions were correlated with BRindex, and their sum appeared to maximize the overall correlation of allergy skin tests with BRindex (r = 0.516). The lowness of the ratio of forced expiratory volume in I second to vital capacity and of percent predicted forced expiratory volume in 1 second added significantly to the skin tests in correlating with BRindex, (multiple r = 0.621). Adding diagnoses and symptoms increased the multiple r to 0.685. Conclusions: The size of the reactions to the four skin tests noted above showed much closet correlations with BR than total serum IgE had shown at age 11, and the relationship was present in asthmatic and nonasthmatic subjects.	MCMASTER UNIV, ST JOSEPHS HOSP, FIRESTONE REG CHEST & ALLERGY UNIT, HAMILTON, ON, CANADA; UNIV OTAGO, SCH MED, DEPT MED, DUNEDIN, NEW ZEALAND; UNIV OTAGO, SCH MED, DEPT PREVENT & SOCIAL MED, DUNEDIN, NEW ZEALAND; UNIV OTAGO, SCH MED, DEPT PAEDIAT & CHILD HLTH, DUNEDIN, NEW ZEALAND	McGill University; McMaster University; University of Otago; University of Otago; University of Otago	BURROWS, B (corresponding author), UNIV ARIZONA, COLL MED, DIV RESP SCI, TUCSON, AZ 85724 USA.			Herbison, Graham Peter/0000-0002-5684-024X	NHLBI NIH HHS [HL-14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1133, DOI 10.1136/adc.64.8.1133; COCKCROFT D, 1994, ANN ALLERGY, V53, P26; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; MORTAGY AK, 1986, BRIT MED J, V293, P525, DOI 10.1136/bmj.293.6546.525; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; RIJCKEN B, 1987, B EUR PHYSIOPATH RES, V23, P391; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P949, DOI 10.1111/j.1365-2222.1993.tb00280.x; Silva P. A., 1990, PAEDIATRIC PERINATAL, V4, P96, DOI [DOI 10.1111/J.1365-3016.1990.TB00621.X, 10.1111/j.1365-3016.1990.tb00621.x]; SPARROW D, 1987, AM REV RESPIR DIS, V135, P1255; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776, DOI 10.1164/ajrccm/144.4.776; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	24	95	96	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					548	556		10.1016/S0091-6749(95)70317-9	http://dx.doi.org/10.1016/S0091-6749(95)70317-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852671				2022-12-18	WOS:A1995QH69700007
J	SHAPIRO, GG; RACHELEFSKY, GS				SHAPIRO, GG; RACHELEFSKY, GS			MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS - INTRODUCTION AND DEFINITION OF SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																			0	95	96	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			417	418		10.1016/0091-6749(92)90160-4	http://dx.doi.org/10.1016/0091-6749(92)90160-4			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527329	Bronze			2022-12-18	WOS:A1992JP52100001
J	GARRIGA, MM; FRIEDMAN, MM; METCALFE, DD				GARRIGA, MM; FRIEDMAN, MM; METCALFE, DD			A SURVEY OF THE NUMBER AND DISTRIBUTION OF MAST-CELLS IN THE SKIN OF PATIENTS WITH MAST-CELL DISORDERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GEORGETOWN UNIV,MED CTR,DIV MOLEC VIROL & IMMUNOL,ROCKVILLE,MD	Georgetown University	GARRIGA, MM (corresponding author), NIAID,MAST CELL PHYSIOL SECT,CLIN INVEST LAB,BLDG 10,ROOM 11N228,BETHESDA,MD 20892, USA.							ATKINS FM, 1987, ARCH DERMATOL, V123, P191, DOI 10.1001/archderm.123.2.191; BINAZZI M, 1959, ITALIAN GENERAL REV, V1, P17; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; EADY RAJ, 1979, BRIT J DERMATOL, V100, P623, DOI 10.1111/j.1365-2133.1979.tb08065.x; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; HAYAT MA, 1972, BASIC ELECTRON MICRO, P87; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KARNOVSKY MJ, 1971, J CELL BIOL, V51, pA146; KASPER CS, 1987, J AM ACAD DERMATOL, V16, P326, DOI 10.1016/S0190-9622(87)70044-9; MEYERS J, 1960, ARCH DERMATOL, V81, P161; MIKHAIL GR, 1964, J INVEST DERMATOL, V43, P249, DOI 10.1038/jid.1964.152; MITCHELL EB, 1986, BRIT J DERMATOL, V114, P65, DOI 10.1111/j.1365-2133.1986.tb02780.x; MOLLENHAUER HH, 1985, J ELECTRON MICR TECH, V2, P557, DOI 10.1002/jemt.1060020605; NISHIOKA K, 1987, ARCH DERMATOL, V123, P205, DOI 10.1001/archderm.123.2.205; OLAFSSON JH, 1986, ACTA DERM-VENEREOL, V66, P16; Roberts L J 2nd, 1982, Trans Assoc Am Physicians, V95, P36; ROBERTS LJ, 1984, HYPERTENSION, V6, P285, DOI 10.1161/01.HYP.6.2_Pt_1.285; SAGHER F, 1967, MASTOCYTOSIS MAST CE; SCOTT HW, 1983, ANN SURG, V197, P507, DOI 10.1097/00000658-198305000-00002; WILKIN JK, 1986, ARCH DERMATOL, V122, P63; WILKIN JK, 1983, RECENT ADV DERMATOLO, V6, P157; WILLINGHAM MC, 1984, J HISTOCHEM CYTOCHEM, V32, P455, DOI 10.1177/32.4.6323574	22	95	97	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				425	432		10.1016/0091-6749(88)90015-2	http://dx.doi.org/10.1016/0091-6749(88)90015-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170991				2022-12-18	WOS:A1988Q322900016
J	GOMEZ, E; CORRADO, OJ; BALDWIN, DL; SWANSTON, AR; DAVIES, RJ				GOMEZ, E; CORRADO, OJ; BALDWIN, DL; SWANSTON, AR; DAVIES, RJ			DIRECT INVIVO EVIDENCE FOR MAST-CELL DEGRANULATION DURING ALLERGEN-INDUCED REACTIONS IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST BARTHOLOMEWS HOSP,DEPT RESP MED,LONDON EC1,ENGLAND									AGIUS RM, 1985, THORAX, V40, P214; ASKENASE PW, 1983, J IMMUNOL, V131, P2687; BIENENSTOCK J, 1983, MONOGR ALLERGY, V18, P124; BOREUS LO, 1961, ACTA PHYSIOL SCAND, V52, P309, DOI 10.1111/j.1748-1716.1961.tb02227.x; CORRADO O J, 1984, Respiration, V46, P85; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DVORAK AM, 1983, PATHOL ANNU, V18, P181; HAIG DM, 1982, NATURE, V300, P188, DOI 10.1038/300188a0; HOWARTH P H, 1984, Respiration, V46, P23; IHLE JN, 1983, J IMMUNOL, V131, P282; KALINER MA, 1980, J ALLERGY CLIN IMMUN, V66, P1, DOI 10.1016/0091-6749(80)90131-1; KAWABORI S, 1983, CLIN ALLERGY, V13, P181, DOI 10.1111/j.1365-2222.1983.tb02586.x; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LENNERT K, 1979, HISTOPATHOLOGY, V3, P349, DOI 10.1111/j.1365-2559.1979.tb03017.x; LEUNG KBP, 1985, CLIN SCI S11, V68, P19; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1122; LICHTENSTEIN LM, 1983, MONOGR ALLERGY, V18, P259; MALMSTEN CL, 1984, CRC CR REV IMMUNOL, V4, P307; METCALFE DD, 1983, CLIN REV ALLERG, V1, P311; MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200; MORRISSEY JF, 1983, MONOGR ALLERGY, V18, P226; MYGIND N, 1974, Rhinology (Utrecht), V12, P131; MYGIND N, 1979, NASAL ALLERGY, P219; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NACLERIO RM, 1983, EUR J RESPIR DIS, V64, P26; NEWSON B, 1983, NEUROSCIENCE, V10, P5565; OKUDA M, 1985, ANN ALLERGY, V54, P69; OKUDA M, 1983, EUR J RESPIR DIS, V64, P7; PEARCE FL, 1982, KLIN WOCHENSCHR, V60, P954, DOI 10.1007/BF01716954; PELIKAN Z, 1977, ANN ALLERGY, V38, P263; PIPKORN U, 1983, ALLERGY, V38, P125, DOI 10.1111/j.1398-9995.1983.tb01596.x; SCHEINMAN BD, 1986, BR MED J, V292, P857; SHAW RJ, 1984, THORAX, V39, P699; SREDNI B, 1983, J IMMUNOL, V131, P915; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; THOMAS WR, 1983, J IMMUNOL, V130, P2565; WASSERMAN SI, 1984, ARTHRITIS RHEUM, V27, P841, DOI 10.1002/art.1780270801; WIHL JA, 1977, ACTA OTO-LARYNGOL, V84, P281, DOI 10.3109/00016487709123968; WINGREN U, 1983, HISTOCHEM, V15, P572; WONG E, 1982, ACTA DERM-VENEREOL, V62, P431	40	95	95	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				637	645		10.1016/0091-6749(86)90082-5	http://dx.doi.org/10.1016/0091-6749(86)90082-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3095410				2022-12-18	WOS:A1986E568200013
J	MYGIND, N				MYGIND, N			MEDIATORS OF NASAL ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MYGIND, N (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT EAR NOSE & THROAT,OTOPATHOL LAB,DK-2100 COPENHAGEN O,DENMARK.							ANGGARD A, 1974, ACTA OTO-LARYNGOL, V78, P232, DOI 10.3109/00016487409126349; BLACKWELL G, 1980, NATURE, V289, P147; BOJSENMOELLER F, 1965, ANN OTO RHINOL LARYN, V74, P363, DOI 10.1177/000348946507400207; BORUM P, 1980, J ALLERGY CLIN IMMUN, V66, P25, DOI 10.1016/0091-6749(80)90134-7; BORUM P, 1979, CLIN OTOLARYNGOL, V4, P407, DOI 10.1111/j.1365-2273.1979.tb01773.x; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; BORUM P, ALLERGY; BORUM P, EUR J DIS CHEST; BROFELDT S, EUR J RESPIR DIS; BRYAN W T, 1959, Trans Am Acad Ophthalmol Otolaryngol, V63, P613; CAUNA N, 1970, ANAT REC, V168, P9, DOI 10.1002/ar.1091680102; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONNELL JT, 1969, J ALLERGY, V43, P182; DAVIS B, 1979, AM REV RESPIR DIS, V120, P547; EGGLESTON PA, 1978, INT ARCH ALLER A IMM, V57, P193, DOI 10.1159/000232103; FANTA CH, 1982, AM REV RESPIR DIS, V125, P61; HASTIE R, 1979, LAB INVEST, V40, P554; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; KAWABORI S, 1981, RHINOLOGY S1, V19, P115; KIRKEGAARD J, BR J DIS CHEST; KIRKEGAARD J, ALLERGY; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; LUNDBERG JM, 1980, P NATL ACAD SCI-BIOL, V77, P1651, DOI 10.1073/pnas.77.3.1651; MALM L, 1981, ALLERGY, V36, P209, DOI 10.1111/j.1398-9995.1981.tb01836.x; MCKENNA EL, 1974, LARYNGOSCOPE, V84, P112, DOI 10.1288/00005537-197401000-00010; MYGIND N, 1973, ARCH KLIN EXP OHR, V204, P123, DOI 10.1007/BF00302160; MYGIND N, 1974, Rhinology (Utrecht), V12, P131; MYGIND N, 1975, ACTA ALLERGOL, V30, P298, DOI 10.1111/j.1398-9995.1975.tb00206.x; MYGIND N, 1982, OTOLARYNGOLOGY LOOSE; MYGIND N, 1979, NASAL ALLERGY, P1; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P241, DOI 10.1007/BF00458318; OKUDA M, 1980, CLIN OTOLARYNGOL, V5, P315, DOI 10.1111/j.1365-2273.1980.tb00897.x; OKUDA M, 1980, TOPICAL STEROID TREA, P22; PARE PD, 1980, TOPICAL STEROID TREA, P12; PATEL KR, 1981, CLIN ALLERGY, V11, P429, DOI 10.1111/j.1365-2222.1981.tb01615.x; Phipps R J, 1981, Int Rev Physiol, V23, P213; PHIPPS RJ, 1980, AM REV RESPIR DIS, V121, P359; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SORENSEN H, 1976, ACTA OTO-LARYNGOL, V82, P260, DOI 10.3109/00016487609120899; TOFT A, CLIN ALLERGY; TOS M, 1976, Rhinology (Utrecht), V14, P155; UDDMAN R, 1980, ACTA OTO-LARYNGOL, V89, P152, DOI 10.3109/00016488009127121; VONSTAEHLIN B, 1960, PRACT OTORHINOLARYNG, V22, P24	46	95	95	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	3					149	159		10.1016/0091-6749(82)90036-7	http://dx.doi.org/10.1016/0091-6749(82)90036-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG384	6125534				2022-12-18	WOS:A1982PG38400001
J	MOORE, VL; PEDERSEN, GM; HAUSER, WC; FINK, JN				MOORE, VL; PEDERSEN, GM; HAUSER, WC; FINK, JN			A STUDY OF LUNG LAVAGE MATERIALS IN PATIENTS WITH HYPERSENSITIVITY PNEUMONITIS - INVITRO RESPONSE TO MITOGEN AND ANTIGEN IN PIGEON-BREEDERS DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,MED CHEST SERV,MILWAUKEE,WI 53233	Medical College of Wisconsin	MOORE, VL (corresponding author), VET ADM HOSP,MED CTR,RES SERV,WOOD,WI 53193, USA.							DANIELE RP, 1975, J CLIN INVEST, V56, P986, DOI 10.1172/JCI108179; DANIELE RP, 1977, AM REV RESPIR DIS, V116, P997; ELLNER JJ, 1978, J IMMUNOL, V121, P2573; EVANS RL, 1977, J EXP MED, V145, P221, DOI 10.1084/jem.145.1.221; GALINDO B, 1970, J IMMUNOL, V105, P227; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HENNEY CS, 1970, SCIENCE, V169, P696, DOI 10.1126/science.169.3946.696; LAUGHTER AH, 1977, J LAB CLIN MED, V89, P1326; LUTZ W, 1973, HDB EXPT IMMUNOLOGY, P1163; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; NASH DR, 1973, CLIN EXP IMMUNOL, V13, P573; REYNOLDS HY, 1974, J LAB CLIN MED, V84, P559; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; ROBERTS RC, 1977, AM REV RESPIR DIS, V116, P1075; SCHATZ M, 1976, CLIN EXP IMMUNOL, V24, P33; WEINBERGER SE, 1978, ANN INTERN MED, V89, P459, DOI 10.7326/0003-4819-89-4-459	16	95	95	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	5					365	370		10.1016/0091-6749(80)90214-6	http://dx.doi.org/10.1016/0091-6749(80)90214-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV955	7372955				2022-12-18	WOS:A1980JV95500008
J	KURLAND, G; WILLIAMS, J; LEWISTON, NJ				KURLAND, G; WILLIAMS, J; LEWISTON, NJ			FATAL MYOCARDIAL TOXICITY DURING CONTINUOUS INFUSION INTRAVENOUS ISOPROTERENOL THERAPY OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STANFORD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305	Children's Hospital Los Angeles; Stanford University; Stanford University								BAKER L D, 1969, Clinical Research, V17, P228; BLOOM S, 1972, AM J PATHOL, V69, P459; COLLINS JM, 1969, BRIT J PHARMACOL, V36, P35, DOI 10.1111/j.1476-5381.1969.tb08301.x; DOWNEY H, 1972, CLIN RES, V21, P817; HACKEL DB, 1953, AM J PATHOL, V29, P369; HAFT JI, 1972, AM J CARDIOL, V29, P268, DOI 10.1016/0002-9149(72)90697-2; INNES IR, 1975, PHARMACOL BASIS, P477; KAHN DS, 1969, ANN NY ACAD SCI, V156, P285, DOI 10.1111/j.1749-6632.1969.tb16735.x; KLAUSTERMEYER, 1975, J ALLERGY CLIN IMMUN, V55, P325; KNUDSON RJ, 1967, J APPL PHYSIOL, V22, P402, DOI 10.1152/jappl.1967.22.3.402; KRASNOW N, 1964, AM J MED, V37, P514, DOI 10.1016/0002-9343(64)90065-8; LOOMIS JC, 1978, 1978 AM SOC AN ANN M, P198; LOVE FM, 1955, AMA AM J DIS CHILD, V89, P468, DOI 10.1001/archpedi.1955.02050110558009; MATSON JR, 1978, J PEDIATR-US, V92, P776, DOI 10.1016/S0022-3476(78)80150-4; MCKINNEY B, 1974, PATHOLOGY CARDIOMYOP, P181; PARRY WH, 1976, AM J DIS CHILD, V130, P39, DOI 10.1001/archpedi.1976.02120020041006; RHATIGAN R, 1970, ANN ALLERGY, V28, P424; ROUNDS VJ, 1954, PEDIATRICS, V14, P528; ROWE GG, 1970, CIRCULATION, V42, P193, DOI 10.1161/01.CIR.42.2.193; SAMPSON C C, 1959, J Natl Med Assoc, V51, P138; SOIFER H, 1957, J PEDIATR-US, V50, P657, DOI 10.1016/S0022-3476(57)80303-5; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; STEINER P, 1975, Journal of Asthma Research, V12, P215, DOI 10.3109/02770907509098949; STRUBELT O, 1976, ACTA PHARMACOL TOX, V39, P383; SZCZEKLIK A, 1977, LANCET, V1, P658; TATTER D, 1964, AM J DIS CHILD, V108, P88, DOI 10.1001/archpedi.1964.02090010090012; VAISRUB S, 1974, JAMA-J AM MED ASSOC, V229, P690, DOI 10.1001/jama.229.6.690; WHITE BH, 1956, J PEDIATR-US, V49, P262, DOI 10.1016/S0022-3476(56)80182-0; WOOD DW, 1973, ANN ALLERGY, V31, P607; WOOD DW, 1972, J ALLERGY CLIN IMMUN, V50, P75, DOI 10.1016/0091-6749(72)90002-4; YOSSEF A, 1975, CHEST, V68, P107	31	95	95	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					407	411		10.1016/0091-6749(79)90214-8	http://dx.doi.org/10.1016/0091-6749(79)90214-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	447942				2022-12-18	WOS:A1979GY51400007
J	SIMON, RA; SCHATZ, M; STEVENSON, DD; CURRY, N; YAMAMOTO, F; PLOW, E; RING, J; ARROYAVE, C				SIMON, RA; SCHATZ, M; STEVENSON, DD; CURRY, N; YAMAMOTO, F; PLOW, E; RING, J; ARROYAVE, C			RADIOGRAPHIC CONTRAST-MEDIA INFUSIONS - MEASUREMENT OF HISTAMINE, COMPLEMENT, AND FIBRIN SPLIT PRODUCTS AND CORRELATION WITH CLINICAL-PARAMETERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USN,REG MED CTR,SAN DIEGO,CA 92134	United States Department of Defense; United States Navy	SIMON, RA (corresponding author), SCRIPPS CLIN MED INST,DIV ALLERGY & IMMUNOL,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				ALYEA EP, 1947, JAMA-J AM MED ASSOC, V135, P25, DOI 10.1001/jama.1947.02890010027008; ANSELL G, 1970, INVEST RADIOL, V5, P374, DOI 10.1097/00004424-197011000-00002; ARROYAVE CM, 1976, J IMMUNOL METHODS, V13, P101, DOI 10.1016/0022-1759(76)90148-4; ARROYAVE CM, 1973, J IMMUNOL, V111, P536; ARROYAVE CM, 1979, J ALLERGY CLIN IMMUN, V63, P276, DOI 10.1016/0091-6749(79)90113-1; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; Beaven MA., 1975, HDB PSYCHOPHARMACOLO, V1, P253; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; BRASCH RC, 1976, INVEST RADIOL, V11, P347, DOI 10.1097/00004424-197609000-00002; BRASCH RC, 1970, INVEST RADIOL, V5, P510, DOI 10.1097/00004424-197011000-00017; CHIESA A, 1975, AM REV RESPIR DIS, V111, P148; COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; DUNN CR, 1975, INVEST RADIOL, V10, P317, DOI 10.1097/00004424-197507000-00006; KELLY JF, 1978, J ALLERGY CLIN IMMUN, V62, P181, DOI 10.1016/0091-6749(78)90104-5; KLEINKNECHT D, 1974, CLIN NEPHROL, V2, P116; LALLI AF, 1974, RADIOLOGY, V112, P267, DOI 10.1148/112.2.267; LANG JH, 1976, INVEST RADIOL, V11, P303, DOI 10.1097/00004424-197607000-00007; LASSER EC, 1971, RADIOLOGY, V100, P683, DOI 10.1148/100.3.683; LASSER EC, 1968, RADIOLOGY, V91, P63, DOI 10.1148/91.1.63; MANCINI G, 1964, PROTIDES BIOLOGICAL, P370; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; MILLER WL, 1975, J ALLERGY CLIN IMMUN, V56, P291, DOI 10.1016/0091-6749(75)90103-7; PATTERSON R, 1975, J ALLERGY CLIN IMMUN, V56, P323; PENDERGRASS HP, 1978, RADIOLOGY, V71, P1; PLOW E, 1973, J CLIN INVEST, V52, P273, DOI 10.1172/JCI107183; RING J, 1978, CLIN EXP IMMUNOL, V32, P105; ROCKOFF SD, 1972, INVEST RADIOL, V7, P403, DOI 10.1097/00004424-197209000-00008; ROCKOFF SD, 1971, INVEST RADIOL, V6, P186; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; SEIDEL G, 1974, AGENTS ACTIONS, V4, P143, DOI 10.1007/BF01970254; SEIGLE RL, 1976, INVEST RADIOL, V11, P98; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; TILL G, 1977, FED PROC, V36, P1264; WAKKERSGARRITSEN BG, 1976, ANN ALLERGY, V36, P122; WARD RA, 1967, J EXP MED, V120, P189; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; ZWEIMAN B, 1975, ANN INTERN MED, V83, P159, DOI 10.7326/0003-4819-83-2-159	39	95	95	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	4					281	288		10.1016/0091-6749(79)90114-3	http://dx.doi.org/10.1016/0091-6749(79)90114-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GR842	85650				2022-12-18	WOS:A1979GR84200010
J	BRUCE, CA; NORMAN, PS; ROSENTHAL, RR; LICHTENSTEIN, LM				BRUCE, CA; NORMAN, PS; ROSENTHAL, RR; LICHTENSTEIN, LM			ROLE OF RAGWEED POLLEN IN AUTUMNAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239	Johns Hopkins University								AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; BRUCE CA, 1976, CLIN EXP IMMUNOL, V25, P67; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; Cooke R. A, 1918, NY MED J, V107, P577; FRANKLAND AW, 1954, LANCET, V1, P1055; Freeman J, 1911, LANCET, V2, P814; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOPEZ M, 1975, J ALLERGY CLIN IMMUN, V55, P90; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROSENBERG GL, 1975, J ALLERGY CLIN IMMUN, V55, P126; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	22	95	95	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	6					449	459		10.1016/0091-6749(77)90009-4	http://dx.doi.org/10.1016/0091-6749(77)90009-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DJ990	68044	Bronze			2022-12-18	WOS:A1977DJ99000008
J	CASSIDY, JT; NORDBY, GL				CASSIDY, JT; NORDBY, GL			HUMAN-SERUM IMMUNOGLOBULIN CONCENTRATIONS - PREVALENCE OF IMMUNOGLOBULIN DEFICIENCIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,MED SCH,RACKHAM ARTHRIT RES UNIT,ANN ARBOR,MI 48104; UNIV MICHIGAN,MED SCH,DEPT INTERN MED,R4633 KRESGE MED RES BLDG,ANN ARBOR,MI 48104; UNIV MICHIGAN,MED SCH,DEPT BIOL CHEM,R4633 KRESGE MED RES BLDG,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								AMMANN A J, 1970, Clinical and Experimental Immunology, V7, P833; AMMANN AJ, 1971, MEDICINE, V50, P223, DOI 10.1097/00005792-197105000-00004; BACHMANN R, 1965, SCAND J CLIN LAB INV, V17, P46, DOI 10.3109/00365516509077282; BACHMANN R, 1965, SCAND J CLIN LAB INV, V17, P316, DOI 10.3109/00365516509077057; BARON S, 1962, J IMMUNOL, V88, P443; BARTELS RCF, 1971, MICHIGAN TERMINAL SY; BUCKLEY CE, 1971, ANN INTERN MED, V75, P673, DOI 10.7326/0003-4819-75-5-673; BURTIN P, 1964, ANN I PASTEUR PARIS, V106, P519; CARPENTER RR, 1966, J CHRON DIS, V19, P117, DOI 10.1016/0021-9681(66)90043-9; CASSIDY JT, 1973, J CLIN INVEST, V52, P1931, DOI 10.1172/JCI107377; CASSIDY JT, 1968, U MICH MED CENT J, V34, P241; CHANDRA RK, 1969, LANCET, V1, P687; CLAMAN HN, 1966, J ALLERGY, V38, P215, DOI 10.1016/0021-8707(66)90055-4; COOPER MD, 1973, NEW ENGL J MED, V288, P966, DOI 10.1056/NEJM197305032881814; CRABBE PA, 1967, AM J MED, V42, P319, DOI 10.1016/0002-9343(67)90031-9; Dixon W, 1969, INTRO STATISTICAL AN, P328; FAHEY JL, 1965, J IMMUNOL, V94, P84; FEINGOLD M, 1969, AM J DIS CHILD, V117, P129, DOI 10.1001/archpedi.1969.02100030131001; FEINGOLD M, 1969, AM J DIS CHILD, V117, P136; FIREMAN P, 1964, LANCET, V1, P1193; FLODIN P, 1962, BIOCHIM BIOPHYS ACTA, V63, P403, DOI 10.1016/0006-3002(62)90104-X; FUDENBERG HH, 1962, ARTHRITIS RHEUM, V5, P565, DOI 10.1002/art.1780050605; Gitlin D, 1959, CELLULAR HUMORAL ASP, P375; GOLDBERG LS, 1968, J LAB CLIN MED, V72, P204; HALD A, 1952, STATISTICAL THEORY E, P522; HANSON LA, 1968, BIRTH DEFECTS OAS, V4, P292; HERMANS PE, 1966, AM J MED, V40, P78, DOI 10.1016/0002-9343(66)90189-6; HOBBS JR, 1968, LANCET, V1, P110; HOBBS JR, 1968, LANCET, V1, P217; HOBBS JR, 1967, BRIT MED J, V4, P583, DOI 10.1136/bmj.4.5579.583; HUNTLEY CC, 1967, AM J DIS CHILD, V113, P411, DOI 10.1001/archpedi.1967.02090190057002; KUNKEL HG, 1952, P SOC EXP BIOL MED, V80, P42; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; MILLER F, 1965, J BIOL CHEM, V240, P3325; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PANUSH RS, 1972, CLIN EXP IMMUNOL, V10, P103; PETERSON EA, 1962, METHOD ENZYMOL, V5, P3, DOI 10.1016/S0076-6879(62)05183-6; PETERSON RD, 1964, LANCET, V1, P1189; ROCKEY JH, 1964, J LAB CLIN MED, V63, P205; ROWE DS, 1970, B WORLD HEALTH ORGAN, V42, P535; ROWE DS, 1972, B WORLD HEALTH ORGAN, V46, P67; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; STEYERMARK A, 1961, QUANTITATIVE ORGANIC, P205; STROBER W, 1972, B RHEUM DIS, V22, P686; Svedberg T, 1940, THE ULTRACENTRIFUGE; TOMASI TB, 1968, NEW ENGL J MED, V279, P1327, DOI 10.1056/NEJM196812122792408; WEST CD, 1962, J CLIN INVEST, V41, P2054, DOI 10.1172/JCI104663; WILSON ID, 1968, GASTROENTEROLOGY, V54, P253; YOUNG RR, 1964, MEDICINE, V43, P423, DOI 10.1097/00005792-196405000-00021; 1972, HYPOGAMMAGLOBULINAEM	50	95	96	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	1					35	48		10.1016/S0091-6749(75)80006-6	http://dx.doi.org/10.1016/S0091-6749(75)80006-6			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V2344	803275	Bronze			2022-12-18	WOS:A1975V234400005
J	POPA, V; DOUGLAS, JS; BOUHUYS, A				POPA, V; DOUGLAS, JS; BOUHUYS, A			AIRWAY RESPONSES TO HISTAMINE, ACETYLCHOLINE, AND PROPRANOLOL IN ANAPHYLACTIC HYPERSENSITIVITY IN GUINEA-PIGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHN B PIERCE FDN LAB,NEW HAVEN,CT 06519; YALE UNIV,LUNG RES CTR,NEW HAVEN,CT 06510	Yale University; The John B Pierce Laboratory, Inc; Yale University								ARMITAGE P, 1952, BRIT J PHARM CHEMOTH, V7, P625, DOI 10.1111/j.1476-5381.1952.tb00730.x; BECKER EL, 1968, TEXTBOOK IMMUNOPATHO; BOUHUYS A, 1960, CLIN SCI, V19, P79; CHAKRAVARTY N, 1959, ACTA PHYSIOL SCAND, V46, P298, DOI 10.1111/j.1748-1716.1959.tb01760.x; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DOUGLAS JS, 1973, J PHARMACOL EXP THER, V184, P169; DOUGLAS JS, 1972, J PHARMACOL EXP THER, V180, P98; Duron B, 1968, J Fr Med Chir Thorac, V22, P5; GITLIN D, 1949, J IMMUNOL, V62, P437; HERXHEIMER H, 1967, KLIN WOCHENSCHR, V45, P1149, DOI 10.1007/BF01727399; HERXHEIMER H, 1952, J PHYSIOL-LONDON, V117, P251, DOI 10.1113/jphysiol.1952.sp004745; HICKS R, 1968, INT ARCH ALLER A IMM, V33, P131, DOI 10.1159/000229983; Kabat EA, 1944, J IMMUNOL, V48, P181; MCNEILL RS, 1964, LANCET, V2, P1101; OKPAKO DT, 1971, INT ARCH ALLER A IMM, V40, P620, DOI 10.1159/000230443; STEIN M, 1961, J ALLERGY, V32, P8, DOI 10.1016/0021-8707(61)90033-8; TAKINO Y, 1971, J ALLERGY, V47, P247, DOI 10.1016/S0091-6749(71)80003-9; Tiffeneau R, 1958, Acta Allergol Suppl (Copenh), V5, P187; ZAPLETAL A, 1969, J APPL PHYSIOL, V26, P308, DOI 10.1152/jappl.1969.26.3.308	19	95	95	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	6					344	356		10.1016/0091-6749(73)90073-0	http://dx.doi.org/10.1016/0091-6749(73)90073-0			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8319	4713710				2022-12-18	WOS:A1973P831900004
J	Cecchi, L; D'Amato, G; Annesi-Maesano, I				Cecchi, Lorenzo; D'Amato, Gennaro; Annesi-Maesano, Isabella			External exposome and allergic respiratory and skin diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aeroallergens; air pollution; airway hyperreactivity; allergens; asthma; atopic dermatitis; biocontaminants; climate change; biodiversity; exposome; microbiome; rhinitis; thunderstorm	HAY-FEVER PREVALENCE; DUST MITE ALLERGEN; CLIMATE-CHANGE; AIR-POLLUTION; CHILDHOOD ASTHMA; PREDICTIVE-VALUE; POLLEN SEASONS; DIESEL EXHAUST; IGE RESPONSES; RISK-FACTORS	Allergies are complex diseases that result from interactions between multiple genetic and environmental factors. However, the increase in allergies observed in the past decades is explained exclusively by environmental changes occurring in the same period. Presently, the exposome, the totality of specific and nonspecific external environmental exposures (external exposome) to which a subject is exposed from preconception onward and their consequences at the organ and cell levels (internal exposome), is being considered to explain the inception, development, and exacerbations of allergic diseases. Among the best-studied environmental factors of the specific external exposome, indoor and outdoor aeroallergens and air pollutants play a key role in the etiopathogenesis of the inflammatory response to allergens and in clinical manifestations of allergic disease. Climate change, urbanization, and loss of biodiversity affect sources, emissions, and concentrations of main aeroallergens and air pollutants and are among the most critical challenges facing the health and quality of life of the still increasing number of allergic patients today and in the coming decades. Thunderstorm-related asthma is a dramatic example of the effects of combined environmental factors and an in vivo model for understanding the mechanisms at work in respiratory allergy. Environment-or lifestyle-driven aberrancies in the gut and skin microbiome composition represent key mediators of allergic diseases. A better knowledge of the effect of the external exposome on allergy development is crucial for urging patients, health professionals, and policymakers to take actions to mitigate the effect of environmental changes and to adapt to them.	[Cecchi, Lorenzo] Univ Florence, Ctr Bioclimatol, Florence, Italy; [Cecchi, Lorenzo] USL Toscana Ctr, SOS Allergy & Clin Immunol, Prato, Italy; [D'Amato, Gennaro] High Specialty Hosp A Cardarelli, Div Resp & Allerg Dis, Naples, Italy; [D'Amato, Gennaro] Univ Naples Federico II, Sch Specializat Resp Dis, Naples, Italy; [Annesi-Maesano, Isabella] Sorbonne Univ, INSERM, Pierre Louis Inst Epidemiol & Publ Hlth, Epidemiol Allerg & Resp Dis Dept EPAR,St Antoine, Paris, France	University of Florence; Antonio Cardarelli Hospital; University of Naples Federico II; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Annesi-Maesano, I (corresponding author), Sorbonne Univ, IPLESP, Epidemiol Allerg & Resp EPAR Dept, 27 Rue Chaligny, F-75571 Paris, France.; Annesi-Maesano, I (corresponding author), Med Sch St Antoine, INSERM, 27 Rue Chaligny, F-75571 Paris, France.	Isabella.annesi-maesano@inserm.fr	Annesi-Maesano, Isabella/D-9173-2016	Annesi-Maesano, Isabella/0000-0002-6340-9300; Cecchi, Lorenzo/0000-0002-0658-2449	European Union ENV Health and Environment-wide Associations based on Large population Surveys (HEALS) project	European Union ENV Health and Environment-wide Associations based on Large population Surveys (HEALS) project	This review was partially supported by the European Union FP7-ENV Health and Environment-wide Associations based on Large population Surveys (HEALS) project.	Ackaert C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104520; Ahn K, 2014, J ALLERGY CLIN IMMUN, V134, P993, DOI 10.1016/j.jaci.2014.09.023; Anderson HR, 2013, AIR QUAL ATMOS HLTH, V6, P541, DOI 10.1007/s11869-012-0184-5; Andrusaityte S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010341; Annesi-Maesano I, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0024-2017; Annesi-Maesano I, 2016, J ALLERGY CLIN IMMUN, V138, P57, DOI 10.1016/j.jaci.2016.02.043; Ayres JG, 2009, EUR RESPIR J, V34, P295, DOI 10.1183/09031936.00003409; Baiz N, 2017, J ALLERGY CLIN IMMUN, V139, P369, DOI 10.1016/j.jaci.2016.07.021; Barry M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01912-2017; Beasley R, 2015, LANCET, V386, P1075, DOI 10.1016/S0140-6736(15)00156-7; Beck IM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069115; Beggs PJ, 2017, ATMOS ENVIRON, V152, P455, DOI 10.1016/j.atmosenv.2016.12.045; Biagioni BJ, 2016, CLIN EXP ALLERGY, V46, P1206, DOI 10.1111/cea.12732; Huynh BT, 2010, PRIM CARE RESP J, V19, P254, DOI 10.4104/pcrj.2010.00027; Bowatte G, 2015, ALLERGY, V70, P245, DOI 10.1111/all.12561; Breton CV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099716; Burbank AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1, DOI 10.1016/j.jaci.2017.05.010; Buters J, 2015, J ALLERGY CLIN IMMUN, V136, P87, DOI 10.1016/j.jaci.2015.01.049; Canova C, 2013, EUR RESPIR J, V42, P935, DOI 10.1183/09031936.00097412; Carinanos P, 2017, ENVIRON RES, V155, P219, DOI 10.1016/j.envres.2017.02.015; Carlsten C, 2016, THORAX, V71, P35, DOI 10.1136/thoraxjnl-2015-207399; Cecchi L, 2013, EUR RESPIR J, V42, P898, DOI 10.1183/09031936.00096413; Chavatte-Palmer P, 2016, INT J ENV RES PUB HE, P13; Christiansen ES, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0147-x; Cuinica LG, 2014, ENVIRON POLLUT, V186, P50, DOI 10.1016/j.envpol.2013.12.001; Custovic A, 2015, CLIN EXP ALLERGY, V45, P54, DOI 10.1111/cea.12450; Custovic A, 2015, J ALLERGY CLIN IMMUN, V136, P1645, DOI 10.1016/j.jaci.2015.03.041; D'Amato G, 2017, J ALLERGY CLIN IMMUN, V139, P1786, DOI 10.1016/j.jaci.2017.03.003; D'Amato G, 2014, EUR RESPIR REV, V23, P161, DOI 10.1183/09059180.00001714; D'Amato G, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0073-0; Damialis A, 2015, INT J BIOMETEOROL, V59, P1157, DOI 10.1007/s00484-014-0927-0; Darrow LA, 2012, J ALLERGY CLIN IMMUN, V130, P630, DOI 10.1016/j.jaci.2012.06.020; Donders TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104774; Dzierzanowski K, 2011, INT J PHYTOREMEDIAT, V13, P1037, DOI 10.1080/15226514.2011.552929; El Kelish A, 2014, BMC PLANT BIOL, V14, DOI 10.1186/1471-2229-14-176; Garcia-Mozo H, 2017, ALLERGY, V72, P1849, DOI 10.1111/all.13210; Garcia-Mozo H, 2015, ANN AGR ENV MED, V22, P421, DOI 10.5604/12321966.1167706; Geary SM, 2016, J ALLERGY CLIN IMMUN, V138, P405, DOI 10.1016/j.jaci.2016.06.009; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Ghiani A, 2012, ALLERGY, V67, P887, DOI 10.1111/j.1398-9995.2012.02846.x; Ghiani A, 2016, SCI REP-UK, V6, DOI 10.1038/srep30438; Gold DR, 2017, J ALLERGY CLIN IMMUN, V140, P933, DOI 10.1016/j.jaci.2017.04.024; Grewling L, 2014, AEROBIOLOGIA, V30, P149, DOI 10.1007/s10453-013-9313-3; Gruzieva O, 2017, ENVIRON HEALTH PERSP, V125, P104, DOI 10.1289/EHP36; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Gunawardena KR, 2017, SCI TOTAL ENVIRON, V584, P1040, DOI 10.1016/j.scitotenv.2017.01.158; Haahtela T, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-3; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Heinrich J, 2016, GEOINFOR GEOSTAT, V4, P4; Hershko AY, 2017, J ALLERGY CLIN IMMUN, V139, P1137, DOI 10.1016/j.jaci.2016.11.016; Hiyoshi K, 2005, ENVIRON RES, V99, P361, DOI 10.1016/j.envres.2005.03.008; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V125, pS81, DOI 10.1016/j.jaci.2009.10.071; Huang CC, 2015, BRIT J DERMATOL, V173, P981, DOI 10.1111/bjd.14039; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; Hughes AM, 2011, PEDIAT ALLERG IMM-UK, V22, P327, DOI 10.1111/j.1399-3038.2010.01099.x; Jackson DJ, 2017, J ALLERGY CLIN IMMUN, V139, P379, DOI 10.1016/j.jaci.2016.12.941; Joung YS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7083; Kanter U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061518; Kathuria P, 2016, PEDIAT ALLERG IMM-UK, V27, P478, DOI 10.1111/pai.12543; Kellberger J, 2012, J ALLERGY CLIN IMMUN, V129, P397, DOI 10.1016/j.jaci.2011.08.016; Knaysi G, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0675-4; Koehler C, 2016, INT ARCH ALLERGY IMM, V171, P27, DOI 10.1159/000450751; Kolarova E, 2014, INT J BIOMETEOROL, V58, P1739, DOI 10.1007/s00484-013-0779-z; Kramer U, 2009, J DERMATOL SCI, V56, P99, DOI 10.1016/j.jdermsci.2009.07.014; Lai ACK, 2000, J AIR WASTE MANAGE, V50, P1688, DOI 10.1080/10473289.2000.10464196; Lang-Yona N, 2016, SCI TOTAL ENVIRON, V541, P365, DOI 10.1016/j.scitotenv.2015.09.058; Li MC, 2017, ENVIRON POLLUT, V229, P655, DOI 10.1016/j.envpol.2017.06.083; Li N, 2016, J ALLERGY CLIN IMMUN, V138, P386, DOI 10.1016/j.jaci.2016.02.023; Loh M, 2017, INT J ENV RES PUB HE, P14; Lynch SV, 2016, ANN AM THORAC SOC, V13, pS51, DOI 10.1513/AnnalsATS.201507-451MG; O'Sullivan D, 2015, SCI REP-UK, V5, DOI 10.1038/srep08082; Pacala S, 2004, SCIENCE, V305, P968, DOI 10.1126/science.1100103; Pasqualini S, 2011, ENVIRON POLLUT, V159, P2823, DOI 10.1016/j.envpol.2011.05.003; Pawankar R., WHITE BOOK ALLERGY 2; Posa D, 2017, J ALLERGY CLIN IMMUN, V139, P541, DOI 10.1016/j.jaci.2016.08.014; Reinmuth-Selzle K, 2017, ENVIRON SCI TECHNOL, V51, P4119, DOI 10.1021/acs.est.6b04908; Renz H, 2017, J ALLERGY CLIN IMMUN, V140, P24, DOI 10.1016/j.jaci.2017.05.015; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Ribeiro H, 2017, SCI TOTAL ENVIRON, V599, P291, DOI 10.1016/j.scitotenv.2017.04.206; Rider CF, 2016, J ALLERGY CLIN IMMUN, V138, P1690, DOI 10.1016/j.jaci.2016.02.038; Ruokolainen L, 2015, ALLERGY, V70, P195, DOI 10.1111/all.12545; Schiavoni G, 2017, ANN ALLERG ASTHMA IM, V118, P269, DOI 10.1016/j.anai.2016.12.019; Senechal H., 2015, SCI WORLD J, V2015; Silverberg JI, 2015, J ALLERGY CLIN IMMUN, V135, P463, DOI 10.1016/j.jaci.2014.08.003; Smith AR, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0674-5; Smith M, 2014, ALLERGY, V69, P913, DOI 10.1111/all.12419; Smith M, 2013, ENVIRON INT, V61, P115, DOI 10.1016/j.envint.2013.08.005; Soomro MH, 2018, ENVIRON HEALTH PERSP, V126, DOI [10.1289/EHP1829, 10.1289/ehp1829]; Steiner AL, 2015, GEOPHYS RES LETT, V42, P3596, DOI 10.1002/2015GL064060; Stinson KA, 2016, OECOLOGIA, V182, P587, DOI 10.1007/s00442-016-3670-x; Thacher JD, 2017, ALLERGY, V72, P967, DOI 10.1111/all.13102; Tham R, 2017, J ALLERGY CLIN IMMUN, V139, P1140, DOI 10.1016/j.jaci.2016.06.046; Threlfall CG, 2017, J APPL ECOL, V54, P1874, DOI 10.1111/1365-2664.12876; Toppila-Salmi S, 2015, ALLERGY, V70, P1112, DOI 10.1111/all.12670; UN (United Nations), 2014, WORLD URB PROSP HIGH; Upperman CR, 2017, J ALLER CL IMM-PRACT, V5, P435, DOI 10.1016/j.jaip.2016.09.016; Velasco-Jimenez MJ, 2014, AEROBIOLOGIA, V30, P91, DOI 10.1007/s10453-013-9311-5; Vernet C, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1015; Watts N, 2017, LANCET; Wickman M, 2017, EBIOMEDICINE, V26, P91, DOI 10.1016/j.ebiom.2017.11.009; Williams PB, 2016, J ALLER CL IMM-PRACT, V4, P386, DOI 10.1016/j.jaip.2015.11.016; Wynes S, 2017, ENVIRON RES LETT, V12, DOI 10.1088/1748-9326/aa7541; Yang IV, 2017, J ALLERGY CLIN IMMUN, V140, P14, DOI 10.1016/j.jaci.2017.05.011; Zanolin ME, 2004, ALLERGY, V59, P306, DOI 10.1046/j.1398-9995.2003.00391.x; Zhang Y, 2014, INT J BIOMETEOROL, V58, P909, DOI 10.1007/s00484-013-0674-7; Zhao F, 2016, PLANT CELL ENVIRON, V39, P147, DOI 10.1111/pce.12601; Ziska LH, 2012, J ALLERGY CLIN IMMUN, V129, P27, DOI 10.1016/j.jaci.2011.10.032	107	94	99	2	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					846	857		10.1016/j.jaci.2018.01.016	http://dx.doi.org/10.1016/j.jaci.2018.01.016			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29519451	Bronze			2022-12-18	WOS:000426974800002
J	Renz, H; Holt, PG; Inouye, M; Logan, AC; Prescott, SL; Sly, PD				Renz, Harald; Holt, Patrick G.; Inouye, Michael; Logan, Alan C.; Prescott, Susan L.; Sly, Peter D.			An exposome perspective: Early-life events and immune development in a changing world	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Environmental microbes; placental microbiome; vaginal microbiome; inflammation; allergy protection; cytokines; biodiversity; colonization; antibiotics; developmental origins of health and disease; ecosystems; prevention; environmental toxicology; endocrine disrupting chemicals; noncommunicable diseases	MCMASTER UNIVERSITY GUIDELINES; ALLERGIC AIRWAY INFLAMMATION; GUT MICROBIOTA COMPOSITION; 99TH DAHLEM CONFERENCE; TOLL-LIKE RECEPTORS; INTESTINAL MICROBIOTA; CESAREAN-SECTION; CORD BLOOD; HEALTH CONSEQUENCES; DIETARY FIBER	Advances in metagenomics, proteomics, metabolomics, and systems biology are providing a new emphasis in research; interdisciplinary work suggests that personalized medicine is on the horizon. These advances are illuminating sophisticated interactions between human-associated microbes and the immune system. The result is a transformed view of future prevention and treatment of chronic noncommunicable diseases, including allergy. Paradigm-shifting gains in scientific knowledge are occurring at a time of rapid global environmental change, urbanization, and biodiversity losses. Multifactorial and multigenerational implications of total environmental exposures, the exposome, require coordinated interdisciplinary efforts. It is clear that the genome alone cannot provide answers to urgent questions. Here we review the historical origins of exposome research and define a new concept, the metaexposome, which considers the bidirectional effect of the environment on human subjects and the human influence on all living systems and their genomes. The latter is essential for human health. We place the metaexposome in the context of early-life immune functioning and describe how various aspects of a changing environment, especially through microbiota exposures, can influence health and disease over the life course.	[Renz, Harald] Philipps Univ Marburg, Inst Lab Med, Baldinger Str, D-35043 Marburg, Germany; [Holt, Patrick G.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Inouye, Michael] Univ Melbourne, Sch Biosci, Ctr Syst Genom, Parkville, Vic, Australia; [Inouye, Michael] Univ Melbourne, Dept Pathol, Parkville, Vic, Australia; [Renz, Harald; Logan, Alan C.; Prescott, Susan L.] Univ Western Australia, Int Inflammat Network, In FLAME, WUN, Perth, WA, Australia; [Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia; [Prescott, Susan L.] Princess Margaret Hosp Children, Perth, WA, Australia; [Sly, Peter D.] Univ Queensland, Child Hlth Res Ctr, Childrens Hlth & Environm Program, Brisbane, Qld, Australia	Philipps University Marburg; Telethon Kids Institute; University of Western Australia; University of Melbourne; University of Melbourne; University of Western Australia; University of Western Australia; University of Western Australia; University of Queensland	Renz, H (corresponding author), Philipps Univ Marburg, Inst Lab Med, Baldinger Str, D-35043 Marburg, Germany.	renzh@med.uni-marburg.de	Sly, Peter D/F-1486-2010; Holt, Patrick/H-1548-2011	Sly, Peter D/0000-0001-6305-2201; Holt, Patrick/0000-0003-1193-0935; Inouye, Michael/0000-0001-9413-6520	Australian NHMRC; Heart Foundation [1061435]; Deutsche Zentrum fur Lungenforschung (DZL) [82DZL00502]; Deutsche Forschungsgemeinschaft (DFG) [SFB 1021]	Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Heart Foundation; Deutsche Zentrum fur Lungenforschung (DZL); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	M.I. is supported by a Career Development Fellowship from the Australian NHMRC and Heart Foundation (no. 1061435). H.R. is supported by Deutsche Zentrum fur Lungenforschung (DZL, German Lung Center, no. 82DZL00502) and Deutsche Forschungsgemeinschaft (DFG)-funded SFB 1021.; S.L.P. is supported by a Practitioner Fellowship from the Australian NHMRC. P.D.S. is a Senior Principal Research Fellow of the Australian NHMRC.	Aagaard K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008599; Aagaard K, 2013, AM J OBSTET GYNECOL, V208, pS218, DOI 10.1016/j.ajog.2012.10.672; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; AlFaleh K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005496.pub4; Aloisio I, 2016, APPL MICROBIOL BIOT, V100, P5537, DOI 10.1007/s00253-016-7410-2; Anthony JC, 2001, BRIT J PSYCHIAT, V178, pS8, DOI 10.1192/bjp.178.40.s8; Arboleya S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050649; Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Avraham R, 2015, CELL, V162, P1309, DOI 10.1016/j.cell.2015.08.027; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Backhed F, 2015, CELL HOST MICROBE, V17, P690, DOI [10.1016/j.chom.2015.05.012, 10.1016/j.chom.2015.04.004]; Bergman A., 2013, STATE SCI ENDOCRINE, DOI DOI 10.1016/J; Beserra BTS, 2015, CLIN NUTR, V34, P845, DOI 10.1016/j.clnu.2014.10.004; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Black M, 2015, JAMA-J AM MED ASSOC, V314, P2271, DOI 10.1001/jama.2015.16176; Blanco-Quiros A, 1999, PEDIATR PULM, V28, P175, DOI 10.1002/(SICI)1099-0496(199909)28:3<175::AID-PPUL3>3.0.CO;2-U; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Bonder MJ, 2016, NAT GENET, V48, P1407, DOI 10.1038/ng.3663; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bont L, 2000, J INFECT DIS, V181, P1772, DOI 10.1086/315433; Bordenstein SR, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002226; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Breton CV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099716; Bunyavanich S, 2015, J ALLERGY CLIN IMMUN, V135, P31, DOI 10.1016/j.jaci.2014.10.015; Canani RB, 2016, ISME J, V10, P742, DOI 10.1038/ismej.2015.151; Cardwell CR, 2008, DIABETOLOGIA, V51, P726, DOI 10.1007/s00125-008-0941-z; Cario E, 2007, GASTROENTEROLOGY, V132, P1359, DOI 10.1053/j.gastro.2007.02.056; Carpenter DO, 2008, ANN NY ACAD SCI, V1140, P201, DOI 10.1196/annals.1454.000; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chatterton Z, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0111-y; Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400; Chung KF, 2017, J ALLERGY CLIN IMMUN, V139, P1071, DOI 10.1016/j.jaci.2017.02.004; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; Cuello-Garcia CA, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0102-7; Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328; Dawson SL, 2016, INT REV NEUROBIOL, V131, P325, DOI 10.1016/bs.irn.2016.08.009; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; De Kleer I, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00423; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Dewailly E, 2000, ENVIRON HEALTH PERSP, V108, P205, DOI 10.2307/3454435; Dixit A, 2016, CELL, V167, P1853, DOI 10.1016/j.cell.2016.11.038; Dominguez-Bello MG, 2016, NAT MED, V22, P250, DOI 10.1038/nm.4039; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Dominguez-Bello MG, 2011, GASTROENTEROLOGY, V140, P1713, DOI 10.1053/j.gastro.2011.02.011; Donaldson GP, 2016, NAT REV MICROBIOL, V14, P20, DOI 10.1038/nrmicro3552; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; DUBOS R, 1966, PEDIATRICS, V38, P789; DUBOS R, 1969, J ALLERGY, V44, P1, DOI 10.1016/0021-8707(69)90042-2; DUBOS R, 1969, WHO CHRON, V23, P499; DUBOS R, 1969, PERSPECT BIOL MED, V12, P479; Dubos R., 1964, BIOSCIENCE, V14, P11; Dubos Ren?J., 1965, MAN ADAPTING; Duta F, 2006, HISTOCHEM CELL BIOL, V126, P495, DOI 10.1007/s00418-006-0188-z; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030; Falony G, 2016, SCIENCE, V352, P560, DOI 10.1126/science.aad3503; Feehley T, 2016, CELL HOST MICROBE, V19, P572, DOI 10.1016/j.chom.2016.04.025; Fiocchi A, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0055-2; Forsberg A, 2016, CLIN EXP ALLERGY, V46, P1506, DOI 10.1111/cea.12838; Forster-Waldl E, 2005, PEDIATR RES, V58, P121, DOI 10.1203/01.PDR.0000163397.53466.0F; Forsythe P, 2014, ADV EXP MED BIOL, V817, P115, DOI 10.1007/978-1-4939-0897-4_5; Fortner KB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083338; Frei R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091097; Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gawad C, 2016, NAT REV GENET, V17, P175, DOI 10.1038/nrg.2015.16; Gawehn E, 2016, MOL INFORM, V35, P3, DOI 10.1002/minf.201501008; Gensollen T, 2017, J ALLERGY CLIN IMMUN, V139, P1084, DOI 10.1016/j.jaci.2017.02.011; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Gerhold K, 2003, J ALLERGY CLIN IMMUN, V112, P389, DOI 10.1067/mai.2003.1646; Goldizen FC, 2016, PEDIATR PULM, V51, P94, DOI 10.1002/ppul.23262; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Goodwin RD, 2017, PSYCHOL MED, V47, P317, DOI [10.1017/S0033291716001896, 10.1017/S003329171600]; Goriely S, 2004, J EXP MED, V199, P1011, DOI 10.1084/jem.20031272; Grant K, 2013, LANCET GLOB HEALTH, V1, pE350, DOI 10.1016/S2214-109X(13)70101-3; Greenblum S, 2015, CELL, V160, P583, DOI 10.1016/j.cell.2014.12.038; Gutierrez-Diaz I, 2017, J AGR FOOD CHEM, V65, P586, DOI 10.1021/acs.jafc.6b04408; Hagendorens MM, 2003, CLIN EXP ALLERGY, V33, P633, DOI 10.1046/j.1365-2222.2003.01649.x; Hagner S, 2013, ALLERGY, V68, P322, DOI 10.1111/all.12094; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Heacock M, 2016, ENVIRON HEALTH PERSP, V124, P550, DOI 10.1289/ehp.1509699; Heilmann C, 2010, ENVIRON HEALTH PERSP, V118, P1434, DOI 10.1289/ehp.1001975; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hertz-Picciotto I, 2008, BASIC CLIN PHARMACOL, V102, P146, DOI 10.1111/j.1742-7843.2007.00190.x; HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; Hollams EM, 2014, AM J RESP CRIT CARE, V189, P401, DOI 10.1164/rccm.201302-0323OC; Holt PG, 2015, J ALLERGY CLIN IMMUN, V136, P15, DOI 10.1016/j.jaci.2015.05.011; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Hu JZ, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0173-2; Huang LS, 2015, J ASTHMA, V52, P16, DOI 10.3109/02770903.2014.952435; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Jacka FN, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0791-y; Jackson CM, 2017, PEDIATR RES, V81, P384, DOI 10.1038/pr.2016.232; Jones CA, 2002, J ALLERGY CLIN IMMUN, V109, P858, DOI 10.1067/mai.2002.123535; Jones CA, 2001, J ALLERGY CLIN IMMUN, V108, P235, DOI 10.1067/mai.2001.117178; Jones CV, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-41; Julia V, 2015, NAT REV IMMUNOL, V15, P308, DOI 10.1038/nri3830; Jung IH, 2012, J APPL MICROBIOL, V113, P1498, DOI 10.1111/j.1365-2672.2012.05437.x; Kettunen J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11122; Kim ES, 2017, AM J EPIDEMIOL, V185, P21, DOI 10.1093/aje/kww182; Kim YS, 2004, IMMUNOLOGY, V112, P624, DOI 10.1111/j.1365-2567.2004.01880.x; Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481; Konig J, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.54; Laborde A, 2015, ENVIRON HEALTH PERSP, V123, P201, DOI 10.1289/ehp.1408292; Landrigan PJ, 2016, ANN GLOB HEALTH, V82, P10, DOI 10.1016/j.aogh.2016.01.005; Laufer BI, 2017, ALCOHOL, V60, P67, DOI 10.1016/j.alcohol.2016.11.009; Lee MN, 2014, SCIENCE, V343, P1119, DOI 10.1126/science.1246980; Legatzki A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0466-0; Li M, 2014, SEMIN REPROD MED, V32, P74, DOI 10.1055/s-0033-1361825; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Lisciandro JG, 2012, J ALLERGY CLIN IMMUN, V130, P1167, DOI 10.1016/j.jaci.2012.06.005; Lisciandro JG, 2012, PEDIAT ALLERG IMM-UK, V23, P173, DOI 10.1111/j.1399-3038.2011.01242.x; Logan AC, 2005, MED HYPOTHESES, V64, P533, DOI 10.1016/j.mehy.2004.08.019; Logan AC, 2016, CLIN PSYCHOPHARM NEU, V14, P131, DOI 10.9758/cpn.2016.14.2.131; Logan AC, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-015-0590-5; Loisel DA, 2016, CLIN EXP ALLERGY, V46, P112, DOI 10.1111/cea.12642; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Luong LMT, 2017, SCI TOTAL ENVIRON, V578, P249, DOI 10.1016/j.scitotenv.2016.08.012; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Macia L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7734; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Mahajan R, 2016, MINI-REV MED CHEM; Manzoni C, 2016, BRIEF BIOINFORM; Martinez-Barricarte R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau6759; Martino DJ, 2013, CURR ALLERGY ASTHM R, V13, P85, DOI 10.1007/s11882-012-0312-1; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Matthias T, 2016, AUTOIMMUN REV, V15, P1111, DOI 10.1016/j.autrev.2016.09.011; McCloskey K, 2017, INT J EPIDEMIOL, V46, P209, DOI 10.1093/ije/dyw042; McDonald SW, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012096; Mendy A, 2011, J ASTHMA, V48, P685, DOI 10.3109/02770903.2011.594140; Metcalfe JR, 2016, CLIN EXP ALLERGY, V46, P308, DOI 10.1111/cea.12608; Miotto R, 2016, SCI REP-UK, V6, DOI 10.1038/srep26094; Moodie R, 2013, LANCET, V381, P670, DOI 10.1016/S0140-6736(12)62089-3; Morin S, 2012, MOL NUTR FOOD RES, V56, P1838, DOI 10.1002/mnfr.201200412; Mostafavi S, 2016, CELL, V164, P564, DOI 10.1016/j.cell.2015.12.032; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Neiderhiser JM, 2001, BRIT J PSYCHIAT, V178, pS12, DOI 10.1192/bjp.178.40.s12; NELSON DJ, 1995, J IMMUNOL, V155, P3517; Nilsson C, 2004, CLIN EXP ALLERGY, V34, P373, DOI 10.1111/j.1365-2222.2004.01896.x; Norman J., 2016, Current Nutrition Reports, V5, P139, DOI 10.1007/s13668-016-0166-6; Ounnas F, 2017, SCI REP-UK, V7, DOI 10.1038/srep40162; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Parkar SG, 2013, ANAEROBE, V23, P12, DOI 10.1016/j.anaerobe.2013.07.009; Patel M, 2005, J IMMUNOL, V174, P7558, DOI 10.4049/jimmunol.174.12.7558; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Petra AI, 2015, CLIN THER, V37, P984, DOI 10.1016/j.clinthera.2015.04.002; PICCINNI MP, 1995, J IMMUNOL, V155, P128; Plunkett CH, 2017, J IMMUNOL, V198, P581, DOI 10.4049/jimmunol.1601266; Prescott SL, 2003, CLIN EXP ALLERGY, V33, P566, DOI 10.1046/j.1365-2222.2003.01659.x; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13111075; Prescott SL, 2013, J ALLERGY CLIN IMMUN, V131, P23, DOI 10.1016/j.jaci.2012.11.019; Prescott SL, 2011, J ALLERGY CLIN IMMUN, V128, P886, DOI 10.1016/j.jaci.2011.05.017; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2006, IMMUNITY, V25, P319, DOI 10.1016/j.immuni.2006.06.010; Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053; Rampelli S, 2015, CURR BIOL, V25, P1682, DOI 10.1016/j.cub.2015.04.055; Rappaport SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154387; Redline RW, 2007, HUM PATHOL, V38, P1439, DOI 10.1016/j.humpath.2007.05.025; Renz-Polster H, 2005, CLIN EXP ALLERGY, V35, P1466, DOI 10.1111/j.1365-2222.2005.02356.x; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Rodriguez B, 2012, FEMS MICROBIOL ECOL, V79, P192, DOI 10.1111/j.1574-6941.2011.01207.x; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Rompa S, 2014, EUR RESPIR J, V44; Rook GAW, 2010, CLIN EXP IMMUNOL, V160, P70, DOI 10.1111/j.1365-2249.2010.04133.x; Roth I, 1996, J EXP MED, V184, P539, DOI 10.1084/jem.184.2.539; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996; Sadeghi K, 2007, J INFECT DIS, V195, P296, DOI 10.1086/509892; Salim SY, 2014, GUT MICROBES, V5, P215, DOI 10.4161/gmic.27251; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Segata N, 2015, CURR BIOL, V25, pR611, DOI 10.1016/j.cub.2015.05.040; Seiquer I, 2014, MOL NUTR FOOD RES, V58, P1552, DOI 10.1002/mnfr.201300847; Sel S, 2007, J IMMUNOL, V178, P7805, DOI 10.4049/jimmunol.178.12.7805; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaheen SO, 2014, J ALLERGY CLIN IMMUN, V133, P225, DOI 10.1016/j.jaci.2013.04.051; Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982; Silver E, 2009, PEDIAT ALLERG IMM-UK, V20, P471, DOI 10.1111/j.1399-3038.2008.00818.x; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Sly PD, 2016, ANN GLOB HEALTH, V82, P3, DOI 10.1016/j.aogh.2016.01.004; Smith K, 2007, SEMIN IMMUNOL, V19, P59, DOI 10.1016/j.smim.2006.10.002; Smits HH, 2016, J ALLERGY CLIN IMMUN, V137, P690, DOI 10.1016/j.jaci.2016.01.004; Sonnenburg ED, 2016, NATURE, V529, P212, DOI 10.1038/nature16504; Sonnenburg JL, 2016, NATURE, V535, P56, DOI 10.1038/nature18846; Steel JH, 2005, PEDIATR RES, V57, P404, DOI 10.1203/01.PDR.0000153869.96337.90; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Stokholm J, 2016, J ALLERGY CLIN IMMUN, V138, P881, DOI 10.1016/j.jaci.2016.01.028; Stout MJ, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.01.018; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Sudo N, 2004, J PHYSIOL-LONDON, V558, P263, DOI 10.1113/jphysiol.2004.063388; Sudo N, 1997, J IMMUNOL, V159, P1739; Suk WA, 2016, ENVIRON HEALTH PERSP, V124, pA41, DOI 10.1289/ehp.1510517; SzekeresBartho J, 1996, AM J REPROD IMMUNOL, V35, P348; Tan J, 2016, CELL REP, V15, P2809, DOI 10.1016/j.celrep.2016.05.047; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Thorburn AN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8320; Thorburn AN, 2014, IMMUNITY, V40, P833, DOI 10.1016/j.immuni.2014.05.014; Torow N, 2017, MUCOSAL IMMUNOL, V10, P5, DOI 10.1038/mi.2016.81; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Tulic MK, 2011, J ALLERGY CLIN IMMUN, V127, P470, DOI 10.1016/j.jaci.2010.09.020; Upham JW, 2009, J ALLERGY CLIN IMMUN, V124, P707, DOI 10.1016/j.jaci.2009.07.009; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002; Van den Heuvell RL, 2002, ENVIRON HEALTH PERSP, V110, P595, DOI 10.1289/ehp.02110595; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Vatanen T, 2016, CELL, V165, P842, DOI 10.1016/j.cell.2016.04.007; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Vogel K, 2008, J ALLERGY CLIN IMMUN, V122, P307, DOI 10.1016/j.jaci.2008.05.016; von Hertzen L, 2015, ANN MED, V47, P218, DOI 10.3109/07853890.2015.1010226; von Mutius E, 2010, CLIN EXP IMMUNOL, V160, P130, DOI 10.1111/j.1365-2249.2010.04138.x; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wadhwa PD, 2009, SEMIN REPROD MED, V27, P358, DOI 10.1055/s-0029-1237424; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WEISGLASKUPERUS N, 1995, PEDIATR RES, V38, P404, DOI 10.1203/00006450-199509000-00022; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; Willing BP, 2011, BIOESSAYS, V33, P414, DOI 10.1002/bies.201100030; Wolfs TGAM, 2014, AM J PHYSIOL-GASTR L, V306, pG382, DOI 10.1152/ajpgi.00260.2013; Woodcock A, 2002, PEDIAT ALLERG IMM-UK, V13, P357, DOI 10.1034/j.1399-3038.2002.01066.x; Woodhouse S, 2016, IMMUNOL CELL BIOL, V94, P256, DOI 10.1038/icb.2015.102; Zhang GC, 2009, AM J RESP CRIT CARE, V179, P205, DOI 10.1164/rccm.200803-438OC; Zhernakova A, 2016, SCIENCE, V352, P565, DOI 10.1126/science.aad3369; Zota AR, 2016, ENVIRON HEALTH PERSP, V124, P1521, DOI 10.1289/ehp.1510803	237	94	94	1	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					24	40		10.1016/j.jaci.2017.05.015	http://dx.doi.org/10.1016/j.jaci.2017.05.015			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28673401	Bronze			2022-12-18	WOS:000404542000003
J	Tan, BK; Klingler, AI; Poposki, JA; Stevens, WW; Peters, AT; Suh, LA; Norton, J; Carter, RG; Hulse, KE; Harris, KE; Grammer, LC; Schleimer, RP; Welch, KC; Smith, SS; Conley, DB; Kern, RC; Kato, A				Tan, Bruce K.; Klingler, Aiko I.; Poposki, Julie A.; Stevens, Whitney W.; Peters, Anju T.; Suh, Lydia A.; Norton, James; Carter, Roderick G.; Hulse, Kathryn E.; Harris, Kathleen E.; Grammer, Leslie C.; Schleimer, Robert P.; Welch, Kevin C.; Smith, Stephanie S.; Conley, David B.; Kern, Robert C.; Kato, Atsushi			Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CELL		[Tan, Bruce K.; Schleimer, Robert P.; Welch, Kevin C.; Smith, Stephanie S.; Conley, David B.; Kern, Robert C.; Kato, Atsushi] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA; [Klingler, Aiko I.; Poposki, Julie A.; Stevens, Whitney W.; Peters, Anju T.; Suh, Lydia A.; Norton, James; Carter, Roderick G.; Hulse, Kathryn E.; Harris, Kathleen E.; Grammer, Leslie C.; Schleimer, Robert P.; Kern, Robert C.; Kato, Atsushi] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Kato, A (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA.	a-kato@northwestern.edu	Smith, Stephanie Shintani/AAY-4854-2020	Smith, Stephanie Shintani/0000-0002-0605-3993; Kato, Atsushi/0000-0001-9144-3138	National Institutes of Health [R01 AI104733, U19 AI106683, K23 DC012067, R37 HL068546]; Ernest S. Bazley Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS023011] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055884] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI104733, U19AI106683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This research was supported in part by the National Institutes of Health (grant nos. R01 AI104733, U19 AI106683, K23 DC012067, and R37 HL068546) and by a grant from the Ernest S. Bazley Foundation.	[Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chang Y, 2011, J ALLERGY CLIN IMMUN, V127, P1046, DOI 10.1016/j.jaci.2010.12.1117; Derycke L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097581; Fokkens Wytske J, 2012, Rhinol Suppl, V23, P1; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Konig K, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0123-3; Laberge S, 1999, INT ARCH ALLERGY IMM, V119, P120, DOI 10.1159/000024186; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Thompson CF, 2016, INT FORUM ALLERGY RH, V6, P500, DOI 10.1002/alr.21687; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x	15	94	99	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					699	+		10.1016/j.jaci.2016.06.063	http://dx.doi.org/10.1016/j.jaci.2016.06.063			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27639939	Green Accepted, Bronze			2022-12-18	WOS:000397002400041
J	Focke-Tejkl, M; Weber, M; Niespodziana, K; Neubauer, A; Huber, H; Henning, R; Stegfellner, G; Maderegger, B; Hauer, M; Stolz, F; Niederberger, V; Marth, K; Eckl-Dorna, J; Weiss, R; Thalhamer, J; Blatt, K; Valent, P; Valenta, R				Focke-Tejkl, Margarete; Weber, Milena; Niespodziana, Katarzyna; Neubauer, Angela; Huber, Hans; Henning, Rainer; Stegfellner, Gottfried; Maderegger, Bernhard; Hauer, Martina; Stolz, Frank; Niederberger, Verena; Marth, Katharina; Eckl-Dorna, Julia; Weiss, Richard; Thalhamer, Josef; Blatt, Katharina; Valent, Peter; Valenta, Rudolf			Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Grass pollen allergy; allergen; recombinant allergen; recombinant hypoallergenic allergen derivative; allergen-specific immunotherapy; peptide-carrier technology	PHLEUM-PRATENSE POLLEN; P 2; BLOCKING ANTIBODIES; IMMUNOGLOBULIN-E; IMMUNOTHERAPY; IGE; EPITOPES; EXTRACTS; IMMUNOGENICITY; RECOGNITION	Background: Grass pollen is one of the most important sources of respiratory allergies worldwide. Objective: This study describes the development of a grass pollen allergy vaccine based on recombinant hypoallergenic derivatives of the major timothy grass pollen allergens Phl p 1, Phl p 2, Phl p 5, and Phl p 6 by using a peptide-carrier approach. Methods: Fusion proteins consisting of nonallergenic peptides from the 4 major timothy grass pollen allergens and the PreS protein from hepatitis B virus as a carrier were expressed in Escherichia coli and purified by means of chromatography. Recombinant PreS fusion proteins were tested for allergenic activity and T-cell activation by means of IgE serology, basophil activation testing, T-cell proliferation assays, and xMAP Luminex technology in patients with grass pollen allergy. Rabbits were immunized with PreS fusion proteins to characterize their immunogenicity. Results: Ten hypoallergenic PreS fusion proteins were constructed, expressed, and purified. According to immunogenicity and induction of allergen-specific blocking IgG antibodies, 4 hypoallergenic fusion proteins (BM321, BM322, BM325, and BM326) representing Phl p 1, Phl p 2, Phl p 5, and Phl p 6 were included as components in the vaccine termed BM32. BM321, BM322, BM325, and BM326 showed almost completely abolished allergenic activity and induced significantly reduced T-cell proliferation and release of proinflammatory cytokines in patients' PBMCs compared with grass pollen allergens. On immunization, they induced allergen-specific IgG antibodies, which inhibited patients' IgE binding to all 4 major allergens of grass pollen, as well as allergen-induced basophil activation. Conclusion: A recombinant hypoallergenic grass pollen allergy vaccine (BM32) consisting of 4 recombinant PreS-fused grass pollen allergen peptides was developed for safe immunotherapy of grass pollen allergy.	[Focke-Tejkl, Margarete; Weber, Milena; Niespodziana, Katarzyna; Marth, Katharina; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, A-1090 Vienna, Austria; [Niederberger, Verena; Eckl-Dorna, Julia] Med Univ Vienna, Dept Otorhinolaryngol, A-1090 Vienna, Austria; [Blatt, Katharina; Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria; [Neubauer, Angela; Huber, Hans; Henning, Rainer; Stegfellner, Gottfried; Maderegger, Bernhard; Hauer, Martina; Stolz, Frank] Biomay AG, Vienna, Austria; [Weiss, Richard; Thalhamer, Josef] Salzburg Univ, Dept Mol Biol, Div Allergy & Immunol, A-5020 Salzburg, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Salzburg University	Valenta, R (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Eckl-Dorna, Julia/AAY-6371-2020; Thalhamer, Josef/E-5787-2011; Gamperl, Susi/V-2715-2019; Valent, Peter/B-8533-2016; Test, PV/U-9451-2019; Weiss, Richard/N-7279-2013; Test, Test/Y-7921-2019	Thalhamer, Josef/0000-0003-2285-6400; Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Weiss, Richard/0000-0003-3185-7253; Valenta, Rudolf/0000-0001-5944-3365; Eckl-Dorna, Julia/0000-0001-5981-1607	Christian Doppler Research Association, Vienna, Austria; Biomay AG, Vienna, Austria; Austrian Science Fund (FWF) [F4604, F4605, F4611, F4613]	Christian Doppler Research Association, Vienna, Austria; Biomay AG, Vienna, Austria; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by research grants from the Christian Doppler Research Association, Vienna, Austria; Biomay AG, Vienna, Austria; and the Austrian Science Fund (FWF), projects F4604, F4605, F4611, and F4613.	Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Banerjee S, 2014, J IMMUNOL, V192, P4867, DOI 10.4049/jimmunol.1400064; Blackley CH., 1873, EXPT RES CAUSES NATU; Burbach GJ, 2009, ALLERGY, V64, P1507, DOI 10.1111/j.1398-9995.2009.02089.x; Calderon M, 2012, ALLERGY, V67, P462, DOI 10.1111/j.1398-9995.2012.02785.x; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Cromwell O, 2011, J ALLERGY CLIN IMMUN, V127, P865, DOI 10.1016/j.jaci.2011.01.047; De Marino S, 1999, STRUCT FOLD DES, V7, P943; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; Focke M, 2008, CLIN EXP ALLERGY, V38, P1400, DOI 10.1111/j.1365-2222.2008.03031.x; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Focke-Tejkl M, 2014, J ALLERGY CLIN IMMUN, V133, P836, DOI 10.1016/j.jaci.2013.08.038; Focke-Tejkl M, 2012, CURR OPIN ALLERGY CL, V12, P555, DOI 10.1097/ACI.0b013e328357ca53; FROSTAD AB, 1983, CLIN ALLERGY, V13, P337, DOI 10.1111/j.1365-2222.1983.tb02609.x; Gangl K, 2013, CLIN EXP ALLERGY, V43, P1202, DOI 10.1111/cea.12128; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Klimek L, 2012, CLIN EXP ALLERGY, V42, P936, DOI 10.1111/j.1365-2222.2012.03971.x; Kundig TM, 2011, ALLERGY, V66, P60, DOI 10.1111/j.1398-9995.2011.02643.x; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Larche M, 2011, CURR TOP MICROBIOL, V352, P107, DOI 10.1007/82_2011_131; Linhart B, 2007, J IMMUNOL, V178, P3924, DOI 10.4049/jimmunol.178.6.3924; Linhart B, 2012, CURR OPIN IMMUNOL, V24, P354, DOI 10.1016/j.coi.2012.03.006; Linhart B, 2012, VACCINE, V30, P4328, DOI 10.1016/j.vaccine.2011.11.011; Marth K, 2013, J IMMUNOL, V190, P3068, DOI 10.4049/jimmunol.1202441; Mascarell L, 2011, CURR TOP MICROBIOL, V352, P85, DOI 10.1007/82_2011_132; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Mothes-Luksch N, 2008, J IMMUNOL, V181, P4864, DOI 10.4049/jimmunol.181.7.4864; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Niespodziana K, 2011, J ALLERGY CLIN IMMUN, V127, P1562, DOI 10.1016/j.jaci.2011.02.004; Noon L, 1911, LANCET, V1, P1572; Padavattan S, 2009, J IMMUNOL, V182, P2141, DOI 10.4049/jimmunol.0803018; Pauli G, 2011, CURR TOP MICROBIOL, V352, P43, DOI 10.1007/82_2011_125; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; Pree I, 2010, CLIN EXP ALLERGY, V40, P1346, DOI 10.1111/j.1365-2222.2010.03548.x; Rancitelli P, 2011, CURR TOP MICROBIOL, V352, P55, DOI 10.1007/82_2011_126; Rendi-Wagner P, 2006, VACCINE, V24, P2781, DOI 10.1016/j.vaccine.2006.01.007; SISKIND GW, 1966, J EXP MED, V123, P673, DOI 10.1084/jem.123.4.673; Suphioglu C, 2000, CLIN EXP ALLERGY, V30, P1335, DOI 10.1046/j.1365-2222.2000.00955.x; Torrero MN, 2009, CLIN EXP ALLERGY, V39, P361, DOI 10.1111/j.1365-2222.2008.03154.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; Valenta R, 2011, ALLERGY, V66, P775, DOI 10.1111/j.1398-9995.2011.02565.x; Valenta R, 2011, J ALLERGY CLIN IMMUN, V127, P860, DOI 10.1016/j.jaci.2011.02.016; Vrtala S, 1998, J IMMUNOL, V160, P6137; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 2007, J IMMUNOL, V179, P1730, DOI 10.4049/jimmunol.179.3.1730; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; Winther L, 2006, CLIN EXP ALLERGY, V36, P254, DOI 10.1111/j.1365-2222.2006.02340.x	56	94	100	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1207	U614		10.1016/j.jaci.2014.09.012	http://dx.doi.org/10.1016/j.jaci.2014.09.012			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25441634	Green Published, hybrid			2022-12-18	WOS:000353980700014
J	Swierczynska-Krepa, M; Sanak, M; Bochenek, G; Strek, P; Cmiel, A; Gielicz, A; Plutecka, H; Szczeklik, A; Nizankowska-Mogilnicka, E				Swierczynska-Krepa, Monika; Sanak, Marek; Bochenek, Grazyna; Strek, Pawel; Cmiel, Adam; Gielicz, Anna; Plutecka, Hanna; Szczeklik, Andrzej; Nizankowska-Mogilnicka, Ewa			Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: A double-blind study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-induced asthma; aspirin-tolerant asthma; oral aspirin desensitization	EXACERBATED RESPIRATORY-DISEASE; INTRANASAL LYSINE-ASPIRIN; LONG-TERM TREATMENT; RHINOSINUSITIS-ASTHMA; NASAL; PATHOGENESIS; METABOLITE; CHALLENGE; HISTAMINE; PLASMA	Background: Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA). These beneficial effects might be attributable to aspirin's potent anti-inflammatory properties, but that supposition requires further corroboration. Objective: We sought to compare the clinical and biochemical responses to chronic oral AD in 20 patients with AIA and 14 patients with aspirin-tolerant asthma (ATA). All of the patients had chronic rhinosinusitis and nasal polyposis, and these responses were investigated in a pilot, double-blind, placebo-controlled study. Methods: Twelve patients with AIA and 6 patients with ATA were randomly assigned to receive 624 mg of aspirin, and 8 patients with AIA and 8 patients with ATA received placebo. Both aspirin and placebo were administered once daily for 6 months. Nasal symptoms, Sino-Nasal Outcome Test (SNOT20) scores, peak nasal inspiratory flows, Asthma Control Questionnaire scores, spirometric parameters, peak expiratory flows, blood eosinophilia, and corticosteroid doses were assessed on a monthly basis. Levels of urinary leukotriene E-4 and the stable plasma prostaglandin (PG) D-2 metabolite 9 alpha, 11 beta-PGF2 were evaluated at baseline and after 1, 3, 5, and 6 months. Results: Only the patients with AIA subjected to AD reported improvements in smell and reductions in sneezing and nasal blockade. The SNOT20 and Asthma Control Questionnaire scores of these patients decreased, and their peak nasal inspiratory flows increased. The dosages of inhaled corticosteroids were reduced. There were no changes in leukotriene E-4 or 9 alpha, 11 beta-PGF(2) levels after AD. Conclusion: The clinically beneficial effects of AD on nasal and bronchial symptoms occurred only in the patients with AIA.	[Swierczynska-Krepa, Monika] Medex, Bielsko Biala, Poland; [Sanak, Marek; Bochenek, Grazyna; Gielicz, Anna; Plutecka, Hanna; Szczeklik, Andrzej; Nizankowska-Mogilnicka, Ewa] Jagiellonian Univ, Sch Med, Dept Med, Div Pulmonol, PL-31066 Krakow, Poland; [Strek, Pawel] Jagiellonian Univ, Sch Med, Dept Otolaryngol, PL-31066 Krakow, Poland; [Cmiel, Adam] AGH Univ Sci & Technol, Dept Appl Math, Krakow, Poland	Jagiellonian University; Jagiellonian University; AGH University of Science & Technology	Nizankowska-Mogilnicka, E (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, Div Pulmonol, Ul Skawinska 8, PL-31066 Krakow, Poland.	ewa.nizankowska@ghml.pl	Sanak, Marek/AAV-1628-2021	Sanak, Marek/0000-0001-7635-8103; Cmiel, Adam/0000-0002-7015-1707	Ministry of Science and Higher Education of Poland [K/ZDS/000362]; Jagiellonian University [K/ZDS/000362]	Ministry of Science and Higher Education of Poland(Ministry of Science and Higher Education, Poland); Jagiellonian University	Supported by university grant no. K/ZDS/000362 (Ministry of Science and Higher Education of Poland in association with Jagiellonian University).	ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; Baker TW, 2011, ALLERGY ASTHMA PROC, V32, P335, DOI 10.2500/aap.2011.32.3457; Berges-Gimeno MP, 2003, ANN ALLERG ASTHMA IM, V90, P338, DOI 10.1016/S1081-1206(10)61803-0; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Bochenek G, 2004, THORAX, V59, P459, DOI 10.1136/thx.2003.013573; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; Burnett T, 2013, IMMUNOL ALLERGY CLIN, V33, P223, DOI 10.1016/j.iac.2012.11.003; Chang JE, 2012, AM J RHINOL ALLERGY, V26, P27, DOI 10.2500/ajra.2012.26.3721; Cortellini G, 2012, EUR ANN ALLERGY CLIN, V44, P160; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Forer B, 2011, RHINOLOGY, V49, P95, DOI 10.4193/Rhino09.113; GIAMPIERO P, 1991, ANN ALLERGY, V67, P588; Global Initiative for Asthma (GINA), 2012, GLOB IN ASTHM GINA; Gosepath J, 2002, LARYNGO RHINO OTOL, V81, P732, DOI 10.1055/s-2002-35002; Havel M, 2012, ARCH OTORHINOLARYNGO, V270, P571; JUERGENS UR, 1995, J ALLERGY CLIN IMMUN, V96, P148, DOI 10.1016/S0091-6749(95)70002-1; Katial RK, 2010, J ALLERGY CLIN IMMUN, V126, P738, DOI 10.1016/j.jaci.2010.06.036; Klimek L, 2009, IMMUNOL ALLERGY CLIN, V29, P669, DOI 10.1016/j.iac.2009.07.008; Kowalski ML, 2011, ALLERGY, V66, P818, DOI 10.1111/j.1398-9995.2011.02557.x; Kumlin M, 2000, AM J RESP CRIT CARE, V161, pS102, DOI 10.1164/ajrccm.161.supplement_1.ltta-20; Laidlaw TM, 2013, IMMUNOL ALLERGY CLIN, V33, P195, DOI 10.1016/j.iac.2012.11.006; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Lee RU, 2011, ALLERGY ASTHMA IMMUN, V3, P3, DOI 10.4168/aair.2011.3.1.3; Lee RU, 2010, ANN ALLERG ASTHMA IM, V105, P130, DOI 10.1016/j.anai.2010.05.020; Lund VJ, 1997, OTOLARYNG HEAD NECK, V117, pS35, DOI 10.1016/S0194-5998(97)70005-6; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; Moebus RG, 2012, AM J RHINOL ALLERGY, V26, P134, DOI 10.2500/ajra.2012.26.3748; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; Nucera E, 2000, THORAX, V55, pS75, DOI 10.1136/thorax.55.suppl_2.S75; Ogata N, 2007, J LARYNGOL OTOL, V121, P1156, DOI 10.1017/S0022215107000515; Parikh AA, 2005, LARYNGOSCOPE, V115, P1385, DOI 10.1097/01.MLG.0000166702.38850.1B; Pezato R, 2012, ALLERGY, V67, P1347, DOI 10.1111/all.12010; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; Rozsasi A, 2008, ALLERGY, V63, P1228, DOI 10.1111/j.1398-9995.2008.01658.x; Shah S, 2012, POSTGRAD MED J, V88, P73, DOI 10.1136/postgradmedj-2011-130291; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Steinke JW, 2012, J ALLERGY CAIRO, V2012; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; Swierczynska M, 2003, J ALLERGY CLIN IMMUN, V112, P995, DOI 10.1016/S0091-6749(03)02015-3; Szczeklik A., 2009, MIDDELTONS ALLERGY P, V7, P1227, DOI [DOI 10.1016/B978-0-323-05659-5.00069-3, 10.1016/b978-0-323-05659-5.00069-3]; White AA, 2012, SEMIN RESP CRIT CARE, V33, P588, DOI 10.1055/s-0032-1325618; White AA, 2011, ALLERGY ASTHMA PROC, V32, P333, DOI 10.2500/aap.2011.32.3437; Williams AN, 2008, CURR ALLERGY ASTHM R, V8, P245, DOI 10.1007/s11882-008-0041-7; Xu JJ, 2013, INT FORUM ALLERGY RH, V3, P915, DOI 10.1002/alr.21202	49	94	96	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					883	890		10.1016/j.jaci.2014.02.041	http://dx.doi.org/10.1016/j.jaci.2014.02.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	24767875	Bronze, Green Submitted			2022-12-18	WOS:000343155700015
J	Chen, R; Giliani, S; Lanzi, G; Mias, GI; Lonardi, S; Dobbs, K; Manis, J; Im, H; Gallagher, JE; Phanstiel, DH; Euskirchen, G; Lacroute, P; Bettinger, K; Moratto, D; Weinacht, K; Montin, D; Gallo, E; Mangili, G; Porta, F; Notarangelo, LD; Pedretti, S; Al-Herz, W; Alfahdli, W; Comeau, AM; Traister, RS; Pai, SY; Carella, G; Facchetti, F; Nadeau, KC; Snyder, M; Notarangelo, LD				Chen, Rui; Giliani, Silvia; Lanzi, Gaetana; Mias, George I.; Lonardi, Silvia; Dobbs, Kerry; Manis, John; Im, Hogune; Gallagher, Jennifer E.; Phanstiel, Douglas H.; Euskirchen, Ghia; Lacroute, Philippe; Bettinger, Keith; Moratto, Daniele; Weinacht, Katja; Montin, Davide; Gallo, Eleonora; Mangili, Giovanna; Porta, Fulvio; Notarangelo, Lucia D.; Pedretti, Stefania; Al-Herz, Waleed; Alfahdli, Wasmi; Comeau, Anne Marie; Traister, Russell S.; Pai, Sung-Yun; Carella, Graziella; Facchetti, Fabio; Nadeau, Kari C.; Snyder, Michael; Notarangelo, Luigi D.			Whole-exome sequencing identifies tetratricopeptide repeat domain 7A (TTC7A) mutations for combined immunodeficiency with intestinal atresias	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Combined immunodeficiency with multiple intestinal atresias; tetratricopeptide repeat domain 7A; whole-exome sequencing; thymus	MULTIPLE GASTROINTESTINAL ATRESIAS; SMALL-BOWEL TRANSPLANTATION; GENE; ANEMIA; AUTOIMMUNITY; FRAMEWORK; TRACT; CELLS; LIVER	Background: Combined immunodeficiency with multiple intestinal atresias (CID-MIA) is a rare hereditary disease characterized by intestinal obstructions and profound immune defects. Objective: We sought to determine the underlying genetic causes of CID-MIA by analyzing the exomic sequences of 5 patients and their healthy direct relatives from 5 unrelated families. Methods: We performed whole-exome sequencing on 5 patients with CID-MIA and 10 healthy direct family members belonging to 5 unrelated families with CID-MIA. We also performed targeted Sanger sequencing for the candidate gene tetratricopeptide repeat domain 7A (TTC7A) on 3 additional patients with CID-MIA. Results: Through analysis and comparison of the exomic sequence of the subjects from these 5 families, we identified biallelic damaging mutations in the TTC7A gene, for a total of 7 distinct mutations. Targeted TTC7A gene sequencing in 3 additional unrelated patients with CID-MIA revealed biallelic deleterious mutations in 2 of them, as well as an aberrant splice product in the third patient. Staining of normal thymus showed that the TTC7A protein is expressed in thymic epithelial cells, as well as in thymocytes. Moreover, severe lymphoid depletion was observed in the thymus and peripheral lymphoid tissues from 2 patients with CID-MIA. Conclusions: We identified deleterious mutations of the TTC7A gene in 8 unrelated patients with CID-MIA and demonstrated that the TTC7A protein is expressed in the thymus. Our results strongly suggest that TTC7A gene defects cause CID-MIA.	[Chen, Rui; Mias, George I.; Im, Hogune; Gallagher, Jennifer E.; Phanstiel, Douglas H.; Euskirchen, Ghia; Lacroute, Philippe; Bettinger, Keith; Snyder, Michael] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Nadeau, Kari C.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Giliani, Silvia; Lanzi, Gaetana; Moratto, Daniele] Univ Brescia, Pediat Clin, A Nocivelli Inst Mol Med, Brescia, Italy; [Giliani, Silvia; Lanzi, Gaetana; Moratto, Daniele] Spedali Civil Brescia, Dept Pathol, Genet Sect, I-25125 Brescia, Italy; [Lonardi, Silvia; Facchetti, Fabio] Univ Brescia, Dept Pathol, Brescia, Italy; [Dobbs, Kerry; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston Childrens Hosp,Div Immunol, Boston, MA USA; [Manis, John] Boston Childrens Hosp, Dept Transfus Med, Boston, MA USA; [Weinacht, Katja] Boston Childrens Hosp, Div Hematol & Oncol, Boston, MA USA; [Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Montin, Davide; Gallo, Eleonora] Univ Turin, Dept Publ Hlth & Pediat, I-10124 Turin, Italy; [Mangili, Giovanna; Pedretti, Stefania] Osped Riuniti Bergamo, USC Patol Neonatale, Bergamo, Italy; [Porta, Fulvio; Notarangelo, Lucia D.] Spedali Civil Brescia, Div Pediat Hematol Oncol, I-25125 Brescia, Italy; [Carella, Graziella] Spedali Civil Brescia, I-25125 Brescia, Italy; [Al-Herz, Waleed] Al Sabah Hosp, Dept Pediat, Kuwait, Kuwait; [Alfahdli, Wasmi] Ibn Sina Hosp, Dept Surg, Kuwait, Kuwait; [Comeau, Anne Marie] Univ Massachusetts, Sch Med, New England Newborn Screening Program, Worcester, MA USA; [Traister, Russell S.] Childrens Hosp Pittsburgh, Dept Internal Med, Boston, MA USA; [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA USA	Stanford University; Stanford University; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; University of Turin; Ospedali Riuniti di Bergamo; Hospital Spedali Civili Brescia; Hospital Spedali Civili Brescia; Al Sabah Hospital; University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School	Snyder, M (corresponding author), Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.	knadeau@stanford.edu; mpsnyder@stanford.edu; Luigi.Notarangelo@childrens.harvard.edu	Pai, Sung-Yun/AAH-7762-2019; Mias, George/J-1138-2019; Im, Hogune/ABG-3002-2021; Facchetti, Fabio/E-7190-2010; Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016	Pai, Sung-Yun/0000-0002-0158-8147; Mias, George/0000-0002-9083-1216; Im, Hogune/0000-0002-2812-4617; Facchetti, Fabio/0000-0003-4975-2388; Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; Snyder, Michael/0000-0003-0784-7987; Dobbs, Kerry/0000-0002-3432-3137; Montin, Davide/0000-0001-8953-2182; Gallagher, Jennifer/0000-0002-6163-3181	Stanford University; National Institutes of Health (NIH); NIH [5P01AI076210-04, 1R01AI00887-01,, 4U54AI082973-04]; Manton Foundation; Dubai Harvard Foundation for Medical Research; Kuwait Foundation for the Advancement of Sciences [2010-1302-05]; Fondazione Nocivelli; University of Brescia; MIUR [20104HBZ8E_002]; Translational Investigator Service award from Boston Children's Hospital; National Human Genome Research Institute of the NIH [K99HG007065]; Damon Runyon Cancer Research Foundation (DRG) [2122-22]; National Genome Research Institute; NIH; NIH/National Institute of Allergy and Infectious Diseases (NIAID); Boston Children's Hospital; NIH/NIAID; NIH/National Heart, Lung, and Blood Institute (NHLBI); Italian Ministry of University and Research; Illumina; Beckman Coulter; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG007919, K99HG007065, R00HG007065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, R01AI100887, U54AI082973] Funding Source: NIH RePORTER	Stanford University(Stanford University); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Manton Foundation; Dubai Harvard Foundation for Medical Research; Kuwait Foundation for the Advancement of Sciences(Kuwait Foundation for the Advancement of Sciences (KFAS)); Fondazione Nocivelli; University of Brescia; MIUR(Ministry of Education, Universities and Research (MIUR)); Translational Investigator Service award from Boston Children's Hospital; National Human Genome Research Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Damon Runyon Cancer Research Foundation (DRG); National Genome Research Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Boston Children's Hospital; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Illumina; Beckman Coulter; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M.S. is funded by grants from Stanford University and the National Institutes of Health (NIH). L.D.N. is supported by NIH grants 5P01AI076210-04, 1R01AI00887-01, and 4U54AI082973-04 (also to S.-Y.P.) and the Manton Foundation. Both L.D.N. and W. A.-H. are supported by a grant from the Dubai Harvard Foundation for Medical Research and by Kuwait Foundation for the Advancement of Sciences (grant 2010-1302-05). S.G. is supported by Fondazione Nocivelli and the University of Brescia. F.F. is supported by MIUR (grant 20104HBZ8E_002). S.-Y.P. is supported by a Translational Investigator Service award from Boston Children's Hospital. G.I.M.'s research reported in this publication was supported by the National Human Genome Research Institute of the NIH under award no. K99HG007065. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. D.H.P. is a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRG-#2122-22).r G. I. Mias has received grants from the National Institutes of Health (NIH) and the National Genome Research Institute. S. Lonardi is employed by the University of Brescia. J. Manis has received grants from NIH. G. Euskirchen receives part of her salary from NIH grants. S.-Y. Pai has received grants from NIH/National Institute of Allergy and Infectious Diseases (NIAID), has received a Translational Investigator Service internal award from Boston Children's Hospital, and has grants/grants pending from the Manton Foundation, NIH/NIAID, and NIH/National Heart, Lung, and Blood Institute (NHLBI). F. Facchetti has received the Bruto salary from the University of Brescia and has grants/grants pending from the Italian Ministry of University and Research. M. Snyder is a scientific advisory board member for Personalis and Genapsys; has consultant arrangements with Illumina; has received payment for lectures, including service on speakers' bureaus, from Illumina and Beckman Coulter; and has stock/stock options in Excelexis. L. D. Notarangelo has received grants from the NIH and the Dubai Harvard Foundation for Medical Research, is a board member for the Immune Disease Institute, is an advisory board member for Meyer Hospital, is employed by Boston Children's Hospital, and receives royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	Abernethy NJ, 2000, IMMUNOL CELL BIOL, V78, P5, DOI 10.1046/j.1440-1711.2000.00866.x; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Ali YA, 2011, BMJ CASE REP, V2011; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; ARNALMONREAL F, 1983, ACTA PAEDIATR SCAND, V72, P773, DOI 10.1111/j.1651-2227.1983.tb09812.x; Bilodeau A, 2004, J PEDIATR SURG, V39, P726, DOI 10.1016/j.jpedsurg.2004.01.031; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.3.CO;2-E; Chen R, 2012, CURR OPIN PHARMACOL, V12, P623, DOI 10.1016/j.coph.2012.07.011; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Conrad C, 2010, J PEDIATR SURG, V45, pE21, DOI 10.1016/j.jpedsurg.2010.01.017; DALLAIRE L, 1974, Birth Defects Original Article Series, V10, P259; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Gahukamble DB, 2002, PEDIATR SURG INT, V18, P40, DOI 10.1007/s003830200009; Gahukamble DB, 2002, PEDIATR SURG INT, V18, P175; Gilroy RK, 2004, BLOOD, V103, P1171, DOI 10.1182/blood-2003-04-1187; Green MR, 2011, P NATL ACAD SCI USA, V108, P2873, DOI 10.1073/pnas.1019537108; GUNGOR N, 1995, CLIN GENET, V47, P245; GUTTMAN FM, 1973, J PEDIATR SURG, V8, P633, DOI 10.1016/0022-3468(73)90401-6; Hale JE, 2010, J ALLERGY CLIN IMMUN, V126, P1073, DOI 10.1016/j.jaci.2010.08.043; Helms C, 2005, EXP BIOL MED, V230, P659; Kimmig S, 2002, J EXP MED, V195, P789, DOI 10.1084/jem.20011756; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Mattsson N, 2005, CELL IMMUNOL, V234, P124, DOI 10.1016/j.cellimm.2005.06.005; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mias George I, 2013, Quant Biol, V1, P71; MISHALANY HG, 1971, J PEDIATR-US, V79, P124, DOI 10.1016/S0022-3476(71)80072-0; Moore SW, 1996, J PEDIATR SURG, V31, P1733, DOI 10.1016/S0022-3468(96)90066-4; MORENO LA, 1990, AM J MED GENET, V37, P143, DOI 10.1002/ajmg.1320370133; Pelsue SC, 1998, EUR J IMMUNOL, V28, P1379, DOI 10.1002/(SICI)1521-4141(199804)28:04<1379::AID-IMMU1379>3.0.CO;2-3; Reyes J, 1997, CLIN TRANSPLANT, V11, P345; Rothenberg M E, 1995, Immunodeficiency, V5, P171; Samuels ME, 2013, J MED GENET, V50, P324, DOI 10.1136/jmedgenet-2012-101483; SHIMIZU K, 1983, LAB ANIM, V17, P198, DOI 10.1258/002367783781070678; Takabayashi S, 2005, EXP ANIM TOKYO, V54, P339, DOI 10.1538/expanim.54.339; Takabayashi S, 2007, EXP BIOL MED, V232, P695; WALKER MW, 1993, J PEDIATR-US, V123, P93, DOI 10.1016/S0022-3476(05)81547-1; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Welner R, 2005, AUTOIMMUNITY, V38, P399, DOI 10.1080/08916930500246206; Welner R, 2004, AUTOIMMUNITY, V37, P227, DOI 10.1080/08916930410001666659; White RA, 2005, GENOMICS, V85, P330, DOI 10.1016/j.ygeno.2004.11.008; Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130	43	94	99	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					656	+		10.1016/j.jaci.2013.06.013	http://dx.doi.org/10.1016/j.jaci.2013.06.013			26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23830146	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000323612000018
J	Caubet, JC; Nowak-Wegrzyn, A; Moshier, E; Godbold, J; Wang, J; Sampson, HA				Caubet, Jean-Christoph; Nowak-Wegrzyn, Anna; Moshier, Erin; Godbold, James; Wang, Julie; Sampson, Hugh A.			Utility of casein-specific IgE levels in predicting reactivity to baked milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COWS MILK; CHILDREN; ALLERGY; FOOD		[Caubet, Jean-Christoph; Nowak-Wegrzyn, Anna; Wang, Julie; Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Moshier, Erin; Godbold, James] Mt Sinai Sch Med, Div Biostat, Dept Prevent Med, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Caubet, JC (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA.	hugh.sampson@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000067] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI044236, K23AI083883] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000067] Funding Source: Medline; NCRR NIH HHS [M01 RR000071, RR026134] Funding Source: Medline; NIAID NIH HHS [U19 AI044236, K23 AI083883, AI44236, P01 AI044236] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ando H, 2008, J ALLERGY CLIN IMMUN, V122, P583, DOI 10.1016/j.jaci.2008.06.016; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Cantani A, 2004, Eur Rev Med Pharmacol Sci, V8, P153; D'Urbano LE, 2010, CLIN EXP ALLERGY, V40, P1561, DOI 10.1111/j.1365-2222.2010.03568.x; Ford LS, 2012, J ALLERGY CLIN IMMUN; GJESING B, 1986, ALLERGY, V41, P51, DOI 10.1111/j.1398-9995.1986.tb00275.x; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023	10	94	95	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					222	224		10.1016/j.jaci.2012.06.049	http://dx.doi.org/10.1016/j.jaci.2012.06.049			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	22921870	Green Accepted, Bronze			2022-12-18	WOS:000312961200027
J	Salam, MT; Byun, HM; Lurmann, F; Breton, CV; Wang, XH; Eckel, SP; Gilliland, FD				Salam, Muhammad T.; Byun, Hyang-Min; Lurmann, Fred; Breton, Carrie V.; Wang, Xinhui; Eckel, Sandrah P.; Gilliland, Frank D.			Genetic and epigenetic variations in inducible nitric oxide synthase promoter, particulate pollution, and exhaled nitric oxide levels in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; biomarker; DNA methylation; epigenetics; genetics; gene-environment interaction; nitrosative stress	DNA METHYLATION PATTERNS; AMBIENT AIR-POLLUTION; CIGARETTE-SMOKE; MULTIETHNIC COHORT; CHILDHOOD ASTHMA; INDUCED SPUTUM; LUNG-FUNCTION; EXPOSURE; SCHOOLCHILDREN; SUSCEPTIBILITY	Background: Inducible nitric oxide synthase (iNOS; encoded by nitric oxide synthase isoform 2 [NOS2]) is the major enzyme for nitric oxide synthesis in airways. As such, measurement of fractional concentration of exhaled nitric oxide (FENO) provides an in vivo assessment of iNOS activity. Short-term exposure to air pollution, haplotypes, and DNA methylation in the NOS2 promoter has been associated independently with iNOS expression, FENO levels, or both. Objective: We aimed to examine the effects of ambient air pollutants, NOS2 promoter haplotypes, and NOS2 promoter methylation on FENO levels in children. Methods: We selected 940 participants in the Children's Health Study who provided buccal samples and had undergone FENO measurement on the same day. DNA methylation was measured with a bisulfite-PCR Pyrosequencing assay. Seven single nucleotide polymorphisms captured the haplotype diversity in the NOS2 promoter. Average particulate matter with an aerodynamic diameter of 2.5 mu m or less (PM(2.5)) and 10 mu m (PM(10)) or less and ozone and nitrogen dioxide levels 7 days before FENO measurement were estimated based on air pollution data obtained at central monitoring sites. Results: We found interrelated effects of PM(2.5), NOS2 promoter haplotypes, and iNOS methylation on FENO levels. Increased 7-day average PM(2.5) exposure was associated with lower iNOS methylation (P = .01). NOS2 promoter haplotypes were globally associated with NOS2 promoter methylation (P = 6.2 x 10(-8)). There was interaction among 1 common promoter haplotype, iNOS methylation level, and PM(2.5) exposure on FENO levels (P(interaction) = .00007). Conclusion: Promoter variants in NOS2 and short-term PM(2.5) exposure affect iNOS methylation. This is one of the first studies showing contributions of genetic and epigenetic variations in air pollution-mediated phenotype expression. (J Allergy Clin Immunol 2012;129:232-9.)	[Salam, Muhammad T.; Breton, Carrie V.; Wang, Xinhui; Eckel, Sandrah P.; Gilliland, Frank D.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA; [Byun, Hyang-Min] Harvard Univ, Sch Publ Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA; [Lurmann, Fred] Sonoma Technol Inc, Petaluma, CA USA	University of Southern California; Harvard University; Harvard T.H. Chan School of Public Health	Salam, MT (corresponding author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 2001 N Soto St,MC 9237, Los Angeles, CA 90089 USA.	msalam@usc.edu	Byun, Hyang-Min/X-2843-2018	Byun, Hyang-Min/0000-0002-6278-3165; Salam, Muhammad/0000-0002-3565-8916	National Heart, Lung, and Blood Institute [5R01HL61768, 5R01HL76647]; Southern California Environmental Health Sciences Center [5P30ES007048]; National Institute of Environmental Health Sciences [5P01ES011627]; Children's Environmental Health Center [5P01ES009581, R826708-01, RD831861-01]; US Environmental Protection Agency; Hastings Foundation; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076647, R01HL061768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009581, P01ES011627, P30ES007048] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Southern California Environmental Health Sciences Center; National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Children's Environmental Health Center; US Environmental Protection Agency(United States Environmental Protection Agency); Hastings Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Heart, Lung, and Blood Institute (grants 5R01HL61768 and 5R01HL76647); the Southern California Environmental Health Sciences Center (grant 5P30ES007048), funded by the National Institute of Environmental Health Sciences; the Children's Environmental Health Center (grants 5P01ES009581, R826708-01 and RD831861-01), funded by the National Institute of Environmental Health Sciences and the US Environmental Protection Agency; the National Institute of Environmental Health Sciences (grant 5P01ES011627); and the Hastings Foundation.; M. T. Salam, C. V. Breton, and F. D. Gilliland receive research support from the National Heart, Lung, and Blood Institute and the National Institute of Environmental Health Sciences. F. Lurmann receives research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Adamkiewicz G, 2004, THORAX, V59, P204, DOI 10.1136/thorax.2003.006445; Allen RW, 2008, INHAL TOXICOL, V20, P423, DOI 10.1080/08958370801903826 ; Anazawa T, 2004, ARTERIOSCL THROM VAS, V24, P1652, DOI 10.1161/01.ATV.0000139925.84444.ad; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P912; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Barraza-Villarreal A, 2008, ENVIRON HEALTH PERSP, V116, P832, DOI 10.1289/ehp.10926; Bastain TM, 2011, EUR RESPIR J, V37, P523, DOI 10.1183/09031936.00021210; Bates CA, 2003, J ALLERGY CLIN IMMUN, V111, P256, DOI 10.1067/mai.2003.103; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10; Berhane K, 2011, EUR RESPIR J, V37, P1029, DOI 10.1183/09031936.00081410; Bhutani M, 2008, CANCER PREV RES, V1, P39, DOI 10.1158/1940-6207.CAPR-08-0058; Boyle JO, 2010, CANCER PREV RES, V3, P266, DOI 10.1158/1940-6207.CAPR-09-0192; Brauer M, 2001, ENVIRON HEALTH PERSP, V109, P1039, DOI 10.2307/3454959; Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445; Chan GC, 2005, J IMMUNOL, V175, P3846, DOI 10.4049/jimmunol.175.6.3846; Chang WC, 2001, ARCH TOXICOL, V75, P28, DOI 10.1007/s002040000168; Chawes BLK, 2010, AM J RESP CRIT CARE, V182, P138, DOI 10.1164/rccm.200909-1377OC; Churg A, 1997, AM J RESP CRIT CARE, V155, P2109, DOI 10.1164/ajrccm.155.6.9196123; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299; Gibson PG, 2003, THORAX, V58, P116, DOI 10.1136/thorax.58.2.116; Islam T, 2010, THORAX, V65, P139, DOI 10.1136/thx.2009.114355; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; Koenig JQ, 2005, ENVIRON HEALTH PERSP, V113, P499, DOI 10.1289/ehp.7511; Kolonel LN, 2000, AM J EPIDEMIOL, V151, P346, DOI 10.1093/oxfordjournals.aje.a010213; Linn WS, 2009, J EXPO SCI ENV EPID, V19, P674, DOI 10.1038/jes.2008.64; Linn WS, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-28; Mar TF, 2005, ENVIRON HEALTH PERSP, V113, P1791, DOI 10.1289/ehp.7883; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Nam HY, 2004, TOXICOL LETT, V148, P95, DOI 10.1016/j.toxlet.2003.12.007; Olin AC, 2010, AM J RESP CRIT CARE, V181, P324, DOI 10.1164/rccm.200907-1079OC; Paredi P, 2002, AM J RESP CRIT CARE, V166, pS31, DOI 10.1164/rccm.2206012; Pritchard JN, 2001, J AEROSOL MED, V14, pS19, DOI 10.1089/08942680150506303; Prophete C, 2006, J TOXICOL ENV HEAL A, V69, P935, DOI 10.1080/15287390500362030; Ronneberg JA, 2008, CANCER RES, V68, P5562, DOI 10.1158/0008-5472.CAN-07-5828; Saito J, 2004, J ALLERGY CLIN IMMUN, V114, P512, DOI 10.1016/j.jaci.2004.05.033; Salam MT, 2011, ALLERGY, V66, P412, DOI 10.1111/j.1398-9995.2010.02492.x; Schalkwyk LC, 2010, AM J HUM GENET, V86, P196, DOI 10.1016/j.ajhg.2010.01.014; Sridhar S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-259; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; Tarantini L, 2009, ENVIRON HEALTH PERSP, V117, P217, DOI 10.1289/ehp.11898; van Berlo D, 2010, ARCH TOXICOL, V84, P553, DOI 10.1007/s00204-010-0551-7; Wilson NM, 2000, THORAX, V55, P768, DOI 10.1136/thorax.55.9.768; Yang HH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009355; Ying ZK, 2009, TOXICOL SCI, V111, P80, DOI 10.1093/toxsci/kfp004; 1999, AM J RESP CRIT CARE, V160, P2104	48	94	102	0	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					232	U338		10.1016/j.jaci.2011.09.037	http://dx.doi.org/10.1016/j.jaci.2011.09.037			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22055874	Green Accepted			2022-12-18	WOS:000298634000030
J	Micol, R; Ben Slama, L; Suarez, F; Le Mignot, L; Beaute, J; Mahlaoui, N; d'Enghien, CD; Lauge, A; Hall, J; Couturier, J; Vallee, L; Delobel, B; Rivier, F; Nguyen, K; de Villemeur, TB; Stephan, JL; Bordigoni, P; Bertrand, Y; Aladjidi, N; Pedespan, JM; Thomas, C; Pellier, I; Koenig, M; Hermine, O; Picard, C; Moshous, D; Neven, B; Lanternier, F; Blanche, S; Tardieu, M; Debre, M; Fischer, A; Stoppa-Lyonnet, D				Micol, Romain; Ben Slama, Lilia; Suarez, Felipe; Le Mignot, Loic; Beaute, Julien; Mahlaoui, Nizar; d'Enghien, Catherine Dubois; Lauge, Anthony; Hall, Janet; Couturier, Jerome; Vallee, Louis; Delobel, Bruno; Rivier, Francois; Nguyen, Karine; de Villemeur, Thierry Billette; Stephan, Jean-Louis; Bordigoni, Pierre; Bertrand, Yves; Aladjidi, Nathalie; Pedespan, Jean-Michel; Thomas, Caroline; Pellier, Isabelle; Koenig, Michel; Hermine, Olivier; Picard, Capucine; Moshous, Despina; Neven, Benedicte; Lanternier, Fanny; Blanche, Stephane; Tardieu, Marc; Debre, Marianne; Fischer, Alain; Stoppa-Lyonnet, Dominique		CEREDIH Network	Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cancer; genetics; leukemia; lymphoma; inherited; DNA repair	LABORATORY FEATURES; IMMUNODEFICIENCY; CANCER; GENE; MUTATIONS; KINASE	Background: Ataxia-telangiectasia (A-T) is a rare genetic disease caused by germline biallelic mutations in the ataxia-telangiectasia mutated gene (ATM) that result in partial or complete loss of ATM expression or activity. The course of the disease is characterized by neurologic manifestations, infections, and cancers. Objective: We studied A-T progression and investigated whether manifestations were associated with the ATM genotype. Methods: We performed a retrospective cohort study in France of 240 patients with A-T born from 1954 to 2005 and analyzed ATM mutations in 184 patients, along with neurologic manifestations, infections, and cancers. Results: Among patients with A-T, the Kaplan-Meier 20-year survival rate was 53.4%; the prognosis for these patients has not changed since 1954. Life expectancy was lower among patients with mutations in ATM that caused total loss of expression or function of the gene product (null mutations) compared with that seen in patients with hypomorphic mutations because of earlier onset of cancer (mainly hematologic malignancies). Cancer (hazard ratio, 2.7; 95% CI, 1.6-4.5) and respiratory tract infections (hazard ratio, 2.3; 95% CI, 1.4-3.8) were independently associated with mortality. Cancer (hazard ratio, 5.8; 95% CI, 2.9-11.6) was a major risk factor for mortality among patients with null mutations, whereas respiratory tract infections (hazard ratio, 4.1; 95% CI, 1.8-9.1) were the leading cause of death among patients with hypomorphic mutations. Conclusion: Morbidity and mortality among patients with A-T are associated with ATM genotype. This information could improve our prognostic ability and lead to adapted therapeutic strategies. (J Allergy Clin Immunol 2011;128:382-9.)	[Micol, Romain; Ben Slama, Lilia; Suarez, Felipe; Le Mignot, Loic; Beaute, Julien; Mahlaoui, Nizar; Stephan, Jean-Louis; Bordigoni, Pierre; Bertrand, Yves; Aladjidi, Nathalie; Thomas, Caroline; Pellier, Isabelle; Hermine, Olivier; Picard, Capucine; Blanche, Stephane; Debre, Marianne; Fischer, Alain] Hop Necker Enfants Malad, CEREDIH Network, French Natl Reference Ctr Primary Immunodeficienc, F-75743 Paris 15, France; [Micol, Romain; Ben Slama, Lilia; Suarez, Felipe; Le Mignot, Loic; Beaute, Julien; Mahlaoui, Nizar; Stephan, Jean-Louis; Bordigoni, Pierre; Bertrand, Yves; Aladjidi, Nathalie; Thomas, Caroline; Pellier, Isabelle; Hermine, Olivier; Picard, Capucine; Blanche, Stephane; Debre, Marianne; Fischer, Alain] Associated Collaborat Ctr, Paris, France; [Micol, Romain; Beaute, Julien; Mahlaoui, Nizar; Picard, Capucine; Moshous, Despina; Neven, Benedicte; Blanche, Stephane; Debre, Marianne; Fischer, Alain] Hop Necker Enfants Malad, Pediat Immunohematol Dept, F-75743 Paris 15, France; [Micol, Romain; Fischer, Alain; Stoppa-Lyonnet, Dominique] Paris Descartes Univ, Paris, France; [Suarez, Felipe; Hermine, Olivier] Hop Necker Enfants Malad, Hematol Unit, F-75743 Paris 15, France; [Le Mignot, Loic] Hop Necker Enfants Malad, Informat & Biostat Dept, F-75743 Paris 15, France; [d'Enghien, Catherine Dubois; Lauge, Anthony; Couturier, Jerome; Stoppa-Lyonnet, Dominique] Inst Curie Hop, Canc Genet Dept, Cytogenet Unit, Paris, France; [Hall, Janet; Stoppa-Lyonnet, Dominique] Inst Curie Rech, INSERM, U830, Paris, France; [Couturier, Jerome] Inst Curie, INSERM, U612, Paris, France; [Vallee, Louis; Delobel, Bruno] Univ Lille, CHRU, Pediat Neurol Unit, Childrens Dept, Lille, France; [Rivier, Francois] Univ Montpellier, Medecine UFR, F-34059 Montpellier, France; [Rivier, Francois] Hop Gui de Chauliac, CHU Montpellier, Pediat Neurol Unit, Montpellier, France; [Nguyen, Karine] CHU Timone Enfants, Dept Med Genet, Marseille, France; [de Villemeur, Thierry Billette] Univ Paris 06, Paris, France; [de Villemeur, Thierry Billette] Hop Enfants Armand Trousseau, AP HP, Pediat Neurol Unit, Paris, France; [Stephan, Jean-Louis] Hop Nord St Etienne, St Etienne CHU, Dept Pediat, St Etienne, France; [Bordigoni, Pierre] CHU Nancy, Hop Enfants, Pediat Hematol Oncol & Bone Marrow Transplantat D, Nancy, France; [Bertrand, Yves] Pediat Hematol Oncol Inst, Lyon, France; [Aladjidi, Nathalie] Ctr Hosp Pellegrin Bordeaux, Dept Pediat, Hop Enfants, Bordeaux, France; [Pedespan, Jean-Michel] Univ Bordeaux 2, Pediat Neurol Dept, F-33076 Bordeaux, France; [Thomas, Caroline] Hop Mere Enfants, Dept Hematol & Oncol, Nantes, France; [Pellier, Isabelle] Ctr Hosp Angers, Pediat Immunohematol Unit, Angers, France; [Koenig, Michel] ULP, Mol & Cellular Biol & Genet Inst, CNRS, INSERM, Illkirch Graffenstaden, France; [Koenig, Michel] Nouvel Hop Civil, Genet Diagnost Lab, Strasbourg, France; [Lanternier, Fanny] Univ Paris 05, Hop Necker Enfants Malad, Necker Pasteur Infect Dis Ctr, Trop & Infect Dis Dept, Paris, France; [Tardieu, Marc] Hop Bicetre, AP HP, Le Kremlin Bicetre, France; [Tardieu, Marc] French Natl Reference Ctr Inflammatory Brain Dis, Le Kremlin Bicetre, France; [Picard, Capucine; Fischer, Alain] Hop Necker Enfants Malad, INSERM, U768, F-75743 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de St Etienne; CHU de Nancy; CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Micol, R (corresponding author), Hop Necker Enfants Malad, AP HP, CEREDIH, 149 Rue Sevres, F-75743 Paris 15, France.	romain.micol@gmail.com	isabelle, pellier/L-5683-2015; Picard, Capucine/H-3914-2017; Lecuit, Marc/M-4126-2019; hall, janet/G-1372-2013; AMOURA, Zahir/P-5324-2017; Philip, Nicole/I-2881-2016; Mathian, Alexis/P-5355-2017; MAHLAOUI, Nizar/AAH-6103-2020; schleinitz, nicolas/AAL-6751-2020; Mahlaoui, Nizar/J-7928-2017; Nguyen, Karine/J-9219-2016; Lanternier, Fanny/AAQ-2815-2021; HACHULLA, ERIC/R-8488-2018; Moshous, Despina/B-7507-2017; Amoura, Zahir/P-5325-2017; Hermine, Olivier/Q-7072-2018; Lecuit, Marc/J-4073-2013	Picard, Capucine/0000-0001-8788-5056; Lecuit, Marc/0000-0002-4491-1063; hall, janet/0000-0002-4397-6295; AMOURA, Zahir/0000-0003-0292-9043; MAHLAOUI, Nizar/0000-0002-0030-8094; schleinitz, nicolas/0000-0001-9449-3392; Mahlaoui, Nizar/0000-0002-0030-8094; Nguyen, Karine/0000-0002-6889-3891; HACHULLA, ERIC/0000-0001-7432-847X; Moshous, Despina/0000-0001-6719-3693; Lecuit, Marc/0000-0002-4491-1063; Hermine, Olivier/0000-0003-2574-3874; Jeziorski, Eric/0000-0003-0318-3044; Dollfus, Helene/0000-0002-2249-895X; bonnotte, bernard/0000-0002-1098-4598; Toutain, Annick/0000-0002-5999-5300; Korganow, Anne-Sophie/0000-0002-1664-6311; Rohrlich, Pierre S/0000-0001-8801-4164	Sophie and Yves Ayache; CEREDIH (French National Reference Center for Primary Immunodeficiencies); INCa (National Cancer Institute of France); CEREDIH	Sophie and Yves Ayache; CEREDIH (French National Reference Center for Primary Immunodeficiencies); INCa (National Cancer Institute of France)(Institut National du Cancer (INCA) France); CEREDIH	Supported by Sophie and Yves Ayache, CEREDIH (French National Reference Center for Primary Immunodeficiencies), and INCa (National Cancer Institute of France).; A. Fischer receives research support from CEREDIH. The rest of the authors have declared that they have no conflict of interest.	Angele S, 2003, HUM MUTAT, V21, P1, DOI 10.1002/humu.9107; AURIAS A, 1981, J GENET HUM, V29, P235; AYACHE R, 1994, ANN BIOL CLIN-PARIS, V52, P117; Barone G, 2009, HUM MUTAT, V30, P1222, DOI 10.1002/humu.21034; BODER E, 1958, PEDIATRICS, V21, P526; Buckley Rebecca H, 2004, Paediatr Respir Rev, V5 Suppl A, pS225, DOI 10.1016/S1526-0542(04)90043-7; CEREDIH: The French PID study group, 2010, CLIN IMMUNOL, V135, P264, DOI [10.1016/j.clim.2010.02.021, DOI 10.1016/J.CLIM.2010.02.021]; Crawford TO, 2006, ARCH DIS CHILD, V91, P610; Eades-Perner AM, 2007, CLIN EXP IMMUNOL, V147, P306, DOI 10.1111/j.1365-2249.2006.03292.x; ERSOY F, 1991, TURKISH J PEDIATR, V33, P205; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Houdayer C, 2008, HUM MUTAT, V29, P975, DOI 10.1002/humu.20765; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Li AR, 2000, AM J MED GENET, V92, P170, DOI 10.1002/(SICI)1096-8628(20000529)92:3<170::AID-AJMG3>3.0.CO;2-#; Mitui M, 2009, HUM MUTAT, V30, P12, DOI 10.1002/humu.20805; Moin M, 2007, PEDIATR NEUROL, V37, P21, DOI 10.1016/j.pediatrneurol.2007.03.002; MORRELL D, 1986, J NATL CANCER I, V77, P89; Nowak-Wegrzyn A, 2004, J PEDIATR-US, V144, P505, DOI 10.1016/j.jpeds.2003.12.046; Plebani A, 2002, CLIN IMMUNOL, V104, P221, DOI 10.1006/clim.2002.5241; Quartier P, 2004, CLIN IMMUNOL, V110, P22, DOI 10.1016/j.clim.2003.10.007; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Staples ER, 2008, CLIN EXP IMMUNOL, V153, P214, DOI 10.1111/j.1365-2249.2008.03684.x; Tavani F, 2003, NEURORADIOLOGY, V45, P315, DOI 10.1007/s00234-003-0945-9; Tavtigian SV, 2006, J MED GENET, V43, P295, DOI 10.1136/jmg.2005.033878; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Triki C, 2000, REV NEUROL-FRANCE, V156, P634; Verhagen MMM, 2009, NEUROLOGY, V73, P430, DOI 10.1212/WNL.0b013e3181af33bd; WOODS CG, 1992, Q J MED, V82, P169	28	94	95	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					382	U400		10.1016/j.jaci.2011.03.052	http://dx.doi.org/10.1016/j.jaci.2011.03.052			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21665257				2022-12-18	WOS:000293280800020
J	Castrejon, JL; Berry, N; El-Ghaiesh, S; Gerber, B; Pichler, WJ; Park, BK; Naisbitt, DJ				Castrejon, J. Luis; Berry, Neil; El-Ghaiesh, Sabah; Gerber, Basil; Pichler, Werner J.; Park, B. Kevin; Naisbitt, Dean J.			Stimulation of human T cells with sulfonamides and sulfonamide metabolites	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human; T cells; drug hypersensitivity; drug metabolism	MAJOR HISTOCOMPATIBILITY COMPLEX; TOXIC EPIDERMAL NECROLYSIS; DRUG-SPECIFIC CD4(+); NITROSO SULFAMETHOXAZOLE; REACTIVE METABOLITES; COVALENT BINDING; IN-VIVO; HYPERSENSITIVITY; RECOGNITION; DISPOSITION	Background: Exposure to sulfonamides is associated with a high incidence of hypersensitivity reactions. Antigen-specific T cells are involved in the pathogenesis; however, the nature of the antigen interacting with specific T-cell receptors is not fully defined. Objective: We sought to explore the frequency of sulfamethoxazole (SMX)- and SMX metabolite-specific T cells in hypersensitive patients, delineate the specificity of clones, define mechanisms of presentation, and explore additional reactivity with structurally related sulfonamide metabolites. Methods: SMX- and SMX metabolite-specific T-cell clones were generated from 3 patients. Antigen specificity, mechanisms of antigen presentation, and cross-reactivity of specific clones were then explored. Low-lying energy conformations of drugs (metabolites) were modeled, and the energies available for protein binding was estimated. Results: Lymphocytes proliferated with parent drugs (SMX, sulfadiazine, and sulfapyridine) and both hydroxylamine and nitroso metabolites. Three patterns of drug (metabolite) stimulation were seen: 44% were SMX metabolite specific, 43% were stimulated with SMX metabolites and SMX, and 14% were stimulated with SMX alone. Most metabolite-responsive T cells were stimulated with nitroso SMX-modified protein through a hapten mechanism involving processing. In contrast to SMX-responsive clones, which were highly specific, greater than 50% of nitroso SMX-specific clones were stimulated with nitroso metabolites of sulfapyridine and sulfadiazine but not nitrosobenzene. Pharmacophore modeling showed that the summation of available binding energies for protein interactions and the preferred spatial arrangement of atoms in each molecule determine a drug's potential to stimulate specific T cells. Conclusions: Nitroso sulfonamide metabolites form potent antigenic determinants for T cells from hypersensitive patients. T-cell responses against drugs (metabolites) bound directly to MHC or MHC/peptide complexes can occur through cross-reactivity with the haptenic immunogen. (J Allergy Clin Immunol 2010;125:411-8.)	[Castrejon, J. Luis; El-Ghaiesh, Sabah; Park, B. Kevin; Naisbitt, Dean J.] Univ Liverpool, MRC Ctr Drug Safety Sci, Dept Pharmacol, Liverpool L69 3GE, Merseyside, England; [Berry, Neil] Univ Liverpool, Dept Chem, Liverpool L69 3GE, Merseyside, England; [Gerber, Basil; Pichler, Werner J.] Univ Bern, Inselspital, Div Allergol, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland	University of Liverpool; University of Liverpool; University of Bern; University Hospital of Bern	Naisbitt, DJ (corresponding author), Univ Liverpool, MRC Ctr Drug Safety Sci, Dept Pharmacol, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	dnes@liv.ac.uk	Berry, Neil G/B-7960-2009; El-Ghaiesh, Sabah H/L-8231-2016	Berry, Neil G/0000-0003-1928-0738; El-Ghaiesh, Sabah H/0000-0001-7032-528X; Naisbitt, Dean/0000-0003-4107-7832; Pichler, Werner J./0000-0002-8117-359X; Castrejon, Luis/0000-0002-2808-2808	Mexican National Council for Science and Technology (CONACyT); Wellcome Trust [078598/2/05/Z]; Medical Research Council (UK) [130700654]; Swiss National Foundation; Wellcome Trust; Astrazeneca; Medical Research Council [G0700654, G0700654B] Funding Source: researchfish; MRC [G0700654] Funding Source: UKRI	Mexican National Council for Science and Technology (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Swiss National Foundation(Swiss National Science Foundation (SNSF)); Wellcome Trust(Wellcome TrustEuropean Commission); Astrazeneca(AstraZeneca); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Declaration of funding sources: J.L.C. is a PhD student funded by the Mexican National Council for Science and Technology (CONACyT). This work was funded by a grant from the Wellcome Trust (078598/2/05/Z) as part of the Centre for Drug Safety Science supported by the Medical Research Council (130700654).; Disclosure of potential conflict of interest: W. J. Pichler has received research support from the Swiss National Foundation. B. K. Park, has received research support from the Medical Research Council (UK), Wellcome Trust. and Astrazeneca. D. J. Naisbitt has received research support from the Medical Research Council (UK) and Wellcome Trust. The rest of the authors have declared that they have no conflict of interest.	Alfirevic A, 2009, PHARMACOGENOMICS, V10, P531, DOI 10.2217/PGS.09.6; BIGBY M, 1986, Journal of the American Medical Association, V256, P3358, DOI 10.1001/jama.256.24.3358; Burkhart C, 2001, BRIT J PHARMACOL, V132, P623, DOI 10.1038/sj.bjp.0703845; Callan HE, 2009, CHEM RES TOXICOL, V22, P937, DOI 10.1021/tx900034r; Cheng LL, 2008, MOL PHARMACOL, V73, P1769, DOI 10.1124/mol.107.043273; Choquet-Kastylevsky G, 2001, TOXICOL LETT, V119, P183, DOI 10.1016/S0378-4274(00)00313-1; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; Depta JPH, 2004, J ALLERGY CLIN IMMUN, V113, P519, DOI 10.1016/j.jaci.2003.11.030; Di Girolamo F, 2009, ECOTOX ENVIRON SAFE, V72, P1601, DOI 10.1016/j.ecoenv.2008.09.006; Farrell J, 2003, J PHARMACOL EXP THER, V306, P229, DOI 10.1124/jpet.103.050112; Gamerdinger K, 2003, J EXP MED, V197, P1345, DOI 10.1084/jem.20030121; Gill HJ, 1997, J PHARMACOL EXP THER, V282, P795; Gruchalla RS, 2006, NEW ENGL J MED, V354, P601, DOI 10.1056/NEJMcp043986; Hopkins JE, 2005, TOXICOLOGY, V206, P221, DOI 10.1016/j.tox.2004.08.010; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; Lu L, 2003, J EXP MED, V197, P567, DOI 10.1084/jem.20021762; Manchanda T, 2002, MOL PHARMACOL, V62, P1011, DOI 10.1124/mol.62.5.1011; Masters PA, 2003, ARCH INTERN MED, V163, P402, DOI 10.1001/archinte.163.4.402; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Moulon C, 2003, J INVEST DERMATOL, V121, P496, DOI 10.1046/j.1523-1747.2003.12405.x; Naisbitt DJ, 1996, BIOORG MED CHEM LETT, V6, P1511, DOI 10.1016/S0960-894X(96)00260-0; Naisbitt DJ, 2005, J ALLERGY CLIN IMMUN, V115, P876, DOI 10.1016/j.jaci.2005.01.011; Naisbitt DJ, 1999, BRIT J PHARMACOL, V126, P1393, DOI 10.1038/sj.bjp.0702453; Naisbitt DJ, 2002, MOL PHARMACOL, V62, P628, DOI 10.1124/mol.62.3.628; Naisbitt DJ, 2001, BRIT J PHARMACOL, V133, P295, DOI 10.1038/sj.bjp.0704074; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Nassif A, 2002, J INVEST DERMATOL, V118, P728, DOI 10.1046/j.1523-1747.2002.01622.x; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175, DOI 10.1111/j.1365-2222.1997.tb00690.x; Park BE, 1998, CHEM RES TOXICOL, V11, P969, DOI 10.1021/tx980058f; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Sanderson JP, 2007, J IMMUNOL, V178, P5533, DOI 10.4049/jimmunol.178.9.5533; Schnyder B, 1998, CLIN EXP ALLERGY, V28, P1412, DOI 10.1046/j.1365-2222.1998.00419.x; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Summan M, 2002, CHEM-BIOL INTERACT, V142, P155, DOI 10.1016/S0009-2797(02)00060-1; VOUGREYERZ S, 1999, J IMMUNOL, V162, P595; Wu Y, 2006, J ALLERGY CLIN IMMUN, V118, P233, DOI 10.1016/j.jaci.2006.03.005	38	94	98	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					411	418		10.1016/j.jaci.2009.10.031	http://dx.doi.org/10.1016/j.jaci.2009.10.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159253				2022-12-18	WOS:000274764000020
J	Schauber, J; Gallo, RL				Schauber, Juergen; Gallo, Richard L.			Antimicrobial peptides and the skin immune defense system (Reprinted from J Allergy Clin Immunol vol 122, pg 261-6, 2008)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Reprint						Antimicrobial peptides; alarmins; skin; cathelicidin; rosacea; atopic dermatitis; psoriasis; 1,25 dihydroxy vitamin D3	INVASIVE BACTERIAL-INFECTION; VITAMIN-D-RECEPTOR; HUMAN KERATINOCYTES; 1,25-DIHYDROXYVITAMIN D-3; CATHELICIDIN LL-37; ATOPIC-DERMATITIS; CUTTING EDGE; ALPHA-DEFENSINS; POTENTIAL ROLE; HOST-DEFENSE	Our skin is constantly challenged by microbes but is rarely infected. Cutaneous production of antimicrobial peptides (AMPs) is a primary system for protection, and expression of some AMPs further increases in response to microbial invasion. Cathelicidins are unique AMPs that protect the skin through 2 distinct pathways: (1) direct antimicrobial activity and (2) initiation of a host response resulting in cytokine release, inflammation, angiogenesis, and reepithelialization. Cathelicidin dysfunction emerges as a central factor in the pathogenesis of several cutaneous diseases, including atopic dermatitis, in which cathelicidin is suppressed; rosacea, in which cathelicidin peptides are abnormally processed to forms that induce inflammation; and psoriasis, in which cathelicidin peptide converts self-DNA to a potent stimulus in an autoinflammatory cascade. Recent work identified vitamin D3 as a major factor involved in the regulation of cathelicidin. Therapies targeting control of cathelicidin and other AMPs might provide new approaches in the management of infectious and inflammatory skin diseases. (Reprinted from J Allergy Clin Immunol 2008; 122: 261-6.)	[Gallo, Richard L.] Univ Calif San Diego, Div Dermatol, San Diego, CA 92161 USA; [Gallo, Richard L.] VA San Diego Healthcare Syst, San Diego, CA 92161 USA; [Schauber, Juergen] Univ Munich, Dept Dermatol & Allergol, Munich, Germany	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Munich	Gallo, RL (corresponding author), Univ Calif San Diego, Div Dermatol, 3350 La Jolla Village Dr,Mail Code 151, San Diego, CA 92161 USA.	rgallo@ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Allain TJ, 2003, GERONTOLOGY, V49, P273, DOI 10.1159/000071707; Allaker RP, 1999, FEMS IMMUNOL MED MIC, V23, P289, DOI 10.1016/S0928-8244(98)00148-5; Bikle DD, 2007, CURR OPIN RHEUMATOL, V19, P383, DOI 10.1097/BOR.0b013e32818e9d58; Bikle DD, 2004, J STEROID BIOCHEM, V89-90, P347, DOI 10.1016/j.jsbmb.2004.03.113; Bikle DD, 2004, J CELL BIOCHEM, V92, P436, DOI 10.1002/jcb.20095; BIKLE DD, 1989, ENDOCRINOLOGY, V124, P655, DOI 10.1210/endo-124-2-655; Blankenvoorde MFJ, 1998, BIOL CHEM, V379, P1371; Braff MH, 2006, CURR TOP MICROBIOL, V306, P91; Braff MH, 2005, J INVEST DERMATOL, V125, P9, DOI 10.1111/j.0022-202X.2004.23587.x; Braff MH, 2005, J INVEST DERMATOL, V124, P394, DOI 10.1111/j.0022-202X.2004.23443.x; Braff MH, 2005, INFECT IMMUN, V73, P6771, DOI 10.1128/IAI.73.10.6771-6781.2005; Buechau AS, 2007, J INVEST DERMATOL, V127, P2596, DOI 10.1038/sj.jid.5700946; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; Cumberbatch M, 2000, IMMUNOLOGY, V100, P21, DOI 10.1046/j.1365-2567.2000.00014.x; Cutuli M, 2000, J LEUKOCYTE BIOL, V67, P233, DOI 10.1002/jlb.67.2.233; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Di Nardo A, 2007, J IMMUNOL, V178, P1829, DOI 10.4049/jimmunol.178.3.1829; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1993, ANAL BIOCHEM, V208, P382, DOI 10.1006/abio.1993.1065; Hollox EJ, 2008, NAT GENET, V40, P23, DOI 10.1038/ng.2007.48; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Iimura M, 2005, J IMMUNOL, V174, P4901, DOI 10.4049/jimmunol.174.8.4901; Jansen T, 2004, J DERMATOL, V31, P244, DOI 10.1111/j.1346-8138.2004.tb00665.x; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kowalska K, 2002, LIFE SCI, V71, P747, DOI 10.1016/S0024-3205(02)01740-X; Lambert RW, 2002, NEUROPEPTIDES, V36, P246, DOI 10.1016/S0143-4179(02)00020-3; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Lebwohl M, 2004, J AM ACAD DERMATOL, V50, P416, DOI 10.1016/j.jaad.2002.12.002; LEE DY, 2008, J INVEST DERMATOL, V17, P17; Lehmann B, 2001, J INVEST DERMATOL, V117, P1179, DOI 10.1046/j.0022-202x.2001.01538.x; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Lopez-Garcia B, 2005, J INVEST DERMATOL, V125, P108, DOI 10.1111/j.0022-202X.2005.23713.x; Marchini G, 2002, BRIT J DERMATOL, V147, P1127, DOI 10.1046/j.1365-2133.2002.05014.x; Meyer-Hoffert U, 2003, EXP DERMATOL, V12, P418, DOI 10.1034/j.1600-0625.2002.120409.x; Moan J, 2008, P NATL ACAD SCI USA, V105, P668, DOI 10.1073/pnas.0710615105; Murakami M, 2005, PEDIATR RES, V57, P10, DOI 10.1203/01.PDR.0000148068.32201.50; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; Niyonsaba F, 2005, J IMMUNOL, V175, P1776, DOI 10.4049/jimmunol.175.3.1776; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Niyonsaba F, 2007, J INVEST DERMATOL, V127, P594, DOI 10.1038/sj.jid.5700599; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Oda Y, 2004, J STEROID BIOCHEM, V89-90, P273, DOI 10.1016/j.jsbmb.2004.03.106; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oppenheim JJ, 2007, ADV EXP MED BIOL, V601, P185; Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005; RADEK KA, 2008, J INVEST DERMAT 0110; Rose FRAJ, 1998, INFECT IMMUN, V66, P3255, DOI 10.1128/IAI.66.7.3255-3263.1998; Schauber J, 2008, J INVEST DERMATOL, V128, P816, DOI 10.1038/sj.jid.5701102; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Schauber J, 2007, J INVEST DERMATOL, V127, P510, DOI 10.1038/sj.jid.5700761; Schauber J, 2006, IMMUNOLOGY, V118, P509, DOI 10.1111/j.1365-2567.2006.02399.x; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x; Simpson AJ, 1999, FEBS LETT, V452, P309, DOI 10.1016/S0014-5793(99)00670-5; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Takahashi M, 2004, EXP DERMATOL, V13, P55, DOI 10.1111/j.0906-6705.2004.00116.x; Tang YQ, 2002, INFECT IMMUN, V70, P6524, DOI 10.1128/IAI.70.12.6524-6533.2002; Tasiemski A, 2002, BLOOD, V100, P553, DOI 10.1182/blood.V100.2.553; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Weber G, 2005, J INVEST DERMATOL, V124, P1080, DOI 10.1111/j.0022-202X.2005.23687.x; Wingens M, 1998, J INVEST DERMATOL, V111, P996, DOI 10.1046/j.1523-1747.1998.00425.x; Yamasaki K, 2007, NAT MED, V13, P975, DOI 10.1038/nm1616; Yamasaki K, 2006, FASEB J, V20, P2068, DOI 10.1096/fj.06-6075com; Yang D, 2001, J LEUKOCYTE BIOL, V69, P691; Yim S, 2007, J CYST FIBROS, V6, P403, DOI 10.1016/j.jcf.2007.03.003; Yu J, 2007, J IMMUNOL, V179, P7684, DOI 10.4049/jimmunol.179.11.7684; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zheng Y, 2007, BRIT J DERMATOL, V157, P1124, DOI 10.1111/j.1365-2133.2007.08196.x	86	94	96	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3		2			R13	R18		10.1016/j.jaci.2009.07.014	http://dx.doi.org/10.1016/j.jaci.2009.07.014			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553NC	19720207	Bronze			2022-12-18	WOS:000274372800004
J	Salo, PM; Sever, ML; Zeldin, DC				Salo, Paeivi M.; Sever, Michelle L.; Zeldin, Darryl C.			Indoor allergens in school and day care environments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; indoor; exposure; asthma; allergy; school; day care	HOUSE-DUST MITE; F-I ALLERGENS; DER-P-I; FEL D 1; URBAN ELEMENTARY-SCHOOLS; CAT ALLERGEN; RESPIRATORY SYMPTOMS; COCKROACH ALLERGEN; BRONCHIAL REACTIVITY; DOMESTIC ALLERGENS	Most studies that have examined exposure to indoor allergens have focused on home environments. However, allergen exposures can be encountered in environments other than the home. For example, many children spend a large part of their time in schools and day care facilities. Over the past 2 decades, a large number of studies have been conducted in school and day care environments. However, the role of indoor exposures in allergy and asthma development or morbidity in these settings is not well characterized. The purpose of this review is to evaluate the importance of indoor allergen exposures in school and day care settings. We summarize the key findings from recent scientific literature, describe exposure characteristics, discuss the role of these exposures in relation to asthma and allergy symptoms, and provide information on the effectiveness of published interventions. (J Allergy Clin Immunol 2009;124:185-92.)	[Salo, Paeivi M.; Sever, Michelle L.; Zeldin, Darryl C.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Zeldin, DC (corresponding author), NIEHS, NIH, 111 Alexander Dr,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Sever, Michelle/0000-0002-2435-1214	National Institutes of Health, National Institute of Environmental Health Sciences [Z01 ES025041]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025041] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01 ES025041).	Abramson SL, 2006, J SCHOOL HEALTH, V76, P246, DOI 10.1111/j.1746-1561.2006.00105.x; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; Amr S, 2003, ANN ALLERG ASTHMA IM, V90, P34, DOI 10.1016/S1081-1206(10)63611-3; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P133, DOI 10.1016/j.jaci.2005.04.022; Arlian Larry G, 2002, Curr Allergy Asthma Rep, V2, P401, DOI 10.1007/s11882-002-0074-2; Beezhold DH, 2008, ALLERGY ASTHMA PROC, V29, P29, DOI 10.2500/aap2008.29.3076; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; Bernstein JA, 2005, INDOOR AIR, V15, P402, DOI 10.1111/j.1600-0668.2005.00379.x; Borres MP, 2002, ALLERGY, V57, P454, DOI 10.1034/j.1398-9995.2002.13650.x; Burge HA, 2000, ENVIRON HEALTH PERSP, V108, P653, DOI 10.2307/3454401; Chew GL, 2005, INDOOR AIR, V15, P228, DOI 10.1111/j.1600-0668.2005.00363.x; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Daisey JM, 2003, INDOOR AIR, V13, P53, DOI 10.1034/j.1600-0668.2003.00153.x; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; DEANDRADE AD, 1995, J ALLERGY CLIN IMMUN, V95, P1158, DOI 10.1016/S0091-6749(95)70071-4; DYBENDAL T, 1994, ALLERGY, V49, P210, DOI 10.1111/j.1398-9995.1994.tb02651.x; EINARSSON R, 1995, J ALLERGY CLIN IMMUN, V95, P1049, DOI 10.1016/S0091-6749(95)70108-7; Engelhart S, 2002, INT J HYG ENVIR HEAL, V205, P453, DOI 10.1078/1438-4639-00192; Fernandez-Caldas E, 2001, ANN ALLERG ASTHMA IM, V87, P196, DOI 10.1016/S1081-1206(10)62225-9; Foarde K, 2004, J EXPO ANAL ENV EPID, V14, pS41, DOI 10.1038/sj.jea.7500357; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Haverinen U, 1999, ENVIRON HEALTH PERSP, V107, P509, DOI 10.1289/ehp.99107s3509; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Instanes C, 2005, INDOOR AIR, V15, P356, DOI 10.1111/j.1600-0668.2005.00381.x; Instanes C, 2004, CLIN EXP ALLERGY, V34, P1634, DOI 10.1111/j.1365-2222.2004.02076.x; Johansson SGO, 1998, ALLERGY, V53, P1; Karlsson AS, 2005, ALLERGY, V60, P961, DOI 10.1111/j.1398-9995.2005.00796.x; Karlsson AS, 2004, J ALLERGY CLIN IMMUN, V113, P1172, DOI 10.1016/j.jaci.2003.12.590; Karlsson AS, 2004, ALLERGY, V59, P661, DOI 10.1111/j.1398-9995.2004.00519.x; Karlsson AS, 2002, CLIN EXP ALLERGY, V32, P1776, DOI 10.1046/j.1365-2222.2002.01553.x; Kim JL, 2007, INDOOR AIR, V17, P153, DOI 10.1111/j.1600-0668.2006.00466.x; Kim JL, 2007, INDOOR AIR, V17, P122, DOI 10.1111/j.1600-0668.2006.00460.x; Kim JL, 2005, INDOOR AIR, V15, P170, DOI 10.1111/j.1600-0668.2005.00334.x; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Leech JA, 2002, J EXPO ANAL ENV EPID, V12, P427, DOI 10.1038/sj.jea.7500244; Lignell U, 2007, J ENVIRON MONITOR, V9, P225, DOI 10.1039/b615459j; Lonnkvist K, 1999, PEDIAT ALLERG IMM-UK, V10, P45, DOI 10.1034/j.1399-3038.1999.101001.x; Mazurek JM, 2008, AM J IND MED, V51, P47, DOI 10.1002/ajim.20539; Meklin T, 2005, INDOOR AIR, V15, P40, DOI 10.1111/j.1600-0668.2005.00357.x; Meklin T, 2002, INDOOR AIR, V12, P175, DOI 10.1034/j.1600-0668.2002.00169.x; Merkle SL, 2006, J SCHOOL HEALTH, V76, P202, DOI 10.1111/j.1746-1561.2006.00096.x; Moonie SA, 2006, J SCHOOL HEALTH, V76, P18, DOI 10.1111/j.1746-1561.2006.00062.x; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; Munir AKM, 1996, ALLERGY, V51, P36; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; NCES, 2007, COND ED; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oldfield Karen, 2007, N Z Med J, V120, pU2400; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; Patovirta R. L., 2004, Central European Journal of Public Health, V12, P36; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; Perry TT, 2008, ANN ALLERG ASTHMA IM, V100, P358, DOI 10.1016/S1081-1206(10)60599-6; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; Portnoy JM, 2005, ANN ALLERG ASTHMA IM, V94, P313, DOI 10.1016/S1081-1206(10)60982-9; Ramachandran G, 2005, J OCCUP ENVIRON HYG, V2, P553, DOI 10.1080/15459620500324453; Ritz BR, 2002, ALLERGY, V57, P357, DOI 10.1034/j.1398-9995.2002.1s3404.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rullo VEV, 2002, J ALLERGY CLIN IMMUN, V110, P582, DOI 10.1067/mai.2002.127511; Rylander R, 1997, ARCH ENVIRON HEALTH, V52, P281, DOI 10.1080/00039899709602199; Santilli J, 2003, ANN ALLERG ASTHMA IM, V90, P203, DOI 10.1016/S1081-1206(10)62142-4; Sarpong SB, 1996, ANN ALLERG ASTHMA IM, V76, P257, DOI 10.1016/S1081-1206(10)63437-0; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; Savilahti R, 2000, ARCH ENVIRON HEALTH, V55, P405, DOI 10.1080/00039890009604038; Sheehan WJ, 2009, ANN ALLERG ASTHMA IM, V102, P125, DOI 10.1016/S1081-1206(10)60242-6; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Smedje G, 2000, ARCH ENVIRON HEALTH, V55, P18, DOI 10.1080/00039890009603380; Smedje G, 2001, INT J TUBERC LUNG D, V5, P1059; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Tortolero SR, 2002, J SCHOOL HEALTH, V72, P33, DOI 10.1111/j.1746-1561.2002.tb06509.x; Tranter DC, 2005, CLIN EXP ALLERGY, V35, P126, DOI 10.1111/j.1365-2222.2005.02149.x; U.S. Environmental Protection Agency, 2001, EPA PUBL; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544, DOI 10.1016/S1081-1206(10)63214-0; Wickman M, 1999, CLIN EXP ALLERGY, V29, P626; Zhang G, 2006, INDOOR AIR, V16, P74, DOI 10.1111/j.1600-0668.2005.00405.x; Zhang L, 1997, CLIN EXP ALLERGY, V27, P876, DOI 10.1111/j.1365-2222.1997.tb01227.x; Zhao ZH, 2006, INDOOR AIR, V16, P404, DOI 10.1111/j.1600-0668.2006.00433.x; ZOCK JP, 1995, CLIN EXP ALLERGY, V25, P549, DOI 10.1111/j.1365-2222.1995.tb01093.x; Zuraimi MS, 2008, PEDIAT ALLERG IMM-UK, V19, P746, DOI 10.1111/j.1399-3038.2007.00714.x; IAQ TOOLS SCH MANAGI	86	94	95	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					185	192		10.1016/j.jaci.2009.05.012	http://dx.doi.org/10.1016/j.jaci.2009.05.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19577284	Green Accepted			2022-12-18	WOS:000268860400002
J	Haczku, A				Haczku, Angela			Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Macrophage; dendritic cell; surfactant; SP-D; SP-A; innate immune regulation	CARBOHYDRATE-RECOGNITION DOMAIN; RESPIRATORY SYNCYTIAL VIRUS; MANNAN-BINDING PROTEIN; C-TYPE LECTIN; SP-D GENE; OBSTRUCTIVE PULMONARY-DISEASE; DUST-MITE ALLERGENS; ALVEOLAR MACROPHAGE PHAGOCYTOSIS; PNEUMOCYSTIS-CARINII INFECTION; ASPERGILLUS-FUMIGATUS CONIDIA	The acute inflammatory airway response is characterized by a time-dependent onset followed by active resolution. Emerging evidence suggests that epithelial cells of the proximal and distal air spaces release host defense mediators that can facilitate both the initiation and the resolution part of inflammatory airway changes. These molecules, also known as the hydrophilic surfactant proteins (surfactant protein [SP]-A and SP-D) belong to the class of collagenous lectins (collectins). The collectins are a small family of soluble pattern recognition receptors containing collagenous regions and C-type lectin domains. SP-A and SP-D are most abundant in the lung. Because of their structural uniqueness, specific localization, and functional versatility, lung collectins are important players of the pulmonary immune responses. Recent studies in our laboratory and others indicated significant associations of lung collectin levels with acute and chronic airway inflammation in both animal models and patients, suggesting the usefulness of these molecules as disease biomarkers. Research on wild-type and mutant recombinant molecules in vivo and in vitro showed that SP-A and SP-D bind carbohydrates, lipids, and nucleic acids with a broad-spectrum specificity and initiate phagocytosis of inhaled pathogens as well as apoptotic cells. Investigations on gene-deficient and conditional overexpresser mice indicated that lung collectins also directly modulate innate immune cell function and T-cell-dependent inflammatory events. Thus, these molecules have a unique, dual-function capacity to induce pathogen elimination and control proinflammatory mechanisms, suggesting a potential suitability for therapeutic prevention and treatment of chronic airway inflammation. This article reviews evidence supporting that the lung collectins play an immune-protective role and are essential for maintenance of the immunologic homeostasis in the lung. (J Allergy Clin Immunol 2008;122:861-79.)	Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Translat Res Labs, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Haczku, A (corresponding author), Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Translat Res Labs, Room 1209,125 S 31st St, Philadelphia, PA 19104 USA.	haczku@mail.med.upenn.edu	HACZKU, ANGELA/A-8486-2013	HACZKU, ANGELA/0000-0002-1301-4941	American Lung Association [R01A1055593, R01HL076646]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055593] Funding Source: NIH RePORTER	American Lung Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by an American Lung Association Career Investigator Award, R01A1055593, and R01HL076646.	Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Alcorn JL, 2005, AM J PHYSIOL-LUNG C, V289, pL1113, DOI 10.1152/ajplung.00436.2004; Allen MJ, 1999, INFECT IMMUN, V67, P4563, DOI 10.1128/IAI.67.9.4563-4569.1999; Allen MJ, 2001, INFECT IMMUN, V69, P2037, DOI 10.1128/IAI.69.4.2037-2044.2001; Allen MJ, 2001, BIOCHEMISTRY-US, V40, P7789, DOI 10.1021/bi002901q; Atochina EN, 2004, J INFECT DIS, V189, P1528, DOI 10.1086/383130; Atochina EN, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-15; Barr FE, 2000, AM J RESP CELL MOL, V23, P586, DOI 10.1165/ajrcmb.23.5.3771; Beharka AA, 2002, J IMMUNOL, V169, P3565, DOI 10.4049/jimmunol.169.7.3565; BENNE CA, 1995, J INFECT DIS, V171, P335, DOI 10.1093/infdis/171.2.335; BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; Borron P, 1996, AM J RESP CELL MOL, V15, P115, DOI 10.1165/ajrcmb.15.1.8679215; Borron P, 1998, AM J PHYSIOL-LUNG C, V275, pL679, DOI 10.1152/ajplung.1998.275.4.L679; Borron PJ, 1998, J IMMUNOL, V161, P4599; Borron PJ, 2002, J IMMUNOL, V169, P5844, DOI 10.4049/jimmunol.169.10.5844; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BRANDT EB, 2008, J ALLERGY CLIN IMMUN, V121; Bridges JP, 2000, J BIOL CHEM, V275, P38848, DOI 10.1074/jbc.M005322200; Brinker KG, 2003, AM J PHYSIOL-LUNG C, V284, pL232, DOI 10.1152/ajplung.00187.2002; Brinker KG, 2001, AM J PHYSIOL-LUNG C, V281, pL1453, DOI 10.1152/ajplung.2001.281.6.L1453; Cao Y, 2004, J ALLERGY CLIN IMMUN, V113, P439, DOI 10.1016/j.jaci.2003.11.031; Cheng G, 2000, BIOCHEM BIOPH RES CO, V270, P831, DOI 10.1006/bbrc.2000.2515; Chiba H, 2001, INFECT IMMUN, V69, P1587, DOI 10.1128/IAI.69.3.1587-1592.2001; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; Clark H, 2003, ANN NY ACAD SCI, V1010, P113, DOI 10.1196/annals.1299.019; Clark H, 2002, J IMMUNOL, V169, P2892, DOI 10.4049/jimmunol.169.6.2892; CLEMENTS JA, 1965, NEW ENGL J MED, V272, P1336, DOI 10.1056/NEJM196506242722507; Collins RA, 2003, PEDIATR RES, V53, P463, DOI 10.1203/01.PDR.0000049464.46191.BF; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; Dave V, 2004, J BIOL CHEM, V279, P34578, DOI 10.1074/jbc.M404296200; Deb R, 2007, J BIOL CHEM, V282, P36808, DOI 10.1074/jbc.M702336200; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; DiAngelo S, 1999, DIS MARKERS, V15, P269, DOI 10.1155/1999/961430; DRICKAMER K, 1987, J BIOL CHEM, V262, P2582; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Drickamer K, 1999, GLYCOBIOLOGY, V9, P1357, DOI 10.1093/glycob/9.12.1357; Dulkerian SJ, 1996, AM J RESP CELL MOL, V15, P781, DOI 10.1165/ajrcmb.15.6.8969273; Eda S, 1997, BIOCHEM J, V323, P393, DOI 10.1042/bj3230393; Elhalwagi BM, 1999, AM J RESP CELL MOL, V21, P380, DOI 10.1165/ajrcmb.21.3.3676; Erpenbeck VJ, 2006, ALLERGY, V61, P598, DOI 10.1111/j.1398-9995.2006.01062.x; Erpenbeck VJ, 2005, AM J PHYSIOL-LUNG C, V288, pL692, DOI 10.1152/ajplung.00362.2004; Fakhrzadeh L, 2004, AM J PHYSIOL-LUNG C, V287, pL279, DOI 10.1152/ajplung.00348.2003; Ferguson JS, 2002, J IMMUNOL, V168, P1309, DOI 10.4049/jimmunol.168.3.1309; Ferguson JS, 1999, J IMMUNOL, V163, P312; Fisher JH, 2002, AM J RESP CELL MOL, V27, P24, DOI 10.1165/ajrcmb.27.1.4563; Fisher JH, 2000, AM J PHYSIOL-LUNG C, V278, pL365, DOI 10.1152/ajplung.2000.278.2.L365; FLOROS J, 1986, J BIOL CHEM, V261, P9029; Floros J, 1998, BBA-MOL BASIS DIS, V1408, P312, DOI 10.1016/S0925-4439(98)00077-5; Floros J, 2000, J INFECT DIS, V182, P1473, DOI 10.1086/315866; Fraser DA, 2008, CURR DRUG TARGETS, V9, P113, DOI 10.2174/138945008783502476; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; Ghildyal R, 1999, J INFECT DIS, V180, P2009, DOI 10.1086/315134; Ghiran I, 2000, J EXP MED, V192, P1797, DOI 10.1084/jem.192.12.1797; Gold JA, 2004, INFECT IMMUN, V72, P645, DOI 10.1128/IAI.72.2.645-650.2004; Gonzales LW, 2001, PEDIATR PATHOL MOL M, V20, P387, DOI 10.1080/15513810109168622; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Grayson MH, 2007, J IMMUNOL, V179, P1438, DOI 10.4049/jimmunol.179.3.1438; Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989; Guo X, 2001, EUR RESPIR J, V18, P482, DOI 10.1183/09031936.01.00043401; Guo XX, 2000, CHEST, V117, p249S, DOI 10.1378/chest.117.5_suppl_1.249S-a; Gupta G, 2007, BIOESSAYS, V29, P452, DOI 10.1002/bies.20573; HAAGSMAN HP, 1994, BIOCHEM SOC T, V22, P100, DOI 10.1042/bst0220100; Haagsman HP, 1998, BBA-MOL BASIS DIS, V1408, P264, DOI 10.1016/S0925-4439(98)00072-6; Haagsman HP, 2001, COMP BIOCHEM PHYS A, V129, P91, DOI 10.1016/S1095-6433(01)00308-7; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; Haataja R, 2002, ANN MED, V34, P324, DOI 10.1080/078538902320772089; Haczku A, 2001, AM J RESP CELL MOL, V25, P45, DOI 10.1165/ajrcmb.25.1.4391; Haczku A, 2006, J IMMUNOL, V176, P3557, DOI 10.4049/jimmunol.176.6.3557; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Haley KJ, 2002, AM J PHYSIOL-LUNG C, V282, pL573, DOI 10.1152/ajplung.00117.2001; Hallman M, 2006, SEMIN PERINATOL, V30, P350, DOI 10.1053/j.semperi.2006.09.002; Hansen S, 2002, IMMUNOBIOLOGY, V205, P498, DOI 10.1078/0171-2985-00150; Hansen S, 2007, AM J RESP CELL MOL, V36, P94, DOI 10.1165/rcmb.2006-0195OC; Hartshorn K, 1996, AM J PHYSIOL-LUNG C, V271, pL753, DOI 10.1152/ajplung.1996.271.5.L753; Hartshorn KL, 2000, BIOCHEM J, V351, P449, DOI 10.1042/0264-6021:3510449; Hartshorn KL, 2003, AM J PHYSIOL-LUNG C, V285, pL1066, DOI 10.1152/ajplung.00057.2003; Hartshorn KL, 2002, BIOCHEM J, V366, P87, DOI 10.1042/BJ20011868; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958, DOI 10.1152/ajplung.1998.274.6.L958; Hartshorn KL, 1996, BLOOD, V87, P3450, DOI 10.1182/blood.V87.8.3450.bloodjournal8783450; Hartshorn KL, 1997, AM J PHYSIOL-LUNG C, V273, pL1156, DOI 10.1152/ajplung.1997.273.6.L1156; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HAURUM JS, 1993, BIOCHEM J, V293, P873, DOI 10.1042/bj2930873; Hawgood S, 2002, AM J PHYSIOL-LUNG C, V283, pL1002, DOI 10.1152/ajplung.00118.2002; Hawgood S, 2001, AM J PHYSIOL-LUNG C, V280, pL1148, DOI 10.1152/ajplung.2001.280.6.L1148; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; He YC, 2002, J BIOL CHEM, V277, P19530, DOI 10.1074/jbc.M201126200; He YC, 2000, J BIOL CHEM, V275, P31051, DOI 10.1074/jbc.M003499200; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.0.CO;2-W; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Hohlfeld JM, 2002, PATHOBIOLOGY, V70, P287, DOI 10.1159/000070744; HOLMSKOV U, 1995, BIOCHEM J, V305, P889, DOI 10.1042/bj3050889; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Holmskov U, 1993, Behring Inst Mitt, P224; Holmskov UL, 2000, APMIS, V108, P7; Homer RJ, 2002, AM J PHYSIOL-LUNG C, V283, pL52, DOI 10.1152/ajplung.00438.2001; Hoover RR, 1999, AM J PHYSIOL-LUNG C, V276, pL917, DOI 10.1152/ajplung.1999.276.6.L917; Hoover RR, 1998, AM J RESP CELL MOL, V18, P353, DOI 10.1165/ajrcmb.18.3.3035; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Hortobagyi L, 2008, J ALLERGY CLIN IMMUN, V122, P521, DOI 10.1016/j.jaci.2008.05.002; Ikegami M, 1998, AM J PHYSIOL-LUNG C, V275, pL247, DOI 10.1152/ajplung.1998.275.2.L247; Ikegami M, 2001, AM J PHYSIOL-LUNG C, V281, pL697, DOI 10.1152/ajplung.2001.281.3.L697; Jack DL, 2006, CLIN INFECT DIS, V43, P1426, DOI 10.1086/508775; Jain-Vora S, 1998, INFECT IMMUN, V66, P4229; Janssen WJ, 2008, AM J RESP CRIT CARE, V178, P158, DOI 10.1164/rccm.200711-1661OC; Ji X, 1997, P NATL ACAD SCI USA, V94, P6340, DOI 10.1073/pnas.94.12.6340; Jounblat R, 2004, INFECT IMMUN, V72, P709, DOI 10.1128/IAI.72.2.709-716.2004; KAWASAKI T, 1978, BIOCHEM BIOPH RES CO, V81, P1018, DOI 10.1016/0006-291X(78)91452-3; Kierstein S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-85; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; Kishore U, 2006, MOL IMMUNOL, V43, P1293, DOI 10.1016/j.molimm.2005.08.004; Kishore U, 2002, IMMUNOBIOLOGY, V205, P610, DOI 10.1078/0171-2985-00158; KLAUS MH, 1961, P NATL ACAD SCI USA, V47, P1858, DOI 10.1073/pnas.47.11.1858; Kohl J, 2007, MOL IMMUNOL, V44, P44, DOI 10.1016/j.molimm.2006.06.016; Kohl K, 2007, EUR J CELL BIOL, V86, P719, DOI 10.1016/j.ejcb.2007.06.007; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; Korfhagen TR, 1998, BBA-MOL BASIS DIS, V1408, P296, DOI 10.1016/S0925-4439(98)00075-1; Koziel H, 1998, AM J RESP CELL MOL, V18, P834, DOI 10.1165/ajrcmb.18.6.3059; KRIZKOVA L, 1994, AM J PHYSIOL, V266, pL519, DOI 10.1152/ajplung.1994.266.5.L519; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; Kuroki Y, 1999, BIOL NEONATE, V76, P19, DOI 10.1159/000047042; Kuroki Y, 2007, CELL MICROBIOL, V9, P1871, DOI 10.1111/j.1462-5822.2007.00953.x; Lag M, 2000, EXP LUNG RES, V26, P383, DOI 10.1080/019021400408326; Lahti M, 2002, PEDIATR RES, V51, P696, DOI [10.1203/00006450-200206000-00006, 10.1023/01.PDR.0000015911.65104.93]; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lawson PR, 1999, AM J RESP CELL MOL, V20, P953, DOI 10.1165/ajrcmb.20.5.3343; Leth-Larsen R, 2005, J IMMUNOL, V174, P1532, DOI 10.4049/jimmunol.174.3.1532; Leth-Larsen R, 2004, MOL HUM REPROD, V10, P149, DOI 10.1093/molehr/gah022; LeVine AM, 2002, AM J PHYSIOL-LUNG C, V282, pL563, DOI 10.1152/ajplung.00280.2001; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; LeVine AM, 2001, MICROBES INFECT, V3, P161, DOI 10.1016/S1286-4579(00)01363-0; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Li G, 2002, AM J RESP CELL MOL, V26, P277, DOI 10.1165/ajrcmb.26.3.4584; Ligtenberg TJM, 2001, BIOCHEM J, V359, P243, DOI 10.1042/0264-6021:3590243; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; Lin Z, 2000, CLIN GENET, V58, P181, DOI 10.1034/j.1399-0004.2000.580305.x; Linke MJ, 2001, J INFECT DIS, V183, P943, DOI 10.1086/319252; Liu CF, 2005, CLIN EXP ALLERGY, V35, P515, DOI 10.1111/j.1365-2222.2005.02205.x; Lofgren J, 2002, J INFECT DIS, V185, P283, DOI 10.1086/338473; LU J, 1990, J IMMUNOL, V144, P2287; Madan T, 2005, J IMMUNOL, V174, P6943, DOI 10.4049/jimmunol.174.11.6943; Madan T, 2002, CLIN CHEM LAB MED, V40, P1002, DOI 10.1515/CCLM.2002.174; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; Madan T, 2001, INFECT IMMUN, V69, P2728, DOI 10.1128/IAI.69.4.2728-2731.2001; Madan T, 2001, J CLIN INVEST, V107, P467, DOI 10.1172/JCI10124; Madsen J, 2003, AM J RESP CELL MOL, V29, P591, DOI 10.1165/rcmb.2002-0274OC; Madsen J, 2003, EUR J IMMUNOL, V33, P2327, DOI 10.1002/eji.200323972; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; Malherbe DC, 2005, AM J PHYSIOL-LUNG C, V289, pL856, DOI 10.1152/ajplung.00009.2005; MALHOTRA R, 1994, BIOCHEM J, V304, P455, DOI 10.1042/bj3040455; MALHOTRA R, 1993, BIOSCIENCE REP, V13, P79, DOI 10.1007/BF01145960; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; Martis PC, 2006, DEVELOPMENT, V133, P1155, DOI 10.1242/dev.02273; McGreal E, 2002, BIOCHEM SOC T, V30, P1010, DOI 10.1042/BST0301010; McGreal EP, 2002, J IMMUNOL, V168, P5222, DOI 10.4049/jimmunol.168.10.5222; McIntosh JC, 1996, AM J PHYSIOL-LUNG C, V271, pL310, DOI 10.1152/ajplung.1996.271.2.L310; Mikerov AN, 2008, AM J PHYSIOL-LUNG C, V294, pL121, DOI 10.1152/ajplung.00288.2007; Mikerov AN, 2007, INFECT IMMUN, V75, P1403, DOI 10.1128/IAI.01341-06; Mishra A, 2001, J BIOL CHEM, V276, P8453, DOI 10.1074/jbc.M009481200; MIYAMURA K, 1994, BBA-LIPID LIPID MET, V1210, P303, DOI 10.1016/0005-2760(94)90233-X; Murakami S, 2002, J BIOL CHEM, V277, P6830, DOI 10.1074/jbc.M106671200; Murray E, 2002, INFECT IMMUN, V70, P1481, DOI 10.1128/IAI.70.3.1481-1487.2002; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Noah TL, 2003, AM J RESP CRIT CARE, V168, P685, DOI 10.1164/rccm.200301-005OC; Oberley RE, 2004, MOL HUM REPROD, V10, P861, DOI 10.1093/molehr/gah117; Oberley RE, 2004, AM J PHYSIOL-LUNG C, V287, pL296, DOI 10.1152/ajplung.00440.2003; Oberley RE, 2003, AM J PHYSIOL-LUNG C, V284, pL871, DOI 10.1152/ajplung.00241.2002; Ofek I, 2001, INFECT IMMUN, V69, P24, DOI 10.1128/IAI.69.1.24-33.2001; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Ohya M, 2006, BIOCHEMISTRY-US, V45, P8657, DOI 10.1021/bi060176z; Paananen R, 2001, AM J PHYSIOL-LUNG C, V281, pL660, DOI 10.1152/ajplung.2001.281.3.L660; Palaniyar N, 2003, ANN NY ACAD SCI, V1010, P471, DOI 10.1196/annals.1299.085; Palaniyar N, 2004, J BIOL CHEM, V279, P32728, DOI 10.1074/jbc.M403763200; Palaniyar N, 2002, J BIOL CHEM, V277, P26971, DOI 10.1074/jbc.M110080200; Pastva Amy M, 2007, Proc Am Thorac Soc, V4, P252, DOI 10.1513/pats.200701-018AW; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; Ramet M, 2001, J PEDIATR-US, V138, P266, DOI 10.1067/mpd.2001.110133; Reidy MF, 2003, AM J PHYSIOL-LUNG C, V285, pL854, DOI 10.1152/ajplung.00439.2002; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; RISHI A, 1992, AM J PHYSIOL, V262, pL566, DOI 10.1152/ajplung.1992.262.5.L566; Rosseau S, 1997, J INFECT DIS, V175, P421, DOI 10.1093/infdis/175.2.421; Rosseau S, 1999, J IMMUNOL, V163, P4495; Runza VL, 2008, IMMUNOBIOLOGY, V213, P297, DOI 10.1016/j.imbio.2007.10.009; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; Rust K, 1996, AM J RESP CELL MOL, V14, P121, DOI 10.1165/ajrcmb.14.2.8630261; Sahly H, 2002, J IMMUNOL, V169, P3267, DOI 10.4049/jimmunol.169.6.3267; Saitoh M, 2000, BIOCHEMISTRY-US, V39, P1059, DOI 10.1021/bi9917939; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; SANO K, 1997, BIOCHEM BIOPH RES CO, V144, P367; Saxena S, 2003, J ALLERGY CLIN IMMUN, V111, P1001, DOI 10.1067/mai.2003.1395; Scanlon ST, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-97; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Schaub B, 2004, CLIN EXP ALLERGY, V34, P1819, DOI 10.1111/j.1365-2222.2004.02068.x; SCHELENZ S, 1995, INFECT IMMUN, V63, P3360, DOI 10.1128/IAI.63.9.3360-3366.1995; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Sekine H, 2001, J IMMUNOL, V167, P4504, DOI 10.4049/jimmunol.167.8.4504; Selman M, 2003, HUM GENET, V113, P542, DOI 10.1007/s00439-003-1015-4; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; Sims MW, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-13; Sin DD, 2008, AM J RESP CRIT CARE, V177, P1207, DOI 10.1164/rccm.200709-1356OC; Singh M, 2003, IMMUNOL LETT, V86, P299, DOI 10.1016/S0165-2478(03)00033-6; Stahlman MT, 2002, J HISTOCHEM CYTOCHEM, V50, P651, DOI 10.1177/002215540205000506; Strong P, 2003, CLIN EXP IMMUNOL, V134, P181, DOI 10.1046/j.1365-2249.2003.02281.x; Strong P, 2002, CLIN EXP IMMUNOL, V130, P19, DOI 10.1046/j.1365-2249.2002.01968.x; Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3; Sullivan LC, 1998, J MOL EVOL, V46, P131, DOI 10.1007/PL00006287; Tagaram HRS, 2007, AM J PHYSIOL-LUNG C, V292, pL1052, DOI 10.1152/ajplung.00249.2006; Takeda K, 2003, AM J RESP CRIT CARE, V168, P783, DOI 10.1164/rccm.200304-548OC; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394, DOI 10.1152/ajplung.2001.281.2.L394; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; TENNER AJ, 1995, IMMUNITY, V3, P485, DOI 10.1016/1074-7613(95)90177-9; Thiel S, 2006, MOL IMMUNOL, V43, P86, DOI 10.1016/j.molimm.2005.06.018; Tino MJ, 1999, AM J RESP CELL MOL, V20, P759, DOI 10.1165/ajrcmb.20.4.3439; Tino MJ, 1999, AM J PHYSIOL-LUNG C, V276, pL164, DOI 10.1152/ajplung.1999.276.1.L164; Turner MW, 2003, MOL IMMUNOL, V40, P423, DOI 10.1016/S0161-5890(03)00155-X; Vaandrager AB, 2000, BIOL NEONATE, V77, P9, DOI 10.1159/000047051; van de Wetering JK, 2004, INFECT IMMUN, V72, P145, DOI 10.1128/IAI.72.1.145-153.2004; van de Wetering JK, 2004, EUR J BIOCHEM, V271, P1229, DOI 10.1111/j.1432-1033.2004.04040.x; Van Rozendaal BAWM, 1997, BIOCHEM SOC T, V25, pS656, DOI 10.1042/bst025s656; van Rozendaal BAWM, 2001, PEDIATR PATHOL MOL M, V20, P319, DOI 10.1080/15513810109168824; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407, DOI 10.1042/bj3030407; Vass G., 2004, Journal of Allergy and Clinical Immunology, V113, pS252, DOI 10.1016/j.jaci.2004.01.375; Vuk-Pavlovic Z, 2001, AM J RESP CELL MOL, V24, P475, DOI 10.1165/ajrcmb.24.4.3504; Walenkamp AME, 1999, EUR J CLIN INVEST, V29, P83, DOI 10.1046/j.1365-2362.1999.00429.x; Wang GR, 2004, BIOCHEMISTRY-US, V43, P4227, DOI 10.1021/bi036023i; Wang GR, 2003, AM J PHYSIOL-LUNG C, V284, pL738, DOI 10.1152/ajplung.00375.2002; Wang GR, 2002, ENVIRON HEALTH PERSP, V110, P79, DOI 10.1289/ehp.0211079; Wang GR, 2000, AM J PHYSIOL-LUNG C, V278, pL946, DOI 10.1152/ajplung.2000.278.5.L946; Wang JY, 1996, CLIN EXP IMMUNOL, V106, P367, DOI 10.1046/j.1365-2249.1996.d01-838.x; Wang JY, 1998, AM J RESP CRIT CARE, V158, P510, DOI 10.1164/ajrccm.158.2.9709111; Watford WT, 2000, AM J PHYSIOL-LUNG C, V279, pL790, DOI 10.1152/ajplung.2000.279.5.L790; Weikert LF, 2000, AM J PHYSIOL-LUNG C, V279, pL216, DOI 10.1152/ajplung.2000.279.2.L216; Weikert LF, 1997, AM J PHYSIOL-LUNG C, V272, pL989, DOI 10.1152/ajplung.1997.272.5.L989; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEISSBACH S, 1994, AM J PHYSIOL-LUNG C, V267, pL660, DOI 10.1152/ajplung.1994.267.6.L660; White CW, 2001, AM J RESP CELL MOL, V25, P51, DOI 10.1165/ajrcmb.25.1.4296; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WILSHER ML, 1988, CLIN EXP IMMUNOL, V74, P465; WILSHER ML, 1988, THORAX, V43, P354, DOI 10.1136/thx.43.5.354; WILSHER ML, 1990, THORAX, V45, P3, DOI 10.1136/thx.45.1.3; Wong CJ, 1996, PEDIATR RES, V39, P930, DOI 10.1203/00006450-199606000-00002; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; WRIGHT JR, 1993, AM J PHYSIOL, V264, pL338, DOI 10.1152/ajplung.1993.264.4.L338; Wu L, 2007, IMMUNITY, V26, P741, DOI 10.1016/j.immuni.2007.06.006; Yong SJ, 2003, INFECT IMMUN, V71, P1662, DOI 10.1128/IAI.71.4.1662-1671.2003; Yoshida M, 2006, RESPIROLOGY, V11, pS37, DOI 10.1111/j.1440-1843.2006.00806.x; Zhang LQ, 2002, J BIOL CHEM, V277, P22453, DOI 10.1074/jbc.M201632200; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200; Zhang LQ, 2002, J BIOL CHEM, V277, P38709, DOI 10.1074/jbc.M206200200; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	270	94	100	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					861	879		10.1016/j.jaci.2008.10.014	http://dx.doi.org/10.1016/j.jaci.2008.10.014			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	19000577	Green Accepted			2022-12-18	WOS:000260940100002
J	Liu, WM; Liang, QL; Balzar, S; Wenzel, S; Gorska, M; Alam, R				Liu, Weimin; Liang, Qiaoling; Balzar, Silvana; Wenzel, Sally; Gorska, Magdalena; Alam, Rafeul			Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial biopsy; mitogen-activated protein kinase; epithelial function; chemokines	BRONCHIAL EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; MAP KINASE; GM-CSF; EXPRESSION; LUNG; INFLAMMATION; PATHWAY; DIFFERENTIATION; PROLIFERATION	Background: Many airway cells manifest signs of chronic activation in asthma. The mechanism of this chronic activation is unknown. Objectives: We sought to study the activation of the mitogen-activated protein kinase (MAPK) signaling pathway in airway cells. Methods: Endobronchial biopsy specimens from patients with severe and mild asthma (n = 17 in each group) and healthy, control subjects (n = 15) were analyzed for the phosphorylated MAPKs extracellular signal-regulated kinase (ERK) 1/2, p38, and Jun N-terminal kinase (JNK) and their downstream effectors by means of immunofluorescence staining. Airway epithelial activation of ERK1/2 and p38 was studied by using Western blotting. Epithelial function was studied by means of real-time PCR, ELISA, and the thymidine incorporation assay. Results: We detected strong phospho-ERK1/2 staining in airway epithelium and smooth muscle cells in biopsy specimens from asthmatic patients. Fluorescent areas per image, as well as mean fluorescence intensity, were significantly (P <.0001) different among the 3 study groups (patients with severe asthma, patients with mild asthma, and healthy control subjects). Patients with severe asthma also demonstrated strong phospho-p38 staining, mostly in epithelial cells, which was significantly different from that in patients with mild asthma (P =.0001) and healthy control subjects (P =.02). Phospho-JNK primarily stained airway smooth muscle cells. Healthy subjects showed the highest intensity of phospho-JNK staining compared with that seen in patients with severe (P =.004) and mild asthma (P =.003). Inhibition of ERKI/2 and p38 in primary airway epithelial cells blocked their proliferation and expression of select, but not all, chemokines. Conclusions: Significant phosphorylation of ERK1/2 and p38 and their correlation with disease severity suggests that the	[Liu, Weimin; Liang, Qiaoling; Gorska, Magdalena; Alam, Rafeul] Natl Jewish Med & Res Ctr, Dept Med, Div Allergy & Immunol, Denver, CO 80206 USA; [Liu, Weimin; Liang, Qiaoling; Gorska, Magdalena; Alam, Rafeul] Univ Colorado Denver, Hlth Sci Ctr, Denver, CO USA; [Balzar, Silvana; Wenzel, Sally] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Alam, R (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Div Allergy & Immunol, 1400 Jackson St, Denver, CO 80206 USA.	alamr@njrc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059719, R01AI068088] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36577] Funding Source: Medline; NIAID NIH HHS [AI059719, R01 AI68088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe MK, 1998, AM J RESP CELL MOL, V18, P562, DOI 10.1165/ajrcmb.18.4.2958; CHEN G, 1920, RESP RES, V7, P2; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408-1006OC; Duan W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/jimmunol.172.11.7053; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hashimoto S, 2000, CLIN EXP ALLERGY, V30, P48; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Joubert P, 2005, J ALLERGY CLIN IMMUN, V116, P713, DOI 10.1016/j.jaci.2005.05.042; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Krunkosky TM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-12; Kujime K, 2000, J IMMUNOL, V164, P3222, DOI 10.4049/jimmunol.164.6.3222; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; Lazaar AL, 2005, J ALLERGY CLIN IMMUN, V116, P488, DOI 10.1016/j.jaci.2005.06.030; Lee PJ, 2006, J CLIN INVEST, V116, P163, DOI 10.1172/JCI25711; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Oltmanns U, 2003, BRIT J PHARMACOL, V139, P1228, DOI 10.1038/sj.bjp.0705345; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; Rahman MS, 2006, J IMMUNOL, V177, P4064, DOI 10.4049/jimmunol.177.6.4064; Ravensberg AJ, 2005, J ALLERGY CLIN IMMUN, V115, P779, DOI 10.1016/j.jaci.2004.11.045; Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Silverman ES, 2002, AM J RESP CELL MOL, V27, P697, DOI 10.1165/rcmb.2002-0011OC; SREEKUMAR GP, 2000, J AM SOC HUM GENET A, V354, P1974; Stahl E, 2000, RESP MED, V94, P735, DOI 10.1053/rmed.2000.0814; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; YUAN Q, 1920, EUR J IMMUNOL, V36, P2700; Zaiss DM, 2006, SCIENCE, V314, P1746, DOI 10.1126/science.1133715; ZEMEL NP, 1996, AM J RESP CRIT CARE, V153, P1902; Zhai WW, 2004, BRIT J PHARMACOL, V143, P1042, DOI 10.1038/sj.bjp.0705971; Zhen GH, 2007, AM J RESP CELL MOL, V36, P244, DOI 10.1165/rcmb.2006-0180OC	38	94	103	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					893	902		10.1016/j.jaci.2008.02.004	http://dx.doi.org/10.1016/j.jaci.2008.02.004			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18395552				2022-12-18	WOS:000254884000013
J	Appleton, SL; Adams, RJ; Wilson, DH; Taylor, AW; Ruffin, RE				Appleton, Sarah L.; Adams, Robert J.; Wilson, David H.; Taylor, Anne W.; Ruffin, Richard E.		NW Adelaide Hlth Study Team	Central obesity is associated with nonatopic but not atopic asthma in a representative population sample	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma epidemiology; obesity; waist circumference; waist-to-hip ratio; atopy	BODY-MASS INDEX; EXHALED NITRIC-OXIDE; WAIST CIRCUMFERENCE; AIRWAY HYPERRESPONSIVENESS; WEIGHT-REDUCTION; ALLERGIC-ASTHMA; PREVALENCE; HEALTH; RISK; ADIPONECTIN	Background: Epidemiologic studies have consistently demonstrated the association between high body mass index (BMI) and asthma, yet the relationship between asthma and the alternative central obesity phenotypes, waist circumference (WC) and waist-to-hip ratio (WHR), has not been assessed in a representative population sample. Objective: To determine the strength of the association of WC and WHR with current asthma and whether the association is modified by atopic status in a representative population sample. Methods: The North West Adelaide Health Study, a biomedical population study of n = 4060, assessed current asthma, respiratory symptoms, and participant demographics by self-completed questionnaire. Clinic assessment included measures of WC and WHR, spirometry, and skin prick tests to a panel of allergens. Results: Logistic regression analysis showed a significant, marginal increased adjusted risk of asthma associated with obese levels of WC and WHR and BMI >= 35.0 kg/m(2) in female subjects only. When the association was considered stratified according to atopic status, the relationship between obese levels of WC and WHR with asthma held only for the nonatopic population in both males (WC: odds ratio [OR] 5.7, 95% confidence interval [CI] 1.1-28.8; WHR: OR 6.2, 95% CI, 1.132.9) and females (WC: OR 2.3,95% CI, 1.2-4.4; WHR: OR 3.0, 95% CI, 1.5-5.9). BMI >= 35.0 kg/m(2) showed an inconsistent pattern in the association with asthma. Conclusion: Central obesity was significantly associated with an increased risk of nonatopic asthma only. The causal pathway is unknown, but this study suggests the involvement of different pathophysiological mechanisms requiring further investigation. Clinical implications: Asthma should be considered in older, nonatopic, centrally obese, symptomatic individuals.	Univ Adelaide, Dept Med, Hlth Observ, Woodville, SA 5011, Australia; S Australian Dept Hlth, Populat Res & Outcomes Studies Unit, Adelaide, SA, Australia	University of Adelaide	Adams, RJ (corresponding author), Univ Adelaide, Dept Med, Hlth Observ, Queen Elizabeth Hosp Campus,Woodville Rd, Woodville, SA 5011, Australia.	robert.adams@adelaide.edu.au	Appleton, Sarah/Y-5206-2019; Adams, Robert/Z-3197-2019; Taylor, Anne w/F-5708-2010; Appleton, Sarah/E-9149-2017	Taylor, Anne w/0000-0002-4422-7974; Appleton, Sarah/0000-0001-7292-9714				Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Adams RJ, 2003, THORAX, V58, P846, DOI 10.1136/thorax.58.10.846; Amin K, 2005, ALLERGY, V60, P1241, DOI 10.1111/j.1398-9995.2005.00823.x; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; Appleton SL, 2005, J ALLERGY CLIN IMMUN, V116, P976, DOI 10.1016/j.jaci.2005.08.034; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Australian Bureau of Statistics, 1999, EST RES POP AG SEX; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045, DOI 10.1164/ajrccm.164.11.2004235; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; Booth ML, 2000, INT J OBESITY, V24, P1058, DOI 10.1038/sj.ijo.0801359; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Cameron AJ, 2003, MED J AUSTRALIA, V178, P427, DOI 10.5694/j.1326-5377.2003.tb05283.x; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; DALES RE, 1988, AM REV RESPIR DIS, V138, P317, DOI 10.1164/ajrccm/138.2.317; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80, DOI 10.1164/ajrccm/148.1.80; Gill T, 2003, SOZ PRAVENTIV MED, V48, P191, DOI 10.1007/s00038-003-2055-1; Grant Janet F, 2006, Epidemiol Perspect Innov, V3, P4, DOI 10.1186/1742-5573-3-4; Gunnbjomsdottir MI, 2004, EUR RESPIR J, V24, P116, DOI 10.1183/09031936.04.00042603; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Henriksen AH, 2000, EUR RESPIR J, V15, P849, DOI 10.1034/j.1399-3003.2000.15e07.x; HUANG S, 1999, CLIN EXP ALLERGY, V32, P831; Janson C, 2005, RESP MED, V99, P45, DOI 10.1016/j.rmed.2004.05.007; Janssen I, 2004, AM J CLIN NUTR, V79, P379; Jarvis D, 2002, CLIN EXP ALLERGY, V32, P831, DOI 10.1046/j.1365-2222.2002.01380.x; Jayaratnam A, 2005, CLIN EXP ALLERGY, V35, P835, DOI 10.1111/j.1365-2222.2005.02283.x; Jouaville LF, 2003, CLIN EXP ALLERGY, V33, P1506, DOI 10.1046/j.1365-2222.2003.01800.x; Karjalainen EM, 2003, RESP MED, V97, P1045, DOI 10.1016/S0954-6111(03)00136-7; Kronander UN, 2004, RESP MED, V98, P1108, DOI 10.1016/j.rmed.2004.03.022; Kumada M, 2004, CIRCULATION, V109, P2046, DOI 10.1161/01.CIR.0000127953.98131.ED; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; *NAT HEART LUNG BL, 1998, 984083 NIH NAT HEART; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Olafsdottir IS, 2005, THORAX, V60, P451, DOI 10.1136/thx.2004.035774; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Seidell JC, 2001, AM J CLIN NUTR, V74, P315; Selim AJ, 1997, CHEST, V111, P1607, DOI 10.1378/chest.111.6.1607; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Snijder MB, 2003, AM J CLIN NUTR, V77, P1192, DOI 10.1093/ajcn/77.5.1192; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Taylor AW, 1998, AUST NZ J PUBL HEAL, V22, P223, DOI 10.1111/j.1467-842X.1998.tb01177.x; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; von Hertzen L, 2005, ALLERGY, V60, P283, DOI 10.1111/j.1398-9995.2005.00769.x; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Wilson DH, 2003, MED J AUSTRALIA, V178, P483, DOI 10.5694/j.1326-5377.2003.tb05320.x; World Health Organization, 1997, OB PREV MAN GLOB EP; Zeibecoglou K, 2000, J ALLERGY CLIN IMMUN, V106, P697, DOI 10.1067/mai.2000.109824; [No title captured]	56	94	96	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1284	1291		10.1016/j.jaci.2006.08.011	http://dx.doi.org/10.1016/j.jaci.2006.08.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157658				2022-12-18	WOS:000242880300012
J	Olynych, TJ; Jakeman, DL; Marshall, JS				Olynych, Timothy J.; Jakeman, David L.; Marshall, Jean S.			Fungal zymosan induces leukotriene production by human mast cells through a dectin-1-dependent mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fungal infection; mast cells; lipid mediators; GM-CSF; IL-1 beta; allergy; bronchoconstriction	BETA-GLUCAN RECEPTOR; TOLL-LIKE RECEPTOR-2; CD8(+) T-CELLS; AIRWAY HYPERRESPONSIVENESS; PATTERN-RECOGNITION; BACTERIAL CLEARANCE; STEEL FACTOR; DECTIN-1; ACTIVATION; ASTHMA	Background: Fungi are capable of causing or exacerbating inflammatory disease in the airways. We have previously demonstrated that zymosan and peptidoglycan induce the production of cysteinyl leukotrienes from human mast cells. However, the mechanisms of pathogen-induced leukotriene production by immune effector cells are very poorly understood. The coreceptor dectin-1, through a Syk tyrosine kinase-dependent pathway, can mediate some responses to fungal challenge, but its expression by mast cells and its involvement in lipid mediator responses have not been assessed. Objective: In the current study, the potential role of dectin-1 in zymosan-induced leukotriene production from human mast cells was examined. Methods: Human mast cells were examined for dectin-1 mRNA and protein expression. Human mast cells were incubated with either zymosan or peptidoglycan in the presence or absence of specific inhibitors for dectin-1 or Syk tyrosine kinase and mediator production examined. Results: Human mast cells were found to express a functional isoform of dectin-1. Both peptidoglycan and zymosan induced significant amounts of leukotriene (LT)-B-4 and LTC4. The dectin-1 inhibitors laminarin and glucan phosphate reduced the LTC4 response to zymosan by more than 60% but did not alter peptidoglycan responses. Inhibitors of Syk tyrosine kinase activity significantly decreased LTC4 production in response to both peptidoglycan and zymosan. Conclusion: These data demonstrate mast cell expression of the coreceptor dectin-1 and a role for this molecule in the generation of cysteinyl leukotrienes. Clinical implications: These findings suggest new approaches to the selective inhibition of lipid mediator production in response to fungal infection or exposure.	Dalhousie Univ, Dalhousie Inflammat Grp, Dept Microbiol & Immunol, Halifax, NS B3H 1X5, Canada; Dalhousie Univ, Dalhousie Inflammat Grp, Dept Pathol, Halifax, NS B3H 1X5, Canada; Dalhousie Univ, Coll Pharm, Halifax, NS B3H 1X5, Canada	Dalhousie University; Dalhousie University; Dalhousie University	Marshall, JS (corresponding author), Dalhousie Univ, Dalhousie Inflammat Grp, Dept Microbiol & Immunol, Sir Charles Tupper Med Bldg,Coll St, Halifax, NS B3H 1X5, Canada.	jean.marshall@dal.ca	Jakeman, David/X-7624-2018	Jakeman, David/0000-0003-3002-3388; Marshall, Jean S./0000-0002-5642-1379				Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hogaboam CM, 2005, MED MYCOL, V43, pS197, DOI 10.1080/13693780400025211; Hohl TM, 2005, PLOS PATHOG, V1, P232, DOI 10.1371/journal.ppat.0010030; Johnston SL, 1997, CLIN EXP ALLERGY, V27, P7, DOI 10.1111/j.1365-2222.1997.tb00666.x; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Lai JYQ, 2003, BIOORG MED CHEM LETT, V13, P3111, DOI 10.1016/S0960-894X(03)00658-9; Law CL, 1996, MOL CELL BIOL, V16, P1305; Lin TJ, 2000, J IMMUNOL, V165, P211, DOI 10.4049/jimmunol.165.1.211; Malaviya R, 2000, J LEUKOCYTE BIOL, V67, P841, DOI 10.1002/jlb.67.6.841; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; McCurdy JD, 2001, J LEUKOCYTE BIOL, V70, P977; Miyahara N, 2005, J IMMUNOL, V174, P4979, DOI 10.4049/jimmunol.174.8.4979; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Saito H, 1996, J IMMUNOL, V157, P343; SAITO H, 1995, INT ARCH ALLERGY IMM, V107, P330, DOI 10.1159/000237018; Sorenson WG, 1998, ANN AGR ENV MED, V5, P65; Supajatura V, 2001, J IMMUNOL, V167, P2250, DOI 10.4049/jimmunol.167.4.2250; Suram S, 2006, J BIOL CHEM, V281, P5506, DOI 10.1074/jbc.M509824200; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Varadaradjalou S, 2003, EUR J IMMUNOL, V33, P899, DOI 10.1002/eji.200323830; VOLLAND H, 1994, J IMMUNOL METHODS, V175, P97, DOI 10.1016/0022-1759(94)90335-2; WILLIAMS DL, 1991, CARBOHYD RES, V219, P203, DOI 10.1016/0008-6215(91)89052-H; Willment JA, 2001, J BIOL CHEM, V276, P43818, DOI 10.1074/jbc.M107715200; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837	41	94	97	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					837	843		10.1016/j.jaci.2006.06.008	http://dx.doi.org/10.1016/j.jaci.2006.06.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030235				2022-12-18	WOS:000241434200009
J	Hashimoto, K; Durbin, JE; Zhou, WS; Collins, RD; Ho, SB; Kolls, JK; Dubin, PJ; Sheller, JR; Goleniewska, K; O'Neal, JF; Olson, SJ; Mitchell, D; Graham, BS; Peebles, RS				Hashimoto, K; Durbin, JE; Zhou, WS; Collins, RD; Ho, SB; Kolls, JK; Dubin, PJ; Sheller, JR; Goleniewska, K; O'Neal, JF; Olson, SJ; Mitchell, D; Graham, BS; Peebles, RS			Respiratory syncytial virus infection in the absence of STAT1 results in airway dysfunction, airway mucus, and augmented IL-17 levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						viral; inflammation; rodent; cytokines; mucus; IL-17; IL-23	TYPE-2 CYTOKINE PRODUCTION; MUCIN GENE-EXPRESSION; SENSITIZED MICE; ALLERGIC-ASTHMA; GOBLET CELLS; ACUTE BRONCHIOLITIS; VIRAL DISEASE; CUTTING EDGE; BALB/C MICE; HYPERRESPONSIVENESS	Background: Respiratory syncytial virus (RSV) is the leading infectious cause of respiratory failure and wheezing in infants and young children. Prematurity is the greatest risk factor for severe RSV-induced disease, and recent studies suggest that premature children have lower levels of the type I IFNs (alpha/beta), for which signal transducer and activator of transcription (STAT) 1 is a critical intracellular signaling molecule. Objective: We hypothesized that RSV infection in STAT-1 knockout (STAT1 KO) mice would result in both increased airway resistance and airway hyperresponsiveness. Methods: Wild-type (WT) and STAT1 KO mice on a BALB/c background were either RSV or mock infected. Phenotypic response to infection was assessed by means of plethysmography, immunohistochemistry, and lung cytokine measurement. Results: We found that STAT1 KO mice infected with RSV (STAT1 KO-RSV) had greater baseline lung resistance (P = .05) and airway responsiveness (P < .001) than mock-infected STAT1 KO (STAT1 KO-MOCK), RSV-infected wild type (WT-RSV), and mock-infected wild type (WT-MOCK) mice. In addition, the STAT1 KO-RSV mice showed induction of mucus production and expression of gob-5 and Muc5ac, conditions not present in any of the other 3 groups. IL-17, a cytokine that regulates Muc5ac expression, was expressed in the lungs of the STAT1 KO-RSV mice, whereas lung levels of IL-17 were undetectable in the remaining groups. Expression of the IL-23-specific p19 subunit was also increased in the STAT1 KO-RSV mice but not in the WT-RSV mice. Conclusion: These results show that STAT1 has an important regulatory role in RSV-induced alteration of airway function.	Vanderbilt Univ, Sch Med, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Fukushima Med Univ, Dept Microbiol, Fukushima, Japan; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Univ Minnesota, Vet Affairs Med Ctr, Dept Med, Minneapolis, MN USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; NIAID, NIH, Bethesda, MD 20892 USA	Vanderbilt University; Vanderbilt University; Fukushima Medical University; University System of Ohio; Ohio State University; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Peebles, RS (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr, Dept Med, T-1217 MCN,221 Kirkland Hall, Nashville, TN 37232 USA.	stokes.peebles@vanderbilt.edu	Kolls, Jay/AAH-1829-2019; Graham, Barney S./AAC-5898-2019; Dubin, Patricia/AAB-9951-2020	Kolls, Jay/0000-0001-5151-6304; Graham, Barney S./0000-0001-8112-0853; 	NHLBI NIH HHS [HL 69949] Funding Source: Medline; NIAID NIH HHS [AI 45512, AI 54660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045512, R01AI054660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boyce TG, 2000, J PEDIATR-US, V137, P865, DOI 10.1067/mpd.2000.110531; Brandenburg AH, 2000, J MED VIROL, V62, P267, DOI 10.1002/1096-9071(200010)62:2&lt;267::AID-JMV20&gt;3.0.CO;2-8; CEDERBLAD B, 1990, PEDIATR RES, V27, P7, DOI 10.1203/00006450-199001000-00002; Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200; Cohn L, 1998, J IMMUNOL, V161, P3813; Dakhama A, 2005, AM J PHYSIOL-LUNG C, V288, pL761, DOI 10.1152/ajplung.00143.2004; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Durbin JE, 2002, J IMMUNOL, V168, P2944, DOI 10.4049/jimmunol.168.6.2944; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; GAROFALO R, 1992, J PEDIATR-US, V120, P28, DOI 10.1016/S0022-3476(05)80592-X; Garofalo R, 1994, Pediatr Allergy Immunol, V5, P111, DOI 10.1111/j.1399-3038.1994.tb00227.x; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432; Hashimoto K, 2004, AM J RESP CRIT CARE, V170, P306, DOI 10.1164/rccm.200301-030OC; Hoshino M, 2002, AM J RESP CRIT CARE, V165, P1132, DOI 10.1164/ajrccm.165.8.2107068; Hovenberg HW, 1996, BIOCHEM J, V318, P319, DOI 10.1042/bj3180319; Hovenberg HW, 1996, GLYCOCONJUGATE J, V13, P839, DOI 10.1007/BF00702348; Jacoby DB, 1998, J CLIN INVEST, V102, P242, DOI 10.1172/JCI1114; Jafri HS, 2004, J INFECT DIS, V189, P1856, DOI 10.1086/386372; Kay AB, 2003, AM J RESP CRIT CARE, V167, P1586, DOI 10.1164/rccm.2304001; Kim CK, 2003, J ALLERGY CLIN IMMUN, V112, P64, DOI 10.1067/mai.2003.1618; Komiya T, 1999, BIOCHEM BIOPH RES CO, V255, P347, DOI 10.1006/bbrc.1999.0168; Larsen GL, 1999, J PEDIATR-US, V135, pS21; Lukacs NW, 2001, J IMMUNOL, V167, P1060, DOI 10.4049/jimmunol.167.2.1060; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; NEUSTOCK P, 1993, LYMPHOKINE CYTOK RES, V12, P109; Peebles RS, 2000, J INFECT DIS, V182, P671; Peebles RS, 2003, VIRAL IMMUNOL, V16, P25, DOI 10.1089/088282403763635429; Peebles RS, 1999, J MED VIROL, V57, P186, DOI 10.1002/(SICI)1096-9071(199902)57:2<186::AID-JMV17>3.0.CO;2-Q; Peebles RS, 2001, J INFECT DIS, V184, P1374; Peebles RS, 2001, J MED VIROL, V63, P178, DOI 10.1002/1096-9071(20000201)63:2<178::AID-JMV1013>3.3.CO;2-F; PRICE JF, 1990, LUNG, V168, P414, DOI 10.1007/BF02718159; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Reijonen TM, 1997, PEDIATR PULM, V24, P35, DOI 10.1002/(SICI)1099-0496(199707)24:1<35::AID-PPUL6>3.3.CO;2-K; Renzi PM, 1997, J PEDIATR-US, V130, P584, DOI 10.1016/S0022-3476(97)70243-9; Rose MC, 2001, AM J RESP CELL MOL, V25, P533, DOI 10.1165/ajrcmb.25.5.f218; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Shahzeidi S, 2003, EXP LUNG RES, V29, P549, DOI 10.1080/01902140390240159; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; van der Sande MAB, 2002, CLIN EXP ALLERGY, V32, P1430, DOI 10.1046/j.1365-2745.2002.01521.x; van Schaik SM, 2000, J MED VIROL, V62, P257, DOI 10.1002/1096-9071(200010)62:2<257::AID-JMV19>3.0.CO;2-M; van Schaik SM, 1998, J INFECT DIS, V177, P269, DOI 10.1086/514208; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wohl MEB, 2003, NEW ENGL J MED, V349, P82, DOI 10.1056/NEJMe030052	49	94	99	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					550	557		10.1016/j.jaci.2005.03.051	http://dx.doi.org/10.1016/j.jaci.2005.03.051			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159623				2022-12-18	WOS:000235686500013
J	Carraro, S; Corradi, M; Zanconato, S; Alinovi, R; Pasquale, MF; Zacchello, F; Baraldi, E				Carraro, S; Corradi, M; Zanconato, S; Alinovi, R; Pasquale, MF; Zacchello, F; Baraldi, E			Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exercise-induced bronchoconstriction; exhaled breath condensate; exhaled nitric oxide; cysteinyl leukotrienes; leukotriene B4; ammonia; montelukast	AIRWAY EOSINOPHILIC INFLAMMATION; INDUCED ASTHMA; NITRIC-OXIDE; RECEPTOR ANTAGONIST; MONTELUKAST; CHALLENGE; DISEASE; HYPERRESPONSIVENESS; RESPONSES; ALLERGEN	Background: It is recognized that airway inflammation has a central role in the pathogenesis of asthma, but how it relates to exercise-induced bronchoconstriction (EIB) is not completely understood. Objective: The aim of our study was to investigate the relationship between EIB and baseline concentrations of cysteinyl leukotrienes (Cys-LTs) and other inflammatory markers in exhaled breath condensate (EBC). Methods: EBC was collected, and the fraction of exhaled nitric oxide (FENO) was measured in a group of 19 asthmatic children, after which they performed a treadmill exercise test. Fourteen healthy children were enrolled as control subjects. Results: The asthmatic children were divided into the EIB group (decrease in FEV1, >= 12%) and the non-EIB group. The EBC was analyzed for the presence of Cys-LTs, leukotriene B-4, and ammonia. Asthmatic patients with EIB (mean FEV1 decrease, 23% +/- 3%) had higher Cys-LT concentrations than either asthmatic patients without EIB or control subjects (42.2 pg/mL [median] vs 11.7 pg/mL and 5.8 pg/mL; P <.05 and P <.001, respectively). Ammonia concentrations were lower in both the EIB and non-EIB groups than in control subjects (253.2 mu M and 334.6 mu M vs 798.4 mu M; P <.01 and P <.05, respectively). No difference in EBC leukotriene B4 levels was found among the 3 groups. Both asthmatic groups had higher FENO levels than control subjects (P <.001). EBC Cys-LT (P <.01; r = 0.7) and FENO (P <.05; r = 0.5) values both correlated significantly with the postexercise FEV1 decrease. Conclusion: this study shows that EBC Cys-LT values are higher in asthmatic children with EIB and correlate with the decrease in FEV1 after exercise. These findings suggest that the pathways of both Cys-LT and nitric oxide are involved in the pathogenesis of EIB.	Univ Padua, Dept Pediat, I-35128 Padua, Italy; Univ Parma, Dept Clin Med Nephrol & Hlth Sci, Lab Ind Toxicol, I-43100 Parma, Italy	University of Padua; University of Parma	Baraldi, E (corresponding author), Univ Padua, Dept Pediat, Via Giustiniani 3, I-35128 Padua, Italy.	baraldi@pediatria.unipd.it	baraldi, eugenio/AAC-5233-2022	BARALDI, EUGENIO/0000-0002-1829-3652; corradi, massimo/0000-0002-2808-4184				Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Becker JM, 2004, J ALLERGY CLIN IMMUN, V113, P264, DOI 10.1016/j.jaci.2003.10.052; BRAVO M, 1988, ANAL BIOCHEM, V175, P482, DOI 10.1016/0003-2697(88)90572-6; Cap P, 2004, THORAX, V59, P465, DOI 10.1136/thx.2003.011866; CLAESSON HE, 1992, INT J IMMUNOPHARMACO, V14, P441, DOI 10.1016/0192-0561(92)90174-J; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Csoma Z, 2002, AM J RESP CRIT CARE, V166, P1345, DOI 10.1164/rccm.200203-233OC; De-Levie R., 1999, AQUEOUS ACID BASE EQ; ElHalawani SM, 2003, CHEST, V124, P639, DOI 10.1378/chest.124.2.639; Ghiro L, 2002, EUR RESPIR J, V20, P630, DOI 10.1183/09031936.02.01512002; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101, DOI 10.1164/ajrccm.165.1.2104131; IIKURA Y, 1988, J ALLERGY CLIN IMMUN, V81, P1050, DOI 10.1016/0091-6749(88)90179-0; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; Kivity S, 2000, RESP MED, V94, P1200, DOI 10.1053/rmed.2000.0951; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Leff AR, 2000, AM J RESP CRIT CARE, V161, pS125, DOI 10.1164/ajrccm.161.supplement_1.ltta-25; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Lloret SM, 2002, J CHROMATOGR A, V978, P59, DOI 10.1016/S0021-9673(02)01431-0; MCFADDEN ER, 1990, LANCET, V335, P880, DOI 10.1016/0140-6736(90)90478-N; Mechiche H, 2003, CLIN EXP ALLERGY, V33, P887, DOI 10.1046/j.1365-2222.2003.01696.x; Melo RE, 2003, J ALLERGY CLIN IMMUN, V111, P301, DOI 10.1067/mai.2003.66; Milgrom H, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.3.e38; Mulder A, 1999, AM J RESP CRIT CARE, V159, P1562, DOI 10.1164/ajrccm.159.5.9810095; *NAT ASTHM ED PREV, 1997, NIH PUBL; O'Byrne PM, 2000, AM J RESP CRIT CARE, V161, pS68, DOI 10.1164/ajrccm.161.supplement_1.ltta-14; Peroni DG, 2002, PEDIAT ALLERG IMM-UK, V13, P434, DOI 10.1034/j.1399-3038.2002.02078.x; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Reiss TF, 1997, THORAX, V52, P1030, DOI 10.1136/thx.52.12.1030; SAMPSON AP, 1995, ARCH DIS CHILD, V73, P221, DOI 10.1136/adc.73.3.221; Schmidt D, 2000, AM J RESP CRIT CARE, V161, pS62, DOI 10.1164/ajrccm.161.supplement_1.ltta-13; Scollo M, 2000, AM J RESP CRIT CARE, V161, P1047, DOI 10.1164/ajrccm.161.3.9905043; SMITH CM, 1991, AM REV RESPIR DIS, V144, P1411, DOI 10.1164/ajrccm/144.6.1411; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879; Zanconato S, 2004, J ALLERGY CLIN IMMUN, V113, P257, DOI 10.1016/j.jaci.2003.10.046	38	94	96	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					764	770		10.1016/j.jaci.2004.10.043	http://dx.doi.org/10.1016/j.jaci.2004.10.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805996				2022-12-18	WOS:000228373400015
J	Brunetti, L; Francavilla, R; Miniello, VL; Platzer, MH; Rizzi, D; Lospalluti, ML; Poulsen, LK; Armenio, L; Skov, PS				Brunetti, L; Francavilla, R; Miniello, VL; Platzer, MH; Rizzi, D; Lospalluti, ML; Poulsen, LK; Armenio, L; Skov, PS			High prevalence of autoimmune urticaria in children with chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic idiopathic urticaria; childhood; autologous serum skin test; serum induced basophil histamine release; autoimmune urticaria	CHRONIC IDIOPATHIC URTICARIA; ANTI-IGE AUTOANTIBODIES; FC-EPSILON-RI; THYROID AUTOIMMUNITY; HISTAMINE ANALYSIS; CELIAC-DISEASE; CHILDHOOD; ACTIVATION; RECEPTOR; RELEASE	Background: The etiology of chronic urticaria (CU) in childhood often remains unrecognized. Recently, in adults it has been shown that approximately 40% of patients with CU have autoimmune urticaria (AU); however, no data are available in children. Objective: To determine the prevalence and possible risk factors for AU in children with CU. Methods: Ninety-three consecutive children (52 male; median age, 7.8 years) with CU were evaluated for AU by means of autologous serum skin test (ASST) in all and serum-induced basophil histamine release (HR-urticaria test) in 52. All other known causes of CU were excluded as appropriate. Results: A cause for CU was identified in 44 children (47%), whereas 49 (53%) remained idiopathic. ASST and HR-urticaria test had positive results in 22 of 49 (45%) and in 16 of 31 (52%) children with idiopathic CU compared with 1 of 44 (2%) and 5 of 21 (24%) with CU of a known cause, respectively (P <.00001; P = .09). Sensitivity, specificity, and positive and negative predictive values of the ASST for diagnosing AU are 78%, 85%, 74%, and 88%. The prevalence of AU in childhood is 31% (15/52; 95% Cl, 24%-51%). None of the variables studied were predictive for development of AU. Conclusion: Our results demonstrate for the first time that children have the same ability as adults to produce functionally active autoantibodies directed against IgE or IgE receptor and that AU occurs in children in as many as 30% of cases. The addition of screening for AU dramatically decreases the rate of the idiopathic form from 52% to 20%.	Univ Bari, Clin Pediat 1, Dept Biomed Eta Evolut, I-70125 Bari, Italy; Natl Univ Hosp, Lab Med Allergol, Copenhagen, Denmark	Universita degli Studi di Bari Aldo Moro	Brunetti, L (corresponding author), Univ Bari, Clin Pediat 1, Dept Biomed Eta Evolut, Piazza Giulio Cesare 11, I-70125 Bari, Italy.	l.brunetti@pediatria3.uniba.it	FRANCAVILLA, RUGGIERO/S-1391-2019; Poulsen, Lars K/J-3065-2019	FRANCAVILLA, RUGGIERO/0000-0002-4603-974X; Poulsen, Lars K/0000-0002-1730-847X				Bakos N, 2003, INT J DERMATOL, V42, P613, DOI 10.1046/j.1365-4362.2003.01759.x; Ehlers I, 1998, ALLERGY, V53, P1074, DOI 10.1111/j.1398-9995.1998.tb03817.x; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Gaig P, 2000, J INVEST ALLERG CLIN, V10, P342; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Grattan CEH, 2002, J AM ACAD DERMATOL, V46, P645, DOI 10.1067/mjd.2002.122759; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; Greaves M, 2000, J ALLERGY CLIN IMMUN, V105, P664, DOI 10.1067/mai.2000.105706; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; Greaves MW, 2000, ALLERGY, V55, P309, DOI 10.1034/j.1398-9995.2000.00116.x; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HARRIS A, 1983, ANN ALLERGY, V51, P161; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; KOBZABLACK A, 1996, CLIN EXP DERMATOL, V21, P424; Levine A, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.2.e25; Meneghetti R, 2004, ARCH DIS CHILD, V89, P293, DOI 10.1136/adc.2003.037259; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; NOLTE H, 1990, ALLERGY, V45, P213, DOI 10.1111/j.1398-9995.1990.tb00486.x; O'Donnell BF, 1999, BRIT J DERMATOL, V140, P853, DOI 10.1046/j.1365-2133.1999.02815.x; ODonnell BF, 1997, BRIT J DERMATOL, V136, P197; Ryhal B, 2001, J INVEST ALLERG CLIN, V11, P16; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; Sabroe RA, 1998, J ALLERGY CLIN IMMUN, V102, P651, DOI 10.1016/S0091-6749(98)70283-0; SKOV PS, 1985, ALLERGY, V40, P213; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; VOLONAKIS M, 1992, ANN ALLERGY, V69, P61	30	94	99	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					922	927		10.1016/j.jaci.2004.07.042	http://dx.doi.org/10.1016/j.jaci.2004.07.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480336				2022-12-18	WOS:000224439100030
J	Matz, J; Emmett, A; Rickard, K; Kalberg, C				Matz, J; Emmett, A; Rickard, K; Kalberg, C			Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						salmeterol xinafoate; fluticasone propionate; long-acting beta(2)-agonist; inhaled corticosteroid; asthma exacerbations	INHALED CORTICOSTEROIDS; MU-G; PROPIONATE; BUDESONIDE; FORMOTEROL; DEVICE	Background: Adding salmeterol to low-dose fluticasone propionate (FP) produces greater improvements in pulmonary function and symptom control than increasing the dose of FP in patients who remain symptomatic with low-dose EP, Objective: We sought to compare the rates and characteristics of asthma exacerbations in patients after adding salmeterol to Low-dose FP with the rates and characteristics of exacerbations in patients receiving higher dose EB Methods: In 2 multicenter, double-blind studies, 925 patients 12 years of age and older receiving 88 mug twice daily FP randomly received either 42 mug of salmeterol and 88 mug of FP or an increased dose of PP (220 mug) twice daily for 24 weeks. Exacerbation rates and clinical measures of asthma worsening were assessed for all patients who experienced an asthma exacerbation, Results: The addition of salmeterol resulted in a significantly lower rate and number of exacerbations compared with higher dose ERA total of 41 (8.8%) patients experienced 47 exacerbations with the addition of salmeterol compared with 63 (13.8%) patients with 75 exacerbations in the group receiving increased-dose FP (P = .017), Salmeterol plus low-dose FP was significantly more protective than increased-dose FP in preventing asthma exacerbations, as assessed by the time to first exacerbation (P < .05), In both groups clinical indicators of worsening asthma showed parallel changes before asthma exacerbation, and greater improvements were observed after exacerbation with salmeterol compared with higher dose FP. Conclusion: Salmeterol plus low-dose FP was more effective than higher dose FP alone in reducing asthma exacerbations in patients with persistent asthma, The ability to detect deteriorating asthma and the severity of exacerbation was similar between groups.	Atlantic Asthma & Allergy Ctr Inc, Baltimore, MD 21236 USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Matz, J (corresponding author), Atlantic Asthma & Allergy Ctr Inc, 7939 Honeygo Blvd,219, Baltimore, MD 21236 USA.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Aubier M, 1999, RESP MED, V93, P876, DOI 10.1016/S0954-6111(99)90053-7; Bleecker E, 1998, J ALLERGY CLIN IMMUN, V101, pS400, DOI 10.1016/S0091-6749(98)70230-1; Condemi JJ, 1999, ANN ALLERG ASTHMA IM, V82, P383, DOI 10.1016/S1081-1206(10)63288-7; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Kalberg CJ, 1998, J ALLERGY CLIN IMMUN, V101, pS6; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; Kelsen SG, 1999, J ASTHMA, V36, P703, DOI 10.3109/02770909909055422; Kemp JP, 1998, J ALLERGY CLIN IMMUN, V101, P188, DOI 10.1016/S0091-6749(98)70383-5; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056; Lanes SF, 1998, AM J RESP CRIT CARE, V158, P857, DOI 10.1164/ajrccm.158.3.9803047; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; Murray JJ, 1999, ALLERGY ASTHMA PROC, V20, P173, DOI 10.2500/108854199778553028; *NIH NAT HEART LUN, 1997, NIH PUBL; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; SUECHU M, 1999, EUR RESPIR J, V14, pS124; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	19	94	100	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					783	789		10.1067/mai.2001.114709	http://dx.doi.org/10.1067/mai.2001.114709			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344343	Bronze			2022-12-18	WOS:000168812300004
J	Arlian, LG; Neal, JS; Morgan, MS; Vyszenski-Moher, DL; Rapp, CM; Alexander, AK				Arlian, LG; Neal, JS; Morgan, MS; Vyszenski-Moher, DL; Rapp, CM; Alexander, AK			Reducing relative humidity is a practical way to control dust mites and their allergens in homes in temperate climates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mites; relative humidity; dehumidification; allergen; Der p 1; Der f 1; dermatophagoides species	DERMATOPHAGOIDES-FARINAE ACARI; MECHANICAL VENTILATION; WATER-BALANCE; HOUSE; PYROGLYPHIDAE; AIR; PTERONYSSINUS; REDUCTION; PREVALENCE; EFFICACY	Background: Maintaining a relative humidity [RH) of less than 50% is one recommendation fur reducing numbers of house dust mites and their allergens in homes, Objective: The purpose of this study was to determine whether, in a humid temperate climate, indoor RH could be sufficiently lowered to control dust mites and their allergens. Methods: During a period spanning 2 humid summers (May 1998 to October 1999), dust mite and allergen densities were determined in 3 groups of homes. One group (low RH group, n = 23) maintained an RN of less than 51%, Most of these homes used a high-efficiency dehumidifier and air conditioning. A second group of homes (group A) used air conditioning only (n = 19) or air conditioning and dehumidification (n = 5) but did not maintain an RH of less than 51%, A third group of homes (group C, n = 24) controlled climate by opening windows and had an RH of greater than 51%. Normal housecleaning was maintained in all homes during the study, Results: The low RH group homes started in June with a mean +/- SE of 401 +/- 124 live mites and 17 +/- 3 mug of total Der 1 allergen per gram of dust. After 17 months of maintaining an RH of less than 51%, these declined significantly to 8 +/- 3 live mites per gram LP =.004) and 4 +/- 1 mug of Der 1 per gram of dust (P <.001). In contrast, group A and C homes exhibited seasonal peaks of 500 to 1000 mites and 40 to 70 <mu>g of Der 1 per gram of dust At all time points after the baseline sample, the low RH group homes had significantly less (P <.001) allergen than the group A and C homes, After 17 months, allergen levels were more than 10 Limes lo,Per in low Rfi homes compared with humid homes, Conclusion: This study showed that it is practical to maintain an indoor RH of less than 51% during the humid summer season in a temperate climate, and this resulted in significant reductions in mite and allergen levels.	Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Arlian, LG (corresponding author), Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA.							ANTONICELLI L, 1991, ALLERGY, V46, P594, DOI 10.1111/j.1398-9995.1991.tb00629.x; Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P852, DOI 10.1016/S0091-6749(99)70298-8; ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1981, PHYSIOL ZOOL, V54, P393, DOI 10.1086/physzool.54.4.30155831; ARLIAN LG, 1975, J MED ENTOMOL, V12, P437, DOI 10.1093/jmedent/12.4.437; Arlian LG, 1999, J MED ENTOMOL, V36, P457, DOI 10.1093/jmedent/36.4.457; Arlian LG, 1998, J MED ENTOMOL, V35, P962, DOI 10.1093/jmedent/35.6.962; BRANDT RL, 1976, J MED ENTOMOL, V13, P327, DOI 10.1093/jmedent/13.3.327; BRONSWIJK JE, 1971, J ALLERGY, V47, P31; CABRERA P, 1995, J ALLERGY CLIN IMMUN, V95, P635, DOI 10.1016/S0091-6749(95)70328-4; Crane J, 1998, ALLERGY, V53, P755, DOI 10.1111/j.1398-9995.1998.tb03971.x; CUSTOVIC A, 1995, CLIN EXP ALLERGY, V25, P312, DOI 10.1111/j.1365-2222.1995.tb01048.x; Custovic A, 1999, ALLERGY, V54, P612, DOI 10.1034/j.1398-9995.1999.00062.x; CUSTOVIC A, 1995, J ALLERGY CLIN IMMUN, V96, P134, DOI 10.1016/S0091-6749(95)70044-7; De Boer R, 1998, J MED ENTOMOL, V35, P905, DOI 10.1093/jmedent/35.6.905; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; deBoer R, 1997, ALLERGY, V52, P299; ELLINGSON AR, 1995, ANN ALLERGY, V55, P680; Fletcher AM, 1996, CLIN EXP ALLERGY, V26, P1051, DOI 10.1111/j.1365-2222.1996.tb00643.x; Glass EV, 1998, EXP APPL ACAROL, V22, P31, DOI 10.1023/A:1006081323887; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; HARVING H, 1991, ALLERGY, V46, P33, DOI 10.1111/j.1398-9995.1991.tb00647.x; KORSGAARD J, 1991, DUST MITE ALLERGENS, P87; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; Niven RM, 1999, J ALLERGY CLIN IMMUN, V103, P756, DOI 10.1016/S0091-6749(99)70416-1; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0	32	94	99	0	16	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					99	104		10.1067/mai.2001.112119	http://dx.doi.org/10.1067/mai.2001.112119			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149998				2022-12-18	WOS:000166533300018
J	Rihs, HP; Chen, ZP; Rueff, F; Petersen, A; Rozynek, P; Heimann, H; Baur, X				Rihs, HP; Chen, ZP; Rueff, F; Petersen, A; Rozynek, P; Heimann, H; Baur, X			IgE binding of the recombinant allergen soybean profilin (rGly m 3) is mediated by conformational epitopes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant profilin; soybean profilin; IgE; conformational epitope; soybean allergy	MAJOR COMPONENT PROTEINS; EPIDEMIC ASTHMA; SENSITIVE PATIENTS; ATOPIC-DERMATITIS; MERCURIALIS-ANNUA; CROSS-REACTIVITY; POLLEN PROFILIN; DUST; IDENTIFICATION; CHILDREN	Background: Soybean proteins are constituents of a number of food products and represent a panel of potential allergens. Thus far, little is known about the molecular characteristics of soybean allergens. Objective: The aim of this study was to identify the soybean profilin by PCR-based complementary (c)DNA cloning and to elucidate its allergenic characteristics. Methods: Highly degenerate profilin-specific primers were used to identify, by means of PCR, 2 soybean profilin isoforms (GmPRO1 and GmPRO2) by using soybean cDNA as a target. One isoform (GmPRO1) with a length of 394 bp corresponding to 131 amino acid residues was subcloned and expressed in fusion with the maltose-binding protein, Moreover, 3 overlapping recombinant soybean profilin fragments comprising amino acid residues 1-65, 38-88, and 50-131 were also prepared as maltose-binding protein fusion proteins, IgE-binding reactivity of the recombinant proteins and the cross-reactivity of soybean profilin with birch profilin was studied by immunoblotting, enzyme-linked allergosorbent assays (EASTs), and competitive inhibition experiments by using serum samples from 13 soybean-sensitized subjects. Results: Results of immunoblot analysis, EAST, and EAST-inhibition experiments indicate the presence of profilin in soybean extract. The recombinant soybean profilin (rGly m 3) was recognized by IgE in 9 (69%) of the 13 sera tested. Only the full-length rGly m 3 was able to bind with IgE antibodies, whereas the 3 soybean profilin fragments did not show significant binding reactivity, indicating that the IgE binding to rGly m 3 depends on the integrity of a conformational structure, which was not present in the overlapping profilin fragments, The rGly m 3 cross-reacted with birch pollen profilin (Bet v 2), and the IgE binding to Bet v 2 could be inhibited by rGly m 3. Conclusions: rGly m 3 represents a new soybean allergen with well-characterized primary sequence, and its IgE-binding reactivity is mediated by conformational epitopes.	Ruhr Univ Bochum, Res Inst Occupat Med, BGFA, D-44789 Bochum, Germany; Univ Munich, Dermatol Clin, Munich, Germany; Res Ctr Borstel, Borstel, Germany	Ruhr University Bochum; University of Munich; Forschungszentrum Borstel	Rihs, HP (corresponding author), Ruhr Univ Bochum, Res Inst Occupat Med, BGFA, Buerkle Camp Pl 1, D-44789 Bochum, Germany.							ANTO JM, 1993, NEW ENGL J MED, V329, P1760, DOI 10.1056/NEJM199312093292402; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Awazuhara H, 1997, CLIN EXP ALLERGY, V27, P325, DOI 10.1046/j.1365-2222.1997.1240800.x; Baur X, 1996, ALLERGY, V51, P326, DOI 10.1111/j.1398-9995.1996.tb00093.x; Baur X, 1989, IMMUNOL ALLERGY PRAC, V11, P13; BURKS AW, 1994, INT ARCH ALLERGY IMM, V105, P143; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BUSH RK, 1988, J ALLERGY CLIN IMMUN, V82, P251, DOI 10.1016/0091-6749(88)91007-X; Cantani A, 1997, PEDIAT ALLERG IMM-UK, V8, P59, DOI 10.1111/j.1399-3038.1997.tb00146.x; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; Codina R, 1997, CLIN EXP ALLERGY, V27, P424, DOI 10.1046/j.1365-2222.1997.d01-514.x; Codina RM, 1997, CHEST, V111, P75, DOI 10.1378/chest.111.1.75; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; GONZALEZ R, 1992, CLIN EXP ALLERGY, V22, P748, DOI 10.1111/j.1365-2222.1992.tb02814.x; GONZALEZ R, 1995, LANCET, V346, P48, DOI 10.1016/S0140-6736(95)92676-3; Helm RM, 1998, INT ARCH ALLERGY IMM, V117, P29, DOI 10.1159/000023987; HERIAN AM, 1990, INT J ALLERGY APPL I, V90, P193; HERNANDO L, 1989, LANCET, V1, P502; KING TP, 1995, CLIN EXP ALLERGY, V25, P27, DOI 10.1111/j.1365-2222.1995.tb00999.x; LAVAUD F, 1994, ALLERGY, V49, P159, DOI 10.1111/j.1398-9995.1994.tb00819.x; Ledesma A, 1998, ALLERGY, V53, P520, DOI 10.1111/j.1398-9995.1998.tb04090.x; NAVARRO C, 1993, EPIDEMIOLOGY, V4, P76, DOI 10.1097/00001648-199301000-00014; OGAWA T, 1991, J NUTR SCI VITAMINOL, V37, P555, DOI 10.3177/jnsv.37.555; RIHS HP, 1994, INT ARCH ALLERGY IMM, V105, P190, DOI 10.1159/000236824; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472; SUNYER J, 1989, LANCET, V1, P179; Synek M, 1996, EUR RESPIR J, V9, P54, DOI 10.1183/09031936.96.09010054; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Vallverdu A, 1997, INT ARCH ALLERGY IMM, V112, P356, DOI 10.1159/000237480; Vallverdu A, 1998, J ALLERGY CLIN IMMUN, V101, P363, DOI 10.1016/S0091-6749(98)70249-0; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; White MC, 1997, AM J EPIDEMIOL, V145, P432, DOI 10.1093/oxfordjournals.aje.a009125	37	94	108	1	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1293	1301		10.1016/S0091-6749(99)70027-8	http://dx.doi.org/10.1016/S0091-6749(99)70027-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589015	Bronze			2022-12-18	WOS:000084289200027
J	Schwingshackl, A; Duszyk, M; Brown, N; Moqbel, R				Schwingshackl, A; Duszyk, M; Brown, N; Moqbel, R			Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; asthma; matrix metalloproteinase; tissue inhibitor of matrix metalloproteinases; tumor necrosis factor alpha	NECROSIS-FACTOR-ALPHA; ASTHMATIC AIRWAY INFLAMMATION; BRONCHOALVEOLAR LAVAGE FLUID; BLOOD EOSINOPHILS; MILD ASTHMA; DISEASE; INHIBITORS; EXPRESSION; CYTOKINES; MIGRATION	Background: The eosinophil is a prominent cell in allergic lung inflammation and is exposed to a range of cytokines, including TNF-alpha, at the site of allergen challenge. Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) produced by inflammatory cells are thought to play a crucial role in interstitial matrix turnover and tissue remodeling in acute and chronic lung diseases. In addition, protein kinase C is known to be important in MMP-9 expression and secretion, Objective: We investigated the regulation of eosinophil-derived MMP-9 and TIMP proteins by TNF-alpha. Methods: Using RT-PCR and gelatin zymography, we investigated the ability of human eosinophils to produce and secrete active MMP-9 on stimulation with TNF-alpha. We also studied the production of TIMP-1 and TIMP-2 in eosinophils by using Western blotting. Results: The gelatinolytic activity of MMP-9 in unstimulated eosinophils was low, but it increased by 95% after TNF-alpha stimulation. This increase was regulated at both the transcriptional and translational levels, The transcription inhibitor actinomycin D, the nuclear factor kappa B (NF kappa B) inhibitor N-CBZ-Leu-Leu-Leu-AL, the protein synthesis inhibitor cycloheximide, and the protein kinase C inhibitor H7 significantly decreased MMP-9 activity in TNF-alpha-treated cells. TIMP-1 and TIMP-2 gene expression and protein production varied significantly among different cell donors, Conclusion: Eosinophils, on stimulation with TNF-alpha, may play a major role in asthmatic airway remodeling through increased MMP-9 production at the inflammatory site.	Univ Alberta, Pulm Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta	Moqbel, R (corresponding author), Univ Alberta, Pulm Res Grp, 5-74 HMRC, Edmonton, AB T6G 2S2, Canada.							ALLEN JN, 1994, AM J RESP CRIT CARE, V150, P1423, DOI 10.1164/ajrccm.150.5.7952571; AUSUBEL F, 1991, CUR PROT MOL BIOL; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465, DOI 10.1164/ajrccm/147.6_Pt_1.1465; CORRIGAN CJ, 1988, LANCET, V1, P1129; Denburg JA, 1998, J ALLERGY CLIN IMMUN, V102, pS74, DOI 10.1016/S0091-6749(98)70034-X; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUJISAWA T, 1989, J ALLERGY CLIN IMM S, pS218; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Hayashi T, 1996, AM J PATHOL, V149, P1241; Holgate ST, 1997, CIBA F SYMP, V206, P5; HOLGATE ST, 1997, CIBA F SYMP, V206, P106; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Ikebe T, 1998, INT J CANCER, V77, P578; JARJOUR NN, 1995, AM J RESP CRIT CARE, V152, P1474, DOI 10.1164/ajrccm.152.5.7582279; Jatakanon A, 1998, EUR RESPIR J, V12, P1084, DOI 10.1183/09031936.98.12051084; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; Mahmudi-Azer S, 1998, J IMMUNOL METHODS, V217, P113, DOI 10.1016/S0022-1759(98)00105-7; Matsuyama G, 1998, INT ARCH ALLERGY IMM, V117, P28, DOI 10.1159/000053567; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; Moller GM, 1996, J HISTOCHEM CYTOCHEM, V44, P67, DOI 10.1177/44.1.8543784; OCONNOR CM, 1994, THORAX, V49, P602, DOI 10.1136/thx.49.6.602; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; PARTRIDGE CA, 1993, AM J PHYSIOL, V265, pL438, DOI 10.1152/ajplung.1993.265.5.L438; RIES C, 1994, BLOOD, V83, P3638; Sato T, 1996, FEBS LETT, V392, P175, DOI 10.1016/0014-5793(96)00808-3; SCEPEK S, 1994, PARASITOL TODAY, V10, P276, DOI 10.1016/0169-4758(94)90146-5; Stampfli M R, 1998, Can Respir J, V5 Suppl A, p31A; Thomas LH, 1996, GEN PHARMACOL-VASC S, V27, P593, DOI 10.1016/0306-3623(95)02045-4; Walsh GM, 1998, J IMMUNOL METHODS, V217, P153, DOI 10.1016/S0022-1759(98)00103-3; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; WARDLAW RM, 1997, ALLERGY ALLERGIC DIS, P171; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wyatt TA, 1997, AM J PHYSIOL-LUNG C, V273, pL1007, DOI 10.1152/ajplung.1997.273.5.L1007; Yao PM, 1997, AM J PHYSIOL-LUNG C, V273, pL866, DOI 10.1152/ajplung.1997.273.4.L866; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123; Zhang YH, 1998, J IMMUNOL, V161, P3071	45	94	99	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					983	990		10.1016/S0091-6749(99)70079-5	http://dx.doi.org/10.1016/S0091-6749(99)70079-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550743	Bronze			2022-12-18	WOS:000083778400021
J	Allmers, H; Brehler, R; Chen, ZP; Raulf-Heimsoth, M; Fels, H; Baur, X				Allmers, H; Brehler, R; Chen, ZP; Raulf-Heimsoth, M; Fels, H; Baur, X			Reduction of latex aeroallergens and latex-specific IgE antibodies in sensitized workers after removal of powdered natural rubber latex gloves in a hospital	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immediate-type allergy; latex; latex aeroallergen; occupational asthma; natural rubber latex gloves; glove powder; IgE antibodies	OPERATING-ROOM; ALLERGY; PREVALENCE	Background: Respiratory symptoms of natural rubber lates (NRL) allergy in health care workers (HCWs) have been reported in rooms with a detectable allergen load. Preventive measures have been proposed to reduce the risk of NRL sensitization. Objectives: Eliminating powdered NRL gloves from the workplace and giving NRL-free material to sensitized workers has been among proposed preventive measures. To appraise the success of such procedures among HCWs, a prospective study was carried out. Methods: Sensitization of HCW's to NRL was determined by skin prick tests and measurements of specific IgE antibodies. NRL allergen concentrations in room air were measured before and after substitution of powdered NRL gloves with powder-free or synthetic gloves in different departments of a hospital and determined by a competitive inhibition immunoassay. Results: The prevalence of HCWs with positive skin prick test responses and NRL-specific IgE-positive HCWs was 8% (n = 7) among the 90 examined staff members before the intervention started. All 7 reported glove-related allergic symptoms. Six of 7 sensitized subjects had a significant decrease of latex-specific IgE antibody concentrations during follow-up examinations in April and September 1997 (P < .003). Within 24 hours after substitution took place, NRL aeroallergen levels (up to 49.9 ng/m(3)) fell below the detection limit in areas with synthetic gloves or powder-free NRL gloves alike. Use of asthma meditation and antiallergic drugs could be discontinued by 2 HCWs with NRL-related respiratory tract symptoms. Conclusions: Our results demonstrate that elimination of powdered NRL gloves is a useful device in reducing aerogen NRL allergen loads below the detection limit and permitting sensitized or allergic personnel to remain on the job.	Ruhr Univ Bochum, Berufsgenossenschaftl Forschungsinst Arbeitsmed, Bochum, Germany; Univ Munster, Dept Dermatol, D-4400 Munster, Germany; Umweltlab ACB, Munster, Germany	Ruhr University Bochum; University of Munster	Allmers, H (corresponding author), Burkle de la Camp Pl 1, D-44789 Bochum, Germany.							Allmers H, 1997, DEUT MED WOCHENSCHR, V122, P1308, DOI 10.1055/s-2008-1047764; Allmers H, 1996, DEUT MED WOCHENSCHR, V121, P823, DOI 10.1055/s-2008-1043073; BAUR X, 1993, LANCET, V342, P1148, DOI 10.1016/0140-6736(93)92127-F; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; Baur X.ChenZ.AllmersH, 1996, ALLERGOL INT, V20, P105; Brehler R., 1997, EUR J SURG S, V579, P23; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; KELLY KJ, 1995, IMMUNOL ALLERGY CLIN, V15, P139; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P139; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; YASSIN MS, 1994, ANN ALLERGY, V85, P626	16	94	99	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					841	846		10.1016/S0091-6749(98)70026-0	http://dx.doi.org/10.1016/S0091-6749(98)70026-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819303				2022-12-18	WOS:000077033400020
J	Meltzer, EO; Weiler, JM; Widlitz, MD				Meltzer, EO; Weiler, JM; Widlitz, MD			Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; cetirizine; park study; loratadine; placebo; seasonal allergic rhinitis	NON-SEDATING ANTIHISTAMINE; DOUBLE-BLIND; HAY-FEVER; TERFENADINE; ASTEMIZOLE; THERAPY; MULTICENTER; HISTAMINE	Background: Cetirizine, a new once-daily highly specific H-1-antagonist, has been shown in conventional studies to be efficacious in the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. Objective: The efficacy, duration and onset of action, and safety of cetirizine, 10 mg once daily, was compared with that of loratadine, 10 mg once daily, and placebo in a field study of patients with seasonal allergic rhinitis. Methods: This was a randomized, double-blind, parallel, double-dummy study conducted over 2 days in spring allergy season at outdoor parks in San Diego and Iowa City. Study medication was administered at 10:00 AM on both days. After screening, eligible patients completed rhinitis symptom diaries in the park hourly from 7:30 to 9:30 AM (baseline); at 10:30 AM and hourly from 11:00 AM to 4:00 PM (period I); at 6:00, 8:00, and 10:00 PM at home (period II); and the next day in the park hourly from 8:00 to 10:00 AM (period III), and from 11:00 AM to 4:00 PM (period IV). Major and total symptom complex scores, global efficacy and overall satisfaction, and adverse events were assessed. Results: Of the 279 patients (140 men and 139 women; mean age, 29 years) randomized to treatment. 278 were included in the efficacy analysis. Cetirizine produced significantly greater mean reductions than loratadine or placebo in major symptom complex severity scores at all periods (p less than or equal to 0.05), except period I for placebo. Cetirizine also produced mean reductions in total symptom complex severity scores that were superior to loratadine at every evaluation period (p < 0.05) and were statistically different from placebo at period II (p < 0.01). A rapid onset of action was observed with cetirizine, as was a better response pattern in the patient global assessment of efficacy compared with loratadine. Study medications were well tolerated; no patient stopped treatment because of side effects. The incidence of somnolence with cetirizine was 13% versus 2% with placebo (p < 0.05); headache occurred more frequently with loratadine (23%) than with cetirizine (11%, p = 0.03). Conclusion: Cetirizine relieved rhinitis symptoms more effectively and quickly than loratadine and placebo in this field study of seasonal allergic rhinitis. Both active agents were generally well tolerated.	UNIV IOWA,COLL MED,IOWA CITY,IA; PFIZER INC,US PHARMACEUT GRP,NEW YORK,NY	University of Iowa; Pfizer	Meltzer, EO (corresponding author), ALLERGY & ASTHMA MED GRP & RES CTR,9610 GRANITE RIDGE DR,SUITE B,SAN DIEGO,CA 92123, USA.							BACKHOUSE CI, 1990, BRIT J CLIN PRACT, V44, P88; BEDARD PM, 1992, CLIN THER, V14, P268; CAIAFFA MF, 1992, J INVEST ALLERG CLIN, V2, P162; CHERVINSKY P, 1994, ANN ALLERGY, V73, P109; CONNELL JT, 1979, ANN ALLERGY, V42, P278; DELCARPIO J, 1989, J ALLERGY CLIN IMMUN, V84, P741; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; DOLOVICH J, 1994, ANN ALLERGY, V73, P235; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; FLEISS JL, 1973, STATISTICAL METHODS; GUTKOWSKI A, 1988, J ALLERGY CLIN IMMUN, V81, P902, DOI 10.1016/0091-6749(88)90948-7; HARCUP JW, 1993, BRIT J CLIN PRACT, V47, P131; HORAK F, 1988, ARZNEIMFORSCH DRUG R, V38, P12; HUMPHREYS F, 1991, BRIT J DERMATOL, V125, P364, DOI 10.1111/j.1365-2133.1991.tb14173.x; IRANDER K, 1990, ALLERGY, V45, P86, DOI 10.1111/j.1398-9995.1990.tb00463.x; KALIVAS J, 1990, J ALLERGY CLIN IMMUN, V86, P1014, DOI 10.1016/S0091-6749(05)80246-5; LOCKEY RF, 1993, ANN ALLERGY, V70, P311; MANSMANN HC, 1992, ANN ALLERGY, V68, P348; MANTEL N, 1959, J NATL CANCER I, V22, P719; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; OEI HD, 1988, ANN ALLERGY, V61, P436; OLSEN OT, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1227; PANAYOTOPOULOS SM, 1990, ANN ALLERGY, V65, P146; RIHOUX JP, 1990, ANN ALLERGY, V65, P139; RIJNTJES E, 1990, J INT MED RES, V18, P219, DOI 10.1177/030006059001800306; SHEFFER AL, 1990, J ALLERGY CLIN IMMUN, V86, P1040, DOI 10.1016/S0091-6749(05)80251-9; SIMONS FER, 1991, ANN ALLERGY, V66, P5; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SPENCER CM, 1993, DRUGS, V46, P1055, DOI 10.2165/00003495-199346060-00008; WASSERMAN SI, 1991, CLIN THER, V13, P707; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	31	94	98	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					617	626		10.1016/S0091-6749(96)70307-X	http://dx.doi.org/10.1016/S0091-6749(96)70307-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621847				2022-12-18	WOS:A1996TW08700007
J	COCKCROFT, DW; OBYRNE, PM; SWYSTUN, VA; BHAGAT, R				COCKCROFT, DW; OBYRNE, PM; SWYSTUN, VA; BHAGAT, R			REGULAR USE OF INHALED ALBUTEROL AND THE ALLERGEN-INDUCED LATE ASTHMATIC RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALBUTEROL; ASTHMA; ALLERGEN CHALLENGE; LATE ASTHMATIC RESPONSE	BRONCHIAL RESPONSIVENESS; AIRWAY RESPONSIVENESS; BETA-AGONISTS; REACTIVITY; HISTAMINE; INCREASE	Background: We have recently demonstrated that a 2-week course of inhaled albuterol 200 mu g four rimes daily caused a near doubling of the allergen-induced early asthmatic response. We hypothesized that this might extend to the more clinically relevant late asthmatic response. Methods: We studied 11 patients with atopic asthma who were free from all medications including inhaled beta(2)-agonists for more than 4 weeks. We performed a double-blind, random-order, crossover study, comparing the effect of 1-week treatment periods of albuterol 200 mu g four times daily and placebo 2 puffs four times daily on the early and late asthmatic responses to the same dose of allergen. Results: Regular use of albuterol did not influence the baseline forced expiratory volume in 1 second (FEV(1)) (3.40 vs 3.42 L, p = 0.84) or the baseline methacholine provocative concentration causing a 20% fall in FEV(1) (PC20) (geometric mean, 2.4 mg/ml vs 1.9 mg/ml, p = 038). However, all aspects of the allergen-induced asthmatic response were increased After the 1-week albuterol treatment, the early asthmatic response was slightly greater (21.1% vs 17.9% FEV(1) fall, p = 0.26), the late response was greater (23.1% vs 13.2% FEV(1) fall, p = 0.0027), and the allergen-induced increase in airway responsiveness (change in log methacholine PC20) was greater (0.37 vs 0.20, p = 0.045). Conclusions: One week of albuterol treatment (200 mu g four times daily) increased the late asthmatic response and allergen-induced increase in airway responsiveness. This suggests that the combination of regular use of inhaled beta(2)-agonist and allergen exposure may cause more airway inflammation than allergen exposure alone.	MCMASTER UNIV,MED CTR,DIV RESP MED,ASTHMA RES GRP,HAMILTON,ON,CANADA	McMaster University	COCKCROFT, DW (corresponding author), ROYAL UNIV HOSP,DEPT MED,DIV RESP MED,ELLIS HALL,5TH FLOOR,SASKATOON,SK S7N 0W8,CANADA.			O'Byrne, Paul/0000-0003-0979-281X				CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1991, PREVENTIVE THERAPY A, P141; Davies R. J., 1993, Thorax, V48, P1060; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; VATHENEN AS, 1988, LANCET, V1, P554; WHITELAW WA, 1991, CHEST, V99, P1507, DOI 10.1378/chest.99.6.1507	18	94	96	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					44	49		10.1016/S0091-6749(95)70031-5	http://dx.doi.org/10.1016/S0091-6749(95)70031-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622762				2022-12-18	WOS:A1995RK38300006
J	KELLY, KJ; KURUP, VP; REIJULA, KE; FINK, JN				KELLY, KJ; KURUP, VP; REIJULA, KE; FINK, JN			THE DIAGNOSIS OF NATURAL-RUBBER LATEX ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CONTACT URTICARIA; BARIUM ENEMA; HYPERSENSITIVITY; ANAPHYLAXIS; IGE; GLOVES		MED COLL WISCONSIN,MILWAUKEE CTY MED CTR,CHILDRENS HOSP WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; CLEMENT ZABLOCKI VET ADM HOSP,MILWAUKEE,WI; OULU REG INST OCCUPAT HLTH,OULU,FINLAND	Children's Hospital of Wisconsin; Medical College of Wisconsin	KELLY, KJ (corresponding author), MED COLL WISCONSIN,MILWAUKEE CTY MED CTR,CHILDRENS HOSP WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53226, USA.			Kelly, Kevin/0000-0002-2954-6117				BASCOM R, 1990, ARCH ENVIRON HEALTH, V45, P15, DOI 10.1080/00039896.1990.9935918; BEUERS U, 1990, LANCET, V335, P1095, DOI 10.1016/0140-6736(90)92664-4; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P443; DECORRES LF, 1993, ANN ALLERGY, V70, P35; FECZKO PJ, 1989, AM J ROENTGENOL, V153, P275, DOI 10.2214/ajr.153.2.275; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KELLY KJ, 1992, J ALLERGY CLIN IMMUN, V89, P226; KURUP VP, 1992, ALLERGY PROC, V13, P329, DOI 10.2500/108854192778816915; KWITTKEN PL, 1992, J ALLERGY CLIN IMMUN, V89, P225; LAGIER F, 1990, LANCET, V336, P516, DOI 10.1016/0140-6736(90)92076-T; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; RADEMAKER M, 1989, GENITOURIN MED, V65, P194; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1992, ANN ALLERGY, V68, P203; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; SWANSON MC, 1992, J ALLERGY CLIN IMMUN, V89, P227; TAYLOR JS, 1989, J AM ACAD DERMATOL, V21, P874, DOI 10.1016/S0190-9622(89)70271-1; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; YASSIN MS, 1993, J ALLERGY CLIN IMMUN, V91, P525; YUNGINGER JW, 1993, J ALLERGY CLIN IMMUN, V91, P403	26	94	94	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					813	816		10.1016/0091-6749(94)90370-0	http://dx.doi.org/10.1016/0091-6749(94)90370-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182220				2022-12-18	WOS:A1994NL91900001
J	STEFFEN, M; PETERSEN, J; OLDIGS, M; KARMEIER, A; MAGNUSSEN, H; THIELE, HG; RAEDLER, A				STEFFEN, M; PETERSEN, J; OLDIGS, M; KARMEIER, A; MAGNUSSEN, H; THIELE, HG; RAEDLER, A			INCREASED SECRETION OF TUMOR-NECROSIS-FACTOR-ALPHA, INTERLEUKIN-1-BETA, AND INTERLEUKIN-6 BY ALVEOLAR MACROPHAGES FROM PATIENTS WITH SARCOIDOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TNF; IL-1; IL-6; ALVEOLAR MACROPHAGES; SARCOIDOSIS	ACTIVE PULMONARY SARCOIDOSIS; LUNG LYMPHOCYTES-T; COLONY-STIMULATING FACTOR; GAMMA-INTERFERON; TNF-ALPHA; BLOOD MONOCYTES; GENE-EXPRESSION; POLYMORPHONUCLEAR LEUKOCYTES; MONONUCLEAR PHAGOCYTES; SPONTANEOUS RELEASE	Background: Alveolar macrophages from patients with sarcoidosis were analyzed for their ability to secrete tumor necrosis factor-alpha (TNF-alpha), interleukin-1-beta (IL-1-beta), and interleukin-6 (IL-6). Results: Constitutive release of all three monokines in these patients was concomitantly increased in the active state of disease in comparison with inactive sarcoidosis or healthy control subjects. Alveolar macrophages from patients with inactive sarcoidosis compared with cells from healthy subjects showed increased spontaneous secretion of TNF-alpha and IL-6 only, whereas the constitutive release of IL-1-beta was similar as in healthy volunteers. In vitro stimulation of alveolar macrophages from healthy control subjects with lipopolysaccharide or pokeweed mitogen led to a time- and dose-dependent enhanced secretion of TNF-alpha, IL-1-beta, and IL-6. In a similar manner, with corresponding cells from patients with sarcoidosis the secretion of all three cytokines could be further increased by stimulation with lipopolysaccharide or pokeweed mitogen. Conclusions: The data presented indicate that an increased release of TNF-alpha, IL-1-beta, and IL-6 correlates to disease activity and may play critical part in the pathogenesis of sarcoidosis.	UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT IMMUNOL,W-2000 HAMBURG 20,GERMANY; CTR PULMONOL & THORAX SURG GROSSHANSDORF,GROSSHANSDORF,GERMANY	University of Hamburg	STEFFEN, M (corresponding author), UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT INTERNAL MED,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.							BACHWICH PR, 1986, BIOCHEM BIOPH RES CO, V136, P94, DOI 10.1016/0006-291X(86)90881-8; BACHWICH PR, 1986, AM J PATHOL, V125, P421; BARBOSA IL, 1991, CLIN EXP IMMUNOL, V86, P173; BAUGHMAN RP, 1990, J LAB CLIN MED, V115, P36; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; BRAUDE AC, 1984, AM REV RESPIR DIS, V130, P783; BROUDY VC, 1987, J IMMUNOL, V138, P4298; CAMPBELL DA, 1986, THORAX, V41, P429, DOI 10.1136/thx.41.6.429; CAVENDER D, 1987, J IMMUNOL, V139, P1855; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; EDEN E, 1986, J CLIN IMMUNOL, V6, P326, DOI 10.1007/BF00917334; ELIAS JA, 1988, AM REV RESPIR DIS, V138, P1595, DOI 10.1164/ajrccm/138.6.1595; FELS AOS, 1987, J CLIN INVEST, V80, P381, DOI 10.1172/JCI113083; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; GERLI R, 1989, CHEST, V95, P811, DOI 10.1378/chest.95.4.811; HANCE AJ, 1985, J IMMUNOL, V134, P284; HOOGSTEDEN HC, 1989, CHEST, V95, P574, DOI 10.1378/chest.95.3.574; HUDSPITH BN, 1987, THORAX, V42, P250, DOI 10.1136/thx.42.4.250; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P634; HUNNINGHAKE GW, 1984, AM REV RESPIR DIS, V129, P569; HUNNINGHAKE GW, 1981, NEW ENGL J MED, V305, P429, DOI 10.1056/NEJM198108203050804; JONES KP, 1991, CLIN EXP IMMUNOL, V83, P30; KELLY PMA, 1988, J CLIN PATHOL, V41, P510, DOI 10.1136/jcp.41.5.510; KERN JA, 1988, AM REV RESPIR DIS, V137, P1180, DOI 10.1164/ajrccm/137.5.1180; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KOEFFLER HP, 1987, BLOOD, V70, P55; LE JM, 1987, LAB INVEST, V56, P234; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; MELIS M, 1991, CHEST, V100, P910, DOI 10.1378/chest.100.4.910; MING WJ, 1987, J IMMUNOL, V138, P1469; MULLERQUERNHEIM J, 1986, J IMMUNOL, V137, P3475; MULLERQUERNHEIM J, 1991, AM REV RESPIR DIS, V144, P1322; MULLERQUERNHEIM J, 1992, AM REV RESPIR DIS, V145, P187; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; NAGAI S, 1991, CHEST, V99, P674, DOI 10.1378/chest.99.3.674; NAKSTAD B, 1989, J PATHOL, V157, P99, DOI 10.1002/path.1711570204; NAWROTH PP, 1986, J EXP MED, V163, P1363, DOI 10.1084/jem.163.6.1363; NEDWIN GE, 1985, J IMMUNOL, V135, P2492; NOMA T, 1987, IMMUNOL LETT, V15, P249, DOI 10.1016/0165-2478(87)90032-0; PHILIP R, 1986, NATURE, V323, P86, DOI 10.1038/323086a0; PINKSTON P, 1983, NEW ENGL J MED, V308, P793, DOI 10.1056/NEJM198304073081401; PINKSTON P, 1987, J IMMUNOL, V139, P755; POBER JS, 1986, J IMMUNOL, V136, P1680; ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852; SALTINI C, 1986, J CLIN INVEST, V77, P1962, DOI 10.1172/JCI112525; SCHEURICH P, 1987, J IMMUNOL, V138, P1786; SEHGAL PB, 1987, SCIENCE, V235, P731, DOI 10.1126/science.3492764; SEMENZATO G, 1984, CLIN EXP IMMUNOL, V57, P331; SHALABY MR, 1985, J IMMUNOL, V135, P2069; SPATAFORA M, 1989, CHEST, V96, P542, DOI 10.1378/chest.96.3.542; SPITERI MA, 1988, CLIN EXP IMMUNOL, V74, P359; SPURZEM JR, 1989, AM REV RESPIR DIS, V140, P89, DOI 10.1164/ajrccm/140.1.89; STEFFEN M, 1993, IN PRESS CLIN EXP IM, V9; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; STRIETER RM, 1989, AM REV RESPIR DIS, V139, P335, DOI 10.1164/ajrccm/139.2.335; THOMAS PD, 1987, AM REV RESPIR DIS, V135, P747; TSUJIMOTO M, 1986, BIOCHEM BIOPH RES CO, V137, P1094, DOI 10.1016/0006-291X(86)90337-2; VENET A, 1985, J CLIN INVEST, V75, P293, DOI 10.1172/JCI111688; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WEWERS MD, 1987, CELL IMMUNOL, V107, P479, DOI 10.1016/0008-8749(87)90255-3; YAMAGUCHI E, 1988, AM REV RESPIR DIS, V138, P645, DOI 10.1164/ajrccm/138.3.645	65	94	95	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					939	949		10.1016/0091-6749(93)90352-G	http://dx.doi.org/10.1016/0091-6749(93)90352-G			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473683				2022-12-18	WOS:A1993KY25100015
J	TOOGOOD, JH; JENNINGS, B; HODSMAN, AB; BASKERVILLE, J; FRAHER, LJ				TOOGOOD, JH; JENNINGS, B; HODSMAN, AB; BASKERVILLE, J; FRAHER, LJ			EFFECTS OF DOSE AND DOSING SCHEDULE OF INHALED BUDESONIDE ON BONE TURNOVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADRENOCORTICAL FUNCTION; ASTHMA; BONE GLA PROTEIN (BETA-GLYCEROPHOSPHATASE); BONE METABOLISM; BUDESONIDE; CORTICOSTEROIDS; HYDROXYPROLINE; INHALED STEROIDS; OSTEOCALCIN; OSTEOPOROSIS	BECLOMETHASONE DIPROPIONATE; STEROID-THERAPY; ASTHMA; CALCIUM; GLUCOCORTICOIDS; HYDROXYPROLINE; COMPLICATIONS; OSTEOPOROSIS; OSTEOCALCIN; PREDNISONE	To assess whether the use of larger than usual doses of inhaled steroid to treat severe asthma may adversely affect bone turnover and whether such an effect may be mitigated by altering the dose schedule, we investigated the effects of budesonide (BUD) on serum osteocalcin and the urinary output of hydroxyproline and calcium. Healthy adults were administered 1.2 or 2.4 mg of BUD per day (N = 40) or placebo (N = 8) in a crossover, double-blind comparison of morning versus diurnal dosing schedules for 1 month each. Both BUD doses reduced the 24-hour urinary free-cortisol output (p < 0.001) and serum osteocalcin (p < 0.001). The larger dose reduced the morning serum cortisol levels (p = 0.002). Neither dose increased the 8 AM urinary calcium or hydroxyproline output. Osteocalcin and plasma cortisol levels were higher on morning than on diurnal dosing (p = 0.01). The 24-hour urinary free-cortisol output was the same with either schedule (p = 0.96). Additional study is required to assess the clinical importance of the inhibitory effect of BUD on bone formation, as evidence by the reduction in osteocalcin levels. Of concern is the possibility of serious bone complications resulting from the long-term use of inhaled steroid, particularly in growing children or patients in whom other risk factors for osteoporosis are present. The clinical advantage, if any, of morning dosing remains questionable.	UNIV WESTERN ONTARIO, DEPT MED, LONDON N6A 3K7, ONTARIO, CANADA; AB DRACO, EXPLORAT CLIN RES DEPT, CLIN PHARMACOL, S-22101 LUND, SWEDEN; UNIV LUND HOSP, DEPT CLIN PHARMACOL, S-22185 LUND, SWEDEN; ST JOSEPHS HOSP, LAWSON RES INST, LONDON N6A 4V2, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT STAT & ACTUARIAL SCI, LONDON N6A 3K7, ONTARIO, CANADA	Western University (University of Western Ontario); Lund University; Skane University Hospital; McGill University; Western University (University of Western Ontario); Western University (University of Western Ontario)			Hodsman, Anthony/G-3303-2011					ADELROTH E, 1985, ALLERGY, V40, P58, DOI 10.1111/j.1398-9995.1985.tb04155.x; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; ANDERSSON P, 1984, J PHARM PHARMACOL, V36, P763, DOI 10.1111/j.2042-7158.1984.tb04868.x; BJORKANDER J, 1982, EUR J RESPIR DIS, V63, P108; BLACK R L, 1957, J Chronic Dis, V5, P751, DOI 10.1016/0021-9681(57)90082-6; BRATTSAND R, 1982, CORTICOSTEROID TREAT, P62; CERESA F, 1969, J CLIN ENDOCR METAB, V29, P1074, DOI 10.1210/jcem-29-8-1074; CHESNEY RW, 1978, AM J DIS CHILD, V132, P768, DOI 10.1001/archpedi.1978.02120330040010; CILLY RG, 1983, INT C S SERIES, V55, P153; CLEARY J, 1974, CLIN CHIM ACTA, V57, P217, DOI 10.1016/0009-8981(74)90400-8; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; DIRAIMONDO VC, 1956, AM J MED, V21, P321, DOI 10.1016/0002-9343(56)90033-X; GENNARI C, 1984, HORM RES, V20, P13, DOI 10.1159/000179970; GRANT SD, 1965, NEW ENGL J MED, V273, P1115, DOI 10.1056/NEJM196511182732101; GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736, DOI 10.1210/jcem-60-4-736; HODGKINSON A, 1982, J CLIN PATHOL, V35, P807, DOI 10.1136/jcp.35.8.807; HODSMAN AB, 1991, J CLIN ENDOCR METAB, V72, P530, DOI 10.1210/jcem-72-3-530; HUNDER GG, 1975, ANN INTERN MED, V82, P613, DOI 10.7326/0003-4819-82-5-613; JENNINGS BH, 1991, EUR J CLIN PHARMACOL, V40, P77, DOI 10.1007/BF00315143; JENNINGS BH, 1990, ASSESSMENT SYSTEMIC, V4, P1; JENNINGS BH, 1990, ASSESSMENT SYSTEMIC, V7, P1; JOHANSSON SA, 1982, EUR J RESPIR DIS, V63, P74; Jones B, 2015, DESIGN ANAL CROSS OV; KJELLMAN M, 1982, EUR J RESPIR DIS, V63, P127; KLEIN RG, 1977, J CLIN INVEST, V60, P253, DOI 10.1172/JCI108762; LAITY A, 1991, Clinical and Investigative Medicine, V14, pA6; LIEBERMAN P, 1972, J ALLERGY CLIN IMMUN, V49, P329, DOI 10.1016/0091-6749(72)90131-5; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MAUNSELL K, 1968, BMJ-BRIT MED J, V1, P661, DOI 10.1136/bmj.1.5593.661; NUGENT CA, 1965, J CHRON DIS, V18, P323, DOI 10.1016/0021-9681(65)90037-8; NUGENT TN, 1965, J CLIN ENDOCRINOL, V25, P343; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; REES HA, 1962, BMJ-BRIT MED J, P1575, DOI 10.1136/bmj.1.5292.1575; REID IR, 1987, HORM RES, V27, P200, DOI 10.1159/000180820; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; RYRFELDT A, 1984, CLIN PHARMACOL THER, V35, P525, DOI 10.1038/clpt.1984.71; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; SMYLLIE HC, 1968, THORAX, V23, P571, DOI 10.1136/thx.23.6.571; SPRINGER C, 1987, ARCH DIS CHILD, V62, P815, DOI 10.1136/adc.62.8.815; STIKSA G, 1982, EUR J RESPIR DIS, V63, P266; TAYLOR AK, 1988, METABOLISM, V37, P872, DOI 10.1016/0026-0495(88)90122-9; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; TOOGOOD JH, 1990, J ALLERGY CLIN IMMUN, V85, P872, DOI 10.1016/0091-6749(90)90071-B; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V83, P528, DOI 10.1016/0091-6749(89)90034-1; TOOGOOD JH, 1988, AM REV RESPIR DIS, V138, P57, DOI 10.1164/ajrccm/138.1.57; VANDENBERG JHM, 1977, CLIN CHIM ACTA, V78, P165, DOI 10.1016/0009-8981(77)90303-5; WARNER JO, 1986, GLUCOCORTICOSTEROIDS, P78; WILLEY RF, 1982, BRIT J DIS CHEST, V76, P61, DOI 10.1016/0007-0971(82)90009-2	51	94	94	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					572	580		10.1016/0091-6749(91)90150-M	http://dx.doi.org/10.1016/0091-6749(91)90150-M			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1918724				2022-12-18	WOS:A1991GL04900005
J	KEATING, MU; KAGEYSOBOTKA, A; HAMILTON, RG; YUNGINGER, JW				KEATING, MU; KAGEYSOBOTKA, A; HAMILTON, RG; YUNGINGER, JW			CLINICAL AND IMMUNOLOGICAL FOLLOW-UP OF PATIENTS WHO STOP VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYMENOPTERA; VENOM; IMMUNOTHERAPY; IGE ANTIBODIES; IGG ANTIBODIES	INSECT HYPERSENSITIVITY; IMMUNOGLOBULIN-G; HYMENOPTERA; ALLERGY; SERUM; IGE	We prospectively studied 51 self-selected Hymenoptera sting-sensitive patients to determine (1) whether a minimal or optimal duration for venom immunotherapy (VIT) exists and (2) whether clinical or immunologic parameters exist that are predictive of clinical immunity after VIT was stopped. After 2 to 10 years of VIT, all patients had deliberate sting challenges (DSCs) from live insects. If DSCs were tolerated, patients voluntarily stopped VIT and returned annually for repeat venom skin tests (VSTs) and DSCs. In most patients, it was possible to monitor VST and venom-specific antibody (Ab) levels before and after VIT was stopped. One-year after VIT, VST and venom-specific IgE and IgG Ab level results were variable; 49 patients tolerated DSC, whereas two patients exhibited generalized reactions. These two patients had pre-VIT histories of grade IV field-sting reactions and had received VIT for 2 years and 4 years, respectively. The short-term (1 year) risk of recurrence of clinical allergy to stings after VIT was higher in patients who had experienced grade IV field-sting reactions before VIT versus patients experiencing grade I to III reactions before VIT (2/15, 13% versus 0/36, 0%) and higher in patients who had received VIT for less than 5 years versus patients who received VIT for 5 or more years (2/20, 10% versus 0/31, 0%). We suggest that VIT should be continued for 5 years in patients with pre-VIT field-sting reactions of grade IV severity. VST and venom-specific Ab results do not reliably predict the outcome of DSC or the subsequent clinical course in individual patients stopping VIT.	MAYO CLIN & MAYO FDN, MAYO MED SCH, DEPT PEDIATR, ROCHESTER, MN 55905 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED ALLERGY, ROCHESTER, MN 55905 USA	Mayo Clinic; Johns Hopkins University; Mayo Clinic					NCRR NIH HHS [RR-585] Funding Source: Medline; NIAID NIH HHS [AI-08270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUSQUET J, 1986, 12 P INT C ALL CLIN, P326; DVORIN D, 1984, Journal of Allergy and Clinical Immunology, V73, P188; FERRANTE A, 1986, INT ARCH ALLER A IMM, V81, P284, DOI 10.1159/000234148; GOLDEN D B K, 1991, Journal of Allergy and Clinical Immunology, V87, P237, DOI 10.1016/0091-6749(91)91675-J; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V83, P273; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GOLDEN DBK, 1983, J ALLERGY CLIN IMMUN, V71, P140, DOI 10.1016/0091-6749(83)90330-5; GOLDEN DBK, 1983, J CLIN IMMUNOASSAY, V6, P172; GRAFT DF, 1987, J ALLERGY CLIN IMMUN, V80, P162, DOI 10.1016/0091-6749(87)90125-4; HAMILTON RG, 1981, J ALLERGY CLIN IMMUN, V67, P14, DOI 10.1016/0091-6749(81)90039-7; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; MUELLER HL, 1975, PEDIATRICS, V55, P530; Norman P, 1986, MANUAL CLIN LABORATO, P660; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477	21	94	97	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				339	348		10.1016/0091-6749(91)90095-6	http://dx.doi.org/10.1016/0091-6749(91)90095-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1890261				2022-12-18	WOS:A1991GG12600027
J	DEMARTINO, M; NOVEMBRE, E; GALLI, L; DEMARCO, A; BOTARELLI, P; MARANO, E; VIERUCCI, A				DEMARTINO, M; NOVEMBRE, E; GALLI, L; DEMARCO, A; BOTARELLI, P; MARANO, E; VIERUCCI, A			ALLERGY TO DIFFERENT FISH SPECIES IN COD-ALLERGIC CHILDREN - INVIVO AND INVITRO STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FOOD HYPERSENSITIVITY; ALLERGENICITY; REACTIVITY; ANTIGENS; POLLEN; EGG	The presence of a positive clinical history and skin test (ST) results for 17 fish species (anchovy, bass, carp, dogfish, eel, gilthead, mackerel, mullet, perch, red millet, salmon, sardine, sole, tench, toothed gilthead, trout, and tuna) were investigated in 20 children with cod-positive clinical history, ST, and RAST, and in 40 children positive to one or more foods different from cod (cow's milk, chicken egg white, peanut, and tomato). In cod-positive children, positive clinical history (60%) and ST (85%) to fish species were more frequent than in cod-negative children (7.5% and 10% respectively). In cod-positive children, a high frequency of positive STs to eel (85%) and to bass, dentex, sole, and tuna (55%) was observed. Positivity to dogfish (10%) was the least frequent. RAST-inhibition experiments suggested the presence of cross-reacting antigen(s) in cod, bass, dentex, eel, sole, and tuna. Results of this study demonstrate that cod allergy might be, on the whole, a reliable index of fish allergy, but cod-positive inclusion in their diet.	UNIV FLORENCE, ANNA MEYER CHILDRENS HOSP, DEPT PEDIAT, DIV ALLERGY & CLIN IMMUNOL, I-50132 FLORENCE, ITALY	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER								AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; AAS K, 1966, INT ARCH ALLER A IMM, V30, P257, DOI 10.1159/000229811; AAS K, 1966, INT ARCH ALLER A IMM, V29, P346, DOI 10.1159/000229716; Aas K., 1987, FOOD ALLERGY INTOLER, P356; AMOROSO S, 1988, INT ARCH ALLER A IMM, V85, P69, DOI 10.1159/000234476; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; de Besche A, 1938, ACTA MED SCAND, V92, P237; DEMARTINO M, 1988, ALLERGY, V43, P206; GALANT SP, 1980, ALLERGIC DISEASES IN, P211; HALMEPURO L, 1985, ALLERGY, V40, P264, DOI 10.1111/j.1398-9995.1985.tb00231.x; HENDRICKSON WA, 1973, J BIOL CHEM, V248, P3327; LAGLER KF, 1977, ICHTHYOLOGY, P2; LANGELAND T, 1983, ALLERGY, V38, P399, DOI 10.1111/j.1398-9995.1983.tb05083.x; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; MONRO J, 1987, FOOD ALLERGY INTOLLE, P303; NOVEMBRE E, 1988, J ALLERGY CLIN IMMUN, V81, P1059, DOI 10.1016/0091-6749(88)90181-9; PALOMBI A, 1981, GLI ANIMALI COMMESTI, P1; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; TUFT L, 1946, J ALLERGY, V17, P329, DOI 10.1016/0021-8707(46)90155-4; VIERRUCCI A, 1989, ALLERGY, V44, P90, DOI 10.1111/j.1398-9995.1989.tb02462.x; WENDEROTH H, 1956, DEUT MED WOCHENSCHR, V81, P1274, DOI 10.1055/s-0028-1115831	24	94	95	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				909	914		10.1016/S0091-6749(05)80154-X	http://dx.doi.org/10.1016/S0091-6749(05)80154-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262645	Bronze			2022-12-18	WOS:A1990EQ04500012
J	PLATTSMILLS, TAE; LONGBOTTOM, J; EDWARDS, J; COCKROFT, A; WILKINS, S				PLATTSMILLS, TAE; LONGBOTTOM, J; EDWARDS, J; COCKROFT, A; WILKINS, S			OCCUPATIONAL ASTHMA AND RHINITIS RELATED TO LABORATORY RATS - SERUM IGG AND IGE ANTIBODIES TO THE RAT URINARY ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,LONDON SW3 6HP,ENGLAND; LLANDOUGH HOSP,MRC,PNEUMOCONIOSIS RES UNIT,PENARTH GP6 1XX,S GLAM,WALES	Royal Brompton Hospital	PLATTSMILLS, TAE (corresponding author), UNIV VIRGINIA,MED CTR,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,BOX 225,CHARLOTTESVILLE,VA 22908, USA.				PHS HHS [A120565] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAOLINH D, 1965, J IMMUNOL, V95, P574; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; COCKCROFT A, 1981, LANCET, V1, P827; DAVIES GE, 1981, INT ARCH ALLER A IMM, V64, P302, DOI 10.1159/000232707; EDWARDS JH, 1971, MED LAB TECHNOL, V28, P172; HARGREAVE FE, 1983, SEMIN RESPIR MED, V4, P224, DOI 10.1055/s-2007-1012487; HOOK WA, 1984, J ALLERGY CLIN IMMUN, V73, P457, DOI 10.1016/0091-6749(84)90355-5; LEVY D A, 1982, Journal of Allergy and Clinical Immunology, V69, P158; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; LONGBOTTOM JL, 1984, CLIN IMMUNOL ALLERGY, V4, P19; LONGBOTTOM JL, 1983, 11 P INT C ALL CLIN; LUTSKY II, 1983, J OCCUP ENVIRON MED, V25, P372; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; PLATTSMILLS TAE, 1982, CLIN ASPECTS IMMUNOT, P639; ROY AK, 1966, P SOC EXP BIOL MED, V121, P894; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; SWANSON MC, 1984, AM REV RESPIR DIS, V129, P844, DOI 10.1164/arrd.1984.129.5.844; TAYLOR AN, 1977, LANCET, V2, P847; TAYLOR G, 1976, NATURE, V260, P280, DOI 10.1038/260280a0; TSE KS, 1973, J ALLERGY CLIN IMMUN, V51, P208, DOI 10.1016/0091-6749(73)90140-1; VALENTINE MD, 1978, IMMUNOLOGICAL DISEAS, P917; WAHN U, 1980, J IMMUNOL, V125, P2544; WALLS AF, 1983, ALLERGY, V38, P419, DOI 10.1111/j.1398-9995.1983.tb05085.x	28	94	97	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					505	515		10.1016/0091-6749(87)90369-1	http://dx.doi.org/10.1016/0091-6749(87)90369-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	3819230				2022-12-18	WOS:A1987G479500014
J	STARK, BJ; EARL, HS; GROSS, GN; LUMRY, WR; GOODMAN, EL; SULLIVAN, TJ				STARK, BJ; EARL, HS; GROSS, GN; LUMRY, WR; GOODMAN, EL; SULLIVAN, TJ			ACUTE AND CHRONIC DESENSITIZATION OF PENICILLIN-ALLERGIC PATIENTS USING ORAL PENICILLIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas								BORRIE P, 1961, BRIT MED J, V2, P1267, DOI 10.1136/bmj.2.5262.1267; BROWN LA, 1982, J ALLERGY CLIN IMMUN, V69, P51, DOI 10.1016/0091-6749(82)90087-2; EARL HS, 1987, J ALLERGY CLIN IMMUN, V79, P477, DOI 10.1016/0091-6749(87)90365-4; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1967, ANN NY ACAD SCI, V145, P298, DOI 10.1111/j.1749-6632.1967.tb50227.x; NACLERIO R, 1983, J ALLERGY CLIN IMMUN, V71, P294, DOI 10.1016/0091-6749(83)90083-0; ODONNOVAN WJ, 1946, LANCET, V2, P444; PARKER CW, 1972, CRC CRIT R TOXICOL, V1, P161; PARKER CW, 1980, CLIN IMMUNOLOGY, P1219; PARKER CW, 1979, NIH79387 PUBL, P509; PATTERSON R, 1973, Journal of Immunology, V110, P1135; SHAPIRO J, 1964, DHEW PUBLICATION, V997, P328; SOGN DD, 1984, J ALLERGY CLIN IMMUN, V74, P589, DOI 10.1016/0091-6749(84)90111-8; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P500, DOI 10.1016/0091-6749(82)90174-9; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1985, NEW ENGL REG ALLERGY, V6, P160; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; SULLIVAN TJ, 1986, J ALLERGY CLIN IMMUN, V77, P223; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; WENDEL GD, 1985, NEW ENGL J MED, V312, P1229, DOI 10.1056/NEJM198505093121905	23	94	97	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					523	532		10.1016/0091-6749(87)90371-X	http://dx.doi.org/10.1016/0091-6749(87)90371-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	3819232				2022-12-18	WOS:A1987G479500016
J	LEITERMANN, K; OHMAN, JL				LEITERMANN, K; OHMAN, JL			CAT ALLERGEN .1. BIOCHEMICAL, ANTIGENIC, AND ALLERGENIC PROPERTIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM OUTPATIENT CLIN, ALLERGY RES LAB, 17 COURT ST, BOSTON, MA 02108 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts University								ANDERSON MC, 1981, J IMMUNOL, V127, P972; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BRYANT DH, 1976, MED J AUSTRALIA, V1, P918, DOI 10.5694/j.1326-5377.1976.tb141170.x; FAZEKAS SDS, 1963, BIOCHIM BIOPHYS ACTA, V71, P377; Freund J, 1942, P SOC EXP BIOL MED, V49, P548; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KING TP, 1979, J ALLERGY CLIN IMMUN, V64, P159, DOI 10.1016/0091-6749(79)90090-3; KURATA JH, 1976, ANN ALLERGY, V37, P398; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL CB, 1965, ANAL BIOCHEM, V10, P358, DOI 10.1016/0003-2697(65)90278-2; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LITTLE JR, 1968, METHODS IMMUNOLOGY I, P346; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1974, J IMMUNOL, V113, P1668; REID MJ, 1981, J ALLERGY CLIN IMMUN, V67, P263, DOI 10.1016/0091-6749(81)90020-8; SARSFIELD JK, 1976, ARCH DIS CHILD, V51, P186, DOI 10.1136/adc.51.3.186; STOKES C R, 1975, Clinical Allergy, V5, P241, DOI 10.1111/j.1365-2222.1975.tb01859.x; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048; 1974, BR J DIS CHEST, V69, P125	21	94	104	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					147	153		10.1016/0091-6749(84)90278-1	http://dx.doi.org/10.1016/0091-6749(84)90278-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6747135				2022-12-18	WOS:A1984TE22600006
J	MALO, JL; OUIMET, G; CARTIER, A; LEVITZ, D; ZEISS, CR				MALO, JL; OUIMET, G; CARTIER, A; LEVITZ, D; ZEISS, CR			COMBINED ALVEOLITIS AND ASTHMA DUE TO HEXAMETHYLENE DIISOCYANATE (HDI), WITH DEMONSTRATION OF CROSSED RESPIRATORY AND IMMUNOLOGICAL REACTIVITIES TO DIPHENYLMETHANE DIISOCYANATE (MDI)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY IMMUNOL SECT, CHICAGO, IL 60611 USA	Northwestern University	MALO, JL (corresponding author), HOP SACRE COEUR, SERV PNEUMOL, MONTREAL H4J 1C5, QUEBEC, CANADA.				NHLBI NIH HHS [HL 15389] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS WGF, 1970, P ROY SOC MED, V63, P378, DOI 10.1177/003591577006300420; BATES DV, 1971, RESPIRATORY FUNCTION, P80; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CHARLES J, 1976, THORAX, V31, P127, DOI 10.1136/thx.31.2.127; CHEN SE, 1982, J ALLERGY CLIN IMMUN, V70, P383, DOI 10.1016/0091-6749(82)90029-X; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTES JE, 1966, BRIT MED J, V1, P1016, DOI 10.1136/bmj.1.5494.1016; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; DIEM JE, 1980, AM REV RESPIR DIS S, V191, P231; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; ENGVALL E, 1972, J IMMUNOL, V109, P129; FINK JN, 1978, AM REV RESPIR DIS, V118, P955; FUCHS S, 1951, Arch Mal Prof, V12, P191; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; HENDRICK DJ, 1980, THORAX, V35, P415, DOI 10.1136/thx.35.6.415; HENSCHLER D., 1962, ARCH TOXIKOLOGIE, V19, P364; LEITH DE, 1974, PROCEDURES STANDARDI; MALO JL, 1982, AM REV RESPIR DIS, V125, P113; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	24	94	95	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					413	419		10.1016/0091-6749(83)90508-0	http://dx.doi.org/10.1016/0091-6749(83)90508-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6619454				2022-12-18	WOS:A1983RN33000013
J	PARKER, JL; SANTRACH, PJ; DAHLBERG, MJE; YUNGINGER, JW				PARKER, JL; SANTRACH, PJ; DAHLBERG, MJE; YUNGINGER, JW			EVALUATION OF HYMENOPTERA-STING SENSITIVITY WITH DELIBERATE STING CHALLENGES - INADEQUACY OF PRESENT DIAGNOSTIC METHODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905; MAYO CLIN & FDN,MAYO GRAD SCH MED,ROCHESTER,MN 55905; MAYO CLIN & FDN,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & FDN,DEPT INTERNAL MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NCRR NIH HHS [RR-585] Funding Source: Medline; NIAID NIH HHS [AI 00107, AI 11483] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CONROY MC, 1977, FED PROC, V36, P1216; GEORGITIS J, 1981, 37TH P ANN M AM AC A, P57; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1981, J IMMUNOL, V126, P575; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; HOFFMAN DR, 1981, ANN ALLERGY, V46, P17; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; NORMAN PS, 1978, ALLERGY PRINCIPLES P, P256; REISMAN RE, 1981, 37TH P ANN M AM AC A, P57; SCHUBERTH KC, 1981, 37TH P ANN M AM AC A, P57; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; Yunginger J. W., 1975, Advances in diagnosis of allergy: RAST (Editor R. Evans, III)., P143; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	18	94	94	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	2					200	207		10.1016/0091-6749(82)90100-2	http://dx.doi.org/10.1016/0091-6749(82)90100-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NC581	7056951				2022-12-18	WOS:A1982NC58100006
J	AGOSTONI, A; CICARDI, M; MARTIGNONI, GC; BERGAMASCHINI, L; MARASINI, B				AGOSTONI, A; CICARDI, M; MARTIGNONI, GC; BERGAMASCHINI, L; MARASINI, B			DANAZOL AND STANOZOLOL IN LONG-TERM PROPHYLACTIC TREATMENT OF HEREDITARY ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MILAN,INST MED PATHOL 3,I-20133 MILAN,ITALY	University of Milan			cicardi, marco/K-9219-2016; BERGAMASCHINI, LUIGI CESARE/T-6367-2017	cicardi, marco/0000-0003-1251-225X; BERGAMASCHINI, LUIGI CESARE/0000-0002-5103-0942				AGOSTONI A, 1978, ALLERGY, V33, P216, DOI 10.1111/j.1398-9995.1978.tb01537.x; AGOSTONI A, 1977, B I SIEROTER MILAN, V56, P22; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; CHEESBROUGH MJ, 1978, BRIT J DERMATOL, V99, P39, DOI 10.1111/j.1365-2133.1978.tb15236.x; COHEN SH, 1978, J ALLERGY CLIN IMMUN, V62, P217, DOI 10.1016/0091-6749(78)90210-5; COHEN SH, 1978, ANN INTERN MED, V88, P429, DOI 10.7326/0003-4819-88-3-429_1; DAVIS PJ, 1974, JOHNS HOPKINS MED J, V135, P391; DAY NK, 1976, CLIN EXP IMMUNOL, V26, P189; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GOULD DJ, 1978, LANCET, V1, P770; HAUPTMANN G, 1975, SCAND J HAEMATOL, V15, P22; HOUSSAY AB, 1973, J DENT RES, V52, P1076, DOI 10.1177/00220345730520051501; JORDON RE, 1974, CLIN EXP IMMUNOL, V18, P407; LACHMANN PJ, 1973, HDB EXPT IMMUNOLOGY, P1; ROSEN FS, 1976, NEW ENGL J MED, V295, P1476, DOI 10.1056/NEJM197612232952608; SAIHAN EM, 1978, BRIT MED J, V1, P367, DOI 10.1136/bmj.1.6109.367-a; SCHREIBER AD, 1976, BLOOD, V48, P567; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; VOSS HE, 1973, HDB EXPT PHARMAKOLOG, V35, P542; WALLINGTON TB, 1978, BRIT J DERMATOL, V99, P39, DOI 10.1111/j.1365-2133.1978.tb15237.x; WESTABY, 1977, LANCET, V2, P261	21	94	94	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					75	79		10.1016/0091-6749(80)90181-5	http://dx.doi.org/10.1016/0091-6749(80)90181-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	6765962	Bronze			2022-12-18	WOS:A1980JB45900013
J	VANMETRE, TE; ADKINSON, NF; AMODIO, FJ; LICHTENSTEIN, LM; MARDINEY, MR; NORMAN, PS; ROSENBERG, GL; SOBOTKA, AK; VALENTINE, MD				VANMETRE, TE; ADKINSON, NF; AMODIO, FJ; LICHTENSTEIN, LM; MARDINEY, MR; NORMAN, PS; ROSENBERG, GL; SOBOTKA, AK; VALENTINE, MD			A COMPARATIVE-STUDY OF THE EFFECTIVENESS OF THE RINKEL METHOD AND THE CURRENT STANDARD METHOD OF IMMUNOTHERAPY FOR RAGWEED POLLEN HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,ALLERGY CLIN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NCRR NIH HHS [5 M 01 RR 00722-07+] Funding Source: Medline; PHS HHS [3 P50 AL 10304-0851, A 1 11936-05] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CONNELL JT, 1964, J ALLERGY, V35, P169, DOI 10.1016/0021-8707(64)90031-0; CONNELL JT, 1967, ANN ALLERGY, V25, P239; CONNELL JT, 1963, J ALLERGY, V34, P409, DOI 10.1016/0021-8707(63)90004-2; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HIRSCH SR, 1980, J ALLERGY CLIN IMMUN, V65, P192; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; KNIKER WT, 1980, J ALLERGY CLIN IMMUN, V65, P193; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; Lieberman P, 1974, Adv Intern Med, V19, P391; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; MELAM HL, 1970, J ALLERGY, V46, P292, DOI 10.1016/0021-8707(70)90069-9; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1973, ROLE IN VITRO ASSAYS; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P205; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P42; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; Sherman WB, 1941, J IMMUNOL, V40, P289; SHERMAN WB, 1957, ALLERGY PEDIATRIC PR, P135; Siegel S., 1956, NONPARAMETRIC STAT B; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; WILLOUGHBY JW, 1974, OTOLARYNG CLIN N AM, V7, P579	37	94	96	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	6					500	513		10.1016/0091-6749(80)90012-3	http://dx.doi.org/10.1016/0091-6749(80)90012-3			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KV363	6159384	Bronze			2022-12-18	WOS:A1980KV36300011
J	GOWER, RG; SAUSKER, WF; KOHLER, PF; THORNE, GE; MCINTOSH, RM				GOWER, RG; SAUSKER, WF; KOHLER, PF; THORNE, GE; MCINTOSH, RM			SMALL VESSEL VASCULITIS CAUSED BY HEPATITIS-B VIRUS IMMUNE-COMPLEXES - SMALL VESSEL VASCULITIS AND HBSAG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,DEPT MED,VA SCULITIS STUDY GRP,DENVER,CO 80202; UNIV COLORADO,MED CTR,DEPT DERMATOL,DENVER,CO 80202; UNIV COLORADO,MED CTR,DEPT PEDIAT,DENVER,CO 80202; FITZSIMONS ARMY MED CTR,DERMATOL SECT,DENVER,CO 80240	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Gower, Richard/0000-0002-5042-7059				BOND HE, 1972, HEPATITIS BLOOD TRAN, P221; BRAVERMAN IM, 1975, J INVEST DERMATOL, V64, P105, DOI 10.1111/1523-1747.ep12510321; COCHRANE CG, 1963, J EXP MED, V118, P489, DOI 10.1084/jem.118.4.489; COMBES B, 1971, LANCET, V2, P234; GOCKE DJ, 1971, J EXP MED, V134, pS330; HUMPHREY CD, 1974, STAIN TECHNOL, V49, P9, DOI 10.3109/10520297409116929; KOHLER PF, 1974, AM J MED, V56, P406, DOI 10.1016/0002-9343(74)90623-8; KOHLER PF, 1974, ANN INTERN MED, V81, P448, DOI 10.7326/0003-4819-81-4-448; KOHLER PF, 1973, MEDICINE, V52, P419, DOI 10.1097/00005792-197309000-00006; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; MCINTOSH RM, 1975, Q J MED, V44, P285; MCINTOSH RM, 1976, Q J MED, V45, P23; MCLEAN JW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077; MOVAT HZ, 1963, AM J PATHOL, V42, P41; Oldstone M.B., 1975, VIRAL IMMUNOL IMMUNO, P341, DOI [10.1016/b978- 0-12-522050-7.50024-1, DOI 10.1016/B978-0-12-522050-7.50024-1]; SAMS WM, 1976, ARCH DERMATOL, V112, P219, DOI 10.1001/archderm.112.2.219; TREPO CG, 1974, J CLIN PATHOL, V27, P863, DOI 10.1136/jcp.27.11.863; VAUGHAN JH, 1973, POSTGRAD MED, V54, P129, DOI 10.1080/00325481.1973.11713616; ZUBLER RH, 1976, J IMMUNOL, V116, P232	19	94	95	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	4					222	228		10.1016/0091-6749(78)90211-7	http://dx.doi.org/10.1016/0091-6749(78)90211-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FS392	701656				2022-12-18	WOS:A1978FS39200005
J	RICHARDSON, JB; BOUCHARD, T				RICHARDSON, JB; BOUCHARD, T			DEMONSTRATION OF A NONADRENERGIC INHIBITORY NERVOUS-SYSTEM IN TRACHEA OF GUINEA-PIG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCGILL UNIV,DEPT THERAPEUTICS,MONTREAL,QUEBEC,CANADA; MCGILL UNIV,DEPT PATHOL,MONTREAL,QUEBEC,CANADA; MCGILL UNIV,DEPT PHARMACOL,MONTREAL,QUEBEC,CANADA	McGill University; McGill University; McGill University								AAS K, 1972, BIOCHEMICAL IMMUNOLO; ADVENIER C, 1972, BRIT J PHARMACOL, V44, P642, DOI 10.1111/j.1476-5381.1972.tb07304.x; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; CASTILLO JC, 1947, J PHARMACOL EXP THER, V90, P104; CHRISTENSEN J, 1973, J CLIN INVEST, V52, pA19; COLEMAN RA, 1973, BRIT J PHARMACOL, V48, P360; CREMA A, 1968, GUT, V9, P633, DOI 10.1136/gut.9.6.633; CREMA A, 1970, BRIT J PHARMACOL, V39, P334, DOI 10.1111/j.1476-5381.1970.tb12897.x; DIAMOND L, 1972, J PHARMACOL EXP THER, V181, P434; FRIGO GM, 1973, GUT, V14, P35, DOI 10.1136/gut.14.1.35; GOLD WM, 1972, J APPL PHYSIOL, V33, P710; HUKUHARA T, 1961, JPN J PHYSIOL, V11, P635; KAO CY, 1966, PHARMACOL REV, V18, P997; MCCULLOCH MW, 1967, EUR J PHARMACOL, V2, P214, DOI 10.1016/0014-2999(67)90090-8; MILLS JE, 1970, BRIT J PHARMACOL, V39, P724, DOI 10.1111/j.1476-5381.1970.tb09898.x; MORALESAGUILERA A, 1965, BRIT J PHARM CHEMOTH, V24, P332, DOI 10.1111/j.1476-5381.1965.tb01719.x; NAGAISHI C, 1972, FUNCTIONAL ANATOMY H; RIKIMARU A, 1971, TOHOKU J EXP MED, V108, P303; SILVA DG, 1974, J ULTRA MOL STRUCT R, V47, P310, DOI 10.1016/S0022-5320(74)90013-6; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TUCH A, 1973, J CLIN INVEST, V52, P14, DOI 10.1172/JCI107157; WEISENTHAL LM, 1971, J PHARMACOL EXP THER, V178, P497; WIDDICOMBE JG, 1963, PHYSIOL REV, V43, P1, DOI 10.1152/physrev.1963.43.1.1	23	94	94	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	6					473	480		10.1016/0091-6749(75)90065-2	http://dx.doi.org/10.1016/0091-6749(75)90065-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ301	1437				2022-12-18	WOS:A1975AZ30100006
J	REED, CE				REED, CE			ABNORMAL AUTONOMIC MECHANISMS IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									UNIV WISCONSIN,MED SCH,ALLERGIC DIS CTR,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								ARTHUR RP, 1938, ANN INTERN MED, V49, P900; ASSEM ESK, 1971, INT ARCH ALLER A IMM, V40, P576, DOI 10.1159/000230439; BERNSTEIN RA, 1972, J LAB CLIN MED, V80, P772; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; CABEZAS GA, 1971, J APPL PHYSIOL, V31, P651, DOI 10.1152/jappl.1971.31.5.651; CARR RH, 1973, J ALLERGY CLIN IMMUN, V51, P255, DOI 10.1016/0091-6749(73)90127-9; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; CULLAM VA, 1969, BRIT J PHARMACOL, V15, P141; DAUTREBANDE L, 1941, PRESSE MED, V49, P942; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; DUNLOP D, 1968, BRIT J PHARMACOL, V32, P201, DOI 10.1111/j.1476-5381.1968.tb00444.x; FISHEL CW, 1970, FED P, V29, P2217; GEORGE WJ, 1970, P NATL ACAD SCI USA, V66, P398, DOI 10.1073/pnas.66.2.398; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; GREENGARD P, 1972, Biochemical Journal, V128, P75; GRIECO MH, 1971, J ALLERGY CLIN IMMUN, V48, P143, DOI 10.1016/0091-6749(71)90009-1; GRIECO MH, 1968, AM J MED, V44, P863, DOI 10.1016/0002-9343(68)90086-7; GROTTI A, 1966, J PHYSIOL, V184, P924; ISHIZAKA T, 1971, J IMMUNOL, V106, P1267; ITKIN IH, 1970, J ALLERGY, V45, P178, DOI 10.1016/0021-8707(70)90126-7; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KIRKPATRICK CH, 1967, AM REV RESPIR DIS, V96, P692; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LEE TP, 1973, J ALLERGY CLIN IMMUN, V51, P93, DOI 10.1016/S0091-6749(73)80033-8; LEE TP, 1972, P NATL ACAD SCI USA, V69, P3287, DOI 10.1073/pnas.69.11.3287; LEFKOWITZ RJ, 1972, LIFE SCI 2-BIOCH GEN, V11, P821, DOI 10.1016/0024-3205(72)90130-0; LEVEY GS, 1971, BIOCHEM BIOPH RES CO, V43, P108, DOI 10.1016/S0006-291X(71)80093-1; LEVY B, 1969, EUR J PHARMACOL, V5, P227, DOI 10.1016/0014-2999(69)90142-3; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MASON RK, 1967, NATURE, V214, P99, DOI 10.1038/214099a0; MCAFEE DA, 1972, SCIENCE, V178, P310, DOI 10.1126/science.178.4058.310; MCNIELL RS, 1964, LANCET, V2, P1101; MIDDLETON E, 1968, J ALLERGY, V41, P109; MIDDLETON E, 1968, J ALLERGY, V42, P29; MILLS JE, BREATHING HERING BRE; MORAN NC, 1966, PHARMACOL REV, V18, P503; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; NADEL JA, 1962, J APPL PHYSIOL, V17, P861, DOI 10.1152/jappl.1962.17.6.861; ORANGE RP, 1971, J EXP MED          S, V134, P136; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PIERSON RN, 1969, AM REV RESPIR DIS, V100, P533; REED CE, 1970, J ALLERGY, V46, P90, DOI 10.1016/0021-8707(70)90076-6; Robinson GA, 1971, CYCLIC AMP; ROSTENBERG A, 1971, IMMUNOLOGIC DISEASES; SAMPTER M, 1933, Z GES EXP MED, V89, P24; SELLICK H, 1971, J APPL PHYSL, V31, P71; SIMONSSO.BG, 1967, AM REV RESPIR DIS, V95, P873; SOLINGER A, 1972, J ALLERGY CLIN IMMUN, V49, P107; SZENTIVANYI A, 1963, J INFECT DIS, V113, P86, DOI 10.1093/infdis/113.2.86; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WIDDICOMBE JG, 1962, J APPL PHYSIOL, V17, P613, DOI 10.1152/jappl.1962.17.4.613; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103	56	94	94	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	1					34	41		10.1016/0091-6749(74)90097-9	http://dx.doi.org/10.1016/0091-6749(74)90097-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R8075	4128524	Bronze			2022-12-18	WOS:A1974R807500005
J	Twelves, S; Mostafa, A; Dand, N; Burri, E; Farkas, K; Wilson, R; Cooper, HL; Irvine, AD; Oon, HH; Kingo, K; Koks, S; Mrowietz, U; Puig, L; Reynolds, N; Tan, EST; Tanew, A; Torz, K; Trattner, H; Valentine, M; Wahie, S; Warren, RB; Wright, A; Bata-Csorgo, Z; Szell, M; Griffiths, CEM; Burden, AD; Choon, SE; Smith, CH; Barker, JN; Navarini, AA; Capon, F				Twelves, Sophie; Mostafa, Alshimaa; Dand, Nick; Burri, Elias; Farkas, Katalin; Wilson, Rosemary; Cooper, Hywel L.; Irvine, Alan D.; Oon, Hazel H.; Kingo, Kulli; Koks, Sulev; Mrowietz, Ulrich; Puig, Luis; Reynolds, Nick; Tan, Eugene Sern-Ting; Tanew, Adrian; Torz, Kaspar; Trattner, Hannes; Valentine, Mark; Wahie, Shyamal; Warren, Richard B.; Wright, Andrew; Bata-Csorgo, Zsuzsa; Szell, Marta; Griffiths, Christopher E. M.; Burden, A. David; Choon, Siew-Eng; Smith, Catherine H.; Barker, Jonathan N.; Navarini, Alexander A.; Capon, Francesca			Clinical and genetic differences between pustular psoriasis subtypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Generalized pustular psoriasis; palmoplantar pustulosis; acrodermatitis continua of Hallopeau; IL36RN; AP1S3; genotype-phenotype correlation	AP1S3 MUTATIONS; IL36RN; CARD14; VARIANTS	Background: The term pustular psoriasis indicates a group of severe skin disorders characterized by eruptions of neutrophil-filled pustules. The disease, which often manifests with concurrent psoriasis vulgaris, can have an acute systemic (generalized pustular psoriasis [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua of Hallopeau [ACH]) presentation. Although mutations have been uncovered in IL36RN and AP1S3, the rarity of the disease has hindered the study of genotype-phenotype correlations. Objective: We sought to characterize the clinical and genetic features of pustular psoriasis through the analysis of an extended patient cohort. Methods: We ascertained a data set of unprecedented size, including 863 unrelated patients (251 with GPP, 560 with PPP, 28 with ACH, and 24 with multiple diagnoses). We undertook mutation screening in 473 cases. Results: Psoriasis vulgaris concurrence was lowest in PPP (15.8% vs 54.4% in GPP and 46.2% in ACH, P<.0005 for both), whereas themean age of onset was earliest in GPP (31.0 vs 43.7 years in PPP and 51.8 years inACH, P<.0001 for both). The percentage of female patients was greater in PPP (77.0%) than in GPP (62.5%; P = 5.8 x 10(-5)). The same applied to the prevalence of smokers (79.8% vs 28.3%, P < 10(-1)5). Although AP1S3 alleles had similar frequency (0.03-0.05) across disease subtypes, IL36RN mutations were less common in patients with PPP (0.03) than in those with GPP (0.19) andACH(0.16; P51.9310 214 and.002, respectively). Importantly, IL36RN disease alleles had a dose-dependent effect on age of onset in all forms of pustular psoriasis (P = .003). Conclusions: The analysis of an unparalleled resource revealed key clinical and genetic differences between patients with PPP and those with GPP.	[Twelves, Sophie; Dand, Nick; Capon, Francesca] Kings Coll London, Sch Basic & Med Biosci, Dept Med & Mol Genet, London, England; [Mostafa, Alshimaa; Burri, Elias; Navarini, Alexander A.] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland; [Mostafa, Alshimaa] Beni Suef Univ, Dept Dermatol, Bani Suwayf, Egypt; [Farkas, Katalin] Univ Szeged, Dept Med Genet, Szeged, Hungary; [Wilson, Rosemary; Smith, Catherine H.; Barker, Jonathan N.] Kings Coll London, St Johns Inst Dermatol, Sch Basic & Med Biosci, London, England; [Cooper, Hywel L.] Portsmouth Hosp Trust, Portsmouth Dermatol Unit, Portsmouth, Hants, England; [Irvine, Alan D.] Trinity Coll Dublin, Our Ladys Childrens Hosp Crumlin & Clin Med, Paediat Dermatol, Dublin, Ireland; [Oon, Hazel H.; Tan, Eugene Sern-Ting] Natl Skin Ctr, Dept Dermatol, Singapore, Singapore; [Kingo, Kulli] Univ Tartu, Dept Dermatol, Tartu, Estonia; [Kingo, Kulli] Tartu Univ Hosp, Clin Dermatol, Tartu, Estonia; [Koks, Sulev] Univ Tartu, Dept Pathophysiol, Tartu, Estonia; [Mrowietz, Ulrich; Torz, Kaspar] Univ Med Ctr, Dept Dermatol, Psoriasis Ctr, Campus Kiel, Schleswig Holstein, Germany; [Puig, Luis] Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain; [Reynolds, Nick] Newcastle Univ, Inst Cellular Med, Med Sch, Newcastle Upon Tyne, Tyne & Wear, England; [Reynolds, Nick] Newcastle Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England; [Tanew, Adrian; Trattner, Hannes] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Valentine, Mark] Univ Washington, Div Dermatol, Sch Med, Seattle, WA 98195 USA; [Wahie, Shyamal] Univ Hosp North Durham, Durham, England; [Wahie, Shyamal] Darlington Mem Hosp, Darlington, Durham, England; [Warren, Richard B.; Griffiths, Christopher E. M.] Univ Manchester, Dermatol Ctr, Salford Royal Hosp, Manchester, Lancs, England; [Warren, Richard B.; Griffiths, Christopher E. M.] Acad Hlth Sci Ctr, Manchester, Lancs, England; [Wright, Andrew] St Lukes Hosp, Bradford, W Yorkshire, England; [Wright, Andrew] Univ Bradford, Ctr Skin Sci, Bradford, W Yorkshire, England; [Bata-Csorgo, Zsuzsa; Szell, Marta] MTA SZTE Dermatol Res Grp, Szeged, Hungary; [Bata-Csorgo, Zsuzsa] Univ Szeged, Dept Dermatol & Allergol, Szeged, Hungary; [Szell, Marta] Univ Szeged, Dept Med Genet, Szeged, Hungary; [Burden, A. David] Univ Glasgow, Inst Infect Inflammat & Immun, Glasgow, Lanark, Scotland; [Choon, Siew-Eng] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Hosp Sultanah Aminah, Dept Dermatol, Johor Baharu, Malaysia	University of London; King's College London; University of Zurich; University Zurich Hospital; Egyptian Knowledge Bank (EKB); Beni Suef University; Szeged University; University of London; King's College London; Portsmouth Hospitals NHS Trust; Trinity College Dublin; National Skin Centre; University of Tartu; University of Tartu; University of Kiel; Schleswig Holstein University Hospital; Hospital of Santa Creu i Sant Pau; Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Medical University of Vienna; University of Washington; University of Washington Seattle; Salford Royal NHS Foundation Trust; Salford Royal Hospital; University of Manchester; University of Manchester; University of Bradford; Eotvos Lorand Research Network; Office for Supported Research Groups (ELKH); Szeged University; Szeged University; University of Glasgow; Monash University; Monash University Sunway	Barker, JN (corresponding author), Kings Coll London, Sch Basic & Med Biosci, St Johns Inst Dermatol, Guys Hosp, 9th Floor Tower Wing, London SE1 9RT, England.	jonathan.barker@kcl.ac.uk	Valentine, Mark/AAS-3262-2021; Irvine, Alan D/A-3982-2008; Oon, Hazel H./X-8317-2018; Capon, Francesca/F-4763-2011; Kingo, Külli/H-3603-2012; CHOON, SIEW ENG/AAU-8192-2021; Navarini, Alexander/C-5504-2014; Warren, Richard/G-4929-2015; Koks, Sulev/H-3655-2015; Smith, Catherine/G-5268-2012	Irvine, Alan D/0000-0002-9048-2044; Oon, Hazel H./0000-0001-7607-3124; Capon, Francesca/0000-0003-2432-5793; CHOON, SIEW ENG/0000-0002-7796-5746; Bata-Csorgo, Zsuzsanna/0000-0002-3732-1743; Navarini, Alexander/0000-0001-7059-632X; Kingo, Kulli/0000-0001-6301-9612; Warren, Richard/0000-0002-2918-6481; Mostafa, Al shimaa/0000-0002-1866-3166; Koks, Sulev/0000-0001-6087-6643; Tan, Eugene/0000-0003-3970-9036; Dand, Nick/0000-0002-1805-6278; Smith, Catherine/0000-0001-9918-1144	Department of Health through the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and comprehensive Biomedical Research Centre; King's College London; King's College Hospital NHS Foundation Trust [guysbrc-2012-1]; Medical Research Council (MRC) Stratified Medicine award [MR/L011808/1]; Efficacy and Mechanism Evaluation (EME) Programme; MRC; NIHR [EME 13/50/17]; Newcastle MRC/EPSRC Molecular Pathology Node; King's Bioscience Institute; Guy's and St Thomas' Charity Prize PhD Programme in Biomedical and Translational Science; PPRC grant from the European Association of Dermatology and Venereology (EADV); MRC [MR/L011808/1, MR/S003126/1, MR/N005872/1] Funding Source: UKRI	Department of Health through the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and comprehensive Biomedical Research Centre; King's College London; King's College Hospital NHS Foundation Trust; Medical Research Council (MRC) Stratified Medicine award; Efficacy and Mechanism Evaluation (EME) Programme; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR(National Institute for Health Research (NIHR)); Newcastle MRC/EPSRC Molecular Pathology Node; King's Bioscience Institute; Guy's and St Thomas' Charity Prize PhD Programme in Biomedical and Translational Science; PPRC grant from the European Association of Dermatology and Venereology (EADV); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Department of Health through the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and comprehensive Biomedical Research Centre awards to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust (guysbrc-2012-1) and to the NIHR-Newcastle Biomedical Research Centre. This work was funded by a Medical Research Council (MRC) Stratified Medicine award (MR/L011808/1; to J.N.B., F.C., and C.H.S.) and by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership (grant EME 13/50/17 to C.H.S., F.C., J.N.B., C.E.M.G., and N.R.). N.R. is also supported by the Newcastle MRC/EPSRC Molecular Pathology Node. S.T. is supported by the King's Bioscience Institute and the Guy's and St Thomas' Charity Prize PhD Programme in Biomedical and Translational Science. The European Rare and Severe Psoriasis Expert Network is funded by a PPRC grant from the European Association of Dermatology and Venereology (EADV; to A.A.N. and J.N.B.). The views expressed in this publication are those of the authors and not necessarily those of the MRC, NHS, NIHR, or Department of Health.	Berki DM, 2015, J INVEST DERMATOL, V135, P2964, DOI 10.1038/jid.2015.288; Burden D, 2016, ROOKS TXB DERMATOLOG, V9, P1133; Chen YT, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1366-0; Di Meglio P, 2014, IMMUNITY, V40, P989, DOI 10.1016/j.immuni.2014.04.019; Ellingford JM, 2016, J EUR ACAD DERMATOL, V30, P302, DOI 10.1111/jdv.13034; Ganesan R, 2017, MABS-AUSTIN, V9, P1143, DOI 10.1080/19420862.2017.1353853; Hussain S, 2015, J ALLERGY CLIN IMMUN, V135, P1067, DOI 10.1016/j.jaci.2014.09.043; Jordan CT, 2012, AM J HUM GENET, V90, P784, DOI 10.1016/j.ajhg.2012.03.012; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Lim KH, 2012, BIOINFORMATICS, V28, P1031, DOI 10.1093/bioinformatics/bts074; Mahil SK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2514; Mahil SK, 2016, J INVEST DERMATOL, V136, P2251, DOI 10.1016/j.jid.2016.06.618; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; Mossner R, 2015, J INVEST DERMATOL, V135, P2538, DOI 10.1038/jid.2015.186; Mossner R, 2018, BRIT J DERMATOL, V178, P740, DOI 10.1111/bjd.15867; Mrowietz U, 2011, BRIT J DERMATOL, V164, P942, DOI 10.1111/j.1365-2133.2011.10233.x; Navarini AA, 2017, J EUR ACAD DERMATOL, V31, P1792, DOI 10.1111/jdv.14386; Onoufriadis A, 2011, AM J HUM GENET, V89, P432, DOI 10.1016/j.ajhg.2011.07.022; R Core Team, 2017, R LANG ENV STAT COMP; Setta-Kaffetzi N, 2014, AM J HUM GENET, V94, P790, DOI 10.1016/j.ajhg.2014.04.005; Setta-Kaffetzi N, 2013, J INVEST DERMATOL, V133, P1366, DOI 10.1038/jid.2012.490; Sugiura K, 2014, J INVEST DERMATOL, V134, P1755, DOI 10.1038/jid.2014.46; Yeo G, 2004, J COMPUT BIOL, V11, P377, DOI 10.1089/1066527041410418	23	93	95	3	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1021	1026		10.1016/j.jaci.2018.06.038	http://dx.doi.org/10.1016/j.jaci.2018.06.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30036598	Green Accepted, hybrid, Green Published			2022-12-18	WOS:000460272900022
J	Buchheit, KM; Cahill, KN; Katz, HR; Murphy, KC; Feng, CL; Lee-Sarwar, K; Lai, JY; Bhattacharyya, N; Israel, E; Boyce, JA; Laidlaw, TM				Buchheit, Kathleen M.; Cahill, Katherine N.; Katz, Howard R.; Murphy, Katherine C.; Feng, Chunli; Lee-Sarwar, Kathleen; Lai, Juying; Bhattacharyya, Neil; Israel, Elliot; Boyce, Joshua A.; Laidlaw, Tanya M.			Thymic stromal lymphopoietin controls prostaglandin D-2 generation in patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; Samter triad; nasal polyps; thymic stromal lymphopoietin; prostaglandin D-2; cysteinyl leukotrienes; innate immunity; mast cells; eosinophils	INNATE LYMPHOID-CELLS; HUMAN EPITHELIAL-CELLS; MAST-CELL; EOSINOPHILIC INFLAMMATION; CYSTEINYL LEUKOTRIENES; CHRONIC RHINOSINUSITIS; ALLERGIC INFLAMMATION; CYTOKINE PRODUCTION; ASTHMATIC AIRWAYS; EXPRESSION	Background: Prostaglandin (PG) D-2 is the dominant COX product of mast cells and is an effector of aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease (AERD). Objective: We evaluated the role of the innate cytokine thymic stromal lymphopoietin (TSLP) acting on mast cells to generate PGD(2) and facilitate tissue eosinophilia and nasal polyposis in patients with AERD. Methods: Urinary eicosanoid levels were measured in aspirin-tolerant control subjects and patients with AERD. Nasal polyp specimens from patients with AERD and chronic rhinosinusitis were analyzed by using quantitative PCR, Western blotting, and immunohistochemistry. Human cord blood-and peripheral blood-derived mast cells were stimulated with TSLP in vitro to assess PGD(2) generation. Results: Urinary levels of a stable PGD(2) metabolite (uPGD-M) were 2-fold higher in patients with AERD relative to those in control subjects and increased further during aspirin-induced reactions. Peak uPGD-Mlevels during aspirin reactions correlated with reductions in blood eosinophil counts and lung function and increases in nasal congestion. Mast cells sorted from nasal polyps expressed PGD(2) synthase (hematopoietic PGD(2) synthase) mRNA at higher levels than did eosinophils from the same tissue. Whole nasal polyp TSLP mRNA expression correlated strongly with mRNA encoding hematopoietic PGD(2) synthase (r = .75), the mast cell-specific marker carboxypeptidase A3 (r = .74), and uPGD-M (r=0.74). Levels of the cleaved active form of TSLP were increased in nasal polyps from patients with AERD relative to those in aspirin-tolerant control subjects. Recombinant TSLP induced PGD(2) generation by cultured human mast cells. Conclusions: Our study demonstrates that mast cell-derived PGD(2) is a major effector of type 2 immune responses driven by TSLP and suggests that dysregulation of this innate system contributes significantly to the pathophysiology of AERD.	[Buchheit, Kathleen M.; Cahill, Katherine N.; Katz, Howard R.; Lee-Sarwar, Kathleen; Israel, Elliot; Boyce, Joshua A.; Laidlaw, Tanya M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Bhattacharyya, Neil] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Buchheit, Kathleen M.; Cahill, Katherine N.; Katz, Howard R.; Murphy, Katherine C.; Feng, Chunli; Lai, Juying; Boyce, Joshua A.; Laidlaw, Tanya M.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA; [Bhattacharyya, Neil] Brigham & Womens Hosp, Div Otolaryngol, 75 Francis St, Boston, MA 02115 USA; [Israel, Elliot] Brigham & Womens Hosp, Div Pulm Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Buchheit, KM (corresponding author), Brigham & Womens Hosp, One Jimmy Fund Way,Smith Bldg,Room 638, Boston, MA 02115 USA.	kbuchheit@partners.org		Cahill, Katherine/0000-0002-8549-1835	National Institutes of Health [T32 AI007306-29, AI007306-27, U19AI095219-01, 5U19AI070412-06, K23HL111113-02]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117945, R01HL128241, K23HL111113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI078908, U19AI095219, R37AI052353, K23AI118804, U19AI070412, T32AI007306] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants T32 AI007306-29, AI007306-27, U19AI095219-01, 5U19AI070412-06, and K23HL111113-02 and by generous contributions from the Vinik Family and the Kaye Family.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; Cook Ellen B, 2012, Clin Mol Allergy, V10, P8, DOI 10.1186/1476-7961-10-8; Corrigan CJ, 2011, J ALLERGY CLIN IMMUN, V128, P116, DOI 10.1016/j.jaci.2011.03.043; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Guo Z, 2014, J ASTHMA, V51, P863, DOI 10.3109/02770903.2014.921196; Gurish MF, 2002, J IMMUNOL, V168, P5730, DOI 10.4049/jimmunol.168.11.5730; Hamada Kazuyuki, 2004, Allergology International, V53, P179, DOI 10.1111/j.1440-1592.2004.00323.x; Han NR, 2014, J INVEST DERMATOL, V134, P2521, DOI 10.1038/jid.2014.198; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; He R, 2010, J ALLERGY CLIN IMMUN, V126, P784, DOI 10.1016/j.jaci.2010.07.006; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Jiang YF, 2006, J IMMUNOL, V177, P2755, DOI 10.4049/jimmunol.177.5.2755; Johns CB, 2014, AM J RHINOL ALLERGY, V28, P287, DOI 10.2500/ajra.2014.28.4054; JOHNSTON SL, 1995, EUR RESPIR J, V8, P411, DOI 10.1183/09031936.95.08030411; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kimura S, 2011, ALLERGY ASTHMA IMMUN, V3, P186, DOI 10.4168/aair.2011.3.3.186; Kupczyk M, 2010, RESP MED, V104, P1404, DOI 10.1016/j.rmed.2010.04.017; Lai E, 2007, CLIN PHARMACOL THER, V81, P849, DOI 10.1038/sj.clpt.6100180; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Liu T, 2011, AM J MED SCI, V341, P40, DOI 10.1097/MAJ.0b013e3181f20489; Luna-Gomes T, 2011, J IMMUNOL, V187, P6518, DOI 10.4049/jimmunol.1101806; Machado-Carvalho L, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0100-7; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; MORROW JD, 1995, J INVEST DERMATOL, V104, P937, DOI 10.1111/1523-1747.ep12606209; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Nagarkar DR, 2012, J ALLERGY CLIN IMMUN, V130, P225, DOI 10.1016/j.jaci.2012.04.019; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Okano M, 2006, CLIN EXP ALLERGY, V36, P1028, DOI 10.1111/j.1365-2222.2006.02528.x; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; Perez-Novo CA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-75; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shaw JL, 2012, INT FORUM ALLERGY RH, V2, P233, DOI 10.1002/alr.21021; SLADEK K, 1993, EUR RESPIR J, V6, P391; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703; Straumann A, 2014, GASTROENTEROL CLIN N, V43, P385, DOI 10.1016/j.gtc.2014.02.005; Vissinga C, 2013, CYTOKINE, V63, P307, DOI 10.1016/j.cyto.2013.06.272; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoshimura Tsuyoshi, 2008, Allergol Int, V57, P429, DOI 10.2332 allergolint.O-08-545	54	93	95	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1566	+		10.1016/j.jaci.2015.10.020	http://dx.doi.org/10.1016/j.jaci.2015.10.020			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26691435	Green Accepted, Bronze			2022-12-18	WOS:000376180200033
J	Roediger, B; Kyle, R; Tay, SS; Mitchell, AJ; Bolton, HA; Guy, TV; Tan, SY; Forbes-Blom, E; Tong, PL; Koller, Y; Shklovskaya, E; Iwashima, M; McCoy, KD; Le Gros, G; Fazekas de St Groth, B; Weninger, W				Roediger, Ben; Kyle, Ryan; Tay, Szun S.; Mitchell, Andrew J.; Bolton, Holly A.; Guy, Thomas V.; Tan, Sioh-Yang; Forbes-Blom, Elizabeth; Tong, Philip L.; Koeller, Yasmin; Shklovskaya, Elena; Iwashima, Makio; McCoy, Kathy D.; Le Gros, Graham; Fazekas de St Groth, Barbara; Weninger, Wolfgang			IL-2 is a critical regulator of group 2 innate lymphoid cell function during pulmonary inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cells; IL-2; eosinophilic crystalline pneumonia; IL-13; pulmonary inflammation	T-CELLS; CYTOKINE PRODUCTION; LUNG INFLAMMATION; PERIPHERAL-BLOOD; GENE-EXPRESSION; T(H)2 CYTOKINES; ALLERGIC-ASTHMA; IN-VIVO; VIRUS; MICE	Background: Group 2 innate lymphoid cells (ILC2) have been implicated in the pathogenesis of allergic lung diseases. However, the upstream signals that regulate ILC2 function during pulmonary inflammation remain poorly understood. ILC2s have been shown to respond to exogenous IL-2, but the importance of endogenous IL-2 in ILC2 function in vivo remains unclear. Objective: We sought to understand the role of IL-2 in the regulation of ILC2 function in the lung. Methods: We used histology, flow cytometry, immunohistochemistry, ELISA, and quantitative PCR with knockout and reporter mice to dissect pulmonary ILC2 function in vivo. We examined the role of ILC2s in eosinophilic crystalline pneumonia, an idiopathic type 2 inflammatory lung condition of mice, and the effect of IL-2 deficiency on this disease. We determined the effect of IL-2 administration on pulmonary ILC2 numbers and function in mice in the steady state and after challenge with IL-33. Results: We discovered an unexpected role for innate cell-derived IL-2 as a major cofactor of ILC2 function during pulmonary inflammation. Specifically, we found that IL-2 was essential for the development of eosinophilic crystalline pneumonia, a type 2 disease characterized by increased numbers of activated ILC2s. We show that IL-2 signaling serves 2 distinct functions in lung ILC2s, namely promoting cell survival/proliferation and serving as a cofactor for the production of type 2 cytokines. We further demonstrate that group 3 innate lymphoid cells are an innate immune source of IL-2 in the lung. Conclusion: Innate cell-derived IL-2 is a critical cofactor in regulating ILC2 function in pulmonary type 2 pathology.	[Roediger, Ben; Tay, Szun S.; Mitchell, Andrew J.; Bolton, Holly A.; Guy, Thomas V.; Tan, Sioh-Yang; Tong, Philip L.; Shklovskaya, Elena; Fazekas de St Groth, Barbara; Weninger, Wolfgang] Centenary Inst, Newtown, NSW 2042, Australia; [Roediger, Ben; Tay, Szun S.; Mitchell, Andrew J.; Bolton, Holly A.; Guy, Thomas V.; Tan, Sioh-Yang; Tong, Philip L.; Shklovskaya, Elena; Fazekas de St Groth, Barbara; Weninger, Wolfgang] Univ Sydney, Discipline Dermatol, Sch Med, Sydney, NSW 2006, Australia; [Kyle, Ryan; Forbes-Blom, Elizabeth; Le Gros, Graham] Malaghan Inst Med Res, Wellington, New Zealand; [Tong, Philip L.; Weninger, Wolfgang] Royal Prince Alfred Hosp, Dept Dermatol, Camperdown, NSW 2050, Australia; [Koeller, Yasmin; McCoy, Kathy D.] Univ Bern, UVCM, Maurice Muller Labs, CH-3012 Bern, Switzerland; [Iwashima, Makio] Loyola Univ Chicago, Dept Microbiol & Immunol, Maywood, IL USA; [Iwashima, Makio] Loyola Univ Chicago, Dept Thorac & Cardiovasc Surg, Maywood, IL USA; [Le Gros, Graham] Victoria Univ Wellington, Wellington, New Zealand	University of Sydney; Centenary Institute; University of Sydney; Malaghan Institute; Victoria University Wellington; University of Sydney; University of Bern; Loyola University Chicago; Loyola University Chicago; Victoria University Wellington	Roediger, B (corresponding author), Centenary Inst, Locked Bag 6, Newtown, NSW 2042, Australia.	b.roediger@centenary.org.au; b.fazekas@centenary.org.au; w.weninger@centenary.org.au	McCoy, Kathy/ABD-5814-2021; de St Groth, Barbara Fazekas/O-3017-2017; Forbes-Blom, Elizabeth/I-3648-2013	de St Groth, Barbara Fazekas/0000-0001-6817-9690; Shklovskaya, Elena/0000-0002-6155-1020; Roediger, Ben/0000-0002-4593-091X; Mitchell, Andrew/0000-0003-4454-853X; Kyle, Ryan/0000-0002-8146-7504; Weninger, Wolfgang/0000-0003-3133-8699; Le Gros, Graham/0000-0002-5721-0442; Bolton, Holly/0000-0003-4628-7708; Tay, Szun S/0000-0003-0186-8154	National Health and Medical Research Council of Australia [1030145, 1047041, 1012524, 1051854]; Health Research Council of New Zealand; European Research Council (ERC) under the European Union's Seventh Framework Programme (FP); ERC [281785]; Swiss National Science Foundation; Cancer Institute New South Wales; National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Health Research Council of New Zealand(Health Research Council of New Zealand); European Research Council (ERC) under the European Union's Seventh Framework Programme (FP)(European Research Council (ERC)); ERC(European Research Council (ERC)European Commission); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Cancer Institute New South Wales; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by grants 1030145 and 1047041 (to W.W.) and 1012524 and 1051854 (to B.F.d.S.G.) from the National Health and Medical Research Council of Australia, the Health Research Council of New Zealand (G.L.G.), the European Research Council (ERC) under the European Union's Seventh Framework Programme (FP/2007-2013) and ERC grant agreement 281785, and the Swiss National Science Foundation (K.D.M.). W.W. is supported by a fellowship from the Cancer Institute New South Wales and B.F.d.S.G. by a fellowship from the National Health and Medical Research Council of Australia.	Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bosse M, 1996, IMMUNOLOGY, V87, P149; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Chang YJ, 2013, J LEUKOCYTE BIOL, V94, P933, DOI 10.1189/jlb.0313127; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cote-Sierra J, 2004, P NATL ACAD SCI USA, V101, P3880, DOI 10.1073/pnas.0400339101; Crellin NK, 2010, IMMUNITY, V33, P752, DOI 10.1016/j.immuni.2010.10.012; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Durant LR, 2013, J VIROL, V87, P10946, DOI 10.1128/JVI.01295-13; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Guo L, 2000, J BIOL CHEM, V275, P8032, DOI 10.1074/jbc.275.11.8032; Guo LY, 2012, TRENDS IMMUNOL, V33, P598, DOI 10.1016/j.it.2012.07.006; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hoenerhoff MJ, 2006, VET PATHOL, V43, P682, DOI 10.1354/vp.43-5-682; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Lin YL, 2008, ALLERGY, V63, P67, DOI 10.1111/j.1398-9995.2007.01526.x; Loebbermann J, 2012, MUCOSAL IMMUNOL, V5, P161, DOI 10.1038/mi.2011.62; MACDONALD D, 1990, BRIT J HAEMATOL, V76, P168, DOI 10.1111/j.1365-2141.1990.tb07867.x; Masters SL, 2013, CLIN IMMUNOL, V147, P223, DOI 10.1016/j.clim.2012.12.006; Matek TR, 2008, ANNU REV IMMUNOL, V26, P453, DOI 10.1146/annurev.immunol.26.021607.090357; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Murawski MR, 2009, J VIROL, V83, P1492, DOI 10.1128/JVI.00671-08; MURRAY AB, 1990, VET PATHOL, V27, P274, DOI 10.1177/030098589002700409; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Shklovskaya E, 2011, P NATL ACAD SCI USA, V108, P18049, DOI 10.1073/pnas.1110076108; Silbermann K, 2008, J GEN VIROL, V89, P2788, DOI 10.1099/vir.0.2008/003699-0; Sojka DK, 2004, J IMMUNOL, V172, P6136, DOI 10.4049/jimmunol.172.10.6136; Spencer SP, 2014, SCIENCE, V343, P432, DOI 10.1126/science.1247606; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; Tomura M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073801; Welch JS, 2002, J BIOL CHEM, V277, P42821, DOI 10.1074/jbc.M205873200; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Yamamoto M, 2013, CYTOKINE, V61, P831, DOI 10.1016/j.cyto.2012.11.026	41	93	95	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1653	U345		10.1016/j.jaci.2015.03.043	http://dx.doi.org/10.1016/j.jaci.2015.03.043			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26025126				2022-12-18	WOS:000366044300028
J	Weng, Z; Patel, AB; Panagiotidou, S; Theoharides, TC				Weng, Zuyi; Patel, Arti B.; Panagiotidou, Smaro; Theoharides, Theoharis C.			The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; inflammation; mast cells; luteolin; tetramethoxyluteolin; calcium; nuclear factor kappa B	NF-KAPPA-B; CORTICOTROPIN-RELEASING HORMONE; CALCIUM-ION LEVELS; FC-EPSILON-RI; SODIUM CROMOGLYCATE; HISTAMINE-SECRETION; MEDIATOR RELEASE; DIFFERENTIAL RELEASE; IL-6 PRODUCTION; IMMUNE CELLS	Background: Mast cells (MCs) are hematopoietic cells that mature in tissues and are involved in allergy, immunity, and inflammation by secreting multiple mediators. The natural flavone luteolin has anti-inflammatory actions and inhibits human mast cells (MCs). Objective: We sought to investigate the ability of luteolin and its novel structural analog 39,49,5,7-tetramethoxyluteolin (methlut) to inhibit human MC mediator expression and release in vitro and in vivo. Methods: Human LAD2 cells and umbilical primary human cord blood-derived cultured mast cells were stimulated with substance P (SP) or IgE/anti-IgE with or without preincubation with luteolin, methlut, or cromolyn (1-100 mu mol/L) for 2 or 24 hours, after which mediator secretion was measured. The effect of the compounds on MC intracellular calcium levels and nuclear factor kappa B activation was also investigated. Pretreatment with methlut was also studied in mice passively sensitized with dinitrophenol-human serum albumin and challenged intradermally. Results: Methlut is a more potent inhibitor than luteolin or cromolyn for beta-hexosaminidase and histamine secretion from LAD2 cells stimulated by either SP or IgE/anti-IgE, but only methlut and luteolin significantly inhibit preformed TNF secretion. Methlut is also a more potent inhibitor than luteolin of de novo-synthesized TNF from LAD2 cells and of CCL2 from human cord blood-derived cultured MCs. This mechanism of action for methlut might be due to its ability to inhibit intracellular calcium level increases, as well as nuclear factor kB induction, at both the transcriptional and translational levels in LAD2 cells stimulated by SP without affecting cell viability. Intraperitoneal treatment with methlut significantly decreases skin vascular permeability of Evans blue dye in mice passively sensitized to dinitrophenol-human serum albumin and challenged intradermally. Conclusion: Methlut is a promising MC inhibitor for the treatment of allergic and inflammatory conditions.	[Weng, Zuyi; Patel, Arti B.; Panagiotidou, Smaro; Theoharides, Theoharis C.] Tufts Univ, Sch Med, Dept Integrat Physiol & Pathobiol, Mol Immunopharmacol & Drug Discovery Lab, Boston, MA 02111 USA; [Weng, Zuyi; Theoharides, Theoharis C.] Tufts Univ, Sackler Sch Grad Biomed Sci, Grad Program Pharmacol, Boston, MA 02111 USA; [Patel, Arti B.; Theoharides, Theoharis C.] Tufts Univ, Sackler Sch Grad Biomed Sci, Grad Program Cell Mol & Dev Biol, Boston, MA 02111 USA; [Theoharides, Theoharis C.] Tufts Univ, Sch Med, Dept Internal Med, Boston, MA 02111 USA; [Theoharides, Theoharis C.] Tufts Med Ctr, Boston, MA USA	Tufts University; Tufts University; Tufts University; Tufts University; Tufts Medical Center	Theoharides, TC (corresponding author), Tufts Univ, Sch Med, Dept Integrat Physiol & Pathobiol, 150 Harrison Ave,J 304, Boston, MA 02111 USA.	theoharis.theoharides@tufts.edu	weng, zuyi/J-4147-2015		National Institute of Health, a Translational Grant from the National Psoriasis Foundation [AR47652]; Theta Biomedical Consulting and Development (Brookline, Mass); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047652] Funding Source: NIH RePORTER	National Institute of Health, a Translational Grant from the National Psoriasis Foundation; Theta Biomedical Consulting and Development (Brookline, Mass); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported in part by National Institute of Health grant AR47652, a Translational Grant from the National Psoriasis Foundation, and Theta Biomedical Consulting and Development (Brookline, Mass) to T.C.T.	Asadi S, 2010, INT J IMMUNOPATH PH, V23, P1015, DOI 10.1177/039463201002300406; Askenase PW, 2005, NEW ENGL J MED, V349, P1294; Azzolina A, 2003, BBA-MOL CELL RES, V1643, P75, DOI 10.1016/j.bbamcr.2003.09.003; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARRETT KE, 1985, J IMMUNOL, V135, P2020; BUTTERFIELD JH, 1990, J LEUKOCYTE BIOL, V47, P409, DOI 10.1002/jlb.47.5.409; Castells M, 2006, IMMUNOL ALLERGY CLIN, V26, P465, DOI 10.1016/j.iac.2006.05.005; Chen CC, 2005, P NATL ACAD SCI USA, V102, P11408, DOI 10.1073/pnas.0504197102; Chen ZJ, 2014, CURR DRUG METAB, V15, P48, DOI 10.2174/138920021501140218125020; COLLIER JG, 1983, BRIT J CLIN PHARMACO, V16, P639, DOI 10.1111/j.1365-2125.1983.tb02234.x; Deckers J, 2013, TRENDS IMMUNOL, V34, P540, DOI 10.1016/j.it.2013.08.004; Donelan J, 2006, P NATL ACAD SCI USA, V103, P7759, DOI 10.1073/pnas.0602210103; dos Santos RV, 2010, BRIT J DERMATOL, V162, P674, DOI 10.1111/j.1365-2133.2009.09516.x; Douglas W W, 1978, Ciba Found Symp, P61; Douglas WW., 1974, SECRETORY MECHANISMS, P116; Eglite S, 2003, J IMMUNOL, V170, P2680, DOI 10.4049/jimmunol.170.5.2680; Han SY, 2013, J NUTR, V143, P632, DOI 10.3945/jn.112.173302; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P28; HOLGATE ST, 1989, RESP MED, V83, P25, DOI 10.1016/S0954-6111(89)80247-1; HORAN RF, 1990, J ALLERGY CLIN IMMUN, V85, P852, DOI 10.1016/0091-6749(90)90067-E; Huang M, 2009, J MOL ENDOCRINOL, V42, P397, DOI 10.1677/JME-08-0120; Jang S, 2008, P NATL ACAD SCI USA, V105, P7534, DOI 10.1073/pnas.0802865105; Jang S, 2010, J NUTR, V140, P1892, DOI 10.3945/jn.110.123273; Jin M, 2011, BIOL PHARM BULL, V34, P1032, DOI 10.1248/bpb.34.1032; Kang OH, 2010, MOLECULES, V15, P385, DOI 10.3390/molecules15010385; Kempuraj D, 2005, BRIT J PHARMACOL, V145, P934, DOI 10.1038/sj.bjp.0706246; Kempuraj D, 2004, ENDOCRINOLOGY, V145, P43, DOI 10.1210/en.2003-0805; Kempuraj D, 2003, INT ARCH ALLERGY IMM, V132, P231, DOI 10.1159/000074304; Kempuraj D, 2008, BRIT J PHARMACOL, V155, P1076, DOI 10.1038/bjp.2008.356; Kimata M, 2000, CLIN EXP ALLERGY, V30, P501, DOI 10.1046/j.1365-2222.2000.00768.x; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; KUDO H, 1988, CONTACT DERMATITIS, V19, P312, DOI 10.1111/j.1600-0536.1988.tb02939.x; Lee JY, 2014, INFLAMM RES, V63, P53, DOI 10.1007/s00011-013-0670-8; Maurer M, 2003, EXP DERMATOL, V12, P886, DOI 10.1111/j.0906-6705.2003.0109a.x; Middleton E, 2000, PHARMACOL REV, V52, P673; Muller-Ladner Ulf, 2002, Curr Rheumatol Rep, V4, P201, DOI 10.1007/s11926-002-0066-1; Oka T, 2012, LAB INVEST, V92, P1472, DOI 10.1038/labinvest.2012.116; PEARCE FL, 1982, J IMMUNOL, V128, P2481; Petra AI, 2014, EXPERT REV CLIN IMMU, V10, P729, DOI 10.1586/1744666X.2014.906302; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; Saito H, 1996, J IMMUNOL, V157, P343; Salamon P, 2005, ALLERGY, V60, P1316, DOI 10.1111/j.1398-9995.2005.00886.x; Shim SY, 2012, J MICROBIOL BIOTECHN, V22, P622, DOI 10.4014/jmb.1111.11060; Sismanopoulos N, 2013, ALLERGY, V68, P8, DOI 10.1111/all.12043; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; Theoharides TC, 2004, J NEUROIMMUNOL, V146, P1, DOI 10.1016/j.jneuroim.2003.10.041; THEOHARIDES TC, 1982, NATURE, V297, P229, DOI 10.1038/297229a0; THEOHARIDES TC, 1980, SCIENCE, V207, P80, DOI 10.1126/science.6153130; Theoharides TC, 2007, IMMUNOL REV, V217, P65, DOI 10.1111/j.1600-065X.2007.00519.x; Theoharides TC, 2013, CLIN THER, V35, P1454, DOI 10.1016/j.clinthera.2013.07.419; Theoharides TC, 2013, CLIN THER, V35, P584, DOI 10.1016/j.clinthera.2013.04.009; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P34, DOI 10.1016/j.bbadis.2010.12.017; Tominari T, 2012, J PHARMACOL SCI, V119, P390, DOI 10.1254/jphs.11188SC; Vasiadi M, 2012, J ALLERGY CLIN IMMUN, V129, P1410, DOI 10.1016/j.jaci.2012.01.041; Vig M, 2009, NAT IMMUNOL, V10, P21, DOI 10.1038/ni.f.220; Walle T, 2007, MOL PHARMACEUT, V4, P826, DOI 10.1021/mp700071d; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; WELLS E, 1983, BIOCHEM PHARMACOL, V32, P837, DOI 10.1016/0006-2952(83)90585-3; Weng Z, 2012, PLOS ONE, V7; Weng ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090739; Yang Y, 2013, BIOCHEM J, V450, P537, DOI 10.1042/BJ20121256; Yazid S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058963; Zhang BD, 2012, INT ARCH ALLERGY IMM, V159, P23, DOI 10.1159/000335178	64	93	95	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1044	+		10.1016/j.jaci.2014.10.032	http://dx.doi.org/10.1016/j.jaci.2014.10.032			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25498791	Green Accepted			2022-12-18	WOS:000352238600027
J	Chang, JE; Doherty, TA; Baum, R; Broide, D				Chang, Jinny E.; Doherty, Taylor A.; Baum, Rachel; Broide, David			Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CRTH2; EOSINOPHILS; ANTAGONIST; BASOPHILS; IMMUNITY		[Chang, Jinny E.; Doherty, Taylor A.; Baum, Rachel; Broide, David] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Chang, Jinny E.] Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute	Chang, JE (corresponding author), Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.	dbroide@ucsd.edu		Doherty, Taylor/0000-0003-3256-0398; Baum, Rachel/0000-0002-8227-7462; Broide, David/0000-0001-8405-9090	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000100] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR031980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI107779, R37AI038425, K08AI080938, U19AI070535, R01AI072115] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1TR000100, UL1 TR000100] Funding Source: Medline; NCRR NIH HHS [UL1 RR031980] Funding Source: Medline; NIAID NIH HHS [AI 70535, R37 AI038425, AI 72115, R01 AI072115, R01 AI107779, AI 107779, KO8 AI 080938, U19 AI070535, K08 AI080938] Funding Source: Medline; PHS HHS [ULRR031980, AL38425] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Royer JF, 2008, EUR J CLIN INVEST, V38, P663, DOI 10.1111/j.1365-2362.2008.01989.x; Scanlon ST, 2012, CURR OPIN IMMUNOL, V24, P707, DOI 10.1016/j.coi.2012.08.009; Sugimoto H, 2003, J PHARMACOL EXP THER, V305, P347, DOI 10.1124/jpet.102.046748	12	93	100	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					899	901		10.1016/j.jaci.2013.09.020	http://dx.doi.org/10.1016/j.jaci.2013.09.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24210841	Green Accepted			2022-12-18	WOS:000332397600040
J	MacGlashan, DW				MacGlashan, Donald W., Jr.			Basophil activation testing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE antibody; basophil	ALLERGEN THRESHOLD-SENSITIVITY; CHRONIC IDIOPATHIC URTICARIA; HISTAMINE-RELEASING FACTOR; HUMAN BLOOD BASOPHILS; FC-GAMMA-RIIB; CD-SENS; CD203C EXPRESSION; DIAGNOSTIC-TESTS; FLOW-CYTOMETRY; LEUKEMIA-CELLS	Both the treatment of patients with allergic diseases and the study of allergic disease mechanisms depend on a wide variety of assays that in various ways assess the presence and function of IgE antibody. The study of allergic diseases could benefit from the study of its 2 principle cellular participants, mast cells and basophils, but the basophil is more accessible than mast cells for ex vivo studies. Its functionality is tested by using 2 predominant methodologies: the secretion of mediators of allergic inflammation and the expression of proteins on the plasma membrane after stimulation. Each approach has benefits. There are also many operational details to consider regardless of which general approach is taken, and proper interpretation of the methods requires a good understanding of the reagents used and the receptors expressed on basophils and a detailed understanding of the factors regulating aggregation of cell-surface IgE.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	MacGlashan, DW (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	dmacglas@jhmi.edu						AERTS NE, 2008, CYTOM PART B-CLIN CY, V76, P8; Amano T, 2001, J BIOCHEM-TOKYO, V129, P739, DOI 10.1093/oxfordjournals.jbchem.a002914; Apostolou E, 2006, ANAESTHESIA, V61, P264, DOI 10.1111/j.1365-2044.2005.04529.x; Aumuller E, 2003, INFLAMM RES, V52, P107, DOI 10.1007/s000110300022; Boumiza Radhia, 2005, Clin Mol Allergy, V3, P9, DOI 10.1186/1476-7961-3-9; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; Buhring HJ, 2004, INT ARCH ALLERGY IMM, V133, P317, DOI 10.1159/000077351; Buhring HJ, 1999, BLOOD, V94, P2343; Cady CT, 2010, IMMUNOL LETT, V130, P57, DOI 10.1016/j.imlet.2009.12.001; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Chen XN, 2013, INT ARCH ALLERGY IMM, V160, P251, DOI 10.1159/000341642; Chirumbolo Salvatore, 2008, Clin Mol Allergy, V6, P12, DOI 10.1186/1476-7961-6-12; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; COOPER AD, 1981, J BIOL CHEM, V256, P9379; Dahlen B, 2011, CLIN EXP ALLERGY, V41, P1091, DOI 10.1111/j.1365-2222.2011.03763.x; de Weck AL, 2008, INT ARCH ALLERGY IMM, V146, P177, DOI 10.1159/000115885; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Dvorak AM, 1996, BLOOD, V88, P4090; DVORAK AM, 1995, BLOOD, V86, P3560; DVORAK AM, 1983, FED PROC, V42, P2510; DVORAK AM, 1991, LAB INVEST, V64, P234; DVORAK AM, 1992, AM J PATHOL, V141, P1309; DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P8, DOI 10.1159/000236796; Dvorak AM, 1992, GRANULOCYTE RESPONSE, P169; Ebo DG, 2007, CLIN EXP ALLERGY, V37, P1668, DOI 10.1111/j.1365-2222.2007.02819.x; Ebo DG, 2012, J IMMUNOL METHODS, V375, P30, DOI 10.1016/j.jim.2011.09.003; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; FEWTRELL C, 1980, J IMMUNOL, V125, P701; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; Furuno T, 1996, BIOCHEM BIOPH RES CO, V219, P740, DOI 10.1006/bbrc.1996.0304; Gauvreau GM, 2005, J ALLERGY CLIN IMMUN, V116, P80, DOI 10.1016/j.jaci.2005.03.014; Gernez Y, 2011, INT ARCH ALLERGY IMM, V154, P318, DOI 10.1159/000321824; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Gober LM, 2007, J ALLERGY CLIN IMMUN, V119, P1181, DOI 10.1016/j.jaci.2007.01.008; GOLDSTEIN B, 1984, BIOPHYS J, V45, P1109, DOI 10.1016/S0006-3495(84)84259-9; Hamilton RG, 2010, IMMUNOL RES, V47, P273, DOI 10.1007/s12026-009-8160-3; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; Hennersdorf F, 2005, CELL RES, V15, P325, DOI 10.1038/sj.cr.7290301; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; KANE P, 1990, IMMUNOL INVEST, V19, P1, DOI 10.3109/08820139009042022; Kawakami T, 2005, J IMMUNOL, V175, P4167, DOI 10.4049/jimmunol.175.7.4167; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; KNAUER KA, 1984, INT ARCH ALLER A IMM, V74, P29, DOI 10.1159/000233511; Knol EF, 2012, ALLERGY, V67, P579, DOI 10.1111/j.1398-9995.2012.02816.x; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; Kraft S, 2005, J EXP MED, V201, P385, DOI 10.1084/jem.20042085; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; Liu ZJ, 2001, P NATL ACAD SCI USA, V98, P7289, DOI 10.1073/pnas.121171998; Lourenco FD, 2008, BRIT J DERMATOL, V158, P979, DOI 10.1111/j.1365-2133.2008.08499.x; MacGlashan D, 2003, J IMMUNOL, V170, P4914, DOI 10.4049/jimmunol.170.10.4914; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; MacGlashan D, 2012, J IMMUNOL METHODS, V385, P51, DOI 10.1016/j.jim.2012.08.006; MacGlashan D, 2012, INT ARCH ALLERGY IMM, V159, P243, DOI 10.1159/000332150; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; MacGlashan DW, 2012, J ALLERGY CLIN IMMUN, V130, P1130, DOI 10.1016/j.jaci.2012.05.038; MACGLASHAN DW, 1983, J IMMUNOL, V130, P4; MACGLASHAN DW, 1985, J IMMUNOL, V135, P4129; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MacGlashan Jr DW, CLIN EXP AL IN PRESS; MacGlashan Jr DW, 2013, J ALLERGY CLIN IMMUN; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MASINI E, 1994, IMMUNOPHARMACOLOGY, V28, P19, DOI 10.1016/0162-3109(94)90035-3; Matsuda K, 2005, J ALLERGY CLIN IMMUN, V116, P1357, DOI 10.1016/j.jaci.2005.08.042; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; Mitre E, 2004, J IMMUNOL, V172, P2439, DOI 10.4049/jimmunol.172.4.2439; Miura K, 1998, J ALLERGY CLIN IMMUN, V102, P512, DOI 10.1016/S0091-6749(98)70142-3; Monneret G, 2005, J PHARMACOL EXP THER, V312, P627, DOI 10.1124/jpet.104.074823; Nagao M, 2008, INT ARCH ALLERGY IMM, V146, P47, DOI 10.1159/000126061; Nopp A, 2007, ALLERGY, V62, P1175, DOI 10.1111/j.1398-9995.2007.01476.x; Nopp A, 2009, ALLERGY, V64, P811, DOI 10.1111/j.1398-9995.2008.01900.x; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OCHENSBERGER B, 1995, BLOOD, V86, P4039, DOI 10.1182/blood.V86.11.4039.bloodjournal86114039; Ocmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002; Oh K, 2007, BLOOD, V109, P2921, DOI 10.1182/blood-2006-07-037739; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Ono E, 2010, J ALLERGY CLIN IMMUN, V125, P483, DOI 10.1016/j.jaci.2009.10.074; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Sonneck K, 2008, INT J IMMUNOPATH PH, V21, P11, DOI 10.1177/039463200802100103; STALLMAN PJ, 1977, INT ARCH ALLER A IMM, V54, P114, DOI 10.1159/000231814; Sudheer PS, 2005, ANAESTHESIA, V60, P251, DOI 10.1111/j.1365-2044.2004.04086.x; Torrero MN, 2009, CLIN EXP ALLERGY, V39, P361, DOI 10.1111/j.1365-2222.2008.03154.x; Tschopp CM, 2006, BLOOD, V108, P2290, DOI 10.1182/blood-2006-03-010348; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Vasagar K, 2006, CLIN EXP ALLERGY, V36, P770, DOI 10.1111/j.1365-2222.2006.02494.x; Vilarino N, 2005, J IMMUNOL, V175, P3006, DOI 10.4049/jimmunol.175.5.3006; Vonakis BM, 2007, J ALLERGY CLIN IMMUN, V119, P441, DOI 10.1016/j.jaci.2006.09.035; Wantke F, 1999, J ALLERGY CLIN IMMUN, V103, P642, DOI 10.1016/S0091-6749(99)70237-X; WARNER JA, 1987, J IMMUNOL METHODS, V105, P107, DOI 10.1016/0022-1759(87)90419-4; Wiegand TW, 1996, J IMMUNOL, V157, P221; Yasnowsky KM, 2006, J ALLERGY CLIN IMMUN, V117, P1430, DOI 10.1016/j.jaci.2006.02.016; Yoshimura C, 2002, J ALLERGY CLIN IMMUN, V109, P817, DOI 10.1067/mai.2002.123532	101	93	95	1	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					777	787		10.1016/j.jaci.2013.06.038	http://dx.doi.org/10.1016/j.jaci.2013.06.038			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23958648				2022-12-18	WOS:000325096500001
J	Brough, HA; Santos, AF; Makinson, K; Penagos, M; Stephens, AC; Douiri, A; Fox, AT; Du Toit, G; Turcanu, V; Lack, G				Brough, Helen A.; Santos, Alexandra F.; Makinson, Kerry; Penagos, Martin; Stephens, Alick C.; Douiri, Abdel; Fox, Adam T.; Du Toit, George; Turcanu, Victor; Lack, Gideon			Peanut protein in household dust is related to household peanut consumption and is biologically active	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; sensitization; allergy; environment; dust; ELISA; biological activity; basophil activation test	RISK-FACTORS; INDOOR ALLERGENS; ORAL TOLERANCE; CHILDREN; SENSITIZATION; PREVALENCE; ASTHMA; EXPOSURE; FEATURES; ARA-H-2	Background: Peanut allergy is an important public health concern. To understand the pathogenesis of peanut allergy, we need to determine the route by which children become sensitized. A dose-response between household peanut consumption (HPC; used as an indirect marker of environmental peanut exposure) and the development of peanut allergy has been observed; however, environmental peanut exposure was not directly quantified. Objective: We sought to explore the relationship between reported HPC and peanut protein levels in an infant's home environment and to determine the biological activity of environmental peanut. Methods: Peanut protein was quantified in wipe and dust samples collected from 45 homes with infants by using a polyclonal peanut ELISA. Environmental peanut protein levels were compared with peanut consumption assessed by using a validated peanut food frequency questionnaire and other clinical and household factors. Biological activity of peanut protein in dust was assessed with a basophil activation assay. Results: There was a positive correlation between peanut protein levels in the infant's bed, crib rail, and play area and reported HPC over 1 and 6 months. On multivariate regression analysis, HPC was the most important variable associated with peanut protein levels in the infant's bed sheet and play area. Dust samples containing high peanut protein levels induced dose-dependent activation of basophils in children with peanut allergy. Conclusions: We have shown that an infant's environmental exposure to peanut is most likely to be due to HPC. Peanut protein in dust is biologically active and should be assessed as a route of possible early peanut sensitization in infants.	[Brough, Helen A.; Santos, Alexandra F.; Makinson, Kerry; Penagos, Martin; Stephens, Alick C.; Fox, Adam T.; Du Toit, George; Turcanu, Victor; Lack, Gideon] Kings Coll London, MRC, Dept Paediat Allergy, London, England; [Brough, Helen A.; Santos, Alexandra F.; Makinson, Kerry; Penagos, Martin; Stephens, Alick C.; Fox, Adam T.; Du Toit, George; Turcanu, Victor; Lack, Gideon] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, Div Asthma Allergy & Lung Biol, London, England; [Brough, Helen A.; Santos, Alexandra F.; Makinson, Kerry; Penagos, Martin; Stephens, Alick C.; Fox, Adam T.; Du Toit, George; Turcanu, Victor; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, London SE1 7EH, England; [Brough, Helen A.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Santos, Alexandra F.] Coimbra Univ Hosp, Immunoallergol Dept, Coimbra, Portugal; [Santos, Alexandra F.] Gulbenkian Programme Adv Med Educ, Lisbon, Portugal; [Douiri, Abdel] Kings Coll London, Dept Publ Hlth Sci, Sch Med, London, England	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Southampton; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); University of London; King's College London	Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, Childrens Allergy Unit, 2nd Floor,Stairwell B,South Wing,Westminster Brid, London SE1 7EH, England.	Gideon.lack@kcl.ac.uk	Fox, Adam/O-3547-2015	Fox, Adam/0000-0002-3533-9798; Santos, Alexandra/0000-0002-7805-1436; Du Toit, George/0000-0002-0321-2928; Douiri, Abdel/0000-0002-4354-4433; Lack, Gideon/0000-0001-7350-4021; Penagos, Martin/0000-0002-9488-194X	National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust; King's College London; Medical Research Council [G0902018]; Department of Health through the NIHR comprehensive Biomedical Research Centre award; King's College Hospital NHS Foundation Trust; Medical Research Council; Gulbenkian Programme for Advanced Medical Education; European Academy of Allergy and Clinical Immunology; Portuguese Society of Allergy and Clinical Immunology; Anaphylaxis Campaign; National Peanut Board; Sodilac; Novartis; Nestle Nutrition; GlaxoSmithKline; Serono Symposia International Foundation; MRC [G0902018] Funding Source: UKRI; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish	National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust; King's College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health through the NIHR comprehensive Biomedical Research Centre award; King's College Hospital NHS Foundation Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Gulbenkian Programme for Advanced Medical Education; European Academy of Allergy and Clinical Immunology; Portuguese Society of Allergy and Clinical Immunology; Anaphylaxis Campaign; National Peanut Board; Sodilac; Novartis(Novartis); Nestle Nutrition(Nestle SA); GlaxoSmithKline(GlaxoSmithKline); Serono Symposia International Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust and King's College London. The work of A.F.S. with basophil activation assays was also funded by the Medical Research Council (G0902018).; H. A. Brough, A. F. Santos, K. Makinson, A. C. Stephens, A. Douiri, and V. Turcanu have received research support from the Department of Health through the NIHR comprehensive Biomedical Research Centre award to Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. A. F. Santos has received research support from the Medical Research Council and the Gulbenkian Programme for Advanced Medical Education and has received travel support from the European Academy of Allergy and Clinical Immunology, the Portuguese Society of Allergy and Clinical Immunology, and the Gulbenkian Programme for Advanced Medical Education. G. Lack has received research support from the Department of Health through the NIHR comprehensive Biomedical Research Centre award to Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust; is on the DBV Technologies scientific advisory board; has received consultancy fees from the Anaphylaxis Campaign and National Peanut Board; has received lecture fees from Sodilac, Novartis, Nestle Nutrition, GlaxoSmithKline, and the Serono Symposia International Foundation; and has stock/options in DBV Technologies. The rest of the authors declare that they have no relevant conflicts of interest.	Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brough H, 2009, ALLERGY, V64, P543; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P623, DOI 10.1016/j.jaci.2013.02.035; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Chan SMH, 2012, ALLERGY, V67, P336, DOI 10.1111/j.1398-9995.2011.02765.x; Crawley H., 1994, FOOD PORTION SIZES F; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Dolle S, 2011, CLIN EXP ALLERGY, V41, P1643, DOI 10.1111/j.1365-2222.2011.03841.x; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; DYBENDAL T, 1994, ALLERGY, V49, P210, DOI 10.1111/j.1398-9995.1994.tb02651.x; Ebo DG, 2008, CYTOM PART B-CLIN CY, V74B, P201, DOI 10.1002/cyto.b.20419; Ewan PW, 1996, BRIT MED J, V312, P1074; Fox AT, 2006, S AFR J CLIN NUTR, V19, P154; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; King RM, 2009, ALLERGY, V64, P461, DOI 10.1111/j.1398-9995.2008.01843.x; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; McDermott RA, 2007, CLIN EXP ALLERGY, V37, P752, DOI 10.1111/j.1365-2222.2007.02701.x; Ocmant A, 2009, CLIN EXP ALLERGY, V39, P1234, DOI 10.1111/j.1365-2222.2009.03292.x; Palmer GW, 2005, CLIN IMMUNOL, V115, P302, DOI 10.1016/j.clim.2005.02.011; Park DL, 2005, J AOAC INT, V88, P156; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Poms RE, 2005, FOOD ADDIT CONTAM A, V22, P104, DOI 10.1080/02652030400027953; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Roy KM, 2011, CLIN PEDIATR, V50, P1045, DOI 10.1177/0009922811412584; Sabato V, 2011, J INVEST ALLERG CLIN, V21, P179; Sheehan WJ, 2012, J ALLERGY CLIN IMMUN, V129, pAB236, DOI 10.1016/j.jaci.2011.12.166; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sofianou K, 2011, WAO J, V4, P38; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Sudo N, 1997, J IMMUNOL, V159, P1739; Trucksess MW, 2004, J AOAC INT, V87, P943; WITTEMAN AM, 1995, INT ARCH ALLERGY IMM, V107, P566, DOI 10.1159/000237100	44	93	93	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					630	638		10.1016/j.jaci.2013.02.034	http://dx.doi.org/10.1016/j.jaci.2013.02.034			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23608730				2022-12-18	WOS:000323612000015
J	Mizesko, MC; Banerjee, PP; Monaco-Shawver, L; Mace, EM; Bernal, WE; Sawalle-Belohradsky, J; Belohradsky, BH; Heinz, V; Freeman, AF; Sullivan, KE; Holland, SM; Torgerson, TR; Al-Herz, W; Chou, J; Hanson, IC; Albert, MH; Geha, RS; Renner, ED; Orange, JS				Mizesko, Melissa C.; Banerjee, Pinaki P.; Monaco-Shawver, Linda; Mace, Emily M.; Bernal, William E.; Sawalle-Belohradsky, Julie; Belohradsky, Bernd H.; Heinz, Valerie; Freeman, Alexandra F.; Sullivan, Kathleen E.; Holland, Steven M.; Torgerson, Troy R.; Al-Herz, Waleed; Chou, Janet; Hanson, Imelda C.; Albert, Michael H.; Geha, Raif S.; Renner, Ellen D.; Orange, Jordan S.			Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DOCK8 deficiency; natural killer cells; actin; cytotoxicity; immunologic synapse	HYPER-IGE SYNDROME; IMMUNOLOGICAL SYNAPSE; DOCK8 DEFICIENCY; LYTIC GRANULES; F-ACTIN; CYTOTOXICITY; CDC42; POLARIZATION; MUTATIONS; TRANSPLANTATION	Background: Dedicator of cytokinesis 8 (DOCK8) mutations are responsible for a rare primary combined immunodeficiency syndrome associated with severe cutaneous viral infections, increased IgE levels, autoimmunity, and malignancy. Natural killer (NK) cells are essential for tumor surveillance and defense against virally infected cells. NK cell function relies on Wiskott-Aldrich syndrome protein for filamentous actin (F-actin) accumulation at the lytic NK cell immunologic synapse. DOCK8 activates cell division cycle 42, which, together with Wiskott-Aldrich syndrome protein, coordinates F-actin reorganization. Although abnormalities in T- and B-cell function have been described in DOCK8-deficient patients, the role of NK cells in this disease is unclear. Objectives: We sought to understand the role of DOCK8 in NK cell function to determine whether NK cell abnormalities explain the pathogenesis of the clinical syndrome of DOCK8 deficiency. Methods: A cohort of DOCK8-deficient patients was assembled, and patients' NK cells, as well as NK cell lines with stably reduced DOCK8 expression, were studied. NK cell cytotoxicity, F-actin content, and lytic immunologic synapse formation were measured. Results: DOCK8-deficient patients' NK cells and DOCK8 knockdown cell lines all had decreased NK cell cytotoxicity, which could not be restored after IL-2 stimulation. Importantly, DOCK8 deficiency impaired F-actin accumulation at the lytic immunologic synapse without affecting overall NK cell F-actin content. Conclusions: DOCK8 deficiency results in severely impaired NK cell function because of an inability to form a mature lytic immunologic synapse through targeted synaptic F-actin accumulation. This defect might underlie and explain important attributes of the DOCK8 deficiency clinical syndrome, including the unusual susceptibility to viral infection and malignancy. (J Allergy Clin Immunol 2013; 131:840-8.)	[Mizesko, Melissa C.; Banerjee, Pinaki P.; Mace, Emily M.; Hanson, Imelda C.; Orange, Jordan S.] Baylor Coll Med, Houston, TX 77030 USA; [Mizesko, Melissa C.; Banerjee, Pinaki P.; Mace, Emily M.; Hanson, Imelda C.; Orange, Jordan S.] Texas Childrens Hosp, Houston, TX 77030 USA; [Monaco-Shawver, Linda; Bernal, William E.; Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA USA; [Sawalle-Belohradsky, Julie; Belohradsky, Bernd H.; Heinz, Valerie; Albert, Michael H.; Renner, Ellen D.] Univ Munich, Univ Childrens Hosp, Munich, Germany; [Freeman, Alexandra F.; Holland, Steven M.] NIAID, NIH, Bethesda, MD 20892 USA; [Torgerson, Troy R.] Univ Washington, Seattle, WA 98195 USA; [Torgerson, Troy R.] Seattle Childrens Hosp, Seattle, WA USA; [Al-Herz, Waleed] Kuwait Univ, Dept Pediat, Fac Med, Kuwait, Kuwait; [Chou, Janet; Geha, Raif S.] Boston Childrens Hosp, Boston, MA USA	Baylor College of Medicine; Baylor College of Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle; Seattle Children's Hospital; Kuwait University; Harvard University; Boston Children's Hospital	Orange, JS (corresponding author), Texas Childrens Hosp, Baylor Coll Med, 1102 Bates Ave,Suite 330, Houston, TX 77030 USA.	orange@bcm.edu	Renner, Ellen/R-7168-2016	Renner, Ellen/0000-0001-9816-8538; Sullivan, Kathleen/0000-0003-4018-1646; Mace, Emily/0000-0003-0226-7393; orange, jordan/0000-0001-7117-7725	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases [R01067946]; German Research Foundation [DFG RE2799/3-1]; Fritz-Thyssen research foundation [Az. 10.07.1.159]; Dubai-Harvard Foundation of Medical Research; Jeffrey Modell Foundation; National Institutes of Health (NIH); Fritz-Thyssen Foundation;  [5P01AI076210-04];  [5R03AI094017-02]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, R01AI100315, R01AI067946, R56AI067946, R03AI094017] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); German Research Foundation(German Research Foundation (DFG)); Fritz-Thyssen research foundation; Dubai-Harvard Foundation of Medical Research; Jeffrey Modell Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fritz-Thyssen Foundation; ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases grant R01067946 (to J.S.O.), the German Research Foundation (DFG RE2799/3-1) and a Fritz-Thyssen research foundation grant (Az. 10.07.1.159; to E. D. R.); and the Dubai-Harvard Foundation of Medical Research, the Jeffrey Modell Foundation, "Role of TACI Mutations in CVID," 5P01AI076210-04, NIH, and "Combined SNP analysis and whole genome sequencing to discover immunodeficiency genes," 5R03AI094017-02, NIH (to R.S.G.).; Disclosure of potential conflict of interest: M. C. Mizesko has received grants from the National Institutes of Health (NIH). L. Monaco-Shawver has received grants from the NIH. T. R. Torgerson has consulted for Baxter Biosciences; has grants/grants pending from Baxter Biosciences and CSL Behring; has received payment for lectures, including service on speakers' bureaus for Baxter Biosciences; has received royalties from New England Biolabs; and has received payment for development of Educational Presentations from Baxter Biosciences. J. Chou is employed by Boston Children's Hospital and has grants/grants pending from the NIH. R. S. Geha has received grants from the NIH. E. D. Renner has received grant money from DFG and the Fritz-Thyssen Foundation. J. S. Orange has received grants from the NIH; has consulted for Baxter Biosciences on lg therapies, CSL Bhering on lg therapies, Grifols on lg therapies, Octapharma USA on the Grants Review Committee, Cangene on lg therapy, and IBT reference laboratories on immunology; has received payment for lectures, including service on speakers' bureaus for Baxter Healthcare; has received royalties from Unimed Publishers for a book on immunoglobulins; and has received payment for development of educational presentations from CSL Bhering for a presentation on lg therapy. The rest of the authors declare that they have no relevant conflicts of interest.	Al-Herz W, 2012, CLIN IMMUNOL, V143, P266, DOI 10.1016/j.clim.2012.03.002; Banerjee PP, 2007, J EXP MED, V204, P2305, DOI 10.1084/jem.20061893; Banerjee PP, 2010, J IMMUNOL METHODS, V355, P1, DOI 10.1016/j.jim.2010.02.003; Barlogis V, 2011, J ALLERGY CLIN IMMUN, V128, P420, DOI 10.1016/j.jaci.2011.03.025; Bittner TC, 2010, KLIN PADIATR, V222, P351, DOI 10.1055/s-0030-1265135; Bryceson YT, 2011, J INNATE IMMUN, V3, P327, DOI 10.1159/000327015; Bryceson YT, 2011, J INNATE IMMUN, V3, P213, DOI 10.1159/000325332; Chu EY, 2012, ARCH DERMATOL, V148, P79, DOI 10.1001/archdermatol.2011.262; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Fehniger TA, 2007, IMMUNITY, V26, P798, DOI 10.1016/j.immuni.2007.04.010; Freeman AF, 2010, DIS MARKERS, V29, P123, DOI [10.1155/2010/580197, 10.3233/DMA-2010-0734]; Gismondi A, 2004, BLOOD, V104, P436, DOI 10.1182/blood-2003-07-2621; Harada Y, 2012, BLOOD, V119, P4451, DOI 10.1182/blood-2012-01-407098; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Lambe T, 2011, EUR J IMMUNOL, V41, P3423, DOI 10.1002/eji.201141759; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; McDonald DR, 2010, J ALLERGY CLIN IMMUN, V126, P1304, DOI 10.1016/j.jaci.2010.07.034; Orange JS, 2006, CURR OPIN ALLERGY CL, V6, P399, DOI 10.1097/ACI.0b013e3280106b65; Orange JS, 2011, J CLIN INVEST, V121, P1535, DOI 10.1172/JCI44862; Orange JS, 2002, MICROBES INFECT, V4, P1545, DOI 10.1016/S1286-4579(02)00038-2; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Randall KL, 2010, DIS MARKERS, V29, P141, DOI [10.1155/2010/143612, 10.3233/DMA-2010-0739]; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Ruusala A, 2004, FEBS LETT, V572, P159, DOI 10.1016/j.febslet.2004.06.095; Sanborn KB, 2011, BLOOD, V118, P5862, DOI 10.1182/blood-2011-03-344846; Sanborn KB, 2009, J IMMUNOL, V182, P6969, DOI 10.4049/jimmunol.0804337; Sinai P, 2010, P NATL ACAD SCI USA, V107, P11912, DOI 10.1073/pnas.0913422107; Stabile H, 2010, BLOOD, V115, P2818, DOI 10.1182/blood-2009-07-235804; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Tskvitaria-Fuller I, 2006, J IMMUNOL, V177, P1708, DOI 10.4049/jimmunol.177.3.1708; Young HA, 2006, CELL RES, V16, P20, DOI 10.1038/sj.cr.7310004; Zhang Q, 2011, CURR OPIN PEDIATR, V23, P653, DOI 10.1097/MOP.0b013e32834c7f65; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	38	93	94	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					840	848		10.1016/j.jaci.2012.12.1568	http://dx.doi.org/10.1016/j.jaci.2012.12.1568			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23380217	Green Accepted			2022-12-18	WOS:000315587800028
J	Gill, MA				Gill, Michelle Ann			The role of dendritic cells in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Dendritic cells; asthma; allergen; T(H)2 inflammation	ALLERGIC AIRWAY INFLAMMATION; HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; VIRAL RESPIRATORY-INFECTIONS; BRONCHIAL EPITHELIAL-CELLS; EPSILON-F-RI; INHALED ANTIGEN; T-CELLS; IMMUNE-RESPONSES; INTERFERON-ALPHA	Dendritic cells (DCs) are known to play a central role in sensing the presence of foreign antigens and infectious agents and in initiating appropriate immune responses. More recently, an additional role has been discovered for DCs in determining whether the response to potential environmental allergens will be one of tolerance or whether a vigorous response along allergic pathways will be initiated. This review discusses ways in which DCs participate specifically in initiating allergic responses, particularly those associated with allergic asthma, and how interventions focused on DCs might lead to new therapeutic approaches to asthma. (J Allergy Clin Immunol 2012;129:889-901.)	Univ Texas SW Med Ctr Dallas, Dept Pediat, Div Infect Dis, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Gill, MA (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pediat, Div Infect Dis, 5323 Harry Hines Blvd,Mail Code 9063, Dallas, TX 75390 USA.	Michelle.Gill@UTSouthwestern.edu						Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Bates EEM, 1998, MOL IMMUNOL, V35, P513, DOI 10.1016/S0161-5890(98)00045-5; Beaty SR, 2007, J IMMUNOL, V178, P1882, DOI 10.4049/jimmunol.178.3.1882; Bleck B, 2006, J IMMUNOL, V176, P7431, DOI 10.4049/jimmunol.176.12.7431; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Bratke K, 2007, THORAX, V62, P168, DOI 10.1136/thx.2006.067793; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cataldo D, 2001, ALLERGY, V56, P145, DOI 10.1034/j.1398-9995.2001.056002145.x; Condon TV, 2011, J LEUKOCYTE BIOL, V90, P883, DOI 10.1189/jlb.0311134; Day SB, 2012, J INNATE IMMUN, V4, P100, DOI 10.1159/000329132; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; del Rio ML, 2007, J IMMUNOL, V178, P6861, DOI 10.4049/jimmunol.178.11.6861; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; English K, 2006, IMMUNOL LETT, V103, P92, DOI 10.1016/j.imlet.2005.09.011; Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; FOKKENS WJ, 1989, ALLERGY, V44, P167, DOI 10.1111/j.1398-9995.1989.tb02257.x; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; Gill MA, 2005, J INFECT DIS, V191, P1105, DOI 10.1086/428589; Gill MA, 2008, J INFECT DIS, V198, P1667, DOI 10.1086/593018; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Gogolak P, 2007, BLOOD, V109, P643, DOI 10.1182/blood-2006-04-016840; GONG JL, 1992, J EXP MED, V175, P797, DOI 10.1084/jem.175.3.797; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Grayson MH, 2007, J IMMUNOL, V179, P1438, DOI 10.4049/jimmunol.179.3.1438; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Grinnan D, 2006, J ALLERGY CLIN IMMUN, V118, P1234, DOI 10.1016/j.jaci.2006.07.036; Hammad H, 2011, ALLERGY, V66, P579, DOI 10.1111/j.1398-9995.2010.02528.x; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hintzen G, 2006, J IMMUNOL, V177, P7346, DOI 10.4049/jimmunol.177.10.7346; Holgate ST, 2011, J ALLERGY CLIN IMMUN, V128, P495, DOI 10.1016/j.jaci.2011.06.052; HOLT PG, 1987, IMMUNOLOGY, V62, P349; Huber JP, 2011, IMMUNOLOGY, V132, P466, DOI 10.1111/j.1365-2567.2011.03412.x; Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Isaksen DE, 2002, J IMMUNOL, V168, P3288, DOI 10.4049/jimmunol.168.7.3288; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kessel CHG, 2008, MUCOSAL IMMUNOL, V1, P442, DOI 10.1038/mi.2008.39; King C, 1998, J IMMUNOL, V161, P3645; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Kuipers H, 2009, J LEUKOCYTE BIOL, V85, P64, DOI 10.1189/jlb.0807519; Lambrecht BN, 2010, LANCET, V376, P835, DOI 10.1016/S0140-6736(10)61226-3; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 1999, AM J RESP CELL MOL, V20, P1165, DOI 10.1165/ajrcmb.20.6.3484; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Lewkowich IP, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-122; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Lommatzsch M, 2007, EUR RESPIR J, V30, P878, DOI 10.1183/09031936.00036307; Maneachotesuwan K, 2009, J ALLERGY CLIN IMMUN, V123, P239, DOI 10.1016/j.jaci.2008.10.018; Masten BJ, 2006, J IMMUNOL, V177, P7784, DOI 10.4049/jimmunol.177.11.7784; Mautino G, 1999, LAB INVEST, V79, P39; MCWILLIAM AS, 1995, IMMUNOL CELL BIOL, V73, P405, DOI 10.1038/icb.1995.63; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; Moschen AR, 2008, IMMUNOBIOLOGY, V213, P779, DOI 10.1016/j.imbio.2008.07.022; Muller T, 2011, AM J RESP CELL MOL, V44, P456, DOI 10.1165/rcmb.2010-0129OC; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nakano H, 2012, MUCOSAL IMMUNOL, V5, P53, DOI 10.1038/mi.2011.47; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; Robays LJ, 2007, J IMMUNOL, V178, P5305, DOI 10.4049/jimmunol.178.8.5305; Rusznak C, 2001, CLIN EXP ALLERGY, V31, P226, DOI 10.1046/j.1365-2222.2001.01000.x; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Schroeder JT, 2010, J ALLERGY CLIN IMMUN, V125, P896, DOI 10.1016/j.jaci.2009.10.021; Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724; SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436; So T, 2006, P NATL ACAD SCI USA, V103, P3740, DOI 10.1073/pnas.0600205103; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Strickland DH, 2010, CURR OPIN IMMUNOL, V22, P789, DOI 10.1016/j.coi.2010.10.019; Sung SSJ, 2001, J IMMUNOL, V166, P1261, DOI 10.4049/jimmunol.166.2.1261; Sung SSJ, 2006, J IMMUNOL, V176, P2161, DOI 10.4049/jimmunol.176.4.2161; Szefler SJ, 2011, J ALLERGY CLIN IMMUN, V128, P485, DOI 10.1016/j.jaci.2011.07.010; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; Upham JW, 2002, CLIN EXP ALLERGY, V32, P818, DOI 10.1046/j.1365-2222.2002.01375.x; van den Berge M, 2004, J ALLERGY CLIN IMMUN, V114, P737, DOI 10.1016/j.jaci.2004.05.071; van Rijt LS, 2011, AM J RESP CRIT CARE, V184, P303, DOI 10.1164/rccm.201101-0019OC; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Vermaelen KY, 2003, J IMMUNOL, V171, P1016, DOI 10.4049/jimmunol.171.2.1016; von Garnier C, 2005, J IMMUNOL, V175, P1609, DOI 10.4049/jimmunol.175.3.1609; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wikstrom ME, 2007, IMMUNOL CELL BIOL, V85, P182, DOI 10.1038/sj.icb.7100039; Wills-Karp M, 2000, IMMUNOPHARMACOLOGY, V48, P263, DOI 10.1016/S0162-3109(00)00223-X; Xu H, 2008, P NATL ACAD SCI USA, V105, P6690, DOI 10.1073/pnas.0708809105; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183	113	93	99	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					889	901		10.1016/j.jaci.2012.02.028	http://dx.doi.org/10.1016/j.jaci.2012.02.028			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22464668				2022-12-18	WOS:000302144600002
J	Sanchez-Garcia, S; del Rio, PR; Escudero, C; Martinez-Gomez, MJ; Ibanez, MD				Sanchez-Garcia, Silvia; Rodriguez del Rio, Pablo; Escudero, Carmelo; Jose Martinez-Gomez, M.; Dolores Ibanez, M.			Possible eosinophilic esophagitis induced by milk oral immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN; ALLERGY		[Sanchez-Garcia, Silvia; Rodriguez del Rio, Pablo; Escudero, Carmelo; Dolores Ibanez, M.] Hosp Infantil Univ Nino Jesus, Dept Allergy, Madrid, Spain; [Jose Martinez-Gomez, M.] Hosp Infantil Univ Nino Jesus, Dept Gastroenterol, Madrid, Spain		Sanchez-Garcia, S (corresponding author), Hosp Infantil Univ Nino Jesus, Dept Allergy, Madrid, Spain.	ssanchez@salud.madrid.org	del Rio, Pablo Rodriguez/P-6184-2019; Escudero, Carmelo/B-5197-2017	del Rio, Pablo Rodriguez/0000-0002-0783-1988; Escudero, Carmelo/0000-0003-2157-8699				Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P555, DOI 10.1016/j.jaci.2011.01.029; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Martorell A, 2011, CLIN EXP ALLERGY, V41, P1297, DOI 10.1111/j.1365-2222.2011.03749.x; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; Ridolo E, 2011, ANN ALLERG ASTHMA IM, V106, P73, DOI 10.1016/j.anai.2010.10.010; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030	9	93	95	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1155	1157		10.1016/j.jaci.2011.11.042	http://dx.doi.org/10.1016/j.jaci.2011.11.042			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22236725				2022-12-18	WOS:000302144600037
J	Cakebread, JA; Xu, YH; Grainge, C; Kehagia, V; Howarth, PH; Holgate, ST; Davies, DE				Cakebread, Julie A.; Xu, Yunhe; Grainge, Chris; Kehagia, Valia; Howarth, Peter H.; Holgate, Stephen T.; Davies, Donna E.			Exogenous IFN-beta has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate immunity; picornaviridae infections; type I interferons; asthma exacerbation	DOUBLE-STRANDED-RNA; NF-KAPPA-B; INTRANASAL INTERFERON-ALPHA-2; VIRAL-INFECTIONS; PROPHYLACTIC EFFICACY; AIRWAY DISEASES; GENE-EXPRESSION; IN-VITRO; EXACERBATIONS; VIRUSES	Background: Rhinoviruses are the major cause of asthma exacerbations. Previous studies suggest that primary bronchial epithelial cells (PBECs) from asthmatic subjects are more susceptible to rhinovirus infection because of deficient IFN-beta production. Although augmenting the innate immune response might provide a novel approach for treatment of virus-induced asthma exacerbations, the potential of IFN-beta to modulate antiviral and proinflammatory responses in asthmatic epithelium is poorly characterized. Objectives: We sought to compare responses of PBECs from nonasthmatic and asthmatic subjects to exogenous IFN-beta and test the inflammatory effects of IFN-beta in response to rhinovirus infection. Methods: PBECs were treated with IFN-beta and infected with a low inoculum of human rhinovirus serotype 1B to simulate a natural viral infection. Expression of interferon-responsive genes and inflammatory responses were analyzed by using reverse transcription-quantitative real-time PCR, cytometric bead arrays, or both; viral titers were assessed by using the 50% tissue culture infection dose. Results: Expression of IFN-beta-stimulated antiviral genes was comparable in PBECs from nonasthmatic or asthmatic donors. Exogenous IFN-beta significantly protected PBECs from asthmatic donors against rhinovirus infection by suppressing viral replication. Interferon-inducible protein 10 (IP-10), RANTES, and IL-6 release in response to rhinovirus infection was triggered only in PBECs from asthmatic donors. Although exogenous IFN-beta alone stimulated some release of IP-10 (but not IL-6 or RANTES), it significantly reduced rhinovirus-induced IP-10, RANTES, and IL-6 expression when tested in combination with rhinovirus. Conclusions: PBECs from asthmatic donors have a normal antiviral response to exogenous IFN-beta. The ability of IFN-beta to suppress viral replication suggests that it might limit virus-induced exacerbations by shortening the duration of the inflammatory response. (J Allergy Clin Immunol 2011;127:1148-54.)	[Davies, Donna E.] Southampton Gen Hosp, Sir Henry Wellcome Labs, Natl Inst Hlth Res, Resp Biomed Res Unit, Southampton SO16 6YD, Hants, England; Univ Southampton, Div Infect Inflammat & Immun, Sch Med, Southampton, Hants, England	University of Southampton; University of Southampton	Davies, DE (corresponding author), Southampton Gen Hosp, Sir Henry Wellcome Labs, Natl Inst Hlth Res, Resp Biomed Res Unit, Mailpoint 810,South Block, Southampton SO16 6YD, Hants, England.	D.E.Davies@soton.ac.uk	Davies, Donna E/H-2993-2012	Grainge, Christopher/0000-0002-6565-9928; Howarth, Peter/0000-0003-0619-7927; Davies, Donna/0000-0002-5117-2991; Cakebread, Julie/0000-0001-5937-6705	Asthma UK; Medical Research Council (UK); GlaxoSmithKline; Allergopharma; Medical Research Council [G19/34, G0501506, G0800766] Funding Source: researchfish; Asthma UK [06/053] Funding Source: researchfish; MRC [G19/34, G0501506, G0800766] Funding Source: UKRI	Asthma UK; Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); GlaxoSmithKline(GlaxoSmithKline); Allergopharma; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by Asthma UK and the Medical Research Council (UK).; Disclosure of potential conflict of interest: P. H. Howarth has received research support from GlaxoSmithKline and Allergopharma. S. T. Holgate is a consultant and nonexecutive director for and a shareholder of Synairgen. D. E. Davies is a shareholder in and a consultant for Synairgen. The rest of the authors have declared that they have no conflict of interest.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bossios A, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-114; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179, DOI 10.1165/ajrcmb.27.2.4699; Chen Y, 2006, AM J RESP CELL MOL, V34, P192, DOI 10.1165/rcmb.2004-0417OC; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; DOUGLAS RM, 1986, NEW ENGL J MED, V314, P65, DOI 10.1056/NEJM198601093140201; FARR BM, 1984, ANTIMICROB AGENTS CH, V26, P31, DOI 10.1128/AAC.26.1.31; Grunberg K, 2001, AM J RESP CRIT CARE, V164, P1816; Hansbro NG, 2008, PHARMACOL THERAPEUT, V117, P313, DOI 10.1016/j.pharmthera.2007.11.002; HAYDEN FG, 1985, ANTIVIR RES, V5, P111, DOI 10.1016/0166-3542(85)90037-3; HAYDEN FG, 1986, NEW ENGL J MED, V314, P71, DOI 10.1056/NEJM198601093140202; HAYDEN FG, 1988, ANTIMICROB AGENTS CH, V32, P224, DOI 10.1128/AAC.32.2.224; HAYDEN FG, 1984, J INFECT DIS, V150, P174, DOI 10.1093/infdis/150.2.174; HAYDEN FG, 1983, J INFECT DIS, V148, P543, DOI 10.1093/infdis/148.3.543; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; ISAACS A, 1987, J INTERFERON RES, V7, P429, DOI 10.1089/jir.1987.7.429; Jackson DJ, 2010, J ALLERGY CLIN IMMUN, V125, P1178, DOI 10.1016/j.jaci.2010.04.021; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Krasnowska Maryla, 1992, Archivum Immunologiae et Therapiae Experimentalis, V40, P75; Kumar A, 2009, ANN ALLERG ASTHMA IM, V103, P181, DOI 10.1016/S1081-1206(10)60178-0; Leung TF, 2010, CHEST, V137, P348, DOI 10.1378/chest.09-1250; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Mallia P, 2006, CHEST, V130, P1203, DOI 10.1378/chest.130.4.1203; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; MONTO AS, 1986, J INFECT DIS, V154, P128, DOI 10.1093/infdis/154.1.128; Monto AS, 2002, AM J MED, V112, p4S; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Proud D, 2008, AM J RESP CRIT CARE, V178, P962, DOI 10.1164/rccm.200805-670OC; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; SPERBER SJ, 1988, J INFECT DIS, V158, P166, DOI 10.1093/infdis/158.1.166; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; Stark GR, 2007, CYTOKINE GROWTH F R, V18, P419, DOI 10.1016/j.cytogfr.2007.06.013; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takeuchi O, 2008, CURR OPIN IMMUNOL, V20, P17, DOI 10.1016/j.coi.2008.01.002; Uller L, 2010, THORAX, V65, P626, DOI 10.1136/thx.2009.125930; Virgolini I, 1997, J NUCL MED, V38, P1475; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; WISELKA MJ, 1991, THORAX, V46, P706, DOI 10.1136/thx.46.10.706	48	93	97	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1148	U416		10.1016/j.jaci.2011.01.023	http://dx.doi.org/10.1016/j.jaci.2011.01.023			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21329968				2022-12-18	WOS:000290018600008
J	DeLong, JH; Simpson, KH; Wambre, E; James, EA; Robinson, D; Kwok, WW				DeLong, Jonathan H.; Simpson, Kelly Hetherington; Wambre, Erik; James, Eddie A.; Robinson, David; Kwok, William W.			Ara h 1-reactive T cells in individuals with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut; Ara h 1; T cells; class II tetramers	EX-VIVO ANALYSIS; DIFFERENTIAL EXPRESSION; TH2 CELLS; RESPONSES; IDENTIFICATION; CHILDREN	Background: Effective immunotherapy for peanut allergy is hampered by a lack of understanding of peanut-reactive CD4(+) T cells. Objective: To identify, characterize, and track Ara h 1-reactive cells in subjects with peanut allergy by using Ara h 1-specific class II tetramers. Methods: Tetramer-guided epitope mapping was used to identify the antigenic peptides within the peanut allergen Ara h 1. Subsequently, HLA class II/Ara h 1-specific tetramers were used to determine the frequency and phenotype of Ara h 1-reactive T cells in subjects with peanut allergy. Cytokine profiles of Ara h 1-reactive T cells were also determined. Results: Multiple Ara h 1 epitopes with defined HLA restriction were identified. Ara h 1-specific CD4(+) T cells were detected in all of the subjects with peanut allergy tested. Ara h 1-reactive T cells in subjects with allergy expressed CCR4 but did not express CRTH2. The percentage of Ara h1-reactive cells that expressed the beta 7 integrin was low compared with total CD4(+) T cells. Ara h 1-reactive cells that secreted IFN-gamma, IL-4, IL-5, IL-10, and IL-17 were detected. Conclusion: In individuals with peanut allergy, Ara h 1-reactive T cells occurred at moderate frequencies, were predominantly CCR4(+) memory cells, and produced IL-4. Class II tetramers can be readily used to detect Ara h 1-reactive T cells in the peripheral blood of subjects with peanut allergy without in vitro expansion and would be effective for tracking peanut-reactive CD4(+) T cells during immunotherapy. (J Allergy Clin Immunol 2011;127:1211-8.)	[DeLong, Jonathan H.; Wambre, Erik; James, Eddie A.; Kwok, William W.] Virginia Mason, Benaroya Res Inst, Seattle, WA 98101 USA; [Robinson, David] Virginia Mason Med Ctr, Seattle, WA 98101 USA; [Simpson, Kelly Hetherington] Univ Washington, Dept Med, Allergy Sect, Seattle, WA USA; [Kwok, William W.] Univ Washington, Dept Immunol, Seattle, WA 98195 USA	Benaroya Research Institute; Virginia Mason Medical Center; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kwok, WW (corresponding author), Virginia Mason, Benaroya Res Inst, 1201 9th Ave, Seattle, WA 98101 USA.	bkwok@benaroyaresearch.org	James, Eddie/V-4929-2019	James, Eddie/0000-0002-7217-5729	NIH [HHSN272200700046C]; NIH/NIAID	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by NIH contract HHSN272200700046C.; Disclosure of potential conflict of interest: D. Robinson and W. W. Kwok receive research support from the NIH/NIAID. The rest of the authors have declared that they have no conflict of interest.	BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Codreanu F, 2011, INT ARCH ALLERGY IMM, V154, P216, DOI 10.1159/000321108; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; Flinterman AE, 2010, CLIN EXP ALLERGY, V40, P590, DOI 10.1111/j.1365-2222.2009.03431.x; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kinnunen T, 2010, EUR J IMMUNOL, V40, P2460, DOI 10.1002/eji.201040328; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Kwok WW, 2010, J ALLERGY CLIN IMMUN, V125, P1407, DOI 10.1016/j.jaci.2010.03.037; Nagata K, 1999, J IMMUNOL, V162, P1278; Nakagome K, 2009, J IMMUNOL, V183, P209, DOI 10.4049/jimmunol.0802712; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Novak EJ, 2001, J IMMUNOL, V166, P6665, DOI 10.4049/jimmunol.166.11.6665; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Oseroff C, 2010, J IMMUNOL, V185, P943, DOI 10.4049/jimmunol.1000405; PICKER LJ, 1990, J IMMUNOL, V145, P3247; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Scurlock AM, 2004, ANN ALLERG ASTHMA IM, V93, pS12, DOI 10.1016/S1081-1206(10)61727-9; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Stephens R, 2002, J IMMUNOL, V169, P5458, DOI 10.4049/jimmunol.169.10.5458; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010	31	93	106	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1211	U503		10.1016/j.jaci.2011.02.028	http://dx.doi.org/10.1016/j.jaci.2011.02.028			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21459424	Green Accepted			2022-12-18	WOS:000290018600016
J	Di Bona, D; Plaia, A; Scafidi, V; Leto-Barone, MS; Di Lorenzo, G				Di Bona, Danilo; Plaia, Antonella; Scafidi, Valeria; Leto-Barone, Maria Stefania; Di Lorenzo, Gabriele			Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Sublingual immunotherapy; rhinitis; grass; meta-analysis	STANDARDIZED 5-GRASS-POLLEN EXTRACT; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; CLINICAL-EFFICACY; POLLEN EXTRACT; SAFETY; CHILDREN; TABLETS	Background: The benefit of sublingual immunotherapy (SLIT) with grass allergens for seasonal allergic rhinitis has been extensively studied, but data on efficacy are still equivocal. Objective: To assess the effectiveness of SLIT with grass allergens in the reduction of symptoms and medication in patients with seasonal allergic rhinitis to grass pollen. Methods: Computerized bibliographic searches of MEDLINE (1995-2010) were supplemented by hand searches of reference lists. Studies were included if they were double-blind randomized controlled trials (RCTs) comparing SLIT to placebo and if they included patients with history of allergy to grass pollen treated with natural grass pollen extracts. Nineteen RCTs with 2971 patients were analyzed. The outcomes assessed were symptom and medication scores. Results: Using a random-effects model, SLIT with grass allergens significantly reduces both symptoms (standardized mean difference, -0.32; 95% CI, -0.44 to -0.21) and medication use (standardized mean difference, -0.33; 95% CI, -0.50 to -0.16) compared with placebo. The treatment is more efficacious in adults than in children. Prolonging duration of preseasonal treatment for more than 12 weeks improves the treatment efficacy. Conclusion: This meta-analysis found that SLIT with grass allergens is effective in patients with seasonal allergic rhinitis compared with placebo. The benefit is clinically modest, and criteria are needed to identify patients most likely to benefit from SLIT. (J Allergy Clin Immunol 2010;126:558-66.)	[Leto-Barone, Maria Stefania; Di Lorenzo, Gabriele] Univ Palermo, Dipartimento Med Clin & Patol Emergenti, I-90127 Palermo, Italy; [Di Bona, Danilo; Scafidi, Valeria] Univ Palermo, CNR, Dipartimento Biopatol & Metodol Biomed, I-90127 Palermo, Italy; [Plaia, Antonella] Univ Palermo, CNR, Dipartimento Sci Stat & Matemat, I-90127 Palermo, Italy; [Scafidi, Valeria] Univ Palermo, CNR, Ist Biomed & Immunol Mol, I-90127 Palermo, Italy; [Di Bona, Danilo] Azienda Osped Univ Policlin Palermo, Unita Operat Immunoematol & Med Trasfus, Palermo, Italy	University of Palermo; Consiglio Nazionale delle Ricerche (CNR); University of Palermo; Consiglio Nazionale delle Ricerche (CNR); University of Palermo; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); University of Palermo	Di Lorenzo, G (corresponding author), Univ Palermo, Dipartimento Med Clin & Patol Emergenti, Via Vespro 141, I-90127 Palermo, Italy.	dilo601@unipa.it	Plaia, Antonella/K-2462-2015	Plaia, Antonella/0000-0001-7811-2430; Di Lorenzo, Gabriele/0000-0002-0197-5665				Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Cochard MM, 2009, J ALLERGY CLIN IMMUN, V124, P378, DOI 10.1016/j.jaci.2009.04.040; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P451, DOI 10.1016/S1081-1206(10)60259-1; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; De Blay F, 2007, ANN ALLERG ASTHMA IM, V99, P453, DOI 10.1016/S1081-1206(10)60571-6; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2007, ALLERGY, V62, P954, DOI 10.1111/j.1398-9995.2007.01402.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Durham SR, 2008, CURR OPIN ALLERGY CL, V8, P577, DOI 10.1097/ACI.0b013e3283196764; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Horak F, 2009, CLIN EXP ALLERGY, V39, P394, DOI 10.1111/j.1365-2222.2008.03153.x; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Incorvaia C, 2010, J ALLERGY CLIN IMMUN, V125, P277, DOI 10.1016/j.jaci.2009.10.033; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Malling HJ, 2009, CLIN EXP ALLERGY, V39, P387, DOI 10.1111/j.1365-2222.2008.03152.x; Mosges R, 2007, ACTA DERMATOVEN ALP, V16, P143; Moreno-Ancillo A, 2007, J INVEST ALLERG CLIN, V17, P399; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2008.01875.x, 10.1111/j.1398-9995.2009.02194.x]; Palma-Carlos A G, 2006, Allergol Immunopathol (Madr), V34, P194, DOI 10.1157/13094026; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Pfaar O, 2008, ANN ALLERG ASTHMA IM, V100, P256, DOI 10.1016/S1081-1206(10)60451-6; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; R Core Team, 2017, R LANGUAGE ENVIRONME; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, pS142, DOI 10.1016/j.jaci.2007.12.1105; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; Schwarzer G., 2010, META METAANALYSIS R; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Stelmach I, 2009, CLIN EXP ALLERGY, V39, P401, DOI 10.1111/j.1365-2222.2008.03159.x; Viechtbauer W., 2010, METAFOR METAANALYSIS; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Worm M, 2006, Eur Ann Allergy Clin Immunol, V38, P355; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305	49	93	94	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					558	566		10.1016/j.jaci.2010.06.013	http://dx.doi.org/10.1016/j.jaci.2010.06.013			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20674964				2022-12-18	WOS:000281512500023
J	Tieu, DD; Peters, AT; Carter, RT; Suh, L; Conley, DB; Chandra, R; Norton, J; Grammer, LC; Harris, KE; Kato, A; Kern, RC; Schleimer, RP				Tieu, David D.; Peters, Anju T.; Carter, Roderick T.; Suh, Lydia; Conley, David B.; Chandra, Rakesh; Norton, James; Grammer, Leslie C.; Harris, Kathleen E.; Kato, Atsushi; Kern, Robert C.; Schleimer, Robert P.			Evidence for diminished levels of epithelial psoriasin and calprotectin in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; S100A7; S100A8/A9; psoriasin; calprotectin; epithelium; barrier; epidermal differentiation complex	PROTEIN PSORIASIN; NASAL POLYPS; EXPRESSION; S100A7; DIFFERENTIATION; GENES; SKIN; DISRUPTION; INFECTION; DISEASES	Background: Decreased epithelial expression of mRNA for S100A7 (psoriasin) and S100A8/A9 (calprotectin) has been reported in patients with chronic rhinosinusitis (CRS). Objectives: We sought to assess whether the expression of S100 proteins is also altered in the sinonasal cavity of patients with CRS. Methods: We determined levels of S100 proteins in nasal lavage fluid and sinonasal tissue extracts from patients with CRS using ELISA and immunohistochemical analysis of nasal polyp tissue from patients with CRS with nasal polyps and uncinate tissue from healthy control subjects, patients with CRSsNP, and patients with CRSwNP. Results: Expression levels of S100 proteins were decreased compared with those seen in control subjects in nasal lavage fluid from both CRS groups (P < .05). Similarly, tissue expression of these proteins assessed by means of immunohistochemistry demonstrated clear reductions, primarily in the epithelial lining. Interestingly, levels of calprotectin were increased in nasal polyp tissue despite lower levels in lavage fluid. Levels of calprotectin in nasal tissues were correlated with levels of neutrophils, as assessed by means of quantification of neutrophil elastase. Conclusions: Several S100 proteins are in the epidermal differentiation complex of genes and have been demonstrated to play a role in maintenance of barrier function and formation of an antimicrobial shield. We demonstrate significantly decreased levels of expression of S100 proteins in the epithelium of patients with CRS, which might lead to diminished innate immune responses and barrier function. Increased levels of calprotectin in nasal polyp tissue might reflect neutrophil recruitment and a compensatory mechanism. Future studies will he important to determine whether reduced levels of S100 proteins lead to decreased antimicrobial responses in the upper airways and sinuses and whether this reduction plays a causative role in CRS pathogenesis and susceptibility to infectious disease. (J Allergy Clin Immunol 2010;125:667-75.)	[Tieu, David D.; Conley, David B.; Chandra, Rakesh; Kern, Robert C.] Northwestern Univ, Dept Otolaryngol Head & Neck Surg, Feinberg Sch Med, Chicago, IL 60607 USA; [Peters, Anju T.; Carter, Roderick T.; Suh, Lydia; Norton, James; Grammer, Leslie C.; Harris, Kathleen E.; Kato, Atsushi; Schleimer, Robert P.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60607 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Tieu, DD (corresponding author), Northwestern Univ, Dept Otolaryngol Head & Neck Surg, Feinberg Sch Med, 676 N St Clair,Suite 1325, Chicago, IL 60607 USA.	d-tieu@md.northwestern.edu		Kato, Atsushi/0000-0001-9144-3138; Grammer, Leslie/0000-0001-6860-2014	National Institutes of Health/National Heart, Lung, and Blood Institute [NIH NHLBI RO1 HL78860]; National Institutes of Health/National Institute of Allergy and Infectious Diseases [NIH NIAID RO1 AI072570]; Northwestern Memorial Hospital; Northwestern University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Northwestern Memorial Hospital; Northwestern University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH NHLBI RO1 HL78860) and the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH NIAID RO1 AI072570). Also supported by an Ernest S. Bazley grant to Northwestern Memorial Hospital and Northwestern University.	Anderson KS, 2009, BRIT J DERMATOL, V160, P325, DOI 10.1111/j.1365-2133.2008.08904.x; Avila PC, 2008, ALLERGY ALLERGIC DIS, P366; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; Bryborn M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-118; Champaiboon C, 2009, J BIOL CHEM, V284, P7078, DOI 10.1074/jbc.M806605200; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cornish CJ, 1996, J CELL PHYSIOL, V166, P427, DOI 10.1002/(SICI)1097-4652(199602)166:2<427::AID-JCP21>3.0.CO;2-6; Diamanti A, 2008, INFLAMM BOWEL DIS, V14, P1229, DOI 10.1002/ibd.20472; Glaser R, 2009, J INVEST DERMATOL, V129, P641, DOI 10.1038/jid.2008.268; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Lee KC, 2007, J INVEST DERMATOL, V127, P945, DOI 10.1038/sj.jid.5700663; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Meyer JE, 2008, MUCOSAL IMMUNOL, V1, P239, DOI 10.1038/mi.2008.3; Michalek M, 2009, DEV COMP IMMUNOL, V33, P740, DOI 10.1016/j.dci.2008.12.005; Nisapakultorn K, 2001, INFECT IMMUN, V69, P4242, DOI 10.1128/IAI.69.7.4242-4247.2001; Richer SL, 2008, AM J RHINOL, V22, P228, DOI 10.2500/ajr.2008.22.3162; Ross KF, 2001, INFECT IMMUN, V69, P3248, DOI 10.1128/IAI.69.5.3248-3254.2001; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Schnekenburger J, 2008, J CELL PHYSIOL, V216, P558, DOI 10.1002/jcp.21433; Sohnle PG, 1996, J INFECT DIS, V174, P1369, DOI 10.1093/infdis/174.6.1369; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Vandal K, 2003, J IMMUNOL, V171, P2602, DOI 10.4049/jimmunol.171.5.2602; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503	28	93	97	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					667	675		10.1016/j.jaci.2009.11.045	http://dx.doi.org/10.1016/j.jaci.2009.11.045			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226301	Green Accepted			2022-12-18	WOS:000275883200024
J	Kelly, MM; O'Connor, TM; Leigh, R; Otis, J; Gwozd, C; Gauvreau, GM; Gauldie, J; O'Byrne, PM				Kelly, Margaret M.; O'Connor, Terence M.; Leigh, Richard; Otis, Joceline; Gwozd, Carol; Gauvreau, Gail M.; Gauldie, Jack; O'Byrne, Paul M.			Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchial provocation tests; bronchoscopy; biopsy; inhaled glucocorticoids; long-acting inhaled beta-agonists	OBSTRUCTIVE PULMONARY-DISEASE; SMOOTH-MUSCLE-CELLS; INHALED BUDESONIDE; LUNG MYOFIBROBLASTS; MODERATE ASTHMA; SALMETEROL; MECHANICS; CHALLENGE; ALPHA; CORTICOSTEROIDS	Background: Combining inhaled corticosteroids with long-acting beta(2)-agonists; results in improved asthma symptom control and fewer asthma exacerbations compared with those seen after inhaled corticosteroids alone. However, there are limited data as to whether these beneficial effects are due to enhanced anti-inflammatory actions or whether such combination therapies affect airway remodeling in patients with asthma. Objective: We sought to determine the effects of inhaled budesonide/formoterol combination therapy versus inhaled budesonide alone or inhaled placebo on allergen-induced airway responses, airway inflammation, and airway remodeling. Methods: Fourteen asthmatic subjects with dual responses after allergen inhalation were included in this prospective, randomized, double-blind, 3-period crossover study. Outcomes included early and late asthmatic responses, changes in airway responsiveness, sputum eosinophilia measured before and after allergen challenge, numbers of airway submucosal myofibroblasts, and smooth muscle area measured before and after study treatment. Results: Allergen-induced sputum eosinophilia was significantly reduced by combination treatment to a greater extent than by budesonide alone. Allergen inhalation resulted in a significant increase in submucosal tissue myofibroblast numbers and produced a significant decrease in percentage smooth muscle farea. Combination therapy, but not budesonide monotherapy, significantly attenuated these changes in myofibroblast numbers and smooth muscle area. Conclusions: The effects on allergen-induced changes in sputum eosinophils, airway myofibroblast numbers, and smooth muscle seen with combination therapy suggest that the benefits associated with this treatment might relate to effects on airway inflammation and remodeling. The attenuation of early asthmatic responses and airway hyperresponsiveness by combination treatment was likely due to the known functional antagonistic effect of formoterol. (J Allergy Clin Immunol 2010;125:349-56.)	[Kelly, Margaret M.; O'Connor, Terence M.; Leigh, Richard; Otis, Joceline; Gauvreau, Gail M.; O'Byrne, Paul M.] McMaster Univ, Firestone Inst Resp Hlth, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Kelly, Margaret M.; Gauldie, Jack] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; [Kelly, Margaret M.; Leigh, Richard; Gwozd, Carol] Univ Calgary, Inst Infect Immun & Inflammat, Calgary, AB, Canada	McMaster University; McMaster University; University of Calgary	O'Byrne, PM (corresponding author), McMaster Univ, Firestone Inst Resp Hlth, Dept Med, HSC 3 W10,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca	Kelly, Margaret M/G-4128-2012	Kelly, Margaret M/0000-0002-1629-3210; O'Byrne, Paul/0000-0003-0979-281X	AstraZeneca, Lund, Sweden; AstraZeneca Ireland; Astrazeneca Canada; GlaxoSmithKline; Novartis Pharmaceuticals Canada; Boehringer-Ingelheim Canada; MedImmune; Ception; Merck-Frosst Canada; Schering-Plough; Bayer	AstraZeneca, Lund, Sweden(AstraZeneca); AstraZeneca Ireland(AstraZeneca); Astrazeneca Canada(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Novartis Pharmaceuticals Canada; Boehringer-Ingelheim Canada(Boehringer Ingelheim); MedImmune(AstraZenecaMedimmune); Ception; Merck-Frosst Canada; Schering-Plough(Merck & CompanySchering Plough Corporation); Bayer(Bayer AG)	Supported by an unrestricted grant from AstraZeneca, Lund, Sweden.; Disclosure of potential conflict of interest: T. M. O'Connor receives research support front AstraZeneca Ireland. R. Leigh is a consultant for Astrazeneca Canada, GlaxoSmithKline, Novartis Pharmaceuticals Canada, and Boehringer-Ingelheim Canada; is on the speakers' bureau for AstraZeneca Canada, GlaxoSmithKline, and Novartis Pharmaceuticals Canada and receives research support from Novartis Pharmaceuticals Canada, MedImmune, Ception, Merck-Frosst Canada, Schering-Plough, and Bayer. G. M. Gauvreau receives grant support from Schering-Plough and MedImmune. P. M. O'Byrne is on the Advisory Board for AstraZeneca. GlaxoSmithKline, Topigen, Wyeth, and Schering-Plough; is on the speakers' bureau for AstraZeneca and GlaxoSmithKline and receives research support from AstraZeneca, GlaxoSmithKline, Merck, Wyeth, Schering-Plough, and Alexion. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Baouz S, 2005, INT IMMUNOL, V17, P1473, DOI 10.1093/intimm/dxh325; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P563, DOI 10.1016/j.jaci.2005.11.036; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bates JHT, 2008, AM J RESP CRIT CARE, V177, P261, DOI 10.1164/rccm.200706-832OC; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bogatkevich GS, 2003, AM J PHYSIOL-LUNG C, V285, pL334, DOI 10.1152/ajplung.00417.2002; Bonacci JV, 2003, BRIT J PHARMACOL, V138, P1203, DOI 10.1038/sj.bjp.0705135; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; COCKCROFT DW, 1997, ASTHMA, P1253; Duong M, 2007, J ALLERGY CLIN IMMUN, V119, P322, DOI 10.1016/j.jaci.2006.10.018; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; Giembycz MA, 2008, BRIT J PHARMACOL, V153, P1090, DOI 10.1038/sj.bjp.0707627; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Juniper EF, 1999, EUR RESPIR J, V14, P1038, DOI 10.1183/09031936.99.14510389; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Kaur M, 2008, MOL PHARMACOL, V73, P203, DOI 10.1124/mol.107.040121; Kelly MM, 2006, CHEST, V130, P741, DOI 10.1378/chest.130.3.741; KELLY MM, 2008, EUR RESPIR J, V30, pP903; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; Madison JM, 2003, AM J RESP CELL MOL, V29, P8, DOI 10.1165/rcmb.F272; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; O'Byrne P, 1998, J ALLERGY CLIN IMMUN, V102, pS85, DOI 10.1016/S0091-6749(98)70036-3; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; OCONNER TM, 2006, EUR RESPIR J, V28, pS441; OCONNOR TM, 2006, AM J RESP CRIT CARE, V3, pA75; PARE PD, 1991, AM REV RESPIR DIS, V143, P1189, DOI 10.1164/ajrccm/143.5_Pt_1.1189; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Schurch W, 1998, AM J SURG PATHOL, V22, P141, DOI 10.1097/00000478-199802000-00001; Sears MR, 2008, EUR RESPIR J, V31, P982, DOI 10.1183/09031936.00104007; Ward C, 2005, CURR OPIN ALLERGY CL, V5, P43, DOI 10.1097/00130832-200502000-00009; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849, DOI 10.1152/jappl.1990.69.3.849; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	51	93	99	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					349	356		10.1016/j.jaci.2009.09.011	http://dx.doi.org/10.1016/j.jaci.2009.09.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	19969339				2022-12-18	WOS:000274764000010
J	He, R; Kim, HY; Yoon, J; Oyoshi, MK; MacGinnitie, A; Goya, S; Freyschmidt, EJ; Bryce, P; McKenzie, ANJ; Umetsu, DT; Oettgen, HC; Geha, RS				He, Rui; Kim, Hye Young; Yoon, Juhan; Oyoshi, Michiko K.; MacGinnitie, Andrew; Goya, Sho; Freyschmidt, Eva-Jasmin; Bryce, Paul; McKenzie, Andrew N. J.; Umetsu, Dale T.; Oettgen, Hans C.; Geha, Raif S.			Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-17; T(H)2 cytokines; atopic dermatitis; asthma	ATOPIC-DERMATITIS; T-CELLS; ALLERGIC-ASTHMA; MURINE MODEL; IFN-GAMMA; HYPERRESPONSIVENESS; INTERLEUKIN-17; EXPRESSION; CYTOKINES; EXPOSURE	Background: Atopic dermatitis (AD) is characterized by local and systemic T(H)2 responses to cutaneously introduced allergens and is a risk factor for asthma. Blockade of T(H)2 cytokines has been suggested as therapy for AD. Objectives: We sought to examine the effect of the absence of IL-4 and IL-13 on the T(H)17 response to epicutaneous sensitization in a murine model of allergic skin inflammation with features of AD. Methods: Wild-type, IL4 knockout (KO), IL13 KO and IL4/13 double KO (DKO) mice were subjected to epicutaneous sensitization with ovalbumin (OVA) or saline and airway challenged with OVA. Systemic immune responses to OVA, skin and airway inflammation, and airway hyperresponsiveness were examined. Results: OVA-sensitized DKO mice exhibited impaired T(H)2-driven responses with undetectable OVA-specific IgE levels and severely diminished eosinophil infiltration at sensitized skin sites but intact dermal infiltration with CD4(+) cells. DKO mice mounted exaggerated IL-17A but normal IFN-gamma and IL-5 systemic responses. Airway challenge of these mice with OVA caused marked upregulation of IL-17 mRNA expression in the lungs, increased neutrophilia in bronchoalveolar lavage fluid, airway inflammation characterized by mononuclear cell infiltration with no detectable eosinophils, and bronchial hyperresponsiveness to methacholine that were reversed by IL-17 blockade. IL-4, but not IL-13, was identified as the major T(H)2 cytokine that downregulates the IL-17 response in epicutaneously sensitized mice. Conclusion: Epicutaneous sensitization in the absence of IL-4/IL-13 induces an exaggerated T(H)17 response systemically and in lungs after antigen challenge that results in airway inflammation and airway hyperresponsiveness. (J Allergy Clin Immunol 2009;124:761-70.)	[He, Rui; Kim, Hye Young; Yoon, Juhan; Oyoshi, Michiko K.; MacGinnitie, Andrew; Freyschmidt, Eva-Jasmin; Bryce, Paul; Umetsu, Dale T.; Oettgen, Hans C.; Geha, Raif S.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; [He, Rui; Kim, Hye Young; Yoon, Juhan; Oyoshi, Michiko K.; MacGinnitie, Andrew; Freyschmidt, Eva-Jasmin; Bryce, Paul; Umetsu, Dale T.; Oettgen, Hans C.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Goya, Sho] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Osaka, Japan; [McKenzie, Andrew N. J.] MRC, Mol Biol Lab, Cambridge, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Osaka University	Geha, RS (corresponding author), 1 Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Kim, Hye Young/AAF-7609-2020; He, Rui/P-7302-2019	Kim, Hye Young/0000-0001-5978-512X; He, Rui/0000-0001-5288-9786	USPHS [AR-047417]; Atopic Dermatitis and Vaccinia immunization Network (ADVN) [N01 AI 40030]; Dyax; Japanese Society for the Promotion of Science; Centocor; Medical Research Council; National Institutes of Health; March of Dimes; MRC [MC_U105178805] Funding Source: UKRI; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER; Medical Research Council [MC_U105178805] Funding Source: researchfish	USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); Atopic Dermatitis and Vaccinia immunization Network (ADVN)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Dyax; Japanese Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Centocor; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by USPHS grants AR-047417 and the Atopic Dermatitis and Vaccinia immunization Network (ADVN) N01 AI 40030.; A. MacGinnitie has received research Support from Dyax. S. Goya has received research support from the Japanese Society for the Promotion of Science. A. N. J. McKenzie has received research support from Centocor and the Medical Research Council. R. S. Geha has received research support from the National Institutes of Health and the March of Dimes and has provided legal consultation or expert witness testimony on the subject of G-MP toxicity. The rest of the authors have declared that they have no conflict of interest.	Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; DOHI M, 1990, INT ARCH ALLER A IMM, V92, P138, DOI 10.1159/000235204; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Eichenfield LF, 2003, PEDIATRICS, V111, P608, DOI 10.1542/peds.111.3.608; FINKELMAN FD, 1991, INT IMMUNOL, V3, P599, DOI 10.1093/intimm/3.6.599; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Junttila IS, 2008, J EXP MED, V205, P2595, DOI 10.1084/jem.20080452; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P1265, DOI 10.1016/j.jaci.2004.10.019; Kibe A, 2003, AM J RESP CRIT CARE, V167, P50, DOI 10.1164/rccm.2110084; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Li L, 1999, J IMMUNOL, V162, P2477; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Miyahara S, 2006, J ALLERGY CLIN IMMUN, V118, P1110, DOI 10.1016/j.jaci.2006.06.014; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nakamura T, 1997, J IMMUNOL, V158, P1085; O'Byrne PM, 2006, CHEST, V130, P244, DOI 10.1378/chest.130.1.244; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Reinhardt RL, 2006, CURR OPIN IMMUNOL, V18, P271, DOI 10.1016/j.coi.2006.03.003; Roh GS, 2005, INT IMMUNOPHARMACOL, V5, P427, DOI 10.1016/j.intimp.2004.09.036; Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Vickery BP, 2007, CURR OPIN PEDIATR, V19, P89, DOI 10.1097/MOP.0b013e328012315a; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	40	93	100	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					761	770		10.1016/j.jaci.2009.07.040	http://dx.doi.org/10.1016/j.jaci.2009.07.040			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19815118	Green Accepted			2022-12-18	WOS:000270802800022
J	Polosa, R; Knoke, JD; Russo, C; Piccillo, G; Caponnetto, P; Sarva, M; Proietti, L; Al-Delaimy, WK				Polosa, Riccardo; Knoke, James D.; Russo, Cristina; Piccillo, Giovita; Caponnetto, Pasquale; Sarva, Maria; Proietti, Lidia; Al-Delaimy, Wael K.			Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; cigarette smoking; cohort study; risk factors	LUNG-FUNCTION; ACTIVE SMOKING; AIRWAY DISEASE; EXPOSURE; CORTICOSTEROIDS; ADULTS; INFLAMMATION; PREVALENCE; SYMPTOMS; CHILDREN	Background: Asthma and rhinitis are often comorbid conditions, and several studies have suggested that rhinitis often precedes asthma. Sensitization to allergen has been shown to be one of the strongest determinants of incident asthma, but little is known about the effects of cigarette smoking among individuals with allergic rhinitis. Objective: We sought to evaluate the importance of cigarette smoking as an additional risk factor for incident asthma in a cohort of hospital-referred nonasthmatic adult subjects with allergic rhinitis. Methods: The study population selected at baseline was invited for a follow-up visit 10 years later to check for possible asthma features. Categories of smokers, exsmokers, and never smokers were used in the analyses together with pack-years to calculate the level of cumulative exposure. Results: Complete data were available from 325 patients. Smoking was significantly related to the risk of incident asthma, with the odds ratio (OR) being 2.67 (95% CI, 1.70-4.19) for univariate and 2.98 (95% CI, 1.81-4.92) for multivariate analyses. A clear dose-response association for exposure to tobacco and risk of new-onset asthma was observed in the multivariate analyses: those with I to 10 pack-years had an OR of 2.05 (95% CI, 0.99-4.27), those with 11 to 20 pack years had an OR of 3.71 (95% CI, 1.77-7.78), and those with 21 or more pack-years had an OR of 5.05 (95% CI, 1.93-13.20) compared with never smokers. Conclusions: The current findings support the hypothesis that cigarette smoking is an important independent risk factor for the development of new asthma cases in adults with allergic rhinitis.	[Polosa, Riccardo; Russo, Cristina; Piccillo, Giovita; Caponnetto, Pasquale; Sarva, Maria] Univ Catania, Dipartimento Med Interna & Specialistica, I-95125 Catania, Italy; [Proietti, Lidia] Univ Catania, Dipartimento Med Interna & Patol Sistemiche, Sezione Med Lavoro, I-95125 Catania, Italy; [Knoke, James D.; Al-Delaimy, Wael K.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA	University of Catania; University of Catania; University of California System; University of California San Diego	Polosa, R (corresponding author), Univ Catania, Dipartimento Med Interna & Specialistica, Via Passo Gravina 187, I-95125 Catania, Italy.	polosa@unict.it	Al-Delaimy, Wael/AAF-8821-2022; Al-Delaimy, Wael/AFK-1530-2022	Al-Delaimy, Wael/0000-0001-8292-0510				AnnesiMaesano I, 1997, INT ARCH ALLERGY IMM, V114, P193, DOI 10.1159/000237666; Apostol GG, 2002, AM J RESP CRIT CARE, V166, P166, DOI 10.1164/rccm.2007035; Austin JB, 2005, ARCH DIS CHILD, V90, P253, DOI 10.1136/adc.2004.049346; Cassino C, 1999, AM J RESP CRIT CARE, V159, P1773, DOI 10.1164/ajrccm.159.6.9809042; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Diaz-Sanchez D, 2006, J ALLERGY CLIN IMMUN, V118, P441, DOI 10.1016/j.jaci.2006.04.047; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681, DOI 10.1164/ajrccm.154.3.8810605; Eisner MD, 2007, NICOTINE TOB RES, V9, P53, DOI 10.1080/14622200601078293; Fletcher CM, 1976, NATURAL HIST CHRONIC; Floreani A A, 1999, Curr Opin Pulm Med, V5, P38, DOI 10.1097/00063198-199901000-00007; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Hellgren J, 2002, AM J IND MED, V42, P23, DOI 10.1002/ajim.10083; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Kim YK, 2002, CLIN EXP ALLERGY, V32, P1706, DOI 10.1046/j.1365-2222.2002.01524.x; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Leynaert N, 2004, J ALLERGY CLIN IMMUN, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097, DOI 10.1164/ajrccm.162.6.2004178; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; Mai SK, 2007, HLTH CONS SMOK REP S, V2, P30; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36, DOI 10.1001/archpedi.155.1.36; MARQUETTE CH, 1992, AM REV RESPIR DIS, V146, P76, DOI 10.1164/ajrccm/146.1.76; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Olsson P, 2003, ACTA OTO-LARYNGOL, V123, P75, DOI 10.1080/0036554021000028071; Piccillo G, 2008, RESP MED, V102, P256, DOI 10.1016/j.rmed.2007.09.004; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920, DOI 10.1164/ajrccm.162.3.9912030; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, pS1, DOI 10.1164/ajrccm.164.supplement_1.2103024; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1034/j.1399-3003.2000.15a07.x; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2002, ARCH ENVIRON HEALTH, V57, P188, DOI 10.1080/00039890209602935; RASMUSSEN FSH, 2000, CHEST, V117, P1; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Siroux V, 2000, EUR RESPIR J, V15, P470, DOI 10.1034/j.1399-3003.2000.15.08.x; Stewart AW, 1997, INT J EPIDEMIOL, V26, P126, DOI 10.1093/ije/26.1.126; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557; VESTERINEN E, 1988, THORAX, V43, P534, DOI 10.1136/thx.43.7.534; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; *WHO, 1997, TOB HLTH GLOB STAT R, P1; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	45	93	101	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1428	1434		10.1016/j.jaci.2008.02.041	http://dx.doi.org/10.1016/j.jaci.2008.02.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18436295				2022-12-18	WOS:000256771700019
J	Bhavsar, P; Ahmad, T; Adcock, IM				Bhavsar, Pankaj; Ahmad, Tehireern; Adcock, Ian M.			The role of histone deacetylases in asthma and allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						histone deacetylase; gene expression; inflammation; glucocorticoids; immune tolerance	GENE; EXPRESSION; INHIBITION; GLUCOCORTICOIDS; TRANSCRIPTION; INFLAMMATION; AGONISTS; GAMMA	Diverse cellular functions, including inflammatory gene expression, DNA repair, and cell proliferation, are regulated by histone acetylation. Transcriptional coactivators possess intrinsic histone acetyltransferase activity, and this activity drives inflammatory gene expression and the development of tolerance in macrophages. Eleven histone deacetylases (HDACs) act to regulate the expression of distinct subsets of inflammatory/immune genes. Other proteins, particularly transcription factors, are also acetylated and are targets for deacetylation by HDACs and sirtuins, a group of protein deacetylases. HDAC inhibitors can further enhance inflammatory gene expression. However, the acetylation/ deacetylation status of nonhistone proteins can also affect the overall expression pattern of inflammatory genes. HDAC2 expression and activity is reduced in lung macrophages, biopsy specimens, and blood cells from patients with severe asthma and smoking-induced asthma, as well as in patients with chronic obstructive pulmonary disease, perhaps accounting for the enhanced inflammation and reduced steroid responsiveness seen in these patients. Targeting specific enzymes involved in this process might lead to new therapeutic agents, particularly in situations in which current anti-inflammatory therapies are suboptimal.	[Bhavsar, Pankaj; Ahmad, Tehireern; Adcock, Ian M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airways Dis Sect, London SW3 6LY, England	Imperial College London	Adcock, IM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airways Dis Sect, Dovehouse St, London SW3 6LY, England.	ian.adcock@imperial.ac.uk	Adcock, Ian/L-3217-2019	Adcock, Ian/0000-0003-2101-8843	Medical Research Council [G0400503B] Funding Source: researchfish; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)		Adcock IM, 2006, CURR OPIN INVEST DR, V7, P966; Adcock IM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-21; Amat R, 2007, J BIOL CHEM, V282, P34066, DOI 10.1074/jbc.M707114200; Bergeron C, 2006, J ALLERGY CLIN IMMUN, V117, P703, DOI 10.1016/j.jaci.2005.12.1344; Bilodeau S, 2006, GENE DEV, V20, P2871, DOI 10.1101/gad.1444606; Boyault C, 2007, ONCOGENE, V26, P5468, DOI 10.1038/sj.onc.1210614; Cao DS, 2007, AM J RESP CELL MOL, V37, P232, DOI 10.1165/rcmb.2006-0449OC; Choi JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/j.1365-2222.2004.02006.x; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Jee YK, 2005, J BIOL CHEM, V280, P23243, DOI 10.1074/jbc.M503659200; KELLY A, 2007, J ALLERGY CLIN IMMUN; Keslacy S, 2007, MOL PHARMACOL, V71, P609, DOI 10.1124/mol.106.030171; Mantelingu K, 2007, CHEM BIOL, V14, P645, DOI 10.1016/j.chembiol.2007.04.011; Nie M, 2005, J IMMUNOL, V175, P478, DOI 10.4049/jimmunol.175.1.478; Nie M, 2005, J BIOL CHEM, V280, P2550, DOI 10.1074/jbc.M410616200; SU RC, 2007, J ALLERGY CLIN IMMUN	19	93	103	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					580	584		10.1016/j.jaci.2007.12.1156	http://dx.doi.org/10.1016/j.jaci.2007.12.1156			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18234319				2022-12-18	WOS:000253918900004
J	Vincenti, F				Vincenti, Flavio			Costimulation blockade in autoimmunity and transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						costimulation; abatacept; belatacept; organ transplantation; autoimmune disease; rheumatoid arthritis	T-CELL COSTIMULATION; ANTI-CD28 MONOCLONAL-ANTIBODY; RHEUMATOID-ARTHRITIS; RENAL-TRANSPLANTATION; ALLOGRAFT-REJECTION; MODULATOR ABATACEPT; CD28; INHIBITION; ACTIVATION; CTLA4IG	Signaling through the costimulation receptors is a critical pathway in the regulation of T-cell activation. The selective costimulation inhibitor abatacept (cytotoxic T lymphocyte-associated antigen 4-Ig) binds to CD80 and CD86 on antigen-presenting cells, blocking interaction with CD28 on T cells, and is approved for the treatment of moderate to severe rheumatoid arthritis. Belatacept (LEA29Y), currently enrolling phase III trials in renal transplantation, was rationally designed from abatacept to bind with more avidity to CD86, providing the more potent immunosuppressive properties required for immunosuppression in transplantation. This review describes the relevant preclinicall studies and summarizes recent clinical findings on these 2 molecules in autoimmune diseases and organ transplantation. Although both inhibit the CD28 costimulatory pathway, they are tailored for specific disease states-abatacept for autoimmune diseases and belatacept for transplantation.	Univ Calif San Francisco, Kidney Transplant Serv, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Vincenti, F (corresponding author), Univ Calif San Francisco, Kidney Transplant Serv, 505 Parnassus Ave,Room 884M, San Francisco, CA 94143 USA.	vincentif@surgery.ucsf.edu						Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; GENANT HK, 2005, ARTHRITIS RHEUM S, V52, pS350; Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524; Halloran PF, 2004, NEW ENGL J MED, V351, P2715, DOI 10.1056/NEJMra033540; Hariharan S, 2002, KIDNEY INT, V62, P311, DOI 10.1046/j.1523-1755.2002.00424.x; Judge TA, 1996, J IMMUNOL, V156, P2294; Kim KS, 2001, AM J PATHOL, V158, P977, DOI 10.1016/S0002-9440(10)64044-8; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kremer JM, 2005, ARTHRITIS RHEUM, V52, P2263, DOI 10.1002/art.21201; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Kremer JM, 2006, ANN INTERN MED, V144, P865, DOI 10.7326/0003-4819-144-12-200606200-00003; Krinzman SJ, 1996, J CLIN INVEST, V98, P2693, DOI 10.1172/JCI119093; Larsen CP, 2005, AM J TRANSPLANT, V5, P443, DOI 10.1111/j.1600-6143.2005.00749.x; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LENSCHOW DJ, 1995, TRANSPLANTATION, V60, P1171, DOI 10.1097/00007890-199511270-00019; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; McAdam AJ, 1998, IMMUNOL REV, V165, P231; Meier-Kriesche HU, 2004, AM J TRANSPLANT, V4, P378, DOI 10.1111/j.1600-6143.2004.00332.x; Nankivell BJ, 2004, TRANSPLANTATION, V78, P557, DOI 10.1097/01.TP.0000128636.70499.6E; Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744; PEARSON TC, 1994, TRANSPLANTATION, V57, P1701, DOI 10.1097/00007890-199457120-00002; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; Shiao SL, 2007, TRANSPLANTATION, V83, P304, DOI 10.1097/01.tp.0000251426.46312.d5; Sidiropoulos P, 2004, ANN RHEUM DIS, V63, P144, DOI 10.1136/ard.2003.015933; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Van Parijs L, 1998, SCIENCE, V280, P243; Vanhove B, 2003, BLOOD, V102, P564, DOI 10.1182/blood-2002-08-2480; Vincenti F, 2005, CONTRIB NEPHROL, V146, P22, DOI 10.1159/000082058; Vincenti F, 2001, TRANSPLANTATION, V71, P1282, DOI 10.1097/00007890-200105150-00017; Vincenti F, 2005, NEW ENGL J MED, V353, P770, DOI 10.1056/NEJMoa050085; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; VINCENTI F, 2007, EUR SOC ORG TRANSPL; Webb LMC, 1996, EUR J IMMUNOL, V26, P2320, DOI 10.1002/eji.1830261008; Weinblatt M, 2006, ARTHRITIS RHEUM, V54, P2807, DOI 10.1002/art.22070; Westhovens R, 2006, ANN RHEUM DIS, V65, P512; Yamada A, 2002, J AM SOC NEPHROL, V13, P559, DOI 10.1681/ASN.V132559	41	93	103	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					299	306		10.1016/j.jaci.2008.01.002	http://dx.doi.org/10.1016/j.jaci.2008.01.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18269922				2022-12-18	WOS:000253337800002
J	Reed, CE				Reed, Charles E.			The natural history of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; natural history; epidemiology; adults; children; allergy; occupational asthma; cause of death; lung function; airway remodeling; bronchiectasis; emphysema; smoking	FOLLOW-UP; CHILDHOOD ASTHMA; LUNG-FUNCTION; ATOPIC SENSITIZATION; OCCUPATIONAL ASTHMA; PULMONARY-FUNCTION; BIRTH COHORT; DISEASE; ADULTS; REMISSION	Asthma begins most often in infants as wheezing with respiratory infections. If these episodes are mild and infrequent, asthma does not usually persist into the school years. However, if they are more frequent and severe, the asthma is likely to persist. After infancy, incidence falls and continues at about 100/100,000 for the rest of the lifespan. Allergic asthma develops most often in the second decade of life and frequently persists into adult years, but young patients with allergic asthma often enjoy a transient or even a permanent remission. More severe disease and continued allergen exposure cause persistence. Some patients with occupational asthma continue to have asthma long after exposure ceases. Asthma beginning after the fourth decade is usually intrinsic and may include the aspirin triad. Its severity tends to increase with time. Many middle-aged and elderly adults have a persistent decline in lung function that is retarded but not completely prevented by aerosol glucocorticoids. This loss of lung function is often the result of coexisting lung diseases, particularly bronchiectasis and COPD. Patients with asthma have the same overall rate and age of death as the general population, but are more likely to die of lung diseases, including cancer.	Mayo Clin & Mayo Grad Sch Med, Boulder Jct, WI 54512 USA	Mayo Clinic	Reed, CE (corresponding author), Mayo Clin & Mayo Grad Sch Med, POB 158, Boulder Jct, WI 54512 USA.	cereed@centurytel.net						Barbee RA, 1998, J ALLERGY CLIN IMMUN, V102, pS65, DOI 10.1016/S0091-6749(98)70006-5; Bauer BA, 1997, CHEST, V111, P303, DOI 10.1378/chest.111.2.303; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; Brown DW, 2005, J ASTHMA, V42, P597, DOI 10.1080/02770900500216234; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; Charpin D, 1999, PEDIATR PULM, P34; Christie GL, 1997, THORAX, V52, P953, DOI 10.1136/thx.52.11.953; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; Eder W, 2004, CURR OPIN ALLERGY CL, V4, P113, DOI 10.1097/01.all.0000123970.96233.fc; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Friedlander Samuel L, 2005, Pediatr Infect Dis J, V24, pS170, DOI 10.1097/01.inf.0000187273.47390.01; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hannaway PJ, 2000, ANN ALLERG ASTHMA IM, V84, P587, DOI 10.1016/S1081-1206(10)62408-8; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laprise C, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-21; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; McCoy L, 2005, J ASTHMA, V42, P757, DOI 10.1080/02770900500308189; McFadden ER, 2000, J ALLERGY CLIN IMMUN, V105, pS535, DOI 10.1016/S0091-6749(00)90057-5; MOLLER DR, 1986, AM REV RESPIR DIS, V134, P175; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Platts-Mills TAE, 2005, ALLERGY, V60, P25, DOI 10.1111/j.1398-9995.2005.00854.x; RACKEMANN FM, 1958, J ALLERGY, V29, P528, DOI 10.1016/0021-8707(58)90025-X; Reed CE, 2002, CLIN REV ALLERG IMMU, V22, P53; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Ronmark E, 1999, THORAX, V54, P611, DOI 10.1136/thx.54.7.611; SAETTA M, 1995, AM J RESP CRIT CARE, V151, P489, DOI 10.1164/ajrccm.151.2.7842211; Savage-Brown A, 2005, J ASTHMA, V42, P519, DOI 10.1081/JAS-200067605; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Settipane GA, 2000, ANN ALLERG ASTHMA IM, V84, P499, DOI 10.1016/S1081-1206(10)62512-4; SILVERMAN EK, 1989, ANN INTERN MED, V111, P982, DOI 10.7326/0003-4819-111-12-982; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; Sunyer J, 2000, INT J EPIDEMIOL, V29, P125, DOI 10.1093/ije/29.1.125; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Thompson JD, 2001, PHYSCHEMCOMM, DOI 10.1039/b105076c; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; Wilson NM, 2004, PEDIATR PULM, V38, P75, DOI 10.1002/ppul.20049; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	54	93	98	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					543	548		10.1016/j.jaci.2006.06.020	http://dx.doi.org/10.1016/j.jaci.2006.06.020			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950268				2022-12-18	WOS:000240649000001
J	O'Connor, GT; Walter, M; Mitchell, H; Kattan, M; Morgan, WJ; Gruchalla, RS; Pongracic, JA; Smartt, E; Stout, JW; Evans, R; Crain, EF; Burge, HA				O'Connor, GT; Walter, M; Mitchell, H; Kattan, M; Morgan, WJ; Gruchalla, RS; Pongracic, JA; Smartt, E; Stout, JW; Evans, R; Crain, EF; Burge, HA			Airborne fungi in the homes of children with asthma in low-income urban communities: The Inner-City Asthma Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airborne fungi; indoor mold; home environmental characteristics; indoor air; inner-city pediatric asthma	INDOOR AIR; MOLD; OUTDOOR; PREVALENCE; ENVIRONMENTS; PROPAGULES; ALLERGENS; EXPOSURE; POLLEN; SPORES	Background: Despite growing evidence of the importance of exposure to fungi as an environmental risk factor for asthma, few data have been reported on the exposure to airborne fungi of asthmatic children living in US inner cities. Objective: We sought to examine the spectrum and concentration of fungi in the air inside and outside of the homes of mold-sensitive children with asthma living in US cities. We also analyzed the relationship of the concentration of fungi in indoor air to home characteristics. Methods: We performed a home environmental survey and measured the concentrations of culturable airborne fungi inside and outside the homes of 414 mold-sensitive children with asthma in 7 urban communities. Results: The airborne fungi encountered indoors generally paralleled those found outdoors, and the similarities between communities were more striking than the differences. Indoor fungal concentrations were correlated with outdoor concentrations measured on the same day, suggesting the need to adjust for the outdoor concentration in analyses by using the indoor concentration as an indicator of the relative moldiness of a home. The concentration of fungi in indoor air in excess of outdoor air-that is, the indoor-outdoor difference-was significantly related to home characteristics, including dampness, having a cat, and cockroach infestation. Conclusion: Mold-sensitive children with asthma living in urban communities across the US are exposed to airborne fungi in indoor and outdoor air. The concentrations of fungi are higher in homes with dampness problems, cockroach infestation, and cats. The indoor-outdoor difference in the concentration of airborne fungi may provide a valuable metric for investigations of the role of fungal exposure as a risk factor for asthma.	Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Rho Inc, Chapel Hill, NC USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Univ Arizona, Resp Sci Ctr, Tucson, AZ USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA; Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; NIAID, Bethesda, MD 20892 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Boston, MA 02115 USA	Boston University; Rho; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Arizona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Northwestern University; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard T.H. Chan School of Public Health	O'Connor, GT (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Room R304,715 Albany St, Boston, MA 02118 USA.	goconnor@bu.edu		Walter, Michelle/0000-0002-3251-487X; O'Connor, George/0000-0002-6476-3926	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI039901, U01AI039785, U01AI039761, U01AI039902, U01AI039900, U01AI039769, U01AI039789, U01AI039776] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00533] Funding Source: Medline; NIAID NIH HHS [AI/ES-39900, AI/ES-39901, AI/ES-39785, AI/ES-39769, AI/ES-39761, AI/ES-39789, AI/ES-39776, AI/ES-39902] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; Burge HA, 2000, CURR MICROBIOL, V40, P10, DOI 10.1007/s002849910003; Bush RK, 2001, J ALLERGY CLIN IMMUN, V107, pS430, DOI 10.1067/mai.2001.113669; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Dillon HK, 1999, ENVIRON HEALTH PERSP, V107, P473, DOI 10.1289/ehp.99107s3473; HIRSCH SR, 1976, ANN ALLERGY, V36, P30; Holt PG, 1999, ENVIRON HEALTH PERSP, V107, P485, DOI 10.1289/ehp.99107s3485; Katial RK, 1997, INT J BIOMETEOROL, V41, P17, DOI 10.1007/s004840050048; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; KODAMA AM, 1986, ARCH ENVIRON HEALTH, V41, P306, DOI 10.1080/00039896.1986.9936702; KOZAK PP, 1979, ANN ALLERGY, V43, P88; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38, DOI 10.1080/00039896.1995.9955011; LI DW, 1995, MYCOLOGIA, V87, P190, DOI 10.2307/3760904; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Ren P, 2001, ALLERGY, V56, P419, DOI 10.1034/j.1398-9995.2001.056005419.x; Ren P, 1999, J EXPO ANAL ENV EPID, V9, P560, DOI 10.1038/sj.jea.7500061; Rylander R, 1999, ENVIRON HEALTH PERSP, V107, P465, DOI 10.1289/ehp.99107s3465; Savilahti R, 2001, ALLERGY, V56, P175, DOI 10.1034/j.1398-9995.2001.056002175.x; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; Sterling DA, 1998, ANN ALLERG ASTHMA IM, V80, P279, DOI 10.1016/S1081-1206(10)62971-7; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; VERHOEFF AP, 1992, ALLERGY, V47, P83, DOI 10.1111/j.1398-9995.1992.tb05093.x; Wu PC, 2000, SCI TOTAL ENVIRON, V253, P111, DOI 10.1016/S0048-9697(00)00423-X	25	93	98	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					599	606		10.1016/j.jaci.2004.05.064	http://dx.doi.org/10.1016/j.jaci.2004.05.064			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356564				2022-12-18	WOS:000223799600020
J	Becker, A; Watson, W; Ferguson, A; Dimich-Ward, H; Chan-Yeung, M				Becker, A; Watson, W; Ferguson, A; Dimich-Ward, H; Chan-Yeung, M			The Canadian asthma primary prevention study: Outcomes at 2 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; risk factors; primary prevention; environmental tobacco smoke; daycare; breast-feeding; early life	CAT ALLERGEN LEVELS; CHILDHOOD ASTHMA; HOUSE-DUST; EARLY-LIFE; MITE ALLERGEN; BIRTH COHORT; RISK-FACTORS; P-I; AVOIDANCE; EXPOSURE	Background: Avoidance of individual risk factors have not been successful in preventing the development of asthma. Objective: We sought to determine the effectiveness of a multifaceted intervention program in primary prevention of asthma in high-risk infants. Methods: We identified 545 high-risk infants on the basis of an immediate family history of asthma. Families were randomized into intervention or control groups. Intervention measures included avoidance of house dust mite, pet allergen, and environmental tobacco smoke. Breast-feeding was encouraged with formula supplementation if necessary, and introduction of solid foods was delayed. Results: At 2 years of age, 19.5% of the children had asthma, and 14.7% had atopy (positive skin test response to one or more common allergens). Significantly fewer children had asthma in the intervention group compared with in the control group (16.3% vs 23.0%), with 60% less persistent asthma at 2 years. There was a 90% reduction for recurrent wheeze in the intervention group compared with that seen in the control group. Exposure to maternal environmental tobacco smoke during pregnancy or the first year was a risk factor for asthma at 2 years of age. A positive skin test response, particularly to food, at 12 months predicted asthma at 2 years. There was no significant difference for atopy between the intervention and control groups, but daycare reduced atopy at 2 years. Conclusion: This multifaceted intervention program during a window of opportunity in the first year of life was effective in preventing asthma in high-risk children at 2 years of age. Future studies with this cohort at school age are important.	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3E 0Z2, Canada; Univ British Columbia, Dept Pediat, Div Allergy, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Med, Div Resp, Occupat & Environm Lung Dis Unit, Vancouver, BC V5Z 1M9, Canada	University of Manitoba; University of British Columbia; University of British Columbia	Becker, A (corresponding author), Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, AE101-671 William Ave, Winnipeg, MB R3E 0Z2, Canada.			Ferguson, Alexander C./0000-0002-3143-5619				ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BJORKSTEN B, 1998, ALLERGY PRINCIPLES P, P816; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chan-Yeung M, 2002, ANN ALLERG ASTHMA IM, V88, P52, DOI 10.1016/S1081-1206(10)63592-2; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681, DOI 10.1164/ajrccm.154.3.8810605; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P822, DOI 10.1164/ajrccm.163.4.2005049; GERGEN PJ, 1992, ANN ALLERGY, V68, P507; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MANFREDA J, 1993, CHEST, V103, P151, DOI 10.1378/chest.103.1.151; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Strunk RC, 2002, PEDIATRICS, V109, P357; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; WEISS ST, 1983, AM REV RESPIR DIS, V128, P933; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	38	93	98	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					650	656		10.1016/j.jaci.2004.01.754	http://dx.doi.org/10.1016/j.jaci.2004.01.754			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100668				2022-12-18	WOS:000220956600010
J	Lieberman, P				Lieberman, P			Anaphylactic reactions during surgical and medical procedures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		anaphylaxis; anaphylactoid reactions; latex; muscle relaxants; anesthesia	OPERATING-ROOM NURSES; NATURAL-RUBBER LATEX; GENERAL-ANESTHESIA; CLINICAL-FEATURES; ALLERGY; AGENTS; MANAGEMENT; PROPHYLAXIS; PREVALENCE; EXPERIENCE	The most common agents that are responsible for intraoperative anaphylaxis are muscle relaxants. However, latex accounts for a significant number of these reactions, and the incidence of intraoperative anaphylaxis caused by latex is increasing. It is now probably the second most important cause of intraoperative anaphylaxis. Following muscle relaxants and latex are probably antibiotics and anesthesia induction agents. Other agents that are responsible include colloids, opioids, and radio-contrast material. However, they account for less than 10% of all reactions. The clinical manifestations of intraoperative reactions differ from those of anaphylactic reactions outside of anesthesia. Cutaneous manifestations are far less common; cardiovascular collapse may be more common. The diagnosis can be made more difficult because patients cannot express symptoms. There is a paucity of cutaneous findings; the patient is draped, and concomitantly administered drugs may alter the manifestations. These additional drugs can also complicate therapy. There are populations who are at-risk for anaphylaxis to latex during surgical procedures: individuals with a genetic predisposition (atopic individuals), individuals with increased previous exposure to latex (eg, anyone who requires chronic bladder care with repeated insertion of latex catheters or chronic indwelling catheters), health care workers who are exposed to latex mainly by inhalation, and possibly patients who have undergone multiple surgical procedures and therefore have been exposed to latex intravascularly and by catheterization on a number of occasions. It has been shown that pretreatment with antihistamines and corticosteroids that are used successfully for the prevention of reactions to radio-contrast material are not as effective in the prevention of anaphylactic reactions to latex. Therefore, the major emphasis has been on prevention. The key elements of prevention include an adequate history, testing for latex allergy in high-risk patients, preadmission measures, and the establishment of a "latex-free environment" while the individual is hospitalized. This is particularly important in the operating and recovery rooms.	Univ Tennessee, Div Allergy & Immunol, Dept Med, Cordova, TN 38018 USA; Univ Tennessee, Div Allergy & Immunol, Dept Pediat, Cordova, TN 38018 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Lieberman, P (corresponding author), Univ Tennessee, Div Allergy & Immunol, Dept Med, 300 Walnut Bend Rd S, Cordova, TN 38018 USA.	asth-mamemphis@msn.com						*AORN, 1999, STAND REC PRACT GUID, P93; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; CLARKE RSJ, 1975, BRIT J ANAESTH, V47, P575, DOI 10.1093/bja/47.5.575; DILLARD SF, 1992, SENSITIVITY LATEX ME, P23; FISHER M, 1984, ANAESTH INTENS CARE, V12, P115, DOI 10.1177/0310057X8401200205; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P226, DOI 10.1177/0310057X8100900304; FISHER MM, 1993, ANN FR ANESTH, V12, P97, DOI 10.1016/S0750-7658(05)81016-0; Fisher MM, 1998, BRIT J ANAESTH, V80, P26, DOI 10.1093/bja/80.1.26; GRANADY LC, 1995, IMMUNOL ALLERGY CLIN, V15, P21; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; Hatton F, 1983, ANN FR ANESTH, V2, P333; KEITH PK, 1992, IMMUNOL ALLERGY CLIN, V12, P671; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Knowles SR, 1996, J ALLERGY CLIN IMMUN, V97, P645; KWITTKEN PL, 1992, ALLERGY PROC, V13, P123, DOI 10.2500/108854192778878782; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Laxenaire MC, 1999, ANN FR ANESTH, V18, P796, DOI 10.1016/S0750-7658(00)88460-9; LAXENAIRE MC, 1993, ANN FR ANESTH, V12, P91, DOI 10.1016/S0750-7658(05)81015-9; Laxenaire MC, 1996, ANN FR ANESTH, V15, P1211, DOI 10.1016/S0750-7658(97)85882-0; Laxenaire MC, 1992, CURR OPIN ANESTHESIO, V5, P436; LEYNADIER F, 1991, CLIN REV ALLERG, V9, P371; Mace SR, 1998, ANN ALLERG ASTHMA IM, V80, P252, DOI 10.1016/S1081-1206(10)62966-3; Mertes PM, 2000, CNS DRUGS, V14, P115, DOI 10.2165/00023210-200014020-00003; MOSCICKI RA, 1990, J ALLERGY CLIN IMMUN, V86, P325, DOI 10.1016/S0091-6749(05)80095-8; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; ORFAN NA, 1992, ALLERGY PROC, V13, P35, DOI 10.2500/108854192778878953; OULIEU S, 1995, THERAPIE, V50, P59; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; PEPYS J, 1994, ANAESTHESIA, V49, P470, DOI 10.1111/j.1365-2044.1994.tb03515.x; Perrin MR, 1999, S AFR J WILDL RES, V29, P72; Ricci G, 1999, BJU INT, V84, P1058; SAGE D, 1981, ANAESTH INTENS CARE, V9, P381, DOI 10.1177/0310057X8100900411; SETLOCK MA, 1993, ANESTH ANALG, V76, P650; Simons KJ, 2001, J ALLERGY CLIN IMMUN, V107, pS58; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1984, ALLERGY S, V2, P35; *US DEP VET AFF, 2000, LAT ALL PREC MEMPH T; Vervloet D, 1999, CLIN REV ALLERG IMMU, V17, P459, DOI 10.1007/BF02737650; Wade J P, 1989, Prog Clin Biol Res, V297, P175; WATKINS J, 1994, ACTA ANAESTH SCAND, V38, P6, DOI 10.1111/j.1399-6576.1994.tb04030.x; Wiggins CA, 1991, IMMUN ALLERGY PRACT, V13, P313; Young M A, 1992, AORN J, V56, P488, DOI 10.1016/S0001-2092(07)70192-8; YUNGINGER JW, 1995, IMMUNOL ALLERGY CLIN, V15, P583	46	93	100	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S64	S69		10.1067/mai.2002.124970	http://dx.doi.org/10.1067/mai.2002.124970			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170245	Bronze			2022-12-18	WOS:000177572200010
J	Lester, LA; Rich, SS; Blumenthal, MN; Togias, A; Murphy, S; Malveaux, F; Miller, ME; Dunston, GM; Solway, J; Wolf, RL; Samet, JM; Marsh, DG; Meyers, DA; Ober, C; Bleecker, ER				Lester, LA; Rich, SS; Blumenthal, MN; Togias, A; Murphy, S; Malveaux, F; Miller, ME; Dunston, GM; Solway, J; Wolf, RL; Samet, JM; Marsh, DG; Meyers, DA; Ober, C; Bleecker, ER		Collaborative Study Genetics Asthm	Ethnic differences in asthma and associated phenotypes: Collaborative Study on the Genetics of Asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial hyperresponsiveness; atopy; ethnic differences	SKIN-TEST REACTIVITY; GENOME-WIDE SEARCH; SERUM IGE LEVELS; SOCIOECONOMIC-STATUS; COCKROACH ALLERGEN; CHILDHOOD ASTHMA; INDOOR ALLERGENS; CHILDREN; RACE; SEVERITY	Background: In the Collaborative Study on the Genetics of Asthma, 314 families with 2584 subjects were characterized for asthma and allergy. Objective: The purpose of this investigation was to examine clinical heterogeneity observed in asthma and allergic characteristics among 3 ethnic groups (African American, white, and Hispanic family members). Methods: pulmonary function parameters and asthma-associated phenotypes were compared among the ethnic groups. Results: In comparison with the other groups, African American sibling pairs had a significantly lower baseline FEV, percent of predicted (P = .0001) and a higher rate of skin test reactivity to cockroach allergen (P = .0001); Hispanic sibling pairs had significantly more skin reactivity overall (P = .001); and white sibling pairs had significantly lower total serum IgE (P < .05). In addition, there were significantly more relatives with asthma among the African American families than among the white and the Hispanic families (P = .001). Conclusion: Although different environmental backgrounds should be considered, these clinical differences could be due to differences in genetic susceptibility among the ethnic groups, such as those suggested by our previous genome screen.	Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Univ Chicago, Chicago, IL 60637 USA; Univ Minnesota, Minneapolis, MN 55455 USA; Johns Hopkins Univ, Baltimore, MD 21218 USA; Univ New Mexico, Albuquerque, NM 87131 USA; Howard Univ, Washington, DC 20059 USA; Univ Maryland, College Pk, MD 20742 USA	Wake Forest University; Wake Forest Baptist Medical Center; University of Chicago; University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University; University of New Mexico; Howard University; University System of Maryland; University of Maryland College Park	Bleecker, ER (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.		Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530; Rich, Stephen/0000-0003-3872-7793	NCRR NIH HHS [MR1 RR00055, M01-RR00400] Funding Source: Medline; NHLBI NIH HHS [UO1 HL/AI49596, U01 HL/AI 49612, UO1 HL 58977, U01 HL/AI49602, HL/AI 49609] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000400] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049612, R01HL049609, U01HL049596, U01HL058977, U01HL049602, U01HL049609] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BLUMENTHAL M, 1992, J IMMUNOL, V148, P411; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; GOLD DR, 1994, AM J RESP CRIT CARE, V149, P1198, DOI 10.1164/ajrccm.149.5.8173760; HOLGATE ST, 1997, NAT GENET, V15, P389; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P393; LIGGETT S, 1996, LUNG BIOL HLTH DIS; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Persky VW, 1998, ANN ALLERG ASTHMA IM, V81, P266, DOI 10.1016/S1081-1206(10)62824-4; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; RICH SS, 1992, CLIN EXP ALLERGY, V22, P1070, DOI 10.1111/j.1365-2222.1992.tb00132.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1998, ANN ALLERG ASTHMA IM, V80, P303, DOI 10.1016/S1081-1206(10)62973-0; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SHERMAN CB, 1993, AM REV RESPIR DIS, V148, P98, DOI 10.1164/ajrccm/148.1.98; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; TASKIN DP, 1992, AM REV RESPIR DIS, V145, P301; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Togias A, 1997, INT ARCH ALLERGY IMM, V113, P87, DOI 10.1159/000237515; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; Winer B. J., 1971, STAT PRINCIPLES EXPT, V2; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; [No title captured]; 1987, AM J RESP CRIT CARE, V136, P1285	35	93	95	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					357	362		10.1067/mai.2001.117796	http://dx.doi.org/10.1067/mai.2001.117796			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544453				2022-12-18	WOS:000171215400005
J	Saini, SS; Klion, AD; Holland, SM; Hamilton, RG; Bochner, BS; MacGlashan, DW				Saini, SS; Klion, AD; Holland, SM; Hamilton, RG; Bochner, BS; MacGlashan, DW			The relationship between serum IgE and surface levels of Fc epsilon R on human leukocytes in various diseases: Correlation of expression with Fc epsilon RI on basophils but not on monocytes or eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE receptors; IgE antibody; basophils; monocytes; eosinophils	IMMUNOGLOBULIN-E; MAST-CELLS; IN-VITRO; MEDIATOR RELEASE; DOWN-REGULATION; RECEPTOR; ALPHA; ACTIVATION; ANTIBODY; GAMMA	Background: Expression of receptors for IgE (Fc epsilon R) have been mainly studied on mast cells and blood basophils in the context of allergic disease, Some reports have noted limited expression of Fc epsilon R on other leukocytes, including blood monocytes and eosinophils in certain patients. An association between human blood basophil expression of Fc epsilon RI alpha and serum IgE has been noted among allergic subjects. Objective: Recent evidence supports regulation of Fc epsilon RI alpha by free IgE on both mast cells and basophils. We hypothesized that this relationship would exist across an extremely wide range of IgE levels for human basophils, irrespective of underlying disease. We further examined whether a similar relationship existed between serum IgE and Fc epsilon RI alpha or Fc epsilon RII (CD23) expression on monocytes and eosinophils in these same subjects. Methods: Blood was obtained from nonallergic subjects (n = 3) and subjects with allergic asthma (n = 5), atopic dermatitis (n = 3), hypereosinophilic syndromes (n = 7), hyper-IgE syndrome (n = 6), helminth infestation (n = 6), or IgE myeloma (n = 1). Levels of serum IgE were determined by using RIA and ranged from 3 to 4.7 mg/mL. Levels of cell surface Fc epsilon RI alpha, Fc epsilon RII, and IgE were measured by using immunofluorescence and now cytometry. Results: Basophil surface IgE density and Fc epsilon RI alpha expression correlated with serum IgE levels (r = 0.67 and r = 0.46, respectively; P < .01; n = 31) regardless of the disease state. In contrast, monocyte Fc epsilon RI alpha expression did not correlate with serum IgE (r = 0.09, P > .5, n = 29), and low-level eosinophil Fc epsilon RI alpha expression was only detected in a single asthmatic subject. CD23 expression was not detected on basophils or eosinophils, except for the eosinophils from the donor with IgE myeloma, CD23 was present on monocytes from some donors but did not correlate with serum IgE levels. Conclusions: In a variety of disease states, Fc epsilon RI alpha expression by basophils, but not monocytes or eosinophils, correlated with serum IgE levels across a 6-log range of IgE. These data support the concept of in vivo regulation of Fc epsilon RI alpha on basophils by serum IgE and further demonstrate that this is independent of allergic disease per se.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol, Baltimore, MD 21205 USA; NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA	Saini, SS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.			Klion, Amy/0000-0002-4986-5326	NIAID NIH HHS [K08 AI001564-03, AI42220, AI07290, AI01564, K08 AI001564-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042220, K08AI001564, Z01AI000646, Z01AI000805] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P800; ALDERSON MR, 1994, CYTOKINE, V6, P407, DOI 10.1016/1043-4666(94)90065-5; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; Bochner BS, 1997, METHODS, V13, P61, DOI 10.1006/meth.1997.0497; DRESKIN SC, 1987, J CLIN INVEST, V79, P1764, DOI 10.1172/JCI113017; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Garraud O, 1999, J ALLERGY CLIN IMMUN, V103, P333, DOI 10.1016/S0091-6749(99)70510-5; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GEORAS SN, 1993, BLOOD, V82, P2872; GILBERT HS, 1975, BLOOD, V46, P279; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Grayson MH, 1998, J EXP MED, V188, P2187, DOI 10.1084/jem.188.11.2187; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Kita H, 1999, J IMMUNOL, V162, P6901; Lin AY, 1998, AM J MED GENET, V76, P229, DOI 10.1002/(SICI)1096-8628(19980319)76:3<229::AID-AJMG6>3.0.CO;2-L; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; MacGlashan D, 1999, J ALLERGY CLIN IMMUN, V104, P492, DOI 10.1016/S0091-6749(99)70399-4; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Mawhorter SD, 1996, J IMMUNOL, V156, P4851; POLLA BS, 1992, J ALLERGY CLIN IMMUN, V89, P545, DOI 10.1016/0091-6749(92)90321-R; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; Saini SS, 1999, J IMMUNOL, V162, P5624; Sano H, 1999, P ASSOC AM PHYSICIAN, V111, P82, DOI 10.1046/j.1525-1381.1999.09668.x; Seminario MC, 1999, J IMMUNOL, V162, P6893; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; SPRY CJF, 1983, Q J MED, V52, P1; Taylor ML, 2000, CLIN IMMUNOL, V94, P33, DOI 10.1006/clim.1999.4803; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; Vangelista L, 1999, J CLIN INVEST, V103, P1571, DOI 10.1172/JCI6551; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; WARNER JA, 1987, J IMMUNOL METHODS, V105, P107, DOI 10.1016/0022-1759(87)90419-4; WERSHIL BK, 1992, GASTROENTEROL CLIN N, V21, P387; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	44	93	97	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					514	520		10.1067/mai.2000.108431	http://dx.doi.org/10.1067/mai.2000.108431			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984372				2022-12-18	WOS:000089471900015
J	Tomee, JFC; van Weissenbruch, R; de Monchy, JGR; Kauffman, HF				Tomee, JFC; van Weissenbruch, R; de Monchy, JGR; Kauffman, HF			Interactions between inhalant allergen extracts and airway epithelial cells: Effect on cytokine production and cell detachment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway epithelial cells; asthma; rhinitis; mites; pollens; protease activity; Dermatophagoides pteronyssinus; Lepidoglyphus destructor; Pleum pratensis; Betula verrucosa	DUST MITE ALLERGEN; BIRCH POLLEN ALLERGEN; DERMATOPHAGOIDES-PTERONYSSINUS; SERINE-PROTEASE; PHYSICOCHEMICAL CHARACTERIZATION; GENE-EXPRESSION; ASTHMA; INTERLEUKIN-8; INFLAMMATION; PROTEINS	Background: The factors responsible for inducing or maintaining airway inflammation are poorly understood. Various studies have focussed on the mechanisms leading to allergic airway inflammation in patients with asthma and rhinitis. The observation of local airway inflammation in nonallergic patients with asthma ol rhinitis, including those with nasal polyposis, suggest that non-IgE-related mechanisms exist that may Lead to airway inflammation. Various lines of evidence suggest that epithelial cells may participate in local inflammation of the airways. Objective: This study focused on the interaction of airway epithelial cells with clinically relevant inhalant allergen extracts in vitro. Methods: Cultures of airway epithelial cells were exposed to mite, Timothy grass pollen, and birch pollen extracts. Production of IL-8, IL-6, monocyte-chemotactic protein-1 (MCP-1), and granulocyte-macrophage colony-stimulating factor and cell detachment were monitored while protease inhibitors and chromatography techniques were applied to identify the factors responsible fur these effects. Results: With the mite extracts, cytokine production and cell detachment was largely dependent on protease activity. With the pollen extracts, cytokine production without cell detachment seemed to be independent of protease activity. Conclusion: These findings support the view that epithelial cells may contribute to the pathogenesis of airway disease by their interaction with inhalant allergen extracts. Furthermore, allergen extracts may enhance airway inflammation by means other than their IgE-binding activity through both protease-dependent and protease-independent mechanisms.	Univ Groningen Hosp, Dept Allergol, Clin Internal Med, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Dept Otorhinolaryngol, Groningen, Netherlands	University of Groningen; University of Groningen	Kauffman, HF (corresponding author), Univ Groningen Hosp, Dept Allergol, Clin Internal Med, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.							Bufe A, 1996, PLANTA, V199, P413, DOI 10.1007/BF00195733; BUFE A, 1995, FEBS LETT, V363, P6, DOI 10.1016/0014-5793(95)00259-C; CAMPBELL AM, 1994, IMMUNOLOGY, V82, P506; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; Frew AJ, 1996, J ALLERGY CLIN IMMUN, V98, P133, DOI 10.1016/S0091-6749(96)70235-X; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HUFFNAGLE GB, 1995, J IMMUNOL, V155, P4790; INOUE H, 1994, AM J RESP CELL MOL, V11, P651, DOI 10.1165/ajrcmb.11.6.7946394; Jankowski R, 1996, ACTA OTO-LARYNGOL, V116, P160, DOI 10.3109/00016489609137813; Kalsheker NA, 1996, BIOCHEM BIOPH RES CO, V221, P59, DOI 10.1006/bbrc.1996.0544; King C, 1996, J ALLERGY CLIN IMMUN, V98, P739, DOI 10.1016/S0091-6749(96)70121-5; KOYAMA S, 1991, J IMMUNOL, V147, P4293; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; Lopez I, 1996, P NATL ACAD SCI USA, V93, P7415, DOI 10.1073/pnas.93.14.7415; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MCKELVY JF, 1969, ARCH BIOCHEM BIOPHYS, V132, P99, DOI 10.1016/0003-9861(69)90341-5; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; Persson CGA, 1996, CLIN EXP ALLERGY, V26, P746, DOI 10.1046/j.1365-2222.1996.d01-374.x; ROBINSON BWS, 1990, J ALLERGY CLIN IMMUN, V86, P726, DOI 10.1016/S0091-6749(05)80176-9; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; ROMERO LS, 1995, INT J DERMATOL, V34, P551, DOI 10.1111/j.1365-4362.1995.tb02951.x; SCALDERON MA, 1997, J ALLERGY CLIN IMMUN, V99, P65; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; Shibata Y, 1996, J IMMUNOL, V156, P772; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STEWART GA, 1992, IMMUNOLOGY, V75, P29; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; STEWART GA, 1991, INT ARCH ALLER A IMM, V95, P248, DOI 10.1159/000235437; STEWART GA, 1992, J ALLERGY CLIN IMMUN, V90, P141, DOI 10.1016/S0091-6749(06)80029-1; STEWART GA, 1994, AM J IND MED, V25, P105, DOI 10.1002/ajim.4700250128; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; TAKAHASHI K, 1990, INT ARCH ALLER A IMM, V91, P80, DOI 10.1159/000235094; THOMPSON AB, 1995, EUR RESPIR J, V8, P127, DOI 10.1183/09031936.95.08010127; Tomee JFC, 1997, J INFECT DIS, V176, P300, DOI 10.1086/517272; TOMEE JFC, 1994, J ALLERGY CLIN IMMUN, V93, P768, DOI 10.1016/0091-6749(94)90257-7; VALENTA R, 1991, INT ARCH ALLER A IMM, V94, P368, DOI 10.1159/000235406; YASUEDA H, 1993, CLIN EXP ALLERGY, V23, P384, DOI 10.1111/j.1365-2222.1993.tb00343.x	44	93	95	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					75	85		10.1016/S0091-6749(98)70057-0	http://dx.doi.org/10.1016/S0091-6749(98)70057-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679850				2022-12-18	WOS:000074909500012
J	Golden, DBK; Marsh, DG; Freidhoff, LR; Kwiterovich, KA; Addison, B; Kagey-Sobotka, A; Lichtenstein, LM				Golden, DBK; Marsh, DG; Freidhoff, LR; Kwiterovich, KA; Addison, B; Kagey-Sobotka, A; Lichtenstein, LM			Natural history of Hymenoptera venom sensitivity in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INSECT STING ALLERGY; IMMUNOTHERAPY; ANAPHYLAXIS; SEVERITY; HYPERSENSITIVITY; CHALLENGES; SYMPTOMS	Background: Epidemiologic studies of Hymenoptera venom allergy in adults show a prevalence of positive venom skin test results. RASTs of 15% to 25%, or both, but most such individuals have had no systemic reactions to stings. The clinical significance and natural history of this apparently common sensitivity is uncertain. Objective: We sought to determine the natural history of venom sensitization by observing the rate of decrease or increase in sensitivity in normal adults over 5 to 10 years. The clinical significance of these findings is related to the frequency of systemic reactions to stings during the period of observation. Methods: Serial observations were planned in 520 volunteers and randomly selected subjects. Two follow-up visits were attempted, once after 2 to 3 years and again after 5 to 9 years, to perform repeat venom skin tests and RASTs and to review any history of interim stings and their outcomes. Results: Follow-up visits were conducted with 398 subjects (375 early visits and 205 late visits). Overall, in the 398 subjects with one or more visits after a mean of 4 years, skin test responses changed from positive to negative in 44 of 98 (45%) and from negative to positive in 27 of 309 (8.7%) of the subjects. Skin test responses changed from positive to negative in 29 of 87 (33%) subjects after 2.5 years and in 43 of 54 (80%) after 6.8 years. Even when the skin test response became negative, venom-specific IgE remained positive in 11 of 29 (38%) subjects after 2.5 years and in 13 of 43 (30%) after 6.8 years. The rate of loss of sensitivity was 12% per year, similar to retrospective estimates. Skin test sensitivity to venoms disappears more rapidly in these subjects without symptoms (half-life, 4 years) than in patients receiving venom immunotherapy (half-life, 7 years). Skin test responses changed from negative to positive in 23 of 288 (8%) subjects after 2.5 years and in 9 of 151 (6%) after 6.8 years. Insect stings caused no reaction in 120 subjects with a negative skin test response, but 17% (11 of 65) of subjects with a positive skin test response (but with a negative history had systemic reactions when stung. There was no difference between the early and late visits in the frequency of systemic reactions reported. The risk may be higher than 17% for the specific individuals (67% after 2.5 years and 20% after 6.8 years) whose positive skin test responses persist for years. This risk is lower than that of patients with a positive history (50%) but higher than that of "normal" adults or venom-treated patients (<2%). It is still not clear whether any subset of adults with a positive skin test response but a negative history can be identified, in whom the risk of systemic sting reaction would justify venom immunotherapy even before any reaction occurs. Conclusion: Asymptomatic venom sensitization in adults is common but transient, disappearing at the rate of 12% per year. However, the risk of a systemic reaction to a subsequent sting is significant in adults without symptoms but with positive venom skin test responses (17%) and may be higher when skin test sensitivity does persist for years.	Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA	Johns Hopkins University	Golden, DBK (corresponding author), Johns Hopkins Univ, Ctr Asthma & Allergy, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI08270, AI20136] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, P50AI020136, R37AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; GADDE J, 1984, Journal of Allergy and Clinical Immunology, V73, P159; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; JARISCH R, 1982, ARCH DERMATOL RES, V273, P173; LICHTENSTEIN LM, 1994, J ALLERGY CLIN IMMUN, V94, P137, DOI 10.1016/0091-6749(94)90030-2; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1994, J ALLERGY CLIN IMMUN, V94, P651, DOI 10.1016/0091-6749(94)90167-8; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SCHWARTZ H J, 1984, Journal of Allergy and Clinical Immunology, V73, P189; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889	23	93	93	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				760	766		10.1016/S0091-6749(97)70270-7	http://dx.doi.org/10.1016/S0091-6749(97)70270-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438483	hybrid			2022-12-18	WOS:000071353600007
J	Keatings, VM; OConnor, BJ; Wright, LG; Huston, DP; Corrigan, CJ; Barnes, PJ				Keatings, VM; OConnor, BJ; Wright, LG; Huston, DP; Corrigan, CJ; Barnes, PJ			Late response to allergen is associated with increased concentrations of tumor necrosis factor-alpha and IL-5 in induced sputum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial provocation test; asthma; allergen; interleukin; IL-5; GM-CSF; TNF-alpha; eosinophils; induced sputum	COLONY-STIMULATING FACTOR; LATE ASTHMATIC REACTION; AIRWAY INFLAMMATION; ENDOTHELIAL-CELLS; CHALLENGE; EOSINOPHILS	Bronchial antigen challenge of sensitized atopic patients with asthma results in an early fall in FEV1, followed in a proportion of patients by a late (4 to 24 hours) fall, The Late response is accompanied by an increase in bronchial reactivity, which is widely believed to reflect local influx and degranulation of inflammatory cells, particularly eosinophils, in association with elevated local secretion of cytokines, We hypothesized that the development of a late-phase bronchoconstrictor response and airway eosinophilia after allergen challenge of sensitized atopic patients with asthma is associated with elevated induced sputum concentrations of the eosinophil-active cytokines IL-5 and granulocyte-macrophage colony-stimulating factor and the proinflammatory cytokine tumor necrosis factor-alpha, We counted inflammatory leukocytes and measured cytokine concentrations in induced sputum at baseline and 24 hours after inhalational allergen challenge of 15 atopic patients with asthma who had previously demonstrated a late response, We observed significant increases in the numbers of eosinophils and the concentrations of their granule products, eosinophil cationic protein and eosinophil peroxidase, In contrast, the numbers of neutrophils and concentrations of two of their products, myeloperoxidase and human neutrophil lipocalin, did not significantly change, The numbers of sputum eosinophils correlated with the maximal late-phase fall in FEV1, Concentrations of IL-5 and tumor necrosis factor-alpha, but not granulocyte-macrophage colony-stimulating factor, were significantly elevated after allergen challenge, We conclude that the relatively noninvasive technique of induced sputum production can be used to monitor the effect of bronchial provocation on cytokine concentrations in asthma.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT THORAC MED,NATL HEART & LUNG INST,LONDON SW3 6LY,ENGLAND; BAYLOR COLL MED,DEPT MED,IMMUNOL SECT,HOUSTON,TX 77030; CHARING CROSS HOSP,DEPT MED,LONDON,ENGLAND	Imperial College London; Baylor College of Medicine; Imperial College London				Huston, David/0000-0002-2332-0010; Barnes, Peter/0000-0002-5122-4018				AALBERS R, 1993, AM REV RESPIR DIS, V147, P76, DOI 10.1164/ajrccm/147.1.76; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BROIDE DH, 1991, J CLIN INVEST, V88, P1048, DOI 10.1172/JCI115366; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465, DOI 10.1164/ajrccm/147.6_Pt_1.1465; DICKASON RR, 1994, CYTOKINE, V6, P647, DOI 10.1016/1043-4666(94)90053-1; FAHY JV, 1994, J ALLERGY CLIN IMMUN, V93, P1031, DOI 10.1016/S0091-6749(94)70052-4; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; KOIKE M, 1994, INT ARCH ALLERGY IMM, V104, P1, DOI 10.1159/000236702; LASSALLE P, 1993, CLIN EXP IMMUNOL, V94, P105; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; POBER JS, 1986, J IMMUNOL, V137, P1893; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379, DOI 10.1164/ajrccm/144.2.379; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866	20	93	98	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					693	698		10.1016/S0091-6749(97)70032-0	http://dx.doi.org/10.1016/S0091-6749(97)70032-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155837	Bronze			2022-12-18	WOS:A1997WY60000018
J	Chen, ZP; Posch, A; Lohaus, C; RaulfHeimsoth, M; Meyer, HE; Baur, X				Chen, ZP; Posch, A; Lohaus, C; RaulfHeimsoth, M; Meyer, HE; Baur, X			Isolation and identification of hevein as a major IgE-binding polypeptide in Hevea latex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hevein; latex allergy; IgE antibody; latex proteins	SPINA-BIFIDA PATIENTS; MASS-SPECTROMETRY; BRASILIENSIS; ALLERGY; PROTEINS; HYPERSENSITIVITY; POLYACRYLAMIDE; PREVALENCE	Background: Polypeptides in Hevea latex are known as the major cause of latex type I sensitivities. So far, only a few of them have been characterized. Methods: Proteins with a molecular weight lower than 10 kd in fresh Hevea latex were separated by ultrafiltration and further characterized by liquid chromatography on-line-coupled electrospray mass spectrometry. Hevein in this fraction was then purified by preparative reverse-phase high-performance liquid chromatography and characterized by matrix-assisted laser desorption ionization mass spectrometry and protein sequencing. Skin prick tests, enzyme-linked allergosorbent tests, and inhibition immunoblotting were performed to show the allergenicity of the purified hevein. Results: Hevein, a 4.7 kd polypeptide, is the predominant component in the fraction with latex proteins of smaller than 10 kd. Specific IgE antibodies to hevein were detected by enzyme-linked allergosorbent test in 48 of 64 (75%) sera from health care workers allergic to latex and in three of 11 (27%) sera from patients with spina bifida and hypersensitivity reactions to latex. Inhibition immunoblotting demonstrated that the preincubation of 14 sera and a serum pool from patients allergic to latex with purified hevein completely inhibited IgE binding to the 20 kd protein, which has been recently reported to be a major allergen in latex (prohevein). Skin prick testing showed a positive reaction to hevein in 17 of 21 (81%) patients with latex allergy. Conclusions: The results clearly demonstrate that hevein is an important latex allergen, and the IgE-binding capacity of prohevein in latex is mostly attributed to hevein, the N-terminal domain of prohevein.	RUHR UNIV BOCHUM, INST PHYSIOL CHEM 1 IMMUNOL, D-4630 BOCHUM, GERMANY	Ruhr University Bochum	Chen, ZP (corresponding author), BGFA, RES INST OCCUPAT MED, BUERKLE CAMP PL 1, D-44789 BOCHUM, GERMANY.							ACHER BL, 1960, BIOCHEM J, V75, P236; AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; BURLINGAME AL, 1994, ANAL CHEM, V66, pR634; Chen Z, 1996, CLIN EXP ALLERGY, V26, P406, DOI 10.1046/j.1365-2222.1996.d01-327.x; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DAUZAC J, 1995, PLANT PHYSIOL BIOCH, V33, P765; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P673; KONZ KR, 1995, J ALLERGY CLIN IMMUN, V95, P950, DOI 10.1016/S0091-6749(95)70094-3; KURUP VP, 1995, IMMUNOL ALLERGY CLIN, V15, P45; KUSH A, 1994, PLANT PHYSIOL BIOCH, V32, P761; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LEE H, 1991, J BIOL CHEM, V266, P15944; LU LJ, 1995, J IMMUNOL, V155, P2721; MOCK K, 1993, J CHROMATOGR, V646, P169, DOI 10.1016/S0021-9673(99)87018-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; SOEDJANAATMADJA UMS, 1995, FEBS LETT, V363, P211, DOI 10.1016/0014-5793(95)00309-W; SOEDJANAATMADJA UMS, 1994, BBA-PROTEIN STRUCT M, V1209, P144, DOI 10.1016/0167-4838(94)90150-3; TOSI LL, 1993, J PEDIATR ORTHOPED, V13, P709, DOI 10.1097/01241398-199311000-00003; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; Walujono K., 1976, P INT RUBBER C KUALA, V2, P518; YASSIN MS, 1994, ANN ALLERGY, V72, P245	28	93	103	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					402	409		10.1016/S0091-6749(97)70059-9	http://dx.doi.org/10.1016/S0091-6749(97)70059-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058697				2022-12-18	WOS:A1997WM42200018
J	Ciprandi, G; Pronzato, C; Passalacqua, G; Ricca, V; Bagnasco, M; Grogen, J; Mela, GS; Canonica, GW				Ciprandi, G; Pronzato, C; Passalacqua, G; Ricca, V; Bagnasco, M; Grogen, J; Mela, GS; Canonica, GW			Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						topical azelastine; antiallergic activity; allergic inflammation; adhesion molecules; allergen specific nasal challenge; early phase; late phase	PERITONEAL MAST-CELLS; HISTAMINE-RELEASE; ALLERGIC SUBJECTS; CYTOLOGIC CHANGES; ASTHMA; CHALLENGE; CHEMOATTRACTANT; INTERLEUKIN-8; INFLAMMATION; INHIBITION	Background: It is well known that allergen-specific nasal challenge (ASNC) is a fruitful tool with which to evaluate antiallergic activity exerted by a drug. Azelastine is a new antihistamine also available in topical form (i.e., nasal spray). Objective: The aim of the study was to evaluate the effects of azelastine nasal spray on inflammatory changes after ASNC in both the early-phase reaction and the late-phase reaction. Methods: The study had a double-blind, placebo-controlled, randomized and parallel-group design. Twenty patients with pollen allergy were enrolled out of pollen season. ASNC was performed at baseline (T0) and after 1 week of washout (T7). At T7, 10 patients sprayed azelastine (1 puff) into their nostrils and 10 patients used placebo. ASNC was performed after 30 minutes. The considered parameters (evaluated during early- and late-phase reactions) were: (1) clinical signs and symptoms, (2) cytologic assessment (neutrophils and eosinophils), (3) assay of mediators (eosinophil cationic protein and myeloperoxidase), and (4) expression of intercellular adhesion molecule-1 (ICAM-1) on nasal epithelial cells. We focused our attention on ICAM-1 because it is the natural ligand of leukocyte functional associated antigen-1 and Mac-1, expressed on eosinophils. In addition, ICAM-1 is expressed on epithelial cells only on allergen exposure (both natural and experimental). Results: Placebo did not exert any modification on the considered parameters. After azelastine administration, significant decreases in total symptom score, eosinophilic and neutrophilic infiltration, and ICAM-1 expression were observed during both early- and late-phase reactions. Furthermore, serum eosinophil cationic protein levels decreased during the late-phase reaction, whereas myeloperoxidase was not affected by the treatment. These findings were confirmed by the powerful Koch's split-plot statistical analysis. Conclusion: Azelastine exerts antiallergic activity mainly affecting eosinophil function and downregulating ICAM-1 expression, on nasal epithelial cells.	UNIV GENOA,DEPT INTERNAL MED,ALLERGY & CLIN IMMUNOL SERV,I-16132 GENOA,ITALY; ASTA MED,INT MED DEPT,FRANKFURT,GERMANY; UNIV GENOA,DEPT INTERNAL MED,CLIN MED B,I-16126 GENOA,ITALY	University of Genoa; University of Genoa			Ciprandi, Giorgio/G-7462-2012; Mela, Giuseppe S/F-6072-2010; canonica, giorgio walter/ABF-2037-2020	Ciprandi, Giorgio/0000-0001-7016-8421; canonica, giorgio walter/0000-0001-8467-2557				ALTMAN LC, 1993, J ALLERGY CLIN IMMUN, V92, P527, DOI 10.1016/0091-6749(93)90077-S; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CALDERON E, 1992, J ALLERGY CLIN IMMUN, V90, P852, DOI 10.1016/0091-6749(92)90112-F; CANONICA GW, 1994, ALLERGY, V49, P135, DOI 10.1111/j.1398-9995.1994.tb00815.x; CHAND N, 1985, AGENTS ACTIONS, V16, P318, DOI 10.1007/BF01982866; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653, DOI 10.1164/ajrccm.150.6.7524984; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; CIPRANDI G, 1994, J ALLERGY CLIN IMMUN, V94, P738, DOI 10.1016/0091-6749(94)90182-1; CIPRANDI G, 1995, ALLERGY, V50, P186; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DURHAM SR, 1991, CLIN EXP ALLERGY, V21, P3, DOI 10.1111/j.1365-2222.1991.tb00797.x; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; FISHER B, 1981, ARZNEIMITTEL-FORSCH, V31, P1193; HAMILTON MA, 1991, TECHNOMETRICS, V33, P327, DOI 10.2307/1268784; KATAYAMA S, 1987, INT ARCH ALLER A IMM, V83, P284, DOI 10.1159/000234309; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; KOCH GG, 1970, BIOMETRICS, V26, P105, DOI 10.2307/2529048; LUNDBOOK J, 1991, CLIN EXP PHARM PHYSL, V18, P379; MCTAVISH D, 1989, DRUGS, V38, P778, DOI 10.2165/00003495-198938050-00005; MELTZER EO, 1994, ANN ALLERGY, V72, P354; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PELIKAN Z, 1988, J ALLERGY CLIN IMMUN, V82, P1103, DOI 10.1016/0091-6749(88)90150-9; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P1068, DOI 10.1016/0091-6749(89)90448-X; SEHMI R, 1993, CLIN EXP ALLERGY, V23, P1027, DOI 10.1111/j.1365-2222.1993.tb00295.x; SHIN MH, 1992, CLIN EXP ALLERGY, V22, P289, DOI 10.1111/j.1365-2222.1992.tb03085.x; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; VILLAR MTA, 1993, AM REV RESPIR DIS, V147, pA242; WALKER C, 1994, CLIN EXP ALLERGY, V24, P203	29	93	99	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1088	1096		10.1016/S0091-6749(96)80196-5	http://dx.doi.org/10.1016/S0091-6749(96)80196-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977510				2022-12-18	WOS:A1996WB37800014
J	Eigenmann, PA; Burks, AW; Bannon, GA; Sampson, HA				Eigenmann, PA; Burks, AW; Bannon, GA; Sampson, HA			Identification of unique peanut and soy allergens in sera adsorbed with cross-reacting antibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; peanut; soybean; legumes cross-reactivity; affinity chromatography	LEGUME BOTANICAL FAMILY; ATOPIC-DERMATITIS; FOOD HYPERSENSITIVITY; CHALLENGES; CHILDREN; PROTEINS; EXTRACTS	Background: Soybean and peanut are members of the legume family and share several common antigenic fractions. Patients allergic to one of these foods have serum IgE antibodies that immunologically cross-react with other legumes. Nevertheless, ingestion of other legumes generally does not induce an allergic reaction, suggesting that cross-reacting antibodies are not clinically relevant. Objective: This study was designed to identify unique peanut or soybean antigenic fi actions, with sera adsorbed to remove cross-reacting antibodies, thus resulting in sera with IgE antibodies unique to either soy or peanut. Methods: Cross-reacting antibodies to soy were removed from the sera of two patients allergic to peanut and soy and three patients allergic to peanut by soy-affinity chromatography. Cross-reacting antibodies to peanut were adsorbed from the sera of a patient allergic to peanut and soy and a patient allergic to peanut by peanut-affinity chromatography. Adequate removal of cross-reacting antibodies was verified by ELISA after each adsorption step. Unadsorbed sera and sera adsorbed to remove cross-reacting antibodies (either to soy or to peanut) were assayed for specific IgE binding to peanut oi soy immunoblots. Results: Unique peanut-specific IgE antibodies (i.e., soy antibody-adsorbed) were found to bind to peanut fractions at 46, 29, 25, 19, 17, 14, and 5 kd on immunoblots of whole peanut protein. Similarly, unique soy-specific IgE (i.e., peanut antibody-adsorbed) were found to bind a fraction at 46 kd, and to a lesser extent, to a fraction at 21 kd on immunoblots of whole soy protein. The 73% reduction of IgE antibody binding to peanut by ELISA after adsorption of cross-reacting antibodies indicates extensive cross-reactivity between soy and peanut antigens. Conclusions: Antigen-affinity chromatography is an effective method for removal of cross-reacting antibodies. We identified IgE antibody binding (with sera where cross-reacting antibodies were removed) to several unique antigenic fractions of peanut and soy. Further studies will determine the clinical significance of these fractions in IgE-mediated food hypersensitivity reactions.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; UNIV ARKANSAS MED SCI HOSP, LITTLE ROCK, AR USA	Johns Hopkins University; University of Arkansas System; University of Arkansas Medical Sciences			Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24439] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P889, DOI 10.1016/0091-6749(92)90461-A; BUSH RK, 1988, J ALLERGY CLIN IMMUN, V82, P251, DOI 10.1016/0091-6749(88)91007-X; Chee P P, 1991, Subcell Biochem, V17, P31; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; HEFLE SL, 1995, J ALLERGY CLIN IMMUN, V95, P837, DOI 10.1016/S0091-6749(95)70127-3; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; OGAWA T, 1991, J NUTR SCI VITAMINOL, V37, P555, DOI 10.3177/jnsv.37.555; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2	19	93	98	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				969	978		10.1016/S0091-6749(96)80014-5	http://dx.doi.org/10.1016/S0091-6749(96)80014-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939161	hybrid			2022-12-18	WOS:A1996VU76400014
J	Altman, DR; Chiaramonte, LT				Altman, DR; Chiaramonte, LT			Public perception of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; food hypersensitivity; food intolerance; allergy; epidemiology; prevalence; perception; diagnosis; self-diagnosis; consumer	ELIMINATION DIETS; MILK ALLERGY; INTOLERANCE; PREVALENCE; POPULATION; CHILDHOOD; CHILDREN; RICKETS; ECZEMA	Background: Although studies that rise the double-blind placebo-controlled food challenge suggest that the prevalence of food allergy is about 2%, public belief in food allergy appears to be considerably higher. Objective: The study was undertaken to deter-mine the magnitude and features of the American public's belief in food allergy by surveying a large, demographically balanced population. Methods: A simple question about food allergy was incorporated into a broad, self-reported, mailed consumer questionnaire. Five thousand demographically representative American households were surveyed by means of quota sample in 1989, 1992 and 1993. Results: The response rates were 79%, 75%, and 74%, respectively. Of responding households, 16.2%, 16.6%, and 13.9%, respectively reported an average of 1.17 household members with food allergy. Individuals reported to be allergic to foods were more likely to be female particularly adult women. Male individuals with reported food allergy tended to be young, whereas no such skew was noted among female subjects. Geographic differences were observed in reported food allergy, with the highest rate in the Pacific region. Milk and chocolate were the individual foods most frequently implicated in food allergy. Trends were consistent over the period studied. Conclusions: Perceived food allergy is widespread and persistent. The characteristics and demographic patterns of this belief are not reflective of known food allergy epidemiology derived from studies in which the double-blind placebo-controlled food challenge is used.	FOOD ALLERGY CTR,LYNBROOK,NY; LONG ISL COLL HOSP,DEPT ALLERGY & IMMUNOL,BROOKLYN,NY 11201	Long Island College Hospital								*AM AC ALL IMM INT, 1993, UND FOOD ALL; BERKMAN HW, 1986, CONSUMER BEHAV CONCE, P41; BIERMAN CW, 1978, J ALLERGY CLIN IMMUN, V61, P119; BOCK SA, 1987, PEDIATRICS, V79, P683; BURKS AW, 1992, J PEDIATR-US, V121, pS64, DOI 10.1016/S0022-3476(05)81409-X; DAVID TJ, 1984, ARCH DIS CHILD, V59, P323, DOI 10.1136/adc.59.4.323; DAVIDOVITS M, 1993, J PEDIATR-US, V122, P249, DOI 10.1016/S0022-3476(06)80124-1; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; GERRARD JW, 1973, ACTA PAEDIATR SC   S, V4, P3; *GOOD HOUS I COM R, 1984, WOM OP FOOD ALL; *GOOD HOUS I CONS, 1989, CHILD CAR FIND 5 CHI; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; JARVIS WT, 1993, NEW YORK STATE J MED, V93, P100; JOHNSON AO, 1993, AM J CLIN NUTR, V57, P399, DOI 10.1093/ajcn/57.3.399; KAYOSAARI M, 1982, ACTA PAEDIATR SCAND, V71, P815; LABIB M, 1989, BRIT MED J, V298, P32; LLOYDSTILL JD, 1979, J PEDIATR-US, V95, P10, DOI 10.1016/S0022-3476(79)80074-8; PEARSON DJ, 1985, PAR PSEUDOALLERGIC R, V4, P59; ROBERTSON DAF, 1988, BRIT MED J, V297, P719, DOI 10.1136/bmj.297.6650.719-a; SAMPSON HA, 1990, CURR OPIN IMMUNOL, V2, P542, DOI 10.1016/0952-7915(90)90008-5; SAMPSON HA, 1991, FOOD ALLERGY ADVERSE, P100; STINTZING G, 1979, ACTA PAEDIATR SCAND, V68, P383, DOI 10.1111/j.1651-2227.1979.tb05024.x; US Bureau of the Census, 1991, STAT ABSTR US; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8	25	93	102	1	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1247	1251		10.1016/S0091-6749(96)70192-6	http://dx.doi.org/10.1016/S0091-6749(96)70192-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648020				2022-12-18	WOS:A1996VD60700012
J	Kristjansson, S; Strannegard, IL; Strannegard, Q; Peterson, C; Enander, I; Wennergren, G				Kristjansson, S; Strannegard, IL; Strannegard, Q; Peterson, C; Enander, I; Wennergren, G			Urinary eosinophil protein X in children with atopic asthma: A useful marker of antiinflammatory treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRONCHOALVEOLAR LAVAGE; CATIONIC PROTEIN; ALLERGIC INFLAMMATION; BUDESONIDE; CELLS; ECP	Background: Bronchial asthma is associated with elevated serum levels of eosinophil products, such as eosinophil protein X (EPX), but the occurrence in urine of this substance in patients with asthma has not previously been studied. Objective: This study was performed to clarify whether increased amounts of eosinophil granulocyte proteins in urine and serum reflect ongoing asthmatic inflammation and whether decreasing values reflect successful treatment. Methods: Twelve children with a median age of 12.5 years who had mild or moderate atopic asthma were studied for 3 months. At the time of inclusion in the study, treatment with inhaled budesonide was initiated. Nine children of the same age without atopic disease served as control subjects. Levels of EPX, eosinophil cationic protein (ECP), and myeloperoxidase in serum and in urine (urinary EPX) were determined at inclusion and then after 3 months of treatment. Spirometry was performed on the same occasions. Results: At the time of inclusion, urinary EPX and serum ECP were significantly higher in children with atopic asthma than in the control subjects (mean, 116.4 vs 43.0 mu g/mmol creatinine [p = 0.004] and 37.0 vs 14.8 mu g/L [p = 0.004]). In the asthma group urinary EPX, as well as serum ECP, decreased significantly after 3 months of treatment with budesonide (116.4 to 68.4 mu g/mmol creatinine [p = 0.005] and 37.0 to 24.0 mu g/L [p = 0.04]). At the same time, peak expiratory flow values increased significantly in the children with asthma (76.0% to 87.8% of predicted value [p = 0.005]) but not in the control subjects (87.0% to 90.1%). In the asthma group the levels of myeloperoxidase were similar to those in the control group, both at inclusion and after 3 months. Conclusion: Increased urinary EPX and serum ECP levels seem to reflect active atopic asthma, whereas decreased levels after antiinflammatory treatment probably reflect normalization of airway inflammation, and indirectly, improved lung function.	GOTHENBURG UNIV,DEPT PAEDIAT,S-41124 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT VIROL,S-41124 GOTHENBURG,SWEDEN; PHARMACIA DIAGNOST AB,S-75182 UPPSALA,SWEDEN	University of Gothenburg; University of Gothenburg; Pfizer; Pharmacia Corporation								ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; AHLSTEDT S, 1992, Pharmaceutical Medicine (London), V6, P99; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CARLSON M, 1988, AM REV RESPIR DIS, V138, P54; COCKCROFT DW, 1991, J ALLERGY CLIN IMMUN, V87, P914, DOI 10.1016/0091-6749(91)90412-H; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FORESI A, 1990, CHEST, V98, P528, DOI 10.1378/chest.98.3.528; FREDENS K, 1982, J ALLERGY CLIN IMMUN, V70, P361, DOI 10.1016/0091-6749(82)90025-2; FRIGAS E, 1991, EUR RESP J S13, V4, P123; FUJISAWA T, 1990, J IMMUNOL, V144, P642; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; Kristjansson S, 1994, Pediatr Allergy Immunol, V5, P223, DOI 10.1111/j.1399-3038.1994.tb00244.x; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; PERIN PV, 1994, J ALLERGY CLIN IMMUN, V94, P517, DOI 10.1016/0091-6749(94)90208-9; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; PFAFF JK, 1994, PEDIATR CLIN N AM, V41, P401; REIMERT CM, 1993, ACTA TROP, V54, P1, DOI 10.1016/0001-706X(93)90063-H; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; VENGE P, 1988, AM REV RESPIR DIS, V138, P54; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WARNER JO, 1992, ARCH DIS CHILD, V67, P240	29	93	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1179	1187		10.1016/S0091-6749(96)70182-3	http://dx.doi.org/10.1016/S0091-6749(96)70182-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648010				2022-12-18	WOS:A1996VD60700002
J	ZIEG, G; LACK, G; HARBECK, RJ; GELFAND, EW; LEUNG, DYM				ZIEG, G; LACK, G; HARBECK, RJ; GELFAND, EW; LEUNG, DYM			IN-VIVO EFFECTS OF GLUCOCORTICOIDS ON IGE PRODUCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; ASTHMA; PREDNISONE; CORTICOSTEROIDS	HUMAN B-CELLS; INTERFERON-GAMMA; POKEWEED MITOGEN; SERUM IGE; T-CELLS; ASTHMA; INTERLEUKIN-4; INDUCTION; HYDROCORTISONE; INHIBITION	Recent in vitro investigations have demonstrated that corticosteroids in combination with interleukin-4 induce the synthesis of IgE. Corticosteroids are increasingly being used to treat the inflammatory component of asthma, This has raised concern over the potential in vivo effects of corticosteroids on IgE production and the correlation of IgE-enhancing effects with clinical effects on asthma. In this study 10 patients with asthma were given a 7-day course of 20 mg of prednisone, administered orally two times a day. All of the patients had a rise in serum IgE levels after the course of prednisone (p = 0.005). Detection of specific IgE to pollen and perennial allergens demonstrated that the rise in serum IgE was polyclonal. Peripheral blood mononuclear cells from patients treated with prednisone produced increased levels of IgE in vitro when exogenous IL-4 was added to their cultures. Peripheral blood mononuclear cells obtained from patients before and after administration of prednisone revealed a significant decrease in interferon-gamma synthesis (p = 0.005), but not in interleukin-4 (p = 0.6), after the course of prednisone. These findings were paralleled by a significant decrease in the frequency of interferon-gamma (p = 0.03), bur not interleukin-4 (p = 1.0) expressing cells. Despite the increase in IgE synthesis, there was a significant increase in forced expiratory volume in 1 second after the course of prednisone (p = 0.01). These data suggest that the observed rise in IgE production associated with prednisone treatment is not clinically deleterious bur reflects the immunomodulatory effects of corticosteroids on T lymphocytes.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206	National Jewish Health					NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-29704] Funding Source: Medline; NIAMS NIH HHS [AR-41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BYRON KA, 1992, IMMUNOLOGY, V77, P624; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DAYNES RA, 1989, EUR J IMMUNOL, V19, P2319, DOI 10.1002/eji.1830191221; GEHA RS, 1992, J ALLERGY CLIN IMMUN, V90, P143, DOI 10.1016/0091-6749(92)90064-9; GESSANI S, 1988, J BIOL CHEM, V263, P7454; HILL MR, 1990, CLIN PHARMACOL THER, V48, P390, DOI 10.1038/clpt.1990.167; JABARA HH, 1991, J IMMUNOL, V147, P1557; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JABARA HH, 1990, J IMMUNOL, V145, P3468; JUJO K, 1993, J ALLERGY CLIN IMMUN, V91, P1206, DOI 10.1016/0091-6749(93)90324-9; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; POSEY WC, 1978, J ALLERGY CLIN IMMUN, V62, P340, DOI 10.1016/0091-6749(78)90134-3; SARFATI M, 1989, J EXP MED, V170, P1775, DOI 10.1084/jem.170.5.1775; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SETTIPANE GA, J ALLERGY CLIN IMMUN, P162; Snedecor G. W, 1989, STAT METHODS, V8th; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; 1987, AM REV RESPIR DIS, V136, P225	23	93	95	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					222	230		10.1016/0091-6749(94)90044-2	http://dx.doi.org/10.1016/0091-6749(94)90044-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064074				2022-12-18	WOS:A1994PC92600013
J	GOURLEY, DS; WHISMAN, BA; JORGENSEN, NL; MARTIN, ME; REID, MJ				GOURLEY, DS; WHISMAN, BA; JORGENSEN, NL; MARTIN, ME; REID, MJ			ALLERGIC BIPOLARIS SINUSITIS - CLINICAL AND IMMUNOPATHOLOGIC CHARACTERISTICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILFORD HALL USAF MED CTR,DEPT MED,ALLERGY & IMMUNOL SERV,LACKLAND AFB,TX 78236; WILFORD HALL USAF MED CTR,DEPT PATHOL,LACKLAND AFB,TX 78236	United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force								ADAM RD, 1986, MEDICINE, V65, P203, DOI 10.1097/00005792-198607000-00001; ANTOINE GA, 1989, OTOLARYNG HEAD NECK, V100, P158; AYRES WW, 1958, AM J CLIN PATHOL, V30, P323, DOI 10.1093/ajcp/30.4.323; BENATAR SR, 1980, THORAX, V35, P515, DOI 10.1136/thx.35.7.515; BRUMMUND W, 1986, JAMA-J AM MED ASSOC, V256, P3249; DEJUAN E, 1983, AM J OPHTHALMOL, V96, P299, DOI 10.1016/S0002-9394(14)77818-3; Ellis M. B., 1971, DEMATIACEOUS HYPHOMY, P415; FRENKEL L, 1987, PEDIATR INFECT DIS J, V6, P1130, DOI 10.1097/00006454-198706120-00012; GOLDSTEIN MF, 1985, J ALLERGY CLIN IMMUN, V76, P515, DOI 10.1016/0091-6749(85)90737-7; HALWIG JM, 1985, AM REV RESPIR DIS, V132, P186; HARPSTER WH, 1985, OTOLARYNG HEAD NECK, V93, P683; HENDRICK DJ, 1982, AM REV RESPIR DIS, V126, P935; JAY WM, 1988, AM J OPHTHALMOL, V105, P366, DOI 10.1016/0002-9394(88)90299-1; JORGENSEN JH, 1986, CLIN DICT BACTERIA F, P70; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; MCALEER R, 1981, THORAX, V36, P338, DOI 10.1136/thx.36.5.338; MCGINNIS MR, 1986, J CLIN MICROBIOL, V24, P250, DOI 10.1128/JCM.24.2.250-259.1986; MILLAR JW, 1981, THORAX, V36, P710; NAUL LG, 1988, AJNR, V8, P574; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PRATT MF, 1988, LARYNGOSCOPE, V97, P1343; REID MJ, 1982, J ALLERGY CLIN IMMUN, V70, P191, DOI 10.1016/0091-6749(82)90041-0; REID MJ, 1985, J ALLERGY CLIN IMMUN, V76, P172, DOI 10.1016/0091-6749(85)90697-9; ROLSTON KVI, 1985, REV INFECT DIS, V7, P525; SOBOL SM, 1984, LARYNGOSCOPE, V94, P620; WAXMAN JE, 1987, LARYNGOSCOPE, V97, P261; YOUNG CN, 1978, J LARYNGOL OTOL, V152, P137; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V57, P293, DOI 10.1016/0091-6749(76)90085-3; ZINREICH SJ, 1988, RADIOLOGY, V169, P439, DOI 10.1148/radiology.169.2.3174990	30	93	98	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					583	591		10.1016/0091-6749(90)90097-N	http://dx.doi.org/10.1016/0091-6749(90)90097-N			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2312993				2022-12-18	WOS:A1990CU66800008
J	HEJJAOUI, A; DHIVERT, H; MICHEL, FB; BOUSQUET, J				HEJJAOUI, A; DHIVERT, H; MICHEL, FB; BOUSQUET, J			IMMUNOTHERAPY WITH A STANDARDIZED DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT .4. SYSTEMIC REACTIONS ACCORDING TO THE IMMUNOTHERAPY SCHEDULE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU MONTPELLIER, MALAD RESP CLIN, AVE MAJOR FLANDRE, F-34059 MONTPELLIER, FRANCE	Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019					AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; ANDERSON JA, 1986, J ALLERGY CLIN IMMUN, V77, P271, DOI 10.1016/S0091-6749(86)80103-8; [Anonymous], 1986, BMJ-BRIT MED J, V293, P948; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; CRAPS LP, 1985, BRONCHIAL ASTHMA MEC, P734; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; DREBORG S, 1987, THESIS LINKOPING U L; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; LESSOF M, 1983, P INT ALLERGY WORKSH, P1; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; NELSON BL, 1986, ANN ALLERGY, V56, P331; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; SCHLEIMER RP, 1988, ALLERGY PRINCIPLES P, P739; SUDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478; THOMPSON RA, 1989, LANCET, V1, P259; VANARSDEL PP, 1957, J ALLERGY, V28, P251, DOI 10.1016/0021-8707(57)90130-2; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x	29	93	97	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					473	479		10.1016/0091-6749(90)90157-Y	http://dx.doi.org/10.1016/0091-6749(90)90157-Y			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2406324				2022-12-18	WOS:A1990CP51100008
J	KUNA, P; ALAM, R; KUZMINSKA, B; ROZNIECKI, J				KUNA, P; ALAM, R; KUZMINSKA, B; ROZNIECKI, J			THE EFFECT OF PRESEASONAL IMMUNOTHERAPY ON THE PRODUCTION OF HISTAMINE-RELEASING FACTOR (HRF) BY MONONUCLEAR-CELLS FROM PATIENTS WITH SEASONAL ASTHMA - RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LODZ MED ACAD,INST INTERNAL MED,DEPT PNEUMONOL & ALLERGOL,LODZ,POLAND					Kuna, Piotr/0000-0003-2401-0070				ALAM R, 1988, J IMMUNOL, V140, P1946; ALAM R, 1985, ALLERGY, V40, P124, DOI 10.1111/j.1398-9995.1985.tb02671.x; ALAM R, 1988, ANN ALLERGY, V60, P163; ALAM R, 1987, J ALLERGY CLIN IMMUN, V79, P103, DOI 10.1016/S0091-6749(87)80023-4; ALAM R, 1984, ANN ALLERGY, V53, P66; BAEZA ML, 1988, J ALLERGY CLIN IMMUN, V81, P225, DOI 10.1016/0091-6749(88)90464-2; BAEZA ML, 1988, CLIN RES, V36, pA539; COCKCROFT DW, 1987, ANN ALLERGY, V59, P405; EZEAMUZIE IC, 1983, AGENTS ACTIONS, V13, P222, DOI 10.1007/BF01967337; GOETZL EJ, 1984, IMMUNOLOGY, V53, P227; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KO HS, 1987, ANN ALLERGY, V59, P441; LEONARD EJ, 1984, J LEUKOCYTE BIOL, V35, P169; LETTBROWN MA, 1984, CELL IMMUNOL, V87, P434, DOI 10.1016/0008-8749(84)90012-1; LICHTENSTEIN LM, 1988, J ALLERGY CLIN IMMUN, V81, P814, DOI 10.1016/0091-6749(88)90936-0; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; METZGER WJ, 1981, J ALLERGY CLIN IMMUN, V68, P442, DOI 10.1016/0091-6749(81)90198-6; MILLER ACML, 1974, CLIN ALLERGY, V4, P49, DOI 10.1111/j.1365-2222.1974.tb01362.x; MORAN DM, 1977, INT ARCH ALLER A IMM, V54, P315, DOI 10.1159/000231843; MOSS RB, 1987, J ALLERGY CLIN IMMUN, V79, P387, DOI 10.1016/0091-6749(87)90160-6; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PATTERSON R, 1983, ALLERGY PRINCIPLES P, P1119; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; THUESON DO, 1979, J IMMUNOL, V123, P626; WARNER JA, 1986, J IMMUNOL, V136, P2583; WHITE M, 1988, FASEB J, V2, pA1232; WHITE MV, 1987, J IMMUNOL, V139, P1624	30	93	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					816	824		10.1016/0091-6749(89)90020-1	http://dx.doi.org/10.1016/0091-6749(89)90020-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2468702				2022-12-18	WOS:A1989U342000017
J	STRAUS, SE; DALE, JK; WRIGHT, R; METCALFE, DD				STRAUS, SE; DALE, JK; WRIGHT, R; METCALFE, DD			ALLERGY AND THE CHRONIC FATIGUE SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID, CLIN INVEST LAB, MAST CELL PHYSIOL SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	STRAUS, SE (corresponding author), NIAID, MED VIROL SECT, BLDG 10, ROOM 11N-113, BETHESDA, MD 20892 USA.							ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BORYSIEWICZ LK, 1986, Q J MED, V58, P111; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CHANYEUNG M, 1985, ARCH ENVIRON HEALTH, V40, P53, DOI 10.1080/00039896.1985.10545889; CLUFF LE, 1959, ARCH INTERN MED, V103, P398, DOI 10.1001/archinte.1959.00270030037004; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; HOLMES GP, 1987, JAMA-J AM MED ASSOC, V257, P2297, DOI 10.1001/jama.257.17.2297; HORWITZ CA, 1985, J INFECT DIS, V151, P1150, DOI 10.1093/infdis/151.6.1150; IMBODEN JB, 1961, ARCH INTERN MED, V108, P393, DOI 10.1001/archinte.1961.03620090065008; IMBODEN JB, 1959, ARCH INTERN MED, V103, P406, DOI 10.1001/archinte.1959.00270030037004; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; KIBLER R, 1985, J CLIN IMMUNOL, V5, P46, DOI 10.1007/BF00915168; KUIS W, 1985, J CLIN IMMUNOL, V5, P377, DOI 10.1007/BF00915334; MILLER G, 1987, J INFECT DIS, V156, P26, DOI 10.1093/infdis/156.1.26; OLSON GB, 1986, J ALLERGY CLIN IMMUN, V78, P308, DOI 10.1016/S0091-6749(86)80081-1; OLSON GB, 1986, J ALLERGY CLIN IMMUN, V78, P315, DOI 10.1016/S0091-6749(86)80082-3; RYSTEDT I, 1984, INT ARCH ALLER A IMM, V75, P179, DOI 10.1159/000233610; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SCHOOLEY RT, 1986, ANN INTERN MED, V104, P636, DOI 10.7326/0003-4819-104-5-636; Scott G M, 1983, Interferon, V5, P85; STEIN M, 1985, J IMMUNOL, V135, pS827; STRANNEGARD IL, 1981, INT ARCH ALLER A IMM, V64, P314, DOI 10.1159/000232709; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; STRAUS SE, 1987, CLIN RES, V35, pA618; TOBI M, 1982, LANCET, V1, P61; TOSATO G, 1985, J IMMUNOL, V134, P3082; ZIMMERMAN B, 1985, CAN MED ASSOC J, V133, P965	29	93	94	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				791	795		10.1016/0091-6749(88)90933-5	http://dx.doi.org/10.1016/0091-6749(88)90933-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	2836490				2022-12-18	WOS:A1988N703600005
J	BOUSQUET, J; HEJJAOUI, A; SKASSABROCIEK, W; GUERIN, B; MAASCH, HJ; DHIVERT, H; MICHEL, FB				BOUSQUET, J; HEJJAOUI, A; SKASSABROCIEK, W; GUERIN, B; MAASCH, HJ; DHIVERT, H; MICHEL, FB			DOUBLE-BLIND, PLACEBO-CONTROLLED IMMUNOTHERAPY WITH MIXED GRASS-POLLEN ALLERGOIDS .1. RUSH IMMUNOTHERAPY WITH ALLERGOIDS AND STANDARDIZED ORCHARD GRASS-POLLEN EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LABS STALLERGENES,JOINVILLE LE PONT,FRANCE; ALLERGOPHARMA JOACHIM GANZER KG,REINBECK,FED REP GER	Stallergenes Greer; Allergopharma	BOUSQUET, J (corresponding author), CHU MONTPELLIER,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; BAUMGARTEN C, 1984, RESPIRATION, V46, P97, DOI 10.1159/000194676; BERG T, 1980, INT ARCH ALLER A IMM, V63, P266, DOI 10.1159/000232636; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COUR P, 1973, POLLEN SPORES, V16, P103; FROSTAD AB, 1980, ALLERGY, V35, P81, DOI 10.1111/j.1398-9995.1980.tb01722.x; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V68, P449, DOI 10.1016/0091-6749(81)90199-8; MERINEY DK, 1986, ANN ALLERGY, V56, P34; NORDVALL SL, 1978, INT ARCH ALLER A IMM, V67, P132; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; PUTTONEN E, 1981, INT ARCH ALLER A IMM, V64, P157, DOI 10.1159/000232687; PUTTONEN E, 1982, INT ARCH ALLER A IMM, V68, P1, DOI 10.1159/000233058; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7	21	93	96	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					591	598		10.1016/0091-6749(87)90013-3	http://dx.doi.org/10.1016/0091-6749(87)90013-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3668124				2022-12-18	WOS:A1987K522400013
J	CARROLL, MP; DURHAM, SR; WALSH, G; KAY, AB				CARROLL, MP; DURHAM, SR; WALSH, G; KAY, AB			ACTIVATION OF NEUTROPHILS AND MONOCYTES AFTER ALLERGEN-INDUCED AND HISTAMINE-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,FULHAM RD,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital								ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; CARROLL M, 1983, CLIN EXP IMMUNOL, V54, P785; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; FEARON DT, 1983, J IMMUNOL, V130, P370; GLASS EJ, 1980, CLIN EXP IMMUNOL, V39, P768; GONZALEZMOLINA A, 1977, J CLIN INVEST, V59, P616, DOI 10.1172/JCI108679; KAY AB, 1979, CLIN EXP IMMUNOL, V38, P294; KAY AB, 1970, CLIN EXP IMMUNOL, V7, P723; LACHMANN PJ, 1978, HDB EXPT IMMUNOLOGY, pCH5; LARSEN GL, 1984, ASTHMA PHYSL IMMUNOP, P245; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PAPAGEORGIOU N, 1983, LANCET, V2, P1220; PRANGBURN MK, 1980, FED PROC, V39, P702; WALSH G, 1984, Journal of Allergy and Clinical Immunology, V73, P171	18	93	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					290	296		10.1016/0091-6749(85)90060-0	http://dx.doi.org/10.1016/0091-6749(85)90060-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	3881502				2022-12-18	WOS:A1985ABZ0500010
J	FORD, A; SEAGROATT, V; PLATTSMILLS, TAE; LOWENSTEIN, H				FORD, A; SEAGROATT, V; PLATTSMILLS, TAE; LOWENSTEIN, H			A COLLABORATIVE STUDY ON THE 1ST INTERNATIONAL STANDARD OF DERMATOPHAGOIDES-PTERONYSSINUS (HOUSE DUST MITE) EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL INST BIOL STAND & CONTROL,STAT SECT,LONDON NW3 6RB,ENGLAND; UNIV VIRGINIA,MED CTR,SCH MED,CHARLOTTESVILLE,VA 22901; UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK	National Institute for Biological Standards & Control; University of Virginia; University of Copenhagen	FORD, A (corresponding author), NATL INST BIOL STAND & CONTROL,IMMUNOL SECT,HOLY HILL,LONDON NW3 6RB,ENGLAND.							AALBERSE R, UNPUB; AAS K, 1978, ALLERGEN EXTRALETE, P38; BAKER P. R. W., 1955, JOUR HYG, V53, P426; BEERENS L, 1975, DER BIOL STAND, V29, P235; BLAKESLEY RW, 1977, ANAL BIOCHEM, V82, P580, DOI 10.1016/0003-2697(77)90197-X; BUCHLER W, 1968, Z ANAL CHEM FRESENIU, V237, P104; CAMPBELL PJ, 1974, J BIOL STAND, V2, P259, DOI 10.1016/0092-1157(74)90034-1; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1981, THESIS LONDON; Finney D, 1978, STATISTICAL METHOD B, P69; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; KAUFFMAN JF, 1984, J ALLERGY CLIN IMMUN, V73, P567; Kirkwood TBL, 1979, BIOMETRICS, V35, P908; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1980, ALLERGY, V35, P227, DOI 10.1111/j.1398-9995.1980.tb01756.x; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; LIND P, 1981, 14 SCAND C ALL GOT; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Meshcheriakova S A, 1971, Lab Delo, V2, P103; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P586; PETRUNOV B, 1979, ALLERGOL IMMUNOPATHO, V5, P319; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; SCHWARTZ J, 1983, INT ARCH ALLERGY, V30, P67; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; Voller A., 1976, AM SOC MICROBIOL, V17, P506; VOORHORST R, 1978, ALLERGOLOGIE, V1, P93; World Health Organization, 2011, WHO TECH REP SER; Yman L, 1975, Dev Biol Stand, V29, P151; 1978, WHO TECH REP SER, V626, P101	35	93	94	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					676	686		10.1016/0091-6749(85)90093-4	http://dx.doi.org/10.1016/0091-6749(85)90093-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	4008796	Bronze			2022-12-18	WOS:A1985ALA8400008
J	SCHWARTZ, HJ				SCHWARTZ, HJ			SENSITIVITY TO INGESTED METABISULFITE - VARIATIONS IN CLINICAL PRESENTATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University								CLAYTON DE, 1980, CLIN ALLERGY, V10, P341, DOI 10.1111/j.1365-2222.1980.tb02116.x; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; PRENNER BM, 1976, ANN ALLERGY, V37, P180; SIMON R A, 1982, Journal of Allergy and Clinical Immunology, V69, P118; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6	5	93	96	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					487	489		10.1016/0091-6749(83)90466-9	http://dx.doi.org/10.1016/0091-6749(83)90466-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6841828				2022-12-18	WOS:A1983QQ74200009
J	BOUCHER, RC; PARE, PD; HOGG, JC				BOUCHER, RC; PARE, PD; HOGG, JC			RELATIONSHIP BETWEEN AIRWAY HYPER-REACTIVITY AND HYPERPERMEABILITY IN ASCARIS-SENSITIVE MONKEYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27514; UNIV BRITISH COLUMBIA,ST PAULS HOSP,PULM RES LAB,VANCOUVER V5Z 1M9,BC,CANADA	University of North Carolina; University of North Carolina Chapel Hill; St. Paul's Hospital; University of British Columbia; University of Saskatchewan			Pare, Peter D/C-7425-2011					BOUCHER R C, 1977, Physiologist, V20, P11; BOUCHER RC, 1977, J ALLERGY CLIN IMMUN, V60, P134, DOI 10.1016/0091-6749(77)90039-2; BOUCHER RC, 1978, J APPL PHYSIOL, V45, P939, DOI 10.1152/jappl.1978.45.6.939; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P27, DOI 10.1159/000227898; JOHNSON J, 1978, AM REV RESPIR DIS, V117, P244; MICHOUD MC, 1978, J APPL PHYSIOL, V45, P846, DOI 10.1152/jappl.1978.45.6.846; NADEL JA, 1965, MED THORAC, V22, P231; PARE PD, 1976, J APPL PHYSIOL, V41, P668, DOI 10.1152/jappl.1976.41.5.668; PATTERSON R, 1976, J LAB CLIN MED, V87, P65; POPA V, 1973, J ALLERGY CLIN IMMUN, V51, P344, DOI 10.1016/0091-6749(73)90073-0; RICHARDSON JB, 1975, J ALLERGY CLIN IMMUN, V56, P473, DOI 10.1016/0091-6749(75)90065-2; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; RUFFIN RE, 1978, AM REV RESPIR DIS, V117, P485; SAMPSON SR, 1978, FED PROC, V37, P712; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2	17	93	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	3					197	201		10.1016/0091-6749(79)90095-2	http://dx.doi.org/10.1016/0091-6749(79)90095-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HL221	112136				2022-12-18	WOS:A1979HL22100007
J	SIMON, RA; STEVENSON, DD; ARROYAVE, CM; TAN, EM				SIMON, RA; STEVENSON, DD; ARROYAVE, CM; TAN, EM			RELATIONSHIP OF PLASMA HISTAMINE TO ACTIVITY OF BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN, INST MED, DIV ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BALDWA VS, 1976, ANN ALLERGY, V36, P117; BEALL GN, 1963, J ALLERGY, V34, P8, DOI 10.1016/0021-8707(63)90080-7; Beaven MA., 1975, HDB PSYCHOPHARMACOLO, V1, P253; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHIESA A, 1975, AM REV RESPIR DIS, V111, P148; CODE CF, 1957, J PHYSIOL-LONDON, V136, P449, DOI 10.1113/jphysiol.1957.sp005773; Code CF, 1939, AM J PHYSIOL, V127, P78, DOI 10.1152/ajplegacy.1939.127.1.78; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; Dale HH, 1919, J PHYSIOL-LONDON, V52, P355; DEGARA PF, 1951, J ALLERGY, V22, P429, DOI 10.1016/0021-8707(51)90146-3; Dragstedt CA, 1932, AM J PHYSIOL, V102, P512, DOI 10.1152/ajplegacy.1932.102.2.512; Gebauer-Fuelnegg E, 1932, AM J PHYSIOL, V102, P520, DOI 10.1152/ajplegacy.1932.102.2.520; JIMENEZDIAZ C, 1955, INT ARCH ALLER A IMM, V6, P243, DOI 10.1159/000228181; Katz G, 1941, J AMER MED ASSOC, V117, P1782, DOI 10.1001/jama.1941.02820470030008; Katz G, 1942, P SOC EXP BIOL MED, V49, P272; Lewis T., 1927, BLOOD VESSELS HUMAN; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; NOAH JW, 1955, J ALLERGY, V26, P385, DOI 10.1016/0021-8707(55)90029-0; NOAH JW, 1954, J ALLERGY, V25, P210, DOI 10.1016/0021-8707(54)90180-X; PATTERSON R, 1976, J LAB CLIN MED, V87, P1016; PORTER JF, 1970, CLIN SCI, V38, P135, DOI 10.1042/cs0380135; RANDOLPH THERON G., 1941, JOUR ALLERGY, V12, P450, DOI 10.1016/S0021-8707(41)90221-6; Rose B, 1941, J CLIN INVEST, V20, P419, DOI 10.1172/JCI101237; SCHILD HO, 1956, HISTAMINE CIBA F S, P138; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; STEVENSON DD, 1975, ARCH INTERN MED, V135, P777, DOI 10.1001/archinte.135.6.777; STEVENSON DD, 1976, CLIN ALLERGY, V6, P493, DOI 10.1111/j.1365-2222.1976.tb01934.x; Weiss S, 1929, AM HEART J, V4, P664, DOI 10.1016/S0002-8703(29)90550-0	30	93	93	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	5					312	316		10.1016/0091-6749(77)90111-7	http://dx.doi.org/10.1016/0091-6749(77)90111-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA243	915147				2022-12-18	WOS:A1977EA24300007
J	TWAROG, FJ; PICONE, FJ; STRUNK, RS; SO, J; COLTEN, HR				TWAROG, FJ; PICONE, FJ; STRUNK, RS; SO, J; COLTEN, HR			IMMEDIATE HYPERSENSITIVITY TO COCKROACH - ISOLATION AND PURIFICATION OF MAJOR ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR, DEPT MED, DIV ALLERGY, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, INA SUE PERLMUTTER CYST FIBROSIS CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School								BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1969, SOUTHERN MED J, V62, P1207, DOI 10.1097/00007611-196910000-00013; BERRENS L, 1974, ANN NY ACAD SCI, V221, P183, DOI 10.1111/j.1749-6632.1974.tb28216.x; Berrens L, 1970, Prog Allergy, V14, P259, DOI 10.1159/000289384; BERRENS L, 1973, CLIN ALLERGY, V3, P449, DOI 10.1111/j.1365-2222.1973.tb01352.x; BUNN HF, 1975, BIOCHEM BIOPH RES CO, V67, P103, DOI 10.1016/0006-291X(75)90289-2; CESKA M, 1973, INT ARCH ALLER A IMM, V45, P808, DOI 10.1159/000231081; COHEN MILTON B., 1939, JOUR ALLERGY, V10, P561, DOI 10.1016/S0021-8707(39)90250-9; COOVIVATHANAVAN.P, 1974, J MED ASSOC THAI, V57, P237; HALPIN LJ, 1963, ANN ALLERGY, V21, P577; JOHNSON P, 1965, EUR POLYM J, V1, P63; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANTOR SZ, 1966, ISRAEL J MED SCI, V2, P534; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MENDOZA J, 1970, ANN ALLERGY, V28, P159; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; OHMAN JL, 1975, J ALLERGY CLIN IMMUN, V55, P16, DOI 10.1016/S0091-6749(75)80004-2; PICONE FJ, 1975, J ALLERGY CLIN IMMUN, V55, P107; SCHULANER FA, 1970, PEDIATRICS, V45, P475; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; WAGNER HC, 1966, J ALLERGY, V7, P224; WEBER K, 1969, J BIOL CHEM, V244, P4406; 1965, 430 US DEP AGR LEAFL	26	93	94	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					154	160		10.1016/0091-6749(77)90218-4	http://dx.doi.org/10.1016/0091-6749(77)90218-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	64484				2022-12-18	WOS:A1977CV62200010
J	DVORAK, HF				DVORAK, HF			CUTANEOUS BASOPHIL HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University								ALLEN J R, 1973, International Journal for Parasitology, V3, P195, DOI 10.1016/0020-7519(73)90024-6; ASKENASE P, 1975, J ALLERGY CLIN IMMUN, V55, P111; ASKENASE PW, 1973, J EXP MED, V138, P1144, DOI 10.1084/jem.138.5.1144; ASKENASE PW, 1975, FED PROC, V34, P1039; BAST RC, 1971, J EXP MED, V133, P202, DOI 10.1084/jem.133.2.202; BOETCHER DA, 1973, IMMUNOL COMMUN, V2, P421, DOI 10.3109/08820137309022813; BURTON AL, 1966, J RETICULOENDOTH SOC, V3, P314; COLVIN RB, 1975, J IMMUNOL, V114, P377; COLVIN RB, 1973, J IMMUNOL, V110, P1279; COLVIN RB, 1974, LANCET, V1, P212, DOI 10.1016/S0140-6736(74)92512-4; Dienes L, 1928, J IMMUNOL, V15, P141; DVORAK AM, 1976, LAB INVEST, V34, P179; DVORAK AM, 1971, J IMMUNOL, V107, P422; DVORAK HF, 1975, J IMMUNOL, V114, P507; DVORAK HF, 1971, J IMMUNOL, V107, P138; DVORAK HF, 1972, HUM PATHOL, V3, P454, DOI 10.1016/S0046-8177(72)80004-2; DVORAK HF, 1974, LAB INVEST, V31, P111; DVORAK HF, 1975, CLIN HAEMATOL, V4, P651; DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; DVORAK HF, 1973, J EXP MED, V137, P751, DOI 10.1084/jem.137.3.751; DVORAK HF, 1972, J EXP MED, V135, P235, DOI 10.1084/jem.135.2.235; DVORAK HF, 1971, J IMMUNOL, V106, P279; DVORAK HF, 1965, J IMMUNOL, V94, P966; DVORAK HF, 1971, J IMMUNOL, V107, P1576; DVORAK HF, 1974, PROGR IMMUNOLOGY, V3, P171; GERSHON RK, 1975, J EXP MED, V142, P732, DOI 10.1084/jem.142.3.732; GOLDMAN MA, 1973, J IMMUNOL, V110, P1511; HAMMOND ME, 1975, J IMMUNOL, V115, P914; HAYNES JD, 1975, FED PROC, V34, P1039; HOENIG EM, 1974, J NEUROPATH EXP NEUR, V33, P251, DOI 10.1097/00005072-197404000-00005; INDERBITZIN T, 1956, INT ARCH ALLER A IMM, V8, P150, DOI 10.1159/000228277; ISHIZAKA T, 1973, BIOLOGICAL ROLE IMMU, P33; Jones TD, 1934, NEW ENGL J MED, V210, P120, DOI 10.1056/NEJM193401182100302; KATZ SI, 1974, J IMMUNOL, V113, P1073; KATZ SI, 1974, NATURE, V248, P612, DOI 10.1038/248612a0; NETA R, 1973, CELL IMMUNOL, V9, P242, DOI 10.1016/0008-8749(73)90075-0; RAFFEL S, 1958, J EXP MED, V108, P823, DOI 10.1084/jem.108.6.823; RICHERSON HB, 1971, J EXP MED, V134, P630, DOI 10.1084/jem.134.3.630; SALVIN SB, 1958, J EXP MED, V107, P109, DOI 10.1084/jem.107.1.109; STADECKER M, 1976, J EXP MED, V143, P206, DOI 10.1084/jem.143.1.206; STADECKER MJ, 1975, FED PROC, V34, P1040; STADECKER MJ, 1973, P SOC EXP BIOL MED, V142, P150; UHR JW, 1957, J EXP MED, V105, P11, DOI 10.1084/jem.105.1.11; VOIOSIN GA, 1960, CIBA F S CELLULAR AS, P373; WARD PA, 1975, J IMMUNOL, V114, P1523	46	93	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					229	240		10.1016/0091-6749(76)90159-7	http://dx.doi.org/10.1016/0091-6749(76)90159-7			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	783235				2022-12-18	WOS:A1976BX74400013
J	CALDWELL, JR; PEARCE, DE; SPENCER, C; WALDMAN, RH				CALDWELL, JR; PEARCE, DE; SPENCER, C; WALDMAN, RH			IMMUNOLOGICAL MECHANISMS IN HYPERSENSITIVITY PNEUMONITIS .1. EVIDENCE FOR CELL-MEDIATED IMMUNITY AND COMPLEMENT-FIXATION IN PIGEON BREEDERS DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,DEPT MED,GAINESVILLE,FL 32601	State University System of Florida; University of Florida								BACH C, 1971, PRESSE MED, V79, P383; CALDWELL JR, UNPUBLISHED OBSERVAT; FINK J, PERSONAL COMMUNICATI; PEARSON CM, PERSONAL COMMUNICATI; Pepys J, 1969, HYPERSENSITIVITY DIS; ROCKLIN RE, 1970, J IMMUNOL, V104, P95; RUDDY S, 1967, J IMMUNOL, V99, P1162; SPITLER L, 1969, J IMMUNOL, V102, P404	8	93	93	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	4					225	230		10.1016/0091-6749(73)90060-2	http://dx.doi.org/10.1016/0091-6749(73)90060-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q9817	4582463				2022-12-18	WOS:A1973Q981700004
J	Jeffres, MN; Narayanan, PP; Shuster, JE; Schramm, GE				Jeffres, Meghan N.; Narayanan, Prasanna P.; Shuster, Jerrica E.; Schramm, Garrett E.			Consequences of avoiding beta-lactams in patients with beta-lactam allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta-Lactam allergy; penicillin allergy; empiric antibiotic; gram-negative; bloodstream infection	IGE-MEDIATED HYPERSENSITIVITY; INFECTIOUS-DISEASES SOCIETY; PENICILLIN ALLERGY; ANTIMICROBIAL THERAPY; HOSPITALIZED-PATIENTS; NOSOCOMIAL PNEUMONIA; PRACTICE GUIDELINES; SEPTIC SHOCK; IMIPENEM/CILASTATIN; TOLERABILITY	Background: The choice of empiric antibiotics for the treatment of gram-negative bacilli (GNB) bloodstream infections (BSIs) in patients presenting with a beta-lactam (BL) allergy is often a difficult decision given that these agents are first-line treatment in many guidelines. Objective: We sought to compare rates of clinical failure between patients with a history of BL allergy who received either a BL or a non-beta-lactam (NBL). Methods: Adult patients with a past medical history of BL allergy and receipt of antibiotics for treatment of a GNB BSI were included from 3 academic medical centers. Treatment groups were classified as BL or NBL groups based on the empiric antibiotics received. Clinical failure was assessed 72 to 96 hours after initiation of empiric antibiotics. Hypersensitivity reactions during receipt of antibiotic therapy for the index BSI were recorded. Results: A total of 552 patients were included for analysis: 433 patients in the BL group and 119 patients in the NBL group. Clinical failure was higher in the NBL group compared with the BL group (38.7% vs 27.4%, P = .030). The most common cause of clinical failure was a temperature of greater than 38.0 degrees C 72 to 96 hours after receipt of empiric antibiotics (NBL group: 22.7% vs BL group: 13.9%, P = .016). Hypersensitivity occurred in 16 (2.9%) of 552 patients. Thirteen (2.5%) of 552 patients experiencing hypersensitivity reactions were exposed to a BL during treatment for GNB BSI. Conclusion: Among patients with a BL allergy, use of BL antibiotics is associated with a lower rate of clinical failure. The low rate of hypersensitivity provides further evidence about the risk of cross-reactivity between BL classes. These results support the practice of using a BL from an alternative class for patients in need of gram-negative antibiotic coverage.	[Jeffres, Meghan N.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Mail Stop C 238,12850 E Montview Blvd,V20-1212, Aurora, CO 80045 USA; [Narayanan, Prasanna P.; Schramm, Garrett E.] Mayo Clin Hosp Rochester, Dept Pharm, Rochester, MN USA; [Shuster, Jerrica E.] Barnes Jewish Hosp, Dept Pharm, St Louis, MO 63110 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Barnes-Jewish Hospital; Washington University (WUSTL)	Jeffres, MN (corresponding author), Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Mail Stop C 238,12850 E Montview Blvd,V20-1212, Aurora, CO 80045 USA.	Meghan.Jeffres@ucdenver.edu						[Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Apter AJ, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.10.052; Atanaskovic-Markovic M, 2009, J ALLERGY CLIN IMMUN, V124, P167, DOI 10.1016/j.jaci.2009.02.031; Buonomo A, 2011, INT ARCH ALLERGY IMM, V155, P155, DOI 10.1159/000318844; Caubet JC, 2011, J ALLERGY CLIN IMMUN, V127, P218, DOI 10.1016/j.jaci.2010.08.025; Chen ZJ, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-217; Dellinger RP, 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Freire AT, 2010, DIAGN MICR INFEC DIS, V68, P140, DOI 10.1016/j.diagmicrobio.2010.05.012; Gaieski DF, 2010, CRIT CARE MED, V38, P1045, DOI 10.1097/CCM.0b013e3181cc4824; Gardiner D, 2010, CLIN INFECT DIS, V50, P229, DOI 10.1086/648720; Garnacho-Montero J, 2003, CRIT CARE MED, V31, P2742, DOI 10.1097/01.CCM.0000098031.24329.10; Geddes A, 1999, J ANTIMICROB CHEMOTH, V44, P799, DOI 10.1093/jac/44.6.799; Hall Margaret Jean, 2011, NCHS Data Brief, P1; Kang CI, 2005, ANTIMICROB AGENTS CH, V49, P760, DOI 10.1128/AAC.49.2.760-766.2005; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kula B, 2014, CLIN INFECT DIS, V59, P1113, DOI 10.1093/cid/ciu587; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Labelle A, 2012, CRIT CARE MED, V40, P2016, DOI 10.1097/CCM.0b013e318250aa72; Lee CE, 2000, ARCH INTERN MED, V160, P2819, DOI 10.1001/archinte.160.18.2819; Li M, 2014, J CLIN PATHOL, V67, P1088, DOI 10.1136/jclinpath-2014-202438; Lipsky BA, 2012, CLIN INFECT DIS, V54, P1679, DOI [10.1093/cid/cis460, 10.1093/cid/cis346]; Ma L, 2014, J ALLERGY CLIN IMMUN, V133, P1075, DOI 10.1016/j.jaci.2013.10.029; Macy E, 2014, J ALLERGY CLIN IMMUN, V133, P790, DOI 10.1016/j.jaci.2013.09.021; Malangoni MA, 2006, ANN SURG, V244, P204, DOI 10.1097/01.sla.0000230024.84190.a8; Morrell M, 2005, ANTIMICROB AGENTS CH, V49, P3640, DOI 10.1128/AAC.49.9.3640-3645.2005; Patriarca G, 2008, INT J IMMUNOPATH PH, V21, P375, DOI 10.1177/039463200802100215; Picard M, 2013, J ALLER CL IMM-PRACT, V1, P252, DOI 10.1016/j.jaip.2013.01.006; Pichichero ME, 2007, OTOLARYNG HEAD NECK, V136, P340, DOI 10.1016/j.otohns.2006.10.007; Rhomberg PR, 2007, DIAGN MICR INFEC DIS, V57, P207, DOI 10.1016/j.diagmicrobio.2006.07.009; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Solomkin JS, 2010, CLIN INFECT DIS, V50, P133, DOI 10.1086/649554; Stevens DL, 2014, CLIN INFECT DIS, V59, pE10, DOI [10.1093/cid/ciu296, 10.1093/cid/ciu444]; Torres A, 2000, THORAX, V55, P1033, DOI 10.1136/thorax.55.12.1033; Towfigh S, 2010, CLIN MICROBIOL INFEC, V16, P1274, DOI 10.1111/j.1469-0691.2010.03122.x; Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368; West M, 2003, CLIN THER, V25, P485, DOI 10.1016/S0149-2918(03)80091-7	37	92	93	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1148	1153		10.1016/j.jaci.2015.10.026	http://dx.doi.org/10.1016/j.jaci.2015.10.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26688516	Bronze			2022-12-18	WOS:000373351200022
J	Mitson-Salazar, A; Yin, YZ; Wansley, DL; Young, M; Bolan, H; Arceo, S; Ho, N; Koh, C; Milner, JD; Stone, KD; Wank, SA; Prussin, C				Mitson-Salazar, Alyssa; Yin, Yuzhi; Wansley, Daniel L.; Young, Michael; Bolan, Hyejeong; Arceo, Sarah; Ho, Nancy; Koh, Christopher; Milner, Joshua D.; Stone, Kelly D.; Wank, Stephen A.; Prussin, Calman			Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human T(H)2 cell subpopulation with enhanced function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eosinophilic inflammation; eosinophilic gastrointestinal disease; IL-5; hematopoietic prostaglandin D synthase; chemoattractant receptor-homologous molecule expressed on T(H)2 cells; T(H)2; CD4; CD161; CD294	CHEMOKINE RECEPTOR EXPRESSION; INNATE LYMPHOID-CELLS; THYMIC STROMAL LYMPHOPOIETIN; HELPER TYPE-2 CELLS; HUMAN TH2 CELLS; CD4(+) T-CELLS; CYTOKINE PRODUCTION; ATOPIC-DERMATITIS; UP-REGULATION; CUTTING EDGE	Background: IL-5 1 pathogenic effector T(H)2 (peT(H)2) cells are a T(H)2 cell subpopulation with enhanced proinflammatory function that has largely been characterized in murine models of allergic inflammation. Objective: We sought to identify phenotype markers for human peT(H)2 cells and characterize their function in patients with allergic eosinophilic inflammatory diseases. Methods: Patients with eosinophilic gastrointestinal disease (EGID), patients with atopic dermatitis (AD), and nonatopic healthy control (NA) subjects were enrolled. peT(H)2 and conventional T(H)2 (cT(H)2) cell phenotype, function, and cytokine production were analyzed by using flow cytometry. Confirmatory gene expression was measured by using quantitative RT-PCR. Prostaglandin D-2 levels were measured with ELISA. Gut T(H)2 cells were obtained by means of esophagogastroduodenoscopy. Results: peT(H)2 cells were identified as chemoattractant receptor-homologous molecule expressed onT(H)2 cells-positive (CRT(H)2(+)), hematopoietic prostaglandin D synthase-positive CD161 hi CD4 T cells. peT(H)2 cells expressed significantly greater IL-5 and IL-13 than did hematopoietic prostaglandin D synthase-negative and CD161 2 cT(H)2 cells. peT(H)2 cells were highly correlated with blood eosinophilia (r = 0.78-0.98) and were present in 30- to 40-fold greater numbers in subjects with EGID and those with AD versus NA subjects. Relative to cT(H)2 cells, peT(H)2 cells preferentially expressed receptors for thymic stromal lymphopoietin, IL-25, and IL-33 and demonstrated greater responsiveness to these innate pro-T(H)2 cytokines. peT(H)2 but not cT(H)2 cells produced prostaglandin D-2. In patients with EGID and those with AD, peT(H)2 cells expressed gut-and skin-homing receptors, respectively. There were significantly greater numbers of peT(H)2 cells in gut tissue from patients with EGID versus NA subjects. Conclusion: peT(H)2 cells are the primary functional proinflammatory human T(H)2 cell subpopulation underlying allergic eosinophilic inflammation. The unambiguous phenotypic identification of human peT(H)2 cells provides a powerful tool to track these cells in future pathogenesis studies and clinical trials.	[Mitson-Salazar, Alyssa; Yin, Yuzhi; Wansley, Daniel L.; Bolan, Hyejeong; Arceo, Sarah; Milner, Joshua D.; Stone, Kelly D.; Prussin, Calman] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Young, Michael] Frederick Natl Lab Canc Res, Clin Res Directorate CMRP, Leidos Biomed Res, Frederick, MD USA; [Ho, Nancy; Koh, Christopher; Wank, Stephen A.] NIDDK, Gastroenterol Sect, NIH, Frederick, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Prussin, C (corresponding author), 10 Ctr Dr,MSC 181, Bethesda, MD 20892 USA.	calmanp@gmail.com		Mitson-Salazar, Alyssa/0000-0003-0359-437X	National Institute of Allergy and Infectious Diseases, Division of Intramural Research, National Institutes of Health [1ZIAAI000993]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001099] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, Division of Intramural Research, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institute of Allergy and Infectious Diseases, Division of Intramural Research, National Institutes of Health, project 1ZIAAI000993.	Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369; Bullock JZ, 2007, J PEDIATR GASTR NUTR, V45, P22, DOI 10.1097/MPG.0b013e318043c097; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Endo Y, 2014, TRENDS IMMUNOL, V35, P69, DOI 10.1016/j.it.2013.11.003; Endo Y, 2011, IMMUNITY, V35, P733, DOI 10.1016/j.immuni.2011.08.017; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; Foster Barbara, 2011, Clin Mol Allergy, V9, P7, DOI 10.1186/1476-7961-9-7; Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X; Givan Alice L, 2004, Methods Mol Biol, V263, P109; Guo LY, 2012, TRENDS IMMUNOL, V33, P598, DOI 10.1016/j.it.2012.07.006; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Islam SA, 2013, J EXP MED, V210, P1889, DOI 10.1084/jem.20130240; Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Le Bourhis L, 2013, CURR OPIN IMMUNOL, V25, P174, DOI 10.1016/j.coi.2013.01.005; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Maggi L, 2010, EUR J IMMUNOL, V40, P2174, DOI 10.1002/eji.200940257; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Okano M, 2006, CLIN EXP ALLERGY, V36, P1028, DOI 10.1111/j.1365-2222.2006.02528.x; Okazaki H, 2002, CLIN EXP ALLERGY, V32, P1236, DOI 10.1046/j.1365-2745.2002.01383.x; Palmer G, 2011, NAT REV RHEUMATOL, V7, P321, DOI 10.1038/nrrheum.2011.53; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Pettipher R, 2008, BRIT J PHARMACOL, V153, pS191, DOI 10.1038/sj.bjp.0707488; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Upadhyaya B, 2011, J IMMUNOL, V187, P3111, DOI 10.4049/jimmunol.1101283; Vinall SL, 2007, IMMUNOLOGY, V121, P577, DOI 10.1111/j.1365-2567.2007.02606.x; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Wilhelm C, 2012, NAT IMMUNOL, V13, P637, DOI 10.1038/ni.2303; Williams CMM, 2012, TOXICOL PATHOL, V40, P205, DOI 10.1177/0192623311430694; Xue LZ, 2009, J IMMUNOL, V182, P7580, DOI 10.4049/jimmunol.0804090; Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531; Yin Y., 2015, CURR PROTOC IMMUNOL, V110; Ziegler SF, 2013, ADV PHARMACOL, V66, P129, DOI 10.1016/B978-0-12-404717-4.00004-4; Zingoni A, 1998, J IMMUNOL, V161, P547	51	92	94	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					907	+		10.1016/j.jaci.2015.08.007	http://dx.doi.org/10.1016/j.jaci.2015.08.007			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26431580				2022-12-18	WOS:000371897500035
J	Saunders, SP; Moran, T; Floudas, A; Wurlod, F; Kaszlikowska, A; Salimi, M; Quinn, EM; Oliphant, CJ; Nunez, G; McManus, R; Hams, E; Irvine, AD; McKenzie, ANJ; Ogg, GS; Fallon, PG				Saunders, Sean P.; Moran, Tara; Floudas, Achilleas; Wurlod, Felicity; Kaszlikowska, Agnieszka; Salimi, Maryam; Quinn, Emma M.; Oliphant, Christopher J.; Nunez, Gabriel; McManus, Ross; Hams, Emily; Irvine, Alan D.; McKenzie, Andrew N. J.; Ogg, Graham S.; Fallon, Padraic G.			Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; atopic dermatitis; atopy; eczema; filag-grin; flaky tail; type 2 innate lymphoid cells; innate immunity; mouse; mutation	GENOME-WIDE ASSOCIATION; LYMPHOID-CELLS; SUSCEPTIBILITY LOCI; STRATUM-CORNEUM; MURINE MODEL; T-CELLS; FILAGGRIN; SKIN; BARRIER; DISEASE	Background: Atopic dermatitis (AD) is an inflammatory skin condition that can occur in early life, predisposing to asthma development in a phenomenon known as the atopic march. Although genetic and environmental factors are known to contribute to AD and asthma, the mechanisms underlying the atopic march remain poorly understood. Filaggrin loss-of-function mutations are a major genetic predisposer for the development of AD and progression to AD-associated asthma. Objective: We sought to experimentally address whether filaggrin mutations in mice lead to the development of spontaneous eczematous inflammation and address the aberrant immunologic milieu arising in a mouse model of filaggrin deficiency. Methods: Filaggrin mutant mice were generated on the proallergic BALB/c background, creating a novel model for the assessment of spontaneous AD-like inflammation. Independently recruited AD case collections were analyzed to define associations between filaggrin mutations and immunologic phenotypes. Results: Filaggrin-deficient mice on a BALB/c background had profound spontaneous AD-like inflammation with progression to compromised pulmonary function with age, reflecting the atopic march in patients with AD. Strikingly, skin inflammation occurs independently of adaptive immunity and is associated with cutaneous expansion of IL-5-producing type 2 innate lymphoid cells. Furthermore, subjects with filaggrin mutations have an increased frequency of type 2 innate lymphoid cells in the skin in comparison with control subjects. Conclusion: This study provides new insights into our understanding of the atopic march, with innate immunity initiating dermatitis and the adaptive immunity required for subsequent development of compromised lung function.	[Saunders, Sean P.; Moran, Tara; Floudas, Achilleas; Wurlod, Felicity; Kaszlikowska, Agnieszka; Hams, Emily; Fallon, Padraic G.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin 2, Ireland; [Saunders, Sean P.; Moran, Tara; Floudas, Achilleas; Wurlod, Felicity; Kaszlikowska, Agnieszka; Hams, Emily; Irvine, Alan D.; Fallon, Padraic G.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland; [Saunders, Sean P.; Moran, Tara; Floudas, Achilleas; Wurlod, Felicity; Kaszlikowska, Agnieszka; Hams, Emily; Irvine, Alan D.; Fallon, Padraic G.] Our Ladys Childrens Hosp, Dept Paediat Dermatol, Dublin, Ireland; [Salimi, Maryam; Ogg, Graham S.] Univ Oxford, Radcliffe Dept Med, NIHR Biomed Res Ctr, MRC Human Immunol Unit, Oxford OX1 2JD, England; [Quinn, Emma M.; McManus, Ross; Fallon, Padraic G.] St James Hosp, Inst Mol Med, Dublin 8, Ireland; [Oliphant, Christopher J.; McKenzie, Andrew N. J.] MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England; [Oliphant, Christopher J.] Babraham Res Campus, Biosceptre, Cambridge, England; [Nunez, Gabriel] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Nunez, Gabriel] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	Trinity College Dublin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; University of Oxford; Trinity College Dublin; MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fallon, PG (corresponding author), Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin 2, Ireland.	pfallon@tcd.ie	Fallon, Padraic/Y-2711-2019; McManus, Ross/AAE-9236-2020; Irvine, Alan D/A-3982-2008; /AAB-3225-2020	Fallon, Padraic/0000-0002-8401-7293; Irvine, Alan D/0000-0002-9048-2044; Floudas, Achilleas/0000-0003-1690-5595; Ogg, Graham/0000-0002-3097-045X; McManus, Ross/0000-0002-0529-9617; Hams, Emily/0000-0002-9745-3246	Wellcome Trust [092530/Z/10/Z, 100963/Z/13/Z]; UK-MRC; Science Foundation Ireland [10/IN.1/B3004]; National Children's Research Centre; Misses Barrie Charitable Trust; NIHR Biomedical Research Centre Programme; Comprehensive Research Network; Medical Research Council [MC_UU_12010/5, MC_U105178805] Funding Source: researchfish; MRC [MC_U105178805, MC_UU_12010/5] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); UK-MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); National Children's Research Centre; Misses Barrie Charitable Trust; NIHR Biomedical Research Centre Programme(National Institute for Health Research (NIHR)); Comprehensive Research Network; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Wellcome Trust (Programme grant 092530/Z/10/Z [to P.G.F.] and Investigator Award 100963/Z/13/Z [to A.N.J.M.]), UK-MRC(to A.N.J.M.), Science Foundation Ireland (10/IN.1/B3004 [to P.G.F.]), the National Children's Research Centre (to P.G.F.), Misses Barrie Charitable Trust (to G.S.O.), the NIHR Biomedical Research Centre Programme (to G.S.O.), and the Comprehensive Research Network (to G.S.O.).	Alenius H, 2002, J ALLERGY CLIN IMMUN, V109, P106, DOI 10.1067/mai.2002.120553; Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Deckers IAG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039803; Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Finkelman FD, 2008, J ALLERGY CLIN IMMUN, V121, P334, DOI 10.1016/j.jaci.2007.11.028; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Gupta J, 2008, J ALLERGY CLIN IMMUN, V121, P725, DOI 10.1016/j.jaci.2007.12.1161; Hams E, 2012, CURR OPIN PHARMACOL, V12, P503, DOI 10.1016/j.coph.2012.06.001; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Irvin CG, 2003, RESPIR RES, V4, DOI 10.1186/rr199; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jakasa I, 2007, J INVEST DERMATOL, V127, P129, DOI 10.1038/sj.jid.5700582; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Leisten S, 2013, J ALLERGY CLIN IMMUN, V131, P1247, DOI 10.1016/j.jaci.2012.12.1576; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Miller AM, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-22; Mohrs K, 2005, IMMUNITY, V23, P419, DOI 10.1016/j.immuni.2005.09.006; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Oyoshi MK, 2011, J CLIN INVEST, V121, P2210, DOI 10.1172/JCI43586; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Rosas LE, 2005, INT IMMUNOL, V17, P1347, DOI 10.1093/intimm/dxh313; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Taieb Alain, 2006, J Allergy Clin Immunol, V117, P378, DOI 10.1016/j.jaci.2005.11.038; von Stebut E, 2003, J EXP MED, V198, P191, DOI 10.1084/jem.20030159; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wenzel SE, 2013, PULM PHARMACOL THER, V26, P710, DOI 10.1016/j.pupt.2013.07.003; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503	53	92	96	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					482	491		10.1016/j.jaci.2015.06.045	http://dx.doi.org/10.1016/j.jaci.2015.06.045			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26299987	Green Published, hybrid			2022-12-18	WOS:000369235500017
J	Custovic, A; Sonntag, HJ; Buchan, IE; Belgrave, D; Simpson, A; Prosperi, MCF				Custovic, Adnan; Sonntag, Hans-Joachim; Buchan, Iain E.; Belgrave, Danielle; Simpson, Angela; Prosperi, Mattia C. F.			Evolution pathways of IgE responses to grass and mite allergens throughout childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; childhood; component-resolved diagnostics; latent class analysis; allergens; dust mite; timothy grass; asthma; wheeze; rhinitis	RESPIRATORY-SOCIETY STATEMENT; ASTHMA; CHILDREN; RHINITIS; ATOPY; QUANTIFICATION; SENSITIZATION; PROBABILITY; PATTERNS; WHEEZE	Background: Little is known about longitudinal patterns of the development of IgE to distinct allergen components. Objective: We sought to investigate the evolution of IgE responses to allergenic components of timothy grass and dust mite during childhood. Methods: In a population-based birth cohort (n = 1184) we measured IgE responses to 15 components from timothy grass and dust mite in children with available samples at 3 time points (ages 5, 8, and 11 years; n = 235). We designed a nested, 2-stage latent class analysis to identify cross-sectional sensitization patterns at each follow-up and their longitudinal trajectories. We then ascertained the association of longitudinal trajectories with asthma, rhinitis, eczema, and lung function in children with component data for at least 2 time points (n = 534). Results: Longitudinal latent class analysis revealed 3 grass sensitization trajectories: (1) no/low sensitization; (2) early onset; and (3) late onset. The early-onset trajectory was associated with asthma and diminished lung function, and the late-onset trajectory was associated with rhinitis. Four longitudinal trajectories emerged for mite: (1) no/low sensitization; (2) group 1 allergens; (3) group 2 allergens; and (3) complete mite sensitization. Children in the complete mite sensitization trajectory had the highest odds ratios (ORs) for asthma (OR, 7.15; 95% CI, 3.80-13.44) and were the only group significantly associated with comorbid asthma, rhinitis, and eczema (OR, 5.91; 95% CI, 2.01-17.37). Among children with wheezing, those in the complete mite sensitization trajectory (but not other longitudinal mite trajectories) had significantly higher risk of severe exacerbations (OR, 3.39; 95% CI, 1.62-6.67). Conclusions: The nature of developmental longitudinal trajectories of IgE responses differed between grass and mite allergen components, with temporal differences (early vs late onset) dominant in grass and diverging patterns of IgE responses (group 1 allergens, group 2 allergens, or both) in mite. Different longitudinal patterns bear different associations with clinical outcomes, which varied by allergen.	[Custovic, Adnan; Sonntag, Hans-Joachim; Belgrave, Danielle; Simpson, Angela; Prosperi, Mattia C. F.] Univ Manchester, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester M13 9PL, Lancs, England; [Custovic, Adnan; Sonntag, Hans-Joachim; Belgrave, Danielle; Simpson, Angela; Prosperi, Mattia C. F.] Univ S Manchester Hosp, Manchester, Lancs, England; [Sonntag, Hans-Joachim; Buchan, Iain E.; Belgrave, Danielle; Prosperi, Mattia C. F.] Univ Manchester, Inst Populat Hlth, Ctr Hlth Informat, Manchester M13 9PL, Lancs, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester	Prosperi, MCF (corresponding author), Univ Manchester, Inst Populat Hlth, CHI, Jean McFarlane Bldg,1st Floor,Rm 1-314,Univ Pl, Manchester M13 9PL, Lancs, England.	mattia.prosperi@manchester.ac.uk	Custovic, Adnan/A-2435-2012; Buchan, Iain E/H-5767-2013	Custovic, Adnan/0000-0001-5218-7071; Buchan, Iain E/0000-0003-3392-1650; Simpson, Angela/0000-0003-2733-6666	J P Moulton Charitable Foundation; Medical Research Council (MRC) [G0601361, MR/K002449/1]; MRC Health eResearch Centre (HeRC) [MR/K006665/1]; MRC [MR/K002449/1, MR/K006665/1, G0601361, MR/K002449/2] Funding Source: UKRI; Medical Research Council [G0601361, MR/K006665/1, MR/K002449/2, MC_PC_13042, MR/K002449/1] Funding Source: researchfish	J P Moulton Charitable Foundation; Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Health eResearch Centre (HeRC); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	MAAS is supported by grants from the J P Moulton Charitable Foundation and Medical Research Council (MRC) grants G0601361 and MR/K002449/1. This study was partly supported by MRC Health eResearch Centre (HeRC) grant MR/K006665/1.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Belgrave DCM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001748; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Belgrave DCM, 2013, J ALLERGY CLIN IMMUN, V132, P575, DOI 10.1016/j.jaci.2013.05.041; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Canty A., BOOT BOOTSTRAP R S P; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2013, CURR OPIN ALLERGY CL, V13, P173, DOI 10.1097/ACI.0b013e32835e82b6; Deliu M, 2014, ALLERGY, V69, P1515, DOI 10.1111/all.12467; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DiCiccio TJ, 1996, STAT SCI, V11, P189; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Hosmer DW, 2013, APPL LOGISTIC REGRES; Ic-Jusufagic AS, 2014, LANCET RESP MED, V2, P621, DOI 10.1016/S2213-2600(14)70096-7; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Linzer DA, 2011, J STAT SOFTW, V42, P1, DOI 10.18637/jss.v042.i10; Marinho S, 2007, ALLERGY, V62, P1379, DOI 10.1111/j.1398-9995.2007.01502.x; Marinho Susana, 2011, Clin Transl Allergy, V1, P16, DOI 10.1186/2045-7022-1-16; Melioli G, 2011, CLIN BIOCHEM, V44, P1005, DOI 10.1016/j.clinbiochem.2011.05.007; Nicolaou N, 2011, CURR OPIN ALLERGY CL, V11, P222, DOI 10.1097/ACI.0b013e32834656c2; Pinart M, 2014, LANCET RESP MED, V2, P131, DOI 10.1016/S2213-2600(13)70277-7; Prosperi MCF, 2014, PEDIAT ALLERG IMM-UK, V25, P71, DOI 10.1111/pai.12139; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Stanojevic S, 2009, AM J RESP CRIT CARE, V180, P547, DOI 10.1164/rccm.200903-0323OC; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Thomas WR, 2010, TRENDS MOL MED, V16, P321, DOI 10.1016/j.molmed.2010.04.008; Treudler R, 2013, CURR ALLERGY ASTHM R, V13, P110, DOI 10.1007/s11882-012-0318-8; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896	38	92	93	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1645	U327		10.1016/j.jaci.2015.03.041	http://dx.doi.org/10.1016/j.jaci.2015.03.041			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	25962900	Green Published, hybrid			2022-12-18	WOS:000366044300027
J	Henriksen, L; Simonsen, J; Haerskjold, A; Linder, M; Kieler, H; Thomsen, SF; Stensballe, LG				Henriksen, Lonny; Simonsen, Jacob; Haerskjold, Ann; Linder, Marie; Kieler, Helle; Thomsen, Simon Francis; Stensballe, Lone Graff			Incidence rates of atopic dermatitis, asthma, and allergic rhinoconjunctivitis in Danish and Swedish children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; children; incidence rate; pharmacoepidemiology	PRESCRIPTION DATA; PREVALENCE; RHINITIS; ECZEMA; TRENDS; ASSOCIATION; LEGISLATION; VALIDATION; REGISTER; COHORT	Background: Several studies have shown that the prevalence of the frequent chronic conditions of atopic dermatitis, asthma, and allergy has increased substantially for reasons not fully understood. Atopic diseases affect quality of life in both children and their family members. Objective: Using national registers, we sought to establish up-to-date incidence rates of atopic dermatitis, asthma, and allergic rhinoconjunctivitis in the Danish and Swedish child populations. Methods: Children born in Denmark from 1997 to 2011 or born in Sweden from 2006 to 2010 participated in this cross-national, population-based cohort study. Incidence rates of atopic dermatitis, asthma, and allergic rhinoconjunctivitis in the Danish and Swedish child cohorts were ascertained through disease-specific dispensed prescribed medication, specific hospital contacts, or both. Results: In both countries the incidence rate of atopic dermatitis was stable during the study periods. The incidence rate of asthma increased until 2006 and stabilized for the rest of the study period in Denmark and increased in Sweden. The incidence rate of allergic rhinoconjunctivitis decreased in both countries. Conclusion: The study revealed similar trends, with stable incidence rates of atopic dermatitis in both Danish and Swedish children, an increase and then stabilization in asthma incidence rates in Denmark and an increase in Sweden, and a decrease in allergic rhinoconjunctivitis incidence rates. At age 5 years, one third of all children were affected with at least one of the conditions of atopic dermatitis, asthma, or allergic rhinoconjunctivitis.	[Henriksen, Lonny; Haerskjold, Ann] Child & Adolescent Clin 4072, Res Unit Womens & Childrens Hlth 7821, Copenhagen, Denmark; [Henriksen, Lonny; Haerskjold, Ann] Rigshosp, Danish Natl Univ Hosp, DK-2100 Copenhagen, Denmark; [Simonsen, Jacob] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; [Linder, Marie; Kieler, Helle] Karolinska Inst, Ctr Pharmacoepidemiol, Stockholm, Sweden; [Thomsen, Simon Francis] Bispebjerg Hosp, Dept Dermatol, DK-2400 Copenhagen, Denmark; [Stensballe, Lone Graff] Rigshosp, Danish Natl Univ Hosp, Child & Adolescent Clin 4072, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Statens Serum Institut; Karolinska Institutet; University of Copenhagen; Bispebjerg Hospital; Rigshospitalet; University of Copenhagen	Henriksen, L (corresponding author), Rigshosp, Res Unit Womens & Childrens Hlth, Dep 7821,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	lonnyhenriksen@gmail.com	Stensballe, Lone Graff/AAS-4137-2020	Stensballe, Lone Graff/0000-0003-1569-153X; Simonsen, Jacob/0000-0002-8700-4826; Henriksen, Lonny/0000-0002-9727-6649; Kieler, Helle/0000-0001-9338-7133; Linder, Marie/0000-0003-2619-2189	Dagmar Marshalls Foundation; Danish Lung Association	Dagmar Marshalls Foundation; Danish Lung Association	Supported by the Dagmar Marshalls Foundation and the Danish Lung Association. The funders played no role in the study design, data collection, analysis, interpretation, writing of the manuscript, or decision to submit the article for publication.	[Anonymous], PRESCR DRUG REG; Bechtold P, 2013, EUR J PUBLIC HEALTH, V23, P873, DOI 10.1093/eurpub/cks066; Cantani A, 2008, EPIDEMIOLOGY NATURAL, P363; Carstensen B, 2007, STAT MED, V26, P3018, DOI 10.1002/sim.2764; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Danish Pharmacy, 2012, LAEG DANM 2012; Duggan EM, 2012, PEDIAT ALLERG IMM-UK, V23, P464, DOI 10.1111/j.1399-3038.2012.01291.x; Duksal F, 2013, INT J PEDIATR OTORHI, V77, P1434, DOI 10.1016/j.ijporl.2013.05.038; Furu K, 2007, EUR J CLIN PHARMACOL, V63, P693, DOI 10.1007/s00228-007-0301-9; Global Strategy for Asthma Management and Prevention, 2009, GLOB STRAT ASTHM MAN; Grize L, 2006, ALLERGY, V61, P556, DOI 10.1111/j.1398-9995.2006.01030.x; Hagerhed-Engman L, 2006, ALLERGY, V61, P447, DOI 10.1111/j.1398-9995.2006.01031.x; Hansen TE, 2013, ACTA PAEDIATR, V102, P47, DOI 10.1111/apa.12030; Hoffmann F, 2010, EUR J CLIN PHARMACOL, V66, P307, DOI 10.1007/s00228-009-0755-z; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Knudsen LB, 1998, DAN MED BULL, V45, P320; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.1093/biomet/80.3.557; Linneberg A, 2006, J ALLERGY CLIN IMMUN, V117, P184, DOI 10.1016/j.jaci.2005.09.042; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Mason K, 2012, ACTA NEUROL SCAND, V125, P213, DOI 10.1111/j.1600-0404.2011.01558.x; McNeill G, 2009, PAEDIATR PERINAT EP, V23, P506, DOI 10.1111/j.1365-3016.2009.01057.x; Millett C, 2013, PEDIATRICS, V131, pE495, DOI 10.1542/peds.2012-2592; Mosbech J, 1995, Ugeskr Laeger, V157, P3741; Moth G, 2007, EUR J CLIN PHARMACOL, V63, P605, DOI 10.1007/s00228-007-0286-4; Naiman A, 2010, CAN MED ASSOC J, V182, P761, DOI 10.1503/cmaj.091130; O'Connell EJ, 2004, ALLERGY, V59, P7, DOI 10.1111/j.1398-9995.2004.00563.x; Olesen AB, 2005, ACTA DERM-VENEREOL, V85, P244, DOI 10.1080/00015550510026343; Ortqvist AK, 2013, PHARMACOEPIDEM DR S, V22, P850, DOI 10.1002/pds.3465; Pedersen CB, 2006, DAN MED BULL, V53, P441; Prescott S, 2011, CLIN EPIGENETICS, V2, P223, DOI 10.1007/s13148-011-0028-4; Schernhammer ES, 2008, PEDIAT ALLERG IMM-UK, V19, P125, DOI 10.1111/j.1399-3038.2007.00597.x; Socialstyrelsen, AMN FOR ROKV; Stensen L, 2008, ALLERGY ASTHMA PROC, V29, P392, DOI 10.2500/aap.2008.29.3139; van Beijsterveldt CEM, 2007, EUR RESPIR J, V29, P516, DOI 10.1183/09031936.00065706; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294; WHO, STRUCT PRINC	37	92	95	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					360	+		10.1016/j.jaci.2015.02.003	http://dx.doi.org/10.1016/j.jaci.2015.02.003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25828267				2022-12-18	WOS:000359004900017
J	Ghebre, MA; Bafadhel, M; Desai, D; Cohen, SE; Newbold, P; Rapley, L; Woods, J; Rugman, P; Pavord, ID; Newby, C; Burton, PR; May, RD; Brightling, CE				Ghebre, Michael A.; Bafadhel, Mona; Desai, Dhananjay; Cohen, Suzanne E.; Newbold, Paul; Rapley, Laura; Woods, Jo; Rugman, Paul; Pavord, Ian D.; Newby, Chris; Burton, Paul R.; May, Richard D.; Brightling, Chris E.			Biological clustering supports both "Dutch'' and "British'' hypotheses of asthma and chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma and COPD overlap; cytokines; factor and cluster analyses	PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; SHORT-TERM RESPONSE; DOUBLE-BLIND; EOSINOPHILIC ASTHMA; SPUTUM-EOSINOPHILIA; EXACERBATIONS; PHENOTYPES; COPD; IDENTIFICATION	Background: Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous diseases. Objective: We sought to determine, in terms of their sputum cellular and mediator profiles, the extent to which they represent distinct or overlapping conditions supporting either the "British'' or "Dutch'' hypotheses of airway disease pathogenesis. Methods: We compared the clinical and physiological characteristics and sputum mediators between 86 subjects with severe asthma and 75 with moderate-to-severe COPD. Biological subgroups were determined using factor and cluster analyses on 18 sputum cytokines. The subgroups were validated on independent severe asthma (n = 166) and COPD (n = 58) cohorts. Two techniques were used to assign the validation subjects to subgroups: linear discriminant analysis, or the best identified discriminator (single cytokine) in combination with subject disease status (asthma or COPD). Results: Discriminant analysis distinguished severe asthma from COPD completely using a combination of clinical and biological variables. Factor and cluster analyses of the sputum cytokine profiles revealed 3 biological clusters: cluster 1: asthma predominant, eosinophilic, high T(H)2 cytokines; cluster 2: asthma and COPD overlap, neutrophilic; cluster 3: COPD predominant, mixed eosinophilic and neutrophilic. Validation subjects were classified into 3 subgroups using discriminant analysis, or disease status with a binary assessment of sputum IL-1 beta expression. Sputum cellular and cytokine profiles of the validation subgroups were similar to the subgroups from the test study. Conclusions: Sputum cytokine profiling can determine distinct and overlapping groups of subjects with asthma and COPD, supporting both the British and Dutch hypotheses. These findings may contribute to improved patient classification to enable stratified medicine.	[Ghebre, Michael A.; Desai, Dhananjay; Newby, Chris; Brightling, Chris E.] Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Ghebre, Michael A.; Desai, Dhananjay; Newby, Chris; Brightling, Chris E.] Univ Hosp Leicester, NIHR Resp Biomed Res Unit, Leicester LE3 9QP, Leics, England; [Ghebre, Michael A.; Newby, Chris; Burton, Paul R.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Bafadhel, Mona; Pavord, Ian D.] Univ Oxford, Nuffield Dept Clin Med, Dept Resp Med, Oxford, England; [Cohen, Suzanne E.; Newbold, Paul; Rapley, Laura; Woods, Jo; Rugman, Paul; May, Richard D.] MedImmune Ltd, Cambridge, England; [Burton, Paul R.] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England	University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; University of Leicester; University of Oxford; AstraZeneca; Medimmune; University of Bristol	Brightling, CE (corresponding author), Univ Hosp Leicester, Inst Lung Hlth, Leicester LE3 9QP, Leics, England.	ceb17@le.ac.uk	Bafadhel, Mona/ABB-1170-2021; Ghebre, Michael A/K-5958-2013	Cohen, Suzanne/0000-0002-4470-1680; brightling, chris/0000-0002-9345-4903; May, Richard/0000-0001-7825-2716; Pavord, Ian/0000-0002-4288-5973; Bafadhel, Mona/0000-0002-9993-2478	Medical Research Council [G0601368]; AstraZeneca; MedImmune; Wellcome Trust Senior Fellowship [WT082265]; European Regional Development Fund [ERDF 05567]; National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit, UK; AirPROM [FP7-270194]; Medical Research Council [G0601369] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10018, NF-SI-0510-10157] Funding Source: researchfish; MRC [G0601369] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); AstraZeneca(AstraZeneca); MedImmune(AstraZenecaMedimmune); Wellcome Trust Senior Fellowship(Wellcome Trust); European Regional Development Fund(European Commission); National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit, UK; AirPROM; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by the Medical Research Council (G0601368), AstraZeneca, MedImmune, and Wellcome Trust Senior Fellowship (WT082265 to C.E.B.). The research was performed in laboratories funded in part by the European Regional Development Fund (grant no. ERDF 05567). This study was also supported in part by the National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit, UK, and AirPROM (FP7-270194). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Bafadhel M, 2012, RESPIRATION, V83, P36, DOI 10.1159/000330667; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Barker BL, 2013, CLIN SCI, V124, P371, DOI 10.1042/CS20120340; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P240, DOI 10.1164/rccm.2604008; Barnes PJ, 2000, CHEST, V117, P10; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; Brightling CE, 2012, CLIN EXP ALLERGY, V42, P638, DOI 10.1111/j.1365-2222.2011.03917.x; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 2005, THORAX, V60, P193, DOI 10.1136/thx.2004.032516; Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028; Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698; Burgel PR, 2010, EUR RESPIR J, V36, P531, DOI 10.1183/09031936.00175109; Claude J., 2008, MORPHOMETRICS R; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Desai D, 2012, ADV CLIN CHEM, V57, P57, DOI 10.1016/B978-0-12-394384-2.00003-6; Frankenberger M, 2011, MOL MED, V17, P762, DOI 10.2119/molmed.2010.00202; FUNKHOUSER GR, 1983, J MARKETING RES, V20, P99, DOI 10.2307/3151417; Garcia-Aymerich J, 2011, THORAX, V66, P430, DOI 10.1136/thx.2010.154484; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Global Initiative for Chronic Obstructive Lung Disease, GLOB STRAT DIAGN MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Harlow LL., 2005, MULTIVARIATE APPL SE; Hinton P.R., 2004, SPSS EXPLAINED; Iwamoto H, 2014, EUR RESPIR J, V43, P421, DOI 10.1183/09031936.00024313; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Therneau T. M., 2011, INTRO RECURSIVE PART; Vanfleteren LEGW, 2014, THORAX, V69, P72, DOI 10.1136/thoraxjnl-2013-203602; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC	42	92	94	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					63	U507		10.1016/j.jaci.2014.06.035	http://dx.doi.org/10.1016/j.jaci.2014.06.035			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25129678	hybrid, Green Published			2022-12-18	WOS:000347298200008
J	Russell, SL; Gold, MJ; Reynolds, LA; Willing, BP; Dimitriu, P; Thorson, L; Redpath, SA; Perona-Wright, G; Blanchet, MR; Mohn, WW; Finlay, BB; McNagny, KM				Russell, Shannon L.; Gold, Matthew J.; Reynolds, Lisa A.; Willing, Benjamin P.; Dimitriu, Pedro; Thorson, Lisa; Redpath, Stephen A.; Perona-Wright, Georgia; Blanchet, Marie-Renee; Mohn, William W.; Finlay, B. Brett; McNagny, Kelly M.			Perinatal antibiotic-induced shifts in gut microbiota have differential effects on inflammatory lung diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antibiotics; Bacteroidetes; Firmicutes; gut microbiota; hypersensitivity pneumonitis; asthma; perinatal	EXPERIMENTAL HYPERSENSITIVITY PNEUMONITIS; EARLY-LIFE; INTESTINAL MICROBIOTA; T-CELLS; EXPOSURE; ASTHMA; SUSCEPTIBILITY; IMMUNOLOGY; INDUCTION; RESPONSES	Background: Resident gut microbiota are now recognized as potent modifiers of host immune responses in various scenarios. Recently, we demonstrated that perinatal exposure to vancomycin, but not streptomycin, profoundly alters gut microbiota and enhances susceptibility to a T(H)2 model of allergic asthma. Objective: Here we sought to further clarify the etiology of these changes by determining whether perinatal antibiotic treatment has a similar effect on the T(H)1/T(H)17-mediated lung disease, hypersensitivity pneumonitis. Methods: Hypersensitivity pneumonitis was induced in C57BL/6 wild-type or recombination-activating gene 1-deficient mice treated perinatally with vancomycin or streptomycin by repeated intranasal administration of Saccharopolyspora rectivirgula antigen. Disease severity was assessed by measuring lung inflammation, pathology, cytokine responses, and serumantibodies. Microbial community analyses were performed on stool samples via 16S ribosomal RNA pyrosequencing and correlations between disease severity and specific bacterial taxa were identified. Results: Surprisingly, in contrast to our findings in an allergic asthma model, we found that the severity of hypersensitivity pneumonitis was unaffected by vancomycin, but increased dramatically after streptomycin treatment. This likely reflects an effect on the adaptive, rather than innate, immune response because the effects of streptomycin were not observed during the early phases of disease and were abrogated in recombination-activating gene 1-deficient mice. Interestingly, Bacteroidetes dominated the intestinal microbiota of streptomycin-treated animals, while vancomycin promoted the expansion of the Firmicutes. Conclusions: Perinatal antibiotics exert highly selective effects on resident gut flora, which, in turn, lead to very specific alterations in susceptibility to T(H)2-or T(H)1/T(H)17-driven lung inflammatory disease.	[Russell, Shannon L.; Dimitriu, Pedro; Redpath, Stephen A.; Perona-Wright, Georgia; Mohn, William W.; Finlay, B. Brett] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; [Russell, Shannon L.; Reynolds, Lisa A.; Willing, Benjamin P.; Thorson, Lisa; Finlay, B. Brett] Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z3, Canada; [Gold, Matthew J.; McNagny, Kelly M.] Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; [Willing, Benjamin P.] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB, Canada; [Dimitriu, Pedro; Redpath, Stephen A.; Perona-Wright, Georgia; Mohn, William W.] Univ British Columbia, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada; [Blanchet, Marie-Renee] Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of Alberta; University of British Columbia; Laval University	McNagny, KM (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	bfinlay@interchange.ubc.ca; Kelly@brc.ubc.ca	Willing, Benjamin/AAA-9650-2019; McNagny, Kelly/P-5239-2014	McNagny, Kelly/0000-0003-4737-3499	Canadian Institutes of Health Research (CIHR) Catalyst Grant; CIHR Emerging Team Grant; Genome BC; AllerGen NCE; AllerGen CAIDATI training award; Tula Foundation	Canadian Institutes of Health Research (CIHR) Catalyst Grant; CIHR Emerging Team Grant(Canadian Institutes of Health Research (CIHR)); Genome BC; AllerGen NCE; AllerGen CAIDATI training award; Tula Foundation	This work was funded by a Canadian Institutes of Health Research (CIHR) Catalyst Grant and a CIHR Emerging Team Grant in partnership with Genome BC and the AllerGen NCE. M.J.G. was supported by an AllerGen CAIDATI training award. P.D. was supported by a fellowship from the Tula Foundation. K.M.M. is a Michael Smith Foundation for Health Research Senior Scholar.	Abdelsamed HA, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-15; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Blanchet MR, 2012, CURR OPIN ALLERGY CL, V12, P467, DOI 10.1097/ACI.0b013e328357cc17; Blanchet MR, 2011, AM J RESP CRIT CARE, V184, P687, DOI 10.1164/rccm.201011-1764OC; Brown EM, 2013, SEMIN IMMUNOL, V25, P378, DOI 10.1016/j.smim.2013.09.003; CORMIER Y, 1985, THORAX, V40, P138, DOI 10.1136/thx.40.2.138; Girard M, 2009, EUR RESPIR J, V34, P749, DOI 10.1183/09031936.00140908; Girard M, 2009, ALLERGY, V64, P322, DOI 10.1111/j.1398-9995.2009.01949.x; Girard M, 2004, CURR OPIN ALLERGY CL, V4, P93, DOI 10.1097/01.all.0000123964.96233.5c; Gudmundsson G, 1998, AM J RESP CELL MOL, V19, P812, DOI 10.1165/ajrcmb.19.5.3153; Gudmundsson G, 1997, J CLIN INVEST, V99, P2386, DOI 10.1172/JCI119420; Hasan SA, 2013, J ALLERGY CLIN IMMUN, V131, P1663, DOI 10.1016/j.jaci.2013.01.015; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hildebrand F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r4; Hill DA, 2012, NAT MED, V18, P538, DOI 10.1038/nm.2657; Israel-Assayag E, 1999, J IMMUNOL, V163, P6794; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Joshi AD, 2009, AM J RESP CRIT CARE, V179, P705, DOI 10.1164/rccm.200811-1700OC; Leavy O, 2012, NAT REV IMMUNOL, V12, P319, DOI 10.1038/nri3213; Marra F, 2009, PEDIATRICS, V123, P1003, DOI 10.1542/peds.2008-1146; Matsuno Y, 2007, AM J RESP CRIT CARE, V176, P1015, DOI 10.1164/rccm.200612-1887OC; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McSharry C, 2002, CLIN EXP IMMUNOL, V128, P3, DOI 10.1046/j.1365-2249.2002.01849.x; Murk W, 2011, PEDIATRICS, V127, P1125, DOI 10.1542/peds.2010-2092; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Russell SL, 2013, GUT MICROBES, V4, P158, DOI 10.4161/gmic.23567; Russell SL, 2012, CURR OPIN GASTROEN, V28, P563, DOI 10.1097/MOG.0b013e3283573017; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schuyler M, 2000, J LAB CLIN MED, V136, P29, DOI 10.1067/mlc.2000.107694; Schuyler M, 1997, CELL IMMUNOL, V177, P169, DOI 10.1006/cimm.1997.1107; Sekirov I, 2008, INFECT IMMUN, V76, P4726, DOI 10.1128/IAI.00319-08; Sharma O P, 1995, Semin Respir Infect, V10, P96; Simonian PL, 2009, TRANSL RES, V154, P222, DOI 10.1016/j.trsl.2009.08.006; Simonian PL, 2009, J IMMUNOL, V182, P657, DOI 10.4049/jimmunol.182.1.657; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Yamasaki H, 1999, J IMMUNOL, V163, P3516	39	92	97	3	48	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					100	U175		10.1016/j.jaci.2014.06.027	http://dx.doi.org/10.1016/j.jaci.2014.06.027			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25145536				2022-12-18	WOS:000347298200012
J	Caldwell, JM; Collins, MH; Stucke, EM; Putnam, PE; Franciosi, JP; Kushner, JP; Abonia, JP; Rothenberg, ME				Caldwell, Julie M.; Collins, Margaret H.; Stucke, Emily M.; Putnam, Philip E.; Franciosi, James P.; Kushner, Jonathan P.; Abonia, J. Pablo; Rothenberg, Marc E.			Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, T(H)2 immunity, and a unique gastric transcriptome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic gastritis; EG transcriptome; IL-13; eosinophils; regulatory T cells; mast cells; CCL26	REGULATORY T-CELLS; GASTROINTESTINAL DISORDERS; ESOPHAGITIS; EXPRESSION; GASTROENTERITIS; SUPPRESSION; PREVALENCE; EOTAXIN-3; CHILDREN; DISEASE	Background: The definition of eosinophilic gastritis (EG) is currently limited to histologic EG based on the tissue eosinophil count. Objective: We aimed to provide additional fundamental information about the molecular, histopathologic, and clinical characteristics of EG. Methods: Genome-wide transcript profiles and histologic features of gastric biopsy specimens, as well as blood eosinophil counts, were analyzed in patients with EG and control subjects (n = 15 each). Results: The peak gastric antrum eosinophil count was 283 +/- 164 eosinophils/x400 high-power field in patients with EG and 11 6 9 eosinophils/x400 high-power field in control subjects (P = 6.1 x 10(-7)). Patients with EG (87%) had coexisting eosinophilic inflammation in multiple gastrointestinal segments; the esophagus represented the most common secondary site. Increased peripheral blood eosinophil counts (patients with EG: 1.09 +/- 0.88 x 10(3)/mu L vs control subjects: 0.09 +/- 0.08 10(3)/mu L, P = .0027) positively correlated with peak gastric eosinophil counts (Pearson r(2) = .8102, P < .0001). MIB-1(+) (proliferating), CD117(+) (mast cells), and FOXP3(+) (regulatory T cells, activated T cells, or both) cell counts were increased in patients with EG. Transcript profiling revealed changes in 8% of the genome in gastric tissue from patients with EG. Only 7% of this EG transcriptome overlapped with the eosinophilic esophagitis transcriptome. Significantly increased IL4, IL5, IL13, IL17, CCL26, and mast cell-specific transcripts and decreased IL33 transcripts were observed. Conclusion: EG is a systemic disorder involving profound blood and gastrointestinal tract eosinophilia, T(H)2 immunity, and a conserved gastric transcriptome markedly distinct from the eosinophilic esophagitis transcriptome. The data herein define germane cellular and molecular pathways of EG and provide a basis for improving diagnosis and treatment.	[Caldwell, Julie M.; Stucke, Emily M.; Abonia, J. Pablo; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Collins, Margaret H.] Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Putnam, Philip E.; Franciosi, James P.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH USA; [Kushner, Jonathan P.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Franciosi, JP (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org		Abonia, Juan/0000-0003-3788-6485	Campaign Urging Research for Eosinophilic Disease (CURED) Foundation; Buckeye Foundation; Food Allergy Research Education; National Institutes of Health [P30 DK078392]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083450, U19AI070235, R37AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER	Campaign Urging Research for Eosinophilic Disease (CURED) Foundation; Buckeye Foundation; Food Allergy Research Education; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the Campaign Urging Research for Eosinophilic Disease (CURED) Foundation, the Buckeye Foundation, Food Allergy Research & Education, and National Institutes of Health P30 DK078392 (Integrative Morphology Core and the Gene and Protein Expression Core of the Digestive Disease Research Core Center in Cincinnati).	Abonia JP, 2013, J ALLERGY CLIN IMMUN, V132, P378, DOI 10.1016/j.jaci.2013.02.030; Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Akuthota P, 2012, SEMIN HEMATOL, V49, P113, DOI 10.1053/j.seminhematol.2012.01.005; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blatman KSH, 2011, J ALLERGY CLIN IMMUN, V127, P1307, DOI 10.1016/j.jaci.2010.12.1118; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Chehade M, 2006, J PEDIATR GASTR NUTR, V42, P516, DOI 10.1097/01.mpg.0000221903.61157.4e; Collins MH, 2009, IMMUNOL ALLERGY CLIN, V29, P109, DOI 10.1016/j.iac.2008.10.005; Danese S, 2006, WORLD J GASTROENTERO, V12, P4807; Dellon ES, 2012, AM J GASTROENTEROL, V107, P1503, DOI 10.1038/ajg.2012.202; Dufort FJ, 2007, J IMMUNOL, V179, P4953, DOI 10.4049/jimmunol.179.8.4953; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Frischmeyer-Guerrerio PA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006448; Fuentebella J, 2010, J PEDIATR GASTR NUTR, V51, P283, DOI 10.1097/MPG.0b013e3181e0817b; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Henderson CJ, 2014, J PEDIATR GASTR NUTR, V58, P553, DOI 10.1097/MPG.0000000000000253; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Hurrell JM, 2011, ADV ANAT PATHOL, V18, P335, DOI 10.1097/PAP.0b013e318229bfe2; Islam SA, 2013, J EXP MED, V210, P1889, DOI 10.1084/jem.20130240; JAFFE JS, 1994, J CLIN IMMUNOL, V14, P299, DOI 10.1007/BF01540983; Katzka DA, 2006, CURR OPIN GASTROEN, V22, P429, DOI 10.1097/01.mog.0000231820.71761.70; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lwin T, 2011, MODERN PATHOL, V24, P556, DOI 10.1038/modpathol.2010.221; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Nguyen KD, 2009, J ALLERGY CLIN IMMUN, V123, P933, DOI 10.1016/j.jaci.2008.11.037; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1016/S1542-3565(04)00240-X; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Pene J, 2008, J IMMUNOL, V180, P7423, DOI 10.4049/jimmunol.180.11.7423; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Souwer Y, 2010, CURR OPIN IMMUNOL, V22, P821, DOI 10.1016/j.coi.2010.10.013; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2008, BEST PRACT RES CL GA, V22, P481, DOI 10.1016/j.bpg.2007.09.001; TALLEY NJ, 1990, GUT, V31, P54, DOI 10.1136/gut.31.1.54; Tantibhaedhyangkul U, 2009, ANN CLIN LAB SCI, V39, P99; Valent P, 2012, J ALLERGY CLIN IMMUN, V130, P607, DOI 10.1016/j.jaci.2012.02.019; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435	43	92	92	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1114	1124		10.1016/j.jaci.2014.07.026	http://dx.doi.org/10.1016/j.jaci.2014.07.026			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25234644	Green Accepted			2022-12-18	WOS:000344938900017
J	Cole, C; Kroboth, K; Schurch, NJ; Sandilands, A; Sherstnev, A; O'Regan, GM; Watson, RM; McLean, WHI; Barton, GJ; Irvine, AD; Brown, SJ				Cole, Christian; Kroboth, Karin; Schurch, Nicholas J.; Sandilands, Aileen; Sherstnev, Alexander; O'Regan, Grainne M.; Watson, Rosemarie M.; McLean, W. H. Irwin; Barton, Geoffrey J.; Irvine, Alan D.; Brown, Sara J.			Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; direct RNA sequencing; eczema; filaggrin; gene expression; single molecule; skin; tissue; transcriptome	DOWN-REGULATES FILAGGRIN; GENE-EXPRESSION; STRATUM-CORNEUM; ICHTHYOSIS VULGARIS; LIPID ORGANIZATION; BARRIER FUNCTION; CELL-DEATH; ECZEMA; MUTATIONS; RISK	Background: Atopic dermatitis (AD; eczema) is characterized by a widespread abnormality in cutaneous barrier function and propensity to inflammation. Filaggrin is a multifunctional protein and plays a key role in skin barrier formation. Loss-of-function mutations in the gene encoding filaggrin (FLG) are a highly significant risk factor for atopic disease, but the molecular mechanisms leading to dermatitis remain unclear. Objective: We sought to interrogate tissue-specific variations in the expressed genome in the skin of children with AD and to investigate underlying pathomechanisms in atopic skin. Methods: We applied single-molecule direct RNA sequencing to analyze the whole transcriptome using minimal tissue samples. Uninvolved skin biopsy specimens from 26 pediatric patients with AD were compared with site-matched samples from 10 nonatopic teenage control subjects. Cases and control subjects were screened for FLG genotype to stratify the data set. Results: Two thousand four hundred thirty differentially expressed genes (false discovery rate, P<.05) were identified, of which 211 were significantly upregulated and 490 downregulated by greater than 2-fold. Gene ontology terms for "extracellular space'' and "defense response'' were enriched, whereas "lipid metabolic processes'' were downregulated. The subset of FLG wild-type cases showed dysregulation of genes involved with lipid metabolism, whereas filaggrin haploinsufficiency affected global gene expression and was characterized by a type 1 interferon-mediated stress response. Conclusion: These analyses demonstrate the importance of extracellular space and lipid metabolism in atopic skin pathology independent of FLG genotype, whereas an aberrant defense response is seen in subjects with FLG mutations. Genotype stratification of the large data set has facilitated functional interpretation and might guide future therapy development.	[Cole, Christian; Schurch, Nicholas J.; Sherstnev, Alexander; Barton, Geoffrey J.] Univ Dundee, Coll Life Sci, Div Computat Biol, Dundee DD1 5EH, Scotland; [Kroboth, Karin; Sandilands, Aileen; McLean, W. H. Irwin; Brown, Sara J.] Univ Dundee, Coll Life Sci, Div Mol Med, Ctr Dermatol & Genet Med, Dundee DD1 5EH, Scotland; [Kroboth, Karin; Sandilands, Aileen; McLean, W. H. Irwin; Brown, Sara J.] Univ Dundee, Coll Med Dent & Nursing, Div Mol Med, Ctr Dermatol & Genet Med, Dundee DD1 5EH, Scotland; [O'Regan, Grainne M.; Watson, Rosemarie M.; Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Dermatol, Dublin, Ireland; [Irvine, Alan D.; Brown, Sara J.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland; [Irvine, Alan D.] Univ Dublin Trinity Coll, Dublin 2, Ireland	University of Dundee; University of Dundee; University of Dundee; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; Trinity College Dublin	Brown, SJ (corresponding author), Univ Dundee, Coll Life Sci, Div Mol Med, Ctr Dermatol & Genet Med, Dundee DD1 5EH, Scotland.	g.j.barton@dundee.ac.uk; irvinea@tcd.ie; s.j.brown@dundee.ac.uk	Schurch, Nicholas/I-4339-2019; Barton, Geoffrey/N-1037-2019; Brown, Sara J/AAF-7095-2019; Irvine, Alan D/A-3982-2008; Barton, Geoffrey J/C-6267-2011	Schurch, Nicholas/0000-0001-9068-9654; Barton, Geoffrey/0000-0002-9014-5355; Brown, Sara J/0000-0002-3232-5251; Irvine, Alan D/0000-0002-9048-2044; Cole, Christian/0000-0002-2560-2484	Wellcome Trust [WT086398MA, 092530/Z/10/Z, 098439/Z/12/Z]; National Children's Research Centre Dublin, Ireland [E/10/3]; Anonymous Trustees, Dundee, United Kingdom	Wellcome Trust(Wellcome TrustEuropean Commission); National Children's Research Centre Dublin, Ireland; Anonymous Trustees, Dundee, United Kingdom	Supported by the Wellcome Trust (Intermediate Clinical Fellowship WT086398MA to SJB and Programme Grant 092530/Z/10/Z to W. H. I. M., G.J.B., and A. D. I.). The Centre for Dermatology and Genetic Medicine, University of Dundee is supported by a Wellcome Trust Strategic Award (098439/Z/12/Z to W. H. I. M. and G.J.B.). This work was supported by the National Children's Research Centre Dublin, Ireland (grant E/10/3 to A. D. I. and S.J.B.) and the Anonymous Trustees, Dundee, United Kingdom (to S.J.B.).	Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Brown SJ, 2009, BRIT J DERMATOL, V161, P884, DOI 10.1111/j.1365-2133.2009.09339.x; Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cheung VG, 2009, NAT REV GENET, V10, P595, DOI 10.1038/nrg2630; Choy DF, 2012, J ALLERGY CLIN IMMUN, V130, P1335, DOI 10.1016/j.jaci.2012.06.044; Eckhart L, 2013, BBA-MOL CELL RES, V1833, P3471, DOI 10.1016/j.bbamcr.2013.06.010; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758; Eyerich K, 2013, ALLERGY, V68, P974, DOI 10.1111/all.12184; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gilad Y, 2008, TRENDS GENET, V24, P408, DOI 10.1016/j.tig.2008.06.001; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Gutowska-Owsiak D, 2011, BRIT J DERMATOL, V165, P492, DOI 10.1111/j.1365-2133.2011.10400.x; Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jakasa I, 2007, J INVEST DERMATOL, V127, P129, DOI 10.1038/sj.jid.5700582; Janssens M, 2013, BBA-BIOMEMBRANES, V1828, P1814, DOI 10.1016/j.bbamem.2013.04.001; Janssens M, 2012, J LIPID RES, V53, P2755, DOI 10.1194/jlr.P030338; Johnson K, 2003, ARTHRITIS RHEUM-US, V48, P1302, DOI 10.1002/art.10927; Kamsteeg M, 2010, BRIT J DERMATOL, V162, P568, DOI 10.1111/j.1365-2133.2009.09547.x; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Lu ZR, 2009, J DERMATOL SCI, V55, P123, DOI 10.1016/j.jdermsci.2009.04.005; Mathay C, 2011, J INVEST DERMATOL, V131, P46, DOI 10.1038/jid.2010.272; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; McGettrick AF, 2013, J BIOL CHEM, V288, P22893, DOI 10.1074/jbc.R113.486464; Mori M, 2006, BIOCHEM BIOPH RES CO, V341, P121, DOI 10.1016/j.bbrc.2005.12.159; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Mudge JM, 2013, GENOME RES, V23, P1961, DOI 10.1101/gr.161315.113; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V126, P574, DOI 10.1016/j.jaci.2010.04.038; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V125, P170, DOI 10.1016/j.jaci.2009.10.046; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Ozsolak F, 2009, NATURE, V461, P814, DOI 10.1038/nature08390; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Plager DA, 2007, EXP DERMATOL, V16, P28, DOI 10.1111/j.1600-0625.2006.00504.x; Rebane A, 2012, J ALLERGY CLIN IMMUN, V129, P1297, DOI 10.1016/j.jaci.2012.02.020; Rinn JL, 2008, J INVEST DERMATOL, V128, P776, DOI 10.1038/sj.jid.5700986; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Saaf AM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004017; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schurch NJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094270; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Taieb Alain, 2006, J Allergy Clin Immunol, V117, P378, DOI 10.1016/j.jaci.2005.11.038; Taylor JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007651; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; van den Bogaard EH, 2013, J CLIN INVEST, V123, P917, DOI 10.1172/JCI65642; van Drongelen V, 2013, EXP DERMATOL, V22, P807, DOI 10.1111/exd.12271; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; Winge MCG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028254	65	92	95	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					82	91		10.1016/j.jaci.2014.04.021	http://dx.doi.org/10.1016/j.jaci.2014.04.021			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24880632	hybrid, Green Published			2022-12-18	WOS:000338930300012
J	Howrylak, JA; Fuhlbrigge, AL; Strunk, RC; Zeiger, RS; Weiss, ST; Raby, BA				Howrylak, Judie A.; Fuhlbrigge, Anne L.; Strunk, Robert C.; Zeiger, Robert S.; Weiss, Scott T.; Raby, Benjamin A.		Childhood Asthma Management Progra	Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; asthma phenotypes; inhaled corticosteroids; cluster analysis; asthma classification; longitudinal study	CLUSTER-ANALYSIS; CHILDREN; ADULT; EXACERBATIONS	Background: Although recent studies have identified the presence of phenotypic clusters in asthmatic patients, the clinical significance and temporal stability of these clusters have not been explored. Objective: Our aim was to examine the clinical relevance and temporal stability of phenotypic clusters in children with asthma. Methods: We applied spectral clustering to clinical data from 1041 children with asthma participating in the Childhood Asthma Management Program. Posttreatment randomization follow-up data collected over 48 months were used to determine the effect of these clusters on pulmonary function and treatment response to inhaled anti-inflammatory medication. Results: We found 5 reproducible patient clusters that could be differentiated on the basis of 3 groups of features: atopic burden, degree of airway obstruction, and history of exacerbation. Cluster grouping predicted long-term asthma control, as measured by the need for oral prednisone (P <.0001) or additional controller medications (P =.001), as well as longitudinal differences in pulmonary function (P <.0001). We also found that the 2 clusters with the highest rates of exacerbation had different responses to inhaled corticosteroids when compared with the other clusters. One cluster demonstrated a positive response to both budesonide (P =.02) and nedocromil (P =.01) compared with placebo, whereas the other cluster demonstrated minimal responses to both budesonide (P =.12) and nedocromil (P =.56) compared with placebo. Conclusion: Phenotypic clustering can be used to identify longitudinally consistent and clinically relevant patient subgroups, with implications for targeted therapeutic strategies and clinical trials design.	[Howrylak, Judie A.] Penn State Milton S Hershey Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Hershey, PA USA; [Fuhlbrigge, Anne L.; Weiss, Scott T.; Raby, Benjamin A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Fuhlbrigge, Anne L.; Weiss, Scott T.; Raby, Benjamin A.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Fuhlbrigge, Anne L.; Weiss, Scott T.; Raby, Benjamin A.] Harvard Univ, Sch Med, Boston, MA USA; [Strunk, Robert C.] Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63130 USA; [Strunk, Robert C.] St Louis Childrens Hosp, St Louis, MO USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Zeiger, Robert S.] Kaiser Permanente, Dept Allergy, San Diego, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); University of California System; University of California San Diego; Kaiser Permanente	Raby, BA (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	rebar@channing.harvard.edu	Raby, Benjamin/AAK-3866-2021	Zeiger, Robert/0000-0001-5788-5063	National Heart, Lung, and Blood Institute (NHLBI); General Clinical Research Center [M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036]; National Center for Research Resources; NHLBI/ National Institutes of Health [R01-086601, R01-093076, RC2-HL101543.];  [NO1-HR16044];  [16045];  [16046];  [16047];  [16048];  [16049];  [16050];  [16051];  [16052]; DIVISION OF LUNG DISEASES [N01HR016044, N01HR016048, N01HR016045, N01HR016052, N01HR016050, N01HR016051, N01HR016046, N01HR016047, N01HR016049] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899, R37HL066289, RC2HL101543, R01HL016052, R01HL086601, R01HL093076, R01HL118455] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI/ National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ; ; ; ; ; ; ; ; ; DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Childhood Asthma Management Program is supported by contracts NO1-HR16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute (NHLBI) and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. B. A. R. is supported by NHLBI/ National Institutes of Health grants R01-086601, R01-093076, and RC2-HL101543.	[Anonymous], 1999, Control Clin Trials, V20, P91; [Anonymous], 2007, EXP PAN REP 3 GUID D; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962, DOI 10.1164/ajrccm.160.6.9902112; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; de Souto MCP, 2008, IEEE IJCNN, P2792, DOI 10.1109/IJCNN.2008.4634191; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Forno E, 2010, CHEST, V138, P1156, DOI 10.1378/chest.09-2426; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P921, DOI 10.1016/j.jaci.2009.09.006; Karatzoglou A., 2004, J STAT SOFTW, V11, P1, DOI 10.18637/jss.v011.i09; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; Larsen GL, 2000, J ALLERGY CLIN IMMUN, V106, pS153; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Ng AY, 2001, NIPS P ADV NEURAL IN; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler SJ, 1997, EUR RESPIR J, V10, P1640, DOI 10.1183/09031936.97.10071640; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tibshirani R, 2001, J ROY STAT SOC B, V63, P411, DOI 10.1111/1467-9868.00293	30	92	93	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1289	U494		10.1016/j.jaci.2014.02.006	http://dx.doi.org/10.1016/j.jaci.2014.02.006			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24892144	Green Accepted, Green Published			2022-12-18	WOS:000335450700008
J	Shearer, WT; Fleisher, TA; Buckley, RH; Ballas, Z; Ballow, M; Blaese, RM; Bonilla, FA; Conley, ME; Cunningham-Rundles, C; Filipovich, AH; Fuleihan, R; Gelfand, EW; Hernandez-Trujillo, V; Holland, SM; Hong, R; Lederman, HM; Malech, HL; Miles, S; Notarangelo, LD; Ochs, HD; Orange, JS; Puck, JM; Routes, JM; Stiehm, ER; Sullivan, K; Torgerson, T; Winkelstein, J				Shearer, William T.; Fleisher, Thomas A.; Buckley, Rebecca H.; Ballas, Zuhair; Ballow, Mark; Blaese, R. Michael; Bonilla, Francisco A.; Conley, Mary Ellen; Cunningham-Rundles, Charlotte; Filipovich, Alexandra H.; Fuleihan, Ramsay; Gelfand, Erwin W.; Hernandez-Trujillo, Vivian; Holland, Steven M.; Hong, Richard; Lederman, Howard M.; Malech, Harry L.; Miles, Stephen; Notarangelo, Luigi D.; Ochs, Hans D.; Orange, Jordan S.; Puck, Jennifer M.; Routes, John M.; Stiehm, E. Richard; Sullivan, Kathleen; Torgerson, Troy; Winkelstein, Jerry		Med Advisory Comm Immune Deficienc	Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Live viral and bacterial vaccines; primary immunodeficiency disease; severe combined immunodeficiency disease; cellular immune reconstitution	STEM-CELL TRANSPLANTATION; POLIOVIRUS; VACCINATION; PERSISTENT; CHILDREN	The present uncertainty of which live viral or bacterial vaccines can be given to immunodeficient patients and the growing neglect of societal adherence to routine immunizations has prompted the Medical Advisory Committee of the Immune Deficiency Foundation to issue recommendations based on published literature and the collective experience of the committee members. These recommendations address the concern for immunodeficient patients acquiring infections from healthy subjects who have not been immunized or who are shedding live vaccine-derived viral or bacterial organisms. Such transmission of infectious agents can occur within the hospital, clinic, or home or at any public gathering. Collectively, we define this type of transmission as close-contact spread of infectious disease that is particularly relevant in patients with impaired immunity who might have an infection when exposed to subjects carrying vaccine-preventable infectious diseases or who have recently received a live vaccine. Immunodeficient patients who have received therapeutic hematopoietic stem transplantation are also at risk during the time when immune reconstitution is incomplete or while they are receiving immunosuppressive agents to prevent or treat graft-versus-host disease. This review recommends the general education of what is known about vaccine-preventable or vaccine-derived diseases being spread to immunodeficient patients at risk for close-contact spread of infection and describes the relative risks for a child with severe immunodeficiency. The review also recommends a balance between the need to protect vulnerable subjects and their social needs to integrate into society, attend school, and benefit from peer education.	[Shearer, William T.; Orange, Jordan S.] Baylor Coll Med, Houston, TX 77030 USA; [Shearer, William T.; Orange, Jordan S.] Texas Childrens Hosp, Houston, TX 77030 USA; [Fleisher, Thomas A.] NIH, Ctr Clin, Bethesda, MD 20892 USA; [Buckley, Rebecca H.] Duke Univ, Sch Med, Durham, NC 27706 USA; [Ballas, Zuhair] Univ Iowa, Iowa City, IA USA; [Ballas, Zuhair] Iowa City Vet Affairs Med Ctr, Iowa City, IA USA; [Ballow, Mark] SUNY Buffalo, Childrens Hosp Buffalo, Buffalo, NY USA; [Blaese, R. Michael] Immune Deficiency Fdn, Columbia, SC USA; [Bonilla, Francisco A.; Notarangelo, Luigi D.] Boston Childrens Hosp, Boston, MA USA; [Conley, Mary Ellen] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA; [Conley, Mary Ellen] St Jude Childrens Res Ctr, Memphis, TN USA; [Cunningham-Rundles, Charlotte] Mt Sinai Med Ctr, New York, NY 10029 USA; [Filipovich, Alexandra H.] Cincinnati Childrens Hosp, Cincinnati, OH USA; [Fuleihan, Ramsay] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; [Gelfand, Erwin W.] Natl Jewish Hlth, Denver, CO USA; [Hernandez-Trujillo, Vivian] Miami Childrens Hosp, Miami, FL USA; [Holland, Steven M.; Malech, Harry L.] Natl Inst Allergy & Infect Dis, Bethesda, MD USA; [Lederman, Howard M.; Winkelstein, Jerry] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Ochs, Hans D.; Torgerson, Troy] Seattle Childrens Hosp, Seattle, WA USA; [Puck, Jennifer M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Routes, John M.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA; [Stiehm, E. Richard] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; [Sullivan, Kathleen] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Duke University; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Boston Children's Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; Icahn School of Medicine at Mount Sinai; Cincinnati Children's Hospital Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; National Jewish Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Seattle Children's Hospital; University of California System; University of California San Francisco; Children's Hospital of Wisconsin; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Shearer, WT (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Dept Pediat & Immunol, Allergy & Immunol Serv, 1102 Bates St,Suite 330, Houston, TX 77030 USA.	wtsheare@TexasChildrensHospital.org	Notarangelo, Luigi D/F-9718-2016; Routes, john/AAA-4833-2021	Notarangelo, Luigi D/0000-0002-8335-0262; Routes, john/0000-0001-8378-3773; Malech, Harry/0000-0001-5874-5775; Knaack, Aaron/0000-0001-7712-1415; Shearer, William/0000-0002-2483-2130; Ballas, Zuhair/0000-0001-5569-1230; orange, jordan/0000-0001-7117-7725	Intramural Research Program of the National Institutes of Health Clinical Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Department of Health and Human Services; NIH [USID Net NIH U24 P0027559, PIDTC NIH U54 A1082973]; Immune Deficiency; Baxter; CSL Behring; Avant; Grifols; Immune Deficiency Foundation; Pediatric Update; Biotest Pharmaceutical Corporation; Sanofi; Merck; March of Dimes; Octapharma; Atlantic Research; BPL; UpToDate; Baxter Biosciences; BD Bioscience; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000647, ZIAAI000644, ZIAAI000645, R13AI069762, R18AI048693, ZIAAI000988, ZIAAI000646, R01AI105776, U54AI082973, U24AI086037] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health Clinical Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Immune Deficiency; Baxter; CSL Behring; Avant; Grifols; Immune Deficiency Foundation; Pediatric Update; Biotest Pharmaceutical Corporation; Sanofi(Sanofi-Aventis); Merck(Merck & Company); March of Dimes(March of Dimes); Octapharma; Atlantic Research; BPL; UpToDate; Baxter Biosciences; BD Bioscience; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Intramural Research Program of the National Institutes of Health Clinical Center (T. A. F.) and the National Institute of Allergy and Infectious Diseases (S. M. H. and H. L. M.). No official endorsement of support by the National Institutes of Health or the Department of Health and Human Services is intended or should be inferred.; T. A. Fleisher is employed by the National Institutes of Health (NIH) and has received royalties as the coeditor of a clinical immunology textbook. R. H. Buckley is employed by the Duke University Medical Center and has stock/stock options in various entities. Z. Ballas has received research support from the NIH, has received consultancy fees from Immune Deficiency, and receives royalties from UpToDate. M. Ballow has received consultancy fees from Baxter and CSL Behring; is employed by USF Health and Windom Allergy; has received research support from CSL Behring; has received lecture fees from Avant, Grifols, and CSL Behring; and has received payment for manuscript preparation from Elsevier and UpToDate. R. M. Blaese has received consultancy fees from the Immune Deficiency Foundation (Consulting Medical Director and MAC member). F. A. Bonilla has received consultancy fees from CSL Behring, has received lecture fees from Pediatric Update, has received royalties from UpToDate, has received travel fees from the Immune Deficiency Foundation, and is a member of the Blood Product Advisory Committee (US Food and Drug Administration). E. W. Gelfand has received consultancy fees from Biotest Pharmaceutical Corporation and CSL Behring, has received research support from the NIH, and is employed by National Jewish Health. V. Hernandez-Trujillo has received consultancy fees from Sanofi and Baxter; has received lecture fees from Merck, Sanofi, Baxter, and CSL; has received travel fees from Baxter; is a spokesperson for Sanofi; and is a spokesperson and member of the Claritin Council for Merck. S. Miles is a voluntary board member for a medical advisory committee. L. D. Notarangelo is a board member for Meyer Pediatric University Hospital in Florence, Italy, and for a program in Molecular and Cellular Medicine; is employed by Boston Children's Hospital; has received research support from the NIH and March of Dimes; and receives royalties from UpToDate. H. D. Ochs is a board member for DSMC and Sigma Tau and has received travel fees from CSL Behring. J. S. Orange has received consultancy fees from Baxter, CSL Behring, Octapharma, Atlantic Research, Grifols, and BPL; has provided expert testimony for the State of Arizona; has received research support from CSL Behring; has received lecture fees from Baxter; and has received royalties from UpToDate. J. M. Puck has received research support from the NIH and has received travel fees from the NIH (USID Net NIH U24 P0027559 and PIDTC NIH U54 A1082973). E. R. Stiehm has received consultancy fees from UpToDate, is employed by the UCLA Medical Center, has received lecture fees and payment for manuscript preparation, and has stock/stock options not related to this work. K. Sullivan has received consultancy fees from the Immune Deficiency Foundation and receives royalties from UpToDate. T. Torgerson has received consultancy fees from Baxter Biosciences and BD Bioscience, has received research support from Baxter Biosciences and CSL Behring, has received lecture fees from Baxter Biosciences, and has received lecture fees from Baxter Biosciences. The rest of the authors declare that they have no relevant conflicts of interest.	Abramson JS, 1999, PEDIATRICS, V104, P1404, DOI 10.1542/peds.104.6.1404; Al-Sukaiti N, 2010, J ALLERGY CLIN IMMUN, V126, P868, DOI 10.1016/j.jaci.2010.07.018; Alexander JP, 2009, J INFECT DIS, V199, P391, DOI 10.1086/596052; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; Bakare N, 2010, VACCINE, V28, P6609, DOI 10.1016/j.vaccine.2010.07.039; Baxter R, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4249; Grohskopf L, 2011, AM J TRANSPLANT, V11, P2250, DOI 10.1111/j.1600-6143.2011.03793.x; Gumede N, 2012, EMERG INFECT DIS, V18, P992, DOI 10.3201/eid1806.120037; Jackson J, 2013, J ALLERGY CLIN IMMUN, V132, P889, DOI 10.1016/j.jaci.2013.05.046; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; Lin M, 2009, J CLIN IMMUNOL, V29, P231, DOI 10.1007/s10875-008-9250-z; Lindegren Mary Lou, 2004, Morbidity and Mortality Weekly Report, V53, P1; MacLennan C, 2004, LANCET, V363, P1509, DOI 10.1016/S0140-6736(04)16150-3; Pickering LK, 2012, RED BOOK 2012 REPORT, P553; Pickering LK, 2012, RED BOOK 2012 REPORT, P74; Platonov AE, 2003, VACCINE, V21, P4437, DOI 10.1016/S0264-410X(03)00440-7; Rosenzweig SD, 2010, PEDIAT ALLERGY PRINC, P133; Sabry AJ, 2014, J ALLERGY CLIN IMMUN; Scharenberg AM, 1993, GENEREVIEWS; Titman P, 2008, BLOOD, V112, P3907, DOI 10.1182/blood-2008-04-151332; WILFERT CM, 1977, NEW ENGL J MED, V296, P1485, DOI 10.1056/NEJM197706302962601	21	92	96	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					961	966		10.1016/j.jaci.2013.11.043	http://dx.doi.org/10.1016/j.jaci.2013.11.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24582311	Green Accepted			2022-12-18	WOS:000333531700003
J	Yoo, JK; Kim, TS; Hufford, MM; Braciale, TJ				Yoo, Jae-Kwang; Kim, Taeg S.; Hufford, Matthew M.; Braciale, Thomas J.			Viral infection of the lung: Host response and sequelae	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Viral sensor molecules; innate immunity; adaptive immunity; T-cell immunity; B-cell immunity; viral clearance; tissue repair; stem cells	RESPIRATORY SYNCYTIAL VIRUS; INNATE LYMPHOID-CELLS; REGULATORY T-CELLS; INFLUENZA-A-VIRUS; COMMUNITY-ACQUIRED PNEUMONIA; CXC CHEMOKINE RECEPTOR-5; DENDRITIC CELLS; STEM-CELLS; EARLY-LIFE; HUMAN MACROPHAGES	Because of its essential role in gas exchange and oxygen delivery, the lung has evolved a variety of strategies to control inflammation and maintain homeostasis. Invasion of the lung by pathogens (and in some instances exposure to certain noninfectious particulates) disrupts this equilibrium and triggers a cascade of events aimed at preventing or limiting colonization (and more importantly infection) by pathogenic microorganisms. In this review we focus on viral infection of the lung and summarize recent advances in our understanding of the triggering of innate and adaptive immune responses to viral respiratory tract infection, mechanisms of viral clearance, and the well-recognized consequences of acute viral infection complicating underlying lung diseases, such as asthma.	[Yoo, Jae-Kwang; Kim, Taeg S.; Hufford, Matthew M.; Braciale, Thomas J.] Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; [Hufford, Matthew M.; Braciale, Thomas J.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA; [Kim, Taeg S.; Braciale, Thomas J.] Univ Virginia, Dept Pathol & Mol Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Braciale, TJ (corresponding author), Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA.	tjb2r@virginia.edu			NATIONAL CANCER INSTITUTE [P30CA044579] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015608, T32AI055432, T32AI007496, U19AI083024, T32AI060519] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA044579] Funding Source: Medline; NHLBI NIH HHS [R01 HL033391] Funding Source: Medline; NIAID NIH HHS [T32 AI007496, T32 AI055432, T32 AI060519, U19 AI083024, R01 AI015608] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; Allen JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002003; Antunes I, 2010, J VIROL, V84, P12564, DOI 10.1128/JVI.01559-10; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; BANGHAM CRM, 1985, J VIROL, V56, P55, DOI 10.1128/JVI.56.1.55-59.1985; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Beauchamp NM, 2010, J VIROL, V84, P10191, DOI 10.1128/JVI.00892-10; Beers MF, 2011, J CLIN INVEST, V121, P2065, DOI 10.1172/JCI45961; Belz GT, 2004, P NATL ACAD SCI USA, V101, P8670, DOI 10.1073/pnas.0402644101; Benoit ME, 2012, J IMMUNOL, V188, P5682, DOI 10.4049/jimmunol.1103760; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Boyd M, 2006, MED J AUSTRALIA, V185, pS44; Braciale TJ, 2012, NAT REV IMMUNOL, V12, P295, DOI 10.1038/nri3166; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Brown DM, 2006, J IMMUNOL, V177, P2888, DOI 10.4049/jimmunol.177.5.2888; Burckstummer T, 2009, NAT IMMUNOL, V10, P266, DOI 10.1038/ni.1702; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cameron MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045842; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; Carlson CM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001136; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; CHANOCK RM, 1961, JAMA-J AM MED ASSOC, V176, P647; Chen F, 2012, NAT MED, V18, P260, DOI 10.1038/nm.2628; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Cilloniz C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000604; Cole BB, 2010, AM J PATHOL, V177, P362, DOI 10.2353/ajpath.2010.090870; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Cretney E, 2011, NAT IMMUNOL, V12, P304, DOI 10.1038/ni.2006; Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Debbabi H, 2005, AM J PHYSIOL-LUNG C, V289, pL274, DOI 10.1152/ajplung.00004.2005; Didierlaurent A, 2008, J EXP MED, V205, P323, DOI 10.1084/jem.20070891; Donnelly RP, 2010, J INTERF CYTOK RES, V30, P555, DOI 10.1089/jir.2010.0078; Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; FISHAUT M, 1980, J PEDIATR-US, V96, P179, DOI 10.1016/S0022-3476(80)80799-2; Fraaij PLA, 2011, VACCINE, V29, P7524, DOI 10.1016/j.vaccine.2011.08.010; Fulton RB, 2010, J IMMUNOL, V185, P2382, DOI 10.4049/jimmunol.1000423; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; GeurtsvanKessel CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007187; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; Giangreco A, 2009, P NATL ACAD SCI USA, V106, P9286, DOI 10.1073/pnas.0900668106; Gorski SA, 2012, CURR OPIN VIROL, V2, P233, DOI 10.1016/j.coviro.2012.04.006; GRAHAM MB, 1994, J EXP MED, V180, P1273, DOI 10.1084/jem.180.4.1273; Graham MB, 1997, J EXP MED, V186, P2063, DOI 10.1084/jem.186.12.2063; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Guo HL, 2010, J VIROL, V84, P7750, DOI 10.1128/JVI.00187-10; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; HALL CB, 1986, NEW ENGL J MED, V315, P77, DOI 10.1056/NEJM198607103150201; Hasegawa S, 2011, PEDIAT ALLERG IMM-UK, V22, pe119, DOI 10.1111/j.1399-3038.2010.01090.x; Hashimoto Y, 2007, J IMMUNOL, V178, P2448, DOI 10.4049/jimmunol.178.4.2448; Heer AK, 2007, J IMMUNOL, V178, P2182, DOI 10.4049/jimmunol.178.4.2182; HEMMING VG, 1985, J INFECT DIS, V152, P1083, DOI 10.1093/infdis/152.5.1083; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; Holt PG, 2008, NAT REV IMMUNOL, V8, P142, DOI 10.1038/nri2236; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Hufford MM, 2011, J EXP MED, V208, P167, DOI 10.1084/jem.20101850; Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861; Ichinohe T, 2009, J EXP MED, V206, P79, DOI 10.1084/jem.20081667; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jennings LC, 2008, THORAX, V63, P42, DOI 10.1136/thx.2006.075077; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Juncadella IJ, 2013, NATURE, V493, P547, DOI 10.1038/nature11714; Kajstura J, 2011, NEW ENGL J MED, V364, P1795, DOI 10.1056/NEJMoa1101324; Kandasamy M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003115; Kanneganti TD, 2006, J BIOL CHEM, V281, P36560, DOI 10.1074/jbc.M607594200; Kennedy JL, 2012, CURR OPIN VIROL, V2, P287, DOI 10.1016/j.coviro.2012.03.008; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim CH, 2001, J EXP MED, V193, P1373, DOI 10.1084/jem.193.12.1373; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim TS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004204; Kopf M, 2002, NAT MED, V8, P373, DOI 10.1038/nm0402-373; Koyama S, 2007, J IMMUNOL, V179, P4711, DOI 10.4049/jimmunol.179.7.4711; Krause Diane S, 2008, Proc Am Thorac Soc, V5, P323, DOI 10.1513/pats.200712-169DR; Kuiken T, 2008, VACCINE, V26, pD59, DOI 10.1016/j.vaccine.2008.07.025; Kumar P, 2013, MUCOSAL IMMUNOL, V6, P69, DOI 10.1038/mi.2012.49; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026; Lam WY, 2008, J VIROL, V82, P2741, DOI 10.1128/JVI.01712-07; Lamkanfi M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000510; Le Goffic R, 2006, PLOS PATHOG, V2, P526, DOI 10.1371/journal.ppat.0020053; Lee BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035812; Lee DCP, 2010, J VIROL, V84, P8790, DOI 10.1128/JVI.00796-10; Lee SK, 2011, J EXP MED, V208, P1377, DOI 10.1084/jem.20102065; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lin KL, 2008, J IMMUNOL, V180, P2562, DOI 10.4049/jimmunol.180.4.2562; Linterman MA, 2010, SEMIN IMMUNOPATHOL, V32, P183, DOI 10.1007/s00281-009-0194-z; Loke P, 2007, J IMMUNOL, V179, P3926, DOI 10.4049/jimmunol.179.6.3926; Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077; Mamas MA, 2008, INT J CARDIOL, V130, P304, DOI 10.1016/j.ijcard.2008.04.044; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; McGill J, 2008, J EXP MED, V205, P1635, DOI 10.1084/jem.20080314; McGill J, 2010, J EXP MED, V207, P521, DOI 10.1084/jem.20091711; MCINTOSH K, 1978, J INFECT DIS, V138, P24, DOI 10.1093/infdis/138.1.24; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Muruve DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Palmer EM, 2010, VIROLOGY, V404, P225, DOI 10.1016/j.virol.2010.05.004; Pang IK, 2013, NAT IMMUNOL, V14, P246, DOI 10.1038/ni.2514; Pang IK, 2011, TRENDS IMMUNOL, V32, P34, DOI 10.1016/j.it.2010.11.004; Pirhonen J, 2001, EUR J IMMUNOL, V31, P726, DOI 10.1002/1521-4141(200103)31:3<726::AID-IMMU726>3.0.CO;2-5; Pirhonen J, 1999, J IMMUNOL, V162, P7322; Pittet LA, 2010, AM J RESP CELL MOL, V42, P450, DOI 10.1165/rcmb.2007-0417OC; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; PLOTKOWSKI MC, 1986, AM REV RESPIR DIS, V134, P1040, DOI 10.1164/arrd.1986.134.5.1040; Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; PRINCE GA, 1985, VIRUS RES, V3, P193, DOI 10.1016/0168-1702(85)90045-0; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Rawlins EL, 2009, CELL STEM CELL, V4, P525, DOI 10.1016/j.stem.2009.04.002; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rintahaka J, 2008, J IMMUNOL, V180, P1749, DOI 10.4049/jimmunol.180.3.1749; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Ruckwardt TJ, 2009, J VIROL, V83, P3019, DOI 10.1128/JVI.00036-09; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Shahangian A, 2009, J CLIN INVEST, V119, P1910, DOI 10.1172/JCI35412; Shen CH, 2010, P NATL ACAD SCI USA, V107, P22587, DOI 10.1073/pnas.1016350108; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Shirey KA, 2010, MUCOSAL IMMUNOL, V3, P291, DOI 10.1038/mi.2010.6; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Smith MW, 2007, COMPARATIVE MED, V57, P82; Snelgrove RJ, 2008, NAT IMMUNOL, V9, P1074, DOI 10.1038/ni.1637; Snelgrove RJ, 2011, TRENDS IMMUNOL, V32, P328, DOI 10.1016/j.it.2011.04.006; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Stasakova J, 2005, J GEN VIROL, V86, P185, DOI 10.1099/vir.0.80422-0; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Stoermer KA, 2011, VIROLOGY, V411, P362, DOI 10.1016/j.virol.2010.12.045; Suarez-Ramirez JE, 2011, EUR J IMMUNOL, V41, P2632, DOI 10.1002/eji.201141546; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; SUFFIN SC, 1979, J IMMUNOL, V123, P10; Sun J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002173; Sun J, 2009, NAT MED, V15, P277, DOI 10.1038/nm.1929; Sun K, 2008, NAT MED, V14, P558, DOI 10.1038/nm1765; Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x; Takeuchi R, 1998, J VIROL, V72, P4498, DOI 10.1128/JVI.72.5.4498-4502.1998; Talbot TR, 2005, AM J MED, V118, P285, DOI 10.1016/j.amjmed.2004.09.016; Templeton KE, 2005, CLIN INFECT DIS, V41, P345, DOI 10.1086/431588; Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006; Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11; Topham DJ, 1996, J IMMUNOL, V157, P2947; Topham DJ, 1998, J VIROL, V72, P882, DOI 10.1128/JVI.72.1.882-885.1998; Trautmann A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.256pe6; van der Sluijs KF, 2004, J IMMUNOL, V172, P7603, DOI 10.4049/jimmunol.172.12.7603; van der Sluijs KF, 2010, CRIT CARE, V14, DOI 10.1186/cc8893; van Zoelen MAD, 2009, VIROLOGY, V391, P265, DOI 10.1016/j.virol.2009.05.032; Vanderstocken G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050385; Varin A, 2009, IMMUNOBIOLOGY, V214, P630, DOI 10.1016/j.imbio.2008.11.009; Vinuesa CG, 2005, NAT REV IMMUNOL, V5, P853, DOI 10.1038/nri1714; Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001; Waffarn EE, 2011, J IMMUNOL, V186, P3823, DOI 10.4049/jimmunol.1002090; Wang GF, 2010, CURR OPIN NEUROL, V23, P305, DOI 10.1097/WCO.0b013e328338f6c9; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; WATT PJ, 1986, CLIN EXP IMMUNOL, V64, P503; Weiss KA, 2011, J IMMUNOL, V187, P3145, DOI 10.4049/jimmunol.1100764; Wilkins C, 2010, CURR OPIN IMMUNOL, V22, P41, DOI 10.1016/j.coi.2009.12.003; Yoneyama M, 2009, IMMUNOL REV, V227, P54, DOI 10.1111/j.1600-065X.2008.00727.x; Yoo JK, 2012, J EXP MED, V209, P1853, DOI 10.1084/jem.20112256; Yoo JK, 2010, ANTIVIR RES, V88, P64, DOI 10.1016/j.antiviral.2010.07.006; Yoo JK, 2010, J EXP MED, V207, P1435, DOI 10.1084/jem.20091373; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720	180	92	96	1	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1263	1276		10.1016/j.jaci.2013.06.006	http://dx.doi.org/10.1016/j.jaci.2013.06.006			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23915713	Bronze, Green Published, Green Accepted			2022-12-18	WOS:000327538200005
J	Jabara, HH; Ohsumi, T; Chou, J; Massaad, MJ; Benson, H; Megarbane, A; Chouery, E; Mikhael, R; Gorka, O; Gewies, A; Portales, P; Nakayama, T; Hosokawa, H; Revy, P; Herrod, H; Le Deist, F; Lefranc, G; Ruland, J; Geha, RS				Jabara, Haifa H.; Ohsumi, Toshiro; Chou, Janet; Massaad, Michel J.; Benson, Halli; Megarbane, Andre; Chouery, Eliane; Mikhael, Raymond; Gorka, Oliver; Gewies, Andreas; Portales, Pierre; Nakayama, Toshinori; Hosokawa, Hiroyuki; Revy, Patrick; Herrod, Henry; Le Deist, Francoise; Lefranc, Gerard; Ruland, Juergen; Geha, Raif S.			A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MALT1; combined immunodeficiency (CID); NF-kappa B	T-CELL; DEFICIENCY; CARD11	Background: Combined immunodeficiency (CID) is characterized by severe recurrent infections with normal numbers of T and B lymphocytes but with deficient cellular and humoral immunity. Most cases are sporadic, but autosomal recessive inheritance has been described. In most cases, the cause of CID remains unknown. Objective: We wanted to identify the genetic cause of CID in 2 siblings, the products of a first-cousin marriage, who experienced recurrent bacterial and candidal infections with bronchiectasis, growth delay, and early death. Methods: We performed immunologic, genetic, and biochemical studies in the 2 siblings, their family members, and healthy controls. Reconstitution studies were performed with T cells from mucosa-associated lymphoid tissue lymphoma-translocation gene 1-deficient (Malt1(-/-)) mice. Results: The numbers of circulating T and B lymphocytes were normal, but T-cell proliferation to antigens and antibody responses to vaccination were severely impaired in both patients. Whole genome sequencing of 1 patient and her parents, followed by DNA sequencing of family members and healthy controls, showed the presence in both patients of a homozygous missense mutation in MALT1 that resulted in loss of protein expression. Analysis of T cells that were available on one of the patients showed severely impaired I kappa B alpha degradation and IL-2 production after activation, 2 events that depend on MALT1. In contrast to wild-type human MALT1, the patients' MALT1 mutant failed to correct defective nuclear factor-kappa B activation and IL-2 production in MALT1-deficient mouse T cells. Conclusions: An autosomal recessive form of CID is associated with homozygous mutations in MALT1. If future patients are found to be similarly affected, they should be considered as candidates for allogeneic hematopoietic cell transplantation.	[Jabara, Haifa H.; Chou, Janet; Massaad, Michel J.; Benson, Halli; Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Jabara, Haifa H.; Chou, Janet; Massaad, Michel J.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Ohsumi, Toshiro] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Ohsumi, Toshiro] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Megarbane, Andre; Chouery, Eliane; Lefranc, Gerard] St Joseph Univ, Fac Med, Med Genet Unit, Beirut, Lebanon; [Mikhael, Raymond] St Joseph Univ, Hotel Dieu Hosp, Dept Pediat, Beirut, Lebanon; [Gorka, Oliver; Gewies, Andreas; Ruland, Juergen] Tech Univ Munich, Klinikum Rechts Isar, Inst Klin Chem & Pathobiochem, D-80290 Munich, Germany; [Gewies, Andreas; Ruland, Juergen] German Canc Consortium DKTK, Heidelberg, Germany; [Gewies, Andreas; Ruland, Juergen] German Canc Res Ctr, Heidelberg, Germany; [Portales, Pierre] Ctr Hosp Univ Montpellier, Immunol Lab, Montpellier, France; [Nakayama, Toshinori; Hosokawa, Hiroyuki] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan; [Revy, Patrick] Univ Paris 05, Inst Imagine, Univ Sorbonne Paris Cite, Paris, France; [Revy, Patrick] INSERM, U768, Paris, France; [Herrod, Henry] Lebonheur Childrens Hosp & Med Ctr, Memphis, TN USA; [Le Deist, Francoise] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada; [Lefranc, Gerard] Inst Human Genet, CNRS UPR 1142, Montpellier, France; [Lefranc, Gerard] Univ Montpellier, F-34059 Montpellier, France; [Ruland, Juergen] German Ctr Infect Res DZIF, Braunschweig, Germany	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; American University of Beirut; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Universite de Montpellier; CHU de Montpellier; Chiba University; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; German Center for Infection Research	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 1 Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Megarbane, Andre/ABD-5574-2021; Ruland, Jürgen/Q-6680-2018; Revy, Patrick/H-8137-2017; Nakayama, Toshinori/E-1067-2017; Chouery, Eliane/AAC-5957-2021; Gorka, Oliver/AAF-1633-2020	Ruland, Jürgen/0000-0002-8381-3597; Nakayama, Toshinori/0000-0002-1434-2007; Gewies, Andreas/0000-0002-7606-6482; Hosokawa, Hiroyuki/0000-0002-9592-2889; Revy, Patrick/0000-0003-0758-8022; Gorka, Oliver/0000-0002-8245-3008	National Institutes of Health [AI-076210, AI094017]; Deutsche Forschungsgemeinschaft; ERC advanced grant ERC-ADG [LS6]; research council of St Joseph; research council of Chiba Universities; Clinical Immunology/Talecris Fellowship Award; AAAAI/GSK Fellow Career Development Award; National Institutes of Health (NIH); NIH; Japanese government (MEXT); Dubai Harvard Foundation for Medical Research;  [5T32AI007512-27];  [K-12 HD052896-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007512, P01AI076210, R03AI094017] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); ERC advanced grant ERC-ADG; research council of St Joseph; research council of Chiba Universities; Clinical Immunology/Talecris Fellowship Award; AAAAI/GSK Fellow Career Development Award; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japanese government (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Dubai Harvard Foundation for Medical Research; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health grants AI-076210 and AI094017 (R.S.G.) and grants 5T32AI007512-27 and K-12 HD052896-01A1 (J.C.), a grant from the Dubai Harvard Foundation for Medical Research (R.S.G.), and SFB grants from Deutsche Forschungsgemeinschaft (J.R.), the ERC advanced grant ERC-2012-ADG, LS6 (J.R.), and grants from research councils of St Joseph and Chiba Universities. J.C. has received a Clinical Immunology/Talecris Fellowship Award and an AAAAI/GSK Fellow Career Development Award.; H. H. Jabara, J. Chou, M. J. Massaad, and R. S. Geha have received grants from the National Institutes of Health (NIH). T. Ohsumi has received grants from the NIH, is employed by Seres Health, and has a patent filed through Massachusetts General Hospital. T. Nakayama has received a grant from the Japanese government (MEXT). The rest of the authors declare that they have no relevant conflicts of interest.	Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Brustle A, 2012, J CLIN INVEST, V122, P4698, DOI 10.1172/JCI63528; Fagarasan S, 2000, IMMUNOL REV, V176, P205; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Gringhuis SI, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001259; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Howrigan DP, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-460; Kingeter LM, 2010, CELL SIGNAL, V22, P9, DOI 10.1016/j.cellsig.2009.09.033; Ohsumi TK, 2012, BIOINFORMATICS, V28, P2412, DOI 10.1093/bioinformatics/bts458; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Pillai S, 2005, ANNU REV IMMUNOL, V23, P161, DOI 10.1146/annurev.immunol.23.021704.115728; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Qiu L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023220; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Saijo S, 2011, INT IMMUNOL, V23, P467, DOI 10.1093/intimm/dxr046; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Stone KD, 2009, CLIN IMMUNOL, V131, P41, DOI 10.1016/j.clim.2008.11.003; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Thome M, 2008, NAT REV IMMUNOL, V8, P495, DOI 10.1038/nri2338; Tusche MW, 2009, J EXP MED, V206, P2671, DOI 10.1084/jem.20091802; Viola JPB, 1999, J CLIN IMMUNOL, V19, P98, DOI 10.1023/A:1020502516196	26	92	101	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					151	158		10.1016/j.jaci.2013.04.047	http://dx.doi.org/10.1016/j.jaci.2013.04.047			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23727036	Green Accepted			2022-12-18	WOS:000321052300020
J	Blom, WM; Vlieg-Boerstra, BJ; Kruizinga, AG; van der Heide, S; Houben, GF; Dubois, AEJ				Blom, W. Marty; Vlieg-Boerstra, Berber J.; Kruizinga, Astrid G.; van der Heide, Sicco; Houben, Geert F.; Dubois, Anthony E. J.			Threshold dose distributions for 5 major allergenic foods in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergenic foods; threshold dose distributions; children; eliciting dose	CASHEW NUT ALLERGY; COWS MILK ALLERGY; DOUBLE-BLIND; RISK-ASSESSMENT; SOY ALLERGY; ANAPHYLACTIC REACTIONS; CLINICAL REACTIVITY; NATURAL-HISTORY; CHALLENGES; PEANUT	Background: For most allergenic foods, insufficient threshold dose information within the population restricts the advice on levels of unintended allergenic foods which should trigger precautionary labeling on prepackaged foods. Objective: We wanted to derive threshold dose distributions for major allergenic foods and to elaborate the protein doses at which a proportion of the allergic population is likely to respond. Methods: For 7 allergenic foods double-blind, placebo-controlled food challenges (DBPCFCs) with a positive outcome for allergic reactions were selected from the clinical database of children routinely tested to diagnose food allergy at the University Medical Center Groningen. For each allergen 2 population threshold distributions were determined with the individual minimal eliciting dose and the preceding dose of each DBPCFC for objective symptoms and any symptom (either subjective or objective). Results: Individual positive DBPCFCs were available for peanut (n = 135), cow's milk (n = 93), hen's egg (n = 53), hazelnut (n = 28), and cashew nut (n = 31). Fewer children were challenged with soy (n = 10) or walnut (n = 13). Threshold dose distributions showed a good statistical and visual fit. The protein dose at which 5% of the allergic population is likely to respond with objective reactions was 1.6 mg for peanut, 1.1 mg for cow's milk, 1.5 mg for hen's egg, 7.4 mg for cashew nut, and 0.29 mg for hazelnut. Thresholds for any symptom were on average 2 to 6 times lower than for objective symptoms. The 95% upper and lower confidence intervals of the threshold distributions were overlapping. The peanut threshold distribution on objective symptoms was similar to the distribution of another European center. Conclusions: Threshold distribution curves and eliciting doses are a powerful tool to compare different allergenic foods and for informing policy on precautionary labeling. (J Allergy Clin Immunol 2013;131:172-9.)	[Blom, W. Marty; Kruizinga, Astrid G.; Houben, Geert F.] Nederlandse Org Toegepast Nat Wetenschappelijk On, Zeist, Netherlands; [Vlieg-Boerstra, Berber J.; Dubois, Anthony E. J.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD GRIAC, Dept Pediat Pulmonol & Pediat Allergy, NL-9700 AB Groningen, Netherlands; [van der Heide, Sicco] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD GRIAC, Lab Allergy & Pulm Dis,Dept Lab Med, NL-9700 AB Groningen, Netherlands	Netherlands Organization Applied Science Research; University of Groningen; University of Groningen	Blom, WM (corresponding author), TNO, POB 360, NL-3700 AJ Zeist, Netherlands.	marty.blom@tno.nl	Vlieg-Boerstra, Berber/O-1922-2019	Vlieg-Boerstra, Berber/0000-0001-7962-5406; Blom, W.M./0000-0002-6853-0900; Houben, Geert/0000-0001-7261-3912	Dutch Ministry of Health; ALK Abello; Nutricia	Dutch Ministry of Health; ALK Abello; Nutricia(Danone Nutricia)	Part of this study was conducted within the framework of the Food Safety Knowledge Development program of TNO, with financial support of the Dutch Ministry of Health.; Disclosure of potential conflict of interest: W. M. Blom and A. Kruizinga have received research support from the Dutch Ministry of Health and are employed by TNO. B. Vlieg-Boerstra has consultant arrangements with Mead Johnson, has received grants from ALK Abello and Nutricia, has received payment for lectures, including service on speakers' bureaus, from Mead Johnson and Nutricia, and has received travel expenses from Mead Johnson and Friso Kindervoeding. G. Houben has received research support from the Dutch Ministry of Health, is employed by TNO, and has received travel expenses from the Food Allergy Research and Resources Programme. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2010, FOOD AUST, V62, P344; Ballmer-Weber BK, 2007, J ALLERGY CLIN IMMUN, V119, P1489, DOI 10.1016/j.jaci.2007.01.049; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Buchanan R, 2008, J FOOD PROTECT, V71, P1043; Buck J, 2010, TOXICOLOGY, V278, P319, DOI 10.1016/j.tox.2010.08.007; Crevel RWR, 2007, FOOD CHEM TOXICOL, V45, P691, DOI 10.1016/j.fct.2006.09.005; Davoren M, 2005, ARCH DIS CHILD, V90, P1084, DOI 10.1136/adc.2005.073817; Eller E, 2012, ANN ALLERG ASTHMA IM, V108, P332, DOI 10.1016/j.anai.2012.03.010; Flinterman AE, 2008, CURR OPIN ALLERGY CL, V8, P261, DOI 10.1097/ACI.0b013e3282ffb145; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V118, P1186, DOI 10.1016/j.jaci.2006.08.017; Grimshaw KEC, 2003, CLIN EXP ALLERGY, V33, P1581, DOI 10.1046/j.1365-2222.2003.01795.x; Hasegawa Miki, 2009, Allergology International, V58, P209, DOI 10.2332/allergolint.08-OA-0010; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Kalbfleisch JD, 2002, STAT ANAL FAILURE TI, P52; Kerbach S, 2009, QUAL ASSUR SAF CROP, V1, P50, DOI 10.1111/j.1757-837X.2009.00009.x; Kruizinga AG, 2008, FOOD CHEM TOXICOL, V46, P1437, DOI 10.1016/j.fct.2007.09.109; Lam HY, 2008, CLIN EXP ALLERGY, V38, P995, DOI 10.1111/j.1365-2222.2008.02968.x; Madsen CB, 2009, FOOD CHEM TOXICOL, V47, P480, DOI 10.1016/j.fct.2008.12.001; Magnolfi CF, 1996, ANN ALLERG ASTHMA IM, V77, P197, DOI 10.1016/S1081-1206(10)63255-3; Morisset M, 2003, CLIN EXP ALLERGY, V33, P1046, DOI 10.1046/j.1365-2222.2003.01734.x; Namork E, 2011, INT J ENV RES PUB HE, V8, P3144, DOI 10.3390/ijerph8083144; Pele M, 2007, FOOD ADDIT CONTAM A, V24, P1334, DOI 10.1080/02652030701458113; Rance F, 2003, ALLERGY, V58, P1311, DOI 10.1046/j.1398-9995.2003.00342.x; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Savage JH, 2010, J ALLERGY CLIN IMMUN, V125, P683, DOI 10.1016/j.jaci.2009.12.994; Sheth SS, 2010, ANN ALLERG ASTHMA IM, V104, P60, DOI 10.1016/j.anai.2009.11.008; Spanjersberg MQI, 2007, FOOD CHEM TOXICOL, V45, P49, DOI 10.1016/j.fct.2006.07.018; Spanjersberg MQI, 2010, FOOD ADDIT CONTAM A, V27, P169, DOI 10.1080/19440040903317513; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Taylor SL, 2009, FOOD CHEM TOXICOL, V47, P1198, DOI 10.1016/j.fct.2009.02.011; van der Zee T, 2011, J ALLERGY CLIN IMMUN, V128, P1031, DOI 10.1016/j.jaci.2011.07.050; Vlieg-Boerstra B, 2005, ALLERGY, V60, P1212, DOI 10.1111/j.1398-9995.2005.00935.x; Vlieg-Boerstra BJ, 2007, ALLERGY, V62, P905, DOI 10.1111/j.1398-9995.2007.01430.x; Vlieg-Boerstra BJ, 2011, ALLERGY, V66, P948, DOI 10.1111/j.1398-9995.2010.02539.x; Vlieg-Boerstra BJ, 2004, J ALLERGY CLIN IMMUN, V113, P341, DOI 10.1016/j.jaci.2003.10.039; Ward R, 2010, TRENDS FOOD SCI TECH, V21, P619, DOI 10.1016/j.tifs.2010.09.004; Zeiger RS, 1999, J PEDIATR-US, V134, P614, DOI 10.1016/S0022-3476(99)70249-0	38	92	97	0	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					172	179		10.1016/j.jaci.2012.10.034	http://dx.doi.org/10.1016/j.jaci.2012.10.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23199599				2022-12-18	WOS:000312961200022
J	Chapel, H; Lucas, M; Patel, S; Lee, M; Cunningham-Rundles, C; Resnick, E; Gerard, L; Oksenhendler, E				Chapel, Helen; Lucas, Mary; Patel, Smita; Lee, Martin; Cunningham-Rundles, Charlotte; Resnick, Elena; Gerard, Laurence; Oksenhendler, Eric			Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NODULAR REGENERATIVE HYPERPLASIA; LIVER		[Chapel, Helen; Lucas, Mary; Patel, Smita] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Primary Immunodeficiency Unit, Oxford OX3 9DU, England; [Lee, Martin] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA; [Cunningham-Rundles, Charlotte; Resnick, Elena] Mt Sinai Sch Med, Inst Immunol, New York, NY USA; [Gerard, Laurence; Oksenhendler, Eric] Hop St Louis, Dept Clin Immunol, Paris, France	University of Oxford; University of California System; University of California Los Angeles; Icahn School of Medicine at Mount Sinai; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Chapel, H (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Primary Immunodeficiency Unit, Oxford OX3 9DU, England.	Helen.chapel@ndm.ox.ac.uk						Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Conley ME, 1998, AM J HUM GENET, V62, P1034, DOI 10.1086/301828; COOPER EH, 1984, J CLIN PATHOL, V37, P1140, DOI 10.1136/jcp.37.10.1140; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Malamut G, 2008, J HEPATOL, V48, P74, DOI 10.1016/j.jhep.2007.08.011; Oksenhendler E, 2008, CLIN INFECT DIS, V46, P1547, DOI 10.1086/587669; Reshamwala PA, 2006, HEPATOLOGY, V44, P7, DOI 10.1002/hep.21258; Rivoisy C, 2012, J CLIN IMMUNOL, V32, P98, DOI 10.1007/s10875-011-9604-9; WANLESS IR, 1990, HEPATOLOGY, V11, P787, DOI 10.1002/hep.1840110512; Ward C, 2008, CLIN EXP IMMUNOL, V153, P331, DOI 10.1111/j.1365-2249.2008.03711.x	12	92	93	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1197	+		10.1016/j.jaci.2012.05.046	http://dx.doi.org/10.1016/j.jaci.2012.05.046			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22819511				2022-12-18	WOS:000310571400022
J	Salmond, RJ; Mirchandani, AS; Besnard, AG; Bain, CC; Thomson, NC; Liew, FY				Salmond, Robert J.; Mirchandani, Ananda S.; Besnard, Anne-Gaelle; Bain, Calum C.; Thomson, Neil C.; Liew, Foo Y.			IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-33; T(H)2; innate lymphoid cells; asthma; mammalian target of rapamycin; rapamycin	PHOSPHATIDYLINOSITOL 3-KINASE; MTOR; HYPERREACTIVITY; CYTOKINE; ST2; DIFFERENTIATION; SELECTIVITY; INHIBITORS; EXPRESSION; EFFECTOR	Background: The IL-1 family cytokine IL-33 is involved in the induction of airway inflammation in allergic patients and after viral infection. Several cell types, including CD4(+) T(H)2 cells and the recently described type 2 innate lymphoid cells (ILCs), are targets for IL-33, yet the mechanisms by which this cytokine modulates their activation are not clear. Objectives: Our goal was to investigate a role for mammalian target of rapamycin (mTOR) signaling in the activation of T(H)2 and ILC responses and the induction of airway inflammation by IL-33. Methods: We biochemically determined the effect of IL-33 on mTOR activation in T(H)2 cells and ILCs and examined the effect of this signaling pathway in vivo using a murine model of IL-33-induced lung inflammation. Results: We found that IL-33 induces mTOR activation through p110 delta phosphoinositide 3-kinase and that blockade of the mTOR pathway inhibited IL-33-induced IL-5 and IL-13 production by T(H)2 cells and ILCs. Furthermore, use of a ribosomal protein S6 kinase 1 inhibitor implicated a role for ribosomal protein S6 kinase 1 in IL-33-induced mTOR-dependent cytokine production. Intranasal administration of IL-33 to wild-type mice induced airway inflammation, whereas adoptive transfer of wildtype ILCs to IL-33 receptor-deficient (St2(-/-)) mice recapitulated this response. Importantly, coadministration of the mTOR inhibitor rapamycin reduced IL-33-dependent ILC, macrophage, and eosinophil accumulation; cytokine secretion; and mucus deposition in the airways. Conclusion: These data reveal a hitherto unrecognized role of mTOR signaling in IL-33-driven, ILC-dependent inflammation in vivo and suggest that manipulation of this pathway might represent a target for therapeutic intervention for airway inflammation. (J Allergy Clin Immunol 2012;130:1159-66.)	[Liew, Foo Y.] Univ Glasgow, Div Immunol Infect & Inflammat, Glasgow Biomed Res Ctr, Glasgow G12 8TA, Lanark, Scotland; [Liew, Foo Y.] King Abdulaziz Univ, CEGMR, Jeddah 21413, Saudi Arabia	University of Glasgow; King Abdulaziz University	Liew, FY (corresponding author), Univ Glasgow, Div Immunol Infect & Inflammat, Glasgow Biomed Res Ctr, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.	foo.liew@glasgow.ac.uk		Thomson, Neil/0000-0003-1632-6630; Bain, Calum/0000-0001-8884-327X	Wellcome Trust; MRC; Medical Research Council Clinical Training fellowship; Medical Research Council [G0801198, G9818261, G0902003] Funding Source: researchfish; MRC [G9818261, G0902003, G0801198] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council Clinical Training fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a Wellcome Trust Program Grant and an MRC project grant awarded to F.Y.L. A.S.M. is the recipient of a Medical Research Council Clinical Training fellowship.; Disclosure of potential conflict of interest: R. J. Salmond, A. G. Besnard, C. C. Bain, and F. Y. Liew have received research support from the Wellcome Trust, MRC. A. S. Mirchandani has received research support from the Wellcome Trust, MRC, and has received travel support from the European Respiratory Society. N. C. Thomson declares that he has no relevant conflicts of interest.	Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Araki K, 2011, CURR OPIN CELL BIOL, V23, P707, DOI 10.1016/j.ceb.2011.08.006; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Choi YS, 2009, BLOOD, V114, P3117, DOI 10.1182/blood-2009-02-203372; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Enoksson M, 2011, J IMMUNOL, V186, P2523, DOI 10.4049/jimmunol.1003383; HACZKU A, 1994, J ALLERGY CLIN IMMUN, V93, P510, DOI 10.1016/0091-6749(94)90361-1; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Ikutani M, 2012, J IMMUNOL, V188, P703, DOI 10.4049/jimmunol.1101270; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kim MS, 2008, J IMMUNOL, V180, P4586, DOI 10.4049/jimmunol.180.7.4586; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Liu QS, 2012, J BIOL CHEM, V287, P9742, DOI 10.1074/jbc.M111.304485; Lloyd CM, 2010, CURR OPIN IMMUNOL, V22, P800, DOI 10.1016/j.coi.2010.10.006; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Mushaben EM, 2011, J IMMUNOL, V187, P5756, DOI 10.4049/jimmunol.1102133; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Pearce LR, 2010, BIOCHEM J, V431, P245, DOI 10.1042/BJ20101024; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Salmond RJ, 2011, EUR J IMMUNOL, V41, P2137, DOI 10.1002/eji.201141523; Salmond RJ, 2009, J IMMUNOL, V183, P7388, DOI 10.4049/jimmunol.0902294; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Stolarski B, 2010, J IMMUNOL, V185, P3472, DOI 10.4049/jimmunol.1000730; Suzukawa M, 2008, J IMMUNOL, V181, P5981, DOI 10.4049/jimmunol.181.9.5981; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Wong CK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029815; Xu D, 2008, P NATL ACAD SCI USA, V105, P10913, DOI 10.1073/pnas.0801898105; Yang Q, 2011, J IMMUNOL, V12, P1045; Zaiss MM, 2011, J IMMUNOL, V186, P6097, DOI 10.4049/jimmunol.1003487	46	92	98	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1159	+		10.1016/j.jaci.2012.05.018	http://dx.doi.org/10.1016/j.jaci.2012.05.018			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22738676	hybrid, Green Published			2022-12-18	WOS:000310571400018
J	Roca-Ferrer, J; Garcia-Garcia, FJ; Pereda, J; Perez-Gonzalez, M; Pujols, L; Alobid, I; Mullol, J; Picado, C				Roca-Ferrer, Jordi; Garcia-Garcia, Francesc J.; Pereda, Javier; Perez-Gonzalez, Maria; Pujols, Laura; Alobid, Isam; Mullol, Joaquim; Picado, Cesar			Reduced expression of COXs and production of prostaglandin E-2 in patients with nasal polyps with or without aspirin-intolerant asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin intolerance; asthma; chronic rhinosinusitis; cyclooxygenase; fibroblast; nasal mucosa; nasal polyp; prostaglandin E-2; alpha-smooth muscle actin	OBSTRUCTIVE PULMONARY-DISEASE; EPITHELIAL-CELLS; MESSENGER-RNA; CYCLOOXYGENASE-2; LUNG; RHINOSINUSITIS; EICOSANOIDS; TOLERANT; ACID	Background: Researchers have debated whether regulation of the COX enzymes (COX-1 and COX-2), which mediate production of prostaglandins (PGs), affects the pathogenesis of nasal polyps (NPs) and aspirin-intolerant asthma (AIA). Objective: We investigated the roles of PGE(2), COX-1 and COX-2, and PGE(2) receptors in the development of NPs and AIA by measuring their expression in fibroblasts derived from nasal mucosa (NM) and NPs. Methods: Fibroblasts were isolated from the NM of subjects without asthma who had septal deviation, turbinate hypertrophy, or both (control subjects, n = 7); NPs of aspirin-tolerant nonasthmatic patients (n = 7); and NPs of patients with asthma who were intolerant of aspirin (n = 7). Polyp samples were collected during endoscopic surgery. Cultures were stimulated with IL-1 beta (10 ng/mL) for 72 hours. We used ELISA, immunoblotting, and immunofluorescence analyses to measure secretion of PGE(2), expression of COX-1 and COX-2, and expression of the PGE(2) receptors EP1 to EP4. Results: Compared with NM from control subjects, PGE(2) concentrations were significantly lower in IL-1 beta-stimulated fibroblasts from patients with NPs who were tolerant to aspirin and even lower in polyps from patients with AIA. Similarly, IL-1 beta exposure induced the expression of COX-1 and COX-2 in fibroblasts from NM of control subjects, had only moderate effects on fibroblasts from NPs of aspirin-tolerant nonasthmatic patients, and almost no effect on fibroblasts from NPs of patients with AIA. IL-1 beta also induced expression of EP2 in fibroblasts from control NM but not in fibroblasts from NPs of aspirin-tolerant nonasthmatic patients or those with AIA. Conclusion: Alterations in the COX pathway (ie, reduced production of PGE(2) and lack of upregulation of COX-1, COX-2, and EP2 under conditions of inflammation) are associated with NPs in patients with or without AIA. (J Allergy Clin Immunol 2011; 128: 66-72.)	[Picado, Cesar] Univ Barcelona, Hosp Clin, Servei Pneumol & Allergia Resp, E-08007 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona	Picado, C (corresponding author), Hosp Clin Barcelona, Serv Pneumol, Villarroel 170, E-08036 Barcelona, Spain.	cpicado@ub.edu	/AAL-7347-2021; Roca-Ferrer, Jordi/AFQ-4652-2022; Gonzalez, Maria Perez/J-5846-2017; Pujols, Laura/G-8920-2015; /AFX-9519-2022; Pereda, Javier/N-2424-2014	Roca-Ferrer, Jordi/0000-0002-9527-2273; Gonzalez, Maria Perez/0000-0001-9013-6785; Pujols, Laura/0000-0003-3708-5098; Pereda, Javier/0000-0002-8690-8938; Perez Gonzalez, Maria/0000-0001-5525-5543	Spanish Ministry of Health [FIS PI030033, FIS PI080249]; Fundacio Catalana de Pneumologia (FUCAP); Fundacion Respira (Spanish Respiratory Society)	Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Fundacio Catalana de Pneumologia (FUCAP); Fundacion Respira (Spanish Respiratory Society)	Supported by grants from the Spanish Ministry of Health (FIS PI030033, FIS PI080249), Fundacio Catalana de Pneumologia (FUCAP), and Fundacion Respira (Spanish Respiratory Society).	Adamjee J, 2006, J PATHOL, V209, P392, DOI 10.1002/path.1979; Antczak A, 2002, AM J RESP CRIT CARE, V166, P301, DOI 10.1164/rccm.2101021; Bunimov N, 2007, BBA-GENE STRUCT EXPR, V1769, P92, DOI 10.1016/j.bbaexp.2007.01.004; Casadevall J, 2000, THORAX, V55, P921, DOI 10.1136/thorax.55.11.921; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Demoly P, 1998, CLIN EXP ALLERGY, V28, P278; Farooque SP, 2009, ANNU REV PHYSIOL, V71, P465, DOI 10.1146/annurev.physiol.010908.163114; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Higashi N, 2010, J ALLERGY CLIN IMMUN, V125, P1084, DOI 10.1016/j.jaci.2009.12.977; Jedrzejczak-Czechowicz M, 2008, CLIN EXP ALLERGY, V38, P1108, DOI 10.1111/j.1365-2222.2008.02989.x; Kang YJ, 2007, PROG LIPID RES, V46, P108, DOI 10.1016/j.plipres.2007.01.001; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Langmack EL, 1998, LUNG BIOL HEALTH DIS, V114, P337; Lohinai Z, 2001, LIFE SCI, V70, P279, DOI 10.1016/S0024-3205(01)01391-1; Mastalerz L, 2008, THORAX, V63, P27, DOI 10.1136/thx.2007.080903; McAdam BF, 2000, J CLIN INVEST, V105, P1473, DOI 10.1172/JCI9523; Mullol J, 2002, J ALLERGY CLIN IMMUN, V109, P824, DOI 10.1067/mai.2002.123534; Okano M, 2006, CLIN EXP ALLERGY, V36, P1028, DOI 10.1111/j.1365-2222.2006.02528.x; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Picado C, 1992, AM REV RESPIR DIS, V145, P1028; Picado C, 2006, CURR ALLERGY ASTHM R, V6, P198, DOI 10.1007/s11882-006-0035-2; Pierzchalska M, 2007, J PHYSIOL PHARMACOL, V58, P207; Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491; Pujols L, 2004, J ALLERGY CLIN IMMUN, V114, P814, DOI 10.1016/j.jaci.2004.07.050; Roca-Ferrer J, 2006, THORAX, V61, P592, DOI 10.1136/thx.2004.039842; Sampson AP, 1998, LUNG BIOL HEALTH DIS, V114, P371; Siegle I, 1998, ARTHRITIS RHEUM-US, V41, P122, DOI 10.1002/1529-0131(199801)41:1<122::AID-ART15>3.3.CO;2-#; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; Togo S, 2008, AM J RESP CRIT CARE, V178, P248, DOI 10.1164/rccm.200706-929OC; Vancheri C, 2004, TRENDS IMMUNOL, V25, P40, DOI 10.1016/j.it.2003.11.001; Wu KK, 2007, PROSTAG OTH LIPID M, V83, P175, DOI 10.1016/j.prostaglandins.2007.01.002; Xaubet A, 2004, SARCOIDOSIS VASC DIF, V21, P35; Ying S, 2006, J ALLERGY CLIN IMMUN, V117, P312, DOI 10.1016/j.jaci.2005.10.037; Yoshimura Tsuyoshi, 2008, Allergol Int, V57, P429, DOI 10.2332 allergolint.O-08-545; ZAKRZEWSKI JT, 1987, BRIT J CLIN PHARMACO, V23, P19, DOI 10.1111/j.1365-2125.1987.tb03004.x	41	92	92	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					66	U110		10.1016/j.jaci.2011.01.065	http://dx.doi.org/10.1016/j.jaci.2011.01.065			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21397936				2022-12-18	WOS:000292245600008
J	Mathias, CB; Hobson, SA; Garcia-Lloret, M; Lawson, G; Poddighe, D; Freyschmidt, EJ; Xing, W; Gurish, MF; Chatila, TA; Oettgen, HC				Mathias, Clinton B.; Hobson, Suejy A.; Garcia-Lloret, Maria; Lawson, Greg; Poddighe, Dimitri; Freyschmidt, Eva-Jasmin; Xing, Wei; Gurish, Michael F.; Chatila, Talal A.; Oettgen, Hans C.			IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; IL-4; tolerance; anaphylaxis; IgE	COWS MILK ALLERGY; T-CELL RESPONSES; MAST-CELLS; INTESTINAL PERMEABILITY; ORAL SENSITIZATION; MURINE MODEL; SERUM IGE; CHILDREN; PEANUT; LYMPHOCYTES	Background: In atopic subjects food ingestion drives the production of IgE antibodies that can trigger hypersensitivity reactions. The IL-4 pathway plays a critical role in this response, and genetic polymorphisms in its components have been linked to allergy. Objective: We sought to test whether an activating mutation in the IL-4 receptor (IL-4R) alpha chain enhances allergic responses to a food antigen. Methods: F709 mice, in which the IL-4R alpha immunoreceptor tyrosine-based inhibitory motif is inactivated, were gavage fed with ovalbumin (OVA). Reactions to OVA challenge and immune responses, including antibody production and T(H)2 responses, were assessed. Results: F709 mice, but not wild-type control animals, sensitized by means of gavage with OVA and either cholera toxin or staphylococcal enterotoxin B, displayed mast cell activation and systemic anaphylaxis on enteral challenge. Anaphylaxis was elicited even in F709 mice enterally sensitized with OVA alone. Bone marrow chimera experiments established that the increased sensitivity conferred by the F709 genotype was mediated mostly by hematopoietic cells but that nonhematopoietic cells also contributed. F709 mice exhibited increased intestinal permeability to macromolecules. The F709 genotype conferred increased OVA-specific IgE but not IgG1 responses, local and systemic TH2 responses, and intestinal mast cell hyperplasia compared with wild-type mice. Anaphylaxis was abrogated in F709 mice lacking IgE or the high-affinity receptor for IgE (FceRI). Conclusion: Augmented IL-4Ra signaling confers increased intestinal permeability and dramatically enhanced sensitivity to food allergens. Unlike anaphylaxis to injected antigens, which in rodents can be mediated by either IgE or IgG antibodies, the food-induced response in F709 mice is solely IgE dependent. (J Allergy Clin Immunol 2011;127:795-805.)	[Mathias, Clinton B.; Poddighe, Dimitri; Freyschmidt, Eva-Jasmin; Oettgen, Hans C.] Childrens Hosp Boston, Div Immunol, Boston, MA 02115 USA; [Mathias, Clinton B.; Poddighe, Dimitri; Freyschmidt, Eva-Jasmin; Gurish, Michael F.; Oettgen, Hans C.] Harvard Univ, Sch Med, Boston, MA USA; [Hobson, Suejy A.; Garcia-Lloret, Maria; Chatila, Talal A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Immunol Allergy & Rheumatol, Los Angeles, CA 90095 USA; [Lawson, Greg] Univ Calif Los Angeles, David Geffen Sch Med, Div Lab Anim Med, Los Angeles, CA 90095 USA; [Xing, Wei; Gurish, Michael F.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Brigham & Women's Hospital	Oettgen, HC (corresponding author), Childrens Hosp Boston, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	hans.oettgen@childrens.harvard.edu	Poddighe, Dimitri/AAI-5712-2020	Poddighe, Dimitri/0000-0001-6431-9334; Chatila, Talal/0000-0001-7439-2762; Mathias, Clinton/0000-0002-0223-4842	National Institutes of Health [NIAID R01-AI054471, 1R21AI087666, 5T32AI007512-24, 2R01AI065617, 1R21AI080002, AI083516]; Howard Hughes Institute; National Institutes of Health/National Institute of Allergy and Infectious Diseases; Novartis; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065617, R01AI054471, R21AI087666, R01AI083516, R21AI080002, T32AI007512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Institute(Howard Hughes Medical Institute); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Novartis(Novartis); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants NIAID R01-AI054471 and 1R21AI087666 (H.C.O.), 5T32AI007512-24 (C.B.M.), 2R01AI065617 and 1R21AI080002 (T.A.C.), and AI083516 (M.F.G.), and by a Howard Hughes Institute Medical Research Fellowship Award (S.A.H.).; S. A. Hobson has received research support from the Howard Hughes Medical Institute. M. F. Gurish has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. H. C. Oettgen is a consultant and scientific advisor for Schering-Plough, is a consultant for Genentech, and has received research support from Novartis. The rest of the authors have declared that they have no conflict of interest.	Berin MC, 1999, AM J PHYSIOL-CELL PH, V276, pC1046, DOI 10.1152/ajpcell.1999.276.5.C1046; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Blaeser F, 2003, J EXP MED, V198, P1189, DOI 10.1084/jem.20030471; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brandt EB, 2009, J ALLERGY CLIN IMMUN, V123, P53, DOI 10.1016/j.jaci.2008.10.001; Bryce PJ, 2006, J CLIN INVEST, V116, P1624, DOI 10.1172/JCI26150; Ceponis PJM, 2000, J BIOL CHEM, V275, P29132, DOI 10.1074/jbc.M003516200; Chatila TA, 2004, TRENDS MOL MED, V10, P493, DOI 10.1016/j.molmed.2004.08.004; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Eigenmann PA, 2008, PEDIAT ALLERG IMM-UK, V19, P26, DOI 10.1111/j.1399-3038.2008.00765.x; Faulkner H, 1997, EUR J IMMUNOL, V27, P2536, DOI 10.1002/eji.1830271011; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Godfraind C, 1998, J IMMUNOL, V160, P3989; Groschwitz KR, 2009, P NATL ACAD SCI USA, V106, P22381, DOI 10.1073/pnas.0906372106; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Jones TG, 2009, J IMMUNOL, V183, P5251, DOI 10.4049/jimmunol.0901471; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Knight AK, 2007, AM J PHYSIOL-GASTR L, V293, pG1234, DOI 10.1152/ajpgi.00323.2007; Kweon MN, 2000, J CLIN INVEST, V106, P199, DOI 10.1172/JCI8490; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Liu X, 2004, J ALLERGY CLIN IMMUN, V113, P489, DOI 10.1016/j.jaci.2003.12.037; Mathias CB, 2009, J IMMUNOL, V182, P2416, DOI 10.4049/jimmunol.0801569; Matsuzawa S, 2003, J IMMUNOL, V170, P3461, DOI 10.4049/jimmunol.170.7.3461; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Munitz A, 2008, P NATL ACAD SCI USA, V105, P7240, DOI 10.1073/pnas.0802465105; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NUSSENZWEIG RS, 1964, J EXP MED, V120, P315, DOI 10.1084/jem.120.2.315; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Proust B, 2008, INT ARCH ALLERGY IMM, V146, P212, DOI 10.1159/000115889; Ramalingam TR, 2008, NAT IMMUNOL, V9, P25, DOI 10.1038/ni1544; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Scott-Taylor TH, 2005, CLIN EXP ALLERGY, V35, P1473, DOI 10.1111/j.1365-2222.2005.02355.x; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Strait Richard, 2004, Novartis Found Symp, V257, P80; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; Tachdjian R, 2010, J ALLERGY CLIN IMMUN, V125, P1128, DOI 10.1016/j.jaci.2010.01.054; Tachdjian R, 2009, J EXP MED, V206, P2191, DOI 10.1084/jem.20091480; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Tiemessen MM, 2004, J ALLERGY CLIN IMMUN, V113, P932, DOI 10.1016/j.jaci.2003.12.016; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; van Wijk F, 2004, CLIN EXP ALLERGY, V34, P1422, DOI 10.1111/j.1365-2222.2004.02062.x; Wang Q, 2001, AM J PHYSIOL-REG I, V281, pR1013, DOI 10.1152/ajpregu.2001.281.3.R1013; Watanabe T, 2003, J ALLERGY CLIN IMMUN, V111, P1375, DOI 10.1067/mai.2003.1466; Wills-Karp M, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1.51.pe55; Zitnik SE, 2009, PEDIAT ALLERG IMM-UK, V20, P551, DOI 10.1111/j.1399-3038.2008.00815.x	55	92	103	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					795	U473		10.1016/j.jaci.2010.11.009	http://dx.doi.org/10.1016/j.jaci.2010.11.009			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21167580	Green Accepted			2022-12-18	WOS:000288018400035
J	DeBrosse, CW; Collins, MH; Butz, BKB; Allen, CL; King, EC; Assa'ad, AH; Abonia, JP; Putnam, PE; Rothenberg, ME; Franciosi, JP				DeBrosse, Charles W.; Collins, Margaret H.; Butz, Bridget K. Buckmeier; Allen, Casey L.; King, Eileen C.; Assa'ad, Amal H.; Abonia, J. Pablo; Putnam, Philip E.; Rothenberg, Marc E.; Franciosi, James P.			Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; incidence; diagnosis; chronic esophagitis; eosinophil; esophagitis; epidemiology; retrospective	ALLERGIC ESOPHAGITIS; CHILDREN; FLUTICASONE; SEVERITY; SERIES; REFLUX	Background: Eosinophilic esophagitis (EE) is now a commonly encountered disorder that was rarely diagnosed a decade ago. Objective: We aimed to determine the epidemiologic and histologic features of retrospective pediatric esophageal eosinophilia before the first case of EE at our institution was recognized. Methods: Esophageal biopsy specimens obtained between 1982 and 1999 with reflux esophagitis were re-examined and reorganized into 2 groups based on peak esophageal eosinophil number (<15 eosinophils per high-powered field [hpf] and >= 15 eosinophils/hpf). The epidemiology and histology of the entire cohort and a population-based cohort were evaluated. Results: Eight hundred seven biopsy specimens from 666 patients were re-examined; 198 patients had 15 eosinophils/hpf or greater. Among a population-based cohort of patients with 15 eosinophils/hpf or greater, there was a modest increase in incidence (P < .001; incidence rate ratio, 1.18; 95% CI, 1.09-1.28). After correcting for a 40-fold increase in the number of endoscopies during this time period, the proportion of biopsy specimens with 15 eosinophils/hpf or greater did not change (0.08 in 1982 vs 0.08 in 1996 [peak]; P = .9; incidence rate ratio, 1.02; 95% CI, 0.73-1.44). Patients who had as few as 5 eosinophils/hpf were more likely to have persistent esophageal eosinophilia on repeat esophagogastroduodenoscopy, evidence of basal layer hyperplasia, and lamina propria fibrosis compared with patients with less than 5 eosinophils/hpf (P < .001). Conclusions: Esophageal eosinophilia at levels consistent with EE was present among 30% of patients given diagnoses of reflux esophagitis, and the incidence of esophageal eosinophilia did not change over time. Patients with 5 eosinophils/hpf or greater had evidence of other histologic abnormalities and were likely to have persistent esophageal eosinophilia. (J Allergy Clin Immunol 2010;126:112-9.)	[DeBrosse, Charles W.; Butz, Bridget K. Buckmeier; Assa'ad, Amal H.; Abonia, J. Pablo; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Collins, Margaret H.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Pathol, Cincinnati, OH 45229 USA; [Allen, Casey L.; Putnam, Philip E.; Franciosi, James P.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; [King, Eileen C.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Biostat & Epidemiol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Allergy & Immunol, 3333 Burnet Ave MLC 7028, Cincinnati, OH 45229 USA.	marc.rothenberg@cchmc.org	King, Eileen/Q-1815-2015	Abonia, Juan/0000-0003-3788-6485	Campaign Urging Research for Eosinophilic Disease (CURED); Food Allergy Project; National Institute of Allergy and Infectious Diseases [T32 AI060515]; PHS [P30 DK078392]; Buckeye Foundation; International Group of Eosinophilic Researchers (TIGER); National Institutes of Health; Ception Therapeutics; Food Allergy & Anaphylaxis Network; Dana Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060515, K08AI057991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER	Campaign Urging Research for Eosinophilic Disease (CURED); Food Allergy Project; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS(United States Department of Health & Human ServicesUnited States Public Health Service); Buckeye Foundation; International Group of Eosinophilic Researchers (TIGER); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ception Therapeutics; Food Allergy & Anaphylaxis Network; Dana Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the Campaign Urging Research for Eosinophilic Disease (CURED), the Food Allergy Project, National Institute of Allergy and Infectious Diseases grant T32 AI060515 (C. W. D.), PHS grant P30 DK078392, the Buckeye Foundation, and the International Group of Eosinophilic Researchers (TIGER).; M. H. Collins has subcontract relationships with GlaxoSmithKline, Ception Therapeutics, and Meritage Pharma. J. P. Abonia has received research support from the National Institutes of Health and Ception Therapeutics. M. E. Rothenberg is a speaker and consultant for Merck and a consultant for Centocor, Ception Therapeutics, Nycomed, and Array Biopharma; has received research support from the National Institutes of Health, the Food Allergy & Anaphylaxis Network, and the Dana Foundation; and is on the medical advisory board of the American Partnership for Eosinophilic Disorders and the executive council of the International Eosinophil Society. The rest of the authors have declared that they have no conflicts of interest.	Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Atkins D, 2009, NAT REV GASTRO HEPAT, V6, P267, DOI 10.1038/nrgastro.2009.45; DeBrosse CW, 2008, CURR OPIN IMMUNOL, V20, P703, DOI 10.1016/j.coi.2008.07.010; Dellon ES, 2007, AM J GASTROENTEROL, V102, P2300, DOI 10.1111/j.1572-0241.2007.01396.x; Franciosi JP, 2009, IMMUNOL ALLERGY CLIN, V29, P19, DOI 10.1016/j.iac.2008.09.001; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gill R, 2007, AM J GASTROENTEROL, V102, P2281, DOI 10.1111/j.1572-0241.2007.01352.x; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Liacouras Chris A, 2007, J Pediatr Gastroenterol Nutr, V45, P370; Ngo P, 2006, AM J GASTROENTEROL, V101, P1666, DOI 10.1111/j.1572-0241.2006.00562.x; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1016/S1542-3565(04)00240-X; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Protheroe C, 2009, CLIN GASTROENTEROL H, V7, P749, DOI 10.1016/j.cgh.2009.03.022; Rothenberg ME, 2009, GASTROENTEROLOGY, V137, P1238, DOI 10.1053/j.gastro.2009.07.007; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Steiner SJ, 2006, J PEDIATR GASTR NUTR, V42, P506, DOI 10.1097/01.mpg.0000221906.06899.1b; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Vanderheyden AD, 2007, ARCH PATHOL LAB MED, V131, P777; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003; Whitney-Miller CL, 2009, AM J CLIN PATHOL, V131, P788, DOI 10.1309/AJCPOMPXJFP7EB4P	23	92	94	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					112	119		10.1016/j.jaci.2010.05.027	http://dx.doi.org/10.1016/j.jaci.2010.05.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20620567	Green Accepted			2022-12-18	WOS:000280061800020
J	Mittermann, I; Zidarn, M; Silar, M; Markovic-Housley, Z; Aberer, W; Korosec, P; Kosnik, M; Valenta, R				Mittermann, Irene; Zidarn, Mihaela; Silar, Mira; Markovic-Housley, Zora; Aberer, Werner; Korosec, Peter; Kosnik, Mitja; Valenta, Rudolf			Recombinant allergen-based IgE testing to distinguish bee and wasp allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Venom allergy; recombinant allergen; in vitro diagnosis; glycosylation	REACTIVE CARBOHYDRATE DETERMINANTS; YELLOW JACKET VENOM; HONEYBEE VENOM; IMMUNOLOGICAL CHARACTERIZATION; HYMENOPTERA VENOMS; DOUBLE POSITIVITY; IMMUNOGLOBULIN-E; INSECT CELLS; N-GLYCANS; DIAGNOSIS	Background: The identification of the disease-causing insect in venom allergy is often difficult. Objective: To establish recombinant allergen-based IgE tests to diagnose bee and yellow jacket wasp allergy. Methods: Sera from patients with bee and/or wasp allergy (n = 43) and patients with pollen allergy with false-positive IgE serology to venom extracts were tested for IgE reactivity in allergen extract-based tests or with purified allergens, including nonglycosylated Escherichia coli expressed recombinant (r) Api m 1, rApi m 2, rVes v 5, and insect cell expressed, glycosylated rApi m 2 as well as 2 natural plant glycoproteins (Phl p 4, bromelain). Results: The patients with venom allergy could be diagnosed with a combination of E coli expressed rApi m 1, rApi m 2, and rVes v 5 whereas patients with pollen allergy remained negative. For a group of 29 patients for whom the sensitizing venom could not be identified with natural allergen extracts, testing with nonglycosylated allergens allowed identification of the sensitizing venom. Recombinant nonglycosylated allergens also allowed definition of the sensitizing venom for those 14 patients who had reacted either with bee or wasp venom extracts. By IgE inhibition studies, it is shown that glycosylated Api m 2 contains carbohydrate epitopes that cross-react with natural Api m 1, Ves v 2, natural Phl p 4, and bromelain, thus identifying cross-reactive structures responsible for serologic false-positive test results or double-positivity to bee and wasp extracts. Conclusion: Nonglycosylated recombinant bee and wasp venom allergens allow the identification of patients with bee and wasp allergy and should facilitate accurate prescription of venom immunotherapy. (J Allergy Clin Immunol 2010;125:1300-7.)	[Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; [Mittermann, Irene] Med Univ Vienna, Christian Doppler Lab Dev Allergen Chips, A-1090 Vienna, Austria; [Markovic-Housley, Zora] Univ Basel, Biozentrum, Dept Biol Struct, CH-4003 Basel, Switzerland; [Aberer, Werner] Graz Univ, Dept Dermatol & Venereol, A-8010 Graz, Austria	Medical University of Vienna; Medical University of Vienna; University of Basel; University of Graz	Valenta, R (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Košnik, Mitja/AAI-2295-2019	Košnik, Mitja/0000-0002-4701-7374; Valenta, Rudolf/0000-0001-5944-3365; Zidarn, Mihaela/0000-0003-0515-5207; Mittermann, Irene/0000-0002-6240-6730; Korosec, Peter/0000-0002-0835-1599	Christian Doppler Research Association, Phadia, Uppsala, Sweden; Biomay, Vienna, Austria; Austrian Science Fund	Christian Doppler Research Association, Phadia, Uppsala, Sweden; Biomay, Vienna, Austria; Austrian Science Fund(Austrian Science Fund (FWF))	Supported by the Christian Doppler Research Association, Phadia, Uppsala, Sweden and Biomay, Vienna, Austria.; Disclosure of potential conflict of interest: R. Valenta receives research support from the Austrian Science Fund, the Christian Doppler Research Association, Phadia, and Biomay. The rest of the authors have declared that they have no conflict of interest.	ALTMANN F, 1991, INSECT BIOCHEM, V21, P467, DOI 10.1016/0020-1790(91)90099-Z; Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Golden DBK, 2006, ANN ALLERG ASTHMA IM, V96, pS16, DOI 10.1016/S1081-1206(10)60897-6; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331; HAMILTON RG, 1993, J ALLERGY CLIN IMMUN, V92, P651, DOI 10.1016/0091-6749(93)90007-3; Hemmer W, 2004, CLIN EXP ALLERGY, V34, P460, DOI 10.1111/j.1365-2222.2004.01897.x; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Kettner A, 2001, J ALLERGY CLIN IMMUN, V107, P914, DOI 10.1067/mai.2001.113867; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; Kochuyt AM, 2005, CLIN EXP ALLERGY, V35, P441, DOI 10.1111/j.1365-2222.2005.02217.x; Mahler V, 2006, CLIN EXP ALLERGY, V36, P1446, DOI 10.1111/j.1365-2222.2006.02587.x; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; MARKOVICHOUSLEY Z, 2000, STRUCTURE FOLD DES, V15, P1025; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Muller U, 1997, CLIN EXP ALLERGY, V27, P915, DOI 10.1111/j.1365-2222.1997.tb01233.x; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; Muller UR, 2001, INT ARCH ALLERGY IMM, V124, P447, DOI 10.1159/000053779; Soldatova LN, 1998, J ALLERGY CLIN IMMUN, V101, P691, DOI 10.1016/S0091-6749(98)70179-4; Stumvoll S, 2002, BIOL CHEM, V383, P1383, DOI 10.1515/BC.2002.157; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4	29	92	94	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1300	1307		10.1016/j.jaci.2010.03.017	http://dx.doi.org/10.1016/j.jaci.2010.03.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20466415				2022-12-18	WOS:000278831000018
J	Ilchmann, A; Burgdorf, S; Scheurer, S; Waibler, Z; Nagai, R; Wellner, A; Yamamoto, Y; Yamamoto, H; Henle, T; Kurts, C; Kalinke, U; Vieths, S; Toda, M				Ilchmann, Anne; Burgdorf, Sven; Scheurer, Stephan; Waibler, Zoe; Nagai, Ryoji; Wellner, Anne; Yamamoto, Yasuhiko; Yamamoto, Hiroshi; Henle, Thomas; Kurts, Christian; Kalinke, Ulrich; Vieths, Stefan; Toda, Masako			Glycation of a food allergen by the Maillard reaction enhances its T-cell immunogenicity: Role of macrophage scavenger receptor class A type I and II	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; food allergen; Maillard reaction; T-cell immunogenicity; dendritic cells; macrophage scavenger receptor	GLYCOSYLATION END-PRODUCTS; HEATED PECAN NUT; DENDRITIC CELLS; ANTIGEN PRESENTATION; MATURATION; PROTEINS; ENDPRODUCTS; BINDING; RAGE; ATHEROSCLEROSIS	Background: The Maillard reaction occurs between reducing sugars and proteins during thermal processing of foods. It produces chemically glycated proteins termed advanced glycation end products (AGEs). The glycation structures of AGES are suggested to function as pathogenesis-related immune epitopes in food allergy. Objective: This study aimed at defining the T-cell immunogenicity of food AGES by using ovalbumin (OVA) as a model allergen. Methods: AGE-OVA was prepared by means of thermal processing of OVA in the presence of glucose. Activation of OVA-specific CD4(+) T cells by AGE-OVA was evaluated in cocultures with bone marrow-derived murine myeloid dendritic cells (mDCs) as antigen-presenting cells. The uptake mechanisms of mDCs for AGE-OVA were investigated by using inhibitors of putative cell-surface receptors for AGES, as well as mDCs deficient for these receptors. Results: Compared with the controls (native OVA and OVA thermally processed without glucose), AGE-OVA enhanced the activation of OVA-specific CD4(+) T cells on coculture with mDCs, indicating that the glycation of OVA enhanced the T-cell immunogenicity of the allergen. The mDC uptake of AGE-OVA was significantly higher than that of the controls. We identified scavenger receptor class A type I and II (SR-AI/II) as a mediator of the AGE-OVA uptake, whereas the receptor for AGEs and galectin-3 were not responsible. Importantly, the activation of OVA-specific CD4(+) T cells by AGE-OVA was attenuated on coculture with SR-AI/II-deficient mDCs. Conclusion: SR-AI/II targets AGE-OVA to the MHC class II loading pathway in mDCs, leading to an enhanced CD4(+) T-cell activation. The Maillard reaction might thus play an important role in the T-cell immunogenicity of food allergens. (J Allergy Clin Immunol 2010;125:175-83.)	[Ilchmann, Anne; Toda, Masako] Paul Ehrlich Inst, Jr Res Grp Expt Allergol 1, D-63225 Langen, Germany; [Waibler, Zoe] Paul Ehrlich Inst, Jr Res Grp Novel Vaccinat Strategies & Early Immu, D-63225 Langen, Germany; [Scheurer, Stephan; Vieths, Stefan] Paul Ehrlich Inst, Div Allergol, D-63225 Langen, Germany; [Burgdorf, Sven; Kurts, Christian] Univ Bonn, Inst Mol Med & Expt Immunol, D-5300 Bonn, Germany; [Nagai, Ryoji] Japan Womens Univ, Dept Food & Nutr, Lab Biochem & Nutr Sci, Tokyo, Japan; [Wellner, Anne; Henle, Thomas] Tech Univ Dresden, Inst Food Chem, Dresden, Germany; [Yamamoto, Yasuhiko; Yamamoto, Hiroshi] Kanazawa Univ, Grad Sch Med Sci, Dept Biochem & Mol Vasc Biol, Kanazawa, Ishikawa 9201192, Japan; [Kalinke, Ulrich] Ctr Expt & Clin Infect Res, TWINCORE, Hannover, Germany	Paul Ehrlich Institute; Paul Ehrlich Institute; Paul Ehrlich Institute; University of Bonn; Japan Womens University; Technische Universitat Dresden; Kanazawa University	Toda, M (corresponding author), Paul Ehrlich Inst, Jr Res Grp Expt Allergol 1, Paul Ehrlich St 59, D-63225 Langen, Germany.	todma@pei.de	Scheurer, Stephan/A-6509-2019; Henle, Thomas/D-8489-2012; Toda, Masako/S-9810-2019	Scheurer, Stephan/0000-0002-2859-562X; Kalinke, Ulrich/0000-0003-0503-9564	Paul-Ehrlich-Institut; Deutsche Forschungsgemeinschaft (DFG) [Vi 165/6]	Paul-Ehrlich-Institut; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	Supported in part by Paul-Ehrlich-Institut and Deutsche Forschungsgemeinschaft (DFG Vi 165/6)	Abraham R, 1997, J IMMUNOL, V158, P4029; ABRAHAM R, 1995, J IMMUNOL, V154, P1; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; Berrens L, 1996, ALLERGY, V51, P277, DOI 10.1111/j.1398-9995.1996.tb00085.x; Burgdorf S, 2008, CURR OPIN IMMUNOL, V20, P89, DOI 10.1016/j.coi.2007.12.002; Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Chung SY, 2003, J AGR FOOD CHEM, V51, P4273, DOI 10.1021/jf021212d; Chung SY, 2001, J AGR FOOD CHEM, V49, P3911, DOI 10.1021/jf001186o; Dumitriu IE, 2005, EUR J IMMUNOL, V35, P2184, DOI 10.1002/eji.200526066; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Forster A, 2005, ANN NY ACAD SCI, V1043, P474, DOI 10.1196/annals.1333.054; Gasic-Milenkovic J, 2003, EUR J NEUROSCI, V17, P813, DOI 10.1046/j.1460-9568.2003.02506.x; Ge JB, 2005, ARTERIOSCL THROM VAS, V25, P2157, DOI 10.1161/01.ATV.0000181744.58265.63; Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558; Gruber P, 2005, J AGR FOOD CHEM, V53, P2289, DOI 10.1021/jf048398w; Henle T, 2005, AMINO ACIDS, V29, P313, DOI 10.1007/s00726-005-0200-2; Henle T, 1991, INT DAIRY J, V1, P125, DOI 10.1016/0958-6946(91)90004-R; Hudson BI, 2003, ARCH BIOCHEM BIOPHYS, V419, P80, DOI 10.1016/j.abb.2003.08.030; HUGHES DA, 1995, EUR J IMMUNOL, V25, P466, DOI 10.1002/eji.1830250224; Huntington JA, 2001, J CHROMATOGR B, V756, P189, DOI 10.1016/S0378-4347(01)00108-6; Malanin K, 1995, ALLERGY, V50, P988, DOI 10.1111/j.1398-9995.1995.tb02513.x; Manfredi AA, 2008, J IMMUNOL, V180, P2270, DOI 10.4049/jimmunol.180.4.2270; Myint KM, 2006, DIABETES, V55, P2510, DOI 10.2337/db06-0221; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Nicoletti A, 1999, EUR J IMMUNOL, V29, P512, DOI 10.1002/(SICI)1521-4141(199902)29:02<512::AID-IMMU512>3.0.CO;2-Y; Ohgami N, 2001, J BIOL CHEM, V276, P13348, DOI 10.1074/jbc.M011613200; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; Pluddemann A, 2007, METHODS, V43, P207, DOI 10.1016/j.ymeth.2007.06.004; Price CL, 2004, DIABETES, V53, P1452, DOI 10.2337/diabetes.53.6.1452; Scheurer S, 2004, J ALLERGY CLIN IMMUN, V114, P900, DOI 10.1016/j.jaci.2004.06.017; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Turner SJ, 1997, J IMMUNOL, V159, P2312; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; Wada Y, 1996, J MASS SPECTROM, V31, P263, DOI 10.1002/(SICI)1096-9888(199603)31:3<263::AID-JMS292>3.0.CO;2-2	39	92	98	4	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					175	183		10.1016/j.jaci.2009.08.013	http://dx.doi.org/10.1016/j.jaci.2009.08.013			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19864011				2022-12-18	WOS:000273660500021
J	van Veen, IH; ten Brinke, A; Gauw, SA; Sterk, PJ; Rabe, KF; Bel, EH				van Veen, Ilonka H.; ten Brinke, Anneke; Gauw, Stefanie A.; Sterk, Peter J.; Rabe, Klaus F.; Bel, Elisabeth H.			Consistency of sputum eosinophilia in difficult-to-treat asthma: A 5-year follow-up study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXACERBATIONS; MEPOLIZUMAB; PHENOTYPES		[van Veen, Ilonka H.] Med Spectrum Twente, Dept Pulmonol, Enschede, Netherlands; [ten Brinke, Anneke] Med Ctr Leeuwarden, Dept Pulmonol, Leeuwarden, Netherlands; [Gauw, Stefanie A.; Sterk, Peter J.; Rabe, Klaus F.] Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands; [Sterk, Peter J.; Bel, Elisabeth H.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1105 AZ Amsterdam, Netherlands	Medical Spectrum Twente; Medical Center Leeuwarden; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam	van Veen, IH (corresponding author), Med Spectrum Twente, Dept Pulmonol, Enschede, Netherlands.	h.vanveen@ziekenhuis-mst.nl	Rabe, Klaus F./AAW-6296-2021; Sterk, P.J./AAK-8175-2020	Rabe, Klaus F./0000-0002-7020-1401; 				Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8	10	92	98	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					615	617		10.1016/j.jaci.2009.06.029	http://dx.doi.org/10.1016/j.jaci.2009.06.029			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19733302				2022-12-18	WOS:000274315900037
J	Rowe, J; Kusel, M; Holt, BJ; Suriyaarachchi, D; Serralha, M; Hollams, E; Yerkovich, ST; Subrata, LS; Ladyman, C; Sadowska, A; Gillett, J; Fisher, E; Loh, R; Soderstrom, L; Ahistedt, S; Sly, PD; Holt, PG				Rowe, Julie; Kusel, Merci; Holt, Barbara J.; Suriyaarachchi, Devinda; Serralha, Michael; Hollams, Elysia; Yerkovich, Stephanie T.; Subrata, Lily S.; Ladyman, Claire; Sadowska, Agata; Gillett, Jamie; Fisher, Elizabeth; Loh, Richard; Soderstrom, Lars; Ahistedt, Staffan; Sly, Peter D.; Holt, Patrick G.			Prenatal versus postnatal sensitization to environmental allergens in a high-risk birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; cytokines; IgE; IgG(4); T-cell memory; T(H)2	HOUSE-DUST MITE; T-CELL RESPONSES; CORD-BLOOD; INHALANT ALLERGENS; INDOOR ALLERGENS; MATERNAL INTAKE; EARLY-CHILDHOOD; GRASS-POLLEN; DIETARY EGG; CHILDREN	Background: The timing of allergen sensitization is controversial, with conflicting evidence suggesting transplacental priming versus exclusively postnatal priming. Resolution of this question is important in relation to rational design of allergy prevention strategies, particularly the issue of allergen avoidance during pregnancy. Objective: To elucidate the kinetics of sensitization in high-risk children during their first 2 years of life. Methods: We prospectively studied house dust mite (HDM)specific IgE and IgG(4) antibody production and associated T-cell immunity in a cohort of 200 high-risk infants. Parallel antibody studies tracked responses against a broader panel of inhalant and dietary allergens including peanut. Results: HDM-induced T-H(2) responses in PBMC from 6 months onward, particularly IL-4 and IL-5, correlated increasingly strongly with sensitization outcomes at 2 years, and a I contrasting negative relationship was observed with IFN-T response capacity. HDM-induced T-cell responses in cord blood, although common, were unrelated to subsequent sensitization. Transient HDM-IgE (and IgG4) production frequently peaked at 6 or 12 months before returning to baseline, which suggests the onset of protective tolerance. This finding contrasted wi th progressively increasing HDM titers in children sensitized by 2 years of age. Comparably contrasting patterns were observed in peanut-specific responses in sensitized versus nonsensitized children. Conclusion: Priming of T-H(2) responses associated with persistent HDM-IgE production occurs entirely postnatally, as HDM reactivity in cord blood seems nonspecific and is unrelated to subsequent development of allergen-specific T-H(2) memory or TgE. Clinical implications: These findings question the scientific basis for existing recommendations for allergen avoidance by high-risk women during pregnancy.	Univ Western Australia, Telethon Inst Child Hlth Res, Div Cell Biol, Ctr Child Hlth Res, Perth, WA 6009, Australia; Princess Margaret Hosp Children, Subiaco, WA, Australia; Phadia AB, Uppsala, Sweden; Karolinska Inst, Stockholm, Sweden	Telethon Kids Institute; University of Western Australia; Thermo Fisher Scientific; Phadia; Karolinska Institutet	Holt, PG (corresponding author), Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	Serralha, Michael/CAA-0940-2022; Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010; Yerkovich, Stephanie/A-9004-2011	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; Serralha, Michael/0000-0002-0121-2879; Soderstrom, Lars/0000-0002-6474-6501; Hollams, Elysia/0000-0002-3481-6396; Yerkovich, Stephanie/0000-0003-4163-4782				AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; Baker SS, 2000, PEDIATRICS, V106, P346; Ballardini N, 2006, ALLERGY, V61, P337, DOI 10.1111/j.1398-9995.2005.00936.x; Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1111/j.1365-2222.1996.tb00607.x; BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BUSINCO L, 1988, CLIN ALLERGY, V18, P269, DOI 10.1111/j.1365-2222.1988.tb02869.x; Cain TW, 2006, ALLERGY CLIN IMMUNOL, V18, P1; Casas R, 2004, CLIN EXP ALLERGY, V34, P591, DOI 10.1111/j.1365-2222.2004.1924.x; Committee on Toxicity of Chemicals in Food, 1998, PEAN ALL; Cressy I, 2006, P 25 C EUR AC ALL CL, P296; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; *DEP HLTH, 1998, PEAN ALL; Evans G, 2000, IMMUNOASSAY HDB; Gavin MA, 1995, IMMUNITY, V3, P793, DOI 10.1016/1074-7613(95)90068-3; GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071; Hagendorens MM, 2004, PEDIAT ALLERG IMM-UK, V15, P308, DOI 10.1111/j.1399-3038.2004.00169.x; HANNAH ML, 2000, NZ MED MED DEVICES S, P22; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Herrmann ME, 1996, EUR J PEDIATR, V155, P770, DOI 10.1007/BF02002904; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; HOLT PG, 2006, PROPHYLAXIS ATOPY AS; Julge K, 2001, CLIN EXP ALLERGY, V31, P1854, DOI 10.1046/j.1365-2222.2001.01235.x; Kihlstrom A, 2003, ALLERGY, V58, P871, DOI 10.1034/j.1398-9995.2003.00232.x; KONDO N, 1992, ARCH DIS CHILD, V67, P1003, DOI 10.1136/adc.67.8.1003; KORSGAARD J, 1983, CLIN ALLERGY, V13, P529, DOI 10.1111/j.1365-2222.1983.tb02634.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kusel MMH, 2005, J ALLERGY CLIN IMMUN, V116, P1067, DOI 10.1016/j.jaci.2005.06.038; Malhotra I, 2006, J INFECT DIS, V193, P1005, DOI 10.1086/500472; Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358, DOI 10.1159/000236692; Platts-Mills TAE, 2000, AM J RESP CRIT CARE, V162, pS128, DOI 10.1164/ajrccm.162.supplement_2.ras-15; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rowe J, 2004, VACCINE, V22, P3986, DOI 10.1016/j.vaccine.2004.03.052; Sasai K, 1996, J PEDIATR-US, V128, P834, DOI 10.1016/S0022-3476(96)70337-2; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Szepfalusi Z, 2000, PEDIATR RES, V48, P404, DOI 10.1203/00006450-200009000-00024; Thornton CA, 2004, J IMMUNOL, V173, P3084, DOI 10.4049/jimmunol.173.5.3084; Turke J, 2005, PEDIAT ALLERG IMM-UK, V16, P512, DOI 10.1111/j.1399-3038.2005.00305.x; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; Vance GHS, 2004, CLIN EXP ALLERGY, V34, P1855, DOI 10.1111/j.1365-2222.2004.02111.x; WOOD RA, 2007, IN PRESS ANN ALLERGY; YMAN L, 2000, IMMUNOASSAY HDB; ZEIGER R, 1995, J ALLERGY CLIN IMMUN, V96, P1179	49	92	94	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1164	1173		10.1016/j.jaci.2007.02.016	http://dx.doi.org/10.1016/j.jaci.2007.02.016			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17412403				2022-12-18	WOS:000246427200017
J	Weichel, M; Glaser, AG; Ballmer-Weber, BK; Schmid-Grendelmeier, P; Crameri, R				Weichel, M; Glaser, AG; Ballmer-Weber, BK; Schmid-Grendelmeier, P; Crameri, R			Wheat and maize thioredoxins: A novel cross-reactive cereal allergen family related to baker's asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						baker's asthma; Triticum aestivum; Zea mays; recombinant allergens; cross-reactivity; cDNA phage display	EXERCISE-INDUCED ANAPHYLAXIS; CYSTIC-FIBROSIS PATIENTS; SKIN-PRICK TEST; BRONCHOPULMONARY ASPERGILLOSIS; DISPLAY TECHNOLOGY; OMEGA-5 GLIADIN; MAJOR ALLERGEN; IDENTIFICATION; FLOUR; REDUCTION	Background: Baker's asthma is a serious problem for a significant proportion of workers in bakeries, confectionaries, and the food industry. Although several wheat allergens related to baker's asthma have been described, standardized reagents for a reliable diagnosis are not yet available. Objective: To clone novel wheat allergens related to baker's asthma and investigate the cross-reactive potential of their maize and human homologues. Methods: A wheat cDNA phage display library was screened with sera from bakers with occupational asthma for IgE-binding structures. Homologous sequences from maize and human thioredoxins were amplified from corresponding cDNA libraries. Results: Within the enriched wheat cDNA repertoire we identified., among others, the sequence encoding wheat thioredoxin-hB (Triticum aesthvum allergen 25 [Tri a 25]). The recombinant protein displayed enzymatic activity, and we observed a sensitization rate of 47% among bakers with occupational asthma and of 35% among patients with grass pollen allergy, but without a clinical history of cereal allergy. Furthermore, the previously characterized maize thioredoxin-h1 (Zea mays allergen 25 [Zea m 25]), sharing 74% identity with Tri a 25, exhibited distinct IgE cross-reactivity with its wheat homologue. Two bakers also showed sensitization to human thioredoxin, which shares 29% identity with Tri a 25. In a comparative study, we included recombinant alpha-amylase inhibitor 0.19, showing a sensitization rate of 65% in individuals with baker's asthma. Conclusion: Thioredoxins represent a novel family of cross-reactive allergens that might contribute to the symptoms of baker's asthma and might in addition be related to grass pollen allergy, as indicated by the reactivity of grass pollen allergic patients to cereal thioredoxins. Clinical implications: The recombinant cereal thioredoxins will, together with the already reported wheat allergens, contribute to a more reliable diagnosis of baker's asthma and, perhaps, become a tool for the development of component-resolved immunotherapy.	Swiss Inst Allergy & Asthma Res, Mol Allergol, CH-7270 Davos, Switzerland; Univ Zurich Hosp, Allergy Unit, Dept Dermatol, Zurich, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; University Zurich Hospital	Crameri, R (corresponding author), Swiss Inst Allergy & Asthma Res, Mol Allergol, Obere Str 22,Davos Pl, CH-7270 Davos, Switzerland.	crameri@siaf.unizh.ch						Amano M, 1998, BIOCHEM J, V330, P1229, DOI 10.1042/bj3301229; Baur X, 1998, J ALLERGY CLIN IMMUN, V102, P984, DOI 10.1016/S0091-6749(98)70337-9; Baur X, 1998, ALLERGY, V53, P562, DOI 10.1111/j.1398-9995.1998.tb03931.x; Baur X, 1999, INT ARCH OCC ENV HEA, V72, P292, DOI 10.1007/s004200050377; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; Eriksson TLJ, 2001, EUR J BIOCHEM, V268, P287, DOI 10.1046/j.1432-1327.2001.01879.x; FRANKEN J, 1994, INT ARCH ALLERGY IMM, V104, P171, DOI 10.1159/000236726; GOMEZ L, 1990, FEBS LETT, V261, P85, DOI 10.1016/0014-5793(90)80642-V; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1155::AID-IMMU1155&gt;3.0.CO;2-6; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Houba R, 1998, AM J IND MED, V34, P529, DOI 10.1002/(SICI)1097-0274(199812)34:6&lt;529::AID-AJIM1&gt;3.0.CO;2-I; *IUIS ALL NOM SUBC, OFF LIST ALL; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; KOBREHEL K, 1992, PLANT PHYSIOL, V99, P919, DOI 10.1104/pp.99.3.919; Mittag D, 2004, MOL NUTR FOOD RES, V48, P380, DOI 10.1002/mnfr.200400016; Nakamura T, 2005, ANTIOXID REDOX SIGN, V7, P60, DOI 10.1089/ars.2005.7.60; Nikolaizik WH, 2002, AM J RESP CRIT CARE, V165, P916, DOI 10.1164/ajrccm.165.7.2109008; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; POSCH A, 1995, ELECTROPHORESIS, V16, P1115, DOI 10.1002/elps.11501601188; SanchezMonge R, 1997, CLIN EXP ALLERGY, V27, P1130, DOI 10.1046/j.1365-2222.1997.1340945.x; Sander I, 2004, ALLERGY, V59, P95, DOI 10.1046/j.1398-9995.2003.00349.x; Sander I, 2001, J ALLERGY CLIN IMMUN, V107, P907, DOI 10.1067/mai.2001.113761; Sander I, 1997, INT ARCH ALLERGY IMM, V112, P378, DOI 10.1159/000237483; SANDIFORD CP, 1995, CLIN EXP ALLERGY, V25, P340, DOI 10.1111/j.1365-2222.1995.tb01052.x; Serrato AJ, 2001, PLANT MOL BIOL, V46, P361, DOI 10.1023/A:1010697331184; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; VARJONEN E, 1995, CLIN EXP ALLERGY, V25, P1100, DOI 10.1111/j.1365-2222.1995.tb03257.x; Weichel M, 2006, ALLERGY, V61, P128, DOI 10.1111/j.1398-9995.2006.00999.x; Weichel M, 2003, ALLERGY, V58, P198, DOI 10.1034/j.1398-9995.2003.23822.x; Weichel M, 2003, CLIN EXP ALLERGY, V33, P72, DOI 10.1046/j.1365-2222.2003.01574.x; Weiss W, 1997, ELECTROPHORESIS, V18, P826, DOI 10.1002/elps.1150180529; 1995, AM J RESP CRIT CARE, V152, P1107	33	92	95	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					676	681		10.1016/j.jaci.2005.11.040	http://dx.doi.org/10.1016/j.jaci.2005.11.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522470				2022-12-18	WOS:000236263100026
J	Raby, BA; Silverman, EK; Kwiatkowski, DJ; Lange, C; Lazarus, R; Weiss, ST				Raby, BA; Silverman, EK; Kwiatkowski, DJ; Lange, C; Lazarus, R; Weiss, ST			ADAM33 polymorphisms and phenotype associations in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; genetics; ADAM33; metalloproteinases; association studies; haplotype	FAMILY-BASED ASSOCIATION; GENETIC DISSECTION; UNIFIED APPROACH; TESTS; LINKAGE; SUSCEPTIBILITY; ADAM-33	Background: A disintegrin and metalloproteinase (ADAM) 33 has been implicated as an asthma susceptibility gene by using a positional cloning approach. However, genetic linkage of asthma phenotypes to chromosome 20p13 (the location of ADAM33) has not been observed in most asthma genome scans, and it is unclear whether these associations with ADAM33 are broadly generalizable. Objective: To examine whether ADAM33 is associated with asthma in a North American population of childhood asthmatic patients. Methods: We performed a family-based association study by using 652 nuclear families ascertained through asthmatic subjects enrolled in a large randomized clinical trial. Seventeen ADAM33 single nucleotide polymorphisms (SNPs; including 9 associated with asthma in the initial report) were genotyped by mass spectrometry. Single-SNP and haplotype association analysis was performed. Results: Among white and African American subjects, no single-SNP association with asthma was observed. However, a common 16-SNP haplotype (frequency, 14.6% in white subjects) was associated with asthma (P = .006). Two SNPs in strong linkage disequilibrium (T1 and T+1) were marginally associated with asthma in the Hispanic cohort (P = .04). These data provide marginal support for an asthma locus in the ADAM33 genomic region. However, the magnitudes of the observed associations are modest at best and are inconsistent with the original report. Conclusions: We conclude that either ADAM33 has only modest effects on asthma susceptibility, and the initial reports of association were a result of analysis in a selected population, or the initial findings were a result of chance. It is also possible that the true asthma susceptibility locus in this genomic region is near, but not at, ADAM33.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Brigham & Womens Hosp, Harvard Partners Ctr Genom, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Raby, BA (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	benjamin.raby@channing.harvard.edu	Raby, Benjamin/AAK-3866-2021	lazarus, ross/0000-0003-3939-1961	NHLBI NIH HHS [K08 HL 74193, N01 HR 16049, P50 HL 67664, T32 HL 07427] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL074193, P50HL067664, T32HL007427] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; Cookson W, 2003, TRENDS GENET, V19, P169, DOI 10.1016/S0168-9525(03)00025-8; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Drazen JM, 2002, NATURE, V418, P383, DOI 10.1038/418383a; HALDANE JBS, 1954, J GENET, V52, P631, DOI 10.1007/BF02985085; HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622; HILL WG, 1974, HEREDITY, V33, P229, DOI 10.1038/hdy.1974.89; Holgate ST, 2003, THORAX, V58, P466, DOI 10.1136/thorax.58.6.466; Howard TD, 2003, J ALLERGY CLIN IMMUN, V112, P717, DOI 10.1016/S0091-6749(03)01939-0; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; KNOWLER WC, 1988, AM J HUM GENET, V43, P520; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lange C, 2002, GENET EPIDEMIOL, V23, P165, DOI 10.1002/gepi.209; Lange C, 2003, AM J HUM GENET, V73, P801, DOI 10.1086/378591; Lind DL, 2003, AM J RESP CRIT CARE, V168, P1312, DOI 10.1164/rccm.200306-877OC; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Pritchard JK, 2001, THEOR POPUL BIOL, V60, P227, DOI 10.1006/tpbi.2001.1543; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Shapiro SD, 2002, NEW ENGL J MED, V347, P936, DOI 10.1056/NEJMcibr022144; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; STEPHENS M, 2001, PHASE; Umland SP, 2003, AM J RESP CELL MOL, V29, P571, DOI 10.1165/rcmb.2003-0028OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wjst M, 1998, BIOINFORMATICS, V14, P827, DOI 10.1093/bioinformatics/14.9.827; Zhang K, 2003, BIOINFORMATICS, V19, P1300, DOI 10.1093/bioinformatics/btg142	31	92	97	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1071	1078		10.1016/j.jaci.2004.03.035	http://dx.doi.org/10.1016/j.jaci.2004.03.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208587	Bronze			2022-12-18	WOS:000222091000011
J	Sutherland, ER; Martin, RJ; Bowler, RP; Zhang, YJ; Rex, MD; Kraft, M				Sutherland, ER; Martin, RJ; Bowler, RP; Zhang, YJ; Rex, MD; Kraft, M			Physiologic correlates of distal lung inflammation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; distal lung; inflammation; small airways	PERIPHERAL LUNG; NOCTURNAL ASTHMA; ALVEOLAR TISSUE; AIRWAY; OBSTRUCTION; RESPONSIVENESS; BECLOMETHASONE; DISEASE; SITE	Background: The distal lung is an important site of inflammation in asthma. Maximal midexpiratory flows and the ratio of maximal:partial flows are purported to reflect distal lung function. Objective: We obtained contemporaneous transbronchial biopsy, spirometry, and plethysmography to describe more accurately the relationship between physiology and distal lung inflammation in asthma. Methods: Ten patients with severe, persistent asthma with mean +/- SE FEV1 of 2.8 +/- 0.2 L and overnight fall in FEV1 of 22.8% +/- 3.8% underwent transbronchial biopsy, spirometry, maximal midexpiratory flows, maximal:partial ratio, and lung volumes, all at 4 AM. Morphometric analysis was performed after immunohistochemistry for eosinophils, lymphocytes, macrophages, mast cells, and neutrophils. Results: Maximal midexpiratory flows, maximal:partial ratio, FEV1, and forced vital capacity were not significantly correlated with alveolar tissue inflammation. However, the degree of eosinophilic alveolar inflammation was significantly and positively correlated with both total lung capacity (Spearman rho = 0.70; P = .03) and thoracic gas volume (rho = 0.62; P = .05). Correlation between eosinophils and other lung volumes was not observed. Other inflammatory cell types did not correlate with lung volumes. Conclusion: Purported physiologic measures of distal lung function are poorly correlated with histopathologic evidence of distal lung inflammation. Measurement of lung volumes more accurately reflects eosinophilic distal lung inflammation.	Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sutherland, ER (corresponding author), 1400 Jackson St,J-217, Denver, CO 80206 USA.	sutherlande@njc.org	Sutherland, Everett Rand/B-7666-2008; Bowler, Russell P/J-8283-2015	Bowler, Russell P/0000-0003-4651-363X	NCRR NIH HHS [M01 RR 00051] Funding Source: Medline; NHLBI NIH HHS [K08 HL 04407, R01 HL 03343, K23 HL 04385] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004407, K23HL004385] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOGGS PB, 1982, ANN ALLERGY, V48, P137; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BURNS CB, 1985, J APPL PHYSIOL, V59, P1590, DOI 10.1152/jappl.1985.59.5.1590; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; GELB AF, 1983, CHEST, V84, P473, DOI 10.1378/chest.84.4.473; Gross G, 1999, CHEST, V115, P343, DOI 10.1378/chest.115.2.343; GUNDERSEN HJG, 1981, J MICROSC-OXFORD, V121, P65, DOI 10.1111/j.1365-2818.1981.tb01199.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Howard C, 1998, UNBIASED STEREOLOGY; INGRAM RH, 1987, AM REV RESPIR DIS, V136, pS62, DOI 10.1164/ajrccm/136.4_Pt_2.S62; INGRAM RH, 1990, LUNG, V168, P237, DOI 10.1007/BF02719700; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551, DOI 10.1164/ajrccm.163.7.2008013; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; MCFADDEN ER, 1972, AM J MED, V52, P725, DOI 10.1016/0002-9343(72)90078-2; *NIH, 1997, NIH PUBL; PLISS LB, 1989, J APPL PHYSIOL, V66, P2298, DOI 10.1152/jappl.1989.66.5.2298; Sutherland ER, 2002, ANN ALLERG ASTHMA IM, V89, P119, DOI 10.1016/S1081-1206(10)61926-6; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; 1994, FED REG, P56276	25	92	96	1	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1046	1050		10.1016/j.jaci.2004.03.016	http://dx.doi.org/10.1016/j.jaci.2004.03.016			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208583				2022-12-18	WOS:000222091000007
J	Vailes, L; Sridhara, S; Cromwell, O; Weber, B; Breitenbach, M; Chapman, M				Vailes, L; Sridhara, S; Cromwell, O; Weber, B; Breitenbach, M; Chapman, M			Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alternaria; Aspergillus; allergen exposure; recombinant allergens; fungi; asthma	ALT-A-I; ALTERNARIA-ALTERNATA; BRONCHIAL HYPERRESPONSIVENESS; ASPERGILLUS-FUMIGATUS; SENSITIZATION; ASTHMA; EXTRACTS; AGE; CLADOSPORIUM; ASSOCIATION	Background: Alternaria is one of the most important fungi associated with allergic disease, whereas Aspergillus fumigatus is involved in a broad spectrum of pulmonary diseases. Currently, fungal extracts used for diagnosis in the United States are unstandardized, and their allergenic content cannot be compared directly. Objective: The goal of this study was to compare the variability of major allergen levels among US allergenic products derived from fungi: specifically, Alt a 1 levels in Alternaria alternata extracts, and Asp f 1 levels in A fumigatus extracts. Methods: A novel a-site monoclonal antibody ELISA was used for measuring Alt a 1 using recombinant Alt a 1 as a standard. Asp fl was also measured by ELISA, Allergenic products produced by 8 US manufacturers over a 2-year period were compared, as were multiple lots produced by a single company, Results: Alt a 1 levels in Alternaria extracts from 8 companies produced in 1998 and 1999 ranged from less than 0.01 to 6.09 mug/mL (mean 1.4 +/- 1.6 mug/mL, n = 15), In general, Alt al levels were consistent within and between companies (1.4 +/- 1.1 mug/mL, n = 27), with 21 of 32 (66%) of all extracts tested containing 0.7 to 2 mug/mL Alt a 1, Aspergillus extracts showed much greater variability in Asp fl levels, with extracts from 8 companies containing from less than 0.1 to 64 mug/mL Asp fl (mean 16.3 +/- 23.9 mug/mL, n = 15), Overall variability was greater for Aspergillus products within and between manufacturers (22 +/- 22 mug/mL Asp f 1, a = 20), Conclusions: ELISA-based assays for specific allergens showed greater consistency among allergenic products derived from Alternaria than from Aspergillus, These assays should facilitate improved quality control and standardization of fungal allergen extracts and lead to the development of more consistent products for clinical use.	Univ Virginia, Dept Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Joachim Ganzer KG, Allergopharma, Reinbek, Germany; Salzburg Univ, A-5020 Salzburg, Austria	University of Virginia; Allergopharma; Salzburg University	Vailes, L (corresponding author), Univ Virginia, Dept Med, Asthma & Allerg Dis Ctr, Box 801355, Charlottesville, VA 22908 USA.			Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, R01AI032557, U19AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34607, AI 32557] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Aden E, 1999, J ALLERGY CLIN IMMUN, V104, P128, DOI 10.1016/S0091-6749(99)70124-7; AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P432, DOI 10.1016/0091-6749(82)90005-7; Al-Doory Y., 1987, MOULD HLTH WHO IS RI; [Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; AUKRUST L, 1985, Allergy (Copenhagen), V40, P43, DOI 10.1111/j.1398-9995.1985.tb02641.x; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; CURRAN IHA, 1993, INT ARCH ALLERGY IMM, V102, P267, DOI 10.1159/000236535; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HELM RM, 1988, J ALLERGY CLIN IMMUN, V81, P651, DOI 10.1016/0091-6749(88)91035-4; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786, DOI 10.1164/ajrccm.151.6.7767521; KLEINETEBBE J, 1993, CLIN EXP ALLERGY, V23, P211, DOI 10.1111/j.1365-2222.1993.tb00884.x; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PARIS S, 1990, J ALLERGY CLIN IMMUN, V85, P941, DOI 10.1016/0091-6749(90)90081-E; PARIS S, 1990, INT ARCH ALLER A IMM, V92, P1, DOI 10.1159/000235216; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; PLATTSMILLS TAE, 1993, AEROBIOLOGY INHALANT, P498; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P930, DOI 10.1016/0091-6749(93)90351-F; Portnoy J, 1998, ANN ALLERG ASTHMA IM, V81, P59; STERINGER I, 1987, INT ARCH ALLER A IMM, V84, P190, DOI 10.1159/000234422; Tariq SM, 1996, CLIN EXP ALLERGY, V26, P794, DOI 10.1111/j.1365-2222.1996.tb00610.x; VANDERHEIDE S, 1985, ALLERGY, V40, P592; VIJAY HM, 1993, J ALLERGY CLIN IMMUN, V91, P826, DOI 10.1016/0091-6749(93)90338-G; VIJAY HM, 1984, INT ARCH ALLER A IMM, V74, P256, DOI 10.1159/000233554; WAHL R, 1989, ANN ALLERGY, V63, P527; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; ZHANG L, 1995, INT ARCH ALLERGY IMM, V108, P254, DOI 10.1159/000237161	35	92	94	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					641	646		10.1067/mai.2001.114118	http://dx.doi.org/10.1067/mai.2001.114118			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295652				2022-12-18	WOS:000168190100015
J	Simon-Nobbe, B; Probst, G; Kajava, AV; Oberkofler, H; Susani, M; Crameri, R; Ferreira, F; Ebner, C; Breitenbach, M				Simon-Nobbe, B; Probst, G; Kajava, AV; Oberkofler, H; Susani, M; Crameri, R; Ferreira, F; Ebner, C; Breitenbach, M			IgE-binding epitopes of enolases, a class of highly conserved fungal allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						enolase; structure; epitope; mold; allergy; Cladosporium herbarum; Alternaria alternata; Aspergillus fumigatus; Candida albicans; Saccharomyces cerevisiae	YEAST SACCHAROMYCES-CEREVISIAE; MOLECULAR CHARACTERIZATION; ALTERNARIA-ALTERNATA; CANDIDA-ALBICANS; EXPRESSION; PROTEIN; IDENTIFICATION; GENE; ANTIBODIES	Background: Cladosporium herbarum and Alternaria alternata are two of the most prominent fungal species inducing type I allergy. Previously, we have demonstrated that enolase (Cla h 6) is the second most important allergen of C herbarum in terms of frequency of sensitization. Objective: IgE-reactive B-cell epitopes of C herbarum enolase were analyzed, and cross-reactivity between fungal enolases was investigated. Methods: Cla h 6 glutathione-S-transferase fusion peptides were constructed by means of PCR cloning, A alternata enolase (Alt a 5) was isolated by screening a complementary (c)DNA expression library with a C herbarum enolase DNA probe. Results: Mapping of Cla h 6 IgE-binding epitopes identified a peptide with a length of 69 amino acids (peptide 9), which bound IgE from 8 of 8 patients. Analysis of the conformation of peptide 9 revealed that it does not form a compact structure but rather spans the whole length of the protein, with side chains exposed to solvent at 3 locations. Peptide 9 in the context of Escherichia coli glutathione-S-transferase not only binds IgE but also competitively inhibits IgE binding to Alt a 5. This result indicates that the epitope or epitopes on peptide 9 constitute a major cross-reacting epitope or epitopes on the enolases from C herbarum and A alternata in the case of the! one patient tested. Conclusions: We demonstrated that the glycolytic enzyme enolase is an allergen not only in C herbarum but also in A alternata. Additionally, enolase was shown to exhibit high cross-reactivity to other fungal enolases. On the basis of the results presented here, we propose the use of recombinant Cia h 6 or maybe even peptide 9 of Cia h 6 for diagnosis and possibly therapy of mold allergy.	Salzburg Univ, Inst Genet & Gen Biol, A-5020 Salzburg, Austria; Univ Vienna, Dept Pathophysiol, Vienna, Austria; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Adv Biol Syst Inc, Salzburg, Austria; Landeskrankenanstalten Salzburg, Dept Lab Med, Salzburg, Austria; NIH, Ctr Mol Modeling, CIT, Bethesda, MD 20892 USA; Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria	Salzburg University; University of Vienna; Swiss Institute of Allergy & Asthma Research; National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); Austrian Academy of Sciences	Simon-Nobbe, B (corresponding author), Salzburg Univ, Inst Genet & Gen Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.		Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019; Kajava, Andrey V/E-1107-2014	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Kajava, Andrey V/0000-0002-2342-6886	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000259] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT))		ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; AKKERDAAS JH, 1995, ALLERGY, V50, P215, DOI 10.1111/j.1398-9995.1995.tb01136.x; Angiolella L, 1996, J INFECT DIS, V173, P684, DOI 10.1093/infdis/173.3.684; BALDO BA, 1988, INT ARCH ALLER A IMM, V86, P201, DOI 10.1159/000234572; BALL T, 1994, J BIOL CHEM, V269, P28323; BREITENBACH M, 1995, INT ARCH ALLERGY IMM, V107, P458, DOI 10.1159/000237081; BURNETT ME, 1992, J BACTERIOL, V174, P6548, DOI 10.1128/JB.174.20.6548-6553.1992; CHIN CCQ, 1981, J BIOL CHEM, V256, P1377; Colombo P, 1998, J IMMUNOL, V160, P2780; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; DUDLER T, 1994, J IMMUNOL, V152, P5514; GIALLONGO A, 1990, EUR J BIOCHEM, V190, P567, DOI 10.1111/j.1432-1033.1990.tb15611.x; IIDA H, 1985, NATURE, V315, P688, DOI 10.1038/315688a0; ITO K, 1995, CLIN EXP ALLERGY, V25, P522, DOI 10.1111/j.1365-2222.1995.tb01089.x; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; KORTEKANGASSAVOLAINEN O, 1993, CLIN EXP ALLERGY, V23, P179, DOI 10.1111/j.1365-2222.1993.tb00879.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIODA L, 1989, J BIOL CHEM, V264, P3685; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Pardo M, 1999, YEAST, V15, P459, DOI 10.1002/(SICI)1097-0061(199904)15:6<459::AID-YEA387>3.0.CO;2-L; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Sambrook J, 1989, MOL CLONING LAB MANU, V1, P1; STEC B, 1990, J MOL BIOL, V211, P235, DOI 10.1016/0022-2836(90)90023-F; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAN DER STRAETEN D, 1991, PLANT CELL, V3, P719, DOI 10.2307/3869253; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5; WESTHEAD EW, 1964, J BIOL CHEM, V239, P2464; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729	30	92	99	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					887	895		10.1067/mai.2000.110799	http://dx.doi.org/10.1067/mai.2000.110799			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080711				2022-12-18	WOS:000167865200013
